PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6:	A1	(11) International Publication Number: WO 00/55351
C12P 21/04, C12N 15/00, C07H 21/02	AI	(43) International Publication Date: 21 September 2000 (21.09.00)
(21) International Application Number: PCT/US (22) International Filing Date: 8 March 2000 (c) (30) Priority Data: 60/124,270 12 March 1999 (12.03.99) (71) Applicant (for all designated States except US): GENOME SCIENCES, INC. [US/US]; 9410 K Avenue, Rockville, MD 20850 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): ROSEN, C [US/US]; 22400 Rolling Hill Road, Laytonsv 20882 (US). RUBEN, Steven, M. [US/US]; 18528 Hills Drive, Laytonsville, MD 20882 (US). (74) Agents: WALES, Michele, M. et al.; Human Genome Inc., 9410 Key West Avenue, Rockville, MD 208.	HUMA (ey Wo	BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published With international search report.

(54) Title: HUMAN COLON CANCER ASSOCIATED GENE SEQUENCES AND POLYPEPTIDES

(57) Abstract

This invention relates to newly identified colon or colon cancer related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "colon cancer antigens", and to the complete gene sequences associated therewith and to the expression products thereof, as well as the use of such colon cancer antigens for detection, prevention and treatment of disorders of the colon, particularly the presence of colon cancer. This invention relates to the colon cancer antigens as well as vectors, host cells, antibodies directed to colon cancer antigens and recombinant and synthetic methods for producing the same. Also provided are diagnostic methods for diagnosing and treating, preventing and/or prognosing disorders related to the colon, including colon cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of colon cancer antigens of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and/or function of the polypeptides of the present invention.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
ΛU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Јарал	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
СН	Switzerland	KG	Kyrgyzstan	NO	Norway	zw	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		•
Cυ	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

WO 00/55351 PCT/US00/05883

1

Human Colon Cancer Associated Gene Sequences and Polypeptides

5

10

15

20

25

30

Field of the Invention

This invention relates to newly identified colon or colon cancer related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "colon cancer antigens," and to the complete gene sequences associated therewith and to the expression products thereof, as well as the use of such colon cancer antigens for detection, prevention and treatment of disorders of the colon, particularly the presence of colon cancer. This invention relates to the colon cancer antigens as well as vectors, host cells, antibodies directed to colon cancer antigens and recombinant and synthetic methods for producing the same. Also provided are diagnostic methods for diagnosing and treating, preventing and/or prognosing disorders related to the colon, including colon cancer, and therapeutic methods for identifying agonists and antagonists of colon cancer antigens of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and/or function of the polypeptides of the present invention.

Background of the Invention

Colorectal cancers are among the most common cancers in men and women in the U.S. and are one of the leading causes of death. Other than surgical resection no other systemic or adjuvant therapy is available. Vogelstein and colleagues have described the sequence of genetic events that appear to be associated with the multistep process of colon cancer development in humans (Trends Genet 9(4):138-41 (1993)). An understanding of the molecular genetics of carcinogenesis, however, has not led to preventative or therapeutic measures. It can be expected that advances in molecular genetics will lead to better risk assessment and early diagnosis but colorectal cancers will remain a deadly disease for a majority of patients due to the

5

10

15

20

25

30

PCT/US00/05883

lack of an adjuvant therapy. Adjuvant or systemic treatments are likely to arise from a better understanding of the autocrine factors responsible for the continued proliferation of cancer cells.

Colorectal carcinoma is a malignant neoplastic disease. There is a high incidence of colorectal carcinoma in the Western world, particularly in the United States. Tumors of this type often metastasize through lymphatic and vascular channels. Many patients with colorectal carcinoma eventually die from this disease. In fact, it is estimated that 62,000 persons in the United States alone die of colorectal carcinoma annually.

At the present time the only systemic treatment available for colon cancer is chemotherapy. However, chemotherapy has not proven to be very effective for the treatment of colon cancers for several reasons, the most important of which is the fact that colon cancers express high levels of the MDR gene (that codes for multi-drug resistance gene products). The MDR gene products actively transport the toxic substances out of the cell before the chemotherapeutic agents can damage the DNA machinery of the cell. These toxic substances harm the normal cell populations more than they harm the colon cancer cells for the above reasons.

There is no effective systemic treatment for treating colon cancers other than surgically removing the cancers. In the case of several other cancers, including breast cancers, the knowledge of growth promoting factors (such as EGF, estradiol, IGF-11) that appear to be expressed or effect the growth of the cancer cells, has been translated for treatment purposes. But in the case of colon cancers this knowledge has not been applied and therefore the treatment outcome for colon cancers remains bleak.

There is a need, therefore, for identification and characterization of such factors that modulate activation and differentiation of colon cells, both normally and in disease states. In particular, there is a need to isolate and characterize additional molecules that mediate apoptosis, DNA repair, tumor-mediated angiogenesis, genetic imprinting, immune responses to tumors and tumor antigens and, among other things, that can play a role in detecting, preventing, ameliorating or correcting dysfunctions or diseases of the colon.

Summary of the Invention

The present invention includes isolated nucleic acid molecules comprising, or alternatively, consisting of, a colon and/or colon cancer associated polynucleotide sequence disclosed in the sequence listing (as SEQ ID Nos:1 to 773) and/or contained in a human cDNA clone described in Tables 1. 2 and 5 and deposited with the American Type Culture Collection ("ATCC"). Fragments, variant, and derivatives of these nucleic acid molecules are also encompassed by the invention. The present invention also includes isolated nucleic acid molecules comprising, or alternatively consisting of, a polynucleotide encoding a colon or colon cancer polypeptide. The present invention further includes colon and/or colon cancer polypeptides encoded by these polynucleotides. Further provided for are amino acid sequences comprising, or alternatively consisting of, colon and/or colon cancer polypeptides as disclosed in the sequence listing (as SEQ ID Nos: 774 to 1546) and/or encoded by a human cDNA clone described in Tables 1, 2 and 5 and deposited with the ATCC. Antibodies that bind these polypeptides are also encompassed by the invention. Polypeptide fragments, variants, and derivatives of these amino acid sequences are also encompassed by the invention, as are polynucleotides encoding these polyneptides and antibodies that bind these polypeptides. Also provided are diagnostic methods for diagnosing and treating, preventing, and/or prognosing disorders related to the colon, including colon cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of colon cancer antigens of the invention.

Detailed Description

25

30

5

10

15

20

Tables

Table 1 summarizes some of the colon cancer antigens encompassed by the invention (including contig sequences (SEQ ID NO:X) and the cDNA clone related to the contig sequence) and further summarizes certain characteristics of the colon cancer polynucleotides and the polypeptides encoded thereby. The first column shows the "SEQ ID NO:" for each of the 773 colon cancer antigen polynucleotide sequences of the invention. The second column provides a unique "Sequence/Contig ID"

WO 00/55351 PCT/US00/05883

4

identification for each colon and/or colon cancer associated sequence. The third column, "Gene Name," and the fourth column, "Overlap," provide a putative identification of the gene based on the sequence similarity of its translation product to an amino acid sequence found in a publicly accessible gene database and the database accession no. for the database sequence having similarity, respectively. The fifth and sixth columns provide the location (nucleotide position nos. within the contig), "Start" and "End", in the polynucleotide sequence "SEQ ID NO:X" that delineate the preferred ORF shown in the sequence listing as SEQ ID NO:Y. The seventh and eighth columns provide the "% Identity" (percent identity) and "% Similarity" (percent similarity), respectively, observed between the aligned sequence segments of the translation product of SEQ ID NO:X and the database sequence. The ninth column provides a unique "Clone ID" for a cDNA clone related to each contig sequence.

5

10

15

20

25

30

Table 2 summarizes ATCC Deposits, Deposit dates, and ATCC designation numbers of deposits made with the ATCC in connection with the present application.

Table 3 indicates public ESTs, of which at least one, two, three, four, five, ten, fifteen or more of any one or more of these public EST sequences are optionally excluded from certain embodiments of the invention.

Table 4 lists residues comprising antigenic epitopes of antigenic epitope-bearing fragments present in most of the colon or colon cancer associated polynucleotides described in Table 1 as predicted by the inventors using the algorithm of Jameson and Wolf, (1988) Comp. Appl. Biosci. 4:181-186. The Jameson-Wolf antigenic analysis was performed using the computer program PROTEAN (Version 3.11 for the Power MacIntosh, DNASTAR, Inc., 1228 South Park Street Madison, WI). Colon and colon cancer associated polypeptides shown in Table 1 may possess one or more antigenic epitopes comprising residues described in Table 4. It will be appreciated that depending on the analytical criteria used to predict antigenic determinants, the exact address of the determinant may vary slightly. The residues and locations shown in Table 4 correspond to the amino acid sequences for most colon and colon cancer associated polypeptide sequence shown in the Sequence Listing.

Table 5 shows the cDNA libraries sequenced, and ATCC designation numbers and vector information relating to these cDNA libraries.

PCT/US00/05883

Definitions

5

10

15

20

25

30

The following definitions are provided to facilitate understanding of certain terms used throughout this specification.

In the present invention, "isolated" refers to material removed from its original environment (e.g., the natural environment if it is naturally occurring), and thus is altered "by the hand of man" from its natural state. For example, an isolated polynucleotide could be part of a vector or a composition of matter, or could be contained within a cell, and still be "isolated" because that vector, composition of matter, or particular cell is not the original environment of the polynucleotide. The term "isolated" does not refer to genomic or cDNA libraries, whole cell total or mRNA preparations, genomic DNA preparations (including those separated by electrophoresis and transferred onto blots), sheared whole cell genomic DNA preparations or other compositions where the art demonstrates no distinguishing features of the polynucleotide/sequences of the present invention.

As used herein, a "polynucleotide" refers to a molecule having a nucleic acid sequence contained in SEQ ID NO:X (as described in column 1 of Table 1) or the related cDNA clone (as described in column 9 of Table 1 and contained within a library deposited with the ATCC). For example, the polynucleotide can contain the nucleotide sequence of the full length cDNA sequence, including the 5' and 3' untranslated sequences, the coding region, as well as fragments, epitopes, domains, and variants of the nucleic acid sequence. Moreover, as used herein, a "polypeptide" refers to a molecule having an amino acid sequence encoded by a polynucleotide of the invention as broadly defined (obviously excluding poly-Phenylalanine or poly-Lysine peptide sequences which result from translation of a polyA tail of a sequence corresponding to a cDNA).

In the present invention, "SEQ ID NO:X" was often generated by overlapping sequences contained in multiple clones (contig analysis). A representative clone containing all or most of the sequence for SEQ ID NO:X is deposited at Human Genome Sciences. Inc. (HGS) in a catalogued and archived library. As shown in column 9 of Table 1, each clone is identified by a cDNA Clone ID. Each Clone ID is unique to an individual clone and the Clone ID is all the information needed to

5

10

15

20

25

30

6

PCT/US00/05883

retrieve a given clone from the HGS library. In addition to the individual cDNA clone deposits, most of the cDNA libraries from which the clones were derived were deposited at the American Type Culture Collection (hereinafter "ATCC"). Table 5 provides a list of the deposited cDNA libraries. One can use the Clone ID to determine the library source by reference to Tables 2 and 5. Table 5 lists the deposited cDNA libraries by name and links each library to an ATCC Deposit. Library names contain four characters, for example, "HTWE." The name of a cDNA clone ("Clone ID") isolated from that library begins with the same four characters, for example "HTWEP07". As mentioned below, Table 1 correlates the Clone ID names with SEQ ID NOs. Thus, starting with a SEQ ID NO, one can use Tables 1, 2 and 5 to determine the corresponding Clone ID. from which library it came and in which ATCC deposit the library is contained. Furthermore, it is possible to retrieve a given cDNA clone from the source library by techniques known in the art and described elsewhere herein. The ATCC is located at 10801 University Boulevard, Manassas, Virginia 20110-2209, USA. The ATCC deposits were made persuant to the terms of the Budapest Treaty on the international recognition of the deposit of microorganisms for the purposes of patent procedure.

A "polynucleotide" of the present invention also includes those polynucleotides capable of hybridizing, under stringent hybridization conditions, to sequences contained in SEQ ID NO:X, or the complement thereof (e.g., the complement of any one, two, three, four, or more of the polynucleotide fragments described herein), and/or sequences contained in the related cDNA clone within a library deposited with the ATCC. "Stringent hybridization conditions" refers to an overnight incubation at 42 degree C in a solution comprising 50% formamide, 5x SSC (750 mM NaCl, 75 mM trisodium citrate), 50 mM sodium phosphate (pH 7.6), 5x Denhardt's solution, 10% dextran sulfate, and 20 µg/ml denatured, sheared salmon sperm DNA, followed by washing the filters in 0.1x SSC at about 65 degree C.

Also included within "polynucleotides" of the present invention are nucleic acid molecules that hybridize to the polynucleotides of the present invention at lower stringency hybridization conditions. Changes in the stringency of hybridization and signal detection are primarily accomplished through the manipulation of formamide concentration (lower percentages of formamide result in lowered stringency); salt

conditions, or temperature. For example, lower stringency conditions include an overnight incubation at 37 degree C in a solution comprising 6X SSPE (20X SSPE = 3M NaCl; 0.2M NaH₂PO₄; 0.02M EDTA, pH 7.4), 0.5% SDS, 30% formamide. 100 ug/ml salmon sperm blocking DNA; followed by washes at 50 degree C with 1XSSPE, 0.1% SDS. In addition, to achieve even lower stringency, washes performed following stringent hybridization can be done at higher salt concentrations (e.g. 5X SSC).

5

10

15

20

25

30

Note that variations in the above conditions may be accomplished through the inclusion and/or substitution of alternate blocking reagents used to suppress background in hybridization experiments. Typical blocking reagents include Denhardt's reagent. BLOTTO, heparin, denatured salmon sperm DNA, and commercially available proprietary formulations. The inclusion of specific blocking reagents may require modification of the hybridization conditions described above, due to problems with compatibility.

Of course, a polynucleotide which hybridizes only to polyA+ sequences (such as any 3' terminal polyA+ tract of a cDNA shown in the sequence listing), or to a complementary stretch of T (or U) residues, would not be included in the definition of "polynucleotide," since such a polynucleotide would hybridize to any nucleic acid molecule containing a poly (A) stretch or the complement thereof (e.g., practically any double-stranded cDNA clone generated using oligo dT as a primer).

The polynucleotides of the present invention can be composed of any polyribonucleotide or polydeoxribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA. For example, polynucleotides can be composed of single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded or a mixture of single- and double-stranded regions. In addition, the polynucleotide can be composed of triple-stranded regions comprising RNA or DNA or both RNA and DNA. A polynucleotide may also contain one or more modified bases or DNA or RNA backbones modified for stability or for other reasons. "Modified" bases include, for example, tritylated bases and unusual bases such as inosine. A variety of

5

10

15

20

25

30

8

PCT/US00/05883

modifications can be made to DNA and RNA: thus, "polynucleotide" embraces chemically, enzymatically, or metabolically modified forms.

In specific embodiments, the polynucleotides of the invention are at least 15, at least 30, at least 50, at least 100, at least 125, at least 500, or at least 1000 continuous nucleotides but are less than or equal to 300 kb. 200 kb, 100 kb, 50 kb, 15 kb, 10 kb, 7.5kb, 5 kb, 2.5 kb, 2.0 kb, or 1 kb, in length. In a further embodiment, polynucleotides of the invention comprise a portion of the coding sequences, as disclosed herein, but do not comprise all or a portion of any intron. In another embodiment, the polynucleotides comprising coding sequences do not contain coding sequences of a genomic flanking gene (i.e., 5' or 3' to the gene of interest in the genome). In other embodiments, the polynucleotides of the invention do not contain the coding sequence of more than 1000, 500, 250, 100, 50, 25, 20, 15, 10, 5, 4, 3, 2, or 1 genomic flanking gene(s).

"SEQ ID NO:X" refers to a colon cancer antigen polynucleotide sequence described in Table 1. SEO ID NO:X is identified by an integer specified in column 1 of Table 1. The polypeptide sequence SEQ ID NO:Y is a translated open reading frame (ORF) encoded by polynucleotide SEQ ID NO:X. There are 773 colon cancer antigen polynucleotide sequences described in Table 1 and shown in the sequence listing (SEO ID NO:1 through SEO ID NO:773). Likewise there are 773 polypeptide sequences shown in the sequence listing, one polypeptide sequence for each of the polynucleotide sequences (SEQ ID NO:774 through SEQ ID NO:1546). The polynucleotide sequences are shown in the sequence listing immediately followed by all of the polypeptide sequences. Thus, a polypeptide sequence corresponding to polynucleotide sequence SEO ID NO:1 is the first polypeptide sequence shown in the sequence listing. The second polypeptide sequence corresponds to the polynucleotide sequence shown as SEQ ID NO:2, and so on. In otherwords, since there are 773 polynucleotide sequences, for any polynucleotide sequence SEO ID NO:X, a corresponding polypeptide SEQ ID NO:Y can be determined by the formula X + 773= Y. In addition, any of the unique "Sequence/Contig ID" defined in column two of Table 1. can be linked to the corresponding polypeptide SEO ID NO:Y by reference to Table 4.

5

10

15

20

25

30

WO 00/55351 PCT/US00/05883

The polypeptides of the present invention can be composed of amino acids joined to each other by peptide bonds or modified peptide bonds, i.e., peptide isosteres, and may contain amino acids other than the 20 gene-encoded amino acids. The polypeptides may be modified by either natural processes, such as posttranslational processing, or by chemical modification techniques which are well known in the art. Such modifications are well described in basic texts and in more detailed monographs, as well as in a voluminous research literature. Modifications can occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. It will be appreciated that the same type of modification may be present in the same or varying degrees at several sites in a given polypeptide. Also, a given polypeptide may contain many types of Polypeptides may be branched, for example, as a result of modifications. ubiquitination, and they may be cyclic, with or without branching. Cyclic, branched, and branched cyclic polypeptides may result from posttranslation natural processes or may be made by synthetic methods. Modifications include acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphotidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cysteine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, pegylation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination. (See, for instance, PROTEINS - STRUCTURE AND MOLECULAR PROPERTIES, 2nd Ed., T. E. Creighton, W. H. Freeman and Company, New York (1993); POSTTRANSLATIONAL COVALENT MODIFICATION OF PROTEINS, B. C. Johnson, Ed., Academic Press, New York, pgs. 1-12 (1983); Seifter et al., Meth Enzymol 182:626-646 (1990); Rattan et al., Ann NY Acad Sci 663:48-62 (1992).)

The colon and colon cancer polypeptides of the invention can be prepared in any suitable manner. Such polypeptides include isolated naturally occurring polypeptides, recombinantly produced polypeptides, synthetically produced

5

10

15

20

25

30

10

PCT/US00/05883

polypeptides, or polypeptides produced by a combination of these methods. Means for preparing such polypeptides are well understood in the art.

The polypeptides may be in the form of the secreted protein, including the mature form, or may be a part of a larger protein, such as a fusion protein (see below). It is often advantageous to include an additional amino acid sequence which contains secretory or leader sequences, pro-sequences, sequences which aid in purification, such as multiple histidine residues, or an additional sequence for stability during recombinant production.

The colon and colon cancer polypeptides of the present invention are preferably provided in an isolated form, and preferably are substantially purified. A recombinantly produced version of a polypeptide, including the secreted polypeptide, can be substantially purified using techniques described herein or otherwise known in the art, such as, for example, by the one-step method described in Smith and Johnson, Gene 67:31-40 (1988). Polypeptides of the invention also can be purified from natural, synthetic or recombinant sources using techniques described herein or otherwise known in the art, such as, for example, antibodies of the invention raised against the polypeptides of the present invention in methods which are well known in the art.

By a polypeptide demonstrating a "functional activity" is meant, a polypeptide capable of displaying one or more known functional activities associated with a full-length (complete) protein of the invention. Such functional activities include, but are not limited to, biological activity, antigenicity [ability to bind (or compete with a polypeptide for binding) to an anti-polypeptide antibody], immunogenicity (ability to generate antibody which binds to a specific polypeptide of the invention), ability to form multimers with polypeptides of the invention, and ability to bind to a receptor or ligand for a polypeptide.

"A polypeptide having functional activity" refers to polypeptides exhibiting activity similar, but not necessarily identical to, an activity of a polypeptide of the present invention, including mature forms, as measured in a particular assay, such as, for example, a biological assay, with or without dose dependency. In the case where dose dependency does exist, it need not be identical to that of the polypeptide, but rather substantially similar to the dose-dependence in a given activity as compared to

5

10

15

20

25

30

11

PCT/US00/05883

the polypeptide of the present invention (i.e., the candidate polypeptide will exhibit greater activity or not more than about 25-fold less and, preferably, not more than about tenfold less activity, and most preferably, not more than about three-fold less activity relative to the polypeptide of the present invention).

The functional activity of the colon cancer antigen polypeptides, and fragments. variants derivatives. and analogs thereof, can be assayed by various methods.

For example, in one embodiment where one is assaying for the ability to bind or compete with full-length polypeptide of the present invention for binding to an antibody to the full length polypeptide antibody, various immunoassays known in the art can be used, including but not limited to, competitive and non-competitive assav systems using techniques such as radioimmunoassays, ELISA (enzyme linked immunosorbent assay), "sandwich" immunoassays, immunoradiometric assays, gel diffusion precipitation reactions, immunodiffusion assays, in situ immunoassays (using colloidal gold, enzyme or radioisotope labels, for example), western blots, precipitation reactions, agglutination assays (e.g., gel agglutination assays, hemagglutination assays), complement fixation assays, immunofluorescence assays, protein A assays, and immunoelectrophoresis assays, etc. In one embodiment. antibody binding is detected by detecting a label on the primary antibody. In another embodiment, the primary antibody is detected by detecting binding of a secondary antibody or reagent to the primary antibody. In a further embodiment, the secondary antibody is labeled. Many means are known in the art for detecting binding in an immunoassay and are within the scope of the present invention.

In another embodiment, where a ligand is identified, or the ability of a polypeptide fragment, variant or derivative of the invention to multimerize is being evaluated, binding can be assayed, e.g., by means well-known in the art, such as, for example, reducing and non-reducing gel chromatography, protein affinity chromatography, and affinity blotting. See generally, Phizicky, E., et al., Microbiol. Rev. 59:94-123 (1995). In another embodiment, physiological correlates polypeptide of the present invention binding to its substrates (signal transduction) can be assaved.

In addition, assays described herein (see Examples) and otherwise known in the art may routinely be applied to measure the ability of polypeptides of the present invention and fragments, variants derivatives and analogs thereof to elicit polypeptide related biological activity (either in vitro or in vivo). Other methods will be known to the skilled artisan and are within the scope of the invention.

5

10

15

Colon and Colon Cancer Associated Polynucleotides and Polypeptides of the Invention

It has been discovered herein that the polynucleotides described in Table 1 are expressed at significantly enhanced levels in human colon and/or colon cancer tissues. Accordingly, such polynucleotides, polypeptides encoded by such polynucleotides, and antibodies specific for such polypeptides find use in the prediction, diagnosis, prevention and treatment of colon related disorders, including colon cancer as more fully described below.

Table 1 summarizes some of the polynucleotides encompassed by the invention (including contig sequences (SEQ ID NO:X) and the related cDNA clones) and further summarizes certain characteristics of these colon and/or colon cancer associated polynucleotides and the polypeptides encoded thereby.

۰	_
	٥
•	Ξ
	≂
ľ	_

	Clone ID		HGBA183	HUKDY21	HCASG85			HCEGY28				HSDFA48					HMQBR31					HOSBO86	
	%	Identity Similarity			98			86				. 86					81					001	
	%	Identity :			73			26				86					. 8					100	
HGS Nucleotide	End		304	292	440			635				393					538					331	
HGS Nu	Start		7	7	3			33				34					206					C1	
	Overlap				gi 415381			gnl PID d1030000				gij3170200					gi 1141751					gn PID e332729	
	Gene Name				Immunoglobulin kappa light chain	variable region 1.25 [Homo sapiens] >pir S41816 S41816 Ig kappa chain V	region L25 - human Length = 119	(AB008790) Grb7V protein [Homo	sapiens] >sp[D1030000[D1030000	ORB/V FRO LEIN: /gll1320333 OR0/ profein [Homo saniens] {\$[JB 130-343}	Length = 447	(AF039700) antigen NY-CO-38 [Homo	sapiens] >splG3170200lG3170200	ANTIGEN NY-CO-38. >gi[3170198	(AF039699) antigen NY-CO-37 [Homo	sapiens] {SUB 1-403} Length = 652	MDA-7 [Homo sapiens]	>sp Q13007 MDA7_HUMAN MDA-7	PROTEIN PRECURSOR (MELANOMA	DIFFERENTIATION ASSOCIATED	PROTEIN 7). Length = 206	disintegrin-protease [Homo sapiens]	PROTEASE. Length = 470
Sequence/	Contig 1D		500802	531091	553147			258860				561730					585938					587785	
	Sed ID No.		_	CI	3			4				\$					9					7	

100 HLDQU56	HMSHB03	HCRME22	HCFBO73	HJMBUIS	94 HSYAM68	100 HCDBX83	HHEMNII	HCDCH84	HOHDDS	93 HAGGX21	HCE5C73 HISAN54
100					94	001				95	
376	260	559	194	249	1140	425	81118	369	762	937	530 385
V	~	254	63	601	238	m	894	193	430	203	207
gi 296636					gi 1857331	gni PID e321513				gn PID e1293754	\- -
Human apoC-II gene for preproapolipoprotein C-II [Homo sapiens] >gi 757915 apoCII protein [Homo sapiens] >gi 178836 apolipoprotein C-II [Homo sapiens] >pir A24238 LPHUC2 apolipoprotein C-II precursor - human					KHS1 [Homo sapiens]	protein kinase Dyrk2 [Homo sapiens] >splQ92630 Q92630 PROTEIN KINASE DYRK2 (PROTEIN KINASE. DYRK2). >gn PID e280618 Dyrk2 [Homo sapiens] {SUB 320-528} [Length = 528				(AJ003061) most expressed alternative spliced form [Homo sapiens] >splO60852 O60852 PROTEIN ENCODED BY SACCHAROMYCES CEREVISIAE SPC98 HOMOLOGUE. Length = 907	
588916	613825	639090	651644	659544	659739	661057	661313	666316	669229	670471	676611 691240
∞	6	01	=	12	13	7	15	91	17	<u>8</u>	19 20

HGCMV09	HWLJX38	HCRND05		HAPTL.75	HCEOQ15	HWLFA47		HUSXP30		HBJIG25		HCRMQ71	HSDZB27	HKABV36	HSRDF23	HWHGD94	HPMFL67	HCHCJ20	HPT-11.69
08		88				64		95		100			16	100					
80		75				62		92		001			87	001					
618	478	534		657	411	886		444		801		289	502	1083	777	814	1396	959	357
35	344	_		_	_	530		_		160		137	C)	_	7	. ~1	1229	414	_
gi 338678		gi 3126975				gi 3818569		gi 3493462		gnl P1D d1034356			gnlP1D c1350748	gi 3342000					
26-kDa cell surface protein TAPA-1 [Homo sapiens] >pirlA35649 A35649 cell surface protein TAPA-1 - human >sp P18582 CD81_HUMAN CD81 ANTIGEN (26 KD CELL SURFACE PROTEIN TAPA-1). Length = 236		(AF062476) retinoic acid-responsive protein; STRA6 [Mus musculus]	>splO70491 O70491 RETINOIC ACID- RESPONSIVE PROTEIN. Length = 670)		(AF076856) small espin [Rattus	norvegicus] >sp G3818569 G3818569 SMALL ESPIN. Length = 253	muskelin [Mus musculus]	Length = 735	(AB015318) gamma2-adaptin [Homo	sapiens] >splO/3843 O/3843 GAMMA2-ADAPTIN. Length = 785		similar to ADP-ribosylation factor;	(AF054179) II beta 58 homolog [Homo sapiens] >sp[075436[075436 II BETA 58 HOMOLOG Lemah = 327					
702977	709517	714730		714834	715016	719584		724637		728392		738716	739056	739143	742329	742557	745481	746035	753731
2	22	23		24	25	26		27		28		56	30	31	32	33	34	35	36

37	754383			m m /	434			HBGMG69 HMEJZ19
	086/5/			365	622			HETIS94
	764818			m	1700			HCE4A59
	765140			~	200			HRODG74
	766893			178	414			HCEOS64
	771338	(AF034745) LNXp80 [Mus musculus] >sp O70263 O70263 LIGAND OF NUMB-PROTEIN X (LNXP80). Length = 728	gi 3041879	-	189	16	96	HCQDR53
44	771412	.		2	109			HCHAG61
		(AF011794) cell cycle progression restoration 8 protein [Homo sapiens] >sp[O14712[O14712 CELL CYCLE PROGRESSION RESTORATION 8	gi 2352906	m	257	001	001	HMVCR68
		PROTEIN. Length = 375						
9‡				36	236			HE2BE05
	773173			514	693			HTEPE82
	780154			다 다	820			HCEZW82
49				1176	1352			HPLBS64
		similar to G9a gene. [Homo sapiens] >sp[Q15047]Q15047 MRNA (KIAA0067) FOR ORF (RELATED TO G9A GENE), COMPLETE CDS (KIAA0067). Length = 1291	gn PID d1007261	134	658	98	98	HAMFLSI
				8901	1337			HDLBC18
	783160	(AF026977) microsomal glutathione Stransferase 3 [Homo sapiens] >spl014880 014880 MICROSOMAL GLUTATHIONE S-TRANSFERASE 3. Length = 152	gi[2583081	25	492	100	001	НЕ9РС68
53	783506	ì		46	825			HODCWS6

54	784446			19	282			HBJFL85
55	784832			134	751			HCGMI84
56	786813			114	347			HE20155
57	792139	(AB002086) p47 [Rattus norvegicus] >gnl[PID]e294068 XY40 protein [Rattus norvegicus] >sp[O35987[O35987 P47, COMPLETE CDS. Length = 370	gnl P1D d1022509	32	334	83	85	H6EEC65
28	793987	,		100	564			HCIAE18
89	805715			513	1226			HDPKI64
09	8				438			HCEDF72
		steroidogenic acute regulatory protein [Mus musculus] >pir A55455 A55455 steroidogenic acute regulatory protein precursor, mitochondrial - mouse Length = 284	gi 1236243	L 1	718	28	50	HWBEX78
62		(AF028722) fetal globin inducing factor [Mus musculus] >splG4103857jG4103857 FETAL GLOBIN INDUCING FACTOR. Length = 238	gi 4103857	36	497	87	94	HDTBD43
63	826518	RNase 4 [Homo sapiens] >pir [52489 [52489 ribonuclease 4 (EC 3.1) precursor - human Length = 147	gnł P1D d1007727	_	231	001	100	HLQCQ62
65 65 67	826704 827720 828102 828180	(AB013456) aquaporin 8 [Homo sapiens] >gnl[PID]d1035202 (AB013456) aquaporin 8 [Homo sapiens] >sp[D1035202 D1035202 AQUAPORIN 8. Length = 261	gnl P1D d1035202	475 789 106 20	726 1076 297 883	83	€	HCQBI18 HFICY86 HSRFC02 HWLFM26

HOHAD26	HLHCO24	HFOYL30	HSVAKSI	HYAAH90	HIBCN46	нмсниз
100	001	001		29	95	39
100	001	66		53	92	30
650	268	199	411	475	205	1097
m	7	C1	163	134	C1	m
gi 3694986	gnl P1D e218263	gnl P1D e254454		gn[PID]e1344082	gi 1145689	gi 1814277
(AF093821) RRM RNA hinding protein GRY-RBP [Mus musculus] >sp[O88991 Q88991 RRM RNA BINDING PROTEIN GRY-RBP. Length = 625	protein-tyrosine-phosphatase [Homo sapiens] >gnl PID d1032930 (AB013601) DUSP6 [Homo sapiens] >gnl PID d1035350 (AB013382) DUSP6 [Homo sapiens] >gnl PID d1035350 (AB01363930 (AB013601) DUSP6 [Homo sapiens] >splQ16828 DUS6_HUMAN DUAL SPECIFICITY PROTEIN	RNA helicase [Homo supiens] >pir S71758 S71758 DEAD box protein MrDb, Myc-regulated - human >sp Q92732 Q92732 RNA HELICASE. Length = 610	•	similar to Glyoxalase [Caenorhabditis elegans] Length = 281	UbcH5B [Homo supiens] >gi]595668 ubiquitin conjugating enzyme [Rattus norvegicus] >gi]1480742 ubiquitin conjugating enzyme [Mus musculus] >pir[S53359]S53359 ubiquitin conjugating enzyme (E217kB) - rat Length = 147	A33 antigen precursor [Homo sapiens] >sp Q99795 A33_HUMAN CELL SURFACE A33 ANTIGEN
828386	828658		829572	830138	830208	830248
89	69	70	7.1	72	73	74

PRECURSOR. Length = 319

HWLFO28	HWLFE46	HWLEL81	HWHOR45	HWLE147	HDPVF62	HWBCR84
100	16	92		88		
001	16	63		29		
647	1488	959	116	1022	156	627
ю	385	m	"	י ה	_	526
gniP1D d1014081	gi 2880033	gi 4009460		pir A45153 A4515 3		
Similar to D.melanogaster parallel sister chromatids protein [Homo sapiens] >splQ92549 Q92549 MYELOBLAST KIAA0261 (FRAGMENT). Length = 1287	interferon-related putative protein [Homo sapiens] >sp[Q12894[Q12894] HYPOTHETICAL 48.0 KD PROTEIN. >gi[1209022 interferon-related putative protein [Homo sapiens] {SUB 2-442} founth = 442	(AF039401) calcium-dependent chloride channel-1 [Homo sapiens] >sp[G4009460[G4009460 CALCIUM-DEPENDENT CHLORIDE CHANNEL-1. Lenvth = 914		inorganic pyrophosphatase (EC 3.6.1.1) - pir A45153 A4515 bovine >sp P37980 IPYR_BOVIN 3 INORGANIC PYROPHOSPHATASE (EC 3.6.1.1) (PYROPHOSPHATE PHOSPHO- IIYDROLASE) (PPASE). Length = 289)	
830275	830286	830347		830364	830394	830398
75	96	77	78	, ,	80	81

82	830412	SDF2 [Homo sapiens] >pirlJC5106[JC5106 stromal cell-derived factor 2 - human >splQ99470[Q99470 SDF2. Length = 211	gnl P1D d1009953	233	928	16	92	нwннq <i>s7</i>
83	830436	(AJ005821) X-like 1 protein [Homo sapiens] >splE1291794[E1291794 X-LIKE 1 PROTEIN, Length = 3027	gnl PID e1291794	83	523	99	78	HWABR83
84	830464	CLP36 [Rattus norvegicus] >pir JC4385 JC4385 LIM protein - rat >sp P52944 CL36_RAT_LIM PROTEIN CLP36_Length = 327	gi 1020151	C1	289	72	≅	HUSGB72
85	830471	0		95	229			HUSIKSI
98	830477	(AF011794) cell cycle progression restoration 8 protein [Homo sapiens] >sp[O14712[O14712 CELL CYCLE PROGRESSION RESTORATION 8 PROTEIN, Length = 375	gi 2352906	911	2389	95	96	HULAT84
87	830500	ORF YGR036c [Saccharomyccs cerevisiae] >pir S64327 S64327 probable membrane protein YGR036c - yeast (Saccharomyces cerevisiae) Length = 239	gnl PID e243385	185	736	38	54	HJPCP29
88	830509	(AL021813) phenylalanyl-trna synthetase gnl PID c1250585 alpha chain [Schizosaccharomyces pombe] >sp O42849 O42849 PHENYLALANYL-TRNA SYNTHETASE ALPHA CHAIN. Length	gni PID c1250585	C1	1081	40	63	HUFAU68

68	830528	hepatoma-derived growth factor [Mus musculus] >pirlJC5662 JC5662	dbj D63850_1	38	1881	78	87	HUFBF32
		hepatoma-derived growth factor-related protein 2 - mouse >spl035540 035540 HEPATOMA-DERIVED GROWTH FACTOR, RELATED PROTEIN 2.1 counts = 650						
06	830542	mitochondrial 3-oxoacyl-CoA thiolase [Homo sapiens] >pir S43440 S43440 3-oxoacyl-CoA thiolase - human Length = 397	gnl PID d1004316	324	1637	92	92	HTTD045
16	830564			702	1343			HTPR179
92	830611	IgM heavy chain VIII region precursor Homo sapiens] Length = 146	gi 2344934	! -	495	78	62	HTJMB28
93 94	830618			655	915			HDTM121
	830630	mitochondrial benzodiazepine receptor [Homo sapiens] >pirl 38724 138724 mitochondrial benzodiazepine receptor - human >gi 3411163 (AF075589) peripheral-type benzodiazepine receptor [Homo sapiens] {SUB 27-169} Length = 150	gi 529946	4	259	001	001	HTGFS43
96	830654	RNA-binding protein {Saccharomyces cerevisiae} Length = 497	gi 295631	C 1	1687	40	51	HSYBQ96
97	830660 830661			122	694			HSYDW13
•	830704	pp21 [Homo sapiens] >pir 153785 153785 gene pp21 protein - human >sp Q15170 Q15170 (PP21). Length = 157	gi 521207	} -	609	51	76	HSUSF13
901	830765			39	236			HSKESII

HSPAX18	HSIFY77	ННРОО94	HAQND53	HHEAA48	HPJCT75	нрівн48	HPHAA84	HONAE45
001		94				66	87	86
66		94				66	87	86
718	828	066	754	898	525	1193	059	019
	595	-	449	464		٣	06	722
gi 903982		gi 3335102				gi 687237	gi 1747521	gi 1432177
methionine aminopeptidase [Homo sapiens] >gi[687243 eIF-2-associated p67 homolog [Homo sapiens] >pir 552112 DPHUM2 methionyl aminopeptidase (EC 3.4.11.18) 2 - human >sp P50579 AMP2_HUMAN METHIONINE AMINOPEPTIDASE 2 (EC 3.4.11.18) (METAP 2) (PEPTIDASE M 2)		(AF039918) CD39L4 [Homo sapiens] >sp O75356 O75356 CD39L4. Length = 428				tumor necrosis factor type 1 receptor associated protein [Homo sapiens] >pir A55877 A55877 tumor necrosis factor type 1 receptor associated protein TRAP-1 - human	microsonnal glutathione S-transferase 2 [Homo sapiens] >sp Q99735 GST2_IIUMAN MICROSOMAL GLUTATHIONE S- TRANSFERASE II (EC 2.5.1.18) (MICROSOMAL GST- II) Length = 147	peroxisome proliferator activated receptor gamma 2 [Homo sapiens] > gi 1711117 ligand activated transcription factor PPARgamma2 [Homo sapiens]
830778	830784	830800	830821	830849	830903	830913	830920	830938
101	102	103	104	105	901	107	801	601

HCESG53	ноевv08	HOBAE30	HNTAT24	HNTCW73	HNTBD04	HMWBR70	HMWCV70	HMWFH12 HMUAR55
86	73		94				93	
95	53		93				16	
289	1188	789	1921	1106	821	579	277	1023
47	310	340	674	т	٣	400	CI	868 36
gi 55819	gi 2315828		gi 3644048				gi 179312	
beta COP [Rattus norvegicus] >pir S13520 S13520 beta-COP protein - rat >sp P23514 COPtB_RAT COATOMER BETA SUBUNIT (BETA- COAT PROTEIN) (BETA-COP). >pir S13636 S13636 110K protein - rabbit {SUB 451-500} Length = 953	(AF016687) similar to alpha-actinin [Caenorhabditis elegans] >spl016785 016785 T21D12.4 PROTEIN. Length = 375		(AF091395) Trio isoform [Homo sapiens] >sp O75962 O75962 TR1O ISOFORM. Lenxth = 3038)			cell surface glycoprotein [Homo sapiens] >gi[567110 [Human CD79b/lg beta/B29 gene, complete coding sequence.], gene product [Homo sapiens] >bbs 122035 membrane immunoglobulin beta chain, lg-beta=Ag receptor complex [human, B cells, Peptide, 229 aa] [Homo	
		831026	831055	831057	831062	831117		831125
011	Ξ	112	114	115	911	117	<u>∞</u> <u>–</u>	119

HMVAIS7	HMVAA24	HCRPE60	HMELQ02 HTAAN07 HAKBB67 HCFLL08	HAGDZ30
16	001	001		&
06	100	001		83
875	1110	1907	378 1267 427 638 443	1670
Ξ	664	m	256 884 152 420 84	31
gi 3115346	gi 2605780	gi 31283		gi 182735
(AC004668) similar to murine cell cycle regulator MIDA1; similar to A57591 (PID:g2137417) [Homo sapiens] >splO60414 O60414 WUGSC:H_RG276003.1A PROTEIN (FRAGMENT). Length = 635	(AF030109) regulator of G protein signaling 12 [Homo sapiens] >gi[2766633 (AF030152) regulator of G protein signaling 12 [Homo sapiens] Length = 799	ezrin (AA 1-586) [Homo sapiens] >pir A34400 A34400 ezrin - human >sp P15311 EZR1_HUMAN EZRIN (P81) (CYTOVILLIN) (VILLIN-2). {SUB 2-586} >gi 340217 cytovillin 2 [Homo sapiens] {SUB 12-586} Length = 586	·	c-fos protein [Homo sapiens] >gi[29004 c-fos gene product [Homo sapiens] >gi[4063509 (AF111167) cfos [Homo sapiens] >pir[A01342]TVHUF1 transforming protein fos - human >sp P01100 FOS_HUMAN P55-C-FOS PROTO-ONCOGENE PROTEIN (G0S7 PROTEIN). >sp G4063509 G406
831152	831157	831160	831193 831197 831217 831239 831248	
121	122	123	124 125 126 127 128	130

HLADA28	HWADP47	HWLLY45	HCQDM23	HKACO81	HKABKSS
	46	001	96	09	
	46	001		32	
344	1744	1586	727	482	1319
- 8	221	717	C1	126	807
	gi 181360	1619877	pir A49963 A4393 2	gi 554574	
	cytochrome P450j [Homo sapiens] >gi[181356 cytochrome P450HE1 [Homo sapiens] >pir[A31949]A31949 cytochrome P450 2E1 - human >spiP05181 CPE1HUMAN CYTOCHROME P450 2E1 (ECL14.14.1) (CYPHE1) (P450-1). >gn P1D d1001366 cytochrome P450HE1 [Homo sapiens]	hydroxymethylglutaryl-CoA synthase [Homo sapiens] >gi[2463646 3-hydroxy-3-methylglutaryl CoA synthase [Homo sapiens] >pir[S71623]S71623 hydroxymethylglutaryl-CoA synthase (EC 4.1.3.5) precursor, mitochondrial -human >spiP54868 HMCM_HUMAN HYDROXYMETHYLGLU	mucin 2 precursor, intestinal - hunian (fragments) >gi 186396 mucin [Homo sapiens] {SUB 626-1895} >gi 186398 MUC2 [Homo sapiens] {SUB 2037-3020} >gi 188874 intestinal mucin [Homo sapiens] {SUB 1916-2193} >gi 188615 mucin-like protein [Homo sapiens] {SUB 23	calcium-modulated protein \$100-beta [artificial sequence] >pir[A91254]BCBOH3 \$-100 protein beta chain - bovine {\$118 2-92} Length = 92	
831371		831387	831410	831448	831450
131	132	. 33	134	135	136

HJMBH59	HKACE68	HWHPX60 HISES08	HICAF79	HCRPH87	HDTIT'02	HDTLJ87
	68		00	69	97	
	68		001	12	 8	
138	3765	1746 616	965	006	572	625
_	40	1231 2	m		102	395
	gi 3089368		gi 182177	gnilPID d1013909	gi 207250	
	(AF020043) chromosome-associated polypeptide [Homo sapiens] >splO60464[O60464 CHROMOSOME-ASSOCIATED POL YPEPTIDE (BAMACAN PROTEIN). >gn PID e1285055 (AJ005015) bamacan protein [Homo sapiens] {SUB 827-1217} Length = 1217		excision repair protein [Homo sapiens] >gi 1821.74 excision repair protein [Homo sapiens] >gi 2583146 (AF001925) excision repair protein [Homo sapiens] >pir A32875 A24781 excision repair protein - human >sp P07992 ERC1_HUMAN DNA EXCISION REPAIR PROTEIN ERC	similar to yeast adenylate cyclase (S56776) [Homo sapiens] >splQ92627 Q92627 MYELOBLAST KIAA0231 (FRAGMENT). Length = 476	growth and transformation dependent protein [Rattus norvegicus] >pir[A26882]A26882 pl1.2 hypothetical protein - rat (fragment) >sp[Q63571]Q63571 RAT GROWTH AND TRANSFORMATION-DEPENDENT (FRAGMENT). Length = 175	
831472	831473	831474 831494		831533	831539	831556
137	138	139 140		142	143	144

HHECUOI	ННЕ DO14	ННЕГВ46	HISAU33	HGBI1Z56
	66	84	100	66
	66	87	96	66
<i>LL</i> 9	802	1154	104	069
117	33	120	m	46
	gi 348243	gi 182067	gi 854124	gn P1D c222211
	protein serine/threonine kinase [Homo sapiens] >gi 468789 CDK activating kinase [Homo sapiens] >gi 485909 MO15/CDK-activating kinase (CAK) [Homo sapiens] >gn PID e257806 Cdk-activating kinase [Homo sapiens] >pir A54820 A54820 CDK-activating protein kinas	translational initiation factor beta subunit [Homo sapiens] >pir[A31226]A31226 translation initiation factor eIF-2 beta chain - human >pir[S13147]S13147 protein synthesis factor - rabbit >spp[P20042]IF2B_HUMAN_EUKARYOTIC_TRANSLATION INITIATION FACTOR 2 BET	Human giant larvae homologue [Homo sapiens] >pir S55474 S55474 Human giant larvae homolog - human >sp Q14521 Q14521 GIANT LARVAE HOMOLOGUE. Length = 1015	alpha 1-acid glycoprotein [Homo sapiens] >gi[1340138 alpha 1-acid glycoprotein [Homo sapiens] {SUB 39-86} Length = 201
831594		831608	831613	831622
145	146	147	148	149

HGBAX75	HGBCC19	HTJNI73	HFVHF47	HFIUT25	HFCA179
00 -		06	54	00-	
001		88	32	8 6	
1173	226	927	662	410	573
00 -	CI	172	E.	96	313
gi 3150035		gi 164905	gi 1465826	gij3712671	
aldose reductase-like peptide [Homo sapiens] >sp[O60218[O60218 ALDOSE REDUCTASE-LIKE PEPTIDE (ALDOSE REDUCTASE-RELATED PROTEIN). >gi[3098514 (Al:044961) aldose reductase-related protein [Homo sapiens] {SUB 232-316; Length = 316		lambda-crystallin precursor [Oryctolagus cuniculus] >pir A31992 A31992 lambda-crystallin - rabbit >sp P14755 CRYL_RABIT LAMBDA-CRYSTALLIN. {SUB 2-320} Length = 320	weak similarity to TPR domains [Caenorhabditis elegans] >sp[Q23049]Q23049 SIMILARITY TO TPR DOMAINS. Length = 458	vascular endothclial growth factor [Homo sapiens] >sp[Q16889]Q16889 VASCULAR ENDOTHELIAL GROWTH FACTOR (FRAGMENT). >pir[A41551]A41551 vascular endothelial growth factor 206 precursor - human {SUB 23-254} >bbs[85194 vascular endothelial growth factor; VEGF	
	831632				831738
150	151	152	153	154	155

HFEBT03	HWME267	HETEH76	HELGH58	HE9RY54	HFIAUS9	HE9QD17	HE90Y91	HEAHA84	HE81'V13	HE80'F93	HERCI 14	HDTDX05
7.7	92				93				66	84		
77	92				93				86	69		
974	924	510	1003	1158	1541	1341	765	793	2307	776	1671	2121
981	-	373	7	892	009	1015	520	83	52	465		
gi 1399745	gnl PID c1288198				gnl PID e250094				gni PID d1006382	gntp1De1347870		
myelodysplasia/myeloid leukemia factor 2 [Homo sapiens] >gi[3387897 (AF070539) myelodysplasia/myeloid leukemia factor 2 [Homo sapiens] >sp[Q15773[Q15773] MYELODYSPLASIA/MYELOID LEUKEMIA FACTOR 2. Length = 248	multidrug resistance protein 3 [Homo sapiens] >gnl PID e1288198 multidrug resistance protein 3 [Homo sapiens] >sp O60922 O60922 MULTIDRUG RESISTANCE PROTEIN 3. Length = 1526				nuclear protein SA-2 [Homo sapiens] >sp O00540 O00540 NUCLEAR PROTEIN SA-2. Length = 1162)			isoleucyl-tRNA synthetase [Homo sapiens] >pir 159314 159314 isoleucine-tRNA ligase (EC 6.1.1.5) - human Length = 1266	Similarity to S. Pombe BEMI/BUD5	odpicaco,	
831741	831754	831760	831780	831796	831800	831807	831812	831813	831830	831860	831872	831896
156	157	158	159	160	191	162	163	164	165	991	167	891

HSYBO86	HE8TX12 HAPOS51	HWLHA60	HDFB006	ווארוא	HCWKS85	HASAB14	HCRNM09	HCRMU71	HTXOUS6	НВК DW03
77		001	ç	70						16
7.7		001	8	70						06
778	1109	786	761	440	1137	1014	617	220	161	1290
C1	3 48	901	555	4	877	751	289	95	81	622
gi 3126874		gi 79772	Unlibi Die 234080	Built 12/524000						gi 2052522
(AF061795) dynamin-like protein Dymple isoform [Homo sapiens] >sp O60709 O60709 DYNAMIN-LIKE PROTEIN DYMPLE ISOFORM. Length = 699		carbonic anhydrase II [Homo sapiens] >gi[179780 carbonic anhydrase II [Homo sapiens] >gi[179795 carbonic anhydrase II [Homo sapiens] >gi[29587 carbonic anhydrase II (AA 1-260) [Homo sapiens]	himan nhasnhatvrasine nhasnhatase	kappa [Homo sapiens] Length = 1439						Ca2+ ATPase of fast-twitch skeletal muscle sacroplasmic reticulum, adult isoform [Homo sapiens] >sp[O14983 O14983 CA2+ ATPASE OF FAST-TWITCH SKELETAL MUSCLE SACROPLASMIC RETICULUM, ADULT ISOFORM. Length = 1001
	831949		831975	00000	832047	832078	832100	832104	832268	
691	170	172	173	-	175	176	177	178	179	08

HBKDN33	HBIAX17	HBBBE52 HDPOA93	HATCO72	HARAG42	HAMGD53	HAGHC54
77	001		96	06	6	
65	100		96	06	64	
1237	719	408	746	316	846	297
7	270	— m	m	7	136	202
gi 608694	gi 897917		gnl PID e303801	gi 2935440	splG249613lG2496 136 13	
acetyl-CoA synthetase [Drosophila melanogaster] >pir[S52154[S52154] acetyl-CoA synthetase - fruit fly (Drosophila melanogaster) >sp[Q24226[Q24226 ACETYL-COENZYME A SYNTHETASE (EC 6.2.1.1) (ACETATE-COA LIGASE) (ACYL-ACTIVATING ENZYME). Length = 581	<pre>11kD protein [Homo sapiens] Length = 111</pre>		sialidase [Homo sapiens] >gi 2773339 (AF040958) lysosomal neuraminidase precursor [Homo sapiens] >gi 4099141 lysosomal sialidase [Homo sapiens] >sp Q99519 Q99519 SIALIDASE PRECURSOR. >sp G4099141 G4099141 LYSOSOMAL SIALIDASE	PRECURSOR (EC 3.2.1.18). Lengt (AF048700) gastrointestinal peptide [Homo sapiens] >sp[060575 060575 GASTROINTESTINAL PEPTIDE. Length = 86	APO-1 ANTIGEN, FAS ANTIGEN. Length = 335	
832279	832317	832354 832364		832385		832485
 	182	183	185	981	187	188

	832494	Ku protein subunit [Homo sapiens] >gil178650 p70 autoantigen [Homo sapiens] >bil339667 thyroid autoantigen [Homo sapiens] >bbs 107206 Ku autoantigen p70 subunit [human, Peptide, 609 aa] [Homo sapiens] >pir[A30299]A30894 70K thyroid autoantigen supram >sn	gi 307095	80	8161	06	06	HAIBY70
·	832512	Similar to Human C219-reactive peptide g (L34688) [Homo sapiens] >splQ92580[Q92580 MYELOBLAST KIA0268 (FRAGMENT). >gi[511639 C219-reactive peptide [Homo sapiens] {SUB 592-727} Length = 1193	gni PID d1014138	٣	1058	87	87	нортт 16
		integrin alpha6 subunit [Homo sapiens] Length = 1067	gi 33942	C1	1660	96	96	HCRPH70
	832526	nuclear factor RIP140 [Homo sapiens] >pir S57348 S57348 nuclear factor RIP140 - human Length = 1158	gi 940539	34	693	95	95	HADCX04
	832575	protein tyrosine kinase [Homo sapiens] >pir A55922 A55922 tyrosine kinase A6 - human >sp Q12792 Q12792 PROTEIN TYROSINE KINASE. Length = 350	gi 451482	49	1203	66	66	H2LAJ21
	832576	BTG1 gene product [Homo sapiens] >gi 293306 BTG1 [Mus musculus] >gi 50188 btg1 [Mus musculus] >pi 501847 S20947 BTG1 protein - human >pir 148272 148272 btg1 protein - mouse >sp P31607 BTG1 HUMAN BTG1 PROTEIN (B-CELL TRANSLOCATION GENE 1 PROTEIN). Length	gi 29509	388	1050	100	001	HKGAJ67

H2LADSI	HCRMZ25 HKAIL83	HRADC46	HHENV68	HWLEQ41	HHGDE66	нЕ8QЕ56
82		- 8		76	100	98
88		77		69	86	88
637	924 542	391	853	744	209	781
7	253	C 1	224	-	C1	C1
gi 511450		gi 37725		gnl PID e229590	gi 4140394	gi 3885470
mitochondrial ATP synthase subunit 9 precursor [Homo sapiens] >pir 138612 138612 ATP synthase chain 9 precursor, mitochondrial - human >sp P48201 AT93_HUMAN ATP SYNTHASE LIPID-BINDING PROTEIN P3 PRECURSOR (EC 3.6.1.34) (ATPASE PROTEIN 9) (SUBUNIT C). Leng		immunoglobulin from VH4 family [Homo sapiens] >pir S13519 S13519 Ig heavy chain V region precursor - human >gi 553385 immunoglobulin heavy chain [Homo sapiens] {SUB 24-125} Length =		novel stromal cell protein [Mus musculus] >pir[JC4761]JC4761 recombination activating gene 1 inducing protein - human >sp[Q62275]Q62275 RECOMBINATION ACTIVATING PROTEIN 1 PROTEIN ACTIVATION (NOVEL STROMAL CELL PROTEIN).	(AF073957) CXC chemokine BRAK [Homo sapiens] Length = 99	(AF061443) G protein-coupled receptor LGR4 [Rattus norvegicus] >splG3885470 G3885470 G PROTEIN-COUPLED RECEPTOR LGR4. Length
832588	832634 832728	833094	833395	834326	834583	834944
195	196 197	861	199	500	201	202

HCCMDSS HLHTJS7	HCROP84	HTSGZ29	HFLUE31 HSLF017 HTPCU04 HAIED73
92	100	001	96
92	100	001	92
344 1818	1080	. 4239	398 2046 624 1549
3 580	268	2218	39 1819 1 767
gnl PID d1036172	gi 3152703	gi 2388555	gi 203267
(AB017169) Slit-3 protein [Homo sapiens] >sp D1036172 D1036172 SLIT-3 PROTEIN. >gn PID d1033429 (AB011538) MEGF5 [Homo sapiens]	{SUB 785-1523} Length = 1523 (AF065389) tetraspan NET-4 [Homo sapiens] >sp O60746 O60746	(AC002528) alpha2(1) collagen [Homo sapiens] >sp[G2388555]G2388555 ALPHA2(1) COLLAGEN (FRAGMENT) 1 and 1186	calmodulin-dependent protein kinase III-delta (EC 2.7.1.37) [Rattus norvegicus] > pirl A 3 4 3 6 6 A 3 4 3 6 6 Ca 2 + / calmodulin-dependent protein kinase (EC 2.7.1.123) II delta chain - rat > sp P1 5 7 9 1 K CCD_RAT CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE TYPE II DELTA CH
835012	835332	835487	836182 836522 836655 836787
203	205	306	208 208 209 210

= 951

211	836789	GP36b glycoprotein [Homo sapiens] >pirlG01447lG01447 GP36b glycoprotein - human >splQ12907lQ12907 GP36B GLYCOPROTEIN PRECURSOR.	gi 505652	_	849	66	66	HKAAD74
212	838577	Length = 356 binding protein [Oryctolagus cuniculus] >gi 182628 FK506-binding protein (FKBP) [Homo sapiens] >gi 182633 FKBP-12 protein [Homo sapiens] >gi 182649 FK506-binding protein 12 [Homo sapiens] >gi 288196 FKBP [Homo sapiens] >gi 665650 FK-506	gi 165023	2	433	,	001	HCRQD09
213	838717	binding protein [H		929	900			11E8UJ03
215	840063	(AF006751) ES/130 [Homo sapiens] >splO75300[O75300 ES/130. Length =	gi 3299885	ı m	2729	**	85	HWLIIX68
216	840533			183	482			HWLLU74
218	841140	(AF081281) lysophospholipase [Homo sapiens] >sp O75608 O75608	gi 3415123	: -	789	001	001	HAJCCSI
219	841386	polypeptide GalNAc transferase-T4 [Mus musculus] >sp 008832 008832 POLYPEPTIDE GALNAC	gi 2121220	491	1258	99	8	HMCCA66
220 221 222	841480 841509 841616	KANSFERASE-14, Lengin = 578		3 3 340	212 662 660			HDQET68 HTELO87 HWLFT95

,,,,								
577	841,900	peptidylarginine deiminase (EC 3.5.3.15) [Rattus norvegicus] >pir[A34339]DIRTR1 protein-arginine deiminase (EC 3.5.3.15) 1 - rat >sp[P20717]PARD_RAT_PROTEIN- ARGININE DEIMINASE (EC 3.5.3.15) (PEPTIDYLARGININE DEIMINASE). Length = 665	gi <u>2</u> 05960	C1	439	%	06	HWLFR87
224	842054	ubiquinone-binding protein (QP) [Homo sapiens] > gi 190816 ubiquinone-binding protein precursor [Homo sapiens] > gi 37580 ubiquinone-binding protein (AA I - 111) [Homo sapiens] > pir A32450 A32450 ubiquinone-binding protein QP-C - human > gi 553631 ubiquinone	gi 190802		369	001	001	нмнрғ06
225		(AB012933) acyl-CoA synthetase 5 [Rattus norvegicus] >splO88813 LCFE_RAT LONG- CHAIN-FATTY-ACIDCOA LIGASE 5 (EC 6.2.1.3) (LONG-CHAIN ACYL- COA SYNTHETASE 5) (LACS 5). Length = 683	gnilPID d1034547	23	2308	- 8	92	HDAAV92
226				7	391			HFLNB80
227	844092	(AF045573) FLI-LRR associated protein- I [Mus musculus] >sp O70323 O70323 FLIGHTLESS-1 ASSOCIATED PROTEIN I (LRR DOMAIN) (FLI-LRR ASSOCIATED PROTEIN-I). Length == 628	gi 3025718	28	837	65	83	нтеко43

228	844270	nuclear antigen EBNA-3B [Human herpesvirus 4] >pir S27921 S27921 nuclear antigen EBNA-3B - human herpesvirus 4 >sp Q69139 Q69139 NUCLEAR ANTIGEN EBNA-3B.	gi 330409	6	373	74	52	HWLBL06
229	844604	(AF071186) WW domain binding protein 11 [Mus musculus] >splO88539 O88539 WW DOMAIN BINDING PROTEIN 11.	gi 3550082	170	2110	99	70	HNTAD40
230	844685	immunoglobulin lambda heavy chain [Homo sapiens] >gi \$67132 This CDS feature is included to show the translation of the corresponding C_region. Presently translation qualifiers on C_region features are illegal [Homo sapiens] {SUB 148-177} Length = 477	gni P1D e1227585	539	1564	96	94	HASAC08
231	844855	titin [Oryctolagus cuniculus] >sp E1355301 E1355301 TITIN (FRAGMENT), Length = 2000	gnlP1D e1355301	т	1634	34	54	HAICQ70
232	845101	(AF089814) growth suppressor related [Homo sapiens] >sp O75956 O75956 GROWTH SUPPRESSOR RELATED.	gi 3661529	46	627	94	94	HHESZ77
233	845141			31	996			HWMF067
234	845220	(AB011105) K1AA0533 protein [Homo sapiens] >sp O15230 O15230 K1AA0533 PROTEIN (LAMININ ALPHA 5 CHAIN) (FRAGMENT). >gn PID e317479 laminin alpha 5 chain [Homo sapiens] {SUB 693-1645} Length	gnl PID d1026389	; cı	9601	001	001	HKADF64

845434	glutathione peroxidase [Synechocystis sp.] > pir[S75885[S75885 glutathione peroxidase homology Synechocystis en	gn PID d1019077	m	290	20	19	HWAF112
	PCC 6803) >splP74250 P74250 GLUTATHIONE PEROXIDASE (EC 1.11.1.9). Length = 169						
	dipeptidyl peptidase III [Rattus norvegicus] >splO55096 O55096 DIPEPTIDYL PEPTIDASE (EC 3.4.14.4) (DIPEPTIDYL PEPTIDASE III) (DIPEPTIDYL AMINOPEPTIDASE	gn PID d1025528	m	683	96	86	HEONN92
	III) (DIPEPTIDYL ARYLAMIDASE III) (RED CELL ANGIOTI:NSINASE) (ENKEPHALINASE B). Length = 827 preprocathepsin B [Homo sapiens] >pir[A26498]K1H41B cathepsin B (EC 3.4.22.1) precursor - human >sp[P07858]CATB_HUMAN	gi 181192	223	1254	66	66	HOEME38
	CATHEPSIN B PRECURSOR (EC 3.4.22.1) (CATHEPSIN B1) (APP SECRETASE). >gi 181178 lysosomal proteinase cathepsin B [Homo sapiens] {SUB 131-33 (AF055666) kincsin light chain 2 [Mus musculus] >sp O88448 O88448 KINESIN LIGHT CHAIN 2. Length = 599	ម្រៀ3347848	4	1155	89	75	HI.HCE82

HLDBS16	HCNAK57	HASDA19	HI.3AA32	HCRNG17	HWMFG64	HAGCZ94	HBJEJ74	HUFBE67	HUTHM43	HLTGU75	HWI,KF77	HWLLK67	HDQIE85	HWLFA67	HWLGX29	HWMFZ29
001		54														
86		36														
390	105	106	1721	288	315	102	287	525	55	274	134	180	203	213	351	404
-	31	203	3	154	-	13	72	355	7	C1	5	_	m	_	136	324
gi 177840		gi 38063														
alpha-1-acid glycoprotein 2 [Homo sapiens] >pirlJT0326 OMHU2 alpha-1-acid glycoprotein 2 precursor - human >sp P19652 A I A I I HUMAN A L. PHA-1-ACID G L. YCOPROTEIN 2 PRECURSOR (AGP 2) (OROSOMUCOID 2) (OMD 2). >gi]388511 alpha 1-acid glycoprotein [Homo sapiens] {SU		epididymal apical protein I-precursor [Macaca fascicularis] >pir S28258 S2858 androgen-regulated epididymal protein precursor - crabeating macaque >sp Q28475 Q28475 EPIDIDYMAL APICAL PROTEIN I-PRECURSOR. Length = 776														
846007	846280	846286	846388	HCRNG17R	HWMFG64R	HAGCZ94R	HBJEJ74R	HUFBE67R	HUTHM43R	HLTGU75R	HWLKF77R	HWLLK67R	HDQIE85R	HWLFA67R	HWLGX29R	HWMFZ29R
239	240	241	242	243	244	245	246	247	248	249	250	251	252	253	254	255

HNTRR03R H6FFP19R			– r	363			HNTRR03
HJMAM83R			1 CI	352			HOEEP19 HJMAM83
(AB018 roretzi)	HAGHF58R (AB018797) calmodulin B [Halocynthia roretzi] >sp D1034943 D1034943 CALMODULIN B. Length = 149	gni PID d1034943	_	138	8 8	8	HAGHF58
(ACOC inhibia >splO APOP (FRAC	HDPHG48R (AC005031) neuronal apoptosis inhibitory protein [Homo sapiens] >sp[075857 075857 NEURONAL APOPTOSIS INHIBITORY PROTEIN (FRAGMENT). Leneth = 1178	gi 3688110	_	354	86	66	HDPHG48
(PID:g	HWLUL19R (AC005154) similar to protein U28928 (PID:g861306) [Homo sapiens] >sp[075223]075223 WUGSC:H_DJ0777023.1 PROTEIN. Length = 188	gi 3242764	7	211	59	62	HWLUL19
(AD0000 transcrip >sp O00 BHLH-Z	HWLLI56R (AD000684) liver-specific bHLH-Zip transcription factor [Homo sapiens] >sp[000112 000112 LIVER-SPECIFIC BHLH-ZIP TRANSCRIPTION FACTOR (FRAGMENT). Length = 479	gi 1905918	-	489	. 61	99	HWLLI56
R (AF00 dehydr >splO0 HYDR DEHY (FRAC	HWMAA87R (AF001904) 3-hydroxyacyl-CoA dehydrogenase isoform 2 [Homo sapiens] >sp[O00397]O00397 3- HYDROXYACYL-COA DEHYDROGENASE ISOFORM 2 (FRAGMENT). Length = 76	gi 2108130	m	92	98	98	HWMAA87
c (AF0078 elegans] (FRAGN	HGLAT96R (AF007861) ce-Mago [Caenorhabditis elegans] >sp O16104 O16104 CE-MAGO (FRAGMENT). Length = 147	gi 2306971	165	359	16	16	HGLAT%

265	HCDMC32R (AF014 [Homo s MEMBI Length =	(AF014118) membrane-associated kinase [Homo sapiens] >sp 014731 014731 MEMBRANE-ASSOCIATED KINASE. Length = 499	gi 2460023	8	272	001	001	нсрмс32
	HCROF25R	(AF034800) liprin-alpha3 [Homo sapiens] >sp[G3309535 G3309535 LIPRIN-ALPHA3 (FRAGMENT). Length = 443	gi 3309535	70	381	09	65	HCROF25
	HTEQO80R	HTEQO80R (AF035840) NADH:ubiquinone oxidoreductase B17 subunit [Homo sapicns] >sp[G3800740]G3800740 NADH:UBIQUINONE OXIDOREDUCTASI: B17 SUBUNIT. Length = 128	gj]3800740	_	327	001	001	нтеоо80
	H2LAU18R		gi 2909830	C1	592	001	001	H2LAU18
	HTXPO87R	— · · · · · — · · · — · ·	gi 2707837	_	330	76	97	HTXPO87

WO 00/55351 PCT/US00/05883

270	H2LAR08R	H2LAR08R (AF040642) contains similarity to RNA recognition motifs (RNP) [Caenorhabditis elegans] >sp O44795 O44795 C50D2.5 PROTEIN. Length = 200	gi 2746787	88	514	75	06	H2LAR08
271	HADAF94R	HADAF94R (AF044957) NADH:ubiquinone oxidoreductase B15 subunit [Homo	gj 4164446	∞	135	8 8	88	HADAF94
272	HEMDA91R	HEMDA91R (AF047473) testis mitotic checkpoint BUB3 [Homo sapiens] >splO43685 O43685 TESTIS MITOTIC CHECKPOINT BUB3. Length = 326	gi 3378104	132	431	88	82	немра91
273	HWMFN58R	HWMFN58R (AF051426) slow delayed rectifier channel subunit [Homo sapiens] >splO60607/O60607 SLOW DELAYED RECTIFIER CHANNEL SUBUNIT. Length = 548	gi 2961249 .	m	344	000	001	HWMFN58
274	HCNDJ66R	HCNDJ66R (AF054643) lambda immunoglobulin light chain variable region [Homo sapiens] >gi 3023109 (AF054643) lambda immunoglobulin light chain variable region [Homo sapiens] Length = 125	gi 3023109	-	276	72	73	HCNDJ66
275	нонрноѕк	HOHDH05R (AF061833) aldehyde dehydrogenase; retinal dehydrogenase; class I aldehyde dehydrogenase; slass I aldehyde dehydrogenase; ALDHI [Xenopus laevis] >sp[G3818533]G3818533 ALDEHYDE DEHYDROGENASE (EC 1.2.1.3). >pir S51188 S51188 aldehyde dehydrogenase (NAD+) (EC 1.2.1.3), cytosolic - clawed f	gi 3818533	59	331	53	08	HOHDH05

HUFBP63	HUFBN90	неве157	HDTDK65	HAIAD82	нғкнр61	H2LAX28	Н WLMY93	HTXNL13
96	96	06	78	11	001	76	16	
92	94	<u>8</u>	9/	89	001	97	16	
463	463	165	434	156	203	268	173	356
13	26	_	٣	-	m	206	æ	٣
gi 3170737	ម្នាំ[3170885	gi 3170895	gi 3328006	gi 3982741	gi 3641538	gi 3342571	gi 3386532	
HUFBP63R (AF062137) immunoglobulin heavy chain variable region [Homo sapiens] Length = 143	HUFBN90R (AF062211) immunoglobulin heavy chain variable region [Homo sapiens] Length = 149	HEBEJ57R (AF062214) immunoglobulin heavy chain variable region [Homo sapiens] Length = 142	HDTDK65R (AF069048) immunoglobulin light chain variable region [Homo sapiens] Length = 120	HAIAD82R (AF069711) urokinasc [Oryctolagus cuniculus] >sp G3982741 G3982741 UROKINASE (FRAGMENT). Length = 128	HFKHD61R (AF073298) 4F5rel [Homo sapiens] >gi 3641536 (AF073297) 4F5rel [Mus musculus] >sp 075918 075918 4F5REL. >sp 088891 088891 4F5REL. Length = 59	H2LAX28R (AF078817) high mobility group protein [Nannospalax ehrenbergi] >sp[O88611 O88611 HIGH MOBILITY GROUP PROTEIN. Length = 215	HWLMY93R (AF078839) Rho related protein Rnd3/Rho8 [Sus scrofa] >sp 077683 077683 RHO RELATED PROTEIN RND3/RHO8. Leneth = 244	
HUFBP63R	HUFBN90R	HEBEJ57R	HDTDK65R	HAIAD82R	HFKHD61R	H2LAX28R	HWLMY93R	HTXNL13R
276	277	278	279	280	281	282	283	284

285	HDPWR89f	HDPWR89R (AJ005259) homologous to Bombyx mori gnl PID e1286414 multiprotein bridging factor (EMBL: AB001078) [Homo sapiens] >sp O60869 O60869 EDF-1 PROTEIN. Length = 148	gni P1D e1286414	-	312	79	83	HDPWR89
286	H2LAK62R)		22	165			H2LAK62
	HWLKTISE	HWLKTISR (AJ235272) UBIQUINONE/MENAQUINONE BIOSYNTHESIS	gn PID e1342961	7	301	20	9/	HWLKT15
		METHLYTRANSFERASE UBIE (ubiE) [Rickettsia prowazekii]						
288	HATAR77F	(AL021546) Cytochrome C Oxidase	gnt PID e1248288	3	413	70	73	HATAR77
		Polypeptide VIa-liver precursor (EC 1.9.3.1) [Homo sapiens]			,			
289	HWLWN07	HWLWN07R (AL022237) bK1191B2.2 (BCL2-	gn1P1D e1359316		183	82	88	HWLWN07
		interacting killer (apoptosis-inducing) (NBK, BP4, BIP1) [Homo sapiens]						
		>sp E1359316 E1359316 BK1191B2.2 (BCL2-INTERACTING KILLER						
		(APOPTOSIS-INDUCING) (NBK, BP4,						
		BIP1) (FRAGMENT). >gi 929655 NBK [Homo sapiens] {SUB 14-173} Le						
290	HWLDI18R	(AL023554) ribosomal protein	gnl P1D e1292696	3	206	43	59	HWLDI18
		[Schizosaccharomyces pombe] >sp[O60118[O60118 RIBOSOMAL						
167	HWMEC68R	PROTEIN. Length = 157 R		٣	419			HWMEC68

CORTICOSTEROID 11-BETA-DEHYDROGENASE, ISOZYME 2 (EC 1.1.1.146) (11-DI12) (11-BIETA-HYDROX HWMEH18R 3',5'-cyclic-GMP phosphodiesterase (EC 3.1.4.35) alpha chain - human >gi]3513491 (AF022380) rod photoreceptor cGMP phosphodiesterase alpha subunit [Homo sapiens] {SUB 1-122} Length = 859 HCWFF03R 5' half of the product is homologues to Bacillus subtiis SAICAR synthetase, 3' half corresponds to the catalytic subunit of AIR carboxylase [Homo sapiens] >pir{S14147 S14147 multifunctional purine biosynthesis protein - human Length = 425 HCNDP66R A33 antigen precursor [Homo sapiens] >sp Q99795 A33_HUMAN CELL
>sp Q99795 A33_HUMAN CELL SURFACE A33_ANTIGEN PRECURSOR. Length = 319 HCRMK82R adenosine A2b receptor [Homo sapiens] >gi 757911 A2b adenosine receptor [Homo sapiens] adenosine receptor A2b - human >sp P29275[AA2B_HUMAN]

ADENOSINE A2B RECEPTOR. Length = 332

297	HCDAN16R alpha-1 Length	alpha-1 collagen (1) [Gallus gallus] Length = 143	gi 555432	C)	133	11	88	HCDAN16
867	HCEOE88R	HCEOE88R amplaxin [Homo sapiens] >pir A48063 A48063 mammary tumor/squamous cell carcinoma- associated protein EMSI - human Length = 550	gi 182087	-	291	93	94	нсеое88
299	HÁLSK30R	HALSK30R angiogenin [Homo sapiens] >pirJA90498 NRHUAG angiogenin precursor - human >sp P03950 ANGI_IIUMAN ANGIOGENIN PRECURSOR (EC 3.1.27). Length = 147	gi 178250	189	416	74	92	HALSK30
300	HDRME43R	HDRME43R anonymous [Homo sapiens] >pir 139463 139463 gene anonymous protein - human >sp Q13769 Q13769 ANONYMOUS. Length = 683	gi 388012	61	346	94	95	HDRME43
301	HHEFA24R	HHEFA24R APP-binding protein I [Rattus norvegicus] >sp G4099878 G4099878 APP-BINDING PROTEIN I. Length = 534	gi 4099878	01	177	63	9	ннеға24
302	HSSGC52R	HSSGC52R argininosuccinate synthetase [Bos taurus] >splP14568 ASSY_BOVIN ARGININOSUCCINATE SYNTHASE (EC 6.3.4.5) (CITRULLINE ASPARTATE LIGASE). Length = 412	gi 162697	_	438	94	95	HSSGC52

303	HCYBN49R ATP synthase beta subunit precursor [Homo sapiens] >pirlA33370[A33370] H+-transporting ATP synthase (EC 3.6.1.34) beta chain precursor, mitochondrial - human >splP06576[ATPB_HUMAN ATP SYNTHASE BETA CHAIN, MITOCHONDRIAL PRECURSOR (EC 3.6.1.34). >gi[28931 be	gi 179281		44 S	76	97	HCYBN49
304	HWMGB90R ATP synthase subunit e [Homo sapiens] >sp P56385 ATPJ_HUMAN ATP SYNTHASE E CHAIN, MITOCHONDRIAL (EC 3.6.1.34). {SUB 2-69} Length = 69	gi 2605592	-	165	88	19	HWMGB90
305	HTEAW21R ATPase coupling factor 6 subunit [Homo sapiens] >pirJT0563JJT0563 coupling factor 6 precursor, mitochondrial - human >sp P18859JATPR HUMAN ATP SYNTHASE COUPLING FACTOR 6, MITOCHONDRIAL PRECURSOR (EC 3.6.1.34) (F6). Length = 108	gil 79275	47	259	93	93	HTEAW21
306	iens] 'NTHASE igth = 226	gni P1D d1007873	147	368	28	19	ж МСОС V96
307	HLTDN74R autotaxin-t [Homo sapiens] >splQ13822 Q13822 AUTOTAXIN-T. >gnlPID d1008938 phosphodiesterase I alpha [Homo sapiens] {SUB 1-45} Length = 863	gi 1160616	C 1	88	85	88	HLTDN74
308	HDABV61R B-creatine kinase [Gallus gallus] Length = 65	gi 211524	٣	230	93	100	HDABV61

H2LAQ68	HDTLN42	HULFN47	HCRM141	HWLIP53	HBAAD60	HCROA35	HCROM64	HEOPS84	HKBAG82	HUTSB76
001	98	68								
001	98	&								
558	361	449	528	409	463	200	512	388	265	418
127	7	m	-	7	7	m	201	7	32	188
gi 312732	gi 176827	gi 176827								
H2LAQ68R beta prime cop [Bos taurus] >pir S35312 S35312 coatomer complex beta' chain - bovine >sp P35605 COPP_BOVIN COATOMER BETA' SUBUNIT (BETA'-COAT PROTEIN) (BETA'- COP) (P102). {SUB 2-906} Length = 906	HDTLN42R beta-2-microglobulin [Pan troglodytes] >gi 177065 beta-2-microglobulin [Gorilla gorilla] >gn PID d1036168 (AB021288) beta 2-microglobulin [Homo sapiens] >pir A90976 MGHUB2 beta-2- microglobulin precursor - human >pir 136963 136963 beta-2-microglobulin	HULFN47R beta-2-microglobulin [Pan troglodytes] >gi 177065 beta-2-microglobulin [Gorilla gorilla] >gn P1D d1036168 (AB021288) beta 2-microglobulin [Homo sapiens] >pir A90976 MGHUB2 beta-2- microglobulin precursor - human >pir 136963 136963 beta-2-microglobulin pre								
H2LAQ68R	HDTLN42R	HULFN47R	HCRMI41R	HWL.IP53R	HBAAD60R	HCROA35R	HCROM64R	HEOPS84R	HKBAG82R	HUTSB76R
309	310	3.1	312	313	314	315	316	317	318	319

HWLJS67 HWLLZ82 HCROM20	HDQMC24	HOCTD89	HTGAZS3	HWLKZ47	HWLLLSI	HRLAJS4	HBAAD69	HWLJZ72	HWMFG06	HPRTO65	HUFDC01	HWLHY44
										76	87	79
										93	87	75
. 662 133 557											326	413
384 2 351	-	212	198	429	204	207	_	25	43	ţ ~	801	E
										gi 179438	gi 179440	gi 1203965
										biliary glycoprotein a [Homo sapiens] >gul[PID]d1015047 biliary glycoprotein, BGPg [Homo sapiens] >gi[3172151 (AC004785) BGPg_HUMAN [Homo sapiens] >pir[JH0394]JH0394 biliary glycoprotein g precursor - human Length = 417	biliary glycoprotein I precursor [Homo sapiens] >gi[37198 TM1-CEA preprotein [Homo sapiens] >gi[3172148 (AC004785) BGP1_HUMAN [Homo sapiens] >pir[A32164]A32164 biliary glycoprotein I precursor - human >sp[P13688]BGP1_HUMAN BILIARY GLYCOPROTEIN I PRECURSOR	HWLHY44R bone-derived growth factor [Homo sapiens] >sp Q13876 Q13876 BONE- DERIVED GROWTH FACTOR
HWLJS67R HWLLZ82R HCROM20R	HDQMC24R	HOCTD89R	HTGAZ53R	HWLKZ47R	HWLLLSIR	HRLAJ54R	HBAAD69R	HWLJZ72R	HWMFG06R		HUFDC01R biliary sapiens [Homo (AC00) sapiens sapiens sapiens Spiens Sp	HWLHY44R
320 321 322	323	324	325	326	327	328	329	330	331	335	333	334

0 HWLGR92	HCNCQ71 HBMCI28	HWLENI	HMSDU92
001 0	84 84	08	83
8 100	3 84	7 80	9
238	93	347	360
122	- -	\$	-
gi 307200	gi 179793	gi 179793	gi 179772
HWLGR92R brain glycogen phosphorylase [Homo sapiens] >pir A29949 A29949 glycogen phosphorylase (EC 2.4.1.1), brain (astrocytoma cell line) - human Length = 863	HCNCQ71R CAG-isl 7 [Homo sapiens] Length = 213 HBMC128R carbonic anhydrase 1 (EC 4.2.1.1) [Homo sapiens] >gi[29600 carbonic anhydrase I (AA 1-261) [Homo sapiens] >pirJQ0786[CRHU1 carbonate dehydratase (EC 4.2.1.1) I - human >sp P00915[CAHI_HUMAN CARBONIC ANHYDRASE I (EC 4.2.1.1) (CARBONATE DEHYDRATASE I) (SI	HWLEN11R carbonic anhydrase I (EC 4.2.1.1) [Homo sapiens] >gi 29600 carbonic anhydrase I (AA 1-261) [Homo sapiens] >pir JQ0786 CRHU1 carbonate dehydratase (EC 4.2.1.1) I - human >sp P00915 CAH1_HUMAN CARBONIC ANHYDRASE I (EC 4.2.1.1) (CARBONATE DEHYDRATASE I J. 1911	HMSDU92R carbonic anhydrase II [Homo sapiens] >gil 179780 carbonic anhydrase II [Homo sapiens] >gil 179795 carbonic anhydrase II [Homo sapiens] >gil 29587 carbonic anhydrase II (AA 1-260) [Homo sapiens] >pir[A27175]CRHU2 carbonate dehydratase (EC 4.2.1.1) II - human
HWLGR92	HCNCQ71	HWLENI	HMSDU92
335	336	338	339

НКАКО78	H2CBD02 HWLCR90	H2LAK66	HSDKC65	H2LAK52	HKAEG12	HKADP43
£ .	09	79	26	001	86	71
<i>LL</i>	34	79	95	001	8 6	17
193	351	632	346	809	392	375
61	- 28	126	179	24	m	_
gi 29979	gi 1519671	gi 180928	gi 1374867	gi 1923243	pir[A32992[A3299 2	gi 576781
Cks1 protein homologue [Homo sapiens] >pirJB36670JB36670 protein kinase cdc2 complex subunit CKS2 - human >spJP33552JCKS2 HUMAN CYCLIN-DEPENDENT KINASES REGULATORY SUBUNIT 2 (CKS-2). Length = 79	H2CBD02R HWLCR90R contains similarity to ATP/GTP-binding site motif (PS:PS00017) [Caenorhabditis elegans] >splQ94180 Q94180 SIMILARITY TO ATP/GTP-BINDING SITE MOTIF. Length = 398	H2LAK66R core protein II precursor [Homo sapiens] >pir[A32629]A32629 ubiquinol cytochrome-c reductase (EC 1.10.2.2)	HSDKC65R CoxII/D-loop DNA fusion protein [Homo sapiens] > splQ34777 Q34777 COXII/D-LOOP DNA FUSION PROTEIN (FRAGMENT) Longth = 125	H2LAK52R CUL-2 [Homo sapiens] >sp[Q13617[CUL2_11UMAN CULLIN HOMOLOG 2 (CUL-2), Length = 745	HKAEG12R cyclin B1 - human >sp P14635 CGB1_HUMAN G2/MITOTIC-SPECIFIC CYCLIN B1.	HKADP43R cyclin F [Homo sapiens] >sp P41002 CG2F_HUMAN G2/MITOTIC-SPECIFIC CYCLIN F.
HKAKO78R Cks1 pr >pirlB3 comple: >splP33 DEPEN REGUL	H2CBD02R HWLCR90R	H2LAK66R	HSDKC65R	H2LAK52R	HKAEGI2R	HKADP43R
349	350 351	352	353	354	355	356

HLXND10	HUSJE17	нгысн82	ннвеғ06
00	86	94	08
00	76	94	75
355	208	901	373
C 1	71	7	167
gi 291927	gi 336514	gi 50527	gj 13010
HLXND10R cystatin B [Homo sapicns] >gi 1235678 cystatin B [Homo sapiens] >sp P04080 CYTB_HUMAN CYSTATIN B (LIVER THIOL PROTEINASE INHIBITOR) (CPI-B) (STEFIN B). Length = 98	HUSJE17R cytochrome c oxidase subunit II [Pan troglodytes] >splP26457 COX2_PANPA CYTOCHROME C OXIDASE POLYPEPTIDE II (EC 1.9.3.1). Length = 227	HLHGH82R cytochrome c oxidase subunit Va preprotein [Mus musculus] >pir S05495 S05495 cytochrome-c oxidase (EC 1.9.3.1) chain Va precursor- mouse >sp P12787 COXA_MOUSE CYTOCHROME C OXIDASE POLYPEPTIDE VA PRECURSOR (EC 1.9.3.1). Length = 145	HHBEF06R cytochrome oxidase III [Homo sapiens] >pir A00482 OTHU3 cytochrome-c oxidase (EC 1.9.3.1) chain III - human mitochondrion (SGC1) >sp P00414 COX3_HUMAN CYTOCHROME C OXIDASE POL YPEPTIDE III (EC 1.9.3.1). >gi 2245564 (AF004341) cytochrome c oxidase subunit I
于	Ħ	귀	±
357	358	359	360

•	•
•	7
~	•

HISCW28	HODEN42	НОЕММ43	HPIAK29
Ξ	¥	H	Ī
98		67	70
83	89	4	63
312	469	180	441
121	302	-	295
gi 530069	gi 530069	gi 530069	gi 530069
HISCW28R cytochrome oxidase subunit II [Homo sapiens] >gi 530071 cytochrome oxidase subunit II [Homo sapiens] >gi 530073 cytochrome oxidase subunit II [Homo sapiens] >gi 530077 cytochrome oxidase subunit II [Homo sapiens] >gi 530077 cytochrome oxidase subunit II [Homo sapiens] >gi 337187 cytochrome oxidase subunit II [HODEN42R cytochrome oxidase subunit II [Homo sapiens] >gi 530071 cytochrome oxidase subunit II [Homo sapiens] >gi 530073 cytochrome oxidase subunit II [Homo sapiens] >gi 530077 cytochrome oxidase subunit II [Homo sapiens] >gi 530077 cytochrome oxidase subunit II [Homo sapiens] >gi 530187	HOEMM43R cytochrome oxidase subunit II [Homo sapiens] >gi 530071 cytochrome oxidase subunit II [Homo sapiens] >gi 530073 cytochrome oxidase subunit II [Homo sapiens] >gi 530077 cytochrome oxidase subunit II [Homo sapiens] >gi 337187 cytochrome oxidase subunit II [Homo sapiens] >gi 337187	HPIAK29R cytochrome oxidase subunit II [Homo sapiens] >gi 530071 cytochrome oxidase subunit II [Homo sapiens] >gi 530073 cytochrome oxidase subunit II [Homo sapiens] >gi 530077 cytochrome oxidase subunit II [Homo sapiens] >gi 337187 cytochrome oxidase subunit II [Homo sapiens] >gi 337187
361	362	363	364

IR cytochrome ov sapiens] >gi[5] subunit II [Ho cytochrome ov		gi 530069	128	367	82	88	HUFAR71
sapiens] > gi 530077 cytochrome oxidase subunit II [Homo sapiens] > gi 337187 cytochrome oxidase subunit II [/tochrome oxidase ens] >gi 337187 ibunit II [
HHEUL74R cytochrome oxidase subunit II [Homo sapiens] >splQ37526 Q37526 CYTOCHROME C OXIDASE POLYPEPTIDE II (EC 1.9.3.1). Length = 227	£	gi 530075	en .	227	70	74	ннеис74
H2LAY36R cytosolic malate dehydrogenase [Homo sapiens] >gi 3133269 malate dehydrogenase [Homo sapiens] >sp P40925 MDHC_HUMAN MALATE DEHYDROGENASE, CYTOPLASMIC (EC 1.1.1.37). {SUB 2-334} Length = 334	ш ()	gn PID d1010156	01	609	84	88	H2LAY36
HOEC121R decay-accelerating factor precursor [Homo sapiens] >gnl[PID]d1023771 (AB003312) decay accelerating factor [Homo sapiens] {SUB 286-340} Length = 376	l tor ength	gi 181463	m	548	73	7.5	HOECIZI
HKAFY51R desmoglein 2 [Homo sapiens] >pir S38673 S38673 desmoglein 2 - human >sp Q14126 DSG2_HUMAN DESMOGLEIN 2 PRECURSOR (HDGC). Length = 1117	sin 2 - JMAN OR	gi 416178	_	429	100	001	HKAFYSI
HMCAR63R diazepam binding inhibitor [Homo sapiens] Length = 104		gi 181478	m	335	001	001	HMCAR63

371	HWMAN061	IIWMAN06R dopamine- and cAMP-regulated neuronal phosphoprotein [Sus scrofa] >sp[Q29277[IPPD_PIG DOPAMINE-AND CAMP-REGULATED NEURONAL PHOSPHOPROTEIN (DARPP-32) (FRAGMENT). Length = 137	gi 972053	-	222	8	83	HWMAN06
372	HDPLD04R	HDPLD04R early growth response 2 protein (EGR2) - pir A40492 A4049 human >gi 181987 early growth response 2 protein [Homo sapiens] {SUB 51-456} Length = 456	ir A40492 A4049 2	_	459	69	70	HDPLD04
373	HCEGK04R	HCEGK04R clongation factor 2 [Callus gallus] >sp[Q90705[EF2_CHICK ELONGATION FACTOR 2 (EF-2). {SUB 2-858} Length = 858	gi 1184958	87	182	95	95	HCEGR04
374	HWLMB57F	HWLMB57R epidermal growth factor receptor kinase substrate [Homo sapiens] >pir[138728 138728 epidermal growth factor receptor kinase substrate - human >sp[Q12929 EPS8_HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR KINASE SUBSTRATE EPS8. Length = 822	gi 530823	-	981	93	93	HWLMB57
375	ннғнғ93		gi 181980	-	180	68	68	ннгн г 93

HCDEM69R	HCDEM69R epiligrin alpha 3 subunit [Homo sapiens] >pir A55347 A55347 adhesive ligand epiligrin, alpha-3 chain form A precursor - human >sp Q16787 LMA3_HUMAN LAMININ ALPHA-3 CHAIN PRECURSOR (EPILIGRIN 170 KD SUBUNIT) (E170). Length = 1713	gi 551597	136	282	\$6	95	нсрем69
HCHNP50R	epithelial cell marker protein 1 [Homo sapiens] >pir S38956 S38956 epithelial cell marker protein 1 - human Length = 248	gi 187302	54	218	94	94	HCHNP50
HAJAW27R ERF pirlS - iactor - gilor - gilor - gilor	ERF-1 gene product [Homo sapiens] >pir\S34854\S34854 epidermal growth factor-response factor 1 - human >gi\972116 ERF-1 protein \Sus scrola\{SUB 299-337\} \text{Length} = 338	gi 825653	m	488	100	001	HAJAW27
HAICY55R	G-rich sequence factor-1 [Homo sapiens] >gi[517196 G-rich sequence factor-1 [Homo sapiens] >sp[Q12849[GRF1_HIJMAN G-RICH SEQUENCE FACTOR-1 (GRSF-1). >pir[S48081[S48081 GRSF-1 protein - human (fragment) {SUB 94-424} Length = 424	gi 517196	m	374	20	90	HAICY55
HWLIA38R	gap junction protein (aa 1-283) [Homo sapiens] >pir B29005 B29005 gap junction protein Cx32 - human >sp P08034 CXB1_HUMAN GAP JUNCTION BETA-1 PROTEIN (CONNEXIN 32) (CX32) (GAP JUNCTION 28 KD LIVER PROTEIN). Length = 283	gi 31647	٣	455	83	88	HWLIA38

НВХСГ69	H2LAP90	HCQCR94	ITTELE03	HJMBN86	HSKJC32	HOEAZ62
29	26	95	100	001	94	č6
19	64	95	001	67	68	68
419	545	114	202	202	642	001
2	234	-	<u> </u>	C 1	_	C1
gi 758591	gi 488476	gi 579930	gi 579930	gi 31746	gi 163528	gi 971836
HBXCL69R glutaminephenylpyruvate aminotransferase [Homo sapiens] >pir S69001 S52790 glutamine phenylpyruvate transaminase (EC 2.6.1.64) - human >sp Q16773 Q16773 GLUTAMINE-PHENYLPYRUVATE AMINOTRANSFERASE (EC 2.6.1.64) (GLUTAMINE TRANSAMINASE K). Length = 422	H2LAP90R glutathione peroxidase [Homo sapiens] Length = 202	HCQCR94R glutathione peroxidase-GI [Homo sapiens] Length = 190		HJMBN86R glutathione-insulin transhydrogenase (216 AA) [Homo sapiens] Length = 216	GTP:AMP phosphotransferase (EC 2.7.4.10) [Bos taurus] > ynl PID d1001680 mitochondrial adenylate kinase isozyme 3 [Bos taurus] > pir A3442 A3442 nucleoside-triphosphate-adenylate kinase (EC 2.7.4.10) 3, mitochondrial - bovine	-spiros roujnados_bovina o i P:Am HOEAZ62R GTP_binding protein [Sus scrola] >sp Q29222 Q29222 GTP_BINDING PROTEIN (FRAGMENT). Length = 92
HBXCL69R	H2LAP90R	HCQCR94R	HTELEO3R	HJMBN86R	HSKJC32R	HOEAZ62R
381	382	383	384	385	386	387

HAOAG76	HCIAD45	H2MAC82	H21.AJ41	HWLGH40
%	∞	96	86	93
98	75	95	86	92
369	262	513	632	597
_	CI	4	75	<u> </u>
gi 386746	gi 183415	19209291	gi 703087	gnl PID d1026110
guanine nucleotide-binding protein G-s-alpha-4 [Homo sapiens] >gi[31913 alpha-S1 (AA 1-380) [Homo sapiens] >pir[C31927]RGHUA1 GTP-binding regulatory protein Gs alpha chain (adenylate cyclase-stimulating), splice form 4 - human Length = 380			H2LAJ41R heat shock protein [Homo sapiens] >pir A32319 HHHU86 heat shock protein 90-alpha - human >gi 184419 heat shock protein 86 [Homo sapiens] {SUB 1-312} >gn PtD d1014121 heat shock protein 90 [Homo sapiens] {SUB 2-732}	HKL1 [Homo sapiens] >sp 060765 060765 HKL1. Length = 605
11AOAG76R guanine alpha-4 S1 (AA >pirlC31 regulato (adenyla	HCIAD45R	H2MAC82R	H2LAJ41R	HWLGH40R HKL1 >sp O6 605
388	389	390	391	392

нвлензз	HISDV92	н Н Б 9 О В 3 5 8 9	HDABQ50
66	72	001	16
&	72	001	16
369	404	388	368
97	51	158	204
gi 306858	gi 306878	gi 32400	gi 1113107
HLA DP4 beta-chain [Homo sapiens] >gi[296648 pot. hla-dp-beta 1 [Homo sapiens] >pir[A02229]HL.HUPB MHC class II histocompatibility antigen HLA-DP beta 1 chain (allele DPB4.1) precursor - human >sp P0440 HB2P_HUMAN HLA CLASS II HISTOCOMPATIBILITY ANTIGEN,			bords [Homo sapiens] >sp[Q13416[ORC2_HUMAN ORIGIN RECOGNITION COMPLEX PROTEIN, SUBUNIT 2. Length = 577
нвјенззк		HMQCG89R HE9QB35R Hox5.4 sapiens protein > sp[P1] HOME	HDABQ50R
393	394	395 396	397

HNTEG83	HFVHM90	HOSNF90	HSDJE56	HWLGC87
正	王	I	工	Ξ
 	46	62	73	96
83	93	89	19	96
391	319	340	70	135
<i>C</i> 1	C1	257	~ 1	_
gi 184503	gi 619877	pirJJC1348JJC1348	pir JC1348 JC1348	pir S12206 S12206
HNTEG83R hydroxymethylglutaryl-CoA lyase [Homo sapiens] >pir[A45470]A45470 hydroxymethylglutaryl-CoA lyase (EC 4.1.3.4) - human >sp P35914 HMGL_HUMAN HYDROXYMETHYLGLUTARYL-COA LYASE PRECURSOR (EC 4.1.3.4) (HMG-COA LYASE) (HL) (3-HYDROXY-3-METHYLGLUTARATE-COA LYASE)	HFVHM90R hydroxymethylglutaryl-CoA synthase [Homo sapiens] >gi 2463646 3-hydroxy-3-methylglutaryl CoA, synthase [Homo sapiens] >pir S71623 S71623 hydroxymethylglutaryl-CoA synthase (EC 4.1.3.5) precursor, mitochondrial -human >sp P54868 HMCM_HUMAN HYDROXYMETHYLGLU	HOSNF90R hypothetical 18K protein (rRNA) - goldfish mitochondrion (SGC1) Length = 166	HSDJE56R hypothetical 18K protein (rRNA) - goldfish mitochondrion (SGC1) Length = 166	HWLGC87R hypothetical protein 2 (rRNA external transcribed spacer) - mouse Length = 153
HNTEG83R	Н FVHM90R	HOSNF90R	HSDJE56R	HWLGC87R
308	399	400	401	405

stin, intestine- AN 1-PLASTIN PLASTIN PLASTIN NATIVELY Length = 216 sapiens] e 1d1 protein - (allotype pir B22360 B2236 2 AAN 1G GION chain constant sapiens] {SUB 1 - chimpanzee pir PT0207 PT020 148 main of 1gG 135-134} muman pir S69131 S69131 1 81 reading frame UB 121-218} [Homo sapiens] gi 441375 11 appa chain V-J 128	92 93 HTPAC28	98 99 HMCGIND7	89 89 HFIBV16	80 80 HBMTT01	70 77 HBMVM66	50 56 HABGC21	75 79 HWL.GE72
gi 405230 sp G998972 G9989 72 gi 457785 pir B22360 B2236 pir PT0207 PT020 7 th pir S69131 S69131 ne s] gi 441375	325	498	238	154	435	. 528	421
2 & £ 5 %	89	_	C1	7	8	_	=
HTPAC28R 1-plastin [Homo sapiens] >pir[A56536 A56536 plastin, intestine-specific - human >sp[O14651 PLSI_HUMAN I-PLASTIN (INTESTINE-SPECIFIC PLASTIN). Length = 629 HMCGN07R ICK=INTYRON-CONTAINING KALLIKREIN {ALTERNATIVELY SPLICED, INTRON 2}. Length = 216 HFIBV16R Id gene product [Homo sapiens] >pir[S47524 S47524 gene Id1 protein - human Length = 154 HBMTT01R Ig alpha-2 chain C region (allotype A2m(1)) - human >sp[P01877]ALC2_HUMAN IG ALPHA-2 CHAIN C REGION. >gil 184761 Ig alpha-2 H-chain constant region (aa at 166) [Homo sapiens] {SUB 2-340} Length = 340 HBMVM66R Ig gamma chain C region - chimpanzee >gnl[P1D]e40518 CH2 domain of IgG [Pan troglodytes] {SUB 135-234} Length = 234 HABGC21R Ig heavy chain (DOT) - human (fragment) >gnl[P1D]e4031 reading frame CH1 [Homo sapiens] {SUB 121-218} Length = 241 HWLGE72R Ig kappa light chain (VJ) [Homo sapiens] >pir[S40343]S40343 Ig kappa chain V-J region - human Length = 128	gi 405230	sp G998972 G9989 72	gi 457785	pir B22360 B2236 0	pir PT0207 PT020 7	pir S69131 S69131	gi 441375
-	HTPAC28R I-plastin [Homo sapiens] >pir A56536 A56536 plastin, intestine- specific - human >sp Q14651 PLSI_HUMAN I-PLASTIN (INTESTINE-SPECIFIC PLASTIN). Length = 629	HMCGN07R ICK=INTRON-CONTAINING KALLIKREIN {ALTERNATIVELY SPLICED, INTRON 2}, Length = 216	HFIBV16R Id1 gene product [Homo sapiens] >pir S47524 S47524 gene Id1 protein - human Length = 154	HBMTT01R lg alpha-2 chain C region (allotype A2m(1)) - human >sp P01877 ALC2_HUMAN IG ALPHA-2 CHAIN C REGION. >gi 184761 lg alpha-2 H-chain constant region (aa at 166) [Homo sapiens] {SUB 2-340} Length = 340	1BMVM66R lg gamma chain C region - chimpanzee >gn PID e40518 CH2 domain of lgG Pan troglodytes] {SUB 25-134} >gn PID e40517 CH3 domain of lgG Pan troglodytes] {SUB 135-234} Length = 234	HABGC21R 1g heavy chain (DOT) - human (fragment) >gnl PtD e4381 reading frame CH1 [Homo sapiens] {SUB 121-218} Length = 241	HWLGE72R lg kappa light chain (VJ) [Homo sapiens] >pir S40343 S40343 lg kappa chain V-J region - human Length = 128

HLIBX69	HWAFW14	HWAFK04	HEPNA09	HCRQD03	HAPSK08
001	001	98	87	82	∞
001	94	78		9/	62
279	139	473	206	573	363
-	~1	48	٣	-	_
gi 541734	gi 37725	gi 567126	gi 567127	gi 567128	gi 1791017
HLIBX69R 1gM B-cell receptor associated protein (BAP) 37 [Mus musculus] >pir S46996 S46996 B-cell receptorassociated protein BAP37 - mouse >sp Q61336 Q61336 BCR-ASSOCIATED PROTEIN 37 (IGM B-CELL RECEPTOR ASSOCIATED PROTEIN 37) (BAP). Length = 298	HWAFW14R immunoglobulin from VH4 family [Homo sapiens] >pir[S13519[S13519 lg heavy chain V region precursor - human >gi[553385 immunoglobulin heavy chain [Homo sapiens] {SUB 24-125} Length = 147	HWAFK04R immunoglobulin heavy chain [Homo sapiens] >pir E36005 E36005 lg heavy chain V region (M72) - human {SUB 36-157} Length = 157	HEPNA09R immunoglobulin heavy chain [Homo sapiens] >pirlG36005 G36005 Ig heavy chain V region (M74) - human {SUB 38-158} Length = 158	HCRQD03R immunoglobulin heavy chain [Homo sapiens] Length = 152	
HLIBX65	HWAFWI	HWAFKO	HEPNA09	HCRQD0.	HAPSK08R
410	14	412	413	414	415

375 68 70 HBMTS11	337 100 100 HCNDR62		308 90 93 HNJBF13	90 93	86 89 87 92	90 93 86 89 87 92 92 88	90 93 86 89 87 92 92 92 92 92 92 92 92 92 92 92 92 92
	245 357	3 308		24 84			
<u>.</u>	gnl P1D c224083	gi 33702	gil33712	֖֖֖֖֖֖֖֖֖֖֖֖֖֖֖֖֖֖֖֖֖֖֖֖֖֖֖֖֖֖֖֖֖֝֡֞֝֝֡	gi 33730	gi 33730	gi 465170
FIBMTSTIK Immunoglobulin IgH heavy chain Fd fragment [Homo sapiens] Length = 221	HCNDR62R immunoglobulin kappa light chain [Homo sapiens] >pir A37927 A37927 Ig kappa chain C region (allotype Inv(1.2)) - human (fragment) {SUB 138-236} Length = 236	immunoglobulin lambda light chain gene product [Homo sapiens] >pir(\$225738 S25738 lg lambda chain - human Length = 231	HLYCD69R immunoglobulin lambda light chain gene	product [Homo sapiens] >pir(S25743 S25743 lg lambda chain - human (fragment) Length = 145	product [Homo sapiens] >pir S25743 S25743 lg lambda chain - human (fragment) Length = 145 HWAFK89R immunoglobulin lambda light chain gene product [Homo sapiens] >pir S25750 S25750 lg lambda chain - human Length = 235	product [Homo sapiens] >pir S25743 S25743 lg lambda chain - human (fragment) Length = 145 HWAFK89R immunoglobulin lambda light chain gene product [Homo sapiens] >pir S25750 S25750 lg lambda chain - human Length = 235 HWCAA53R immunoglobulin light chain variable region [Homo sapiens] >gil3142470 (AF063703) immunoglobulin lambda light chain variable region [Homo sapiens] {SUB 20-127} >gil575243 immunoglobulin lambda chain precursor [Homo sapiens] {SUB 26-127} >gn PID d1020826 V	product [Homo sapiens] >pir S25743 S25743 lg lambda chain - human (fragment) Length = 145 HWAFK89R immunoglobulin lambda light chain gene product [Homo sapiens] >pir S25750 S25750 lg lambda chain - human Length = 235 HWCAA53R immunoglobulin light chain variable region [Homo sapiens] >gil3142470 (AF063703) immunoglobulin lambda light chain variable region [Homo sapiens] {SUB 20-127} >gil575243 immunoglobulin lambda chain precursor [Homo sapiens] {SUB 26-127} >gnl PID d1020826 V HYAAY47R immunoglobulin light chain variable region [Homo sapiens] Length = 154
HBMTSIIR	HCNDR62R	HNJBF13R	HLYCD69R	7	HWAFK89R	HWCAA53R i	HWCAA53R I
416	417	8 7	419		. 420	420	420

. 425	HFVGPLIR	HFVGP11R L-FABP [Homo sapiens] >pir A22289 FZ14UL. fatty acid-binding protein, hepatic - human >sp P07148 FABL_HUMAN FATTY ACID-BINDING PROTEIN, LIVER (L-FABP). Length = 127	gi 182358	59	322	86	8 6	HFVGPII
426	HWLQH07R	•		٣	554			HWLQH07
427	HSIGN24R	HSIGN24R Irp gene product [Homo sapiens] >pir S57723 S57723 Irp protein - human >sp Q14764 MVP_HUMAN MAJOR VAULT PROTEIN (MVP) (LUNG RESISTANCE-RELATED PROTEIN).	gi 895840	. 7	250	68	93	HSIGN24
		Lengin - 690						
428	HWLKH07R	HWLKH07R lysophosphatidic acid acyltransferase- beta [Homo sapiens] Length = 278	gi 2155240	74	298	96	97	IIWLKH07
429	HAPQC14R	HAPQC14R macrophage capping protein [Homo sapiens] > pir A43358 A43358	gi 187456	CI	538	96	86	HAPQC14
		macrophage capping protein - human >sp P40121 CAPG_HUMAN						
		MACROPHAGE CAPPING PROTEIN						
		(ACTIN-REGULATORY PROTEIN						
		CAP-G). >gi 515505 Cap-G [Homo						
Ç	00000	sapiens] {SUB 1-172} Length = 348		ć	ì	(6
430	HSCIDB48K	malonyi-CoA decarboxylase (EC 4.1.1.9) pirjA33313 A3331 - goose >gi 305323 malonyl CoA	-[A33313 A3331 3	35	466	//	-	HSODB48
		decarboxylase [Anser anser] {SUB 33-						
		462 Length = 462						
431	HBEAC75R	HBEAC75R membrane glycoprotein [Homo sapiens] Length = 385	gi 307132	C 1	217	73	62	HBEAC75
432	HBGMJ24R	HBGMJ24R mitochondrial RNA polymerase [Homo	gi 2114396	3	479	100	100	HBGMJ24
		sapiciis j Lengin – 1230						

433

434

HBJEN94R	HBJEN94R mitotic kinase-like protein-1 [Homo sapiens] >pir \$28262 \$28262 kinesin-related protein MKLP-1 - human >sp Q02241 MKLP_HUMAN MITOTIC KINESIN-LIKE PROTEIN-1. Length = 960	gi 34672	_	327	88	68	HBJEN94
HCIAE73R	HCIAE73R motor protein [Homo sapiens] Length = 721	gnlP1D d1005183	73	324	100	100	HCIAE73
HCNDN88R mucin 2 (fragme sapiens) MUC2 3020	(fragments) >gi 186396 mucin [Homo sapiens] {SUB 626-1895} >gi 186398 MUC2 [Homo sapiens] {SUB 2037-3020} >gi 188874 intestinal mucin [Homo sapiens] {SUB 1916-2193} >gi 188615 mucin-like protein [Homo sapiens] {SUB 1916-2193} >gi 188615 mucin-like protein [Homo sapiens] {SUB 23	pir A49963 A4393 2	-	171	95	76	HCNDN88
HSIDX70R	N-benzoyl-L-tyrosyl-p-amino-benzoic acid hydrolase alpha subunit [Homo sapiens] >pir S60193 HYHUMA meprin A (EC 3.4.24.18) alpha chain precursor human >sp Q16819 MEPA_HUMAN MEPRIN A ALPIIA-SUBUNIT PRECURSOR (EC 3.4.24.18) (ENDOPEPTIDASE-2) (N- BENZOYL-L-	gi 535475	C 1	253	96	94	HSIDX70

, ני	4000000		00000	(000	;	1	
\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	III. W DCJYN NAFRT [human, sapiens] exchang >splP190 SODIUN 1 (NA(+ 1) (NA+	In Nat/Int exclidinger NITC-1 Isolonin [human, heart, Peptide, 815 aa] [Homo sapiens] >pir[157487][57487 Na+/H+-exchanging protein NHE-1 - human >sp[P19634]NAH1_HUMAN SODIUM/HYDROGEN EXCHANGER 1 (NA(+)/H(+) EXCHANGER 1) (NA+/H+ ANTIPORTER, AMILORIDE-SENSI	00S 1433.22	71	8 8 7			HLWBC39
438	HWLAA06R	ubiquinone) (EC anzee (fragment) NTR NADH- NREDUCTASE FRAGMENT).	pir A00435 A0043 5	99	194	98		HWL,AA06
439	HASCH25R	HASCH25R NADH-UBIQUINONE splQ16795 NUEM OXIDOREDUCTASE 39 KD SUBUNIT HUMAN PRECURSOR (EC 1.6.5.3) (EC 1.6.99.3) (COMPLEX 1-39KD). >gi 189049 NADH dehydrogenase (ubiquinone) [Homo sapiens] {SUB 3-377}. Length = 377	splQ16795 NUEM _HUMAN	57	143	78	83	HASCH25
440	HLQGB87R	NADPHferrihemoprotein reductase (EC 1.6.2.4) - human >sp P16435 NCPR_HUMAN NADPH-CYTOCHROME P450 REDUCTASE (EC 1.6.2.4) (CPR). {SUB 2-677} Length = 677.	pirjA33421JA6055 7	_	4 	92	93	HLQGB87

	III:DMD17R neutrophil gelatinase associated lipocalin [Homo sapiens] >sp[P80188]NGAL_HUMAN NEUTROPHIL GELATINASE- ASSOCIATED LIPOCALIN PRECURSOR (NGAL) (P25) (25 KD ALPHA-2-MICROGLOBULIN- RELATED SUBUNIT OF MMP-9) (LIPOCALIN-2) (ONCOGENE 24P3).	ينا ⁰ 29657	_	129	74	78	H-DMD17
142	Lengin = 136 HAOAC69R nuclear autoantigen [Homo sapiens] >pir A37244 A37244 nuclear autoantigen Sp-100 - human Length ≅ 480	gi 178689	٣	500	88	88	HAOAC69
	HWLEQ08R Nuclear localization signal at AA 569-573, 576-580, 579-583; acidic transcr. activ. domain 620-640.; homeobox motif 653-676 [Homo sapiens] >pir[A47456]A47456 down-regulated in adenoma (DRA) - human >splP40879]DRA_HUMAN DRA PROTEIN (DOWN-REGULATED IN ADENO	gi 291964	161	364	27	\$	IIWL.EQ08
44 4	HKAAV70R nucleic acid binding protein [Homo sapiens] >pir 138191 138191 nucleic acid binding protein - human (fragment) >sp Q15410 Q15410 NUCLEIC ACID BINDING PROTEIN (FRAGMENT).	gi 431953	~	432	73	73	HKAAV70

HOCT1B64	HOFNB62	HAUAU04	HNFJE41	нскон92	HOUID53
06	. 06	88	76	93 1	49
88	88	87	94	93	45
212	312	267	423		213
n	_	_	_	2	85
gnl PLD e307278	gi 1036793	gi 189106	gi 2754713	pir B27430 B2743 0	oir A61382 A6138 2
ORIGINAL PIGR [unidentified] >gi[456346 Polymeric immunoglobulin receptor [Homo sapiens] >bbs[62408 transmembrane secretory component, poly-lg receptor, SC [human, colonic adenocarcinoma cell line, Peptide, 764 aa] [Homo sapiens] >bbs[113253 transmembrane	HOFNB62R ornithine decarboxylase [Bos taurus] >gi 163449 ornithine decarboxylase [Bos taurus] >sp P27117 DCOR_BOVINORNITHINE DECARBOXYLASE (EC4.1.17) (ODC). >gi 604513 ornithine decarboxylase [Bos taurus] {SUB 1-34} Length = 461	HAUAU04R p22 phagocyte b-cytochrome [Homo sapiens] >pir[A28201[A28201] acytochrome b-245 alpha chain - human >sp[P13498[C24A_HUMAN CYTOCHROME B-245 LIGHT CHAIN (P22 PHAGOCYTE B-CYTOCHROME) (NEUTROPHIL CYTOCHROME B, 22 KD POLYPEPTIDE) (P22-PHOX) (CYTOCHROME B(558) AL	p47-phox [Homo sapiens] >sp O43842 O43842 P47-PHOX. Length = 390	HCFOH92R phosphoprotein phosphatase (EC 3.1.3.16) catalytic beta chain - pig (fragment) Length = 293	phosphorylation regulatory protein HP-10 pir A61382 A6138 - human Length = 492
HOCTB64R ORIGI >gil45 recepte transm poly-1g adenoc adenoc transm	HOFNB62R	HAUAU04R	HNFJE41R	HCFOH92R	HOUIDS3R
145	446	447	448	149	450

∞

151	FICRMW41R	HCRMW41R polypeptide BM28 [Homo sapiens] Length = 892	gi 468704	_	282	001	100	IICRMW41
452	HOVAX78R P	porin [Homo sapiens] >pir[A45972]A45972 mitochondrial porin, long form - human >splP45880]POR2_HUMAN VOLTAGE-DEPENDENT ANION- SELECTIVE CHANNEL PROTEIN 2 (VDAC2) (OUTER MITOCHONDRIAL MEMBRANE PROTEIN PORIN). >gil190201 porin [Homo sapiens] {SUB	gi 190200	C 1	214	94	86	HOVAX78
453	HWAEH57R p	precursor [Homo sapiens] >sp P06314 KV4C_HUMAN IG KAPPA CHAIN PRECURSOR V-1V REGION (B17). Length = 134	gi 37910	-	462	16	93	нwаенs7
454	HHBHJ76R p	presenilin 1-463 [Homo sapiens] >pir S63683 S63683 presenilin 1-463 - human Length = 463	gi 1244638	-	303	86	86	ннвн176
455	HBJFA18R P	prosomal P27K protein [Homo sapiens] >gnl PID d1002062 proteasome subunit R-IOTA [Rattus sp.] >pir S30274 S30274 multicatalytic endopeptidase complex (EC 3.4.99.46) iota chain - human >pir JX0230 JX0230 multicatalytic endopeptidase complex (EC 3.4.99.46)	gi 35682	178	402	79	83	HBJFA18
456	HCRNF16R p	protein kinase [Homo sapiens] >sp PS1956 NEK3_HUMAN SERINE/THREONINE-PROTEIN KINASE NEK3 (EC 2.7.1) (NIMA- RELATED PROTEIN KINASE 3) (HSPK 36) (FRAGMENT). Length = 459	gi 479173	336	473	73	79	HCRNF16

НАНЕК76	неорт38	HOSCG81	HTFMD43	нотсф68
98	100	96	001	001
83	001	96	001	001
440	316	297	242	291
33	C 1	-	n	43
gni PIDje188111	gni P1D d1001551	gi 337457	gi 1373419	gi 337495
HAHEK76R putative surface glycoprotein [Homo sapiens] >splP53801 C211_HUMAN PUTATIVE SURFACE GLYCOPROTEIN C210RF1	HEOPT38R renin-binding protein [Homo sapiens] >gi 1302662 renin-binding protein [Homo sapiens] >pir 1X0188 JX0188 renin-binding protein - human Length =	HOSCG81R ribonucleoprotein La [Homo sapiens] >sp Q15367 Q15367 RIBONUCL.EOPROTEIN (LA) (FRAGMENT). >gi 338496 SS-B/La protein [Homo sapiens] {SUB 121-171} Length = 355	HTFMD43R ribosonnal protein L39 [Homo sapiens] >gnl[P1D]d1012131 ribosomal protein L39 [Homo sapiens] >gi 575382 ribosomal protein L39 [Rattus norvegicus] >pir JC4229 R6RT39 ribosomal protein L39 - rat >pir G02654 G02654 ribosomal protein L39 - human Length = 51	HDTGQ68R ribosomal protein L7a large subunit [Homo sapiens] >gi[34203 L7a protein [Homo sapiens] >si[35512 PLA-X polypeptide [Homo sapiens] >gi[36647 ribosomal protein L7a [Homo sapiens] >gi[56956 ribosomal protein L7a (AA 1-266) [Rattus rattus] >pir[S19717]R5HU7A
HAHEK76R	НЕОРТ38R	HOSCG81R	HTFMD43R	HDTGQ68R
457	458	459	460	461

23 505 100 100 H2LAR73	3 458 97 97 HAMFM26	I 219 53 55 HBMTM61	198 320 56 64 HWHPK71	4 2 127 81 84 HWBBJ39	2 319 96 98 HSLJJ36	0 2 232 61 70 HSODD94	I 330 82 82 HMIAG25	2 304 78 82 HWLEM94
gi 495273	gi 292457	gi 488299	gi 829617	gnl PID e236014	gi 1000284	gnlP1D c1192260	gi 507213	gi[2507613
H2LAR73R ribosomal protein S15a [Rattus norvegicus] >pir JC2234 JC2234 ribosomal protein S15a - rat Length = 130	HAMFM26R ribosomal protein S6 kinase 1 [Homo sapiens] >pir[151901 151901 ribosomal protein S6 kinase 2 - human >sp[Q15418]KS61_HUMAN RIBOSOMAL PROTEIN S6 KINASE II ALPHA 1 (EC 2.7.1) (S6KII-ALPHA 1) (1990-RSK 1) (RIBOSOMAL S6 KINASE 1) (Lenuth =	Rieske Fe-S protein [Homo sapiens] Length = 274	IWITPK71R RIP Homo sapiens >pir 138992 138992 receptor interacting protein RIP - human (fragment) Length = 372	Sec23 protein [Homo sapiens] Length = 767	selenium donor protein [Homo sapiens] Length = 383	HSODD94R selenoprotein P [Homo sapiens] Length = 381	HMIAG2SR serine kinase [Homo sapiens] >pir[S45337 S45337 serine protein kinase SRPK1 - human >sp[Q12890 Q12890 SERINE KINASE. Length = 655	serine protease [Homo sapiens] Length =
H2LAR73R	HAMFM26R	HBMTM61R Rieske Length	HWHPK71R	HWBBJ39R Sec23	HSLJJ36R	HSODD94R	HMIAG25R	HWLEM94R serine
462	463	464	594	466	467	468	469	470

> Synaptosome associated protein of 23 kilodaltons, isotorm A [Homo sapiens] > pur DC5296 DC5296 vesicle-membrane fusion protein SNAP-23A - human > sp O00161 O00161 VESICLE- MEMBRANE FUSION PROTEIN SN HULFN68R sorcin CP-22 [Homo sapiens] > gi 459836 sorcin [Homo sapiens] > pir S52094 S52094 sorcin - human > gi 2772536 (AC003991) calcium binding protein amplified in multidrug- resistant cells [Homo sapiens] {SUB 1- 68} Length = 198 HMEJD77R SRp30c [Homo sapiens] {SUB 1- 68} Length = 198 sapiens] > gi 4099429 splicing factor SRp30c [Homo sapiens] > pir S59075 S59075 S59075 splicing factor SRp30c - human > splC4099429 SPLICING SRp30c - human > splC4099429 SPLICING SRp30c - human > splC4009429 SPLICING SRp30c - human > splC4009429 SPLICING SRp30c - human > splC4009429 SPLICING
FACTOR SRP30C. Length = 22 stimulator of TAR RNA binding [Homo gi 1200184 sapiens] Length = 539

476	HTEJJ32R	STM-7 [Homo sapiens] >splQ92749 Q92749 TYPE I PHOSPHATIDYLINOSITOL-4- PHOSPHATE 5-KINASE BETA (EC 2.7.1.68) (STM-7 PROTEIN). >gi 1743883 type I phosphatidylinositol- 4-phosphate 5-kinase beta [Homo sapiens] {SUB 112-502} >gi 1743879	gnl PID e206448	m	341	001	001	нтел32
477	HETIF46R	type I phosphatidylinosi sulfate transporter [Flomo sapiens] >sp P50443 DTD_HUMAN SULFATE TRANSPORTER (DIASTROPHIC DVSPI ASIA PROTEIN) I enath = 730	gi 549988		228	17	7.1	HET1F46
478	H2CBS58R	thrombospondin 2 [Flomo sapiens] >pir[A47379]TSHUP2 thrombospondin 2 precursor - human [enoth = 1172	gi 307506		455	96	64	H2CBS58
479	H2LAB77R	H2LAB77R thymosin beta-4 precursor [Rattus norvegicus] >pir[152084 152084 thymosin beta-4 precursor - rat (fragment) >gi[339689 thymosin beta-4 [Homo sapiens] {SUB 13-56} >pir[A01521 TNBOB4 thymosin beta-4 - bovine {SUB 14-56} >gi[825683 open reading frame [Homo s	gi 207318	86	265	001	001	H2LAB77
480	HODAJ23R	HODAJ23R tissue-specific secretory protein [unidentified] >gi]32051 HE4 protein [Homo sapiens] >pir[S25454]S25454 HE4 protein - human >sp Q14508 EP4_HUMAN MAJOR EPIDIDYMIS-SPECIFIC PROTEIN E4 PRECURSOR (HE4) (EPIDIDYMAL SECRETORY PROTEIN E4). Length =	gi[583141	6	223	62	62	HODAJ23

481	HWAFP88R TRAN (RNA TRAN = 204	TRANSCRIPTION FACTOR BTF3 (RNA POLYMERASE B TRANSCRIPTION FACTOR 3). Length = 204	splQ64152lBTF3_ MOUSE	82	471	95	93	HWAFP88
:482	HDTHISIR	HDTHISIR transcription factor-like protein 4 - húman Leneth = 298	pir JC5333 JC5333	C1	265	82	98	ISHITAH
483	HWMEB67R	HWMEB67R tryptase-III [Homo sapiens] >sp[Q15664[Q15664 TRYPTASE-III (FRAGMENT). Length = 267	gi 339985	21	218	92	65	HWMEB67
484	HTXOU93R	tumor susceptibility protein [Homo sapiens] >sp[Q99816[Q99816 TUMOR SUSCEPTIBILITY PROTEIN. Length = 390	gi 3184258	C 1	439	001	001	IITXOU93
485	HANKB37R	HANKB37R ubiquitin [Plasmodium falciparum] >sp Q26029 Q26029 UBIQUITIN. Length = 77	gi 552237	=	115	70	73	HANKB37
486	HWLHN38R	ubiquitin-conjugating enzyme [Mus musculus] >sp O88738 O88738 UBIQUITIN-CONJUGATING	gnl PID e1311091	129	347	77		HWLHN38

125

HOSDZ35	HKMAA52	H2LAB37	H2LAP46	H6BSE61	H6EEE76	H6EEV26	HABAF88	HABGD41	HACBS75	IACCA48	HACCS19	HADAB25	HAGGL96
1	86						_		_	_	_	_	_
88	86												
786	284	290	998	369	773	88	917	11	87	91	341	198	347
C1	m			. 29							m		m
gni PIDje209711	gi 624725												
acetylgalactosaminyltransferas [Homo sapiens] >sp[Q14435 Q14435 POLYPEPTIDE N-ACETYLGALACTOSAMINYLTRANS FERASE (EC 2.4.1.41) (PROTEIN-UDP ACETYLGALACTOSAMINYLTRANS FERASE) (UDP-GALNAC:POLYPEPTIDE, N-ACETYLGALACTOSAMINYLTRANS FERASE)	HKMAA52R UDP-glucuronosyltransferase [Homo sapiens] >pir A31340 A31340 glucuronosyltransferase (EC 2.4.1.17) UGT1A1 precursor - human >sp G245274 G245274 PHENOL. TRANSFERASE=UGT1F PRODUCT. {SUB 1-286} >gi 2645491 (AF014112) phenol UDP-glucuronosyltransferase [Homo	~	~	~	~	~	œ.	~	~	~	~	~	
HOSDZ35R	HKMAA52	H2LAB37R	H2LAP46R	H6BSE61R	H6EEE76R	H6EEV26R	HABAF88R	HABGD41R	HACBS75R	HACCA48R	HACCS19R	HADAB25R	HAGGL96R
487	88	486	490	161	492	493	104	56t	96†	161	1 08	466	200

e		113	HAGGT37
27	7	347	HAHDR66
791	54	418	HAJCC53
3		122	HAJCL80
37;	21	999	HANKF43
69	6	152	HAPCMII
_		99	HAPNT66
2	~1	148	HAQAG47
3		260	HAQBW58
16	_	363	HAQMH45
_		183	HAQM194
84	7	272	HARNC74
86	90	202	HATBA87
17,	74	392	HATBG77
		231	HBAGQ79
2	~ 1	82	HBCAN64
_		123	HBGCA44
3	~	281	HBGFX27
40	0	429	HBGMU38
		93	HBJBO10
2	~ !	901	HBJCC53
		252	HBJEDSS
2	٥,	901	HBJGR39
39	6	344	HBJLU30
93	3	245	HBKEC78
~		192	HBMST81
15(.0	323	HBMTJ51
_		Ξ	HBMWF72
2	~ 1	226	HBWBD78
2	- 21	79	HBXCU02
		138	HCDAK65

HAGGT37R HAHDR66R HAJCC53R HAJCL80R HANKF43R HAPCM11R	HAQAG47R HAQBW58R HAQMH45R HAQMI94R HARNC74R	TBG AGG CAN GCA GFX GFX JBO	ひし スコクロンとロコオ
501 502 503 504 505 506		514 515 516 517 517 519 520	521 522 523 524 524 525 526 527 528 529 530

HCUBMUS	HCDCP10	HCDDQ63	нсеен05	HCEIQ92	HCFCD01	HCFCR43	HCFLT83	HCHA092	HCHOH49	HCHPG05	HCIAD24	HCNCA90	HCNCN80	HCNCYSI	HCNCY63	HCND071	HCNDV83	HCNUB26	HCQBN22	HCQCL27	HCQCL48	96ПООСПОВ	HCQDC74	нсорн94	HCQDJ42	HCRMD77	HCRME02	FICRMX88	HCRNA70	HCRNP66
339	206	911	380	06	228	360	104	342	344	919	301	532	353	267	81	213	303	289	94	235	251	430	360	92	388	185	293	284	204	431
130	72	'n	204	_	5 8	64	3	193	183	365	86	380	120	184	_	_	64	611	7	911	23	287	145	50	149	3	٣	3	40	٣

HCDBM08R	HCDCP10R	000	HCEEH05R	HCEIQ92R	HCFCD01R	HCFCR43R	HCFLT83R	Η	HCHOH49R	HCHPG05R	HCIAD24R	HCNCA90R	IICNCN80R	HCNCYSIR	HCNCY63R	HCND071R	HCNDV83R	HCNUB26R	HCQBN22R	HCQCL27R	HCQCL48R	HCQCL96R	HCQDC74R	HCQDH94R	HCQDJ42R	2	HCRME02R	HCRMX88R	RNA70	HCRNP66R
\sim	533	534	535	536	3	538	539	540	541	542	543	544	545	246	547	548	549	550	2	552	553	554	555	Š	Š	Ġ.	Š	995	9	262

HE/1140 HE9FH12	268 307	
11E6DJ45	64	C1
HE6CS28	213	O .
HDT:MJ22	809	192
HDT.1085	197	36
HDRMI91	911	~
HDQEX80	492	274
HDQDB15	417	220
HDPLB08	360	142
HDPG003	352	011
HDDAA85	258	139
HDCAA21	120	-
HCWDS78	558	322
HCRQC89	85	7
HCRPV74	409	179
HCRPS40	321	208
HCRPN52	161	~
HCRPL80	235 .	59
HCRPG28	229	95
HCRPC61	194	٣
HCROZ66	427	239
HCROQ54	86	٣
HCROQ34	136	53
HCROM30	365	3
HCROK94	210	_
HCROK68	208	ر.
HCROJ68	239	3
HCROJ05	170	99
HCROH25	128	~
HCRNX32	961	C1

HCROM232R HCROH25R HCROJ05R HCROJ68R	OK94 OM30		HCROZ66R HCRPC61R	HCRPG28R HCRP1 80B	HCRPN52R	HCRPS40R	FICKPV /4K FICKQC89R	HCWDS78R	HDCAA21R HDDAA85R	HDPG003R	DPLB08	B15	QEX80	RMI91	1.1085	TMJ22	HE6CS28R	HE6DJ45R	HE7TJ40R	HE9FH12R
563 564 565 566 567	568 569	570 571	572 573	574	276	577	578 579	280	581	583	584	285		∞				S		593

3	74 506	HE9HJ57 HE90H08
961 198	390 425	HE9TC50
_	150	HEAAL59
448	675	HEGAR32
361	534	HEGAR85
32	187	HELFE05
۲	343	HEMF188
83	397	HEMFR18
2	92	HEONL43
3	116	HESAC53
_	138	HETJB05
	102	HETJC36
_	78	HFADM62
C 1	361	HFATE31
3	152	HFATZ30
33	278	HFCEL77
174	491	HFFBN43
272	469	HFGAF10
	144	HFIEC01
317	427	HFIIR75
2	124	HFIUB90
37	159	HFIUM71
_	117	HFOXL53
961	408	HFPBO66
47	220	HFTB157
-	126	HFTCC22
_	114	HFXGX46
6	661	HGAME72
142	279	HGBCS53
. 87	221	HGBHP81

HE9HJ57R HE9QH08R HE9TCS0R	AAL59 GAR32	GAR85	HELFE05R	HEMF188R	HEMFRI8R HEONI 43R	HESACS3R	18	HETJC36R	HFADM62R	HFATE31R	HFATZ30R	HFCEL77R	HFEBN43R	HFGAF10R	HFIECOIR	HFIIR75R	HFIUB90R	HFIUM71R	HFOXL53R	HFPBO66R	HFTB157R	HFTCC22R	HFXGX46R	HGAME72R	BCS53	HGBHP81R
594 595 596	6	299		601	603		605	909	209	809	609	019	611				_	_	617		619		CI			624

												,	<i>,</i> , ,																	
HGCOX03	HHBES92	HHBEW72	HHERT59	HHMMD64	HHSGT13	HISED82	11JMAH76	HJMAN56	HJMAO54	HKDAD56	HKLSD93	HLMFH16	HLQBD52	HLQCQ73	HLQEF47	HLQFM50	HLQFY61	HLQGA76	HI.QGE53	HLTEV09	HLXNE63	HLXTF64	HMACF85	HMAIA15	HMCHZ07	HMCIS54	HMSFW88	HMSMW71	HNHMR05	HNJBB78
511	483	219	88	252	619	126	253	180	291	601	298	447	195	350	503	291	575	404	99	371	258	136	430	452	402	242	69	514	868	282
323	349	13	C1	31	428	_	C1	-	-	2	68	_	_	٣	348	136	411	210	_	210	142	CI	23	108	247	%	_	290	11	16
		٠																												

HGCOX03R	HHBES92R	HI:BEW72R	HHERT59R	HHMMD64R	HHSGT13R	HISED82R	HJMAH76R	HJMAN56R	IIJMAO54R	HKDAD56R	HKLSD93R	HLMFH16R	HLQBD52R	HLQCQ73R	HLQEF47R	HLQFM50R	HLQFY61R	HLQGA76R	HLQGE53R	HLTEV09R	HLXNE63R	HLXTF64R	HMACF85R	HMAIAISR	HMCHZ07R	\overline{c}	5	HMSMW71R	RO	HNIRR78R
625	Ć.	Ċ	628	679		631	632	633	m	635	636	637	638	639	640	641	642	643	4	645	9+9	647	648	649	059	651		653	Ś	

٣	362	HNTMA96
130	291	HNT/RL32
۲3	397	HNTST76
29	156	HOCNCSS
147	275	HOCND06
133	273	HOCND49
7	154	НОДЕН30
263	550	HODFA26
106	279	HODHL89
C1	364	HOEJM67
147	380	HOGBN48
C1	364	HOHCX95
٣	365	HORBP43
235	345	HOUHN53
7.2	254	HOUNE 10
107	211	HPBEE63
_	237	HPEBO20
_	312	HPJBE91
32	133	HPTRW82
33	272	HPWDC51
_	330	HPWDK52
C1	334	HRDBJ82
C 1	121	HRODI493
_	120	HS2AD53
m	203	IISATR92
>	136	HSDZG83
7	118	HSICQ60
ری	449	HSIFA64
108	527	HSKNN36
C1	124	HSK YES2
C 1	691	HSLJA55

HPTRW82R HPWDC51R HPWDK52R HRDBJ82R HROBH93R

HS2AD53R HSATR92R

HSDZG83R HSICQ60R

ISKNN36R 4SK YE52R

HSIFA64R

HORBP43R HOUHNS3R HOUIE10R HPBEE63R

HPEBO20R

HPJBE91R

HOGBN48R HOHCX95R

HNTMA96R HNTST76R

HOCNCSSR HOCND49R HODEH30R HODFA26R HODHL89R HODHL89R

HSODA95	HSPBS19	HSSGK43	HSXFJ91	HTEMB57	HTGBR05	HTLGA72	H17.LIX61	HTNTF25	HTWCP79	HTXFA64	HUSJF91	HUSJN48	HUSIX68	HUSZN23	111.17.51)20	HWACHIO	HWAF163	HWAGZ89	IIWBAQ20	HWHHM83	HWLAC24	HWLAC81	HWLBF27	HWLBS90	HWLCU10	HWLEHI3	HWLEJ67	HWLEM49	HWLFP27	HWLGG20
169	372	155	242	410	138	455	102	426	180	263	412	462	493	131	256	275	272	385	177	298	133	360	149	347	120	379	527	354	79	208
7	_	~	٣	891	37	ιŋ	-	307	16	ιŋ	218	259	86	36	104	90	3	176	_	C1	=	64	m	195	55	CI	375	244	C 1	92

HWAF163R HWAGZ89R HWBAQ20R HWHHM83R HUSZN23R HUSZN23R HUTSD20R HWACHIOR HTGBR05R HTLGA72R HTLIX61R HTNTF25R HUSJF91R HUSJN48R HWLAC24R HTEMB57R HTWCP79R HTXFA64R HWLAC81R HWLBF27R HWLBS90R HWLCUIOR HWLEHI3R HWLEM49R HSODA95R HWLE167R HSSGK43R HSPBS19R HSXFJ91R

HWLGK22	HWLGM21	HWLGP37	HWLGS46	HWLGU40	HWLGX65	IIWLIID09	HWLHD50	HWLFIM40	HWLHW89	HWLID17	HWLIM20	HWLJA26	HWLJA28	HWLJG57	HWLJL19	HWLJP50	HWLKG82	HWLKG95	HWLK153	HWLKM09	HWLKM86	HWLKM95	HWLKU25	HWLQS83	HWLQU65	HWLRLS9	HWLRP86	HWL.RQ49	HWLUF60	HWLU137
373	354	181	324	202	230	310	86	208	382	276	158	135	108	404	292	147	360	300	144	100	226	184	137	117	558	225	253	158	218	263
209	244	œ	40	C1	~	۲	٣	C1	99	64	'n	. .		240	119	_	_	_	_	7	44	Cì	٣	_	361	_	L1	3	84	21

22	HWLGM21R	HWLGP37R	HWLGS46R	HWLGU40R	HWLGX65R	HWLHD09R	HWLHD50R	LE IM	HWLHW89R	9	HWLIM20R	Ϋ́	JA28	JG57	HWLJL19R	HWLJP50R	HWLKG82R	\odot	HWLK153R	\geq	χX	HWLKM95R	¥.	\subseteq	9	~	WLR	LRQ49	WLUF60	IWLU13
_	_	$^{\circ}$	121	722	CI	CI	2	C.I	727	\sim	CI	\sim	3	3	733	3	735	736	3	738	Ē	740	741	742	743	744	ন	246	7	748

HWLUR41 HWLVV50 HWLVV50 HWMAN61 HWMEH13 HWMEH26 HWMEL50 HWMFB31 IIWMFL66 HWMF093 HWMFP01 HZAAD81	HFIXK57	HMAFE48
	76	001
	06	
155 174 72 107 185 256 341 400 285 153 79 160	211	205
33 2 2 2 87 131 100 61 2	2	74
	gi 13011	gi 13011
	URF 3 (NADH dehydrogenase subunit) [Homo sapiens] >gil506832 protein 3 [Homo sapiens] >pir A00422 DNHUN3 NADH dehydrogenase (ubiquinone) (EC 1.6.5.3) chain 3 - human mitochondrion (SGC1) >sp P03897 NU3M_HUMAN NADH-UBIQUINONE OXIDOREDUCTASE CHAIN 3 (EC 1.6	URF 3 (NADH dehydrogenase subunit) [Homo sapiens] >pit 506832 protein 3 [Homo sapiens] >pit A00422[DNHUN3 NADH dehydrogenase (ubiquinone) (EC 1.6.5.3) chain 3 - human mitochondrion (SGC1) >sp P03897 NU3M_HUMAN NADH-UBIQUINONE OXIDOREDUCTASE CHAIN 3 (EC 1.6
HWLUR4IR HWLVV50R HWMAN6IR HWMEH13R HWMEH26R HWMEL50R HWMFL50R HWMFL66R HWMFC03R HWMFC03R HWMFP01R HWMFP01R	HFIXK57R	HMAFE48R
749 750 751 752 753 754 755 755 757 757 757 750 760	763	764

HRODJ88	HWLAR31	HNHLH26	H2LAU24	HATDR94	HWLL185
94	001	92	09	100	80
83	-	64	45	95	09
213	214	243	488	367	580
55		73	78	2	410
gi 13011	gi 13011	gi 1912453	gi 746495	gi 306893	gi 3123843
URF 3 (NADH dehydrogenase subunit) [Homo sapiens] >gi \$06832 protein 3 [Homo sapiens] >pir A00422 DNHUN3 NADH dehydrogenase (ubiquinone) (EC 1.6.5.3) chain 3 - human mitochondrion (SGC1) >sp P03897 NU3M_HUMAN NADH-UBIQUINONE	HWLAR31R URF 3 (NADH dehydrogenase subunit) [Homo sapiens] >gi 506832 protein 3 [Homo sapiens] >pir A00422 DNHUN3 NADH dehydrogenase (ubiquinone) (EC 1.6.5.3) chain 3 - human mitochondrion (SGC1) >sp P03897 NU3M_HUMAN NADH-UBIQUINONE OXIDOREDUCTASE CHAIN 3 (EC 1.6	v-SNARE {Cricetulus griseus} >sp 008522 008522 V-SNARE. Length = 250	weakly similar to gastrula zinc finger protein [Caenorhabditis elegans] >splQ09998 Q09998 PUTATIVE 55.5 KD ZINC FINGER PROTEIN R144.3 IN CHROMOSOME III. Length = 492	HATDR94R X box binding protein-1 [Homo sapiens] >pir A36299 A36299 transcription factor hXBP-1 - human Length = 260	HWLL185R X-linked deafness dystonia protein [Homo sapiens] >splO60220 O60220 X- LINKED DEAFNISS DYSTONIA PROTEIN. Length = 97
HRODJ88R	HWLAR31R	HNHLH26R v-SNA >sp O0 = 250	H2LAU24R weakly protein >sp Q00 KD ZIN CHRON	HATDR94R	HWLL185R
765	766	797	768	692	770

177	НВНМF67R	HBHMF67R XP-C repair complementing protein (p58/HHR23B) [Homo sapiens] >pir S44346 S44346 RAD23 protein homolog - human Length = 409	gnlPtD d1005181	m	161	96	96	HBHMF67
772	HSYCH41R	HSYCH41R yeast methionyl-tRNA synthetase homolog [Homo sapiens] >pirJIC5224[JC5224 methioninetRNA ligase (EC 6.1.1.10) - human >gil804996 mitoxantrone-resistance associated gene [Homo sapiens] {SUB 423-900} Length = 900	gnl PlD e218477	61	373	06	06	HSYCH41
773	HWLJR53R	HWLJR53R zinc finger protein PZF [Mus musculus] >pir 48724 48724 zinc finger protein PZF - mouse >sp Q6251 Q6251 ZINC FINGER PROTEIN PZF. Length = 455	gi 453376	_	552	18	83	HWLJR53

WO 00/55351

5

10

15

20

25

30

89

PCT/US00/05883

The first column of Table 1 shows the "SEQ ID NO:" for each of the 773 colon cancer antigen polynucleotide sequences of the invention.

The second column in Table 1, provides a unique "Sequence/Contig ID" identification for each colon and/or colon cancer associated sequence. The third column in Table 1. "Gene Name," provides a putative identification of the gene based on the sequence similarity of its translation product to an amino acid sequence found in a publicly accessible gene database, such as GenBank (NCBI). The great majority of the cDNA sequences reported in Table 1 are unrelated to any sequences previously described in the literature. The fourth column, in Table 1, "Overlap," provides the database accession no. for the database sequence having similarity. The fifth and sixth columns in Table 1 provide the location (nucleotide position nos. within the contig), "Start" and "End", in the polynucleotide sequence "SEQ ID NO:X" that delineate the preferred ORF shown in the sequence listing as SEQ ID NO:Y. In one embodiment, the invention provides a protein comprising, or alternatively consisting of, a polypeptide encoded by the portion of SEQ ID NO:X delineated by the nucleotide position nos. "Start" and "End". Also provided are polynucleotides encoding such proteins and the complementary strand thereto. The seventh and eighth columns provide the "% Identity" (percent identity) and "% Similarity" (percent similarity) observed between the aligned sequence segments of the translation product of SEO ID NO:X and the database sequence.

The ninth column of Table 1 provides a unique "Clone ID" for a clone related to each contig sequence. This clone ID references the cDNA clone which contains at least the 5' most sequence of the assembled contig and at least a portion of SEQ ID NO:X was determined by directly sequencing the referenced clone. The reference clone may have more sequence than described in the sequence listing or the clone may have less. In the vast majority of cases, however, the clone is believed to encode a full-length polypeptide. In the case where a clone is not full-length, a full-length cDNA can be obtained by methods described elsewhere herein.

Table 3 indicates public ESTs, of which at least one, two, three, four, five, ten, or more of any one or more of these public ESTs are optionally excluded from the invention.

SEQ ID NO:X (where X may be any of the polynucleotide sequences disclosed in the sequence listing as SEQ ID NO:1 through SEQ ID NO:773) and the translated SEQ ID NO:Y (where Y may be any of the polypeptide sequences disclosed in the sequence listing as SEQ ID NO:774 through SEQ ID NO:1546) are sufficiently accurate and otherwise suitable for a

WO 00/55351

5

10

15

20

25

30

PCT/US00/05883

variety of uses well known in the art and described further below. For instance, SEQ ID NO:X has uses including, but not limited to, in designing nucleic acid hybridization probes that will detect nucleic acid sequences contained in SEQ ID NO:X or the related cDNA clone contained in a library deposited with the ATCC. These probes will also hybridize to nucleic acid molecules in biological samples, thereby enabling immediate applications in chromosome mapping, linkage analysis, tissue identification and/or typing, and a variety of forensic and diagnostic methods of the invention. Similarly, polypeptides identified from SEQ ID NO:Y have uses that include, but are not limited to, generating antibodies which bind specifically to the colon cancer antigen polypeptides, or fragments thereof, and/or to the colon cancer antigen polypeptides encoded by the cDNA clones identified in Table 1.

Nevertheless, DNA sequences generated by sequencing reactions can contain sequencing errors. The errors exist as misidentified nucleotides, or as insertions or deletions of nucleotides in the generated DNA sequence. The erroneously inserted or deleted nucleotides cause frame shifts in the reading frames of the predicted amino acid sequence. In these cases, the predicted amino acid sequence diverges from the actual amino acid sequence, even though the generated DNA sequence may be greater than 99.9% identical to the actual DNA sequence (for example, one base insertion or deletion in an open reading frame of over 1000 bases).

Accordingly, for those applications requiring precision in the nucleotide sequence or the amino acid sequence, the present invention provides not only the generated nucleotide sequence identified as SEQ ID NO:X, the predicted translated amino acid sequence identified as SEQ ID NO:Y, but also a sample of plasmid DNA containing the related cDNA clone (deposited with the ATCC, as set forth in Table 1). The nucleotide sequence of each deposited clone can readily be determined by sequencing the deposited clone in accordance with known methods. Further, techniques known in the art can be used to verify the nucleotide sequences of SEQ ID NO:X.

The predicted amino acid sequence can then be verified from such deposits. Moreover, the amino acid sequence of the protein encoded by a particular clone can also be directly determined by peptide sequencing or by expressing the protein in a suitable host cell containing the deposited human cDNA, collecting the protein, and determining its sequence.

The present invention also relates to vectors or plasmids which include such DNA sequences, as well as the use of the DNA sequences. The material deposited with the ATCC on:

Table 2

5

10

15

ATCC Deposits	Deposit Date	ATCC Designation Number
LP01, LP02, LP03, LP04,	May-20-97	209059, 209060, 209061, 209062.
LP05, LP06, LP07, LP08,		209063, 209064. 209065, 209066,
LP09, LP10, LP11,		209067, 209068. 209069
LP12	Jan-12-98	209579
LP13	Jan-12-98	209578
LP14	Jul-16-98	203067
LP15	Jul-16-98	203068
LP16	Feb-1-99	203609
LP17	Feb-1-99	203610
LP20	Nov-17-98	203485
LP21	Jun-18-99	PTA-252
LP22	Jun-18-99	PTA-253
LP23	Dec-22-99	PTA-1081

each is a mixture of cDNA clones derived from a variety of human tissue and cloned in either a plasmid vector or a phage vector, as shown in Table 5. These deposits are referred to as "the deposits" herein. The tissues from which the clones were derived are listed in Table 5, and the vector in which the cDNA is contained is also indicated in Table 5. The deposited material includes the cDNA clones which were partially sequenced and are related to the SEQ ID NO:X described in Table 1 (column 9). Thus, a clone which is isolatable from the ATCC Deposits by use of a sequence listed as SEQ ID NO:X may include the entire coding region of a human gene or in other cases such clone may include a substantial portion of the coding region of a human gene. Although the sequence listing lists only a portion of the DNA sequence in a clone included in the ATCC Deposits, it is well within the ability of one skilled in the art to complete the sequence of the DNA included in a clone isolatable from the

WO 00/55351 PCT/US00/05883

ATCC Deposits by use of a sequence (or portion thereof) listed in Table 1 by procedures hereinafter further described, and others apparent to those skilled in the art.

Also provided in Table 5 is the name of the vector which contains the cDNA clone. Each vector is routinely used in the art. The following additional information is provided for convenience.

5

10

20

25

30

Vectors Lambda Zap (U.S. Patent Nos. 5,128,256 and 5,286,636), Uni-Zap XR (U.S. Patent Nos. 5,128, 256 and 5,286,636), Zap Express (U.S. Patent Nos. 5,128,256 and 5,286,636), pBluescript (pBS) (Short, J. M. et al., Nucleic Acids Res. 16:7583-7600 (1988); Alting-Mees, M. A. and Short, J. M., Nucleic Acids Res. 17:9494 (1989)) and pBK (Alting-Mees, M. A. et al., Strategies 5:58-61 (1992)) are commercially available from Stratagene Cloning Systems, Inc., 11011 N. Torrey Pines Road. La Jolla, CA, 92037. pBS contains an ampicillin resistance gene and pBK contains a neomycin resistance gene. Phagemid pBS may be excised from the Lambda Zap and Uni-Zap XR vectors, and phagemid pBK may be excised from the Zap Express vector. Both phagemids may be transformed into E. coli strain XL-1 Blue, also available from Stratagene.

Vectors pSport1, pCMVSport 1.0, pCMVSport 2.0 and pCMVSport 3.0, were obtained from Life Technologies, Inc., P. O. Box 6009. Gaithersburg, MD 20897. All Sport vectors contain an ampicillin resistance gene and may be transformed into *E. coli* strain DH10B, also available from Life Technologies. See, for instance, Gruber, C. E., et al., *Focus* 15:59 (1993). Vector lafmid BA (Bento Soares, Columbia University, New York, NY) contains an ampicillin resistance gene and can be transformed into *E. coli* strain XL-1 Blue. Vector pCR[®]2.1, which is available from Invitrogen, 1600 Faraday Avenue, Carlsbad, CA 92008, contains an ampicillin resistance gene and may be transformed into *E. coli* strain DH10B, available from Life Technologies. See, for instance, Clark, J. M., *Nuc. Acids Res.* 16:9677-9686 (1988) and Mead, D. et al., Bio/Technology 9: (1991).

The present invention also relates to the genes corresponding to SEQ ID NO:X, SEQ ID NO:Y, and/or the cDNA contained in a deposited cDNA clone. The corresponding gene can be isolated in accordance with known methods using the sequence information disclosed herein. Such methods include, but are not limited to, preparing probes or primers from the disclosed sequence and identifying or amplifying the corresponding gene from appropriate sources of genomic material.

Also provided in the present invention are allelic variants, orthologs, and/or species homologs. Procedures known in the art can be used to obtain full-length genes, allelic variants, splice variants, full-length coding portions, orthologs, and/or species homologs of genes corresponding to SEQ ID NO:X, SEQ ID NO:Y, and/or the cDNA contained in the related cDNA clone in the deposit, using information from the sequences disclosed herein or the clones deposited with the ATCC. For example, allelic variants and/or species homologs may be isolated and identified by making suitable probes or primers from the sequences provided herein and screening a suitable nucleic acid source for allelic variants and/or the desired homologue.

5

10

15

20

25

30

The present invention provides a polynucleotide comprising, or alternatively consisting of, the nucleic acid sequence of SEQ ID NO:X, and/or the related cDNA clone (See, e.g., columns 1 and 9 of Table 1). The present invention also provides a polypeptide comprising, or alternatively, consisting of, the polypeptide sequence of SEQ ID NO:Y, a polypeptide encoded by SEQ ID NO:X, and/or a polypeptide encoded by the cDNA in the related cDNA clone contained in a deposited library. Polynucleotides encoding a polypeptide comprising, or alternatively consisting of, the polypeptide sequence of SEQ ID NO:Y, a polypeptide encoded by SEQ ID NO:X, and/or a polypeptide encoded by the the cDNA in the related cDNA clone contained in a deposited library, are also encompassed by the invention. The present invention further encompasses a polynucleotide comprising, or alternatively consisting of, the complement of the nucleic acid sequence of SEQ ID NO:X, and/or the complement of the coding strand of the related cDNA clone contained in a deposited library.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would unduly burden the disclosure of this application. Accordingly, for each "Contig Id" listed in the first column of Table 3, preferably excluded are one or more polynucleotides comprising a nucleotide sequence described in the second column of Table 3 by the general formula of a-b, each of which are uniquely defined for the SEQ ID NO:X corresponding to that Contig Id in Table 1. Additionally, specific embodiments are directed to polynucleotide sequences excluding at least one, two, three, four, five, ten, or more of the specific polynucleotide sequences referenced by the Genbank Accession No. for each Contig Id which may be

WO 00/55351 PCT/US00/05883

94

included in column 3 of Table 3. In no way is this listing meant to encompass all of the sequences which may be excluded by the general formula, it is just a representative example.

Table 3.

Sequence/	General formula	Genbank Accession No.
500802	Preferably excluded from the present invention are	
300802	one or more polynucleotides comprising a nucleotide	
	sequence described by the general formula of a-b.	
	where a is any integer between 1 to 619 of SEQ ID	
	NO:1, b is an integer of 15 to 633, where both a and	
	b correspond to the positions of nucleotide residues	
	shown in SEQ ID NO:1, and where b is greater than	
631001	or equal to a + 14.	
531091	Preferably excluded from the present invention are	
	one or more polynucleotides comprising a nucleotide	
	sequence described by the general formula of a-b.	
	where a is any integer between 1 to 281 of SEQ ID	
	NO:2, b is an integer of 15 to 295, where both a and	
	b correspond to the positions of nucleotide residues	
	shown in SEQ ID NO:2, and where b is greater than	
	or equal to a + 14.	
553147	Preferably excluded from the present invention are	
	one or more polynucleotides comprising a nucleotide	
	sequence described by the general formula of a-b.	
	where a is any integer between 1 to 428 of SEQ ID	
	NO:3, b is an integer of 15 to 442, where both a and	
	b correspond to the positions of nucleotide residues	
	shown in SEQ ID NO:3, and where b is greater than	
	or equal to a + 14.	
558860	Preferably excluded from the present invention are	
	one or more polynucleotides comprising a nucleotide	
	sequence described by the general formula of a-b,	
	where a is any integer between 1 to 740 of SEQ ID	
	NO:4, b is an integer of 15 to 754, where both a and	
	b correspond to the positions of nucleotide residues	
	shown in SEQ ID NO:4, and where b is greater than	
	or equal to a + 14.	
561730	Preferably excluded from the present invention are	
	one or more polynucleotides comprising a nucleotide	
	sequence described by the general formula of a-b.	
-	where a is any integer between 1 to 379 of SEQ ID	·
	NO:5, b is an integer of 15 to 393, where both a and	
	b correspond to the positions of nucleotide residues	
	shown in SEQ ID NO:5, and where b is greater than	
	or equal to a + 14.	
585938	Preferably excluded from the present invention are	
	one or more polynucleotides comprising a nucleotide	
	sequence described by the general formula of a-b,	
	where a is any integer between 1 to 525 of SEQ ID	
	NO:6, b is an integer of 15 to 539, where both a and	
	b correspond to the positions of nucleotide residues	
	shown in SEQ ID NO:6, and where b is greater than	
	or equal to a + 14.	
587785	Preferably excluded from the present invention are	
	one or more polynucleotides comprising a nucleotide	
	sequence described by the general formula of a-b.	
	where a is any integer between 1 to 790 of SEQ ID	

	NO:7, b is an integer of 15 to 804, where both a and	
	b correspond to the positions of nucleotide residues	
	shown in SEQ ID NO:7, and where b is greater than	
1	or equal to a + 14.	
588916	Preferably excluded from the present invention are	
	one or more polynucleotides comprising a nucleotide	
i	sequence described by the general formula of a-b,	
	where a is any integer between 1 to 706 of SEQ ID	
	NO:8, b is an integer of 15 to 720, where both a and	
	b correspond to the positions of nucleotide residues	
	shown in SEQ ID NO:8, and where b is greater than	
	or equal to a + 14.	
613825	Preferably excluded from the present invention are	
	one or more polynucleotides comprising a nucleotide	,
İ	sequence described by the general formula of a-b.	
}	where a is any integer between 1 to 526 of SEQ ID	
	NO:9, b is an integer of 15 to 540, where both a and	
	b correspond to the positions of nucleotide residues	
Ì	shown in SEQ ID NO:9, and where b is greater than	
{	or equal to a + 14.	
639090	Preferably excluded from the present invention are	
	one or more polynucleotides comprising a nucleotide	
ļ	sequence described by the general formula of a-b,	•
[where a is any integer between 1 to 547 of SEQ ID	
1	NO:10, b is an integer of 15 to 561, where both a and	
	b correspond to the positions of nucleotide residues	
1	shown in SEQ ID NO:10, and where b is greater than	
	or equal to a + 14.	
651644	Preferably excluded from the present invention are	
	one or more polynucleotides comprising a nucleotide	
	sequence described by the general formula of a-b,	
j	where a is any integer between 1 to 379 of SEQ ID	
	NO:11, b is an integer of 15 to 393, where both a and	
	b correspond to the positions of nucleotide residues	
	shown in SEQ ID NO:11, and where b is greater than	·
	or equal to a + 14.	
659544	Preferably excluded from the present invention are	
	one or more polynucleotides comprising a nucleotide	
	sequence described by the general formula of a-b,	
	where a is any integer between 1 to 308 of SEQ ID	
	NO:12, b is an integer of 15 to 322, where both a and	
	b correspond to the positions of nucleotide residues	
	shown in SEQ ID NO:12, and where b is greater than	
650770	or equal to a + 14.	
659739	Preferably excluded from the present invention are	
	one or more polynucleotides comprising a nucleotide	
	sequence described by the general formula of a-b,	
	where a is any integer between 1 to 1893 of SEQ ID	
	NO:13, b is an integer of 15 to 1907, where both a	
	and b correspond to the positions of nucleotide	
	residues shown in SEQ ID NO:13, and where b is	
661057	greater than or equal to a + 14. Preferably excluded from the present invention are	
00103/		
	one or more polynucleotides comprising a nucleotide	
	sequence described by the general formula of a-b,	
	where a is any integer between 1 to 1126 of SEQ ID	
	NO:14. b is an integer of 15 to 1140. where both a	· · · · · · · · · · · · · · · · · · ·

and b correspond to the positions of nucleotide residues shown in SEQ ID NO:14, and where b is ereater than or equal to a + 14. 661313 Perferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1994 of SEQ ID NO:15, b is an integer of 15 to 2008, where both a nad b correspond to the positions of nucleotide residues shown in SEQ ID NO:15, and where b is greater than or equal to a + 14. 666316 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 357 of SEQ ID NO:16, b is an integer of 15 to 371, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:16, and where b is greater than or equal to a + 14. 669229 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 749 of SEQ ID NO:17, b is an integer of 15 to 375, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:17, and where b is greater than or equal to a + 14. 670471 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 749 of SEQ ID NO:18, b is an integer of 15 to 753, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:18, b is an integer of 15 to 1926, where both a not be correspond to the positions of nucleotide residues shown in SEQ ID NO:18, and where b is greater than or equal to a + 14. 670471 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1912 of SEQ ID NO:19, b is an integer			
egreater than or equal to a + 14. 661313 Preferably excluded from the present invention are one or more polymucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1994 of SEQ ID NO:15. bis an integer of 15 to 2008, where both a nand b correspond to the positions of nucleotide residues shown in SEQ ID NO:15, and where b is greater than or equal to a + 14. 666316 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer of 15 to 371, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:16, and where b is greater than or equal to a + 14. 669229 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 749 of SEQ ID NO:17, bis an integer of 15 to 376, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:17, and where b is greater than or equal to a + 14. 6670471 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 749 of SEQ ID NO:18, bis an integer of 15 to 1926, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:18, and where b is greater than or equal to a + 14. 6670471 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1912 of SEQ ID NO:18, bi is an integer of 15 to 1926, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:19, and where b is greater than or equal to a + 14. Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide se		and b correspond to the positions of nucleotide	
one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1994 of SEQ ID NO:15, b is an integer of 15 to 2008, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:15, and where b is greater than or equal to a + 14. 666316 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 357 of SEQ ID NO:16, b is an integer of 15 to 371, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:16, and where b is greater than or equal to a + 14. 669229 Preferable vecluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 749 of SEQ ID NO:17, b is an integer of 15 to 73, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:17, and where b is greater than or equal to a + 14. 670471 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1912 of SEQ ID NO:18, b is an integer of 15 to 1926, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:18, and where b is greater than or equal to a + 14. 670471 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1912 of SEQ ID NO:19, b is an integer of 15 to 1926, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:19, and where b is greater than or equal to a + 14. Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, w			
one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b. where a is any integer between 1 to 1994 of SEQ ID NO:15. bis an integer of 15 to 2008, where both a nad b correspond to the positions of nucleotide residues shown in SEQ ID NO:15, and where b is greater than or equal to a + 14. 666316 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b. where a is any integer between 1 to 357 of SEQ ID NO:16, b is an integer of 15 to 371, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:16, and where b is greater than or equal to a + 14. 669229 Preferably excluded from the present invention are nor more polynucleotides comprising a nucleotide sequence described by the general formula of a-b. where a is any integer between 1 to 749 of SEQ ID NO:17, b is an integer of 15 to 763, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:17, and where b is greater than or equal to a + 14. 670471 Preferably excluded from the present invention are none or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1912 of SEQ ID NO:18, b is an integer of 15 to 100, where b is greater than or equal to a + 14. 670471 Preferably excluded from the present invention are none or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1912 of SEQ ID NO:18, b is an integer of 15 to 1926, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:19, and where b is greater than or equal to a + 14. 670410 Preferably excluded from the present invention are no er more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2287 of SEQ ID NO:20, b is an integer of 15 to 338, where			
sequence described by the general formula of a-b. where a is any integer between 1 to 1994 of SEQ ID NO:15, b is an integer of 15 to 2008. where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:15, and where b is greater than or equal to a + 14. 666316 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b. where a is any integer between 1 to 357 of SEQ ID NO:16, b is an integer of 15 to 371, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:16, and where b is greater than or equal to a + 14. 669229 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 749 of SEQ ID NO:17, b is an integer of 15 to 763, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:17, and where b is greater than or equal to a + 14. 670471 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 749 of SEQ ID NO:18, b is an integer of 15 to 1926, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:18, and where b is greater than or equal to a + 14. 670471 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1912 of SEQ ID NO:19, b is an integer of 15 to 1926, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:19, and where b is greater than or equal to a + 14. 670471 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 287 of SEQ	661313		
where a is any integer between 1 to 1994 of SEQ ID NO:15.b is an integer of 15 to 2008, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:15, and where b is greater than or equal to a + 14. 666316 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 357 of SEQ ID NO:16, b is an integer of 15 to 371, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:16, and where b is greater than or equal to a + 14. 669229 Preferably excluded from the present invention are nor more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 749 of SEQ ID NO:17, b is an integer of 15 to 763, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:17, and where b is greater than or equal to a + 14. 670471 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1912 of SEQ ID NO:18, b is an integer of 15 to 1926, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:18, and where b is greater than or equal to a + 14. 676611 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2287 of SEQ ID NO:19, b is an integer of 15 to 2301, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:19, and where b is greater than or equal to a + 14. 691240 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2287 of SEQ ID NO:20, b is an integer of 15 to 338, where both			
NO:15. b is an integer of 15 to 2008, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:15, and where b is greater than or equal to a ± 14. 666316 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a -b. where a is any integer between 1 to 357 of SEQ ID NO:16. b is an integer of 15 to 371, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:16. and where b is greater than or equal to a ± 14. 669220 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b. where a is any integer between 1 to 749 of SEQ ID NO:17. b is an integer of 15 to 763, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:17. and where b is greater than or equal to a ± 14. 670471 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a -b, where a is any integer between 1 to 1912 of SEQ ID NO:18. b is an integer of 15 to 1926, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:18. and where b is greater than or equal to a ± 14. 676611 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide residues shown in SEQ ID NO:18. and where b is greater than or equal to a ± 14. 676611 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 328 of SEQ ID NO:19. b is an integer of 15 to 331, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:20, b is an integer of 15 to 331, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:20, and where b is greater than or each of th		sequence described by the general formula of a-b.	
and b correspond to the positions of nucleotide residues shown in SEQ ID NO:15, and where b is greater than or equal to a + 14. 666316 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b. where a is any integer between 1 to 357 of SEQ ID NO:16, b is an integer of 15 to 371, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:16, and where b is greater than or equal to a + 14. 669229 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b. where a is any integer between 1 to 749 of SEQ ID NO:17, b is an integer of 15 to 763, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:17, and where b is greater than or equal to a + 14. 670471 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1912 of SEQ ID NO:18, b is an integer of 15 to 1926, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:18, and where b is greater than or equal to a + 14. 676611 676611 Freferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2287 of SEQ ID NO:19, b is an integer of 15 to 2301, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:19, and where b is greater than or equal to a + 14. 691240 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 234 of SEQ ID NO:20, b is an integer of 15 to 538, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:20, and		where a is any integer between 1 to 1994 of SEQ ID	
and b correspond to the positions of nucleotide residues shown in SEQ ID NO:15, and where b is greater than or equal to a + 14. 666316 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b. where a is any integer between 1 to 357 of SEQ ID NO:16, b is an integer of 15 to 371, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:16, and where b is greater than or equal to a + 14. 669229 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b. where a is any integer between 1 to 749 of SEQ ID NO:17, b is an integer of 15 to 763, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:17, and where b is greater than or equal to a + 14. 670471 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1912 of SEQ ID NO:18, b is an integer of 15 to 1926, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:18, and where b is greater than or equal to a + 14. 676611 676611 Freferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2287 of SEQ ID NO:19, b is an integer of 15 to 2301, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:19, and where b is greater than or equal to a + 14. 691240 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 234 of SEQ ID NO:20, b is an integer of 15 to 538, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:20, and			
residues shown in SEQ ID NO:15, and where b is greater than or equal to a + 14. 666316 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 357 of SEQ ID NO:16, b is an integer of 15 to 371, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:16, and where b is greater than or equal to a + 14. 669229 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 749 of SEQ ID NO:17, b is an integer of 15 to 763, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:17, and where b is greater than or equal to a + 14. 670471 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1912 of SEQ ID NO:18, b is an integer of 15 to 1926, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:18, and where b is greater than or equal to a + 14. 670611 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide residues shown in SEQ ID NO:18, and where b is greater than or equal to a + 14. 670611 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2301, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:19, and where b is greater than or equal to a + 14. 691240 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 339 of SEQ ID NO:20, b is an integer of 15 to 1403, where both a			
ereater than or equal to a + 14. 666316 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b. where a is any integer between 1 to 357 of SEQ ID NO:16, b is an integer of 15 to 371, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:16, and where b is greater than or equal to a + 14. 669229 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b. where a is any integer between 1 to 749 of SEQ ID NO:17, b is an integer of 15 to 763, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:17, and where b is greater than or equal to a + 14. 670471 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1912 of SEQ ID NO:18, b is an integer of 15 to 1926, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:18, and where b is greater than or equal to a + 14. 676611 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2287 of SEQ ID NO:19, b is an integer of 15 to 2301, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:19, and where b is greater than or equal to a + 14. 691240 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 528 of SEQ ID NO:20, b is an integer of 15 to 538, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:20, and where b is greater than or equal to a + 14. Preferably excluded from the present invention are one or			
666316 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 357 of SEQ ID NO:16. b is an integer of 15 to 371, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:16. and where b is greater than or equal to a + 14. 669229 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 749 of SEQ ID NO:17. b is an integer of 15 to 763, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:17, and where b is greater than or equal to a + 14. 670471 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1912 of SEQ ID NO:18. b is an integer of 15 to 1926, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:18, and where b is greater than or equal to a + 14. 676611 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2287 of SEQ ID NO:19, b is an integer of 15 to 2301, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:19, and where b is greater than or equal to a + 14. 691240 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 234 of SEQ ID NO:20, b is an integer of 15 to 338, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:20, and where b is greater than or equal to a + 14. 702977 Preferably excluded from the present invention are one or more polynucleotides comprising			
one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b. where a is any integer between 1 to 357 of SEQ ID NC:16, b is an integer of 15 to 371, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NC:16, and where b is greater than or equal to a + 14. 669229 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b. where a is any integer between 1 to 749 of SEQ ID NC:17, b is an integer of 15 to 763, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NC:17, and where b is greater than or equal to a + 14. 670471 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1912 of SEQ ID NC:18, b is an integer of 15 to 1926, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NC:18, and where b is greater than or equal to a + 14. 676611 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide residues shown in SEQ ID NC:18, and where b is greater than or equal to a + 14. 676610 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2287 of SEQ ID NC:19, b is an integer of 15 to 2301, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NC:19, and where b is greater than or equal to a + 14. 691240 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 252 of SEQ ID NC:20, b is an integer of 15 to 538, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NC:20, and where b i	666316		
sequence described by the general formula of a-b. where a is any integer between 1 to 357 of SEQ ID NO:16. b is an integer of 15 to 371, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:16. and where b is greater than or equal to a + 14. 669229 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b. where a is any integer between 1 to 749 of SEQ ID NO:17. b is an integer of 15 to 763, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:17. and where b is greater than or equal to a + 14. 670471 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1912 of SEQ ID NO:18. b is an integer of 15 to 1926, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:18, and where b is greater than or equal to a + 14. 676611 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2287 of SEQ ID NO:19, b is an integer of 15 to 2301, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:19, and where b is greater than or equal to a + 14. 691240 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 524 of SEQ ID NO:20, b is an integer of 15 to 538, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:20, and where b is greater than or equal to a + 14. 702977 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 524 of SEQ	000310		
where a is any integer between 1 to 357 of SEQ ID NO:16, b is an integer of 15 to 371, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:16, and where b is greater than or equal to a + 14. 669229 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 749 of SEQ ID NO:17, b is an integer of 15 to 763, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:17, and where b is greater than or equal to a + 14. 670471 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1912 of SEQ ID NO:18, b is an integer of 15 to 1926, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:18, and where b is greater than or equal to a + 14. 676611 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 287 of SEQ ID NO:19, b is an integer of 15 to 2301, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:19, and where b is greater than or equal to a + 14. 691240 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 284 of SEQ ID NO:20, b is an integer of 15 to 538, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:20, and where b is greater than or equal to a + 14. 702977 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 254 of SEQ ID NO:21, b is an integer of 15 to 1403, where both			
NO:16. b is an integer of 15 to 371, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:16, and where b is greater than or equal to a + 14. 669229 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 749 of SEQ ID NO:17. b is an integer of 15 to 763, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:17, and where b is greater than or equal to a + 14. 670471 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1912 of SEQ ID NO:18. b is an integer of 15 to 1926, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:18, and where b is greater than or equal to a + 14. 676611 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2287 of SEQ ID NO:19. b is an integer of 15 to 2301, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:19, and where b is greater than or equal to a + 14. 691240 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 524 of SEQ ID NO:20, b is an integer of 15 to 538, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:20, and where b is greater than or equal to a + 14. 702977 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 524 of SEQ ID NO:21, b is an integer of 15 to 1403, where both a			
b correspond to the positions of nucleotide residues shown in SEQ ID NO:16, and where b is greater than or equal to a + 14. 669229 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 749 of SEQ ID NO:17, b is an integer of 15 to 763, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:17, and where b is greater than or equal to a + 14. 670471 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1912 of SEQ ID NO:18, b is an integer of 15 to 1926, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:18, and where b is greater than or equal to a + 14. 676611 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2287 of SEQ ID NO:19, b is an integer of 15 to 2301, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:19, and where b is greater than or equal to a + 14. 691240 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 524 of SEQ ID NO:20, b is an integer of 15 to 533, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:20, and where b is greater than or equal to a + 14. 702977 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 524 of SEQ ID NO:20, and where b is greater than or equal to a + 14.			
shown in SEQ ID NO:16, and where b is greater than or equal to a + 14. 669229 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b. where a is any integer between 1 to 749 of SEQ ID NO:17, b is an integer of 15 to 763, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:17, and where b is greater than or equal to a + 14. 670471 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1912 of SEQ ID NO:18, b is an integer of 15 to 1926, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:18, and where b is greater than or equal to a + 14. 676611 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2287 of SEQ ID NO:19, b is an integer of 15 to 2301, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:19, and where b is greater than or equal to a + 14. 691240 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 524 of SEQ ID NO:20, b is an integer of 15 to 538, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:20, and where b is greater than or equal to a + 14. 702977 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1389 of SEQ ID NO:21, b is an integer of 15 to 1403, where both a			
or equal to a + 14. 669229 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 749 of SEQ ID NO:17. bis an integer of 15 to 763, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:17, and where b is greater than or equal to a + 14. 670471 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1912 of SEQ ID NO:18. b is an integer of 15 to 1926, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:18, and where b is greater than or equal to a + 14. 676611 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2287 of SEQ ID NO:19, b is an integer of 15 to 2301, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:19, and where b is greater than or equal to a + 14. 691240 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 524 of SEQ ID NO:20, b is an integer of 15 to 538, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:20, and where b is greater than or equal to a + 14. 702977 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1389 of SEQ ID NO:21, b is an integer of 15 to 1403, where both a one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1389 of SEQ ID			
Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 749 of SEQ ID NO:17. b is an integer of 15 to 763, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:17, and where b is greater than or equal to a + 14. 670471 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1912 of SEQ ID NO:18. b is an integer of 15 to 1926, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:18, and where b is greater than or equal to a + 14. 676611 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2287 of SEQ ID NO:19, b is an integer of 15 to 2301, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:19, and where b is greater than or equal to a + 14. 691240 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 524 of SEQ ID NO:20, b is an integer of 15 to 538, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:20, and where b is greater than or equal to a + 14. 702977 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer of 15 to 538, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:20, and where b is greater than or equal to a + 14.			
one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b. where a is any integer between 1 to 749 of SEQ ID NO:17. b is an integer of 15 to 763, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:17, and where b is greater than or equal to a + 14. 670471 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1912 of SEQ ID NO:18. b is an integer of 15 to 1926, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:18, and where b is greater than or equal to a + 14. 676611 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2287 of SEQ ID NO:19, b is an integer of 15 to 2301, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:19, and where b is greater than or equal to a + 14. 691240 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 224 of SEQ ID NO:20, b is an integer of 15 to 538, where both a and b correspond to the positions of nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 524 of SEQ ID NO:20, b is an integer of 15 to 538, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:20, and where b is greater than or equal to a + 14. 702977 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1389 of SEQ ID NO:21, b is an integer of 15 to 1403, where both a			
sequence described by the general formula of a-b, where a is any integer between 1 to 749 of SEQ ID NO:17, b is an integer of 15 to 763, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:17, and where b is greater than or equal to a + 14. 670471 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1912 of SEQ ID NO:18, b is an integer of 15 to 1926, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:18, and where b is greater than or equal to a + 14. 676611 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2287 of SEQ ID NO:19, b is an integer of 15 to 2301, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:19, and where b is greater than or equal to a + 14. 691240 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 524 of SEQ ID NO:20, b is an integer of 15 to 538, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:20, and where b is greater than or equal to a + 14. 702977 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1389 of SEQ ID NO:21, b is an integer of 15 to 1403, where both a	669229		
where a is any integer between 1 to 749 of SEQ ID NO:17, b is an integer of 15 to 763, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:17, and where b is greater than or equal to a + 14. 670471 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1912 of SEQ ID NO:18, b is an integer of 15 to 1926, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:18, and where b is greater than or equal to a + 14. 676611 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2287 of SEQ ID NO:19, b is an integer of 15 to 2301, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:19, and where b is greater than or equal to a + 14. 691240 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 524 of SEQ ID NO:20, b is an integer of 15 to 538, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:20, and where b is greater than or equal to a + 14. 702977 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1389 of SEQ ID NO:21, b is an integer of 15 to 1403, where both a		one or more polynucleotides comprising a nucleotide	
NO:17. b is an integer of 15 to 763, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:17, and where b is greater than or equal to a + 14. 670471 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1912 of SEQ ID NO:18. b is an integer of 15 to 1926, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:18, and where b is greater than or equal to a + 14. 676611 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2287 of SEQ ID NO:19. b is an integer of 15 to 2301, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:19. and where b is greater than or equal to a + 14. 691240 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 524 of SEQ ID NO:20. b is an integer of 15 to 538, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:20, and where b is greater than or equal to a + 14. 702977 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 528 of SEQ ID NO:20, b is an integer of 15 to 1403, where both a		sequence described by the general formula of a-b.	
b correspond to the positions of nucleotide residues shown in SEQ ID NO:17, and where b is greater than or equal to a + 14. 670471 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1912 of SEQ ID NO:18, b is an integer of 15 to 1926, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:18, and where b is greater than or equal to a + 14. 676611 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2287 of SEQ ID NO:19, b is an integer of 15 to 2301, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:19, and where b is greater than or equal to a + 14. 691240 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 524 of SEQ ID NO:20, b is an integer of 15 to 538, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:20, and where b is greater than or equal to a + 14. 702977 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1389 of SEQ ID NO:21, b is an integer between 1 to 1389 of SEQ ID NO:21, b is an integer between 1 to 1389 of SEQ ID NO:21, b is an integer between 1 to 1389 of SEQ ID NO:21, b is an integer between 1 to 1389 of SEQ ID NO:21, b is an integer between 1 to 1389 of SEQ ID NO:21, b is an integer between 1 to 1389 of SEQ ID NO:21, b is an integer between 1 to 1389 of SEQ ID NO:21, b is an integer between 1 to 1389 of SEQ ID		where a is any integer between 1 to 749 of SEQ ID	
b correspond to the positions of nucleotide residues shown in SEQ ID NO:17, and where b is greater than or equal to a + 14. 670471 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1912 of SEQ ID NO:18, b is an integer of 15 to 1926, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:18, and where b is greater than or equal to a + 14. 676611 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2287 of SEQ ID NO:19, b is an integer of 15 to 2301, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:19, and where b is greater than or equal to a + 14. 691240 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 524 of SEQ ID NO:20, b is an integer of 15 to 538, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:20, and where b is greater than or equal to a + 14. 702977 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1389 of SEQ ID NO:21, b is an integer between 1 to 1389 of SEQ ID NO:21, b is an integer between 1 to 1389 of SEQ ID NO:21, b is an integer between 1 to 1389 of SEQ ID NO:21, b is an integer between 1 to 1389 of SEQ ID NO:21, b is an integer between 1 to 1389 of SEQ ID NO:21, b is an integer between 1 to 1389 of SEQ ID NO:21, b is an integer between 1 to 1389 of SEQ ID NO:21, b is an integer between 1 to 1389 of SEQ ID		NO:17, b is an integer of 15 to 763, where both a and	
shown in SEQ ID NO:17, and where b is greater than or equal to a + 14. 670471 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1912 of SEQ ID NO:18. b is an integer of 15 to 1926, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:18, and where b is greater than or equal to a + 14. 676611 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2287 of SEQ ID NO:19, b is an integer of 15 to 2301, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:19, and where b is greater than or equal to a + 14. 691240 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 524 of SEQ ID NO:20, b is an integer of 15 to 538, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:20, and where b is greater than or equal to a + 14. 702977 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1389 of SEQ ID NO:21, b is an integer of 15 to 1403, where both a			
or equal to a + 14. 670471 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1912 of SEQ ID NO:18. b is an integer of 15 to 1926, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:18, and where b is greater than or equal to a + 14. 676611 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2287 of SEQ ID NO:19. b is an integer of 15 to 2301, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:19, and where b is greater than or equal to a + 14. 691240 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 524 of SEQ ID NO:20, b is an integer of 15 to 538, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:20, and where b is greater than or equal to a + 14. 702977 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1389 of SEQ ID NO:21, b is an integer of 15 to 1403, where both a			
670471 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1912 of SEQ ID NO:18, b is an integer of 15 to 1926, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:18, and where b is greater than or equal to a + 14. 676611 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2287 of SEQ ID NO:19, b is an integer of 15 to 2301, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:19, and where b is greater than or equal to a + 14. 691240 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 524 of SEQ ID NO:20, b is an integer of 15 to 538, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:20, and where b is greater than or equal to a + 14. 702977 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1389 of SEQ ID NO:21, b is an integer of 15 to 1403, where both a		•	
one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1912 of SEQ ID NO:18. b is an integer of 15 to 1926, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:18, and where b is greater than or equal to a + 14. 676611 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2287 of SEQ ID NO:19, b is an integer of 15 to 2301, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:19, and where b is greater than or equal to a + 14. 691240 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 524 of SEQ ID NO:20, b is an integer of 15 to 538, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:20, and where b is greater than or equal to a + 14. 702977 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1389 of SEQ ID NO:21, b is an integer of 15 to 1403, where both a	670471		
sequence described by the general formula of a-b, where a is any integer between 1 to 1912 of SEQ ID NO:18. b is an integer of 15 to 1926, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:18, and where b is greater than or equal to a + 14. 676611 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2287 of SEQ ID NO:19. b is an integer of 15 to 2301, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:19, and where b is greater than or equal to a + 14. 691240 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 524 of SEQ ID NO:20. b is an integer of 15 to 538, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:20, and where b is greater than or equal to a + 14. 702977 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1389 of SEQ ID NO:21, b is an integer of 15 to 1403, where both a	070471		
where a is any integer between 1 to 1912 of SEQ ID NO:18. b is an integer of 15 to 1926, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:18, and where b is greater than or equal to a + 14. 676611 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2287 of SEQ ID NO:19, b is an integer of 15 to 2301, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:19, and where b is greater than or equal to a + 14. 691240 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 524 of SEQ ID NO:20, b is an integer of 15 to 538, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:20, and where b is greater than or equal to a + 14. 702977 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1389 of SEQ ID NO:21, b is an integer of 15 to 1403, where both a			
NO:18. b is an integer of 15 to 1926, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:18, and where b is greater than or equal to a + 14. 676611 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2287 of SEQ ID NO:19, b is an integer of 15 to 2301, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:19, and where b is greater than or equal to a + 14. 691240 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 524 of SEQ ID NO:20, b is an integer of 15 to 538, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:20, and where b is greater than or equal to a + 14. 702977 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1389 of SEQ ID NO:21, b is an integer of 15 to 1403, where both a			
and b correspond to the positions of nucleotide residues shown in SEQ ID NO:18, and where b is greater than or equal to a + 14. 676611 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2287 of SEQ ID NO:19, b is an integer of 15 to 2301, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:19, and where b is greater than or equal to a + 14. 691240 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 524 of SEQ ID NO:20, b is an integer of 15 to 538, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:20, and where b is greater than or equal to a + 14. 702977 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1389 of SEQ ID NO:21, b is an integer of 15 to 1403, where both a			
residues shown in SEQ ID NO:18, and where b is greater than or equal to a + 14. 676611 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2287 of SEQ ID NO:19, b is an integer of 15 to 2301, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:19, and where b is greater than or equal to a + 14. 691240 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 524 of SEQ ID NO:20, b is an integer of 15 to 538, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:20, and where b is greater than or equal to a + 14. 702977 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1389 of SEQ ID NO:21, b is an integer of 15 to 1403, where both a			
greater than or equal to a + 14. 676611 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2287 of SEQ ID NO:19, b is an integer of 15 to 2301, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:19, and where b is greater than or equal to a + 14. 691240 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 524 of SEQ ID NO:20, b is an integer of 15 to 538, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:20, and where b is greater than or equal to a + 14. 702977 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1389 of SEQ ID NO:21, b is an integer of 15 to 1403, where both a			
Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2287 of SEQ ID NO:19, b is an integer of 15 to 2301, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:19, and where b is greater than or equal to a + 14. Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 524 of SEQ ID NO:20, b is an integer of 15 to 538, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:20, and where b is greater than or equal to a + 14. Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1389 of SEQ ID NO:21, b is an integer of 15 to 1403, where both a			
one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2287 of SEQ ID NO:19, b is an integer of 15 to 2301, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:19, and where b is greater than or equal to a + 14. 691240 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 524 of SEQ ID NO:20, b is an integer of 15 to 538, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:20, and where b is greater than or equal to a + 14. 702977 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1389 of SEQ ID NO:21, b is an integer of 15 to 1403, where both a			
sequence described by the general formula of a-b, where a is any integer between 1 to 2287 of SEQ ID NO:19, b is an integer of 15 to 2301, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:19, and where b is greater than or equal to a + 14. 691240 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 524 of SEQ ID NO:20, b is an integer of 15 to 538, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:20, and where b is greater than or equal to a + 14. 702977 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1389 of SEQ ID NO:21, b is an integer of 15 to 1403, where both a	676611		
where a is any integer between 1 to 2287 of SEQ ID NO:19, b is an integer of 15 to 2301, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:19, and where b is greater than or equal to a + 14. 691240 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 524 of SEQ ID NO:20, b is an integer of 15 to 538, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:20, and where b is greater than or equal to a + 14. 702977 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1389 of SEQ ID NO:21, b is an integer of 15 to 1403, where both a			
NO:19, b is an integer of 15 to 2301, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:19, and where b is greater than or equal to a + 14. 691240 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 524 of SEQ ID NO:20, b is an integer of 15 to 538, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:20, and where b is greater than or equal to a + 14. 702977 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1389 of SEQ ID NO:21, b is an integer of 15 to 1403, where both a			
and b correspond to the positions of nucleotide residues shown in SEQ ID NO:19, and where b is greater than or equal to a + 14. 691240 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 524 of SEQ ID NO:20, b is an integer of 15 to 538, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:20, and where b is greater than or equal to a + 14. 702977 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1389 of SEQ ID NO:21, b is an integer of 15 to 1403, where both a			
residues shown in SEQ ID NO:19, and where b is greater than or equal to a + 14. 691240 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 524 of SEQ ID NO:20, b is an integer of 15 to 538, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:20, and where b is greater than or equal to a + 14. 702977 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1389 of SEQ ID NO:21, b is an integer of 15 to 1403, where both a		NO:19, b is an integer of 15 to 2301, where both a	
greater than or equal to a + 14. 691240 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 524 of SEQ ID NO:20. b is an integer of 15 to 538, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:20, and where b is greater than or equal to a + 14. 702977 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1389 of SEQ ID NO:21, b is an integer of 15 to 1403, where both a		and b correspond to the positions of nucleotide	
691240 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 524 of SEQ ID NO:20, b is an integer of 15 to 538, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:20, and where b is greater than or equal to a + 14. 702977 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1389 of SEQ ID NO:21, b is an integer of 15 to 1403, where both a		residues shown in SEQ ID NO:19, and where b is	·
one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 524 of SEQ ID NO:20, b is an integer of 15 to 538, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:20, and where b is greater than or equal to a + 14. 702977 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1389 of SEQ ID NO:21, b is an integer of 15 to 1403, where both a		greater than or equal to a + 14.	
one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 524 of SEQ ID NO:20, b is an integer of 15 to 538, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:20, and where b is greater than or equal to a + 14. 702977 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1389 of SEQ ID NO:21, b is an integer of 15 to 1403, where both a	691240	Preferably excluded from the present invention are	
sequence described by the general formula of a-b, where a is any integer between 1 to 524 of SEQ ID NO:20, b is an integer of 15 to 538, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:20, and where b is greater than or equal to a + 14. 702977 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1389 of SEQ ID NO:21, b is an integer of 15 to 1403, where both a		one or more polynucleotides comprising a nucleotide	
where a is any integer between 1 to 524 of SEQ ID NO:20, b is an integer of 15 to 538, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:20, and where b is greater than or equal to a + 14. 702977 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1389 of SEQ ID NO:21, b is an integer of 15 to 1403, where both a			
NO:20. b is an integer of 15 to 538, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:20, and where b is greater than or equal to a + 14. 702977 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1389 of SEQ ID NO:21, b is an integer of 15 to 1403, where both a			
b correspond to the positions of nucleotide residues shown in SEQ ID NO:20, and where b is greater than or equal to a + 14. 702977 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1389 of SEQ ID NO:21, b is an integer of 15 to 1403, where both a			
shown in SEQ ID NO:20, and where b is greater than or equal to a + 14. 702977 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1389 of SEQ ID NO:21, b is an integer of 15 to 1403, where both a			
or equal to a + 14. 702977 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1389 of SEQ ID NO:21, b is an integer of 15 to 1403, where both a			
702977 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1389 of SEQ ID NO:21, b is an integer of 15 to 1403, where both a			
one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1389 of SEQ ID NO:21, b is an integer of 15 to 1403, where both a	702077		
sequence described by the general formula of a-b, where a is any integer between 1 to 1389 of SEQ ID NO:21, b is an integer of 15 to 1403, where both a	/029//		·
where a is any integer between 1 to 1389 of SEQ ID NO:21, b is an integer of 15 to 1403, where both a			
NO:21, b is an integer of 15 to 1403, where both a			
and b correspond to the positions of nucleotide			
		and b correspond to the positions of nucleotide	

	residues shown in SEQ ID NO:21, and where b is	
	greater than or equal to a + 14.	
709517	Preferably excluded from the present invention are	
	one or more polynucleotides comprising a nucleotide	
	sequence described by the general formula of a-b.	
	where a is any integer between 1 to 464 of SEQ ID	
	NO:22, b is an integer of 15 to 478, where both a and	
	b correspond to the positions of nucleotide residues	
	shown in SEQ 1D NO:22, and where b is greater than	
	or equal to a + 14.	
714730	Preferably excluded from the present invention are	
714730	one or more polynucleotides comprising a nucleotide	
	sequence described by the general formula of a-b.	
	where a is any integer between 1 to 1238 of SEQ ID	,
	NO:23, b is an integer of 15 to 1252, where both a	
	and b correspond to the positions of nucleotide	
	residues shown in SEQ ID NO:23, and where b is	
71.4024	greater than or equal to a + 14.	
714834	Preferably excluded from the present invention are	
	one or more polynucleotides comprising a nucleotide	
	sequence described by the general formula of a-b.	
	where a is any integer between 1 to 1060 of SEQ ID	
	NO:24, b is an integer of 15 to 1074, where both a	
	and b correspond to the positions of nucleotide	
	residues shown in SEQ ID NO:24, and where b is	
	greater than or equal to a + 14.	
715016	Preferably excluded from the present invention are	
	one or more polynucleotides comprising a nucleotide	
	sequence described by the general formula of a-b,	
	where a is any integer between 1 to 1172 of SEQ ID	
	NO:25, b is an integer of 15 to 1186, where both a	
	and b correspond to the positions of nucleotide	
	residues shown in SEQ ID NO:25, and where b is	
	greater than or equal to a + 14.	
719584	Preferably excluded from the present invention are	
	one or more polynucleotides comprising a nucleotide	
	sequence described by the general formula of a-b,	
	where a is any integer between 1 to 874 of SEQ ID	
	NO:26, b is an integer of 15 to 888, where both a and	
	b correspond to the positions of nucleotide residues	
	shown in SEQ ID NO:26, and where b is greater than	
	or equal to a + 14.	
724637	Preferably excluded from the present invention are	•
	one or more polynucleotides comprising a nucleotide	
	sequence described by the general formula of a-b,	
	where a is any integer between 1 to 775 of SEQ ID	
	NO:27, b is an integer of 15 to 789, where both a and	
	b correspond to the positions of nucleotide residues	
	shown in SEQ ID NO:27, and where b is greater than	
	or equal to a + 14.	
728392	Preferably excluded from the present invention are	
	one or more polynucleotides comprising a nucleotide	
	sequence described by the general formula of a-b.	
	where a is any integer between 1 to 833 of SEQ ID	
	NO:28, b is an integer of 15 to 847, where both a and	
	b correspond to the positions of nucleotide residues	
	shown in SEQ ID NO:28, and where b is greater than	
	phonin in one in the real in the real in the real in that	L

	or equal to a + 14.	
738716	Preferably excluded from the present invention are	
730710	one or more polynucleotides comprising a nucleotide	
	sequence described by the general formula of a-b.	·
	where a is any integer between 1 to 652 of SEQ ID	
	NO:29. b is an integer of 15 to 666. where both a and	
	b correspond to the positions of nucleotide residues	
	shown in SEQ ID NO:29, and where b is greater than	
739056	or equal to a + 14. Preferably excluded from the present invention are	
739030	one or more polynucleotides comprising a nucleotide	
	sequence described by the general formula of a-b.	
	where a is any integer between 1 to 503 of SEQ ID	
	NO:30, b is an integer of 15 to 517, where both a and	
	b correspond to the positions of nucleotide residues	
	shown in SEQ ID NO:30, and where b is greater than	
	or equal to a + 14.	
739143	Preferably excluded from the present invention are	
	one or more polynucleotides comprising a nucleotide	
	sequence described by the general formula of a-b.	
	where a is any integer between 1 to 2661 of SEQ ID	
	NO:31, b is an integer of 15 to 2675, where both a	
	and b correspond to the positions of nucleotide	
	residues shown in SEQ ID NO:31, and where b is	
	greater than or equal to a + 14.	
742329	Preferably excluded from the present invention are	
	one or more polynucleotides comprising a nucleotide	
	sequence described by the general formula of a-b,	
	where a is any integer between 1 to 263 of SEQ ID	
	NO:32, b is an integer of 15 to 277, where both a and	-
	b correspond to the positions of nucleotide residues	
	shown in SEQ ID NO:32, and where b is greater than	
	or equal to a + 14.	
742557	Preferably excluded from the present invention are	
	one or more polynucleotides comprising a nucleotide	
	sequence described by the general formula of a-b,	
	where a is any integer between 1 to 907 of SEQ ID	
	NO:33, b is an integer of 15 to 921, where both a and	
	b correspond to the positions of nucleotide residues	
	shown in SEQ ID NO:33, and where b is greater than	
	or equal to a + 14.	
745481	Preferably excluded from the present invention are	
	one or more polynucleotides comprising a nucleotide	
	sequence described by the general formula of a-b,	
	where a is any integer between 1 to 1453 of SEQ ID	
	NO:34, b is an integer of 15 to 1467, where both a	
	and b correspond to the positions of nucleotide	1
	residues shown in SEQ ID NO:34, and where b is	·
	greater than or equal to a + 14.	
746035	Preferably excluded from the present invention are	
	one or more polynucleotides comprising a nucleotide	·
	sequence described by the general formula of a-b.	
	where a is any integer between 1 to 2063 of SEQ ID	
	NO:35, b is an integer of 15 to 2077, where both a	
	and b correspond to the positions of nucleotide	
	residues shown in SEQ ID NO:35, and where b is	
<u>.</u>	greater than or equal to a + 14.	<u> </u>

	In	
753731	Preferably excluded from the present invention are	
	one or more polynucleotides comprising a nucleotide	
	sequence described by the general formula of a-b,	
	where a is any integer between 1 to 370 of SEQ ID	
	NO:36, b is an integer of 15 to 384, where both a and	
	b correspond to the positions of nucleotide residues	
	shown in SEQ ID NO:36, and where b is greater than	
	or equal to a + 14.	
754383	Preferably excluded from the present invention are	
	one or more polynucleotides comprising a nucleotide	
	sequence described by the general formula of a-b,	
	where a is any integer between 1 to 454 of SEQ ID	
	NO:37, b is an integer of 15 to 468, where both a and	
•	b correspond to the positions of nucleotide residues	
	shown in SEQ ID NO:37, and where b is greater than	
	or equal to a + 14.	
756749	Preferably excluded from the present invention are	
120147	one or more polynucleotides comprising a nucleotide	
	sequence described by the general formula of a-b.	
	where a is any integer between 1 to 1081 of SEQ ID	
	NO:38, b is an integer of 15 to 1095, where both a	
-		
	and b correspond to the positions of nucleotide	
	residues shown in SEQ ID NO:38, and where b is	
7.7000	greater than or equal to a + 14.	D20214 D42240 D70721 H01441
757980	Preferably excluded from the present invention are	R38216, R63249, R78721, H01441,
	one or more polynucleotides comprising a nucleotide	H02557, H02640, H86258, H86321,
	sequence described by the general formula of a-b,	N21599, W16868. W31882, W56228.
	where a is any integer between 1 to 1743 of SEQ ID	N90610, AA047227, AA056107,
	NO:39, b is an integer of 15 to 1757, where both a	AA058568. AA100609, AA115890
	and b correspond to the positions of nucleotide	
	residues shown in SEQ ID NO:39, and where b is	
	greater than or equal to a + 14.	
764818	Preferably excluded from the present invention are	
	one or more polynucleotides comprising a nucleotide	
	sequence described by the general formula of a-b,	
	where a is any integer between 1 to 1931 of SEQ ID	
	NO:40, b is an integer of 15 to 1945, where both a	
	and b correspond to the positions of nucleotide	
	residues shown in SEQ ID NO:40, and where b is	
	greater than or equal to a + 14.	
765140	Preferably excluded from the present invention are	
	one or more polynucleotides comprising a nucleotide	
	sequence described by the general formula of a-b,	
	where a is any integer between 1 to 574 of SEQ ID	
	NO:41, b is an integer of 15 to 588, where both a and	
	b correspond to the positions of nucleotide residues	
	shown in SEQ ID NO:41, and where b is greater than	,
	or equal to a + 14.	
766893		R69702, R76994, R77002, H01357
100073	one or more polynucleotides comprising a nucleotide	107.02, 10.077, 10.7002, 1101337
	sequence described by the general formula of a-b,	
	where a is any integer between 1 to 1554 of SEQ ID	
	NO:42, b is an integer of 15 to 1568, where both a	
	and b correspond to the positions of nucleotide	
	residues shown in SEQ ID NO:42, and where b is	
	greater than or equal to a + 14.	
771338	Preferably excluded from the present invention are	

sequence described by the general formula of a-b. where a is any integer between 1 to 1046 of SEQ ID NO.43. b is an integer of 15 to 1060, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO.43. and where b is greater than or equal to a + 14. 771412 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b. where a is any integer between 1 to 1330 of SEQ ID NO.44. b is an integer of 15 to 1344, where both a not b correspond to the positions of nucleotide residues shown in SEQ ID NO.44. and where b is greater than or equal to a + 14. 772226 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b. where a is any integer between 1 to 878 of SEQ ID NO.45.b. is an integer of 15 to 892. where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO.45. and where b is greater than or equal to a + 14. 773057 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b. where a is any integer between 1 to 820 of SEQ ID NO.46.b is an integer of 15 to 496, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO.46.b is an integer of 15 to 496, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO.47. and where b is greater than or equal to a + 14. 773173 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between to 135 of SEQ ID NO.47, b is an integer of 15 to 1229, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO.48. and where b is greater than or equal to a + 14. 780154 Preferably excluded from the present invention are one or more polynucleotides c			·
where a is any integer between 1 to 1046 of SEQ ID NO-33. b is an integer of 15 to 1060, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO-43. and where b is greater than or equal to a + 14. 771-412 Preferably excluded from the present invention are nor or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1330 of SEQ ID NO-44. b is an integer of 15 to 1344. where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO-44. and where b is greater than or equal to a + 14. 772236 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b. where a is any integer between 1 to 878 of SEO ID NO-45. b is an integer of 15 to 892. where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO-45. and where b is greater than or equal to a + 14. 773057 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b. where a is any integer between 1 to 482 of SEQ ID NO-46. b is an integer of 15 to 496, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO-46, and where b is greater than or equal to a + 14. 773173 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b. where a is any integer between 1 to 125 of SEQ ID NO-47, and where b is greater than or equal to a + 14. 773173 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1397 of SEQ ID NO-47, b is an integer of 15 to 1229, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO-47, and where b is greater than or equal		one or more polynucleotides comprising a nucleotide	
NO.43, b is an integer of 15 to 1060, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO.43, and where b is greater than or equal to a + 14. 771412 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1330 of SEQ ID NO.44, b is an integer of 15 to 1344, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO.44, and where b is greater than or equal to a + 14. 772226 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 878 of SEQ ID NO.45, b is an integer of 15 to 892, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO.45, and where b is greater than or equal to a + 14. 773057 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 482 of SEQ ID NO.46, b is an integer of 15 to 496, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO.46, and where b is greater than or equal to a + 14. 773173 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1215 of SEQ ID NO.47, b is an integer of 15 to 1229, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO.47, and where b is greater than or equal to a + 14. 780154 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 137 of SEQ ID NO.47, b is an integer of 15 to 1411, where both a and b correspond to the positions of nucleoti	İ	sequence described by the general formula of a-b.	
and b correspond to the positions of nucleotide residues shown in SEQ ID NO:43, and where b is greater than or equal to a + 14. 771412 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b. where a is any integer between 1 to 1330 of SEQ ID NO:44, b is an integer of 15 to 1344. where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:44, and where b is greater than or equal to a + 14. 772226 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b. where a is any integer between 1 to 878 of SEQ ID NO:45, b is an integer of 15 to 892, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:45, and where b is greater than or equal to a + 14. 773057 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b. where a is any integer between 1 to 482 of SEQ ID NO:46, b is an integer of 15 to 496, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:46, and where b is greater than or equal to a + 14. 773173 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1215 of SEQ ID NO:47. b is an integer of 15 to 1229, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:47, and where b is greater than or equal to a + 14. 780154 780154 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 137 of SEQ ID NO:48, b is an integer of 15 to 1685, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:49, and		where a is any integer between 1 to 1046 of SEQ ID	
and b correspond to the positions of nucleotide residues shown in SEQ ID NO:43, and where b is greater than or equal to a + 14. 771412 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b. where a is any integer between 1 to 1330 of SEQ ID NO:44, b is an integer of 15 to 1344, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:44, and where b is greater than or equal to a + 14. 772226 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b. where a is any integer between 1 to 878 of SEQ ID NO:45, b is an integer of 15 to 892, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:45, and where b is greater than or equal to a + 14. 773057 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b. where a is any integer between 1 to 482 of SEQ ID NO:46, b is an integer of 15 to 496, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:46, and where b is greater than or equal to a + 14. 773173 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1215 of SEQ ID NO:47, b is an integer of 15 to 1229, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:47, and where b is greater than or equal to a + 14. 780154 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 137 of SEQ ID NO:48, b is an integer of 15 to 1611, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:49, and where b		NO:43, b is an integer of 15 to 1060, where both a	
residues shown in SEQ ID NO:43, and where b is areater than or equal to a + 14. 771412 77141			
realer than or equal to a + 14. 771412 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b. where a is any integer between 1 to 1330 of SEQ ID NO-44. bis an integer of 15 to 1344, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO-44, and where b is greater than or equal to a + 14. 772226 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b. where a is any integer between 1 to 878 of SEQ ID NO-45. b is an integer of 15 to 892, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO-45. and where b is greater than or equal to a + 14. 773057 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b. where a is any integer between 1 to 482 of SEQ ID NO-46. b is an integer of 15 to 496, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO-46, and where b is greater than or equal to a + 14. 773173 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b. where a is any integer between 1 to 1215 of SEQ ID NO-47. b is an integer of 15 to 1229, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO-47, and where b is greater than or equal to a + 14. 780154 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 137 of SEQ ID NO-48, b is an integer of 15 to 1411, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO-48, and where b is greater than or equal to a + 14.			
preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1330 of SEQ ID NO:44. b is an integer of 15 to 1344, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:44. and where b is greater than or equal to a + 14. 772226 772227 772226 772227 77227 77227 77227 77228 77228 77229 77220	1		
one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b. where a is any integer between 1 to 1330 of SEQ ID NO:44. b is an integer of 15 to 1344, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:44. and where b is greater than or equal to a + 14. 772226 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b. where a is any integer between 1 to 878 of SEQ ID NO:45. b is an integer of 15 to 892, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:45. and where b is greater than or equal to a + 14. 773057 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 482 of SEQ ID NO:46. b is an integer of 15 to 496, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:46, and where b is greater than or equal to a + 14. 773173 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1215 of SEQ ID NO:47, b is an integer of 15 to 1299, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:47, and where b is greater than or equal to a + 14. 780154 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 137 of SEQ ID NO:48, b is an integer of 15 to 1411, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:48, and where b is greater than or equal to a + 14. 780768 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of	771.112		
sequence described by the general formula of a-b, where a is any integer between 1 to 1330 of SEQ ID NO:44. b is an integer of 15 to 1344, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:44, and where b is greater than or equal to a + 14. 772226 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 878 of SEO ID NO:45. b is an integer of 15 to 892, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:45. and where b is greater than or equal to a + 14. 773057 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 482 of SEQ ID NO:46. b is an integer of 15 to 496, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:46, and where b is greater than or equal to a + 14. 773173 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1215 of SEQ ID NO:47. b is an integer of 15 to 1229, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:47, and where b is greater than or equal to a + 14. 780154 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1315 of SEQ ID NO:48, b is an integer of 15 to 1411, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:48, and where b is greater than or equal to a + 14. 780768 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1871 of S	771412		
where a is any integer between 1 to 1330 of SEQ ID NO:44, b is an integer of 15 to 1344, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:44, and where b is greater than or equal to a + 14. 772226 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b. where a is any integer between 1 to 878 of SEO ID NO:45, b is an integer of 15 to 892, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:45, and where b is greater than or equal to a + 14. Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 482 of SEQ ID NO:46, b is an integer of 15 to 496, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:46, and where b is greater than or equal to a + 14. Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1215 of SEQ ID NO:47, b is an integer of 15 to 1229, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:47, and where b is greater than or equal to a + 14. Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide residues shown in SEQ ID NO:47, and where b is greater than or equal to a + 14. Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 137 of SEQ ID NO:48, b is an integer of 15 to 1411, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:48, and where b is greater than or equal to a + 14. Preferably excluded from the present invention are one or more polynucleotides comprising a	į		
NO.44, b is an integer of 15 to 1344, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO.44, and where b is greater than or equal to a + 14. 772226 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b. where a is any integer between 1 to 878 of SEO ID NO.45, b is an integer of 15 to 892. where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO.45, and where b is greater than or equal to a + 14. 773057 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b. where a is any integer between 1 to 482 of SEQ ID NO.46, b is an integer of 15 to 496, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO.46, and where b is greater than or equal to a + 14. 773173 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b. where a is any integer between 1 to 1215 of SEQ ID NO.47, b is an integer of 15 to 1229, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO.47, and where b is greater than or equal to a + 14. 780154 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide residues shown in SEQ ID NO.47, and where b is greater than or equal to a + 14. 780768 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide residues shown in SEQ ID NO.48, and where b is greater than or equal to a + 14. 780768 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide residues shown in SEQ ID NO.48, and where b is greater than or equal to a + 14. 780768 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence descr			
and b correspond to the positions of nucleotide residues shown in SEQ ID NO:44, and where b is greater than or equal to a + 14. 772226 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b. where a is any integer between 1 to 878 of SEQ ID NO:45, b is an integer of 15 to 892, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:45, and where b is greater than or equal to a + 14. 773057 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b. where a is any integer between 1 to 482 of SEQ ID NO:46, b is an integer of 15 to 496, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:46, and where b is greater than or equal to a + 14. 773173 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1215 of SEQ ID NO:47, b is an integer of 15 to 1229, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:47, and where b is greater than or equal to a + 14. 780154 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide residues shown in SEQ ID NO:47, and where b is greater than or equal to a + 14. 780168 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1397 of SEQ ID NO:48, b is an integer of 15 to 1411, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:48, and where b is greater than or equal to a + 14. 780768 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where			
residues shown in SEQ ID NO:44. and where b is greater than or equal to a + 14. 772226 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b. where a is any integer between 1 to 878 of SEO ID NO:45. b is an integer of 15 to 892, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:45. and where b is greater than or equal to a + 14. 773057 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b. where a is any integer between 1 to 482 of SEQ ID NO:46. b is an integer of 15 to 496, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:46, and where b is greater than or equal to a + 14. 773173 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1215 of SEQ ID NO:47, b is an integer of 15 to 1290, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:47, and where b is greater than or equal to a + 14. 780154 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide residues shown in SEQ ID NO:47, and where b is greater than or equal to a + 14. Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide residues shown in SEQ ID NO:48, and where b is greater than or equal to a + 14. Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide residues shown in SEQ ID NO:48, and where b is greater than or equal to a + 14.	ĺ		
recater than or equal to a + 14. 772226 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b. where a is any integer between 1 to 878 of SEQ ID NO:45. b is an integer of 15 to 892, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:45. and where b is greater than or equal to a + 14. 773057 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b. where a is any integer between 1 to 482 of SEQ ID NO:46. b is an integer of 15 to 496, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:46, and where b is greater than or equal to a + 14. 773173 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1215 of SEQ ID NO:47. b is an integer of 15 to 1229, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:47, and where b is greater than or equal to a + 14. 780154 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1397 of SEQ ID NO:48. b is an integer of 15 to 1411, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:48. and where b is greater than or equal to a + 14. 780768 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1671 of SEQ ID NO:49, b is an integer of 15 to 1685, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:49, and where b is			
772226 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b. where a is any integer between 1 to 878 of SEQ ID NO:45. b is an integer of 15 to 892. where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:45, and where b is greater than or equal to a + 14. 773057 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b. where a is any integer between 1 to 482 of SEQ ID NO:46, b is an integer of 15 to 496, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:46, and where b is greater than or equal to a + 14. 773173 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b. where a is any integer between 1 to 1215 of SEQ ID NO:47, b is an integer of 15 to 1229, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:47, and where b is greater than or equal to a + 14. 780154 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide residues shown in SEQ ID NO:48, and where b is greater than or equal to a + 14. 780768 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide residues shown in SEQ ID NO:48, and where b is greater than or equal to a + 14. 780768 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide residues shown in SEQ ID NO:48, and where b is greater than or equal to a + 14. 780768 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide residues shown in SEQ ID NO:48, and where b is greater than or equal to a + 14.			·
one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b. where a is any integer between 1 to 878 of SEQ ID NO:45. b is an integer of 15 to 892, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:45, and where b is greater than or equal to a + 14. 773057 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 482 of SEQ ID NO:46. b is an integer of 15 to 496, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:46, and where b is greater than or equal to a + 14. 773173 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1215 of SEQ ID NO:47, b is an integer of 15 to 1229, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:47, and where b is greater than or equal to a + 14. 780154 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1397 of SEQ ID NO:48, b is an integer of 15 to 1411, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:48, and where b is greater than or equal to a + 14. 780768 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide residues shown in SEQ ID NO:48, and where b is greater than or equal to a + 14. Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide residues shown in SEQ ID NO:49, and where b is greater than or equal to a + 14. Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any i			
sequence described by the general formula of a-b. where a is any integer between 1 to 878 of SEQ ID NO:45. b is an integer of 15 to 892, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:45. and where b is greater than or equal to a + 14. 773057 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b. where a is any integer between 1 to 482 of SEQ ID NO:46. b is an integer of 15 to 496, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:46, and where b is greater than or equal to a + 14. 773173 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1215 of SEQ ID NO:47. b is an integer of 15 to 1229, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:47, and where b is greater than or equal to a + 14. 780154 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1397 of SEQ ID NO:48. b is an integer of 15 to 1411, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:48. and where b is greater than or equal to a + 14. 780768 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1671 of SEQ ID NO:49, b is an integer of 15 to 1685, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:49, and where b is	772226	Preferably excluded from the present invention are	
where a is any integer between 1 to 878 of SEO ID NO:45. b is an integer of 15 to 892. where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:45. and where b is greater than or equal to a + 14. 773057 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 482 of SEQ ID NO:46. b is an integer of 15 to 496, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:46, and where b is greater than or equal to a + 14. 773173 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1215 of SEQ ID NO:47. b is an integer of 15 to 1229, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:47, and where b is greater than or equal to a + 14. 780154 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1397 of SEQ ID NO:48. b is an integer of 15 to 1411, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:48. and where b is greater than or equal to a + 14. Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1671 of SEQ ID NO:49, b is an integer of 15 to 1685, where both a and b correspond to the positions of nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1671 of SEQ ID NO:49, b is an integer of 15 to 1685, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:49, and where b is		one or more polynucleotides comprising a nucleotide	
NO:45. b is an integer of 15 to 892, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:45. and where b is greater than or equal to a + 14. 773057 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 482 of SEQ ID NO:46. b is an integer of 15 to 496, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:46, and where b is greater than or equal to a + 14. 773173 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1215 of SEQ ID NO:47. b is an integer of 15 to 1229, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:47, and where b is greater than or equal to a + 14. 780154 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1397 of SEQ ID NO:48, b is an integer of 15 to 1411, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:48, and where b is greater than or equal to a + 14. 780768 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1671 of SEQ ID NO:49, b is an integer of 15 to 1685, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:49, and where b is		sequence described by the general formula of a-b.	
NO:45. b is an integer of 15 to 892, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:45. and where b is greater than or equal to a + 14. 773057 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 482 of SEQ ID NO:46. b is an integer of 15 to 496, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:46, and where b is greater than or equal to a + 14. 773173 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1215 of SEQ ID NO:47. b is an integer of 15 to 1229, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:47, and where b is greater than or equal to a + 14. 780154 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1397 of SEQ ID NO:48, b is an integer of 15 to 1411, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:48, and where b is greater than or equal to a + 14. 780768 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1671 of SEQ ID NO:49, b is an integer of 15 to 1685, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:49, and where b is		where a is any integer between 1 to 878 of SEQ ID	
b correspond to the positions of nucleotide residues shown in SEQ ID NO:45, and where b is greater than or equal to a + 14. 773057 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 182 of SEQ ID NO:46, b is an integer of 15 to 496, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:46, and where b is greater than or equal to a + 14. 773173 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1215 of SEQ ID NO:47, b is an integer of 15 to 1229, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:47, and where b is greater than or equal to a + 14. 780154 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1397 of SEQ ID NO:48, b is an integer of 15 to 1411, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:48, and where b is greater than or equal to a + 14. 780768 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1671 of SEQ ID NO:49, b is an integer of 15 to 1685, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:49, and where b is greater than or equal to a + 14.			
shown in SEQ ID NO:45, and where b is greater than or equal to a + 14. 773057 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 482 of SEQ ID NO:46, b is an integer of 15 to 496, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:46, and where b is greater than or equal to a + 14. 773173 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1215 of SEQ ID NO:47, b is an integer of 15 to 1229, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:47, and where b is greater than or equal to a + 14. 780154 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1397 of SEQ ID NO:48, b is an integer of 15 to 1411, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:48, and where b is greater than or equal to a + 14. 780768 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1671 of SEQ ID NO:49, b is an integer of 15 to 1685, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:49, and where b is			
or equal to a + 14. 773057 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b. where a is any integer between 1 to 482 of SEQ ID NO:46. b is an integer of 15 to 496, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:46, and where b is greater than or equal to a + 14. 773173 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b. where a is any integer between 1 to 1215 of SEQ ID NO:47. b is an integer of 15 to 1229, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:47, and where b is greater than or equal to a + 14. 780154 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1397 of SEQ ID NO:48. b is an integer of 15 to 1411, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:48, and where b is greater than or equal to a + 14. 780768 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1671 of SEQ ID NO:49, b is an integer of 15 to 1685, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:49, and where b is			
Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 482 of SEQ ID NO:46. b is an integer of 15 to 496, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:46, and where b is greater than or equal to a + 14. 773173 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1215 of SEQ ID NO:47, b is an integer of 15 to 1229, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:47, and where b is greater than or equal to a + 14. 780154 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1397 of SEQ ID NO:48, b is an integer of 15 to 1411, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:48, and where b is greater than or equal to a + 14. 780768 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide residues shown in SEQ ID NO:48, and where b is greater than or equal to a + 14. 780768 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1671 of SEQ ID NO:49, b is an integer of 15 to 1685, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:49, and where b is		,	
one or more polynucleotides comprising a nucleotide sequence described by the general formula of a -b. where a is any integer between 1 to 482 of SEQ ID NO:46. b is an integer of 15 to 496, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:46, and where b is greater than or equal to a + 14. 773173 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a -b, where a is any integer between 1 to 1215 of SEQ ID NO:47. b is an integer of 15 to 1229, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:47, and where b is greater than or equal to a + 14. 780154 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1397 of SEQ ID NO:48. b is an integer of 15 to 1411, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:48. and where b is greater than or equal to a + 14. 780768 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1671 of SEQ ID NO:49. b is an integer of 15 to 1685, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:49, and where b is	773057	· 	N41725
sequence described by the general formula of a-b, where a is any integer between 1 to 482 of SEQ ID NO:46. b is an integer of 15 to 496, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:46, and where b is greater than or equal to a + 14. 773173 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1215 of SEQ ID NO:47. b is an integer of 15 to 1229, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:47, and where b is greater than or equal to a + 14. Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1397 of SEQ ID NO:48. b is an integer of 15 to 1411, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:48, and where b is greater than or equal to a + 14. Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide residues shown in SEQ ID NO:48, and where b is greater than or equal to a + 14. Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1671 of SEQ ID NO:49, b is an integer of 15 to 1685, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:49, and where b is	113037		177723
where a is any integer between 1 to 482 of SEQ ID NO:46, b is an integer of 15 to 496, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:46, and where b is greater than or equal to a + 14. 773173 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1215 of SEQ ID NO:47, b is an integer of 15 to 1229, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:47, and where b is greater than or equal to a + 14. 780154 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1397 of SEQ ID NO:48, b is an integer of 15 to 1411, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:48, and where b is greater than or equal to a + 14. 780768 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1671 of SEQ ID NO:49, b is an integer of 15 to 1685, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:49, and where b is			
NO:46. b is an integer of 15 to 496, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:46, and where b is greater than or equal to a + 14. 773173 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1215 of SEQ ID NO:47, b is an integer of 15 to 1229, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:47, and where b is greater than or equal to a + 14. 780154 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1397 of SEQ ID NO:48, b is an integer of 15 to 1411, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:48, and where b is greater than or equal to a + 14. 780768 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1671 of SEQ ID NO:49, b is an integer of 15 to 1685, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:49, and where b is			
b correspond to the positions of nucleotide residues shown in SEQ ID NO:46, and where b is greater than or equal to a + 14. 773173 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1215 of SEQ ID NO:47, b is an integer of 15 to 1229, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:47, and where b is greater than or equal to a + 14. 780154 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1397 of SEQ ID NO:48, b is an integer of 15 to 1411, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:48, and where b is greater than or equal to a + 14. 780768 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1671 of SEQ ID NO:49, b is an integer of 15 to 1685, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:49, and where b is			
shown in SEQ ID NO:46, and where b is greater than or equal to a + 14. 773173 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1215 of SEQ ID NO:47, b is an integer of 15 to 1229, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:47, and where b is greater than or equal to a + 14. 780154 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1397 of SEQ ID NO:48, b is an integer of 15 to 1411, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:48, and where b is greater than or equal to a + 14. 780768 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1671 of SEQ ID NO:49, b is an integer of 15 to 1685, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:49, and where b is			
or equal to a + 14. Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1215 of SEQ ID NO:47, b is an integer of 15 to 1229, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:47, and where b is greater than or equal to a + 14. Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1397 of SEQ ID NO:48, b is an integer of 15 to 1411, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:48, and where b is greater than or equal to a + 14. Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1671 of SEQ ID NO:49, b is an integer of 15 to 1685, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:49, b where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:49, and where b is	}		
Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1215 of SEQ ID NO:47, b is an integer of 15 to 1229, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:47, and where b is greater than or equal to a + 14. Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1397 of SEQ ID NO:48, b is an integer of 15 to 1411, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:48, and where b is greater than or equal to a + 14. Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1671 of SEQ ID NO:49, b is an integer of 15 to 1685, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:49, and where b is			
one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1215 of SEQ ID NO:47, b is an integer of 15 to 1229, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:47, and where b is greater than or equal to a + 14. 780154 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1397 of SEQ ID NO:48, b is an integer of 15 to 1411, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:48, and where b is greater than or equal to a + 14. Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1671 of SEQ ID NO:49, b is an integer of 15 to 1685, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:49, and where b is			
sequence described by the general formula of a-b, where a is any integer between 1 to 1215 of SEQ ID NO:47, b is an integer of 15 to 1229, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:47, and where b is greater than or equal to a + 14. 780154 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1397 of SEQ ID NO:48, b is an integer of 15 to 1411, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:48, and where b is greater than or equal to a + 14. 780768 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1671 of SEQ ID NO:49, b is an integer of 15 to 1685, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:49, and where b is	773173		
where a is any integer between 1 to 1215 of SEQ ID NO:47, b is an integer of 15 to 1229, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:47, and where b is greater than or equal to a + 14. 780154 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1397 of SEQ ID NO:48, b is an integer of 15 to 1411, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:48, and where b is greater than or equal to a + 14. 780768 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1671 of SEQ ID NO:49, b is an integer of 15 to 1685, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:49, and where b is			
NO:47, b is an integer of 15 to 1229, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:47, and where b is greater than or equal to a + 14. 780154 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1397 of SEQ ID NO:48, b is an integer of 15 to 1411, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:48, and where b is greater than or equal to a + 14. 780768 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1671 of SEQ ID NO:49, b is an integer of 15 to 1685, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:49, and where b is			
and b correspond to the positions of nucleotide residues shown in SEQ ID NO:47, and where b is greater than or equal to a + 14. 780154 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1397 of SEQ ID NO:48, b is an integer of 15 to 1411, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:48, and where b is greater than or equal to a + 14. 780768 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1671 of SEQ ID NO:49, b is an integer of 15 to 1685, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:49, and where b is			
residues shown in SEQ ID NO:47, and where b is greater than or equal to a + 14. 780154 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1397 of SEQ ID NO:48, b is an integer of 15 to 1411, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:48, and where b is greater than or equal to a + 14. 780768 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1671 of SEQ ID NO:49, b is an integer of 15 to 1685, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:49, and where b is			
greater than or equal to a + 14. 780154 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1397 of SEQ ID NO:48. b is an integer of 15 to 1411, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:48. and where b is greater than or equal to a + 14. 780768 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1671 of SEQ ID NO:49. b is an integer of 15 to 1685, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:49, and where b is		and b correspond to the positions of nucleotide	
Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1397 of SEQ ID NO:48. b is an integer of 15 to 1411, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:48, and where b is greater than or equal to a + 14. Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1671 of SEQ ID NO:49, b is an integer of 15 to 1685, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:49, and where b is		residues shown in SEQ ID NO:47, and where b is	
Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1397 of SEQ ID NO:48. b is an integer of 15 to 1411, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:48, and where b is greater than or equal to a + 14. Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1671 of SEQ ID NO:49, b is an integer of 15 to 1685, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:49, and where b is	ı	greater than or equal to a + 14.	
one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1397 of SEQ ID NO:48. b is an integer of 15 to 1411, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:48, and where b is greater than or equal to a + 14. 780768 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1671 of SEQ ID NO:49, b is an integer of 15 to 1685, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:49, and where b is	780154		
sequence described by the general formula of a-b, where a is any integer between 1 to 1397 of SEQ ID NO:48. b is an integer of 15 to 1411, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:48. and where b is greater than or equal to a + 14. Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1671 of SEQ ID NO:49, b is an integer of 15 to 1685, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:49, and where b is		•	
where a is any integer between 1 to 1397 of SEQ ID NO:48. b is an integer of 15 to 1411, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:48. and where b is greater than or equal to a + 14. Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1671 of SEQ ID NO:49, b is an integer of 15 to 1685, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:49, and where b is			
NO:48. b is an integer of 15 to 1411, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:48, and where b is greater than or equal to a + 14. 780768 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1671 of SEQ ID NO:49, b is an integer of 15 to 1685, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:49, and where b is			
and b correspond to the positions of nucleotide residues shown in SEQ ID NO:48, and where b is greater than or equal to a + 14. 780768 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1671 of SEQ ID NO:49, b is an integer of 15 to 1685, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:49, and where b is			
residues shown in SEQ ID NO:48, and where b is greater than or equal to a + 14. 780768 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1671 of SEQ ID NO:49, b is an integer of 15 to 1685, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:49, and where b is			
greater than or equal to a + 14. 780768 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1671 of SEQ ID NO:49, b is an integer of 15 to 1685, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:49, and where b is			
780768 Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1671 of SEQ ID NO:49, b is an integer of 15 to 1685, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:49, and where b is			
one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1671 of SEQ ID NO:49, b is an integer of 15 to 1685, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:49, and where b is	7907/0		
sequence described by the general formula of a-b, where a is any integer between 1 to 1671 of SEQ ID NO:49, b is an integer of 15 to 1685, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:49, and where b is	700/08		
where a is any integer between 1 to 1671 of SEQ ID NO:49, b is an integer of 15 to 1685, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:49, and where b is			
NO:49, b is an integer of 15 to 1685, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:49, and where b is			
and b correspond to the positions of nucleotide residues shown in SEQ ID NO:49, and where b is			
residues shown in SEQ ID NO:49, and where b is			
ereater than or equal to a + 14.			
		greater than or equal to a + 14.	
780779 Preferably excluded from the present invention are			
one or more polynucleotides comprising a nucleotide		one or more polynucleotides comprising a nucleotide	

	
	<u>·</u>
	R24689, R25853, R34457, R66839,
one or more polynucleotides comprising a nucleotide	R68536, H22874, H45555, N50184,
sequence described by the general formula of a-b,	AA015963. AA028939. AA028938
where a is any integer between 1 to 1558 of SEQ ID	
NO:51, b is an integer of 15 to 1572, where both a	
and b correspond to the positions of nucleotide	
residues shown in SEQ ID NO:51, and where b is	
	·
greater than or equal to a + 14.	
	W44740, AA235981
one or more polynucleotides comprising a nucleotide	
because a described by the conerel formula of a b	
sequence described by the general formula of a-b.	
where a is any integer between 1 to 668 of SEQ ID	
where a is any integer between 1 to 668 of SEQ ID NO:56, b is an integer of 15 to 682, where both a and	
where a is any integer between 1 to 668 of SEQ ID NO:56, b is an integer of 15 to 682, where both a and b correspond to the positions of nucleotide residues	
where a is any integer between 1 to 668 of SEQ ID NO:56. b is an integer of 15 to 682, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:56. and where b is greater than	
where a is any integer between 1 to 668 of SEQ ID NO:56, b is an integer of 15 to 682, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:56, and where b is greater than or equal to a + 14.	
where a is any integer between 1 to 668 of SEQ ID NO:56. b is an integer of 15 to 682, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:56. and where b is greater than	
	sequence described by the general formula of a-b, where a is any integer between 1 to 1558 of SEQ ID NO:51, b is an integer of 15 to 1572, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:51, and where b is greater than or equal to a + 14. Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 621 of SEQ ID NO:52, b is an integer of 15 to 635, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:52, and where b is greater than or equal to a + 14. Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1353 of SEQ ID NO:53, b is an integer of 15 to 1367, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:53, and where b is greater than or equal to a + 14. Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 364 of SEQ ID NO:54, b is an integer of 15 to 378, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:54, and where b is greater than or equal to a + 14. Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 364 of SEQ ID NO:55, b is an integer of 15 to 1058, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:55, and where b is greater than or equal to a + 14. Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1044 of SEQ ID NO:55, b is an integer of 15 t

WO 00/55351 PCT/US00/05883

103

	where a is any integer between 1 to 630 of SEQ 1D	
	NO:57. b is an integer of 15 to 644. where both a and	
	b correspond to the positions of nucleotide residues	
	shown in SEQ ID NO:57, and where b is greater than	
	or equal to a + 14.	
793987	Preferably excluded from the present invention are	
1	one or more polynucleotides comprising a nucleotide	
1	sequence described by the general formula of a-b,	
	where a is any integer between 1 to 752 of SEQ ID	
1	NO:58. b is an integer of 15 to 766. where both a and	
ł	b correspond to the positions of nucleotide residues	
	shown in SEQ 1D NO:58, and where b is greater than	
	or equal to a + 14.	į
805715	Preferably excluded from the present invention are	
	one or more polynucleotides comprising a nucleotide	
1	sequence described by the general formula of a-b.	
Ì	where a is any integer between 1 to 2347 of SEQ ID	
1	NO:59, b is an integer of 15 to 2361, where both a	
	and b correspond to the positions of nucleotide	
	residues shown in SEQ ID NO:59, and where b is	
	greater than or equal to a + 14.	
811111		R11325, R11326, R43655, R43655.
"		R72437, R78096. H23850. N20947,
		N22686, N25829, N27270, N31401.
	where a is any integer between 1 to 1458 of SEQ ID	N40002, N46020, W92748, W92871.
	NO:60, b is an integer of 15 to 1472, where both a	AA461202, AA461382
	and b correspond to the positions of nucleotide	
	residues shown in SEQ ID NO:60, and where b is	
	greater than or equal to a + 14.	
811113	Preferably excluded from the present invention are	
011115	one or more polynucleotides comprising a nucleotide	
-	sequence described by the general formula of a-b,	
-	where a is any integer between 1 to 1658 of SEQ ID	
ĺ	NO:61, b is an integer of 15 to 1672, where both a	
	and b correspond to the positions of nucleotide	
	residues shown in SEQ ID NO:61, and where b is	
	greater than or equal to a + 14.	
823902	Preferably excluded from the present invention are	
823902	one or more polynucleotides comprising a nucleotide	
	sequence described by the general formula of a-b,	:
	where a is any integer between 1 to 1526 of SEQ ID	
1	NO:62, b is an integer of 15 to 1540, where both a	
i	and b correspond to the positions of nucleotide	
	residues shown in SEQ ID NO:62, and where b is	
1	greater than or equal to a + 14.	
826518		T60163, T60223, T61894, R12251, T81471,
020310	· · · · · · · · · · · · · · · · · · ·	T81679, T95899, R98321, R98322.
1		H52605. H59085. N27268, N31506,
1		N53499, N54486, N58236, N92460,
		AA027189, AA045077, AA127016.
1		AA418935, AA426582
1	residues shown in SEQ ID NO:63, and where b is	1 1 1 1 0 0 0 0 1 1 1 1 1 1 1 1 1 1 1 1
	greater than or equal to a + 14.	
826704	Preferably excluded from the present invention are	
620704	one or more polynucleotides comprising a nucleotide	
1	sequence described by the general formula of a-b.	
1	where a is any integer between 1 to 837 of SEQ ID	
L	where a is any integer between 1 to 637 of SEQ ID	L

	1	,
	NO:64. b is an integer of 15 to 851, where both a and	
	b correspond to the positions of nucleotide residues	
	shown in SEQ ID NO:64, and where b is greater than	
	or equal to a + 14.	
827720	Preferably excluded from the present invention are	
	one or more polynucleotides comprising a nucleotide	
	sequence described by the general formula of a-b.	
	where a is any integer between 1 to 2779 of SEQ ID	
	NO:65, b is an integer of 15 to 2793, where both a	
-	and b correspond to the positions of nucleotide	
	residues shown in SEQ ID NO:65, and where b is	
	greater than or equal to a + 14.	
828102	Preferably excluded from the present invention are	
020102	one or more polynucleotides comprising a nucleotide	
	sequence described by the general formula of a-b.	
	where a is any integer between 1 to 289 of SEQ ID	
	NO:66. b is an integer of 15 to 303. where both a and	
	b correspond to the positions of nucleotide residues	
	shown in SEQ ID NO:66, and where b is greater than	
	or equal to a + 14.	
828180	Preferably excluded from the present invention are	
	one or more polynucleotides comprising a nucleotide	
	sequence described by the general formula of a-b,	
	where a is any integer between 1 to 1396 of SEQ ID	
1	NO:67, b is an integer of 15 to 1410, where both a	
	and b correspond to the positions of nucleotide	
	residues shown in SEQ ID NO:67, and where b is	
	greater than or equal to a + 14.	
828386	Preferably excluded from the present invention are	į
	one or more polynucleotides comprising a nucleotide	
	sequence described by the general formula of a-b,	
	where a is any integer between 1 to 1010 of SEQ ID	
	NO:68, b is an integer of 15 to 1024, where both a	
	and b correspond to the positions of nucleotide	
	residues shown in SEQ ID NO:68, and where b is	
	greater than or equal to a + 14.	
828658	Preferably excluded from the present invention are	
	one or more polynucleotides comprising a nucleotide	
· ·	sequence described by the general formula of a-b,	
	where a is any integer between 1 to 1834 of SEQ ID	
	NO:69, b is an integer of 15 to 1848, where both a	İ
	and b correspond to the positions of nucleotide	·
	residues shown in SEQ 1D NO:69, and where b is	
	greater than or equal to a + 14.	
828919	Preferably excluded from the present invention are	T66771, T66772, T71638, R08935, R09044,
020717	one or more polynucleotides comprising a nucleotide	R09373, T80114, T85695, R00758.
	sequence described by the general formula of a-b,	R00759, R12645, R19577, R20545,
	where a is any integer between 1 to 2668 of SEQ ID	R22041, R22097, R20545, R59701,
	NO:70, b is an integer of 15 to 2682, where both a	R59811, R60034, R60096, R60694,
_	and b correspond to the positions of nucleotide	R76255, R81371, R81370, H04390,
•		
	residues shown in SEQ ID NO:70, and where b is	H04415. H05912. H47622, H47647,
	greater than or equal to a + 14.	R83679, H71735, H72298, N25487,
		N35542. N49731. N52660. N67681.
		N75596, W03490, AA044638, AA044702,
		AA165090. AA164628, AA215698,
		AA215699, AA233182, AA233196,
		AA236759, AA256822, AA429489.

		AA428534
829572	Preferably excluded from the present invention are	Т63032
	one or more polynucleotides comprising a nucleotide	Į
	sequence described by the general formula of a-b.	
	where a is any integer between 1 to 398 of SEQ ID	
	NO:71. b is an integer of 15 to 412, where both a and	_
	b correspond to the positions of nucleotide residues	
	shown in SEQ ID NO:71, and where b is greater than	
	or equal to a + 14.	
830138	Preferably excluded from the present invention are	
	one or more polynucleotides comprising a nucleotide	
	sequence described by the general formula of a-b.	
	where a is any integer between 1 to 1347 of SEQ ID	•
	NO:72, b is an integer of 15 to 1361, where both a	
	and b correspond to the positions of nucleotide	
	residues shown in SEQ ID NO:72, and where b is	
	greater than or equal to a + 14.	
830208	Preferably excluded from the present invention are	R01611, N76461, W74577, W79757.
030200	one or more polynucleotides comprising a nucleotide	AA045350. AA056064. AA190524
	sequence described by the general formula of a-b.	
	where a is any integer between 1 to 914 of SEQ ID	
	NO:73. b is an integer of 15 to 928, where both a and	
	b correspond to the positions of nucleotide residues	
	shown in SEQ ID NO:73, and where b is greater than	
	or equal to a + 14.	Į
920249	Preferably excluded from the present invention are	
830248	one or more polynucleotides comprising a nucleotide	
	sequence described by the general formula of a-b,	
	where a is any integer between 1 to 1172 of SEQ ID	
	NO:74, b is an integer of 15 to 1186, where both a	
	and b correspond to the positions of nucleotide	
	residues shown in SEQ ID NO:74, and where b is	
030375	greater than or equal to a + 14.	
830275	Preferably excluded from the present invention are	İ
	one or more polynucleotides comprising a nucleotide	
	sequence described by the general formula of a-b,	
	where a is any integer between 1 to 919 of SEQ ID	
	NO:75, b is an integer of 15 to 933, where both a and	
	b correspond to the positions of nucleotide residues	
	shown in SEQ ID NO:75, and where b is greater than	
000001	or equal to a + 14.	T00274 D46154 D46154 A 224222
830286	Preferably excluded from the present invention are	T90376, R46154, R46154, AA224239,
	one or more polynucleotides comprising a nucleotide	AA467906, AA483293, AA502593,
•	sequence described by the general formula of a-b.	AA513313, AA594445. AA594570,
	where a is any integer between 1 to 1950 of SEQ ID	AA594876, AA579404, AA720893.
	NO:76. b is an integer of 15 to 1964, where both a	AA767344, AA857646. AA877489,
	and b correspond to the positions of nucleotide	AA954868, AA991634, Al014751, C02074
	residues shown in SEQ ID NO:76, and where b is	AA093141
	greater than or equal to a + 14.	
830347	Preferably excluded from the present invention are	
	one or more polynucleotides comprising a nucleotide	
	sequence described by the general formula of a-b,	
	where a is any integer between 1 to 1788 of SEQ ID	
	NO:77, b is an integer of 15 to 1802, where both a	
	and b correspond to the positions of nucleotide	
	residues shown in SEQ ID NO:77, and where b is	
	greater than or equal to a + 14.	

830348	Preferably excluded from the present invention are	A.A983601
	one or more polynucleotides comprising a nucleotide	
	sequence described by the general formula of a-b.	
	where a is any integer between 1 to 981 of SEQ ID	
•	NO:78, b is an integer of 15 to 995, where both a and	
	b correspond to the positions of nucleotide residues	
	shown in SEQ ID NO:78, and where b is greater than	
	or equal to a + 14.	
830364	Preferably excluded from the present invention are	
03020.	one or more polynucleotides comprising a nucleotide	
	sequence described by the general formula of a-b.	
1	where a is any integer between 1 to 1201 of SEQ ID	
	NO:79, b is an integer of 15 to 1215, where both a	
•	and b correspond to the positions of nucleotide	
	residues shown in SEQ ID NO:79, and where b is	
030204	greater than or equal to a + 14.	<u> </u>
830394	Preferably excluded from the present invention are	
	one or more polynucleotides comprising a nucleotide	
	sequence described by the general formula of a-b.	
	where a is any integer between 1 to 2646 of SEQ ID	
	NO:80. b is an integer of 15 to 2660, where both a	
	and b correspond to the positions of nucleotide	
ļ	residues shown in SEQ ID NO:80, and where b is	
	greater than or equal to a + 14.	
830398	Preferably excluded from the present invention are	
	one or more polynucleotides comprising a nucleotide	
	sequence described by the general formula of a-b.	
1	where a is any integer between 1 to 1776 of SEQ ID	
	NO:81, b is an integer of 15 to 1790, where both a	
•	and b correspond to the positions of nucleotide	
	residues shown in SEQ ID NO:81, and where b is	
	greater than or equal to a + 14.	
830412	Preferably excluded from the present invention are	
	one or more polynucleotides comprising a nucleotide	
	sequence described by the general formula of a-b.	
	where a is any integer between I to 1336 of SEQ ID	
	NO:82. b is an integer of 15 to 1350, where both a	
	and b correspond to the positions of nucleotide	ĺ
	residues shown in SEQ ID NO:82, and where b is	
	greater than or equal to a + 14.	
830436	Preferably excluded from the present invention are	T89041, R38418, R51559, R62385,
050450		R63785, H21426, N55384, AA009460,
	sequence described by the general formula of a-b,	AA039527, AA039526, AA490811,
		AA588539, AA574253, AA827525,
		AA975094, D79482, D79908, N55964,
	and b correspond to the positions of nucleotide	C14631, C14891, C14892
	residues shown in SEQ ID NO:83, and where b is	
930464	greater than or equal to a + 14.	110(2)(7, 13)0227, 33(5)(7)
830464	Preferably excluded from the present invention are	H06247, H19227, W52470
	one or more polynucleotides comprising a nucleotide	
	sequence described by the general formula of a-b.	
	where a is any integer between 1 to 1477 of SEQ ID	
	NO:84, b is an integer of 15 to 1491, where both a	
	and b correspond to the positions of nucleotide	
	residues shown in SEQ ID NO:84, and where b is	
	greater than or equal to a + 14.	
830471	Preferably excluded from the present invention are	R28064. R28282, AA143044. AA151127.

	han as more polynyalostidas competities a surface	AA165093, AA164631, AA256943.
	one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 954 of SEQ ID NO:85, b is an integer of 15 to 968, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:85, and where b is greater than or equal to a + 14.	AA765384, D80554
830477	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 3054 of SEQ ID NO:86, b is an integer of 15 to 3068, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:86, and where b is greater than or equal to a + 14.	T71686, R81413, R81414, H52583, H84987, H87923, H88319, H88319, W74073, W79680, AA021098, AA179389, AA182649, AA188175, AA191449, AA228943, AA228942, AA594459, AA737972, C02737
830500	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2216 of SEQ ID NO:87, b is an integer of 15 to 2230, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:87, and where b is greater than or equal to a + 14.	
830509	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1149 of SEQ ID NO:88. b is an integer of 15 to 1163, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:88, and where b is greater than or equal to a + 14.	
830528	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1925 of SEQ ID NO:89, b is an integer of 15 to 1939, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:89, and where b is greater than or equal to a + 14.	
830542	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2018 of SEQ ID NO:90, b is an integer of 15 to 2032, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:90, and where b is greater than or equal to a + 14.	T60268, T61648, T68371, T88743, R00503, R13392, R40908, R40908, H02114, H07926, H29767, H29768, H38826, H93354, W42415, W42513, W61060, W72566, W76560, AA011078, AA011079, AA031697, AA031863, AA058529, AA100913, AA100912, AA129619, AA129593, AA129330, AA128581, AA160087, AA160675, AA173629, AA173985, AA186698, AA188326, AA480672, AA587251, AA576938, AA743161, AA834774, AA872783, AA877207, AA878505, AA923685, AA934427, AA962214, AA995455, AA995857, N88876
830564	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b.	

	where a is any integer between 1 to 1774 of SEQ ID	
	NO:91. b is an integer of 15 to 1788, where both a	
	and b correspond to the positions of nucleotide	
	residues shown in SEQ ID NO:91, and where b is	
	greater than or equal to a + 14.	
83061		
	one or more polynucleotides comprising a nucleotide	
	sequence described by the general formula of a-b.	
	where a is any integer between 1 to 481 of SEQ ID	
	NO:92. b is an integer of 15 to 495, where both a and	1
	b correspond to the positions of nucleotide residues shown in SEQ ID NO:92, and where b is greater than	
	· · · · · · · · · · · · · · · · · · ·	
83061	or equal to a + 14. Preferably excluded from the present invention are	R43709. R43709, H09113. H43746.
83001	one or more polynucleotides comprising a nucleotide	N92632, AA022453, AA120876.
	sequence described by the general formula of a-b.	AA120889, AA493651, AA493785.
	where a is any integer between 1 to 1363 of SEQ ID	AA494347. AA565392. AA743179.
	NO:93. b is an integer of 15 to 1377, where both a	IAA769161
	and b correspond to the positions of nucleotide	1,0,10.
	residues shown in SEQ ID NO:93, and where b is	1
	greater than or equal to a + 14.	
83062		
	one or more polynucleotides comprising a nucleotide	
	sequence described by the general formula of a-b.	
	where a is any integer between 1 to 2805 of SEQ ID	
	NO:94, b is an integer of 15 to 2819, where both a	
	and b correspond to the positions of nucleotide	
1	residues shown in SEQ ID NO:94, and where b is	
	greater than or equal to a + 14.	
83063	Preferably excluded from the present invention are	
İ	one or more polynucleotides comprising a nucleotide	
	sequence described by the general formula of a-b.	
	where a is any integer between 1 to 691 of SEQ ID	
	NO:95. b is an integer of 15 to 705, where both a and	
	b correspond to the positions of nucleotide residues	
ļ	shown in SEQ ID NO:95, and where b is greater than	
	or equal to a + 14.	
83065	1	
	one or more polynucleotides comprising a nucleotide	
	sequence described by the general formula of a-b.	
	where a is any integer between 1 to 3458 of SEQ ID	
	NO:96, b is an integer of 15 to 3472, where both a and b correspond to the positions of nucleotide	·
	residues shown in SEQ ID NO:96, and where b is	Ì
	greater than or equal to a + 14.	
83066		
55000	one or more polynucleotides comprising a nucleotide	
	sequence described by the general formula of a-b,	
1	where a is any integer between 1 to 1202 of SEQ ID	
	NO:97, b is an integer of 15 to 1216, where both a	
	and b correspond to the positions of nucleotide	
	residues shown in SEQ ID NO:97, and where b is	
l	greater than or equal to a + 14.	
83066		
	one or more polynucleotides comprising a nucleotide	
	sequence described by the general formula of a-b.	
1	where a is any integer between 1 to 1172 of SEQ 1D	

	NO. 00 11 1100 1100	r
	NO:98. b is an integer of 15 to 1186, where both a	
	and b correspond to the positions of nucleotide	
	residues shown in SEQ ID NO:98, and where b is	
	greater than or equal to a + 14.	
830704	Preferably excluded from the present invention are	
	one or more polynucleotides comprising a nucleotide	
	sequence described by the general formula of a-b.	
	where a is any integer between 1 to 1106 of SEQ ID	
	NO:99, b is an integer of 15 to 1120, where both a	
	and b correspond to the positions of nucleotide	
	residues shown in SEQ ID NO:99, and where b is	
	greater than or equal to a + 14.	
830765	Preferably excluded from the present invention are	
	one or more polynucleotides comprising a nucleotide	
	sequence described by the general formula of a-b.	
	where a is any integer between 1 to 1211 of SEQ ID	
	NO:100, b is an integer of 15 to 1225, where both a	
	and b correspond to the positions of nucleotide	
	residues shown in SEQ ID NO:100, and where b is	
•	greater than or equal to a + 14.	
830778		
830778	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide	
	sequence described by the general formula of a-b.	
	where a is any integer between 1 to 1199 of SEQ ID	
	NO:101, b is an integer of 15 to 1213, where both a	
	and b correspond to the positions of nucleotide	
	residues shown in SEQ ID NO:101, and where b is	
	greater than or equal to a + 14.	D(2200 D(6524 A A 401620
830784	Preferably excluded from the present invention are	R63323, R66534, AA491630
	one or more polynucleotides comprising a nucleotide	
	sequence described by the general formula of a-b,	
	where a is any integer between 1 to 1550 of SEQ ID	
	NO:102, b is an integer of 15 to 1564, where both a	
	and b correspond to the positions of nucleotide	
	residues shown in SEQ ID NO:102, and where b is	
	greater than or equal to a + 14.	
830800	Preferably excluded from the present invention are	·
	one or more polynucleotides comprising a nucleotide	
	sequence described by the general formula of a-b,	
	where a is any integer between 1 to 1443 of SEQ 1D	
	NO:103, b is an integer of 15 to 1457, where both a	
	and b correspond to the positions of nucleotide	
	residues shown in SEQ ID NO:103, and where b is	
	greater than or equal to a + 14.	
830821	Preferably excluded from the present invention are	
00002.	one or more polynucleotides comprising a nucleotide	
	sequence described by the general formula of a-b.	
	where a is any integer between 1 to 771 of SEQ ID	
	NO:104, b is an integer of 15 to 785, where both a	
	and b correspond to the positions of nucleotide	
	residues shown in SEQ ID NO:104, and where b is	
	greater than or equal to a + 14.	
920940	Preferably excluded from the present invention are	AA258128, AA259034, AA262104.
830849	one or more polynucleotides comprising a nucleotide	AA742612, AA804402
		MA 142012, MAOU44V2
	sequence described by the general formula of a-b.	
	where a is any integer between 1 to 907 of SEQ ID	
	NO:105, b is an integer of 15 to 921, where both a	L

		T
]	and b correspond to the positions of nucleotide	
	residues shown in SEQ ID NO:105, and where b is	•
	greater than or equal to a + 14.	
830903	Preferably excluded from the present invention are	
	one or more polynucleotides comprising a nucleotide	
	sequence described by the general formula of a-b.	
	where a is any integer between 1 to 578 of SEQ ID	
	NO:106. b is an integer of 15 to 592. where both a	
•	and b correspond to the positions of nucleotide	
	residues shown in SEQ ID NO:106, and where b is	
	greater than or equal to a + 14.	
830913	Preferably excluded from the present invention are	R06463, R06517, R48006, R51455,
	one or more polynucleotides comprising a nucleotide	R61502, R72398, R72399, R74489,
	sequence described by the general formula of a-b.	R74599, H07933, H08039, H61149.
	where a is any integer between 1 to 2234 of SEQ ID	H62056, H90758, H90809, N32837,
	NO:107, b is an integer of 15 to 2248, where both a	N42283, W40284, W45325, AA079353,
	and b correspond to the positions of nucleotide	AA079592, AA100814, AA102342,
	residues shown in SEQ ID NO:107, and where b is	AA111844, AA122150. AA134127,
	greater than or equal to a + 14.	AA134128, AA148738, AA148709.
		AA164240, AA164899. AA164275.
		AA171881, AA179310, AA179453,
		AA180811, AA180955, AA187432,
		AA190377, AA190791, AA190383,
		AA458475, AA427428, AA468548.
		AA554518, AA595768, AA595893,
		AA640601, AA574035, AA658143,
		AA863401, AA906604, AA995159,
		C03746. C04875. C05396. AA033510
020020	D C 11 1 1 1 C 1 1 1 C 1 1 1 C 1 1 1 1 1	C03740, C04873, C03370, AA033310
830920	Preferably excluded from the present invention are	
	one or more polynucleotides comprising a nucleotide	
	sequence described by the general formula of a-b,	
	where a is any integer between 1 to 771 of SEQ ID	
	NO:108, b is an integer of 15 to 785, where both a	
	and b correspond to the positions of nucleotide	
	residues shown in SEQ ID NO:108, and where b is	
	greater than or equal to a + 14.	
830938	Preferably excluded from the present invention are	AA053612
050750	one or more polynucleotides comprising a nucleotide	[
	sequence described by the general formula of a-b.	
	where a is any integer between 1 to 597 of SEQ ID	
	NO:109, b is an integer of 15 to 611, where both a	
	and b correspond to the positions of nucleotide]
	residues shown in SEQ ID NO:109, and where b is	
	greater than or equal to a + 14.	
830980	Preferably excluded from the present invention are	
	one or more polynucleotides comprising a nucleotide	
	sequence described by the general formula of a-b.	
	where a is any integer between 1 to 650 of SEQ ID	
	NO:110, b is an integer of 15 to 664, where both a	
	and b correspond to the positions of nucleotide	
	residues shown in SEQ ID NO:110, and where b is	
	greater than or equal to a + 14.	
831014	Preferably excluded from the present invention are	
	one or more polynucleotides comprising a nucleotide	
		i e e e e e e e e e e e e e e e e e e e
	sequence described by the general formula of a-b.	
	sequence described by the general formula of a-b, where a is any integer between 1 to 4051 of SEO ID	
	where a is any integer between 1 to 4051 of SEQ ID NO:111, b is an integer of 15 to 4065, where both a	

	had be assessed to the positions of supleatide	T
	and b correspond to the positions of nucleotide	
	residues shown in SEQ ID NO:111, and where b is	
22.02.6	ercater than or equal to a + 14.	
831026	Preferably excluded from the present invention are	
ļ	one or more polynucleotides comprising a nucleotide	1
	sequence described by the general formula of a-b.	
}	where a is any integer between 1 to 1478 of SEQ ID	
İ	NO:112, b is an integer of 15 to 1492, where both a	
	and b correspond to the positions of nucleotide	
	residues shown in SEQ ID NO:112, and where b is	
	greater than or equal to a + 14.	
831031	Preferably excluded from the present invention are	R46004, R46004, H06850, N27532.
	one or more polynucleotides comprising a nucleotide	N30567. N30842, N34647, N40349.
	sequence described by the general formula of a-b,	N41369, N49777, N52708, N62958,
	where a is any integer between 1 to 1468 of SEQ ID	W68355. W68490, AA054602. AA193410,
·	NO:113, b is an integer of 15 to 1482, where both a	AA193648, AA503204, AA688236,
	and b correspond to the positions of nucleotide	AA730103. AA736540, AA747555.
	residues shown in SEQ ID NO:113, and where b is	AA811522. AA863169. N79861
	greater than or equal to a + 14.	
831055	Preferably excluded from the present invention are	
021023	one or more polynucleotides comprising a nucleotide	
	sequence described by the general formula of a-b,	
	where a is any integer between 1 to 3717 of SEQ ID	
ļ	1	
	NO:114, b is an integer of 15 to 3731, where both a	
1	and b correspond to the positions of nucleotide	
	residues shown in SEQ ID NO:114, and where b is	
	greater than or equal to a + 14.	
831057	Preferably excluded from the present invention are	R69415, R69546, H14127, H62767.
		N62927. N63320, W00649, W01189.
	sequence described by the general formula of a-b.	AA053293, AA058396, AA149075,
	1 - 1	AA458528, AA418699, AA418770,
		AA505598, AA576507, AA730033,
		AA805864, AA988279, AA991217,
	residues shown in SEQ ID NO:115, and where b is	D82661. C21298
	greater than or equal to a + 14.	
831062	Preferably excluded from the present invention are	
	one or more polynucleotides comprising a nucleotide	
	sequence described by the general formula of a-b.	
	where a is any integer between 1 to 1306 of SEQ ID	
	NO:116, b is an integer of 15 to 1320, where both a	
	and b correspond to the positions of nucleotide	
	residues shown in SEQ ID NO:116, and where b is	
	greater than or equal to a + 14.	
831117		R80585, R80586, N49020, AA173625,
		AA173981, AA557142, AA627866,
		AA847195, AI015673
	where a is any integer between 1 to 2011 of SEQ ID	
	NO:117, b is an integer of 15 to 2025, where both a	
	and b correspond to the positions of nucleotide	
	residues shown in SEQ ID NO:117, and where b is	
	greater than or equal to a + 14.	
831122		R72079. R72128. AA715820. AA804163,
031122		AA809123. AA641490
	sequence described by the general formula of a-b,	(1/1007) 23. A. 1041490
	where a is any integer between 1 to 1281 of SEQ ID	
	NO:118, b is an integer of 15 to 1295, where both a	
	and b correspond to the positions of nucleotide	

	residues shown in SEQ ID NO:118, and where b is	
	greater than or equal to a + 14.	
831125	Preferably excluded from the present invention are	N80647, AA114140. AA143553,
	one or more polynucleotides comprising a nucleotide	AA156386, N68188, AA070867
]	sequence described by the general formula of a-b.	
}	where a is any integer between 1 to 1243 of SEQ ID	
	NO:119, b is an integer of 15 to 1257, where both a	
	and b correspond to the positions of nucleotide	
]	residues shown in SEQ ID NO:119, and where b is	
	greater than or equal to a + 14.	
831132	Preferably excluded from the present invention are	
	one or more polynucleotides comprising a nucleotide	
	sequence described by the general formula of a-b,	
	where a is any integer between 1 to 383 of SEQ ID	
	NO:120, b is an integer of 15 to 397, where both a	
	and b correspond to the positions of nucleotide	
	residues shown in SEQ ID NO:120, and where b is	
	greater than or equal to a + 14.	
831152	Preferably excluded from the present invention are	AA765155
<u></u>	one or more polynucleotides comprising a nucleotide	
	sequence described by the general formula of a-b,	
	where a is any integer between 1 to 862 of SEQ ID	
	NO:121. b is an integer of 15 to 876, where both a	
	and b correspond to the positions of nucleotide	
	residues shown in SEQ ID NO:121, and where b is	
	greater than or equal to a + 14.	
831157	Preferably excluded from the present invention are	T57943, R34275, R35472, R77406,
631137	one or more polynucleotides comprising a nucleotide	R77405, N23203, N59015, AA160841.
		AA610280, AA857624. A1089936,
	sequence described by the general formula of a-b,	II.
	where a is any integer between 1 to 1264 of SEQ ID	A1094724, A1094954
	NO:122, b is an integer of 15 to 1278, where both a	
	and b correspond to the positions of nucleotide	
	residues shown in SEQ ID NO:122, and where b is	
831160	greater than or equal to a + 14.	
931100	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide	
	sequence described by the general formula of a-b,	
	where a is any integer between 1 to 3101 of SEQ ID	
	NO:123, b is an integer of 15 to 3115, where both a	
	and b correspond to the positions of nucleotide residues shown in SEO ID NO:123, and where b is	
	F	
021102	greater than or equal to a + 14.	7 2 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
831193	Preferably excluded from the present invention are	
	one or more polynucleotides comprising a nucleotide	
	sequence described by the general formula of a-b,	
	where a is any integer between 1 to 365 of SEQ ID	
	NO:124, b is an integer of 15 to 379, where both a	
	and b correspond to the positions of nucleotide	
	residues shown in SEQ ID NO:124, and where b is	
00000=	greater than or equal to a + 14.	1
831197	Preferably excluded from the present invention are	AA134613
	one or more polynucleotides comprising a nucleotide	
	sequence described by the general formula of a-b.	
	where a is any integer between 1 to 1253 of SEQ ID	
	NO:125, b is an integer of 15 to 1267, where both a	
	and b correspond to the positions of nucleotide	
	residues shown in SEQ ID NO:125, and where b is	L

		·
	greater than or equal to a + 14.	
831217	Preferably excluded from the present invention are	
	one or more polynucleotides comprising a nucleotide	
	sequence described by the general formula of a-b.	
	where a is any integer between 1 to 827 of SEQ ID	
	NO:126. b is an integer of 15 to 841. where both a	
	and b correspond to the positions of nucleotide	
	residues shown in SEQ ID NO:126, and where b is	
	greater than or equal to a + 14.	7/0/07 700000 700000 700000
831239	Preferably excluded from the present invention are	T68487, T88923, T88994, R09550, R09663,
	one or more polynucleotides comprising a nucleotide	R26714. R26937. H27046, H28228.
	sequence described by the general formula of a-b.	H30272. H30335, N27966, N36884.
	where a is any integer between I to 1158 of SEQ ID	N46156, N93575, W21407, W44513.
	NO:127, b is an integer of 15 to 1172, where both a	W44514, W47626, W47627, W56215.
	and b correspond to the positions of nucleotide	W60528, W80465, W80574, W92729,
	residues shown in SEQ ID NO:127, and where b is	AA002237. AA002076. AA099290.
	greater than or equal to a ÷ 14.	AA099291. AA127753. AA127706.
		AA128275. AA128572. AA148737.
		AA149497. AA419078. AA423819.
		AA506117, AA534694, AA552105,
		AA552219. AA583468. AA622094.
		AA633205. AA878663. AA911544.
		AA916173. AA974873. AA988860,
		A1056396. A1074163. W92753
831248	Preferably excluded from the present invention are	
	one or more polynucleotides comprising a nucleotide	
	sequence described by the general formula of a-b.	
	where a is any integer between 1 to 877 of SEQ ID	
	NO:128, b is an integer of 15 to 891, where both a	
	and b correspond to the positions of nucleotide	
	residues shown in SEQ ID NO:128, and where b is	
021212	greater than or equal to a + 14.	T61093, T97774, R13148, R31511,
831313	Preferably excluded from the present invention are	•
		R32943. R33906, R33921, R37053, R44148, R44148. R74449, R79209.
	sequence described by the general formula of a-b,	R79476, H12271, H27631, H30122.
	where a is any integer between I to 2447 of SEQ ID	1
	NO:129, b is an integer of 15 to 2461, where both a	R84834, H63166, H71003, H71015,
	and b correspond to the positions of nucleotide residues shown in SEQ ID NO:129, and where b is	H83387, N23726, N23730, N23773,
	greater than or equal to a + 14.	N52416. N66497, N67917, N68137, N73801. N99428, W95944, AA018712,
	greater than or equal to a + t4.	AA020879. AA429721. AA470397,
		AA493243, AA507952, AA515358,
		AA583463, AA617991, AA618186,
		AA631437, AA566089, AA746085,
		AA837997, AA878863. AA922678.
		AA985597, AA947992, A1074096, C03207,
 		C17030. C18106
831369	Preferably excluded from the present invention are	017050. 010100
606160	one or more polynucleotides comprising a nucleotide	
	sequence described by the general formula of a-b,	
	where a is any integer between 1 to 2183 of SEQ ID	
	NO:130, b is an integer of 15 to 2197, where both a	
	and b correspond to the positions of nucleotide	
	residues shown in SEQ ID NO:130, and where b is	
	greater than or equal to $a + 14$.	
831371	Preferably excluded from the present invention are	
1/5150	one or more polynucleotides comprising a nucleotide	
	one of more polynaciconaes comprising a naciconae	<u> </u>

	.,	
	sequence described by the general formula of a-b.	
l.	where a is any integer between 1 to 450 of SEQ ID	
İ	NO:131, b is an integer of 15 to 464, where both a	
	and b correspond to the positions of nucleotide	
	residues shown in SEQ ID NO:131, and where b is	
	greater than or equal to a + 14.	
831373	Preferably excluded from the present invention are	T50786, T50949, T53797, T53916, T64650,
031373	one or more polynucleotides comprising a nucleotide	T71681, T71836, T71876, T71877, T74596,
ľ	sequence described by the general formula of a-b.	T74656, H30426, H46449, H46671,
ŀ		H46670, H46990, H50500, AA419051,
ŀ	where a is any integer between 1 to 1936 of SEQ ID	AA423809, AA928986
	NO:132, b is an integer of 15 to 1950, where both a	AA423809, AA928988
ŀ	and b correspond to the positions of nucleotide	
İ	residues shown in SEQ ID NO:132, and where b is	
	greater than or equal to a + 14.	
831387	Preferably excluded from the present invention are	
	one or more polynucleotides comprising a nucleotide	
1	sequence described by the general formula of a-b.	
	where a is any integer between 1 to 2079 of SEQ ID	
	NO:133, b is an integer of 15 to 2093, where both a	
	and b correspond to the positions of nucleotide	
	residues shown in SEQ ID NO:133, and where b is	
	greater than or equal to a + 14.	
831410	Preferably excluded from the present invention are	
051.110	one or more polynucleotides comprising a nucleotide	
	sequence described by the general formula of a-b,	
	where a is any integer between 1 to 715 of SEQ ID	
	NO:134, b is an integer of 15 to 729, where both a	
	and b correspond to the positions of nucleotide	
ł	residues shown in SEQ ID NO:134, and where b is	
	greater than or equal to a + 14.	
831448	Preferably excluded from the present invention are	
ľ	one or more polynucleotides comprising a nucleotide	
ľ	sequence described by the general formula of a-b,	
	where a is any integer between 1 to 1175 of SEQ ID	
	NO:135, b is an integer of 15 to 1189, where both a	
	and b correspond to the positions of nucleotide	
	residues shown in SEQ ID NO:135, and where b is	
	greater than or equal to a + 14.	
831450	Preferably excluded from the present invention are	
İ	one or more polynucleotides comprising a nucleotide	
]	sequence described by the general formula of a-b,	
	where a is any integer between 1 to 1452 of SEQ ID	
	NO:136, b is an integer of 15 to 1466, where both a	
i	and b correspond to the positions of nucleotide	
	residues shown in SEQ ID NO:136, and where b is	
	greater than or equal to a + 14.	
831472	Preferably excluded from the present invention are	
0514/2	one or more polynucleotides comprising a nucleotide	
	sequence described by the general formula of a-b,	
1	where a is any integer between 1 to 126 of SEQ ID	
1	NO:137, b is an integer of 15 to 140, where both a	
	and b correspond to the positions of nucleotide	
i	residues shown in SEQ ID NO:137, and where b is	
	greater than or equal to a + 14.	
831473	Preferably excluded from the present invention are	
1	one or more polynucleotides comprising a nucleotide	
	sequence described by the general formula of a-b,	<u> </u>

	where a is any integer between 1 to 4128 of SEQ ID	
l	NO:138, b is an integer of 15 to 4142, where both a	
	and b correspond to the positions of nucleotide	
1	residues shown in SEQ ID NO:138, and where b is	
	greater than or equal to a + 14.	•
831474	Preferably excluded from the present invention are	T66054, T89542, R10967, T78297, T83524,
0314/4	one or more polynucleotides comprising a nucleotide	T97793, R13138, H08701, H10662.
]	sequence described by the general formula of a-b,	R82956. R96295, R98912, H66237,
		1
1	where a is any integer between 1 to 1733 of SEQ ID	H79525, N31425, N36736, W76142.
l	NO:139, b is an integer of 15 to 1747, where both a	W81053, AA010227, AA011652,
	and b correspond to the positions of nucleotide	AA057613, AA057653, AA069088.
ŀ	residues shown in SEQ ID NO:139, and where b is	AA083946, AA084193, AA126186,
	greater than or equal to a + 14.	H70618. H79526, W72916. W80802.
ł		AA011433, AA057699, AA057752,
		AA069023
831494	Preferably excluded from the present invention are	H14081, H14102, N34979, N42213,
	one or more polynucleotides comprising a nucleotide	N43740, N68241, W69584, W69583,
	sequence described by the general formula of a-b.	AA507828, AA877181, AA975100,
	where a is any integer between 1 to 1226 of SEQ ID	A1000204
	NO:140, b is an integer of 15 to 1240, where both a	Į.
	and b correspond to the positions of nucleotide	
	residues shown in SEQ ID NO:140, and where b is	
	greater than or equal to a + 14.	
831506	Preferably excluded from the present invention are	AA035596. AA577792, AA903617,
03.300	one or more polynucleotides comprising a nucleotide	AA972775, AA996054. C00084
	sequence described by the general formula of a-b.	111,5,2,7,3,111,5,5005.1. 000001
	where a is any integer between 1 to 657 of SEQ ID	
1	NO:141, b is an integer of 15 to 671, where both a	
ŀ		
ł	and b correspond to the positions of nucleotide	
	residues shown in SEQ ID NO:141, and where b is	·
021522	greater than or equal to a + 14.	
831533	Preferably excluded from the present invention are	
	one or more polynucleotides comprising a nucleotide	
	sequence described by the general formula of a-b,	
	where a is any integer between 1 to 3251 of SEQ ID	
	NO:142, b is an integer of 15 to 3265, where both a	·
	and b correspond to the positions of nucleotide	
	residues shown in SEQ ID NO.142, and where b is	
	greater than or equal to a + 14.	
831539	Preferably excluded from the present invention are	
	one or more polynucleotides comprising a nucleotide	
	sequence described by the general formula of a-b,	
	where a is any integer between 1 to 751 of SEQ ID	
	NO:143, b is an integer of 15 to 765, where both a	
	and b correspond to the positions of nucleotide	
	residues shown in SEQ ID NO:143, and where b is	
	greater than or equal to a + 14.	
831556	Preferably excluded from the present invention are	H01879, H01880, H43546, H43547,
	one or more polynucleotides comprising a nucleotide	H43548, N58813, N75148, AA428902.
	sequence described by the general formula of a-b,	AA429101, AA278337, AA662009.
	where a is any integer between 1 to 1680 of SEQ ID	AA928907, AA988624
	NO:144, b is an integer of 15 to 1694, where both a	
	and b correspond to the positions of nucleotide	
	residues shown in SEQ ID NO:144, and where b is	
	greater than or equal to a + 14.	
831594	Preferably excluded from the present invention are	
466160	one or more polynucleotides comprising a nucleotide	<u> </u>
	one of more polynacieodides comprising a nucleotide	<u></u>

	sequence described by the general formula of a-b,	
	where a is any integer between 1 to 809 of SEQ ID	
	NO:145, b is an integer of 15 to 823, where both a	
	and b correspond to the positions of nucleotide	
	residues shown in SEQ ID NO:145, and where b is	
	greater than or equal to a + 14.	
831598	Preferably excluded from the present invention are	
021270	one or more polynucleotides comprising a nucleotide	
	sequence described by the general formula of a-b,	
	where a is any integer between 1 to 1120 of SEQ ID	
	NO:146, b is an integer of 15 to 1134, where both a	
	and b correspond to the positions of nucleotide	
	residues shown in SEQ ID NO:146, and where b is	
	greater than or equal to a + 14.	
831608	Preferably excluded from the present invention are	
	one or more polynucleotides comprising a nucleotide	Ì
	sequence described by the general formula of a-b,	
	where a is any integer between 1 to 1472 of SEQ ID	
	NO:147. b is an integer of 15 to 1486, where both a	
	and b correspond to the positions of nucleotide]
	residues shown in SEQ ID NO:147, and where b is	
	greater than or equal to a + 14.	
831613	Preferably excluded from the present invention are	
	one or more polynucleotides comprising a nucleotide	
	sequence described by the general formula of a-b,	}
	where a is any integer between 1 to 139 of SEQ ID	
	NO:148, b is an integer of 15 to 153, where both a	
	and b correspond to the positions of nucleotide	
	residues shown in SEQ ID NO:148, and where b is	
	greater than or equal to a + 14.	-
831622	Preferably excluded from the present invention are	T40013, T40117, T55842, T55892, T58738,
031022	one or more polynucleotides comprising a nucleotide	
		T58764, T58805, T58835, T58963, T60293,
	sequence described by the general formula of a-b,	T60386, T61270, T61322, T61371, T61395,
	where a is any integer between 1 to 868 of SEQ ID	T61404, T61721, T61734, T61735, T61841,
	NO:149, b is an integer of 15 to 882, where both a	T61856, T61857, T61884, T62049, T62065,
	and b correspond to the positions of nucleotide	T62070, T62087, T62113, T62126, T62146,
	residues shown in SEQ ID NO:149, and where b is	T41021, T62664, T62668, T62669, T62676,
	greater than or equal to a + 14.	T62816, T62819, T62820, T62827, T64118,
		T64230, T64368, T64422, T64678, T64698,
		T64747, T67429, T67590, T67709, T67724,
		T67754, T67785, T67831, T67863, T67888,
		T67996, T68022, T68038, T68104, T68142,
		T68217, T68418, T68465, T68484, T68531,
		T68548, T68557, T68575, T68623, T68633,
		T68648, T68653, T68760, T68826, T68895,
		T68969, T68981, T69056, T69126, T69184,
		T69428, T69605, T69622, T69678, T69699,
		T70483, T70907, T70960, T71019, T71080,
		T71224, T71297, T71437, T71660, T71885,
		T71903, T71985. T72050, T72115, T72129,
		T72147, T72158, T72263, T72310, T72415,
		[72769, T72775, T72802, T72897, T72903,
		[72922, 772924, 773035, 773068, 773167,
		[73224, 773305, 773392, 773458, 773473,
		T73482, T73525, T73540, T73541, T73551,
	I	T73560, T73599. T73606. T73619. T73637,
		T73644, T73655, T73659, T73660, T73800,

		T73887, T73913, T73945, T73950, T74048, T74200, T74201, T74423, T74477, T74559.
		T74706, T74827, T99112, R05781, R05867, H47944, R95831, H60131, H65347,
		H65551, H68454, H68777, H73380, H73381, H79275, H79386, H82213,
		H82307, H93202, H93992, H93991,
		H94491, H94804, H95257, H95307,
		H95341, N28274, N58244, N68733, N77623, N80767, N91623, W07555,
		W80697, AA004677, AA004255,
		AA033869. AA034057. AA234464,
831631	Preferably excluded from the present invention are	AA491842, C20927
027007	one or more polynucleotides comprising a nucleotide	
	sequence described by the general formula of a-b,	
	where a is any integer between 1 to 1494 of SEQ ID NO:150, b is an integer of 15 to 1508, where both a	
	and b correspond to the positions of nucleotide	
	residues shown in SEQ ID NO:150, and where b is	
921/22	greater than or equal to a + 14. Preferably excluded from the present invention are	T60158, T60218, T62213, T62652, T62877.
831632	one or more polynucleotides comprising a nucleotide	T62966, T63329, T63951, T64542, T64634,
	sequence described by the general formula of a-b.	T65965, T90119, T91565, T91610, T92138,
	where a is any integer between 1 to 1218 of SEQ ID	T94160, T94999, T90219, T83025, T84028,
	NO:151, b is an integer of 15 to 1232, where both a	T84029, T84511, R22325, R22619, R22620, R25250, R25595, R26992,
	and b correspond to the positions of nucleotide residues shown in SEQ ID NO:151, and where b is	R27328, R32850, R32954, R33282,
	greater than or equal to a + 14.	R44282, R47779, R48151, R48152,
		R48322, R48428, R48538, R50415,
		R52277, R52278, R54608, R44282, R55376, R70352, R72103, R72155,
	·	R72280, R72317, R72367, R72368,
		R72371, R72372, R72716, R73784,
		R74375, R77393, R77394, R77892,
		R77987, R81485, R81725, H05676.
		H15941, H22149, H22193, H24533, H25059, H26810, H27743, H27803,
		H28012, H28066, H28290, H28291,
	·	H30654, H39748, H39761, H41932,
		H41979, H42063, H42642, H42766,
		H42767, H44628, H45776, H45777, H46386, H46404, R93135, R93942,
		R94660, R94661, H50708, H50709,
		H50720, H50812, H50811, H50826,
		H61352, H62379, H63665, H63944,
		H66336, H66385, H70746, H73887, H74080, H74176, H82646, H82647.
		H86555, H87065, H87719, H91147,
		H91197, H93078, H93211, H98788,
		N24993, N25111, N30229, N32159.
		N34033, N36553, N41829, N42292,
		N46951. N49340, N52921, N55462,
		N57121, N69863, N76837, N80667, N92844, N93333, N93683, N94449,
		N95075, W16427, W15325, W23470.
		W23480, W25070, W25186, W30795,

		W38675, W39219, W39393, W69270.
ļ		W69557, AA019864, AA022662,
]		AA022669, AA022768, AA025335,
		AA024417, AA031282, AA031281.
	ļ	AA032192, AA039752, AA040328.
•		AA040307. AA041359, AA041442.
		AA057720, AA074855, AA086192.
		AA099717, AA099716, AA100416,
1		AA142927, AA143150. AA149895.
1		1
		AA150239, AA150313, AA176193.
		AA459294, AA464165, AA425845,
		AA425899, AA428397, AA430393,
		AA427364, AA469113, AA505259,
		AA515918, AA516032, AA527677.
		AA533908, AA541266, AA554671,
		AA555247, AA557794, AA565267,
		AA582247. AA584415, AA588477,
		AA593255. AA595311, AA595376.
		AA604354, AA622137, AA573444.
		AA574244, AA732469, AA740323,
1		AA741360, AA742872, AA749432,
		AA807903, AA808285, AA872498.
		AA873181, AA878139, AA878294,
		AA909748, AA937058, AA987672,
		AA994225, A1076066, W07696
831653	Preferably excluded from the present invention are	
	one or more polynucleotides comprising a nucleotide	
	sequence described by the general formula of a-b,	
	where a is any integer between 1 to 985 of SEQ ID	
	NO:152, b is an integer of 15 to 999, where both a	
	and b correspond to the positions of nucleotide	
	residues shown in SEQ ID NO:152, and where b is	
	greater than or equal to a + 14.	
831655		N95539, W24228, W37689, AA019086,
1 (31033	•	AA430215
	sequence described by the general formula of a-b,	
	where a is any integer between 1 to 1198 of SEQ ID	· ·
i		
1	NO:153, b is an integer of 15 to 1212, where both a	.
1	and b correspond to the positions of nucleotide	
Î	residues shown in SEQ ID NO:153, and where b is	
	greater than or equal to a + 14.	
831708	Preferably excluded from the present invention are	
	one or more polynucleotides comprising a nucleotide	
1	sequence described by the general formula of a-b,	
	where a is any integer between 1 to 2347 of SEQ 1D	
	NO:154, b is an integer of 15 to 2361, where both a	
	and b correspond to the positions of nucleotide	
	residues shown in SEQ ID NO:154, and where b is	<u> </u>
	greater than or equal to a + 14.	
921720	Preferably excluded from the present invention are	
831738		}
	one or more polynucleotides comprising a nucleotide	
	sequence described by the general formula of a-b,	
	where a is any integer between 1 to 1817 of SEQ ID	
	NO:155, b is an integer of 15 to 1831, where both a	
}	and b correspond to the positions of nucleotide	
	residues shown in SEQ ID NO:155, and where b is	
	greater than or equal to a + 14.	

<u> </u>		
831741	Preferably excluded from the present invention are	T47689, T80213, H11356, H13411,
	one or more polynucleotides comprising a nucleotide	R86865. R87546. N35663. AA081442.
	sequence described by the general formula of a-b.	AA161001, C17978, C18946
	where a is any integer between 1 to 1172 of SEQ ID	
	NO:156, b is an integer of 15 to 1186, where both a	
	and b correspond to the positions of nucleotide	
	residues shown in SEQ ID NO:156, and where b is	
	greater than or equal to a + 14.	
831754	Preferably excluded from the present invention are	
	one or more polynucleotides comprising a nucleotide	
	sequence described by the general formula of a-b.	
	where a is any integer between 1 to 1434 of SEQ ID	
	NO:157, b is an integer of 15 to 1448, where both a	
	and b correspond to the positions of nucleotide	
	residues shown in SEQ ID NO:157, and where b is	
	greater than or equal to a + 14.	
831760	Preferably excluded from the present invention are	R73907, R74000. N64405. AA196765.
	one or more polynucleotides comprising a nucleotide	AA232516. AA806432. AA837776.
	sequence described by the general formula of a-b.	A1017699
	where a is any integer between 1 to 990 of SEQ ID	
	NO:158, b is an integer of 15 to 1004, where both a	<u> </u>
	and b correspond to the positions of nucleotide	
	residues shown in SEQ ID NO:158, and where b is	
	greater than or equal to a + 14.	
831780	Preferably excluded from the present invention are	AA100654. AA112750, AA594472,
	one or more polynucleotides comprising a nucleotide	AA731487
	sequence described by the general formula of a-b,	1
	where a is any integer between I to 1495 of SEQ ID	
	NO:159, b is an integer of 15 to 1509, where both a	
	and b correspond to the positions of nucleotide	
	residues shown in SEQ ID NO:159, and where b is	
	greater than or equal to a + 14.	
831796	Preferably excluded from the present invention are	H14891, W74005, AA623010, D80585,
	one or more polynucleotides comprising a nucleotide	A1096496. W38434
	sequence described by the general formula of a-b,	
	where a is any integer between 1 to 2146 of SEQ ID	
	NO:160, b is an integer of 15 to 2160, where both a	
	and b correspond to the positions of nucleotide	
	residues shown in SEQ ID NO:160, and where b is	
	greater than or equal to a + 14.	
831800	Preferably excluded from the present invention are	
	one or more polynucleotides comprising a nucleotide	
	sequence described by the general formula of a-b,	
	where a is any integer between 1 to 3595 of SEQ ID	
		I and the second
İ	NO:161, b is an integer of 15 to 3609, where both a	
ı	NO:161, b is an integer of 15 to 3609, where both a and b correspond to the positions of nucleotide	
Ī	and b correspond to the positions of nucleotide	
	and b correspond to the positions of nucleotide residues shown in SEQ ID NO:161, and where b is	
021027	and b correspond to the positions of nucleotide residues shown in SEQ ID NO:161, and where b is greater than or equal to a + 14.	
831807	and b correspond to the positions of nucleotide residues shown in SEQ ID NO:161, and where b is greater than or equal to a + 14. Preferably excluded from the present invention are	
831807	and b correspond to the positions of nucleotide residues shown in SEQ ID NO:161, and where b is greater than or equal to a + 14. Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide	
831807	and b correspond to the positions of nucleotide residues shown in SEQ ID NO:161, and where b is greater than or equal to a + 14. Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b,	
831807	and b correspond to the positions of nucleotide residues shown in SEQ ID NO:161, and where b is greater than or equal to a + 14. Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide	
831807	and b correspond to the positions of nucleotide residues shown in SEQ ID NO:161, and where b is greater than or equal to a + 14. Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1589 of SEQ ID	
831807	and b correspond to the positions of nucleotide residues shown in SEQ ID NO:161, and where b is greater than or equal to a + 14. Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1589 of SEQ ID NO:162, b is an integer of 15 to 1603, where both a	
831807	and b correspond to the positions of nucleotide residues shown in SEQ ID NO:161, and where b is greater than or equal to a + 14. Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1589 of SEQ ID NO:162, b is an integer of 15 to 1603, where both a and b correspond to the positions of nucleotide	
831807	and b correspond to the positions of nucleotide residues shown in SEQ ID NO:161, and where b is greater than or equal to a + 14. Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1589 of SEQ ID NO:162, b is an integer of 15 to 1603, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:162, and where b is	
831807	and b correspond to the positions of nucleotide residues shown in SEQ ID NO:161, and where b is greater than or equal to a + 14. Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1589 of SEQ ID NO:162, b is an integer of 15 to 1603, where both a and b correspond to the positions of nucleotide	

	one or more polynucleotides comprising a nucleotide	
	sequence described by the general formula of a-b,	
	where a is any integer between 1 to 839 of SEQ ID	
	NO:163, b is an integer of 15 to 853. where both a	
	and b correspond to the positions of nucleotide	
	residues shown in SEQ ID NO:163, and where b is	
	greater than or equal to a + 14.	
831813	Preferably excluded from the present invention are	H14269, AA069213, AA808661
031013	one or more polynucleotides comprising a nucleotide	114209. AA009213, AA000001
		,
]	sequence described by the general formula of a-b,	·
1	where a is any integer between 1 to 1903 of SEQ ID	
	NO:164, b is an integer of 15 to 1917, where both a	
1	and b correspond to the positions of nucleotide	1 -
	residues shown in SEQ ID NO:164, and where b is	
	greater than or equal to a + 14.	
831830	Preferably excluded from the present invention are	H04695. AA112742. AA251641,
	one or more polynucleotides comprising a nucleotide	AA506539
1	sequence described by the general formula of a-b,	
j	where a is any integer between 1 to 2406 of SEQ ID	
1	NO:165, b is an integer of 15 to 2420, where both a	
	and b correspond to the positions of nucleotide	
<u> </u>	residues shown in SEQ ID NO:165, and where b is	
	greater than or equal to a + 14.	
831860	Preferably excluded from the present invention are	
831860		
1	one or more polynucleotides comprising a nucleotide	
	sequence described by the general formula of a-b,	
	where a is any integer between 1 to 2047 of SEQ ID	
	NO:166, b is an integer of 15 to 2061, where both a	
	and b correspond to the positions of nucleotide	
	residues shown in SEQ ID NO:166, and where b is	
	greater than or equal to a + 14.	
831872	Preferably excluded from the present invention are	R15368, R36227, R36228, R36669,
1	one or more polynucleotides comprising a nucleotide	R39751, H12331, H12382, H47986,
1	sequence described by the general formula of a-b,	R84945, R97224, R97223, W78107,
	where a is any integer between 1 to 2553 of SEQ ID	AA149874, AA193466, AA193348,
1	NO:167, b is an integer of 15 to 2567, where both a	AA287444, AA535607, AA687414,
	and b correspond to the positions of nucleotide	AA689396, AA748665, AA809715
i	residues shown in SEQ ID NO:167, and where b is	
}	greater than or equal to a + 14.	•
831896	Preferably excluded from the present invention are	R59635, N28389, AA158646, AA158659,
051050	•	AA188594, AA190705, AA459426,
	sequence described by the general formula of a-b,	AA465652
	where a is any integer between 1 to 2310 of SEQ ID	CAT-00002
	NO:168, b is an integer of 15 to 2324, where both a	
	and b correspond to the positions of nucleotide	
	residues shown in SEQ ID NO:168, and where b is	
	greater than or equal to a + 14.	
831928	Preferably excluded from the present invention are	
	one or more polynucleotides comprising a nucleotide	
	sequence described by the general formula of a-b,	
	where a is any integer between 1 to 1770 of SEQ ID	
	NO:169, b is an integer of 15 to 1784, where both a	}
	and b correspond to the positions of nucleotide	
	residues shown in SEQ ID NO:169, and where b is	
	greater than or equal to a + 14.	
831949	Preferably excluded from the present invention are	
051747	one or more polynucleotides comprising a nucleotide	·
L	one of more polymaciconaes comprising a maciconae	<u> </u>

	sequence described by the general formula of a-b.	
1	where a is any integer between 1 to 1282 of SEQ ID	
Ì	NO:170, b is an integer of 15 to 1296, where both a	
ŀ	and b correspond to the positions of nucleotide	
	residues shown in SEQ ID NO:170, and where b is	
	greater than or equal to a + 14.	
831950	Preferably excluded from the present invention are	
}	one or more polynucleotides comprising a nucleotide	
	sequence described by the general formula of a-b,	
	where a is any integer between 1 to 1883 of SEQ ID	
	NO:171, b is an integer of 15 to 1897, where both a	
	and b correspond to the positions of nucleotide	}
ł	residues shown in SEQ ID NO:171, and where b is	
	greater than or equal to a + 14.	
831953	Preferably excluded from the present invention are	
	one or more polynucleotides comprising a nucleotide	į
	sequence described by the general formula of a-b,	<u> </u>
	where a is any integer between 1 to 1709 of SEQ ID	
	NO:172, b is an integer of 15 to 1723, where both a	
	and b correspond to the positions of nucleotide	
	residues shown in SEQ ID NO:172, and where b is	
	greater than or equal to a + 14.	İ
831975	Preferably excluded from the present invention are	
03.773	one or more polynucleotides comprising a nucleotide	
	sequence described by the general formula of a-b,	
	where a is any integer between 1 to 1402 of SEQ ID	1
	NO:173, b is an integer of 15 to 1416, where both a	į
	and b correspond to the positions of nucleotide	
1	residues shown in SEQ ID NO:173, and where b is	
	greater than or equal to a + 14.	
832036	Preferably excluded from the present invention are	R60820, R78776, R79082, H01912,
1	one or more polynucleotides comprising a nucleotide	H04427, N34789, N44513, W20183,
	sequence described by the general formula of a-b.	W35150, AA159701, AA159628.
	where a is any integer between 1 to 1942 of SEQ ID	AA470753, AA659808
	NO:174, b is an integer of 15 to 1956, where both a	111170733, 111037000
	and b correspond to the positions of nucleotide	·
	residues shown in SEQ ID NO:174, and where b is	
	greater than or equal to a + 14.	
832047	Preferably excluded from the present invention are	R21952, R21968, R26963, R78028,
032047		H75703, H75632, H84015, H88136,
	sequence described by the general formula of a-b,	H88135, H94007, H95012, N24834,
	where a is any integer between 1 to 1675 of SEQ ID	N30818, N31761, N41592, N79533,
Į	NO:175, b is an integer of 15 to 1689, where both a	W16686, W24639, W38979, W87777,
	and b correspond to the positions of nucleotide	
	residues shown in SEQ ID NO:175, and where b is	W87875, AA121146, AA122426,
	greater than or equal to a + 14.	AA131874, AA131978, AA147083,
	greater than or equal to a + 14.	AA147140, AA282507, AA282605.
	1	AA558945, H84016, AA587558,
		AA830662, AA866026, AA917653,
832078	Preferably evaluded from the accept investigation	AI017813. C06340
032076	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide	
		·
	sequence described by the general formula of a-b,	
	where a is any integer between 1 to 1002 of SEQ ID	
	NO:176, b is an integer of 15 to 1016, where both a	
	and b correspond to the positions of nucleotide	
	residues shown in SEQ ID NO:176, and where b is greater than or equal to a + 14.	
	Eleater than of Equal to a + 14.	

		
832100	Preferably excluded from the present invention are	
	one or more polynucleotides comprising a nucleotide	
1	sequence described by the general formula of a-b,	
[where a is any integer between 1 to 1350 of SEQ ID	
1	NO:177, b is an integer of 15 to 1364, where both a	
	and b correspond to the positions of nucleotide	
ł	residues shown in SEQ ID NO:177, and where b is	
	greater than or equal to a + 14.	
832104	Preferably excluded from the present invention are	
052104	one or more polynucleotides comprising a nucleotide	
	sequence described by the general formula of a-b.	
	where a is any integer between 1 to 726 of SEQ ID	
	NO:178, b is an integer of 15 to 740, where both a	
	and b correspond to the positions of nucleotide	
	residues shown in SEQ ID NO:178, and where b is	
	greater than or equal to a + 14.	
832268	Preferably excluded from the present invention are	
	one or more polynucleotides comprising a nucleotide	
1	sequence described by the general formula of a-b.	
1	where a is any integer between 1 to 1396 of SEQ ID	
	NO:179. b is an integer of 15 to 1410. where both a	
1	and b correspond to the positions of nucleotide	
1	residues shown in SEQ ID NO:179, and where b is	
1	greater than or equal to a + 14.	
832270	Preferably excluded from the present invention are	
1	one or more polynucleotides comprising a nucleotide	
1	sequence described by the general formula of a-b.	
1	where a is any integer between 1 to 1479 of SEQ ID	
1	NO:180, b is an integer of 15 to 1493, where both a	
1	and b correspond to the positions of nucleotide	
1	residues shown in SEQ ID NO:180, and where b is	
	greater than or equal to a + 14.	
832279	Preferably excluded from the present invention are	
0322/9	one or more polynucleotides comprising a nucleotide	
l .	sequence described by the general formula of a-b,	
	where a is any integer between 1 to 2026 of SEQ ID	
1		
	NO:181, b is an integer of 15 to 2040, where both a	
	and b correspond to the positions of nucleotide	
	residues shown in SEQ ID NO:181, and where b is	
	greater than or equal to a + 14.	D01500 1112474 1104045 4 4 052747
832317	Preferably excluded from the present invention are	R81508, H12476, H86945, AA053747,
		AA115783, AA133749, AA134163,
}	sequence described by the general formula of a-b,	AA134164, AA224985, AA228334,
	where a is any integer between 1 to 955 of SEQ ID	AA228423, AA229297, AA640471,
	NO:182, b is an integer of 15 to 969, where both a	AA657793, AA687568. AA904162,
ł	and b correspond to the positions of nucleotide	AA983632
	residues shown in SEQ ID NO:182, and where b is	
	greater than or equal to a + 14.	
832354	Preferably excluded from the present invention are	
	one or more polynucleotides comprising a nucleotide	
	sequence described by the general formula of a-b.	
l	where a is any integer between 1 to 1438 of SEQ ID	
	NO:183. b is an integer of 15 to 1452, where both a	
İ	and b correspond to the positions of nucleotide	
	residues shown in SEQ ID NO:183, and where b is	
ļ	greater than or equal to a + 14.	
832364	Preferably excluded from the present invention are	
1 832304	r leterably excluded from the present invention are	<u> </u>

		·
	one or more polynucleotides comprising a nucleotide	
	sequence described by the general formula of a-b.	
ľ	where a is any integer between 1 to 2105 of SEQ ID	
	NO:184. b is an integer of 15 to 2119, where both a	
	and b correspond to the positions of nucleotide	
	residues shown in SEQ ID NO:184, and where b is	
022220	greater than or equal to a + 14.	
832378	Preferably excluded from the present invention are	
	one or more polynucleotides comprising a nucleotide	
i	sequence described by the general formula of a-b.	
	where a is any integer between 1 to 1311 of SEQ ID	
	NO:185, b is an integer of 15 to 1325, where both a	;
	and b correspond to the positions of nucleotide	
	residues shown in SEQ ID NO:185, and where b is	
	greater than or equal to a + 14.	
832385	Preferably excluded from the present invention are	
052505	one or more polynucleotides comprising a nucleotide	
	sequence described by the general formula of a-b.	
	where a is any integer between 1 to 419 of SEQ ID	
	NO:186. b is an integer of 15 to 433, where both a	
	and b correspond to the positions of nucleotide	
	residues shown in SEQ ID NO:186, and where b is	
	greater than or equal to a + 14.	
832428	Preferably excluded from the present invention are	AA031420
	one or more polynucleotides comprising a nucleotide	
1	sequence described by the general formula of a-b.	
	where a is any integer between 1 to 845 of SEQ ID	
	NO:187. b is an integer of 15 to 859, where both a	
	and b correspond to the positions of nucleotide	
	residues shown in SEQ ID NO:187, and where b is	
	greater than or equal to a + 14.	
832485	Preferably excluded from the present invention are	R63025. R66741. H53264. H53265.
	one or more polynucleotides comprising a nucleotide	H53769, H53822, H54405, H54489,
	sequence described by the general formula of a-b.	H81182, H91282, AA526672, H81181
	where a is any integer between 1 to 819 of SEQ ID	
	NO:188, b is an integer of 15 to 833, where both a	
	and b correspond to the positions of nucleotide	
	residues shown in SEQ ID NO:188, and where b is	
	greater than or equal to a + 14.	
922404	Preferably excluded from the present invention are	T61040, T61591, T90055. T90157, T92840,
832494		T93714, T96177, T77726, H04686,
	one or more polynucleotides comprising a nucleotide	· ·
	sequence described by the general formula of a-b.	H05450, H06997, H20176, H20366,
	where a is any integer between 1 to 2197 of SEQ ID	R92666, H65144, H92413, N64053,
	NO:189, b is an integer of 15 to 2211, where both a	N64060. N66714, N71338, N71388,
	and b correspond to the positions of nucleotide	N79742, N95497, N99884, W07259.
	residues shown in SEQ ID NO:189, and where b is	W24989, W37394, W37657, W40208,
	greater than or equal to a + 14.	W40260. W40532. W45430, W56165,
	Ţ ·	W60427. W60986. W61080. W63739,
	·	W72328, W73757, W74394. AA025512,
		AA026057, AA065019. AA069295,
		AA069798, AA069845, AA070441,
		1
		AA075793, AA083393, AA083394,
		AA084576, AA086181, AA099019.
		AA099097, AA099493, AA102003,
		AA100395. AA100554. AA100555.
		AA100638, AA101578, AA113226,
		AA113811. AA115645, AA115646.

		AA115888, AA115889, AA122231.
İ		AA121108, AA121596, AA121671.
		AA121743, AA126075, AA126102.
İ		AA126181. AA126295. AA126404.
		AA129470, AA129665, AA133945.
	•	AA133946. AA146752, AA155947.
		AA157140. AA157228. AA159947.
		AA160900, AA164889, AA164890.
		AA164840. AA164839. AA172107.
		AA182040. AA171714. AA187244.
		AA187376, AA186418, AA188846.
		AA189131, AA196155, AA196257.
		AA196611. AA196789. AA196961.
	*	
		AA223155. AA223415. AA226816.
		AA226856. AA227026. AA227109.
		AA227208. AA243161. AA243205.
		AA428759, AA429347, AA514858,
		AA535250. AA555125. AA565075,
		AA565168. AA581531. AA587192.
		AA576761, AA580523, AA659699.
		AA688240. AA689484. AA689543.
		AA689313. AA729979. AA740203.
		AA747258, AA747399, AA747993.
		AA837961, AA865930, AA906561,
		AA910350, AA919085. AA931143,
		AA999884, A1051141, F19298, W22294,
İ	*	W22759, W22970, W25820, W73709,
		C02713, C02766, C03390, C03613,
		C04202, C05262, C05272, R28954.
		R29028, R29032, AA062628, AA090039,
		C18989
832512	Preferably excluded from the present invention are	j
	one or more polynucleotides comprising a nucleotide	
	sequence described by the general formula of a-b.	
	where a is any integer between 1 to 1645 of SEQ ID	
	NO:190, b is an integer of 15 to 1659, where both a	
ļ	and b correspond to the positions of nucleotide]
	residues shown in SEQ ID NO:190, and where b is	
	greater than or equal to a + 14.	
832515	Preferably excluded from the present invention are	
	one or more polynucleotides comprising a nucleotide	
1	sequence described by the general formula of a-b.	
1	where a is any integer between 1 to 3880 of SEQ ID	
	NO:191, b is an integer of 15 to 3894, where both a	
	and b correspond to the positions of nucleotide	
1	residues shown in SEQ ID NO:191, and where b is	
1	greater than or equal to a + 14.	<u> </u>
832526	Preferably excluded from the present invention are	
	one or more polynucleotides comprising a nucleotide	
	sequence described by the general formula of a-b,	
	where a is any integer between 1 to 681 of SEQ ID	
	NO:192, b is an integer of 15 to 695, where both a	j
1	and b correspond to the positions of nucleotide	
ļ.	residues shown in SEQ ID NO:192, and where b is	
}	greater than or equal to a + 14.	
832575	Preferably excluded from the present invention are	R28543. R28684. R55782. R55862,
552575		R62797. R62843, R67670, R71154,
L	burn ar more bord manner and another mine a manner	

	sequence described by the general formula of a-b.	R71651, N20642, N24838, N25562,
	where a is any integer between 1 to 3117 of SEQ ID	N29014. N31768. N34161. N57560.
ĺ	NO:193. b is an integer of 15 to 3131, where both a	N72111, W00338, W00374, W30889,
1	and b correspond to the positions of nucleotide	W52729, W59982, W68047, W68189,
	residues shown in SEQ ID NO:193, and where b is	AA019459. AA043870. AA044336.
1	greater than or equal to a + 14.	AA045040, AA045041, AA115599,
1		AA115134, AA131177, AA165259,
1		AA165260, AA165191, AA165192.
1		AA164549. AA164550. AA261988.
		AA424972, AA279863, AA458832,
		AA459024. AA505193. AA507542.
		AA514388, AA622542, AA689232,
		AA689233, AA804910, AA807169,
		AA832321, AA878091, AA904023,
1		AA936069. AA936071. AA946621.
1		C00143. N86645. AA010988. AA641236.
		AA641464. C18301
832576	Preferably excluded from the present invention are	
	one or more polynucleotides comprising a nucleotide	
	sequence described by the general formula of a-b.	
	where a is any integer between 1 to 2044 of SEQ ID	
	NO:194, b is an integer of 15 to 2058, where both a	
	and b correspond to the positions of nucleotide	
	residues shown in SEQ ID NO:194, and where b is	
	greater than or equal to a + 14.	
832588	Preferably excluded from the present invention are	
	one or more polynucleotides comprising a nucleotide	
1	sequence described by the general formula of a-b.	
	where a is any integer between 1 to 817 of SEQ ID	
į	NO:195, b is an integer of 15 to 831, where both a	1
	and b correspond to the positions of nucleotide	
	residues shown in SEQ ID NO:195, and where b is	
	greater than or equal to a + 14.	
832634	Preferably excluded from the present invention are	
	one or more polynucleotides comprising a nucleotide	
ļ	sequence described by the general formula of a-b.	
	where a is any integer between 1 to 947 of SEQ ID	
1	NO:196, b is an integer of 15 to 961, where both a	
	and b correspond to the positions of nucleotide	
	residues shown in SEQ ID NO:196, and where b is	
	greater than or equal to a + 14.	
832728	Preferably excluded from the present invention are	
	one or more polynucleotides comprising a nucleotide	
	sequence described by the general formula of a-b,	
	where a is any integer between 1 to 592 of SEQ ID	
	NO:197, b is an integer of 15 to 606, where both a	
1	and b correspond to the positions of nucleotide	
1	residues shown in SEQ ID NO:197, and where b is	
1	greater than or equal to a + 14.	
833094	Preferably excluded from the present invention are	
Ì	one or more polynucleotides comprising a nucleotide	
1	sequence described by the general formula of a-b,	
	where a is any integer between 1 to 379 of SEQ ID	
ł	NO:198, b is an integer of 15 to 393, where both a	
	and b correspond to the positions of nucleotide	
	residues shown in SEQ ID NO:198, and where b is	
]	greater than or equal to a + 14.	
<u> </u>	Division adam to a . 1.4.	<u> </u>

833395	Preferably excluded from the present invention are	
	one or more polynucleotides comprising a nucleotide	
	sequence described by the general formula of a-b.	
Ī	where a is any integer between 1 to 1047 of SEQ ID	
	NO:199, b is an integer of 15 to 1061, where both a	
	and b correspond to the positions of nucleotide	
	residues shown in SEQ ID NO:199, and where b is	
	greater than or equal to a + 14.	
834326	Preferably excluded from the present invention are	
	one or more polynucleotides comprising a nucleotide	
	sequence described by the general formula of a-b.	
	where a is any integer between 1 to 1345 of SEQ ID	
	NO:200, b is an integer of 15 to 1359, where both a	
	and b correspond to the positions of nucleotide	
	residues shown in SEQ ID NO:200, and where b is	
	greater than or equal to a + 14.	
834583	Preferably excluded from the present invention are	
	one or more polynucleotides comprising a nucleotide	
	sequence described by the general formula of a-b.	
	where a is any integer between 1 to 712 of SEQ ID	
	NO:201, b is an integer of 15 to 726, where both a	
	and b correspond to the positions of nucleotide	
	residues shown in SEQ ID NO:201, and where b is	
	ercater than or equal to a + 14.	
834944	Preferably excluded from the present invention are	
	one or more polynucleotides comprising a nucleotide	
	sequence described by the general formula of a-b.	
	where a is any integer between 1 to 2700 of SEQ ID	
	NO:202, b is an integer of 15 to 2714, where both a	
	and b correspond to the positions of nucleotide	
f	residues shown in SEQ 1D NO:202, and where b is	
	greater than or equal to a + 14.	
835012	Preferably excluded from the present invention are	
	one or more polynucleotides comprising a nucleotide	
	sequence described by the general formula of a-b.	
	where a is any integer between 1 to 408 of SEQ ID	
	NO:203, b is an integer of 15 to 422, where both a	
	and b correspond to the positions of nucleotide	
	residues shown in SEQ ID NO:203, and where b is	
	greater than or equal to a + 14.	
835104	Preferably excluded from the present invention are	
-	one or more polynucleotides comprising a nucleotide	
	sequence described by the general formula of a-b.	
	where a is any integer between 1 to 2325 of SEQ ID	
	NO:204, b is an integer of 15 to 2339, where both a	
	and b correspond to the positions of nucleotide	
	residues shown in SEQ ID NO:204, and where b is	
	greater than or equal to a + 14.	
835332	Preferably excluded from the present invention are	
	one or more polynucleotides comprising a nucleotide	
	sequence described by the general formula of a-b.	
	where a is any integer between 1 to 1641 of SEQ ID	
	NO:205. b is an integer of 15 to 1655, where both a	
	and b correspond to the positions of nucleotide	
	residues shown in SEQ ID NO:205, and where b is	
	greater than or equal to a + 14.	
835487	Preferably excluded from the present invention are	

,		
1	one or more polynucleotides comprising a nucleotide	
	sequence described by the general formula of a-b.	
i	where a is any integer between 1 to 5131 of SEQ ID	
	NO:206, b is an integer of 15 to 5145, where both a	
	and b correspond to the positions of nucleotide	
	residues shown in SEQ ID NO:206, and where b is	
	greater than or equal to a + 14.	
836182	Preferably excluded from the present invention are	
03012	one or more polynucleotides comprising a nucleotide	
	sequence described by the general formula of a-b.	
	where a is any integer between 1 to 473 of SEQ ID	
	NO:207. b is an integer of 15 to 487. where both a	
	and b correspond to the positions of nucleotide	
	residues shown in SEQ ID NO:207, and where b is	
	ercater than or equal to a + 14.	
836522	Preferably excluded from the present invention are	
	one or more polynucleotides comprising a nucleotide	
	sequence described by the general formula of a-b.	
	where a is any integer between 1 to 2282 of SEQ ID	
	NO:208, b is an integer of 15 to 2296, where both a	
	and b correspond to the positions of nucleotide	
	residues shown in SEQ ID NO:208, and where b is	
	greater than or equal to a + 14.	
836655	Preferably excluded from the present invention are	
	one or more polynucleotides comprising a nucleotide	
	sequence described by the general formula of a-b.	
	where a is any integer between 1 to 611 of SEQ ID	
	NO:209, b is an integer of 15 to 625, where both a	
	and b correspond to the positions of nucleotide	
	residues shown in SEQ ID NO:209, and where b is	
	greater than or equal to a + 14.	
836787	Preferably excluded from the present invention are	W56241, W56321, AA009901, AA521313,
830/8/	one or more polynucleotides comprising a nucleotide	AA732599, AA730271, AA766911.
		· ·
	sequence described by the general formula of a-b.	AA767313, W27009
	where a is any integer between 1 to 1537 of SEQ ID	
	NO:210, b is an integer of 15 to 1551, where both a	
	and b correspond to the positions of nucleotide	
	residues shown in SEQ ID NO:210, and where b is	
	greater than or equal to a + 14.	
836789	Preferably excluded from the present invention are	T68817. R22374, R27362. H38950,
	one or more polynucleotides comprising a nucleotide	R89148. R91088, H68416, H93594,
	sequence described by the general formula of a-b.	N33889. N47045, N56761. W19886.
	where a is any integer between 1 to 997 of SEQ ID	W44630. W61370, W86385, AA036993,
	NO:211, b is an integer of 15 to 1011, where both a	AA065062, AA101017, AA121107,
	and b correspond to the positions of nucleotide	AA130485, AA147474, AA160596,
	residues shown in SEQ ID NO:211, and where b is	AA282977
	greater than or equal to a + 14.	
838577	Preferably excluded from the present invention are	T53501. T40735, T63398, T63985, T64053.
	one or more polynucleotides comprising a nucleotide	T64155, T64284, T93511, T94941, T94995,
	sequence described by the general formula of a-b,	T96340. R00890. R01553, R12738,
	where a is any integer between 1 to 1625 of SEQ ID	R12739, R39790, R54423, R66373,
	NO:212, b is an integer of 15 to 1639, where both a	R66595. R67104. R67219. R79151.
	and b correspond to the positions of nucleotide	R79152, R82180, R82224, R82470.
	residues shown in SEQ ID NO:212, and where b is	
		R82471, H01963, H02048, H02758,
	greater than or equal to a + 14.	H02759, H05982, H19484, H19567,
	1	H19882. H19900, H44901, H44938,
		H44978, H46289, H46871, H49538,

		H49781, H53114, H53220, H54300.
1		H56079, H56279, H79695, H79696.
		N23140. N25755, N25850, N26983,
	<u> </u>	N29784, N32719, N36477, N40104.
		N42924, N44580, N50724, N55052,
		N67751, N93444, N98425, N98537.
		W02803, W21105, W23673, W30688,
		W30899, W35106, W45448, W45449.
		W45661, W44441, W46823, W46872.
1		W47373, W47374, W52205, W58331,
		W58652, W96332, AA007386, AA007676,
		AA011363, AA016311, AA017511.
		AA018464. AA019899, AA025040,
		AA025039, AA029796, AA029797,
		AA031472, AA035395, AA035396,
	1	AA037272, AA040791, AA041228.
		AA042893, AA043029, AA055565,
		AA056185, AA056186, AA056621.
		AA056726, AA069193, AA079705.
		AA082517, AA084044, AA084043,
		AA115273, AA115056, AA132031.
		AA132153, AA149267, AA149284.
1		AA149378. AA158093. AA158103.
Ī		AA158364, AA158904, AA158905.
1	·	AA165106, AA220957, AA235312.
		AA251169, AA421302, AA421425,
		AA428706, AA429291, AA513790,
1		AA531603, AA551736, AA554236.
		AA605236, AA604674, AA604939.
		AA612935, AA617731, AA627300,
ŀ		AA687527, AA732095, AA740760,
		AA765135, AA765136, AA765296,
		AA765891, AA888144, AA908665.
		AA928038, AA936934, AA961143,
		AA987647, AA975856, W03595, C03206,
ł		C18055, AA164690, AA218956,
		AA291352, AA292329, AA293276,
		AA393988, AA398076, AA410772.
		D12417, AA442678, AA442969.
		AA454814, AA454888, AA482370,
		AA486098, AA486161. AA625879,
		AA678365, AA679281, AA703505,
		AA722872, AA732793. AA989559,
]		A1003448, A1014938, A1022070,
1	·	A1084792, A1092360
838717	Preferably excluded from the present invention are	
	one or more polynucleotides comprising a nucleotide	
	sequence described by the general formula of a-b,	
	where a is any integer between 1 to 2113 of SEQ ID	
	NO:213, b is an integer of 15 to 2127, where both a	
	and b correspond to the positions of nucleotide	
	residues shown in SEQ ID NO:213, and where b is	
1	greater than or equal to a + 14.	
839008	Preferably excluded from the present invention are	
] 53,000	one or more polynucleotides comprising a nucleotide	
	sequence described by the general formula of a-b.	
	where a is any integer between 1 to 1152 of SEQ ID	
<u> </u>		<u> </u>

	NO:214, b is an integer of 15 to 1166, where both a	
	and b correspond to the positions of nucleotide	
	residues shown in SEQ ID NO:214. and where b is	
	greater than or equal to a + 14.	
840063	Preferably excluded from the present invention are	
	one or more polynucleotides comprising a nucleotide	
1	sequence described by the general formula of a-b.	
]	where a is any integer between 1 to 3309 of SEQ ID	
	NO:215, b is an integer of 15 to 3323, where both a	
	and b correspond to the positions of nucleotide	
	residues shown in SEQ ID NO:215. and where b is	
	greater than or equal to $a + 14$.	į
840533	Preferably excluded from the present invention are	
040333		
	one or more polynucleotides comprising a nucleotide	
	sequence described by the general formula of a-b,	
	where a is any integer between 1 to 1394 of SEQ ID	
	NO:216, b is an integer of 15 to 1408, where both a	
	and b correspond to the positions of nucleotide	
1	residues shown in SEQ ID NO:216, and where b is	
	greater than or equal to a + 14.	
840669	Preferably excluded from the present invention are	T71029, T79145, T79226, T99989, R59589,
	one or more polynucleotides comprising a nucleotide	R61735, R61734, R66190, R67070.
	sequence described by the general formula of a-b.	H16201, H16200, H22960, H84137,
	where a is any integer between 1 to 2097 of SEQ ID	H85574, H98850, N23572, N26340.
	NO:217, b is an integer of 15 to 2111, where both a	N56614, W72249, W76334, W86530,
	and b correspond to the positions of nucleotide	W87654, W87653, AA057869, AA122103,
	residues shown in SEQ ID NO:217, and where b is	AA129545, AA136524, AA137122.
}	greater than or equal to a + 14.	AA429808, AA525242. AA558970.
	greater than or equal to a 1 14.	H99223, AA584317, AA595168.
		AA825180, AA931521, AA938437.
.		A1017369, N29659. N68604. W86674, AA007246
041140		AA007246
841140	Preferably excluded from the present invention are	
	one or more polynucleotides comprising a nucleotide	
	sequence described by the general formula of a-b.	
j	where a is any integer between 1 to 2479 of SEQ ID	
	NO:218, b is an integer of 15 to 2493, where both a	
İ	and b correspond to the positions of nucleotide	
Ī	residues shown in SEQ ID NO:218, and where b is	
	greater than or equal to a + 14.	
841386	Preferably excluded from the present invention are	AA429393, AA429394. AA493187,
		AA807096, AA836046
	sequence described by the general formula of a-b,	
	where a is any integer between 1 to 1245 of SEQ ID	
	NO:219, b is an integer of 15 to 1259, where both a	
	and b correspond to the positions of nucleotide	
	residues shown in SEQ ID NO:219, and where b is	
	greater than or equal to a + 14.	
841480	Preferably excluded from the present invention are	
041480		
	one or more polynucleotides comprising a nucleotide	
	sequence described by the general formula of a-b.	
	where a is any integer between 1 to 1835 of SEQ ID	
	NO:220. b is an integer of 15 to 1849, where both a	
	and b correspond to the positions of nucleotide	
	residues shown in SEQ ID NO:220, and where b is	
	greater than or equal to a + 14.	
841509	Preferably excluded from the present invention are	

	one or more polynucleotides comprising a nucleotide	
	sequence described by the general formula of a-b.	
	where a is any integer between 1 to 1253 of SEQ ID	
	NO:221, b is an integer of 15 to 1267, where both a	
	and b correspond to the positions of nucleotide	
	residues shown in SEQ ID NO:221, and where b is	
	greater than or equal to a + 14.	
841616	Preferably excluded from the present invention are	
841010		
	one or more polynucleotides comprising a nucleotide	
	sequence described by the general formula of a-b.	
	where a is any integer between 1 to 740 of SEQ ID	
ļ.	NO:222, b is an integer of 15 to 754, where both a	
	and b correspond to the positions of nucleotide	
	residues shown in SEQ ID NO:222, and where b is	
	greater than or equal to a + 14.	
841900	Preferably excluded from the present invention are	R87848, AA806230, Z28656
i	one or more polynucleotides comprising a nucleotide	
1	sequence described by the general formula of a-b.	
1	where a is any integer between 1 to 1244 of SEQ ID	
1	NO:223, b is an integer of 15 to 1258, where both a	
İ	and b correspond to the positions of nucleotide	
ļ	residues shown in SEQ ID NO:223, and where b is	
1	greater than or equal to a + 14.	
842054	Preferably excluded from the present invention are	
842034	one or more polynucleotides comprising a nucleotide	
	sequence described by the general formula of a-b,	
	where a is any integer between I to 570 of SEQ ID	
	NO:224, b is an integer of 15 to 584, where both a	
	and b correspond to the positions of nucleotide	
	residues shown in SEQ ID NO:224, and where b is	
	greater than or equal to a + 14.	
843061	Preferably excluded from the present invention are	
	one or more polynucleotides comprising a nucleotide	•
	sequence described by the general formula of a-b.	
]	where a is any integer between 1 to 3435 of SEQ 1D	
1	NO:225, b is an integer of 15 to 3449, where both a	
1	and b correspond to the positions of nucleotide	
İ	residues shown in SEQ ID NO:225, and where b is	
	greater than or equal to a + 14.	<u> </u>
843544	Preferably excluded from the present invention are	
	one or more polynucleotides comprising a nucleotide	
1	sequence described by the general formula of a-b.	
	where a is any integer between 1 to 1852 of SEQ ID	
	NO:226, b is an integer of 15 to 1866, where both a	
1	and b correspond to the positions of nucleotide	
1	residues shown in SEQ ID NO:226, and where b is	
	greater than or equal to a + 14.	
944002	Preferably excluded from the present invention are	
844092	one or more polynucleotides comprising a nucleotide	
1		
1	sequence described by the general formula of a-b,	
	where a is any integer between I to 1050 of SEQ ID	
	NO:227, b is an integer of 15 to 1064, where both a	
	and b correspond to the positions of nucleotide	
	residues shown in SEQ ID NO:227, and where b is	
	greater than or equal to a + 14.	
844270	Preferably excluded from the present invention are	
]	one or more polynucleotides comprising a nucleotide	

•
,
28992. H29096,
W72320, AA459289,
85, AA746169
0J, AA/40109
,

	where a is any integer between 1 to 1307 of SEQ ID	
	NO:235. b is an integer of 15 to 1321. where both a	
	and b correspond to the positions of nucleotide	
	residues shown in SEQ ID NO:235, and where b is	
ļ	greater than or equal to a + 14.	
845510	Preferably excluded from the present invention are	
1 3.55	one or more polynucleotides comprising a nucleotide	
1	sequence described by the general formula of a-b,	
	where a is any integer between 1 to 669 of SEQ 1D	
	NO:236. b is an integer of 15 to 683, where both a	
	and b correspond to the positions of nucleotide	
	residues shown in SEQ ID NO:236. and where b is	
ŀ	greater than or equal to a + 14.	•
845600	Preferably excluded from the present invention are	
043000	one or more polynucleotides comprising a nucleotide	
		•
	sequence described by the general formula of a-b.	
	where a is any integer between 1 to 2101 of SEQ ID	
	NO:237. b is an integer of 15 to 2115, where both a	
	and b correspond to the positions of nucleotide	
	residues shown in SEQ ID NO:237, and where b is	
0.45000	greater than or equal to a + 14.	
845882	Preferably excluded from the present invention are	
	one or more polynucleotides comprising a nucleotide	
	sequence described by the general formula of a-b,	
	where a is any integer between 1 to 1628 of SEQ ID	
	NO:238, b is an integer of 15 to 1642, where both a	
ļ	and b correspond to the positions of nucleotide	
	residues shown in SEQ ID NO:238, and where b is	
	greater than or equal to a + 14.	1101404
846007	prototably bittered trains and production and	H81424
ļ	one or more polynucleotides comprising a nucleotide	
	sequence described by the general formula of a-b.	
[where a is any integer between 1 to 454 of SEQ ID	
	NO:239, b is an integer of 15 to 468, where both a	
	and b correspond to the positions of nucleotide	
	residues shown in SEQ ID NO:239, and where b is	
	greater than or equal to a + 14.	
846280	Preferably excluded from the present invention are	
	one or more polynucleotides comprising a nucleotide	
	sequence described by the general formula of a-b,	
	where a is any integer between 1 to 1315 of SEQ ID	
1	NO:240, b is an integer of 15 to 1329, where both a	
	and b correspond to the positions of nucleotide	
İ	residues shown in SEQ ID NO:240, and where b is	
<u></u>	greater than or equal to a + 14.	
846286	Preferably excluded from the present invention are	
	one or more polynucleotides comprising a nucleotide	
	sequence described by the general formula of a-b.	
	where a is any integer between 1 to 1638 of SEQ 1D	
	NO:241, b is an integer of 15 to 1652, where both a	
1	and b correspond to the positions of nucleotide	
1	residues shown in SEQ ID NO:241, and where b is	
L	greater than or equal to a + 14.	
846388	Preferably excluded from the present invention are	
[one or more polynucleotides comprising a nucleotide	
	sequence described by the general formula of a-b, where a is any integer between 1 to 1932 of SEQ ID	

NO:242. b is an integer of 15 to 1946. where both a	
and b correspond to the positions of nucleotide	
residues shown in SEQ ID NO:242, and where b is	
greater than or equal to a + 14.	

Polynucleotide and Polypeptide Variants

5

10

15

20

25

30

The present invention is directed to variants of the polynucleotide sequence disclosed in SEQ ID NO:X or the complementary strand thereto, and/or the cDNA sequence contained in a cDNA clone contained in the deposit.

The present invention also encompasses variants of a colon and/or colon cancer polypeptide sequence disclosed in SEQ ID NO:Y, a polypeptide sequence encoded by the polynucleotide sequence in SEQ ID NO:X, and/or a polypeptide sequence encoded by the cDNA in the related cDNA clone contained in the deposit.

"Variant" refers to a polynucleotide or polypeptide differing from the polynucleotide or polypeptide of the present invention, but retaining essential properties thereof. Generally, variants are overall closely similar, and, in many regions, identical to the polynucleotide or polypeptide of the present invention.

The present invention is also directed to nucleic acid molecules which comprise, or alternatively consist of, a nucleotide sequence which is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100%, identical to, for example, the nucleotide coding sequence in SEQ ID NO:X or the complementary strand thereto, the nucleotide coding sequence of the related cDNA contained in a deposited library or the complementary strand thereto, a nucleotide sequence encoding the polypeptide of SEO ID NO:Y, a nucleotide sequence encoding a polypeptide sequence encoded by the nucleotide sequence in SEQ ID NO:X, a nucleotide sequence encoding the polypeptide encoded by the cDNA in the related cDNA contained in a deposited library, and/or polynucleotide fragments of any of these nucleic acid molecules (e.g., those fragments described herein). Polypeptides encoded by these nucleic acid molecules are also encompassed by the invention. In another embodiment, the invention encompasses nucleic acid molecules which comprise or alternatively consist of, a polynucleotide which hybridizes under stringent hybridization conditions, or alternatively, under low stringency conditions, to the nucleotide coding sequence in SEQ ID NO:X, the nucleotide coding sequence of the related cDNA clone contained in a deposited library, a nucleotide sequence encoding the polypeptide of SEQ ID NO:Y, a nucleotide sequence encoding a polypeptide sequence encoded by the nucleotide sequence in SEQ ID NO:X, a nucleotide sequence encoding the polypeptide encoded by the cDNA in the related cDNA clone contained in a deposited library, and/or polynucleotide fragments of any of these nucleic acid molecules (e.g., those fragments described herein). Polynucleotides which hybridize to the complement of these nucleic acid molecules under stringent hybridization conditions or alternatively, under lower stringency conditions, are also encompassed by the invention, as are polypeptides encoded by these polynucleotides.

5

10

15

20

25

30

The present invention is also directed to polypeptides which comprise, or alternatively consist of, an amino acid sequence which is at least 80%, 85%, 90%, 95%, 96%, 97%. 98%. 99% or 100% identical to, for example, the polypeptide sequence shown in SEQ ID NO:Y, a polypeptide sequence encoded by the nucleotide sequence in SEQ ID NO:X, a polypeptide sequence encoded by the cDNA in the related cDNA clone contained in a deposited library, and/or polypeptide fragments of any of these polypeptides (e.g., those fragments described herein). Polynucleotides which hybridize to the complement of the nucleic acid molecules encoding these polypeptides under stringent hybridization conditions, or alternatively, under lower stringency conditions, are also encompassed by the invention, as are polypeptides encoded by these polynucleotides.

By a nucleic acid having a nucleotide sequence at least, for example, 95% "identical" to a reference nucleotide sequence of the present invention, it is intended that the nucleotide sequence of the nucleic acid is identical to the reference sequence except that the nucleotide sequence may include up to five point mutations per each 100 nucleotides of the reference nucleotide sequence encoding the polypeptide. In other words, to obtain a nucleic acid having a nucleotide sequence at least 95% identical to a reference nucleotide sequence, up to 5% of the nucleotides in the reference sequence may be deleted or substituted with another nucleotide, or a number of nucleotides up to 5% of the total nucleotides in the reference sequence may be inserted into the reference sequence. The query sequence may be, for example, an entire sequence referred to in Table 1, an ORF (open reading frame), or any fragment specified as described herein.

As a practical matter, whether any particular nucleic acid molecule or polypeptide is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to a nucleotide sequence of the present invention can be determined conventionally using known computer programs. A preferred method for determining the best overall match between a query sequence (a sequence of the present invention) and a subject sequence, also referred to as a global sequence alignment, can be determined using the FASTDB computer program based on the algorithm of Brutlag et al. (Comp. App. Biosci. 6:237-245 (1990)). In a sequence alignment the query and subject sequences are both DNA sequences. An RNA sequence can be

10

15

20

25

30

compared by converting U's to T's. The result of said global sequence alignment is in percent identity. Preferred parameters used in a FASTDB alignment of DNA sequences to calculate percent identity are: Matrix=Unitary, k-tuple=4, Mismatch Penalty=1, Joining Penalty=30. Randomization Group Length=0, Cutoff Score=1. Gap Penalty=5, Gap Size Penalty 0.05, Window Size=500 or the length of the subject nucleotide sequence, whichever is shorter.

If the subject sequence is shorter than the query sequence because of 5' or 3' deletions, not because of internal deletions, a manual correction must be made to the results. This is because the FASTDB program does not account for 5' and 3' truncations of the subject sequence when calculating percent identity. For subject sequences truncated at the 5' or 3' ends, relative to the query sequence, the percent identity is corrected by calculating the number of bases of the query sequence that are 5' and 3' of the subject sequence, which are not matched/aligned, as a percent of the total bases of the query sequence. Whether a nucleotide is matched/aligned is determined by results of the FASTDB sequence alignment. This percentage is then subtracted from the percent identity, calculated by the above FASTDB program using the specified parameters, to arrive at a final percent identity score. This corrected score is what is used for the purposes of the present invention. Only bases outside the 5' and 3' bases of the subject sequence, as displayed by the FASTDB alignment, which are not matched/aligned with the query sequence, are calculated for the purposes of manually adjusting the percent identity score.

For example, a 90 base subject sequence is aligned to a 100 base query sequence to determine percent identity. The deletions occur at the 5' end of the subject sequence and therefore, the FASTDB alignment does not show a matched/alignment of the first 10 bases at 5' end. The 10 unpaired bases represent 10% of the sequence (number of bases at the 5' and 3' ends not matched/total number of bases in the query sequence) so 10% is subtracted from the percent identity score calculated by the FASTDB program. If the remaining 90 bases were perfectly matched the final percent identity would be 90%. In another example, a 90 base subject sequence is compared with a 100 base query sequence. This time the deletions are internal deletions so that there are no bases on the 5' or 3' of the subject sequence which are not matched/aligned with the query. In this case the percent identity calculated by FASTDB is not manually corrected. Once again, only bases 5' and 3' of the subject sequence which are not matched/aligned with the query sequence are manually corrected for. No other

10

15

20

25

30

manual corrections are to made for the purposes of the present invention.

By a polypeptide having an amino acid sequence at least, for example, 95% "identical" to a query amino acid sequence of the present invention, it is intended that the amino acid sequence of the subject polypeptide is identical to the query sequence except that the subject polypeptide sequence may include up to five amino acid alterations per each 100 amino acids of the query amino acid sequence. In other words, to obtain a polypeptide having an amino acid sequence at least 95% identical to a query amino acid sequence, up to 5% of the amino acid residues in the subject sequence may be inserted, deleted, (indels) or substituted with another amino acid. These alterations of the reference sequence may occur at the amino or carboxy terminal positions of the reference amino acid sequence or anywhere between those terminal positions, interspersed either individually among residues in the reference sequence or in one or more contiguous groups within the reference sequence.

As a practical matter, whether any particular polypeptide is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to, for instance, the amino acid sequence in SEQ ID NO:Y or a fragment thereof, the amino acid sequence encoded by the nucleotide sequence in SEQ ID NO:X or a fragment thereof, or the amino acid sequence encoded by the cDNA in the related cDNA clone contained in a deposited library, or a fragment thereof, can be determined conventionally using known computer programs. A preferred method for determing the best overall match between a query sequence (a sequence of the present invention) and a subject sequence, also referred to as a global sequence alignment, can be determined using the FASTDB computer program based on the algorithm of Brutlag et al. (Comp. App. Biosci.6:237- 245(1990)). In a sequence alignment the query and subject sequences are either both nucleotide sequences or both amino acid sequences. The result of said global sequence alignment is in percent identity. Preferred parameters used in a FASTDB amino acid alignment are: Matrix=PAM 0, k-tuple=2, Mismatch Penalty=1, Joining Penalty=20, Randomization Group Length=0, Cutoff Score=1, Window Size=sequence length, Gap Penalty=5, Gap Size Penalty=0.05, Window Size=500 or the length of the subject amino acid sequence, whichever is shorter.

If the subject sequence is shorter than the query sequence due to N- or C-terminal deletions, not because of internal deletions, a manual correction must be made to the results. This is because the FASTDB program does not account for N- and C-terminal truncations of the subject sequence when calculating global percent identity. For subject sequences

truncated at the N- and C-termini, relative to the query sequence, the percent identity is corrected by calculating the number of residues of the query sequence that are N- and C-terminal of the subject sequence, which are not matched/aligned with a corresponding subject residue, as a percent of the total bases of the query sequence. Whether a residue is matched/aligned is determined by results of the FASTDB sequence alignment. This percentage is then subtracted from the percent identity, calculated by the above FASTDB program using the specified parameters, to arrive at a final percent identity score. This final percent identity score is what is used for the purposes of the present invention. Only residues to the N- and C-termini of the subject sequence, which are not matched/aligned with the query sequence, are considered for the purposes of manually adjusting the percent identity score. That is, only query residue positions outside the farthest N- and C- terminal residues of the subject sequence.

5

10

15

20

25

30

For example, a 90 amino acid residue subject sequence is aligned with a 100 residue query sequence to determine percent identity. The deletion occurs at the N-terminus of the subject sequence and therefore, the FASTDB alignment does not show a matching/alignment of the first 10 residues at the N-terminus. The 10 unpaired residues represent 10% of the sequence (number of residues at the N- and C-termini not matched/total number of residues in the query sequence) so 10% is subtracted from the percent identity score calculated by the FASTDB program. If the remaining 90 residues were perfectly matched the final percent identity would be 90%. In another example, a 90 residue subject sequence is compared with a 100 residue query sequence. This time the deletions are internal deletions so there are no residues at the N- or C-termini of the subject sequence which are not matched/aligned with the query. In this case the percent identity calculated by FASTDB is not manually corrected. Once again, only residue positions outside the N- and C-terminal ends of the subject sequence, as displayed in the FASTDB alignment, which are not matched/aligned with the query sequence are manually corrected for. No other manual corrections are to made for the purposes of the present invention.

The variants may contain alterations in the coding regions, non-coding regions, or both. Especially preferred are polynucleotide variants containing alterations which produce silent substitutions, additions, or deletions, but do not alter the properties or activities of the encoded polypeptide. Nucleotide variants produced by silent substitutions due to the degeneracy of the genetic code are preferred. Moreover, variants in which less than 50, less

10

15

20

25

30

than 40, less than 30, less than 20, less than 10, or 5-50, 5-25, 5-10, 1-5, or 1-2 amino acids are substituted, deleted, or added in any combination are also preferred. Polynucleotide variants can be produced for a variety of reasons, e.g., to optimize codon expression for a particular host (change codons in the human mRNA to those preferred by a bacterial host such as E. coli).

Naturally occurring variants are called "allelic variants," and refer to one of several alternate forms of a gene occupying a given locus on a chromosome of an organism. (Genes II. Lewin, B., ed., John Wiley & Sons, New York (1985).) These allelic variants can vary at either the polynucleotide and/or polypeptide level and are included in the present invention. Alternatively, non-naturally occurring variants may be produced by mutagenesis techniques or by direct synthesis.

Using known methods of protein engineering and recombinant DNA technology, variants may be generated to improve or alter the characteristics of the polypeptides of the present invention. For instance, as discussed herein, one or more amino acids can be deleted from the N-terminus or C-terminus of the polypeptide of the present invention without substantial loss of biological function. The authors of Ron et al., J. Biol. Chem. 268: 2984-2988 (1993), reported variant KGF proteins having heparin binding activity even after deleting 3, 8, or 27 amino-terminal amino acid residues. Similarly, Interferon gamma exhibited up to ten times higher activity after deleting 8-10 amino acid residues from the carboxy terminus of this protein. (Dobeli et al., J. Biotechnology 7:199-216 (1988).)

Moreover, ample evidence demonstrates that variants often retain a biological activity similar to that of the naturally occurring protein. For example, Gayle and coworkers (J. Biol. Chem 268:22105-22111 (1993)) conducted extensive mutational analysis of human cytokine IL-1a. They used random mutagenesis to generate over 3,500 individual IL-1a mutants that averaged 2.5 amino acid changes per variant over the entire length of the molecule. Multiple mutations were examined at every possible amino acid position. The investigators found that "[m]ost of the molecule could be altered with little effect on either [binding or biological activity]." (See, Abstract.) In fact, only 23 unique amino acid sequences, out of more than 3,500 nucleotide sequences examined, produced a protein that significantly differed in activity from wild-type.

Furthermore, as discussed herein, even if deleting one or more amino acids from the N-terminus or C-terminus of a polypeptide results in modification or loss of one or more

10

15

20

25

30

biological functions, other biological activities may still be retained. For example, the ability of a deletion variant to induce and/or to bind antibodies which recognize the secreted form will likely be retained when less than the majority of the residues of the secreted form are removed from the N-terminus or C-terminus. Whether a particular polypeptide lacking N- or C-terminal residues of a protein retains such immunogenic activities can readily be determined by routine methods described herein and otherwise known in the art.

Thus, the invention further includes polypeptide variants which show a functional activity (e.g., biological activity) of the polypeptide of the invention of which they are a variant. Such variants include deletions, insertions, inversions, repeats, and substitutions selected according to general rules known in the art so as have little effect on activity.

The present application is directed to nucleic acid molecules at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to the nucleic acid sequences disclosed herein or fragments thereof, (e.g., including but not limited to fragments encoding a polypeptide having the amino acid sequence of an N and/or C terminal deletion), irrespective of whether they encode a polypeptide having functional activity. This is because even where a particular nucleic acid molecule does not encode a polypeptide having functional activity, one of skill in the art would still know how to use the nucleic acid molecule, for instance, as a hybridization probe or a polymerase chain reaction (PCR) primer. Uses of the nucleic acid molecules of the present invention that do not encode a polypeptide having functional activity include, inter alia, (1) isolating a gene or allelic or splice variants thereof in a cDNA library; (2) in situ hybridization (e.g., "FISH") to metaphase chromosomal spreads to provide precise chromosomal location of the gene, as described in Verma et al., Human Chromosomes: A Manual of Basic Techniques, Pergamon Press, New York (1988); and (3) Northern Blot analysis for detecting mRNA expression in specific tissues.

Preferred, however, are nucleic acid molecules having sequences at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to the nucleic acid sequences disclosed herein, which do, in fact, encode a polypeptide having a functional activity of a polypeptide of the invention.

Of course, due to the degeneracy of the genetic code, one of ordinary skill in the art will immediately recognize that a large number of the nucleic acid molecules having a sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to, for example, the nucleic acid sequence of the cDNA in the related cDNA clone contained in a

WO 00/55351

5

10

15

20

25

30

141

PCT/US00/05883

deposited library, the nucleic acid sequence referred to in Table 1 (SEQ ID NO:X), or fragments thereof, will encode polypeptides "having functional activity." In fact, since degenerate variants of any of these nucleotide sequences all encode the same polypeptide, in many instances, this will be clear to the skilled artisan even without performing the above described comparison assay. It will be further recognized in the art that, for such nucleic acid molecules that are not degenerate variants, a reasonable number will also encode a polypeptide having functional activity. This is because the skilled artisan is fully aware of amino acid substitutions that are either less likely or not likely to significantly effect protein function (e.g., replacing one aliphatic amino acid with a second aliphatic amino acid), as further described below.

For example, guidance concerning how to make phenotypically silent amino acid substitutions is provided in Bowie et al., "Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions," Science 247:1306-1310 (1990), wherein the authors indicate that there are two main strategies for studying the tolerance of an amino acid sequence to change.

The first strategy exploits the tolerance of amino acid substitutions by natural selection during the process of evolution. By comparing amino acid sequences in different species, conserved amino acids can be identified. These conserved amino acids are likely important for protein function. In contrast, the amino acid positions where substitutions have been tolerated by natural selection indicates that these positions are not critical for protein function. Thus, positions tolerating amino acid substitution could be modified while still maintaining biological activity of the protein.

The second strategy uses genetic engineering to introduce amino acid changes at specific positions of a cloned gene to identify regions critical for protein function. For example, site directed mutagenesis or alanine-scanning mutagenesis (introduction of single alanine mutations at every residue in the molecule) can be used. (Cunningham and Wells, Science 244:1081-1085 (1989).) The resulting mutant molecules can then be tested for biological activity.

As the authors state, these two strategies have revealed that proteins are surprisingly tolerant of amino acid substitutions. The authors further indicate which amino acid changes are likely to be permissive at certain amino acid positions in the protein. For example, most buried (within the tertiary structure of the protein) amino acid residues require nonpolar side

WO 00/55351

5

10

15

20

25

30

chains, whereas few features of surface side chains are generally conserved. Moreover, tolerated conservative amino acid substitutions involve replacement of the aliphatic or hydrophobic amino acids Ala, Val, Leu and Ile; replacement of the hydroxyl residues Ser and Thr; replacement of the acidic residues Asp and Glu; replacement of the amide residues Asn and Gln, replacement of the basic residues Lys, Arg, and His; replacement of the aromatic residues Phe, Tyr, and Trp, and replacement of the small-sized amino acids Ala, Ser, Thr, Met, and Gly. Besides conservative amino acid substitution, variants of the present invention include (i) substitutions with one or more of the non-conserved amino acid residues, where the substituted amino acid residues may or may not be one encoded by the genetic code, or (ii) substitution with one or more of amino acid residues having a substituent group, or (iii) fusion of the mature polypeptide with another compound, such as a compound to increase the stability and/or solubility of the polypeptide (for example, polyethylene glycol), or (iv) fusion of the polypeptide with additional amino acids, such as, for example, an IgG Fc fusion region peptide, or leader or secretory sequence, or a sequence facilitating purification. Such variant polypeptides are deemed to be within the scope of those skilled in the art from the teachings herein.

For example, polypeptide variants containing amino acid substitutions of charged amino acids with other charged or neutral amino acids may produce proteins with improved characteristics, such as less aggregation. Aggregation of pharmaceutical formulations both reduces activity and increases clearance due to the aggregate's immunogenic activity. (Pinckard et al., Clin. Exp. Immunol. 2:331-340 (1967); Robbins et al., Diabetes 36: 838-845 (1987); Cleland et al., Crit. Rev. Therapeutic Drug Carrier Systems 10:307-377 (1993).)

A further embodiment of the invention relates to a polypeptide which comprises the amino acid sequence of a polypeptide having an amino acid sequence which contains at least one amino acid substitution, but not more than 50 amino acid substitutions, even more preferably, not more than 40 amino acid substitutions, still more preferably, not more than 30 amino acid substitutions, and still even more preferably, not more than 20 amino acid substitutions. Of course it is highly preferable for a polypeptide to have an amino acid sequence which comprises the amino acid sequence of a polypeptide of SEQ ID NO:Y, an amino acid sequence encoded by SEQ ID NO:X, and/or the amino acid sequence encoded by the cDNA in the related cDNA clone contained in a deposited library which contains, in order of ever-increasing preference, at least one, but not more than 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1

10

15

20

25

30

amino acid substitutions. In specific embodiments, the number of additions, substitutions, and/or deletions in the amino acid sequence of SEQ ID NO:Y or fragments thereof (e.g., the mature form and/or other fragments described herein), an amino acid sequence encoded by SEQ ID NO:X or fragments thereof, and/or the amino acid sequence encoded by the cDNA in the related cDNA clone contained in a deposited library or fragments thereof, is 1-5, 5-10, 5-25, 5-50, 10-50 or 50-150, conservative amino acid substitutions are preferable.

Polynucleotide and Polypeptide Fragments

The present invention is also directed to polynucleotide fragments of the colon and/or colon cancer polynucleotides (nucleic acids) of the invention. In the present invention, a "polynucleotide fragment" refers, for example, to a polynucleotide having a nucleic acid sequence which: is a portion of the cDNA contained in a depostied cDNA clone; or is a portion of a polynucleotide sequence encoding the polypeptide encoded by the cDNA contained in a deposited cDNA clone; or is a portion of the polynucleotide sequence in SEQ ID NO:X or the complementary strand thereto; or is a polynucleotide sequence encoding a portion of the polypeptide of SEO ID NO:Y; or is a polynucleotide sequence encoding a portion of a polypeptide encoded by SEQ ID NO:X or the complementary strand thereto. The nucleotide fragments of the invention are preferably at least about 15 nt, and more preferably at least about 20 nt, still more preferably at least about 30 nt, and even more preferably, at least about 40 nt, at least about 50 nt, at least about 75 nt, at least about 100 nt, at least about 125 nt or at least about 150 nt in length. A fragment "at least 20 nt in length," for example, is intended to include 20 or more contiguous bases from, for example, the sequence contained in the cDNA in a related cDNA clone contained in a deposited library, the nucleotide sequence shown in SEQ ID NO:X or the complementary stand thereto. In this context "about" includes the particularly recited value or a value larger or smaller by several (5, 4, 3, 2, or 1) nucleotides. These nucleotide fragments have uses that include, but are not limited to, as diagnostic probes and primers as discussed herein. Of course, larger fragments (e.g., at least 150, 175, 200, 250, 500, 600, 1000, or 2000 nucleotides in length) are also encompassed by the invention.

Moreover, representative examples of polynucleotide fragments of the invention, include, for example, fragments comprising, or alternatively consisting of, a sequence from about nucleotide number 1-50, 51-100, 101-150, 151-200, 201-250, 251-300, 301-350, 351-

WO 00/55351 PCT/US00/05883

5

10

15

20

25

30

400, 401-450, 451-500, 501-550, 551-600, 651-700, 701-750, 751-800, 800-850, 851-900, 901-950, 951-1000, 1001-1050, 1051-1100, 1101-1150, 1151-1200, 1201-1250, 1251-1300, 1301-1350, 1351-1400, 1401-1450, 1451-1500, 1501-1550, 1551-1600, 1601-1650, 1651-1700, 1701-1750, 1751-1800, 1801-1850, 1851-1900, 1901-1950, 1951-2000, 2001-2050. 2051-2100, 2101-2150, 2151-2200, 2201-2250, 2251-2300, 2301-2350, 2351-2400, 2401-2450, 2451-2500, 2501-2550, 2551-2600, 2601-2650, 2651-2700, 2701-2750, 2751-2800, 2801-2850, 2851-2900, 2901-2950, 2951-3000, 3001-3050, 3051-3100, 3101-3150, 3151-3200, 3201-3250, 3251-3300, 3301-3350, 3351-3400, 3401-3450, 3451-3500, 3501-3550, 3551-3600, 3601-3650, 3651-3700, 3701-3750, 3751-3800, 3801-3850, 3851-3900, 3901-3950, 3951-4000, 4001-4050, 4051-4100, and 4101 to the end of SEQ ID NO:X, or the complementary strand thereto. In this context "about" includes the particularly recited range or a range larger or smaller by several (5, 4, 3, 2, or 1) nucleotides, at either terminus or at both termini. Preferably, these fragments encode a polypeptide which has a functional activity (e.g., biological activity) of the polypeptide encoded by the polynucleotide of which the sequence is a portion. More preferably, these fragments can be used as probes or primers as discussed herein. Polynucleotides which hybridize to one or more of these nucleic acid molecules under stringent hybridization conditions or alternatively, under lower stringency conditions, are also encompassed by the invention, as are polypeptides encoded by these polynucleotides or fragments.

Moreover, representative examples of polynucleotide fragments of the invention, include, for example, fragments comprising, or alternatively consisting of, a sequence from about nucleotide number 1-50, 51-100, 101-150, 151-200, 201-250, 251-300, 301-350, 351-400, 401-450, 451-500, 501-550, 551-600, 651-700,701- 750, 751-800, 800-850, 851-900, 901-950, 951-1000, 1001-1050, 1051-1100, 1101-1150, 1151-1200, 1201-1250, 1251-1300, 1301-1350, 1351-1400, 1401-1450, 1451-1500, 1501-1550, 1551-1600, 1601-1650, 1651-1700, 1701-1750, 1751-1800, 1801-1850, 1851-1900, 1901-1950, 1951-2000, 2001-2050, 2051-2100, 2101-2150, 2151-2200, 2201-2250, 2251-2300, 2301-2350, 2351-2400, 2401-2450, 2451-2500, 2501-2550, 2551-2600, 2601-2650, 2651-2700, 2701-2750, 2751-2800, 2801-2850, 2851-2900, 2901-2950, 2951-3000, 3001-3050, 3051-3100, 3101-3150, 3151-3200, 3201-3250, 3251-3300, 3301-3350, 3351-3400, 3401-3450, 3451-3500, 3501-3550, 3551-3600, 3601-3650, 3651-3700, 3701-3750, 3751-3800, 3801-3850, 3851-3900, 3901-3950, 3951-4000, 4001-4050, 4051-4100, and 4101 to the end of the cDNA nucleotide

5

10

15

20

25

30

sequence contained in the deposited cDNA clone, or the complementary strand thereto. In this context "about" includes the particularly recited range, or a range larger or smaller by several (5, 4, 3, 2, or 1) nucleotides, at either terminus or at both termini. Preferably, these fragments encode a polypeptide which has a functional activity (e.g., biological activity) of the polypeptide encoded by the cDNA nucleotide sequence contained in the deposited cDNA clone. More preferably, these fragments can be used as probes or primers as discussed herein. Polynucleotides which hybridize to one or more of these fragments under stringent hybridization conditions or alternatively, under lower stringency conditions, are also encompassed by the invention, as are polypeptides encoded by these polynucleotides or fragments.

In the present invention, a "polypeptide fragment" refers to an amino acid sequence which is a portion of that contained in SEQ ID NO:Y, a portion of an amino acid sequence encoded by the polynucleotide sequence of SEQ ID NO:X, and/or encoded by the cDNA contained in the related cDNA clone contained in a deposited library. Protein (polypeptide) fragments may be "free-standing," or comprised within a larger polypeptide of which the fragment forms a part or region, most preferably as a single continuous region. Representative examples of polypeptide fragments of the invention, include, for example, fragments comprising, or alternatively consisting of, an amino acid sequence from about amino acid number 1-20, 21-40, 41-60, 61-80, 81-100, 102-120, 121-140, 141-160, 161-180, 181-200, 201-220, 221-240, 241-260, 261-280, 281-300, 301-320, 321-340, 341-360, 361-380, 381-400, 401-420, 421-440, 441-460, 461-480, 481-500, 501-520, 521-540, 541-560, 561-580, 581-600, 601-620, 621-640, 641-660, 661-680, 681-700, 701-720, 721-740, 741-760, 761-780, 781-800, 801-820, 821-840, 841-860, 861-880, 881-900, 901-920, 921-940, 941-960, 961-980, 981-1000, 1001-1020, 1021-1040, 1041-1060, 1061-1080, 1081-1100, 1101-1120, 1121-1140, 1141-1160, 1161-1180, 1181-1200, 1201-1220, 1221-1240, 1241-1260, 1261-1280, 1281-1300, 1301-1320, 1321-1340, 1341-1360, and 1361 to the end of SEO ID NO:Y. Moreover, polypeptide fragments of the invention may be at least about 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 100, 110, 120, 130, 140, or 150 amino acids in length. In this context "about" includes the particularly recited ranges or values, or ranges or values larger or smaller by several (5, 4, 3, 2, or 1) amino acids, at either terminus or at both termini. Polynucleotides encoding these polypeptide fragments are also encompassed by the invention.

Even if deletion of one or more amino acids from the N-terminus of a protein results in modification of loss of one or more biological functions of the protein, other functional activities (e.g., biological activities, ability to multimerize, ability to bind a ligand) may still be retained. For example, the ability of shortened muteins to induce and/or bind to antibodies which recognize the complete or mature forms of the polypeptides generally will be retained when less than the majority of the residues of the complete or mature polypeptide are removed from the N-terminus. Whether a particular polypeptide lacking N-terminal residues of a complete polypeptide retains such immunologic activities can readily be determined by routine methods described herein and otherwise known in the art. It is not unlikely that a mutein with a large number of deleted N-terminal amino acid residues may retain some biological or immunogenic activities. In fact, peptides composed of as few as six amino acid residues may often evoke an immune response.

5

10

15

20

25

30

Accordingly, polypeptide fragments of the invention include the secreted protein as well as the mature form. Further preferred polypeptide fragments include the secreted protein or the mature form having a continuous series of deleted residues from the amino or the carboxy terminus, or both. For example, any number of amino acids, ranging from 1-60, can be deleted from the amino terminus of either the secreted polypeptide or the mature form. Similarly, any number of amino acids, ranging from 1-30, can be deleted from the carboxy terminus of the secreted protein or mature form. Furthermore, any combination of the above amino and carboxy terminus deletions are preferred. Similarly, polynucleotides encoding these polypeptide fragments are also preferred.

The present invention further provides polypeptides having one or more residues deleted from the amino terminus of the amino acid sequence of a polypeptide disclosed herein (e.g., a polypeptide of SEQ ID NO:Y, a polypeptide encoded by the polynucleotide sequence contained in SEQ ID NO:X, and/or a polypeptide encoded by the cDNA contained in the related cDNA clone contained in a deposited library). In particular, N-terminal deletions may be described by the general formula m-q, where q is a whole integer representing the total number of amino acid residues in a polypeptide of the invention (e.g., the polypeptide disclosed in SEQ ID NO:Y), and m is defined as any integer ranging from 2 to q-6. Polynucleotides encoding these polypeptides are also encompassed by the invention.

Also as mentioned above, even if deletion of one or more amino acids from the C-terminus of a protein results in modification of loss of one or more biological functions of

5

10

15

20

25

30

147

PCT/US00/05883

the protein, other functional activities (e.g., biological activities, ability to multimerize, ability to bind a ligand) may still be retained. For example the ability of the shortened mutein to induce and/or bind to antibodies which recognize the complete or mature forms of the polypeptide generally will be retained when less than the majority of the residues of the complete or mature polypeptide are removed from the C-terminus. Whether a particular polypeptide lacking C-terminal residues of a complete polypeptide retains such immunologic activities can readily be determined by routine methods described herein and otherwise known in the art. It is not unlikely that a mutein with a large number of deleted C-terminal amino acid residues may retain some biological or immunogenic activities. In fact, peptides composed of as few as six amino acid residues may often evoke an immune response.

Accordingly, the present invention further provides polypeptides having one or more residues from the carboxy terminus of the amino acid sequence of a polypeptide disclosed herein (e.g., a polypeptide of SEQ ID NO:Y, a polypeptide encoded by the polynucleotide sequence contained in SEQ ID NO:X, and/or a polypeptide encoded by the cDNA contained in the related cDNA referenced in Table 1). In particular, C-terminal deletions may be described by the general formula 1-n, where n is any whole integer ranging from 6 to q-1, and where n corresponds to the position of an amino acid residue in a polypeptide of the invention. Polynucleotides encoding these polypeptides are also encompassed by the invention.

In addition, any of the above described N- or C-terminal deletions can be combined to produce a N- and C-terminal deleted polypeptide. The invention also provides polypeptides having one or more amino acids deleted from both the amino and the carboxyl termini, which may be described generally as having residues m-n of a polypeptide encoded by SEQ ID NO:X (e.g., including, but not limited to, the preferred polypeptide disclosed as SEQ ID NO:Y), and/or the cDNA in the related cDNA clone contained in a deposited library, where n and m are integers as described above. Polynucleotides encoding these polypeptides are also encompassed by the invention.

Any polypeptide sequence contained in the polypeptide of SEQ ID NO:Y, encoded by the polynucleotide sequences set forth as SEQ ID NO:X, or encoded by the cDNA in the related cDNA clone contained in a deposited library may be analyzed to determine certain preferred regions of the polypeptide. For example, the amino acid sequence of a polypeptide encoded by a polynucleotide sequence of SEQ ID NO:X, or the cDNA in a deposited cDNA

5

10

15

20

25

30

148

PCT/US00/05883

clone may be analyzed using the default parameters of the DNASTAR computer algorithm (DNASTAR, Inc., 1228 S. Park St., Madison, WI 53715 USA; http://www.dnastar.com/).

Polypeptide regions that may be routinely obtained using the DNASTAR computer algorithm include, but are not limited to, Garnier-Robson alpha-regions, beta-regions, turn-regions, and coil-regions, Chou-Fasman alpha-regions, beta-regions, and turn-regions, Kyte-Doolittle hydrophilic regions and hydrophobic regions, Eisenberg alpha- and beta-amphipathic regions, Karplus-Schulz flexible regions, Emini surface-forming regions and Jameson-Wolf regions of high antigenic index. Among highly preferred polynucleotides of the invention in this regard are those that encode polypeptides comprising regions that combine several structural features, such as several (e.g., 1, 2, 3 or 4) of the features set out above.

Additionally, Kyte-Doolittle hydrophilic regions and hydrophobic regions. Emini surface-forming regions, and Jameson-Wolf regions of high antigenic index (i.e., containing four or more contiguous amino acids having an antigenic index of greater than or equal to 1.5, as identified using the default parameters of the Jameson-Wolf program) can routinely be used to determine polypeptide regions that exhibit a high degree of potential for antigenicity. Regions of high antigenicity are determined from data by DNASTAR analysis by choosing values which represent regions of the polypeptide which are likely to be exposed on the surface of the polypeptide in an environment in which antigen recognition may occur in the process of initiation of an immune response.

Preferred polypeptide fragments of the invention are fragments comprising, or alternatively consisting of, an amino acid sequence that displays a functional activity of the polypeptide sequence of which the amino acid sequence is a fragment.

By a polypeptide demonstrating a "functional activity" is meant, a polypeptide capable of displaying one or more known functional activities associated with a full-length (complete) protein of the invention. Such functional activities include, but are not limited to, biological activity, antigenicity [ability to bind (or compete with a polypeptide for binding) to an anti-polypeptide antibody], immunogenicity (ability to generate antibody which binds to a specific polypeptide of the invention), ability to form multimers with polypeptides of the invention, and ability to bind to a receptor or ligand for a polypeptide.

Other preferred polypeptide fragments are biologically active fragments. Biologically active fragments are those exhibiting activity similar, but not necessarily identical, to an

WO 00/55351 PCT/US00/05883

149

activity of the polypeptide of the present invention. The biological activity of the fragments may include an improved desired activity, or a decreased undesirable activity.

In preferred embodiments, polypeptides of the invention comprise, or alternatively consist of, one, two, three, four, five or more of the antigenic fragments of the polypeptide of SEQ ID NO:Y, or portions thereof. Polynucleotides encoding these polypeptides are also encompassed by the invention.

5

Table 4.

Sequence/ Contig ID	Predicted Epitopes
500802	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 774 as residues: Gln-1 to Ser-17. Ser-19 to Ile-25. Leu-29 to Arg-41. Ser-46 to Glu-57.
553147	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 776 as residues: Phe-1 to Ile-20.
558860	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 777 as residues: Ser-6 to Arg-11.
561730	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 778 as residues: Asn-1 to Arg-7, Lcu-28 to Pro-45.
585938	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 779 as residues: Arg-10 to Ser-23. Gln-69 to His-74.
587785	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 780 as residues: 1le-1 to Ser-11. Leu-20 to Thr-30. Cys-74 to Cys-82, Leu-94 to Glu-110.
588916	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 781 as residues: Val-43 to Pro-55. Glu-92 to Ser-99.
613825	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 782 as residues: Asn-1 to Trp-11. Ser-15 to Gln-22. Ser-43 to Ala-51. Lys-58 to Gly-66.
639090	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 783 as residues: Ser-29 to Ser-35. Pro-43 to Gly-48. Gln-60 to Ser-65.
659544	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 785 as residues: Lcu-10 to Glu-15, His-19 to Glu-26.
659739	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 786 as residues: Lys-70 to His-78, Lys-149 to Asn-154, Gly-209 to Leu-217, Lys-248 to Val-255, Ilc-259 to Arg-264. Arg-280 to Ala-287.
661057	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 787 as residues: Cys-59 to Arg-64. Gly-110 to Asp-115. Pro-127 to Trp-132.
661313	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 788 as residues: Glu-1 to Phe-7. Lys-42 to Leu-48.
666316	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 789 as residues: Lvs-27 to Asn-52.
669229	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 790 as residues: Asp-1 to Phe-12, Val-92 to Ser-103.
670471	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 791 as residues: Lys-75 to Asp-81, Glu-145 to Gln-156, Glu-163 to Arg-170, Lys-225 to Leu-231.
676611	Preferred epitopes include those comprising a sequence shown in SEQ 1D NO. 792 as residues: Tyr-4 to Lys-12. Thr-23 to Asn-31, Val-52 to Thr-63, Arg-90 to Met-95.
691240	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 793 as residues: Pro-74 to Glu-79, Ser-116 to Lys-121.
702977	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 794 as residues: Pro-8 to Tyr-20.
709517	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 795 as residues: Leu-7 to Gly-12, Cys-20 to His-27.
714730	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 796 as residues: Pro-14 to Arg-23, Ala-171 to Ser-178.
714834	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 797 as residues: Ala-6 to Gly-12, Gln-18 to Arg-32.
719584	Preferred epitopes include those comprising a sequence shown in SEQ 1D NO. 799 as residues: Pro-22 to Ile-31.
724637	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 800 as residues: Val-11 to Arg-34, Asn-54 to Cys-59.
728392	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 801 as

	residues: Arg-31 to Glu-45. Glv-76 to Pro-88. Asn-143 to Asp-148.
738716	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 802 as residues: Pro-40 to Pro-46.
739056	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 803 as residues: Ser-28 to Ala-33. Pro-44 to Phe-49, Arg-113 to Gly-118. Pro-131 to Arg-142. Asp-155 to Leu-166.
739143	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 804 as
	residues: Ala-I to Gly-14. Glu-21 to Gly-27. Asp-54 to Lys-59. Lys-64 to Glu-71. Gln-92 to Leu-97. Asn-114 to His-120. Leu-135 to Asp-142. Glu-149 to Ser-154. Ser-256 to The 361. Asp-200 to Lys-301. Gly-315 to Gly-323. Lys-321 to Asp-342.
	Thr-261. Asp-290 to Lys-301. Glu-315 to Gln-323, Lys-331 to Asn-342. Arg-346 to Met-361.
742329	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 805 as residues: Arg-7 to Ala-13. Gln-21 to Ser-27. Gln-68 to Gly-73. Pro-75 to Val-88.
745481	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 807 as residues: Asn-1 to Lys-14. Arg-32 to His-39. Asn-46 to Gly-51.
753731	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 809 as residues: Arg-22 to Ser-39. Val-42 to Thr-54. Gln-61 to His-69.
754383	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 810 as residues: Ala-2 to Gly-12.
756749	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 811 as residues: His-1 to Thr-11. Thr-13 to Ser-18. Gly-25 to Gly-30, Pro-63 to Pro-69. Glu-84 to Tyr-101. Asn-110 to Ala-140.
757980	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 812 as residues: Phe-9 to His-21.
764818	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 813 as residues: Pro-12 to Trp-17, Asn-22 to Ala-37. Arg-45 to Gly-54, Asp-72 to Thr-95. Pro-97 to Glu-116. Gly-137 to Lys-151. Glu-164 to Asp-171, Ser-175 to Gly-185. Glu-187 to Gly-213, Lys-270 to Glu-276, Leu-281 to Lys-286. Asp-314 to Gly-321. Glu-324 to Glu-
765140	331, Val-333 to Arg-340. Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 814 as residues: Thr-15 to Asp-27.
766893	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 815 as residues: Arg-6 to Leu-11. Arg-21 to Tyr-27. Phe-37 to Lys-46. Gly-59 to Gly-64.
771412	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 817 as residues: Pro-1 to His-6. Pro-37 to Arg-47.
772226	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 818 as residues: Phe-16 to Arg-30. Glu-35 to Trp-58, Lys-60 to Gln-68, Pro-80 to Tyr-85.
773057	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 819 as residues: Gly-37 to Arg-43.
773173	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 820 as residues: Pro-19 to Asn-26.
780154	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 821 as residues: Arg-20 to Ile-31, Pro-34 to Ala-59, Glu-66 to Pro-125, Leu-132 to Lys-137, Lys-155 to Arg-259.
780768	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 822 as residues: Phe-12 to Lys-17.
780779	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 823 as residues: Ser-1 to Ser-11, Gln-64 to Gln-69, Arg-117 to Arg-127.
782394	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 824 as residues: Phc-18 to Gly-24.
783160	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 825 as residues: Lys-35 to Lys-41. Thr-50 to His-56. Thr-110 to Gly-119.
783506	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 826 as residues: Thr-3 to Thr-9.
792139	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 830 as residues: Arg-1 to Thr-13. Arg-21 to Pro-30. Ser-70 to Arg-79. Asp-89 to Arg-101.
	residues. Arg-1 to 1111-13. Arg-21 to Pro-30. Ser-10 to Arg-19. Asp-89 to Arg-101.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 832 as residues: Met-7 to Ala-17. Arg-26 to Lcu-32, Lys-47 to Lys-52, Asn-67 to Asn-72. V 77 to Tyr-82, Pro-101 to Arg-107, Arg-137 to Arg-146, Ser-168 to Thr-173. Asp-189 Lys-199. Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 833 as residues: His-24 to Asn-31.	
77 to Tyr-82, Pro-101 to Arg-107, Arg-137 to Arg-146, Ser-168 to Thr-173, Asp-189 Lys-199. 811111 Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 833 as	
Lys-199. 811111 Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 833 as	0
Preferred epitopes include those comprising a sequence shown in SEQ 1D NO. 833 as	
· · · · · · · · · · · · · · · · · · ·	
811113 Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 834 as	
residues: Gln-1 to Ala-9, Cys-56 to Gly-61, Trp-105 to Thr-110, Arg-150 to Thr-155.	
Leu-189 to Lys-195.	
823902 Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 835 as	
residues: Thr-18 to Glu-23.	
Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 836 as	
residues: 1le-20 to Lys-26, Cys-39 to Arg-46.	
Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 837 as	
residues: His-14 to Phe-20. Glu-70 to Leu-83.	
Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 840 as	
residues: Glu-38 to Arg-52, Ser-56 to Val-62.	
Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 842 as	
residues: Asp-1 to Pro-12, Gly-59 to Lys-64, Asp-70 to Leu-76, Pro-160 to Pro-166,	
Thr-174 to Asn-179.	
Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 843 as residues: Thr-49 to Val-54, Leu-83 to Lys-91. Gly-121 to Thr-130, Asp-165 to Glu-1	כז
Thr-180 to Gly-188.	۷,
830208 Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 846 as	
residues: Lys-49 to Asn-56. Glu-61 to Ala-67.	
Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 847 as	
residues: Pro-17 to Asp-36, Pro-102 to Glu-108, Pro-122 to Lys-128, His-150 to Gly-	
155. Asn-162 to Tyr-168. Pro-186 to Gln-193. Ser-205 to Pro-211. Gln-305 to Gly-31	7.
Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 848 as	
residues: Ser-16 to Glu-22, Asn-45 to Ser-50. Thr-121 to Gly-136, Lys-150 to Arg-15	7,
Ser-175 to Cys-181, Gly-198 to Ser-203.	
Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 849 as	
residues: His-11 to Pro-18, Thr-241 to Thr-258, Ala-352 to Ala-365.	
Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 850 as residues: Asp-33 to Ala-39.	
830348 Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 851 as	
residues: Gln-5 to Arg-15, Ile-96 to Asn-101. Asp-122 to Gly-128.	
830364 Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 852 as	
residues: Val-76 to Asn-82, Lys-87 to Tyr-94. Glu-118 to Gln-125, Pro-140 to Ile-14.	i ,
Gly-149 to Pro-173, Ala-215 to Lys-222, Lys-230 to Gly-235, Pro-250 to Asn-256, Se	r-
302 to Arg-307, Ser-321 to Glu-332.	
Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 853 as	
residues: Thr-37 to Thr-44, Leu-57 to Ser-63. Ser-74 to Lys-86, Gln-107 to Leu-112,	
Lys-140 to Ala-145, Asp-154 to Ser-163.	
Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 855 as	_
residues: His-65 to Gly-74, Asp-85 to Ser-97, Leu-133 to Glu-138, Glu-144 to Asp-1	53,
Arg-170 to Ser-175, Gly-184 to Arg-189, Gln-202 to Tyr-208.	
Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 857 as residues: Val-3 to Val-11, Gln-16 to Gln-27. Glu-41 to Asp-51.	
830471 Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 858 as	
residues: Glu-10 to His-22, Ser-37 to Lys-45.	
830477 Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 859 as	
residues: Lys-1 to Cys-13, Thr-32 to Cys-37, Ser-44 to Glu-50, Glu-57 to Asn-64, Gl	1-
85 to Glu-93, Ala-129 to Ser-139, Gln-157 to Thr-185, Gln-199 to Gly-215, Ile-241 to	
Leu-247, Asp-254 to Leu-263, Gln-265 to Gln-270, Glu-298 to Gln-309, Glu-316 to A	
321, Leu-325 to Glu-334, Glu-340 to Ser-345, Leu-348 to His-367, Lys-384 to Arg-39	

	1 - 400 3 417 A 421 to A 427 DL - 441 to L 440 Alo 456 to Ch. 404 L
	Leu-409 to Asn-417, Arg-431 to Arg-437, Phe-441 to Leu-448, Ala-456 to Glu-484, Lys-
	509 to Val-519. Glu-521 to Asp-528. Asp-546 to Phe-553. Glu-558 to Phe-567, Pro-573
020500	to Thr-588.
830500	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 860 as residues: Gln-27 to Gly-34.
830509	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 861 as
	residues: Pro-2 to Asp-7, Gln-13 to Gln-29, Pro-35 to Trp-41.
830528	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 862 as
	residues: Gln-1 to Arg-12, Asp-22 to Pro-44, Lys-52 to Asp-62, Pro-68 to Lys-93, Pro-
	99 to Pro-129. Ala-138 to Ser-150. Lys-156 to Val-194. Ile-197 to Glu-210. Ala-213 to
	Ala-287. Leu-289 to Lys-327. Lys-330 to Gly-340. Asp-344 to Gln-360. Ile-396 to Thr-
2222	401, Lys-409 to Asp-418, Mct-450 to Ala-460, Glu-468 to Gly-475.
830542	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 863 as
	residues: Val-1 to Gly-10, Arg-24 to Asp-36. Leu-225 to Trp-231. Val-249 to Met-258.
	Glu-262 to Thr-269, Val-279 to Gly-284, Asp-307 to Asn-313, Arg-411 to Lys-416.
830564	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 864 as
030(11	residues: Trp-103 to Glu-113. Lys-118 to Tyr-125.
830611	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 865 as
020620	residues: Glu-51 to Ser-57, Arg-128 to Ala-133. Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 867 as
830620	
020620	residues: Lys-54 to Arg-59, Arg-66 to Arg-71. Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 868 as
830630	residues: Pro-12 to Gly-17.
020654	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 869 as
830654	residues: Leu-1 to Asp-6.
930660	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 870 as
830660	residues: Lys-111 to Trp-116. Glu-139 to Gly-148. Arg-182 to Ser-189.
830704	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 872 as
830704	residues: Asn-1 to Glu-8, Ala-38 to Gly-46, Gln-58 to Asp-71, Ala-75 to Cys-103. Met-
	106 to Ala-140, Gln-153 to Ile-159.
830765	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 873 as
830703	residues: Ser-19 to Thr-26. Pro-47 to Thr-59.
830778	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 874 as
030770	residues: Asp-35 to Gly-40. Glu-104 to Glu-109. Ser-226 to Tvr-231.
830784	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 875 as
030707	residues: Pro-34 to Leu-41
830800	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 876 as
	residues: Ser-16 to Lys-24, Gly-91 to Thr-96.
830821	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 877 as
	residues: Leu-2 to Thr-8, Asp-15 to Gly-26, Phe-64 to Ser-70, Pro-77 to Trp-82, Pro-85
	to Lys-90.
830849	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 878 as
	residues: Leu-2 to Ser-18. Gly-31 to Ser-40. Asn-56 to Thr-86. Asp-114 to Arg-120.
830903	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 879 as
	residues: Thr-21 to Thr-33.
830913	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 880 as
	residues: Glv-48 to Pro-53. Gln-66 to Pro-74. Thr-151 to Gly-156. Asn-292 to Asn-297.
830920	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 881 as
	residues: Asp-15 to Ser-25, Ser-33 to Val-38, Lys-181 to Phe-187.
830938	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 882 as
	residues: Thr-65 to Asp-70, Leu-89 to Ala-95.
831014	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 884 as
	residues: Ala-2 to Gln-11, Glu-71 to Leu-78, Leu-89 to Trp-98, Ser-163 to Ala-170, Glu-
	261 to Asp-269. Phe-286 to Val-292.
831026	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 885 as
	residues: Lys-41 to Gly-46, Tyr-64 to Phe-75.

831055	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 887 as
	residues: Trp-37 to His-50. Lys-108 to Phe-114. Lys-131 to Thr-137. Arg-351 to Ser-
021055	356. Pro-363 to Cys-369. Glu-390 to Asp-397.
831057	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 888 as
	residues: Arg-1 to Gly-14. Thr-19 to Gly-25, Ala-31 to Ala-41. Glu-53 to Ile-62. Val-66
921062	to Glu-75. Ser-103 to Asp-113. Ala-135 to Asp-140.
831062	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 889 as
831117	residues: Scr-24 to Ala-31. Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 890 as
631117	residues: Lys-50 to Tyr-55.
831122	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 891 as
	residues: Phe-8 to Gly-14. Arg-58 to Gly-68, Lys-107 to Ser-131. Gln-151 to Val-160,
	Lys-180 to Lys-186. Lys-211 to Thr-223.
831132	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 893 as
	residues: Gly-1 to Ser-16.
831152	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 894 as
	residucs: Ser-8 to Arg-13, Lys-59 to Ala-65, Glu-71 to Glu-86, Leu-98 to His-108. Arg-
	118 to Ilc-126. His-138 to Ala-145. Pro-148 to Tyr-156. Pro-170 to Ala-175. Val-187 to
	Lys-194. Glu-206 to Val-217. Gly-221 to Ser-226. Asp-250 to Lys-255.
831157	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 895 as
	residues: Val-1 to Asn-11, Glu-13 to Gly-25, Ser-31 to Ala-49, Arg-61 to Gly-66, Ala-
	84 to Ala-90.
831160	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 896 as
	residues: His-1 to Ala-7, Asp-43 to Lys-52, Tyr-98 to Gly-103, Glu-118 to Leu-125,
	Phe-183 to Tyr-195, Gln-209 to Arg-220, Ile-257 to Gly-262, Glu-278 to Thr-284, Ile-
	309 to Pro-314, Leu-339 to Asp-347, Ala-358 to Gln-388, Gln-401 to Leu-414, Glu-425
	to Ala-440. Ala-448 to Glu-453. Ile-460 to Gln-465. Glu-482 to Glu-492. Ala-498 to
	Glu-511, Pro-520 to Val-526, Gly-556 to Gln-577, Leu-587 to His-598, Glu-605 to Asp-630.
831197	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 898 as
031177	residues: Ser-28 to Leu-39, Phe-48 to Phe-55, Pro-60 to Gln-66, Arg-73 to Thr-78.
831217	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 899 as
03.2.7	residues: Asp-52 to Val-63, Asn-75 to Glu-83.
831248	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 901 as
	residues: Pro-24 to Glv-34, Lys-108 to Arg-118.
831369	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 903 as
	residues: Ala-1 to Gly-8.
831371	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 904 as
	residues: Arg-39 to Ser-44. Arg-66 to Arg-76.
831373	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 905 as
	residues: Gly-7 to Ser-13, Gln-40 to Trp-45, Lys-109 to Gly-116, Gly-134 to Arg-141,
	Arg-149 to Arg-164, Arg-174 to Phe-181, Lys-202 to Lys-210, Glu-263 to Leu-272, Pro-
	274 to Leu-280, Glu-289 to Glu-296, Pro-334 to His-341, Tyr-413 to Pro-426, Glu-432
831387	to Lys-449. Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 906 as
63138/	residues: Tyr-21 to Leu-28, Cys-51 to Phe-72, Ser-107 to Leu-113, Leu-125 to Leu-134,
	Ser-142 to Ala-152, His-159 to Tyr-164, Arg-276 to Val-290.
831410	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 907 as
331410	residues: Arg-7 to Lys-13. Pro-28 to Cys-34. Gly-100 to Asn-109. Cys-155 to Arg-162.
831448	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 908 as
1	residues: Ala-10 to Cys-20, Tyr-36 to Lys-41, Asp-68 to Ala-75, Ala-84 to Arg-89, Glu-
	112 to Ser-119.
831450	Preferred epitopes include those comprising a sequence shown in SEQ 1D NO. 909 as
	residues: Pro-23 to Gly-28, Thr-52 to Pro-63.
831472	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 910 as
<u></u>	residues: Scr-16 to Ala-26.

831473	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 911 as
,	residues: Arg-37 to Gln-42, Asn-59 to Asn-65, Asn-109 to Val-121. Arg-191 to Glu-
	199. Lys-205 to Ile-214.
831474	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 912 as
	residues: Glu-I to Leu-8. Ser-50 to Arg-56. Thr-61 to Arg-66. Val-69 to Arg-82.
831494	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 913 as
	residues: Arg-21 to Ser-27, Arg-77 to Asp-82, Glu-116 to Ilc-134, Ser-139 to Ser-162.
	Leu-167 to Gly-190. Cys-192 to Gly-205.
831506	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 914 as
	residues: Val-6 to Tyr-12, Lys-77 to Ala-82, Ser-102 to Arg-108, Ser-145 to Ser-151.
831533	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 915 as
	residues: Thr-9 to Cys-16, Arg-52 to Tyr-57, Ser-61 to Ser-69.
831539	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 916 as
1	residues: Thr-32 to Arg-39, Cys-44 to Arg-60, Lys-65 to Gln-70. Gly-78 to Ile-86. Lys-
	126 to Thr-134. Leu-140 to Glu-148.
831556	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 917 as
	residues: Gly-45 to Asp-52.
831598	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 919 as
	residues: Asn-1 to Val-6. Phc-76 to Tyr-83, Gly-129 to Gln-135, Thr-145 to Asp-153.
	Pro-213 to Gln-220. Thr-230 to Asn-236. Lys-242 to Ala-248.
831608	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 920 as
	residues: Thr-23 to Pro-34, Glu-39 to Asp-83, Asn-89 to Lys-99, Asp-118 to Asp-128.
	Asn-135 to Glu-150. Glu-153 to Gly-168, Gly-181 to Thr-187, Arg-200 to Asp-205. Arg-
	273 to IIe-279, Thr-295 to Asp-300, Thr-316 to Cys-321,
831613	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 921 as
	residues: Pro-1 to Glu-7, Arg-9 to Phe-15, Thr-27 to Gly-34.
831655	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 926 as
	residues: Tyr-31 to Gln-38.
831708	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 927 as
	residues: Glu-22 to Ile-27, Gly-43 to Gly-49, His-83 to Arg-105.
831741	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 929 as
	residues: Asp-22 to Asp-27, Pro-64 to Gln-74, Ser-126 to Gly-131, Lys-134 to Arg-143,
	Arg-150 to Gly-162, Gln-180 to Tyr-196, Asp-209 to Leu-224, Gly-233 to Gly-241, Pro-
	246 to Arg-251.
831754	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 930 as
	residues: Arg-40 to Glu-50, Gly-57 to Gly-68, Phe-72 to Tyr-79.
831760	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 931 as
	residues: His-24 to Asp-39.
831780	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 932 as
	residues: Arg-92 to Thr-101.
831796	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 933 as
	residues: Pro-1 to Ser-8.
831800	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 934 as
	residues: Asp-1 to Ser-6, Glu-16 to Ser-26, Lys-66 to Pro-76, Leu-93 to Arg-99, Val-153
	to Lys-164, Glu-177 to Asp-183, Ser-188 to Leu-193, Arg-210 to Ser-220, Thr-229 to
	Ser-244, Pro-283 to Phe-297.
831813	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 937 as
	residues: Pro-20 to Ala-30.
831830	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 938 as
1	residues: Arg-12 to Lys-17. Gln-51 to Phe-60, Asp-97 to Trp-102. Glu-132 to Cys-137.
	Asp-160 to Leu-168. Glu-210 to Gln-219. Lys-302 to Pro-308, Phe-416 to Asp-421. Leu-
1	444 to Leu-449, Val-457 to Asn-464. Leu-466 to Trp-472, lle-474 to Trp-480. Ser-527 to
	Ser-533, Pro-558 to Phe-565, Ile-578 to Trp-584, Asp-614 to Asp-627, Asn-698 to Asp-
	710, Pro-738 to Ser-744.
831860	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 939 as
I	residues: Pro-19 to Tyr-25.

031007	In Condition in the base of the condition of the conditio
831896	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 941 as
	residues: Ser-18 to Phc-30. Leu-34 to Asn-41. Ala-48 to Tyr-56, Leu-103 to Ala-110,
	Asp-124 to Val-130. Ilc-141 to Leu-150. Leu-188 to Ser-196. Glu-229 to Asn-238. Thr-
001000	248 to Cys-259.
831928	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 942 as residues: Asn-55 to Asp-60.
831949	
631949	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 943 as
	residues: Arg-I to Glu-9. Glu-19 to Arg-32. Ala-77 to Thr-90, Thr-95 to Thr-104. Lys-
021050	106 to Ser-119, Leu-136 to Arg-141, Tyr-165 to Asn-174.
831950	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 944 as
021075	residues: Ser-18 to Glu-26. Phe-93 to Arg-102. Leu-137 to Gln-143. Pro-148 to Gly-157.
831975	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 946 as
032045	residues: His-41 to Thr-48.
832047	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 948 as
	residues: Arg-57 to Glu-62, Pro-73 to Gly-80.
832078	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 949 as
	residues: Pro-14 to Leu-21, Cys-34 to Gly-39.
832100	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 950 as
	residues: Tyr-37 to Val-45.
832104	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 951 as
	residues: Thr-1 to Ser-6. Arg-14 to Cvs-20.
832279	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 954 as
	residues: Ser-28 to Pro-34, Pro-134 to Ser-139, Gln-178 to Gly-183, Thr-193 to Gly-
	198, His-244 to Gly-257, Asp-263 to Tyr-273, Lys-337 to Arg-347, Pro-366 to Lys-372.
	Ala-382 to Asp-387.
832317	Preferred epitopes include those comprising a sequence shown in SEQ 1D NO. 955 as
	residues: Thr-32 to Gln-39. Asn-58 to Trp-71. Glu-96 to Trp-108. Cys-126 to Gly-133.
832364	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 957 as
	residues: Glu-2 to Met-9, Asp-17 to Asn-22, Leu-27 to Val-35.
832428	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 960 as
	residues: Arg-35 to Gly-41.
832485	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 961 as
	residues: Ser-121 to Cys-127.
832494	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 962 as
002.77	residues: Ser-10 to Leu-28, Ser-31 to Asp-40, Scr-55 to Thr-62, Thr-94 to Asn-102, Asp-
	124 to Phe-135, Asn-175 to Lys-193, Glu-238 to Leu-243, Val-250 to Ala-259, Lys-291
	to Asn-308, Ser-318 to Gly-327, Lys-335 to Asp-346, Tyr-404 to Ile-410, Gln-420 to
	Gln-430. Thr-476 to Phe-482, Pro-536 to Val-561, Tyr-563 to Leu-568.
832512	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 963 as
0,2,2,1,2	residues: Arg-1 to Ala-7, Leu-9 to Ser-24, Glu-32 to Asp-43, Glu-71 to Glu-86, Val-92
	to Ile-104. Asp-143 to Ser-154, Lys-190 to Glu-202. Glu-218 to Lys-241.
832515	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 964 as
0,2,1,1	residues: Glu-3 to Gly-12, Arg-20 to Gln-30. Leu-34 to Gln-39, Asp-51 to Arg-58, Gln-
	69 to Val-77, Gly-105 to Lys-117, Cys-123 to Phe-132.
832526	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 965 as
032320	residues: Pro-15 to Asn-25, Glu-48 to Phe-59.
922575	
832575	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 966 as
	residues: Thr-24 to Arg-29, Ala-55 to Tyr-60, Tyr-77 to Asp-89, Leu-108 to Gly-115,
033636	Thr-142 to Gly-149.
832576	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 967 as
	residues: Arg-1 to Leu-11, Pro-21 to Gly-28, Pro-37 to His-47, Lys-79 to Gln-88, Pro-
30000	108 to Gly-116. Pro-179 to Thr-188, Arg-207 to Asn-213.
832634	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 969 as
·	residues: Leu-2 to Ser-12, Pro-125 to Asp-133.
832728	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 970 as
	residues: Gln-16 to Glv-32. Leu-100 to Gly-106. Gly-118 to Lys-132. Pro-156 to Leu-

	162.
833395	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 972 as residues: Ser-3 to Gly-9.
834326	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 973 as residues: Ser-1 to Trp-19. Asn-148 to Leu-153. Tyr-235 to Trp-244.
834944	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 975 as residues: Glu-42 to Gln-51, Pro-115 to Asp-120, Arg-127 to Gly-133, Gln-199 to Gln-211.
835104	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 977 as residues: Thr-1 to Arg-14. Val-18 to Pro-23. Thr-37 to Met-44, Gln-51 to Leu-57.
835332	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 978 as residues: Thr-1 to Glu-13, Arg-135 to Asp-142, Thr-150 to Gln-155, Cys-173 to Cys-183, Cys-203 to Asp-214.
835487	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 979 as residues: Ala-13 to Arg-22, Pro-43 to Glu-57, Ala-73 to Pro-90, Arg-102 to Ser-109. Pro-114 to Gly-122, Arg-127 to Arg-138, Glu-153 to Gly-158, Pro-165 to Pro-171, Gly-185 to Arg-190, Pro-211 to Pro-216, Glu-231 to Asn-261. Ala-280 to Pro-291. Pro-303 to Gly-311, Arg-313 to Gly-326, Ala-358 to Ala-364, Pro-369 to Gly-377, Pro-390 to Gly-407, Tyr-420 to Tyr-441. Glu-461 to Thr-470, Pro-479 to Trp-487, Asp-489 to Cys-494, Gln-515 to Lys-532, Ala-572 to Asn-582, Asp-588 to Leu-594, Cys-625 to Trp-632. Tyr-639 to Arg-646.
836182	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 980 as residues: Ala-7 to Thr-17, Arg-31 to Thr-36.
836522	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 981 as residues: Gly-59 to Cys-65.
836789	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 984 as residues: Gly-18 to Gly-25. Glu-59 to Glu-64.
838577	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 985 as residues: Pro-15 to Trp-20, Pro-46 to Gln-57, Glu-68 to Phe-83.
839008	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 987 as residues: Arg-1 to Arg-13, Gln-125 to Glu-131, Asn-137 to Val-142, Gly-183 to Tyr-188, Asn-245 to Ser-251, Gln-302 to Asn-311.
840063	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 988 as residues: Gly-1 to Gly-31.
840533	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 989 as residues: Thr-16 to Pro-23, Pro-39 to Trp-48, Arg-50 to Lvs-55, Glv-73 to Gly-79.
840669	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 990 as residues: Met-27 to Gln-33, Gln-49 to Gly-56, Thr-63 to Leu-70, Thr-115 to Arg-127, Pro-174 to Asn-184.
841140	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 991 as residues: Arg-17 to Phe-24, Pro-113 to Gly-121, Thr-235 to Met-240.
841386	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 992 as residues: Val-58 to Met-66, Pro-134 to Lys-143, Tyr-163 to Ala-170, Val-178 to Lys-187, Pro-207 to Gly-212.
841900	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 996 as residues: Ile-2 to Phe-12.
842054	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 997 as residues: Asp-27 to Trp-32, Pro-89 to Glu-99, Arg-112 to Lys-123.
843061	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 998 as residues: Leu-3 to Gly-18, His-36 to His-57, Lys-136 to Leu-145. Gly-174 to Trp-184, Lys-188 to Tyr-196, Lys-204 to Asp-211, Pro-293 to Ser-305, Glu-321 to Asp-333, Gly-342 to Lys-348, Ala-371 to Asp-377, Asp-439 to Lcu-449. Ala-521 to Gly-529, Tyr-583 to Trp-599, Asn-639 to Ser-644, Leu-738 to Leu-745.
843544	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 999 as residues: Tyr-11 to Phe-18. Ser-34 to Lys-43.
844092	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1000 as

	11 - Cl. 1 - Cl. 20 - Cl. 20 - Cl. 27 -
A	residues: Gln-1 to Lys-6. Glu-30 to Glu-37. Glu-40 to Thr-53.
844270	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1001 as residues: Thr-10 to Gly-20. Pro-44 to Thr-50.
944604	
844604	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1002 as
	residues: Gly-8 to Phe-20, Pro-23 to Arg-43, Asp-62 to Asp-67, Pro-73 to Asn-80, Val-
	83 to Phe-95, Glu-103 to Ile-109, Tyr-120 to Ala-125, Thr-176 to Thr-183, Pro-200 to
	Pro-214. Pro-232 to Met-240. Gln-248 to Asp-292. Arg-297 to Ser-310. Pro-320 to Glu-
	β32. Glu-347 to Ser-390. Ala-392 to Pro-404. Pro-425 to Gly-435. Pro-438 to Gly-443.
	Gly-467 to Pro-480, Pro-486 to Pro-499. Pro-506 to Met-512. Pro-572 to Glu-580, Arg-
	592 to Gly-597, Ala-601 to Ser-610. Ala-618 to Pro-623.
844685	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1003 as
	residues: Ser-14 to Ser-19, Pro-25 to Gly-32, Asn-98 to Lys-108.
844855	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1004 as
	residues: Ala-9 to Ser-15. Pro-21 to Arg-26.
845101	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1005 as
	residues: Ala-2 to Glv-13, Pro-31 to Pro-42, Gln-89 to Tvr-95, Gln-169 to Leu-189.
845141	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1006 as
	residues: Gly-13 to Met-26. Arg-34 to Gly-39. Ile-60 to Ser-80. Ala-85 to Thr-98.
845220	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1007 as
	residues: Pro-14 to Gly-24. Glu-33 to Ala-39. Asp-145 to Pro-168. Ala-238 to Arg-250.
	Pro-258 to Phe-269, Arg-285 to Pro-290. Ala-340 to Cys-364.
845434	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1008 as
043434	residues: Ala-1 to Glu-7, Gln-29 to Phe-34, Gly-67 to Ala-75, Gln-78 to Leu-83, Asn-96
	to Ile-109, Thr-144 to Trp-151.
845510	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1009 as
043310	
	residues: Arg-79 to Leu-86, Met-114 to Asp-122, Lcu-129 to Leu-134, Gln-145 to Arg-
045600	152.
845600	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1010 as
	residues: Ala-22 to Phe-28.
845882	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1011 as
	residues: Ala-1 to Gly-7, Arg-29 to Lys-35. Lys-72 to Ala-79, Leu-94 to Val-101, Gly-
	137 to Asn-142, Arg-145 to Leu-150, Gly-180 to Lys-187, Glu-194 to Gly-208, Arg-257
	to Ser-267, Ser-278 to Asp-290, Gly-312 to Ser-319, Leu-338 to Lys-351. Tyr-358 to
	Ser-363.
846007	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1012 as
	residues: Tyr-16 to Ala-24, Arg-59 to Ser-66. Thr-78 to Glu-83, Glu-90 to Ser-103, Gln-
	108 to Thr-113, Ser-115 to Cys-124.
HCRNG17R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1016 as
	residues: Pro-16 to Asp-21.
HWMFG64R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1017 as
	residues: Ser-70 to Asp-76. Lys-87 to Leu-95.
HAGCZ94R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1018 as
	residues: Val-3 to Lys-9.
HBJEJ74R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1019 as
HUJUJ/TK	residues: Pro-1 to Asp-8.
HUTHM43R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1021 as
no i nivi43K	· · · · · · · · · · · · · · · · · · ·
III TOUZED	residues: Pro-7 to Arg-15.
HLTGU75R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1022 as
	residues: Ser-1 to Gly-11.
HWLKF77R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1023 as
	residues: Leu-10 to Asn-28.
HWLGX29R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1027 as
	residues: Val-3 to Ile-10. Pro-34 to Gln-40.
HWMFZ29R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1028 as
	residues: Leu-7 to Leu-13.
H6EEP19R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1030 as

	residues: Ala-1 to Trp-8, Lys-10 to Asp-27.
HJMAM83R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1031 as
<u> </u>	residues: Ser-I to Val-11, Glu-19 to Ala-29, Asp-52 to Ala-68, Gly-78 to Lys-94.
HAGHF58R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1032 as
	residues: Lys-1 to Val-7.
HDPHG48R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1033 as
	residues: Gly-24 to Lys-34.
HCDMC32R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1038 as
	residues: Pro-2 to Arg-17. Lys-36 to Pro-47. Phe-61 to Trp-68. Gln-72 to Ala-86.
HTEQO80R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1040 as
	residues: Gly-1 to Val-15, Pro-17 to Pro-23, Leu-32 to Met-41, Lys-102 to His-109.
H2LAR08R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1043 as
	residues: Asn-58 to Gly-64.
HWMFN58R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1046 as
	residues: Glu-6 to Asn-14. Arg-22 to Asp-31. Gly-49 to Thr-56.
HUFBP63R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1049 as
	residues: Pro-1 to Gln-8, Thr-57 to Gly-64, Arg-69 to Arg-74, Gly-80 to Asp-91, Asp-
	105 to Gln-110. Arg-130 to Tyr-148.
HUFBN90R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1050 as
	residues: Glu-34 to Ala-40. Arg-111 to Ala-116.
HFKHD61R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1054 as
	residues: Arg-11 to Gly-38, Arg-44 to Glu-50, Gln-53 to Lys-67.
HTXNL13R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1057 as
	residues: Ser-48 to Arg-57, Glu-89 to Pro-95. Ser-102 to Asn-107.
H2LAK62R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1059 as
// // // // // // // // // // // // //	residues: Pro-20 to Ser-25.
HATAR77R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1061 as
IIAIAK//K	residues: Gly-2 to Arg-16.
HWMEH18R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1066 as
11 WWILLIAM	residues: Gln-61 to Ser-67.
HCNDP66R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1068 as
HENDFOOK	residues: Leu-8 to Arg-15, Gln-46 to Pro-54.
HCRMK82R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1069 as
HCKWK62K	residues: Ser-32 to Arg-38, Ala-72 to Lys-79, Arg-103 to Phe-111.
HSSGC52R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1075 as
113300328	residues: Gly-1 to Pro-6. Arg-25 to Ile-30.
HCYBN49R	
IC I DIN49K	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1076 as residues: Gly-16 to Gly-21, Ile-99 to Gln-109.
HWMGB90R	
11 WIVIODSUK	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1077 as
UTEAWOID	residues: Gly-1 to Ala-7, Asp-17 to Arg-27. Glu-32 to Leu-40.
HTEAW21R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1078 as
LIDI ACCOR	residues: Glu-1 to Gly-6, Gln-19 to Leu-37.
H2LAQ68R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1082 as
IID A A D COD	residues: Val-2 to Trp-10, Leu-25 to Lys-33.
HBAAD60R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1087 as
HOROLOGO	residues: Pro-1 to Lys-32.
HCROA35R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1088 as
WOD OL COLO	residues: Gly-6 to Lys-12.
HCROM64R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1089 as
	residues: Asn-1 to Arg-7.
HKBAG82R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1091 as
	residues: Pro-9 to Gly-28.
HUTSB76R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1092 as
· · · · · · · · · · · · · · · · · · ·	residues: Lys-1 to Ser-17.
HWLJS67R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1093 as
	residues: Gln-3 to Lys-18, Gln-44 to Glu-49.

HTGAZ53R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1098 as residues: Ser-1 to Ala-16. Gln-36 to Thr-48.
HWLLL51R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1100 as residues: Gln-6 to Gly-18.
HWLJZ72R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1103 as residues: Ile-1 to Ser-19.
HWMFG06R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1104 as residues: Arg-1 to Lys-14, Gln-40 to Glu-45, Arg-65 to Arg-80.
HPRTO65R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1105 as residues: Thr-12 to Thr-17. Cys-35 to Ser-40.
HUFDC01R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1106 as residues: Pro-11 to Glu-26.
HWLHY44R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1107 as residues: Pro-14 to Gln-24, Cys-34 to Leu-39, Thr-72 to Val-77, Glu-94 to Thr-99, Asp-101 to Met-107, Lys-109 to Pro-116.
HWLGR92R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1108 as residues: Pro-17 to Gly-22.
HCNCQ71R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1109 as residues: Glu-22 to Leu-30.
HWLENIIR	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1111 as residues: Pro-6 to Lys-21, Ala-26 to Val-34, Lys-37 to Ser-46.
HWLEH56R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1116 as residues: Thr-23 to Ala-28, Asn-88 to Trp-98, Cys-114 to Asp-131.
H2LAD26R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1117 as residues: Pro-20 to Gly-31.
H2LAK66R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1125 as residues: Pro-33 to Leu-39, Glu-54 to Val-59. Gly-69 to Ser-76.
HSDKC65R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1126 as residues: Asn-32 to Pro-39, Pro-41 to Pro-49.
H2LAK52R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1127 as residues: Pro-20 to Ala-28.
HKAEG12R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1128 as residues: Asp-47 to Lys-52.
HKADP43R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1129 as residues: Pro-7 to Pro-15. Arg-35 to Val-44.
HUSJE17R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1131 as residues: Pro-26 to Gln-32.
HHBEF06R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1133 as residues: Pro-1 to Gly-6.
HISCW28R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1134 as residues: Pro-26 to Gln-32.
HPIAK29R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1137 as residues: Thr-1 to Tyr-7.
HUFAR71R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1138 as residues: Pro-26 to Gln-32.
HOECI21R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1141 as residues: Asn-11 to Pro-20, Pro-22 to Thr-30, Glu-49 to Glu-70, Ser-84 to Thr-96, Thr-108 to Thr-113.
HMCAR63R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1143 as residues: Ala-1 to Gly-9, Lys-41 to Glu-47, Asn-65 to Gly-70, Glu-85 to Asp-93, Glu-103 to Tyr-109.
HAICY55R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1152 as residues: Glu-2 to His-9.
HWLIA38R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1153 as residues: Arg-60 to Gly-74. Ser-80 to Ile-88. Leu-92 to Ser-98.
HBXCL69R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1154 as

residues: Ser-2 to Cys-8, Pro-10 to Leu-17. H2LAP90R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 11 residues: Thr-3 to Gln-9, Asn-11 to Pro-19, Gln-35 to Glu-42. HTELE03R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 11 residues: Asp-1 to Gln-9, Asn-11 to Arg-16, Cys-28 to Ser-44, Gln-50 to Gln-56 HJMBN86R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 11 residues: Ser-31 to Glu-47. HSKJC32R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 11 residues: Gln-151 to Glu-158, Glu-168 to Pro-173, Ser-188 to Ile-195. HAOAG76R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 11 residues: Glv-1 to Ala-14. HCIAD45R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 11 residues: Glv-1 to Ala-14.	
residues: Thr-3 to Gln-9. Asn-11 to Pro-19. Gln-35 to Glu-42. HTELEO3R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 11 residues: Asp-1 to Gln-9. Asn-11 to Arg-16. Cvs-28 to Ser-44. Gln-50 to Gln-56 HJMBN86R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 11 residues: Ser-31 to Glu-47. HSKJC32R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 11 residues: Gln-151 to Glu-158. Glu-168 to Pro-173. Ser-188 to Ile-195. HAOAG76R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 11 residues: Glv-1 to Ala-14. HCIAD45R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 11 residues: Pro-1 to Lys-23, Pro-43 to Leu-49.	
HTELE03R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 11 residues: Asp-1 to Gln-9, Asn-11 to Arg-16, Cys-28 to Ser-44, Gln-50 to Gln-56 HJMBN86R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 11 residues: Ser-31 to Glu-47. HSKJC32R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 11 residues: Gln-151 to Glu-158, Glu-168 to Pro-173, Ser-188 to Ile-195. HAOAG76R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 11 residues: Gly-1 to Ala-14. HCIAD45R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 11 residues: Pro-1 to Lys-23, Pro-43 to Leu-49.	58 as 59 as
HJMBN86R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 11 residues: Ser-31 to Glu-47. HSKJC32R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 11 residues: Gln-151 to Glu-158. Glu-168 to Pro-173. Ser-188 to Ile-195. HAOAG76R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 11 residues: Gly-1 to Ala-14. HCIAD45R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 11 residues: Pro-1 to Lys-23, Pro-43 to Leu-49.	59 as 61 as
HSKJC32R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 11 residues: Gln-151 to Glu-158. Glu-168 to Pro-173. Ser-188 to Ile-195. HAOAG76R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 11 residues: Gly-1 to Ala-14. HCIAD45R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 11 residues: Pro-1 to Lys-23, Pro-43 to Leu-49.	61 as
residues: Gln-151 to Glu-158. Glu-168 to Pro-173. Ser-188 to Ile-195. HAOAG76R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 11 residues: Gly-1 to Ala-14. HCIAD45R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 11 residues: Pro-1 to Lys-23, Pro-43 to Leu-49.	61 as
residues: Glv-1 to Ala-14. HCIAD45R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 13 residues: Pro-1 to Lvs-23, Pro-43 to Leu-49.	
residues: Pro-1 to Lys-23, Pro-43 to Leu-49.	62 as
H2MAC82R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 11 residues: Lys-54 to Lys-59.	63 as
H2LAJ41R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 11	64 as
residues: Met-20 to Val-36. Ser-82 to Lys-93. Pro-101 to Arg-106. HBJFH33R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 11	66 as
residues: Glv-10 to Tvr-26, Asn-29 to Leu-37, Thr-52 to His-59. HISDV92R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1	(7
residues: Pro-3 to Ser-8. Asn-48 to Tvr-54.	_
HE9QB35R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 11 residues: Gly-1 to Asp-6, Pro-20 to Gln-33, Tyr-46 to Arg-52, Asn-72 to Lys-85.	
to Ala-110.	Gill-91
HDABQ50R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 11 residues: Ser-9 to Lys-17. Lys-41 to Arg-46.	70 as
HTPAC28R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 11 residues: Lys-10 to Thr-15, Thr-17 to Leu-23.	76 as
HMCGN07R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 11 residues: Asn-88 to Ser-98, Pro-123 to Val-129.	77 as
HBMVM66R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 11 residues: Ser-2 to Gly-7, Arg-10 to Phe-24, Ala-36 to Arg-41.	80 as
HEPNA09R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 11 residues: Ser-1 to Pro-6.	86 as
HCNDR62R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 11 residues: Pro-14 to Ser-21.	90 as
HNJBF13R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 11 residues: Asp-18 to Asp-28.	91 as
HLYCD69R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 11 residues: Gly-90 to Thr-109.	92 as
HWCAA53R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 11 residues: Ser-22 to Gly-28, Glu-37 to Ile-45, Val-67 to Arg-85, Asn-91 to Trp-99	
HFVGP11R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 11 residues: Ala-4 to Asn-13.	
HWLQH07R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 11	99 as
residues: Lys-1 to Lys-25. HWLKH07R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 12	Ol as
residues: Pro-49 to Asp-58. HAPQC14R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 12	02 as
residues: Lys-1 to Met-8.	
HSODB48R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 12 residues: Ser-24 to Glv-31. Ala-37 to Ser-44. Pro-57 to Ser-64. Pro-97 to Gly-10-	
HBEAC75R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 12 residues: Pro-1 to Arg-9.	
HBGMJ24R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 12 residues: Tyr-11 to Val-17, Thr-30 to Phe-48, Gln-150 to Thr-155.	05 as

HBJEN94R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1206 as residues: Gln-1 to Asn-6.
HLQGB87R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1213 as residues: Lys-2 to Ser-7.
HAOAC69R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1215 as residues: Ser-2 to Arg-10.
HWLEQ08R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1216 as residues: Glu-21 to His-31.
HKAAV70R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1217 as residues: Gly-6 to Thr-93, Glu-95 to Glu-104, Asp-117 to Asp-125.
HNFJE41R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1221 as residues: Arg-15 to His-21, Pro-48 to Ala-58. Asn-61 to Leu-66. Val-92 to Thr-110. Pro-114 to Thr-120.
HCRMW41R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1224 as residues: Phe-14 to Asn-19.
HOVAX78R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1225 as residues: Gly-1 to Thr-8.
HWAEH57R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1226 as residues: Ser-54 to Tyr-60. Gln-65 to Pro-72. Thr-81 to Gly-92.
HAHEK76R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1230 as residues: Cys-20 to Cys-28.
HOSCG81R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1232 as residues: Thr-8 to Asn-13.
HTFMD43R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1233 as residues: Lys-44 to Ile-52, Arg-57 to Lys-77.
H2LAR73R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1235 as residues: Pro-20 to Arg-27, Asn-47 to Lys-53, Asp-116 to Asn-123, Glu-145 to Gly-154.
HWHPK71R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1238 as residues: Asp-15 to His-24. Pro-27 to Leu-39.
HWBBJ39R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1239 as residues: His-1 to Lys-6.
HSODD94R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1241 as residues: Gly-7 to Glu-15, Gly-29 to Lys-41, Pro-43 to Ser-52, Pro-68 to His-73.
HMIAG25R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1242 as residues: Arg-19 to Ser-41. Pro-43 to Glu-54. Ser-59 to Gly-74.
HCNDW17R	Preferred cpitopes include those comprising a sequence shown in SEQ ID NO. 1244 as residues: Lys-7 to Lys-15, Thr-54 to Asn-59.
HWLEY08R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1245 as residues: Glu-9 to Arg-14, Thr-19 to Arg-27, Asp-48 to Ile-57, Gln-63 to Leu-75, Cys-89 to Thr-104, Gly-106 to Pro-113.
HULFN68R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1246 as residues: Ser-1 to Cys-16, Lys-18 to Gly-23, Pro-31 to Tyr-37, Gly-53 to Pro-58.
HTEJJ32R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1249 as residues: Ser-17 to Cys-23, Gln-42 to Leu-51, Ser-68 to Asp-73.
H2CBS58R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1251 as residues: Ser-82 to Phe-88, Lys-110 to Gly-118.
H2LAB77R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1252 as residues: Met-13 to Asp-18, Glu-23 to Ser-43, Glu-45 to Gly-54.
HWAFP88R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1254 as residues: Arg-8 to Lys-13, Gly-35 to Lys-42, Ala-48 to Lys-54.
HWMEB67R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1256 as residues: Arg-9 to Arg-16.
HKMAA52R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1261 as residues: Gly-2 to Lys-10. Asp-36 to Asn-42.
H2LAB37R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1262 as residues: Glu-52 to Thr-59.

H2LAP46R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1263 as residues: Pro-40 to Asn-46. Tyr-71 to Arg-79.
H6BSE61R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1264 as residues: 1le-36 to Asp-41, Ala-54 to Pro-63.
HACBS75R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1269 as residues: Arg-20 to Ser-27, Arg-45 to Trp-59.
HACCA48R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1270 as residues: Lys-12 to Lys-26.
HACCS19R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1271 as residues: Gly-1 to Gly-10.
HAGGL96R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1273 as residues: Ser-74 to Phe-88.
HAGGT37R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1274 as residues: Phe-17 to Pro-22.
HAHDR66R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1275 as residues: Gly-11 to Ala-18.
HAJCL80R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1277 as residues: Asn-22 to Phe-32.
HAQMH45R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1283 as residues: Pro-2 to Tvr-13, Leu-21 to Gly-47, Val-49 to Gly-55, Pro-63 to Glu-78.
HBGCA44R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1290 as residues: Thr-20 to Trp-25. Lys-32 to Leu-40.
HBGFX27R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1291 as residues: Ser-1 to Pro-6.
HBGMU38R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1292 as residues: Gln-1 to Phe-8, Thr-34 to Trp-53, Arg-56 to Gly-63, Arg-86 to Cys-102.
HBJED55R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1295 as residues: Arg-6 to Pro-14.
HBMTJ51R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1300 as residues: Cys-8 to Asp-13.
HBWBD78R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1302 as residues: Pro-51 to Ala-58.
HCDDQ63R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1307 as residues: Gln-1 to Lys-10.
HCFCD01R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1310 as residues: Ser-1 to Thr-6.
HCFCR43R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1311 as residues: Arg-10 to Thr-20.
HCHAO92R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1313 as residues: Asn-19 to Arg-25.
HCHOH49R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1314 as residues: Asn-19 to Asp-30.
HCHPG05R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1315 as residues: Pro-6 to Ser-11.
HCIAD24R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1316 as residues: Lys-1 to Gly-7.
HCNCY51R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1319 as residues: Lys-10 to Arg-16.
HCNCY63R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1320 as residues: Gly-1 to Lys-9.
HCNDO71R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1321 as residues: Lys-33 to Ile-42. Arg-51 to Phe-64.
HCQBN22R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1324 as residues: Lys-1 to Asn-11.
HCQCL27R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1325 as residues: Gly-7 to His-27.

HCQCL48R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1326 as residues: Ala-1 to Thr-13. HCQDJ42R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1330 as residues: Glu-8 to Asn-13. Arg-16 to Glu-24. HCRMD77R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1331 as residues: Asn-4 to Asn-10. HCROJ68R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1339 as residues: Bl-2 to His-8. HCROM30R HCROM30R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1342 as residues: Glu-1 to Glu-7. Pro-26 to Leu-32. Gly-37 to Gln-44. Thr-84 to Thr-92. HCROQ34R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1343 as residues: Asn-1 to Asp-11. HCROZ66R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1345 as residues: Arg-7 to Ly-3. HCRPC61R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1346 as residues: Arg-7 to Ly-3. HCRPC62R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1346 as residues: Pro-26 to Ser-33. HCRPN52R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1347 as residues: Pro-26 to Ser-33. HCRPN52R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1349 as residues: Pro-26 to Ser-32. HDCAA21R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1354 as residues: Pro-26 to Ser-34. HDDAA85R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1356 as residues: Lys-18 to Lys-24. HDPGO3R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1356 as residues: Ala-4 to Gln-17. HDPLB08R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1356 as residues: Ala-4 to Gln-17. HDPLB08R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1360 as residues: Ala-4 to Gln-17. HDPLB08R Preferred epitopes include those compri
residues: Glu-8 to Asn-13, Arg-16 to Glu-24. HCRMD77R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1331 as residues: Asn-4 to Asn-10. HCROJ68R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1339 as residues: Ile-2 to His-8. HCROM30R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1342 as residues: Glu-1 to Glu-7. Pro-26 to Leu-32. Glv-37 to Gln-44. Thr-84 to Thr-92. HCROQ34R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1343 as residues: Asn-1 to Asp-11. HCROZ66R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1345 as residues: Asn-1 to Asp-11. HCRPC61R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1346 as residues: Ala-3 to Gly-8. HCRPG28R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1347 as residues: Pro-26 to Ser-32. HCRPN52R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1349 as residues: Pro-26 to Ser-32. HDCAA21R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1354 as residues: Ser-24 to Lys-30. Lys-54 to Ser-61. HDDAA85R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1355 as residues: Lys-18 to Lys-24. HDPG003R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1356 as residues: Lys-18 to Lys-24. Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1356 as residues: Ala-4 to Gln-17. Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1359 as residues: Ala-4 to Gln-17. Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1359 as residues: Ala-4 to Gln-17. Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1360 as residues: Pro-2 to Tyr-13. Leu-21 to Ala-36. Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1360 as residues: Pro-1 to Asn-8. HEGAR32R Preferred epitopes includ
HCRMD77R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1331 as residues: Asn-4 to Asn-10. HCROJ68R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1339 as residues: Ile-2 to His-8. HCROM30R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1342 as residues: Glu-1 to Glu-7. Pro-26 to Leu-32. Glv-37 to Gln-44. Thr-84 to Thr-92. HCROQ34R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1343 as residues: Asn-1 to Asp-11. HCROZ66R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1345 as residues: Arg-7 to Lys-13. HCRPC61R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1346 as residues: Ala-3 to Gly-8. HCRPG28R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1347 as residues: Pro-26 to Ser-32. HCRPN52R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1349 as residues: Pro-6 to Val-12. Ile-15 to Phe-20. HDCAA21R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1354 as residues: Phe-6 to Val-12. Ile-15 to Phe-20. HDPG003R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1355 as residues: Lys-18 to Lys-24. HDPG003R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1356 as residues: Ala-4 to Gln-17. Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1359 as residues: Pro-2 to Tyr-13. Leu-21 to Ala-36. HDQEX80R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1359 as residues: Arg-1 to Arg-6. Phe-27 to Arg-32, Pro-37 to Lys-42, Arg-47 to Trp-53, Arg-55 to Ser-61. Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1360 as residues: Pro-1 to Asn-8. Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1364 as residues: Pro-1 to Asn-8. Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1366 as residues: Pro-
HCROJ68R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1339 as residues: Ile-2 to His-8. HCROM30R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1342 as residues: Glu-1 to Glu-7. Pro-26 to Leu-32. Gly-37 to Gln-44. Thr-84 to Thr-92. HCROQ34R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1343 as residues: Asn-1 to Asp-11. HCROZ66R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1345 as residues: Arg-7 to Lys-13. HCRPC61R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1346 as residues: Ala-3 to Gly-8. HCRPG28R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1347 as residues: Pro-26 to Ser-32. HCRPN52R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1349 as residues: Ser-24 to Lys-30. Lys-54 to Ser-61. HDCAA21R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1354 as residues: Phe-6 to Val-12. Ile-15 to Phe-20. HDDAA85R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1356 as residues: Lys-18 to Lys-24. HDPG003R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1356 as residues: Ala-4 to Gln-17. HDPLB08R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1357 as residues: Pro-2 to Tyr-13. Leu-21 to Ala-36. HDQEX80R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1359 as residues: Pro-2 to Tyr-13. Leu-21 to Ala-36. HDRM191R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1360 as residues: Pro-1 to Arg-6, Phe-27 to Arg-32, Pro-37 to Lys-42, Arg-47 to Trp-53, Arg-55 to Ser-61. Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1364 as residues: Pro-1 to Asn-8. HE9FH12R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1366 as residues: Pro-1 to Asn-8. Preferred epitopes include those comprising a sequence shown
residues: Glu-1 to Glu-7. Pro-26 to Leu-32. Gly-37 to Gln-44. Thr-84 to Thr-92. Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1343 as residues: Asn-1 to Asp-11. Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1345 as residues: Ala-3 to Gly-8. Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1346 as residues: Ala-3 to Gly-8. Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1347 as residues: Pro-26 to Ser-32. Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1349 as residues: Ser-24 to Lys-30. Lys-54 to Ser-61. HDCAA21R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1354 as residues: Pre-6 to Val-12. Ite-15 to Phe-20. HDDAA85R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1355 as residues: Lys-18 to Lys-24. HDPGO03R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1356 as residues: Ala-4 to Gln-17. HDPLB08R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1357 as residues: Pro-2 to Tyr-13. Leu-21 to Ala-36. HDQEX80R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1359 as residues: Pro-1 to Arg-6, Phe-27 to Arg-32, Pro-37 to Lys-42, Arg-47 to Trp-53, Arg-55 to Ser-61. HDRMI91R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1360 as residues: Pro-1 to Asn-8. HE6DJ45R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1364 as residues: Pro-1 to Asn-8. Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1360 as residues: Pro-1 to Asn-8. Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1370 as residues: Gln-20 to Asn-25. HEGAR32R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1370 as residues: Gln-20 to Asn-25.
HCROQ34R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1343 as residues: Asn-1 to Asp-11. HCROZ66R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1345 as residues: Arg-7 to Lys-13. HCRPC61R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1346 as residues: Ala-3 to Gly-8. HCRPG28R HCRPG28R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1347 as residues: Pro-26 to Ser-32. HCRPN52R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1349 as residues: Ser-24 to Lys-30. Lys-54 to Ser-61. HDCAA21R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1354 as residues: Phe-6 to Val-12. Ile-15 to Phe-20. HDDAA85R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1355 as residues: Lys-18 to Lys-24. HDPG003R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1356 as residues: Ala-4 to Gln-17. HDPLB08R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1357 as residues: Pro-2 to Tyr-13. Leu-21 to Ala-36. HDQEX80R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1359 as residues: Arg-1 to Arg-6, Phe-27 to Arg-32, Pro-37 to Lys-42, Arg-47 to Trp-53, Arg-55 to Ser-61. HDRMI91R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1360 as residues: Pro-1 to Asn-8. HE6DJ45R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1364 as residues: Pro-1 to Asn-8. Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1360 as residues: Pro-1 to Asn-8. Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1370 as residues: Gln-20 to Asn-25. HEGAR32R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1370 as residues: Gln-20 to Asn-25. Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1371 as residues: Ser-16 to His-46, Arg-49 to Thr-58.
residues: Arg-7 to Lys-13. HCRPC61R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1346 as residues: Ala-3 to Gly-8. HCRPG28R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1347 as residues: Pro-26 to Ser-32. HCRPN52R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1349 as residues: Ser-24 to Lys-30. Lys-54 to Ser-61. HDCAA21R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1354 as residues: Phe-6 to Val-12. Ite-15 to Phe-20. HDDAA85R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1355 as residues: Lys-18 to Lys-24. HDPG003R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1356 as residues: Ala-4 to Gln-17. HDPLB08R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1357 as residues: Pro-2 to Tyr-13. Leu-21 to Ala-36. HDQEX80R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1359 as residues: Arg-1 to Arg-6, Phe-27 to Arg-32, Pro-37 to Lys-42, Arg-47 to Trp-53, Arg-55 to Ser-61. HDRM191R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1360 as residues: Thr-1 to Lys-8. HE6DJ45R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1366 as residues: Thr-1 to Ash-8. HE9FH12R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1366 as residues: Ash-12 to Ser-20. Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1370 as residues: Gln-20 to Ash-25. Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1371 as residues: Lys-9 to Ser-19. HEGAR32R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1371 as residues: Ser-16 to His-46, Arg-49 to Thr-58.
HCRPG28R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1347 as residues: Pro-26 to Ser-32. HCRPN52R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1349 as residues: Ser-24 to Lys-30. Lys-54 to Ser-61. HDCAA21R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1354 as residues: Phe-6 to Val-12. Ile-15 to Phe-20. HDDAA85R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1355 as residues: Lys-18 to Lys-24. HDPGO03R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1356 as residues: Ala-4 to Gln-17. HDPLB08R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1357 as residues: Pro-2 to Tyr-13. Leu-21 to Ala-36. HDQEX80R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1359 as residues: Arg-1 to Arg-6, Phe-27 to Arg-32, Pro-37 to Lys-42, Arg-47 to Trp-53, Arg-55 to Ser-61. HDRM191R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1360 as residues: Thr-1 to Lys-8. HE6DJ45R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1364 as residues: Pro-1 to Asn-8. HE9FH12R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1366 as residues: Asn-12 to Ser-20. HEAAL59R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1370 as residues: Gln-20 to Asn-25. Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1371 as residues: Lys-9 to Ser-19. HEGAR32R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1371 as residues: Ser-16 to His-46. Arg-49 to Thr-58.
HCRPN52R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1349 as residues: Ser-24 to Lys-30. Lys-54 to Ser-61. Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1354 as residues: Phe-6 to Val-12. Ile-15 to Phe-20. HDDAA85R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1355 as residues: Lys-18 to Lys-24. HDPGO03R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1356 as residues: Ala-4 to Gln-17. HDPLB08R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1357 as residues: Pro-2 to Tyr-13. Leu-21 to Ala-36. HDQEX80R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1359 as residues: Arg-1 to Arg-6, Phe-27 to Arg-32, Pro-37 to Lys-42, Arg-47 to Trp-53, Arg-55 to Ser-61. HDRM191R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1360 as residues: Thr-1 to Lys-8. HE6DJ45R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1364 as residues: Pro-1 to Asn-8. HE9FH12R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1366 as residues: Asn-12 to Ser-20. Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1370 as residues: Gln-20 to Asn-25. Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1371 as residues: Lys-9 to Ser-19. Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1371 as residues: Lys-9 to Ser-19. Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1371 as residues: Ser-16 to His-46, Arg-49 to Thr-58.
residues: Ser-24 to Lys-30. Lys-54 to Ser-61. HDCAA21R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1354 as residues: Phe-6 to Val-12. Ile-15 to Phe-20. HDDAA85R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1355 as residues: Lys-18 to Lys-24. HDPGO03R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1356 as residues: Ala-4 to Gln-17. HDPLB08R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1357 as residues: Pro-2 to Tyr-13. Leu-21 to Ala-36. HDQEX80R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1359 as residues: Arg-1 to Arg-6. Phe-27 to Arg-32, Pro-37 to Lys-42, Arg-47 to Trp-53, Arg-55 to Ser-61. HDRMI91R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1360 as residues: Thr-1 to Lys-8. HE6DJ45R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1364 as residues: Pro-1 to Asn-8. HE9FH12R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1366 as residues: Asn-12 to Ser-20. Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1370 as residues: Gln-20 to Asn-25. HEGAR32R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1371 as residues: Lys-9 to Ser-19. Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1371 as residues: Ser-16 to His-46. Arg-49 to Thr-58.
HDDAA85R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1355 as residues: Lys-18 to Lys-24. HDPGO03R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1356 as residues: Ala-4 to Gln-17. HDPLB08R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1357 as residues: Pro-2 to Tyr-13. Leu-21 to Ala-36. HDQEX80R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1359 as residues: Arg-1 to Arg-6, Phe-27 to Arg-32, Pro-37 to Lys-42, Arg-47 to Trp-53, Arg-55 to Ser-61. HDRMI91R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1360 as residues: Thr-1 to Lys-8. HE6DJ45R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1364 as residues: Pro-1 to Asn-8. HE9FH12R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1366 as residues: Asn-12 to Ser-20. Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1370 as residues: Gln-20 to Asn-25. Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1371 as residues: Lys-9 to Ser-19. HEGAR32R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1371 as residues: Lys-9 to Ser-19. HEGAR85R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1372 as residues: Ser-16 to His-46, Arg-49 to Thr-58.
HDDAA85R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1355 as residues: Lys-18 to Lys-24. HDPGO03R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1356 as residues: Ala-4 to Gln-17. HDPLB08R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1357 as residues: Pro-2 to Tyr-13. Leu-21 to Ala-36. HDQEX80R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1359 as residues: Arg-1 to Arg-6, Phe-27 to Arg-32, Pro-37 to Lys-42, Arg-47 to Trp-53, Arg-55 to Ser-61. HDRM191R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1360 as residues: Thr-1 to Lys-8. HE6DJ45R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1364 as residues: Pro-1 to Asn-8. HE9FH12R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1366 as residues: Asn-12 to Ser-20. HEAAL59R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1370 as residues: Gln-20 to Asn-25. HEGAR32R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1371 as residues: Lys-9 to Ser-19. HEGAR85R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1372 as residues: Ser-16 to His-46. Arg-49 to Thr-58.
residues: Ala-4 to Gln-17. HDPLB08R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1357 as residues: Pro-2 to Tyr-13. Leu-21 to Ala-36. HDQEX80R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1359 as residues: Arg-1 to Arg-6, Phe-27 to Arg-32, Pro-37 to Lys-42, Arg-47 to Trp-53, Arg-55 to Ser-61. HDRMI91R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1360 as residues: Thr-1 to Lys-8. Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1364 as residues: Pro-1 to Asn-8. HE9FH12R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1366 as residues: Asn-12 to Ser-20. Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1370 as residues: Gln-20 to Asn-25. Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1371 as residues: Lys-9 to Ser-19. Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1372 as residues: Ser-16 to His-46, Arg-49 to Thr-58.
residues: Pro-2 to Tyr-13. Leu-21 to Ala-36. HDQEX80R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1359 as residues: Arg-1 to Arg-6, Phe-27 to Arg-32, Pro-37 to Lys-42, Arg-47 to Trp-53, Arg-55 to Ser-61. HDRM191R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1360 as residues: Thr-1 to Lys-8. Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1364 as residues: Pro-1 to Asn-8. HE9FH12R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1366 as residues: Asn-12 to Ser-20. Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1370 as residues: Gln-20 to Asn-25. HEGAR32R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1371 as residues: Lys-9 to Ser-19. HEGAR85R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1372 as residues: Ser-16 to His-46. Arg-49 to Thr-58.
residues: Arg-1 to Arg-6, Phe-27 to Arg-32, Pro-37 to Lys-42, Arg-47 to Trp-53, Arg-55 to Ser-61. HDRMI91R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1360 as residues: Thr-1 to Lys-8. HE6DJ45R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1364 as residues: Pro-1 to Asn-8. HE9FH12R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1366 as residues: Asn-12 to Ser-20. HEAAL59R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1370 as residues: Gln-20 to Asn-25. HEGAR32R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1371 as residues: Lys-9 to Ser-19. HEGAR85R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1372 as residues: Ser-16 to His-46. Arg-49 to Thr-58.
residues: Thr-1 to Lys-8. HE6DJ45R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1364 as residues: Pro-1 to Asn-8. HE9FH12R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1366 as residues: Asn-12 to Ser-20. HEAAL59R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1370 as residues: Gln-20 to Asn-25. HEGAR32R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1371 as residues: Lys-9 to Ser-19. HEGAR85R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1372 as residues: Ser-16 to His-46. Arg-49 to Thr-58.
residues: Pro-1 to Asn-8. HE9FH12R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1366 as residues: Asn-12 to Ser-20. HEAAL59R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1370 as residues: Gln-20 to Asn-25. HEGAR32R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1371 as residues: Lys-9 to Ser-19. HEGAR85R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1372 as residues: Ser-16 to His-46. Arg-49 to Thr-58.
residues: Asn-12 to Ser-20. HEAAL59R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1370 as residues: Gln-20 to Asn-25. HEGAR32R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1371 as residues: Lys-9 to Ser-19. HEGAR85R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1372 as residues: Ser-16 to His-46. Arg-49 to Thr-58.
residues: Gln-20 to Asn-25. HEGAR32R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1371 as residues: Lys-9 to Ser-19. HEGAR85R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1372 as residues: Ser-16 to His-46. Arg-49 to Thr-58.
residues: Lys-9 to Ser-19. HEGAR85R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1372 as residues: Ser-16 to His-46. Arg-49 to Thr-58.
residues: Ser-16 to His-46, Arg-49 to Thr-58.
TIPLEFORD ID-G
HELFE05R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1373 as residues: Tyr-8 to Leu-16.
HEMF188R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1374 as residues: Pro-6 to Ala-13.
HEMFR18R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1375 as residues: Ala-1 to Ala-10, Pro-12 to Gly-17, Ala-22 to Cys-27, Glu-30 to Arg-35, Pro-43 to Ser-50.
HEONL43R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1376 as residues: Arg-1 to Val-10.
HFADM62R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1380 as residues: Lys-6 to Lys-14.
HFATE31R Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1381 as residues: Asp-1 to Arg-9, Arg-20 to Arg-26, Glu-33 to Gly-40.

HFCEL77R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1383 as residues: Glu-33 to Ser-48. Ile-54 to Ile-63, Leu-79 to Asp-84.
HFTBI57R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1392 as residues: Pro-18 to Ser-23.
HFXGX46R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1394 as residues: Pro-11 to Gln-28.
HHBEW72R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1400 as residues: Pro-20 to Thr-27.
HHERT59R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1401 as residues: Arg-1 to Trp-9.
HJMAH76R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1405 as residues: Cys-10 to Ala-15.
HJMAN56R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1406 as residues: Ala-45 to Asp-60.
HJMAO54R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1407 as residues: Pro-28 to Gln-39. Pro-65 to Cys-80.
HKLSD93R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1409 as residues: Gly-11 to Gly-17.
HLMFH16R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1410 as residues: Gly-1 to Asp-8.
HLQCQ73R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1412 as residues: Glu-1 to Gly-6. Arg-8 to Phe-13.
HLQEF47R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1413 as residues: Leu-8 to Leu-13.
HLQFM50R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1414 as residues: Gly-29 to Asp-34.
HLQGA76R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1416 as residues: Ser-16 to Ser-33.
HLTEV09R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1418 as residues: Arg-9 to Asn-17.
HMACF85R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1421 as residues: Glu-29 to Lys-34. Leu-113 to Gln-120.
HMAIA15R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1422 as residues: Lys-15 to Gln-21, Ile-51 to Gly-57, Lys-72 to Gly-83.
HMCIS54R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1424 as residues: Lys-3 to His-24.
HNHMR05R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1427 as residues: Pro-9 to Gly-20. Thr-26 to Arg-42, Ala-48 to Ser-54.
HNJBB78R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1428 as residues: Thr-6 to Lys-13. Leu-48 to Asn-54.
HOCND06R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1433 as residues: Pro-2 to Tyr-13. Leu-21 to Ala-35.
HOCND49R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1434 as residues: Asn-2 to Gly-12. Ile-14 to Ala-30.
HODFA26R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1436 as residues: Glu-1 to His-6. Gly-19 to Asp-29. Leu-44 to Leu-49.
HODHL89R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1437 as residues: Ser-16 to His-46. Arg-49 to Thr-58.
HOEJM67R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1438 as residues: Ser-19 to Lys-25. Asp-29 to Glu-55, Ser-102 to Thr-107.
HOGBN48R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1439 as residues: Lys-14 to Arg-19. Asp-25 to Phe-32.
HOUHN53R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1442 as residues: Glu-1 to His-6. Gly-19 to Trp-31.
HPBEE63R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1444 as residues: Pro-14 to Glv-20. His-28 to Arg-35.

HPJBE91R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1446 as
	residues: Ser-15 to Asn-20. Ala-22 to Ile-49. Lys-52 to Val-57, Tyr-71 to Cys-83, Thr-
HSDZG83R	90 to Tyr-95. Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1454 as
113D2G63K	residues: Val-17 to Lys-22.
HSICQ60R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1455 as
	residues: Val-12 to Gly-17.
HSIFA64R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1456 as
	residues: His-17 to Ile-22. Leu-33 to Pro-40.
HSKYE52R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1458 as
	residues: Pro-2 to Ser-7.
HSODA95R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1460 as
	residues: Ser-14 to His-44, Arg-47 to Thr-56.
HSSGK43R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1462 as
UTYEACID	residues: Ser-24 to Leu-35. Pro-38 to Ser-45.
HTXFA64R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1470 as residues: Thr-1 to Glu-8.
HUSJF91R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1471 as
110331711	residues: Glv-1 to Glv-6.
HUSJN48R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1472 as
	residues: Ser-16 to Tvr-24.
HUSZN23R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1474 as
	residues: Ser-16 to Lys-24.
HUTSD20R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1475 as
	residues: Arg-10 to Asn-20.
HWAF163R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1477 as
	residues: Pro-15 to Gly-24, Pro-26 to Arg-45.
HWAGZ89R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1478 as
111111111111111111111111111111111111111	residues: Ser-47 to Lys-52.
HWHHM83R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1480 as residues: Leu-1 to Gly-6.
HWLBS90R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1484 as
IIW EBS/OK	residues: Lys-37 to Asn-44.
HWLEH13R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1486 as
	residues: Gln-22 to Glu-29.
HWLEJ67R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1487 as
	residues: Asn-5 to Trp-13.
HWLEM49R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1488 as
	residues: Glu-1 to His-6, Gly-19 to Trp-31.
HWLGM21R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1492 as
IIIVI CCACE	residues: Glu-1 to His-6, Gly-19 to Trp-31.
HWLGS46R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1494 as residues: Glu-17 to Asn-23. Glu-38 to Gly-49.
HWLGU40R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1495 as
1117110101	residues: His-10 to Pro-15.
HWLGX65R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1496 as
De la Delitoria	residues: Glu-1 to Asn-7.
HWLHD09R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1497 as
	residues: Pro-6 to Ala-37, Arg-40 to Ser-49.
HWLHW89R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1500 as
	residues: Asn-1 to Lys-16. Glu-32 to Ser-41. Leu-57 to Gly-71.
HWLJL19R	Preferred epitopes include those comprising a sequence shown in SEQ 1D NO. 1506 as
111111 11 0005	residues: Arg-46 to Phe-58.
	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1508 as
	residues: Pro-5 to Gly-25, Ser-29 to Leu-36. Arg-49 to Phe-55.
TIWLVIVIOR	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1512 as

	residues: Arg-10 to Lys-23.
HWLQS83R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1515 as
11.1.203031	residues: Ala-1 to Arg-6.
HWLRP86R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1518 as
	residues: Tyr-3 to Gly-10.
HWLRQ49R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1519 as
	residues: Pro-19 to Ser-26. Gln-44 to Lys-52.
HWLUF60R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1520 as
	residues: Gln-7 to Lys-31.
HWLUR41R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1522 as
	residues: Ser-24 to Trp-30.
HWLVD60R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1523 as
	residues: Cys-15 to Lys-51.
HWMAN61R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1525 as
	residues: Ser-21 to Asp-26.
HWMEH26R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1528 as
	residues: Ser-16 to His-46. Arg-49 to Thr-58.
HWMEL50R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1529 as
	residues: Pro-24 to Thr-40. Phe-63 to Arg-69.
HWMFB31R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1530 as
	residues: Asn-2 to Lys-10. Cys-16 to Pro-28. Ser-36 to Glu-41.
HWMFO93R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1532 as
11144 55 100	residues: Ser-8 to Gln-14.
HMAFE48R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1537 as
UDODISSB	residues: Glu-9 to Gly-17. Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1538 as
HRODJ88R	residues: Glv-6 to Tyr-14.
HWLAR31R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1539 as
HWLAKSIK	residues: Glu-9 to Gly-17.
H2LAU24R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1541 as
112670248	residues: Glu-11 to Glv-19.
HATDR94R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1542 as
	residues: Glu-14 to Lys-19. Asn-21 to Gly-27.
HWLLI85R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1543 as
	residues: Val-19 to Asn-32.
HSYCH41R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1545 as
	residues: Thr-71 to Ile-79.

5

10

15

20

25

30

168

PCT/US00/05883

The present invention encompasses polypeptides comprising, or alternatively consisting of, an epitope of the polypeptide sequence shown in SEQ ID NO:Y, or an epitope of the polypeptide sequence encoded by the cDNA in the related cDNA clone contained in a deposited library or encoded by a polynucleotide that hybridizes to the complement of an epitope encoding sequence of SEQ ID NO:X, or an epitope encoding sequence contained in the deposited cDNA clone under stringent hybridization conditions, or alternatively, under lower stringency hybridization conditions, as defined supra. The present invention further encompasses polynucleotide sequences encoding an epitope of a polypeptide sequence of the invention (such as, for example, the sequence disclosed in SEQ ID NO:X), polynucleotide sequences of the complementary strand of a polynucleotide sequence encoding an epitope of the invention, and polynucleotide sequences which hybridize to this complementary strand under stringent hybridization conditions or alternatively, under lower stringency hybridization conditions, as defined supra.

The term "epitopes," as used herein, refers to portions of a polypeptide having antigenic or immunogenic activity in an animal, preferably a mammal, and most preferably in a human. In a preferred embodiment, the present invention encompasses a polypeptide comprising an epitope, as well as the polynucleotide encoding this polypeptide. An "immunogenic epitope," as used herein, is defined as a portion of a protein that elicits an antibody response in an animal, as determined by any method known in the art, for example, by the methods for generating antibodies described infra. (See, for example, Geysen et al., Proc. Natl. Acad. Sci. USA 81:3998- 4002 (1983)). The term "antigenic epitope," as used herein, is defined as a portion of a protein to which an antibody can immunospecifically bind its antigen as determined by any method well known in the art, for example, by the immunoassays described herein. Immunospecific binding excludes non-specific binding but does not necessarily exclude cross- reactivity with other antigens. Antigenic epitopes need not necessarily be immunogenic.

Fragments which function as epitopes may be produced by any conventional means. (See, e.g., Houghten, R. A., Proc. Natl. Acad. Sci. USA 82:5131-5135 (1985) further described in U.S. Patent No. 4,631,211.)

In the present invention, antigenic epitopes preferably contain a sequence of at least 4, at least 5, at least 6, at least 7, more preferably at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 20, at least 25, at least 30, at least 40, at

WO 00/55351 PCT/US00/05883

least 50, and, most preferably, between about 15 to about 30 amino acids. Preferred polypeptides comprising immunogenic or antigenic epitopes are at least 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 amino acid residues in length. Additional non-exclusive preferred antigenic epitopes include the antigenic epitopes disclosed herein, as well as portions thereof. Antigenic epitopes are useful, for example, to raise antibodies, including monoclonal antibodies, that specifically bind the epitope. Preferred antigenic epitopes include the antigenic epitopes disclosed herein, as well as any combination of two, three, four, five or more of these antigenic epitopes. Antigenic epitopes can be used as the target molecules in immunoassays. (See, for instance, Wilson et al., Cell 37:767-778 (1984); Sutcliffe et al., Science 219:660-666 (1983)).

Similarly, immunogenic epitopes can be used, for example, to induce antibodies according to methods well known in the art. (See, for instance, Sutcliffe et al., supra; Wilson et al., supra; Chow et al., Proc. Natl. Acad. Sci. USA 82:910-914; and Bittle et al., J. Gen. Virol. 66:2347-2354 (1985). Preferred immunogenic epitopes include the immunogenic epitopes disclosed herein, as well as any combination of two, three, four, five or more of these immunogenic epitopes. The polypeptides comprising one or more immunogenic epitopes may be presented for eliciting an antibody response together with a carrier protein, such as an albumin, to an animal system (such as rabbit or mouse), or, if the polypeptide is of sufficient length (at least about 25 amino acids), the polypeptide may be presented without a carrier. However, immunogenic epitopes comprising as few as 8 to 10 amino acids have been shown to be sufficient to raise antibodies capable of binding to, at the very least, linear epitopes in a denatured polypeptide (e.g., in Western blotting).

Epitope-bearing polypeptides of the present invention may be used to induce antibodies according to methods well known in the art including, but not limited to, in vivo immunization, in vitro immunization, and phage display methods. See, e.g., Sutcliffe et al., supra; Wilson et al., supra, and Bittle et al., J. Gen. Virol., 66:2347-2354 (1985). If in vivo immunization is used, animals may be immunized with free peptide; however, anti-peptide antibody titer may be boosted by coupling the peptide to a macromolecular carrier, such as keyhole limpet hemacyanin (KLH) or tetanus toxoid. For instance, peptides containing cysteine residues may be coupled to a carrier using a linker such as maleimidobenzoyl- N-hydroxysuccinimide ester (MBS), while other peptides may be coupled to carriers using a more general linking agent such as glutaraldehyde. Animals such as rabbits, rats and mice

10

15

20

25

30

PCT/US00/05883

are immunized with either free or carrier- coupled peptides, for instance, by intraperitoneal and/or intradermal injection of emulsions containing about 100 µg of peptide or carrier protein and Freund's adjuvant or any other adjuvant known for stimulating an immune response. Several booster injections may be needed, for instance, at intervals of about two weeks, to provide a useful titer of anti-peptide antibody which can be detected, for example, by ELISA assay using free peptide adsorbed to a solid surface. The titer of anti-peptide antibodies in serum from an immunized animal may be increased by selection of anti-peptide antibodies, for instance, by adsorption to the peptide on a solid support and elution of the selected antibodies according to methods well known in the art.

As one of skill in the art will appreciate, and as discussed above, the polypeptides of the present invention, and immunogenic and/or antigenic epitope fragments thereof can be fused to other polypeptide sequences. For example, the polypeptides of the present invention may be fused with the constant domain of immunoglobulins (IgA, IgE, IgG, IgM), or portions thereof (CH1, CH2, CH3, or any combination thereof and portions thereof) resulting in chimeric polypeptides. Such fusion proteins may facilitate purification and may increase half-life in vivo. This has been shown for chimeric proteins consisting of the first two domains of the human CD4-polypeptide and various domains of the constant regions of the heavy or light chains of mammalian immunoglobulins. See, e.g., EP 394,827; Traunecker et al., Nature, 331:84-86 (1988). Enhanced delivery of an antigen across the epithelial barrier to the immune system has been demonstrated for antigens (e.g., insulin) conjugated to an FcRn binding partner such as IgG or Fc fragments (see, e.g., PCT Publications WO 96/22024 and WO 99/04813). IgG Fusion proteins that have a disulfide-linked dimeric structure due to the IgG portion desulfide bonds have also been found to be more efficient in binding and neutralizing other molecules than monomeric polypeptides or fragments thereof alone. See, e.g., Fountoulakis et al., J. Biochem., 270:3958-3964 (1995).

Similarly, EP-A-O 464 533 (Canadian counterpart 2045869) discloses fusion proteins comprising various portions of constant region of immunoglobulin molecules together with another human protein or part thereof. In many cases, the Fc part in a fusion protein is beneficial in therapy and diagnosis, and thus can result in, for example, improved pharmacokinetic properties. (EP-A 0232 262.) Alternatively, deleting the Fc part after the fusion protein has been expressed, detected, and purified, may be desired. For example, the Fc portion may hinder therapy and diagnosis if the fusion protein is used as an antigen for

10

15

20

25

30

immunizations. In drug discovery, for example, human proteins, such as hIL-5, have been fused with Fc portions for the purpose of high-throughput screening assays to identify antagonists of hIL-5. (See, D. Bennett et al., J. Molecular Recognition 8:52-58 (1995); K. Johanson et al., J. Biol. Chem. 270:9459-9471 (1995).)

Moreover, the polypeptides of the present invention can be fused to marker sequences, such as a peptide which facilitates purification of the fused polypeptide. In preferred embodiments, the marker amino acid sequence is a hexa-histidine peptide, such as the tag provided in a pQE vector (QIAGEN, Inc., 9259 Eton Avenue, Chatsworth, CA, 91311), among others, many of which are commercially available. As described in Gentz et al., Proc. Natl. Acad. Sci. USA 86:821-824 (1989), for instance, hexa-histidine provides for convenient purification of the fusion protein. Another peptide tag useful for purification, the "HA" tag, corresponds to an epitope derived from the influenza hemagglutinin protein. (Wilson et al., Cell 37:767 (1984).)

Thus, any of these above fusions can be engineered using the polynucleotides or the polypeptides of the present invention.

Nucleic acids encoding the above epitopes can also be recombined with a gene of interest as an epitope tag (e.g., the hemagglutinin ("HA") tag or flag tag) to aid in detection and purification of the expressed polypeptide. For example, a system described by Janknecht et al. allows for the ready purification of non-denatured fusion proteins expressed in human cell lines (Janknecht et al., Proc. Natl. Acad. Sci. USA 88:8972-897 (1991)). In this system, the gene of interest is subcloned into a vaccinia recombination plasmid such that the open reading frame of the gene is translationally fused to an amino-terminal tag consisting of six histidine residues. The tag serves as a matrix binding domain for the fusion protein. Extracts from cells infected with the recombinant vaccinia virus are loaded onto Ni2+ nitriloacetic acid-agarose column and histidine-tagged proteins can be selectively eluted with imidazole-containing buffers.

Additional fusion proteins of the invention may be generated through the techniques of gene-shuffling, motif-shuffling, exon-shuffling, and/or codon-shuffling (collectively referred to as "DNA shuffling"). DNA shuffling may be employed to modulate the activities of polypeptides of the invention, such methods can be used to generate polypeptides with altered activity, as well as agonists and antagonists of the polypeptides. See, generally, U.S. Patent Nos. 5,605,793; 5,811,238; 5,830,721; 5,834,252; and 5,837,458, and Patten et al.,

Curr. Opinion Biotechnol. 8:724-33 (1997); Harayama, Trends Biotechnol. 16(2):76-82 (1998); Hansson, et al., J. Mol. Biol. 287:265-76 (1999); and Lorenzo and Blasco, Biotechniques 24(2):308-13 (1998) (each of these patents and publications are hereby incorporated by reference in its entirety). In one embodiment, alteration of polynucleotides corresponding to SEQ ID NO:X and the polypeptides encoded by these polynucleotides may be achieved by DNA shuffling. DNA shuffling involves the assembly of two or more DNA segments by homologous or site-specific recombination to generate variation in the polynucleotide sequence. In another embodiment, polynucleotides of the invention, or the encoded polypeptides, may be altered by being subjected to random mutagenesis by errorprone PCR, random nucleotide insertion or other methods prior to recombination. In another embodiment, one or more components, motifs, sections, parts. domains, fragments, etc., of a polynucleotide encoding a polypeptide of the invention may be recombined with one or more components, motifs, sections, parts, domains, fragments, etc. of one or more heterologous molecules.

5

10

15

20

25

30

As discussed herein, any polypeptide of the present invention can be used to generate fusion proteins. For example, the polypeptide of the present invention, when fused to a second protein, can be used as an antigenic tag. Antibodies raised against the polypeptide of the present invention can be used to indirectly detect the second protein by binding to the polypeptide. Moreover, because secreted proteins target cellular locations based on trafficking signals, polypeptides of the present invention which are shown to be secreted can be used as targeting molecules once fused to other proteins.

Examples of domains that can be fused to polypeptides of the present invention include not only heterologous signal sequences, but also other heterologous functional regions. The fusion does not necessarily need to be direct, but may occur through linker sequences.

In certain preferred embodiments, proteins of the invention comprise fusion proteins wherein the polypeptides are N and/or C- terminal deletion mutants. In preferred embodiments, the application is directed to nucleic acid molecules at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to the nucleic acid sequences encoding polypeptides having the amino acid sequence of the specific N- and C-terminal deletions mutants. Polynucleotides encoding these polypeptides are also encompassed by the invention.

Moreover, fusion proteins may also be engineered to improve characteristics of the polypeptide of the present invention. For instance, a region of additional amino acids, particularly charged amino acids, may be added to the N-terminus of the polypeptide to improve stability and persistence during purification from the host cell or subsequent handling and storage. Also, peptide moieties may be added to the polypeptide to facilitate purification. Such regions may be removed prior to final preparation of the polypeptide. The addition of peptide moieties to facilitate handling of polypeptides are familiar and routine techniques in the art.

10 Vectors, Host Cells, and Protein Production

5

15

20

25

30

The present invention also relates to vectors containing the polynucleotide of the present invention, host cells, and the production of polypeptides by recombinant techniques. The vector may be, for example, a phage, plasmid, viral, or retroviral vector. Retroviral vectors may be replication competent or replication defective. In the latter case, viral propagation generally will occur only in complementing host cells.

The polynucleotides of the invention may be joined to a vector containing a selectable marker for propagation in a host. Generally, a plasmid vector is introduced in a precipitate, such as a calcium phosphate precipitate, or in a complex with a charged lipid. If the vector is a virus, it may be packaged in vitro using an appropriate packaging cell line and then transduced into host cells.

The polynucleotide insert should be operatively linked to an appropriate promoter, such as the phage lambda PL promoter, the E. coli lac, trp, phoA and tac promoters, the SV40 early and late promoters and promoters of retroviral LTRs, to name a few. Other suitable promoters will be known to the skilled artisan. The expression constructs will further contain sites for transcription initiation, termination, and, in the transcribed region, a ribosome binding site for translation. The coding portion of the transcripts expressed by the constructs will preferably include a translation initiating codon at the beginning and a termination codon (UAA, UGA or UAG) appropriately positioned at the end of the polypeptide to be translated.

As indicated, the expression vectors will preferably include at least one selectable marker. Such markers include dihydrofolate reductase, G418 or neomycin resistance for eukaryotic cell culture and tetracycline, kanamycin or ampicillin resistance genes for culturing in E. coli and other bacteria. Representative examples of appropriate hosts include,

but are not limited to, bacterial cells, such as E. coli, Streptomyces and Salmonella typhimurium cells; fungal cells, such as yeast cells (e.g., Saccharomyces cerevisiae or Pichia pastoris (ATCC Accession No. 201178)); insect cells such as Drosophila S2 and Spodoptera Sf9 cells; animal cells such as CHO, COS, 293, and Bowes melanoma cells; and plant cells. Appropriate culture mediums and conditions for the above-described host cells are known in the art.

5

10

15

20

25

30

Among vectors preferred for use in bacteria include pQE70, pQE60 and pQE-9, available from QIAGEN, Inc.; pBluescript vectors, Phagescript vectors, pNH8A, pNH16a, pNH18A, pNH46A, available from Stratagene Cloning Systems, Inc.; and ptrc99a, pKK223-3, pKK233-3, pDR540, pRIT5 available from Pharmacia Biotech, Inc. Among preferred eukaryotic vectors are pWLNEO, pSV2CAT. pOG44, pXT1 and pSG available from Stratagene; and pSVK3, pBPV, pMSG and pSVL available from Pharmacia. Preferred expression vectors for use in yeast systems include, but are not limited to pYES2, pYD1, pTEF1/Zeo, pYES2/GS, pPICZ, pGAPZ, pGAPZalph, pPIC9, pPIC3.5, pHIL-D2, pHIL-S1, pPIC3.5K, pPIC9K, and PAO815 (all available from Invitrogen, Carlbad, CA). Other suitable vectors will be readily apparent to the skilled artisan.

Introduction of the construct into the host cell can be effected by calcium phosphate transfection, DEAE-dextran mediated transfection, cationic lipid-mediated transfection, electroporation, transduction, infection, or other methods. Such methods are described in many standard laboratory manuals, such as Davis et al., Basic Methods In Molecular Biology (1986). It is specifically contemplated that the polypeptides of the present invention may in fact be expressed by a host cell lacking a recombinant vector.

A polypeptide of this invention can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. Most preferably, high performance liquid chromatography ("HPLC") is employed for purification.

Polypeptides of the present invention can also be recovered from: products purified from natural sources, including bodily fluids, tissues and cells, whether directly isolated or cultured; products of chemical synthetic procedures; and products produced by recombinant techniques from a prokaryotic or eukaryotic host, including, for example, bacterial, yeast,

10

15

20

25

30

higher plant, insect, and mammalian cells. Depending upon the host employed in a recombinant production procedure, the polypeptides of the present invention may be glycosylated or may be non-glycosylated. In addition, polypeptides of the invention may also include an initial modified methionine residue, in some cases as a result of host-mediated processes. Thus, it is well known in the art that the N-terminal methionine encoded by the translation initiation codon generally is removed with high efficiency from any protein after translation in all eukaryotic cells. While the N-terminal methionine on most proteins also is efficiently removed in most prokaryotes, for some proteins, this prokaryotic removal process is inefficient, depending on the nature of the amino acid to which the N-terminal methionine is covalently linked.

In one embodiment, the yeast *Pichia pastoris* is used to express polypeptides of the invention in a eukaryotic system. *Pichia pastoris* is a methylotrophic yeast which can metabolize methanol as its sole carbon source. A main step in the methanol metabolization pathway is the oxidation of methanol to formaldehyde using O₂. This reaction is catalyzed by the enzyme alcohol oxidase. In order to metabolize methanol as its sole carbon source, *Pichia pastoris* must generate high levels of alcohol oxidase due, in part, to the relatively low affinity of alcohol oxidase for O₂. Consequently, in a growth medium depending on methanol as a main carbon source, the promoter region of one of the two alcohol oxidase genes (*AOXI*) is highly active. In the presence of methanol, alcohol oxidase produced from the *AOXI* gene comprises up to approximately 30% of the total soluble protein in *Pichia pastoris*. See, Ellis, S.B., et al., Mol. Cell. Biol. 5:1111-21 (1985); Koutz, P.J, et al., Yeast 5:167-77 (1989); Tschopp, J.F., et al., Nucl. Acids Res. 15:3859-76 (1987). Thus, a heterologous coding sequence, such as, for example, a polynucleotide of the present invention, under the transcriptional regulation of all or part of the *AOXI* regulatory sequence is expressed at exceptionally high levels in *Pichia* yeast grown in the presence of methanol.

In one example, the plasmid vector pPIC9K is used to express DNA encoding a polypeptide of the invention, as set forth herein, in a *Pichea* yeast system essentially as described in "*Pichia* Protocols: Methods in Molecular Biology," D.R. Higgins and J. Cregg, eds. The Humana Press. Totowa, NJ, 1998. This expression vector allows expression and secretion of a polypeptide of the invention by virtue of the strong *AOX1* promoter linked to

the *Pichia pastoris* alkaline phosphatase (PHO) secretory signal peptide (i.e., leader) located upstream of a multiple cloning site.

Many other yeast vectors could be used in place of pPIC9K, such as, pYES2. pYD1, pTEF1/Zeo. pYES2/GS, pPICZ, pGAPZ, pGAPZalpha, pPIC9, pPIC3.5, pHIL-D2, pHIL-S1, pPIC3.5K, and PAO815. as one skilled in the art would readily appreciate, as long as the proposed expression construct provides appropriately located signals for transcription, translation, secretion (if desired), and the like, including an in-frame AUG as required.

5

10

15

20

25

30

In another embodiment, high-level expression of a heterologous coding sequence, such as, for example, a polynucleotide of the present invention, may be achieved by cloning the heterologous polynucleotide of the invention into an expression vector such as, for example, pGAPZ or pGAPZalpha, and growing the yeast culture in the absence of methanol.

In addition to encompassing host cells containing the vector constructs discussed herein, the invention also encompasses primary, secondary, and immortalized host cells of vertebrate origin. particularly mammalian origin, that have been engineered to delete or replace endogenous genetic material (e.g., coding sequence), and/or to include genetic material (e.g., heterologous polynucleotide sequences) that is operably associated with polynucleotides of the invention, and which activates, alters, and/or amplifies endogenous polynucleotides. For example, techniques known in the art may be used to operably associate heterologous control regions (e.g., promoter and/or enhancer) and endogenous polynucleotide sequences via homologous recombination (see, e.g., U.S. Patent No. 5,641,670, issued June 24, 1997; International Publication No. WO 96/29411, published September 26, 1996; International Publication No. WO 94/12650, published August 4, 1994; Koller et al., Proc. Natl. Acad. Sci. USA 86:8932-8935 (1989); and Zijlstra et al., Nature 342:435-438 (1989), the disclosures of each of which are incorporated by reference in their entireties).

In addition, polypeptides of the invention can be chemically synthesized using techniques known in the art (e.g., see Creighton, 1983, Proteins: Structures and Molecular Principles, W.H. Freeman & Co., N.Y., and Hunkapiller et al., *Nature*, 310:105-111 (1984)). For example, a polypeptide corresponding to a fragment of a polypeptide can be synthesized by use of a peptide synthesizer. Furthermore, if desired, nonclassical amino acids or chemical amino acid analogs can be introduced as a substitution or addition into the

5

10

15

20

25

30

polypeptide sequence. Non-classical amino acids include, but are not limited to, to the D-isomers of the common amino acids, 2,4-diaminobutyric acid, a-amino isobutyric acid, 4-aminobutyric acid, Abu, 2-amino butyric acid, g-Abu, e-Ahx, 6-amino hexanoic acid, Aib, 2-amino isobutyric acid, 3-amino propionic acid, ornithine, norleucine, norvaline, hydroxyproline, sarcosine, citrulline, homocitrulline, cysteic acid, t-butylglycine, t-butylalanine, phenylglycine, cyclohexylalanine, b-alanine, fluoro-amino acids, designer amino acids such as b-methyl amino acids, Ca-methyl amino acids, Na-methyl amino acids, and amino acid analogs in general. Furthermore, the amino acid can be D (dextrorotary) or L (levorotary).

Non-naturally occurring variants may be produced using art-known mutagenesis techniques, which include, but are not limited to oligonucleotide mediated mutagenesis, alanine scanning, PCR mutagenesis, site directed mutagenesis (see, e.g., Carter et al., Nucl. Acids Res. 13:4331 (1986); and Zoller et al., Nucl. Acids Res. 10:6487 (1982)), cassette mutagenesis (see, e.g., Wells et al., Gene 34:315 (1985)), restriction selection mutagenesis (see, e.g., Wells et al., Philos. Trans. R. Soc. London SerA 317:415 (1986)).

The invention additionally, encompasses polypeptides of the present invention which are differentially modified during or after translation, e.g., by glycosylation, acetylation, phosphorylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, linkage to an antibody molecule or other cellular ligand, etc. Any of numerous chemical modifications may be carried out by known techniques, including but not limited, to specific chemical cleavage by cyanogen bromide, trypsin, chymotrypsin, papain, V8 protease, NaBH₄; acetylation, formylation, oxidation, reduction; metabolic synthesis in the presence of tunicamycin; etc.

Additional post-translational modifications encompassed by the invention include, for example, e.g., N-linked or O-linked carbohydrate chains, processing of N-terminal or C-terminal ends), attachment of chemical moieties to the amino acid backbone, chemical modifications of N-linked or O-linked carbohydrate chains, and addition or deletion of an N-terminal methionine residue as a result of procaryotic host cell expression. The polypeptides may also be modified with a detectable label, such as an enzymatic, fluorescent, isotopic or affinity label to allow for detection and isolation of the protein.

Also provided by the invention are chemically modified derivatives of the polypeptides of the invention which may provide additional advantages such as increased

10

15

20

25

30

solubility, stability and circulating time of the polypeptide, or decreased immunogenicity (see U.S. Patent No. 4,179,337). The chemical moieties for derivitization may be selected from water soluble polymers such as polyethylene glycol, ethylene glycol/propylene glycol copolymers, carboxymethylcellulose, dextran, polyvinyl alcohol and the like. The polypeptides may be modified at random positions within the molecule, or at predetermined positions within the molecule and may include one, two, three or more attached chemical moieties.

The polymer may be of any molecular weight, and may be branched or unbranched. For polyethylene glycol, the preferred molecular weight is between about 1 kDa and about 100 kDa (the term "about" indicating that in preparations of polyethylene glycol, some molecules will weigh more, some less, than the stated molecular weight) for ease in handling and manufacturing. Other sizes may be used, depending on the desired therapeutic profile (e.g., the duration of sustained release desired, the effects, if any on biological activity, the ease in handling, the degree or lack of antigenicity and other known effects of the polyethylene glycol to a therapeutic protein or analog). For example, the polyethylene glycol may have an average molecular weight of about 200; 500; 1000; 1500; 2000; 2500; 3000; 3500; 4000; 4500; 5000; 5500; 6000; 6500; 7000; 7500; 8000; 8500; 9000; 9500; 10,000; 10,500; 11,000; 11,500; 12,000; 12,500; 13,000; 13,500; 14,000; 14,500; 15,000; 15,500; 16,000; 16,500; 17,000; 17,500; 18,000; 18,500; 19,000; 19,500; 20,000; 25,000; 30,000; 35,000; 40,000; 50,000; 55,000; 60,000; 65,000; 70,000; 75,000; 80,000; 85,000; 90,000; 95,000; or 100,000 kDa.

As noted above, the polyethylene glycol may have a branched structure. Branched polyethylene glycols are described, for example, in U.S. Patent No. 5,643,575; Morpurgo et al., Appl. Biochem. Biotechnol. 56:59-72 (1996); Vorobjev et al., Nucleosides Nucleotides 18:2745-2750 (1999); and Caliceti et al., Bioconjug. Chem. 10:638-646 (1999), the disclosures of each of which are incorporated herein by reference.

The polyethylene glycol molecules (or other chemical moieties) should be attached to the protein with consideration of effects on functional or antigenic domains of the protein. There are a number of attachment methods available to those skilled in the art, e.g., EP 0 401 384, herein incorporated by reference (coupling PEG to G-CSF), see also Malik et al., Exp. Hematol. 20:1028-1035 (1992) (reporting pegylation of GM-CSF using tresyl chloride). For example, polyethylene glycol may be covalently bound through amino acid residues via a

5

10

15

20

25

30

reactive group, such as, a free amino or carboxyl group. Reactive groups are those to which an activated polyethylene glycol molecule may be bound. The amino acid residues having a free amino group may include lysine residues and the N-terminal amino acid residues: those having a free carboxyl group may include aspartic acid residues glutamic acid residues and the C-terminal amino acid residue. Sulfhydryl groups may also be used as a reactive group for attaching the polyethylene glycol molecules. Preferred for therapeutic purposes is attachment at an amino group, such as attachment at the N-terminus or lysine group.

As suggested above, polyethylene glycol may be attached to proteins via linkage to any of a number of amino acid residues. For example, polyethylene glycol can be linked to a proteins via covalent bonds to lysine, histidine, aspartic acid, glutamic acid, or cysteine residues. One or more reaction chemistries may be employed to attach polyethylene glycol to specific amino acid residues (e.g., lysine, histidine, aspartic acid, glutamic acid, or cysteine) of the protein or to more than one type of amino acid residue (e.g., lysine, histidine, aspartic acid, glutamic acid, cysteine and combinations thereof) of the protein.

One may specifically desire proteins chemically modified at the N-terminus. Using polyethylene glycol as an illustration of the present composition, one may select from a variety of polyethylene glycol molecules (by molecular weight, branching, etc.), the proportion of polyethylene glycol molecules to protein (polypeptide) molecules in the reaction mix, the type of pegylation reaction to be performed, and the method of obtaining the selected N-terminally pegylated protein. The method of obtaining the N-terminally pegylated preparation (i.e., separating this moiety from other monopegylated moieties if necessary) may be by purification of the N-terminally pegylated material from a population of pegylated protein molecules. Selective proteins chemically modified at the N-terminus modification may be accomplished by reductive alkylation which exploits differential reactivity of different types of primary amino groups (lysine versus the N-terminal) available for derivatization in a particular protein. Under the appropriate reaction conditions, substantially selective derivatization of the protein at the N-terminus with a carbonyl group containing polymer is achieved.

As indicated above, pegylation of the proteins of the invention may be accomplished by any number of means. For example, polyethylene glycol may be attached to the protein either directly or by an intervening linker. Linkerless systems for attaching polyethylene glycol to proteins are described in Delgado et al., Crit. Rev. Thera. Drug Carrier Sys. 9:249-

10

15

20

25

30

304 (1992); Francis et al., Intern. J. of Hematol. 68:1-18 (1998); U.S. Patent No. 4,002,531; U.S. Patent No. 5,349,052; WO 95/06058; and WO 98/32466, the disclosures of each of which are incorporated herein by reference.

One system for attaching polyethylene glycol directly to amino acid residues of proteins without an intervening linker employs tresylated MPEG, which is produced by the modification of monmethoxy polyethylene glycol (MPEG) using tresylchloride (ClSO₂CH₂CF₃). Upon reaction of protein with tresylated MPEG, polyethylene glycol is directly attached to amine groups of the protein. Thus, the invention includes protein-polyethylene glycol conjugates produced by reacting proteins of the invention with a polyethylene glycol molecule having a 2,2,2-trifluoreothane sulphonyl group.

Polyethylene glycol can also be attached to proteins using a number of different intervening linkers. For example, U.S. Patent No. 5,612,460, the entire disclosure of which is incorporated herein by reference, discloses urethane linkers for connecting polyethylene glycol to proteins. Protein-polyethylene glycol conjugates wherein the polyethylene glycol is attached to the protein by a linker can also be produced by reaction of proteins with compounds such as MPEG-succinimidylsuccinate, MPEG activated with 1,1'-carbonyldimidazole, MPEG-2,4,5-trichloropenylcarbonate, MPEG-pnitrophenolcarbonate, and various MPEG-succinate derivatives. A number additional polyethylene glycol derivatives and reaction chemistries for attaching polyethylene glycol to proteins are described in WO 98/32466, the entire disclosure of which is incorporated herein by reference. Pegylated protein products produced using the reaction chemistries set out herein are included within the scope of the invention.

The number of polyethylene glycol moieties attached to each protein of the invention (i.e., the degree of substitution) may also vary. For example, the pegylated proteins of the invention may be linked, on average, to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 15, 17, 20, or more polyethylene glycol molecules. Similarly, the average degree of substitution within ranges such as 1-3, 2-4, 3-5, 4-6, 5-7, 6-8, 7-9, 8-10, 9-11, 10-12, 11-13, 12-14, 13-15, 14-16, 15-17, 16-18, 17-19, or 18-20 polyethylene glycol moieties per protein molecule. Methods for determining the degree of substitution are discussed, for example, in Delgado et al., Crit. Rev. Thera. Drug Carrier Sys. 9:249-304 (1992).

The colon cancer antigen polypeptides of the invention may be in monomers or multimers (i.e., dimers, trimers, tetramers and higher multimers). Accordingly, the present

5

10

15

20

25

30

181

PCT/US00/05883

invention relates to monomers and multimers of the polypeptides of the invention, their preparation, and compositions (preferably, Therapeutics) containing them. In specific embodiments, the polypeptides of the invention are monomers, dimers, trimers or tetramers. In additional embodiments, the multimers of the invention are at least dimers, at least trimers, or at least tetramers.

Multimers encompassed by the invention may be homomers or heteromers. As used herein, the term homomer, refers to a multimer containing only polypeptides corresponding to the amino acid sequence of SEQ ID NO:Y or an amino acid sequence encoded by SEQ ID NO:X, and/or an amino acid sequence encoded by the cDNA in a related cDNA clone contained in a deposited library (including fragments, variants, splice variants, and fusion proteins, corresponding to any one of these as described herein). These homomers may contain polypeptides having identical or different amino acid sequences. In a specific embodiment, a homomer of the invention is a multimer containing only polypeptides having an identical amino acid sequence. In another specific embodiment, a homomer of the invention is a multimer containing polypeptides having different amino acid sequences. In specific embodiments, the multimer of the invention is a homodimer (e.g., containing polypeptides having identical or different amino acid sequences) or a homotrimer (e.g., containing polypeptides having identical and/or different amino acid sequences). In additional embodiments, the homomeric multimer of the invention is at least a homodimer, at least a homotrimer, or at least a homotetramer.

As used herein, the term heteromer refers to a multimer containing one or more heterologous polypeptides (i.e., polypeptides of different proteins) in addition to the polypeptides of the invention. In a specific embodiment, the multimer of the invention is a heterodimer, a heterotrimer, or a heterotetramer. In additional embodiments, the heteromeric multimer of the invention is at least a heterodimer, at least a heterotrimer, or at least a heterotetramer.

Multimers of the invention may be the result of hydrophobic, hydrophilic, ionic and/or covalent associations and/or may be indirectly linked, by for example, liposome formation. Thus, in one embodiment, multimers of the invention, such as, for example, homodimers or homotrimers, are formed when polypeptides of the invention contact one another in solution. In another embodiment, heteromultimers of the invention, such as, for example, heterotrimers or heterotetramers, are formed when polypeptides of the invention

5

10

15

20

25

30

contact antibodies to the polypeptides of the invention (including antibodies to the heterologous polypeptide sequence in a fusion protein of the invention) in solution. In other embodiments, multimers of the invention are formed by covalent associations with and/or between the polypeptides of the invention. Such covalent associations may involve one or more amino acid residues contained in the polypeptide sequence (e.g., that recited in SEO ID NO:Y, or contained in a polypeptide encoded by SEQ ID NO:X, and/or by the cDNA in the related cDNA clone contained in a deposited library). In one instance, the covalent associations are cross-linking between cysteine residues located within the polypeptide sequences which interact in the native (i.e., naturally occurring) polypeptide. In another instance, the covalent associations are the consequence of chemical or recombinant manipulation. Alternatively, such covalent associations may involve one or more amino acid residues contained in the heterologous polypeptide sequence in a fusion protein. In one example, covalent associations are between the heterologous sequence contained in a fusion protein of the invention (see, e.g., US Patent Number 5,478,925). In a specific example, the covalent associations are between the heterologous sequence contained in a Fc fusion protein of the invention (as described herein). In another specific example, covalent associations of fusion proteins of the invention are between heterologous polypeptide sequence from another protein that is capable of forming covalently associated multimers, such as for example, oseteoprotegerin (see, e.g., International Publication NO: WO 98/49305, the contents of which are herein incorporated by reference in its entirety). In another embodiment, two or more polypeptides of the invention are joined through peptide linkers. Examples include those peptide linkers described in U.S. Pat. No. 5,073,627 (hereby incorporated by reference). Proteins comprising multiple polypeptides of the invention separated by peptide linkers may be produced using conventional recombinant DNA technology.

Another method for preparing multimer polypeptides of the invention involves use of polypeptides of the invention fused to a leucine zipper or isoleucine zipper polypeptide sequence. Leucine zipper and isoleucine zipper domains are polypeptides that promote multimerization of the proteins in which they are found. Leucine zippers were originally identified in several DNA-binding proteins (Landschulz et al., Science 240:1759, (1988)), and have since been found in a variety of different proteins. Among the known leucine zippers are naturally occurring peptides and derivatives thereof that dimerize or trimerize. Examples of leucine zipper domains suitable for producing soluble multimeric proteins of the

5

10

15

20

25

30

PCT/US00/05883

invention are those described in PCT application WO 94/10308, hereby incorporated by reference. Recombinant fusion proteins comprising a polypeptide of the invention fused to a polypeptide sequence that dimerizes or trimerizes in solution are expressed in suitable host cells, and the resulting soluble multimeric fusion protein is recovered from the culture supernatant using techniques known in the art.

183

Trimeric polypeptides of the invention may offer the advantage of enhanced biological activity. Preferred leucine zipper moieties and isoleucine moieties are those that preferentially form trimers. One example is a leucine zipper derived from lung surfactant protein D (SPD), as described in Hoppe et al. (FEBS Letters 344:191, (1994)) and in U.S. patent application Ser. No. 08/446,922, hereby incorporated by reference. Other peptides derived from naturally occurring trimeric proteins may be employed in preparing trimeric polypeptides of the invention.

In another example, proteins of the invention are associated by interactions between Flag® polypeptide sequence contained in fusion proteins of the invention containing Flag® polypeptide sequence. In a further embodiment, associations proteins of the invention are associated by interactions between heterologous polypeptide sequence contained in Flag® fusion proteins of the invention and anti-Flag® antibody.

The multimers of the invention may be generated using chemical techniques known in the art. For example, polypeptides desired to be contained in the multimers of the invention may be chemically cross-linked using linker molecules and linker molecule length optimization techniques known in the art (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety). Additionally, multimers of the invention may be generated using techniques known in the art to form one or more inter-molecule cross-links between the cysteine residues located within the sequence of the polypeptides desired to be contained in the multimer (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety). Further, polypeptides of the invention may be routinely modified by the addition of cysteine or biotin to the C-terminus or N-terminus of the polypeptide and techniques known in the art may be applied to generate multimers containing one or more of these modified polypeptides (see, e.g., US Patent Number 5.478.925, which is herein incorporated by reference in its entirety). Additionally, techniques known in the art may be applied to generate liposomes containing the polypeptide

components desired to be contained in the multimer of the invention (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety).

Alternatively, multimers of the invention may be generated using genetic engineering techniques known in the art. In one embodiment, polypeptides contained in multimers of the invention are produced recombinantly using fusion protein technology described herein or otherwise known in the art (see. e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety). In a specific embodiment, polynucleotides coding for a homodimer of the invention are generated by ligating a polynucleotide sequence encoding a polypeptide of the invention to a sequence encoding a linker polypeptide and then further to a synthetic polynucleotide encoding the translated product of the polypeptide in the reverse orientation from the original C-terminus to the N-terminus (lacking the leader sequence) (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety). In another embodiment, recombinant techniques described herein or otherwise known in the art are applied to generate recombinant polypeptides of the invention which contain a transmembrane domain (or hyrophobic or signal peptide) and which can be incorporated by membrane reconstitution techniques into liposomes (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety).

Antibodies

5

10

15

20

25

30

Further polypeptides of the invention relate to antibodies and T-cell antigen receptors (TCR) which immunospecifically bind a polypeptide, polypeptide fragment, or variant of SEQ ID NO:Y, and/or an epitope, of the present invention (as determined by immunoassays well known in the art for assaying specific antibody-antigen binding). Antibodies of the invention include, but are not limited to, polyclonal, monoclonal, multispecific, human, humanized or chimeric antibodies, single chain antibodies, Fab fragments, F(ab') fragments, fragments produced by a Fab expression library, anti-idiotypic (anti-Id) antibodies (including, e.g., anti-Id antibodies to antibodies of the invention), and epitope-binding fragments of any of the above. The term "antibody," as used herein, refers to immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, i.e., molecules that contain an antigen binding site that immunospecifically binds an antigen. The immunoglobulin molecules of the invention can be of any type (e.g., IgG,

10

15

20

25

30

IgE, IgM, IgD, IgA and IgY), class (e.g., IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2) or subclass of immunoglobulin molecule.

Most preferably the antibodies are human antigen-binding antibody fragments of the present invention and include, but are not limited to, Fab, Fab' and F(ab')2, Fd, single-chain Fvs (scFv), single-chain antibodies, disulfide-linked Fvs (sdFv) and fragments comprising either a VL or VH domain. Antigen-binding antibody fragments, including single-chain antibodies, may comprise the variable region(s) alone or in combination with the entirety or a portion of the following: hinge region, CH1, CH2, and CH3 domains. Also included in the invention are antigen-binding fragments also comprising any combination of variable region(s) with a hinge region, CH1, CH2, and CH3 domains. The antibodies of the invention may be from any animal origin including birds and mammals. Preferably, the antibodies are human, murine (e.g., mouse and rat), donkey, ship rabbit, goat, guinea pig, camel, horse, or chicken. As used herein, "human" antibodies include antibodies having the amino acid sequence of a human immunoglobulin and include antibodies isolated from human immunoglobulin libraries or from animals transgenic for one or more human immunoglobulin and that do not express endogenous immunoglobulins, as described infra and, for example in, U.S. Patent No. 5,939,598 by Kucherlapati et al.

The antibodies of the present invention may be monospecific, bispecific, trispecific or of greater multispecificity. Multispecific antibodies may be specific for different epitopes of a polypeptide of the present invention or may be specific for both a polypeptide of the present invention as well as for a heterologous epitope, such as a heterologous polypeptide or solid support material. See, e.g., PCT publications WO 93/17715; WO 92/08802; WO 91/00360; WO 92/05793; Tutt, et al., J. Immunol. 147:60-69 (1991); U.S. Patent Nos. 4,474,893; 4,714,681: 4,925,648; 5,573,920; 5,601,819; Kostelny et al., J. Immunol. 148:1547-1553 (1992).

Antibodies of the present invention may be described or specified in terms of the epitope(s) or portion(s) of a polypeptide of the present invention which they recognize or specifically bind. The epitope(s) or polypeptide portion(s) may be specified as described herein, e.g., by N-terminal and C-terminal positions, or by size in contiguous amino acid residues. Antibodies which specifically bind any epitope or polypeptide of the present invention may also be excluded. Therefore, the present invention includes antibodies that

10

15

20

25

30

specifically bind polypeptides of the present invention, and allows for the exclusion of the same.

Antibodies of the present invention may also be described or specified in terms of their cross-reactivity. Antibodies that do not bind any other analog, ortholog, or homolog of a polypeptide of the present invention are included. Antibodies that bind polypeptides with at least 95%, at least 90%, at least 85%, at least 80%, at least 75%, at least 70%, at least 65%, at least 60%, at least 55%, and at least 50% identity (as calculated using methods known in the art and described herein) to a polypeptide of the present invention are also included in the present invention. In specific embodiments, antibodies of the present invention cross-react with murine, rat and/or rabbit homologs of human proteins and the corresponding epitopes thereof. Antibodies that do not bind polypeptides with less than 95%, less than 90%, less than 85%, less than 80%, less than 75%, less than 70%, less than 65%, less than 60%, less than 55%, and less than 50% identity (as calculated using methods known in the art and described herein) to a polypeptide of the present invention are also included in the present invention. In a specific embodiment, the above-described cross-reactivity is with respect to any single specific antigenic or immunogenic polypeptide, or combination(s) of 2, 3, 4, 5, or more of the specific antigenic and/or immunogenic polypeptides disclosed herein. Further included in the present invention are antibodies which bind polypeptides encoded by polynucleotides which hybridize to a polynucleotide of the present invention under stringent hybridization conditions (as described herein). Antibodies of the present invention may also be described or specified in terms of their binding affinity to a polypeptide of the invention. Preferred binding affinities include those with a dissociation constant or Kd less than 5 X 10⁻² M, 10⁻² M, 5 X 10^{-3} M, 10^{-3} M, 5 X 10^{-4} M, 10^{-4} M, 5 X 10^{-5} M, 10^{-5} M, 5 X 10^{-6} M, 10^{-6} M, 5 X 10^{-7} $M, 10^7 M, 5 \times 10^{-8} M, 10^{-8} M, 5 \times 10^{-9} M, 10^{-9} M, 5 \times 10^{-10} M, 10^{-10} M, 5 \times 10^{-11} M, 10^{-11}$ M, 5 X 10^{-12} M, $^{10-12}$ M, 5 X 10^{-13} M, 10^{-13} M, 5 X 10^{-14} M, 10^{-14} M, 5 X 10^{-15} M, or $^{10-15}$ M.

The invention also provides antibodies that competitively inhibit binding of an antibody to an epitope of the invention as determined by any method known in the art for determining competitive binding, for example, the immunoassays described herein. In preferred embodiments, the antibody competitively inhibits binding to the epitope by at least 95%, at least 90%, at least 85 %, at least 80%, at least 75%, at least 70%, at least 60%, or at least 50%.

5

10

15

20

25

30

Antibodies of the present invention may act as agonists or antagonists of the polypeptides of the present invention. For example, the present invention includes antibodies which disrupt the receptor/ligand interactions with the polypeptides of the invention either partially or fully. Preferrably, antibodies of the present invention bind an antigenic epitope disclosed herein, or a portion thereof. The invention features both receptor-specific antibodies and ligand-specific antibodies. The invention also features receptor-specific antibodies which do not prevent ligand binding but prevent receptor activation. Receptor activation (i.e., signaling) may be determined by techniques described herein or otherwise known in the art. For example, receptor activation can be determined by detecting the phosphorylation (e.g., tyrosine or serine/threonine) of the receptor or its substrate by immunoprecipitation followed by western blot analysis (for example, as described supra). In specific embodiments, antibodies are provided that inhibit ligand activity or receptor activity by at least 95%, at least 90%, at least 85%, at least 80%, at least 75%, at least 70%, at least 60%, or at least 50% of the activity in absence of the antibody.

The invention also features receptor-specific antibodies which both prevent ligand binding and receptor activation as well as antibodies that recognize the receptor-ligand complex. and, preferably, do not specifically recognize the unbound receptor or the unbound ligand. Likewise, included in the invention are neutralizing antibodies which bind the ligand and prevent binding of the ligand to the receptor, as well as antibodies which bind the ligand. thereby preventing receptor activation, but do not prevent the ligand from binding the receptor. Further included in the invention are antibodies which activate the receptor. These antibodies may act as receptor agonists, i.e., potentiate or activate either all or a subset of the biological activities of the ligand-mediated receptor activation, for example, by inducing dimerization of the receptor. The antibodies may be specified as agonists, antagonists or inverse agonists for biological activities comprising the specific biological activities of the peptides of the invention disclosed herein. The above antibody agonists can be made using methods known in the art. See, e.g., PCT publication WO 96/40281; U.S. Patent No. 5,811,097; Deng et al., Blood 92(6):1981-1988 (1998); Chen et al., Cancer Res. 58(16):3668-3678 (1998); Harrop et al., J. Immunol. 161(4):1786-1794 (1998); Zhu et al., Cancer Res. 58(15):3209-3214 (1998); Yoon et al., J. Immunol. 160(7):3170-3179 (1998); Prat et al., J. Cell. Sci. 111(Pt2):237-247 (1998); Pitard et al., J. Immunol. Methods 205(2):177-190 (1997); Liautard et al., Cytokine 9(4):233-241 (1997); Carlson et al., J. Biol.

10

15

20

25

30

Chem. 272(17):11295-11301 (1997); Taryman et al., Neuron 14(4):755-762 (1995); Muller et al., Structure 6(9):1153-1167 (1998); Bartunek et al., Cytokine 8(1):14-20 (1996) (which are all incorporated by reference herein in their entireties).

Antibodies of the present invention may be used, for example, but not limited to, to purify, detect, and target the polypeptides of the present invention, including both in vitro and in vivo diagnostic and therapeutic methods. For example, the antibodies have use in immunoassays for qualitatively and quantitatively measuring levels of the polypeptides of the present invention in biological samples. See, e.g., Harlow et al., Antibodies: A Laboratory Manual. (Cold Spring Harbor Laboratory Press, 2nd ed. 1988) (incorporated by reference herein in its entirety).

As discussed in more detail below, the antibodies of the present invention may be used either alone or in combination with other compositions. The antibodies may further be recombinantly fused to a heterologous polypeptide at the N- or C-terminus or chemically conjugated (including covalently and non-covalently conjugations) to polypeptides or other compositions. For example, antibodies of the present invention may be recombinantly fused or conjugated to molecules useful as labels in detection assays and effector molecules such as heterologous polypeptides, drugs, radionuclides, or toxins. See, e.g., PCT publications WO 92/08495; WO 91/14438; WO 89/12624; U.S. Patent No. 5,314,995; and EP 396,387.

The antibodies of the invention include derivatives that are modified, i.e, by the covalent attachment of any type of molecule to the antibody such that covalent attachment does not prevent the antibody from generating an anti-idiotypic response. For example, but not by way of limitation, the antibody derivatives include antibodies that have been modified, e.g., by glycosylation, acetylation, pegylation, phosphylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, linkage to a cellular ligand or other protein, etc. Any of numerous chemical modifications may be carried out by known techniques, including, but not limited to specific chemical cleavage, acetylation, formylation, metabolic synthesis of tunicamycin, etc. Additionally, the derivative may contain one or more non-classical amino acids.

The antibodies of the present invention may be generated by any suitable method known in the art. Polyclonal antibodies to an antigen-of- interest can be produced by various procedures well known in the art. For example, a polypeptide of the invention can be administered to various host animals including, but not limited to, rabbits, mice, rats, etc. to

induce the production of sera containing polyclonal antibodies specific for the antigen. Various adjuvants may be used to increase the immunological response, depending on the host species, and include but are not limited to, Freund's (complete and incomplete), mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanins, dinitrophenol, and potentially useful human adjuvants such as BCG (bacille Calmette-Guerin) and corynebacterium parvum. Such adjuvants are also well known in the art.

5

10

15

20

25

30

Monoclonal antibodies can be prepared using a wide variety of techniques known in the art including the use of hybridoma, recombinant, and phage display technologies, or a combination thereof. For example, monoclonal antibodies can be produced using hybridoma techniques including those known in the art and taught, for example, in Harlow et al., Antibodies: A Laboratory Manual. (Cold Spring Harbor Laboratory Press, 2nd ed. 1988); Hammerling, et al., in: Monoclonal Antibodies and T-Cell Hybridomas 563-681 (Elsevier, N.Y., 1981) (said references incorporated by reference in their entireties). The term "monoclonal antibody" as used herein is not limited to antibodies produced through hybridoma technology. The term "monoclonal antibody" refers to an antibody that is derived from a single clone, including any eukaryotic, prokaryotic, or phage clone, and not the method by which it is produced.

Methods for producing and screening for specific antibodies using hybridoma technology are routine and well known in the art and are discussed in detail in the Examples. In a non-limiting example, mice can be immunized with a polypeptide of the invention or a cell expressing such peptide. Once an immune response is detected, e.g., antibodies specific for the antigen are detected in the mouse serum, the mouse spleen is harvested and splenocytes isolated. The splenocytes are then fused by well known techniques to any suitable myeloma cells, for example cells from cell line SP20 available from the ATCC. Hybridomas are selected and cloned by limited dilution. The hybridoma clones are then assayed by methods known in the art for cells that secrete antibodies capable of binding a polypeptide of the invention. Ascites fluid, which generally contains high levels of antibodies, can be generated by immunizing mice with positive hybridoma clones.

Accordingly, the present invention provides methods of generating monoclonal antibodies as well as antibodies produced by the method comprising culturing a hybridoma cell secreting an antibody of the invention wherein, preferably, the hybridoma is generated by

WO 00/55351 PCT/US00/05883

5

10

15

20

25

30

190

fusing splenocytes isolated from a mouse immunized with an antigen of the invention with myeloma cells and then screening the hybridomas resulting from the fusion for hybridoma clones that secrete an antibody able to bind a polypeptide of the invention.

Antibody fragments which recognize specific epitopes may be generated by known techniques. For example, Fab and F(ab')2 fragments of the invention may be produced by proteolytic cleavage of immunoglobulin molecules, using enzymes such as papain (to produce Fab fragments) or pepsin (to produce F(ab')2 fragments). F(ab')2 fragments contain the variable region, the light chain constant region and the CH1 domain of the heavy chain.

For example, the antibodies of the present invention can also be generated using various phage display methods known in the art. In phage display methods, functional antibody domains are displayed on the surface of phage particles which carry the polynucleotide sequences encoding them. In a particular embodiment, such phage can be utilized to display antigen binding domains expressed from a repertoire or combinatorial antibody library (e.g., human or murine). Phage expressing an antigen binding domain that binds the antigen of interest can be selected or identified with antigen, e.g., using labeled antigen or antigen bound or captured to a solid surface or bead. Phage used in these methods are typically filamentous phage including fd and M13 binding domains expressed from phage with Fab, Fv or disulfide stabilized Fv antibody domains recombinantly fused to either the phage gene III or gene VIII protein. Examples of phage display methods that can be used to make the antibodies of the present invention include those disclosed in Brinkman et al., J. Immunol. Methods 182:41-50 (1995); Ames et al., J. Immunol. Methods 184:177-186 (1995); Kettleborough et al., Eur. J. lmmunol. 24:952-958 (1994); Persic et al., Gene 187 9-18 (1997); Burton et al., Advances in Immunology 57:191-280 (1994); PCT application No. PCT/GB91/01134; PCT publications WO 90/02809; WO 91/10737; WO 92/01047; WO 92/18619; WO 93/11236; WO 95/15982; WO 95/20401; and U.S. Patent Nos. 5,698,426; 5,223,409; 5,403,484; 5,580,717; 5,427,908; 5,750,753; 5,821,047; 5,571,698; 5,427,908; 5,516,637; 5,780,225; 5,658,727; 5,733,743 and 5,969,108; each of which is incorporated herein by reference in its entirety.

As described in the above references, after phage selection, the antibody coding regions from the phage can be isolated and used to generate whole antibodies, including human antibodies, or any other desired antigen binding fragment, and expressed in any desired host, including mammalian cells, insect cells, plant cells, yeast, and bacteria, e.g., as

5

10

15

20

25

30

described in detail below. For example, techniques to recombinantly produce Fab. Fab' and F(ab')2 fragments can also be employed using methods known in the art such as those disclosed in PCT publication WO 92/22324; Mullinax et al., BioTechniques 12(6):864-869 (1992); and Sawai et al., AJRI 34:26-34 (1995); and Better et al., Science 240:1041-1043 (1988) (said references incorporated by reference in their entireties).

Examples of techniques which can be used to produce single-chain Fvs and antibodies include those described in U.S. Patents 4,946,778 and 5,258,498; Huston et al., Methods in Enzymology 203:46-88 (1991); Shu et al., PNAS 90:7995-7999 (1993); and Skerra et al., Science 240:1038-1040 (1988). For some uses, including in vivo use of antibodies in humans and in vitro detection assays, it may be preferable to use chimeric, humanized, or human antibodies. A chimeric antibody is a molecule in which different portions of the antibody are derived from different animal species, such as antibodies having a variable region derived from a murine monoclonal antibody and a human immunoglobulin constant region. Methods for producing chimeric antibodies are known in the art. See e.g., Morrison, Science 229:1202 (1985); Oi et al., BioTechniques 4:214 (1986); Gillies et al., (1989) J. Immunol. Methods 125:191-202; U.S. Patent Nos. 5,807,715; 4,816,567; and 4,816397, which are incorporated herein by reference in their entirety. Humanized antibodies are antibody molecules from non-human species antibody that binds the desired antigen having one or more complementarity determining regions (CDRs) from the non-human species and a framework regions from a human immunoglobulin molecule. Often, framework residues in the human framework regions will be substituted with the corresponding residue from the CDR donor antibody to alter, preferably improve, antigen binding. These framework substitutions are identified by methods well known in the art, e.g., by modeling of the interactions of the CDR and framework residues to identify framework residues important for antigen binding and sequence comparison to identify unusual framework residues at particular positions. (See, e.g., Queen et al., U.S. Patent No. 5,585,089; Riechmann et al., Nature 332:323 (1988), which are incorporated herein by reference in their entireties.) Antibodies can be humanized using a variety of techniques known in the art including, for example, CDR-grafting (EP 239,400; PCT publication WO 91/09967; U.S. Patent Nos. 5.225.539; 5,530,101; and 5,585.089), veneering or resurfacing (EP 592,106; EP 519,596; Padlan, Molecular Immunology 28(4/5):489-498 (1991); Studnicka et al., Protein

10

15

20

25

30

Engineering 7(6):805-814 (1994); Roguska. et al., PNAS 91:969-973 (1994)), and chain shuffling (U.S. Patent No. 5,565,332).

Completely human antibodies are particularly desirable for therapeutic treatment of human patients. Human antibodies can be made by a variety of methods known in the art including phage display methods described above using antibody libraries derived from human immunoglobulin sequences. See also, U.S. Patent Nos. 4,444,887 and 4,716,111; and PCT publications WO 98/46645, WO 98/50433, WO 98/24893, WO 98/16654, WO 96/34096. WO 96/33735, and WO 91/10741: each of which is incorporated herein by reference in its entirety.

Human antibodies can also be produced using transgenic mice which are incapable of expressing functional endogenous immunoglobulins, but which can express human immunoglobulin genes. For example, the human heavy and light chain immunoglobulin gene complexes may be introduced randomly or by homologous recombination into mouse embryonic stem cells. Alternatively, the human variable region, constant region, and diversity region may be introduced into mouse embryonic stem cells in addition to the human heavy and light chain genes. The mouse heavy and light chain immunoglobulin genes may be rendered non-functional separately or simultaneously with the introduction of human immunoglobulin loci by homologous recombination. In particular, homozygous deletion of the JH region prevents endogenous antibody production. The modified embryonic stem cells are expanded and microinjected into blastocysts to produce chimeric mice. The chimeric mice are then bred to produce homozygous offspring which express human antibodies. The transgenic mice are immunized in the normal fashion with a selected antigen, e.g., all or a portion of a polypeptide of the invention. Monoclonal antibodies directed against the antigen can be obtained from the immunized, transgenic mice using conventional hybridoma technology. The human immunoglobulin transgenes harbored by the transgenic mice rearrange during B cell differentiation, and subsequently undergo class switching and somatic mutation. Thus, using such a technique, it is possible to produce therapeutically useful IgG, IgA, IgM and IgE antibodies. For an overview of this technology for producing human antibodies, see Lonberg and Huszar, Int. Rev. Immunol. 13:65-93 (1995). For a detailed discussion of this technology for producing human antibodies and human monoclonal antibodies and protocols for producing such antibodies, see, e.g., PCT publications WO 98/24893; WO 92/01047; WO 96/34096; WO 96/33735; European Patent

10

15

20

25

30

No. 0 598 877; U.S. Patent Nos. 5,413,923; 5,625,126; 5,633,425; 5,569,825; 5,661,016; 5,545,806; 5,814,318; 5,885,793; 5,916,771; and 5,939,598, which are incorporated by reference herein in their entirety. In addition, companies such as Abgenix, Inc. (Freemont, CA) and Genpharm (San Jose, CA) can be engaged to provide human antibodies directed against a selected antigen using technology similar to that described above.

Completely human antibodies which recognize a selected epitope can be generated using a technique referred to as "guided selection." In this approach a selected non-human monoclonal antibody, e.g., a mouse antibody, is used to guide the selection of a completely human antibody recognizing the same epitope. (Jespers et al., Bio/technology 12:899-903 (1988)).

Further, antibodies to the polypeptides of the invention can, in turn, be utilized to generate anti-idiotype antibodies that "mimic" polypeptides of the invention using techniques well known to those skilled in the art. (See, e.g., Greenspan & Bona, FASEB J. 7(5):437-444; (1989) and Nissinoff, J. Immunol. 147(8):2429-2438 (1991)). For example, antibodies which bind to and competitively inhibit polypeptide multimerization and/or binding of a polypeptide of the invention to a ligand can be used to generate anti-idiotypes that "mimic" the polypeptide multimerization and/or binding domain and, as a consequence, bind to and neutralize polypeptide and/or its ligand. Such neutralizing anti-idiotypes or Fab fragments of such anti-idiotypes can be used in therapeutic regimens to neutralize polypeptide ligand. For example, such anti-idiotypic antibodies can be used to bind a polypeptide of the invention and/or to bind its ligands/receptors, and thereby block its biological activity.

Polynucleotides Encoding Antibodies

The invention further provides polynucleotides comprising a nucleotide sequence encoding an antibody of the invention and fragments thereof. The invention also encompasses polynucleotides that hybridize under stringent or alternatively, under lower stringency hybridization conditions, e.g., as defined supra, to polynucleotides that encode an antibody, preferably, that specifically binds to a polypeptide of the invention, preferably, an antibody that binds to a polypeptide having the amino acid sequence of SEQ ID NO:Y.

The polynucleotides may be obtained, and the nucleotide sequence of the polynucleotides determined, by any method known in the art. For example, if the nucleotide sequence of the antibody is known, a polynucleotide encoding the antibody may be

WO 00/55351 PCT/US00/05883

5

10

15

20

25

30

194

assembled from chemically synthesized oligonucleotides (e.g., as described in Kutmeier et al., BioTechniques 17:242 (1994)), which, briefly, involves the synthesis of overlapping oligonucleotides containing portions of the sequence encoding the antibody, annealing and ligating of those oligonucleotides, and then amplification of the ligated oligonucleotides by PCR.

Alternatively, a polynucleotide encoding an antibody may be generated from nucleic acid from a suitable source. If a clone containing a nucleic acid encoding a particular antibody is not available, but the sequence of the antibody molecule is known, a nucleic acid encoding the immunoglobulin may be chemically synthesized or obtained from a suitable source (e.g., an antibody cDNA library, or a cDNA library generated from, or nucleic acid, preferably poly A+ RNA, isolated from, any tissue or cells expressing the antibody, such as hybridoma cells selected to express an antibody of the invention) by PCR amplification using synthetic primers hybridizable to the 3' and 5' ends of the sequence or by cloning using an oligonucleotide probe specific for the particular gene sequence to identify, e.g., a cDNA clone from a cDNA library that encodes the antibody. Amplified nucleic acids generated by PCR may then be cloned into replicable cloning vectors using any method well known in the art.

Once the nucleotide sequence and corresponding amino acid sequence of the antibody is determined, the nucleotide sequence of the antibody may be manipulated using methods well known in the art for the manipulation of nucleotide sequences, e.g., recombinant DNA techniques, site directed mutagenesis, PCR, etc. (see, for example, the techniques described in Sambrook et al., 1990, Molecular Cloning, A Laboratory Manual, 2d Ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, NY and Ausubel et al., eds., 1998, Current Protocols in Molecular Biology, John Wiley & Sons, NY, which are both incorporated by reference herein in their entireties), to generate antibodies having a different amino acid sequence, for example to create amino acid substitutions, deletions, and/or insertions.

In a specific embodiment, the amino acid sequence of the heavy and/or light chain variable domains may be inspected to identify the sequences of the complementarity determining regions (CDRs) by methods that are well know in the art, e.g., by comparison to known amino acid sequences of other heavy and light chain variable regions to determine the regions of sequence hypervariability. Using routine recombinant DNA techniques, one or more of the CDRs may be inserted within framework regions, e.g., into human framework

10

15

20

25

30

PCT/US00/05883

regions to humanize a non-human antibody, as described supra. The framework regions may be naturally occurring or consensus framework regions, and preferably human framework regions (see, e.g., Chothia et al., J. Mol. Biol. 278: 457-479 (1998) for a listing of human framework regions). Preferably, the polynucleotide generated by the combination of the framework regions and CDRs encodes an antibody that specifically binds a polypeptide of the invention. Preferably, as discussed supra, one or more amino acid substitutions may be made within the framework regions, and, preferably, the amino acid substitutions improve binding of the antibody to its antigen. Additionally, such methods may be used to make amino acid substitutions or deletions of one or more variable region cysteine residues participating in an intrachain disulfide bond to generate antibody molecules lacking one or more intrachain disulfide bonds. Other alterations to the polynucleotide are encompassed by the present invention and within the skill of the art.

In addition, techniques developed for the production of "chimeric antibodies" (Morrison et al., Proc. Natl. Acad. Sci. 81:851-855 (1984); Neuberger et al., Nature 312:604-608 (1984); Takeda et al., Nature 314:452-454 (1985)) by splicing genes from a mouse antibody molecule of appropriate antigen specificity together with genes from a human antibody molecule of appropriate biological activity can be used. As described supra, a chimeric antibody is a molecule in which different portions are derived from different animal species, such as those having a variable region derived from a murine mAb and a human immunoglobulin constant region, e.g., humanized antibodies.

Alternatively, techniques described for the production of single chain antibodies (U.S. Patent No. 4,946,778; Bird, Science 242:423- 42 (1988); Huston et al., Proc. Natl. Acad. Sci. USA 85:5879-5883 (1988); and Ward et al., Nature 334:544-54 (1989)) can be adapted to produce single chain antibodies. Single chain antibodies are formed by linking the heavy and light chain fragments of the Fv region via an amino acid bridge, resulting in a single chain polypeptide. Techniques for the assembly of functional Fv fragments in E. coli may also be used (Skerra et al., Science 242:1038-1041 (1988)).

Methods of Producing Antibodies

The antibodies of the invention can be produced by any method known in the art for the synthesis of antibodies, in particular, by chemical synthesis or preferably, by recombinant expression techniques.

10

15

20

25

30

Recombinant expression of an antibody of the invention, or fragment, derivative or analog thereof, (e.g., a heavy or light chain of an antibody of the invention or a single chain antibody of the invention), requires construction of an expression vector containing a polynucleotide that encodes the antibody. Once a polynucleotide encoding an antibody molecule or a heavy or light chain of an antibody, or portion thereof (preferably containing the heavy or light chain variable domain), of the invention has been obtained, the vector for the production of the antibody molecule may be produced by recombinant DNA technology using techniques well known in the art. Thus, methods for preparing a protein by expressing a polynucleotide containing an antibody encoding nucleotide sequence are described herein. Methods which are well known to those skilled in the art can be used to construct expression vectors containing antibody coding sequences and appropriate transcriptional and translational control signals. These methods include, for example, in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination. The invention, thus, provides replicable vectors comprising a nucleotide sequence encoding an antibody molecule of the invention, or a heavy or light chain thereof, or a heavy or light chain variable domain, operably linked to a promoter. Such vectors may include the nucleotide sequence encoding the constant region of the antibody molecule (see, e.g., PCT Publication WO 86/05807; PCT Publication WO 89/01036; and U.S. Patent No. 5,122,464) and the variable domain of the antibody may be cloned into such a vector for expression of the entire heavy or light chain.

The expression vector is transferred to a host cell by conventional techniques and the transfected cells are then cultured by conventional techniques to produce an antibody of the invention. Thus, the invention includes host cells containing a polynucleotide encoding an antibody of the invention, or a heavy or light chain thereof, or a single chain antibody of the invention, operably linked to a heterologous promoter. In preferred embodiments for the expression of double-chained antibodies, vectors encoding both the heavy and light chains may be co-expressed in the host cell for expression of the entire immunoglobulin molecule, as detailed below.

A variety of host-expression vector systems may be utilized to express the antibody molecules of the invention. Such host-expression systems represent vehicles by which the coding sequences of interest may be produced and subsequently purified, but also represent cells which may, when transformed or transfected with the appropriate nucleotide coding sequences, express an antibody molecule of the invention in situ. These include but are not

10

15

20

25

30

WO 00/55351 PCT/US00/05883

limited to microorganisms such as bacteria (e.g., E. coli, B. subtilis) transformed with recombinant bacteriophage DNA, plasmid DNA or cosmid DNA expression vectors containing antibody coding sequences; yeast (e.g., Saccharomyces, Pichia) transformed with recombinant yeast expression vectors containing antibody coding sequences: insect cell systems infected with recombinant virus expression vectors (e.g., baculovirus) containing antibody coding sequences; plant cell systems infected with recombinant virus expression vectors (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or transformed with recombinant plasmid expression vectors (e.g., Ti plasmid) containing antibody coding sequences; or mammalian cell systems (e.g., COS, CHO. BHK, 293, 3T3 cells) harboring recombinant expression constructs containing promoters derived from the genome of mammalian cells (e.g., metallothionein promoter) or from mammalian viruses (e.g., the adenovirus late promoter; the vaccinia virus 7.5K promoter). Preferably, bacterial cells such as Escherichia coli, and more preferably, eukaryotic cells, especially for the expression of whole recombinant antibody molecule, are used for the expression of a recombinant antibody molecule. For example, mammalian cells such as Chinese hamster ovary cells (CHO), in conjunction with a vector such as the major intermediate early gene promoter element from human cytomegalovirus is an effective expression system for antibodies (Foecking et al., Gene 45:101 (1986); Cockett et al., Bio/Technology 8:2 (1990)).

In bacterial systems, a number of expression vectors may be advantageously selected depending upon the use intended for the antibody molecule being expressed. For example, when a large quantity of such a protein is to be produced, for the generation of pharmaceutical compositions of an antibody molecule, vectors which direct the expression of high levels of fusion protein products that are readily purified may be desirable. Such vectors include, but are not limited, to the E. coli expression vector pUR278 (Ruther et al., EMBO J. 2:1791 (1983)), in which the antibody coding sequence may be ligated individually into the vector in frame with the lac Z coding region so that a fusion protein is produced; pIN vectors (Inouye & Inouye, Nucleic Acids Res. 13:3101-3109 (1985); Van Heeke & Schuster, J. Biol. Chem. 24:5503-5509 (1989)); and the like. pGEX vectors may also be used to express foreign polypeptides as fusion proteins with glutathione S-transferase (GST). In general, such fusion proteins are soluble and can easily be purified from lysed cells by adsorption and binding to matrix glutathione-agarose beads followed by elution in the presence of free

glutathione. The pGEX vectors are designed to include thrombin or factor Xa protease cleavage sites so that the cloned target gene product can be released from the GST moiety.

In an insect system. Autographa californica nuclear polyhedrosis virus (AcNPV) is used as a vector to express foreign genes. The virus grows in *Spodoptera frugiperda* cells. The antibody coding sequence may be cloned individually into non-essential regions (for example the polyhedrin gene) of the virus and placed under control of an AcNPV promoter (for example the polyhedrin promoter).

5

10

15

20

25

30

In mammalian host cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, the antibody coding sequence of interest may be ligated to an adenovirus transcription/translation control complex, e.g., the late promoter and tripartite leader sequence. This chimeric gene may then be inserted in the adenovirus genome by in vitro or in vivo recombination. Insertion in a non- essential region of the viral genome (e.g., region E1 or E3) will result in a recombinant virus that is viable and capable of expressing the antibody molecule in infected hosts. (e.g., see Logan & Shenk, Proc. Natl. Acad. Sci. USA 81:355-359 (1984)). Specific initiation signals may also be required for efficient translation of inserted antibody coding sequences. These signals include the ATG initiation codon and adjacent sequences. Furthermore, the initiation codon must be in phase with the reading frame of the desired coding sequence to ensure translation of the entire insert. These exogenous translational control signals and initiation codons can be of a variety of origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of appropriate transcription enhancer elements, transcription terminators, etc. (see Bittner et al., Methods in Enzymol. 153:51-544 (1987)).

In addition, a host cell strain may be chosen which modulates the expression of the inserted sequences, or modifies and processes the gene product in the specific fashion desired. Such modifications (e.g., glycosylation) and processing (e.g., cleavage) of protein products may be important for the function of the protein. Different host cells have characteristic and specific mechanisms for the post-translational processing and modification of proteins and gene products. Appropriate cell lines or host systems can be chosen to ensure the correct modification and processing of the foreign protein expressed. To this end, eukarvotic host cells which possess the cellular machinery for proper processing of the primary transcript, glycosylation, and phosphorylation of the gene product may be used. Such mammalian host cells include but are not limited to CHO, VERY, BHK, Hela, COS,

10

15

20

25

30

MDCK, 293, 3T3, WI38, and in particular, breast cancer cell lines such as, for example, BT483, Hs578T, HTB2, BT20 and T47D, and normal mammary gland cell line such as, for example, CRL7030 and Hs578Bst.

For long-term, high-yield production of recombinant proteins, stable expression is preferred. For example, cell lines which stably express the antibody molecule may be engineered. Rather than using expression vectors which contain viral origins of replication, host cells can be transformed with DNA controlled by appropriate expression control elements (e.g., promoter, enhancer, sequences, transcription terminators, polyadenylation sites, etc.), and a selectable marker. Following the introduction of the foreign DNA, engineered cells may be allowed to grow for 1-2 days in an enriched media, and then are switched to a selective media. The selectable marker in the recombinant plasmid confers resistance to the selection and allows cells to stably integrate the plasmid into their chromosomes and grow to form foci which in turn can be cloned and expanded into cell lines. This method may advantageously be used to engineer cell lines which express the antibody molecule. Such engineered cell lines may be particularly useful in screening and evaluation of compounds that interact directly or indirectly with the antibody molecule.

A number of selection systems may be used, including but not limited to the herpes simplex virus thymidine kinase (Wigler et al., Cell 11:223 (1977)), hypoxanthine-guanine phosphoribosyltransferase (Szybalska & Szybalski, Proc. Natl. Acad. Sci. USA 48:202 (1992)), and adenine phosphoribosyltransferase (Lowy et al., Cell 22:817 (1980)) genes can be employed in tk-, hgprt- or aprt- cells, respectively. Also, antimetabolite resistance can be used as the basis of selection for the following genes: dhfr, which confers resistance to methotrexate (Wigler et al., Natl. Acad. Sci. USA 77:357 (1980); O'Hare et al., Proc. Natl. Acad. Sci. USA 78:1527 (1981)); gpt, which confers resistance to mycophenolic acid (Mulligan & Berg, Proc. Natl. Acad. Sci. USA 78:2072 (1981)); neo, which confers resistance to the aminoglycoside G-418 Clinical Pharmacy 12:488-505; Wu and Wu, Biotherapy 3:87-95 (1991); Tolstoshev, Ann. Rev. Pharmacol. Toxicol. 32:573-596 (1993); Mulligan, Science 260:926-932 (1993); and Morgan and Anderson, Ann. Rev. Biochem. 62:191-217 (1993); May, 1993, TIB TECH 11(5):155-215); and hygro, which confers resistance to hygromycin (Santerre et al., Gene 30:147 (1984)). Methods commonly known in the art of recombinant DNA technology may be routinely applied to select the desired recombinant clone, and such methods are described, for example, in Ausubel et al. (eds.),

10

15

20

25

30

Current Protocols in Molecular Biology, John Wiley & Sons, NY (1993); Kriegler, Gene Transfer and Expression, A Laboratory Manual. Stockton Press, NY (1990); and in Chapters 12 and 13, Dracopoli et al. (eds), Current Protocols in Human Genetics, John Wiley & Sons, NY (1994); Colberre-Garapin et al., J. Mol. Biol. 150:1 (1981), which are incorporated by reference herein in their entireties.

The expression levels of an antibody molecule can be increased by vector amplification (for a review, see Bebbington and Hentschel, The use of vectors based on gene amplification for the expression of cloned genes in mammalian cells in DNA cloning, Vol.3. (Academic Press, New York, 1987)). When a marker in the vector system expressing antibody is amplifiable, increase in the level of inhibitor present in culture of host cell will increase the number of copies of the marker gene. Since the amplified region is associated with the antibody gene, production of the antibody will also increase (Crouse et al., Mol. Cell. Biol. 3:257 (1983)).

The host cell may be co-transfected with two expression vectors of the invention, the first vector encoding a heavy chain derived polypeptide and the second vector encoding a light chain derived polypeptide. The two vectors may contain identical selectable markers which enable equal expression of heavy and light chain polypeptides. Alternatively, a single vector may be used which encodes, and is capable of expressing, both heavy and light chain polypeptides. In such situations, the light chain should be placed before the heavy chain to avoid an excess of toxic free heavy chain (Proudfoot, Nature 322:52 (1986); Kohler, Proc. Natl. Acad. Sci. USA 77:2197 (1980)). The coding sequences for the heavy and light chains may comprise cDNA or genomic DNA.

Once an antibody molecule of the invention has been produced by an animal, chemically synthesized, or recombinantly expressed, it may be purified by any method known in the art for purification of an immunoglobulin molecule, for example, by chromatography (e.g., ion exchange, affinity, particularly by affinity for the specific antigen after Protein A, and sizing column chromatography), centrifugation, differential solubility, or by any other standard technique for the purification of proteins. In addition, the antibodies of the present invention or fragments thereof can be fused to heterologous polypeptide sequences described herein or otherwise known in the art, to facilitate purification.

The present invention encompasses antibodies recombinantly fused or chemically conjugated (including both covalently and non-covalently conjugations) to a polypeptide (or

WO 00/55351 PCT/US00/05883

portion thereof, preferably at least 10, 20, 30, 40, 50, 60, 70, 80, 90 or 100 amino acids of the polypeptide) of the present invention to generate fusion proteins. The fusion does not necessarily need to be direct, but may occur through linker sequences. The antibodies may be specific for antigens other than polypeptides (or portion thereof, preferably at least 10, 20, 30, 40, 50, 60, 70, 80, 90 or 100 amino acids of the polypeptide) of the present invention. For example, antibodies may be used to target the polypeptides of the present invention to particular cell types, either in vitro or in vivo, by fusing or conjugating the polypeptides of the present invention to antibodies specific for particular cell surface receptors. Antibodies fused or conjugated to the polypeptides of the present invention may also be used in in vitro immunoassays and purification methods using methods known in the art. See e.g., Harbor et al., supra, and PCT publication WO 93/21232; EP 439,095; Naramura et al., Immunol. Lett. 39:91-99 (1994); U.S. Patent 5,474,981; Gillies et al., PNAS 89:1428-1432 (1992); Fell et al., J. Immunol. 146:2446-2452(1991), which are incorporated by reference in their entireties.

5

10

15

20

25

30

The present invention further includes compositions comprising the polypeptides of the present invention fused or conjugated to antibody domains other than the variable regions. For example, the polypeptides of the present invention may be fused or conjugated to an antibody Fc region, or portion thereof. The antibody portion fused to a polypeptide of the present invention may comprise the constant region, hinge region, CH1 domain, CH2 domain, and CH3 domain or any combination of whole domains or portions thereof. The polypeptides may also be fused or conjugated to the above antibody portions to form multimers. For example, Fc portions fused to the polypeptides of the present invention can form dimers through disulfide bonding between the Fc portions. Higher multimeric forms can be made by fusing the polypeptides to portions of IgA and IgM. Methods for fusing or conjugating the polypeptides of the present invention to antibody portions are known in the art. See, e.g., U.S. Patent Nos. 5,336,603; 5,622,929; 5,359,046; 5,349,053; 5,447,851; 5,112,946; EP 307,434; EP 367,166; PCT publications WO 96/04388; WO 91/06570; Ashkenazi et al., Proc. Natl. Acad. Sci. USA 88:10535-10539 (1991); Zheng et al., J. Immunol. 154:5590-5600 (1995); and Vil et al., Proc. Natl. Acad. Sci. USA 89:11337-11341(1992) (said references incorporated by reference in their entireties).

As discussed, supra, the polypeptides corresponding to a polypeptide, polypeptide fragment, or a variant of SEQ ID NO:Y may be fused or conjugated to the above antibody portions to increase the in vivo half life of the polypeptides or for use in immunoassays using

5

10

15

20

25

30

methods known in the art. Further, the polypeptides corresponding to SEQ ID NO:Y may be fused or conjugated to the above antibody portions to facilitate purification. One reported example describes chimeric proteins consisting of the first two domains of the human CD4polypeptide and various domains of the constant regions of the heavy or light chains of mammalian immunoglobulins. (EP 394,827; Traunecker et al., Nature 331:84-86 (1988). The polypeptides of the present invention fused or conjugated to an antibody having disulfide- linked dimeric structures (due to the IgG) may also be more efficient in binding and neutralizing other molecules, than the monomeric secreted protein or protein fragment alone. (Fountoulakis et al., J. Biochem. 270:3958-3964 (1995)). In many cases, the Fc part in a fusion protein is beneficial in therapy and diagnosis, and thus can result in, for example, improved pharmacokinetic properties. (EP A 232,262). Alternatively, deleting the Fc part after the fusion protein has been expressed, detected, and purified, would be desired. For example, the Fc portion may hinder therapy and diagnosis if the fusion protein is used as an antigen for immunizations. In drug discovery, for example, human proteins, such as hIL-5, have been fused with Fc portions for the purpose of high-throughput screening assays to identify antagonists of hIL-5. (See, Bennett et al., J. Molecular Recognition 8:52-58 (1995); Johanson et al., J. Biol. Chem. 270:9459-9471 (1995).

Moreover, the antibodies or fragments thereof of the present invention can be fused to marker sequences, such as a peptide to facilitate purification. In preferred embodiments, the marker amino acid sequence is a hexa-histidine peptide, such as the tag provided in a pQE vector (QIAGEN, Inc., 9259 Eton Avenue, Chatsworth, CA, 91311), among others, many of which are commercially available. As described in Gentz et al., Proc. Natl. Acad. Sci. USA 86:821-824 (1989), for instance, hexa-histidine provides for convenient purification of the fusion protein. Other peptide tags useful for purification include, but are not limited to, the "HA" tag, which corresponds to an epitope derived from the influenza hemagglutinin protein (Wilson et al., Cell 37:767 (1984)) and the "flag" tag.

The present invention further encompasses antibodies or fragments thereof conjugated to a diagnostic or therapeutic agent. The antibodies can be used diagnostically to, for example, monitor the development or progression of a tumor as part of a clinical testing procedure to, e.g., determine the efficacy of a given treatment regimen. Detection can be facilitated by coupling the antibody to a detectable substance. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent

10

15

20

25

30

203

materials, bioluminescent materials, radioactive materials, positron emitting metals using various positron emission tomographies, and nonradioactive paramagnetic metal ions. The detectable substance may be coupled or conjugated either directly to the antibody (or fragment thereof) or indirectly, through an intermediate (such as, for example, a linker known in the art) using techniques known in the art. See, for example, U.S. Patent No. 4,741,900 for metal ions which can be conjugated to antibodies for use as diagnostics according to the present invention. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, beta-galactosidase, or acetylcholinesterase: examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin: examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol: examples of bioluminescent materials include luciferase, luciferin, and aequorin; and examples of suitable radioactive material include 1251, 1311, 1111n or 99Tc.

Further, an antibody or fragment thereof may be conjugated to a therapeutic moiety such as a cytotoxin, e.g., a cytostatic or cytocidal agent, a therapeutic agent or a radioactive metal ion, e.g., alpha-emitters such as, for example, 213Bi. A cytotoxin or cytotoxic agent includes any agent that is detrimental to cells. Examples include paclitaxol, cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicin, doxorubicin, daunorubicin, dihydroxy anthracin dione, mitoxantrone, mithramycin, actinomycin D, 1-dehydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, and puromycin and analogs or homologs thereof. Therapeutic agents include, but are not limited to, antimetabolites (e.g., methotrexate, 6-mercaptopurine, 6thioguanine, cytarabine, 5-fluorouracil decarbazine), alkylating agents (e.g., mechlorethamine, thioepa chlorambucil, melphalan, carmustine (BSNU) and lomustine (CCNU), cyclothosphamide, busulfan, dibromomannitol, streptozotocin, mitomycin C, and cis- dichlorodiamine platinum (II) (DDP) cisplatin), anthracyclines (e.g., daunorubicin (formerly daunomycin) and doxorubicin), antibiotics (e.g., dactinomycin (formerly actinomycin), bleomycin, mithramycin, and anthramycin (AMC)), and anti-mitotic agents (e.g., vincristine and vinblastine).

The conjugates of the invention can be used for modifying a given biological response, the therapeutic agent or drug moiety is not to be construed as limited to classical

10

15

20

25

30

chemical therapeutic agents. For example, the drug moiety may be a protein or polypeptide possessing a desired biological activity. Such proteins may include, for example, a toxin such as abrin, ricin A, pseudomonas exotoxin, or diphtheria toxin; a protein such as tumor necrosis factor, a-interferon, \(\beta\)-interferon, nerve growth factor, platelet derived growth factor, tissue plasminogen activator, an apoptotic agent, e.g., TNF-alpha, TNF-beta, AIM I (See, International Publication No. WO 97/33899), AIM II (See, International Publication No. WO 97/34911), Fas Ligand (Takahashi et al., Int. Immunol., 6:1567-1574 (1994)), VEGI (See, International Publication No. WO 99/23105), a thrombotic agent or an anti- angiogenic agent, e.g., angiostatin or endostatin; or, biological response modifiers such as, for example, lymphokines, interleukin-1 ("IL-1"), interleukin-2 ("IL-2"), interleukin-6 ("IL-6"), granulocyte macrophage colony stimulating factor ("GM-CSF"), granulocyte colony stimulating factor ("GM-CSF"), or other growth factors.

Antibodies may also be attached to solid supports, which are particularly useful for immunoassays or purification of the target antigen. Such solid supports include, but are not limited to, glass, cellulose, polyacrylamide, nylon, polystyrene, polyvinyl chloride or polypropylene.

Techniques for conjugating such therapeutic moiety to antibodies are well known, see, e.g., Arnon et al., "Monoclonal Antibodies For Immunotargeting Of Drugs In Cancer Therapy", in Monoclonal Antibodies And Cancer Therapy, Reisfeld et al. (eds.), pp. 243-56 (Alan R. Liss, Inc. 1985); Hellstrom et al., "Antibodies For Drug Delivery", in Controlled Drug Delivery (2nd Ed.), Robinson et al. (eds.), pp. 623-53 (Marcel Dekker, Inc. 1987); Thorpe, "Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: A Review", in Monoclonal Antibodies '84: Biological And Clinical Applications, Pinchera et al. (eds.), pp. 475-506 (1985); "Analysis, Results, And Future Prospective Of The Therapeutic Use Of Radiolabeled Antibody In Cancer Therapy", in Monoclonal Antibodies For Cancer Detection And Therapy, Baldwin et al. (eds.), pp. 303-16 (Academic Press 1985), and Thorpe et al., "The Preparation And Cytotoxic Properties Of Antibody-Toxin Conjugates", Immunol. Rev. 62:119-58 (1982).

Alternatively, an antibody can be conjugated to a second antibody to form an antibody heteroconjugate as described by Segal in U.S. Patent No. 4.676,980, which is incorporated herein by reference in its entirety.

PCT/US00/05883

An antibody, with or without a therapeutic moiety conjugated to it, administered alone or in combination with cytotoxic factor(s) and/or cytokine(s) can be used as a therapeutic.

Immunophenotyping

5

10

15

20

25

30

WO 00/55351

The antibodies of the invention may be utilized for immunophenotyping of cell lines and biological samples. The translation product of the gene of the present invention may be useful as a cell specific marker, or more specifically as a cellular marker that is differentially expressed at various stages of differentiation and/or maturation of particular cell types. Monoclonal antibodies directed against a specific epitope, or combination of epitopes, will allow for the screening of cellular populations expressing the marker. Various techniques can be utilized using monoclonal antibodies to screen for cellular populations expressing the marker(s), and include magnetic separation using antibody-coated magnetic beads, "panning" with antibody attached to a solid matrix (i.e., plate), and flow cytometry (See, e.g., U.S. Patent 5,985,660; and Morrison et al., Cell, 96:737-49 (1999)).

These techniques allow for the screening of particular populations of cells, such as might be found with hematological malignancies (i.e. minimal residual disease (MRD) in acute leukemic patients) and "non-self" cells in transplantations to prevent Graft-versus-Host Disease (GVHD). Alternatively, these techniques allow for the screening of hematopoietic stem and progenitor cells capable of undergoing proliferation and/or differentiation, as might be found in human umbilical cord blood.

Assays For Antibody Binding

The antibodies of the invention may be assayed for immunospecific binding by any method known in the art. The immunoassays which can be used include but are not limited to competitive and non-competitive assay systems using techniques such as western blots, radioimmunoassays, ELISA (enzyme linked immunosorbent assay), "sandwich" immunoassays, immunoprecipitation assays, precipitin reactions, gel diffusion precipitin reactions, immunodiffusion assays, agglutination assays, complement-fixation assays, immunoradiometric assays, fluorescent immunoassays, protein A immunoassays, to name but a few. Such assays are routine and well known in the art (see, e.g., Ausubel et al, eds, 1994, Current Protocols in Molecular Biology, Vol. 1, John Wiley & Sons, Inc., New York,

5

10

15

20

25

30

which is incorporated by reference herein in its entirety). Exemplary immunoassays are described briefly below (but are not intended by way of limitation).

Immunoprecipitation protocols generally comprise lysing a population of cells in a lysis buffer such as RIPA buffer (1% NP-40 or Triton X- 100, 1% sodium deoxycholate, 0.1% SDS, 0.15 M NaCl, 0.01 M sodium phosphate at pH 7.2, 1% Trasylol) supplemented with protein phosphatase and/or protease inhibitors (e.g., EDTA, PMSF, aprotinin, sodium vanadate), adding the antibody of interest to the cell lysate, incubating for a period of time (e.g., 1-4 hours) at 4° C, adding protein A and/or protein G sepharose beads to the cell lysate, incubating for about an hour or more at 4° C, washing the beads in lysis buffer and resuspending the beads in SDS/sample buffer. The ability of the antibody of interest to immunoprecipitate a particular antigen can be assessed by, e.g., western blot analysis. One of skill in the art would be knowledgeable as to the parameters that can be modified to increase the binding of the antibody to an antigen and decrease the background (e.g., preclearing the cell lysate with sepharose beads). For further discussion regarding immunoprecipitation protocols see, e.g., Ausubel et al, eds, 1994, Current Protocols in Molecular Biology, Vol. 1, John Wiley & Sons, Inc., New York at 10.16.1.

Western blot analysis generally comprises preparing protein samples, electrophoresis of the protein samples in a polyacrylamide gel (e.g., 8%- 20% SDS-PAGE depending on the molecular weight of the antigen), transferring the protein sample from the polyacrylamide gel to a membrane such as nitrocellulose, PVDF or nylon, blocking the membrane in blocking solution (e.g., PBS with 3% BSA or non-fat milk), washing the membrane in washing buffer (e.g., PBS-Tween 20), blocking the membrane with primary antibody (the antibody of interest) diluted in blocking buffer, washing the membrane in washing buffer, blocking the membrane with a secondary antibody (which recognizes the primary antibody, e.g., an antihuman antibody) conjugated to an enzymatic substrate (e.g., horseradish peroxidase or alkaline phosphatase) or radioactive molecule (e.g., 32P or 125I) diluted in blocking buffer, washing the membrane in wash buffer, and detecting the presence of the antigen. One of skill in the art would be knowledgeable as to the parameters that can be modified to increase the signal detected and to reduce the background noise. For further discussion regarding western blot protocols see, e.g., Ausubel et al. eds, 1994, Current Protocols in Molecular Biology, Vol. 1, John Wiley & Sons, Inc., New York at 10.8.1.

PCT/US00/05883

ELISAs comprise preparing antigen, coating the well of a 96 well microtiter plate with the antigen, adding the antibody of interest conjugated to a detectable compound such as an enzymatic substrate (e.g., horseradish peroxidase or alkaline phosphatase) to the well and incubating for a period of time, and detecting the presence of the antigen. In ELISAs the antibody of interest does not have to be conjugated to a detectable compound: instead, a second antibody (which recognizes the antibody of interest) conjugated to a detectable compound may be added to the well. Further, instead of coating the well with the antigen, the antibody may be coated to the well. In this case, a second antibody conjugated to a detectable compound may be added following the addition of the antigen of interest to the coated well. One of skill in the art would be knowledgeable as to the parameters that can be modified to increase the signal detected as well as other variations of ELISAs known in the art. For further discussion regarding ELISAs see, e.g., Ausubel et al, eds. 1994. Current Protocols in Molecular Biology, Vol. 1, John Wiley & Sons, Inc., New York at 11.2.1.

The binding affinity of an antibody to an antigen and the off-rate of an antibody-antigen interaction can be determined by competitive binding assays. One example of a competitive binding assay is a radioimmunoassay comprising the incubation of labeled antigen (e.g., 3H or 1251) with the antibody of interest in the presence of increasing amounts of unlabeled antigen, and the detection of the antibody bound to the labeled antigen. The affinity of the antibody of interest for a particular antigen and the binding off-rates can be determined from the data by scatchard plot analysis. Competition with a second antibody can also be determined using radioimmunoassays. In this case, the antigen is incubated with antibody of interest conjugated to a labeled compound (e.g., 3H or 1251) in the presence of increasing amounts of an unlabeled second antibody.

Therapeutic Uses

5

10

15

20

25

30

The present invention is further directed to antibody-based therapies which involve administering antibodies of the invention to an animal, preferably a mammal, and most preferably a human, patient for treating one or more of the disclosed diseases, disorders, or conditions. Therapeutic compounds of the invention include, but are not limited to, antibodies of the invention (including fragments, analogs and derivatives thereof as described herein) and nucleic acids encoding antibodies of the invention (including fragments, analogs and derivatives thereof and anti-idiotypic antibodies as described herein). The antibodies of

5

10

15

20

25

30

208

PCT/US00/05883

the invention can be used to treat, inhibit or prevent diseases, disorders or conditions associated with aberrant expression and/or activity of a polypeptide of the invention, including, but not limited to, any one or more of the diseases, disorders, or conditions described herein. The treatment and/or prevention of diseases, disorders, or conditions associated with aberrant expression and/or activity of a polypeptide of the invention includes, but is not limited to, alleviating symptoms associated with those diseases, disorders or conditions. Antibodies of the invention may be provided in pharmaceutically acceptable compositions as known in the art or as described herein.

A summary of the ways in which the antibodies of the present invention may be used therapeutically includes binding polynucleotides or polypeptides of the present invention locally or systemically in the body or by direct cytotoxicity of the antibody, e.g. as mediated by complement (CDC) or by effector cells (ADCC). Some of these approaches are described in more detail below. Armed with the teachings provided herein, one of ordinary skill in the art will know how to use the antibodies of the present invention for diagnostic, monitoring or therapeutic purposes without undue experimentation.

The antibodies of this invention may be advantageously utilized in combination with other monoclonal or chimeric antibodies, or with lymphokines or hematopoietic growth factors (such as, e.g., IL-2, IL-3 and IL-7), for example, which serve to increase the number or activity of effector cells which interact with the antibodies.

The antibodies of the invention may be administered alone or in combination with other types of treatments (e.g., radiation therapy, chemotherapy, hormonal therapy, immunotherapy and anti-tumor agents). Generally, administration of products of a species origin or species reactivity (in the case of antibodies) that is the same species as that of the patient is preferred. Thus, in a preferred embodiment, human antibodies, fragments derivatives, analogs, or nucleic acids, are administered to a human patient for therapy or prophylaxis.

It is preferred to use high affinity and/or potent in vivo inhibiting and/or neutralizing antibodies against polypeptides or polynucleotides of the present invention, fragments or regions thereof, for both immunoassays directed to and therapy of disorders related to polynucleotides or polypeptides, including fragments thereof, of the present invention. Such antibodies, fragments, or regions, will preferably have an affinity for polynucleotides or polypeptides of the invention, including fragments thereof. Preferred binding affinities

include those with a dissociation constant or Kd less than 5 X 10⁻² M, 10⁻² M, 5 X 10⁻³ M. 10^{-3} M, 5 X 10^{-4} M, 10^{-4} M, 5 X 10^{-5} M, 10^{-5} M, 5 X 10^{-6} M, 10^{-6} M, 5 X 10^{-7} M, 10^{-7} M, 5 X 10^{-8} M, 10^{-8} M, 5 X 10^{-9} M, 10^{-9} M, 5 X 10^{-10} M, 10^{-10} M, 5 X 10^{-11} M, 10^{-11} M, 5 X 10^{-12} M, 10^{-12} M, 5 X 10^{-13} M, 10^{-13} M, 5 X 10^{-14} M, 10^{-14} M, 5 X 10^{-15} M, and 10^{-15} M.

5

10

15

20

25

30

Gene Therapy

In a specific embodiment, nucleic acids comprising sequences encoding antibodies or functional derivatives thereof, are administered to treat, inhibit or prevent a disease or disorder associated with aberrant expression and/or activity of a polypeptide of the invention, by way of gene therapy. Gene therapy refers to therapy performed by the administration to a subject of an expressed or expressible nucleic acid. In this embodiment of the invention, the nucleic acids produce their encoded protein that mediates a therapeutic effect.

Any of the methods for gene therapy available in the art can be used according to the present invention. Exemplary methods are described below.

For general reviews of the methods of gene therapy, see Goldspiel et al., Clinical Pharmacy 12:488-505 (1993); Wu and Wu, Biotherapy 3:87-95 (1991); Tolstoshev, Ann. Rev. Pharmacol. Toxicol. 32:573-596 (1993); Mulligan, Science 260:926-932 (1993); and Morgan and Anderson, Ann. Rev. Biochem. 62:191-217 (1993); May, TIBTECH 11(5):155-215 (1993). Methods commonly known in the art of recombinant DNA technology which can be used are described in Ausubel et al. (eds.), Current Protocols in Molecular Biology, John Wiley & Sons, NY (1993); and Kriegler, Gene Transfer and Expression, A Laboratory Manual, Stockton Press, NY (1990).

In a preferred aspect, the compound comprises nucleic acid sequences encoding an antibody, said nucleic acid sequences being part of expression vectors that express the antibody or fragments or chimeric proteins or heavy or light chains thereof in a suitable host. In particular, such nucleic acid sequences have promoters operably linked to the antibody coding region, said promoter being inducible or constitutive, and, optionally, tissue-specific. In another particular embodiment, nucleic acid molecules are used in which the antibody coding sequences and any other desired sequences are flanked by regions that promote homologous recombination at a desired site in the genome, thus providing for intrachromosomal expression of the antibody encoding nucleic acids (Koller and Smithies, Proc. Natl. Acad. Sci. USA 86:8932-8935 (1989); Zijlstra et al., Nature 342:435-438 (1989).

WO 00/55351 PCT/US00/05883

210

In specific embodiments, the expressed antibody molecule is a single chain antibody; alternatively, the nucleic acid sequences include sequences encoding both the heavy and light chains, or fragments thereof, of the antibody.

Delivery of the nucleic acids into a patient may be either direct, in which case the patient is directly exposed to the nucleic acid or nucleic acid- carrying vectors, or indirect, in which case, cells are first transformed with the nucleic acids in vitro, then transplanted into the patient. These two approaches are known, respectively, as in vivo or ex vivo gene therapy.

5

10

15

20

25

30

In a specific embodiment, the nucleic acid sequences are directly administered in vivo, where it is expressed to produce the encoded product. This can be accomplished by any of numerous methods known in the art, e.g., by constructing them as part of an appropriate nucleic acid expression vector and administering it so that they become intracellular, e.g., by infection using defective or attenuated retrovirals or other viral vectors (see U.S. Patent No. 4,980,286), or by direct injection of naked DNA, or by use of microparticle bombardment (e.g., a gene gun; Biolistic, Dupont), or coating with lipids or cell-surface receptors or transfecting agents, encapsulation in liposomes, microparticles, or microcapsules, or by administering them in linkage to a peptide which is known to enter the nucleus, by administering it in linkage to a ligand subject to receptor-mediated endocytosis (see, e.g., Wu and Wu, J. Biol. Chem. 262:4429-4432 (1987)) (which can be used to target cell types specifically expressing the receptors), etc. In another embodiment, nucleic acidligand complexes can be formed in which the ligand comprises a fusogenic viral peptide to disrupt endosomes, allowing the nucleic acid to avoid lysosomal degradation. In yet another embodiment, the nucleic acid can be targeted in vivo for cell specific uptake and expression, by targeting a specific receptor (see, e.g., PCT Publications WO 92/06180; WO 92/22635; WO92/20316; WO93/14188, WO 93/20221). Alternatively, the nucleic acid can be introduced intracellularly and incorporated within host cell DNA for expression, by homologous recombination (Koller and Smithies, Proc. Natl. Acad. Sci. USA 86:8932-8935 (1989); Zijlstra et al., Nature 342:435-438 (1989)).

In a specific embodiment, viral vectors that contains nucleic acid sequences encoding an antibody of the invention are used. For example, a retroviral vector can be used (see Miller et al., Meth. Enzymol. 217:581-599 (1993)). These retroviral vectors contain the components necessary for the correct packaging of the viral genome and integration into the

5

10

15

20

25

30

host cell DNA. The nucleic acid sequences encoding the antibody to be used in gene therapy are cloned into one or more vectors, which facilitates delivery of the gene into a patient. More detail about retroviral vectors can be found in Boesen et al.. Biotherapy 6:291-302 (1994), which describes the use of a retroviral vector to deliver the mdrl gene to hematopoietic stem cells in order to make the stem cells more resistant to chemotherapy. Other references illustrating the use of retroviral vectors in gene therapy are: Clowes et al., J. Clin. Invest. 93:644-651 (1994); Kiem et al., Blood 83:1467-1473 (1994); Salmons and Gunzberg, Human Gene Therapy 4:129-141 (1993): and Grossman and Wilson. Curr. Opin. in Genetics and Devel. 3:110-114 (1993).

Adenoviruses are other viral vectors that can be used in gene therapy. Adenoviruses are especially attractive vehicles for delivering genes to respiratory epithelia. Adenoviruses naturally infect respiratory epithelia where they cause a mild disease. Other targets for adenovirus-based delivery systems are liver, the central nervous system, endothelial cells, and muscle. Adenoviruses have the advantage of being capable of infecting non-dividing cells. Kozarsky and Wilson, Current Opinion in Genetics and Development 3:499-503 (1993) present a review of adenovirus-based gene therapy. Bout et al., Human Gene Therapy 5:3-10 (1994) demonstrated the use of adenovirus vectors to transfer genes to the respiratory epithelia of rhesus monkeys. Other instances of the use of adenoviruses in gene therapy can be found in Rosenfeld et al., Science 252:431-434 (1991); Rosenfeld et al., Cell 68:143-155 (1992); Mastrangeli et al., J. Clin. Invest. 91:225-234 (1993); PCT Publication WO94/12649; and Wang, et al., Gene Therapy 2:775-783 (1995). In a preferred embodiment, adenovirus vectors are used.

Adeno-associated virus (AAV) has also been proposed for use in gene therapy (Walsh et al., Proc. Soc. Exp. Biol. Med. 204:289-300 (1993); U.S. Patent No. 5,436,146).

Another approach to gene therapy involves transferring a gene to cells in tissue culture by such methods as electroporation, lipofection, calcium phosphate mediated transfection, or viral infection. Usually, the method of transfer includes the transfer of a selectable marker to the cells. The cells are then placed under selection to isolate those cells that have taken up and are expressing the transferred gene. Those cells are then delivered to a patient.

In this embodiment, the nucleic acid is introduced into a cell prior to administration in vivo of the resulting recombinant cell. Such introduction can be carried out by any method

WO 00/55351 PCT/US00/05883

212

known in the art, including but not limited to transfection, electroporation, microinjection, infection with a viral or bacteriophage vector containing the nucleic acid sequences, cell fusion, chromosome-mediated gene transfer, microcell-mediated gene transfer, spheroplast fusion, etc. Numerous techniques are known in the art for the introduction of foreign genes into cells (see, e.g., Loeffler and Behr, Meth. Enzymol. 217:599-618 (1993); Cohen et al., Meth. Enzymol. 217:618-644 (1993); Cline, Pharmac. Ther. 29:69-92m (1985) and may be used in accordance with the present invention, provided that the necessary developmental and physiological functions of the recipient cells are not disrupted. The technique should provide for the stable transfer of the nucleic acid to the cell, so that the nucleic acid is expressible by the cell and preferably heritable and expressible by its cell progeny.

5

10

15

20

25

30

The resulting recombinant cells can be delivered to a patient by various methods known in the art. Recombinant blood cells (e.g., hematopoietic stem or progenitor cells) are preferably administered intravenously. The amount of cells envisioned for use depends on the desired effect, patient state, etc., and can be determined by one skilled in the art.

Cells into which a nucleic acid can be introduced for purposes of gene therapy encompass any desired, available cell type, and include but are not limited to epithelial cells, endothelial cells, keratinocytes, fibroblasts, muscle cells, hepatocytes; blood cells such as Tlymphocytes, Blymphocytes, monocytes, macrophages, neutrophils, eosinophils, megakaryocytes, granulocytes; various stem or progenitor cells, in particular hematopoietic stem or progenitor cells, e.g., as obtained from bone marrow, umbilical cord blood, peripheral blood, fetal liver, etc.

In a preferred embodiment, the cell used for gene therapy is autologous to the patient.

In an embodiment in which recombinant cells are used in gene therapy, nucleic acid sequences encoding an antibody are introduced into the cells such that they are expressible by the cells or their progeny, and the recombinant cells are then administered in vivo for therapeutic effect. In a specific embodiment, stem or progenitor cells are used. Any stem and/or progenitor cells which can be isolated and maintained in vitro can potentially be used in accordance with this embodiment of the present invention (see e.g. PCT Publication WO 94/08598; Stemple and Anderson, Cell 71:973-985 (1992); Rheinwald, Meth. Cell Bio. 21A:229 (1980); and Pittelkow and Scott, Mayo Clinic Proc. 61:771 (1986)).

In a specific embodiment, the nucleic acid to be introduced for purposes of gene therapy comprises an inducible promoter operably linked to the coding region, such that expression of the nucleic acid is controllable by controlling the presence or absence of the appropriate inducer of transcription. Demonstration of Therapeutic or Prophylactic Activity

The compounds or pharmaceutical compositions of the invention are preferably tested in vitro, and then in vivo for the desired therapeutic or prophylactic activity, prior to use in humans. For example, in vitro assays to demonstrate the therapeutic or prophylactic utility of a compound or pharmaceutical composition include, the effect of a compound on a cell line or a patient tissue sample. The effect of the compound or composition on the cell line and/or tissue sample can be determined utilizing techniques known to those of skill in the art including, but not limited to, rosette formation assays and cell lysis assays. In accordance with the invention, in vitro assays which can be used to determine whether administration of a specific compound is indicated, include in vitro cell culture assays in which a patient tissue sample is grown in culture, and exposed to or otherwise administered a compound, and the effect of such compound upon the tissue sample is observed.

Therapeutic/Prophylactic Administration and Composition

5

10

15

20

25

30

The invention provides methods of treatment, inhibition and prophylaxis by administration to a subject of an effective amount of a compound or pharmaceutical composition of the invention, preferably a polypeptide or antibody of the invention. In a preferred aspect, the compound is substantially purified (e.g., substantially free from substances that limit its effect or produce undesired side-effects). The subject is preferably an animal, including but not limited to animals such as cows, pigs, horses, chickens, cats, dogs, etc., and is preferably a mammal, and most preferably human.

Formulations and methods of administration that can be employed when the compound comprises a nucleic acid or an immunoglobulin are described above; additional appropriate formulations and routes of administration can be selected from among those described herein below.

Various delivery systems are known and can be used to administer a compound of the invention, e.g., encapsulation in liposomes, microparticles, microcapsules, recombinant cells capable of expressing the compound, receptor-mediated endocytosis (see, e.g., Wu and Wu, J. Biol. Chem. 262:4429-4432 (1987)), construction of a nucleic acid as part of a retroviral or other vector, etc. Methods of introduction include but are not limited to intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, and oral

WO 00/55351 PCT/US00/05883

routes. The compounds or compositions may be administered by any convenient route, for example by infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (e.g., oral mucosa, rectal and intestinal mucosa, etc.) and may be administered together with other biologically active agents. Administration can be systemic or local. In addition, it may be desirable to introduce the pharmaceutical compounds or compositions of the invention into the central nervous system by any suitable route, including intraventricular and intrathecal injection; intraventricular injection may be facilitated by an intraventricular catheter, for example, attached to a reservoir, such as an Ommaya reservoir. Pulmonary administration can also be employed, e.g., by use of an inhaler or nebulizer, and formulation with an aerosolizing agent.

5

10

15

20

25

30

In a specific embodiment, it may be desirable to administer the pharmaceutical compounds or compositions of the invention locally to the area in need of treatment; this may be achieved by, for example, and not by way of limitation, local infusion during surgery, topical application, e.g., in conjunction with a wound dressing after surgery, by injection, by means of a catheter, by means of a suppository, or by means of an implant, said implant being of a porous, non-porous, or gelatinous material, including membranes, such as sialastic membranes, or fibers. Preferably, when administering a protein, including an antibody, of the invention, care must be taken to use materials to which the protein does not absorb.

In another embodiment, the compound or composition can be delivered in a vesicle, in particular a liposome (see Langer, Science 249:1527-1533 (1990); Treat et al., in Liposomes in the Therapy of Infectious Disease and Cancer, Lopez-Berestein and Fidler (eds.), Liss, New York, pp. 353- 365 (1989); Lopez-Berestein, ibid., pp. 317-327; see generally ibid.)

In yet another embodiment, the compound or composition can be delivered in a controlled release system. In one embodiment, a pump may be used (see Langer, supra; Sefton, CRC Crit. Ref. Biomed. Eng. 14:201 (1987); Buchwald et al., Surgery 88:507 (1980); Saudek et al., N. Engl. J. Med. 321:574 (1989)). In another embodiment, polymeric materials can be used (see Medical Applications of Controlled Release, Langer and Wise (eds.), CRC Pres., Boca Raton, Florida (1974); Controlled Drug Bioavailability, Drug Product Design and Performance. Smolen and Ball (eds.), Wiley, New York (1984); Ranger and Peppas, J., Macromol. Sci. Rev. Macromol. Chem. 23:61 (1983); see also Levy et al., Science 228:190 (1985); During et al., Ann. Neurol. 25:351 (1989); Howard et al.,

WO 00/55351 PCT/US00/05883

215

J.Neurosurg. 71:105 (1989)). In yet another embodiment, a controlled release system can be placed in proximity of the therapeutic target, i.e., the brain, thus requiring only a fraction of the systemic dose (see, e.g., Goodson, in Medical Applications of Controlled Release, supra, vol. 2, pp. 115-138 (1984)).

Other controlled release systems are discussed in the review by Langer (Science 249:1527-1533 (1990)).

5

10

15

20

25

30

In a specific embodiment where the compound of the invention is a nucleic acid encoding a protein, the nucleic acid can be administered in vivo to promote expression of its encoded protein. by constructing it as part of an appropriate nucleic acid expression vector and administering it so that it becomes intracellular, e.g., by use of a retroviral vector (see U.S. Patent No. 4.980,286), or by direct injection, or by use of microparticle bombardment (e.g., a gene gun; Biolistic, Dupont), or coating with lipids or cell-surface receptors or transfecting agents, or by administering it in linkage to a homeobox-like peptide which is known to enter the nucleus (see e.g., Joliot et al., Proc. Natl. Acad. Sci. USA 88:1864-1868 (1991)), etc. Alternatively, a nucleic acid can be introduced intracellularly and incorporated within host cell DNA for expression, by homologous recombination.

The present invention also provides pharmaceutical compositions. Such compositions comprise a therapeutically effective amount of a compound, and a pharmaceutically acceptable carrier. In a specific embodiment, the term "pharmaceutically acceptable" means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans. The term "carrier" refers to a diluent, adjuvant, excipient, or vehicle with which the therapeutic is administered. Such pharmaceutical carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. Water is a preferred carrier when the pharmaceutical composition is administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions. Suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, tale, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like. The composition, if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents. These compositions can take the form of solutions, suspensions, emulsion, tablets, pills, capsules, powders, sustained-release formulations and the like. The composition can be formulated as a suppository, with traditional binders and carriers such as triglycerides. Oral formulation can include standard carriers such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, etc. Examples of suitable pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences" by E.W. Martin. Such compositions will contain a therapeutically effective amount of the compound, preferably in purified form, together with a suitable amount of carrier so as to provide the form for proper administration to the patient. The formulation should suit the mode of administration.

5

10

15

20

25

30.

In a preferred embodiment, the composition is formulated in accordance with routine procedures as a pharmaceutical composition adapted for intravenous administration to human beings. Typically, compositions for intravenous administration are solutions in sterile isotonic aqueous buffer. Where necessary, the composition may also include a solubilizing agent and a local anesthetic such as lignocaine to ease pain at the site of the injection. Generally, the ingredients are supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized powder or water free concentrate in a hermetically sealed container such as an ampoule or sachette indicating the quantity of active agent. Where the composition is to be administered by infusion, it can be dispensed with an infusion bottle containing sterile pharmaceutical grade water or saline. Where the composition is administered by injection, an ampoule of sterile water for injection or saline can be provided so that the ingredients may be mixed prior to administration.

The compounds of the invention can be formulated as neutral or salt forms. Pharmaceutically acceptable salts include those formed with anions such as those derived from hydrochloric, phosphoric, acetic, oxalic, tartaric acids, etc., and those formed with cations such as those derived from sodium, potassium, ammonium, calcium, ferric hydroxides, isopropylamine, triethylamine, 2-ethylamino ethanol, histidine, procaine, etc.

The amount of the compound of the invention which will be effective in the treatment, inhibition and prevention of a disease or disorder associated with aberrant expression and/or activity of a polypeptide of the invention can be determined by standard clinical techniques. In addition, in vitro assays may optionally be employed to help identify optimal dosage ranges. The precise dose to be employed in the formulation will also depend

on the route of administration, and the seriousness of the disease or disorder, and should be decided according to the judgment of the practitioner and each patient's circumstances. Effective doses may be extrapolated from dose-response curves derived from in vitro or animal model test systems.

For antibodies, the dosage administered to a patient is typically 0.1 mg/kg to 100 mg/kg of the patient's body weight. Preferably, the dosage administered to a patient is between 0.1 mg/kg and 20 mg/kg of the patient's body weight, more preferably 1 mg/kg to 10 mg/kg of the patient's body weight. Generally, human antibodies have a longer half-life within the human body than antibodies from other species due to the immune response to the foreign polypeptides. Thus, lower dosages of human antibodies and less frequent administration is often possible. Further, the dosage and frequency of administration of antibodies of the invention may be reduced by enhancing uptake and tissue penetration (e.g., into the brain) of the antibodies by modifications such as, for example, lipidation.

The invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions of the invention. Optionally associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration.

20

25

30

5

10

15

Diagnosis and Imaging

Labeled antibodies, and derivatives and analogs thereof, which specifically bind to a polypeptide of interest can be used for diagnostic purposes to detect, diagnose, or monitor diseases, disorders, and/or conditions associated with the aberrant expression and/or activity of a polypeptide of the invention. The invention provides for the detection of aberrant expression of a polypeptide of interest, comprising (a) assaying the expression of the polypeptide of interest in cells or body fluid of an individual using one or more antibodies specific to the polypeptide interest and (b) comparing the level of gene expression with a standard gene expression level, whereby an increase or decrease in the assayed polypeptide gene expression level compared to the standard expression level is indicative of aberrant expression.

WO 00/55351 PCT/US00/05883

The invention provides a diagnostic assay for diagnosing a disorder, comprising (a) assaying the expression of the polypeptide of interest in cells or body fluid of an individual using one or more antibodies specific to the polypeptide interest and (b) comparing the level of gene expression with a standard gene expression level, whereby an increase or decrease in the assayed polypeptide gene expression level compared to the standard expression level is indicative of a particular disorder. With respect to cancer, the presence of a relatively high amount of transcript in biopsied tissue from an individual may indicate a predisposition for the development of the disease, or may provide a means for detecting the disease prior to the appearance of actual clinical symptoms. A more definitive diagnosis of this type may allow health professionals to employ preventative measures or aggressive treatment earlier thereby preventing the development or further progression of the cancer.

Antibodies of the invention can be used to assay protein levels in a biological sample using classical immunohistological methods known to those of skill in the art (e.g., see Jalkanen, et al., J. Cell. Biol. 101:976-985 (1985); Jalkanen, et al., J. Cell. Biol. 105:3087-3096 (1987)). Other antibody-based methods useful for detecting protein gene expression include immunoassays, such as the enzyme linked immunosorbent assay (ELISA) and the radioimmunoassay (RIA). Suitable antibody assay labels are known in the art and include enzyme labels, such as, glucose oxidase; radioisotopes, such as iodine (1251, 1211), carbon (14C), sulfur (35S), tritium (3H), indium (112In), and technetium (99Tc); luminescent labels, such as luminol; and fluorescent labels, such as fluorescein and rhodamine, and biotin.

One aspect of the invention is the detection and diagnosis of a disease or disorder associated with aberrant expression of a polypeptide of interest in an animal, preferably a mammal and most preferably a human. In one embodiment, diagnosis comprises: a) administering (for example, parenterally, subcutaneously, or intraperitoneally) to a subject an effective amount of a labeled molecule which specifically binds to the polypeptide of interest; b) waiting for a time interval following the administering for permitting the labeled molecule to preferentially concentrate at sites in the subject where the polypeptide is expressed (and for unbound labeled molecule to be cleared to background level); c) determining background level; and d) detecting the labeled molecule in the subject, such that detection of labeled molecule above the background level indicates that the subject has a particular disease or disorder associated with aberrant expression of the polypeptide of interest. Background level can be determined by various methods including, comparing the

WO 00/55351

5

10

15

20

25

30

PCT/US00/05883

amount of labeled molecule detected to a standard value previously determined for a particular system.

It will be understood in the art that the size of the subject and the imaging system used will determine the quantity of imaging moiety needed to produce diagnostic images. In the case of a radioisotope moiety, for a human subject, the quantity of radioactivity injected will normally range from about 5 to 20 millicuries of 99mTc. The labeled antibody or antibody fragment will then preferentially accumulate at the location of cells which contain the specific protein. In vivo tumor imaging is described in S.W. Burchiel et al., "Immunopharmacokinetics of Radiolabeled Antibodies and Their Fragments." (Chapter 13 in Tumor Imaging: The Radiochemical Detection of Cancer, S.W. Burchiel and B. A. Rhodes, eds., Masson Publishing Inc. (1982).

Depending on several variables, including the type of label used and the mode of administration, the time interval following the administration for permitting the labeled molecule to preferentially concentrate at sites in the subject and for unbound labeled molecule to be cleared to background level is 6 to 48 hours or 6 to 24 hours or 6 to 12 hours. In another embodiment the time interval following administration is 5 to 20 days or 5 to 10 days.

In an embodiment, monitoring of the disease or disorder is carried out by repeating the method for diagnosing the disease or disease, for example, one month after initial diagnosis, six months after initial diagnosis, one year after initial diagnosis, etc.

Presence of the labeled molecule can be detected in the patient using methods known in the art for in vivo scanning. These methods depend upon the type of label used. Skilled artisans will be able to determine the appropriate method for detecting a particular label. Methods and devices that may be used in the diagnostic methods of the invention include, but are not limited to, computed tomography (CT), whole body scan such as position emission tomography (PET), magnetic resonance imaging (MRI), and sonography.

In a specific embodiment, the molecule is labeled with a radioisotope and is detected in the patient using a radiation responsive surgical instrument (Thurston et al., U.S. Patent No. 5,441,050). In another embodiment, the molecule is labeled with a fluorescent compound and is detected in the patient using a fluorescence responsive scanning instrument. In another embodiment, the molecule is labeled with a positron emitting metal and is detected in the patent using positron emission-tomography. In yet another embodiment, the molecule

is labeled with a paramagnetic label and is detected in a patient using magnetic resonance imaging (MRI).

Kits

5

10

15

20

25

30

The present invention provides kits that can be used in the above methods. In one embodiment, a kit comprises an antibody of the invention, preferably a purified antibody, in one or more containers. In a specific embodiment, the kits of the present invention contain a substantially isolated polypeptide comprising an epitope which is specifically immunoreactive with an antibody included in the kit. Preferably, the kits of the present invention further comprise a control antibody which does not react with the polypeptide of interest. In another specific embodiment, the kits of the present invention contain a means for detecting the binding of an antibody to a polypeptide of interest (e.g., the antibody may be conjugated to a detectable substrate such as a fluorescent compound, an enzymatic substrate, a radioactive compound or a luminescent compound, or a second antibody which recognizes the first antibody may be conjugated to a detectable substrate).

In another specific embodiment of the present invention, the kit is a diagnostic kit for use in screening serum containing antibodies specific against proliferative and/or cancerous polynucleotides and polypeptides. Such a kit may include a control antibody that does not react with the polypeptide of interest. Such a kit may include a substantially isolated polypeptide antigen comprising an epitope which is specifically immunoreactive with at least one anti-polypeptide antigen antibody. Further, such a kit includes means for detecting the binding of said antibody to the antigen (e.g., the antibody may be conjugated to a fluorescent compound such as fluorescein or rhodamine which can be detected by flow cytometry). In specific embodiments, the kit may include a recombinantly produced or chemically synthesized polypeptide antigen. The polypeptide antigen of the kit may also be attached to a solid support.

In a more specific embodiment the detecting means of the above-described kit includes a solid support to which said polypeptide antigen is attached. Such a kit may also include a non-attached reporter-labeled anti-human antibody. In this embodiment, binding of the antibody to the polypeptide antigen can be detected by binding of the said reporter-labeled antibody.

10

15

20

25

30

In an additional embodiment, the invention includes a diagnostic kit for use in screening serum containing antigens of the polypeptide of the invention. The diagnostic kit includes a substantially isolated antibody specifically immunoreactive with polypeptide or polynucleotide antigens, and means for detecting the binding of the polynucleotide or polypeptide antigen to the antibody. In one embodiment, the antibody is attached to a solid support. In a specific embodiment, the antibody may be a monoclonal antibody. The detecting means of the kit may include a second, labeled monoclonal antibody. Alternatively, or in addition, the detecting means may include a labeled, competing antigen.

In one diagnostic configuration, test serum is reacted with a solid phase reagent having a surface-bound antigen obtained by the methods of the present invention. After binding with specific antigen antibody to the reagent and removing unbound serum components by washing, the reagent is reacted with reporter-labeled anti-human antibody to bind reporter to the reagent in proportion to the amount of bound anti-antigen antibody on the solid support. The reagent is again washed to remove unbound labeled antibody, and the amount of reporter associated with the reagent is determined. Typically, the reporter is an enzyme which is detected by incubating the solid phase in the presence of a suitable fluorometric, luminescent or colorimetric substrate (Sigma, St. Louis, MO).

The solid surface reagent in the above assay is prepared by known techniques for attaching protein material to solid support material, such as polymeric beads, dip sticks, 96-well plate or filter material. These attachment methods generally include non-specific adsorption of the protein to the support or covalent attachment of the protein, typically through a free amine group, to a chemically reactive group on the solid support, such as an activated carboxyl, hydroxyl, or aldehyde group. Alternatively, streptavidin coated plates can be used in conjunction with biotinylated antigen(s).

Thus, the invention provides an assay system or kit for carrying out this diagnostic method. The kit generally includes a support with surface- bound recombinant antigens, and a reporter-labeled anti-human antibody for detecting surface-bound anti-antigen antibody.

Uses of the Polynucleotides

Each of the polynucleotides identified herein can be used in numerous ways as reagents. The following description should be considered exemplary and utilizes known techniques.

The colon cancer antigen polynucleotides of the present invention are useful for chromosome identification. There exists an ongoing need to identify new chromosome markers, since few chromosome marking reagents, based on actual sequence data (repeat polymorphisms), are presently available. Each sequence is specifically targeted to and can hybridize with a particular location on an individual human chromosome, thus each polynucleotide of the present invention can routinely be used as a chromosome marker using techniques known in the art.

5

10

15

20

25

30

Briefly, sequences can be mapped to chromosomes by preparing PCR primers (preferably at least 15 bp (e.g., 15-25 bp) from the sequences shown in SEQ ID NO:X, or the complement thereto. Primers can optionally be selected using computer analysis so that primers do not span more than one predicted exon in the genomic DNA. These primers are then used for PCR screening of somatic cell hybrids containing individual human chromosomes. Only those hybrids containing the human gene corresponding to SEQ ID NO:X will yield an amplified fragment.

Similarly, somatic hybrids provide a rapid method of PCR mapping the polynucleotides to particular chromosomes. Three or more clones can be assigned per day using a single thermal cycler. Moreover, sublocalization of the polynucleotides can be achieved with panels of specific chromosome fragments. Other gene mapping strategies that can be used include in situ hybridization, prescreening with labeled flow-sorted chromosomes, preselection by hybridization to construct chromosome specific-cDNA libraries, and computer mapping techniques (See, e.g., Shuler, Trends Biotechnol 16:456-459 (1998) which is hereby incorporated by reference in its entirety).

Precise chromosomal location of the polynucleotides can also be achieved using fluorescence in situ hybridization (FISH) of a metaphase chromosomal spread. This technique uses polynucleotides as short as 500 or 600 bases; however, polynucleotides 2,000-4,000 bp are preferred. For a review of this technique, see Verma et al., "Human Chromosomes: a Manual of Basic Techniques," Pergamon Press, New York (1988).

For chromosome mapping, the polynucleotides can be used individually (to mark a single chromosome or a single site on that chromosome) or in panels (for marking multiple sites and/or multiple chromosomes).

10

15

20

25

30

PCT/US00/05883

Thus, the present invention also provides a method for chromosomal localization which involves (a) preparing PCR primers from the polynucleotide sequences in Table 3 and SEQ ID NO:X and (b) screening somatic cell hybrids containing individual chromosomes.

The polynucleotides of the present invention would likewise be useful for radiation hybrid mapping, HAPPY mapping, and long range restriction mapping. For a review of these techniques and others known in the art, see, e.g. Dear, "Genome Mapping: A Practical Approach," IRL Press at Oxford University Press, London (1997); Aydin, J. Mol. Med. 77:691-694 (1999); Hacia et al., Mol. Psychiatry 3:483-492 (1998); Herrick et al., Chromosome Res. 7:409-423 (1999); Hamilton et al., Methods Cell Biol. 62:265-280 (2000); and/or Ott, J. Hered. 90:68-70 (1999) each of which is hereby incorporated by reference in its entirety.

Once a polynucleotide has been mapped to a precise chromosomal location, the physical position of the polynucleotide can be used in linkage analysis. Linkage analysis establishes coinheritance between a chromosomal location and presentation of a particular disease. (Disease mapping data are found, for example, in V. McKusick, Mendelian Inheritance in Man (available on line through Johns Hopkins University Welch Medical Library).) Assuming 1 megabase mapping resolution and one gene per 20 kb, a cDNA precisely localized to a chromosomal region associated with the disease could be one of 50-500 potential causative genes.

Thus, once coinheritance is established, differences in a polynucleotide of the invention and the corresponding gene between affected and unaffected individuals can be examined. First, visible structural alterations in the chromosomes, such as deletions or translocations, are examined in chromosome spreads or by PCR. If no structural alterations exist, the presence of point mutations are ascertained. Mutations observed in some or all affected individuals, but not in normal individuals, indicates that the mutation may cause the disease. However, complete sequencing of the polypeptide and the corresponding gene from several normal individuals is required to distinguish the mutation from a polymorphism. If a new polymorphism is identified, this polymorphic polypeptide can be used for further linkage analysis.

Furthermore, increased or decreased expression of the gene in affected individuals as compared to unaffected individuals can be assessed using the polynucleotides of the

WO 00/55351 PCT/US00/05883

5

10

15

20

25

30

224

invention. Any of these alterations (altered expression, chromosomal rearrangement, or mutation) can be used as a diagnostic or prognostic marker.

Thus, the invention provides a method of detecting increased or decreased expression levels of the colon cancer polynucleotides in affected individuals as compared to unaffected individuals using polynucleotides of the present invention and techniques known in the art, including but not limited to the method described in Example 11. Any of these alterations (altered expression, chromosomal rearrangement, or mutation) can be used as a diagnostic or prognostic marker.

Thus, the invention also provides a diagnostic method useful during diagnosis of a colon related disorder, including colon cancer, involving measuring the expression level of colon cancer polynucleotides in colon tissue or other cells or body fluid from an individual and comparing the measured gene expression level with a standard colon cancer polynucleotide expression level, whereby an increase or decrease in the gene expression level compared to the standard is indicative of a colon related disorder.

In still another embodiment, the invention includes a kit for analyzing samples for the presence of proliferative and/or cancerous polynucleotides derived from a test subject. In a general embodiment, the kit includes at least one polynucleotide probe containing a nucleotide sequence that will specifically hybridize with a polynucleotide of the invention and a suitable container. In a specific embodiment, the kit includes two polynucleotide probes defining an internal region of the polynucleotide of the invention, where each probe has one strand containing a 31'mer-end internal to the region. In a further embodiment, the probes may be useful as primers for polymerase chain reaction amplification.

Where a diagnosis of a colon related disorder, including, for example, diagnosis of a tumor, has already been made according to conventional methods, the present invention is useful as a prognostic indicator, whereby patients exhibiting enhanced or depressed colon cancer polynucleotide expression will experience a worse clinical outcome relative to patients expressing the gene at a level nearer the standard level.

By "measuring the expression level of colon cancer polynucleotides" is intended qualitatively or quantitatively measuring or estimating the level of the colon cancer polypeptide or the level of the mRNA encoding the colon cancer polypeptide in a first biological sample either directly (e.g., by determining or estimating absolute protein level or mRNA level) or relatively (e.g., by comparing to the colon cancer polypeptide level or

10

15

20

25

30

mRNA level in a second biological sample). Preferably, the colon cancer polypeptide level or mRNA level in the first biological sample is measured or estimated and compared to a standard colon cancer polypeptide level or mRNA level, the standard being taken from a second biological sample obtained from an individual not having the colon related disorder or being determined by averaging levels from a population of individuals not having a colon related disorder. As will be appreciated in the art, once a standard colon cancer polypeptide level or mRNA level is known, it can be used repeatedly as a standard for comparison.

By "biological sample" is intended any biological sample obtained from an individual, body fluid, cell line, tissue culture, or other source which contains colon cancer polypeptide or the corresponding mRNA. As indicated, biological samples include body fluids (such as lymph, sera, plasma, urine, bile, synovial fluid and spinal fluid) which contain the colon cancer polypeptide, colon tissue, and other tissue sources found to express the colon cancer polypeptide. Methods for obtaining tissue biopsies and body fluids from mammals are well known in the art. Where the biological sample is to include mRNA, a tissue biopsy is the preferred source.

The method(s) provided above may preferrably be applied in a diagnostic method and/or kits in which polynucleotides and/or polypeptides of the invention are attached to a solid support. In one exemplary method, the support may be a "gene chip" or a "biological chip" as described in US Patents 5,837,832, 5,874,219, and 5,856,174. Further, such a gene chip with colon cancer polynucleotides attached may be used to identify polymorphisms between the colon cancer polynucleotide sequences, with polynucleotides isolated from a test subject. The knowledge of such polymorphisms (i.e. their location, as well as, their existence) would be beneficial in identifying disease loci for many disorders, such as for example, in neural disorders, immune system disorders, muscular disorders, reproductive disorders, gastrointestinal disorders, pulmonary disorders, cardiovascular disorders, renal disorders, proliferative disorders, and/or cancerous diseases and conditions, though most preferably in colon related proliferative, and/or cancerous diseases and conditions. Such a method is described in US Patents 5,858,659 and 5,856,104. The US Patents referenced supra are hereby incorporated by reference in their entirety herein.

The present invention encompasses colon cancer polynucleotides that are chemically synthesized, or reproduced as peptide nucleic acids (PNA), or according to other methods known in the art. The use of PNAs would serve as the preferred form if the polynucleotides

10

15

20

25

30

of the invention are incorporated onto a solid support, or gene chip. For the purposes of the present invention, a peptide nucleic acid (PNA) is a polyamide type of DNA analog and the monomeric units for adenine, guanine, thymine and cytosine are available commercially (Perceptive Biosystems). Certain components of DNA, such as phosphorus, phosphorus oxides, or deoxyribose derivatives, are not present in PNAs. As disclosed by P. E. Nielsen, M. Egholm, R. H. Berg and O. Buchardt, Science 254, 1497 (1991); and M. Egholm. O. Buchardt, L.Christensen, C. Behrens, S. M. Freier, D. A. Driver, R. H. Berg, S. K. Kim, B. Norden, and P. E. Nielsen, Nature 365, 666 (1993), PNAs bind specifically and tightly to complementary DNA strands and are not degraded by nucleases. In fact, PNA binds more strongly to DNA than DNA itself does. This is probably because there is no electrostatic repulsion between the two strands, and also the polyamide backbone is more flexible. Because of this, PNA/DNA duplexes bind under a wider range of stringency conditions than DNA/DNA duplexes, making it easier to perform multiplex hybridization. Smaller probes can be used than with DNA due to the strong binding. In addition, it is more likely that single base mismatches can be determined with PNA/DNA hybridization because a single mismatch in a PNA/DNA 15-mer lowers the melting point (T.sub.m) by 8°-20° C, vs. 4°-16° C for the DNA/DNA 15-mer duplex. Also, the absence of charge groups in PNA means that hybridization can be done at low ionic strengths and reduce possible interference by salt during the analysis.

The present invention have uses which include, but are not limited to, detecting cancer in mammals. In particular the invention is useful during diagnosis of pathological cell proliferative neoplasias which include, but are not limited to: acute myelogenous leukemias including acute monocytic leukemia, acute myeloblastic leukemia, acute promyelocytic leukemia, acute myelomonocytic leukemia, acute erythroleukemia, acute megakaryocytic leukemia, and acute undifferentiated leukemia, etc.; and chronic myelogenous leukemias including chronic myelomonocytic leukemia, chronic granulocytic leukemia, etc. Preferred mammals include monkeys, apes, cats, dogs, cows, pigs, horses, rabbits and humans. Particularly preferred are humans.

Pathological cell proliferative disorders are often associated with inappropriate activation of proto-oncogenes. (Gelmann, E. P. et al., "The Etiology of Acute Leukemia: Molecular Genetics and Viral Oncology," in Neoplastic Diseases of the Blood, Vol 1., Wiernik, P. H. et al. eds., 161-182 (1985)). Neoplasias are now believed to result from the

WO 00/55351

5

10

15

20

25

30

227

qualitative alteration of a normal cellular gene product, or from the quantitative modification of gene expression by insertion into the chromosome of a viral sequence, by chromosomal translocation of a gene to a more actively transcribed region, or by some other mechanism. (Gelmann et al., supra) It is likely that mutated or altered expression of specific genes is involved in the pathogenesis of some leukemias, among other tissues and cell types. (Gelmann et al., supra) Indeed, the human counterparts of the oncogenes involved in some animal neoplasias have been amplified or translocated in some cases of human leukemia and carcinoma. (Gelmann et al., supra)

For example, c-myc expression is highly amplified in the non-lymphocytic leukemia cell line HL-60. When HL-60 cells are chemically induced to stop proliferation, the level of c-myc is found to be downregulated. (International Publication Number WO 91/15580). However, it has been shown that exposure of HL-60 cells to a DNA construct that is complementary to the 5' end of c-myc or c-myb blocks translation of the corresponding mRNAs which downregulates expression of the c-myc or c-myb proteins and causes arrest of cell proliferation and differentiation of the treated cells. (International Publication Number WO 91/15580; Wickstrom et al., Proc. Natl. Acad. Sci. 85:1028 (1988); Anfossi et al., Proc. Natl. Acad. Sci. 86:3379 (1989)). However, the skilled artisan would appreciate the present invention's usefulness is not limited to treatment of proliferative disorders of hematopoietic cells and tissues, in light of the numerous cells and cell types of varying origins which are known to exhibit proliferative phenotypes.

In addition to the foregoing, a colon cancer antigen polynucleotide can be used to control gene expression through triple helix formation or through antisense DNA or RNA. Antisense techniques are discussed, for example, in Okano, J. Neurochem. 56: 560 (1991); "Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988). Triple helix formation is discussed in, for instance Lee et al., Nucleic Acids Research 6: 3073 (1979); Cooney et al., Science 241: 456 (1988); and Dervan et al., Science 251: 1360 (1991). Both methods rely on binding of the polynucleotide to a complementary DNA or RNA. For these techniques, preferred polynucleotides are usually oligonucleotides 20 to 40 bases in length and complementary to either the region of the gene involved in transcription (triple helix - see Lee et al., Nucl. Acids Res. 6:3073 (1979); Cooney et al., Science 241:456 (1988); and Dervan et al., Science 251:1360 (1991)) or to the mRNA itself (antisense - Okano, J. Neurochem. 56:560 (1991); Oligodeoxy-nucleotides as Antisense

10

15

20

25

30

Inhibitors of Gene Expression, CRC Press, Boca Raton. FL (1988).) Triple helix formation optimally results in a shut-off of RNA transcription from DNA, while antisense RNA hybridization blocks translation of an mRNA molecule into polypeptide. The oligonucleotide described above can also be delivered to cells such that the antisense RNA or DNA may be expressed in vivo to inhibit production of polypeptide of the present invention antigens. Both techniques are effective in model systems, and the information disclosed herein can be used to design antisense or triple helix polynucleotides in an effort to treat disease, and in particular, for the treatment of proliferative diseases and/or conditions.

Polynucleotides of the present invention are also useful in gene therapy. One goal of gene therapy is to insert a normal gene into an organism having a defective gene, in an effort to correct the genetic defect. The polynucleotides disclosed in the present invention offer a means of targeting such genetic defects in a highly accurate manner. Another goal is to insert a new gene that was not present in the host genome, thereby producing a new trait in the host cell.

The polynucleotides are also useful for identifying individuals from minute biological samples. The United States military, for example, is considering the use of restriction fragment length polymorphism (RFLP) for identification of its personnel. In this technique, an individual's genomic DNA is digested with one or more restriction enzymes, and probed on a Southern blot to yield unique bands for identifying personnel. This method does not suffer from the current limitations of "Dog Tags" which can be lost, switched, or stolen, making positive identification difficult. The polynucleotides of the present invention can be used as additional DNA markers for RFLP.

The polynucleotides of the present invention can also be used as an alternative to RFLP, by determining the actual base-by-base DNA sequence of selected portions of an individual's genome. These sequences can be used to prepare PCR primers for amplifying and isolating such selected DNA, which can then be sequenced. Using this technique, individuals can be identified because each individual will have a unique set of DNA sequences. Once an unique ID database is established for an individual, positive identification of that individual, living or dead, can be made from extremely small tissue samples.

Forensic biology also benefits from using DNA-based identification techniques as disclosed herein. DNA sequences taken from very small biological samples such as tissues,

WO 00/55351

5

10

15

20

25

30

229

PCT/US00/05883

e.g., hair or skin, or body fluids, e.g., blood, saliva, semen, synovial fluid, amniotic fluid, breast milk, lymph, pulmonary sputum or surfactant, urine, fecal matter, etc., can be amplified using PCR. In one prior art technique, gene sequences amplified from polymorphic loci, such as DQa class II HLA gene, are used in forensic biology to identify individuals. (Erlich, H., PCR Technology, Freeman and Co. (1992).) Once these specific polymorphic loci are amplified, they are digested with one or more restriction enzymes, yielding an identifying set of bands on a Southern blot probed with DNA corresponding to the DQa class II HLA gene. Similarly, polynucleotides of the present invention can be used as polymorphic markers for forensic purposes.

There is also a need for reagents capable of identifying the source of a particular tissue. Such need arises, for example, in forensics when presented with tissue of unknown origin. Appropriate reagents can comprise, for example, DNA probes or primers specific to colon or colon cancer polynucleotides prepared from the sequences of the present invention. Panels of such reagents can identify tissue by species and/or by organ type. In a similar fashion, these reagents can be used to screen tissue cultures for contamination.

The polynucleotides of the present invention are also useful as hybridization probes for differential identification of the tissue(s) or cell type(s) present in a biological sample. Similarly, polypeptides and antibodies directed to polypeptides of the present invention are useful to provide immunological probes for differential identification of the tissue(s) (e.g., immunohistochemistry assays) or cell type(s) (e.g., immunocytochemistry assays). In addition, for a number of disorders of the above tissues or cells, significantly higher or lower levels of gene expression of the polynucleotides/polypeptides of the present invention may be detected in certain tissues (e.g., tissues expressing polypeptides and/or polynucleotides of the present invention, colon and colon cancer tissues and/or cancerous and/or wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) taken from an individual having such a disorder, relative to a "standard" gene expression level, i.e., the expression level in healthy tissue from an individual not having the disorder.

Thus, the invention provides a diagnostic method of a disorder, which involves: (a) assaying gene expression level in cells or body fluid of an individual; (b) comparing the gene expression level with a standard gene expression level, whereby an increase or decrease in the assayed gene expression level compared to the standard expression level is indicative of a disorder.

10

15

20

25

30

In the very least, the polynucleotides of the present invention can be used as molecular weight markers on Southern gels, as diagnostic probes for the presence of a specific mRNA in a particular cell type, as a probe to "subtract-out" known sequences in the process of discovering novel polynucleotides, for selecting and making oligomers for attachment to a "gene chip" or other support, to raise anti-DNA antibodies using DNA immunization techniques, and as an antigen to elicit an immune response.

Uses of the Polypeptides

Each of the polypeptides identified herein can be used in numerous ways. The following description should be considered exemplary and utilizes known techniques.

Polypeptides and antibodies directed to polypeptides of the present invention are useful to provide immunological probes for differential identification of the tissue(s) (e.g., immunohistochemistry assays such as, for example, ABC immunoperoxidase (Hsu et al., J. Histochem. Cytochem. 29:577-580 (1981)) or cell type(s) (e.g., immunocytochemistry assays).

Antibodies can be used to assay levels of polypeptides encoded by polynucleotides of the invention in a biological sample using classical immunohistological methods known to those of skill in the art (e.g., see Jalkanen, et al., J. Cell. Biol. 101:976-985 (1985); Jalkanen, et al., J. Cell. Biol. 105:3087-3096 (1987)). Other antibody-based methods useful for detecting protein gene expression include immunoassays, such as the enzyme linked immunosorbent assay (ELISA) and the radioimmunoassay (RIA). Suitable antibody assay labels are known in the art and include enzyme labels, such as, glucose oxidase; radioisotopes, such as iodine (¹³¹I, ¹²⁵I, ¹²³I, ¹²¹I), carbon (¹⁴C), sulfur (³⁵S), tritium (³H), indium (^{115m}In, ^{113m}In, ¹¹²In, ¹¹¹In), and technetium (⁹⁹Tc, ^{99m}Tc), thallium (²⁰¹Ti), gallium (⁶⁸Ga, ⁶⁷Ga), palladium (¹⁰³Pd), molybdenum (⁹⁹Mo), xenon (¹³³Xe), fluorine (¹⁸F), ¹⁵³Sm, ¹⁷⁵Lu, ¹⁵⁹Gd, ¹⁴⁹Pm, ¹⁴⁰La, ¹⁷⁵Yb, ¹⁶⁶Ho, ⁹⁰Y, ⁴⁷Sc, ¹⁸⁶Re, ¹⁸⁸Re, ¹⁴²Pr, ¹⁰⁵Rh, ⁹⁷Ru; luminescent labels, such as luminol; and fluorescent labels, such as fluorescein and rhodamine, and biotin.

In addition to assaying levels of polypeptide of the present invention in a biological sample, proteins can also be detected in vivo by imaging. Antibody labels or markers for in vivo imaging of protein include those detectable by X-radiography, NMR or ESR. For X-radiography, suitable labels include radioisotopes such as barium or cesium, which emit

10

15

20

25

30

PCT/US00/05883

detectable radiation but are not overtly harmful to the subject. Suitable markers for NMR and ESR include those with a detectable characteristic spin, such as deuterium, which may be incorporated into the antibody by labeling of nutrients for the relevant hybridoma.

A protein-specific antibody or antibody fragment which has been labeled with an appropriate detectable imaging moiety, such as a radioisotope (for example, 131 I. 112 In, 99mTc, (131 I, 125 I, 123 I, 121 I), carbon (14C), sulfur (35S), tritium (3H), indium (115m In, 113m In, 112 In, 111 In), and technetium (99Tc, 99mTc), thallium (201Ti), gallium (68Ga, 67Ga), palladium (103Pd), molybdenum (99Mo), xenon (133Xe), fluorine (18F, 153Sm, 177Lu, 159Gd, 149Pm, 140La, 175Yb, ¹⁶⁶Ho. ⁹⁰Y. ⁴⁷Sc. ¹⁸⁶Re, ¹⁸⁸Re, ¹⁴²Pr, ¹⁰⁵Rh, ⁹⁷Ru), a radio-opaque substance, or a material detectable by nuclear magnetic resonance, is introduced (for example, parenterally, subcutaneously or intraperitoneally) into the mammal to be examined for immune system disorder. It will be understood in the art that the size of the subject and the imaging system used will determine the quantity of imaging moiety needed to produce diagnostic images. In the case of a radioisotope moiety, for a human subject, the quantity of radioactivity injected will normally range from about 5 to 20 millicuries of 99mTc. The labeled antibody or antibody fragment will then preferentially accumulate at the location of cells which express the polypeptide encoded by a polynucleotide of the invention. In vivo tumor imaging is described in S.W. Burchiel et al., "Immunopharmacokinetics of Radiolabeled Antibodies and Their Fragments" (Chapter 13 in Tumor Imaging: The Radiochemical Detection of Cancer, S.W. Burchiel and B. A. Rhodes, eds., Masson Publishing Inc. (1982)).

In one embodiment, the invention provides a method for the specific delivery of compositions of the invention to cells by administering polypeptides of the invention (e.g., polypeptides encoded by polynucleotides of the invention and/or antibodies) that are associated with heterologous polypeptides or nucleic acids. In one example, the invention provides a method for delivering a therapeutic protein into the targeted cell. In another example, the invention provides a method for delivering a single stranded nucleic acid (e.g., antisense or ribozymes) or double stranded nucleic acid (e.g., DNA that can integrate into the cell's genome or replicate episomally and that can be transcribed) into the targeted cell.

In another embodiment, the invention provides a method for the specific destruction of cells (e.g., the destruction of tumor cells) by administering polypeptides of the invention in association with toxins or cytotoxic prodrugs.

WO 00/55351

5

10

15

20

25

30

232

PCT/US00/05883

By "toxin" is meant one or more compounds that bind and activate endogenous cytotoxic effector systems, radioisotopes, holotoxins, modified toxins, catalytic subunits of toxins, or any molecules or enzymes not normally present in or on the surface of a cell that under defined conditions cause the cell's death. Toxins that may be used according to the methods of the invention include, but are not limited to, radioisotopes known in the art, compounds such as, for example, antibodies (or complement fixing containing portions thereof) that bind an inherent or induced endogenous cytotoxic effector system, thymidine kinase, endonuclease, RNAse, alpha toxin, ricin, abrin, *Pseudomonas* exotoxin A, diphtheria toxin, saporin, momordin, gelonin, pokeweed antiviral protein, alpha-sarcin and cholera toxin. "Toxin" also includes a cytostatic or cytocidal agent, a therapeutic agent or a radioactive metal ion, e.g., alpha-emitters such as, for example, ²¹³Bi, or other radioisotopes such as, for example, ¹⁰³Pd, ¹³³Xe, ¹³¹I, ⁶⁸Ge, ⁵⁷Co, ⁶⁵Zn, ⁸⁵Sr, ³²P, ³⁵S, ⁹⁰Y, ¹⁵³Sm, ¹⁵³Gd, ¹⁶⁹Yb, ⁵¹Cr, ⁵⁴Mn, ⁷⁵Se, ¹¹³Sn, ⁹⁰Yttrium, ¹¹⁷Tin, ¹⁸⁶Rhenium, ¹⁶⁶Holmium, and ¹⁸⁸Rhenium; luminescent labels, such as luminol; and fluorescent labels, such as fluorescein and rhodamine, and biotin.

Techniques known in the art may be applied to label polypeptides of the invention (including antibodies). Such techniques include, but are not limited to, the use of bifunctional conjugating agents (see e.g., U.S. Patent Nos. 5,756,065; 5,714,631; 5,696,239; 5,652,361; 5,505,931; 5,489,425; 5,435,990; 5,428,139; 5,342,604; 5,274,119; 4,994,560; and 5.808,003; the contents of each of which are hereby incorporated by reference in its entirety).

Thus, the invention provides a diagnostic method of a disorder, which involves (a) assaying the expression level of a colon cancer polypeptide of the present invention in cells or body fluid of an individual, or more preferrably, assaying the expression level of a colon cancer polypeptide of the present invention in colon cells or sera of an individual; and (b) comparing the assayed polypeptide expression level with a standard polypeptide expression level, whereby an increase or decrease in the assayed polypeptide expression level compared to the standard expression level is indicative of a disorder. With respect to cancer, the presence of a relatively high amount of transcript in biopsied tissue from an individual may indicate a predisposition for the development of the disease, or may provide a means for detecting the disease prior to the appearance of actual clinical symptoms. A more definitive diagnosis of this type may allow health professionals to employ preventative measures or

WO 00/55351 PCT/US00/05883

aggressive treatment earlier thereby preventing the development or further progression of the cancer.

5

10

15

20

25

Moreover, colon cancer antigen polypeptides of the present invention can be used to treat or prevent diseases or conditions such as, for example, neural disorders, immune system disorders, muscular disorders, reproductive disorders, gastrointestinal disorders, pulmonary disorders, cardiovascular disorders, renal disorders, proliferative disorders, and/or cancerous diseases and conditions, preferably proliferative disorders of the colon, and/or cancerous disease and conditions. For example, patients can be administered a polypeptide of the present invention in an effort to replace absent or decreased levels of the polypeptide (e.g., insulin), to supplement absent or decreased levels of a different polypeptide (e.g., hemoglobin S for hemoglobin B. SOD, catalase, DNA repair proteins), to inhibit the activity of a polypeptide (e.g., an oncogene or tumor supressor), to activate the activity of a polypeptide (e.g., by binding to a receptor), to reduce the activity of a membrane bound receptor by competing with it for free ligand (e.g., soluble TNF receptors used in reducing inflammation), or to bring about a desired response (e.g., blood vessel growth inhibition, enhancement of the immune response to proliferative cells or tissues).

Similarly, antibodies directed to a polypeptide of the present invention can also be used to treat disease (as described supra, and elsewhere herein). For example, administration of an antibody directed to a polypeptide of the present invention can bind, and/or neutralize the polypeptide. and/or reduce overproduction of the polypeptide. Similarly, administration of an antibody can activate the polypeptide, such as by binding to a polypeptide bound to a membrane (receptor).

At the very least, the polypeptides of the present invention can be used as molecular weight markers on SDS-PAGE gels or on molecular sieve gel filtration columns using methods well known to those of skill in the art. Polypeptides can also be used to raise antibodies, which in turn are used to measure protein expression from a recombinant cell, as a way of assessing transformation of the host cell. Moreover, the polypeptides of the present invention can be used to test the following biological activities.

Gene Therapy Methods

5

10

15

20

25

30

Another aspect of the present invention is to gene therapy methods for treating or preventing disorders, diseases and conditions. The gene therapy methods relate to the introduction of nucleic acid (DNA, RNA and antisense DNA or RNA) sequences into an animal to achieve expression of the polypeptide of the present invention. This method requires a polynucleotide which codes for a polypeptide of the present invention operatively linked to a promoter and any other genetic elements necessary for the expression of the polypeptide by the target tissue. Such gene therapy and delivery techniques are known in the art, see, for example, WO90/11092, which is herein incorporated by reference.

Thus, for example, cells from a patient may be engineered with a polynucleotide (DNA or RNA) comprising a promoter operably linked to a polynucleotide of the present invention ex vivo, with the engineered cells then being provided to a patient to be treated with the polypeptide of the present invention. Such methods are well-known in the art. For example, see Belldegrun, A., et al., J. Natl. Cancer Inst. 85: 207-216 (1993); Ferrantini, M. et al., Cancer Research 53: 1107-1112 (1993); Ferrantini, M. et al., J. Immunology 153: 4604-4615 (1994); Kaido, T., et al., Int. J. Cancer 60: 221-229 (1995); Ogura, H., et al., Cancer Research 50: 5102-5106 (1990); Santodonato, L., et al., Human Gene Therapy 7:1-10 (1996); Santodonato, L., et al., Gene Therapy 4:1246-1255 (1997); and Zhang, J.-F. et al., Cancer Gene Therapy 3: 31-38 (1996)), which are herein incorporated by reference. In one embodiment, the cells which are engineered are arterial cells. The arterial cells may be reintroduced into the patient through direct injection to the artery, the tissues surrounding the artery, or through catheter injection.

As discussed in more detail below, the polynucleotide constructs can be delivered by any method that delivers injectable materials to the cells of an animal, such as, injection into the interstitial space of tissues (heart, muscle, skin, lung, liver, and the like). The polynucleotide constructs may be delivered in a pharmaceutically acceptable liquid or aqueous carrier.

In one embodiment, the polynucleotide of the present invention is delivered as a naked polynucleotide. The term "naked" polynucleotide, DNA or RNA refers to sequences that are free from any delivery vehicle that acts to assist, promote or facilitate entry into the cell, including viral sequences, viral particles, liposome formulations, lipofectin or precipitating agents and the like. However, the polynucleotide of the present invention can

WO 00/55351 PCT/US00/05883

235

also be delivered in liposome formulations and lipofectin formulations and the like can be prepared by methods well known to those skilled in the art. Such methods are described, for example, in U.S. Patent Nos. 5,593.972. 5,589,466. and 5,580,859, which are herein incorporated by reference.

The polynucleotide vector constructs used in the gene therapy method are preferably constructs that will not integrate into the host genome nor will they contain sequences that allow for replication. Appropriate vectors include pWLNEO, pSV2CAT, pOG44, pXT1 and pSG available from Stratagene: pSVK3, pBPV, pMSG and pSVL available from Pharmacia; and pEF1/V5, pcDNA3.1, and pRc/CMV2 available from Invitrogen. Other suitable vectors will be readily apparent to the skilled artisan.

5

10

15

20

25

30

Any strong promoter known to those skilled in the art can be used for driving the expression of the polynucleotide sequence. Suitable promoters include adenoviral promoters, such as the adenoviral major late promoter: or heterologous promoters, such as the cytomegalovirus (CMV) promoter; the respiratory syncytial virus (RSV) promoter; inducible promoters, such as the MMT promoter, the metallothionein promoter; heat shock promoters; the albumin promoter; the ApoAI promoter; human globin promoters; viral thymidine kinase promoters, such as the Herpes Simplex thymidine kinase promoter; retroviral LTRs; the bactin promoter; and human growth hormone promoters. The promoter also may be the native promoter for the polynucleotide of the present invention.

Unlike other gene therapy techniques, one major advantage of introducing naked nucleic acid sequences into target cells is the transitory nature of the polynucleotide synthesis in the cells. Studies have shown that non-replicating DNA sequences can be introduced into cells to provide production of the desired polypeptide for periods of up to six months.

The polynucleotide construct can be delivered to the interstitial space of tissues within the an animal, including of muscle, skin, brain, lung, liver, spleen, bone marrow, thymus, heart, lymph, blood, bone, cartilage, pancreas, kidney, gall bladder, stomach, intestine, testis, ovary, uterus, rectum, nervous system, eye, gland, and connective tissue. Interstitial space of the tissues comprises the intercellular, fluid, mucopolysaccharide matrix among the reticular fibers of organ tissues, elastic fibers in the walls of vessels or chambers, collagen fibers of fibrous tissues, or that same matrix within connective tissue ensheathing muscle cells or in the lacunae of bone. It is similarly the space occupied by the plasma of the circulation and the lymph fluid of the lymphatic channels. Delivery to the interstitial space of muscle tissue is

WO 00/55351 PCT/US00/05883

5

10

15

20

25

30

236

preferred for the reasons discussed below. They may be conveniently delivered by injection into the tissues comprising these cells. They are preferably delivered to and expressed in persistent, non-dividing cells which are differentiated, although delivery and expression may be achieved in non-differentiated or less completely differentiated cells, such as, for example, stem cells of blood or skin fibroblasts. In vivo muscle cells are particularly competent in their ability to take up and express polynucleotides.

For the naked nucleic acid sequence injection, an effective dosage amount of DNA or RNA will be in the range of from about 0.05 mg/kg body weight to about 50 mg/kg body weight. Preferably the dosage will be from about 0.005 mg/kg to about 20 mg/kg and more preferably from about 0.05 mg/kg to about 5 mg/kg. Of course, as the artisan of ordinary skill will appreciate, this dosage will vary according to the tissue site of injection. The appropriate and effective dosage of nucleic acid sequence can readily be determined by those of ordinary skill in the art and may depend on the condition being treated and the route of administration.

The preferred route of administration is by the parenteral route of injection into the interstitial space of tissues. However, other parenteral routes may also be used, such as, inhalation of an aerosol formulation particularly for delivery to lungs or bronchial tissues, throat or mucous membranes of the nose. In addition, naked DNA constructs can be delivered to arteries during angioplasty by the catheter used in the procedure.

The naked polynucleotides are delivered by any method known in the art, including, but not limited to, direct needle injection at the delivery site, intravenous injection, topical administration, catheter infusion, and so-called "gene guns". These delivery methods are known in the art.

The constructs may also be delivered with delivery vehicles such as viral sequences, viral particles, liposome formulations, lipofectin, precipitating agents, etc. Such methods of delivery are known in the art.

In certain embodiments, the polynucleotide constructs are complexed in a liposome preparation. Liposomal preparations for use in the instant invention include cationic (positively charged), anionic (negatively charged) and neutral preparations. However, cationic liposomes are particularly preferred because a tight charge complex can be formed between the cationic liposome and the polyanionic nucleic acid. Cationic liposomes have been shown to mediate intracellular delivery of plasmid DNA (Felgner et al., Proc. Natl. Acad. Sci. USA (1987) 84:7413-7416, which is herein incorporated by reference); mRNA

(Malone et al., Proc. Natl. Acad. Sci. USA (1989) 86:6077-6081, which is herein incorporated by reference); and purified transcription factors (Debs et al., J. Biol. Chem. (1990) 265:10189-10192, which is herein incorporated by reference), in functional form.

Cationic liposomes are readily available. For example, N[1-2.3-dioleyloxy)propyl]-N,N,N-triethylammonium (DOTMA) liposomes are particularly useful and are available under the trademark Lipofectin, from GIBCO BRL, Grand Island, N.Y. (See, also, Felgner et al., Proc. Natl Acad. Sci. USA (1987) 84:7413-7416, which is herein incorporated by reference). Other commercially available liposomes include transfectace (DDAB/DOPE) and DOTAP/DOPE (Boehringer).

5

10

15

20

25

30

Other cationic liposomes can be prepared from readily available materials using techniques well known in the art. See, e.g. PCT Publication No. WO 90/11092 (which is herein incorporated by reference) for a description of the synthesis of DOTAP (1,2-bis(oleoyloxy)-3-(trimethylammonio)propane) liposomes. Preparation of DOTMA liposomes is explained in the literature, see, e.g., P. Felgner et al., Proc. Natl. Acad. Sci. USA 84:7413-7417, which is herein incorporated by reference. Similar methods can be used to prepare liposomes from other cationic lipid materials.

Similarly, anionic and neutral liposomes are readily available, such as from Avanti Polar Lipids (Birmingham, Ala.), or can be easily prepared using readily available materials. Such materials include phosphatidyl, choline, cholesterol, phosphatidyl ethanolamine, dioleoylphosphatidyl choline (DOPC), dioleoylphosphatidyl glycerol (DOPG), dioleoylphoshatidyl ethanolamine (DOPE), among others. These materials can also be mixed with the DOTMA and DOTAP starting materials in appropriate ratios. Methods for making liposomes using these materials are well known in the art.

For example, commercially dioleoylphosphatidyl choline (DOPC), dioleoylphosphatidyl glycerol (DOPG), and dioleoylphosphatidyl ethanolamine (DOPE) can be used in various combinations to make conventional liposomes, with or without the addition of cholesterol. Thus, for example, DOPG/DOPC vesicles can be prepared by drying 50 mg each of DOPG and DOPC under a stream of nitrogen gas into a sonication vial. The sample is placed under a vacuum pump overnight and is hydrated the following day with deionized water. The sample is then sonicated for 2 hours in a capped vial, using a Heat Systems model 350 sonicator equipped with an inverted cup (bath type) probe at the maximum setting while the bath is circulated at 15EC. Alternatively, negatively charged

10

15

20

25

30

vesicles can be prepared without sonication to produce multilamellar vesicles or by extrusion through nucleopore membranes to produce unilamellar vesicles of discrete size. Other methods are known and available to those of skill in the art.

The liposomes can comprise multilamellar vesicles (MLVs), small unilamellar vesicles (SUVs), or large unilamellar vesicles (LUVs), with SUVs being preferred. The various liposome-nucleic acid complexes are prepared using methods well known in the art. See, e.g., Straubinger et al., Methods of Immunology (1983), 101:512-527, which is herein incorporated by reference. For example, MLVs containing nucleic acid can be prepared by depositing a thin film of phospholipid on the walls of a glass tube and subsequently hydrating with a solution of the material to be encapsulated. SUVs are prepared by extended sonication of MLVs to produce a homogeneous population of unilamellar liposomes. The material to be entrapped is added to a suspension of preformed MLVs and then sonicated. When using liposomes containing cationic lipids, the dried lipid film is resuspended in an appropriate solution such as sterile water or an isotonic buffer solution such as 10 mM Tris/NaCl, sonicated, and then the preformed liposomes are mixed directly with the DNA. The liposome and DNA form a very stable complex due to binding of the positively charged liposomes to the cationic DNA. SUVs find use with small nucleic acid fragments. LUVs are prepared by a number of methods, well known in the art. Commonly used methods include Ca2+-EDTA chelation (Papahadiopoulos et al., Biochim. Biophys. Acta (1975) 394:483; Wilson et al., Cell (1979) 17:77); ether injection (Deamer, D. and Bangham, A., Biochim. Biophys. Acta (1976) 443:629; Ostro et al., Biochem. Biophys. Res. Commun. (1977) 76:836; Fraley et al., Proc. Natl. Acad. Sci. USA (1979) 76:3348); detergent dialysis (Enoch, H. and Strittmatter, P., Proc. Natl. Acad. Sci. USA (1979) 76:145); and reverse-phase evaporation (REV) (Fraley et al., J. Biol, Chem. (1980) 255:10431; Szoka, F. and Papahadjopoulos, D., Proc. Natl. Acad. Sci. USA (1978) 75:145; Schaefer-Ridder et al., Science (1982) 215:166), which are herein incorporated by reference.

Generally, the ratio of DNA to liposomes will be from about 10:1 to about 1:10. Preferably, the ration will be from about 5:1 to about 1:5. More preferably, the ration will be about 3:1 to about 1:3. Still more preferably, the ratio will be about 1:1.

U.S. Patent No. 5,676,954 (which is herein incorporated by reference) reports on the injection of genetic material, complexed with cationic liposomes carriers, into mice. U.S. Patent Nos. 4,897,355, 4,946,787, 5,049,386, 5,459,127, 5,589,466, 5,693,622, 5,580,859,

10

15

20

25

30

5.703.055, and international publication no. WO 94/9469 (which are herein incorporated by reference) provide cationic lipids for use in transfecting DNA into cells and mammals. U.S. Patent Nos. 5,589,466, 5,693.622, 5,580.859, 5,703,055, and international publication no. WO 94/9469 (which are herein incorporated by reference) provide methods for delivering DNA-cationic lipid complexes to mammals.

In certain embodiments, cells are engineered, ex vivo or in vivo, using a retroviral particle containing RNA which comprises a sequence encoding a polypeptide of the present invention. Retroviruses from which the retroviral plasmid vectors may be derived include, but are not limited to, Moloney Murine Leukemia Virus, spleen necrosis virus, Rous sarcoma Virus, Harvey Sarcoma Virus, avian leukosis virus, gibbon ape leukemia virus, human immunodeficiency virus, Myeloproliferative Sarcoma Virus, and mammary tumor virus.

The retroviral plasmid vector is employed to transduce packaging cell lines to form producer cell lines. Examples of packaging cells which may be transfected include, but are not limited to, the PE501, PA317, R-2, R-AM, PA12, T19-14X, VT-19-17-H2, RCRE, RCRIP, GP+E-86, GP+envAm12, and DAN cell lines as described in Miller, Human Gene Therapy 1:5-14 (1990), which is incorporated herein by reference in its entirety. The vector may transduce the packaging cells through any means known in the art. Such means include, but are not limited to, electroporation, the use of liposomes, and CaPO₄ precipitation. In one alternative, the retroviral plasmid vector may be encapsulated into a liposome, or coupled to a lipid, and then administered to a host.

The producer cell line generates infectious retroviral vector particles which include polynucleotide encoding a polypeptide of the present invention. Such retroviral vector particles then may be employed, to transduce eukaryotic cells, either in vitro or in vivo. The transduced eukaryotic cells will express a polypeptide of the present invention.

In certain other embodiments, cells are engineered, ex vivo or in vivo, with polynucleotide contained in an adenovirus vector. Adenovirus can be manipulated such that it encodes and expresses a polypeptide of the present invention, and at the same time is inactivated in terms of its ability to replicate in a normal lytic viral life cycle. Adenovirus expression is achieved without integration of the viral DNA into the host cell chromosome, thereby alleviating concerns about insertional mutagenesis. Furthermore, adenoviruses have been used as live enteric vaccines for many years with an excellent safety profile (Schwartz, A. R. et al. (1974) Am. Rev. Respir. Dis.109:233-238). Finally, adenovirus mediated gene

WO 00/55351

5

10

15

20

25

30

transfer has been demonstrated in a number of instances including transfer of alpha-1-antitrypsin and CFTR to the lungs of cotton rats (Rosenfeld, M. A. et al. (1991) Science 252:431-434; Rosenfeld et al., (1992) Cell 68:143-155). Furthermore, extensive studies to attempt to establish adenovirus as a causative agent in human cancer were uniformly negative (Green, M. et al. (1979) Proc. Natl. Acad. Sci. USA 76:6606).

Suitable adenoviral vectors useful in the present invention are described, for example, in Kozarsky and Wilson, Curr. Opin. Genet. Devel. 3:499-503 (1993): Rosenfeld et al., Cell 68:143-155 (1992); Engelhardt et al., Human Genet. Ther. 4:759-769 (1993); Yang et al., Nature Genet. 7:362-369 (1994); Wilson et al., Nature 365:691-692 (1993); and U.S. Patent No. 5,652,224, which are herein incorporated by reference. For example, the adenovirus vector Ad2 is useful and can be grown in human 293 cells. These cells contain the E1 region of adenovirus and constitutively express Ela and Elb, which complement the defective adenoviruses by providing the products of the genes deleted from the vector. In addition to Ad2, other varieties of adenovirus (e.g., Ad3, Ad5, and Ad7) are also useful in the present invention.

Preferably, the adenoviruses used in the present invention are replication deficient. Replication deficient adenoviruses require the aid of a helper virus and/or packaging cell line to form infectious particles. The resulting virus is capable of infecting cells and can express a polynucleotide of interest which is operably linked to a promoter, but cannot replicate in most cells. Replication deficient adenoviruses may be deleted in one or more of all or a portion of the following genes: E1a, E1b, E3, E4, E2a, or L1 through L5.

In certain other embodiments, the cells are engineered, ex vivo or in vivo, using an adeno-associated virus (AAV). AAVs are naturally occurring defective viruses that require helper viruses to produce infectious particles (Muzyczka, N., Curr. Topics in Microbiol. Immunol. 158:97 (1992)). It is also one of the few viruses that may integrate its DNA into non-dividing cells. Vectors containing as little as 300 base pairs of AAV can be packaged and can integrate. but space for exogenous DNA is limited to about 4.5 kb. Methods for producing and using such AAVs are known in the art. See, for example, U.S. Patent Nos. 5,139,941, 5,173,414, 5,354,678, 5,436,146, 5,474,935, 5,478,745. and 5.589,377.

For example, an appropriate AAV vector for use in the present invention will include all the sequences necessary for DNA replication, encapsidation, and host-cell integration. The polynucleotide construct is inserted into the AAV vector using standard cloning

WO 00/55351 PCT/US00/05883

methods, such as those found in Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Press (1989). The recombinant AAV vector is then transfected into packaging cells which are infected with a helper virus, using any standard technique, including lipofection, electroporation, calcium phosphate precipitation, etc. Appropriate helper viruses include adenoviruses, cytomegaloviruses, vaccinia viruses, or herpes viruses. Once the packaging cells are transfected and infected, they will produce infectious AAV viral particles which contain the polynucleotide construct. These viral particles are then used to transduce eukaryotic cells, either ex vivo or in vivo. The transduced cells will contain the polynucleotide construct integrated into its genome, and will express a polypeptide of the invention.

5

10

15

20

25

30

Another method of gene therapy involves operably associating heterologous control regions and endogenous polynucleotide sequences (e.g. encoding a polypeptide of the present invention) via homologous recombination (see, e.g., U.S. Patent No. 5,641,670, issued June 24, 1997; International Publication No. WO 96/29411, published September 26, 1996; International Publication No. WO 94/12650, published August 4, 1994; Koller et al., Proc. Natl. Acad. Sci. USA 86:8932-8935 (1989); and Zijlstra et al., Nature 342:435-438 (1989). This method involves the activation of a gene which is present in the target cells, but which is not normally expressed in the cells, or is expressed at a lower level than desired.

Polynucleotide constructs are made, using standard techniques known in the art, which contain the promoter with targeting sequences flanking the promoter. Suitable promoters are described herein. The targeting sequence is sufficiently complementary to an endogenous sequence to permit homologous recombination of the promoter-targeting sequence with the endogenous sequence. The targeting sequence will be sufficiently near the 5' end of the desired endogenous polynucleotide sequence so the promoter will be operably linked to the endogenous sequence upon homologous recombination.

The promoter and the targeting sequences can be amplified using PCR. Preferably, the amplified promoter contains distinct restriction enzyme sites on the 5' and 3' ends. Preferably, the 3' end of the first targeting sequence contains the same restriction enzyme site as the 5' end of the amplified promoter and the 5' end of the second targeting sequence contains the same restriction site as the 3' end of the amplified promoter. The amplified promoter and targeting sequences are digested and ligated together.

The promoter-targeting sequence construct is delivered to the cells, either as naked polynucleotide, or in conjunction with transfection-facilitating agents, such as liposomes, viral sequences, viral particles, whole viruses, lipofection, precipitating agents, etc., described in more detail above. The P promoter-targeting sequence can be delivered by any method, included direct needle injection, intravenous injection, topical administration, catheter infusion, particle accelerators, etc. The methods are described in more detail below.

5

10

15

20

25

30

The promoter-targeting sequence construct is taken up by cells. Homologous recombination between the construct and the endogenous sequence takes place, such that an endogenous sequence is placed under the control of the promoter. The promoter then drives the expression of the endogenous sequence.

Preferably, the polynucleotide encoding a polypeptide of the present invention contains a secretory signal sequence that facilitates secretion of the protein. Typically, the signal sequence is positioned in the coding region of the polynucleotide to be expressed towards or at the 5' end of the coding region. The signal sequence may be homologous or heterologous to the polynucleotide of interest and may be homologous or heterologous to the cells to be transfected. Additionally, the signal sequence may be chemically synthesized using methods known in the art.

Any mode of administration of any of the above-described polynucleotides constructs can be used so long as the mode results in the expression of one or more molecules in an amount sufficient to provide a therapeutic effect. This includes direct needle injection, systemic injection, catheter infusion, biolistic injectors, particle accelerators (i.e., "gene guns"), gelfoam sponge depots, other commercially available depot materials, osmotic pumps (e.g., Alza minipumps), oral or suppositorial solid (tablet or pill) pharmaceutical formulations, and decanting or topical applications during surgery. For example, direct injection of naked calcium phosphate-precipitated plasmid into rat liver and rat spleen or a protein-coated plasmid into the portal vein has resulted in gene expression of the foreign gene in the rat livers (Kaneda et al., Science 243:375 (1989)).

A preferred method of local administration is by direct injection. Preferably, a recombinant molecule of the present invention complexed with a delivery vehicle is administered by direct injection into or locally within the area of arteries. Administration of a composition locally within the area of arteries refers to injecting the composition centimeters and preferably, millimeters within arteries.

10

15

20

25

Another method of local administration is to contact a polynucleotide construct of the present invention in or around a surgical wound. For example, a patient can undergo surgery and the polynucleotide construct can be coated on the surface of tissue inside the wound or the construct can be injected into areas of tissue inside the wound.

Therapeutic compositions useful in systemic administration, include recombinant molecules of the present invention complexed to a targeted delivery vehicle of the present invention. Suitable delivery vehicles for use with systemic administration comprise liposomes comprising ligands for targeting the vehicle to a particular site.

Preferred methods of systemic administration, include intravenous injection. aerosol, oral and percutaneous (topical) delivery. Intravenous injections can be performed using methods standard in the art. Aerosol delivery can also be performed using methods standard in the art (see, for example, Stribling et al., Proc. Natl. Acad. Sci. USA 189:11277-11281, 1992, which is incorporated herein by reference). Oral delivery can be performed by complexing a polynucleotide construct of the present invention to a carrier capable of withstanding degradation by digestive enzymes in the gut of an animal. Examples of such carriers, include plastic capsules or tablets, such as those known in the art. Topical delivery can be performed by mixing a polynucleotide construct of the present invention with a lipophilic reagent (e.g., DMSO) that is capable of passing into the skin.

Determining an effective amount of substance to be delivered can depend upon a number of factors including, for example, the chemical structure and biological activity of the substance, the age and weight of the animal, the precise condition requiring treatment and its severity, and the route of administration. The frequency of treatments depends upon a number of factors, such as the amount of polynucleotide constructs administered per dose, as well as the health and history of the subject. The precise amount, number of doses, and timing of doses will be determined by the attending physician or veterinarian.

Therapeutic compositions of the present invention can be administered to any animal, preferably to mammals and birds. Preferred mammals include humans, dogs, cats, mice, rats, rabbits sheep, cattle, horses and pigs, with humans being particularly preferred.

30 Biological Activities

Polynucleotides or polypeptides, or agonists or antagonists of the present invention, can be used in assays to test for one or more biological activities. If these polynucleotides or

polypeptides. or agonists or antagonists of the present invention, do exhibit activity in a particular assay, it is likely that these molecules may be involved in the diseases associated with the biological activity. Thus, the polynucleotides and polypeptides, and agonists or antagonists could be used to treat the associated disease.

5

10

15

20

25

30

Immune Activity

A polypeptide or polynucleotide, or agonists or antagonists of the present invention may be useful in treating deficiencies or disorders of the immune system, by activating or inhibiting the proliferation, differentiation, or mobilization (chemotaxis) of immune cells. Immune cells develop through a process called hematopoiesis, producing myeloid (platelets, red blood cells, neutrophils, and macrophages) and lymphoid (B and T lymphocytes) cells from pluripotent stem cells. The etiology of these immune deficiencies or disorders may be genetic, somatic, such as cancer or some autoimmune disorders, acquired (e.g., by chemotherapy or toxins), or infectious. Moreover, polynucleotides or polypeptides, or agonists or antagonists of the present invention can be used as a marker or detector of a particular immune system disease or disorder.

Polynucleotides or polypeptides, or agonists or antagonists of the present invention may be useful in treating or detecting deficiencies or disorders of hematopoietic cells. Polynucleotides or polypeptides, or agonists or antagonists of the present invention could be used to increase differentiation and proliferation of hematopoietic cells, including the pluripotent stem cells, in an effort to treat those disorders associated with a decrease in certain (or many) types hematopoietic cells. Examples of immunologic deficiency syndromes include, but are not limited to: blood protein disorders (e.g. agammaglobulinemia, dysgammaglobulinemia), ataxia telangiectasia, common variable immunodeficiency, Digeorge Syndrome, HIV infection, HTLV-BLV infection, leukocyte adhesion deficiency syndrome, lymphopenia, phagocyte bactericidal dysfunction, severe combined immunodeficiency (SCIDs), Wiskott-Aldrich Disorder, anemia, thrombocytopenia, or hemoglobinuria.

Moreover, polynucleotides or polypeptides, or agonists or antagonists of the present invention could also be used to modulate hemostatic (the stopping of bleeding) or thrombolytic activity (clot formation). For example, by increasing hemostatic or thrombolytic activity, polynucleotides or polypeptides, or agonists or antagonists of the

10

15

20

25

30

present invention could be used to treat blood coagulation disorders (e.g., afibrinogenemia, factor deficiencies), blood platelet disorders (e.g., thrombocytopenia), or wounds resulting from trauma, surgery, or other causes. Alternatively, polynucleotides or polypeptides, or agonists or antagonists of the present invention that can decrease hemostatic or thrombolytic activity could be used to inhibit or dissolve clotting. These molecules could be important in the treatment of heart attacks (infarction), strokes, or scarring.

Polynucleotides or polypeptides, or agonists or antagonists of the present invention may also be useful in treating or detecting autoimmune disorders. Many autoimmune disorders result from inappropriate recognition of self as foreign material by immune cells. This inappropriate recognition results in an immune response leading to the destruction of the host tissue. Therefore, the administration of polynucleotides or polypeptides, or agonists or antagonists of the present invention that can inhibit an immune response, particularly the proliferation, differentiation, or chemotaxis of T-cells, may be an effective therapy in preventing autoimmune disorders.

Examples of autoimmune disorders that can be treated or detected include, but are not limited to: Addison's Disease, hemolytic anemia, antiphospholipid syndrome, rheumatoid arthritis, dermatitis, allergic encephalomyelitis, glomerulonephritis, Goodpasture's Syndrome, Graves' Disease, Multiple Sclerosis, Myasthenia Gravis, Neuritis, Ophthalmia, Bullous Pemphigoid, Pemphigus, Polyendocrinopathies, Purpura, Reiter's Disease, Stiff-Man Syndrome, Autoimmune Thyroiditis, Systemic Lupus Erythematosus, Autoimmune Pulmonary Inflammation, Guillain-Barre Syndrome, insulin dependent diabetes mellitis, and autoimmune inflammatory eye disease.

Similarly, allergic reactions and conditions, such as asthma (particularly allergic asthma) or other respiratory problems, may also be treated by polynucleotides or polypeptides, or agonists or antagonists of the present invention. Moreover, these molecules can be used to treat anaphylaxis, hypersensitivity to an antigenic molecule, or blood group incompatibility.

Polynucleotides or polypeptides, or agonists or antagonists of the present invention may also be used to treat and/or prevent organ rejection or graft-versus-host disease (GVHD). Organ rejection occurs by host immune cell destruction of the transplanted tissue through an immune response. Similarly, an immune response is also involved in GVHD, but, in this case, the foreign transplanted immune cells destroy the host tissues. The administration of

polynucleotides or polypeptides, or agonists or antagonists of the present invention that inhibits an immune response, particularly the proliferation, differentiation, or chemotaxis of T-cells, may be an effective therapy in preventing organ rejection or GVHD.

Similarly, polynucleotides or polypeptides. or agonists or antagonists of the present invention may also be used to modulate inflammation. For example, polynucleotides or polypeptides, or agonists or antagonists of the present invention may inhibit the proliferation and differentiation of cells involved in an inflammatory response. These molecules can be used to treat inflammatory conditions, both chronic and acute conditions, including chronic prostatitis, granulomatous prostatitis and malacoplakia, inflammation associated with infection (e.g., septic shock, sepsis, or systemic inflammatory response syndrome (SIRS)), ischemia-reperfusion injury, endotoxin lethality, arthritis, complement-mediated hyperacute rejection, nephritis, cytokine or chemokine induced lung injury, inflammatory bowel disease, Crohn's disease, or resulting from over production of cytokines (e.g., TNF or IL-1.)

15 Hyperproliferative Disorders

5

10

20

25

30

Polynucleotides or polypeptides, or agonists or antagonists of the present invention can be used to treat or detect hyperproliferative disorders, including neoplasms. Polynucleotides or polypeptides, or agonists or antagonists of the present invention may inhibit the proliferation of the disorder through direct or indirect interactions. Alternatively, Polynucleotides or polypeptides, or agonists or antagonists of the present invention may proliferate other cells which can inhibit the hyperproliferative disorder.

For example, by increasing an immune response, particularly increasing antigenic qualities of the hyperproliferative disorder or by proliferating, differentiating, or mobilizing T-cells, hyperproliferative disorders can be treated. This immune response may be increased by either enhancing an existing immune response, or by initiating a new immune response. Alternatively, decreasing an immune response may also be a method of treating hyperproliferative disorders, such as a chemotherapeutic agent.

Examples of hyperproliferative disorders that can be treated or detected by Polynucleotides or polypeptides, or agonists or antagonists of the present invention include, but are not limited to neoplasms located in the: colon, abdomen, bone, breast, digestive system, liver, pancreas, peritoneum, endocrine glands (adrenal, parathyroid, pituitary,

WO 00/55351

5

10

15

20

25

30

247

PCT/US00/05883

testicles, ovary, thymus, thyroid), eye, head and neck, nervous (central and peripheral), lymphatic system, pelvic, skin, soft tissue, spleen, thoracic, and urogenital.

Similarly, other hyperproliferative disorders can also be treated or detected by polynucleotides or polypeptides, or agonists or antagonists of the present invention. Examples of such hyperproliferative disorders include, but are not limited to: hypergammaglobulinemia, lymphoproliferative disorders, paraproteinemias, purpura, sarcoidosis, Sezary Syndrome, Waldenstron's Macroglobulinemia, Gaucher's Disease, histiocytosis, and any other hyperproliferative disease, besides neoplasia, located in an organ system listed above.

One preferred embodiment utilizes polynucleotides of the present invention to inhibit aberrant cellular division, by gene therapy using the present invention, and/or protein fusions or fragments thereof.

Thus, the present invention provides a method for treating cell proliferative disorders by inserting into an abnormally proliferating cell a polynucleotide of the present invention, wherein said polynucleotide represses said expression.

Another embodiment of the present invention provides a method of treating cellproliferative disorders in individuals comprising administration of one or more active gene copies of the present invention to an abnormally proliferating cell or cells. In a preferred embodiment, polynucleotides of the present invention is a DNA construct comprising a recombinant expression vector effective in expressing a DNA sequence encoding said polynucleotides. In another preferred embodiment of the present invention, the DNA construct encoding the poynucleotides of the present invention is inserted into cells to be treated utilizing a retrovirus, or more preferrably an adenoviral vector (See G J. Nabel, et. al., PNAS 1999 96: 324-326, which is hereby incorporated by reference). In a most preferred embodiment, the viral vector is defective and will not transform non-proliferating cells, only proliferating cells. Moreover, in a preferred embodiment, the polynucleotides of the present invention inserted into proliferating cells either alone, or in combination with or fused to other polynucleotides, can then be modulated via an external stimulus (i.e. magnetic, specific small molecule, chemical, or drug administration, etc.), which acts upon the promoter upstream of said polynucleotides to induce expression of the encoded protein product. As such the beneficial therapeutic affect of the present invention may be expressly modulated

(i.e. to increase, decrease, or inhibit expression of the present invention) based upon said external stimulus.

Polynucleotides of the present invention may be useful in repressing expression of oncogenic genes or antigens. By "repressing expression of the oncogenic genes" is intended the suppression of the transcription of the gene, the degradation of the gene transcript (premessage RNA), the inhibition of splicing, the destruction of the messenger RNA, the prevention of the post-translational modifications of the protein, the destruction of the protein, or the inhibition of the normal function of the protein.

5

10

15

20

25

30

For local administration to abnormally proliferating cells, polynucleotides of the present invention may be administered by any method known to those of skill in the art including, but not limited to transfection, electroporation, microinjection of cells, or in vehicles such as liposomes, lipofectin, or as naked polynucleotides, or any other method described throughout the specification. The polynucleotide of the present invention may be delivered by known gene delivery systems such as, but not limited to, retroviral vectors (Gilboa, J. Virology 44:845 (1982); Hocke, Nature 320:275 (1986); Wilson, et al., Proc. Natl. Acad. Sci. U.S.A. 85:3014), vaccinia virus system (Chakrabarty et al., Mol. Cell Biol. 5:3403 (1985) or other efficient DNA delivery systems (Yates et al., Nature 313:812 (1985)) known to those skilled in the art. These references are exemplary only and are hereby incorporated by reference. In order to specifically deliver or transfect cells which are abnormally proliferating and spare non-dividing cells, it is preferable to utilize a retrovirus, or adenoviral (as described in the art and elsewhere herein) delivery system known to those of skill in the art. Since host DNA replication is required for retroviral DNA to integrate and the retrovirus will be unable to self replicate due to the lack of the retrovirus genes needed for its life cycle. Utilizing such a retroviral delivery system for polynucleotides of the present invention will target said gene and constructs to abnormally proliferating cells and will spare the nondividing normal cells.

The polynucleotides of the present invention may be delivered directly to cell proliferative disorder/disease sites in internal organs, body cavities and the like by use of imaging devices used to guide an injecting needle directly to the disease site. The polynucleotides of the present invention may also be administered to disease sites at the time of surgical intervention.

By "cell proliferative disease" is meant any human or animal disease or disorder, affecting any one or any combination of organs, cavities, or body parts, which is characterized by single or multiple local abnormal proliferations of cells, groups of cells, or tissues, whether benign or malignant.

5

10

15

20

25

30

Any amount of the polynucleotides of the present invention may be administered as long as it has a biologically inhibiting effect on the proliferation of the treated cells. Moreover, it is possible to administer more than one of the polynucleotide of the present invention simultaneously to the same site. By "biologically inhibiting" is meant partial or total growth inhibition as well as decreases in the rate of proliferation or growth of the cells. The biologically inhibitory dose may be determined by assessing the effects of the polynucleotides of the present invention on target malignant or abnormally proliferating cell growth in tissue culture, tumor growth in animals and cell cultures, or any other method known to one of ordinary skill in the art.

The present invention is further directed to antibody-based therapies which involve administering of anti-polypeptides and anti-polynucleotide antibodies to a mammalian, preferably human, patient for treating one or more of the described disorders. Methods for producing anti-polypeptides and anti-polynucleotide antibodies polyclonal and monoclonal antibodies are described in detail elsewhere herein. Such antibodies may be provided in pharmaceutically acceptable compositions as known in the art or as described herein.

A summary of the ways in which the antibodies of the present invention may be used therapeutically includes binding polynucleotides or polypeptides of the present invention locally or systemically in the body or by direct cytotoxicity of the antibody, e.g. as mediated by complement (CDC) or by effector cells (ADCC). Some of these approaches are described in more detail below. Armed with the teachings provided herein, one of ordinary skill in the art will know how to use the antibodies of the present invention for diagnostic, monitoring or therapeutic purposes without undue experimentation.

In particular, the antibodies, fragments and derivatives of the present invention are useful for treating a subject having or developing cell proliferative and/or differentiation disorders as described herein. Such treatment comprises administering a single or multiple doses of the antibody, or a fragment, derivative, or a conjugate thereof.

The antibodies of this invention may be advantageously utilized in combination with other monoclonal or chimeric antibodies, or with lymphokines or hematopoietic growth

factors. for example., which serve to increase the number or activity of effector cells which interact with the antibodies.

It is preferred to use high affinity and/or potent in vivo inhibiting and/or neutralizing antibodies against polypeptides or polynucleotides of the present invention. fragments or regions thereof, for both immunoassays directed to and therapy of disorders related to polynucleotides or polypeptides, including fragements thereof, of the present invention. Such antibodies, fragments, or regions, will preferably have an affinity for polynucleotides or polypeptides, including fragements thereof. Preferred binding affinities include those with a dissociation constant or Kd less than 5X10⁻⁶M, 10⁻⁶M, 5X10⁻⁷M, 10⁻⁷M, 5X10⁻⁸M, 10⁻⁸M, 5X10⁻¹⁹M, 5X10⁻¹⁰M, 10⁻¹⁰M, 5X10⁻¹¹M, 10⁻¹¹M, 5X10⁻¹²M, 5X10⁻¹³M, 10⁻¹³M, 5X10⁻¹⁴M, 5X10⁻¹⁵M, and 10⁻¹⁵M.

5

10

15

20

25

30

Moreover, polypeptides of the present invention are useful in inhibiting the angiogenesis of proliferative cells or tissues, either alone, as a protein fusion, or in combination with other polypeptides directly or indirectly, as described elsewhere herein. In a most preferred embodiment, said anti-angiogenesis effect may be achieved indirectly, for example, through the inhibition of hematopoietic, tumor-specific cells, such as tumor-associated macrophages (See Joseph IB, et al. J Natl Cancer Inst, 90(21):1648-53 (1998), which is hereby incorporated by reference). Antibodies directed to polypeptides or polynucleotides of the present invention may also result in inhibition of angiogenesis directly, or indirectly (See Witte L, et al., Cancer Metastasis Rev. 17(2):155-61 (1998), which is hereby incorporated by reference)).

Polypeptides, including protein fusions, of the present invention, or fragments thereof may be useful in inhibiting proliferative cells or tissues through the induction of apoptosis. Said polypeptides may act either directly, or indirectly to induce apoptosis of proliferative cells and tissues, for example in the activation of a death-domain receptor, such as tumor necrosis factor (TNF) receptor-1, CD95 (Fas/APO-1), TNF-receptor-related apoptosis-mediated protein (TRAMP) and TNF-related apoptosis-inducing ligand (TRAIL) receptor-1 and -2 (See Schulze-Osthoff K, et.al., Eur J Biochem 254(3):439-59 (1998), which is hereby incorporated by reference). Moreover, in another preferred embodiment of the present invention, said polypeptides may induce apoptosis through other mechanisms, such as in the activation of other proteins which will activate apoptosis, or through stimulating the expression of said proteins, either alone or in combination with small molecule drugs or

adjuviants, such as apoptonin, galectins, thioredoxins, antiinflammatory proteins (See for example, Mutat Res 400(1-2):447-55 (1998), Med Hypotheses.50(5):423-33 (1998), Chem Biol Interact. Apr 24;111-112:23-34 (1998), J Mol Med.76(6):402-12 (1998), Int J Tissue React;20(1):3-15 (1998), which are all hereby incorporated by reference).

Polypeptides, including protein fusions to. or fragments thereof. of the present invention are useful in inhibiting the metastasis of proliferative cells or tissues. Inhibition may occur as a direct result of administering polypeptides, or antibodies directed to said polypeptides as described elsewere herein, or indirectly, such as activating the expression of proteins known to inhibit metastasis, for example alpha 4 integrins, (See, e.g., Curr Top Microbiol Immunol 1998;231:125-41, which is hereby incorporated by reference). Such thereapeutic affects of the present invention may be achieved either alone, or in combination with small molecule drugs or adjuvants.

In another embodiment, the invention provides a method of delivering compositions containing the polypeptides of the invention (e.g., compositions containing polypeptides or polypeptide antibodes associated with heterologous polypeptides, heterologous nucleic acids, toxins, or prodrugs) to targeted cells expressing the polypeptide of the present invention. Polypeptides or polypeptide antibodes of the invention may be associated with with heterologous polypeptides, heterologous nucleic acids, toxins, or prodrugs via hydrophobic, hydrophilic, ionic and/or covalent interactions. Polypeptides, protein fusions to, or fragments thereof, of the present invention are useful in enhancing the immunogenicity and/or antigenicity of proliferating cells or tissues, either directly, such as would occur if the polypeptides of the present invention 'vaccinated' the immune response to respond to proliferative antigens and immunogens, or indirectly, such as in activating the expression of proteins known to enhance the immune response (e.g. chemokines), to said antigens and immunogens.

Cardiovascular Disorders

5

10

15

20

25

30

Polynucleotides or polypeptides, or agonists or antagonists of the present invention, may be used to treat cardiovascular disorders, including peripheral artery disease, such as limb ischemia.

Cardiovascular disorders include cardiovascular abnormalities, such as arterio-arterial fistula, arteriovenous fistula, cerebral arteriovenous malformations, congenital heart defects,

pulmonary atresia, and Scimitar Syndrome. Congenital heart defects include aortic coarctation, cor triatriatum, coronary vessel anomalies, crisscross heart, dextrocardia, patent ductus arteriosus, Ebstein's anomaly, Eisenmenger complex, hypoplastic left heart syndrome, levocardia, tetralogy of fallot, transposition of great vessels, double outlet right ventricle, tricuspid atresia, persistent truncus arteriosus, and heart septal defects, such as aortopulmonary septal defect, endocardial cushion defects, Lutembacher's Syndrome, trilogy of Fallot, ventricular heart septal defects.

5

10

15

20

25

30

Cardiovascular disorders also include heart disease, such as arrhythmias, carcinoid heart disease, high cardiac output, low cardiac output, cardiac tamponade, endocarditis (including bacterial), heart aneurysm. cardiac arrest, congestive heart failure, congestive cardiomyopathy, paroxysmal dyspnea, cardiac edema, heart hypertrophy, congestive cardiomyopathy, left ventricular hypertrophy, right ventricular hypertrophy, post-infarction heart rupture, ventricular septal rupture, heart valve diseases, myocardial diseases, myocardial ischemia, pericardial effusion, pericarditis (including constrictive and tuberculous), pneumopericardium, postpericardiotomy syndrome, pulmonary heart disease, rheumatic heart disease, ventricular dysfunction, hyperemia, cardiovascular pregnancy complications, Scimitar Syndrome, cardiovascular syphilis, and cardiovascular tuberculosis.

Arrhythmias include sinus arrhythmia, atrial fibrillation, atrial flutter, bradycardia, extrasystole, Adams-Stokes Syndrome, bundle-branch block, sinoatrial block, long QT syndrome, parasystole, Lown-Ganong-Levine Syndrome, Mahaim-type pre-excitation syndrome, Wolff-Parkinson-White syndrome, sick sinus syndrome, tachycardias, and ventricular fibrillation. Tachycardias include paroxysmal tachycardia, supraventricular tachycardia, accelerated idioventricular rhythm, atrioventricular nodal reentry tachycardia, ectopic atrial tachycardia, ectopic junctional tachycardia, sinoatrial nodal reentry tachycardia, sinus tachycardia, Torsades de Pointes, and ventricular tachycardia.

Heart valve disease include aortic valve insufficiency, aortic valve stenosis, hear murmurs, aortic valve prolapse, mitral valve prolapse, tricuspid valve prolapse, mitral valve insufficiency, mitral valve stenosis, pulmonary atresia, pulmonary valve insufficiency, pulmonary valve stenosis, tricuspid atresia, tricuspid valve insufficiency, and tricuspid valve stenosis.

Myocardial diseases include alcoholic cardiomyopathy, congestive cardiomyopathy, hypertrophic cardiomyopathy, aortic subvalvular stenosis, pulmonary subvalvular stenosis,

10

15

20

25

30

restrictive cardiomyopathy, Chagas cardiomyopathy, endocardial fibroelastosis, endomyocardial fibrosis, Kearns Syndrome. myocardial reperfusion injury, and myocarditis.

Myocardial ischemias include coronary disease, such as angina pectoris, coronary aneurysm. coronary arteriosclerosis, coronary thrombosis, coronary vasospasm, myocardial infarction and myocardial stunning.

Cardiovascular diseases also include vascular diseases such as aneurysms, angiodysplasia, angiomatosis, bacillary angiomatosis, Hippel-Lindau Disease, Klippel-Trenaunay-Weber Syndrome, Sturge-Weber Syndrome, angioneurotic edema, aortic diseases, Takayasu's Arteritis, aortitis. Leriche's Syndrome, arterial occlusive diseases, arteritis, enarteritis, polyarteritis nodosa, cerebrovascular disorders, diabetic angiopathies, diabetic retinopathy, embolisms, thrombosis, erythromelalgia, hemorrhoids, hepatic veno-occlusive disease, hypertension, hypotension, ischemia, peripheral vascular diseases, phlebitis, pulmonary veno-occlusive disease, Raynaud's disease, CREST syndrome, retinal vein occlusion, Scimitar syndrome, superior vena cava syndrome, telangiectasia, atacia telangiectasia, hereditary hemorrhagic telangiectasia, varicocele, varicose veins, varicose ulcer, vasculitis, and venous insufficiency.

Aneurysms include dissecting aneurysms, false aneurysms, infected aneurysms, ruptured aneurysms, aortic aneurysms, cerebral aneurysms, coronary aneurysms, heart aneurysms, and iliac aneurysms.

Arterial occlusive diseases include arteriosclerosis, intermittent claudication, carotid stenosis, fibromuscular dysplasias, mesenteric vascular occlusion, Moyamoya disease, renal artery obstruction, retinal artery occlusion, and thromboangiitis obliterans.

Cerebrovascular disorders include carotid artery diseases, cerebral amyloid angiopathy, cerebral aneurysm, cerebral anoxia, cerebral arteriosclerosis, cerebral arteriovenous malformation, cerebral artery diseases, cerebral embolism and thrombosis, carotid artery thrombosis, sinus thrombosis, Wallenberg's syndrome, cerebral hemorrhage, epidural hematoma, subdural hematoma, subaraxhnoid hemorrhage, cerebral infarction, cerebral ischemia (including transient), subclavian steal syndrome, periventricular leukomalacia, vascular headache, cluster headache, migraine, and vertebrobasilar insufficiency.

Embolisms include air embolisms, amniotic fluid embolisms, cholesterol embolisms, blue toe syndrome, fat embolisms, pulmonary embolisms, and thromoboembolisms.

Thrombosis include coronary thrombosis, hepatic vein thrombosis, retinal vein occlusion, carotid artery thrombosis, sinus thrombosis. Wallenberg's syndrome, and thrombophlebitis.

Ischemia includes cerebral ischemia, ischemic colitis, compartment syndromes, anterior compartment syndrome, myocardial ischemia. reperfusion injuries, and peripheral limb ischemia. Vasculitis includes aortitis, arteritis. Behcet's Syndrome. Churg-Strauss Syndrome, mucocutaneous lymph node syndrome, thromboangiitis obliterans, hypersensitivity vasculitis, Schoenlein-Henoch purpura, allergic cutaneous vasculitis, and Wegener's granulomatosis.

Polynucleotides or polypeptides, or agonists or antagonists of the present invention, are especially effective for the treatment of critical limb ischemia and coronary disease.

Polypeptides may be administered using any method known in the art, including, but not limited to, direct needle injection at the delivery site, intravenous injection, topical administration, catheter infusion, biolistic injectors, particle accelerators, gelfoam sponge depots, other commercially available depot materials, osmotic pumps, oral or suppositorial solid pharmaceutical formulations, decanting or topical applications during surgery, aerosol delivery. Such methods are known in the art. Polypeptides may be administered as part of a Therapeutic, described in more detail below. Methods of delivering polynucleotides are described in more detail herein.

20 Anti-Angiogenesis Activity

5

10

15

25

30

The naturally occurring balance between endogenous stimulators and inhibitors of angiogenesis is one in which inhibitory influences predominate. Rastinejad et al., Cell 56:345-355 (1989). In those rare instances in which neovascularization occurs under normal physiological conditions, such as wound healing, organ regeneration, embryonic development, and female reproductive processes, angiogenesis is stringently regulated and spatially and temporally delimited. Under conditions of pathological angiogenesis such as that characterizing solid tumor growth, these regulatory controls fail. Unregulated angiogenesis becomes pathologic and sustains progression of many neoplastic and non-neoplastic diseases. A number of serious diseases are dominated by abnormal neovascularization including solid tumor growth and metastases, arthritis, some types of eye disorders, and psoriasis. See, e.g., reviews by Moses et al., Biotech. 9:630-634 (1991); Folkman et al., N. Engl. J. Med., 333:1757-1763 (1995); Auerbach et al., J. Microvasc. Res.

5

10

15

20

25

30

255

29:401-411 (1985); Folkman, Advances in Cancer Research, eds. Klein and Weinhouse, Academic Press. New York, pp. 175-203 (1985); Patz, Am. J. Opthalmol. 94:715-743 (1982); and Folkman et al.. Science 221:719-725 (1983). In a number of pathological conditions, the process of angiogenesis contributes to the disease state. For example, significant data have accumulated which suggest that the growth of solid tumors is dependent on angiogenesis. Folkman and Klagsbrun, Science 235:442-447 (1987).

The polynucleotides encoding a polypeptide of the present invention may be administered along with other polynucleotides encoding an angiogenic protein. Examples of angiogenic proteins include, but are not limited to, acidic and basic fibroblast growth factors. VEGF-1, VEGF-2, VEGF-3, epidermal growth factor alpha and beta, platelet-derived endothelial cell growth factor, platelet-derived growth factor, tumor necrosis factor alpha, hepatocyte growth factor, insulin like growth factor, colony stimulating factor, macrophage colony stimulating factor, granulocyte/macrophage colony stimulating factor, and nitric oxide synthase.

The present invention provides for treatment of diseases or disorders associated with neovascularization by administration of the polynucleotides and/or polypeptides of the invention, as well as agonists or antagonists of the present invention. Malignant and metastatic conditions which can be treated with the polynucleotides and polypeptides, or agonists or antagonists of the invention include, but are not limited to, malignancies, solid tumors, and cancers described herein and otherwise known in the art (for a review of such disorders, see Fishman et al., Medicine, 2d Ed., J. B. Lippincott Co., Philadelphia (1985)). Thus, the present invention provides a method of treating an angiogenesis-related disease and/or disorder, comprising administering to an individual in need thereof a therapeutically effective amount of a polynucleotide, polypeptide, antagonist and/or agonist of the invention. For example, polynucleotides, polypeptides, antagonists and/or agonists may be utilized in a variety of additional methods in order to therapeutically treat a cancer or tumor. Cancers which may be treated with polynucleotides, polypeptides, antagonists and/or agonists include, but are not limited to solid tumors, including colon, rectum, prostate, lung, breast, ovarian, stomach, pancreas, larynx, esophagus, testes, liver, parotid, biliary tract, cervix, uterus, endometrium, kidney, bladder, thyroid cancer; primary tumors and metastases; melanomas; glioblastoma; Kaposi's sarcoma; leiomyosarcoma; non- small cell lung cancer; colorectal cancer; advanced malignancies; and blood born tumors such as leukemias. For

example, polynucleotides, polypeptides, antagonists and/or agonists may be delivered topically, in order to treat cancers such as skin cancer, head and neck tumors, breast tumors, and Kaposi's sarcoma.

Within yet other aspects, polynucleotides, polypeptides, antagonists and/or agonists may be utilized to treat superficial forms of bladder cancer by, for example, intravesical administration. Polynucleotides, polypeptides, antagonists and/or agonists may be delivered directly into the tumor, or near the tumor site, via injection or a catheter. Of course, as the artisan of ordinary skill will appreciate, the appropriate mode of administration will vary according to the cancer to be treated. Other modes of delivery are discussed herein.

5

10

15

20

25

30

Polynucleotides, polypeptides, antagonists and/or agonists may be useful in treating other disorders, besides cancers, which involve angiogenesis. These disorders include, but are not limited to: benign tumors, for example hemangiomas, acoustic neuromas, neurofibromas, trachomas, and pyogenic granulomas; artheroscleric plaques; ocular angiogenic diseases, for example, diabetic retinopathy, retinopathy of prematurity, macular degeneration, corneal graft rejection, neovascular glaucoma, retrolental fibroplasia, rubeosis, retinoblastoma, uvietis and Pterygia (abnormal blood vessel growth) of the eye; rheumatoid arthritis; psoriasis; delayed wound healing; endometriosis; vasculogenesis; granulations; hypertrophic scars (keloids); nonunion fractures; scleroderma; trachoma; vascular adhesions; myocardial angiogenesis; coronary collaterals; cerebral collaterals; arteriovenous malformations; ischemic limb angiogenesis; Osler-Webber Syndrome: plaque neovascularization; telangiectasia; hemophiliac joints; angiofibroma; fibromuscular dysplasia; wound granulation; Crohn's disease; and atherosclerosis.

For example, within one aspect of the present invention methods are provided for treating hypertrophic scars and keloids, comprising the step of administering a polynucleotide, polypeptide, antagonist and/or agonist of the invention to a hypertrophic scar or keloid.

Within one embodiment of the present invention polynucleotides, polypeptides, antagonists and/or agonists are directly injected into a hypertrophic scar or keloid, in order to prevent the progression of these lesions. This therapy is of particular value in the prophylactic treatment of conditions which are known to result in the development of hypertrophic scars and keloids (e.g., burns), and is preferably initiated after the proliferative phase has had time to progress (approximately 14 days after the initial injury), but before

hypertrophic scar or keloid development. As noted above, the present invention also provides methods for treating neovascular diseases of the eye, including for example, corneal neovascularization, neovascular glaucoma, proliferative diabetic retinopathy, retrolental fibroplasia and macular degeneration.

5

10

15

20

25

30

Moreover, Ocular disorders associated with neovascularization which can be treated with the polynucleotides and polypeptides of the present invention (including agonists and/or antagonists) include, but are not limited to: neovascular glaucoma, diabetic retinopathy, retinoblastoma, retrolental fibroplasia, uveitis, retinopathy of prematurity macular degeneration, corneal graft neovascularization, as well as other eye inflammatory diseases, ocular tumors and diseases associated with choroidal or iris neovascularization. See, e.g., reviews by Waltman et al., Am. J. Ophthal. 85:704-710 (1978) and Gartner et al., Surv. Ophthal. 22:291-312 (1978).

Thus, within one aspect of the present invention methods are provided for treating neovascular diseases of the eye such as corneal neovascularization (including corneal graft neovascularization), comprising the step of administering to a patient a therapeutically effective amount of a compound (as described above) to the cornea, such that the formation of blood vessels is inhibited. Briefly, the cornea is a tissue which normally lacks blood vessels. In certain pathological conditions however, capillaries may extend into the cornea from the pericorneal vascular plexus of the limbus. When the cornea becomes vascularized, it also becomes clouded, resulting in a decline in the patient's visual acuity. Visual loss may become complete if the cornea completely opacitates. A wide variety of disorders can result in corneal neovascularization, including for example, corneal infections (e.g., trachoma, herpes simplex keratitis, leishmaniasis and onchocerciasis), immunological processes (e.g., graft rejection and Stevens-Johnson's syndrome), alkali burns, trauma, inflammation (of any cause), toxic and nutritional deficiency states, and as a complication of wearing contact lenses.

Within particularly preferred embodiments of the invention, may be prepared for topical administration in saline (combined with any of the preservatives and antimicrobial agents commonly used in ocular preparations), and administered in eyedrop form. The solution or suspension may be prepared in its pure form and administered several times daily. Alternatively, anti-angiogenic compositions, prepared as described above, may also be administered directly to the cornea. Within preferred embodiments, the anti-angiogenic

composition is prepared with a muco-adhesive polymer which binds to cornea. Within further embodiments, the anti-angiogenic factors or anti-angiogenic compositions may be utilized as an adjunct to conventional steroid therapy. Topical therapy may also be useful prophylactically in corneal lesions which are known to have a high probability of inducing an angiogenic response (such as chemical burns). In these instances the treatment, likely in combination with steroids, may be instituted immediately to help prevent subsequent complications.

Within other embodiments, the compounds described above may be injected directly into the corneal stroma by an ophthalmologist under microscopic guidance. The preferred site of injection may vary with the morphology of the individual lesion, but the goal of the administration would be to place the composition at the advancing front of the vasculature (i.e., interspersed between the blood vessels and the normal cornea). In most cases this would involve perilimbic corneal injection to "protect" the cornea from the advancing blood vessels. This method may also be utilized shortly after a corneal insult in order to prophylactically prevent corneal neovascularization. In this situation the material could be injected in the perilimbic cornea interspersed between the corneal lesion and its undesired potential limbic blood supply. Such methods may also be utilized in a similar fashion to prevent capillary invasion of transplanted corneas. In a sustained-release form injections might only be required 2-3 times per year. A steroid could also be added to the injection solution to reduce inflammation resulting from the injection itself.

Within another aspect of the present invention, methods are provided for treating neovascular glaucoma, comprising the step of administering to a patient a therapeutically effective amount of a polynucleotide, polypeptide, antagonist and/or agonist to the eye, such that the formation of blood vessels is inhibited. In one embodiment, the compound may be administered topically to the eye in order to treat early forms of neovascular glaucoma. Within other embodiments, the compound may be implanted by injection into the region of the anterior chamber angle. Within other embodiments, the compound may also be placed in any location such that the compound is continuously released into the aqueous humor. Within another aspect of the present invention, methods are provided for treating proliferative diabetic retinopathy, comprising the step of administering to a patient a therapeutically effective amount of a polynucleotide, polypeptide, antagonist and/or agonist to the eyes, such that the formation of blood vessels is inhibited.

Within particularly preferred embodiments of the invention, proliferative diabetic retinopathy may be treated by injection into the aqueous humor or the vitreous, in order to increase the local concentration of the polynucleotide, polypeptide, antagonist and/or agonist in the retina. Preferably, this treatment should be initiated prior to the acquisition of severe disease requiring photocoagulation.

5

10

15

20

25

30

Within another aspect of the present invention, methods are provided for treating retrolental fibroplasia, comprising the step of administering to a patient a therapeutically effective amount of a polynucleotide, polypeptide, antagonist and/or agonist to the eye, such that the formation of blood vessels is inhibited. The compound may be administered topically, via intravitreous injection and/or via intraocular implants.

Additionally, disorders which can be treated with the polynucleotides, polypeptides, agonists and/or agonists include, but are not limited to, hemangioma, arthritis, psoriasis, angiofibroma, atherosclerotic plaques, delayed wound healing, granulations, hemophilic joints, hypertrophic scars, nonunion fractures, Osler-Weber syndrome, pyogenic granuloma, scleroderma, trachoma, and vascular adhesions.

Moreover, disorders and/or states, which can be treated with be treated with the polynucleotides, polypeptides, agonists and/or agonists include, but are not limited to, solid tumors, blood born tumors such as leukemias, tumor metastasis, Kaposi's sarcoma. benign tumors, for example hemangiomas, acoustic neuromas, neurofibromas, trachomas, and pyogenic granulomas, rheumatoid arthritis, psoriasis, ocular angiogenic diseases, for example, diabetic retinopathy, retinopathy of prematurity, macular degeneration, corneal graft rejection, neovascular glaucoma, retrolental fibroplasia, rubeosis, retinoblastoma, and uvietis, delayed wound healing, endometriosis, vascluogenesis, granulations, hypertrophic scars (keloids), nonunion fractures, scleroderma, trachoma, vascular adhesions, myocardial angiogenesis, coronary collaterals, cerebral collaterals, arteriovenous malformations, ischemic limb angiogenesis, Osler-Webber Syndrome, plaque neovascularization, telangiectasia, hemophiliac joints, angiofibroma fibromuscular dysplasia, wound granulation, Crohn's disease, atherosclerosis, birth control agent by preventing vascularization required for embryo implantation controlling menstruation, diseases that have angiogenesis as a pathologic consequence such as cat scratch disease (Rochele minalia quintosa). ulcers (Helicobacter pylori), Bartonellosis and bacillary angiomatosis.

260

In one aspect of the birth control method, an amount of the compound sufficient to block embryo implantation is administered before or after intercourse and fertilization have occurred, thus providing an effective method of birth control, possibly a "morning after" method. Polynucleotides, polypeptides, agonists and/or agonists may also be used in controlling menstruation or administered as either a peritoneal lavage fluid or for peritoneal implantation in the treatment of endometriosis.

5

10

15

20

25

30

Polynucleotides, polypeptides, agonists and/or agonists of the present invention may be incorporated into surgical sutures in order to prevent stitch granulomas.

Polynucleotides, polypeptides, agonists and/or agonists may be utilized in a wide variety of surgical procedures. For example, within one aspect of the present invention a compositions (in the form of, for example, a spray or film) may be utilized to coat or spray an area prior to removal of a tumor, in order to isolate normal surrounding tissues from malignant tissue, and/or to prevent the spread of disease to surrounding tissues. Within other aspects of the present invention, compositions (e.g., in the form of a spray) may be delivered via endoscopic procedures in order to coat tumors, or inhibit angiogenesis in a desired locale. Within yet other aspects of the present invention, surgical meshes which have been coated with anti- angiogenic compositions of the present invention may be utilized in any procedure wherein a surgical mesh might be utilized. For example, within one embodiment of the invention a surgical mesh laden with an anti-angiogenic composition may be utilized during abdominal cancer resection surgery (e.g., subsequent to colon resection) in order to provide support to the structure, and to release an amount of the anti-angiogenic factor.

Within further aspects of the present invention, methods are provided for treating tumor excision sites, comprising administering a polynucleotide, polypeptide, agonist and/or agonist to the resection margins of a tumor subsequent to excision, such that the local recurrence of cancer and the formation of new blood vessels at the site is inhibited. Within one embodiment of the invention, the anti-angiogenic compound is administered directly to the tumor excision site (e.g., applied by swabbing, brushing or otherwise coating the resection margins of the tumor with the anti-angiogenic compound). Alternatively, the anti-angiogenic compounds may be incorporated into known surgical pastes prior to administration. Within particularly preferred embodiments of the invention, the anti-angiogenic compounds are applied after hepatic resections for malignancy, and after neurosurgical operations.

Within one aspect of the present invention, polynucleotides, polypeptides, agonists and/or agonists may be administered to the resection margin of a wide variety of tumors, including for example, breast, colon, brain and hepatic tumors. For example, within one embodiment of the invention, anti-angiogenic compounds may be administered to the site of a neurological tumor subsequent to excision, such that the formation of new blood vessels at the site are inhibited.

5

10

15

20

25

30

The polynucleotides. polypeptides. agonists and/or agonists of the present invention may also be administered along with other anti-angiogenic factors. Representative examples of other anti-angiogenic factors include: Anti-Invasive Factor, retinoic acid and derivatives thereof, paclitaxel, Suramin, Tissue Inhibitor of Metalloproteinase-1, Tissue Inhibitor of Metalloproteinase-2, Plasminogen Activator Inhibitor-1. Plasminogen Activator Inhibitor-2, and various forms of the lighter "d group" transition metals.

Lighter "d group" transition metals include, for example, vanadium, molybdenum, tungsten, titanium, niobium, and tantalum species. Such transition metal species may form transition metal complexes. Suitable complexes of the above-mentioned transition metal species include oxo transition metal complexes.

Representative examples of vanadium complexes include oxo vanadium complexes such as vanadate and vanadyl complexes. Suitable vanadate complexes include metavanadate and orthovanadate complexes such as, for example, ammonium metavanadate, sodium metavanadate, and sodium orthovanadate. Suitable vanadyl complexes include, for example, vanadyl acetylacetonate and vanadyl sulfate including vanadyl sulfate hydrates such as vanadyl sulfate mono- and trihydrates.

Representative examples of tungsten and molybdenum complexes also include oxo complexes. Suitable oxo tungsten complexes include tungstate and tungsten oxide complexes. Suitable tungstate complexes include ammonium tungstate, calcium tungstate, sodium tungstate dihydrate, and tungstic acid. Suitable tungsten oxides include tungsten (IV) oxide and tungsten (VI) oxide. Suitable oxo molybdenum complexes include molybdate, molybdenum oxide, and molybdenyl complexes. Suitable molybdate complexes include ammonium molybdate and its hydrates, sodium molybdate and its hydrates, and potassium molybdate and its hydrates. Suitable molybdenum oxides include molybdenum (VI) oxide. molybdenum (VI) oxide, and molybdic acid. Suitable molybdenyl complexes include, for

example, molybdenyl acetylacetonate. Other suitable tungsten and molybdenum complexes include hydroxo derivatives derived from, for example, glycerol, tartaric acid, and sugars.

A wide variety of other anti-angiogenic factors may also be utilized within the context of the present invention. Representative examples include platelet factor 4; protamine sulphate: sulphated chitin derivatives (prepared from queen crab shells), (Murata et al., Cancer Res. 51:22-26, 1991); Sulphated Polysaccharide Peptidoglycan Complex (SP-PG) (the function of this compound may be enhanced by the presence of steroids such as estrogen, and tamoxifen citrate); Staurosporine: modulators of matrix metabolism, including for example, proline analogs, cishydroxyproline, d,L-3,4-dehydroproline, Thiaproline, alpha, alpha-dipyridyl, aminopropionitrile fumarate: 4-propyl-5-(4-pyridinyl)-2(3H)oxazolone; Methotrexate; Mitoxantrone; Heparin; Interferons; 2 Macroglobulin-serum; ChIMP-3 (Pavloff et al., J. Bio. Chem. 267:17321-17326, 1992); Chymostatin (Tomkinson et al., Biochem J. 286:475-480, 1992); Cyclodextrin Tetradecasulfate; Eponemycin; Camptothecin; Fumagillin (Ingber et al., Nature 348:555-557, 1990); Gold Sodium Thiomalate ("GST"; Matsubara and Ziff, J. Clin. Invest. 79:1440-1446, 1987); anticollagenase-serum; alpha2-antiplasmin (Holmes et al., J. Biol. Chem. 262(4):1659-1664, 1987); Bisantrene (National Cancer Institute); Lobenzarit disodium (N-(2)-carboxyphenyl-4chloroanthronilic acid disodium or "CCA"; Takeuchi et al., Agents Actions 36:312-316, 1992); Thalidomide; Angostatic steroid; AGM-1470; carboxynaminolmidazole; and metalloproteinase inhibitors such as BB94.

Diseases at the Cellular Level

5

10

15

20

25

30

Diseases associated with increased cell survival or the inhibition of apoptosis that could be treated or detected by polynucleotides or polypeptides, as well as antagonists or agonists of the present invention, include cancers (such as follicular lymphomas, carcinomas with p53 mutations, and hormone-dependent tumors, including, but not limited to colon cancer, cardiac tumors, pancreatic cancer, melanoma, retinoblastoma, glioblastoma, lung cancer, intestinal cancer, testicular cancer, stomach cancer, neuroblastoma, myxoma, myoma, lymphoma, endothelioma, osteoblastoma, osteoclastoma, osteosarcoma, chondrosarcoma, adenoma, breast cancer, prostate cancer, Kaposi's sarcoma and ovarian cancer); autoimmune disorders (such as, multiple sclerosis, Sjogren's syndrome, Hashimoto's thyroiditis, biliary cirrhosis, Behcet's disease, Crohn's disease, polymyositis, systemic lupus erythematosus and

immune-related glomerulonephritis and rheumatoid arthritis) and viral infections (such as herpes viruses, pox viruses and adenoviruses), inflammation, graft v. host disease, acute graft rejection, and chronic graft rejection. In preferred embodiments, polynucleotides, polypeptides, and/or antagonists of the invention are used to inhibit growth, progression, and/or metasis of cancers, in particular those listed above.

5

10

15

20

25

30

Additional diseases or conditions associated with increased cell survival that could be treated or detected by polynucleotides or polypeptides, or agonists or antagonists of the present invention include, but are not limited to, progression, and/or metastases of malignancies and related disorders such as leukemia (including acute leukemias (e.g., acute lymphocytic leukemia, acute myelocytic leukemia (including myeloblastic, promyelocytic, myelomonocytic, monocytic, and erythroleukemia)) and chronic leukemias (e.g., chronic myelocytic (granulocytic) leukemia and chronic lymphocytic leukemia)), polycythemia vera, lymphomas (e.g., Hodgkin's disease and non-Hodgkin's disease), multiple myeloma, Waldenstrom's macroglobulinemia, heavy chain disease, and solid tumors including, but not limited to, sarcomas and carcinomas such as fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilm's tumor, cervical cancer, testicular tumor, lung carcinoma, small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, menangioma, melanoma, neuroblastoma, and retinoblastoma.

Diseases associated with increased apoptosis that could be treated or detected by polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, include AIDS; neurodegenerative disorders (such as Alzheimer's disease, Parkinson's disease, Amyotrophic lateral sclerosis, Retinitis pigmentosa, Cerebellar degeneration and brain tumor or prior associated disease); autoimmune disorders (such as, multiple sclerosis, Sjogren's

WO 00/55351

5

10

15

20

25

30

syndrome. Hashimoto's thyroiditis, biliary cirrhosis, Behcet's disease, Crohn's disease, polymyositis, systemic lupus erythematosus and immune-related glomerulonephritis and rheumatoid arthritis) myelodysplastic syndromes (such as aplastic anemia), graft v. host disease, ischemic injury (such as that caused by myocardial infarction, stroke and reperfusion injury), liver injury (e.g., hepatitis related liver injury, ischemia/reperfusion injury, cholestosis (bile duct injury) and liver cancer); toxin-induced liver disease (such as that caused by alcohol), septic shock, cachexia and anorexia.

Wound Healing and Epithelial Cell Proliferation

In accordance with yet a further aspect of the present invention, there is provided a process for utilizing polynucleotides or polypeptides, as well as agonists or antagonists of the present invention. for therapeutic purposes, for example, to stimulate epithelial cell proliferation and basal keratinocytes for the purpose of wound healing, and to stimulate hair follicle production and healing of dermal wounds. Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, may be clinically useful in stimulating wound healing including surgical wounds, excisional wounds, deep wounds involving damage of the dermis and epidermis, eye tissue wounds, dental tissue wounds, oral cavity wounds, diabetic ulcers, dermal ulcers, cubitus ulcers, arterial ulcers, venous stasis ulcers, burns resulting from heat exposure or chemicals, and other abnormal wound healing conditions such as uremia, malnutrition, vitamin deficiencies and complications associted with systemic treatment with steroids, radiation therapy and antineoplastic drugs and antimetabolites. Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could be used to promote dermal reestablishment subsequent to dermal loss

Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could be used to increase the adherence of skin grafts to a wound bed and to stimulate re-epithelialization from the wound bed. The following are types of grafts that polynucleotides or polypeptides, agonists or antagonists of the present invention, could be used to increase adherence to a wound bed: autografts, artificial skin, allografts, autodermic graft, autoepdermic grafts, avacular grafts, Blair-Brown grafts, bone graft, brephoplastic grafts, cutis graft, delayed graft, dermic graft, epidermic graft, fascia graft, full thickness graft, heterologous graft, xenograft, homologous graft, hyperplastic graft, lamellar graft,

mesh graft, mucosal graft, Ollier-Thiersch graft, omenpal graft, patch graft, pedicle graft, penetrating graft, split skin graft, thick split graft. Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, can be used to promote skin strength and to improve the appearance of aged skin.

5

10

15

20

25

30

It is believed that polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, will also produce changes in hepatocyte proliferation, and epithelial cell proliferation in the lung, breast, pancreas, stomach, small intesting, and large intestine. Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could promote proliferation of epithelial cells such as sebocytes, hair follicles, hepatocytes, type II pneumocytes, mucin-producing goblet cells, and other epithelial cells and their progenitors contained within the skin, lung, liver, and gastrointestinal tract. Polynucleotides or polypeptides, agonists or antagonists of the present invention, may promote proliferation of endothelial cells, keratinocytes, and basal keratinocytes.

Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could also be used to reduce the side effects of gut toxicity that result from radiation, chemotherapy treatments or viral infections. Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, may have a cytoprotective effect on the small intestine mucosa. Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, may also stimulate healing of mucositis (mouth ulcers) that result from chemotherapy and viral infections.

Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could further be used in full regeneration of skin in full and partial thickness skin defects, including burns, (i.e., repopulation of hair follicles, sweat glands, and sebaceous glands), treatment of other skin defects such as psoriasis. Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could be used to treat epidermolysis bullosa, a defect in adherence of the epidermis to the underlying dermis which results in frequent, open and painful blisters by accelerating reepithelialization of these lesions. Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could also be used to treat gastric and doudenal ulcers and help heal by scar formation of the mucosal lining and regeneration of glandular mucosa and duodenal mucosal lining more rapidly. Inflamamatory bowel diseases, such as Crohn's disease and ulcerative colitis, are diseases which result in destruction of the mucosal surface of the small or large intestine,

respectively. Thus, polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could be used to promote the resurfacing of the mucosal surface to aid more rapid healing and to prevent progression of inflammatory bowel disease. Treatment with polynucleotides or polypeptides, agonists or antagonists of the present invention, is expected to have a significant effect on the production of mucus throughout the gastrointestinal tract and could be used to protect the intestinal mucosa from injurious substances that are ingested or following surgery. Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could be used to treat diseases associate with the under expression.

5

10

15

20

25

30

Moreover, polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could be used to prevent and heal damage to the lungs due to various pathological states. Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, which could stimulate proliferation and differentiation and promote the repair of alveoli and brochiolar epithelium to prevent or treat acute or chronic lung damage. For example, emphysema, which results in the progressive loss of aveoli, and inhalation injuries, i.e., resulting from smoke inhalation and burns, that cause necrosis of the bronchiolar epithelium and alveoli could be effectively treated using polynucleotides or polypeptides, agonists or antagonists of the present invention. Also, polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could be used to stimulate the proliferation of and differentiation of type II pneumocytes, which may help treat or prevent disease such as hyaline membrane diseases, such as infant respiratory distress syndrome and bronchopulmonary displasia, in premature infants.

Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could stimulate the proliferation and differentiation of hepatocytes and, thus, could be used to alleviate or treat liver diseases and pathologies such as fulminant liver failure caused by cirrhosis, liver damage caused by viral hepatitis and toxic substances (i.e., acetaminophen, carbon tetraholoride and other hepatotoxins known in the art).

In addition, polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could be used treat or prevent the onset of diabetes mellitus. In patients with newly diagnosed Types I and II diabetes, where some islet cell function remains, polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could be used to maintain the islet function so as to alleviate, delay or prevent permanent

manifestation of the disease. Also, polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could be used as an auxiliary in islet cell transplantation to improve or promote islet cell function.

5 Neurological Diseases

10

15

20

25

30

In accordance with yet a further aspect of the present invention, there is provided a process for utilizing polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, for therapeutic purposes, for example, to stimulate neurological cell proliferation and/or differentiation. Therefore, polynucleotides, polypeptides, agonists and/or antagonists of the invention may be used to treat and/or detect neurologic diseases. Moreover, polynucleotides or polypeptides, or agonists or antagonists of the invention, can be used as a marker or detector of a particular nervous system disease or disorder.

Examples of neurologic diseases which can be treated or detected with polynucleotides, polypeptides, agonists, and/or antagonists of the present invention include brain diseases, such as metabolic brain diseases which includes phenylketonuria such as maternal phenylketonuria, pyruvate carboxylase deficiency, pyruvate dehydrogenase complex deficiency, Wernicke's Encephalopathy, brain edema, brain neoplasms such as cerebellar neoplasms which include infratentorial neoplasms, cerebral ventricle neoplasms such as choroid plexus neoplasms, hypothalamic neoplasms, supratentorial neoplasms, canavan disease, cerebellar diseases such as cerebellar ataxia which include spinocerebellar degeneration such as ataxia telangiectasia, cerebellar dyssynergia, Friederich's Ataxia, Machado-Joseph Disease, olivopontocerebellar atrophy, cerebellar neoplasms such as infratentorial neoplasms, diffuse cerebral sclerosis such as encephalitis periaxialis, globoid cell leukodystrophy, metachromatic leukodystrophy and subacute sclerosing panencephalitis, cerebrovascular disorders (such as carotid artery diseases which include carotid artery thrombosis, carotid stenosis and Moyamoya Disease, cerebral amyloid angiopathy, cerebral aneurysm, cerebral anoxia, cerebral arteriosclerosis, cerebral arteriovenous malformations, cerebral artery diseases, cerebral embolism and thrombosis such as carotid artery thrombosis, sinus thrombosis and Wallenberg's Syndrome, cerebral hemorrhage such as epidural hematoma, subdural hematoma and subarachnoid hemorrhage, cerebral infarction, cerebral ischemia such as transient cerebral ischemia, Subclavian Steal Syndrome and vertebrobasilar insufficiency, vascular dementia such as multi-infarct dementia, periventricular leukomalacia,

10

15

20

25

30

vascular headache such as cluster headache. migraine. dementia such as AIDS Dementia Complex. presenile dementia such as Alzheimer's Disease and Creutzfeldt-Jakob Syndrome, senile dementia such as Alzheimer's Disease and progressive supranuclear palsy, vascular dementia such as multi-infarct dementia, encephalitis which include encephalitis periaxialis, viral encephalitis such as epidemic encephalitis, Japanese Encephalitis, St. Louis Encephalitis, tick-borne encephalitis and West Nile Fever, acute disseminated encephalomyelitis, meningoencephalitis such as uveomeningoencephalitic syndrome, Postencephalitic Parkinson Disease and subacute sclerosing panencephalitis, encephalomalacia such as periventricular leukomalacia, epilepsy such as generalized epilepsy which includes infantile spasms, absence epilepsy, myoclonic epilepsy which includes MERRF Syndrome, tonic-clonic epilepsy, partial epilepsy such as complex partial epilepsy, frontal lobe epilepsy and temporal lobe epilepsy, post-traumatic epilepsy, status epilepticus such as Epilepsia Partialis Continua, Hallervorden-Spatz Syndrome, hydrocephalus such as Dandy-Walker Syndrome and normal pressure hydrocephalus, hypothalamic diseases such as hypothalamic neoplasms, cerebral malaria, narcolepsy which includes cataplexy, bulbar poliomyelitis, cerebri pseudotumor, Rett Syndrome, Reye's Syndrome, thalamic diseases, cerebral toxoplasmosis, intracranial tuberculoma and Zellweger Syndrome, central nervous system infections such as AIDS Dementia Complex, Brain Abscess, subdural empyema, encephalomyelitis such as Equine Encephalomyelitis, Venezuelan Equine Encephalomyelitis, Necrotizing Hemorrhagic Encephalomyelitis, Visna, cerebral malaria, meningitis such as arachnoiditis, aseptic meningtitis such as viral meningtitis which includes lymphocytic choriomeningitis. Bacterial meningtitis which includes Haemophilus Meningtitis, Listeria Meningtitis. Meningococcal Meningtitis such as Waterhouse-Friderichsen Syndrome, Pneumococcal Meningtitis and meningeal tuberculosis, fungal meningitis such as Cryptococcal Meningtitis, subdural effusion, meningoencephalitis such as uvemeningoencephalitic syndrome, myelitis such as transverse myelitis, neurosyphilis such as tabes dorsalis, poliomyelitis which includes bulbar poliomyelitis and postpoliomyelitis syndrome, prion diseases (such as Creutzfeldt-Jakob Syndrome, Bovine Spongiform Encephalopathy, Gerstmann-Straussler Syndrome, Kuru, Scrapie) cerebral toxoplasmosis, central nervous system neoplasms such as brain neoplasms that include cerebellear neoplasms such as infratentorial neoplasms, cerebral ventricle neoplasms such as choroid plexus neoplasms, hypothalamic neoplasms and supratentorial neoplasms, meningeal

10

15

20

25

30

neoplasms, spinal cord neoplasms which include epidural neoplasms, demyelinating diseases such as Canavan Diseases, diffuse cerebral sceloris which includes adrenoleukodystrophy, encephalitis periaxialis, globoid cell leukodystrophy, diffuse cerebral sclerosis such as metachromatic leukodystrophy, allergic encephalomyelitis, necrotizing hemorrhagic encephalomyelitis, progressive multifocal leukoencephalopathy, multiple sclerosis, central pontine myelinolysis, transverse myelitis, neuromyelitis optica, Scrapie, Swayback, Chronic Fatigue Syndrome, Visna, High Pressure Nervous Syndrome, Meningism, spinal cord diseases such as amyotonia congenita, amyotrophic lateral sclerosis, spinal muscular atrophy such as Werdnig-Hoffmann Disease, spinal cord compression, spinal cord neoplasms such as epidural neoplasms, syringomyelia, Tabes Dorsalis, Stiff-Man Syndrome, mental retardation such as Angelman Syndrome, Cri-du-Chat Syndrome, De Lange's Syndrome, Down Syndrome, Gangliosidoses such as gangliosidoses G(M1), Sandhoff Disease, Tay-Sachs Disease, Hartnup Disease, homocystinuria, Laurence-Moon- Biedl Syndrome, Lesch-Nyhan Syndrome, Maple Syrup Urine Disease, mucolipidosis such as fucosidosis, neuronal ceroidlipofuscinosis, oculocerebrorenal syndrome, phenylketonuria such as maternal phenylketonuria, Prader-Willi Syndrome, Rett Syndrome, Rubinstein-Taybi Syndrome, Tuberous Sclerosis, WAGR Syndrome, nervous system abnormalities such as holoprosencephaly, neural tube defects such as anencephaly which includes hydrangencephaly, Arnold-Chairi Deformity, encephalocele, meningocele. meningomyelocele, spinal dysraphism such as spina bifida cystica and spina bifida occulta. hereditary motor and sensory neuropathies which include Charcot-Marie Disease, Hereditary optic atrophy, Refsum's Disease, hereditary spastic paraplegia, Werdnig-Hoffmann Disease, Hereditary Sensory and Autonomic Neuropathies such as Congenital Analgesia and Familial Dysautonomia, Neurologic manifestations (such as agnosia that include Gerstmann's Syndrome, Amnesia such as retrograde amnesia, apraxia, neurogenic bladder, cataplexy, communicative disorders such as hearing disorders that includes deafness, partial hearing loss, loudness recruitment and tinnitus, language disorders such as aphasia which include agraphia, anomia, broca aphasia, and Wernicke Aphasia, Dyslexia such as Acquired Dyslexia, language development disorders, speech disorders such as aphasia which includes anomia, broca aphasia and Wernicke Aphasia, articulation disorders, communicative disorders such as speech disorders which include dysarthria, echolalia, mutism and stuttering, voice disorders such as aphonia and hoarseness, decerebrate state, delirium, fasciculation,

10

15

20

25

30

hallucinations, meningism, movement disorders such as angelman syndrome, ataxia, athetosis, chorea, dystonia, hypokinesia, muscle hypotonia, myoclonus, tic, torticollis and tremor, muscle hypertonia such as muscle rigidity such as stiff-man syndrome, muscle spasticity, paralysis such as facial paralysis which includes Herpes Zoster Oticus, Gastroparesis. Hemiplegia, ophthalmoplegia such as diplopia, Duane's Syndrome, Horner's Syndrome, Chronic progressive external ophthalmoplegia such as Kearns Syndrome, Bulbar Paralysis, Tropical Spastic Paraparesis, Paraplegia such as Brown-Sequard Syndrome, quadriplegia, respiratory paralysis and vocal cord paralysis, paresis, phantom limb, taste disorders such as ageusia and dysgeusia, vision disorders such as amblyopia, blindness, color vision defects, diplopia, hemianopsia, scotoma and subnormal vision, sleep disorders such as hypersomnia which includes Kleine-Levin Syndrome, insomnia, and somnambulism, spasm such as trismus, unconsciousness such as coma, persistent vegetative state and syncope and vertigo, neuromuscular diseases such as amyotonia congenita, amyotrophic lateral sclerosis, Lambert-Eaton Myasthenic Syndrome, motor neuron disease, muscular atrophy such as spinal muscular atrophy, Charcot-Marie Disease and Werdnig-Hoffmann Disease, Postpoliomyelitis Syndrome, Muscular Dystrophy, Myasthenia Gravis, Myotonia Atrophica, Myotonia Confenita, Nemaline Myopathy, Familial Periodic Paralysis, Multiplex Paramyloclonus, Tropical Spastic Paraparesis and Stiff-Man Syndrome, peripheral nervous system diseases such as acrodynia, amyloid neuropathies, autonomic nervous system diseases such as Adie's Syndrome, Barre-Lieou Syndrome, Familial Dysautonomia, Horner's Syndrome, Reflex Sympathetic Dystrophy and Shy-Drager Syndrome, Cranial Nerve Diseases such as Acoustic Nerve Diseases such as Acoustic Neuroma which includes Neurofibromatosis 2, Facial Nerve Diseases such as Facial Neuralgia, Melkersson-Rosenthal Syndrome, ocular motility disorders which includes amblyopia, nystagmus, oculomotor nerve paralysis, ophthalmoplegia such as Duane's Syndrome, Horner's Syndrome, Chronic Progressive External Ophthalmoplegia which includes Kearns Syndrome, Strabismus such as Esotropia and Exotropia, Oculomotor Nerve Paralysis, Optic Nerve Diseases such as Optic Atrophy which includes Hereditary Optic Atrophy, Optic Disk Drusen. Optic Neuritis such as Neuromyelitis Optica, Papilledema, Trigeminal Neuralgia, Vocal Cord Paralysis, Demyelinating Diseases such as Neuromyelitis Optica and Swayback. Diabetic neuropathies such as diabetic foot, nerve compression syndromes such as carpal tunnel syndrome, tarsal tunnel syndrome, thoracic outlet syndrome such as cervical rib syndrome, ulnar nerve

compression syndrome. neuralgia such as causalgia, cervico-brachial neuralgia, facial neuralgia and trigeminal neuralgia, neuritis such as experimental allergic neuritis, optic neuritis, polyneuritis, polyradiculoneuritis and radiculities such as polyradiculitis, hereditary motor and sensory neuropathies such as Charcot-Marie Disease. Hereditary Optic Atrophy, Refsum's Disease, Hereditary Spastic Paraplegia and Werdnig-Hoffmann Disease. Hereditary Sensory and Autonomic Neuropathies which include Congenital Analgesia and Familial Dysautonomia, POEMS Syndrome, Sciatica, Gustatory Sweating and Tetany).

Infectious Disease

5

10

15

20

25

30

Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention can be used to treat or detect infectious agents. For example, by increasing the immune response, particularly increasing the proliferation and differentiation of B and/or T cells, infectious diseases may be treated. The immune response may be increased by either enhancing an existing immune response, or by initiating a new immune response. Alternatively, polynucleotides or polypeptides, as well as agonists or antagonists of the present invention may also directly inhibit the infectious agent, without necessarily eliciting an immune response.

Viruses are one example of an infectious agent that can cause disease or symptoms that can be treated or detected by a polynucleotide or polypeptide and/or agonist or antagonist of the present invention. Examples of viruses, include, but are not limited to Examples of viruses, include, but are not limited to the following DNA and RNA viruses and viral families: Arbovirus, Adenoviridae, Arenaviridae, Arterivirus, Birnaviridae, Bunyaviridae, Caliciviridae, Circoviridae, Coronaviridae, Dengue, EBV, HIV, Flaviviridae, Hepadnaviridae (Hepatitis), Herpesviridae (such as, Cytomegalovirus, Herpes Simplex, Herpes Zoster), Mononegavirus (e.g., Paramyxoviridae, Morbillivirus, Rhabdoviridae), Orthomyxoviridae (e.g., Influenza A, Influenza B, and parainfluenza), Papiloma virus, Papovaviridae, Parvoviridae, Picornaviridae, Poxviridae (such as Smallpox or Vaccinia), Reoviridae (e.g., Rotavirus), Retroviridae (HTLV-I, HTLV-II, Lentivirus), and Togaviridae (e.g., Rubivirus). Viruses falling within these families can cause a variety of diseases or symptoms, including, but not limited to: arthritis. bronchiollitis. respiratory syncytial virus. encephalitis, eye infections (e.g., conjunctivitis, keratitis), chronic fatigue syndrome, hepatitis (A, B, C, E, Chronic Active, Delta), Japanese B encephalitis, Junin, Chikungunya, Rift Valley fever,

yellow fever. meningitis. opportunistic infections (e.g., AIDS), pneumonia. Burkitt's Lymphoma, chickenpox, hemorrhagic fever, Measles, Mumps, Parainfluenza, Rabies, the common cold. Polio, leukemia, Rubella, sexually transmitted diseases, skin diseases (e.g., Kaposi's, warts), and viremia, polynucleotides or polypeptides, or agonists or antagonists of the invention, can be used to treat or detect any of these symptoms or diseases. In specific embodiments, polynucleotides, polypeptides, or agonists or antagonists of the invention are used to treat: meningitis, Dengue, EBV, and/or hepatitis (e.g., hepatitis B). In an additional specific embodiment polynucleotides, polypeptides, or agonists or antagonists of the invention are used to treat patients nonresponsive to one or more other commercially available hepatitis vaccines. In a further specific embodiment polynucleotides, polypeptides, or agonists or antagonists of the invention are used to treat AIDS.

5

10

15

20

25

30

Similarly, bacterial or fungal agents that can cause disease or symptoms and that can be treated or detected by a polynucleotide or polypeptide and/or agonist or antagonist of the present invention include, but not limited to, include, but not limited to, the following Gram-Negative and Gram-positive bacteria and bacterial families and fungi. Actinomycetales (e.g., Corynebacterium, Mycobacterium, Norcardia), Cryptococcus neoformans, Aspergillosis, Bacillaceae (e.g., Anthrax, Clostridium), Bacteroidaceae, Blastomycosis, Bordetella, Borrelia (e.g., Borrelia burgdorferi, Brucellosis, Candidiasis, Campylobacter, Coccidioidomycosis, Cryptococcosis, Dermatocycoses, E. coli (e.g., Enterotoxigenic E. coli and Enterohemorrhagic E. coli), Enterobacteriaceae (Klebsiella, Salmonella (e.g., Salmonella typhi, and Salmonella paratyphi), Serratia, Yersinia), Erysipelothrix, Helicobacter, Legionellosis. Leptospirosis, Listeria, Mycoplasmatales, Mycobacterium leprae, Vibrio cholerae, Neisseriaceae (e.g., Acinetobacter, Gonorrhea, Menigococcal), Meisseria meningitidis, Pasteurellacea Infections (e.g., Actinobacillus, Heamophilus (e.g., Heamophilus influenza type B), Pasteurella), Pseudomonas, Rickettsiaceae, Chlamydiaceae, Syphilis, Shigella spp., Staphylococcal, Meningiococcal, Pneumococcal and Streptococcal (e.g., Streptococcus pneumoniae and Group B Streptococcus). These bacterial or fungal families can cause the following diseases or symptoms, including, but not limited to: bacteremia, endocarditis, eye infections (conjunctivitis, tuberculosis, uveitis), gingivitis, opportunistic infections (e.g., AIDS related infections), paronychia, prosthesis-related infections. Reiter's Disease, respiratory tract infections, such as Whooping Cough or Empyema, sepsis, Lyme Disease, Cat-Scratch Disease, Dysentery, Paratyphoid Fever, food poisoning, Typhoid,

10

15

20

25

30

pneumonia, Gonorrhea, meningitis (e.g., mengitis types A and B). Chlamydia, Syphilis, Diphtheria, Leprosy. Paratuberculosis, Tuberculosis, Lupus, Botulism, gangrene, tetanus, impetigo, Rheumatic Fever, Scarlet Fever, sexually transmitted diseases, skin diseases (e.g., cellulitis, dermatocycoses), toxemia, urinary tract infections, wound infections. Polynucleotides or polypeptides, agonists or antagonists of the invention, can be used to treat or detect any of these symptoms or diseases. In specific embodiments, Ppolynucleotides, polypeptides, agonists or antagonists of the invention are used to treat: tetanus, Diptheria, botulism, and/or meningitis type B.

Moreover, parasitic agents causing disease or symptoms that can be treated or detected by a polynucleotide or polypeptide and/or agonist or antagonist of the present invention include, but not limited to, the following families or class: Amebiasis, Babesiosis, Coccidiosis, Cryptosporidiosis, Dientamoebiasis, Dourine, Ectoparasitic, Giardiasis, Helminthiasis, Leishmaniasis, Theileriasis, Toxoplasmosis, Trypanosomiasis, and Trichomonas and Sporozoans (e.g., Plasmodium virax, Plasmodium falciparium, Plasmodium malariae and Plasmodium ovale). These parasites can cause a variety of diseases or symptoms, including, but not limited to: Scabies, Trombiculiasis, eye infections, intestinal disease (e.g., dysentery, giardiasis), liver disease, lung disease, opportunistic infections (e.g., AIDS related), malaria, pregnancy complications, and toxoplasmosis, polynucleotides or polypeptides, or agonists or antagonists of the invention, can be used to treat or detect any of these symptoms or diseases.

Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention of the present invention could either be by administering an effective amount of a polypeptide to the patient, or by removing cells from the patient, supplying the cells with a polynucleotide of the present invention, and returning the engineered cells to the patient (ex vivo therapy). Moreover, the polypeptide or polynucleotide of the present invention can be used as an antigen in a vaccine to raise an immune response against infectious disease.

Regeneration

Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention can be used to differentiate, proliferate, and attract cells, leading to the regeneration of tissues. (See, Science 276:59-87 (1997).) The regeneration of tissues could be used to repair, replace, or protect tissue damaged by congenital defects, trauma (wounds, burns,

incisions, or ulcers), age, disease (e.g. osteoporosis, osteocarthritis, periodontal disease, liver failure), surgery, including cosmetic plastic surgery, fibrosis, reperfusion injury, or systemic cytokine damage.

Tissues that could be regenerated using the present invention include organs (e.g., pancreas, liver, intestine, kidney, skin, endothelium), muscle (smooth, skeletal or cardiac), vasculature (including vascular and lymphatics), nervous, hematopoietic, and skeletal (bone, cartilage, tendon, and ligament) tissue. Preferably, regeneration occurs without or decreased scarring. Regeneration also may include angiogenesis.

Moreover, polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, may increase regeneration of tissues difficult to heal. For example, increased tendon/ligament regeneration would quicken recovery time after damage. Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention could also be used prophylactically in an effort to avoid damage. Specific diseases that could be treated include of tendinitis, carpal tunnel syndrome, and other tendon or ligament defects. A further example of tissue regeneration of non-healing wounds includes pressure ulcers, ulcers associated with vascular insufficiency, surgical, and traumatic wounds.

Similarly, nerve and brain tissue could also be regenerated by using polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, to proliferate and differentiate nerve cells. Diseases that could be treated using this method include central and peripheral nervous system diseases, neuropathies, or mechanical and traumatic disorders (e.g., spinal cord disorders, head trauma, cerebrovascular disease, and stoke). Specifically, diseases associated with peripheral nerve injuries, peripheral neuropathy (e.g., resulting from chemotherapy or other medical therapies), localized neuropathies, and central nervous system diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and Shy-Drager syndrome), could all be treated using the polynucleotides or polypeptides, as well as agonists or antagonists of the present invention.

Chemotaxis

5

10

15

20

25

30

Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention may have chemotaxis activity. A chemotaxic molecule attracts or mobilizes cells (e.g., monocytes, fibroblasts, neutrophils, T-cells, mast cells, eosinophils, epithelial and/or endothelial cells) to a particular site in the body, such as inflammation, infection, or site of

hyperproliferation. The mobilized cells can then fight off and/or heal the particular trauma or abnormality.

Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention may increase chemotaxic activity of particular cells. These chemotactic molecules can then be used to treat inflammation, infection, hyperproliferative disorders, or any immune system disorder by increasing the number of cells targeted to a particular location in the body. For example, chemotaxic molecules can be used to treat wounds and other trauma to tissues by attracting immune cells to the injured location. Chemotactic molecules of the present invention can also attract fibroblasts, which can be used to treat wounds.

It is also contemplated that polynucleotides or polypeptides, as well as agonists or antagonists of the present invention may inhibit chemotactic activity. These molecules could also be used to treat disorders. Thus, polynucleotides or polypeptides, as well as agonists or antagonists of the present invention could be used as an inhibitor of chemotaxis.

15 **Binding Activity**

5

10

20

25

30

A polypeptide of the present invention may be used to screen for molecules that bind to the polypeptide or for molecules to which the polypeptide binds. The binding of the polypeptide and the molecule may activate (agonist), increase, inhibit (antagonist), or decrease activity of the polypeptide or the molecule bound. Examples of such molecules include antibodies, oligonucleotides, proteins (e.g., receptors), or small molecules.

Preferably, the molecule is closely related to the natural ligand of the polypeptide, e.g., a fragment of the ligand, or a natural substrate, a ligand, a structural or functional mimetic. (See, Coligan et al., Current Protocols in Immunology 1(2):Chapter 5 (1991).) Similarly, the molecule can be closely related to the natural receptor to which the polypeptide binds, or at least, a fragment of the receptor capable of being bound by the polypeptide (e.g., active site). In either case, the molecule can be rationally designed using known techniques.

Preferably, the screening for these molecules involves producing appropriate cells which express the polypeptide. Preferred cells include cells from mammals, yeast, Drosophila, or *E. coli*. Cells expressing the polypeptide (or cell membrane containing the expressed polypeptide) are then preferably contacted with a test compound potentially containing the molecule to observe binding, stimulation, or inhibition of activity of either the polypeptide or the molecule.

The assay may simply test binding of a candidate compound to the polypeptide, wherein binding is detected by a label, or in an assay involving competition with a labeled competitor. Further, the assay may test whether the candidate compound results in a signal generated by binding to the polypeptide.

Alternatively, the assay can be carried out using cell-free preparations, polypeptide/molecule affixed to a solid support, chemical libraries, or natural product mixtures. The assay may also simply comprise the steps of mixing a candidate compound with a solution containing a polypeptide, measuring polypeptide/molecule activity or binding, and comparing the polypeptide/molecule activity or binding to a standard.

5

10

15

20

25

30

Preferably, an ELISA assay can measure polypeptide level or activity in a sample (e.g., biological sample) using a monoclonal or polyclonal antibody. The antibody can measure polypeptide level or activity by either binding, directly or indirectly, to the polypeptide or by competing with the polypeptide for a substrate.

Additionally, the receptor to which the polypeptide of the present invention binds can be identified by numerous methods known to those of skill in the art, for example, ligand panning and FACS sorting (Coligan, et al., Current Protocols in Immun., 1(2), Chapter 5, (1991)). For example, expression cloning is employed wherein polyadenylated RNA is prepared from a cell responsive to the polypeptides, for example, NIH3T3 cells which are known to contain multiple receptors for the FGF family proteins, and SC-3 cells, and a cDNA library created from this RNA is divided into pools and used to transfect COS cells or other cells that are not responsive to the polypeptides. Transfected cells which are grown on glass slides are exposed to the polypeptide of the present invention, after they have been labelled. The polypeptides can be labeled by a variety of means including iodination or inclusion of a recognition site for a site-specific protein kinase.

Following fixation and incubation, the slides are subjected to auto-radiographic analysis. Positive pools are identified and sub-pools are prepared and re-transfected using an iterative sub-pooling and re-screening process, eventually yielding a single clones that encodes the putative receptor.

As an alternative approach for receptor identification, the labeled polypeptides can be photoaffinity linked with cell membrane or extract preparations that express the receptor molecule. Cross-linked material is resolved by PAGE analysis and exposed to X-ray film. The labeled complex containing the receptors of the polypeptides can be excised, resolved

WO 00/55351

5

10

15

20

25

30

into peptide fragments, and subjected to protein microsequencing. The amino acid sequence obtained from microsequencing would be used to design a set of degenerate oligonucleotide probes to screen a cDNA library to identify the genes encoding the putative receptors.

Moreover, the techniques of gene-shuffling, motif-shuffling, exon-shuffling, and/or codon-shuffling (collectively referred to as "DNA shuffling") may be employed to modulate the activities of the polypeptide of the present invention thereby effectively generating agonists and antagonists of the polypeptide of the present invention. See generally, U.S. Patent Nos. 5,605,793, 5,811,238, 5,830,721, 5,834,252, and 5,837,458, and Patten, P. A., et al., Curr. Opinion Biotechnol. 8:724-33 (1997); Harayama, S. Trends Biotechnol. 16(2):76-82 (1998); Hansson, L. O., et al., J. Mol. Biol. 287:265-76 (1999); and Lorenzo, M. M. and Blasco, R. Biotechniques 24(2):308-13 (1998) (each of these patents and publications are hereby incorporated by reference). In one embodiment, alteration of polynucleotides and corresponding polypeptides may be achieved by DNA shuffling. DNA shuffling involves the assembly of two or more DNA segments into a desired molecule by homologous, or sitespecific, recombination. In another embodiment, polynucleotides and corresponding polypeptides may be alterred by being subjected to random mutagenesis by error-prone PCR, random nucleotide insertion or other methods prior to recombination. In another embodiment, one or more components, motifs, sections, parts, domains, fragments, etc., of the polypeptide of the present invention may be recombined with one or more components, motifs, sections, parts, domains, fragments, etc. of one or more heterologous molecules. In preferred embodiments, the heterologous molecules are family members. In further preferred embodiments, the heterologous molecule is a growth factor such as, for example, platelet-derived growth factor (PDGF), insulin-like growth factor (IGF-I), transforming growth factor (TGF)-alpha, epidermal growth factor (EGF), fibroblast growth factor (FGF), TGF-beta, bone morphogenetic protein (BMP)-2, BMP-4, BMP-5, BMP-6, BMP-7, activins A and B, decapentaplegic(dpp), 60A, OP-2, dorsalin, growth differentiation factors (GDFs), nodal, MIS, inhibin-alpha, TGF-beta1, TGF-beta2, TGF-beta3, TGF-beta5, and glial-derived neurotrophic factor (GDNF).

Other preferred fragments are biologically active fragments of the polypeptide of the present invention. Biologically active fragments are those exhibiting activity similar, but not necessarily identical, to an activity of the polypeptide of the present invention. The

278

biological activity of the fragments may include an improved desired activity, or a decreased undesirable activity.

Additionally, this invention provides a method of screening compounds to identify those which modulate the action of the polypeptide of the present invention. An example of such an assay comprises combining a mammalian fibroblast cell, a the polypeptide of the present invention, the compound to be screened and ³[H] thymidine under cell culture conditions where the fibroblast cell would normally proliferate. A control assay may be performed in the absence of the compound to be screened and compared to the amount of fibroblast proliferation in the presence of the compound to determine if the compound stimulates proliferation by determining the uptake of ³[H] thymidine in each case. The amount of fibroblast cell proliferation is measured by liquid scintillation chromatography which measures the incorporation of ³[H] thymidine. Both agonist and antagonist compounds may be identified by this procedure.

5

10

15

20

25

30

In another method, a mammalian cell or membrane preparation expressing a receptor for a polypeptide of the present invention is incubated with a labeled polypeptide of the present invention in the presence of the compound. The ability of the compound to enhance or block this interaction could then be measured. Alternatively, the response of a known second messenger system following interaction of a compound to be screened and the receptor is measured and the ability of the compound to bind to the receptor and elicit a second messenger response is measured to determine if the compound is a potential agonist or antagonist. Such second messenger systems include but are not limited to, cAMP guanylate cyclase, ion channels or phosphoinositide hydrolysis.

All of these above assays can be used as diagnostic or prognostic markers. The molecules discovered using these assays can be used to treat disease or to bring about a particular result in a patient (e.g., blood vessel growth) by activating or inhibiting the polypeptide/molecule. Moreover, the assays can discover agents which may inhibit or enhance the production of the polypeptides of the invention from suitably manipulated cells or tissues.

Therefore, the invention includes a method of identifying compounds which bind to a polypeptide of the invention comprising the steps of: (a) incubating a candidate binding compound with a polypeptide of the present invention; and (b) determining if binding has

279

occurred. Moreover, the invention includes a method of identifying agonists/antagonists comprising the steps of: (a) incubating a candidate compound with a polypeptide of the present invention, (b) assaying a biological activity, and (b) determining if a biological activity of the polypeptide has been altered.

5

Targeted Delivery

In another embodiment, the invention provides a method of delivering compositions to targeted cells expressing a receptor for a polypeptide of the invention, or cells expressing a cell bound form of a polypeptide of the invention.

10

As discussed herein, polypeptides or antibodies of the invention may be associated with heterologous polypeptides, heterologous nucleic acids, toxins, or prodrugs via hydrophobic, hydrophilic, ionic and/or covalent interactions. In one embodiment, the invention provides a method for the specific delivery of compositions of the invention to cells by administering polypeptides of the invention (including antibodies) that are associated with heterologous polypeptides or nucleic acids. In one example, the invention provides a method for delivering a therapeutic protein into the targeted cell. In another example, the invention provides a method for delivering a single stranded nucleic acid (e.g., antisense or ribozymes) or double stranded nucleic acid (e.g., DNA that can integrate into the cell's genome or replicate episomally and that can be transcribed) into the targeted cell.

20

15

In another embodiment, the invention provides a method for the specific destruction of cells (e.g., the destruction of tumor cells) by administering polypeptides of the invention (e.g., polypeptides of the invention or antibodies of the invention) in association with toxins or cytotoxic prodrugs.

25

30

By "toxin" is meant compounds that bind and activate endogenous cytotoxic effector systems, radioisotopes, holotoxins, modified toxins, catalytic subunits of toxins, or any molecules or enzymes not normally present in or on the surface of a cell that under defined conditions cause the cell's death. Toxins that may be used according to the methods of the invention include, but are not limited to, radioisotopes known in the art, compounds such as, for example, antibodies (or complement fixing containing portions thereof) that bind an inherent or induced endogenous cytotoxic effector system, thymidine kinase, endonuclease, RNAse, alpha toxin, ricin, abrin, *Pseudomonas* exotoxin A, diphtheria toxin, saporin,

momordin, gelonin. pokeweed antiviral protein. alpha-sarcin and cholera toxin. By "cytotoxic prodrug" is meant a non-toxic compound that is converted by an enzyme, normally present in the cell, into a cytotoxic compound. Cytotoxic prodrugs that may be used according to the methods of the invention include. but are not limited to, glutamyl derivatives of benzoic acid mustard alkylating agent, phosphate derivatives of etoposide or mitomycin C, cytosine arabinoside, daunorubisin, and phenoxyacetamide derivatives of doxorubicin.

Drug Screening

5

10

15

20

25

30

Further contemplated is the use of the polypeptides of the present invention, or the polynucleotides encoding these polypeptides, to screen for molecules which modify the activities of the polypeptides of the present invention. Such a method would include contacting the polypeptide of the present invention with a selected compound(s) suspected of having antagonist or agonist activity, and assaying the activity of these polypeptides following binding.

This invention is particularly useful for screening therapeutic compounds by using the polypeptides of the present invention, or binding fragments thereof, in any of a variety of drug screening techniques. The polypeptide or fragment employed in such a test may be affixed to a solid support, expressed on a cell surface, free in solution, or located intracellularly. One method of drug screening utilizes eukaryotic or prokaryotic host cells which are stably transformed with recombinant nucleic acids expressing the polypeptide or fragment. Drugs are screened against such transformed cells in competitive binding assays. One may measure, for example, the formulation of complexes between the agent being tested and a polypeptide of the present invention.

Thus, the present invention provides methods of screening for drugs or any other agents which affect activities mediated by the polypeptides of the present invention. These methods comprise contacting such an agent with a polypeptide of the present invention or a fragment thereof and assaying for the presence of a complex between the agent and the polypeptide or a fragment thereof, by methods well known in the art. In such a competitive binding assay, the agents to screen are typically labeled. Following incubation. free agent is separated from that present in bound form, and the amount of free or uncomplexed label is a

measure of the ability of a particular agent to bind to the polypeptides of the present invention.

Another technique for drug screening provides high throughput screening for compounds having suitable binding affinity to the polypeptides of the present invention, and is described in great detail in European Patent Application 84/03564, published on September 13, 1984, which is incorporated herein by reference herein. Briefly stated, large numbers of different small peptide test compounds are synthesized on a solid substrate, such as plastic pins or some other surface. The peptide test compounds are reacted with polypeptides of the present invention and washed. Bound polypeptides are then detected by methods well known in the art. Purified polypeptides are coated directly onto plates for use in the aforementioned drug screening techniques. In addition, non-neutralizing antibodies may be used to capture the peptide and immobilize it on the solid support.

This invention also contemplates the use of competitive drug screening assays in which neutralizing antibodies capable of binding polypeptides of the present invention specifically compete with a test compound for binding to the polypeptides or fragments thereof. In this manner, the antibodies are used to detect the presence of any peptide which shares one or more antigenic epitopes with a polypeptide of the invention.

Antisense And Ribozvme (Antagonists)

5

10

15

20

25

30

In specific embodiments, antagonists according to the present invention are nucleic acids corresponding to the sequences contained in SEQ ID NO:X, or the complementary strand thereof, and/or to nucleotide sequences contained in the cDNA contained in the related cDNA clone identified in Table 1. In one embodiment, antisense sequence is generated internally, by the organism, in another embodiment, the antisense sequence is separately administered (see, for example, O'Connor, J., Neurochem. 56:560 (1991). Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988). Antisense technology can be used to control gene expression through antisense DNA or RNA, or through triple-helix formation. Antisense techniques are discussed for example, in Okano, J., Neurochem. 56:560 (1991); Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression. CRC Press, Boca Raton, FL (1988). Triple helix formation is discussed in, for instance, Lee et al., Nucleic Acids Research 6:3073 (1979); Cooney et al.,

10

15

20

25

30

Science 241:456 (1988): and Dervan et al., Science 251:1300 (1991). The methods are based on binding of a polynucleotide to a complementary DNA or RNA.

282

PCT/US00/05883

For example, the use of c-myc and c-myb antisense RNA constructs to inhibit the growth of the non-lymphocytic leukemia cell line HL-60 and other cell lines was previously described. (Wickstrom et al. (1988); Anfossi et al. (1989)). These experiments were performed in vitro by incubating cells with the oligoribonucleotide. A similar procedure for in vivo use is described in WO 91/15580. Briefly, a pair of oligonucleotides for a given antisense RNA is produced as follows: A sequence complimentary to the first 15 bases of the open reading frame is flanked by an EcoR1 site on the 5 end and a HindIII site on the 3 end. Next, the pair of oligonucleotides is heated at 90°C for one minute and then annealed in 2X ligation buffer (20mM TRIS HCl pH 7.5, 10mM MgCl2, 10MM dithiothreitol (DTT) and 0.2 mM ATP) and then ligated to the EcoR1/Hind III site of the retroviral vector PMV7 (WO 91/15580).

For example, the 5' coding portion of a polynucleotide that encodes the polypeptide of the present invention may be used to design an antisense RNA oligonucleotide of from about 10 to 40 base pairs in length. A DNA oligonucleotide is designed to be complementary to a region of the gene involved in transcription thereby preventing transcription and the production of the receptor. The antisense RNA oligonucleotide hybridizes to the mRNA in vivo and blocks translation of the mRNA molecule into receptor polypeptide.

In one embodiment, the antisense nucleic acid of the invention is produced intracellularly by transcription from an exogenous sequence. For example, a vector or a portion thereof, is transcribed, producing an antisense nucleic acid (RNA) of the invention. Such a vector would contain a sequence encoding the antisense nucleic acid. Such a vector can remain episomal or become chromosomally integrated, as long as it can be transcribed to produce the desired antisense RNA. Such vectors can be constructed by recombinant DNA technology methods standard in the art. Vectors can be plasmid, viral, or others known in the art, used for replication and expression in vertebrate cells. Expression of the sequence encoding the polypeptide of the present invnetion or fragments thereof, can be by any promoter known in the art to act in vertebrate, preferably human cells. Such promoters can be inducible or constitutive. Such promoters include, but are not limited to, the SV40 early promoter region (Bernoist and Chambon, Nature 29:304-310 (1981), the promoter contained in the 3' long terminal repeat of Rous sarcoma virus (Yamamoto et al., Cell 22:787-797

(1980), the herpes thymidine promoter (Wagner et al., Proc. Natl. Acad. Sci. U.S.A. 78:1441-1445 (1981), the regulatory sequences of the metallothionein gene (Brinster, et al., Nature 296:39-42 (1982)), etc.

5

10

15

20

25

30

The antisense nucleic acids of the invention comprise a sequence complementary to at least a portion of an RNA transcript of a gene of the present invention. However, absolute complementarity, although preferred, is not required. A sequence "complementary to at least a portion of an RNA," referred to herein, means a sequence having sufficient complementarity to be able to hybridize with the RNA, forming a stable duplex; in the case of double stranded antisense nucleic acids, a single strand of the duplex DNA may thus be tested, or triplex formation may be assayed. The ability to hybridize will depend on both the degree of complementarity and the length of the antisense nucleic acid. Generally, the larger the hybridizing nucleic acid, the more base mismatches with a RNA it may contain and still form a stable duplex (or triplex as the case may be). One skilled in the art can ascertain a tolerable degree of mismatch by use of standard procedures to determine the melting point of the hybridized complex.

Oligonucleotides that are complementary to the 5' end of the message, e.g., the 5' untranslated sequence up to and including the AUG initiation codon, should work most efficiently at inhibiting translation. However, sequences complementary to the 3' untranslated sequences of mRNAs have been shown to be effective at inhibiting translation of See generally, Wagner, R., 1994, Nature 372:333-335. mRNAs as well. oligonucleotides complementary to either the 5'- or 3'- non- translated, non-coding regions of polynucleotide sequences described herein could be used in an antisense approach to inhibit translation of endogenous mRNA. Oligonucleotides complementary to the 5' untranslated region of the mRNA should include the complement of the AUG start codon. Antisense oligonucleotides complementary to mRNA coding regions are less efficient inhibitors of translation but could be used in accordance with the invention. Whether designed to hybridize to the 5'-, 3'- or coding region of mRNA of the present invention, antisense nucleic acids should be at least six nucleotides in length, and are preferably oligonucleotides ranging from 6 to about 50 nucleotides in length. In specific aspects the oligonucleotide is at least 10 nucleotides, at least 17 nucleotides, at least 25 nucleotides or at least 50 nucleotides.

The polynucleotides of the invention can be DNA or RNA or chimeric mixtures or derivatives or modified versions thereof, single-stranded or double-stranded. The

WO 00/55351

5

10

15

20

25

30

PCT/US00/05883

284

oligonucleotide can be modified at the base moiety, sugar moiety, or phosphate backbone, for example, to improve stability of the molecule, hybridization, etc. The oligonucleotide may include other appended groups such as peptides (e.g., for targeting host cell receptors in vivo), or agents facilitating transport across the cell membrane (see, e.g., Letsinger et al., 1989, Proc. Natl. Acad. Sci. U.S.A. 86:6553-6556; Lemaitre et al., 1987, Proc. Natl. Acad. Sci. 84:648-652; PCT Publication No. WO88/09810, published December 15, 1988) or the blood-brain barrier (see, e.g., PCT Publication No. WO89/10134, published April 25, 1988), hybridization-triggered cleavage agents. (See, e.g., Krol et al., 1988, BioTechniques 6:958-976) or intercalating agents. (See, e.g., Zon, 1988, Pharm. Res. 5:539-549). To this end, the oligonucleotide may be conjugated to another molecule, e.g., a peptide, hybridization triggered cross-linking agent, transport agent, hybridization-triggered cleavage agent, etc.

The antisense oligonucleotide may comprise at least one modified base moiety which is selected from the group including, but not limited to, 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xantine, 4-acetylcytosine, 5-(carboxyhydroxylmethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine.

The antisense oligonucleotide may also comprise at least one modified sugar moiety selected from the group including, but not limited to, arabinose, 2-fluoroarabinose, xylulose, and hexose.

In yet another embodiment, the antisense oligonucleotide comprises at least one modified phosphate backbone selected from the group including, but not limited to, a phosphorothioate, a phosphorodithioate, a phosphoramidothioate. a phosphoramidate, a phosphordiamidate, a methylphosphonate, an alkyl phosphotriester, and a formacetal or analog thereof.

285

In yet another embodiment, the antisense oligonucleotide is an a-anomeric oligonucleotide. An a-anomeric oligonucleotide forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual b-units, the strands run parallel to each other (Gautier et al., 1987, Nucl. Acids Res. 15:6625-6641). The oligonucleotide is a 2'-0-methylribonucleotide (Inoue et al., 1987, Nucl. Acids Res. 15:6131-6148), or a chimeric RNA-DNA analogue (Inoue et al., 1987, FEBS Lett. 215:327-330).

5

10

15

20

25

30

Polynucleotides of the invention may be synthesized by standard methods known in the art, e.g. by use of an automated DNA synthesizer (such as are commercially available from Biosearch, Applied Biosystems, etc.). As examples, phosphorothicate oligonucleotides may be synthesized by the method of Stein et al. (1988, Nucl. Acids Res. 16:3209), methylphosphonate oligonucleotides can be prepared by use of controlled pore glass polymer supports (Sarin et al., 1988, Proc. Natl. Acad. Sci. U.S.A. 85:7448-7451), etc.

While antisense nucleotides complementary to the coding region sequence could be used, those complementary to the transcribed untranslated region are most preferred.

Potential antagonists according to the invention also include catalytic RNA, or a ribozyme (See, e.g., PCT International Publication WO 90/11364, published October 4, 1990; Sarver et al, Science 247:1222-1225 (1990). While ribozymes that cleave mRNA at site specific recognition sequences can be used to destroy mRNAs, the use of hammerhead ribozymes is preferred. Hammerhead ribozymes cleave mRNAs at locations dictated by flanking regions that form complementary base pairs with the target mRNA. The sole requirement is that the target mRNA have the following sequence of two bases: 5'-UG-3'. The construction and production of hammerhead ribozymes is well known in the art and is described more fully in Haseloff and Gerlach, Nature 334:585-591 (1988). There are numerous potential hammerhead ribozyme cleavage sites within the nucleotide sequence of SEQ ID NO:X. Preferably, the ribozyme is engineered so that the cleavage recognition site is located near the 5' end of the mRNA; i.e., to increase efficiency and minimize the intracellular accumulation of non-functional mRNA transcripts.

As in the antisense approach, the ribozymes of the invention can be composed of modified oligonucleotides (e.g. for improved stability, targeting, etc.) and should be delivered to cells which express in vivo. DNA constructs encoding the ribozyme may be introduced into the cell in the same manner as described above for the introduction of antisense encoding DNA. A preferred method of delivery involves using a DNA construct "encoding" the

- 10

15

20

25

30

ribozyme under the control of a strong constitutive promoter, such as, for example, pol III or pol II promoter, so that transfected cells will produce sufficient quantities of the ribozyme to destroy endogenous messages and inhibit translation. Since ribozymes unlike antisense molecules, are catalytic, a lower intracellular concentration is required for efficiency.

Antagonist/agonist compounds may be employed to inhibit the cell growth and proliferation effects of the polypeptides of the present invention on neoplastic cells and tissues, i.e. stimulation of angiogenesis of tumors, and, therefore, retard or prevent abnormal cellular growth and proliferation, for example, in tumor formation or growth.

The antagonist/agonist may also be employed to prevent hyper-vascular diseases, and prevent the proliferation of epithelial lens cells after extracapsular cataract surgery. Prevention of the mitogenic activity of the polypeptides of the present invention may also be desirous in cases such as restenosis after balloon angioplasty.

The antagonist/agonist may also be employed to prevent the growth of scar tissue during wound healing.

The antagonist/agonist may also be employed to treat the diseases described herein.

Thus, the invention provides a method of treating disorders or diseases, including but not limited to the disorders or diseases listed throughout this application, associated with overexpression of a polynucleotide of the present invention by administering to a patient (a) an antisense molecule directed to the polynucleotide of the present invention, and/or (b) a ribozyme directed to the polynucleotide of the present invention.

Other Activities

A polypeptide, polynucleotide, agonist, or antagonist of the present invention, as a result of the ability to stimulate vascular endothelial cell growth, may be employed in treatment for stimulating re-vascularization of ischemic tissues due to various disease conditions such as thrombosis, arteriosclerosis, and other cardiovascular conditions. The polypeptide, polynucleotide, agonist, or antagonist of the present invention may also be employed to stimulate angiogenesis and limb regeneration, as discussed above.

A polypeptide, polynucleotide, agonist, or antagonist of the present invention may also be employed for treating wounds due to injuries, burns, post-operative tissue repair, and ulcers since they are mitogenic to various cells of different origins, such as fibroblast cells

287

and skeletal muscle cells, and therefore, facilitate the repair or replacement of damaged or diseased tissue.

A polypeptide, polynucleotide, agonist, or antagonist of the present invention may also be employed stimulate neuronal growth and to treat and prevent neuronal damage which occurs in certain neuronal disorders or neuro-degenerative conditions such as Alzheimer's disease, Parkinson's disease, and AIDS-related complex. A polypeptide, polynucleotide, agonist, or antagonist of the present invention may have the ability to stimulate chondrocyte growth, therefore, they may be employed to enhance bone and periodontal regeneration and aid in tissue transplants or bone grafts.

5

10

15

20

25

30

A polypeptide, polynucleotide, agonist, or antagonist of the present invention may be also be employed to prevent skin aging due to sunburn by stimulating keratinocyte growth.

A polypeptide, polynucleotide, agonist, or antagonist of the present invention may also be employed for preventing hair loss, since FGF family members activate hair-forming cells and promotes melanocyte growth. Along the same lines, a polypeptide, polynucleotide, agonist, or antagonist of the present invention may be employed to stimulate growth and differentiation of hematopoietic cells and bone marrow cells when used in combination with other cytokines.

A polypeptide, polynucleotide, agonist, or antagonist of the present invention may also be employed to maintain organs before transplantation or for supporting cell culture of primary tissues. A polypeptide, polynucleotide, agonist, or antagonist of the present invention may also be employed for inducing tissue of mesodermal origin to differentiate in early embryos.

A polypeptide, polynucleotide, agonist, or antagonist of the present invention may also increase or decrease the differentiation or proliferation of embryonic stem cells, besides, as discussed above, hematopoietic lineage.

A polypeptide, polynucleotide, agonist, or antagonist of the present invention may also be used to modulate mammalian characteristics. such as body height, weight, hair color, eye color, skin, percentage of adipose tissue, pigmentation, size, and shape (e.g., cosmetic surgery). Similarly, a polypeptide, polynucleotide, agonist, or antagonist of the present invention may be used to modulate mammalian metabolism affecting catabolism, anabolism, processing, utilization, and storage of energy.

A polypeptide, polynucleotide, agonist, or antagonist of the present invention may be used to change a mammal's mental state or physical state by influencing biorhythms, caricadic rhythms, depression (including depressive disorders), tendency for violence, tolerance for pain, reproductive capabilities (preferably by Activin or Inhibin-like activity), hormonal or endocrine levels, appetite, libido, memory, stress, or other cognitive qualities.

A polypeptide, polynucleotide, agonist, or antagonist of the present invention may also be used as a food additive or preservative, such as to increase or decrease storage capabilities, fat content, lipid, protein, carbohydrate, vitamins, minerals, cofactors or other nutritional components.

The above-recited applications have uses in a wide variety of hosts. Such hosts include, but are not limited to, human, murine, rabbit, goat, guinea pig, camel, horse, mouse, rat, hamster, pig, micro-pig, chicken, goat, cow, sheep, dog, cat, non-human primate, and human. In specific embodiments, the host is a mouse, rabbit, goat, guinea pig, chicken, rat, hamster, pig, sheep, dog or cat. In preferred embodiments, the host is a mammal. In most preferred embodiments, the host is a human.

Other Preferred Embodiments

5

10

15

20

25

30

Other preferred embodiments of the claimed invention include an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least about 50 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X or the complementary strand thereto, and/or the cDNA in the related cDNA clone contained in the deposit.

Also preferred is a nucleic acid molecule wherein said sequence of contiguous nucleotides is included in the nucleotide sequence of SEQ ID NO:X in the range of positions identified as "Start" and "End" in columns 7 and 8 as defined for SEQ ID NO:X in Table 1.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least about 150 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X or the complementary strand thereto, and/or the cDNA in the related cDNA clone contained in the deposit.

Further preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least about 500 contiguous

10

15

20

25

30

nucleotides in the nucleotide sequence of SEQ ID NO:X or the complementary strand thereto, and/or the cDNA in the related cDNA clone contained in the deposit.

A further preferred embodiment is a nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the nucleotide sequence of SEQ ID NO:X in the range of positions identified as "Start" and "End" in columns 7 and 8 as defined for SEQ ID NO:X in Table 1.

A further preferred embodiment is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the complete nucleotide sequence of SEQ ID NO:X or the complementary strand thereto, and/or the cDNA in the related cDNA clone contained in the deposit.

Also preferred is an isolated nucleic acid molecule which hybridizes under stringent hybridization conditions to a nucleic acid molecule comprising a nucleotide sequence of SEQ ID NO:X or the complementary strand thereto, and/or the cDNA in the related cDNA clone contained in the deposit, wherein said nucleic acid molecule which hybridizes does not hybridize under stringent hybridization conditions to a nucleic acid molecule having a nucleotide sequence consisting of only A residues or of only T residues.

Also preferred is a composition of matter comprising a DNA molecule which comprises a cDNA clone contained in the deposit.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least 50 contiguous nucleotides in the nucleotide sequence of the cDNA in the related cDNA clone contained in the deposit.

Also preferred is an isolated nucleic acid molecule, wherein said sequence of at least 50 contiguous nucleotides is included in the nucleotide sequence of an open reading frame sequence encoded by the cDNA in the related cDNA clone contained in the deposit.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to sequence of at least 150 contiguous nucleotides in the nucleotide sequence encoded by the cDNA in the related cDNA clone contained in the deposit.

A further preferred embodiment is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to sequence of at least 500 contiguous nucleotides in the nucleotide sequence encoded by the cDNA in the related cDNA clone contained in the deposit.

A further preferred embodiment is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the complete nucleotide sequence encoded by the cDNA in the related cDNA clone contained in the deposit.

5

10

15

20

25

30

A further preferred embodiment is a method for detecting in a biological sample a nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X or the complementary strand thereto; and a nucleotide sequence encoded by the cDNA in the related cDNA clone contained in the deposit; which method comprises a step of comparing a nucleotide sequence of at least one nucleic acid molecule in said sample with a sequence selected from said group and determining whether the sequence of said nucleic acid molecule in said sample is at least 95% identical to said selected sequence.

Also preferred is the above method wherein said step of comparing sequences comprises determining the extent of nucleic acid hybridization between nucleic acid molecules in said sample and a nucleic acid molecule comprising said sequence selected from said group. Similarly, also preferred is the above method wherein said step of comparing sequences is performed by comparing the nucleotide sequence determined from a nucleic acid molecule in said sample with said sequence selected from said group. The nucleic acid molecules can comprise DNA molecules or RNA molecules.

A further preferred embodiment is a method for identifying the species, tissue or cell type of a biological sample which method comprises a step of detecting nucleic acid molecules in said sample, if any, comprising a nucleotide sequence that is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X or the complementary strand thereto; and a nucleotide sequence encoded by the cDNA in the related cDNA clone contained in the deposit.

Also preferred is the above method for identifying the species, tissue or cell type of a biological sample which comprises a step of detecting nucleic acid molecules comprising a nucleotide sequence in a panel of at least two nucleotide sequences, wherein at least one sequence in said panel is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from said group.

10

15

20

25

30

PCT/US00/05883

Also preferred is a method for diagnosing in a subject a pathological condition associated with abnormal structure or expression of a nucleotide sequence of SEQ ID NO:X; or the cDNA contained in the related cDNA clone referenced in Table 1 which encodes a protein, wherein the method comprises a step of detecting in a biological sample obtained from said subject nucleic acid molecules, if any, comprising a nucleotide sequence that is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X or the complementary strand thereto; and a nucleotide sequence of the cDNA in the related cDNA clone contained in the deposit.

Also preferred is the above method for diagnosing a pathological condition which comprises a step of detecting nucleic acid molecules comprising a nucleotide sequence in a panel of at least two nucleotide sequences, wherein at least one sequence in said panel is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from said group.

Also preferred is a composition of matter comprising isolated nucleic acid molecules wherein the nucleotide sequences of said nucleic acid molecules comprise a panel of at least two nucleotide sequences, wherein at least one sequence in said panel is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X or the complementary strand thereto; and a nucleotide sequence encoded by the cDNA in the related cDNA clone contained in the deposit. The nucleic acid molecules can comprise DNA molecules or RNA molecules.

Also preferred is a composition of matter comprising isolated nucleic acid molecules wherein the nucleotide sequences of said nucleic acid molecules comprise a DNA microarray or "chip" of at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 40, 50, 100, 150, 200, 250, 300, 500, 1000, 2000, 3000 or 4000 nucleotide sequences, wherein at least one sequence in said DNA microarray or "chip" is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X or the complementary strand thereto; and a nucleotide sequence encoded by the cDNA in the cDNA clone referenced in Table 1. The nucleic acid molecules can comprise DNA molecules or RNA molecules.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 90% identical to a sequence of at least about 10 contiguous amino acids in the polypeptide sequence of SEQ ID NO:Y; a polypeptide encoded by SEQ ID NO:X; and/or a polypeptide encoded by the cDNA in the related cDNA clone contained in the deposit.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 30 contiguous amino acids in the amino acid sequence of SEQ ID NO:Y; a polypeptide encoded by SEQ ID NO:X; and/or a polypeptide encoded by the cDNA in the related cDNA clone contained in the deposit.

5

15

20

25

30

Further preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 100 contiguous amino acids in the amino acid sequence of SEQ ID NO:Y; a polypeptide encoded by SEQ ID NO:X; and/or a polypeptide encoded by the cDNA in the related cDNA clone contained in the deposit.

Further preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to the complete amino acid sequence of SEQ ID NO:Y; a polypeptide encoded by SEQ ID NO:X; and/or a polypeptide encoded by the cDNA in the related cDNA clone contained in the deposit.

Further preferred is an isolated polypeptide comprising an amino acid sequence at least 90% identical to a sequence of at least about 10 contiguous amino acids in the complete amino acid sequence of a polypeptide encoded by the cDNA clone referenced in Table 1.

Also preferred is a polypeptide wherein said sequence of contiguous amino acids is included in the amino acid sequence of a portion of said polypeptide encoded by the cDNA clone referenced in Table 1; a polypeptide encoded by SEQ ID NO:X; and/or the polypeptide sequence of SEQ ID NO:Y.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 30 contiguous amino acids in the amino acid sequence of a polypeptide encoded by the cDNA clone referenced in Table 1.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 100 contiguous amino acids in the amino acid sequence of a polypeptide encoded by the cDNA clone referenced in Table 1.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to the amino acid sequence of a polypeptide encoded by the cDNA clone referenced in Table 1.

WO 00/55351

5

10

15

20

25

30

293

PCT/US00/05883

Further preferred is an isolated antibody which binds specifically to a polypeptide comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: a polypeptide sequence of SEQ ID NO:Y; a polypeptide encoded by SEQ ID NO:X; and a polypeptide encoded by the cDNA in the related cDNA clone contained in the deposit.

Further preferred is a method for detecting in a biological sample a polypeptide comprising an amino acid sequence which is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: a polypeptide sequence of SEQ ID NO:Y; a polypeptide encoded by SEQ ID NO:X; and a polypeptide encoded by the cDNA in the related cDNA clone referenced in Table 1; which method comprises a step of comparing an amino acid sequence of at least one polypeptide molecule in said sample with a sequence selected from said group and determining whether the sequence of said polypeptide molecule in said sample is at least 90% identical to said sequence of at least 10 contiguous amino acids.

Also preferred is the above method wherein said step of comparing an amino acid sequence of at least one polypeptide molecule in said sample with a sequence selected from said group comprises determining the extent of specific binding of polypeptides in said sample to an antibody which binds specifically to a polypeptide comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: a polypeptide sequence of SEQ ID NO:Y; a polypeptide encoded by SEQ ID NO:X; and a polypeptide encoded by the cDNA in the related cDNA clone referenced in Table 1.

Also preferred is the above method wherein said step of comparing sequences is performed by comparing the amino acid sequence determined from a polypeptide molecule in said sample with said sequence selected from said group.

Also preferred is a method for identifying the species, tissue or cell type of a biological sample which method comprises a step of detecting polypeptide molecules in said sample, if any, comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: polypeptide sequence of SEQ ID NO:Y; a polypeptide encoded by SEQ ID NO:X; and a polypeptide encoded by the cDNA in the related cDNA clone referenced in Table 1.

Also preferred is the above method for identifying the species, tissue or cell type of a biological sample, which method comprises a step of detecting polypeptide molecules comprising an amino acid sequence in a panel of at least two amino acid sequences, wherein at least one sequence in said panel is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the above group.

5

10

15

20

25

30

Also preferred is a method for diagnosing in a subject a pathological condition associated with abnormal structure or expression of a nucleic acid sequence identified in Table 1 encoding a polypeptide, which method comprises a step of detecting in a biological sample obtained from said subject polypeptide molecules comprising an amino acid sequence in a panel of at least two amino acid sequences, wherein at least one sequence in said panel is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: polypeptide sequence of SEQ ID NO:Y; a polypeptide encoded by SEQ ID NO:X; and a polypeptide encoded by the cDNA in the related cDNA clone referenced in Table 1.

In any of these methods, the step of detecting said polypeptide molecules includes using an antibody.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a nucleotide sequence encoding a polypeptide wherein said polypeptide comprises an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: polypeptide sequence of SEQ ID NO:Y; a polypeptide encoded by SEQ ID NO:X; and a polypeptide encoded by the cDNA in the related cDNA clone referenced in Table 1.

Also preferred is an isolated nucleic acid molecule, wherein said nucleotide sequence encoding a polypeptide has been optimized for expression of said polypeptide in a prokaryotic host.

Also preferred is an isolated nucleic acid molecule, wherein said polypeptide comprises an amino acid sequence selected from the group consisting of: polypeptide sequence of SEQ ID NO:Y; a polypeptide encoded by SEQ ID NO:X: and a polypeptide encoded by the cDNA in the related cDNA clone referenced in Table 1.

Further preferred is a method of making a recombinant vector comprising inserting any of the above isolated nucleic acid molecule into a vector. Also preferred is the recombinant vector produced by this method. Also preferred is a method of making a

295

recombinant host cell comprising introducing the vector into a host cell, as well as the recombinant host cell produced by this method.

Also preferred is a method of making an isolated polypeptide comprising culturing this recombinant host cell under conditions such that said polypeptide is expressed and recovering said polypeptide. Also preferred is this method of making an isolated polypeptide, wherein said recombinant host cell is a eukaryotic cell and said polypeptide is a human protein comprising an amino acid sequence selected from the group consisting of: polypeptide sequence of SEQ ID NO:Y; a polypeptide encoded by SEQ ID NO:X; and a polypeptide encoded by the cDNA in the related cDNA clone referenced in Table 1. The isolated polypeptide produced by this method is also preferred.

5

10

15

20

Also preferred is a method of treatment of an individual in need of an increased level of a protein activity, which method comprises administering to such an individual a Therapeutic comprising an amount of an isolated polypeptide, polynucleotide, immunogenic fragment or analogue thereof, binding agent, antibody, or antigen binding fragment of the claimed invention effective to increase the level of said protein activity in said individual.

Also preferred is a method of treatment of an individual in need of a decreased level of a protein activity, which method comprised administering to such an individual a Therapeutic comprising an amount of an isolated polypeptide, polynucleotide, immunogenic fragment or analogue thereof, binding agent, antibody, or antigen binding fragment of the claimed invention effective to decrease the level of said protein activity in said individual.

Having generally described the invention, the same will be more readily understood by reference to the following examples, which are provided by way of illustration and are not intended as limiting.

296

Examples

5

10

25

30

Example 1: Isolation of a Selected cDNA Clone From the Deposited Sample

Each deposited cDNA clone is contained in a plasmid vector. Table 5 identifies the vectors used to construct the cDNA library from which each clone was isolated. In many cases, the vector used to construct the library is a phage vector from which a plasmid has been excised. The following correlates the related plasmid for each phage vector used in constructing the cDNA library. For example, where a particular clone is identified in Table 5 as being isolated in the vector "Lambda Zap," the corresponding deposited clone is in "pBluescript."

	Vector Used to Construct Library	Corresponding Deposited Plasmid
	Lambda Zap	pBluescript (pBS)
15	Uni-Zap XR	pBluescript (pBS)
	Zap Express	pBK
	lafmid BA	plafmid BA
	pSport1	pSport1
	pCMVSport 2.0	pCMVSport 2.0
20	pCMVSport 3.0	pCMVSport 3.0
	pCR [®] 2.1	pCR ⁸ 2.1

Vectors Lambda Zap (U.S. Patent Nos. 5,128,256 and 5,286,636), Uni-Zap XR (U.S. Patent Nos. 5,128, 256 and 5,286,636), Zap Express (U.S. Patent Nos. 5,128,256 and 5,286,636), pBluescript (pBS) (Short, J. M. et al., Nucleic Acids Res. 16:7583-7600 (1988); Alting-Mees, M. A. and Short, J. M., Nucleic Acids Res. 17:9494 (1989)) and pBK (Alting-Mees, M. A. et al., Strategies 5:58-61 (1992)) are commercially available from Stratagene Cloning Systems, Inc., 11011 N. Torrey Pines Road, La Jolla. CA, 92037. pBS contains an ampicillin resistance gene and pBK contains a neomycin resistance gene. Both can be transformed into E. coli strain XL-1 Blue, also available from Stratagene. pBS comes in 4 forms SK+, SK-, KS+ and KS. The S and K refers to the orientation of the polylinker to the T7 and T3 primer sequences which flank the polylinker region ("S" is for SacI and "K" is for Kpnl which are the first sites on each respective end of the linker). "+" or "-" refer to the

297

orientation of the fl origin of replication ("ori"), such that in one orientation, single stranded rescue initiated from the fl ori generates sense strand DNA and in the other, antisense.

5

15

Vectors pSport1, pCMVSport 2.0 and pCMVSport 3.0, were obtained from Life Technologies, Inc., P. O. Box 6009, Gaithersburg, MD 20897. All Sport vectors contain an ampicillin resistance gene and may be transformed into E. coli strain DH10B, also available from Life Technologies. (See, for instance, Gruber, C. E., et al., Focus 15:59 (1993).)

Vector lafmid BA (Bento Soares, Columbia University, NY) contains an ampicillin resistance gene and can be transformed into E. coli strain XL-1 Blue. Vector pCR[®]2.1, which is available from Invitrogen, 1600 Faraday Avenue, Carlsbad, CA 92008, contains an ampicillin resistance gene and may be transformed into E. coli strain DH10B, available from Life Technologies. (See, for instance, Clark, J. M., Nuc. Acids Res. 16:9677-9686 (1988) and Mead, D. et al., Bio/Technology 9: (1991).) Preferably, a polynucleotide of the present invention does not comprise the phage vector sequences identified for the particular clone in Table 5, as well as the corresponding plasmid vector sequences designated above.

The deposited material in the sample assigned the ATCC Deposit Number cited by reference to Table 2 and 5 for any given cDNA clone also may contain one or more additional plasmids, each comprising a cDNA clone different from that given clone. Thus, deposits sharing the same ATCC Deposit Number contain at least a plasmid for each cDNA clone referenced in Table 1.

TABLE 5

Libraries owned by Catalog	Catalog Description	Vector	ATCC Deposit
HUKA HUKB HUKC HUKD HUKE HUKF HUKG	Human Uterine Cancer	Lambda ZAP II	LP01
HCNA HCNB	Human Colon	Lambda Zap II	LP01
HFFA	Human Fetal Brain, random primed	Lambda Zap II	LP01
HTWA	Resting T-Cell	Lambda ZAP II	LP01
HBQA	Early Stage Human Brain, random primed	Lambda ZAP II	LP01
HLMB HLMF HLMG HLMH HLMI HLMJ HLMM HLMN	breast lymph node CDNA library	Lambda ZAP II	LP01
HCQA HCQB	human colon cancer	Lamda ZAP II	LP01
HMEA HMEC HMED HMEE HMEF HMEG HMEI HMEJ HMEK HMEL	Human Microvascular Endothelial Cells. fract. A	Lambda ZAP II	LP01
HUSA HUSC	Human Umbilical Vein Endothelial Cells, fract, A	Lambda ZAP II	LP01
HLQA HLQB	Hepatocellular Tumor	Lambda ZAP II	LP01
HHGA HHGB HHGC HHGD	Hemangiopericytoma	Lambda ZAP II	LP01
HSDM	Human Striatum Depression, re-rescue	Lambda ZAP II	LP01
HUSH	H Umbilical Vein Endothelial Cells, frac	Lambda ZAP II	LP01
HSGS	Salivary gland, subtracted	Lambda ZAP II	LP01
HFXA HFXB HFXC HFXD HFXE HFXF HFXG HFXH	Brain frontal cortex	Lambda ZAP II	LP01
HPQA HPQB HPQC	PERM TF274	Lambda ZAP II	LP01
HFXJ HFXK	Brain Frontal Cortex, re-excision	Lambda ZAP II	LP01
HCWA HCWB HCWC HCWD HCWE HCWF HCWG HCWH HCWI HCWJ HCWK	CD34 positive cells (Cord Blood)	ZAP Express	LP02
HCUA HCUB HCUC	CD34 depleted Buffy Coat (Cord Blood)	ZAP Express	LP02
HRSM	A-14 cell line	ZAP Express	LP02
HRSA	A1-CELL LINE	ZAP Express	LP02
HCUD HCUE HCUF HCUG HCUH HCUI	CD34 depleted Buffy Coat (Cord Blood), re-excision	ZAP Express	LP02
HBXE HBXF HBXG		ZAP Express	LP02
HRLM	L8 cell line	ZAP Express	LP02
НВХА НВХВ НВХС НВХD	Human Whole Brain #2 - Oligo dT >	ZAP Express	LP02
HUDA HUDB HUDC		ZAP Express	LP02
ннтм ннто ннто	H. hypothalamus, frac A;re-excision	ZAP Express	LP02
HHTL	H. hypothalamus, frac A	ZAP Express	LP02
HASA HASD	1	Uni-ZAP XR	LP03
HFKC HFKD HFKE HFKF HFKG	Human Fetal Kidney	Uni-ZAP XR	LP03
HE8A HE8B HE8C HE8D HE8E HE8F HE8M HE8N	Human 8 Week Whole Embryo	Uni-ZAP XR	LP03
HGBA HGBD HGBE HGBF HGBG HGBH HGBI	Human Gall Bladder	Uni-ZAP XR	LP03
HLHA HLHB HLHC HLHD HLHE	Human Fetal Lung III	Uni-ZAP XR	LP03

Libraries owned by Catalog	Catalog Description	Vector	ATCC Deposit
НЕНЕ НЕНО НЕНН НЕНО			
НРМА НРМВ НРМС НРМО НРМЕ НРМГ НРМС НРМН	Human Placenta	Uni-ZAP XR	LP03
HPRA HPRB HPRC HPRD	Human Prostate	Uni-ZAP XR	LP03
HSIA HSIC HSID HSIE	Human Adult Small Intestine	Uni-ZAP XR	LP03
HTEA HTEB HTEC HTED HTEE HTEF HTEG HTEH HTEI HTEJ HTEK	Human Testes	Uni-ZAP XR	LP03
HTPA HTPB HTPC HTPD HTPE	Human Pancreas Tumor	Uni-ZAP XR	LP03
HTTA HTTB HTTC HTTD HTTE HTTF	Human Testes Tumor	Uni-ZAP XR	LP03
НАРА НАРВ НАРС НАРМ	Human Adult Pulmonary	Uni-ZAP XR	LP03
HETA HETB HETC HETD HETE HETF HETG HETH HETI	Human Endometrial Tumor	Uni-ZAP XR	LP03
ннгв ннгс ннго ннге ннгг ннго ннги ннгі	Human Fetal Heart	Uni-ZAP XR	LP03
ННРВ ННРС ННРО ННРЕ ННРҒ ННРG ННРН	Human Hippocampus	Uni-ZAP XR	LP03
HCE1 HCE2 HCE3 HCE4 HCE5 HCEB HCEC HCED HCEE HCEF HCEG	Human Cerebellum	Uni-ZAP XR	LP03
HUVB HUVC HUVD HUVE	Human Umbilical Vein, Endo. remake	Uni-ZAP XR	LP03
HSTA HSTB HSTC HSTD	Human Skin Tumor	Uni-ZAP XR	LP03
HTAA HTAB HTAC HTAD HTAE	Human Activated T-Cells	Uni-ZAP XR	LP03
HFEA HFEB HFEC	Human Fetal Epithelium (Skin)	Uni-ZAP XR	LP03
НЈРА НЈРВ НЈРС НЈРD	HUMAN JURKAT MEMBRANE BOUND POLYSOMES	Uni-ZAP XR	LP03
HESA	Human epithelioid sarcoma	Uni-Zap XR	LP03
HLTA HLTB HLTC HLTD HLTE HLTF	Human T-Cell Lymphoma	Uni-ZAP XR	LP03
HFTA HFTB HFTC HFTD	Human Fetal Dura Mater	Uni-ZAP XR	LP03
HRDA HRDB HRDC HRDD HRDE HRDF	Human Rhabdomyosarcoma	Uni-ZAP XR	LP03
НСАА НСАВ НСАС	Cem cells cyclohexamide treated	Uni-ZAP XR	LP03
HRGA HRGB HRGC HRGD	Raji Cells. cyclohexamide treated	Uni-ZAP XR	LP03
HSUA HSUB HSUC HSUM	Supt Cells, cyclohexamide treated	Uni-ZAP XR	LP03
HT4A HT4C HT4D	Activated T-Cells, 12 hrs.	Uni-ZAP XR	LP03
HE9A HE9B HE9C HE9D HE9E HE9F HE9G HE9H HE9M HE9N	Nine Weck Old Early Stage Human	Uni-ZAP XR	LP03
HATA HATB HATC HATD HATE	Human Adrenal Gland Tumor	Uni-ZAP XR	LP03
HT5A	Activated T-Cells. 24 hrs.	Uni-ZAP XR	LP03
HFGA HFGM	Human Fetal Brain	Uni-ZAP XR	LP03
HNEA HNEB HNEC HNED HNEE	Human Neutrophil	Uni-ZAP XR	LP03
нвсв нвср	Human Primary Breast Cancer	Uni-ZAP XR	LP03
HBNA HBNB	Human Normal Breast	Uni-ZAP XR	LP03
HCAS	Cem Cells, cyclohexamide treated, subtra	Uni-ZAP XR	LP03
HHPS	Human Hippocampus, subtracted	pBS	LP03
HKCS HKCU	Human Colon Cancer, subtracted	pBS	LP03

Libraries owned by Catalog	Catalog Description	Vector	ATCC Deposit
HRGS	Raji cells, cyclohexamide treated.	pBS	LP03
HSUT	Supt cells, cyclohexamide treated, differentially expressed	pBS	LP03
HT4S	Activated T-Cells, 12 hrs. subtracted	Uni-ZAP XR	LP03
HCDA HCDB HCDC HCDD HCDE	Human Chondrosarcoma	Uni-ZAP XR	LP03
НОАА НОАВ НОАС	Human Osteosarcoma	Uni-ZAP XR	LP03
HTLA HTLB HTLC HTLD HTLE	Human adult testis, large inserts	Uni-ZAP XR	LP03
HLMA HLMC HLMD	Breast Lymph node cDNA library	Uni-ZAP XR	LP03
Н6ЕА Н6ЕВ Н6ЕС	HL-60. PMA 4H	Uni-ZAP XR	LP03
HTXA HTXB HTXC HTXD HTXE HTXF HTXG HTXH	Activated T-Cell (12hs)/Thiouridine labelledEco	Uni-ZAP XR	LP03
INFA HNFB HNFC HNFD HNFE INFF HNFG HNFH HNFJ	Human Neutrophil. Activated	Uni-ZAP XR	LP03
тов нтос	HUMAN TONSILS. FRACTION 2	Uni-ZAP XR	LP03
НМСВ	Human OB MG63 control fraction I	Uni-ZAP XR	LP03
НОРВ	Human OB HOS control fraction I	Uni-ZAP XR	LP03
HORB	Human OB HOS treated (10 nM E2) fraction I	Uni-ZAP XR	LP03
ISVA HSVB HSVC	Human Chronic Synovitis	Uni-ZAP XR	LP03
HROA	HUMAN STOMACH	Uni-ZAP XR	LP03
НВЈА НВЈВ НВЈС НВЈО НВЈЕ НВЈ НВЈС НВЈН НВЈІ НВЈЈ НВЈК	F HUMAN B CELL LYMPHOMA	Uni-ZAP XR	LP03
HCRA HCRB HCRC	human corpus colosum	Uni-ZAP XR	LP03
HODA HODB HODC HODD	human ovarian cancer	Uni-ZAP XR	LP03
IDSA	Dermatofibrosarcoma Protuberance	Uni-ZAP XR	LP03
HMWA HMWB HMWC HMWD HMWE HMWF HMWG HMWH HMWI HMWJ	Bone Marrow Cell Line (RS4;11)	Uni-ZAP XR	LP03
ISOA	stomach cancer (human)	Uni-ZAP XR	LP03
IERA	SKIN	Uni-ZAP XR	LP03
HMDA	Brain-medulloblastoma	Uni-ZAP XR	LP03
IGLA HGLB HGLD	Glioblastoma	Uni-ZAP XR	LP03
I EAA	H. Atrophic Endometrium	Uni-ZAP XR	LP03
ВСА НВСВ	H. Lymph node breast Cancer	Uni-ZAP XR	LP03
HPWT	Human Prostate BPH, re-excision	Uni-ZAP XR	LP03
HFVG HFVH HFVI	Fetal Liver, subtraction II	pBS	LP03
Infi	Human Neutrophils, Activated, re-	pBS	LP03
нвмв нвмс нвмр	Human Bone Marrow, re-excision	pBS	LP03
KML HKMM HKMN	H. Kidney Medulla, re-excision	pBS	LP03
KIX HKIY	H. Kidney Cortex. subtracted	pBS	LP03
ADT	H. Amygdala Depression, subtracted	pBS	LP03
16AS	HI-60, untreated, subtracted	Uni-ZAP XR	LP03
16ES	HL-60. PMA 4H, subtracted	Uni-ZAP XR	LP03
H6BS	HL-60. RA 4h. Subtracted	Uni-ZAP XR	LP03

Libraries owned by Catalog	Catalog Description	Vector	ATCC Deposit
H6CS	HL-60, PMA 1d, subtracted	Uni-ZAP XR	LP03
НТХЈ НТХК	Activated T-cell(12h)/Thiouridine-re- excision	Uni-ZAP XR	LP03
HMSA HMSB HMSC HMSD HMSE HMSF HMSG HMSH HMSI HMSJ HMSK	Monocyte activated	Uni-ZAP XR	LP03
HAGA HAGB HAGC HAGD HAGE HAGF	Human Amygdala	Uni-ZAP XR	LP03
HSRA HSRB HSRE	STROMAL -OSTEOCLASTOMA	Uni-ZAP XR	LP03
HSRD HSRF HSRG HSRH	Human Osteoclastoma Stromal Cells - unamplified	Uni-ZAP XR	LP03
HSQA HSQB HSQC HSQD HSQE HSQF HSQG	Stromal cell TF274	Uni-ZAP XR	LP03
HSKA HSKB HSKC HSKD HSKE HSKF HSKZ	Smooth muscle, serum treated	Uni-ZAP XR	LP03
HSLA HSLB HSLC HSLD HSLE HSLF HSLG	Smooth muscle.control	Uni-ZAP XR	LP03
HSDA HSDD HSDE HSDF HSDG HSDH	Spinal cord	Uni-ZAP XR	LP03
HPWS	Prostate-BPH subtracted II	pBS	LP03
HSKW HSKX HSKY	Smooth Muscle- HASTE normalized	pBS	LP03
НЕРВ НЕРС HEPD	H. Frontal cortex.epileptic:re-excision	Uni-ZAP XR	LP03
HSDI HSDJ HSDK	Spinal Cord. re-excision	Uni-ZAP XR	LP03
HSKN HSKO	Smooth Muscle Serum Treated, Norm	pBS	LP03
HSKG HSKH HSKI	Smooth muscle, serum induced.re-exc	pBS	LP03
HFCA HFCB HFCC HFCD HFCE	Human Fetal Brain	Uni-ZAP XR	LP04
НРТА НРТВ НРТ D	Human Pituitary	Uni-ZAP XR	LP04
НТНВ HTHC HTHD	Human Thymus	Uni-ZAP XR	LP04
HE6B HE6C HE6D HE6E HE6F HE6G HE6S	Human Whole Six Week Old Embryo	Uni-ZAP XR	LP04
HSSA HSSB HSSC HSSD HSSE HSSF HSSG HSSH HSSI HSSJ HSSK	Human Synovial Sarcoma	Uni-ZAP XR	LP04
HE7T	7 Week Old Early Stage Human, subtracted	Uni-ZAP XR	LP04
НЕРА НЕРВ НЕРС	Human Epididymus	Uni-ZAP XR	LP04
ISNA HSNB HSNC HSNM HSNN	Human Synovium	Uni-ZAP XR	LP04
HPFB HPFC HPFD HPFE	Human Prostate Cancer, Stage C fraction	Uni-ZAP XR	LP04
HE2A HE2D HE2E HE2H HE2I HE2M HE2N HE2O		Uni-ZAP XR	LP04
HE2B HE2C HE2F HE2G HE2P HE2Q	12 Week Old Early Stage Human, II	Uni-ZAP XR	LP04
IPTS HPTT HPTU	Human Pituitary, subtracted	Uni-ZAP XR	LP04
HAUA HAUB HAUC	Amniotic Cells - TNF induced	Uni-ZAP XR	LP04
HAQA HAQB HAQC HAQD	Amniotic Cells - Primary Culture	Uni-ZAP XR	LP04
HWTA HWTB HWTC	wilm's tumor	Uni-ZAP XR	LP04
HBSD	Bone Cancer, re-excision	Uni-ZAP XR	LP04
HSGB	Salivary gland, re-excision	Uni-ZAP XR	LP04
HSJA HSJB HSJC	Smooth muscle-ILb induced	Uni-ZAP XR	LP04
HSXA HSXB HSXC HSXD	Human Substantia Nigra	Uni-ZAP XR	LP04

Libraries owned by Catalog	Catalog Description	Vector	ATCC Deposit
HSHA HSHB HSHC	Smooth muscle, IL1b induced	Uni-ZAP XR	LP04
HOUA HOUB HOUC HOUD HOUE	Adipocytes	Uni-ZAP XR	LP04
HPWA HPWB HPWC HPWD HPWE	Prostate BPH	Uni-ZAP XR	LP04
HELA HELB HELC HELD HELE HELF HELG HELH	Endothelial cells-control	Uni-ZAP XR	LP04
HEMA HEMB HEMC HEMD HEME HEMF HEMG HEMH	Endothelial-induced	Uni-ZAP XR	LP04
HBIA HBIB HBIC	Human Brain. Striatum	Uni-ZAP XR	LP04
HHSA HHSB HHSC HHSD HHSE	Human Hypothalmus.Schizophrenia	Uni-ZAP XR	LP04
HNGA HNGB HNGC HNGD HNGE HNGF HNGG HNGH HNGI HNGJ	neutrophils control	Uni-ZAP XR	LP04
HNHA HNHB HNHC HNHD HNHE HNHF HNHG HNHH HNHI HNHJ	Neutrophils IL-1 and LPS induced	Uni-ZAP XR	LP04
HSDB HSDC	STRIATUM DEPRESSION	Uni-ZAP XR	LP04
ННРТ	Hypothalamus	Uni-ZAP XR	LP04
HSAT HSAU HSAV HSAW HSAX HSAY HSAZ	Anergic T-cell	Uni-ZAP XR	LP04
HBMS HBMT HBMU HBMV HBMW HBMX	Bone marrow	Uni-ZAP XR	LP04
HOEA HOEB HOEC HOED HOEE HOEF HOEJ	Osteoblasts	Uni-ZAP XR	LP04
HAIA HAIB HAIC HAID HAIE HAIF	Epithelial-TNFa and INF induced	Uni-ZAP XR	LP04
HTGA HTGB HTGC HTGD	Apoptotic T-cell	Uni-ZAP XR	LP04
HMCA HMCB HMCC HMCD HMCE	Macrophage-oxLDL	Uni-ZAP XR	LP04
HMAA HMAB HMAC HMAD HMAE HMAF HMAG	Macrophage (GM-CSF treated)	Uni-ZAP XR	LP04
НРНА	Normal Prostate	Uni-ZAP XR	LP04
НРІА НРІВ НРІС	LNCAP prostate cell line	Uni-ZAP XR	LP04
НРЈА НРЈВ НРЈС	PC3 Prostate cell line	Uni-ZAP XR	LP04
HOSE HOSF HOSG	Human Osteoclastoma, re-excision	Uni-ZAP XR	LP04
HTGE HTGF	Apoptotic T-cell. re-excision	Uni-ZAP XR	LP04
НМАЈ НМАК	H Macrophage (GM-CSF treated), re- excision	Uni-ZAP XR	LP04
AACB HACC HACD	Human Adipose Tissue, re-excision	Uni-ZAP XR	LP04
HFPA	H. Frontal Cortex. Epileptic	Uni-ZAP XR	LP04
IFAA HFAB HFAC HFAD HFAE	Alzheimers, spongy change	Uni-ZAP XR	LP04
HFAM	Frontal Lobe, Dementia	Uni-ZAP XR	LP04
НМІА НМІВ НМІС	Human Manic Depression Tissue	Uni-ZAP XR	LP04
ITSA HTSE HTSF HTSG HTSH	Human Thymus	pBS	LP05
ІРВА НРВВ НРВС НРВО НРВЕ	Human Pineal Gland	pBS	LP05
ISAA HSAB HSAC	HSA 172 Cells	pBS	LP05
ISBA HSBB HSBC HSBM	HSC172 cells	pBS	LP05
IJAA HJAB HJAC HJAD	Jurkat T-cell G1 phase	pBS	LP05
ІЈВА НЈВВ НЈВС НЈВD	Jurkat T-Cell, S phase	pBS	LP05
ААГА НАГВ	Aorta endothelial cells + TNF-a	pBS	LP05
IAWA HAWB HAWC	Human White Adipose	pBS	LP05
ITNA HTNB	Human Thyroid	pBS	LP05

Libraries owned by Catalog	Catalog Description	Vector	ATCC Deposit
HONA	Normal Ovary, Premenopausal	pBS	LP05
HARA HARB	Human Adult Retina	pBS	LP05
HLJA HLJB	Human Lung	pCMVSport I	LP06
НОГМ НОГО	H. Ovarian Tumor, II. OV5232	pCMVSport 2.0	LP07
HOGA HOGB HOGC	OV 10-3-95	pCMVSport 2.0	LP07
HCGL	CD34+cells. II	pCMVSport 2.0	LP07
HDLA	Hodgkin's Lymphoma I	pCMVSport 2.0	LP07
HDTA HDTB HDTC HDTD HDTE	Hodgkin's Lymphoma II	pCMVSport 2.0	LP07
HKAA HKAB HKAC HKAD HKAE HKAF HKAG HKAH	Keratinocyte	pCMVSport2.0	LP07
НСІМ	CAPFINDER, Crohn's Disease, lib 2	pCMVSport 2.0	LP07
HKAL	Keratinocyte, lib 2	pCMVSport2.0	LP07
HKAT	Keratinocyte. lib 3	pCMVSport2.0	LP07
HNDA	Nasal polyps	pCMVSport2.0	LP07
HDRA	H. Primary Dendritic Cells.lib 3	pCMVSport2.0	LP07
НОНА НОНВ НОНС	Human Osteoblasts II	pCMVSport2.0	LP07
HLDA HLDB HLDC	Liver, Hepatoma	pCMVSport3.0	LP08
HLDN HLDO HLDP	Human Liver. normal	pCMVSport3.0	LP08
НМТА	pBMC stimulated w/ poly I/C	pCMVSport3.0	LP08
HNTA	NTERA2. control	pCMVSport3.0	LP08
HDPA HDPB HDPC HDPD HDPF HDPG HDPH HDPI HDPJ HDPK	Primary Dendritic Cells, lib 1	pCMVSport3.0	LP08
HDPM HDPN HDPO HDPP	Primary Dendritic cells.frac 2	pCMVSport3.0	LP08
НМИА НМИВ НМИС	Myoloid Progenitor Cell Line	pCMVSport3.0	LP08
ННЕА ННЕВ ННЕС ННЕD	T Cell helper I	pCMVSport3.0	LP08
ННЕМ ННЕО ННЕР	T cell helper II	pCMVSport3.0	LP08
HEQA HEQB HEQC	Human endometrial stromal cells	pCMVSport3.0	LP08
нјма нјмв	Human endometrial stromal cells-treated with progesterone		LP08
HSWA HSWB HSWC	Human endometrial stromal cells-treated with estradiol		LP08
HSYA HSYB HSYC	Human Thymus Stromal Cells	pCMVSport3.0	LP08
HLWA HLWB HLWC	Human Placenta	pCMVSport3.0	LP08
HRAA HRAB HRAC	Rejected Kidney, lib 4	pCMVSport3.0	LP08
нмтм	PCR, pBMC I/C treated	PCRII	LP09
НМЈА	H. Meniingima, M6	pSport 1	LP10
HMKA HMKB HMKC HMKD HMKE		pSport I	LP10
HUSG HUSI	IL-4 induced	pSport I	LP10
HUSX HUSY	Human Umbilical Vein Endothelial Cells, uninduced	pSport 1	LP10
НОГА		pSport I	LP10
HCFA HCFB HCFC HCFD	T-Cell PHA 16 hrs	pSport I	LP10
HCFL HCFM HCFN HCFO		pSport I	LP10
HADA HADC HADD HADE HADF HADG	Human Adipose	pSport 1	LP10

Libraries owned by Catalog	Catalog Description	Vector	ATCC Deposit
НОУА НОУВ НОУС	Human Ovary	pSport 1	LP10
HTWB HTWC HTWD HTWE HTWF	Resting T-Cell Library.ll	pSport 1	LP10
НММА	Spleen metastic melanoma	pSport 1	LP10
HLYA HLYB HLYC HLYD HLYE	Spleen. Chronic lymphocytic leukemia	pSport 1	LP10
HCGA	CD34+ cell. I	pSport I	LP10
НЕОМ НЕОМ	Human Eosinophils	pSport 1	LP10
HTDA	Human Tonsil. Lib 3	pSport I	LP10
HSPA	Salivary Gland, Lib 2	pSport !	LP10
НСНА НСНВ НСНС	Breast Cancer cell line, MDA 36	pSport I	LP10
нснм нсни	Breast Cancer Cell line, angiogenic	pSport I	LP10
HCIA	Crohn's Disease	pSport I	LP10
НДАА НДАВ НДАС	HEL cell line	pSport I	LP10
НАВА	Human Astrocyte	pSport 1	LP10
HUFA HUFB HUFC	Ulcerative Colitis	pSport 1	LP10
HNTM	NTERA2 + retinoic acid. 14 days	pSport I	LP10
HDQA	Primary Dendritic cells.CapFinder2, frac	pSport I	LP10
HDQM	Primary Dendritic Cells. CapFinder, frac	pSport 1	LP10
HLDX	Human Liver, normal, CapFinder	pSport I	LP10
HULA HULB HULC	Human Dermal Endothelial Cells untreated	pSport1	LP10
НИМА	Human Dermal Endothelial cells,treated	pSporti	LP10
HCJA	Human Stromal Endometrial fibroblasts, untreated	pSport I	LP10
НСЈМ	treated w/ estradiol	pSport1	LP10
HEDA	Human Stromal endometrial fibroblasts. treated with progesterone	pSport1	LP10
HFNA	Human ovary tumor cell OV350721	pSport1	LP10
HKGA HKGB HKGC HKGD	Merkel Cells	pSporti	LP10
HISA HISB HISC	Pancreas Islet Cell Tumor	pSport1	LP10
HLSA	Skin, burned	pSport1	LP10
HBZA	Prostate,BPH. Lib 2	pSport l	LP10
HBZS	Prostate BPH, Lib 2. subtracted	pSport 1	LP10
HFIA HFIB HFIC	Synovial Fibroblasts (control)	pSport l	LP10
HFIH HFII HFIJ	Synovial hypoxia	pSport I	LP10
HFIT HFIU HFIV	Synovial IL-1/TNF stimulated	pSport 1	LP10
HGCA		pSport1	LP10
НМУА НМУВ НМУС	Bone Marrow Stromal Cell, untreated	pSportl	LP10
HFIX HFIY HFIZ	Synovial Fibroblasts (III/TNF), subt	pSport l	LP10
HFOX HFOY HFOZ	Synovial hypoxia-RSF subtracted	pSport1	LP10
HMQA HMQB HMQC HMQD	Human Activated Monocytes	Uni-ZAP XR	LPII
HLIA HLIB HLIC	Human Liver	pCMVSport I	LP012
НВА ННВВ ННВС ННВО ННВЕ	Human Heart	pCMVSport I	LP012
НВВА НВВВ	Human Brain	pCMVSport I	LP012

Libraries owned by Catalog	Catalog Description	Vector	ATCC Deposit
HLJA HLJB HLJC HLJD HLJE	Human Lung	pCMVSport 1	LP012
HOGA HOGB HOGC	Ovarian Tumor	pCMVSport 2.0	LP012
МТЛМ	Human Tonsils. Lib 2	pCMVSport 2.0	LP012
HAMF HAMG	КМН2	pCMVSport 3.0	LP012
НАЈА НАЈВ НАЈС	L428	pCMVSport 3.0	LP012
HWBA HWBB HWBC HWBD HWBE	Dendritic cells, pooled	pCMVSport 3.0	LP012
HWAA HWAB HWAC HWAD HWAE	Human Bone Marrow, treated	pCMVSport 3.0	LP012
НҮАА НҮАВ НҮАС	B Cell lymphoma	pCMVSport 3.0	LP012
нwнg нwнн нwні	Healing groin wound, 6.5 hours post incision	pCMVSport 3.0	LP012
НWНР HWHQ HWHR	Healing groin wound: 7.5 hours post incision	pCMVSpoπ 3.0	LP012
HARM	Healing groin wound - zero hr post- incision (control)	pCMVSport 3.0	LP012
нвім	Olfactory epithelium: nasalcavity	pCMVSport 3.0	LP012
HWDA	Healing Abdomen wound: 70&90 min post incision	pCMVSport 3.0	LP012
HWEA	Healing Abdomen Wound; 15 days post incision	pCMVSport 3.0	LP012
HWJA	Healing Abdomen Wound:21&29 days	pCMVSport 3.0	LP012
HNAL	Human Tongue, trac 2	pSport1	LP012
НМЈА	H. Meniingima, M6	pSport1	LP012
НМКА НМКВ НМКС НМКД НМКЕ	H. Meningima, M1	pSport1	LP012
HOFA	Ovarian Tumor I. OV5232	pSportI	LP012
HCFA HCFB HCFC HCFD	T-Cell PHA 16 hrs	pSport1	LP012
HCFL HCFM HCFN HCFO	T-Cell PHA 24 hrs	pSporti	LP012
НММА НММВ НММС	Spleen metastic melanoma	pSport1	LP012
HTDA	Human Tonsil. Lib 3	pSport1	LP012
HDBA	Human Fetal Thymus	pSport1	LP012
HDUA	Pericardium	pSportI	LP012
HBZA	Prostate.BPH. Lib 2	pSport1	LP012
HWCA	Larynx tumor	pSport1	LP012
HWKA	Normal lung	pSportI	LP012
нsмв 	Bone marrow stroma.treated	pSport1	LP012
нвнм	Normal trachea	pSport1	LP012
HLFC	Human Larynx	pSportI	LP012
HLRB	Siebben Polyposis	pSport1	LP012
INIA	Mammary Gland	pSport1	LP012
INJB	Palate carcinoma	pSport1	LP012
INKA	Palate normal	pSport I	LP012
HMZA	Pharynx carcinoma	pSport1	LP012
łabg	Cheek Carcinoma	pSport1	LP012
HMZM	Pharynx Carcinoma	pSport1	LP012
IDRM	Larynx Carcinoma	pSport1	LP012
AAVI	Pancreas normal PCA4 No	pSportI	LP012
HICA	Tongue carcinoma	pSport1	LP012

Libraries owned by Catalog	Catalog Description	Vector	ATCC Deposit
HUKA HUKB HUKC HUKD HUKE	Human Uterine Cancer	Lambda ZAP II	LP013
HFFA	Human Fetal Brain, random primed	Lambda ZAP II	LP013
HTUA	Activated T-cell labeled with 4-thioluri	Lambda ZAP II	LP013
HBQA	Early Stage Human Brain, random primed	Lambda ZAP II	LP013
нмев	Human microvascular Endothelial cells. fract. B	Lambda ZAP II	LP013
HUSH	Human Umbilical Vein Endothelial cells, fract. A. re-excision	Lambda ZAP II	LP013
HLQC HLQD	Hepatocellular tumor. re-excision	Lambda ZAP II	LP013
HTWJ HTWK HTWL	Resting T-cell, re-excision	Lambda ZAP II	LP013
HF6S	Human Whole 6 week Old Embryo (11), subt	pBluescript	LP013
HHPS	Human Hippocampus, subtracted	pBluescript	LP013
HLIS	LNCAP, differential expression	pBluescript	LP013
HLHS HLHT	Early Stage Human Lung. Subtracted	pBluescript	LP013
HSUS	Supt cells, cyclohexamide treated, subtracted	pBluescript	LP013
HSUT	Supt cells, cyclohexamide treated. differentially expressed	pBluescript	LP013
HSDS	H. Striatum Depression, subtracted	pBluescript	LP013
HPTZ	Human Pituitary. Subtracted VII	pBlucscript	LP013
HSDX	H. Striatum Depression, subt Il	pBluescript	LP013
HSDZ	H. Striatum Depression. subt	pBluescript	LP013
НРВА НРВВ НРВС НРВО НРВЕ	Human Pineal Gland	pBluescript SK-	LP013
HRTA	Colorectal Tumor	pBluescript SK-	LP013
HSBA HSBB HSBC HSBM	HSC172 cells	pBluescript SK-	LP013
HJAA HJAB HJAC HJAD	Jurkat T-cell G1 phase	pBluescript SK-	LP013
НЈВА НЈВВ НЈВС НЈВD	Jurkat T-cell, S1 phase	pBluescript SK-	LP013
HTNA HTNB	Human Thyroid	pBluescript SK-	LP013
НАНА НАНВ	Human Adult Heart	Uni-ZAP XR	LP013
HE6A	Whole 6 week Old Embryo	Uni-ZAP XR	LP013
HFCA HFCB HFCC HFCD HFCE	Human Fetal Brain	Uni-ZAP XR	LP013
HFKC HFKD HFKE HFKF HFKG	Human Fetal Kidney	Uni-ZAP XR	LP013
HGBA HGBD HGBE HGBF HGBG	Human Gall Bladder	Uni-ZAP XR	LP013
HPRA HPRB HPRC HPRD	Human Prostate	Uni-ZAP XR	LP013
HTEA HTEB HTEC HTED HTEE	Human Testes	Uni-ZAP XR	LP013
HTTA HTTB HTTC HTTD HTTE	Human Testes Tumor	Uni-ZAP XR	LP013
нүва нүвв	Human Fetal Bone	Uni-ZAP XR	LP013
HFLA	Human Fetal Liver	Uni-ZAP XR	LP013
ННГВ ННГС ННГО ННГЕ ННГГ	Human Fetal Heart	Uni-ZAP XR	LP013
HUVB HUVC HUVD HUVE	Human Umbilical Vein. End. remake	Uni-ZAP XR	LP013
НТНВ НТНС НТНD	Human Thymus	Uni-ZAP XR	LP013
HSTA HSTB HSTC HSTD	Human Skin Tumor	Uni-ZAP XR	LP013
HTAA HTAB HTAC HTAD HTAE	Human Activated T-cells	Uni-ZAP XR	LP013
НЕА НЕВ НЕС	Human Fetal Epithelium (skin)	Uni-ZAP XR	LP013
НЈРА НЈРВ НЈРС НЈРО		Uni-ZAP XR	LP013
HESA	· · · · · · · · · · · · · · · · · · ·	Uni-ZAP XR	LP013

Libraries owned by Catalog	Catalog Description	Vector	ATCC Deposit
HALS	Human Adult Liver. Subtracted	Uni-ZAP XR	LP013
HFTA HFTB HFTC HFTD	Human Fetal Dura Mater	Uni-ZAP XR	LP013
НСАА НСАВ НСАС	Cem cells, cyclohexamide treated	Uni-ZAP XR	LP013
HRGA HRGB HRGC HRGD	Raji Cells, cyclohexamide treated	Uni-ZAP XR	LP013
НЕ9А НЕ9В НЕ9С НЕ9D НЕ9E	Nine Week Old Early Stage Human	Uni-ZAP XR	LP013
HSFA	Human Fibrosarcoma	Uni-ZAP XR	LP013
HATA HATB HATC HATD HATE	Human Adrenal Gland Tumor	Uni-ZAP XR	LP013
НTRA	Human Trachea Tumor	Uni-ZAP XR	LP013
HE2A HE2D HE2E HE2H HE2I	12 Week Old Early Stage Human	Uni-ZAP XR	LP013
HE2B HE2C HE2F HE2G HE2P	12 Week Old Early Stage Human, Il	Uni-ZAP XR	LP013
HNEA HNEB HNEC HNED HNEE	Human Neutrophil	Uni-ZAP XR	LP013
HBGA	Human Primary Breast Cancer	Uni-ZAP XR	LP013
HPTS HPTT HPTU	Human Pituitary, subtracted	Uni-ZAP XR	LP013
HMQA HMQB HMQC HMQD	Human Activated Monocytes	Uni-ZAP XR	LP013 ·
НОАА НОЛВ НОАС	Human Osteosarcoma	Uni-ZAP XR	LP013
HTOA HTOD HTOE HTOF HTOG	human tonsils	Uni-ZAP XR	LP013
НМСВ	Human OB MG63 control fraction I	Uni-ZAP XR	LP013
НОРВ	Human OB HOS control fraction I	Uni-ZAP XR	LP013
ноов	Human OB HOS treated (1 nM E2) fraction I	Uni-ZAP XR	LP013
HAUA HAUB HAUC	Amniotic Cells - TNF induced	Uni-ZAP XR	LP013
HAQA HAQB HAQC HAQD	Amniotic Cells - Primary Culture	Uni-ZAP XR	LP013
HROA HROC	HUMAN STOMACH	Uni-ZAP XR	LP013
НВЈА НВЈВ НВЈС НВЈ D НВЈЕ	HUMAN B CELL LYMPHOMA	Uni-ZAP XR	LP013
HODA HODB HODC HODD	human ovarian cancer	Uni-ZAP XR	LP013
НСРА	Corpus Callosum	Uni-ZAP XR	LP013
HSOA	stomach cancer (human)	Uni-ZAP XR	LP013
HERA	SKIN	Uni-ZAP XR	LP013
HMDA	Brain-medulloblastoma	Uni-ZAP XR	LP013
HGLA HGLB HGLD	Glioblastoma	Uni-ZAP XR	LP013
НЖТА НЖТВ НЖТС	wilm's tumor	Uni-ZAP XR	LP013
HEAA	H. Atrophic Endometrium	Uni-ZAP XR	LP013
HAPN HAPO HAPP HAPQ HAPR	Human Adult Pulmonary:re-excision	Uni-ZAP XR	LP013
HLTG HLTH	Human T-cell lymphoma;re-excision	Uni-ZAP XR	LP013
НАНС НАНО НАНЕ	Human Adult Heart:re-excision	Uni-ZAP XR	LP013
HAGA HAGB HAGC HAGD HAGE	Human Amygdala	Uni-ZAP XR	LP013
HSJA HSJB HSJC	Smooth muscle-ILb induced	Uni-ZAP XR	LP013
HSHA HSHB HSHC	Smooth muscle, IL1b induced	Uni-ZAP XR	LP013
HPWA HPWB HPWC HPWD HPWE	Prostate BPH	Uni-ZAP XR	LP013
НРІА НРІВ НРІС	LNCAP prostate cell line	Uni-ZAP XR	LP013
НРЈА НРЈВ НРЈС	PC3 Prostate cell line	Uni-ZAP XR	LP013
НВТА	Bone Marrow Stroma, TNF&LPS ind	Uni-ZAP XR	LP013
HMCF HMCG HMCH HMCI HMCJ	Macrophage-oxLDL; re-excision	Uni-ZAP XR	LP013
HAGG HAGH HAGI	Human Amygdala:re-excision	Uni-ZAP XR	LP013
HACA	H. Adipose Tissue	Uni-ZAP XR	LP013
НКГВ	K562 + PMA (36 hrs).re-excision	ZAP Express	LP013
HCWT HCWU HCWV	CD34 positive cells (cord blood),re-ex	ZAP Express	LP013

Libraries owned by Catalog	Catalog Description	Vector	ATCC Deposit
HBWA	Whole brain	ZAP Express	LP013
НВХА НВХВ НВХС НВХО	Human Whole Brain #2 - Oligo dT > 1.5Kb	ZAP Express	LP013
HAVM	Temporal cortex-Alzheizmer	pT-Adv	LP014
HAVT	Hippocampus. Alzheimer Subtracted	pT-Adv	LP014
HHAS	CHME Cell Line	Uni-ZAP XR	LP014
HAJR	Larynx normal	pSport 1	LP014
HWLE HWLF HWLG HWLH	Colon Normal	pSport 1	LP014
HCRM HCRN HCRO	Colon Carcinoma	pSport 1	LP014
HWLI HWLJ HWLK	Colon Normal	pSport I	LP014
HWLQ HWLR HWLS HWLT	Colon Tumor	pSport I	LP014
НВГМ	Gastrocnemius Muscle	pSport 1	LP014
HBOD HBOE	Quadriceps Muscle	pSport 1	LP014
НВКД НВКЕ	Soleus Muscle	pSport 1	LP014
НССМ	Pancreatic Langerhans	pSport 1	LP014
HWGA	Larynx carcinoma	pSport I	LP014
HWGM HWGN	Larynx carcinoma	pSport 1	LP014
HWLA HWLB HWLC	Normal colon	pSport 1	LP014
HWLM HWLN	Colon Tumor	pSport 1	LP014
HVAM HVAN HVAO	Pancreas Tumor	pSport 1	LP014
HWGQ	Larynx carcinoma	pSport 1	LP014
HAQM HAQN	Salivary Gland	pSport 1	LP014
HASM .	Stomach; normal	pSport I	LP014
НВСМ	Uterus; normal	pSport 1	LP014
HCDM	Testis: normal	pSport 1	LP014
HDIM	Brain; normal	pSport I	LP014
НЕГМ	Adrenal Gland.normal	pSport 1	LP014
НВАА	Rectum normal	pSport 1	LP014
HFDM	Rectum tumour	pSport I	LP014
HGAM	Colon, normal	pSport I	LP014
ННММ	Colon, tumour	pSport 1	LP014
нсьв нсьс	Human Lung Cancer	Lambda Zap II	LP015
HRLA	L1 Cell line	ZAP Express	LP015
ННАМ	Hypothalamus, Alzheimer's	pCMVSport 3.0	LP015
НКВА	Ku 812F Basophils Line	pSport 1	LP015
HS2S	Saos2, Dexamethosome Treated	pSport 1	LP016
HA5A	Lung Carcinoma A549 TNFalpha activated	pSport I	LP016
НТҒМ	TF-1 Cell Line GM-CSF Treated	pSport I	LP016
HYAS	Thyroid Tumour	pSport 1	LP016
HUTS	Larynx Normal	pSport I	LP016
HXOA	Larynx Tumor	pSport I	LP016
НЕАН	Ea.hy.926 cell line	pSport I	LP016
HINA	Adenocarcinoma Human	pSport 1	LP016
HRMA	Lung Mesothelium	pSport 1	LP016
HLCL	Human Pre-Differentiated Adipocytes	Uni-Zap XR	LP017
HS2A	Saos2 Cells	pSport 1	LP020

Libraries owned by Catalog	Catalog Description	Vector	ATCC Deposit
HS2I	Saos2 Cells: Vitamin D3 Treated	pSport I	LP020
нисм	CHME Cell Line, untreated	pSport I	LP020
HEPN	Arvepiglottis Normal	pSport 1	LP020
HPSN	Sinus Piniformis Tumour	pSport I	LP020
HNSA	Stomach Normal	pSport 1	LP020
HNSM	Stomach Tumour	pSport I	LP020
HNLA	Liver Normal Met5No	pSport 1	LP020
HUTA	Liver Tumour Met 5 Tu	pSport 1	LP020
HOCN	Colon Normal	pSport I	LP020
ност	Colon Tumor	pSport I	LP020
HTNT	Tongue Tumour	pSport I	LP020
HLXN	Larynx Normal	pSport 1	LP020
HLXT	Larvnx Tumour	pSport I	LP020
HTYN	Thymus	pSport I	LP020
HPLN	Placenta	pSport 1	LP020
HTNG	Tongue Normal	pSport I	LP020
HZAA	Thyroid Normal (SDCA2 No)	pSport I	LP020
HWES	Thyroid Thyroiditis	pSport I	LP020
HFHD	Ficolled Human Stromal Cells, 5Fu	pTrip1Ex2	LP021
HFAD 	treated		
НЕНМ,НЕНИ	Ficolled Human Stromal Cells. Untreated	pTrip1Ex2	LP021
HPCI	Hep G2 Cells, lambda library	lambda Zap-CMV XR	LP021
НВСА,НВСВ.НВСС	H. Lymph node breast Cancer	Uni-ZAP XR	LP021
HCOK	Chondrocytes	pSPORT1	LP022
HDCA, HDCB, HDCC	Dendritic Cells From CD34 Cells	pSPORT1	LP022
HDMA, HDMB	CD40 activated monocyte dendritic cells	pSPORT1	LP022
HDDM, HDDN, HDDO	LPS activated derived dendritic cells	pSPORTI	LP022
HPCR	Hep G2 Cells, PCR library	lambda Zap-CMV XR	LP022
НАЛА, НААВ, НААС	Lung. Cancer (4005313A3): Invasive Poorly Differentiated Lung Adenocarcinoma	pSPORT1	LP022
HIPA, HIPB. HIPC		pSPORT1	LP022
ноон, нооі	Ovary. Cancer: (4004562 B6) Papillary Serous Cystic Neoplasm. Low Malignant Pot	pSPORT1	LP022
HIDA	Lung. Normal: (4005313 B1)	pSPORT1	LP022
HUJA.HUJB.HUJC.HUJD.HUJE		pCMVSport 3.0	LP022
HNOA.HNOB.HNOC.HNOD	Ovary, Normal: (9805C040R)	pSPORTI	LP022
HNLM	Lung. Normal: (4005313 B1)	pSPORT1	LP022
HSCL	Stromal Cells	pSPORT1	LP022
HAAX	Lung. Cancer: (4005313 A3) Invasive Poorly-differentiated Metastatic lung adenocarcinoma	pSPORT1	LP022
HUUA.HUUB.HUUC.HUUD		pTrip1Ex2	LP022
HWWA,HWWB.HWWC,HWWD.H WE,HWWF,HWWG		pSPORTI	LP022
нссс	Colon. Cancer: (9808C064R)	pCMVSport 3.0	LP023

Libraries owned by Catalog	Catalog Description	Vector	ATCC Deposit
HPDO HPDP HPDQ HPDR HPD	Ovary, Cancer (9809C332): Poorly differentiated adenocarcinoma	pSport I	LP023
НРСО НРСР НРСО НРСТ	Ovary, Cancer (15395A1F): Grade II Papillary Carcinoma	pSport 1	LP023
носм носо носр носо	Ovary, Cancer: (15799A1F) Poorly differentiated carcinoma	pSport 1	LP023
НСВМ НСВО НСВО	Breast, Cancer: (4004943 A5)	pSport 1	LP023
HNBT HNBU HNBV	Breast, Normal: (4005522B2)	pSport I	LP023
нвср нвсо	Breast, Cancer: (4005522 A2)	pSport I	LP023
НВСЈ	Breast, Cancer: (9806C012R)	pSport I	LP023
HSAM HSAN	Stromal cells 3.88	pSport 1	LP023
HVCA HVCB HVCC HVCD	Ovary, Cancer: (4004332 A2)	pSport 1	LP023
HSCK HSEN HSEO	Stromal cells (HBM3.18)	pSport 1	LP023
HSCP HSCQ	stromal cell clone 2.5	pSport 1	LP023
HUXA	Breast Cancer: (4005385 A2)	pSport I	LP023
НСОМ НСОО НСОР НСОО	Ovary, Cancer (4004650 A3): Well- Differentiated Micropapillary Serous Carcinoma	рЅроп І	LP023
нвим	Breast, Cancer: (9802C020E)	pSport I	LP023
HVVA HVVB HVVC HVVD HVVE	Human Bone Marrow, treated	pSport I	LP023

10

15

20

25

30

311

Two approaches can be used to isolate a particular clone from the deposited sample of plasmid DNAs cited for that clone in Table 5. First, a plasmid is directly isolated by screening the clones using a polynucleotide probe corresponding to the nucleotide sequence of SEO ID NO:X.

Particularly, a specific polynucleotide with 30-40 nucleotides is synthesized using an Applied Biosystems DNA synthesizer according to the sequence reported. The oligonucleotide is labeled, for instance, with ³²P-γ-ATP using T4 polynucleotide kinase and purified according to routine methods. (E.g., Maniatis et al., Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Press, Cold Spring. NY (1982).) The plasmid mixture is transformed into a suitable host, as indicated above (such as XL-1 Blue (Stratagene)) using techniques known to those of skill in the art, such as those provided by the vector supplier or in related publications or patents cited above. The transformants are plated on 1.5% agar plates (containing the appropriate selection agent, e.g., ampicillin) to a density of about 150 transformants (colonies) per plate. These plates are screened using Nylon membranes according to routine methods for bacterial colony screening (e.g., Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd Edit., (1989), Cold Spring Harbor Laboratory Press, pages 1.93 to 1.104), or other techniques known to those of skill in the art.

Alternatively, two primers of 17-20 nucleotides derived from both ends of the nucleotide sequence of SEQ ID NO:X are synthesized and used to amplify the desired cDNA using the deposited cDNA plasmid as a template. The polymerase chain reaction is carried out under routine conditions, for instance, in 25 µl of reaction mixture with 0.5 ug of the above cDNA template. A convenient reaction mixture is 1.5-5 mM MgCl₂, 0.01% (w/v) gelatin, 20 µM each of dATP, dCTP, dGTP, dTTP, 25 pmol of each primer and 0.25 Unit of Taq polymerase. Thirty five cycles of PCR (denaturation at 94°C for 1 min; annealing at 55°C for 1 min; elongation at 72°C for 1 min) are performed with a Perkin-Elmer Cetus automated thermal cycler. The amplified product is analyzed by agarose gel electrophoresis and the DNA band with expected molecular weight is excised and purified. The PCR product is verified to be the selected sequence by subcloning and sequencing the DNA product.

Several methods are available for the identification of the 5' or 3' non-coding portions of a gene which may not be present in the deposited clone. These methods include but are not

limited to, filter probing, clone enrichment using specific probes, and protocols similar or identical to 5' and 3' "RACE" protocols which are well known in the art. For instance, a method similar to 5' RACE is available for generating the missing 5' end of a desired full-length transcript. (Fromont-Racine et al., Nucleic Acids Res. 21(7):1683-1684 (1993).)

Briefly, a specific RNA oligonucleotide is ligated to the 5' ends of a population of RNA presumably containing full-length gene RNA transcripts. A primer set containing a primer specific to the ligated RNA oligonucleotide and a primer specific to a known sequence of the gene of interest is used to PCR amplify the 5' portion of the desired full-length gene. This amplified product may then be sequenced and used to generate the full length gene.

5

10

15

20

25

30

This above method starts with total RNA isolated from the desired source, although poly-A+ RNA can be used. The RNA preparation can then be treated with phosphatase if necessary to eliminate 5' phosphate groups on degraded or damaged RNA which may interfere with the later RNA ligase step. The phosphatase should then be inactivated and the RNA treated with tobacco acid pyrophosphatase in order to remove the cap structure present at the 5' ends of messenger RNAs. This reaction leaves a 5' phosphate group at the 5' end of the cap cleaved RNA which can then be ligated to an RNA oligonucleotide using T4 RNA ligase.

This modified RNA preparation is used as a template for first strand cDNA synthesis using a gene specific oligonucleotide. The first strand synthesis reaction is used as a template for PCR amplification of the desired 5' end using a primer specific to the ligated RNA oligonucleotide and a primer specific to the known sequence of the gene of interest. The resultant product is then sequenced and analyzed to confirm that the 5' end sequence belongs to the desired gene.

Example 2: Isolation of Genomic Clones Corresponding to a Polynucleotide

A human genomic P1 library (Genomic Systems, Inc.) is screened by PCR using primers selected for the sequence corresponding to SEQ ID NO:X, according to the method described in Example 1. (See also. Sambrook.)

Example 3: Tissue specific expression analysis

The Human Genome Sciences, Inc. (HGS) database is derived from sequencing tissue specific cDNA libraries. Libraries generated from a particular tissue are selected and the specific tissue expression pattern of EST groups or assembled contigs within these libraries is determined by comparison of the expression patterns of those groups or contigs within the entire database. ESTs which show tissue specific expression are selected.

The original clone from which the specific EST sequence was generated, is obtained from the catalogued library of clones and the insert amplified by PCR using methods known in the art. The PCR product is denatured then transferred in 96 well format to a nylon membrane (Schleicher and Scheull) generating an array filter of tissue specific clones. Housekeeping genes, maize genes, and known tissue specific genes are included on the filters. These targets can be used in signal normalization and to validate assay sensitivity. Additional targets are included to monitor probe length and specificity of hybridization.

Radioactively labeled hybridization probes are generated by first strand cDNA synthesis per the manufacturer's instructions (Life Technologies) from mRNA/RNA samples prepared from the specific tissue being analyzed. The hybridization probes are purified by gel exclusion chromatography, quantitated, and hybridized with the array filters in hybridization bottles at 65°C overnight. The filters are washed under stringent conditions and signals are captured using a Fuji phosphorimager.

Data is extracted using AIS software and following background subtraction, signal normalization is performed. This includes a normalization of filter-wide expression levels between different experimental runs. Genes that are differentially expressed in the tissue of interest are identified and the full length sequence of these clones is generated.

25

30

5

10

15

20

Example 4: Chromosomal Mapping of the Polynucleotides

An oligonucleotide primer set is designed according to the sequence at the 5' end of SEQ ID NO:X. This primer preferably spans about 100 nucleotides. This primer set is then used in a polymerase chain reaction under the following set of conditions: 30 seconds, 95°C; 1 minute, 56°C; 1 minute, 70°C. This cycle is repeated 32 times followed by one 5 minute

cycle at 70°C. Human, mouse, and hamster DNA is used as template in addition to a somatic cell hybrid panel containing individual chromosomes or chromosome fragments (Bios, Inc). The reactions is analyzed on either 8% polyacrylamide gels or 3.5 % agarose gels. Chromosome mapping is determined by the presence of an approximately 100 bp PCR fragment in the particular somatic cell hybrid.

Example 5: Bacterial Expression of a Polypeptide

5

10

15

20

25

30

A polynucleotide encoding a polypeptide of the present invention is amplified using PCR oligonucleotide primers corresponding to the 5' and 3' ends of the DNA sequence, as outlined in Example 1, to synthesize insertion fragments. The primers used to amplify the cDNA insert should preferably contain restriction sites, such as BamHI and XbaI, at the 5' end of the primers in order to clone the amplified product into the expression vector. For example, BamHI and XbaI correspond to the restriction enzyme sites on the bacterial expression vector pQE-9. (Qiagen, Inc., Chatsworth, CA). This plasmid vector encodes antibiotic resistance (Amp^r), a bacterial origin of replication (ori), an IPTG-regulatable promoter/operator (P/O), a ribosome binding site (RBS), a 6-histidine tag (6-His), and restriction enzyme cloning sites.

The pQE-9 vector is digested with BamHI and XbaI and the amplified fragment is ligated into the pQE-9 vector maintaining the reading frame initiated at the bacterial RBS. The ligation mixture is then used to transform the E. coli strain M15/rep4 (Qiagen, Inc.) which contains multiple copies of the plasmid pREP4, which expresses the lacI repressor and also confers kanamycin resistance (Kan^I). Transformants are identified by their ability to grow on LB plates and ampicillin/kanamycin resistant colonies are selected. Plasmid DNA is isolated and confirmed by restriction analysis.

Clones containing the desired constructs are grown overnight (O/N) in liquid culture in LB media supplemented with both Amp (100 ug/ml) and Kan (25 ug/ml). The O/N culture is used to inoculate a large culture at a ratio of 1:100 to 1:250. The cells are grown to an optical density 600 (O.D.⁶⁰⁰) of between 0.4 and 0.6. IPTG (Isopropyl-B-D-thiogalacto pyranoside) is then added to a final concentration of 1 mM. IPTG induces by inactivating the lacI repressor, clearing the P/O leading to increased gene expression.

WO 00/55351

5

10

15

20

25

30

Cells are grown for an extra 3 to 4 hours. Cells are then harvested by centrifugation (20 mins at 6000Xg). The cell pellet is solubilized in the chaotropic agent 6 Molar Guanidine HCl by stirring for 3-4 hours at 4°C. The cell debris is removed by centrifugation, and the supernatant containing the polypeptide is loaded onto a nickel-nitrilo-tri-acetic acid ("Ni-NTA") affinity resin column (available from QIAGEN, Inc., *supra*). Proteins with a 6 x His tag bind to the Ni-NTA resin with high affinity and can be purified in a simple one-step procedure (for details see: The QIAexpressionist (1995) QIAGEN, Inc., *supra*).

Briefly, the supernatant is loaded onto the column in 6 M guanidine-HCl, pH 8, the column is first washed with 10 volumes of 6 M guanidine-HCl, pH 8, then washed with 10 volumes of 6 M guanidine-HCl pH 6, and finally the polypeptide is eluted with 6 M guanidine-HCl, pH 5.

The purified protein is then renatured by dialyzing it against phosphate-buffered saline (PBS) or 50 mM Na-acetate, pH 6 buffer plus 200 mM NaCl. Alternatively, the protein can be successfully refolded while immobilized on the Ni-NTA column. The recommended conditions are as follows: renature using a linear 6M-1M urea gradient in 500 mM NaCl, 20% glycerol, 20 mM Tris/HCl pH 7.4, containing protease inhibitors. The renaturation should be performed over a period of 1.5 hours or more. After renaturation the proteins are eluted by the addition of 250 mM immidazole. Immidazole is removed by a final dialyzing step against PBS or 50 mM sodium acetate pH 6 buffer plus 200 mM NaCl. The purified protein is stored at 4°C or frozen at -80°C.

In addition to the above expression vector, the present invention further includes an expression vector comprising phage operator and promoter elements operatively linked to a polynucleotide of the present invention, called pHE4a. (ATCC Accession Number 209645, deposited on February 25, 1998.) This vector contains: 1) a neomycinphosphotransferase gene as a selection marker, 2) an E. coli origin of replication, 3) a T5 phage promoter sequence, 4) two lac operator sequences, 5) a Shine-Delgarno sequence, and 6) the lactose operon repressor gene (lacIq). The origin of replication (oriC) is derived from pUC19 (LTI, Gaithersburg, MD). The promoter sequence and operator sequences are made synthetically.

DNA can be inserted into the pHEa by restricting the vector with Ndel and Xbal, BamHI. Xhol, or Asp718, running the restricted product on a gel, and isolating the larger fragment (the stuffer fragment should be about 310 base pairs). The DNA insert is generated according to the PCR protocol described in Example 1, using PCR primers having restriction

10

15

20

25

30

sites for Ndel (5' primer) and Xbal, BamHI. Xhol, or Asp718 (3' primer). The PCR insert is gel purified and restricted with compatible enzymes. The insert and vector are ligated according to standard protocols.

The engineered vector could easily be substituted in the above protocol to express protein in a bacterial system.

Example 6: Purification of a Polypeptide from an Inclusion Body

The following alternative method can be used to purify a polypeptide expressed in E coli when it is present in the form of inclusion bodies. Unless otherwise specified, all of the following steps are conducted at $4-10^{\circ}$ C.

Upon completion of the production phase of the *E. coli* fermentation, the cell culture is cooled to 4-10°C and the cells harvested by continuous centrifugation at 15,000 rpm (Heraeus Sepatech). On the basis of the expected yield of protein per unit weight of cell paste and the amount of purified protein required, an appropriate amount of cell paste, by weight, is suspended in a buffer solution containing 100 mM Tris, 50 mM EDTA, pH 7.4. The cells are dispersed to a homogeneous suspension using a high shear mixer.

The cells are then lysed by passing the solution through a microfluidizer (Microfuidics, Corp. or APV Gaulin, Inc.) twice at 4000-6000 psi. The homogenate is then mixed with NaCl solution to a final concentration of 0.5 M NaCl, followed by centrifugation at 7000 xg for 15 min. The resultant pellet is washed again using 0.5M NaCl, 100 mM Tris, 50 mM EDTA, pH 7.4.

The resulting washed inclusion bodies are solubilized with 1.5 M guanidine hydrochloride (GuHCl) for 2-4 hours. After 7000 xg centrifugation for 15 min., the pellet is discarded and the polypeptide containing supernatant is incubated at 4°C overnight to allow further GuHCl extraction.

Following high speed centrifugation (30,000 xg) to remove insoluble particles, the GuHCl solubilized protein is refolded by quickly mixing the GuHCl extract with 20 volumes of buffer containing 50 mM sodium, pH 4.5, 150 mM NaCl. 2 mM EDTA by vigorous stirring. The refolded diluted protein solution is kept at 4°C without mixing for 12 hours prior to further purification steps.

To clarify the refolded polypeptide solution, a previously prepared tangential filtration unit equipped with 0.16 μm membrane filter with appropriate surface area (e.g., Filtron), equilibrated with 40 mM sodium acetate, pH 6.0 is employed. The filtered sample is loaded onto a cation exchange resin (e.g., Poros HS-50, Perseptive Biosystems). The column is washed with 40 mM sodium acetate, pH 6.0 and eluted with 250 mM, 500 mM, 1000 mM, and 1500 mM NaCl in the same buffer, in a stepwise manner. The absorbance at 280 nm of the effluent is continuously monitored. Fractions are collected and further analyzed by SDS-PAGE.

Fractions containing the polypeptide are then pooled and mixed with 4 volumes of water. The diluted sample is then loaded onto a previously prepared set of tandem columns of strong anion (Poros HQ-50, Perseptive Biosystems) and weak anion (Poros CM-20, Perseptive Biosystems) exchange resins. The columns are equilibrated with 40 mM sodium acetate, pH 6.0. Both columns are washed with 40 mM sodium acetate, pH 6.0, 200 mM NaCl. The CM-20 column is then eluted using a 10 column volume linear gradient ranging from 0.2 M NaCl, 50 mM sodium acetate, pH 6.0 to 1.0 M NaCl, 50 mM sodium acetate, pH 6.5. Fractions are collected under constant A₂₈₀ monitoring of the effluent. Fractions containing the polypeptide (determined, for instance, by 16% SDS-PAGE) are then pooled.

The resultant polypeptide should exhibit greater than 95% purity after the above refolding and purification steps. No major contaminant bands should be observed from Commassie blue stained 16% SDS-PAGE gel when 5 µg of purified protein is loaded. The purified protein can also be tested for endotoxin/LPS contamination, and typically the LPS content is less than 0.1 ng/ml according to LAL assays.

Example 7: Cloning and Expression of a Polypeptide in a Baculovirus Expression System

25

30

20

5

10

15

In this example, the plasmid shuttle vector pA2 is used to insert a polynucleotide into a baculovirus to express a polypeptide. This expression vector contains the strong polyhedrin promoter of the *Autographa californica* nuclear polyhedrosis virus (AcMNPV) followed by convenient restriction sites such as BamHI, Xba I and Asp718. The polyadenylation site of the simian virus 40 ("SV40") is used for efficient polyadenylation. For easy selection of recombinant virus, the plasmid contains the beta-galactosidase gene from *E. coli* under control of a weak Drosophila promoter in the same orientation, followed by the

WO 00/55351

5

10

15

20

25

30

polyadenylation signal of the polyhedrin gene. The inserted genes are flanked on both sides by viral sequences for cell-mediated homologous recombination with wild-type viral DNA to generate a viable virus that express the cloned polynucleotide.

Many other baculovirus vectors can be used in place of the vector above, such as pAc373, pVL941, and pAcIM1, as one skilled in the art would readily appreciate, as long as the construct provides appropriately located signals for transcription, translation, secretion and the like, including a signal peptide and an in-frame AUG as required. Such vectors are described, for instance, in Luckow et al., Virology 170:31-39 (1989).

Specifically, the cDNA sequence contained in the deposited clone, including the AUG initiation codon, is amplified using the PCR protocol described in Example 1. If a naturally occurring signal sequence is used to produce the polypeptide of the present invention, the pA2 vector does not need a second signal peptide. Alternatively, the vector can be modified (pA2 GP) to include a baculovirus leader sequence, using the standard methods described in Summers et al., "A Manual of Methods for Baculovirus Vectors and Insect Cell Culture Procedures," Texas Agricultural Experimental Station Bulletin No. 1555 (1987).

The amplified fragment is isolated from a 1% agarose gel using a commercially available kit ("Geneclean," BIO 101 Inc., La Jolla, Ca.). The fragment then is digested with appropriate restriction enzymes and again purified on a 1% agarose gel.

The plasmid is digested with the corresponding restriction enzymes and optionally, can be dephosphorylated using calf intestinal phosphatase, using routine procedures known in the art. The DNA is then isolated from a 1% agarose gel using a commercially available kit ("Geneclean" BIO 101 Inc., La Jolla, Ca.).

The fragment and the dephosphorylated plasmid are ligated together with T4 DNA ligase. E. coli HB101 or other suitable E. coli hosts such as XL-1 Blue (Stratagene Cloning Systems, La Jolla, CA) cells are transformed with the ligation mixture and spread on culture plates. Bacteria containing the plasmid are identified by digesting DNA from individual colonies and analyzing the digestion product by gel electrophoresis. The sequence of the cloned fragment is confirmed by DNA sequencing.

Five μg of a plasmid containing the polynucleotide is co-transfected with 1.0 μg of a commercially available linearized baculovirus DNA ("BaculoGold™ baculovirus DNA", Pharmingen, San Diego, CA), using the lipofection method described by Felgner et al., Proc.

WO 00/55351

5

10

15

20

25

30

Natl. Acad. Sci. USA 84:7413-7417 (1987). One μg of BaculoGoldTM virus DNA and 5 μg of the plasmid are mixed in a sterile well of a microtiter plate containing 50 μl of serum-free Grace's medium (Life Technologies Inc., Gaithersburg, MD). Afterwards, 10 μl Lipofectin plus 90 μl Grace's medium are added, mixed and incubated for 15 minutes at room temperature. Then the transfection mixture is added drop-wise to Sf9 insect cells (ATCC CRL 1711) seeded in a 35 mm tissue culture plate with 1 ml Grace's medium without serum. The plate is then incubated for 5 hours at 27° C. The transfection solution is then removed from the plate and 1 ml of Grace's insect medium supplemented with 10% fetal calf serum is added. Cultivation is then continued at 27° C for four days.

After four days the supernatant is collected and a plaque assay is performed, as described by Summers and Smith, *supra*. An agarose gel with "Blue Gal" (Life Technologies Inc., Gaithersburg) is used to allow easy identification and isolation of gal-expressing clones, which produce blue-stained plaques. (A detailed description of a "plaque assay" of this type can also be found in the user's guide for insect cell culture and baculovirology distributed by Life Technologies Inc., Gaithersburg, page 9-10.) After appropriate incubation, blue stained plaques are picked with the tip of a micropipettor (e.g., Eppendorf). The agar containing the recombinant viruses is then resuspended in a microcentrifuge tube containing 200 µl of Grace's medium and the suspension containing the recombinant baculovirus is used to infect Sf9 cells seeded in 35 mm dishes. Four days later the supernatants of these culture dishes are harvested and then they are stored at 4° C.

To verify the expression of the polypeptide, Sf9 cells are grown in Grace's medium supplemented with 10% heat-inactivated FBS. The cells are infected with the recombinant baculovirus containing the polynucleotide at a multiplicity of infection ("MOI") of about 2. If radiolabeled proteins are desired, 6 hours later the medium is removed and is replaced with SF900 II medium minus methionine and cysteine (available from Life Technologies Inc., Rockville, MD). After 42 hours, 5 μ Ci of ³⁵S-methionine and 5 μ Ci ³⁵S-cysteine (available from Amersham) are added. The cells are further incubated for 16 hours and then are harvested by centrifugation. The proteins in the supernatant as well as the intracellular proteins are analyzed by SDS-PAGE followed by autoradiography (if radiolabeled).

Microsequencing of the amino acid sequence of the amino terminus of purified protein may be used to determine the amino terminal sequence of the produced protein.

Example 8: Expression of a Polypeptide in Mammalian Cells

10

15

20

25

30

The polypeptide of the present invention can be expressed in a mammalian cell. A typical mammalian expression vector contains a promoter element, which mediates the initiation of transcription of mRNA, a protein coding sequence, and signals required for the termination of transcription and polyadenylation of the transcript. Additional elements include enhancers, Kozak sequences and intervening sequences flanked by donor and acceptor sites for RNA splicing. Highly efficient transcription is achieved with the early and late promoters from SV40, the long terminal repeats (LTRs) from Retroviruses, e.g., RSV, HTLVI, HIVI and the early promoter of the cytomegalovirus (CMV). However, cellular elements can also be used (e.g., the human actin promoter).

Suitable expression vectors for use in practicing the present invention include, for example, vectors such as pSVL and pMSG (Pharmacia, Uppsala, Sweden), pRSVcat (ATCC 37152), pSV2dhfr (ATCC 37146), pBC12MI (ATCC 67109), pCMVSport 2.0, and pCMVSport 3.0. Mammalian host cells that could be used include, human Hela, 293, H9 and Jurkat cells, mouse NIH3T3 and C127 cells, Cos 1, Cos 7 and CV1, quail QC1-3 cells, mouse L cells and Chinese hamster ovary (CHO) cells.

Alternatively, the polypeptide can be expressed in stable cell lines containing the polynucleotide integrated into a chromosome. The co-transfection with a selectable marker such as DHFR, gpt, neomycin, hygromycin allows the identification and isolation of the transfected cells.

The transfected gene can also be amplified to express large amounts of the encoded protein. The DHFR (dihydrofolate reductase) marker is useful in developing cell lines that carry several hundred or even several thousand copies of the gene of interest. (See, e.g., Alt, F. W., et al., J. Biol. Chem. 253:1357-1370 (1978); Hamlin, J. L. and Ma, C., Biochem. et Biophys. Acta, 1097:107-143 (1990); Page, M. J. and Sydenham, M. A., Biotechnology 9:64-68 (1991).) Another useful selection marker is the enzyme glutamine synthase (GS) (Murphy et al., Biochem J. 227:277-279 (1991); Bebbington et al., Bio/Technology 10:169-175 (1992). Using these markers, the mammalian cells are grown in selective medium and the cells with the highest resistance are selected. These cell lines contain the amplified gene(s) integrated into a chromosome. Chinese hamster ovary (CHO) and NSO cells are often used for the production of proteins.

Derivatives of the plasmid pSV2-dhfr (ATCC Accession No. 37146), the expression vectors pC4 (ATCC Accession No. 209646) and pC6 (ATCC Accession No.209647) contain the strong promoter (LTR) of the Rous Sarcoma Virus (Cullen et al., Molecular and Cellular Biology, 438-447 (March, 1985)) plus a fragment of the CMV-enhancer (Boshart et al., Cell 41:521-530 (1985).) Multiple cloning sites, e.g., with the restriction enzyme cleavage sites BamHl, XbaI and Asp718, facilitate the cloning of the gene of interest. The vectors also contain the 3' intron, the polyadenylation and termination signal of the rat preproinsulin gene, and the mouse DHFR gene under control of the SV40 early promoter.

5

10

15

20

25

30

Specifically, the plasmid pC6, for example, is digested with appropriate restriction enzymes and then dephosphorylated using calf intestinal phosphates by procedures known in the art. The vector is then isolated from a 1% agarose gel.

A polynucleotide of the present invention is amplified according to the protocol outlined in Example 1. If a naturally occurring signal sequence is used to produce the polypeptide of the present invention, the vector does not need a second signal peptide. Alternatively, if a naturally occurring signal sequence is not used, the vector can be modified to include a heterologous signal sequence. (See, e.g., WO 96/34891.)

The amplified fragment is isolated from a 1% agarose gel using a commercially available kit ("Geneclean," BIO 101 Inc., La Jolla, Ca.). The fragment then is digested with appropriate restriction enzymes and again purified on a 1% agarose gel.

The amplified fragment is then digested with the same restriction enzyme and purified on a 1% agarose gel. The isolated fragment and the dephosphorylated vector are then ligated with T4 DNA ligase. *E. coli* HB101 or XL-1 Blue cells are then transformed and bacteria are identified that contain the fragment inserted into plasmid pC6 using, for instance, restriction enzyme analysis.

Chinese hamster ovary cells lacking an active DHFR gene is used for transfection. Five µg of the expression plasmid pC6 or pC4 is cotransfected with 0.5 µg of the plasmid pSVneo using lipofectin (Felgner et al., supra). The plasmid pSV2-neo contains a dominant selectable marker, the neo gene from Tn5 encoding an enzyme that confers resistance to a group of antibiotics including G418. The cells are seeded in alpha minus MEM supplemented with 1 mg/ml G418. After 2 days, the cells are trypsinized and seeded in hybridoma cloning plates (Greiner, Germany) in alpha minus MEM supplemented with 10, 25, or 50 ng/ml of metothrexate plus 1 mg/ml G418. After about 10-14 days single clones

are trypsinized and then seeded in 6-well petri dishes or 10 ml flasks using different concentrations of methotrexate (50 nM, 100 nM, 200 nM, 400 nM, 800 nM). Clones growing at the highest concentrations of methotrexate are then transferred to new 6-well plates containing even higher concentrations of methotrexate (1 μ M, 2 μ M, 5 μ M, 10 mM, 20 mM). The same procedure is repeated until clones are obtained which grow at a concentration of 100 - 200 μ M. Expression of the desired gene product is analyzed, for instance, by SDS-PAGE and Western blot or by reversed phase HPLC analysis.

Example 9: Protein Fusions

10

15

20

25

30

5

The polypeptides of the present invention are preferably fused to other proteins. These fusion proteins can be used for a variety of applications. For example, fusion of the present polypeptides to His-tag, HA-tag, protein A, IgG domains, and maltose binding protein facilitates purification. (See Example 5; see also EP A 394,827; Traunecker, et al., Nature 331:84-86 (1988).) Similarly, fusion to IgG-1, IgG-3, and albumin increases the halflife time in vivo. Nuclear localization signals fused to the polypeptides of the present invention can target the protein to a specific subcellular localization, while covalent heterodimer or homodimers can increase or decrease the activity of a fusion protein. Fusion proteins can also create chimeric molecules having more than one function. Finally, fusion proteins can increase solubility and/or stability of the fused protein compared to the nonfused protein. All of the types of fusion proteins described above can be made by modifying the following protocol, which outlines the fusion of a polypeptide to an IgG molecule, or the protocol described in Example 5.

Briefly, the human Fc portion of the IgG molecule can be PCR amplified, using primers that span the 5' and 3' ends of the sequence described below. These primers also should have convenient restriction enzyme sites that will facilitate cloning into an expression vector, preferably a mammalian expression vector.

For example, if pC4 (Accession No. 209646) is used, the human Fc portion can be ligated into the BamHI cloning site. Note that the 3' BamHI site should be destroyed. Next, the vector containing the human Fc portion is re-restricted with BamHI, linearizing the vector, and a polynucleotide of the present invention, isolated by the PCR protocol described in Example 1, is ligated into this BamHI site. Note that the polynucleotide is cloned without

a stop codon, otherwise a fusion protein will not be produced.

If the naturally occurring signal sequence is used to produce the polypeptide of the present invention, pC4 does not need a second signal peptide. Alternatively, if the naturally occurring signal sequence is not used, the vector can be modified to include a heterologous signal sequence. (See, e.g., WO 96/34891.)

Human IgG Fc region:

5

10

15

20

30

GGGATCCGGAGCCCAAATCTTCTGACAAAACTCACACATGCCCACCGTGCCCAG
CACCTGAATTCGAGGGTGCACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGA
CACCTCATGATCTCCCGGACTCCTGAGGTCACATGCGTGGTGGACGTAAGC
CACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCAT
AATGCCAAGACAAAGCCGCGGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTC
AGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGC
AAGGTCTCCAACAAAGCCCTCCCAACCCCCATCGAGAAAACCATCTCCAAAGCC
AAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGATGAG
CTGACCAAGAACCAGGTCAGCCTGACCTGCTCAAAGGCTTCTATCCAAGC
GACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGAC
CACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCTCTCACAGCAAGCTCACC
GTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCCTCTCTCCGGGTAAAT
GAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAAT
GAGTGCGACGACGCCGGACTCTAGAGGAT (SEQ ID NO:1547)

Example 10: Production of an Antibody from a Polypeptide

25 a) Hybridoma Technology

The antibodies of the present invention can be prepared by a variety of methods. (See, Current Protocols, Chapter 2.) As one example of such methods, cells expressing polypeptide of the present invention are administered to an animal to induce the production of sera containing polyclonal antibodies. In a preferred method, a preparation of polypeptide of the present invention is prepared and purified to render it substantially free of natural contaminants. Such a preparation is then introduced into an animal in order to produce polyclonal antisera of greater specific activity.

5

10

15

20

25

30

324

Monoclonal antibodies specific for polypeptide of the present invention are prepared using hybridoma technology. (Kohler et al., Nature 256:495 (1975); Kohler et al., Eur. J. Immunol. 6:511 (1976); Kohler et al., Eur. J. Immunol. 6:292 (1976); Hammerling et al., in: Monoclonal Antibodies and T-Cell Hybridomas. Elsevier, N.Y., pp. 563-681 (1981)). In general, an animal (preferably a mouse) is immunized with polypeptide of the present invention or, more preferably, with a secreted polypeptide of the present invention-expressing cell. Such polypeptide-expressing cells are cultured in any suitable tissue culture medium, preferably in Earle's modified Eagle's medium supplemented with 10% fetal bovine serum (inactivated at about 56°C), and supplemented with about 10 g/l of nonessential amino acids. about 1,000 U/ml of penicillin, and about 100 µg/ml of streptomycin.

The splenocytes of such mice are extracted and fused with a suitable myeloma cell line. Any suitable myeloma cell line may be employed in accordance with the present invention; however, it is preferable to employ the parent myeloma cell line (SP2O), available from the ATCC. After fusion, the resulting hybridoma cells are selectively maintained in HAT medium, and then cloned by limiting dilution as described by Wands et al. (Gastroenterology 80:225-232 (1981)). The hybridoma cells obtained through such a selection are then assayed to identify clones which secrete antibodies capable of binding the polypeptide of the present invention.

Alternatively, additional antibodies capable of binding to polypeptide of the present invention can be produced in a two-step procedure using anti-idiotypic antibodies. Such a method makes use of the fact that antibodies are themselves antigens, and therefore, it is possible to obtain an antibody which binds to a second antibody. In accordance with this method, protein specific antibodies are used to immunize an animal, preferably a mouse. The splenocytes of such an animal are then used to produce hybridoma cells, and the hybridoma cells are screened to identify clones which produce an antibody whose ability to bind to the polypeptide of the present invention-specific antibody can be blocked by polypeptide of the present invention-specific antibody and are used to immunize an animal to induce formation of further polypeptide of the present invention-specific antibody and are used to immunize an animal to induce formation of further polypeptide of the present invention-specific antibodies.

For in vivo use of antibodies in humans, an antibody is "humanized". Such antibodies can be produced using genetic constructs derived from hybridoma cells producing the monoclonal antibodies described above. Methods for producing chimeric and humanized

325

antibodies are known in the art and are discussed herein. (See, for review, Morrison, Science 229:1202 (1985); Oi et al., BioTechniques 4:214 (1986); Cabilly et al., U.S. Patent No. 4,816,567; Taniguchi et al., EP 171496; Morrison et al., EP 173494; Neuberger et al., WO 8601533; Robinson et al., WO 8702671; Boulianne et al., Nature 312:643 (1984); Neuberger et al., Nature 314:268 (1985).)

5

10

15

20

25

30

b) Isolation Of Antibody Fragments Directed Against Polypeptide of the Present Invention From A Library Of scFvs

Naturally occurring V-genes isolated from human PBLs are constructed into a library of antibody fragments which contain reactivities against polypeptide of the present invention to which the donor may or may not have been exposed (see e.g., U.S. Patent 5,885,793 incorporated herein by reference in its entirety).

Rescue of the Library. A library of scFvs is constructed from the RNA of human PBLs as described in PCT publication WO 92/01047. To rescue phage displaying antibody fragments, approximately 109 E. coli harboring the phagemid are used to inoculate 50 ml of 2xTY containing 1% glucose and 100 μg/ml of ampicillin (2xTY-AMP-GLU) and grown to an O.D. of 0.8 with shaking. Five ml of this culture is used to innoculate 50 ml of 2xTY-AMP-GLU, 2 x 108 TU of delta gene 3 helper (M13 delta gene III, see PCT publication WO 92/01047) are added and the culture incubated at 37°C for 45 minutes without shaking and then at 37°C for 45 minutes with shaking. The culture is centrifuged at 4000 r.p.m. for 10 min. and the pellet resuspended in 2 liters of 2xTY containing 100 μg/ml ampicillin and 50 ug/ml kanamycin and grown overnight. Phage are prepared as described in PCT publication WO 92/01047.

M13 delta gene III is prepared as follows: M13 delta gene III helper phage does not encode gene III protein, hence the phage(mid) displaying antibody fragments have a greater avidity of binding to antigen. Infectious M13 delta gene III particles are made by growing the helper phage in cells harboring a pUC19 derivative supplying the wild type gene III protein during phage morphogenesis. The culture is incubated for 1 hour at 37° C without shaking and then for a further hour at 37°C with shaking. Cells are spun down (IEC-Centra 8,400 r.p.m. for 10 min), resuspended in 300 ml 2xTY broth containing 100 µg ampicillin/ml and 25 µg kanamycin/ml (2xTY-AMP-KAN) and grown overnight, shaking at 37°C. Phage particles are purified and concentrated from the culture medium by two PEG-precipitations

(Sambrook et al., 1990), resuspended in 2 ml PBS and passed through a 0.45 µm filter (Minisart NML; Sartorius) to give a final concentration of approximately 1013 transducing units/ml (ampicillin-resistant clones).

5

10

15

20

25

30

Panning of the Library. Immunotubes (Nunc) are coated overnight in PBS with 4 ml of either 100 μg/ml or 10 μg/ml of a polypeptide of the present invention. Tubes are blocked with 2% Marvel-PBS for 2 hours at 37°C and then washed 3 times in PBS. Approximately 1013 TU of phage is applied to the tube and incubated for 30 minutes at room temperature tumbling on an over and under turntable and then left to stand for another 1.5 hours. Tubes are washed 10 times with PBS 0.1% Tween-20 and 10 times with PBS. Phage are eluted by adding 1 ml of 100 mM triethylamine and rotating 15 minutes on an under and over turntable after which the solution is immediately neutralized with 0.5 ml of 1.0M Tris-HCl, pH 7.4. Phage are then used to infect 10 ml of mid-log E. coli TG1 by incubating eluted phage with bacteria for 30 minutes at 37°C. The E. coli are then plated on TYE plates containing 1% glucose and 100 μg/ml ampicillin. The resulting bacterial library is then rescued with delta gene 3 helper phage as described above to prepare phage for a subsequent round of selection. This process is then repeated for a total of 4 rounds of affinity purification with tube-washing increased to 20 times with PBS, 0.1% Tween-20 and 20 times with PBS for rounds 3 and 4.

Characterization of Binders. Eluted phage from the 3rd and 4th rounds of selection are used to infect E. coli HB 2151 and soluble scFv is produced (Marks, et al., 1991) from single colonies for assay. ELISAs are performed with microtitre plates coated with either 10 pg/ml of the polypeptide of the present invention in 50 mM bicarbonate pH 9.6. Clones positive in ELISA are further characterized by PCR fingerprinting (see, e.g., PCT publication WO 92/01047) and then by sequencing. These ELISA positive clones may also be further characterized by techniques known in the art, such as, for example, epitope mapping, binding affinity, receptor signal transduction, ability to block or competitively inhibit antibody/antigen binding, and competitive agonistic or antagonistic activity.

Example 11: Method of Determining Alterations in a Gene Corresponding to a Polynucleotide

RNA isolated from entire families or individual patients presenting with a phenotype of interest (such as a disease) is be isolated. cDNA is then generated from these RNA

samples using protocols known in the art. (See, Sambrook.) The cDNA is then used as a template for PCR, employing primers surrounding regions of interest in SEQ ID NO:X; and/or the nucleotide sequence of the related cDNA in the cDNA clone contained in a deposited library. Suggested PCR conditions consist of 35 cycles at 95 degrees C for 30 seconds; 60-120 seconds at 52-58 degrees C; and 60-120 seconds at 70 degrees C, using buffer solutions described in Sidransky et al., Science 252:706 (1991).

5

10

15

20

25

30

PCR products are then sequenced using primers labeled at their 5' end with T4 polynucleotide kinase, employing SequiTherm Polymerase. (Epicentre Technologies). The intron-exon borders of selected exons is also determined and genomic PCR products analyzed to confirm the results. PCR products harboring suspected mutations is then cloned and sequenced to validate the results of the direct sequencing.

PCR products is cloned into T-tailed vectors as described in Holton et al., Nucleic Acids Research, 19:1156 (1991) and sequenced with T7 polymerase (United States Biochemical). Affected individuals are identified by mutations not present in unaffected individuals.

Genomic rearrangements are also observed as a method of determining alterations in a gene corresponding to a polynucleotide. Genomic clones isolated according to Example 2 are nick-translated with digoxigenindeoxy-uridine 5'-triphosphate (Boehringer Manheim), and FISH performed as described in Johnson et al., Methods Cell Biol. 35:73-99 (1991). Hybridization with the labeled probe is carried out using a vast excess of human cot-1 DNA for specific hybridization to the corresponding genomic locus.

Chromosomes are counterstained with 4,6-diamino-2-phenylidole and propidium iodide, producing a combination of C- and R-bands. Aligned images for precise mapping are obtained using a triple-band filter set (Chroma Technology, Brattleboro, VT) in combination with a cooled charge-coupled device camera (Photometrics, Tucson, AZ) and variable excitation wavelength filters. (Johnson et al., Genet. Anal. Tech. Appl., 8:75 (1991).) Image collection, analysis and chromosomal fractional length measurements are performed using the ISee Graphical Program System. (Inovision Corporation, Durham, NC.) Chromosome alterations of the genomic region hybridized by the probe are identified as insertions, deletions, and translocations. These alterations are used as a diagnostic marker for an associated disease.

Example 12: Method of Detecting Abnormal Levels of a Polypeptide in a Biological Sample

A polypeptide of the present invention can be detected in a biological sample, and if an increased or decreased level of the polypeptide is detected, this polypeptide is a marker for a particular phenotype. Methods of detection are numerous, and thus, it is understood that one skilled in the art can modify the following assay to fit their particular needs.

For example, antibody-sandwich ELISAs are used to detect polypeptides in a sample, preferably a biological sample. Wells of a microtiter plate are coated with specific antibodies, at a final concentration of 0.2 to 10 ug/ml. The antibodies are either monoclonal or polyclonal and are produced by the method described in Example 10. The wells are blocked so that non-specific binding of the polypeptide to the well is reduced.

The coated wells are then incubated for > 2 hours at RT with a sample containing the polypeptide. Preferably, serial dilutions of the sample should be used to validate results. The plates are then washed three times with deionized or distilled water to remove unbounded polypeptide.

Next, 50 ul of specific antibody-alkaline phosphatase conjugate, at a concentration of 25-400 ng, is added and incubated for 2 hours at room temperature. The plates are again washed three times with deionized or distilled water to remove unbounded conjugate.

Add 75 ul of 4-methylumbelliferyl phosphate (MUP) or p-nitrophenyl phosphate (NPP) substrate solution to each well and incubate 1 hour at room temperature. Measure the reaction by a microtiter plate reader. Prepare a standard curve, using serial dilutions of a control sample, and plot polypeptide concentration on the X-axis (log scale) and fluorescence or absorbance of the Y-axis (linear scale). Interpolate the concentration of the polypeptide in the sample using the standard curve.

Example 13: Formulation

5

10

15

20

25

30

The invention also provides methods of treatment and/or prevention of diseases or disorders (such as, for example, any one or more of the diseases or disorders disclosed herein) by administration to a subject of an effective amount of a Therapeutic. By therapeutic is meant a polynucleotides or polypeptides of the invention (including fragments and variants), agonists or antagonists thereof, and/or antibodies thereto, in combination with

a pharmaceutically acceptable carrier type (e.g., a sterile carrier).

5

10

15

20

25

30

The Therapeutic will be formulated and dosed in a fashion consistent with good medical practice, taking into account the clinical condition of the individual patient (especially the side effects of treatment with the Therapeutic alone), the site of delivery, the method of administration, the scheduling of administration, and other factors known to practitioners. The "effective amount" for purposes herein is thus determined by such considerations.

As a general proposition, the total pharmaceutically effective amount of the Therapeutic administered parenterally per dose will be in the range of about lug/kg/day to 10 mg/kg/day of patient body weight, although, as noted above, this will be subject to therapeutic discretion. More preferably, this dose is at least 0.01 mg/kg/day, and most preferably for humans between about 0.01 and 1 mg/kg/day for the hormone. If given continuously, the Therapeutic is typically administered at a dose rate of about 1 ug/kg/hour to about 50 ug/kg/hour, either by 1-4 injections per day or by continuous subcutaneous infusions, for example, using a mini-pump. An intravenous bag solution may also be employed. The length of treatment needed to observe changes and the interval following treatment for responses to occur appears to vary depending on the desired effect.

Therapeutics can be are administered orally, rectally, parenterally, intracistemally, intravaginally, intraperitoneally, topically (as by powders, ointments, gels, drops or transdermal patch), bucally, or as an oral or nasal spray. "Pharmaceutically acceptable carrier" refers to a non-toxic solid, semisolid or liquid filler, diluent, encapsulating material or formulation auxiliary of any. The term "parenteral" as used herein refers to modes of administration which include intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injection and infusion.

Therapeutics of the invention are also suitably administered by sustained-release systems. Suitable examples of sustained-release Therapeutics are administered orally, rectally, parenterally, intracistemally, intravaginally, intraperitoneally, topically (as by powders, ointments, gels, drops or transdermal patch), bucally, or as an oral or nasal spray. "Pharmaceutically acceptable carrier" refers to a non-toxic solid, semisolid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type. The term "parenteral" as used herein refers to modes of administration which include intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injection and infusion.

Therapeutics of the invention are also suitably administered by sustained-release systems. Suitable examples of sustained-release Therapeutics include suitable polymeric materials (such as, for example, semi-permeable polymer matrices in the form of shaped articles, e.g., films, or mirocapsules), suitable hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, and sparingly soluble derivatives (such as, for example, a sparingly soluble salt).

5

10

15

20

25

30

Sustained-release matrices include polylactides (U.S. Pat. No. 3,773,919, EP 58,481), copolymers of L-glutamic acid and gamma-ethyl-L-glutamate (Sidman et al., Biopolymers 22:547-556 (1983)), poly (2- hydroxyethyl methacrylate) (Langer et al., J. Biomed. Mater. Res. 15:167-277 (1981), and Langer, Chem. Tech. 12:98-105 (1982)), ethylene vinyl acetate (Langer et al., Id.) or poly-D- (-)-3-hydroxybutyric acid (EP 133,988).

Sustained-release Therapeutics also include liposomally entrapped Therapeutics of the invention (see generally, Langer, Science 249:1527-1533 (1990); Treat et al., in Liposomes in the Therapy of Infectious Disease and Cancer, Lopez-Berestein and Fidler (eds.), Liss, New York, pp. 317 -327 and 353-365 (1989)). Liposomes containing the Therapeutic are prepared by methods known per se: DE 3,218,121; Epstein et al., Proc. Natl. Acad. Sci. (USA) 82:3688-3692 (1985); Hwang et al., Proc. Natl. Acad. Sci. (USA) 77:4030-4034 (1980); EP 52,322; EP 36,676; EP 88,046; EP 143,949; EP 142,641; Japanese Pat. Appl. 83-118008; U.S. Pat. Nos. 4,485,045 and 4,544,545; and EP 102,324. Ordinarily, the liposomes are of the small (about 200-800 Angstroms) unilamellar type in which the lipid content is greater than about 30 mol. percent cholesterol, the selected proportion being adjusted for the optimal Therapeutic.

In yet an additional embodiment, the Therapeutics of the invention are delivered by way of a pump (see Langer, supra; Sefton, CRC Crit. Ref. Biomed. Eng. 14:201 (1987); Buchwald et al., Surgery 88:507 (1980); Saudek et al., N. Engl. J. Med. 321:574 (1989)).

Other controlled release systems are discussed in the review by Langer (Science 249:1527-1533 (1990)).

For parenteral administration, in one embodiment, the Therapeutic is formulated generally by mixing it at the desired degree of purity, in a unit dosage injectable form (solution, suspension, or emulsion), with a pharmaceutically acceptable carrier, i.e., one that is non-toxic to recipients at the dosages and concentrations employed and is compatible with other ingredients of the formulation. For example, the formulation preferably does not

331

include oxidizing agents and other compounds that are known to be deleterious to the Therapeutic.

Generally, the formulations are prepared by contacting the Therapeutic uniformly and intimately with liquid carriers or finely divided solid carriers or both. Then, if necessary, the product is shaped into the desired formulation. Preferably the carrier is a parenteral carrier, more preferably a solution that is isotonic with the blood of the recipient. Examples of such carrier vehicles include water, saline, Ringer's solution, and dextrose solution. Non-aqueous vehicles such as fixed oils and ethyl oleate are also useful herein, as well as liposomes.

5

10

15

20

25

30

The carrier suitably contains minor amounts of additives such as substances that enhance isotonicity and chemical stability. Such materials are non-toxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, succinate, acetic acid, and other organic acids or their salts; antioxidants such as ascorbic acid; low molecular weight (less than about ten residues) polypeptides, e.g., polyarginine or tripeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids, such as glycine, glutamic acid, aspartic acid, or arginine; monosaccharides, disaccharides, and other carbohydrates including cellulose or its derivatives, glucose, manose, or dextrins; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; counterions such as sodium; and/or nonionic surfactants such as polysorbates, poloxamers, or PEG.

The Therapeutic is typically formulated in such vehicles at a concentration of about 0.1 mg/ml to 100 mg/ml, preferably 1-10 mg/ml, at a pH of about 3 to 8. It will be understood that the use of certain of the foregoing excipients, carriers, or stabilizers will result in the formation of polypeptide salts.

Any pharmaceutical used for therapeutic administration can be sterile. Sterility is readily accomplished by filtration through sterile filtration membranes (e.g., 0.2 micron membranes). Therapeutics generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle.

Therapeutics ordinarily will be stored in unit or multi-dose containers, for example, sealed ampoules or vials, as an aqueous solution or as a lyophilized formulation for reconstitution. As an example of a lyophilized formulation, 10-ml vials are filled with 5 ml of sterile-filtered 1% (w/v) aqueous Therapeutic solution, and the resulting mixture is

lyophilized. The infusion solution is prepared by reconstituting the lyophilized Therapeutic using bacteriostatic Water-for-Injection.

The invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the Therapeutics of the invention. Associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration. In addition, the Therapeutics may be employed in conjunction with other therapeutic compounds.

5

10

15

20

25

30

The Therapeutics of the invention may be administered alone or in combination with adjuvants. Adjuvants that may be administered with the Therapeutics of the invention include, but are not limited to, alum, alum plus deoxycholate (ImmunoAg), MTP-PE (Biocine Corp.), QS21 (Genentech, Inc.), BCG, and MPL. In a specific embodiment, Therapeutics of the invention are administered in combination with alum. In another specific embodiment, Therapeutics of the invention are administered in combination with QS-21. Further adjuvants that may be administered with the Therapeutics of the invention include, but are not limited to, Monophosphoryl lipid immunomodulator, AdjuVax 100a, QS-21, QS-18, CRL1005, Aluminum salts, MF-59, and Virosomal adjuvant technology. Vaccines that may be administered with the Therapeutics of the invention include, but are not limited to, vaccines directed toward protection against MMR (measles, mumps, rubella), polio, varicella, tetanus/diptheria, hepatitis A, hepatitis B, haemophilus influenzae B, whooping cough, pneumonia, influenza, Lyme's Disease, rotavirus, cholera, yellow fever, Japanese encephalitis, poliomyelitis, rabies, typhoid fever, and pertussis. Combinations may be administered either concomitantly, e.g., as an admixture, separately but simultaneously or concurrently; or sequentially. This includes presentations in which the combined agents are administered together as a therapeutic mixture, and also procedures in which the combined agents are administered separately but simultaneously, e.g., as through separate intravenous lines into the same individual. Administration "in combination" further includes the separate administration of one of the compounds or agents given first, followed by the second.

The Therapeutics of the invention may be administered alone or in combination with other therapeutic agents. Therapeutic agents that may be administered in combination with the Therapeutics of the invention, include but not limited to, other members of the TNF

family, chemotherapeutic agents, antibiotics, steroidal and non-steroidal anti-inflammatories. conventional immunotherapeutic agents, cytokines and/or growth factors. Combinations may be administered either concomitantly, e.g., as an admixture, separately but simultaneously or concurrently; or sequentially. This includes presentations in which the combined agents are administered together as a therapeutic mixture, and also procedures in which the combined agents are administered separately but simultaneously, e.g., as through separate intravenous lines into the same individual. Administration "in combination" further includes the separate administration of one of the compounds or agents given first, followed by the second.

5

10

15

20

25

30

In one embodiment, the Therapeutics of the invention are administered in combination with members of the TNF family. TNF, TNF-related or TNF-like molecules that may be administered with the Therapeutics of the invention include, but are not limited to, soluble forms of TNF-alpha, lymphotoxin-alpha (LT-alpha, also known as TNF-beta), LT-beta (found in complex heterotrimer LT-alpha2-beta). OPGL, FasL, CD27L, CD30L, CD40L, 4-1BBL, DcR3, OX40L, TNF-gamma (International Publication No. WO 96/14328), AIM-I (International Publication No. WO 97/33899), endokine-alpha (International Publication No. WO 98/07880), TR6 (International Publication No. WO 98/30694), OPG, and neutrokine-alpha (International Publication No. WO 98/18921, OX40, and nerve growth factor (NGF), and soluble forms of Fas, CD30, CD27, CD40 and 4-IBB, TR2 (International Publication No. WO 96/34095), DR3 (International Publication No. WO 97/33904), DR4 (International Publication No. WO 98/32856), TR5 (International Publication No. WO 98/30693), TR6 (International Publication No. WO 98/30694), TR7 (International Publication No. WO 98/41629), TRANK, TR9 (International Publication No. WO 98/56892), TR10 (International Publication No. WO 98/54202), 312C2 (International Publication No. WO 98/06842), and TR12, and soluble forms CD154, CD70, and CD153.

In certain embodiments, Therapeutics of the invention are administered in combination with antiretroviral agents, nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors that may be administered in combination with the Therapeutics of the invention, include, but are not limited to, RETROVIRTM (zidovudine/AZT), VIDEXTM (didanosine/ddI), HIVIDTM (zalcitabine/ddC), ZERITTM (stavudine/d4T), EPIVIRTM (lamivudine/3TC), and COMBIVIRTM (zidovudine/lamivudine). Non-nucleoside reverse transcriptase inhibitors that may be administered in combination with the Therapeutics of the

invention. include, but are not limited to. VIRAMUNE™ (nevirapine). RESCRIPTOR™ (delavirdine). and SUSTIVA™ (efavirenz). Protease inhibitors that may be administered in combination with the Therapeutics of the invention, include, but are not limited to, CRIXIVAN™ (indinavir), NORVIR™ (ritonavir), INVIRASE™ (saquinavir), and VIRACEPT™ (nelfinavir). In a specific embodiment, antiretroviral agents, nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, and/or protease inhibitors may be used in any combination with Therapeutics of the invention to treat AIDS and/or to prevent or treat HIV infection.

5

10

15

20

25

30

In other embodiments, Therapeutics of the invention may be administered in combination with anti-opportunistic infection agents. Anti-opportunistic agents that may be administered in combination with the Therapeutics of the invention, include, but are not TRIMETHOPRIM-SULFAMETHOXAZOLE™, DAPSONE™, limited PENTAMIDINE™, ATOVAQUONE™. ISONIAZID™, RIFAMPIN™, PYRAZINAMIDE™, ETHAMBUTOL™, RIFABUTIN™, CLARITHROMYCIN™, AZITHROMYCIN™, GANCICLOVIR™, FOSCARNET™, CIDOFOVIR™, FLUCONAZOLE™, ITRACONAZOLE™, KETOCONAZOLE™, ACYCLOVIR™, FAMCICOLVIR™, PYRIMETHAMINE™, LEUCOVORIN™, NEUPOGEN™ (filgrastim/G-CSF), and LEUKINE™ (sargramostim/GM-CSF). In a specific embodiment, Therapeutics of the invention are used in any combination with TRIMETHOPRIM-SULFAMETHOXAZOLE™. DAPSONE™, PENTAMIDINE™, and/or ATOVAQUONE™ to prophylactically treat or prevent an opportunistic Pneumocystis carinii pneumonia infection. In another specific embodiment, Therapeutics of the invention are used in any combination with ISONIAZIDTM, RIFAMPIN™, PYRAZINAMIDE™, and/or ETHAMBUTOL™ to prophylactically treat or prevent an opportunistic Mycobacterium avium complex infection. In another specific embodiment, Therapeutics of the invention are used in any combination with RIFABUTIN™, CLARITHROMYCIN™, and/or AZITHROMYCIN™ to prophylactically treat or prevent an opportunistic Mycobacterium tuberculosis infection. In another specific embodiment, Therapeutics of the invention are used in any combination with GANCICLOVIR™, FOSCARNET™, and/or CIDOFOVIR™ to prophylactically treat or prevent an opportunistic cytomegalovirus infection. In another specific embodiment, Therapeutics of the invention are used in any combination with FLUCONAZOLE[™], ITRACONAZOLE[™], and/or

KETOCONAZOLE™ to prophylactically treat or prevent an opportunistic fungal infection. In another specific embodiment, Therapeutics of the invention are used in any combination with ACYCLOVIR™ and/or FAMCICOLVIR™ to prophylactically treat or prevent an opportunistic herpes simplex virus type I and/or type II infection. In another specific embodiment, Therapeutics of the invention are used in any combination with PYRIMETHAMINE™ and/or LEUCOVORIN™ to prophylactically treat or prevent an opportunistic *Toxoplasma gondii* infection. In another specific embodiment, Therapeutics of the invention are used in any combination with LEUCOVORIN™ and/or NEUPOGEN™ to prophylactically treat or prevent an opportunistic bacterial infection.

5

10

15

20

25

30

In a further embodiment, the Therapeutics of the invention are administered in combination with an antiviral agent. Antiviral agents that may be administered with the Therapeutics of the invention include, but are not limited to, acyclovir, ribavirin, amantadine, and remantidine.

In a further embodiment, the Therapeutics of the invention are administered in combination with an antibiotic agent. Antibiotic agents that may be administered with the Therapeutics of the invention include, but are not limited to, amoxicillin, beta-lactamases, aminoglycosides, beta-lactam (glycopeptide), beta-lactamases, Clindamycin, chloramphenicol, cephalosporins, ciprofloxacin, ciprofloxacin, erythromycin, fluoroquinolones, macrolides, metronidazole, penicillins, quinolones, rifampin, streptomycin, sulfonamide, tetracyclines, trimethoprim, trimethoprim-sulfamthoxazole, and vancomycin.

Conventional nonspecific immunosuppressive agents, that may be administered in combination with the Therapeutics of the invention include, but are not limited to, steroids, cyclosporine, cyclosporine analogs, cyclophosphamide methylprednisone, prednisone, azathioprine, FK-506, 15-deoxyspergualin, and other immunosuppressive agents that act by suppressing the function of responding T cells.

In specific embodiments, Therapeutics of the invention are administered in combination with immunosuppressants. Immunosuppressants preparations that may be administered with the Therapeutics of the invention include, but are not limited to, ORTHOCLONETM (OKT3), SANDIMMUNETM/NEORALTM/SANGDYATM (cyclosporin), PROGRAFTM (tacrolimus), CELLCEPTTM (inycophenolate), Azathioprine, glucorticosteroids, and RAPAMUNETM (sirolimus). In a specific embodiment, immunosuppressants may be

used to prevent rejection of organ or bone marrow transplantation.

5

10

15

20

25

30

In an additional embodiment, Therapeutics of the invention are administered alone or in combination with one or more intravenous immune globulin preparations. Intravenous immune globulin preparations that may be administered with the Therapeutics of the invention include, but not limited to, GAMMARTM, IVEEGAMTM, SANDOGLOBULINTM, GAMMAGARD S/DTM, and GAMIMUNETM. In a specific embodiment, Therapeutics of the invention are administered in combination with intravenous immune globulin preparations in transplantation therapy (e.g., bone marrow transplant).

In an additional embodiment, the Therapeutics of the invention are administered alone or in combination with an anti-inflammatory agent. Anti-inflammatory agents that may be administered with the Therapeutics of the invention include, but are not limited to, glucocorticoids and the nonsteroidal anti-inflammatories, aminoarylcarboxylic acid derivatives, arylacetic acid derivatives, arylbutyric acid derivatives, arylcarboxylic acids, arylpropionic acid derivatives, pyrazoles, pyrazolones, salicylic acid derivatives, thiazinecarboxamides, e-acetamidocaproic acid, S-adenosylmethionine, 3-amino-4-hydroxybutyric acid, amixetrine, bendazac, benzydamine, bucolome, difenpiramide, ditazol, emorfazone, guaiazulene, nabumetone, nimesulide, orgotein, oxaceprol, paranyline, perisoxal, pifoxime, proquazone, proxazole, and tenidap.

In another embodiment, compostions of the invention are administered in combination with a chemotherapeutic agent. Chemotherapeutic agents that may be administered with the Therapeutics of the invention include, but are not limited to, antibiotic derivatives (e.g., doxorubicin, bleomycin, daunorubicin, and dactinomycin); antiestrogens (e.g., tamoxifen); antimetabolites (e.g., fluorouracil, 5-FU, methotrexate, floxuridine, interferon alpha-2b, glutamic acid, plicamycin, mercaptopurine, and 6-thioguanine); cytotoxic agents (e.g., carmustine, BCNU, lomustine, CCNU, cytosine arabinoside, cyclophosphamide, estramustine, hydroxyurea, procarbazine, mitomycin, busulfan, cis-platin, and vincristine sulfate); hormones (e.g., medroxyprogesterone, estramustine phosphate sodium, ethinyl estradiol, estradiol, megestrol acetate, methyltestosterone, diethylstilbestrol diphosphate, chlorotrianisene, and testolactone); nitrogen mustard derivatives (e.g., mephalen, chorambucil, mechlorethamine (nitrogen mustard) and thiotepa); steroids and combinations (e.g., bethamethasone sodium phosphate); and others (e.g., dicarbazine, asparaginase, mitotane, vincristine sulfate, vinblastine sulfate, and etoposide).

WO 00/55351

5

10

15

20

25

30

337

PCT/US00/05883

In a specific embodiment, Therapeutics of the invention are administered in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) or any combination of the components of CHOP. In another embodiment, Therapeutics of the invention are administered in combination with Rituximab. In a further embodiment, Therapeutics of the invention are administered with Rituxmab and CHOP, or Rituxmab and any combination of the components of CHOP.

In an additional embodiment, the Therapeutics of the invention are administered in combination with cytokines. Cytokines that may be administered with the Therapeutics of the invention include, but are not limited to, IL2, IL3, IL4, IL5, IL6, IL7, IL10, IL12, IL13, IL15, anti-CD40, CD40L, IFN-gamma and TNF-alpha. In another embodiment, Therapeutics of the invention may be administered with any interleukin, including, but not limited to, IL-1alpha, IL-1beta, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17, IL-18, IL-19, IL-20, and IL-21.

In an additional embodiment, the Therapeutics of the invention are administered in combination with angiogenic proteins. Angiogenic proteins that may be administered with the Therapeutics of the invention include, but are not limited to, Glioma Derived Growth Factor (GDGF), as disclosed in European Patent Number EP-399816; Platelet Derived Growth Factor-A (PDGF-A), as disclosed in European Patent Number EP-682110; Platelet Derived Growth Factor-B (PDGF-B), as disclosed in European Patent Number EP-282317; Placental Growth Factor (PIGF), as disclosed in International Publication Number WO 92/06194; Placental Growth Factor-2 (PIGF-2), as disclosed in Hauser et al., Gorwth Factors, 4:259-268 (1993); Vascular Endothelial Growth Factor (VEGF), as disclosed in International Publication Number WO 90/13649; Vascular Endothelial Growth Factor-A (VEGF-A), as disclosed in European Patent Number EP-506477; Vascular Endothelial Growth Factor-2 (VEGF-2), as disclosed in International Publication Number WO 96/39515; Vascular Endothelial Growth Factor B (VEGF-3); Vascular Endothelial Growth Factor B-186 (VEGF-B186), as disclosed in International Publication Number WO 96/26736; Vascular Endothelial Growth Factor-D (VEGF-D), as disclosed in International Publication Number WO 98/02543; Vascular Endothelial Growth Factor-D (VEGF-D), as disclosed in International Publication Number WO 98/07832: and Vascular Endothelial Growth Factor-E (VEGF-E), as disclosed in German Patent Number DE19639601. The above mentioned references are incorporated herein by reference herein.

PCT/US00/05883

In an additional embodiment, the Therapeutics of the invention are administered in combination with hematopoietic growth factors. Hematopoietic growth factors that may be administered with the Therapeutics of the invention include, but are not limited to, LEUKINE (SARGRAMOSTIM) and NEUPOGEN (FILGRASTIM).

In an additional embodiment, the Therapeutics of the invention are administered in combination with Fibroblast Growth Factors. Fibroblast Growth Factors that may be administered with the Therapeutics of the invention include, but are not limited to, FGF-1, FGF-2, FGF-3, FGF-4, FGF-5, FGF-6, FGF-7, FGF-8, FGF-9, FGF-10, FGF-11, FGF-12, FGF-13, FGF-14, and FGF-15.

In additional embodiments, the Therapeutics of the invention are administered in combination with other therapeutic or prophylactic regimens, such as, for example, radiation therapy.

Example 14: Method of Treating Decreased Levels of the Polypeptide

15

20

25

30

10

5

The present invention relates to a method for treating an individual in need of an increased level of a polypeptide of the invention in the body comprising administering to such an individual a composition comprising a therapeutically effective amount of an agonist of the invention (including polypeptides of the invention). Moreover, it will be appreciated that conditions caused by a decrease in the standard or normal expression level of a polypeptide of the present invention in an individual can be treated by administering the agonist or antagonist of the present invention. Thus, the invention also provides a method of treatment of an individual in need of an increased level of the polypeptide comprising administering to such an individual a Therapeutic comprising an amount of the agonist or antagonist to increase the activity level of the polypeptide in such an individual.

For example, a patient with decreased levels of a polypeptide receives a daily dose 0.1-100 ug/kg of the agonist or antagonist for six consecutive days. The exact details of the dosing scheme, based on administration and formulation, are provided in Example 13.

Example 15: Method of Treating Increased Levels of the Polypeptide

The present invention also relates to a method of treating an individual in need of a

decreased level of a polypeptide of the invention in the body comprising administering to such an individual a composition comprising a therapeutically effective amount of an antagonist of the invention (including polypeptides and antibodies of the invention).

In one example, antisense technology is used to inhibit production of a polypeptide of the present invention. This technology is one example of a method of decreasing levels of a polypeptide, due to a variety of etiologies, such as cancer.

For example, a patient diagnosed with abnormally increased levels of a polypeptide is administered intravenously antisense polynucleotides at 0.5, 1.0, 1.5, 2.0 and 3.0 mg/kg day for 21 days. This treatment is repeated after a 7-day rest period if the treatment was well tolerated. The formulation of the antisense polynucleotide is provided in Example 13.

Example 16: Method of Treatment Using Gene Therapy-Ex Vivo

5

10

15

20

25

30

One method of gene therapy transplants fibroblasts, which are capable of expressing a polypeptide, onto a patient. Generally, fibroblasts are obtained from a subject by skin biopsy. The resulting tissue is placed in tissue-culture medium and separated into small pieces. Small chunks of the tissue are placed on a wet surface of a tissue culture flask, approximately ten pieces are placed in each flask. The flask is turned upside down, closed tight and left at room temperature over night. After 24 hours at room temperature, the flask is inverted and the chunks of tissue remain fixed to the bottom of the flask and fresh media (e.g., Ham's F12 media, with 10% FBS, penicillin and streptomycin) is added. The flasks are then incubated at 37 degree C for approximately one week.

At this time, fresh media is added and subsequently changed every several days. After an additional two weeks in culture, a monolayer of fibroblasts emerge. The monolayer is trypsinized and scaled into larger flasks.

pMV-7 (Kirschmeier, P.T. et al., DNA, 7:219-25 (1988)), flanked by the long terminal repeats of the Moloney murine sarcoma virus, is digested with EcoRl and HindIII and subsequently treated with calf intestinal phosphatase. The linear vector is fractionated on agarose gel and purified, using glass beads.

The cDNA encoding a polypeptide of the present invention can be amplified using PCR primers which correspond to the 5' and 3' end sequences respectively as set forth in Example 1 using primers and having appropriate restriction sites and initiation/stop codons, if

5

10

15

20

25

30

necessary. Preferably, the 5' primer contains an EcoRI site and the 3' primer includes a HindIII site. Equal quantities of the Moloney murine sarcoma virus linear backbone and the amplified EcoRI and HindIII fragment are added together, in the presence of T4 DNA ligase. The resulting mixture is maintained under conditions appropriate for ligation of the two fragments. The ligation mixture is then used to transform bacteria HB101, which are then plated onto agar containing kanamycin for the purpose of confirming that the vector has the gene of interest properly inserted.

The amphotropic pA317 or GP+am12 packaging cells are grown in tissue culture to confluent density in Dulbecco's Modified Eagles Medium (DMEM) with 10% calf serum (CS), penicillin and streptomycin. The MSV vector containing the gene is then added to the media and the packaging cells transduced with the vector. The packaging cells now produce infectious viral particles containing the gene (the packaging cells are now referred to as producer cells).

Fresh media is added to the transduced producer cells, and subsequently, the media is harvested from a 10 cm plate of confluent producer cells. The spent media, containing the infectious viral particles, is filtered through a millipore filter to remove detached producer cells and this media is then used to infect fibroblast cells. Media is removed from a subconfluent plate of fibroblasts and quickly replaced with the media from the producer cells. This media is removed and replaced with fresh media. If the titer of virus is high, then virtually all fibroblasts will be infected and no selection is required. If the titer is very low, then it is necessary to use a retroviral vector that has a selectable marker, such as neo or his. Once the fibroblasts have been efficiently infected, the fibroblasts are analyzed to determine whether protein is produced.

The engineered fibroblasts are then transplanted onto the host, either alone or after having been grown to confluence on cytodex 3 microcarrier beads.

Example 17: Gene Therapy Using Endogenous Genes Corresponding To Polynucleotides of the Invention

Another method of gene therapy according to the present invention involves operably associating the endogenous polynucleotide sequence of the invention with a promoter via homologous recombination as described, for example, in U.S. Patent NO: 5,641,670, issued

5

10

15

20

25

30

June 24, 1997; International Publication NO: WO 96/29411, published September 26, 1996; International Publication NO: WO 94/12650, published August 4, 1994; Koller et al., *Proc. Natl. Acad. Sci. USA*, 86:8932-8935 (1989); and Zijlstra et al., *Nature*, 342:435-438 (1989). This method involves the activation of a gene which is present in the target cells, but which is not expressed in the cells, or is expressed at a lower level than desired.

Polynucleotide constructs are made which contain a promoter and targeting sequences, which are homologous to the 5' non-coding sequence of endogenous polynucleotide sequence, flanking the promoter. The targeting sequence will be sufficiently near the 5' end of the polynucleotide sequence so the promoter will be operably linked to the endogenous sequence upon homologous recombination. The promoter and the targeting sequences can be amplified using PCR. Preferably, the amplified promoter contains distinct restriction enzyme sites on the 5' and 3' ends. Preferably, the 3' end of the first targeting sequence contains the same restriction enzyme site as the 5' end of the amplified promoter and the 5' end of the second targeting sequence contains the same restriction site as the 3' end of the amplified promoter.

The amplified promoter and the amplified targeting sequences are digested with the appropriate restriction enzymes and subsequently treated with calf intestinal phosphatase. The digested promoter and digested targeting sequences are added together in the presence of T4 DNA ligase. The resulting mixture is maintained under conditions appropriate for ligation of the two fragments. The construct is size fractionated on an agarose gel then purified by phenol extraction and ethanol precipitation.

In this Example, the polynucleotide constructs are administered as naked polynucleotides via electroporation. However, the polynucleotide constructs may also be administered with transfection-facilitating agents, such as liposomes, viral sequences, viral particles, precipitating agents, etc. Such methods of delivery are known in the art.

Once the cells are transfected, homologous recombination will take place which results in the promoter being operably linked to the endogenous polynucleotide sequence. This results in the expression of polynucleotide corresponding to the polynucleotide in the cell. Expression may be detected by immunological staining, or any other method known in the art.

Fibroblasts are obtained from a subject by skin biopsy. The resulting tissue is placed in DMEM + 10% fetal calf serum. Exponentially growing or early stationary phase

342

fibroblasts are trypsinized and rinsed from the plastic surface with nutrient medium. An aliquot of the cell suspension is removed for counting, and the remaining cells are subjected to centrifugation. The supernatant is aspirated and the pellet is resuspended in 5 ml of electroporation buffer (20 mM HEPES pH 7.3, 137 mM NaCl. 5 mM KCl, 0.7 mM Na₂ HPO₄, 6 mM dextrose). The cells are recentrifuged, the supernatant aspirated, and the cells resuspended in electroporation buffer containing 1 mg/ml acetylated bovine serum albumin. The final cell suspension contains approximately 3X10⁶ cells/ml. Electroporation should be performed immediately following resuspension.

5

10

15

20

25

30

Plasmid DNA is prepared according to standard techniques. For example, to construct a plasmid for targeting to the locus corresponding to the polynucleotide of the invention, plasmid pUC18 (MBI Fermentas, Amherst, NY) is digested with HindIII. The CMV promoter is amplified by PCR with an XbaI site on the 5' end and a BamHI site on the 3'end. Two non-coding sequences are amplified via PCR: one non-coding sequence (fragment 1) is amplified with a HindIII site at the 5' end and an Xba site at the 3'end; the other non-coding sequence (fragment 2) is amplified with a BamHI site at the 5'end and a HindIII site at the 3'end. The CMV promoter and the fragments (1 and 2) are digested with the appropriate enzymes (CMV promoter - XbaI and BamHI; fragment 1 - XbaI; fragment 2 - BamHI) and ligated together. The resulting ligation product is digested with HindIII, and ligated with the HindIII-digested pUC18 plasmid.

Plasmid DNA is added to a sterile cuvette with a 0.4 cm electrode gap (Bio-Rad). The final DNA concentration is generally at least $120 \,\mu\text{g/ml}$. 0.5 ml of the cell suspension (containing approximately $1.5.X10^6$ cells) is then added to the cuvette, and the cell suspension and DNA solutions are gently mixed. Electroporation is performed with a Gene-Pulser apparatus (Bio-Rad). Capacitance and voltage are set at 960 μF and 250-300 V, respectively. As voltage increases, cell survival decreases, but the percentage of surviving cells that stably incorporate the introduced DNA into their genome increases dramatically. Given these parameters, a pulse time of approximately 14-20 mSec should be observed.

Electroporated cells are maintained at room temperature for approximately 5 min, and the contents of the cuvette are then gently removed with a sterile transfer pipette. The cells are added directly to 10 ml of prewarmed nutrient media (DMEM with 15% calf serum) in a 10 cm dish and incubated at 37 degree C. The following day, the media is aspirated and replaced with 10 ml of fresh media and incubated for a further 16-24 hours.

The engineered fibroblasts are then injected into the host, either alone or after having been grown to confluence on cytodex 3 microcarrier beads. The fibroblasts now produce the protein product. The fibroblasts can then be introduced into a patient as described above.

Example 18: Method of Treatment Using Gene Therapy - In Vivo

5

10

15

20

25

30

Another aspect of the present invention is using *in vivo* gene therapy methods to treat disorders, diseases and conditions. The gene therapy method relates to the introduction of naked nucleic acid (DNA, RNA, and antisense DNA or RNA) sequences into an animal to increase or decrease the expression of the polypeptide. The polynucleotide of the present invention may be operatively linked to a promoter or any other genetic elements necessary for the expression of the polypeptide by the target tissue. Such gene therapy and delivery techniques and methods are known in the art, see, for example, WO90/11092, WO98/11779; U.S. Patent NO. 5693622, 5705151, 5580859; Tabata et al., Cardiovasc. Res. 35(3):470-479 (1997); Chao et al., Pharmacol. Res. 35(6):517-522 (1997); Wolff, Neuromuscul. Disord. 7(5):314-318 (1997); Schwartz et al., Gene Ther. 3(5):405-411 (1996); Tsurumi et al., Circulation 94(12):3281-3290 (1996) (incorporated herein by reference).

The polynucleotide constructs may be delivered by any method that delivers injectable materials to the cells of an animal, such as, injection into the interstitial space of tissues (heart, muscle, skin, lung, liver, intestine and the like). The polynucleotide constructs can be delivered in a pharmaceutically acceptable liquid or aqueous carrier.

The term "naked" polynucleotide, DNA or RNA, refers to sequences that are free from any delivery vehicle that acts to assist, promote, or facilitate entry into the cell, including viral sequences, viral particles, liposome formulations, lipofectin or precipitating agents and the like. However, the polynucleotides of the present invention may also be delivered in liposome formulations (such as those taught in Felgner P.L. et al. (1995) Ann. NY Acad. Sci. 772:126-139 and Abdallah B. et al. (1995) Biol. Cell 85(1):1-7) which can be prepared by methods well known to those skilled in the art.

The polynucleotide vector constructs used in the gene therapy method are preferably constructs that will not integrate into the host genome nor will they contain sequences that allow for replication. Any strong promoter known to those skilled in the art can be used for driving the expression of DNA. Unlike other gene therapies techniques, one major advantage

WO 00/55351

5

10

15

20

25

30

344

PCT/US00/05883

of introducing naked nucleic acid sequences into target cells is the transitory nature of the polynucleotide synthesis in the cells. Studies have shown that non-replicating DNA sequences can be introduced into cells to provide production of the desired polypeptide for periods of up to six months.

The polynucleotide construct can be delivered to the interstitial space of tissues within the an animal, including of muscle, skin, brain, lung, liver, spleen, bone marrow, thymus, heart, lymph, blood, bone, cartilage, pancreas, kidney, gall bladder, stomach, intestine, testis, ovary, uterus, rectum, nervous system, eye, gland, and connective tissue. Interstitial space of the tissues comprises the intercellular fluid, mucopolysaccharide matrix among the reticular fibers of organ tissues, elastic fibers in the walls of vessels or chambers, collagen fibers of fibrous tissues, or that same matrix within connective tissue ensheathing muscle cells or in the lacunae of bone. It is similarly the space occupied by the plasma of the circulation and the lymph fluid of the lymphatic channels. Delivery to the interstitial space of muscle tissue is preferred for the reasons discussed below. They may be conveniently delivered by injection into the tissues comprising these cells. They are preferably delivered to and expressed in persistent, non-dividing cells which are differentiated, although delivery and expression may be achieved in non-differentiated or less completely differentiated cells, such as, for example, stem cells of blood or skin fibroblasts. *In vivo* muscle cells are particularly competent in their ability to take up and express polynucleotides.

For the naked polynucleotide injection, an effective dosage amount of DNA or RNA will be in the range of from about 0.05 g/kg body weight to about 50 mg/kg body weight. Preferably the dosage will be from about 0.005 mg/kg to about 20 mg/kg and more preferably from about 0.05 mg/kg to about 5 mg/kg. Of course, as the artisan of ordinary skill will appreciate, this dosage will vary according to the tissue site of injection. The appropriate and effective dosage of nucleic acid sequence can readily be determined by those of ordinary skill in the art and may depend on the condition being treated and the route of administration. The preferred route of administration is by the parenteral route of injection into the interstitial space of tissues. However, other parenteral routes may also be used, such as, inhalation of an aerosol formulation particularly for delivery to lungs or bronchial tissues, throat or mucous membranes of the nose. In addition, naked polynucleotide constructs can be delivered to arteries during angioplasty by the catheter used in the procedure.

The dose response effects of injected polynucleotide in muscle in vivo is determined

PCT/US00/05883

as follows. Suitable template DNA for production of mRNA coding for polypeptide of the present invention is prepared in accordance with a standard recombinant DNA methodology. The template DNA, which may be either circular or linear, is either used as naked DNA or complexed with liposomes. The quadriceps muscles of mice are then injected with various amounts of the template DNA.

Five to six week old female and male Balb/C mice are anesthetized by intraperitoneal injection with 0.3 ml of 2.5% Avertin. A 1.5 cm incision is made on the anterior thigh, and the quadriceps muscle is directly visualized. The template DNA is injected in 0.1 ml of carrier in a 1 cc syringe through a 27 gauge needle over one minute, approximately 0.5 cm from the distal insertion site of the muscle into the knee and about 0.2 cm deep. A suture is placed over the injection site for future localization, and the skin is closed with stainless steel clips.

After an appropriate incubation time (e.g., 7 days) muscle extracts are prepared by excising the entire quadriceps. Every fifth 15 um cross-section of the individual quadriceps muscles is histochemically stained for protein expression. A time course for protein expression may be done in a similar fashion except that quadriceps from different mice are harvested at different times. Persistence of DNA in muscle following injection may be determined by Southern blot analysis after preparing total cellular DNA and HIRT supernatants from injected and control mice. The results of the above experimentation in mice can be use to extrapolate proper dosages and other treatment parameters in humans and other animals using naked DNA.

Example 19: Transgenic Animals

5

10

15

20

25

30

The polypeptides of the invention can also be expressed in transgenic animals. Animals of any species, including, but not limited to, mice, rats, rabbits, hamsters, guinea pigs, pigs, micro-pigs, goats, sheep, cows and non-human primates, e.g., baboons, monkeys, and chimpanzees may be used to generate transgenic animals. In a specific embodiment, techniques described herein or otherwise known in the art, are used to express polypeptides of the invention in humans. as part of a gene therapy protocol.

Any technique known in the art may be used to introduce the transgene (i.e., polynucleotides of the invention) into animals to produce the founder lines of transgenic

WO 00/55351

5

10

15

20

25

30

PCT/US00/05883

animals. Such techniques include, but are not limited to, pronuclear microinjection (Paterson et al., Appl. Microbiol. Biotechnol. 40:691-698 (1994); Carver et al., Biotechnology (NY) 11:1263-1270 (1993); Wright et al., Biotechnology (NY) 9:830-834 (1991); and Hoppe et al., U.S. Pat. No. 4,873,191 (1989)); retrovirus mediated gene transfer into germ lines (Van der Putten et al., Proc. Natl. Acad. Sci., USA 82:6148-6152 (1985)), blastocysts or embryos; gene targeting in embryonic stem cells (Thompson et al., Cell 56:313-321 (1989)); electroporation of cells or embryos (Lo, 1983, Mol Cell. Biol. 3:1803-1814 (1983)); introduction of the polynucleotides of the invention using a gene gun (see, e.g., Ulmer et al., Science 259:1745 (1993); introducing nucleic acid constructs into embryonic pleuripotent stem cells and transferring the stem cells back into the blastocyst; and sperm-mediated gene transfer (Lavitrano et al., Cell 57:717-723 (1989); etc. For a review of such techniques, see Gordon, "Transgenic Animals," Intl. Rev. Cytol. 115:171-229 (1989), which is incorporated by reference herein in its entirety.

Any technique known in the art may be used to produce transgenic clones containing polynucleotides of the invention, for example, nuclear transfer into enucleated oocytes of nuclei from cultured embryonic, fetal, or adult cells induced to quiescence (Campell et al., Nature 380:64-66 (1996); Wilmut et al., Nature 385:810-813 (1997)).

The present invention provides for transgenic animals that carry the transgene in all their cells, as well as animals which carry the transgene in some, but not all their cells, *i.e.*, mosaic animals or chimeric. The transgene may be integrated as a single transgene or as multiple copies such as in concatamers, *e.g.*, head-to-head tandems or head-to-tail tandems. The transgene may also be selectively introduced into and activated in a particular cell type by following, for example, the teaching of Lasko et al. (Lasko et al., Proc. Natl. Acad. Sci. USA 89:6232-6236 (1992)). The regulatory sequences required for such a cell-type specific activation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art. When it is desired that the polynucleotide transgene be integrated into the chromosomal site of the endogenous gene, gene targeting is preferred. Briefly, when such a technique is to be utilized, vectors containing some nucleotide sequences homologous to the endogenous gene are designed for the purpose of integrating, via homologous recombination with chromosomal sequences. into and disrupting the function of the nucleotide sequence of the endogenous gene. The transgene may also be selectively introduced into a particular cell type, thus inactivating the endogenous gene in only that cell type, by following, for example,

the teaching of Gu et al. (Gu et al., Science 265:103-106 (1994)). The regulatory sequences required for such a cell-type specific inactivation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art.

Once transgenic animals have been generated, the expression of the recombinant gene may be assayed utilizing standard techniques. Initial screening may be accomplished by Southern blot analysis or PCR techniques to analyze animal tissues to verify that integration of the transgene has taken place. The level of mRNA expression of the transgene in the tissues of the transgenic animals may also be assessed using techniques which include, but are not limited to, Northern blot analysis of tissue samples obtained from the animal, *in situ* hybridization analysis, and reverse transcriptase-PCR (rt-PCR). Samples of transgenic gene-expressing tissue may also be evaluated immunocytochemically or immunohistochemically using antibodies specific for the transgene product.

Once the founder animals are produced, they may be bred, inbred, outbred, or crossbred to produce colonies of the particular animal. Examples of such breeding strategies include, but are not limited to: outbreeding of founder animals with more than one integration site in order to establish separate lines; inbreeding of separate lines in order to produce compound transgenics that express the transgene at higher levels because of the effects of additive expression of each transgene; crossing of heterozygous transgenic animals to produce animals homozygous for a given integration site in order to both augment expression and eliminate the need for screening of animals by DNA analysis; crossing of separate homozygous lines to produce compound heterozygous or homozygous lines; and breeding to place the transgene on a distinct background that is appropriate for an experimental model of interest.

Transgenic animals of the invention have uses which include, but are not limited to, animal model systems useful in elaborating the biological function of polypeptides of the present invention, studying conditions and/or disorders associated with aberrant expression, and in screening for compounds effective in ameliorating such conditions and/or disorders.

Example 20: Knock-Out Animals

30

25

5

10

15

20

Endogenous gene expression can also be reduced by inactivating or "knocking out" the gene and/or its promoter using targeted homologous recombination. (E.g., see Smithies

et al., Nature 317:230-234 (1985); Thomas & Capecchi, Cell 51:503-512 (1987); Thompson et al., Cell 5:313-321 (1989); each of which is incorporated by reference herein in its entirety). For example, a mutant, non-functional polynucleotide of the invention (or a completely unrelated DNA sequence) flanked by DNA homologous to the endogenous polynucleotide sequence (either the coding regions or regulatory regions of the gene) can be used, with or without a selectable marker and/or a negative selectable marker, to transfect cells that express polypeptides of the invention in vivo. In another embodiment, techniques known in the art are used to generate knockouts in cells that contain, but do not express the gene of interest. Insertion of the DNA construct, via targeted homologous recombination, results in inactivation of the targeted gene. Such approaches are particularly suited in research and agricultural fields where modifications to embryonic stem cells can be used to generate animal offspring with an inactive targeted gene (e.g., see Thomas & Capecchi 1987 and Thompson 1989, supra). However this approach can be routinely adapted for use in humans provided the recombinant DNA constructs are directly administered or targeted to the required site in vivo using appropriate viral vectors that will be apparent to those of skill in the art.

5

10

15

20

25

30

In further embodiments of the invention, cells that are genetically engineered to express the polypeptides of the invention, or alternatively, that are genetically engineered not to express the polypeptides of the invention (e.g., knockouts) are administered to a patient in vivo. Such cells may be obtained from the patient (i.e., animal, including human) or an MHC compatible donor and can include, but are not limited to fibroblasts, bone marrow cells, blood cells (e.g., lymphocytes), adipocytes, muscle cells, endothelial cells etc. The cells are genetically engineered in vitro using recombinant DNA techniques to introduce the coding sequence of polypeptides of the invention into the cells, or alternatively, to disrupt the coding sequence and/or endogenous regulatory sequence associated with the polypeptides of the invention, e.g., by transduction (using viral vectors, and preferably vectors that integrate the transgene into the cell genome) or transfection procedures, including, but not limited to, the use of plasmids, cosmids, YACs, naked DNA, electroporation, liposomes, etc. The coding sequence of the polypeptides of the invention can be placed under the control of a strong constitutive or inducible promoter or promoter/enhancer to achieve expression, and preferably secretion, of the polypeptides of the invention. The engineered cells which express and preferably secrete the polypeptides of the invention can be introduced into the

5

10

15

20

25

30

patient systemically, e.g., in the circulation, or intraperitoneally.

Alternatively, the cells can be incorporated into a matrix and implanted in the body, e.g., genetically engineered fibroblasts can be implanted as part of a skin graft; genetically engineered endothelial cells can be implanted as part of a lymphatic or vascular graft. (See, for example, Anderson et al. U.S. Patent No. 5,399,349; and Mulligan & Wilson, U.S. Patent No. 5,460,959 each of which is incorporated by reference herein in its entirety).

When the cells to be administered are non-autologous or non-MHC compatible cells, they can be administered using well known techniques which prevent the development of a host immune response against the introduced cells. For example, the cells may be introduced in an encapsulated form which, while allowing for an exchange of components with the immediate extracellular environment, does not allow the introduced cells to be recognized by the host immune system.

Transgenic and "knock-out" animals of the invention have uses which include, but are not limited to, animal model systems useful in elaborating the biological function of polypeptides of the present invention, studying conditions and/or disorders associated with aberrant expression, and in screening for compounds effective in ameliorating such conditions and/or disorders.

Example 22: Assays Detecting Stimulation or Inhibition of B cell Proliferation and Differentiation

Generation of functional humoral immune responses requires both soluble and cognate signaling between B-lineage cells and their microenvironment. Signals may impart a positive stimulus that allows a B-lineage cell to continue its programmed development, or a negative stimulus that instructs the cell to arrest its current developmental pathway. To date, numerous stimulatory and inhibitory signals have been found to influence B cell responsiveness including IL-2, IL-4, IL-5, IL-6, IL-7, IL10, IL-13, IL-14 and IL-15. Interestingly, these signals are by themselves weak effectors but can, in combination with various co-stimulatory proteins, induce activation, proliferation, differentiation, homing, tolerance and death among B cell populations.

One of the best studied classes of B-cell co-stimulatory proteins is the TNF-superfamily. Within this family CD40, CD27, and CD30 along with their respective ligands

WO 00/55351

5

10

15

20

25

30

CD154. CD70, and CD153 have been found to regulate a variety of immune responses. Assays which allow for the detection and/or observation of the proliferation and differentiation of these B-cell populations and their precursors are valuable tools in determining the effects various proteins may have on these B-cell populations in terms of proliferation and differentiation. Listed below are two assays designed to allow for the detection of the differentiation, proliferation, or inhibition of B-cell populations and their precursors.

In Vitro Assay- Agonists or antagonists of the invention can be assessed for its ability to induce activation, proliferation, differentiation or inhibition and/or death in B-cell populations and their precursors. The activity of the agonists or antagonists of the invention on purified human tonsillar B cells, measured qualitatively over the dose range from 0.1 to 10,000 ng/mL, is assessed in a standard B-lymphocyte co-stimulation assay in which purified tonsillar B cells are cultured in the presence of either formalin-fixed Staphylococcus aureus Cowan I (SAC) or immobilized anti-human IgM antibody as the priming agent. Second signals such as IL-2 and IL-15 synergize with SAC and IgM crosslinking to elicit B cell proliferation as measured by tritiated-thymidine incorporation. Novel synergizing agents can be readily identified using this assay. The assay involves isolating human tonsillar B cells by magnetic bead (MACS) depletion of CD3-positive cells. The resulting cell population is greater than 95% B cells as assessed by expression of CD45R(B220).

Various dilutions of each sample are placed into individual wells of a 96-well plate to which are added 10⁵ B-cells suspended in culture medium (RPMI 1640 containing 10% FBS, 5 X 10⁻⁵M 2ME, 100U/ml penicillin, 10ug/ml streptomycin, and 10⁻⁵ dilution of SAC) in a total volume of 150ul. Proliferation or inhibition is quantitated by a 20h pulse (1uCi/well) with 3H-thymidine (6.7 Ci/mM) beginning 72h post factor addition. The positive and negative controls are IL2 and medium respectively.

In Vivo Assay- BALB/c mice are injected (i.p.) twice per day with buffer only, or 2 mg/Kg of agonists or antagonists of the invention, or truncated forms thereof. Mice receive this treatment for 4 consecutive days, at which time they are sacrificed and various tissues and serum collected for analyses. Comparison of H&E sections from normal spleens and spleens treated with agonists or antagonists of the invention identify the results of the activity of the agonists or antagonists on spleen cells, such as the diffusion of peri-arterial lymphatic sheaths, and/or significant increases in the nucleated cellularity of the red pulp regions, which

may indicate the activation of the differentiation and proliferation of B-cell populations. Immunohistochemical studies using a B cell marker, anti-CD45R(B220), are used to determine whether any physiological changes to splenic cells. such as splenic disorganization, are due to increased B-cell representation within loosely defined B-cell zones that infiltrate established T-cell regions.

Flow cytometric analyses of the spleens from mice treated with agonist or antagonist is used to indicate whether the agonists or antagonists specifically increases the proportion of ThB+, CD45R(B220)dull B cells over that which is observed in control mice.

Likewise, a predicted consequence of increased mature B-cell representation in vivo is a relative increase in serum Ig titers. Accordingly, serum IgM and IgA levels are compared between buffer and agonists or antagonists-treated mice.

The studies described in this example tested activity of agonists or antagonists of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides or polypeptides of the invention (e.g., gene therapy).

Example 23: T Cell Proliferation Assav

5

10

15

20

25

30

A CD3-induced proliferation assay is performed on PBMCs and is measured by the uptake of ³H-thymidine. The assay is performed as follows. Ninety-six well plates are coated with 100 μl/well of mAb to CD3 (HIT3a, Pharmingen) or isotype-matched control mAb (B33.1) overnight at 4 degrees C (1 μg/ml in .05M bicarbonate buffer, pH 9.5), then washed three times with PBS. PBMC are isolated by F/H gradient centrifugation from human peripheral blood and added to quadruplicate wells (5 x 10⁴/well) of mAb coated plates in RPMI containing 10% FCS and P/S in the presence of varying concentrations of agonists or antagonists of the invention (total volume 200 ul). Relevant protein buffer and medium alone are controls. After 48 hr. culture at 37 degrees C, plates are spun for 2 min. at 1000 rpm and 100 μl of supernatant is removed and stored –20 degrees C for measurement of IL-2 (or other cytokines) if effect on proliferation is observed. Wells are supplemented with 100 ul of medium containing 0.5 uCi of ³H-thymidine and cultured at 37 degrees C for 18-24 hr. Wells are harvested and incorporation of ³H-thymidine used as a measure of proliferation. Anti-CD3 alone is the positive control for proliferation. IL-2 (100 U/ml) is also used as a control which enhances proliferation. Control antibody which does not induce proliferation

of T cells is used as the negative controls for the effects of agonists or antagonists of the invention.

The studies described in this example tested activity of agonists or antagonists of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides or polypeptides of the invention (e.g., gene therapy).

Example 24: Effect of Agonists or Antagonists of the Invention on the Expression of MHC Class II. Costimulatory and Adhesion Molecules and Cell Differentiation of Monocytes and Monocyte-Derived Human Dendritic Cells

10

15

20

5

Dendritic cells are generated by the expansion of proliferating precursors found in the peripheral blood: adherent PBMC or elutriated monocytic fractions are cultured for 7-10 days with GM-CSF (50 ng/ml) and IL-4 (20 ng/ml). These dendritic cells have the characteristic phenotype of immature cells (expression of CD1, CD80, CD86, CD40 and MHC class II antigens). Treatment with activating factors, such as TNF-α, causes a rapid change in surface phenotype (increased expression of MHC class I and II, costimulatory and adhesion molecules, downregulation of FCγRII, upregulation of CD83). These changes correlate with increased antigen-presenting capacity and with functional maturation of the dendritic cells.

FACS analysis of surface antigens is performed as follows. Cells are treated 1-3 days with increasing concentrations of agonist or antagonist of the invention or LPS (positive control), washed with PBS containing 1% BSA and 0.02 mM sodium azide, and then incubated with 1:20 dilution of appropriate FITC- or PE-labeled monoclonal antibodies for 30 minutes at 4 degrees C. After an additional wash, the labeled cells are analyzed by flow cytometry on a FACScan (Becton Dickinson).

25

30

Effect on the production of cytokines. Cytokines generated by dendritic cells, in particular IL-12, are important in the initiation of T-cell dependent immune responses. IL-12 strongly influences the development of Thl helper T-cell immune response, and induces cytotoxic T and NK cell function. An ELISA is used to measure the IL-12 release as follows. Dendritic cells (10⁶/ml) are treated with increasing concentrations of agonists or antagonists of the invention for 24 hours. LPS (100 ng/ml) is added to the cell culture as positive control. Supernatants from the cell cultures are then collected and analyzed for IL-12 content using

5

10

15

20

25

30

commercial ELISA kit (e..g, R & D Systems (Minneapolis, MN)). The standard protocols provided with the kits are used.

Effect on the expression of MHC Class II, costimulatory and adhesion molecules. Three major families of cell surface antigens can be identified on monocytes: adhesion molecules, molecules involved in antigen presentation, and Fc receptor. Modulation of the expression of MHC class II antigens and other costimulatory molecules, such as B7 and ICAM-1, may result in changes in the antigen presenting capacity of monocytes and ability to induce T cell activation. Increase expression of Fc receptors may correlate with improved monocyte cytotoxic activity, cytokine release and phagocytosis.

FACS analysis is used to examine the surface antigens as follows. Monocytes are treated 1-5 days with increasing concentrations of agonists or antagonists of the invention or LPS (positive control), washed with PBS containing 1% BSA and 0.02 mM sodium azide, and then incubated with 1:20 dilution of appropriate FITC- or PE-labeled monoclonal antibodies for 30 minutes at 4 degreesC. After an additional wash, the labeled cells are analyzed by flow cytometry on a FACScan (Becton Dickinson).

Monocyte activation and/or increased survival. Assays for molecules that activate (or alternatively, inactivate) monocytes and/or increase monocyte survival (or alternatively, decrease monocyte survival) are known in the art and may routinely be applied to determine whether a molecule of the invention functions as an inhibitor or activator of monocytes. Agonists or antagonists of the invention can be screened using the three assays described below. For each of these assays, Peripheral blood mononuclear cells (PBMC) are purified from single donor leukopacks (American Red Cross, Baltimore, MD) by centrifugation through a Histopaque gradient (Sigma). Monocytes are isolated from PBMC by counterflow centrifugal elutriation.

Monocyte Survival Assay. Human peripheral blood monocytes progressively lose viability when cultured in absence of serum or other stimuli. Their death results from internally regulated process (apoptosis). Addition to the culture of activating factors, such as TNF-alpha dramatically improves cell survival and prevents DNA fragmentation. Propidium iodide (PI) staining is used to measure apoptosis as follows. Monocytes are cultured for 48 hours in

5

10

15

20

25

30

polypropylene tubes in serum-free medium (positive control), in the presence of 100 ng/ml TNF-alpha (negative control), and in the presence of varying concentrations of the compound to be tested. Cells are suspended at a concentration of 2 x 10⁶/ml in PBS containing PI at a final concentration of 5 µg/ml, and then incubated at room temperature for 5 minutes before FACScan analysis. Pl uptake has been demonstrated to correlate with DNA fragmentation in this experimental paradigm.

Effect on cytokine release. An important function of monocytes/macrophages is their regulatory activity on other cellular populations of the immune system through the release of cytokines after stimulation. An ELISA to measure cytokine release is performed as follows. Human monocytes are incubated at a density of $5x10^5$ cells/ml with increasing concentrations of agonists or antagonists of the invention and under the same conditions, but in the absence of agonists or antagonists. For IL-12 production, the cells are primed overnight with IFN (100 U/ml) in presence of agonist or antagonist of the invention. LPS (10 ng/ml) is then added. Conditioned media are collected after 24h and kept frozen until use. Measurement of TNF-alpha, IL-10, MCP-1 and IL-8 is then performed using a commercially available ELISA kit (e. g, R & D Systems (Minneapolis, MN)) and applying the standard protocols provided with the kit.

Oxidative burst. Purified monocytes are plated in 96-w plate at $2\text{-}1x10^5$ cell/well. Increasing concentrations of agonists or antagonists of the invention are added to the wells in a total volume of 0.2 ml culture medium (RPMI 1640 + 10% FCS, glutamine and antibiotics). After 3 days incubation, the plates are centrifuged and the medium is removed from the wells. To the macrophage monolayers, 0.2 ml per well of phenol red solution (140 mM NaCl, 10 mM potassium phosphate buffer pH 7.0, 5.5 mM dextrose, 0.56 mM phenol red and 19 U/ml of HRPO) is added, together with the stimulant (200 nM PMA). The plates are incubated at 37° C for 2 hours and the reaction is stopped by adding 20 μ l 1N NaOH per well. The absorbance is read at 610 nm. To calculate the amount of H_2O_2 produced by the macrophages. a standard curve of a H_2O_2 solution of known molarity is performed for each experiment.

The studies described in this example tested activity of agonists or antagonists of the invention. However, one skilled in the art could easily modify the exemplified studies to test

355

the activity of polynucleotides or polypeptides of the invention (e.g., gene therapy).

Example 25: Biological Effects of Agonists or Antagonists of the Invention

Astrocyte and Neuronal Assays.

5

10

15

20

25

30

Agonists or antagonists of the invention, expressed in *Escherichia coli* and purified as described above, can be tested for activity in promoting the survival, neurite outgrowth, or phenotypic differentiation of cortical neuronal cells and for inducing the proliferation of glial fibrillary acidic protein immunopositive cells, astrocytes. The selection of cortical cells for the bioassay is based on the prevalent expression of FGF-1 and FGF-2 in cortical structures and on the previously reported enhancement of cortical neuronal survival resulting from FGF-2 treatment. A thymidine incorporation assay, for example, can be used to elucidate an agonist or antagonist of the invention's activity on these cells.

Moreover, previous reports describing the biological effects of FGF-2 (basic FGF) on cortical or hippocampal neurons in vitro have demonstrated increases in both neuron survival and neurite outgrowth (Walicke et al., "Fibroblast growth factor promotes survival of dissociated hippocampal neurons and enhances neurite extension." *Proc. Natl. Acad. Sci. USA 83*:3012-3016. (1986), assay herein incorporated by reference in its entirety). However, reports from experiments done on PC-12 cells suggest that these two responses are not necessarily synonymous and may depend on not only which FGF is being tested but also on which receptor(s) are expressed on the target cells. Using the primary cortical neuronal culture paradigm, the ability of an agonist or antagonist of the invention to induce neurite outgrowth can be compared to the response achieved with FGF-2 using, for example, a thymidine incorporation assay.

Fibroblast and endothelial cell assays.

Human lung fibroblasts are obtained from Clonetics (San Diego, CA) and maintained in growth media from Clonetics. Dermal microvascular endothelial cells are obtained from Cell Applications (San Diego, CA). For proliferation assays, the human lung fibroblasts and

5

10

15

25

30

dermal microvascular endothelial cells can be cultured at 5,000 cells/well in a 96-well plate for one day in growth medium. The cells are then incubated for one day in 0.1% BSA basal medium. After replacing the medium with fresh 0.1% BSA medium, the cells are incubated with the test proteins for 3 days. Alamar Blue (Alamar Biosciences, Sacramento, CA) is added to each well to a final concentration of 10%. The cells are incubated for 4 hr. Cell viability is measured by reading in a CytoFluor fluorescence reader. For the PGE₂ assays, the human lung fibroblasts are cultured at 5,000 cells/well in a 96-well plate for one day. After a medium change to 0.1% BSA basal medium, the cells are incubated with FGF-2 or agonists or antagonists of the invention with or without IL-1α for 24 hours. The supernatants are collected and assayed for PGE₂ by EIA kit (Cayman, Ann Arbor, MI). For the IL-6 assays, the human lung fibroblasts are cultured at 5,000 cells/well in a 96-well plate for one day. After a medium change to 0.1% BSA basal medium, the cells are incubated with FGF-2 or with or without agonists or antagonists of the invention IL-1α for 24 hours. The supernatants are collected and assayed for IL-6 by ELISA kit (Endogen, Cambridge, MA).

Human lung fibroblasts are cultured with FGF-2 or agonists or antagonists of the invention for 3 days in basal medium before the addition of Alamar Blue to assess effects on growth of the fibroblasts. FGF-2 should show a stimulation at 10 - 2500 ng/ml which can be used to compare stimulation with agonists or antagonists of the invention.

20 Parkinson Models.

The loss of motor function in Parkinson's disease is attributed to a deficiency of striatal dopamine resulting from the degeneration of the nigrostriatal dopaminergic projection neurons. An animal model for Parkinson's that has been extensively characterized involves the systemic administration of 1-methyl-4 phenyl 1,2,3,6-tetrahydropyridine (MPTP). In the CNS, MPTP is taken-up by astrocytes and catabolized by monoamine oxidase B to 1-methyl-4-phenyl pyridine (MPP⁺) and released. Subsequently, MPP⁺ is actively accumulated in dopaminergic neurons by the high-affinity reuptake transporter for dopamine. MPP⁺ is then concentrated in mitochondria by the electrochemical gradient and selectively inhibits nicotidamide adenine disphosphate: ubiquinone oxidoreductionase (complex I), thereby interfering with electron transport and eventually generating oxygen radicals.

It has been demonstrated in tissue culture paradigms that FGF-2 (basic FGF) has

trophic activity towards nigral dopaminergic neurons (Ferrari et al., Dev. Biol. 1989). Recently, Dr. Unsicker's group has demonstrated that administering FGF-2 in gel foam implants in the striatum results in the near complete protection of nigral dopaminergic neurons from the toxicity associated with MPTP exposure (Otto and Unsicker, J. Neuroscience, 1990).

Based on the data with FGF-2, agonists or antagonists of the invention can be evaluated to determine whether it has an action similar to that of FGF-2 in enhancing dopaminergic neuronal survival in vitro and it can also be tested in vivo for protection of dopaminergic neurons in the striatum from the damage associated with MPTP treatment. The potential effect of an agonist or antagonist of the invention is first examined in vitro in a dopaminergic neuronal cell culture paradigm. The cultures are prepared by dissecting the midbrain floor plate from gestation day 14 Wistar rat embryos. The tissue is dissociated with trypsin and seeded at a density of 200,000 cells/cm² on polyorthinine-laminin coated glass coverslips. The cells are maintained in Dulbecco's Modified Eagle's medium and F12 medium containing hormonal supplements (N1). The cultures are fixed with paraformaldehyde after 8 days in vitro and are processed for tyrosine hydroxylase, a specific marker for dopminergic neurons, immunohistochemical staining. Dissociated cell cultures are prepared from embryonic rats. The culture medium is changed every third day and the factors are also added at that time.

Since the dopaminergic neurons are isolated from animals at gestation day 14, a developmental time which is past the stage when the dopaminergic precursor cells are proliferating, an increase in the number of tyrosine hydroxylase immunopositive neurons would represent an increase in the number of dopaminergic neurons surviving *in vitro*. Therefore, if an agonist or antagonist of the invention acts to prolong the survival of dopaminergic neurons, it would suggest that the agonist or antagonist may be involved in Parkinson's Disease.

The studies described in this example tested activity of agonists or antagonists of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides or polypeptides of the invention (e.g., gene therapy).

5

10

15

20

25

5

10

15

25

30

Vascular Endothelial Cells

On day 1, human umbilical vein endothelial cells (HUVEC) are seeded at 2-5x10⁴ cells/35 mm dish density in M199 medium containing 4% fetal bovine serum (FBS), 16 units/ml heparin, and 50 units/ml endothelial cell growth supplements (ECGS, Biotechnique, Inc.). On day 2, the medium is replaced with M199 containing 10% FBS, 8 units/ml heparin. An agonist or antagonist of the invention, and positive controls, such as VEGF and basic FGF (bFGF) are added, at varying concentrations. On days 4 and 6, the medium is replaced. On day 8, cell number is determined with a Coulter Counter.

An increase in the number of HUVEC cells indicates that the compound of the invention may proliferate vascular endothelial cells, while a decrease in the number of HUVEC cell indicates that the compound of the invention inhibits vascular endothelial cells.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

Example 27: Rat Corneal Wound Healing Model

This animal model shows the effect of an agonist or antagonist of the invention on neovascularization. The experimental protocol includes:

- a) Making a 1-1.5 mm long incision from the center of cornea into the stromal layer.
- b) Inserting a spatula below the lip of the incision facing the outer corner of the eye.
 - c) Making a pocket (its base is 1-1.5 mm form the edge of the eye).
- d) Positioning a pellet, containing 50ng- 5ug of an agonist or antagonist of the invention, within the pocket.
- e) Treatment with an agonist or antagonist of the invention can also be applied topically to the corneal wounds in a dosage range of 20mg 500mg (daily treatment for five days).

The studies described in this example tested activity of agonists or antagonists of the invention. However, one skilled in the art could easily modify the exemplified studies to test

the activity of polynucleotides or polypeptides of the invention (e.g., gene therapy).

Example 28: Diabetic Mouse and Glucocorticoid-Impaired Wound Healing Models

A. Diabetic db+/db+ Mouse Model.

5

10

15

20

25

30

To demonstrate that an agonist or antagonist of the invention accelerates the healing process, the genetically diabetic mouse model of wound healing is used. The full thickness wound healing model in the db+/db+ mouse is a well characterized, clinically relevant and reproducible model of impaired wound healing. Healing of the diabetic wound is dependent on formation of granulation tissue and re-epithelialization rather than contraction (Gartner, M.H. et al., J. Surg. Res. 52:389 (1992); Greenhalgh, D.G. et al., Am. J. Pathol. 136:1235 (1990)).

The diabetic animals have many of the characteristic features observed in Type II diabetes mellitus. Homozygous (db+/db+) mice are obese in comparison to their normal heterozygous (db+/+m) littermates. Mutant diabetic (db+/db+) mice have a single autosomal recessive mutation on chromosome 4 (db+) (Coleman et al. Proc. Natl. Acad. Sci. USA 77:283-293 (1982)). Animals show polyphagia, polydipsia and polyuria. Mutant diabetic mice (db+/db+) have elevated blood glucose, increased or normal insulin levels, and suppressed cell-mediated immunity (Mandel et al., J. Immunol. 120:1375 (1978); Debray-Sachs, M. et al., Clin. Exp. Immunol. 51(1):1-7 (1983); Leiter et al., Am. J. of Pathol. 114:46-55 (1985)). Peripheral neuropathy, myocardial complications, and microvascular lesions, basement membrane thickening and glomerular filtration abnormalities have been described in these animals (Norido, F. et al., Exp. Neurol. 83(2):221-232 (1984); Robertson et al., Diabetes 29(1):60-67 (1980); Giacomelli et al., Lab Invest. 40(4):460-473 (1979); Coleman, D.L., Diabetes 31 (Suppl):1-6 (1982)). These homozygous diabetic mice develop hyperglycemia that is resistant to insulin analogous to human type II diabetes (Mandel et al., J. Immunol. 120:1375-1377 (1978)).

The characteristics observed in these animals suggests that healing in this model may be similar to the healing observed in human diabetes (Greenhalgh, et al., Am. J. of Pathol. 136:1235-1246 (1990)).

Genetically diabetic female C57BL/KsJ (db+/db+) mice and their non-diabetic (db+/+m) heterozygous littermates are used in this study (Jackson Laboratories). The

animals are purchased at 6 weeks of age and are 8 weeks old at the beginning of the study. Animals are individually housed and received food and water ad libitum. All manipulations are performed using aseptic techniques. The experiments are conducted according to the rules and guidelines of Human Genome Sciences, Inc. Institutional Animal Care and Use Committee and the Guidelines for the Care and Use of Laboratory Animals.

5

10

15

20

25

30

Wounding protocol is performed according to previously reported methods (Tsuboi, R. and Rifkin, D.B., J. Exp. Med. 172:245-251 (1990)). Briefly, on the day of wounding, animals are anesthetized with an intraperitoneal injection of Avertin (0.01 mg/mL), 2,2,2-tribromoethanol and 2-methyl-2-butanol dissolved in deionized water. The dorsal region of the animal is shaved and the skin washed with 70% ethanol solution and iodine. The surgical area is dried with sterile gauze prior to wounding. An 8 mm full-thickness wound is then created using a Keyes tissue punch. Immediately following wounding, the surrounding skin is gently stretched to eliminate wound expansion. The wounds are left open for the duration of the experiment. Application of the treatment is given topically for 5 consecutive days commencing on the day of wounding. Prior to treatment, wounds are gently cleansed with sterile saline and gauze sponges.

Wounds are visually examined and photographed at a fixed distance at the day of surgery and at two day intervals thereafter. Wound closure is determined by daily measurement on days 1-5 and on day 8. Wounds are measured horizontally and vertically using a calibrated Jameson caliper. Wounds are considered healed if granulation tissue is no longer visible and the wound is covered by a continuous epithelium.

An agonist or antagonist of the invention is administered using at a range different doses, from 4mg to 500mg per wound per day for 8 days in vehicle. Vehicle control groups received 50mL of vehicle solution.

Animals are euthanized on day 8 with an intraperitoneal injection of sodium pentobarbital (300mg/kg). The wounds and surrounding skin are then harvested for histology and immunohistochemistry. Tissue specimens are placed in 10% neutral buffered formalin in tissue cassettes between biopsy sponges for further processing.

Three groups of 10 animals each (5 diabetic and 5 non-diabetic controls) are evaluated: 1) Vehicle placebo control, 2) untreated group, and 3) treated group.

Wound closure is analyzed by measuring the area in the vertical and horizontal axis and obtaining the total square area of the wound. Contraction is then estimated by establishing

361

the differences between the initial wound area (day 0) and that of post treatment (day 8). The wound area on day 1 is 64mm², the corresponding size of the dermal punch. Calculations are made using the following formula:

[Open area on day 8] - [Open area on day 1] / [Open area on day 1]

5

10

15

20

25

30

Specimens are fixed in 10% buffered formalin and paraffin embedded blocks are sectioned perpendicular to the wound surface (5mm) and cut using a Reichert-Jung microtome. Routine hematoxylin-eosin (H&E) staining is performed on cross-sections of bisected wounds. Histologic examination of the wounds are used to assess whether the healing process and the morphologic appearance of the repaired skin is altered by treatment with an agonist or antagonist of the invention. This assessment included verification of the presence of cell accumulation, inflammatory cells, capillaries, fibroblasts, re-epithelialization and epidermal maturity (Greenhalgh, D.G. et al., Am. J. Pathol. 136:1235 (1990)). A calibrated lens micrometer is used by a blinded observer.

Tissue sections are also stained immunohistochemically with a polyclonal rabbit antihuman keratin antibody using ABC Elite detection system. Human skin is used as a positive tissue control while non-immune IgG is used as a negative control. Keratinocyte growth is determined by evaluating the extent of reepithelialization of the wound using a calibrated lens micrometer.

Proliferating cell nuclear antigen/cyclin (PCNA) in skin specimens is demonstrated by using anti-PCNA antibody (1:50) with an ABC Elite detection system. Human colon cancer served as a positive tissue control and human brain tissue is used as a negative tissue control. Each specimen included a section with omission of the primary antibody and substitution with non-immune mouse IgG. Ranking of these sections is based on the extent of proliferation on a scale of 0-8, the lower side of the scale reflecting slight proliferation to the higher side reflecting intense proliferation.

Experimental data are analyzed using an unpaired t test. A p value of < 0.05 is considered significant.

B. Steroid Impaired Rat Model

The inhibition of wound healing by steroids has been well documented in various in vitro and

WO 00/55351

5

10

15

20

25

30

in vivo systems (Wahl, Glucocorticoids and Wound healing. In: Anti-Inflammatory Steroid Action: Basic and Clinical Aspects. 280-302 (1989); Wahlet al., J. Immunol. 115: 476-481 (1975); Werb et al., J. Exp. Med. 147:1684-1694 (1978)). Glucocorticoids retard wound healing by inhibiting angiogenesis, decreasing vascular permeability (Ebert et al., An. Intern. Med. 37:701-705 (1952)), fibroblast proliferation, and collagen synthesis (Beck et al., Growth Factors. 5: 295-304 (1991); Haynes et al., J. Clin. Invest. 61: 703-797 (1978)) and producing a transient reduction of circulating monocytes (Haynes et al., J. Clin. Invest. 61: 703-797 (1978); Wahl, "Glucocorticoids and wound healing", In: Antiinflammatory Steroid Action: Basic and Clinical Aspects, Academic Press, New York, pp. 280-302 (1989)). The systemic administration of steroids to impaired wound healing is a well establish phenomenon in rats (Beck et al., Growth Factors. 5: 295-304 (1991); Haynes et al., J. Clin. Invest. 61: 703-797 (1978); Wahl, "Glucocorticoids and wound healing", In: Antiinflammatory Steroid Action: Basic and Clinical Aspects, Academic Press, New York, pp. 280-302 (1989); Pierce et al., Proc. Natl. Acad. Sci. USA 86: 2229-2233 (1989)).

To demonstrate that an agonist or antagonist of the invention can accelerate the healing process, the effects of multiple topical applications of the agonist or antagonist on full thickness excisional skin wounds in rats in which healing has been impaired by the systemic administration of methylprednisolone is assessed.

Young adult male Sprague Dawley rats weighing 250-300 g (Charles River Laboratories) are used in this example. The animals are purchased at 8 weeks of age and are 9 weeks old at the beginning of the study. The healing response of rats is impaired by the systemic administration of methylprednisolone (17mg/kg/rat intramuscularly) at the time of wounding. Animals are individually housed and received food and water ad libitum. All manipulations are performed using aseptic techniques. This study is conducted according to the rules and guidelines of Human Genome Sciences, Inc. Institutional Animal Care and Use Committee and the Guidelines for the Care and Use of Laboratory Animals.

The wounding protocol is followed according to section A, above. On the day of wounding, animals are anesthetized with an intramuscular injection of ketamine (50 mg/kg) and xylazine (5 mg/kg). The dorsal region of the animal is shaved and the skin washed with 70% ethanol and iodine solutions. The surgical area is dried with sterile gauze prior to wounding. An 8 mm full-thickness wound is created using a Keyes tissue punch. The wounds are left open for the duration of the experiment. Applications of the testing materials

WO 00/55351

5

10

15

20

25

30

are given topically once a day for 7 consecutive days commencing on the day of wounding and subsequent to methylprednisolone administration. Prior to treatment, wounds are gently cleansed with sterile saline and gauze sponges.

Wounds are visually examined and photographed at a fixed distance at the day of wounding and at the end of treatment. Wound closure is determined by daily measurement on days 1-5 and on day 8. Wounds are measured horizontally and vertically using a calibrated Jameson caliper. Wounds are considered healed if granulation tissue is no longer visible and the wound is covered by a continuous epithelium.

The agonist or antagonist of the invention is administered using at a range different doses, from 4mg to 500mg per wound per day for 8 days in vehicle. Vehicle control groups received 50mL of vehicle solution.

Animals are euthanized on day 8 with an intraperitoneal injection of sodium pentobarbital (300mg/kg). The wounds and surrounding skin are then harvested for histology. Tissue specimens are placed in 10% neutral buffered formalin in tissue cassettes between biopsy sponges for further processing.

Four groups of 10 animals each (5 with methylprednisolone and 5 without glucocorticoid) are evaluated: 1) Untreated group 2) Vehicle placebo control 3) treated groups.

Wound closure is analyzed by measuring the area in the vertical and horizontal axis and obtaining the total area of the wound. Closure is then estimated by establishing the differences between the initial wound area (day 0) and that of post treatment (day 8). The wound area on day 1 is 64mm², the corresponding size of the dermal punch. Calculations are made using the following formula:

[Open area on day 8] - [Open area on day 1] / [Open area on day 1]

Specimens are fixed in 10% buffered formalin and paraffin embedded blocks are sectioned perpendicular to the wound surface (5mm) and cut using an Olympus microtome. Routine hematoxylin-eosin (H&E) staining is performed on cross-sections of bisected wounds. Histologic examination of the wounds allows assessment of whether the healing process and the morphologic appearance of the repaired skin is improved by treatment with an agonist or antagonist of the invention. A calibrated lens micrometer is used by a blinded observer to

determine the distance of the wound gap.

Experimental data are analyzed using an unpaired t test. A p value of < 0.05 is considered significant.

The studies described in this example tested activity of agonists or antagonists of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides or polypeptides of the invention (e.g., gene therapy).

Example 29: Lymphadema Animal Model

5

10

15

20

25

30

The purpose of this experimental approach is to create an appropriate and consistent lymphedema model for testing the therapeutic effects of an agonist or antagonist of the invention in lymphangiogenesis and re-establishment of the lymphatic circulatory system in the rat hind limb. Effectiveness is measured by swelling volume of the affected limb, quantification of the amount of lymphatic vasculature, total blood plasma protein, and histopathology. Acute lymphedema is observed for 7-10 days. Perhaps more importantly, the chronic progress of the edema is followed for up to 3-4 weeks.

Prior to beginning surgery, blood sample is drawn for protein concentration analysis. Male rats weighing approximately ~350g are dosed with Pentobarbital. Subsequently, the right legs are shaved from knee to hip. The shaved area is swabbed with gauze soaked in 70% EtOH. Blood is drawn for serum total protein testing. Circumference and volumetric measurements are made prior to injecting dye into paws after marking 2 measurement levels (0.5 cm above heel, at mid-pt of dorsal paw). The intradermal dorsum of both right and left paws are injected with 0.05 ml of 1% Evan's Blue. Circumference and volumetric measurements are then made following injection of dye into paws.

Using the knee joint as a landmark, a mid-leg inguinal incision is made circumferentially allowing the femoral vessels to be located. Forceps and hemostats are used to dissect and separate the skin flaps. After locating the femoral vessels, the lymphatic vessel that runs along side and underneath the vessel(s) is located. The main lymphatic vessels in this area are then electrically coagulated or suture ligated.

Using a microscope, muscles in back of the leg (near the semitendinosis and adductors) are bluntly dissected. The popliteal lymph node is then located. The 2 proximal and 2 distal lymphatic vessels and distal blood supply of the popliteal node are then and

10

15

20

25

30

ligated by suturing. The popliteal lymph node, and any accompanying adipose tissue, is then removed by cutting connective tissues.

Care is taken to control any mild bleeding resulting from this procedure. After lymphatics are occluded, the skin flaps are sealed by using liquid skin (Vetbond) (AJ Buck). The separated skin edges are sealed to the underlying muscle tissue while leaving a gap of ~0.5 cm around the leg. Skin also may be anchored by suturing to underlying muscle when necessary.

To avoid infection, animals are housed individually with mesh (no bedding). Recovering animals are checked daily through the optimal edematous peak, which typically occurred by day 5-7. The plateau edematous peak are then observed. To evaluate the intensity of the lymphedema, the circumference and volumes of 2 designated places on each paw before operation and daily for 7 days are measured. The effect plasma proteins on lymphedema is determined and whether protein analysis is a useful testing perimeter is also investigated. The weights of both control and edematous limbs are evaluated at 2 places. Analysis is performed in a blind manner.

Circumference Measurements: Under brief gas anesthetic to prevent limb movement, a cloth tape is used to measure limb circumference. Measurements are done at the ankle bone and dorsal paw by 2 different people then those 2 readings are averaged. Readings are taken from both control and edematous limbs.

Volumetric Measurements: On the day of surgery, animals are anesthetized with Pentobarbital and are tested prior to surgery. For daily volumetrics animals are under brief halothane anesthetic (rapid immobilization and quick recovery), both legs are shaved and equally marked using waterproof marker on legs. Legs are first dipped in water, then dipped into instrument to each marked level then measured by Buxco edema software(Chen/Victor). Data is recorded by one person, while the other is dipping the limb to marked area.

Blood-plasma protein measurements: Blood is drawn, spun, and serum separated prior to surgery and then at conclusion for total protein and Ca2+ comparison.

Limb Weight Comparison: After drawing blood, the animal is prepared for tissue collection. The limbs are amputated using a quillitine, then both experimental and control legs are cut at the ligature and weighed. A second weighing is done as the tibio-cacaneal joint is disarticulated and the foot is weighed.

Histological Preparations: The transverse muscle located behind the knee (popliteal)

area is dissected and arranged in a metal mold. filled with freezeGel, dipped into cold methylbutane, placed into labeled sample bags at - 80EC until sectioning. Upon sectioning, the muscle is observed under fluorescent microscopy for lymphatics..

The studies described in this example tested activity of agonists or antagonists of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides or polypeptides of the invention (e.g., gene therapy).

Example 30: Suppression of TNF alpha-induced adhesion molecule expression by a Agonist or Antagonist of the Invention

10

15

20

25

30

5

The recruitment of lymphocytes to areas of inflammation and angiogenesis involves specific receptor-ligand interactions between cell surface adhesion molecules (CAMs) on lymphocytes and the vascular endothelium. The adhesion process, in both normal and pathological settings, follows a multi-step cascade that involves intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and endothelial leukocyte adhesion molecule-1 (E-selectin) expression on endothelial cells (EC). The expression of these molecules and others on the vascular endothelium determines the efficiency with which leukocytes may adhere to the local vasculature and extravasate into the local tissue during the development of an inflammatory response. The local concentration of cytokines and growth factor participate in the modulation of the expression of these CAMs.

Tumor necrosis factor alpha (TNF-a), a potent proinflammatory cytokine, is a stimulator of all three CAMs on endothelial cells and may be involved in a wide variety of inflammatory responses, often resulting in a pathological outcome.

The potential of an agonist or antagonist of the invention to mediate a suppression of TNF-a induced CAM expression can be examined. A modified ELISA assay which uses ECs as a solid phase absorbent is employed to measure the amount of CAM expression on TNF-a treated ECs when co-stimulated with a member of the FGF family of proteins.

To perform the experiment, human umbilical vein endothelial cell (HUVEC) cultures are obtained from pooled cord harvests and maintained in growth medium (EGM-2; Clonetics. San Diego, CA) supplemented with 10% FCS and 1% penicillin/streptomycin in a 37 degree C humidified incubator containing 5% CO₂. HUVECs are seeded in 96-well plates at concentrations of 1 x 10⁴ cells/well in EGM medium at 37 degree C for 18-24 hrs or

until confluent. The monolayers are subsequently washed 3 times with a serum-free solution of RPMI-1640 supplemented with 100 U/ml penicillin and 100 mg/ml streptomycin, and treated with a given cytokine and/or growth factor(s) for 24 h at 37 degree C. Following incubation, the cells are then evaluated for CAM expression.

5

10

15

20

25

30

Human Umbilical Vein Endothelial cells (HUVECs) are grown in a standard 96 well plate to confluence. Growth medium is removed from the cells and replaced with 90 ul of 199 Medium (10% FBS). Samples for testing and positive or negative controls are added to the plate in triplicate (in 10 ul volumes). Plates are incubated at 37 degree C for either 5 h (selectin and integrin expression) or 24 h (integrin expression only). Plates are aspirated to remove medium and 100 µl of 0.1% paraformaldehyde-PBS(with Ca++ and Mg++) is added to each well. Plates are held at 4°C for 30 min.

Fixative is then removed from the wells and wells are washed 1X with PBS(+Ca,Mg)+0.5% BSA and drained. Do not allow the wells to dry. Add 10 μl of diluted primary antibody to the test and control wells. Anti-ICAM-1-Biotin, Anti-VCAM-1-Biotin and Anti-E-selectin-Biotin are used at a concentration of 10 μg/ml (1:10 dilution of 0.1 mg/ml stock antibody). Cells are incubated at 37°C for 30 min. in a humidified environment. Wells are washed X3 with PBS(+Ca,Mg)+0.5% BSA.

Then add 20 μ l of diluted ExtrAvidin-Alkaline Phosphotase (1:5,000 dilution) to each well and incubated at 37°C for 30 min. Wells are washed X3 with PBS(+Ca,Mg)+0.5% BSA. I tablet of p-Nitrophenol Phosphate pNPP is dissolved in 5 ml of glycine buffer (pH 10.4). 100 μ l of pNPP substrate in glycine buffer is added to each test well. Standard wells in triplicate are prepared from the working dilution of the ExtrAvidin-Alkaline Phosphotase in glycine buffer: 1:5,000 (10°) > 10°0.5 > 10°1.5.5 μ l of each dilution is added to triplicate wells and the resulting AP content in each well is 5.50 ng, 1.74 ng, 0.55 ng, 0.18 ng. 100 μ l of pNNP reagent must then be added to each of the standard wells. The plate must be incubated at 37°C for 4h. A volume of 50 μ l of 3M NaOH is added to all wells. The results are quantified on a plate reader at 405 nm. The background subtraction option is used on blank wells filled with glycine buffer only. The template is set up to indicate the concentration of AP-conjugate in each standard well [5.50 ng; 1.74 ng; 0.55 ng; 0.18 ng]. Results are indicated as amount of bound AP-conjugate in each sample.

The studies described in this example tested activity of agonists or antagonists of the invention. However, one skilled in the art could easily modify the exemplified studies to test

the activity of polynucleotides or polypeptides of the invention (e.g., gene therapy).

Example 31: Production Of Polypeptide of the Invention For High-Throughput Screening Assays

5

10

15

20

25

The following protocol produces a supernatant containing polypeptide of the present invention to be tested. This supernatant can then be used in the Screening Assays described in Examples 33-42.

First, dilute Poly-D-Lysine (644 587 Boehringer-Mannheim) stock solution (1mg/ml in PBS) 1:20 in PBS (w/o calcium or magnesium 17-516F Biowhittaker) for a working solution of 50ug/ml. Add 200 ul of this solution to each well (24 well plates) and incubate at RT for 20 minutes. Be sure to distribute the solution over each well (note: a 12-channel pipetter may be used with tips on every other channel). Aspirate off the Poly-D-Lysine solution and rinse with 1ml PBS (Phosphate Buffered Saline). The PBS should remain in the well until just prior to plating the cells and plates may be poly-lysine coated in advance for up to two weeks.

Plate 293T cells (do not carry cells past P+20) at 2 x 10⁵ cells/well in .5ml DMEM(Dulbecco's Modified Eagle Medium)(with 4.5 G/L glucose and L-glutamine (12-604F Biowhittaker))/10% heat inactivated FBS(14-503F Biowhittaker)/1x Penstrep(17-602E Biowhittaker). Let the cells grow overnight.

The next day, mix together in a sterile solution basin: 300 ul Lipofectamine (18324-012 Gibco/BRL) and 5ml Optimem I (31985070 Gibco/BRL)/96-well plate. With a small volume multi-channel pipetter, aliquot approximately 2ug of an expression vector containing a polynucleotide insert, produced by the methods described in Examples 8-10, into an appropriately labeled 96-well round bottom plate. With a multi-channel pipetter, add 50ul of the Lipofectamine/Optimem I mixture to each well. Pipette up and down gently to mix. Incubate at RT 15-45 minutes. After about 20 minutes, use a multi-channel pipetter to add 150ul Optimem I to each well. As a control, one plate of vector DNA lacking an insert should be transfected with each set of transfections.

- 30

Preferably, the transfection should be performed by tag-teaming the following tasks. By tag-teaming, hands on time is cut in half, and the cells do not spend too much time on PBS. First, person A aspirates off the media from four 24-well plates of cells, and then

10

15

20

25

30

person B rinses each well with .5-1ml PBS. Person A then aspirates off PBS rinse, and person B, using a12-channel pipetter with tips on every other channel, adds the 200ul of DNA/Lipofectamine/Optimem I complex to the odd wells first, then to the even wells, to each row on the 24-well plates. Incubate at 37 degree C for 6 hours.

While cells are incubating, prepare appropriate media, either 1%BSA in DMEM with 1x penstrep, or HGS CHO-5 media (116.6 mg/L of CaCl2 (anhyd); 0.00130 mg/L CuSO₄-5H₂O; 0.050 mg/L of Fe(NO₃)₃-9H₂O; 0.417 mg/L of FeSO₄-7H₂O; 311.80 mg/L of Kcl; 28.64 mg/L of MgCl₂; 48.84 mg/L of MgSO₄; 6995.50 mg/L of NaCl: 2400.0 mg/L of NaHCO₃; 62.50 mg/L of NaH₂PO₄-H₂0; 71.02 mg/L of Na₂HPO₄; .4320 mg/L of ZnSO₄-7H2O; .002 mg/L of Arachidonic Acid; 1.022 mg/L of Cholesterol; .070 mg/L of DL-alpha-Tocopherol-Acetate; 0.0520 mg/L of Linoleic Acid; 0.010 mg/L of Linolenic Acid; 0.010 mg/L of Myristic Acid; 0.010 mg/L of Oleic Acid; 0.010 mg/L of Palmitric Acid; 0.010 mg/L of Palmitic Acid; 100 mg/L of Pluronic F-68; 0.010 mg/L of Stearic Acid; 2.20 mg/L of Tween 80; 4551 mg/L of D-Glucose; 130.85 mg/ml of L- Alanine; 147.50 mg/ml of L-Arginine-HCL; 7.50 mg/ml of L-Asparagine-H₂0; 6.65 mg/ml of L-Aspartic Acid; 29.56 mg/ml of L-Cystine-2HCL-H20; 31.29 mg/ml of L-Cystine-2HCL; 7.35 mg/ml of L-Glutamic Acid; 365.0 mg/ml of L-Glutamine; 18.75 mg/ml of Glycine; 52.48 mg/ml of L-Histidine-HCL-H₂0; 106.97 mg/ml of L-Isoleucine; 111.45 mg/ml of L-Leucine; 163.75 mg/ml of L-Lysine HCL; 32.34 mg/ml of L-Methionine; 68.48 mg/ml of L-Phenylalainine; 40.0 mg/ml of L-Proline; 26.25 mg/ml of L-Serine; 101.05 mg/ml of L-Threonine; 19.22 mg/ml of L-Tryptophan; 91.79 mg/ml of L-Tryrosine-2Na-2H20; and 99.65 mg/ml of L-Valine: 0.0035 mg/L of Biotin; 3.24 mg/L of D-Ca Pantothenate; 11.78 mg/L of Choline Chloride; 4.65 mg/L of Folic Acid; 15.60 mg/L of i-Inositol; 3.02 mg/L of Niacinamide; 3.00 mg/L of Pyridoxal HCL; 0.031 mg/L of Pyridoxine HCL; 0.319 mg/L of Riboflavin; 3.17 mg/L of Thiamine HCL; 0.365 mg/L of Thymidine; 0.680 mg/L of Vitamin B₁₂; 25 mM of HEPES Buffer; 2.39 mg/L of Na Hypoxanthine; 0.105 mg/L of Lipoic Acid; 0.081 mg/L of Sodium Putrescine-2HCL; 55.0 mg/L of Sodium Pyruvate; 0.0067 mg/L of Sodium Selenite: 20uM of Ethanolamine; 0.122 mg/L of Ferric Citrate; 41.70 mg/L of Methyl-B-Cyclodextrin complexed with Linoleic Acid; 33.33 mg/L of Methyl-B-Cyclodextrin complexed with Oleic Acid: 10 mg/L of Methyl-B-Cyclodextrin complexed with Retinal Acetate. Adjust

10

15

20

25

30

osmolarity to 327 mOsm) with 2mm glutamine and 1x penstrep. (BSA (81-068-3 Bayer) 100gm dissolved in 1L DMEM for a 10% BSA stock solution). Filter the media and collect 50 ul for endotoxin assay in 15ml polystyrene conical.

The transfection reaction is terminated, preferably by tag-teaming, at the end of the incubation period. Person A aspirates off the transfection media, while person B adds 1.5ml appropriate media to each well. Incubate at 37 degree C for 45 or 72 hours depending on the media used: 1%BSA for 45 hours or CHO-5 for 72 hours.

On day four, using a 300ul multichannel pipetter, aliquot 600ul in one 1ml deep well plate and the remaining supernatant into a 2ml deep well. The supernatants from each well can then be used in the assays described in Examples 33-40.

It is specifically understood that when activity is obtained in any of the assays described below using a supernatant, the activity originates from either the polypeptide of the present invention directly (e.g., as a secreted protein) or by polypeptide of the present invention inducing expression of other proteins, which are then secreted into the supernatant. Thus, the invention further provides a method of identifying the protein in the supernatant characterized by an activity in a particular assay.

Example 32: Construction of GAS Reporter Construct

One signal transduction pathway involved in the differentiation and proliferation of cells is called the Jaks-STATs pathway. Activated proteins in the Jaks-STATs pathway bind to gamma activation site "GAS" elements or interferon-sensitive responsive element ("ISRE"), located in the promoter of many genes. The binding of a protein to these elements alter the expression of the associated gene.

GAS and ISRE elements are recognized by a class of transcription factors called Signal Transducers and Activators of Transcription, or "STATs." There are six members of the STATs family. Stat1 and Stat3 are present in many cell types, as is Stat2 (as response to IFN-alpha is widespread). Stat4 is more restricted and is not in many cell types though it has been found in T helper class 1, cells after treatment with IL-12. Stat5 was originally called mammary growth factor, but has been found at higher concentrations in other cells including myeloid cells. It can be activated in tissue culture cells by many cytokines.

The STATs are activated to translocate from the cytoplasm to the nucleus upon

WO 00/55351

5

10

15

20

tyrosine phosphorylation by a set of kinases known as the Janus Kinase ("Jaks") family. Jaks represent a distinct family of soluble tyrosine kinases and include Tyk2, Jak1, Jak2. and Jak3. These kinases display significant sequence similarity and are generally catalytically inactive in resting cells.

The Jaks are activated by a wide range of receptors summarized in the Table below. (Adapted from review by Schidler and Darnell, Ann. Rev. Biochem. 64:621-51 (1995).) A cytokine receptor family, capable of activating Jaks, is divided into two groups: (a) Class 1 includes receptors for IL-2, IL-3, IL-4, IL-6, IL-7, IL-9, IL-11, IL-12, IL-15, Epo, PRL, GH, G-CSF, GM-CSF, LIF, CNTF, and thrombopoietin; and (b) Class 2 includes IFN-a, IFN-g, and IL-10. The Class 1 receptors share a conserved cysteine motif (a set of four conserved cysteines and one tryptophan) and a WSXWS motif (a membrane proximal region encoding Trp-Ser-Xxx-Trp-Ser (SEO ID NO:1548)).

Thus, on binding of a ligand to a receptor, Jaks are activated, which in turn activate STATs, which then translocate and bind to GAS elements. This entire process is encompassed in the Jaks-STATs signal transduction pathway.

Therefore, activation of the Jaks-STATs pathway, reflected by the binding of the GAS or the ISRE element, can be used to indicate proteins involved in the proliferation and differentiation of cells. For example, growth factors and cytokines are known to activate the Jaks-STATs pathway. (See Table below.) Thus, by using GAS elements linked to reporter molecules, activators of the Jaks-STATs pathway can be identified.

372

			<u>JAKs</u>		STATS GAS(elements) or ISRE		
	<u>Ligand</u>	tvk2	<u>Jak l</u>	Jak2	Jak3		
	IFN family						
5	IFN-a/B	+	+	-	-	1,2,3	ISRE
	IFN-g		+	+	-	1.	GAS
	(IRF1>Lys6>IFP)						
	11-10	+	?	?	-	1,3	
10	gp130 family						
	IL-6 (Pleiotrohic)	+	+	+	? ·	1,3	GAS
	(IRF1>Lys6>IFP)						
	II-11(Pleiotrohic)	?	+	?	?	1,3	
	OnM(Pleiotrohic)	?	+	+	?	1,3	
15	LIF(Pleiotrohic)	?	+	+	?	1,3	
	CNTF(Pleiotrohic)	-/+	+	+	?	1,3	
	G-CSF(Pleiotrohic)	?	+	?	?	1,3	
	IL-12(Pleiotrohic)	+	-	+	+	1,3	
20	g-C family						
	IL-2 (lymphocytes)	•	+	_	+	1,3,5	GAS
	IL-4 (lymph/myeloid)	_	+	-	+	6	GAS (IRF1 = IFP
	>>Ly6)(lgH)					_	,
	IL-7 (lymphocytes)	-	+	-	+	5	GAS
25	IL-9 (lymphocytes)		+	-	+	5	GAS
23	IL-13 (lymphocyte)	-	+	?	?	6	GAS
	IL-15	?	+	?	+	5	GAS
	gp140 family						
30	IL-3 (myeloid)	-	•	+	-	5	GAS
	(IRF1>IFP>>Ly6)						
	IL-5 (myeloid)	•	-	+	-	5	GAS
	GM-CSF (myeloid)	•	-	+	-	5	GAS

373

	Growth hormone fami	lγ					
	GH	?	-	+	-	5	
	PRL	?	+/-	+	-	1,3,5	
5	EPO	?	-	+	-	5	GAS(B-
	CAS>IRFI=IFP>>Ly	6)					
	Receptor Tyrosine Kir	<u>iases</u>					
	EGF	?	+	+	-	1,3	GAS (IRF1)
10							
	PDGF	?	+	+	-	1,3	
	CSF-1	2	+	+	-	1.3	GAS (not IRF1)

10

15

20

25

30

To construct a synthetic GAS containing promoter element, which is used in the Biological Assays described in Examples 33-34, a PCR based strategy is employed to generate a GAS-SV40 promoter sequence. The 5' primer contains four tandem copies of the GAS binding site found in the IRF1 promoter and previously demonstrated to bind STATs upon induction with a range of cytokines (Rothman et al., Immunity 1:457-468 (1994).), although other GAS or ISRE elements can be used instead. The 5' primer also contains 18bp of sequence complementary to the SV40 early promoter sequence and is flanked with an XhoI site. The sequence of the 5' primer is:

5':GCGCCTCGAGATTTCCCCGAAATCTAGATTTCCCCGAAATGATTTCCCC GAAATGATTTCCCCGAAATATCTGCCATCTCAATTAG:3' (SEQ ID NO:1549)

The downstream primer is complementary to the SV40 promoter and is flanked with a Hind III site: 5':GCGGCAAGCTTTTTGCAAAGCCTAGGC:3' (SEQ ID NO:1550)

PCR amplification is performed using the SV40 promoter template present in the B-gal:promoter plasmid obtained from Clontech. The resulting PCR fragment is digested with Xhol/Hind III and subcloned into BLSK2-. (Stratagene.) Sequencing with forward and reverse primers confirms that the insert contains the following sequence:

5':CTCGAGATTTCCCCGAAATCTAGATTTCCCCGAAATGATTTCCCCGAAA
TGATTTCCCCGAAATATCTGCCATCTCAATTAGTCAGCAACCATAGTCCCG
CCCCTAACTCCGCCCATCCCGCCCCTAACTCCGCCCAGTTCCGCCCATTCT
CCGCCCCATGGCTGACTAATTTTTTTTATTTATTTATGCAGAGGCCGAGGCCGCC
TCGGCCTCTGAGCTATTCCAGAAGTAGTGAGGAGGCCTTTTTTGGAGGCCTA
GGCTTTTGCAAAAAGCTT:3' (SEQ ID NO:1551)

With this GAS promoter element linked to the SV40 promoter, a GAS:SEAP2 reporter construct is next engineered. Here, the reporter molecule is a secreted alkaline phosphatase, or "SEAP." Clearly, however, any reporter molecule can be instead of SEAP, in this or in any of the other Examples. Well known reporter molecules that can be used instead of SEAP include chloramphenicol

10

15

acetyltransferase (CAT), luciferase, alkaline phosphatase, B-galactosidase, green fluorescent protein (GFP), or any protein detectable by an antibody.

The above sequence confirmed synthetic GAS-SV40 promoter element is subcloned into the pSEAP-Promoter vector obtained from Clontech using HindIII and Xhol, effectively replacing the SV40 promoter with the amplified GAS:SV40 promoter element, to create the GAS-SEAP vector. However, this vector does not contain a neomycin resistance gene, and therefore, is not preferred for mammalian expression systems.

Thus, in order to generate mammalian stable cell lines expressing the GAS-SEAP reporter, the GAS-SEAP cassette is removed from the GAS-SEAP vector using Sall and Notl, and inserted into a backbone vector containing the neomycin resistance gene, such as pGFP-1 (Clontech), using these restriction sites in the multiple cloning site, to create the GAS-SEAP/Neo vector. Once this vector is transfected into mammalian cells, this vector can then be used as a reporter molecule for GAS binding as described in Examples 33-34.

Other constructs can be made using the above description and replacing GAS with a different promoter sequence. For example, construction of reporter molecules containing NFK-B and EGR promoter sequences are described in Examples 35 and 36. However, many other promoters can be substituted using the protocols described in these Examples. For instance, SRE, IL-2, NFAT, or Osteocalcin promoters can be substituted, alone or in combination (e.g., GAS/NF-KB/EGR, GAS/NF-KB, Il-2/NFAT, or NF-KB/GAS). Similarly, other cell lines can be used to test reporter construct activity, such as HELA (epithelial), HUVEC (endothelial), Reh (B-cell), Saos-2 (osteoblast), HUVAC (aortic), or Cardiomyocyte.

25

30

20

Example 33: High-Throughput Screening Assay for T-cell Activity.

The following protocol is used to assess T-cell activity by identifying factors, and determining whether supernate containing a polypeptide of the invention proliferates and/or differentiates T-cells. T-cell activity is assessed using the

GAS/SEAP/Neo construct produced in Example 32. Thus, factors that increase SEAP activity indicate the ability to activate the Jaks-STATS signal transduction pathway. The T-cell used in this assay is Jurkat T-cells (ATCC Accession No. TIB-152), although Molt-3 cells (ATCC Accession No. CRL-1552) and Molt-4 cells (ATCC Accession No. CRL-1582) cells can also be used.

5

10

15

20

25

30

Jurkat T-cells are lymphoblastic CD4+ Th1 helper cells. In order to generate stable cell lines, approximately 2 million Jurkat cells are transfected with the GAS-SEAP/neo vector using DMRIE-C (Life Technologies)(transfection procedure described below). The transfected cells are seeded to a density of approximately 20,000 cells per well and transfectants resistant to 1 mg/ml genticin selected. Resistant colonies are expanded and then tested for their response to increasing concentrations of interferon gamma. The dose response of a selected clone is demonstrated.

Specifically, the following protocol will yield sufficient cells for 75 wells containing 200 ul of cells. Thus, it is either scaled up, or performed in multiple to generate sufficient cells for multiple 96 well plates. Jurkat cells are maintained in RPMI + 10% serum with 1%Pen-Strep. Combine 2.5 mls of OPTI-MEM (Life Technologies) with 10 ug of plasmid DNA in a T25 flask. Add 2.5 ml OPTI-MEM containing 50 ul of DMRIE-C and incubate at room temperature for 15-45 mins.

During the incubation period, count cell concentration, spin down the required number of cells (10⁷ per transfection), and resuspend in OPTI-MEM to a final concentration of 10⁷ cells/ml. Then add 1ml of 1 x 10⁷ cells in OPTI-MEM to T25 flask and incubate at 37 degree C for 6 hrs. After the incubation, add 10 ml of RPMI + 15% serum.

The Jurkat:GAS-SEAP stable reporter lines are maintained in RPMI + 10% serum, 1 mg/ml Genticin, and 1% Pen-Strep. These cells are treated with supernatants containing polypeptide of the present invention or polypeptide of the present invention induced polypeptides as produced by the protocol described in Example 31.

On the day of treatment with the supernatant, the cells should be washed and

10

15

20

25

30

resuspended in fresh RPMI + 10% serum to a density of 500.000 cells per ml. The exact number of cells required will depend on the number of supernatants being screened. For one 96 well plate, approximately 10 million cells (for 10 plates, 100 million cells) are required.

Transfer the cells to a triangular reservoir boat, in order to dispense the cells into a 96 well dish, using a 12 channel pipette. Using a 12 channel pipette, transfer 200 ul of cells into each well (therefore adding 100, 000 cells per well).

After all the plates have been seeded, 50 ul of the supernatants are transferred directly from the 96 well plate containing the supernatants into each well using a 12 channel pipette. In addition, a dose of exogenous interferon gamma (0.1, 1.0, 10 ng) is added to wells H9, H10, and H11 to serve as additional positive controls for the assay.

The 96 well dishes containing Jurkat cells treated with supernatants are placed in an incubator for 48 hrs (note: this time is variable between 48-72 hrs). 35 ul samples from each well are then transferred to an opaque 96 well plate using a 12 channel pipette. The opaque plates should be covered (using sellophene covers) and stored at -20 degree C until SEAP assays are performed according to Example 37. The plates containing the remaining treated cells are placed at 4 degree C and serve as a source of material for repeating the assay on a specific well if desired.

As a positive control, 100 Unit/ml interferon gamma can be used which is known to activate Jurkat T cells. Over 30 fold induction is typically observed in the positive control wells.

The above protocol may be used in the generation of both transient, as well as, stable transfected cells, which would be apparent to those of skill in the art.

Example 34: High-Throughput Screening Assay Identifying Myeloid Activity

The following protocol is used to assess myeloid activity of polypeptide of the present invention by determining whether polypeptide of the present invention proliferates and/or differentiates myeloid cells. Myeloid cell activity is assessed using

the GAS/SEAP/Neo construct produced in Example 32. Thus, factors that increase SEAP activity indicate the ability to activate the Jaks-STATS signal transduction pathway. The myeloid cell used in this assay is U937, a pre-monocyte cell line. although TF-1, HL60, or KG1 can be used.

To transiently transfect U937 cells with the GAS/SEAP/Neo construct produced in Example 32, a DEAE-Dextran method (Kharbanda et. al., 1994, Cell Growth & Differentiation, 5:259-265) is used. First, harvest 2x10e7 U937 cells and wash with PBS. The U937 cells are usually grown in RPMI 1640 medium containing 10% heat-inactivated fetal bovine serum (FBS) supplemented with 100 units/ml penicillin and 100 mg/ml streptomycin.

5

10

15

20

25

30

Next, suspend the cells in 1 ml of 20 mM Tris-HCl (pH 7.4) buffer containing 0.5 mg/ml DEAE-Dextran, 8 ug GAS-SEAP2 plasmid DNA, 140 mM NaCl, 5 mM KCl, 375 uM Na₂HPO₄.7H₂O, 1 mM MgCl₂, and 675 uM CaCl₂. Incubate at 37 degrees C for 45 min.

Wash the cells with RPMI 1640 medium containing 10% FBS and then resuspend in 10 ml complete medium and incubate at 37 degree C for 36 hr.

The GAS-SEAP/U937 stable cells are obtained by growing the cells in 400 ug/ml G418. The G418-free medium is used for routine growth but every one to two months, the cells should be re-grown in 400 ug/ml G418 for couple of passages.

These cells are tested by harvesting 1×10^8 cells (this is enough for ten 96-well plates assay) and wash with PBS. Suspend the cells in 200 ml above described growth medium, with a final density of 5×10^5 cells/ml. Plate 200 ul cells per well in the 96-well plate (or 1x10⁵ cells/well).

Add 50 ul of the supernatant prepared by the protocol described in Example 31. Incubate at 37 degee C for 48 to 72 hr. As a positive control, 100 Unit/ml interferon gamma can be used which is known to activate U937 cells. Over 30 fold induction is typically observed in the positive control wells. SEAP assay the supernatant according to the protocol described in Example 37.

10

15

20

25

30

When cells undergo differentiation and proliferation, a group of genes are activated through many different signal transduction pathways. One of these genes. EGR1 (early growth response gene 1), is induced in various tissues and cell types upon activation. The promoter of EGR1 is responsible for such induction. Using the EGR1 promoter linked to reporter molecules, activation of cells can be assessed by polypeptide of the present invention.

Particularly, the following protocol is used to assess neuronal activity in PC12 cell lines. PC12 cells (rat phenochromocytoma cells) are known to proliferate and/or differentiate by activation with a number of mitogens, such as TPA (tetradecanoyl phorbol acetate), NGF (nerve growth factor), and EGF (epidermal growth factor). The EGR1 gene expression is activated during this treatment. Thus, by stably transfecting PC12 cells with a construct containing an EGR promoter linked to SEAP reporter, activation of PC12 cells by polypeptide of the present invention can be assessed.

The EGR/SEAP reporter construct can be assembled by the following protocol. The EGR-1 promoter sequence (-633 to +1)(Sakamoto K et al., Oncogene 6:867-871 (1991)) can be PCR amplified from human genomic DNA using the following primers:

- 5' GCGCTCGAGGGATGACAGCGATAGAACCCCGG -3' (SEQ ID NO: 1552)
- 5' GCGAAGCTTCGCGACTCCCGGATCCGCCTC-3' (SEQ ID NO: 1553)

Using the GAS:SEAP/Neo vector produced in Example 32, EGR1 amplified product can then be inserted into this vector. Linearize the GAS:SEAP/Neo vector using restriction enzymes XhoI/HindIII, removing the GAS/SV40 stuffer. Restrict the EGR1 amplified product with these same enzymes. Ligate the vector and the EGR1 promoter.

To prepare 96 well-plates for cell culture, two mls of a coating solution (1:30 dilution of collagen type I (Upstate Biotech Inc. Cat#08-115) in 30% ethanol (filter

sterilized)) is added per one 10 cm plate or 50 ml per well of the 96-well plate, and allowed to air dry for 2 hr.

PC12 cells are routinely grown in RPMI-1640 medium (Bio Whittaker) containing 10% horse serum (JRH BIOSCIENCES, Cat. # 12449-78P), 5% heatinactivated fetal bovine serum (FBS) supplemented with 100 units/ml penicillin and 100 ug/ml streptomycin on a precoated 10 cm tissue culture dish. One to four split is done every three to four days. Cells are removed from the plates by scraping and resuspended with pipetting up and down for more than 15 times.

Transfect the EGR/SEAP/Neo construct into PC12 using the Lipofectamine protocol described in Example 31. EGR-SEAP/PC12 stable cells are obtained by growing the cells in 300 ug/ml G418. The G418-free medium is used for routine growth but every one to two months, the cells should be re-grown in 300 ug/ml G418 for couple of passages.

To assay for neuronal activity, a 10 cm plate with cells around 70 to 80% confluent is screened by removing the old medium. Wash the cells once with PBS (Phosphate buffered saline). Then starve the cells in low serum medium (RPMI-1640 containing 1% horse serum and 0.5% FBS with antibiotics) overnight.

The next morning, remove the medium and wash the cells with PBS. Scrape off the cells from the plate, suspend the cells well in 2 ml low serum medium. Count the cell number and add more low serum medium to reach final cell density as $5x10^5$ cells/ml.

Add 200 ul of the cell suspension to each well of 96-well plate (equivalent to $1x10^5$ cells/well). Add 50 ul supernatant produced by Example 31, 37 degree C for 48 to 72 hr. As a positive control, a growth factor known to activate PC12 cells through EGR can be used, such as 50 ng/ul of Neuronal Growth Factor (NGF). Over fifty-fold induction of SEAP is typically seen in the positive control wells. SEAP assay the supernatant according to Example 37.

Example 36: High-Throughput Screening Assay for T-cell Activity

5

10

15

20

25

10

15

20

25

30

NF-KB (Nuclear Factor KB) is a transcription factor activated by a wide variety of agents including the inflammatory cytokines IL-1 and TNF. CD30 and CD40, lymphotoxin-alpha and lymphotoxin-beta, by exposure to LPS or thrombin, and by expression of certain viral gene products. As a transcription factor, NF-KB regulates the expression of genes involved in immune cell activation, control of apoptosis (NF- KB appears to shield cells from apoptosis), B and T-cell development, anti-viral and antimicrobial responses, and multiple stress responses.

In non-stimulated conditions, NF- KB is retained in the cytoplasm with I-KB (Inhibitor KB). However, upon stimulation, I- KB is phosphorylated and degraded, causing NF- KB to shuttle to the nucleus, thereby activating transcription of target genes. Target genes activated by NF- KB include IL-2, IL-6, GM-CSF, ICAM-1 and class I MHC.

Due to its central role and ability to respond to a range of stimuli, reporter constructs utilizing the NF-KB promoter element are used to screen the supernatants produced in Example 31. Activators or inhibitors of NF-KB would be useful in treating, preventing, and/or diagnosing diseases. For example, inhibitors of NF-KB could be used to treat those diseases related to the acute or chronic activation of NF-KB, such as rheumatoid arthritis.

To construct a vector containing the NF-KB promoter element, a PCR based strategy is employed. The upstream primer contains four tandem copies of the NF-KB binding site (GGGGACTTTCCC) (SEQ ID NO:1554), 18 bp of sequence complementary to the 5' end of the SV40 early promoter sequence, and is flanked with an XhoI site:

5':GCGGCCTCGAGGGGACTTTCCCGGGGACTTTCCGGGAC TTTCCATCCTGCCATCTCAATTAG:3' (SEQ ID NO:1555)

The downstream primer is complementary to the 3' end of the SV40 promoter and is flanked with a Hind III site:

5':GCGGCAAGCTTTTTGCAAAGCCTAGGC:3' (SEQ ID NO:1550)

PCR amplification is performed using the SV40 promoter template present in the pB-gal:promoter plasmid obtained from Clontech. The resulting PCR fragment is digested with XhoI and Hind III and subcloned into BLSK2-. (Stratagene) Sequencing with the T7 and T3 primers confirms the insert contains the following sequence:

5':CTCGAGGGGACTTTCCCGGGGACTTTCCGGGACTTTCC
ATCTGCCATCTCAATTAGTCAGCAACCATAGTCCCGCCCCTAACTCCGCCC
ATCCCGCCCCTAACTCCGCCCAGTTCCGCCCATTCTCCGCCCCATGGCTGA
CTAATTTTTTTATTTATGCAGAGGCCGAGGCCGCCTCGGCCTCTGAGCTA
TTCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCTAGGCTTTTTGCAAAAA
GCTT:3' (SEQ ID NO:1556)

Next, replace the SV40 minimal promoter element present in the pSEAP2-promoter plasmid (Clontech) with this NF-KB/SV40 fragment using XhoI and HindIII. However, this vector does not contain a neomycin resistance gene, and therefore, is not preferred for mammalian expression systems.

In order to generate stable mammalian cell lines, the NF-KB/SV40/SEAP cassette is removed from the above NF-KB/SEAP vector using restriction enzymes Sall and NotI, and inserted into a vector containing neomycin resistance. Particularly, the NF-KB/SV40/SEAP cassette was inserted into pGFP-1 (Clontech), replacing the GFP gene, after restricting pGFP-1 with Sall and NotI.

Once NF-KB/SV40/SEAP/Neo vector is created, stable Jurkat T-cells are created and maintained according to the protocol described in Example 33. Similarly, the method for assaying supernatants with these stable Jurkat T-cells is also described in Example 33. As a positive control, exogenous TNF alpha (0.1,1, 10 ng) is added to wells H9, H10, and H11, with a 5-10 fold activation typically observed.

Example 37: Assay for SEAP Activity

5

10

15

20

25

30

As a reporter molecule for the assays described in Examples 33-36, SEAP activity is assayed using the Tropix Phospho-light Kit (Cat. BP-400) according to the following general procedure. The Tropix Phospho-light Kit supplies the Dilution, Assay, and Reaction Buffers used below.

Prime a dispenser with the 2.5x Dilution Buffer and dispense 15 ul of 2.5x dilution buffer into Optiplates containing 35 ul of a supernatant. Seal the plates with a plastic sealer and incubate at 65 degree C for 30 min. Separate the Optiplates to avoid uneven heating.

Cool the samples to room temperature for 15 minutes. Empty the dispenser and prime with the Assay Buffer. Add 50 ml Assay Buffer and incubate at room temperature 5 min. Empty the dispenser and prime with the Reaction Buffer (see the table below). Add 50 ul Reaction Buffer and incubate at room temperature for 20 minutes. Since the intensity of the chemiluminescent signal is time dependent, and it takes about 10 minutes to read 5 plates on luminometer, one should treat 5 plates at each time and start the second set 10 minutes later.

Read the relative light unit in the luminometer. Set H12 as blank, and print the results. An increase in chemiluminescence indicates reporter activity.

Reaction Buffer Formulation:

5

10

15

# of plates	Rxn buffer diluent (ml)	CSPD (ml)
10	60	3
11	65	3.25
12	70	3.5
13	75	3.75
14	80	4
15	85	4.25
16	90	4.5
17	95	4.75
18	100	5
19	105	5.25
20	110	5.5
21	115	5.75
22	120	6
23	125	6.25
2-4	130	6.5

384

	•	
25	135	6.75
26	140	7
27	145	7.25
28	150	7.5
29	155	7.75
30	160	8
31	165	8.25
32	170	8.5
33	175	8.75
34	180	9
35	185	9.25
36	190	9.5
37	195	9.75
38	200	10
39	205	10.25
40	210	10.5
41	215	10.75
42	220	11
43	225	11.25
44	230	11.5
45	235	11.75
46	240	12
47	245	12.25
48 .	250	12.5
49	255	12.75
50	260	. 13

Example 38: High-Throughput Screening Assay Identifying Changes in Small Molecule Concentration and Membrane Permeability

Binding of a ligand to a receptor is known to alter intracellular levels of small molecules, such as calcium, potassium, sodium, and pH. as well as alter membrane potential. These alterations can be measured in an assay to identify supernatants which bind to receptors of a particular cell. Although the following protocol

WO 00/55351

_. 5

10

15

20

25

30

385

PCT/US00/05883

describes an assay for calcium, this protocol can easily be modified to detect changes in potassium, sodium, pH, membrane potential, or any other small molecule which is detectable by a fluorescent probe.

The following assay uses Fluorometric Imaging Plate Reader ("FLIPR") to measure changes in fluorescent molecules (Molecular Probes) that bind small molecules. Clearly, any fluorescent molecule detecting a small molecule can be used instead of the calcium fluorescent molecule. fluo-4 (Molecular Probes, Inc.; catalog no. F-14202), used here.

For adherent cells, seed the cells at 10,000 -20,000 cells/well in a Co-star black 96-well plate with clear bottom. The plate is incubated in a CO₂ incubator for 20 hours. The adherent cells are washed two times in Biotek washer with 200 ul of HBSS (Hank's Balanced Salt Solution) leaving 100 ul of buffer after the final wash.

A stock solution of 1 mg/ml fluo-4 is made in 10% pluronic acid DMSO. To load the cells with fluo-4, 50 ul of 12 ug/ml fluo-4 is added to each well. The plate is incubated at 37 degrees C in a CO₂ incubator for 60 min. The plate is washed four times in the Biotek washer with HBSS leaving 100 ul of buffer.

For non-adherent cells, the cells are spun down from culture media. Cells are re-suspended to 2-5x10⁶ cells/ml with HBSS in a 50-ml conical tube. 4 ul of 1 mg/ml fluo-4 solution in 10% pluronic acid DMSO is added to each ml of cell suspension. The tube is then placed in a 37 degrees C water bath for 30-60 min. The cells are washed twice with HBSS, resuspended to 1x10⁶ cells/ml, and dispensed into a microplate, 100 ul/well. The plate is centrifuged at 1000 rpm for 5 min. The plate is then washed once in Denley Cell Wash with 200 ul, followed by an aspiration step to 100 ul final volume.

For a non-cell based assay, each well contains a fluorescent molecule, such as fluo-4. The supernatant is added to the well, and a change in fluorescence is detected.

To measure the fluorescence of intracellular calcium, the FLIPR is set for the following parameters: (1) System gain is 300-800 mW; (2) Exposure time is 0.4 second: (3) Camera F/stop is F/2; (4) Excitation is 488 nm; (5) Emission is 530 nm;

386

and (6) Sample addition is 50 ul. Increased emission at 530 nm indicates an extracellular signaling event caused by the a molecule, either polypeptide of the present invention or a molecule induced by polypeptide of the present invention, which has resulted in an increase in the intracellular Ca⁺⁺ concentration.

5

10

Example 40: High-Throughput Screening Assay Identifying Tyrosine Kinase Activity

The Protein Tyrosine Kinases (PTK) represent a diverse group of transmembrane and cytoplasmic kinases. Within the Receptor Protein Tyrosine Kinase RPTK) group are receptors for a range of mitogenic and metabolic growth factors including the PDGF, FGF, EGF, NGF, HGF and Insulin receptor subfamilies. In addition there are a large family of RPTKs for which the corresponding ligand is unknown. Ligands for RPTKs include mainly secreted small proteins, but also membrane-bound and extracellular matrix proteins.

15

20

Activation of RPTK by ligands involves ligand-mediated receptor dimerization, resulting in transphosphorylation of the receptor subunits and activation of the cytoplasmic tyrosine kinases. The cytoplasmic tyrosine kinases include receptor associated tyrosine kinases of the src-family (e.g., src, yes, lck, lyn, fyn) and non-receptor linked and cytosolic protein tyrosine kinases, such as the Jak family, members of which mediate signal transduction triggered by the cytokine superfamily of receptors (e.g., the Interleukins, Interferons, GM-CSF, and Leptin).

25

Because of the wide range of known factors capable of stimulating tyrosine kinase activity, identifying whether polypeptide of the present invention or a molecule induced by polypeptide of the present invention is capable of activating tyrosine kinase signal transduction pathways is of interest. Therefore, the following protocol is designed to identify such molecules capable of activating the tyrosine kinase signal transduction pathways.

2 30 ì

Seed target cells (e.g., primary keratinocytes) at a density of approximately 25,000 cells per well in a 96 well Loprodyne Silent Screen Plates purchased from Nalge Nunc (Naperville, IL). The plates are sterilized with two 30 minute rinses with

100% ethanol, rinsed with water and dried overnight. Some plates are coated for 2 hr with 100 ml of cell culture grade type I collagen (50 mg/ml), gelatin (2%) or polylysine (50 mg/ml), all of which can be purchased from Sigma Chemicals (St. Louis, MO) or 10% Matrigel purchased from Becton Dickinson (Bedford,MA), or calf serum, rinsed with PBS and stored at 4 degree C. Cell growth on these plates is assayed by seeding 5,000 cells/well in growth medium and indirect quantitation of cell number through use of alamarBlue as described by the manufacturer Alamar Biosciences. Inc. (Sacramento, CA) after 48 hr. Falcon plate covers #3071 from Becton Dickinson (Bedford,MA) are used to cover the Loprodyne Silent Screen Plates. Falcon Microtest III cell culture plates can also be used in some proliferation experiments.

5

10

15

20

25

30

To prepare extracts, A431 cells are seeded onto the nylon membranes of Loprodyne plates (20,000/200ml/well) and cultured overnight in complete medium. Cells are quiesced by incubation in serum-free basal medium for 24 hr. After 5-20 minutes treatment with EGF (60ng/ml) or 50 ul of the supernatant produced in Example 31, the medium was removed and 100 ml of extraction buffer ((20 mM HEPES pH 7.5, 0.15 M NaCl, 1% Triton X-100, 0.1% SDS, 2 mM Na3VO4, 2 mM Na4P2O7 and a cocktail of protease inhibitors (# 1836170) obtained from Boeheringer Mannheim (Indianapolis, IN) is added to each well and the plate is shaken on a rotating shaker for 5 minutes at 4°C. The plate is then placed in a vacuum transfer manifold and the extract filtered through the 0.45 mm membrane bottoms of each well using house vacuum. Extracts are collected in a 96-well catch/assay plate in the bottom of the vacuum manifold and immediately placed on ice. To obtain extracts clarified by centrifugation, the content of each well, after detergent solubilization for 5 minutes, is removed and centrifuged for 15 minutes at 4 degree C at 16,000 x g.

Test the filtered extracts for levels of tyrosine kinase activity. Although many methods of detecting tyrosine kinase activity are known, one method is described here.

Generally, the tyrosine kinase activity of a supernatant is evaluated by

10

15

20

25

30

determining its ability to phosphorylate a tyrosine residue on a specific substrate (a biotinylated peptide). Biotinylated peptides that can be used for this purpose include PSK1 (corresponding to amino acids 6-20 of the cell division kinase cdc2-p34) and PSK2 (corresponding to amino acids 1-17 of gastrin). Both peptides are substrates for a range of tyrosine kinases and are available from Boehringer Mannheim.

The tyrosine kinase reaction is set up by adding the following components in order. First, add 10ul of 5uM Biotinylated Peptide, then 10ul ATP/Mg₂₊ (5mM ATP/50mM MgCl₂), then 10ul of 5x Assay Buffer (40mM imidazole hydrochloride, pH7.3, 40 mM beta-glycerophosphate, 1mM EGTA, 100mM MgCl₂, 5 mM MnCl₂, 0.5 mg/ml BSA), then 5ul of Sodium Vanadate(1mM), and then 5ul of water. Mix the components gently and preincubate the reaction mix at 30 degree C for 2 min. Initial the reaction by adding 10ul of the control enzyme or the filtered supernatant.

The tyrosine kinase assay reaction is then terminated by adding 10 ul of 120mm EDTA and place the reactions on ice.

Tyrosine kinase activity is determined by transferring 50 ul aliquot of reaction mixture to a microtiter plate (MTP) module and incubating at 37 degree C for 20 min. This allows the streptavadin coated 96 well plate to associate with the biotinylated peptide. Wash the MTP module with 300ul/well of PBS four times. Next add 75 ul of anti-phospotyrosine antibody conjugated to horse radish peroxidase(anti-P-Tyr-POD(0.5u/ml)) to each well and incubate at 37 degree C for one hour. Wash the well as above.

Next add 100ul of peroxidase substrate solution (Boehringer Mannheim) and incubate at room temperature for at least 5 mins (up to 30 min). Measure the absorbance of the sample at 405 nm by using ELISA reader. The level of bound peroxidase activity is quantitated using an ELISA reader and reflects the level of tyrosine kinase activity.

Example 41: High-Throughput Screening Assay Identifying Phosphorylation Activity

As a potential alternative and/or compliment to the assay of protein tyrosine

kinase activity described in Example 40. an assay which detects activation (phosphorylation) of major intracellular signal transduction intermediates can also be used. For example, as described below one particular assay can detect tyrosine phosphorylation of the Erk-1 and Erk-2 kinases. However, phosphorylation of other molecules, such as Raf, JNK, p38 MAP. Map kinase kinase (MEK), MEK kinase, Src, Muscle specific kinase (MuSK), IRAK, Tec, and Janus, as well as any other phosphoserine, phosphotyrosine, or phosphothreonine molecule, can be detected by substituting these molecules for Erk-1 or Erk-2 in the following assay.

5

10

15

20

25

30

Specifically, assay plates are made by coating the wells of a 96-well ELISA plate with 0.1ml of protein G (lug/ml) for 2 hr at room temp, (RT). The plates are then rinsed with PBS and blocked with 3% BSA/PBS for 1 hr at RT. The protein G plates are then treated with 2 commercial monoclonal antibodies (100ng/well) against Erk-1 and Erk-2 (1 hr at RT) (Santa Cruz Biotechnology). (To detect other molecules, this step can easily be modified by substituting a monoclonal antibody detecting any of the above described molecules.) After 3-5 rinses with PBS, the plates are stored at 4 degree C until use.

A431 cells are seeded at 20,000/well in a 96-well Loprodyne filterplate and cultured overnight in growth medium. The cells are then starved for 48 hr in basal medium (DMEM) and then treated with EGF (6ng/well) or 50 ul of the supernatants obtained in Example 31 for 5-20 minutes. The cells are then solubilized and extracts filtered directly into the assay plate.

After incubation with the extract for 1 hr at RT, the wells are again rinsed. As a positive control, a commercial preparation of MAP kinase (10ng/well) is used in place of A431 extract. Plates are then treated with a commercial polyclonal (rabbit) antibody (1ug/ml) which specifically recognizes the phosphorylated epitope of the Erk-1 and Erk-2 kinases (1 hr at RT). This antibody is biotinylated by standard procedures. The bound polyclonal antibody is then quantitated by successive incubations with Europium-streptavidin and Europium fluorescence enhancing reagent in the Wallac DELFIA instrument (time-resolved fluorescence). An increased fluorescent signal over background indicates a phosphorylation by polypeptide of the

390

present invention or a molecule induced by polypeptide of the present invention.

Example 42: Assay for the Stimulation of Bone Marrow CD34+ Cell Proliferation

5

10

15

20

25

30

This assay is based on the ability of human CD34+ to proliferate in the presence of hematopoietic growth factors and evaluates the ability of isolated polypeptides expressed in mammalian cells to stimulate proliferation of CD34+ cells.

It has been previously shown that most mature precursors will respond to only a single signal. More immature precursors require at least two signals to respond. Therefore, to test the effect of polypeptides on hematopoietic activity of a wide range of progenitor cells, the assay contains a given polypeptide in the presence or absence of other hematopoietic growth factors. Isolated cells are cultured for 5 days in the presence of Stem Cell Factor (SCF) in combination with tested sample. SCF alone has a very limited effect on the proliferation of bone marrow (BM) cells, acting in such conditions only as a "survival" factor. However, combined with any factor exhibiting stimulatory effect on these cells (e.g., IL-3), SCF will cause a synergistic effect. Therefore, if the tested polypeptide has a stimulatory effect on a hematopoietic progenitors, such activity can be easily detected. Since normal BM cells have a low level of cycling cells, it is likely that any inhibitory effect of a given polypeptide, or agonists or antagonists thereof, might not be detected. Accordingly, assays for an inhibitory effect on progenitors is preferably tested in cells that are first subjected to in vitro stimulation with SCF+IL+3, and then contacted with the compound that is being evaluated for inhibition of such induced proliferation.

Briefly, CD34+ cells are isolated using methods known in the art. The cells are thawed and resuspended in medium (QBSF 60 serum-free medium with 1% L-glutamine (500ml) Quality Biological, Inc., Gaithersburg, MD Cat# 160-204-101). After several gentle centrifugation steps at 200 x g, cells are allowed to rest for one hour. The cell count is adjusted to 2.5 x 10⁵ cells/ml. During this time, 100 µl of sterile water is added to the peripheral wells of a 96-well plate. The cytokines that can be tested with a given polypeptide in this assay is rhSCF (R&D Systems,

10

15

20

25

30

Minneapolis. MN, Cat# 255-SC) at 50 ng/ml alone and in combination with rhSCF and rhIL-3 (R&D Systems. Minneapolis, MN, Cat# 203-ML) at 30 ng/ml. After one hour, 10 μ l of prepared cytokines, 50 μ l of the supernatants prepared in Example 31 (supernatants at 1:2 dilution = 50 μ l) and 20 μ l of diluted cells are added to the media which is already present in the wells to allow for a final total volume of 100 μ l. The plates are then placed in a 37°C/5% CO₂ incubator for five days.

Eighteen hours before the assay is harvested, 0.5 μCi/well of [3H] Thymidine is added in a 10 μl volume to each well to determine the proliferation rate. The experiment is terminated by harvesting the cells from each 96-well plate to a filtermat using the Tomtec Harvester 96. After harvesting, the filtermats are dried, trimmed and placed into OmniFilter assemblies consisting of one OmniFilter plate and one OmniFilter Tray. 60 μl Microscint is added to each well and the plate sealed with TopSeal-A press-on sealing film A bar code 15 sticker is affixed to the first plate for counting. The sealed plates is then loaded and the level of radioactivity determined via the Packard Top Count and the printed data collected for analysis. The level of radioactivity reflects the amount of cell proliferation.

The studies described in this example test the activity of a given polypeptide to stimulate bone marrow CD34+ cell proliferation. One skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), antibodies, agonists, and/or antagonists and fragments and variants thereof. As a nonlimiting example, potential antagonists tested in this assay would be expected to inhibit cell proliferation in the presence of cytokines and/or to increase the inhibition of cell proliferation in the presence of cytokines and a given polypeptide. In contrast, potential agonists tested in this assay would be expected to enhance cell proliferation and/or to decrease the inhibition of cell proliferation in the presence of cytokines and a given polypeptide.

The ability of a gene to stimulate the proliferation of bone marrow CD34+ cells indicates that polynucleotides and polypeptides corresponding to the gene are useful for the diagnosis and treatment of disorders affecting the immune system and hematopoiesis. Representative uses are described in the "Immune Activity" and

392

"Infectious Disease" sections above, and elsewhere herein.

5

10

15

20

25

30

Example 43: Assay for Extracellular Matrix Enhanced Cell Response (EMECR)

The objective of the Extracellular Matrix Enhanced Cell Response (EMECR) assay is to identify gene products (e.g., isolated polypeptides) that act on the hematopoietic stem cells in the context of the extracellular matrix (ECM) induced signal.

Cells respond to the regulatory factors in the context of signal(s) received from the surrounding microenvironment. For example, fibroblasts, and endothelial and epithelial stem cells fail to replicate in the absence of signals from the ECM. Hematopoietic stem cells can undergo self-renewal in the bone marrow, but not in *in vitro* suspension culture. The ability of stem cells to undergo self-renewal *in vitro* is dependent upon their interaction with the stromal cells and the ECM protein fibronectin (fn). Adhesion of cells to fn is mediated by the α_5 β_1 and α_4 β_1 integrin receptors, which are expressed by human and mouse hematopoietic stem cells. The factor(s) which integrate with the ECM environment and responsible for stimulating stem cell self-renewal has not yet been identified. Discovery of such factors should be of great interest in gene therapy and bone marrow transplant applications

Briefly, polystyrene, non tissue culture treated, 96-well plates are coated with fn fragment at a coating concentration of $0.2~\mu g/$ cm². Mouse bone marrow cells are plated (1,000 cells/well) in 0.2~ml of serum-free medium. Cells cultured in the presence of IL-3 (5~ng/ml) + SCF (50~ng/ml) would serve as the positive control, conditions under which little self-renewal but pronounced differentiation of the stem cells is to be expected. Gene products of the invention (e.g., including, but not limited to, polynucleotides and polypeptides of the present invention, and supernatants produced in Example 31), are tested with appropriate negative controls in the presence and absence of SCF(5.0~ng/ml), where test factor supernates represent 10% of the total assay volume. The plated cells are then allowed to grow by incubating in a low oxygen environment (5% CO₂, 7% O₂, and 88% N₂) tissue culture incubator

10

15

20

25

30

for 7 days. The number of proliferating cells within the wells is then quantitated by measuring thymidine incorporation into cellular DNA. Verification of the positive hits in the assay will require phenotypic characterization of the cells, which can be accomplished by scaling up of the culture system and using appropriate antibody reagents against cell surface antigens and FACScan.

One skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), antibodies, agonists, and/or antagonists and fragments and variants thereof.

If a particular polypeptide of the present invention is found to be a stimulator of hematopoietic progenitors, polynucleotides and polypeptides corresponding to the gene encoding said polypeptide may be useful for the diagnosis and treatment of disorders affecting the immune system and hematopoiesis. Representative uses are described in the "Immune Activity" and "Infectious Disease" sections above, and elsewhere herein. The gene product may also be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types.

Additionally, the polynucleotides and/or polypeptides of the gene of interest and/or agonists and/or antagonists thereof, may also be employed to inhibit the proliferation and differentiation of hematopoietic cells and therefore may be employed to protect bone marrow stem cells from chemotherapeutic agents during chemotherapy. This antiproliferative effect may allow administration of higher doses of chemotherapeutic agents and, therefore, more effective chemotherapeutic treatment.

Moreover, polynucleotides and polypeptides corresponding to the gene of interest may also be useful for the treatment and diagnosis of hematopoietic related disorders such as, for example, anemia, pancytopenia, leukopenia, thrombocytopenia or leukemia since stromal cells are important in the production of cells of hematopoietic lineages. The uses include bone marrow cell ex-vivo culture, bone marrow transplantation, bone marrow reconstitution, radiotherapy or chemotherapy of neoplasia.

Example 44: Human Dermal Fibroblast and Aortic Smooth Muscle Cell Proliferation

10

15

20

25

30

The polypeptide of interest is added to cultures of normal human dermal fibroblasts (NHDF) and human aortic smooth muscle cells (AoSMC) and two coassays are performed with each sample. The first assay examines the effect of the polypeptide of interest on the proliferation of normal human dermal fibroblasts (NHDF) or aortic smooth muscle cells (AoSMC). Aberrant growth of fibroblasts or smooth muscle cells is a part of several pathological processes, including fibrosis, and restenosis. The second assay examines IL6 production by both NHDF and SMC. IL6 production is an indication of functional activation. Activated cells will have increased production of a number of cytokines and other factors, which can result in a proinflammatory or immunomodulatory outcome. Assays are run with and without co-TNFa stimulation, in order to check for costimulatory or inhibitory activity.

Briefly, on day 1, 96-well black plates are set up with 1000 cells/well (NHDF) or 2000 cells/well (AoSMC) in 100 µl culture media. NHDF culture media contains: Clonetics FB basal media, 1mg/ml hFGF, 5mg/ml insulin, 50mg/ml gentamycin, 2%FBS, while AoSMC culture media contains Clonetics SM basal media, 0.5 µg/ml hEGF, 5mg/ml insulin, 1µg/ml hFGF, 50mg/ml gentamycin, 50 µg/ml Amphotericin B, 5%FBS. After incubation at 37°C for at least 4-5 hours, culture media is aspirated and replaced with growth arrest media. Growth arrest media for NHDF contains fibroblast basal media, 50mg/ml gentamycin, 2% FBS, while growth arrest media for AoSMC contains SM basal media, 50mg/ml gentamycin, 50µg/ml Amphotericin B, 0.4% FBS. Incubate at 37°C until day 2.

On day 2, serial dilutions and templates of the polypeptide of interest are designed such that they always include media controls and known-protein controls. For both stimulation and inhibition experiments, proteins are diluted in growth arrest media. For inhibition experiments, TNFa is added to a final concentration of 2ng/ml (NHDF) or 5ng/ml (AoSMC). Add 1/3 vol media containing controls or polypeptides of the present invention and incubate at 37°C/5% CO₂ until day 5.

Transfer 60µl from each well to another labeled 96-well plate, cover with a plate-sealer, and store at 4°C until Day 6 (for IL6 ELISA). To the remaining 100 µl in the cell culture plate, aseptically add Alamar Blue in an amount equal to 10% of the culture volume (10µl). Return plates to incubator for 3 to 4 hours. Then measure fluorescence with excitation at 530nm and emission at 590nm using the CytoFluor. This yields the growth stimulation/inhibition data.

5

10

15

20

25

30

On day 5, the IL6 ELISA is performed by coating a 96 well plate with 50-100 ul/well of Anti-Human IL6 Monoclonal antibody diluted in PBS, pH 7.4, incubate ON at room temperature.

On day 6, empty the plates into the sink and blot on paper towels. Prepare Assay Buffer containing PBS with 4% BSA. Block the plates with 200 µl/well of Pierce Super Block blocking buffer in PBS for 1-2 hr and then wash plates with wash buffer (PBS, 0.05% Tween-20). Blot plates on paper towels. Then add 50 µl/well of diluted Anti-Human IL-6 Monoclonal, Biotin-labeled antibody at 0.50 mg/ml. Make dilutions of IL-6 stock in media (30, 10, 3, 1, 0.3, 0 ng/ml). Add duplicate samples to top row of plate. Cover the plates and incubate for 2 hours at RT on shaker. Plates are washed with wash buffer and blotted on paper towels. Dilute EU-labeled Streptavidin 1:1000 in Assay buffer, and add 100 µl/well. Cover the plate and incubate 1 h at RT. Plates are again washed with wash buffer and blotted on paper towels. Add 100 µl/well of Enhancement Solution and shake for 5 minutes. Read the plate on the Wallac DELFIA Fluorometer. Readings from triplicate samples in each assay are tabulated and averaged.

A positive result in this assay suggests AoSMC cell proliferation and that the polypeptide of the present invention may be involved in dermal fibroblast proliferation and/or smooth muscle cell proliferation. A positive result also suggests many potential uses of polypeptides, polynucleotides, agonists and/or antagonists of the polynucleotide/polypeptide of the present invention which gives a positive result. For example, inflammation and immune responses, wound healing, and angiogenesis, as detailed throughout this specification. Particularly, polypeptides of the present invention and polynucleotides of the present invention may be used in wound healing

and dermal regeneration, as well as the promotion of vasculargenesis, both of the blood vessels and lymphatics. The growth of vessels can be used in the treatment of, for example, cardiovascular diseases. Additionally, antagonists of polypeptides and polynucleotides of the invention may be useful in treating diseases, disorders, and/or conditions which involve angiogenesis by acting as an anti-vascular (e.g., antiangiogenesis). These diseases, disorders, and/or conditions are known in the art and/or are described herein, such as, for example, malignancies, solid tumors, benign tumors, for example hemangiomas, acoustic neuromas, neurofibromas, trachomas, and pyogenic granulomas; artheroscleric plaques; ocular angiogenic diseases, for example, diabetic retinopathy, retinopathy of prematurity, macular degeneration, corneal graft rejection, neovascular glaucoma, retrolental fibroplasia, rubeosis, retinoblastoma, uvietis and Pterygia (abnormal blood vessel growth) of the eye; rheumatoid arthritis; psoriasis; delayed wound healing; endometriosis; vasculogenesis; granulations; hypertrophic scars (keloids); nonunion fractures; scleroderma; trachoma; vascular adhesions; myocardial angiogenesis; coronary collaterals; cerebral collaterals; arteriovenous malformations; ischemic limb angiogenesis; Osler-Webber Syndrome; plaque neovascularization; telangiectasia; hemophiliac joints; angiofibroma; fibromuscular dysplasia; wound granulation; Crohn's disease; and atherosclerosis. Moreover, antagonists of polypeptides and polynucleotides of the invention may be useful in treating anti-hyperproliferative diseases and/or anti-inflammatory known in the art and/or described herein.

One skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), antibodies, agonists, and/or antagonists and fragments and variants thereof.

25

30

20

5

10

15

Example 45: Cellular Adhesion Molecule (CAM) Expression on Endothelial Cells

The recruitment of lymphocytes to areas of inflammation and angiogenesis involves specific receptor-ligand interactions between cell surface adhesion molecules

WO 00/55351

5

10

15

20

25

30

PCT/US00/05883

397

(CAMs) on lymphocytes and the vascular endothelium. The adhesion process, in both normal and pathological settings, follows a multi-step cascade that involves intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and endothelial leukocyte adhesion molecule-1 (E-selectin) expression on endothelial cells (EC). The expression of these molecules and others on the vascular endothelium determines the efficiency with which leukocytes may adhere to the local vasculature and extravasate into the local tissue during the development of an inflammatory response. The local concentration of cytokines and growth factor participate in the modulation of the expression of these CAMs.

Briefly, endothelial cells (e.g., Human Umbilical Vein Endothelial cells (HUVECs)) are grown in a standard 96 well plate to confluence, growth medium is removed from the cells and replaced with 100 µl of 199 Medium (10% fetal bovine serum (FBS)). Samples for testing and positive or negative controls are added to the plate in triplicate (in 10 µl volumes). Plates are then incubated at 37°C for either 5 h (selectin and integrin expression) or 24 h (integrin expression only). Plates are aspirated to remove medium and 100 µl of 0.1% paraformaldehyde-PBS(with Ca++ and Mg++) is added to each well. Plates are held at 4°C for 30 min. Fixative is removed from the wells and wells are washed 1X with PBS(+Ca,Mg) + 0.5% BSA and drained. 10 ul of diluted primary antibody is added to the test and control wells. Anti-ICAM-1-Biotin, Anti-VCAM-1-Biotin and Anti-E-selectin-Biotin are used at a concentration of 10 µg/ml (1:10 dilution of 0.1 mg/ml stock antibody). Cells are incubated at 37°C for 30 min. in a humidified environment. Wells are washed three times with PBS(+Ca,Mg) + 0.5% BSA. 20 µl of diluted ExtrAvidin-Alkaline Phosphotase (1:5,000 dilution, referred to herein as the working dilution) are added to each well and incubated at 37°C for 30 min. Wells are washed three times with PBS(+Ca,Mg)+0.5% BSA. Dissolve 1 tablet of p-Nitrophenol Phosphate pNPP per 5 ml of glycine buffer (pH 10.4). 100 µl of pNPP substrate in glycine buffer is added to each test well. Standard wells in triplicate are prepared from the working dilution of the ExtrAvidin-Alkaline Phosphotase in glycine buffer: $1.5,000 (10^0) > 10^{-0.5} > 10^{-1} >$ 10^{-1.5}, 5 ul of each dilution is added to triplicate wells and the resulting AP content in

each well is 5.50 ng, 1.74 ng, 0.55 ng, 0.18 ng. 100 µl of pNNP reagent is then added to each of the standard wells. The plate is incubated at 37°C for 4h. A volume of 50 µl of 3M NaOH is added to all wells. The plate is read on a plate reader at 405 nm using the background subtraction option on blank wells filled with glycine buffer only. Additionally, the template is set up to indicate the concentration of AP-conjugate in each standard well [5.50 ng; 1.74 ng; 0.55 ng; 0.18 ng]. Results are indicated as amount of bound AP-conjugate in each sample.

Example 46: Alamar Blue Endothelial Cells Proliferation Assay

10

15

20

25

30

5

This assay may be used to quantitatively determine protein mediated inhibition of bFGF-induced proliferation of Bovine Lymphatic Endothelial Cells (LECs), Bovine Aortic Endothelial Cells (BAECs) or Human Microvascular Uterine Myometrial Cells (UTMECs). This assay incorporates a fluorometric growth indicator based on detection of metabolic activity. A standard Alamar Blue Proliferation Assay is prepared in EGM-2MV with 10 ng /ml of bFGF added as a source of endothelial cell stimulation. This assay may be used with a variety of endothelial cells with slight changes in growth medium and cell concentration. Dilutions of the protein batches to be tested are diluted as appropriate. Serum-free medium (GIBCO SFM) without bFGF is used as a non-stimulated control and Angiostatin or TSP-1 are included as a known inhibitory controls.

Briefly, LEC, BAECs or UTMECs are seeded in growth media at a density of 5000 to 2000 cells/well in a 96 well plate and placed at 37-C overnight. After the overnight incubation of the cells, the growth media is removed and replaced with GIBCO EC-SFM. The cells are treated with the appropriate dilutions of the protein of interest or control protein sample(s) (prepared in SFM) in triplicate wells with additional bFGF to a concentration of 10 ng/ml. Once the cells have been treated with the samples, the plate(s) is/are placed back in the 37° C incubator for three days. After three days 10 ml of stock alamar blue (Biosource Cat# DAL1100) is added to each well and the plate(s) is/are placed back in the 37°C incubator for four hours. The

plate(s) are then read at 530nm excitation and 590nm emission using the CytoFluor fluorescence reader. Direct output is recorded in relative fluorescence units.

Alamar blue is an oxidation-reduction indicator that both fluoresces and changes color in response to chemical reduction of growth medium resulting from cell growth. As cells grow in culture, innate metabolic activity results in a chemical reduction of the immediate surrounding environment. Reduction related to growth causes the indicator to change from oxidized (non-fluorescent blue) form to reduced (fluorescent red) form. i.e. stimulated proliferation will produce a stronger signal and inhibited proliferation will produce a weaker signal and the total signal is proportional to the total number of cells as well as their metabolic activity. The background level of activity is observed with the starvation medium alone. This is compared to the output observed from the positive control samples (bFGF in growth medium) and protein dilutions.

Example 47: Detection of Inhibition of a Mixed Lymphocyte Reaction

5

10

15

20

25

30

This assay can be used to detect and evaluate inhibition of a Mixed Lymphocyte Reaction (MLR) by gene products (e.g., isolated polypeptides). Inhibition of a MLR may be due to a direct effect on cell proliferation and viability, modulation of costimulatory molecules on interacting cells, modulation of adhesiveness between lymphocytes and accessory cells, or modulation of cytokine production by accessory cells. Multiple cells may be targeted by these polypeptides since the peripheral blood mononuclear fraction used in this assay includes T, B and natural killer lymphocytes, as well as monocytes and dendritic cells.

Polypeptides of interest found to inhibit the MLR may find application in diseases associated with lymphocyte and monocyte activation or proliferation. These include, but are not limited to, diseases such as asthma, arthritis, diabetes, inflammatory skin conditions, psoriasis, eczema, systemic lupus erythematosus, multiple sclerosis, glomerulonephritis, inflammatory bowel disease, crohn's disease, ulcerative colitis, arteriosclerosis, cirrhosis, graft vs. host disease, host vs. graft

disease, hepatitis, leukemia and lymphoma.

5

10

15

20

25

30

Briefly. PBMCs from human donors are purified by density gradient centrifugation using Lymphocyte Separation Medium (LSM®, density 1.0770 g/ml, Organon Teknika Corporation, West Chester, PA). PBMCs from two donors are adjusted to 2 x 10⁶ cells/ml in RPMI-1640 (Life Technologies, Grand Island, NY) supplemented with 10% FCS and 2 mM glutamine. PBMCs from a third donor is adjusted to 2 x 10⁵ cells/ml. Fifty microliters of PBMCs from each donor is added to wells of a 96-well round bottom microtiter plate. Dilutions of test materials (50 µl) is added in triplicate to microtiter wells. Test samples (of the protein of interest) are added for final dilution of 1:4; rhuIL-2 (R&D Systems, Minneapolis, MN, catalog number 202-IL) is added to a final concentration of 1 µg/ml; anti-CD4 mAb (R&D Systems, clone 34930.11, catalog number MAB379) is added to a final concentration of 10 µg/ml. Cells are cultured for 7-8 days at 37°C in 5% CO₂, and 1 µC of [³H] thymidine is added to wells for the last 16 hrs of culture. Cells are harvested and thymidine incorporation determined using a Packard TopCount. Data is expressed as the mean and standard deviation of triplicate determinations.

Samples of the protein of interest are screened in separate experiments and compared to the negative control treatment, anti-CD4 mAb, which inhibits proliferation of lymphocytes and the positive control treatment, IL-2 (either as recombinant material or supernatant), which enhances proliferation of lymphocytes.

One skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), antibodies, agonists, and/or antagonists and fragments and variants thereof.

It will be clear that the invention may be practiced otherwise than as particularly described in the foregoing description and examples. Numerous modifications and variations of the present invention are possible in light of the above teachings and, therefore, are within the scope of the appended claims.

The entire disclosure of each document cited (including patents, patent applications, journal articles, abstracts, laboratory manuals, books, or other disclosures) in the Background of the Invention, Detailed Description, and Examples

401

is hereby incorporated herein by reference. Further, the hard copy of the sequence listing submitted herewith and the corresponding computer readable form are both incorporated herein by reference in their entireties. Moreover, the hard copy of and the corresponding computer readable form of the Sequence Listing of Serial No.

5 60/124,270 are also incorporated herein by reference in their entireties.

Applicant's or agent's file reference number	PA102PCT	International application No.	UNASSIGNED
		<u> </u>	

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

A. The indications made below relate to the microorganism re	eferred to in the description	
on page 91 , line	N/A .	
B. IDENTIFICATIONOF DEPOSIT	Further deposits are identified on an additional sheet	
Name of depositary institution American Type Culture Co	ollection	
Address of depositary institution (including postal code and c 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America	iounity)	
Date of deposit	Accession Number	
20 May 1997	209059	
C. ADDITIONAL INDICATIONS (leave blank if not appli	cable) This information is continued on an additional sheet	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States) Europe In respect to those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28 (4) EPC).		
E. SEPARATE FURNISHING OF INDICATIONS (led	ave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later ispecify the general nature of the indications e.g., "Accession Number of Deposit")		
For receiving Office use only	For International Bureau use only	
This sheet was received with the international application	This sheet was received by the International Bureau on:	
Authorized officer	Authorized officer	

403

ATCC Deposit No.: 209059

CANADA

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

UNITED KINGDOM

404

ATCC Deposit No.: 209059

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later that at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

NETHERLANDS

Applicant's or agent's file	DA 102DCT	International application No.	UNASSIGNED
reference number	PA102PCT	Ì	UNASSIGNED

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

A. The indications made below relate to the microorganism referred to in the description on page91, line		
B. IDENTIFICATION OF DEPOSIT	Further deposits are identified on an additional sheet	
Name of depositary institution American Type Culture Colle	ction	
Address of depositary institution fincluding postal code and count 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America	ליִת	
Date of deposit	Accession Number	
20 May 1997	209060	
C. ADDITIONAL INDICATIONS (leave blank if not applicable	This information is continued on an additional sheet	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States) Europe In respect to those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28 (4) EPC).		
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable) The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")		
For receiving Office use only This sheet was received with the international application	For International Bureau use only This sheet was received by the International Bureau on:	
Authorized officer	Authorized officer	

406

ATCC Deposit No.: 209060

CANADA

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

UNITED KINGDOM

407

ATCC Deposit No.: 209060

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later that at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

NETHERLANDS

Applicant's or agent's file	PA102PCT	International application No.	UNASSIGNED

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

A. The indications made below relate to the microorganism refe	rred to in the description N/A
on page 91 , line	IVA .
B. IDENTIFICATION OF DEPOSIT	Further deposits are identified on an additional sheet
Name of depositary institution American Type Culture Coll	ection
Address of depositary institution (including postal code and cour	יי) .
10801 University Boulevard Manassas, Virginia 20110-2209	
United States of America	
Date of deposit	Accession Number
20 May 1997	209061
C. ADDITIONAL INDICATIONS (leave blank if not applicable)	ble) This information is continued on an additional sheet
	ł
D. DESIGNATED STATES FOR WHICH INDICATION	NS ARE MADE (if the indications are not for all designated States)
Europe In respect to those designations in which a European F	Patent is sought a sample of the denosited
microorganism will be made available until the publicat	tion of the mention of the grant of the European patent
or until the date on which application has been refused	for withdrawn or is deemed to be withdrawn, only by
the issue of such a sample to an expert nominated by	the person requesting the sample (Rule 28 (4) EPC).
E. SEPARATE FURNISHING OF INDICATIONS (leave	
The indications listed below will be submitted to the Internation Number of Deposit")	onal Burcau later (specify the general nature of the indications e.g., "Accession
minute of Deposit /	
For receiving Office use only	For International Bureau use only
This sheet was received with the international application	This sheet was received by the International Bureau on:
	-
Authorized officer	Authorized officer

ATCC Deposit No.: 209061

CANADA

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

UNITED KINGDOM

ATCC Deposit No.: 209061

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later that at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

NETHERLANDS

Applicant's or agent's file reference number	PA102PCT	International application No.	UNASSIGNED

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

A. The indications made below	relate to the microorganism refe	
on page 9	line	N/A
B. IDENTIFICATIONOFDI	EPOSIT	Further deposits are identified on an additional sheet
Name of depositary institution A	merican Type Culture Coll	ection
Address of depositary instituti 10801 University Boulevar Manassas, Virginia 2011 United States of America	d	n(r;)
Date of deposit		Accession Number
20 M	ay 1997	209062
C. ADDITIONAL INDICA	TIONS (leave blank if not applica-	ble) This information is continued on an additional sheet
Europe In respect to those designal microorganism will be made or until the date on which at the issue of such a sample	ions in which a European leavailable until the publical oplication has been refused to an expert nominated by	Patent is sought a sample of the deposited tion of the mention of the grant of the European patent or withdrawn or is deemed to be withdrawn, only by the person requesting the sample (Rule 28 (4) EPC).
E. SEPARATE FURNISHI		
The indications listed below wi Number of Deposit")	ll be submitted to the Internation	onal Bureau later (specify the general nature of the indications e.g., "Accession
For receiving O	ffice use only	For International Bureau use only
_	the international application	This sheet was received by the International Bureau on:
Authorized officer		Authorized officer

ATCC Deposit No.: 209062

CANADA

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

UNITED KINGDOM

413

ATCC Deposit No.: 209062

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later that at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

NETHERLANDS

Applicant's or agent's file PA102PCT International application No. UNASSIGNED	
---	--

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

<u> </u>		
A. The indications made below relate to the microorganism refer on page91, line	red to in the description N/A .	
B. IDENTIFICATIONOF DEPOSIT	Further deposits are identified on an additional sheet	
Name of depositary institution American Type Culture Colle	ection	
Address of depositary institution (including postal code and coun 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America	(יְתְּי	
Date of deposit	Accession Number	
20 May 1997	209063	
C. ADDITIONAL INDICATIONS (leave blank if not applicab	(le) This information is continued on an additional sheet	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States) Europe In respect to those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28 (4) EPC).		
E. SEPARATE FURNISHING OF INDICATIONS (leave to	olankifnoi applicable)	
The indications listed below will be submitted to the Internation Number of Deposit")	nal Bureau later ispecifi: the general nature of the indications e.g., "Accession	
For receiving Office use only	For International Bureau use only	
This sheet was received with the international application	This sheet was received by the International Bureau on:	
Authorized officer	Authorized officer	

415

ATCC Deposit No.: 209063

CANADA

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

UNITED KINGDOM

ATCC Deposit No.: 209063

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later that at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

NETHERLANDS

Applicant's or agent's file reference number	PA102PCT	International application No.	UNASSIGNED

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page91, line		
B. IDENTIFICATIONOF DEPOSIT	Further deposits are identified on an additional sheet	
Name of depositary institution American Type Culture Colle	ection	
Address of depositary institution (including postal code and coun 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America	(יְתִּי	
Date of deposit	Accession Number	
20 May 1997	209064	
C. ADDITIONAL INDICATIONS (leave blank if not applicable	(e) This information is continued on an additional sheet	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States) Europe In respect to those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28 (4) EPC).		
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable) The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g "Accession Number of Deposit")		
For receiving Office use only This sheet was received with the international application	For International Bureau use only This sheet was received by the International Bureau on:	
Authorized officer	Authorized officer	

Form PCT/RO/134 (July 1992)

ATCC Deposit No.: 209064

CANADA

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

UNITED KINGDOM

419

ATCC Deposit No.: 209064

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later that at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

NETHERLANDS

Applicant's or agent's file reference number	PA102PCT	International application No.	UNASSIGNED

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

A.	A. The indications made below relate to the microorganism referred to in the description				
	0	праде	91	, line	N/A
B.	. n	DENTIFICA	TIONOFDEPOSIT		Further deposits are identified on an additional sheet
Na	ame	e of depositary	institution American	Type Culture Colle	ection
		-	tary institution (including	g posial code and coun	ייטוי) .
			y Boulevard inia 20110-2209		
		ed States of			
		· · · · ·			
Da	ate c	ofdeposit			Accession Number
_	·		20 May 1997		209065
C.	A	DDITIONA	L INDICATIONS (lea	we blank if not applicab	(le) This information is continued on an additional sheet
					
D.	D:	ESIGNATE	D STATES FOR WH	ICH INDICATIO	NS ARE MADE (if the indications are not for all designated States)
Eur	rop	e post to the	a designations in wh	ich a European B	stant is sought a sample of the deposited
					atent is sought a sample of the deposited on of the mention of the grant of the European patent
or t	unt	il the date o	on which application i	has been refused	or withdrawn or is deemed to be withdrawn, only by
the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28 (4) EPC).					
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)					
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")					
	Number of Deposit)				
		Fo	r receiving Office use onl	у —	For International Bureau use only
] т		received with the internat	· 1	This sheet was received by the International Bureau on:
	-			1	
Aut	tho	rized officer			Authorized officer
				İ	
				i	

ATCC Deposit No.: 209065

CANADA

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

UNITED KINGDOM

422

ATCC Deposit No.: 209065

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later that at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

NETHERLANDS

Applicant's or agent's file	PA102PCT	International application No.	UNASSIGNED
reference number			

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

	A. The indications made below relate to the microorganism referred to in the description			
on page 91	,line	N/A		
B. IDENTIFICATIONOF DE	POSIT	Further deposits are identified on an additional sheet		
Name of depositary institution A	merican Type Culture Co	ollection		
Address of depositary institution 10801 University Boulevard Manassas, Virginia 20110 United States of America	}	ountr _i .)		
Date of deposit		Accession Number		
20 Ma	ıy 1997	209066		
C. ADDITIONAL INDICAT	FIONS (leave blank if not applic	rable) This information is continued on an additional sheet		
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States) Europe In respect to those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28 (4) EPC).				
E. SEPARATE FURNISHING OF INDICATIONS (leave blank in not applicable)				
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g "Accession Number of Deposit") For receiving Office use only This sheet was received with the international application Authorized officer Authorized officer				

424

ATCC Deposit No.: 209066

CANADA

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

UNITED KINGDOM

425

ATCC Deposit No.: 209066

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later that at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

NETHERLANDS

Applicant's or agent's file		International application No.	
Applicant 5 of agent 5 file	DAAGODOT	International application 140.	LINIACCIONED
	PA102PCT	1	UNASSIGNED
reference number		?	•

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

A. The indications made below relate to the microorganism refer on page 91, line	red to in the description N/A		
B. IDENTIFICATIONOF DEPOSIT	Further deposits are identified on an additional sheet		
Name of depositary institution American Type Culture Colle	ction		
Address of depositary institution tincluding postal code and count 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America	(ייָר		
Date of deposit	Accession Number		
20 May 1997	209067		
C. ADDITIONAL INDICATIONS (leave blank if not applicable	This information is continued on an additional sheet		
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE tif the indications are not for all designated States) Europe In respect to those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28 (4) EPC).			
E. SEPARATE FURNISHING OF INDICATIONS (leave be			
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")			
For receiving Office use only	For International Bureau use only		
This sheet was received with the international application	This sheet was received by the International Bureau on:		
Authorized officer	Authorized officer		

ATCC Deposit No.: 209067

CANADA

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

UNITED KINGDOM

428

ATCC Deposit No.: 209067

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later that at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

NETHERLANDS

Applicant's or agent's file reference number	PA102PCT	International application No.	UNASSIGNED
1010101100 IIIIIIIOCI			

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

A. The indications made below relate to the microorganism referred to in the description on page91, lineN/A			
B. IDENTIFICATIONOF DEPOSIT	Further deposits are identified on an additional sheet		
Name of depositary institution American Type Culture Collection			
Address of depositary institution fincluding postal code and counting 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America			
Date of deposit	Accession Number		
20 May 1997	209068		
C. ADDITIONAL INDICATIONS (leave blank if not applicab	This information is continued on an additional sheet		
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States) Europe In respect to those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28 (4) EPC).			
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable) The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")			
For receiving Office use only This sheet was received with the international application	For International Bureau use only This sheet was received by the International Bureau on:		
Authorized officer	Authorized officer		

430

ATCC Deposit No.: 209068

CANADA

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

UNITED KINGDOM

431

ATCC Deposit No.: 209068

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later that at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

NETHERLANDS

Applicant's or agent's file	PA102PCT	International application No.	UNASSIGNED
reference number	17(1021 01		011/100/01/125

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page91 , lineN/A			
B. IDENTIFICATIONOF DEPOSIT	Further deposits are identified on an additional sheet		
Name of depositary institution American Type Culture Colle	ction		
Address of depositary institution (including postal code and count 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America	, ,		
Date of deposit	Accession Number		
20 May 1997	209069		
C. ADDITIONAL INDICATIONS (leave blank if not applicable	This information is continued on an additional sheet		
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States) Europe In respect to those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28 (4) EPC).			
	E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)		
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")			
For receiving Office use only	For International Bureau use only		
This sheet was received with the international application	This sheet was received by the International Bureau on:		
Authorized officer	Authorized officer		

433

ATCC Deposit No.: 209069

CANADA

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

UNITED KINGDOM

434

ATCC Deposit No.: 209069

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later that at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

NETHERLANDS

Applicant's as a gent's title		International application No.	
Applicant's or agent's life	PA102PCT	international application (vo.	UNASSIGNED
reference number			

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page91 line		
B. IDENTIFICATIONOF DEPOSIT	Further deposits are identified on an additional sheet	
Name of depositary institution American Type Culture Colle	ection	
Address of depositary institution (including postal code and cour 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America	olry)	
Date of deposit	Accession Number	
12 January 1998	209579	
C. ADDITIONAL INDICATIONS (leave blank if not applicable	tle) This information is continued on an additional sheet	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States) Europe In respect to those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28 (4) EPC).		
E. SEPARATE FURNISHING OF INDICATIONS (leave	blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")		
For receiving Office use only	For International Bureau use only	
This sheet was received with the international application	This sheet was received by the International Bureau on:	
Authorized officer	Authorized officer	

ATCC Deposit No.: 209579

CANADA

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

UNITED KINGDOM

437

ATCC Deposit No.: 209579

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later that at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

NETHERLANDS

Applicant's or agent's file	PA102PCT	International application No.	UNASSIGNED
reference number			

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

		···		
A.	The indica	tions made below relate to the	microorganism refe	·
	on page	91	line	N/A
B.	IDENTIF	ICATION OF DEPOSIT		Further deposits are identified on an additional sheet
N	me of depos	itary institution American 7	ype Culture Coll	ection
10 M)801 Unive anassas, \	positary institution (including ersity Boulevard /irginia 20110-2209 s of America	posial code and cour	นทุง)
Da	ite of deposit			Accession Number
		12 January 1998		209578
C.	ADDITIC	NAL INDICATIONS (lea	ve blank if not applicab	le) This information is continued on an additional sheet
Eu In i mid or i the	D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE tif the indications are not for all designated States) Europe In respect to those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28 (4) EPC). E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)			
				nal Bureau later (specify the general nature of the indications e.g., "Accession
Number of Deposit")				
		For receiving Office use only	y ———	For International Bureau use only
	This sheet	was received with the internat		This sheet was received by the International Bureau on:
Au	thorizedoffic	eer		Authorized officer

439

ATCC Deposit No.: 209578

CANADA

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

UNITED KINGDOM

440

ATCC Deposit No.: 209578

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later that at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

NETHERLANDS

Applicant's or agent's file reference number	PA102PCT	International application No.	UNASSIGNED	
reference number				

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism refer on page 91, line	ted to in the description N/A .	
B. IDENTIFICATIONOF DEPOSIT	Further deposits are identified on an additional sheet	
Name of depositary institution American Type Culture Colle	ection	
Address of depositary institution (including postal code and coun 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America	ury)	
Date of deposit 16 July 1998	Accession Number 203067	
C. ADDITIONAL INDICATIONS (leave blank if not applicab		
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States) Europe In respect to those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28 (4) EPC).		
E. SEPARATE FURNISHING OF INDICATIONS (leave t	blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")		
For receiving Office use only	For International Bureau use only	
This sheet was received with the international application	This sheet was received by the International Bureau on:	
Authorized officer	Authorized officer	

Form PCT/RO/134 (July 1992)

ATCC Deposit No.: 203067

CANADA

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

UNITED KINGDOM

443

ATCC Deposit No.: 203067

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later that at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

NETHERLANDS

Applicant's or agent's file	PA102PCT	International application No.	UNASSIGNED
reference number	FAIUZFOI	!	DIANGGIONED

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism refer on page 91 . line	red to in the description N/A
B. IDENTIFICATIONOF DEPOSIT	Further deposits are identified on an additional sheet
Name of depositary institution American Type Culture Colle	ction
Address of depositary institution (including postal code and count 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America	ליח
Date of deposit	Accession Number
16 July 1998	203068
C. ADDITIONAL INDICATIONS (leave blank if not applicable	This information is continued on an additional sheet
D. DESIGNATED STATES FOR WHICH INDICATION Europe In respect to those designations in which a European Particle or until the publication or until the date on which application has been refused the issue of such a sample to an expert nominated by the second of the instance of the instan	atent is sought a sample of the deposited on of the mention of the grant of the European patent or withdrawn or is deemed to be withdrawn, only by the person requesting the sample (Rule 28 (4) EPC).
E. SEPARATE FURNISHING OF INDICATIONS (leave be The indications listed below will be submitted to the Internation	
For receiving Office use only This sheet was received with the international application Authorized officer	For International Bureau use only This sheet was received by the International Bureau on: Authorized officer

Form PCT/RO/134 (July 1992)

445

ATCC Deposit No.: 203068

CANADA

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

UNITED KINGDOM

446

ATCC Deposit No.: 203068

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later that at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

NETHERLANDS

Applicant's or agent's file reference number	PA102PCT	International application No.	UNASSIGNED

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism refe	erred to in the description		
on page 91 , line	N/A .		
B. IDENTIFICATIONOF DEPOSIT	Further deposits are identified on an additional sheet		
Name of depositary institution American Type Culture Coll	ection		
Address of depositary institution tincluding postal code and count 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America	ntrv)		
Date of deposit	Accession Number		
01 February 1999	203609		
C. ADDITIONAL INDICATIONS (leave blank if not applicate	ble) This information is continued on an additional sheet		
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States) Europe In respect to those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28 (4) EPC).			
E. SEPARATE FURNISHING OF INDICATIONS (leave	·		
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")			
For receiving Office use only	For International Bureau use only		
This sheet was received with the international application	This sheet was received by the International Bureau on:		
Authorized officer	Authorized officer		

448

ATCC Deposit No.: 203609

CANADA

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

UNITED KINGDOM

449

ATCC Deposit No.: 203609

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later that at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

NETHERLANDS

Applicant's or agent's file	PA102PCT	International application No.	UNASSIGNED
reference number		<u> </u>	

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism refer on page	N/A .
B. IDENTIFICATIONOF DEPOSIT	Further deposits are identified on an additional sheet
Name of depositary institution American Type Culture College	ection
Address of depositary institution (including postal code and coun 10801 University Boulevard	מורי)
Manassas, Virginia 20110-2209 United States of America	
Officed States of America	
Date of deposit	Accession Number
01 February 1999	203610
C. ADDITIONAL INDICATIONS (leave blank if not applicab	tle) This information is continued on an additional sheet
D. DESIGNATED STATES FOR WHICH INDICATION	NS ARE MADE (if the indications are not for all designated States)
	NS ARE MADE (if the indications are not for all designated States)
Europe	
Europe n respect to those designations in which a European P nicroorganism will be made available until the publicati	Patent is sought a sample of the deposited ion of the mention of the grant of the European patent
Europe n respect to those designations in which a European P nicroorganism will be made available until the publicati	Patent is sought a sample of the deposited ion of the mention of the grant of the European patent
Europe n respect to those designations in which a European P nicroorganism will be made available until the publicati or until the date on which application has been refused	Patent is sought a sample of the deposited ion of the mention of the grant of the European patent or withdrawn or is deemed to be withdrawn, only by
Europe n respect to those designations in which a European P nicroorganism will be made available until the publicati or until the date on which application has been refused	Patent is sought a sample of the deposited ion of the mention of the grant of the European patent or withdrawn or is deemed to be withdrawn, only by
Europe In respect to those designations in which a European P Inicroorganism will be made available until the publication In until the date on which application has been refused In the issue of such a sample to an expert nominated by the	Patent is sought a sample of the deposited ion of the mention of the grant of the European patent or withdrawn or is deemed to be withdrawn, only by he person requesting the sample (Rule 28 (4) EPC).
Europe In respect to those designations in which a European Proceed in the publication of the date on which application has been refused the issue of such a sample to an expert nominated by the separate FURNISHING OF INDICATIONS (leave the separate for the sepa	Patent is sought a sample of the deposited ion of the mention of the grant of the European patent or withdrawn or is deemed to be withdrawn, only by he person requesting the sample (Rule 28 (4) EPC).
Europe In respect to those designations in which a European Phicroorganism will be made available until the publication until the date on which application has been refused the issue of such a sample to an expert nominated by the E. SEPARATE FURNISHING OF INDICATIONS (leave to the indications listed below will be submitted to the Internation)	Patent is sought a sample of the deposited ion of the mention of the grant of the European patent or withdrawn or is deemed to be withdrawn, only by he person requesting the sample (Rule 28 (4) EPC).
Europe In respect to those designations in which a European Phicroorganism will be made available until the publication until the date on which application has been refused the issue of such a sample to an expert nominated by the E. SEPARATE FURNISHING OF INDICATIONS (leave to the indications listed below will be submitted to the Internation)	Patent is sought a sample of the deposited ion of the mention of the grant of the European patent or withdrawn or is deemed to be withdrawn, only by he person requesting the sample (Rule 28 (4) EPC).
Europe In respect to those designations in which a European Phicroorganism will be made available until the publication until the date on which application has been refused the issue of such a sample to an expert nominated by the E. SEPARATE FURNISHING OF INDICATIONS (leave to the indications listed below will be submitted to the Internation)	Patent is sought a sample of the deposited ion of the mention of the grant of the European patent or withdrawn or is deemed to be withdrawn, only by he person requesting the sample (Rule 28 (4) EPC).
Europe In respect to those designations in which a European Phicroorganism will be made available until the publication until the date on which application has been refused the issue of such a sample to an expert nominated by the E. SEPARATE FURNISHING OF INDICATIONS (leave to the indications listed below will be submitted to the Internation)	Patent is sought a sample of the deposited ion of the mention of the grant of the European patent or withdrawn or is deemed to be withdrawn, only by he person requesting the sample (Rule 28 (4) EPC).
Europe In respect to those designations in which a European Phicroorganism will be made available until the publication until the date on which application has been refused the issue of such a sample to an expert nominated by the E. SEPARATE FURNISHING OF INDICATIONS (leave to the indications listed below will be submitted to the Internation)	Patent is sought a sample of the deposited ion of the mention of the grant of the European patent or withdrawn or is deemed to be withdrawn, only by he person requesting the sample (Rule 28 (4) EPC).
Europe In respect to those designations in which a European Procession will be made available until the publication until the date on which application has been refused the issue of such a sample to an expert nominated by the second such a sample to an expert nominated by the second such a sample to an expert nominated by the second such as second s	Patent is sought a sample of the deposited ion of the mention of the grant of the European patent or withdrawn or is deemed to be withdrawn, only by he person requesting the sample (Rule 28 (4) EPC). blank if not applicable) nat Bureau later (specify the general nature of the indications e.g., "Accession
Europe In respect to those designations in which a European Procession will be made available until the publication until the date on which application has been refused the issue of such a sample to an expert nominated by the issue of such a sample to an expert nominated by the indications listed below will be submitted to the Internation Number of Deposit") For receiving Office use only	Patent is sought a sample of the deposited ion of the mention of the grant of the European patent or withdrawn or is deemed to be withdrawn, only by he person requesting the sample (Rule 28 (4) EPC). Inal Bureau later (specify the general nature of the indications e.g., "Accession For International Bureau use only
Europe In respect to those designations in which a European Procession will be made available until the publication until the date on which application has been refused the issue of such a sample to an expert nominated by the second such a sample to an expert nominated by the second such a sample to an expert nominated by the second such as second s	Patent is sought a sample of the deposited ion of the mention of the grant of the European patent or withdrawn or is deemed to be withdrawn, only by he person requesting the sample (Rule 28 (4) EPC). blank if not applicable) nat Bureau later (specify the general nature of the indications e.g., "Accession
Europe In respect to those designations in which a European Price or particular to the publication of until the date on which application has been refused the issue of such a sample to an expert nominated by the indications listed below will be submitted to the Internation Number of Deposit") For receiving Office use only This sheet was received with the international application	Patent is sought a sample of the deposited ion of the mention of the grant of the European patent or withdrawn or is deemed to be withdrawn, only by he person requesting the sample (Rule 28 (4) EPC). Inal Bureau later (specify the general nature of the indications e.g., "Accession For International Bureau use only This sheet was received by the International Bureau on:
The indications listed below will be submitted to the Internation Number of Deposit") For receiving Office use only	Patent is sought a sample of the deposited ion of the mention of the grant of the European patent or withdrawn or is deemed to be withdrawn, only by he person requesting the sample (Rule 28 (4) EPC). Inal Bureau later (specify the general nature of the indications e.g., "Accession For International Bureau use only

Form PCT/RO/134 (July 1992)

451

ATCC Deposit No.: 203610

CANADA

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

UNITED KINGDOM

ATCC Deposit No.: 203610

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later that at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

NETHERLANDS

Applicant's or agent's file		International application No.	
reference number	PA102PCT		UNASSIGNED

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A.	The in	ndications	made below relate to the	microorganism refer	red to in the description
	on pa	ge	91	, line	N/A
B.	IDEN	TIFICA	ΠΟΝΟΓΦΕΡΟSIT		Further deposits are identified on an additional sheet
Na	me of d	lepositary	institution American	Type Culture Colle	ection
<u> </u>					
			ary institution (including Boulevard	g postal code and coun	try)
			nia 20110-2209		
Ur	nited S	States of	America		
Da	ite of de	posit			Accession Number
L			17 November 199	8	203485
C.	ADD	ITIONA	L INDICATIONS (lea	we blank if not applicab	le) This information is continued on an additional sheet
				· · · · · · · · · · · · · · · · · · ·	
					:
D.	DESI	GNATE	D STATES FOR WH	ICH INDICATIO	NS ARE MADE (if the indications are not for all designated States)
E	rope				
lin r	respec	t to thos	e designations in wh	nich a European P	atent is sought a sample of the deposited
mic	croorg	anism w	ill be made available	until the publicati	on of the mention of the grant of the European patent or withdrawn or is deemed to be withdrawn, only by
or t	untii th Lissue	e date c	n wnich application a sample to an expe	nas been relused ert nominated by t	the person requesting the sample (Rule 28 (4) EPC).
			202	•	
_					
			FURNISHING OF IN		
Th Nu	The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")				
					•
		- Fo	r receiving Office use on	ly	For International Bureau use only
	This		received with the interna		This sheet was received by the International Bureau on:
	-				
Αu	thorize	dofficer			Authorized officer

454

ATCC Deposit No.: 203485

CANADA

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

UNITED KINGDOM

455

ATCC Deposit No.: 203485

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later that at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

NETHERLANDS

Applicant's or agent's file		International application No.	
Application of agent 3 inc	DA 400DOT	international application ivo.	LINIA COLONICO
reference number	PA102PCT	•	UNASSIGNED
1 cici circe italianet	· · · · · · · •	\$	• • • • • • • • • • • • • • • • • • • •

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page 91 , line N/A .			
B. IDENTIFICATIONOF DEPOSIT	Further deposits are identified on an additional sheet		
Name of depositary institution American Type Culture Colle	ection		
Address of depositary institution (including postal code and cound 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America	ירְחוּ)		
Date of deposit .	Accession Number		
18 June 1999	PTA-252		
C. ADDITIONAL INDICATIONS (leave blank if not applicab	This information is continued on an additional sheet		
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States) Europe In respect to those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28 (4) EPC).			
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)			
The indications listed below will be submitted to the International Bureau later tspecify the general nature of the indications e.g., "Accession Number of Deposit")			
For receiving Office use only	For International Bureau use only		
This sheet was received with the international application	This sheet was received by the International Bureau on:		
Authorized officer	Authorized officer		

Form PCT/RO/134 (July 1992)

457

ATCC Deposit No.: PTA-252

CANADA

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

UNITED KINGDOM

458

ATCC Deposit No.: PTA-252

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later that at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

NETHERLANDS

			
Applicant's or agent's tile		International application No.	
Applicant's or agent's file	D440000T	I titterilational application (40.	LINIACCIONICO
	PA102PCT	1	UNASSIGNED
reference number		1	•

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page 91, line N/A					
B. IDENTIFICATIONOF DEPOSIT	Further deposits are identified on an additional sheet				
Name of depositary institution American Type Culture Colle	Name of depositary institution American Type Culture Collection				
Address of depositary institution (including postal code and count 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America	(יבי				
Date of deposit	Accession Number				
18 June 1999	PTA-253				
C. ADDITIONAL INDICATIONS (leave blank if not applicable	(e) This information is continued on an additional sheet				
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States) Europe In respect to those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28 (4) EPC).					
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)					
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")					
For receiving Office use only	For International Bureau use only				
This sheet was received with the international application	This sheet was received by the International Bureau on:				
Authorized officer	Authorized officer				

ATCC Deposit No.: PTA-253

CANADA

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

UNITED KINGDOM

ATCC Deposit No.: PTA-253

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later that at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

NETHERLANDS

		II	
Applicant's or agent's file	DA402DCT	International application No.	UNASSIGNED
reference number	PA102PCT	1	UNASSIGNED
10.0.0.0.00			

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

			 	
A.	A. The indications made below relate to the microorganism referred to in the description			
	on page	91	, line	N/A .
B.	IDENT	IFICATION OF DEPOSIT		Further deposits are identified on an additional sheet
Na	me of dep	ositary institution American	Type Culture Coll	ection
<u> </u>				
		depositary institution (including versity Boulevard	g postal code and cour	(içalırı)
		, Virginia 20110-2209		
Ur	nited Sta	ites of America		
Da	ite of depo	sit		Accession Number
		22 December 199	9	PTA-1081
C.	ADDIT	IONAL INDICATIONS (lea	ive blank if noi applicat	ole) This information is continued on an additional sheet
İ				
l				
D.	DESIG	NATED STATES FOR WH	ICH INDICATIO	NS ARE MADE (if the indications are not for all designated States)
Eu	rope			
in r	espect 1	o those designations in wh	nich a European F	Patent is sought a sample of the deposited
mic	roorgar	ism will be made available	until the publicat	ion of the mention of the grant of the European patent of withdrawn or is deemed to be withdrawn, only by
the	issue o	f such a sample to an expe	ert nominated by	the person requesting the sample (Rule 28 (4) EPC).
			·	
	E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)			
Th <i>Nui</i>	The indications listed below will be submitted to the International Bureau later (specify the general nance of the indications e.g., "Accession Number of Deposit")			
		For receiving Office use on	v —	For International Bureau use only
_	This sh	eet was received with the interna	*	This sheet was received by the International Bureau on:
	,		· ····································	
	ر د نام	<u> </u>		Authorized officer
Au	thorized o	Incer		Audorizedonicei

463

ATCC Deposit No.: PTA-1081

CANADA

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

UNITED KINGDOM

464

ATCC Deposit No.: PTA-1081

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later that at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

NETHERLANDS

What Is Claimed Is:

5

10

15

20

25

30

- 1. An isolated nucleic acid molecule comprising a polynucleotide having a nucleotide sequence at least 95% identical to a sequence selected from the group consisting of:
- (a) a polynucleotide fragment of SEQ ID NO:X or a polynucleotide fragment of the cDNA sequence included in the related cDNA clone, which is hybridizable to SEQ ID NO:X;
- (b) a polynucleotide encoding a polypeptide fragment of SEQ ID NO:Y or a polypeptide fragment encoded by the cDNA sequence included in the related cDNA clone, which is hybridizable to SEQ ID NO:X;
- (c) a polynucleotide encoding a polypeptide fragment of a polypeptide encoded by SEQ ID NO:X or a polypeptide fragment encoded by the cDNA sequence included in the related cDNA clone, which is hybridizable to SEQ ID NO:X;
- (d) a polynucleotide encoding a polypeptide domain of SEQ ID NO:Y or a polypeptide domain encoded by the cDNA sequence included in the related cDNA clone, which is hybridizable to SEQ ID NO:X;
- (e) a polynucleotide encoding a polypeptide epitope of SEQ ID NO:Y or a polypeptide epitope encoded by the cDNA sequence included in the related cDNA clone, which is hybridizable to SEQ ID NO:X;
- (f) a polynucleotide encoding a polypeptide of SEQ ID NO:Y or the cDNA sequence included in the related cDNA clone, which is hybridizable to SEQ ID NO:X, having biological activity;
 - (g) a polynucleotide which is a variant of SEQ ID NO:X;
 - (h) a polynucleotide which is an allelic variant of SEQ ID NO:X;
- (i) a polynucleotide which encodes a species homologue of the SEQ ID NO:Y;
- (j) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(i), wherein said polynucleotide does not hybridize under stringent conditions to a nucleic acid molecule having a nucleotide

PCT/US00/05883

sequence of only A residues or of only T residues.

2. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises a nucleotide sequence encoding a protein.

5

3. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises a nucleotide sequence encoding the sequence identified as SEQ ID NO:Y or the polypeptide encoded by the cDNA sequence included in the related cDNA clone, which is hybridizable to SEQ ID NO:X.

10

4. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises the entire nucleotide sequence of SEQ ID NO:X or the cDNA sequence included in the related cDNA clone, which is hybridizable to SEQ ID NO:X.

15

5. The isolated nucleic acid molecule of claim 2, wherein the nucleotide sequence comprises sequential nucleotide deletions from either the C-terminus or the N-terminus.

20

- 6. The isolated nucleic acid molecule of claim 3, wherein the nucleotide sequence comprises sequential nucleotide deletions from either the C-terminus or the N-terminus.
- 7. A recombinant vector comprising the isolated nucleic acid molecule of claim 1.
 - 8. A method of making a recombinant host cell comprising the isolated nucleic acid molecule of claim 1.
- A recombinant host cell produced by the method of claim 8.

- 10. The recombinant host cell of claim 9 comprising vector sequences.
- 11. An isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence selected from the group consisting of:
 - (a) a polypeptide fragment of SEQ ID NO:Y or of the sequence encoded by the cDNA included in the related cDNA clone;
 - (b) a polypeptide fragment of SEQ ID NO:Y or of the sequence encoded by the cDNA included in the related cDNA clone, having biological activity;
- (c) a polypeptide domain of SEQ ID NO:Y or of the sequence encoded by the cDNA included in the related cDNA clone;
 - (d) a polypeptide epitope of SEQ ID NO:Y or of the sequence encoded by the cDNA included in the related cDNA clone;
- (e) a full length protein of SEQ ID NO:Y or of the sequence encoded by the cDNA included in the related cDNA clone;
 - (f) a variant of SEQ ID NO:Y;
 - (g) an allelic variant of SEQ ID NO:Y; or
 - (h) a species homologue of the SEQ ID NO:Y.
- 20 12. The isolated polypeptide of claim 11, wherein the full length protein comprises sequential amino acid deletions from either the C-terminus or the N-terminus.
- 13. An isolated antibody that binds specifically to the isolated polypeptide of claim 11.
 - 14. A recombinant host cell that expresses the isolated polypeptide of claim 11.
- 30 15. A method of making an isolated polypeptide comprising:

WO 00/55351 PCT/US00/05883

468

(a) culturing the recombinant host cell of claim 14 under conditions such that said polypeptide is expressed; and

- (b) recovering said polypeptide.
- 5 16. The polypeptide produced by claim 15.
 - 17. A method for preventing, treating, or ameliorating a medical condition, comprising administering to a mammalian subject a therapeutically effective amount of the polypeptide of claim 11 or the polynucleotide of claim 1.

10

20

- 18. A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising:
- (a) determining the presence or absence of a mutation in the polynucleotide of claim 1; and
- (b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or absence of said mutation.
 - 19. A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising:
 - (a) determining the presence or amount of expression of the polypeptide of claim 11 in a biological sample; and
 - (b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or amount of expression of the polypeptide.
- 25 20. A method for identifying a binding partner to the polypeptide of claim 11 comprising:
 - (a) contacting the polypeptide of claim 11 with a binding partner; and
 - (b) determining whether the binding partner effects an activity of the polypeptide.

WO 00/55351 PCT/US00/05883

469

- 21. The gene corresponding to the cDNA sequence of SEQ ID NO:Y.
- 22. A method of identifying an activity in a biological assay, wherein the method comprises:
- 5 (a) expressing SEQ ID NO:X in a cell:
 - (b) isolating the supernatant;
 - (c) detecting an activity in a biological assay; and
 - (d) identifying the protein in the supernatant having the activity.
- The product produced by the method of claim 20.

```
SEQUENCE LISTING
<110> Craig Rosen,
      Steve Ruben
<120> Human Colon Cancer Associated Gene Sequences and Polypeptides
<130> PA102PCT
<140> Usassigned
<141> 2000-03-08
<150> 60/124,270
<151> 1999-03-12
<160> 1556
<170> PatentIn Ver. 2.0
<210> 1
<211> 633
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (206)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (606)
<223> n equals a,t,q, or c
<220>
<221> misc feature
<222> (616)
<223> n equals a,t,q, or c
<400> 1
gcaggatgag ctacaggaag aatcagaaat gtcagaaaaa aagtcatgct cctcttctcc 60
cacccaaagt gagatatcca catcgctgcc tccagataga caaaggagaa aaagggagct 120
tegeacettt teattttetg aegatgaaaa taaaceteet teaceaaagg aaataaggat 180
cgaagttgct gaaggcttca cctggnacag taaccccttg aagtggagtg tggcagacgt 240
tgtgcggttc atcagatcca ctgactgtgc ctccattagc aagaatattc ctwgaccagg 300
aaattgatgg gcaggccctg ttgctcctta cccttcccac tgttcaagaa tgcatggact 360
taaaattggg ccctgcatca aactttgcca tcacatagag aggrtcaagt ttgcttttta 420
tgagcagttt gccaactgag aaggacaacc aaagtgagct gggatctttg aaggcacaaa 480
tgcaggcaaa tccttcaccc tgctttatta agtgggagct gggaatagtc ctggggggct 540
tetgggggee ttgcagggta ttcagetttg etetettttg geaetttteg gggggaaggg 600
aggganttca cagttnaggg gaaggccaaa aac
                                                                   633
```

```
<210> 2
 <211> 295
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (147)
<223> n equals a,t,g, or c
<400> 2
ageggeacga geggeacgag aageeetaet eggatgggge aeggaetgte cacettttet 60
aatgtgtgtt gtcagcctgt gctgtggcat agacatggat gcaaggacca ctttggagac 120
tggggtggcc tcaagagcac acagagnaag ggaagaaggg gccatcacag gatgccagcc 180
cctgcctggg ttgggggcac tcagccacgg accagcccct tcctgggtat ttattctcta 240
tttattgggg gataggagaa gaggcattct rcctgggtgg gacaaacccc tttaa
<210> 3
<211> 442
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (378)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (422)
<223> n equals a,t,g, or c
<400> 3
aattoggoag agagagotgo toagttagga occagaggga accatggaaa coccagogoa 60
ttkctyttcc tcctgctact ctggctccca gatattaccg cagaaattgt gttgacgcat 120
ttccagacac cctgtctttg tctcctgggg aaagagccac cctctcctgc aggaccagtc 180
agagtgttgg cagcaacttc ttaacctggt atgaacaaaa atctggccag tytcccaggc 240
tectcatgtt tggtaactee egeagseeae tggcateeea gacagggtea gtggcagtgg 300
gtctgggaca gayttcacty tcaccatcag cagactggag gytgaagatt ttgcagtgta 360
ttwctgttca acaatwingg titcgttcaa caatgittca attitgggcc agggggccma 420
                                                                   442
gnttggaaty aaaggactgt gg
<210> 4
<211> 754
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (446)
```

```
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (662)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (700)
<223> n equals a,t,q, or c
<400> 4
ccaggawtct gggggttcct agacggagcc agayttcgga agggtgtcct gctactcctg 120
ctggggctcc tccaggacaa gggcacacaa ctggttccgt taagcccctc tytcgctcag 180
acgccatgga gctggatctg tctccacctc atcttagcag ctctccggaa gacctttgcc 240
cagcccctgg aacccctcct ggaactcccc ggccccctga tacccctctg cctgaggagg 300
taaagaggtc ccagcctctc ctcatcccaa ccaccggcag gaaacttcga gaggaggaga 360
ggcgtgccac ctccctccc tctatcccca accccttccc tgagctctgc agtcctccct 420
cacagagece catteteggg ggecenteca gtgcaagggg getgeteece gegaatgeca 480
gccgcccca tgtagtaaag gtgtacagtg aggatggggc ctgcagtctg tggaggtggc 540
agcaggtgcc acagytcgcc acgtgtgtga aatgctggtg cacgagctma sgcttgagcg 600
acgagacctg ggggtttgtg gagtgccacc ccaactagca tggagcgggt tttgaggacc 660
angatecetg ttgaagtgea gttgetggee etgggggagn tageegtteg ttteeggaaa 720
tttggcaagt aggattttta aggttccaaa ttct
                                                                754
<210> 5
<211> 393
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (273)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (274)
<223> n equals a,t,g, or c
<400> 5
ttttctcttt gatgttctgg ccctgacttc tgaaaccagt gttctgggga gaggcatttg 60
agagtgaccc agggcctggg aaccggggct tttctcggtg gtcttaggcc tgttctgcaa 120
ccaaggcaag gccaggattt ccggaaatat gaggaaggct ttgaccccta ctctatgttc 180
accecagage agateatggg gaaggatgte eggeteetae geateaagaa ggagggatee 240
ttagacctgg ccctggaagg cggtgtggac tcnnccattg ggaaggtggt cgtttctgct 300
gtgtatgagc ggggagctgc tgagcggcat ggtggcattg tgaaagggga cgagatcatg 360
                                                                393
gcaatcaacg gcaagattgt gacagattac acc
```

```
<210> 6
 <211> 539
 <212> DNA
 <213> Homo sapiens
 <220>
 <221> misc feature
 <222> (486)
 <223> n equals a,t,g, or c
 <400> 6
 gctcgtgccg ctgaaatgac ttccacggct gggacgggaa ccttccaccc acagctatgc 60
 ctctgattgg tgaatggtga aggtgcctgt ctaacttttc tgtaaaaaga accagctgcc 120
 tccaggcagc magccctcaa gcatcactta caggaccaga gggacaagac atgactgtga 180
 tgaggagctg ctttcgccaa tttaacacca agaagaattg aggctgcttg ggaggaaggc 240
caggaggaac acgagactga gagatgaatt ttcaacagag gctgcaaagc tgtggacttt 300
agccagaccc ttctgccctc ctttgctggc gacacttctt caaatgcaga tggttgtgct 360
cccttgcctg ggttttaccc tgcttctytg gagccaggta tcaggggccc agggccaaga 420
attccacttt gggccctgcc aagtgaaggg ggttgttccc cagaaamtkt gggaagsctt 480
ctgggntgtg aaagacayta tgcaagytca ggwtaacatc asgrgtsccc ggttgttgc 539
<210> 7
<211> 804
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (758)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (759)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (771)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (802)
<223> n equals a,t,g, or c
<400> 7
aattoggcac gagttcaaca ccaagtgtoo ototggcagt tgtgtgatga atcagtatot 60
gagttcaaaa ttcccaaagg atttcagtac atcttgccgt gcacattttg aaagatacct 120
tttatctcag aaaccaaagt gcctgctgca agcacctatt cctacaaata taatgacaac 180
accagtgtgt gggaaccacc ttctagaagt gggagaagac tgtgattgtg gctctcctaa 240
```

<220>

```
ggagtgtacc aatctctgct gtgaagccct aacgtgtaaa ctgaagcctg gaactgattg 300
cggaggagat gctccaaacc ataccacaga gtgaatccaa aagtctgctt cactgagatg 360
ctaccttgcc aggacaagaa ccaagaacty taactgtccc aggaatcttg tgaattttca 420
cccataatgg tctttcactt gtcattctac tttctatatt gttatcagtc caggaaacag 480
gtaaacagat gtaattagag acattggctc tttgtttagg cctaatcttt ctttttactt 540
ttttttttt ttttaaagat catgaatttg tgacttagtt ctgcccyttg 600
gagaacaaaa gaaagcagto ttocatcaaa toacottaaa atgcacggot aaactattoa 660
gagttaacac tecagaattg ttaaattaca agtaetatge tttaatgett ettteatett 720
actagtaagg cctattaaaa aaaataatac cacttganng gtgaaggctt ngcaatagga 780
agaagataga atccaggttt angg
<210> 8
<211> 720
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (714)
<223> n equals a,t,g, or c
<400> 8
gtgaggacag cctgccagag tctggtctct ggacactatg ggcacacgac tcctcccage 60
tetgtttett gteeteetgg tattgggatt tgeeceaegg geteteetga cacactetee 120
ccctgcagag gtccagggga cccaacagcc ccagcaagat gagatgccta gcccgacctt 180
cctcacccag gtgaaggaat ctctctccag ttactgggag tcagcaaaga cagccgccca 240
gaacctgtac gagaagacat acctgcccgc tgtagatgag aaactcaggg acttgtacag 300
caaaagcaca gcagccatga gcacttacac aggcattttt actgaccaag ttctttctgt 360
gctgaaggga gaggagtaac agccagaccc cccatcagtg gacaagggga gagtccccta 420
ctcccctgat cccccaggtt cagactgagc tcccccttcc cagtagctct tgcatcctcc 480
toccaactet ageetgaatt etttteaata aaaaatacaa tteaagttge tteteatgga 540
tggcactgct tttctgagga ctcaaggtgc caagatggag gggctgactc agtccagcca 600
acatttaatg agcacctact ttatgtatgg agctctaacc catgggtcca tgggaataaa 660
gcagtgaata gtaacaataa ataattgtaa cagcaaaaaa aaaaaaaaa aaanaaaaaa 720
<210> 9
<211> 540
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (463)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (524)
<223> n equals a,t,g, or c
```

```
<221> misc feature
<222> (535)
<223> n equals a,t,q, or c
<400> 9
ccaacagaga tgtatccaga gatccacagt tctggaggct gagaagtcta aaatcaaggc 60
accagcagat tecacatete gtgaaggete actetetget teacagatgg cactgtettg 120
ctgtgttctc acatggcaga aggggcaaac aagcccccct gggcctcttt tataaaggca 180
ctaactctat gcctaaaggc agggccctca tgactctatc acctaccaaa aggctccact 240
tctttatact attggagggg tagaaggaac ttcctttcta gaccttgaag gtttaagaat 300
ttgaatctat aaaacaagct gacaatagac agattaacag gagaaaaagc atatacattt 360
tttaatgtgg gccagatggc agaagcttaa ataacacccc aagctacagg gaagtgaggc 420
ctctgatggg ggaggtagtt gacacaggct gtggggaggg gtnaggggga ggaatctgtg 480
gtggagcaaa tttgccttat tacactgata aatggtaatt tacnctaatt aagcntgggt 540
<210> 10
<211> 561
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (406)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (450)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (546)
<223> n equals a,t,g, or c
<400> 10
agaatgtcac tgagtggcct gaaccaaagc tcatggatac tggagatgaa gaaccagcag 60
gagaccccag gtgtgctctc atccgtactc tgtgacaccc cttagtggac tgttccaacc 120
agttgggccc gggagaagga ctagggaagc ttccttccca tctgcacctc ccagcctgga 180
gaggagcctg tgacttgccc tgttccttgg ctcctcaggc tggggtaagg tgtgggggtg 240
gctccagcct tgaggccagt ctcctgatgc tggattcctt gttttccctg caggcatcaa 300
acagaaaggc cttttgctaa gtagcagcct gatgcactcc gagtcagagc tggacagcga 360
tgatgccatc tttacatggc cagaccgaga gaagggcaaa ctcctngcat ggtcagaatg 420
gctctgtacc caacgggcag accectctgn aaggccagga gcccgcggga rgagatectg 480
tagccacctg gtctgtctyc tcagggcarg gccaggcaca attgcccggc cagttcttct 540
                                                                   561
aacttnccga gttttgcggg g
<210> 11
<211> 393
<212> DNA
<213> Homo sapiens
```

<220>

```
<221> misc feature
<222> (346)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (381)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (383)
<223> n equals a,t,g, or c
<400> 11
tegacceacg cgteegggtg agtgeeatet taaaacttac tggagattgg ttttatattt 60
agatttatat aactggttat gtgaatatat ttaaatactg gggaaattgc ttcactgtct 120
tagaaccaag caagattcac ctgtgttttg tgttcatgtt catttgcctc ttaaaggcaa 180
gggttgaaga taaataaggt agcaatgtct atagttttgg ccttaactat gccaatctaa 240
ttataattcc ctgtatttaa aatggtttct tttacttatt gaaaggcatt ttagtgtggt 300
ktatgtgtaa tattaaagat tattcaacac ctctcaraaa aaaaanraaa aaggggggcc 360
cccctgggg gtcccaagct nancgtacgc ggg
<210> 12
<211> 322
<212> DNA
<213> Homo sapiens
<400> 12
taagaataca aaattagcca agcatgctgg cacatgcctg taatcccagc tactcgggag 60
gctgaggtac gagaatcgct tgaacctggg aggcagagga tgcagtgagc cgggatcacg 120
ccattgcact ccagcctggg ggacaagagt gaatctgtgt ctcaccaaaa aaaaaaagaa 180
aaagaaagat gottaacaaa ggttaccata agccacaaat toatraccac ttatcottoo 240
aaaaaaaaa ag
                                                              322
<210> 13
<211> 1907
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (1834)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (1843)
```

```
<223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (1888)
 <223> n equals a,t,g, or c
 <400> 13
 gagaaataat aatatagctt tatagaattt tccatcttgt attaaaataa tcacatgtac 60
 atcattgtaa ctcagtccat aacataagat tttgtacaac aatttctttt tgtgtgctgg 120
 catcattaag gtttagtctg cccagatcac ctattagtac ctaatttata tattctgaat 180
 taaaattatc tgttaattta aaaacatttt atctattgtc tttcaaaata gtattaactg 240
agggtttttt tgtgtgtgtt tttctatttt gcttggcttt ttgaacatta ctggactctc 300
gttttagaag gaaaaacctt tcagctctac tctcacaatc ttatagcttt gtttgaacat 360
gccaaaaaac caggattagc tgcccatatt caaactcaca ggtttccaga ccgaatacta 420
ccaagaaaat tegetttaac aacaaagatt eetgatacaa aaggetgeea caaatgttge 480
atagtcagaa accettacae gggacataaa tacetetgtg gagetttaca gtetggaatt 540
gttttacttc agtggtatga gccaatgcag aaattcatgt tgataaagca ctttgatttt 600
cctttgccaa gtcctttgaa tgtttttgaa atgctggtga tacctgaaca ggaataccct 660
atcaatttga actctgcatc ttcatggttt acagaaattg gtgcaggcag ccagcagtta 780
gattccattc atgtaacaca gttggagaga gataccgttt tagtgtgttt agacaaattt 840
gtgaaaattg taaatctaca aggaaaatta aaatcaagta agaaactggc ctctgagtta 900
agttttgatt ttcgcattga atctgtagta tgccttcaag acagtgtgtt ggctttctgg 960
aaacatggga tgcagggtaa aagcttcaag tcagatgagg ttacccagga gatttcagat 1020
gaaacaagag ttttccgctt attaggatca gacagggttg tcgttttgga aagtaggcca 1080
acagaaaatc ctactgcaca cagcaatctc tacatcttgg ctggacatga aaatagttac 1140
taagcaacag aaactgatct caaatgacag gaaaatgaat atactccatt gaaaggaaaa 1200
ataaggaaat tcaatacaaa ctgcactatg atttgcttta actattatgg gttatattgc 1260
aaatgatotg tactttaggg tagaattcaa tattttotgo agotggaaac agotagtota 1320
totottgoca otgtgtggtg gttatatoaa gtttgottaa taaaagotat gagacaaata 1380
gtcctctagt tccaggaaac acagtctttt tttaaaaaaa acaatgtttg taacaagggt 1440
gccatggtat ttttagataa ctcgtgatta tcttaagaga ggtaaattta gtgatcattt 1500
tatatcatgt cttattcctt cttaatgaac ataatttgtt aaattctcaa gcaaggtttt 1560
cacttttata ttggccattc tgtatgtttt tgtaaaacag aatatttaat ccttatttat 1620
taatctcttg ctggagtggt gtaatgtatc taacttttag caaaggaggg ttgcagagca 1680
gcttaaattt tttttataat gtataagaat tttgtttatc ttttaagagt agtaaagtac 1740
tttgagtgtt tgggggtcaa cacacacatg caatttgctt aacaaaagta ttttataata 1800
cagttcatac agaataccyt aaaagggagc ytangtttcc acnacagata agtggtaagg 1860
gtcataccgg agataatgat gatagtgnaa tatcctagaa gggggtg
                                                                 1907
<210> 14
<211> 1140
<212> DNA
<213> Homo sapiens
<400> 14
agaataaatt ccagggette agtetgeett tggttegeaa gtttgeecae tegattetge 60
agtgcttgga tgctttgcac aaaaacagaa taattcactg tgaccttaag cccgagaaca 120
ttttgttaaa gcagcagggt agaagcggta ttaaagtaat tgattttggc tccagttgtt 180
acgagcatca gcgtgtctac acgtacatcc agtcgcgttt ttaccgggct ccagaagtga 240
```

<210> 15 <211> 2008

<212> DNA

<213> Homo sapiens

<400> 15

gccaggagac cctgaaacat gaaaccaaac aggctttgat atttttttt ttttaattac 60 tttccccttt tgcttgattc ttcttccttg gtatcatatt caaaggagga aagaatggat 120 gacacttagg gacaggtcac taagcagaat aggtattagt tggtttttta ttatttttaa 180 atttatatag ctctcatgta ttgaaggtgc tactttaaaa actgtgttaa tgtacttgca 240 aatctcctgc tggctcatga aacagcagaa ttccagccaa ggcaaattca gttggatcta 300 gggcttgaaa actgcccaag attaaagagc taagatgaaa tagtttgaat aaactggtaa 360 aataacaatt catactatct ctacatattt ttaggatatg aattttttt tcctgctggg 420 tagattgtcc agtgacttat ggcatgaatt tcttttcatg ctaccttcaa tcttcaacta 480 aagatttcta aaaggggtaa gaaatgaggc agtagtttat taaatacata gaagtacaca 540 gctattatat gctgtggctt tgagaagtta acttttgtgg aatatgaaac caaaggaaga 600 atttccatgt agataaatta agaataggga aaaacatcta cctaaaagat ggttgtccct 660 aaaaaactgg aaacatctga aatgctctat ttatgttatt attcctggga gcttatagcc 720 cattattttt acttttttt tttaattcag aagactagaa cagaacttaa attttacaaa 780 cttttgatca taatgetttt geccatactg tetegteett agecceagtg acatgtgetg 840 atcctcctgc ctttagttct aaatggttct gaatagcttt aaaagatgaa taagaaaaaa 900 gatcaagete ttttgagget agagggetea tatggagate taaaaecete catgtteatt 960 tccagacttg gtcaggcaca tacatagtaa attataatca atcatgggaa ttacataagg 1020 ataatgaggc ccaactgaaa ccaagtttca gtctgcctta cctttacccg tccttgagaa 1080 cagcggtcca ggagaatcag gcagtctgtg gcctcctgta gcagggcgct cttaacagac 1140 tcaggtgtaa ggtttggatc ccttgctaca tcacaaatca gtttcaagag ggccttcagt 1200 aagaccacaa gtctgcagga aactctggaa tcaggaagaa aagctatgtt catactctaa 1260 atctggatat taaaattgga agagacttca aagactgtca agtggaaagc tatcatttcc 1320 taaattaagg aacttaggtc aaagttaaat gaaaaagacc taaaaacaga accaaagaca 1380 gcctctagat ttcttaccct caagtctcct gttagcatac tgcctataca cacagacaca 1440 ccctctgcca cactgctctc ttccttccag aagcttggtt ctactgtaag caacagctcc 1500 ttcatgggct gagaagggga aaccaggatc tccccaacca agggcctata cttttatttt 1560 tcaactctat taactgaact atgcttggag agagccctga atcctttaac tttaatgcca 1620 tcttaggcct ggaagttaga gtgagggaaa tgagcttggc ttctgggact gtgtcaagtt 1680 gaattttctg tcatttaatt tcagatccta gctcatcatc agtgaagtcc agcctactta 1740

PCT/US00/05883 WO 00/55351 10

```
cttgtaacta ttaacctttc taaaagtttt catcgccttg gtaaagctcc agaaatggac 1800
 aatgctagtg actgcacaat attgtgactg tacttaatgc cactgaactg tacactttaa 1860
 aatggaaaat ttatatgtat ttttaccaca ataaacaaaa aaccctaaaa aaactttaat 1920
 gaaaggtgga aaataattta acttayaatg tgaaaataca atgtgaaatg tacaataaat 1980
 catatttatg gcaaaaaaaa aaaaaatt
                                                               2008
 <210> 16
 <211> 371
 <212> DNA
 <213> Homo sapiens
 <220>
 <221> misc feature
 <222> (350)
\cdot <223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (360)
<223> n equals a,t,g, or c
<400> 16
agagagetag agggaetagg agataatgtg tatgtaggtt tatgtgatgg gatateacee 60
tgaagagttg tgtcttttgt ggccagtgac aaatccagga aatgaatgtt gctgataggg 120
ataaatettg aggetgaggg egggtggtae agatgtgtat gggaaaceee aaceeetata 180
tattgtaaat agatgggctg ggctaaacat tgttgccgtt tcatacttct accaactcag 240
cccccccc c
                                                              371
<210> 17
<211> 763
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (6)
<223> n equals a,t,g, or c
<400> 17
aaaaanaaaa aaaaaaaaaa aaacggaaat aaagtttaaa aaatcaatca acatggcctt 60
taattttaac aattttaaca gcaagtggtg gggggagttc tcagatgagc aactggagct 120
ggaagcactt ctgtggtcaa gcaggcagcc catggggttg catcttcctg ttgggggatc 180
atccattttc ttcaatgaat agttttaagt cttgtcaaat gctcacacag aggcccgcta 240
ttaaggaggc agacaggcaa cattcaatac gaaggcagga caagctcagc cccgctcctt 300
cattegggca tgtgtcatta gggatgacat tetetgaagg etgeeegget tgaatggeea 360
aatccctgca tcatggcttt ctttaattcc ctctgctccc aactcacaaa atgaggacct 420
ctcttttaag acgaraaagg cactgttcct caaaggtata catttggaac ttcaataatg 480
aaagcatctc ttgcttggca ggtggaatat aggcaatttt ggatttttaa tgcatggcat 540
9999cgggag tgaaatatct tgccagggct tgtttgccct ataatgggag agaaccaggc 600
```

ctctggatga tacggtatca aacactgctg ctcctttctg ttttcttttg tgggaaaggg 660 aggaggatag aatggagagg aattagtggg agcctggggg aagttcaaaa taaagaaact 720 gtgaaatcct ccacctcaaa gttgggtctg caccaggatt ctg <210> 18 <211> 1926 <212> DNA <213> Homo sapiens <220> <221> misc feature <222> (898) <223> n equals a,t,g, or c <220> <221> misc feature <222> (1024) <223> n equals a,t,g, or c<220> <221> misc feature <222> (1083) <223> n equals a,t,g, or c <400> 18 aataacttga ctggaattct agaaaccgct gtcagagcca ccaacgcaca gtttgacagt 60 cctgagatcc tgcgaaggct ggacgtgcgg ctgctggagg tctctccagg tgacactgga 120 tgggatgtct tcagcctcga ttatcatgtt gacggaccaa ttgcaactgt gtttactcga 180 gaatgtatga gccactacct aagagtattt aacttcctct ggagggcgac ggatggaata 240 catecteact gacataegga agggacaeat gtgcaatgca aageteetga gaaacatgce 300 agagttetee ggggtgetge accagtgtea cattttggee tetgagatgg tecattteat 360 tcatcagatg cagtattaca tcacatttga ggtgcttgaa tgttcttggg atgagctttg 420 gaacaaagtc cagcaggccc aggatttgga tcacatcatt gctgcacacg aggtgttctt 480 agacaccatc atctcccgct gcctgctgga cagtgactcc agggcacttt taaatcaact 540 tagagetgtg tttgateaaa ttattgaact teagaatget caagatgeaa tatacagage 600 tgctctggaa gaattgcaga gacgattaca gtttgaagag aaaaagaaac agcgtgaaat 660 tgagggccag tggggagtga cggcagcaga ggaagaggag gaaaataaga ggattggaga 720 atttaaagaa totataccaa aaatgtgoto acagttgoga atattgacco atttotacca 780 gggtatcgtg cagcagtttt tggtgttact gacgaccagc tctgacgaga gtcttcggtt 840 tottagette aggetggaet teaacgagea ttacaaagee agggageeea ggeteegntg 900 tgtctctggg taccaggggg cggcgcattc ccacacgtga arctcgcggt cctcccargg 960 agctgcgggt gatgttcgtt gcactgctag acacgaaatt cccattgacg tcctgcagga 1020 actnatkret geaggtgtee tgeeetteeg eecaegagtg egeeatgttt eageggagge 1080 cgntgtggga gaagccacgt cgtgtttcam atgtcggagt cgaatgcatt tktaaatccc 1140 taagtcaagt aggctggctg cactgttcac atttgtctct aaaagtcttc atcgctaaaa 1200 gataccataa titgcigagg citcitaagc titciatgtt ataatitata titgicacti 1260 🗀 taaaaaatcc atttctttta gaaaaaatta gggtgatagg atattcatta gttaagatgg 1320 taacgtcatt gctatttttt taacatcctc tttagaggta atttttgtta acataaccaa 1380 aaattaaatt gaaacaaaat gtcccaacta agaaaatata tagagcattt tatttttttt 1440 tagtgttgta aaatattaac ctctgtgaga tcctttgtat cttaatgcat tacctttaca 1500 catatttatt cttattttct ctcctttcag agtttacatt tttatattta atttactatt 1560

WO 00/55351 PCT/US00/05883 12

```
tcagattttt aaaatagtat agaaaaaagt aggagtgata gagaacaaaa atactcttat 1620
acagtgcaac ccaaataccg cgaatgcatc agctaaagca gcgtgtaaat aggagtgacg 1680
agaaagttaa tggagtattt tattttcaaa gttcctgata agcattggaa agaaatcgac 1740
atggataatg aagatttcct ttttccttgc ctatttttc attgtaaata tttatatact 1800
actgmccaag atgttggggt ggggggatt gttttttgta aaaatgtcat tatcaggtca 1860
cataaatctg cctttatgtt gcataagtga aaatttagaa aattaaaagc aattatcttt 1920
magaaa
                                                                   1926
<210> 19
<211> 2301
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (190)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (2052)
<223> n equals a,t,g, or c
<400> 19
tettateaca tetaageett accaggtaga gaaggtaeta aatacaettt agaagtaaaa 60
atatgaagta ccgagaggct aaacccactg gcctaagatc tcaccaaagt tcatgaaaac 120
caggactagg acccacgget eccaaageee gttettgetg tgttgtgetg cetecatate 180
cgtcagaagn agcctttcca gaatgattct gggcatatac taagaagagc aggtatggaa 240
agatctattg tcagggaatc ttagaattcc ctacacgagt gggagaaaga tgtccaaatt 300
ccttacgcat ggtattcatg atggtgccct atctaagtcc aggactgttt tcctacagcg 360
tgcctcaaaa gtgttgtaga gggcaggatt ctacattcac agcctgttcc atctacgaga 420
ttttccagat gctacttgtg gtagacattc ctaactcatg gtacttagcc accagagatc 480
atgatggaat gagtgggtgg cttttctacc tgccattccc tcagaattca tgargggtgg 540
gggacagggg gaccggaatt gtcttagcac cccaatgtta tgacaaaact atgctacttt 600
agaaacgcag tctgtttttc accaattgac atactactga tctgaagtaa ccagtgccat 660
cataagaaat tactgcatta agaaaatcct tgctgtgccc tttgaaaaagc tgttcagaaa 720
tcatttacag tgatctttca tctcggtcgc tgtagtgaac attttagtgt gataaatttc 780
aaaattctaa acaaattacc cacttttata ttggaaatct ctaccagaac tccctcttca 840
tttttwaagg catacatttg cttgttttca agatcaagaa ttctgagcta gctttaagta 900
gcaaactgat ttatatgtgc aattatagga tgcattaaga tgaatgatag cctttacata 960
ttgaaaactt tgcagacgtt ttgttttgaa aatggcattg tatagtaaat gcaaattaat 1020
tttgtaaaat tatgttaaag agtatgttca gacactttct gccatggcca aaaagtatgt 1080
atgaaagtat gtgtgtattt gtttgtaaaa ggatgccaat gttttacctg atatcttagt 1140
gacacttcag ttatctatgc attctttaga tctgtgattc ggtaaacagg cagccatgtt 1200
cacgatgcct tctatgtctt accatatttt taattaacct gttaaataca gcttaaaata 1260
tttttatttt atttattcta tttttactga aatatactgc attattgtgt taatgtatta 1320
tettteetgg atattatete ceagtgtate eagatetaag taateteagt gaactataea 1380
ttgcctaaaa agtggttttg taatgatttg tagtcacatt tctattggga tatgtagaag 1440
aaaaggcaaa atgcttaaag ttccttttat tttttaaaag cagctagata gacacagact 1500
tgccacctca tacatctgct ccttggcaac atcaagggga acgactagcc aacatgccta 1560
tggctaaaaa ctttcctttg cagactaaag cactgcttgg tgcttcgttt ttctaccctt 1620
```

```
cacaacatgt gtgatttcat ctaagagata tatacatgta cacatgccct ttgtttccac 1680
 ctggatacaa gatcactcat agctaattag gaccattgtt ttttgttcat ctgtcttgtt 1740
 gcatgaaggg acattagacc catttccatt aaaataagtt cttggtgata aactgtggca 1800
 ctgctacttc tttttaaatc cactttatga tttcaagatg gacacttgta agatgactcg 1860
 acacaaggcc attgcctgga agccccagag ctttcctctg tttgtatggc ccgttcatgt 1920
 cccaggcatt gcaacacaaa ctcaagattt caccacaaca tgacaagcat tttcctaact 1980
 gatattagca caatttaact aataagcccc ttcgctctct agttggccag gcttaaccta 2040
 atacacatet anactgtgtg ceacaeggee agtagaaagt ttaaetteag etteagggea 2100
 aagataccca ctcacaccgt gtcaacgcaa gcagtagttc ctggcctcca gagcagctta 2160
 cttcccctga aagaacgctt tgttttcctt tatgcccttt tcctgttgac cacttttaca 2220
 gcggccgctc gcgatctaga a
                                                                 2301
 <210> 20
<211> 538
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (507)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (514)
<223> n equals a,t,g, or c
<400> 20
agaggccgcc aacatgatcc tggtggatga tgacttctca gccatcatga atgcagtgga 60
ggaaggcaag ggtatttttt acaacatcaa aaactttgtc cgattccagc tgagcacgag 120
catctccgcc ctgagtetca tcactctgtc caccgtgttc aacctgccca gcccctcaa 180
cgccatgcag atcctatgga tcaacatcat catggatggg ccaccgggca gaggtgaggc 240
agggcggctg ggagccctgt gtctctttac ctacctgcgg ggcttcctcc aggggctgct 300
ggctgtgccc aaggctatag ggatgaacaa atacagccac tttccatcag gagttcccag 360
aaaactgaag tgtgttgcac tggagtgaga ctgggagtag aaggcagagg agaaagtacc 420
tgggccggca gagctgggtg aggatggaac tttctgcttc ctctggctgg atgctctctc 480
tgggcaaacc tgcatgggtt aattctnatg cttnaatttc aagtcaccca gtcactgg
<210> 21
<211> 1403
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (1370)
<223> n equals a,t,g, or c
<220>
<221> misc feature
```

```
<222> (1386)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (1393)
 <223> n equals a,t,g, or c
<400> 21
ggcacgagtg gccacatttc cagtacccag tagtcatctg tgccaggggg ttatccaggt 60
acagaacatt cccatcgttg cagaaggttc tatcagctag cactgggttg gacgacactt 120
gccaagacga gctggctaga ggatrgttct ccggacctgg tcccacgtgg ttcccagctg 180
gctggaggcg tgatcctggg tgtggccctg tggctccgcc atgacccgca gaccaccaac 240
ctcctgtatc tggagctggg agacaagccc gcgcccaaca ccttctatgt aggcatctac 300
atcctcatcg ctgtgggcgc tgtcatgatg ttcgttggct tcctgggctg ctacggggcc 360
atccaggaat cccagtgcct gctggggacg ttcttcacct gcctggtcat cctgtttgcc 420
tgtgaggtgg ccgccggcat ctggggcttt gtcaacaagg accagatcgc caaggatgtg 480
aagcagttet atgaccagge cetacageag geegtggtgg atgatgaege caacaaegee 540
aaggctgtgg tgaagacctt ccacgagacg cttgactgct gtggctccag cacactgact 600
gctttgacca cctcagtgct caagaacaat ttgtgtccct cgggcagcaa catcatcagc 660
aacetettea aggaggaetg ceaceagaag ategatgaee tetteteegg gaagetgtae 720
ctcatcggca ttgctgccat cgtggtcgct gtgatcatga tcttcgagat gatcctgagc 780
atggtgctgt gctgtggcat ccggaacagc tccgtgtact gaggccccgc agctctggcc 840
acagggacet etgeagtgee ceetaagtga eeeggacaet teegaggggg ceateacege 900
ctgtgtatat aacgtttccg gtattactct gctacacgta gcctttttac ttttggggtt 960
ttgtttttgt tctgaacttt cctgttacct tttcagggct gacgtcacat gtaggtggcg 1020
tgtatgagtg gagacgggcc tgggtcttgg ggactggagg gcaggggtcc ttctgccctg 1080
gggtcccagg gtgctctgcc tgctcagcca ggcctctcct gggagccact cgcccagaga 1140
ctcagcttgg ccaacttggg gggctgtgtc cacccagccc gcccgtcctg tgggctgcac 1200
ageteacett gtteceteet geeceggtte gagageegag tetgtgggea etetetgeet 1260
teatgeacet greettreta acaegregee treaactgta areacaacat cetacteegt 1320
catttaataa agaaggaaca tcaggcatqc taaaaaaaaa aaaaaaaaan ksgggggggg 1380
gcccgntacc canttggccc aat
                                                                   1403
<210> 22
<211> 478
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (474)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (475)
<223> n equals a,t,g, or c
<220>
<221> misc feature
```

WO 00/55351 PCT/US00/05883

```
<222> (476)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (478)
<223> n equals a,t,g, or c
<400> 22
gagcagaaag tagatgctta atggcagtgt tctctgaccc agacatgaat cagaatcacc 60
tggaagggct tgttaataca aattgctagg ccacaaccct aaagtttctg attcagggta 120
gggcaaggcg aggcttaaac ttcaggccag gggccacttt aagaattgct atatggccag 180
ggccgggcgc ggtggctcac gcctgtaatc ccagcacttt gggaggccga ggtgggcgga 240
teacaaggte aggagatega gaccateetg getaacaegg tgaaaceetg tetgtagtaa 300
aaatacaaaa aaattagcca ggcatggtgg tgggtgcctg tagtcccagc tacttgggag 360
gctgaggcag gagaatggtg tgaacccagg aggtggagct tgcagtgagc cgagatcgtg 420
ccactgcact ccagcctggg caacagagcg agacttccgt ctcaaaaaaa aaannncn
<210> 23
<211> 1252
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (1227)
<223> n equals a,t,g, or c
<400> 23
tttcgagctc tgcaccgagg agctgccctg gacttgagtc ccttgcatcg gagtccccat 60
ccctcccgcc aagccatatt ctgttggatg agcttcagtg cctaccagac agcctttatc 120
tgccttgggc tcctggtgca gcagatcatc ttcttcctgg gaaccacggc cctggccttc 180
ctggtgctca tgcctgtgct ccatggcagg aacctcctgc tcttccgttc cctggagtcc 240
tegtggeect tetggetgae tttggeectg getgtgatee tgeagaacat ggeageecat 300
tgggtcttcc tggagactca tgatggacac ccacagctga ccaaccggcg agtgctctat 360
gcagccacct ttcttctctt cccctcaat gtgctggtgg gtgccatggt ggccacctgg 420
cgagtgctcc tctctgccct ctacaacgcc atccaccttg gccagatgga cctcagcctg 480
ctgccaccga gagccgcact ctcgaccccg gctactacac gtaccgaaac ttcttgaaga 540
ttgaagtcag ccagtcgcat ccagccatga cagccttctg ctccctgctc ctgcaagcgc 600
agageeteet acceaggace atggeageee eccaggacag ceteagacea ggggaggaag 660
acgaagggat gcagctgcta cagacaaagg rctccatggc caagggagct aggcccgggg 720
ccageegegg cagggetege tggggtetgg cctacaeget getgeacaae ccaaecetge 780
aggtetteeg caagaeggee etgttgggtg ceaatggtge ceagecetga gggeagggaa 840
ggtcaaccca cctgcccatc tgtgctgagg catgttcctg cctaccatcc tcctccctcc 900
coggetetee teccageate acaccageea tgeagecage aggteeteeg gateacygtg 960
gttkggtgga ggtctgtctg cactgggagc ctcargargg ctctgctcca cccacttggc 1020
tatgggagag ccagcagggg ttctggagaa aaaaactggt gggttagggc cttggtccag 1080
gagecagttg agecagggea gecacateca ggegtetece taccetgget etgecateag 1140
ccttgaaagg gcctcgaata aaccttctct tggaaccact ccaagcccag ctccactcag 1200
ccttggcctt cacgcttgtg gaaacancca aggcattcct ccaccctca ag
```

WO 00/55351 PCT/US00/05883

```
<210> 24
<211> 1074
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (928)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (934)
<223> n equals a,t,g, or c
<220> · ·
<221> misc feature
<222> (1028)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (1031)
<223> n equals a,t,g, or c
<400> 24
gctggccttt gctctgcgga ctggcggccc cctggcacag aggtgacatc tcaagggccc 60
aggcagccct cttctagtgg tgccaagagg cggaggctgc gggctgccct tggtccccag 120
cccactcgct cagccctgag gtttccctct gcttccccag ggagcttgaa ggccaagcag 180
tocatggcgg gaatccstgg tagggagagt aatgccccat ctgtgcccac tgtctccctg 240
ctgccggggg cgcctggagg caatgccagc tccaggacag aggctcaggt gcccaacggg 300
caaggcagee cagggggetg tgtetgttea agteaggett eeeeggeeee tegegeagea 360
gegeeteeae gggeageeeg gggeeecace ceaegeactg aagaggeege etgggetgee 420
atggecetga cetteetget ggtgetgete accetggeea egetetgeae acggytgeae 480
agaaacttcc gacgeggga gageatytac tgggggeeca cageggacag ccaggacaca 540
gtggctgctg tgctgaagcg gaggctgctg cagccctcgc gccgggtcaa gcgctcgcgc 600
cggagacccc tectecegee caegeeggae ageggeeegg aaggegagag eteggagtga 660
cggcctggga cctgccactg tggcgtgcgg ctcctccccg cgccgcgagg ccgcgacctc 720
tgccacgtgg accgcgcgc gggcgctccc tggtggcgat ggcgcgcac tggccgagca 780
ctgcgggggc tttcctcctt gttggttgct gagtgggcgg ccaaggggag aaaaggagcc 840
gcttctgcct cccttgccaa aactccgttt ctaattaaat tatttttagt agaaaaaaaa 900
aaaaaaaaa aaaaaggcgg ccgtttanag gatncctcga aggggcccaa gttaacgcgt 960
gcatgcgaag tcataactct ctccctataa tgatcgtatt ataagtaagc actggccgtc 1020
gtttttanaa ngtcgtgaat ggggaaattt gctaactttg ggaacttttt gaaa
<210> 25
<211> 1186
<212> DNA
<213> Homo sapiens
<400> 25
```

```
tatcagetca agecttacae cayeeacete ateaaggace tecaettttt cettegagtg 60
ctcatccaac tgtaccaccg tatccctcac aagctacaca tcataccact ttgggaccgg 120
gaccccagca ccagcettet ggaacaggge cacattgtee attacetgte acaggteete 180
atctccagcc ccaaggacca aacagtattc caacacctac tgcttcaggg ttctgtcctc 240
atcctggctc tgtggccctg ccacatgggg ttcaaggacc tcagcaggca tctccagtgc 300
ctggacagat tccaattcac agagcacagg tgccaccaac atttcaaaac aattaccatg 360
ggtcagggtg gcattaaaat ggactccaaa aacatttttt taaatgttct gtaagataaa 420
ctgtatattt catatgtacc tgttaaggta ctttttaaag cttgtacatg aacctttgta 480
taaaaaacac cagtgctctt tcgttgtatt tttctcattt ttgcttttta aaattccttt 540
aaaaaatgtg ctgttaagcc agtattaggt atctttattt tgtaagtgaa cattccagct 600
gtttttttct ggcagatctg atgctgattt gatgctgtat gatctttttt tttttttag 660
ttaaattcat ttagtgaatg ttctattatt ttatacatac acattaagta ctcagctaag 720
taatggcact atgaggattt tttttttctt tcctgtcagc agcagttctg tgaatgcatc 780
ttaggtataa aaatgcaata cagattttta tattttggtg tggacatggc tcattttgtt 840
ttaccagtta tttgcaagca aaatgtaatt taatgtatag atgatttcta atgtctcctg 900
acaaactgta aatactgcat ttcttttgcg tatataattg cttacagctt ttctcatttg 960
atatatagca ttgtacatat gacaagtett ttgcaaaaet gtgtgatett tgtgaaagta 1020
gtacagtata tgacctttaa tttcttttt attttaaata tactgtcaca ctgaagcact 1080
ggttgggcat tttaattcat gttaataaat cacaattatg tcagttccca cgcgtccgcg 1140
gacgcgtggg cggacgcgtg ggcggacgcg tgggcggacg cgtggg
                                                                   1186
<210> 26
<211> 888
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (670)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (675)
<223> n equals a,t,g, or c
<400> 26
gccccaccc gctgtgactg cattctggga tccccagcct gggaatccaa gagctgtcgg 60
cccattttat tcctccctcc cagacctgac cccttcatcg gggctcaaga gacctctctc 120
tccaaatctc catttgcctc ctctggctaa gctggaaaat gcacactctg ccctgggtgt 180
ttccatatta tccgcctgcc cttcctcctg ggtgcctccc gtagccttag taagggctct 240
gctttcctgg gcccctagag ctgagccatg ctttgccata aaggtgctcc cggcttgcaa 300
ccaatgtgtc tgcttgtgca tctgtctgtg ggtgtggtgg ggagggaggg gaccaggtgg 360
gtactggcac tctggggtcc ggactttatg tccatggagg ccccaattga ctcagttcaa 420
gggtcactga ggctttgctg atgtagggag agggccagag ggaggctcca ccccagccgg 480
gctgagccag ggaacctggg acaaaggtca ggtggctgat tccaggtagt gttttggagc 540
tgggcagtca gtggctgggc ggggacatat gcccaagagc caccatgaac tcccaggggc 600
ctccaggcag gggccctcca tcccgcacca agtctttcaa catgatgtcc ccgacgggcg 660
acaactoggn ctacnggotg agattaaggo aggoaagago otgaagooga ogooccagag 720
caaggggetg accacagtgt tttcaggcat cgggcagccg gccttccagg taggcgggcc 780
```

cagcaggage etgegaeeeg getteeetgg eeetaggeea eegggegete ageeeeaeeg 840

```
cttctccctg cagcccgatt cgccgctgcc ttctgtgtca cctgcact
                                                                   888
<210> 27
<211> 789
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (420)
<223> n equals a,t,g, or c
<400> 27
gggtcgaccc acgcgtccgg ttggtcttgt gtctataaga atgatcaagc tgcaaaggat 60
aatccaacta aaagtcttca ggaagaagaa ccatgtccaa ggtttgccca tcagcttgta 120
tacgatgagc tacacaaggt tcattactta tttggtggga atccaggaaa atcttgctct 180
ccaaagatga gattagatga cttctggtca ctgaagttgt gtagaccttc aaaagattat 240
ttactgaggc attgcaagta cctcataaga aaacacakgt ttgaagaaaa ggcccaagtg 300
gatcccctta gtgctctgaa atatttacaa aatgatcttt atataactgt ggatcattca 360
gacccagaag agacaaaaga gtttcagctc ctggcatcag ctctattcaa atctggttcn 420
agattttaca gctctgggct tttctgatgt ggatcacacc tatgctcaaa gaactcagct 480
ctttgacacc ttagtaaatt tctttcctga cagcatgact cctcctaaag gcaacctggt 540
agaceteate acaetgtaae tgaagagtea etggacaeag aaatggaaaa eaggagtega 600
ttttccgtcy tttggattgc agctccactg actgacagta aagctgcagt gattgaggac 660
tgcaccagag ttctgaaggg atcttaacca tcacaagttt ttaccctctt ccttcatgcc 720
tgacctcaac cccgctctcc tcatcctatt cctaaattag gctaataaag tgaaattggt 780
atactttcc
                                                                   789
<210> 28
<211> 847
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (799)
<223> n equals a,t,g, or c
<400> 28
ctgtcctgag ctgttcactg cttggtggct accttctaag agtgagcatc tcacaagcag 60
9tgtcttaag tgaggaaatg gaagctgcag cttcttaaac ctgggaatta gtagagcatt 120
accectgetg tattetatta gaggteaage cateactgaa gecatattea aggagaggga 180
tegtgeacae tetteeggaa atacgaceae atgagggetg ceateetgga aaaaatgeet 240
cttgtggagc gagatggccc tcaggctgat gaggaagcaa aggaaagcaa agaagcagcc 300
cagctttcag aagcageeee agtgeeeaca gageeeeagg ceteacaget cetggatetg 360
ctagatetee tggatgggge ttetggggat gtecageate eteceeatet ggaceetee 420
ccaggaggtg ccctggtaca cctgcttgac cttccctgtg twcctccacc cccagctccc 480
atcccagate teamagtgtt tgagegtgar ggagtacage tgamtetgte tttcmttegm 540
cccctgaaa accctgcttt gctgttaatc accatcactg ccaccaactt ctcagagggt 600
gatgtcaccc atttcatctg ccaggctgct gtgcccaaga gtctccagct gcagctgcag 660
gccccagtg ggaacacagt tccagctcgg ggtggccttc ctatcaccca gctcttcaga 720
```

PCT/US00/05883

```
atcctcaatc ctaacaaggc ccccctgcgg ctaaagctgc gctcactacg accactttca 780
 ccagtcggtg caggagatnt ttgaggtgaa caactgcctg tggaatcgtg gcagtaatgt 840
 <210> 29
 <211> 666
 <212> DNA
 <213> Homo sapiens
<220>
<221> misc feature
<222> (4)
<223> n equals a,t,g, or c
<400> 29
gganccatgg gagtatgcac atgggatcat aatccattct gtggtttgga aaaagaaaat 60
gttaacctct gctttagagg gtagctacta gctttgttgg ggataaaagt gtaatacatg 120
cacttttgaa ctctgaaagt ttgccaatct gaaaaggggt gtttctgaag accactatct 180
tttacgaaca cttaaaaata agtgtttgca gttgtgtatg ggcacgatac tgtattcttt 240
acatttttat ggccctacag ctacttctta tccctgcaag tatataaatt aaaaccaagt 300
cactttagaa cagctttgaa actagagttt caaaggtaaa aggatctcat gtttctgaat 360
ctgcgtaaag caagatggct gtgatttgac aggtttaatt gctagktttt ataggtggat 420
agaaatgaat agtttggagt ctttaaaatg ttttaaaaaa tgtttgctta ctatctatat 480
atatgacatt attoccaatt agttttatat ctocaagata tatatatgta tataggtata 540
tacacatatg tatatataca tagtctatat attctatata agaatatatt ccaataagaa 600
tatattccat acgggaatat attagtcatt gatgtatttt gccggtaaaa ttaaaagata 660
ttttaa
<210> 30
<211> 517
<212> DNA
<213> Homo sapiens
<400> 30
egeteggett cetgggtetg getgetgeeg eeegeeggtg teegeeegtg tegegeeggg 60
gcaccaagga gccgttggag ggtccggcc gaggcccgct cgtgtggaag tcgtcgacgc 120
egeegetegt eegteeteee gteegttete geteeeggee geeateatge tggegeteat 180
ctcccgcctg ctggactggt tccgttcgct cttctggaag gaagagatgg agctgacgct 240
cgtggggctg cagtactcgg gcaagaccac cttcgtcaat gtcatcgcgt caggtcaatt 300
cagtgaagat atgataccca cagtgggctt caacatgagg aaggtaacta aaggtaacgt 360
cacaataaag atctgggaca taggaggaca accccgattt cgaagcatgt gggagcggta 420
ttgcagagga gtcaatgcta ttgtttacat gatagatgct gcagatcgtg aaaagataga 480
agcttcccga aatgagctaa cataatcttc tagataa
<210> 31
<211> 2675
<212> DNA
<213> Homo sapiens
<400> 31
gcgaggtcac gtgacggagc gccggagcgg agggagccgg ggctgggagt tctcctgagg 60
```

```
gaagaggagt ggagtagggg ggacgcggcg gcggcgttga caatgagttt tcttggaggc 120
ttttttggtc caatttgtga gatcgatatt gttcttaatg atggggaaac caggaaaatg 180
gcagaaatga aaactgaaga tggcaaagta gaaaaacact atctcttcta tgacggagaa 240
tccgtttcag gaaaggtaaa cctagccttt aagcaacctg gaaagaggct agaacaccaa 300
ggaattagaa ttgaatttgt aggtcaaatt gaacttttca atgacaagag taatactcat 360
gaatttgtaa acctagtgaa agaactagcc ttacctggag aactgactca gagcagaagt 420
tatgattttg aatttatgca agttgaaaag ccatatgaat cttacatcgg tgccaatgtc 480
cgcttgaggt attttcttaa agtgacaata gtgagaagac tgacagattt ggtaaaagag 540
tatgatetta ttgtteacea gettgeeace tateetgatg ttaacaacte tattaagatg 600
gaagtgggca ttgaagattg tctacatata gaatttgaat ataataaatc aaagtatcat 660
ttaaaggatg tgattgttgg aaaaatttac ttcttattag taagaataaa aatacaacat 720
atggagttac agctgatcaa aaaagagatc acaggaattg gacccagtac cacaacagaa 780
acagaaacaa togocaaata tgaaataatg gatggtgcac cagtaaaagg tgaatcaatt 840
ccaataaggc tatttttagc aqqatatqac ccaactccaa caatqaqaqa tgtqaacaaa 900
aaattttcag taaggtactt tttgaattta gtgcttgttg atgaggaaga ccggagtagc 960
ttcaaacagc aggagataat tttatggaga aaagctcctg aaaaactgag gaaacagaga 1020
acaaactttc accagcgatt tgaatctcca gaatcacagg catctgccga acagcctgaa 1080
atgtgaactg aacaggagaa aaaaagaaaa gcmaaaaact cctgtwaccc ttgarattaa 1140
gttcagcagg ttaaagatgg ttgcagctgg agggggcgga aaaaggccaa aactccatat 1200
atgttagtct tcctttatct tacagcgcay wtttatttta tgatataatg aaatgttcgt 1260
tcatgtatat acatttttaa aagtgctttc tttgaaacac tggaactttg ttaagctgcc 1320
tttttttttt taacttccta ctttgatgat aagcactcag atatatatca gcgtaaacat 1380
gaaaaatttt catgtgagta ggctggtatt tgtaattttg ctttctttct gcataatgtt 1440
gattataaat cotototttt caggotaatg attacotott attototaca tgcaaaaaat 1500
taaatatttt gtgttcaaat aaaattagaa aacytgagtg gcctcttgtg tcctgcagag 1560
atttaaaaca tggcatctca atatttttga gaactacatt tgtttttaac atatgtgttt 1620
gagaaaagca tatggagtgt ttcaccgcag gcacttctga gtaccattcc atggcttcca 1680
gaattttatc ctctttqagg tcttctgtgc tatgaatatt agatttcttt ccccaaggga 1740
ttatgtggca ggtcattatg gccttctttt ttttggccat attaagtaac agttttgcta 1800
tattccagta gtaccgttgt gtgttttctg caatgtggag ttgacttagc ttggcatttt 1860
agatttgtta aaactatttt ttccataaat actttgaaac gtatttatat atttcaattt 1920
aaggaatctt tttgccatgt gtatgcaaat attatttct tcatacattc attttctttt 1980
caggggaaaa ttttgggatg ggggactcag gaggacctgt gaagcatgta gttatctaga 2040
tctgggtaat ttcatgttta ttaaactcga actttggcta gttaaactca tattgaaact 2100
tcatctagtc tcttaatttt ttaacactaa attcaagtca tttgttttaa gtctctaaaa 2160
aagaagattg cagtcatcca ttcatatgca tggggtctga tcgcaaatac actaaatgtg 2220
gagtgtagga accaaaatga aacctgctgt atggaaacta ctttcactta tggttcattg 2280
gtttttgtac caatattttt tatgcacttc agtgcaagtc ttgtcagtta accttacttt 2340
atgagtaage taaataacce aaattacatt tetttaaace tgttttaeta etatggeact 2400
ttgataaaat ggtcaggaac caactttact ggcaaaaggg tccatgtacc accatgtgct 2460
ggagcatctg ttctacatgt ggatatcwat gaatggtaat gttttccttc atgtaagtgc 2520
ctattcagag tttcagaatt ttaaaatgcc aaatattttc atggtcattt gcatgtagta 2580
agccagaaaa tattcaaaga gattttgaaa accaattgta tttaaccagc ctcaaattgt 2640
                                                                  2675
gcaaccatga tgtataataa agaatttgaa acaga
```

<210> 32

<211> 277

<212> DNA

<213> Homo sapiens

```
<221> misc feature
<222> (109)
<223> n equals a,t,g, or c
<400> 32
agccgcaccc ccagcacttc ggacatggcc gaggaaggca gagtggccag cgggggcccc 60
ccagggctgg agacctcgga gtctctcagt gactcactct acgactcgnt gtcctcttgt 120
gggagtcagg gctgaggggc tgcgccacgc cacggccccg ctggagctgg ggaccacaga 180
ctggaccggc tetetteatg cccagecece ggagacgggg acceetteee tgaagggace 240
aaggaggcag gtggataaga aggttgaaaa gggggtt
<210> 33
<211> 921
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (2)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (839)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (846)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (886)
<223> n equals a,t,g, or c
<400> 33
engtggettt cetgeaceae tgeececeae eaggatgatg gagagtaaga tgattgetge 60
catacactcc agcagtgcag atgccaccag cagttcaaat tatcattcct ttgtcactgc 120
ttcatccacc tctgtggacg atgcattgcc tttaccactt cctgtcccac aacctaagca 180
tgcttctcag aaaacagttt actcctcctt tgctaggccc gatgtcacca ctgaaccctt 240
tggtccagat aactgtttgc atttcaatat gactccaaac tgccagtacc gtccccagag 300
tgtacctccc catcacaata aattggagca gcaccaagtg tatggtgcca ggtcagagcc 360
accagectee atgggtette gttataacae atatgtggee ecaggaagaa acgeatetgg 420
acaccactcc aagccatgca gccgggtcga gtatgtgtct tctttgagct cctctgtcag 480
gaatacctgt taccccgaag acattccacc gtaccctacc atccggagag tgcagtctct 540
ccatgctccg ccgtcttcca tgattcgctc tgttcccatt tcacggacag aagttccccc 600
agatgatgag ccagcctact gcccaagacc tctgtaccaa tataagccat atcagtcctc 660
ccaggcccgc tcagattatc atgtcactca gcttcagcct tactttgaga atggccgggt 720
ccactacagg tatagcccat attccagttc ttctagttcc tattacagtc cagatggggc 780
cctqtqtqat qtqqatqcct atggacartc caqttqaqac cctttcaacq gctttccant 840
```

```
cgagantttg ttttttacaa tcctaggttg caaggaaaga gctttntaca gttatgctgg 900
                                                                   921
gtttgggtcc aggtccccgg g
<210> 34
<211> 1467
<212> DNA
<213> Homo sapiens
<400> 34
aaaaaaaaa gaaaagttct gtgttgatgt acagtttctc ctaagaagaa gcgaggtggt 60
tgaattttgg aagcacttct tgaatcggat taacccatgc tcttattgaa ttttttcatc 120
tgctctgttt agtttgatat taaagcaaaa ttaagaggtc ttagtttttc ctatagaact 180
tttaatatgt caaaagctat attgtctaaa tttcagtact taagcaaata ctgagtagtg 240
ttttaaattc agaaatagag cttctattat gaacacatga gaatgatttt tttctcttaa 300
tcattattaa ggaaatattt taatttcatg gtcatataat ggtgataagt aatacctgat 360
tgtttccttt tctgttctag taactcagag gagatacgtg ttttatttgt gatagcaaat 420
tcctaaatga acattaggca agtggtatca ttatcaggcc agctgcagcc tcttgccttg 480
acctgcattc ctagaatttc tttgttgctg taattcttga ttaagtgacc ttgactttca 540
ttttgtaatt ttgctaatca tcagcaaatt cacttgcatg acgttactgc caaatatgaa 600
ggcagttgaa ttattatgag tgattgtggc agaggtttgt gccatggtga aaactttgat 660
gtttgtctgt gttcattgga tccatctttt taaatgacat taccatgagt ctgttgtcaa 720
acctaaatat ctttgtttga atttaaaatg ggactctata ttgttgtagt tcaggtcttc 780
attgactaag agattgagag aaatctgaca taagaaaata ttgttttcac tgcaggaata 840
aagaggaagt aacagtgaat ccaatatagt tcatattgtt attgtccaat catcaagtta 900
actaagcatt atcagattac gtttatttct catacatatg gatattaact taaggtaaaa 960
aagctggatg tgaaggatct gaaaaggcat taatttatgt actaattcta taaacatgta 1020
ttaataattg cagtattatt aaatacagat ggactcaatg tacctttgaa aagaccacta 1080
atttagaaaa caaagctaag tgcagtcatt acaagaagca aagaaatact taagttagaa 1140
aaaaattaaa atgaagggat ggtctaagtt ttcttcatgc tggaacaaat gttaaagaag 1200
cagtgattgc ttacaatgta tgtgataaaa taataccttt cacaatcaaa attttaatag 1260
taaatataag ataaaattta tattaaataa tgaaaacgta tttgtactga atttagtcac 1320
tagagaacat cgtaacaaaa tacatgaaac aaaagtagcc agaaatgtta gaacaggtgg 1380
aaatgtatac attatttgat ggtttgtttt tttatggaaa taaacaacat acatagaatt 1440
                                                                   1467
aaatggtgat caaaaacatg gaaaaaa
<210> 35
<211> 2077
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (12)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (15)
<223> n equals a,t,g, or c
<220>
```

```
<221> misc feature
<222> (423)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (730)
<223> n equals a,t,g, or c
<400> 35
cggacggtgg gncgncgaca caatgggcca yggagttccc gttcgatgtg gacgcgctgt 60
teccggageg gateaeggtg etggaceage acetggagge ecceageeeg eegaceegga 120
accacaacgc cggcccgtgt tgatctacag cagcaaatta tgaccattat agatgaactg 180
ggcaaggctt ctgccaaqqc ccagaatctt tccgctccta tcactagtgc atcaaggatg 240
cagagtaacc gccatgttgt ttatattctc aaagacagtt cagcccgacc ggctggaaaa 300
ggagccatta ttggtttcat caaagttgga tacaagaagc tctttgtact ggatgatcgt 360
gaggeteata atgaggtaga accaetttge atcetggaet tttacateca tgagtetgtg 420
cangccatgg ccatgggcga gaactcttcc agtatatgtt gcagaaggag cgagtggaac 480
cgcaccaact ggcaattgac cgaccctcac agaagctgct gaaattcctg aataagcact 540
acaatctgga qaccacaqtc ccacaqqtqa acaactttgt qatctttgaa ggcttctttg 600
cccatcaaca tcctccagca aggaagctgc cacccaagag agcagaggga gacatcaagc 660
catactcctc tagtgaccga gaatttctga aggtagctgt ggagcctcct tggcccctaa 720
acagggeeen tegeogegee acaceteeag escaceceace ecceegetee ageageetgg 780
gaaactcacc agaacgaggt cccctccgcc cctttgtgcc agagcaggag ctgctgcgtt 840
cettgegeet etgeceecea caccetaceg eccgeettet gttggetget gaccetgggg 900
gcagcccagc tcaacgtcgt cgcaccagct cccttccccg ctctgaggag agtcgatact 960
aacagctace etetecetge eetgggagae etggggtggg cagggaacee etecetgaga 1020
acctcagacc cactcttcca ttgcatcctg taggacccag tggaacctga cagagcccat 1080
aggattccct cttctacttt cttagacagc agggatgtca gggtctcaaa ctgcctaaca 1140
ctttgtagct tttcttaaca caaaagcacc ccttctctcc taacttgggc tctgaatact 1200
ttcccaacag gaagtctgat ctgttgccag acttcttggt tagatggctc atacatttat 1260
ctagagaagc acactettgc ttgctgtcaa actttagamc accatggaag gtctaagggc 1320
atcctgtgcc agggaaactt tttaaggaat tttatctatg ggataaaccc catattccct 1380
ctagtgtcta ctggtggctc taatactgct ttgtgctgcc tgccacactt gccctttgag 1440
cctgcgaatg gccgctagtg agcaagctct gcttcagagc agtctagtta ggtagaacag 1500
ggacttacca gcttcccaaa gggatctact caccattgcc aaactcttca tttccacatt 1560
ttgtgtaggt gtcagggaac cccaaactgg tgttgctttg gggtctctaa aggagattgg 1620
ctgacaccac catttccccc agatccagat tctctgaggg aggttgtttc ttgagagtag 1680
atccagagtg tcaaggatct gttagatcct ggaatccctt cttgcatcca tccctccctg 1740
tetteetetg teetteetet eteetteet ceatageaag gacgacette eetgeteeat 1860
gcccagagta tagctagatc ccttcccctc cctaccctct gaatgtgtgc tagatcaggt 1920
gccccactgt gtttcctgaa atccttggga gccggatctc cccatctccc ctactcactc 1980
ttcccttttc ttctctcagt gttgtctgaa taaagtgtga aatcttttgt gttttctaaa 2040
                                                                2077
ttgacatttt caatgaaaaa aagaatcaca aaaaaaa
<210> 36
```

<211> 384

<212> DNA

<213> Homo sapiens

```
<220>
<221> misc feature
<222> (366)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (370)
<223> n equals a,t,g, or c
<400> 36
ccagcaggag aatcctcccc tgccccttgg ctcaaaggcc ctggagccca cctcccagaa 60
gcccggtgtg ggggcgggcc acgggggaga tcccaagetc agtccccaca aagttcaggg 120
ccggtcggag gcaggggcag gtccgggtcc aaagcaagga caccacagct cttccgactc 180
cagcagcagc tecagegatt eggacaegga tgtraagtee caegetgetg getecaagca 240
gcacgagagc atcccgggca aggccaagaa gcccaaagtg aagaagaagg agaagggcaa 300
gaaggagaag ggcaagaaga aggaggctcc ccactgaagg gcctggacaa ggctcattaa 360
acttentetn tgccaaaaaa aaaa
                                                                   384
<210> 37
<211> 468
<212> DNA
<213> Homo sapiens
<400> 37
gcgatgctgg gtgtggcagg cctcctgagc cggctggagg aggacaggct gctgctgcta 60
ccgaaggagg atgkctgtcg ctgggccttg gctgtaggca gctgggctta ctgccgggcc 120
ctgcatacac agcgcctcca gtgggagtga cagttggata cagccaggca gggtttctgc 180
cctgccgaac actttccctc ccacctgcct gctcctggcg ccttctccct aggggtagac 240
tettetgeet actgaagtgg gtttgetgea cattgactgg teaggggeag agtetgggtg 300
ctgtcctttg gccacgtgtg gggacttgtc tagaccagaa tgaaaggaca gggtcccaga 360
cacgtttggg ggtcctgatt ctgggctgga cacggttgtg gatccagaga agaggcctag 420
tctccaataa atcttaggaa ttttgcagga aaaaaaaaa aaaaaaaa
<210> 38
<211> 1095
<212> DNA
<213> Homo sapiens
<400> 38
ggcacgagga taatgagcat aagcgttcac tgaccaagac tccagccaga aagtctgcac 60
atgtgaccgt gtctgggggc acccaaaaag gcgaggctgt gcttgggaca cacaaattaa 120
agaccatcac ggggaattet getgetgtta ttaccccatt caagttgaca actgaggcaa 180
cgcagactcc agtctccaat aagaaaccag tgtttgatct taaagcaagt ttgtctcgtc 240
ccctcaacta tgaaccacac aaaggaaagc taaaaccatg ggggcaatct aaagaaaata 300
attatctaaa tcaacatgtc aacagaatta acttctacaa gaaaacttac aaacaacccc 360
atctccagac aaaggaagag caacggaaga aacgcgagca agaacgaaag gagaagaaag 420
caaaggtttt gggaatgcga aggggcctca ttttggctga agattaataa ttttttaaca 480
tottgtaaat attoctgtat totcaacttt tttccttttg taaatttttt ttttttgctg 540
tcatccccac tttagtcacg agatcttttt ctgctaactg ttcatagtct gtgtagtgtc 600
catgggttct tcatgtgcta tgatctctga aaagacgtta tcaccttaaa gctcaaattc 660
```

```
tttgggatgg tttttactta aqtccattaa caattcaggt ttctaacgag acccatccta 720
 aaattotgtt totagatttt taatgtoaag ttoccaagtt coccotgotg gttotaatat 780
 taacagaact gcagtcttct gctagccaat agcatttacc tgatggcagc tagttatgca 840
 agcttcagga gaatttgaac aataacaaga atagggtaag ctgggataga aaggccacct 900
 cttcactctc tatagaatat agtaaccttt atgaaacggg gccatatagt ttggttatga 960
 catcaatatt ttacctaggt qaaattgttt aggcttatgt accttcgttc aaatatcctc 1020
 atgtaattgc catctgtcac tcactatatt cacaaaaata aaactctaca actcatctaa 1080
                                                                    1095
 catgcttact taaaa
 <210> 39
 <211> 1757
 <212> DNA
 <213> Homo sapiens
 <220>
 <221> misc feature
 <222> (596)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (647)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (648)
 <223> n equals a,t,g, or c
 <400> 39
 gccagccacc attttatctc tctaaagtct ggtcccagta ttaaacctat tctttagtaa 60
 actcatatta ctgttctaaa ttgaagaaat tatttattac tctgtacttc tagactcaaa 120
 attetttate aaagatagte teaaagaggt agtacaagte etgtttaact geacttttte 180
 acattcacag tgcttcctct gatatctttc cttacatcat tatacactgt tgatatcatt 240
 ttactcttct ttctcttcta catttcttaa attttggttc ttttcctgta catgtgtttt 300
 aggggggcc ttttctttga actttgtcta attagcctgt acatttttgt ttcttttaag 360
 gtagaacaga totttttttg tttctccttt taagtotact ggttttaaaa gaggtaaatg 420
 tatccataga ccacagtgcc ttgctttttc ctctgccagc acatggagca cgggattaga 480
 tgcacaaacc tatttaggga actattttgg tagatgtttg agtttataca gaaattgcag 540
 ctggtatttt attttgctgt acatttactc aacttgtcca ttagtattta actatntcca 600
 gagtttgttt aggagtaaga attgacccat tcgttagttt accatanntt ttcctggtat 660
 aaaaaggagc cagaaataag ccttattgct aaataattaa ttatgtaagc ccacctaggt 720
 cctgcataag atcccctca catacttcac aatatatatg tgtgtgtgtg tgtgtgtgtg 780
 tgtgtgtgtg tgtgtgtgt tgtgtatktg gctaaaaaat tatactgcca aaattactga 840
 ttataaatac ttgactacac tgattgatgg gacaaaatga ttaaagtatt ttcagggatc 900
 ttattccata tgtcaccacc aaagatttct acagtgttat aaagtatata aatattccaa 960
. atttctgtgg ttaaatattt ttttcttttt tttccttttt tagaataaca cagtctgtgc 1020
 tttccaaaaa tqcttqaact tttatgttgt taagaaatat ataatgatat cttacattaa 1080
 gcatgagtct aatttgtatt aattgggatg gactaaattt tcatttgatt atcaggaaaa 1140
 ttaaggagtt atatatttaa aagcaatttt ctgtgttttc ttctttgtaa gttgactcat 1200
 ttgtgaagca attaggcaaa ttttgagaag atcattgtta ttgtggtttg cagtatatat 1260
```

PCT/US00/05883 WO 00/55351

```
ttcttagtaa atatcactta agattaaatt tttcagaaag aaaattatag cttttttccc 1320
aaaatatttt taagatttaa totttttgta gtatgotaca gatttaatta tattaactot 1380
tttttaagac attgaccatg acttaacatt ttgccttcta acacctttta aatctatgta 1440
ctttaatagt taagagaaaa taagtttgca gatttttaat aatctgtttg taaaaggcta 1500
tctctaagcc tagtatgtgg gtaattttac aggtgtgttt tttgataact ttaatataaa 1560
ataaactcat tttatttgtg gcaattcgcg tttcttttt tatgccagag tacatatgtt 1620
ggattccatg aattggtatt acttattatt atgtgttgat taaatatatg cacacactta 1680
ggattacaga tcacagagca aattatgaaa atcataaaca ttctggtatg gtcatccata 1740
                                                                  1757
ggattatgaa aaagaaa
```

<210> 40 <211> 1945 <212> DNA <213> Homo sapiens

. <400> 40

accgggaget ggtgacggat ggcggggccg ccagcccctg gcgctgcaac tgggaacagt 60 tgttgaaccc gcgaccaagc gaggcggacc ctgaagcgga ccccgaggaa gccactgctg 120 ccagggtgat tgacaggttt gatgaagggg aagatgggga aggtgatttc ctagtagtgg 180 gtagcattag aaaactggca tcagcctccc tcttggacac ggacaaaagg tattgcggca 240 aaaccacctc tagaaaagca tggaatgaag accattggga gcagactctg ccaggwtcgt 300 ctgatgagga aatatctgat gaggaagggt ctggagatga agattcagag ggactgggtc 360 tggaggaata tgatgaggac gacctgggtg ctgctgagga acaggagtgt ggtgatcaca 420 gggagagcaa gaagagcaga agccactctg caaaaacacc gggcttcagt gtccagagta 480 tcagtgactt tgagaaattt accaagggaa tggatgacct tgggagcagt gaggaggagg 540 aagacgaaga gagtggcatg gaagaagggg atgacgcgga agactcccaa ggcgagagtg 600 aggaagacag ggctggagat agaaacagtg aggatgatgg tgtggtgatg accttctcta 660 gtgtcaaagt ttctgaggaa gtggagaaag gaagagccgt gaagaaccag atagcactgt 720 gggaccagct cttggaagga aggatcaaac tacaaaaaagc tctgttgacc accaaccagc 780 ttcctcaacc agatgttttc ccattgttca aggacaaagg tggcccagaa ttttccagtg 840 ccctgaaaaa tagtcacaag gcacttaaag cattgttgag gtcattggta ggtcttcagg 900 aagagttgct tttccagtac ccagacacta gatatctagt agatgggaca aagcccaatg 960 gargaagggt ccctgcaaag aggaagctgg agatggagga ctatcccagc ttcatggcaa 1080 agegetttge egaetttaea gtetacagga acegeacaet teagaaatgg caegataaga 1140 ccaaactggc ttctggaaaa ctggggaagg gttttggtgc ctttgaacgc tcaatcttga 1200 ctcagatcga ccatattctg atggacaaag agagattact tcgaaggaca cagaccaagc 1260 gctcygtcta tcgagttctt ggcaaacctg agccagcagc tcagcctgtc ccagagagtt 1320 tgccagggga accggagatc cttcctcaag cccctgctaa tgctcatctg aaggacttgg 1380 atgaagaaat ctttgatgat gatgactttt accaccagct ccttcgagaa ctcatagaac 1440 ggaagaccag ctccttggat cccaacgatc aggtggccat gggaaggcag tggcttgcaa 1500 tccagaagtt acgaagcaaa atccacaaaa aagtagatag gaaagccagc aaaggcagga 1560 aacttcggtt tcatgtcctt agcaagctac tgagtttcat ggcacctatt gaccatacta 1620 caatgaatga tgatgccagg acagaactgt accgctctct ttttggccag ctccaccctc 1680 ccgacgaagg ccacggggat tgacatcgcc cacctccgac acccagtggg cgccttggct 1740 ggtgcggctg ctggtccaga tggaggaaac cagtgacttt atggggctga gctagtaggg 1800 aagcccctgg aaagatgctg cgttccgaac ctgtgcctaa tacacgcaag ggcgctgtcc 1860 cgcccaaccc cgcctttaaa cgccacaaat aaagagcatt gttaccgcca agtacgacgc 1920 ggccgcgaat taccggaccg gtaac 1945

```
<211> 588
<212> DNA
<213> Homo sapiens
<400> 41
aggogtatac caccatgact gaaaacaaaa gactttttt tgagactccc tctcaaaaac 60
aaaacaaaac aaaaaaatta gacaaatgct acattaatgt ttgggtggtc agattctact 120
ttgaatctga agtttgcaga tatgcctata gatttttgga gtttaccact ttcttattct 180
gtatcattaa tgtaatattt taaattacta tatatgttac catttttctg gatttagtaa 240
gaaatttgca gttttggttt gatgtaacaa gggttttaat gtaatttatg ttagattttg 300
catttttttc attactgtta tattttaacc tgactgactg atctaattgt attagtattg 360
tgaataatca tgtgaaatgt tttgagacag agtactatat ttgtgaatat aattttatgg 420
tttttttcac ttagaacctt tctgtgtgga aaactaagaa aattgctttc tgctgtataa 480
totggcatto attgtagatt aaagottatt tttotgtgaa taaaacgtat toaataaaat 540
                                                                   588
actattcttt aaaattawaw mawaaaaaaa aaaaaaaaa aaaaaaaa
<210> 42
<211> 1568
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (104)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (112)
<223> n equals a,t,g, or c
<400> 42
cattagattt cacttttta aaaaacccag tggacattgc tataaataag atttatttgg 60
ctacaaataa cctgggatgt tgcttattat gattgatgcc tgcnggtttg tncccaagct 120
gagtgaaatt gaacctcgtc ctccctactc attttgatga ctgaggctgg tttataagaa 180
aaggaagttt ggagaagaaa accgagatta gaaaatatca tgttttggtt ggagataaga 240
accagggatg gcaagtacca gtgtgtacaa atgtatttca cggagtttga aggaacgcat 300
aatcaagagg gaaaacaatt tgtccttcat tggacgtatt atttggattt gggtgagcaa 360
caaaatggaa tgtggtctgt taggagcatt ctgtttgttc ttttgtccct gatgtgatga 420
atcattgcca catgctagat ggactcttca tatccaggtt ttgtccctca gggctgagca 480
ctgtattaaa gagtttttgt tgagtcattt aaccttagtg tccacatcca gatcagctgt 540
aaaatgggga agacgtgtgc tgatttggaa tgaatgcaaa atatcactat cattttccta 600
attacagagg agcaaaggtt atcttcagcc ctttcagttc tatgctcaca tattcaaata 660
tcaaatgtaa tttagctgaa gttatttaat aatcaagtct ttcaatatct gttcaaagaa 720
aaagaacaca ctttgaaaat tctgcaaagc tgtctcccag tctttaaaat gtctggaagc 780
actotoctto titacaatac caacatoact ggcocagaat citcoctgtg ctaggitigta 840
aatataaata aattacttgt tttgtaaact tttgtaaaga atattttggt agaaatactt 900
caaacatatt ctttgggtta tatttataca tatgtgaaat aaatatacta tcaaaaggtt 960
atattttata caaaaagtaa attgctacct tttgtatgct aatatgcaaa gttttgtata 1020
atatgatggt ttatttttag ctctacactt aaaccatagg tggttgagtg ggaacttttg 1080
aaaactatca agaggcttgt tagacaaatt tatattctga aacctcaata agaaagcatt 1140
```

WO 00/55351 PCT/US00/05883

```
ccaggtttca atccttgttt tttgtcctgc tcccaaattc ttttttaaac ccatagttct 1200
 tgtgtcttat ttgattcttc tgctgtgcac attgtattgg tccttgttgc atgtagtcta 1260
ctgtgtgttt tccgatttta taaggcagca tttctccata caaaaaraaa aaaaatgatg 1320
tacatataaa cgcttttrtt gtatggctcc tccatgttac tgtatatatc tgccagcact 1380
tcccagttac actcctgtga gtcagcttat ttttacccta acataaatag tatgttttgt 1440
agtagttatc aaatttaaga gataaagcaa tcagaatgtt tggattttct tctatcttaa 1500
tgtgaatttc ataattaatg tctatttatt cagctattca ttaaaataca ggattctttg 1560
gggaaaaa
                                                                 1568
<210> 43
<211> 1060
<212> DNA
<213> Homo sapiens
<400> 43
gcttgtcatg agaaggtggt aaatatccaa aaagaccccg gtgaatctct cggcatgacc 60
gtcgcagggg gagcatcaca tagaraatgg gatttgccta tctatgtcat cagtgttgag 120
cccggaggag tcataagcag agatggaaga ataaaaacag gtgacatttt gttgaatgtg 180
gatggggtcg aactgacaga ggtcagccgg agtgaggcag tggcattatt gaaaagaaca 240
tcatcctcga tagtactcaa agctttggaa gtcaaagagt atgagcccca ggaagmctgc 300
agcageceag cagecetgga etecaaceae aacatggeee caeceagtga etggteecea 360
tcctgggtca tgtggctgga attaccacgg tgcttgtata actgtaaaga tattgtatta 420
cgaagaaaca cagctggaag totgggotto tgcattgtag gaggttatga agaatacaat 480
ggaaacaaac cttttttcat caaatccatt gttgaaggaa caccagcata caatgatgga 540
agaattagat gtggtgatat tcttcttgct gtcaatggta gaagtacatc aggaatgata 600
catgottgot tggcaagact gotgaaagaa ottaaaggaa gaattactot aactattgtt 660
tottggcotg gcacttttt atagaatcaa tgatgggtca gaggaaaaca gaaaaatcac 720
aaataggota agaagttgaa acactatatt tatottgtoa gtttttatat ttaaagaaag 780
aatacattgt aaaaatgtca ggaaaagtat gatcatctaa tgaaagccag ttacacctca 840
gaaaatatga ttccaaaaaa attaaaacta ctagtttttt ttcagtgtgg aggatttctc 900
attactctac aacattgttt atattttttc tattcaataa aaagccctaa aacaacaaaa 960
ccaagettac gtacgegtge atgegacgte atagetette
                                                                1060
<210> 44
<211> 1344
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (144)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (163)
<223> n equals a,t,g, or c
<400> 44
cccacgcgtc cggggccacc agggcctcct ggcccccctg ggcccccagc ccctgttggg 60
```

ccacccatg cccggatctc ccagcatgga gacccattgc tgtccaacac cttcactgag 120

```
accaacaacc actggcccca gggnacccac tgggcctcca ggncytccag ggcccatggg 180
 teccectggg cetectggee ceaeaggtgt ecetgggagt cetggteaca taggaceece 240
 aggccccact ggacccaaag gaatctctgg ccacccagga gagaagggcg agagaggact 300
 9C9t9999ag cctggccccc aaggctctgc tggggcagcg gggggaactg gccctaaggg 360
 agaccetggt gagaagagee actgggetee tagettacag agetteetge ageageagge 420
 tcagctggag ctcctggcca gamgggtcam cctcctggaa gccatcatct ggccagaacc 480
agagetgggg tetggggegg geeetgeegg cacaggeace eccageetee tteggggeaa 540
gaggggcgga catgcaacca actaccggat cgtggccccc aggagccggg acgagagag 600
ggccagctgc ctccagggac cgcccgtcca tatttattaa tgtcctcagg gtcccttctg 720
ccatctaggc cttaggggta agcaggtctc agtcctggca ccatgcacat gtctgaggct 780
gagcaagggc tgagaggaga ggcttgggcc tcagtttccc tctgtgaagt ggggggaggc 840
aggccttcaa ggagggatag aggtacaagg cttcgtctca tctgctgtct gagcatccag 900
gcccaaaggc actgagggag tcaggagctg gggctcggca catgcagaga tgacagggca 960
99999cagtc ttcctcccc tccccgacca aacctcgggg agccctcctg tgcccctccc 1020
teettgttgt ccagtgetgg gyteeceace eegaggteag getgeecaat cetetgaetg 1080
gatcaccggg ggcttcttgc ctcagttctt ccctctgagc ccccaggccc tcccgcatct 1140
caggttgggg atgggggacat ggagaggaag gggccgccta ctcctgcaaa tgcttgtgac 1200
agatgccagg aggtagatgt gtgctggcca ataaaggccc ctacctgatt ccccgcaaaa 1260
aaaaaaaaaa aaaaaaaaaa aaaaaaaagg gcggccgctc tagaggatcc aagcttacgt 1320
acgcgtgcaa cgcgggtcat agct
                                                                 1344
<210> 45
<211> 892
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (890)
<223> n equals a,t,g, or c
<400> 45
ttgagaagtt ggatgaatat atatatagac acttctttgg tcacactttt tcccctccat 60
atggacccag tcgacctgat aaaaagcaac gtatggtaaa tattgaaaac tccaggcatc 120
gaaaacaaga gcagaagcac cttcagccac agccttataa aagggaaggt aaatggcata 180
aatatggtcg cactaatgga agacaaatgg caaatcttga aatagaattg gggcaattac 240
cttttgatcc tcaatactga ttcacaattg agttaaatta gacaactgta agagaaaaat 300
ttatgctttg tataatgttt ggtattgaaa ctaatgaaat taccaagatg acaatgtctt 360
ttcttttgtt tctaagtatc agtttgataa ctttatatta ttcctcagaa gcattagtta 420
aaagtctact aacctgcatt ttcctgtagt ttagcttcgt tgaatttttt ttqacactgq 480
aaatgttcaa ctgtagtttt attaaggaag ccaggcatgc aacagatttt gtgcatgaaa 540
tgagacttcc tttcagtgta agagcttaaa gcaagctcag tcatacatga caaagtgtaa 600
ttaacactga tgtttgtgtt aaatttgcag cagagcttga gaaaagtaca ttgttctgga 660
atttcatcat taacatttta taatettaca eteaettett gtetttttgt gggttcaaga 720
gccctctgac ttgtgaagaa tttgctgccc tcttaagagc ttgctgactt gttttcttgt 780
gaaatttttt gcacatctga atatcgtgga agaaacaata aaactacacc atgaggaaaa 840
aaaaaaaaa aaaaaaaaa aaaaaaaaaa aaaaccccgg ggggggccn ga
```

```
<222> (476)
 <223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (478)
<223> n equals a,t,g, or c
<400> 22
gagcagaaag tagatgctta atggcagtgt tctctgaccc agacatgaat cagaatcacc 60
tggaaggget tgttaataca aattgctagg ccacaaccet aaagtttetg atteagggta 120
gggcaaggcg aggcttaaac ttcaggccag gggccacttt aagaattgct atatggccag 180
ggccgggcgc ggtggctcac gcctgtaatc ccagcacttt gggaggccga ggtgggcgga 240
tcacaaggtc aggagatcga gaccatcctg gctaacacgg tgaaaccctg tctgtagtaa 300
aaatacaaaa aaattagcca ggcatggtgg tgggtgcctg tagtcccagc tacttgggag 360
gctgaggcag gagaatggtg tgaacccagg aggtggagct tgcagtgagc cgagatcgtg 420
ccactgcact ccagcctggg caacagagcg agacttccgt ctcaaaaaaa aaannncn 478
<210> 23
<211> 1252
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (1227)
<223> n equals a,t,g, or c
<400> 23
tttcgagctc tgcaccgagg agctgccctg gacttgagtc ccttgcatcg gagtccccat 60
ccctcccgcc aagccatatt ctgttggatg agcttcagtg cctaccagac agcctttatc 120
tgccttgggc tcctggtgca gcagatcatc ttcttcctgg gaaccacggc cctggccttc 180
ctggtgctca tgcctgtgct ccatggcagg aacctcctgc tcttccgttc cctggagtcc 240
tegtggeeet tetggetgae tttggeeetg getgtgatee tgeagaacat ggeageeeat 300
tgggtcttcc tggagactca tgatggacac ccacagctga ccaaccggcg agtgctctat 360
gcagccacct ttcttctctt cccctcaat gtgctggtgg gtgccatggt ggccacctgg 420
cgagtgctcc tctctgccct ctacaacgcc atccaccttg gccagatgga cctcagcctg 480
ctgccaccga gagccgcact ctcgaccccg gctactacac gtaccgaaac ttcttgaaga 540
ttgaagtcag ccagtcgcat ccagccatga cagccttctg ctccctgctc ctgcaagcgc 600
agageeteet acceaggace atggeageee eccaggacag ceteagacea ggggaggaag 660
acgaagggat gcagctgcta cagacaaagg rctccatggc caagggagct aggcccgggg 720
ccagccgcgg cagggctcgc tggggtctgg cctacacgct gctgcacaac ccaaccctgc 780
aggicticcg caagacggcc cigitgggtg ccaatggigc ccagccciga gggcagggaa 840
ggtcaaccca cctgcccatc tgtgctgagg catgttcctg cctaccatcc tcctccctcc 900
eeggetetee teecageate acaccageea tgeagecage aggteeteeg gateacygtg 960
gttkggtgga ggtctgtctg cactgggagc ctcargargg ctctgctcca cccacttggc 1020
tatgggagag ccagcagggg ttctggagaa aaaaactggt gggttagggc cttggtccag 1080
gagecagttg agecagggea gecacateca ggegtetece taccetgget etgecateag 1140
ccttgaaagg gcctcgaata aaccttctct tggaaccact ccaagcccag ctccactcag 1200
ccttggcctt cacgcttgtg gaaacancca aggcattcct ccacccctca ag
                                                                1252
```

```
<210> 24
<211> 1074
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (928)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (934)
<223> n equals a,t,g, or c
<220> · ·
<221> misc feature
<222> (1028)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (1031)
<223> n equals a,t,g, or c
<400> 24
gctggccttt gctctgcgga ctggcggccc cctggcacag aggtgacatc tcaagggccc 60
aggcagccct cttctagtgg tgccaagagg cggaggctgc gggctgccct tggtccccag 120
cccactcgct cagecetgag gtttecetet getteeceag ggagettgaa ggecaageag 180
tocatggcgg gaatccstgg tagggagagt aatgccccat ctgtgcccac tgtctccctg 240
ctgccggggg cgcctggagg caatgccagc tccaggacag aggctcaggt gcccaacggg 300
caaggcagcc cagggggctg tgtctgttca agtcaggctt ccccggcccc tcgcgcagca 360
gcgcctccac gggcagcccg gggccccacc ccacgcactg aagaggccgc ctgggctgcc 420
atggccctga ccttcctgct ggtgctgctc accctggcca cgctctgcac acggytgcac 480
agaaacttcc gacgcgggga gagcatytac tgggggccca cagcggacag ccaggacaca 540
gtggctgctg tgctgaagcg gaggctgctg cagccctcgc gccgggtcaa gcgctcgcgc 600
eggagacece tectecegee caegeeggae ageggeeegg aaggegagag eteggagtga 660
cggcctggga cctgccactg tggcgtgcgg ctcctccccg cgccgcgagg ccgcgacctc 720
tgccacgtgg accgcgcgcg gggcgctccc tggtggcgat ggcgcggcac tggccgagca 780
ctgcgggggc tttcctcctt gttggttgct gagtgggcgg ccaaggggag aaaaggagcc 840
gcttctgcct cccttgccaa aactccgttt ctaattaaat tatttttagt agaaaaaaa 900
aaaaaaaaaa aaaaaggcgg ccgtttanag gatncctcga aggggcccaa gttaacgcgt 960
gcatgcgaag tcataactct ctccctataa tgatcgtatt ataagtaagc actggccgtc 1020
gtttttanaa ngtcgtgaat ggggaaattt gctaactttg ggaacttttt gaaa
<210> 25
<211> 1186
<212> DNA
<213> Homo sapiens
<400> 25
```

```
tatcagetca ageettacae cayeeacete ateaaggace tecaettttt cettegagtg 60
ctcatccaac tgtaccaccg tatccctcac aagctacaca tcataccact ttgggaccgg 120
gaccccagca ccagcettet ggaacaggge cacattgtee attacetgte acaggteete 180
atotocagoo ccaaggacca aacagtatto caacacotac tgottcaggg ttotgtcoto 240
atcctggctc tgtggccctg ccacatgggg ttcaaggacc tcagcaggca tctccagtgc 300
ctggacagat tccaattcac agagcacagg tgccaccaac atttcaaaac aattaccatg 360
ggtcagggtg gcattaaaat ggactccaaa aacatttttt taaatgttct gtaagataaa 420
ctgtatattt catatgtacc tgttaaggta ctttttaaag cttgtacatg aacctttgta 480
taaaaaaacac cagtgctctt tcgttgtatt tttctcattt ttgcttttta aaattccttt 540
aaaaaatgtg ctgttaagcc agtattaggt atctttattt tgtaagtgaa cattccagct 600
gtttttttct ggcagatctg atgctgattt gatgctgtat gatctttttt tttttttag 660
ttaaattcat ttagtgaatg ttctattatt ttatacatac acattaagta ctcagctaag 720
taatggcact atgaggattt tttttttctt tcctgtcagc agcagttctg tgaatgcatc 780
ttaggtataa aaatgcaata cagattttta tattttggtg tggacatggc tcattttgtt 840
ttaccagtta tttgcaagca aaatgtaatt taatgtatag atgatttcta atgtctcctg 900
acaaactgta aatactgcat ttcttttgcg tatataattg cttacagctt ttctcatttg 960
atatatagca ttgtacatat gacaagtett ttgcaaaact gtgtgatett tgtgaaagta 1020
gtacagtata tgacctttaa tttcttttt attttaaata tactgtcaca ctgaagcact 1080
ggttgggcat tttaattcat gttaataaat cacaattatg tcagttccca cgcgtccgcg 1140
gacgcgtggg cggacgcgtg ggcggacgcg tgggcggacg cgtggg
                                                                   1186
<210> 26
<211> 888
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (670)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (675)
<223> n equals a,t,g, or c
<400> 26
gccccaccc gctgtgactg cattctggga tccccagcct gggaatccaa gagctgtcgg 60
cccattttat tectecetee cagacetgae ccetteateg gggeteaaga gacetetete 120
tccaaatctc catttgcctc ctctggctaa gctggaaaat gcacactctg ccctgggtgt 180
ttccatatta teegeetgee etteeteetg ggtgeeteee gtageettag taagggetet 240
gettteetgg geceetagag etgageeatg etttgeeata aaggtgetee eggettgeaa 300
ccaatgtgtc tgcttgtgca tctgtctgtg ggtgtggtgg ggagggaggg gaccaggtgg 360
gtactggcac tetggggtee ggaetttatg tecatggagg ceceaattga eteagtteaa 420
gggtcactga ggctttgctg atgtagggag agggccagag ggaggctcca ccccagccgg 480
gctgagccag ggaacctggg acaaaggtca ggtggctgat tccaggtagt gttttggagc 540
tgggcagtca gtggctgggc ggggacatat gcccaagagc caccatgaac tcccaggggc 600
ctccaggcag gggccctcca tcccgcacca agtctttcaa catgatgtcc ccgacgggcg 660
acaacteggn ctaenggetg agattaagge aggeaagage etgaageega egeeceagag 720
caaggggetg accacagtgt tttcaggcat cgggcagccg gccttccagg taggcgggcc 780
cagcaggage etgegaceeg getteeetgg eectaggeea eegggegete ageeceaeeg 840
```

```
cttctccctg cagcccgatt cgccgctgcc ttctgtgtca cctgcact
                                                                   888
<210> 27
<211> 789
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (420)
<223> n equals a,t,g, or c
<400> 27
gggtcgaccc acgcgtccgg ttggtcttgt gtctataaga atgatcaagc tgcaaaggat 60
aatccaacta aaagtettea ggaagaagaa ecatgteeaa ggtttgeeea teagettgta 120
tacgatgagc tacacaaggt tcattactta tttggtggga atccaggaaa atcttgctct 180
ccaaagatga gattagatga cttctggtca ctgaagttgt gtagaccttc aaaagattat 240
ttactgaggc attgcaagta cctcataaga aaacacakgt ttgaagaaaa ggcccaagtg 300
gatcccctta gtgctctgaa atatttacaa aatgatcttt atataactgt ggatcattca 360
gacccagaag agacaaaaga gtttcagctc ctggcatcag ctctattcaa atctggttcn 420
agattttaca getetggget tttetgatgt ggateacace tatgeteaaa gaacteaget 480
ctttgacacc ttagtaaatt tctttcctga cagcatgact cctcctaaag gcaacctggt 540
agaceteate acaetgtaae tgaagagtea etggacaeag aaatggaaaa caggagtega 600
ttttccgtcy tttggattgc agctccactg actgacagta aagctgcagt gattgaggac 660
tgcaccagag ttctgaaggg atcttaacca tcacaagttt ttaccctctt ccttcatgcc 720
tgacctcaac cocgetetee teatectatt eetaaattag getaataaag tgaaattggt 780
atactttcc
                                                                   789
<210> 28
<211> 847
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (799)
<223> n equals a,t,g, or c
<400> 28
ctgtcctgag ctgttcactg cttggtggct accttctaag agtgagcatc tcacaagcag 60
gtgtcttaag tgaggaaatg gaagctgcag cttcttaaac ctgggaatta gtagagcatt 120
acccctgctg tattctatta gaggtcaagc catcactgaa gccatattca aggagaggga 180
tcgtgcacac tcttccggaa atacgaccac atgagggctg ccatcctgga aaaaatgcct 240
cttgtggagc gagatggccc tcaggctgat gaggaagcaa aggaaagcaa agaagcagcc 300
cagettteag aageageeee agtgeecaca gageeceagg ceteacaget cetggatetg 360
ctagatetee tggatgggge ttetggggat gtecageate etececatet ggacecetee 420
ccaggaggtg ccctggtaca cctgcttgac cttccctgtg twcctccacc cccagctccc 480
atcccagatc tcaaagtgtt tgagcgtgar ggagtacagc tgaatctgtc tttcattcga 540
eccectgaaa accetgettt getgttaate accateactg ceaceaactt eteagagggt 600
gatgtcaccc atttcatctg ccaggctgct gtgcccaaga gtctccagct gcagctgcag 660
gcccccagtg ggaacacagt tccagctcgg ggtggccttc ctatcaccca gctcttcaga 720
```

```
atcctcaatc ctaacaaggc ccccctgcgg ctaaagctgc gctcactacg accactttca 780
ccagtcggtg caggagatnt ttgaggtgaa caactgcctg tggaatcgtg gcagtaatgt 840
ctccaat
<210> 29
<211> 666
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (4)
<223> n equals a,t,g, or c
<400> 29
gganccatgg gagtatgcac atgggatcat aatccattct gtggtttgga aaaagaaaat 60
gttaacctct gctttagagg gtagctacta gctttgttgg ggataaaagt gtaatacatg 120
cacttttgaa ctctgaaagt ttgccaatct gaaaaggggt gtttctgaag accactatct 180
tttacgaaca cttaaaaata agtgtttgca gttgtgtatg ggcacgatac tgtattcttt 240
acatttttat ggccctacag ctacttctta tccctgcaag tatataaatt aaaaccaagt 300
cactttagaa cagctttgaa actagagttt caaaggtaaa aggatctcat gtttctgaat 360
ctgcgtaaag caagatggct gtgatttgac aggtttaatt gctagktttt ataggtggat 420
agaaatgaat agtttggagt ctttaaaatg ttttaaaaaa tgtttgctta ctatctatat 480
atatgacatt atteceaatt agttttatat etecaagata tatatatgta tataggtata 540
tacacatatg tatatataca tagtotatat attotatata agaatatatt ccaataagaa 600
tatattccat acgggaatat attagtcatt gatgtatttt gccggtaaaa ttaaaagata 660
ttttaa
<210> 30
<211> 517
<212> DNA
<213> Homo sapiens
<400> 30
egeteggett cetgggtetg getgetgeeg eeegeeggtg teegeeegtg tegegeeggg 60
gcaccaagga gccgttggag ggtccgggcg gaggcccgct cgtgtggaag tcgtcgacgc 120
egeegetegt eegteeteee gteegttete geteeeggee geeateatge tggegeteat 180
ctcccgcctg ctggactggt tccgttcgct cttctggaag gaagagatgg agctgacgct 240
cgtggggctg cagtactcgg gcaagaccac cttcgtcaat gtcatcgcgt caggtcaatt 300
cagtgaagat atgataccca cagtgggctt caacatgagg aaggtaacta aaggtaacgt 360
cacaataaag atctgggaca taggaggaca accccgattt cgaagcatgt gggagcggta 420
ttgcagagga gtcaatgcta ttgtttacat gatagatgct gcagatcgtg aaaagataga 480
agcttcccga aatgagctaa cataatcttc tagataa
<210> 31
<211> 2675
<212> DNA
<213> Homo sapiens
<400> 31
gcgaggtcac gtgacggagc gccggagcgg agggagccgg ggctgggagt tctcctgagg 60
```

WO 00/55351 PCT/US00/05883

```
gaagaggagt ggagtagggg ggacgcggcg gcggcgttga caatgagttt tcttggaggc 120
ttttttggtc caatttgtga gatcgatatt gttcttaatg atggggaaac caggaaaatg 180
gcagaaatga aaactgaaga tggcaaagta gaaaaacact atctcttcta tgacggagaa 240
tccgtttcag gaaaggtaaa cctagccttt aagcaacctg gaaagaggct agaacaccaa 300
ggaattagaa ttgaatttgt aggtcaaatt gaacttttca atgacaagag taatactcat 360
gaatttgtaa acctagtgaa agaactagcc ttacctggag aactgactca gagcagaagt 420
tatgattttg aatttatgca agttgaaaag ccatatgaat cttacatcgg tgccaatgtc 480
cgcttgaggt attttcttaa agtgacaata gtgagaagac tgacagattt ggtaaaagag 540
tatgatetta tigiteacea getigeeace tateetgatg tiaacaacte tattaagatg 600
gaagtgggca ttgaagattg tctacatata gaatttgaat ataataaatc aaagtatcat 660
ttaaaggatg tgattgttgg aaaaatttac ttcttattag taagaataaa aatacaacat 720
atggagttac agctgatcaa aaaagagatc acaggaattg gacccagtac cacaacagaa 780
acagaaacaa tcgccaaata tgaaataatg gatggtgcac cagtaaaagg tgaatcaatt 840
ccaataaggc tatttttagc aggatatgac ccaactccaa caatgagaga tgtgaacaaa 900
aaattttcag taaggtactt tttgaattta gtgcttgttg atgaggaaga ccggagtagc 960
ttcaaacagc aggagataat tttatggaga aaagctcctg aaaaactgag gaaacagaga 1020
acaaactttc accagcgatt tgaatctcca gaatcacagg catctgccga acagcctgaa 1080
atgtgaactg aacaggagaa aaaaagaaaa gcmaaaaact cctgtwaccc ttgarattaa 1140
gttcagcagg ttaaagatgg ttgcagctgg aggggggga aaaaaggccaa aactccatat 1200
atgttagtct tcctttatct tacagcgcay wtttatttta tgatataatg aaatgttcgt 1260
toatgtatat acatttttaa aagtgctttc tttgaaacac tggaactttg ttaagctgcc 1320
tttttttttt taacttccta ctttgatgat aagcactcag atatatatca gcgtaaacat 1380
gaaaaatttt catgtgagta ggctggtatt tgtaattttg ctttctttct gcataatgtt 1440
gattataaat cotototttt caggotaatg attacotott attototaca tgcaaaaaat 1500
taaatatttt gtgttcaaat aaaattagaa aacytgagtg gcctcttgtg tcctgcagag 1560
atttaaaaca tggcatctca atatttttga gaactacatt tgtttttaac atatgtgttt 1620
gagaaaagca tatggagtgt ttcaccgcag gcacttctga gtaccattcc atggcttcca 1680
gaattttatc ctctttgagg tcttctgtgc tatgaatatt agatttcttt ccccaaggga 1740
ttatgtggca ggtcattatg gccttctttt ttttggccat attaagtaac agttttgcta 1800
tattccagta gtaccgttgt gtgttttctg caatgtggag ttgacttagc ttggcatttt 1860
agatttgtta aaactatttt ttccataaat actttgaaac gtatttatat atttcaattt 1920
aaggaatett titgeeatgt gtatgeaaat attattiet teatacatte attitettit 1980
caggggaaaa ttttgggatg ggggactcag gaggacctgt gaagcatgta gttatctaga 2040
totgggtaat ttoatgttta ttaaactoga actttggcta gttaaactoa tattgaaact 2100
tcatctagtc tcttaatttt ttaacactaa attcaagtca tttgttttaa gtctctaaaa 2160
aagaagattg cagtcatcca ttcatatgca tggggtctga tcgcaaatac actaaatgtg 2220
gagtgtagga accaaaatga aacctgctgt atggaaacta ctttcactta tggttcattg 2280
gtttttgtac caatattttt tatgcacttc agtgcaagtc ttgtcagtta accttacttt 2340
atgagtaagc taaataaccc aaattacatt tctttaaacc tgttttacta ctatggcact 2400
ttgataaaat ggtcaggaac caactttact ggcaaaaggg tccatgtacc accatgtgct 2460
ggagcatctg ttctacatgt ggatatcwat gaatggtaat gttttccttc atgtaagtgc 2520
ctattcagag tttcagaatt ttaaaatgcc aaatattttc atggtcattt gcatgtagta 2580
agccagaaaa tattcaaaga gattttgaaa accaattgta tttaaccagc ctcaaattgt 2640
                                                                  2675
gcaaccatga tgtataataa agaatttgaa acaga
```

<210> 32

<211> 277

<212> DNA

<213> Homo sapiens

```
<221> misc feature
<222> (109)
<223> n equals a,t,g, or c
<400> 32
agcogcacco coagoactto ggacatggoo gaggaaggoa gagtggocag ogggggocco 60
ccagggctgg agacctcgga gtctctcagt gactcactct acgactcgnt gtcctcttgt 120
gggagtcagg gctgaggggc tgcgccacgc cacggccccg ctggagctgg ggaccacaga 180
ctggaccggc tetetteatg eccageeece ggagacgggg acceetteee tgaagggace 240
aaggaggcag gtggataaga aggttgaaaa gggggtt
<210> 33
<211> 921
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (2)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (839)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (846)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (886)
<223> n equals a,t,g, or c
<400> 33
cngtggcttt cctgcaccac tgcccccac caggatgatg gagagtaaga tgattgctgc 60
catacactcc agcagtgcag atgccaccag cagttcaaat tatcattcct ttgtcactgc 120
ttcatccacc tctgtggacg atgcattgcc tttaccactt cctgtcccac aacctaagca 180
tgcttctcag aaaacagttt actcctcctt tgctaggccc gatgtcacca ctgaaccctt 240
tggtccagat aactgtttgc atttcaatat gactccaaac tgccagtacc gtccccagag 300
tgtacctccc catcacaata aattggagca gcaccaagtg tatggtgcca ggtcagagcc 360
accageetee atgggtette gttataacae atatgtggee eeaggaagaa acgeatetgg 420
acaccactee aageeatgea geegggtega gtatgtgtet tetttgaget eetetgteag 480
gaatacetgt tacceegaag acattecace gtaccetace atceggagag tgcagtetet 540
ccatgeteeg eegtetteea tgattegete tgtteecatt teaeggacag aagtteecee 600
agatgatgag ccagcctact gcccaagacc tctgtaccaa tataagccat atcagtcctc 660
ccaggcccgc tcagattatc atgtcactca gcttcagcct tactttgaga atggccgggt 720
ccactacagg tatageceat attecagtte ttetagttee tattacagte cagatgggge 780
cctgtgtgat gtggatgcct atggacartc cagttgagac cctttcaacg gctttccant 840
```

```
cgagantttg tttttacaa tcctaggttg caaggaaaga gctttntaca gttatgctgg 900
                                                                   921
gtttgggtcc aggtccccgg g
<210> 34
<211> 1467
<212> DNA
<213> Homo sapiens
<400> 34
aaaaaaaaa gaaaagttot gtgttgatgt acagtttoto otaagaagaa gcgaggtggt 60
tgaattttgg aagcacttct tgaatcggat taacccatgc tcttattgaa ttttttcatc 120
tgctctgttt agtttgatat taaagcaaaa ttaagaggtc ttagtttttc ctatagaact 180
tttaatatgt caaaagctat attgtctaaa tttcagtact taagcaaata ctgagtagtg 240
ttttaaattc agaaatagag cttctattat gaacacatga gaatgatttt tttctcttaa 300
tcattattaa ggaaatattt taatttcatg gtcatataat ggtgataagt aatacctgat 360
tgtttccttt tctgttctag taactcagag gagatacgtg ttttatttgt gatagcaaat 420
tcctaaatga acattaggca agtggtatca ttatcaggcc agctgcagcc tcttgccttg 480
acctgcattc ctagaatttc tttgttgctg taattcttga ttaagtgacc ttgactttca 540
ttttgtaatt ttgctaatca tcagcaaatt cacttgcatg acgttactgc caaatatgaa 600
ggcagttgaa ttattatgag tgattgtggc agaggtttgt gccatggtga aaactttgat 660
gtttgtctgt gttcattgga tccatctttt taaatgacat taccatgagt ctgttgtcaa 720
acctaaatat ctttgtttga atttaaaatg ggactctata ttgttgtagt tcaggtcttc 780
attgactaag agattgagag aaatctgaca taagaaaata ttgttttcac tgcaggaata 840
aagaggaagt aacagtgaat ccaatatagt tcatattgtt attgtccaat catcaagtta 900
actaagcatt atcagattac gtttatttct catacatatg gatattaact taaggtaaaa 960
aagctggatg tgaaggatct gaaaaggcat taatttatgt actaattcta taaacatgta 1020
ttaataattg cagtattatt aaatacagat ggactcaatg tacctttgaa aagaccacta 1080
atttagaaaa caaagctaag tgcagtcatt acaagaagca aagaaatact taagttagaa 1140
aaaaattaaa atgaagggat ggtctaagtt ttcttcatgc tggaacaaat gttaaagaag 1200
cagtgattgc ttacaatgta tgtgataaaa taataccttt cacaatcaaa attttaatag 1260
taaatataag ataaaattta tattaaataa tgaaaacgta tttgtactga atttagtcac 1320
tagagaacat cgtaacaaaa tacatgaaac aaaagtagcc agaaatgtta gaacaggtgg 1380
aaatgtatac attatttgat ggtttgtttt tttatggaaa taaacaacat acatagaatt 1440
                                                                   1467
aaatggtgat caaaaacatg gaaaaaa
<210> 35
<211> 2077
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (12)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (15)
<223> n equals a,t,g, or c
<220>
```

```
<221> misc feature
<222> (423)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (730)
<223> n equals a,t,g, or c
<400> 35
eggacggtgg gnegnegaca caatgggeea yggagtteee gttegatgtg gaegegetgt 60
teceggageg gateaeggtg etggaceage acetggagge ecceageeeg eegaceegga 120
accacaacgc cggcccgtgt tgatctacag cagcaaatta tgaccattat agatgaactg 180
ggcaaggctt ctgccaaggc ccagaatctt tccgctccta tcactagtgc atcaaggatg 240
cagagtaacc gccatgttgt ttatattctc aaagacagtt cagcccgacc ggctggaaaa 300
ggagccatta ttggtttcat caaagttgga tacaagaagc tctttgtact ggatgatcgt 360
gaggeteata atgaggtaga accaetttge atcetggaet tttacateca tgagtetgtg 420
cangccatgg ccatgggcga gaactcttcc agtatatgtt gcagaaggag cgagtggaac 480
egeaceaact ggeaattgae egaceeteae agaagetget gaaatteetg aataageact 540 -
acaatctgga gaccacagtc ccacaggtga acaactttgt gatctttgaa ggcttctttg 600
cccatcaaca tcctccagca aggaagctgc cacccaagag agcagaggga gacatcaagc 660
catactcctc tagtgaccga gaatttctga aggtagctgt ggagcctcct tggcccctaa 720
acagggeeen tegeogegee acaceteeag escaceceace ecceegetee ageageetgg 780
gaaactcacc agaacgaggt cecetecgee cetttgtgee agageaggag etgetgegtt 840
cettgegeet etgececca caccetaceg ecegeettet gttggetget gaccetgggg 900
gcagcccagc tcaacgtcqt cgcaccagct cccttccccg ctctgaggag agtcgatact 960
aacagctacc ctctccctgc cctgggagac ctggggtggg cagggaaccc ctccctgaga 1020
acctcagacc cactcttcca ttgcatcctg taggacccag tggaacctga cagagcccat 1080
aggattccct cttctacttt cttagacagc agggatgtca gggtctcaaa ctgcctaaca 1140
ctttgtaget tttcttaaca caaaageace cettetetee taacttggge tetgaatact 1200
ttcccaacag gaagtctgat ctgttgccag acttcttggt tagatggctc atacatttat 1260
ctagagaagc acactettgc ttgctgtcaa actttagamc accatggaag gtctaagggc 1320
atcctgtgcc agggaaactt tttaaggaat tttatctatg ggataaaccc catattccct 1380
ctagtgtcta ctggtggctc taatactgct ttgtgctgcc tgccacactt gccctttgag 1440
cctgcgaatg gccgctagtg agcaagctct gcttcagagc agtctagtta ggtagaacag 1500
ggacttacca gcttcccaaa gggatctact caccattgcc aaactcttca tttccacatt 1560
ttgtgtaggt gtcagggaac cccaaactgg tgttgctttg gggtctctaa aggagattgg 1620
ctgacaccac catttccccc agatccagat tctctgaggg aggttgtttc ttgagagtag 1680
atccagagtg tcaaggatct gttagatcct ggaatccctt cttgcatcca tccctccctg 1740
tetteetetg teetteetet eteettteet eeatageaag gaegacette eetgeteeat 1860
geocagagta tagetagate cetteceete ectaceetet gaatgtgtge tagateaggt 1920
gccccactgt gtttcctgaa atccttggga gccggatctc cccatctccc ctactcactc 1980
ttcccttttc ttctctcagt gttgtctgaa taaagtgtga aatcttttgt gttttctaaa 2040
ttgacatttt caatgaaaaa aagaatcaca aaaaaaa
                                                                2077
<210> 36
<211> 384
```

23

<212> DNA

<213> Homo sapiens

```
<220>
<221> misc feature
<222> (366)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (370)
<223> n equals a,t,g, or c
<400> 36
ccagcaggag aatcctcccc tgccccttgg ctcaaaggcc ctggagccca cctcccagaa 60
gcccggtgtg ggggcgggcc acgggggaga tcccaagctc agtccccaca aagttcaggg 120
ccggtcggag gcaggggcag gtccgggtcc aaagcaagga caccacagct cttccgactc 180
cagcagcagc tecagegatt eggacaegga tgtraagtee eaegetgetg getecaagea 240
gcacgagagc atcccgggca aggccaagaa gcccaaagtg aagaagaagg agaagggcaa 300
gaaggagaag ggcaagaaga aggaggctcc ccactgaagg gcctggacaa ggctcattaa 360
acttcntctn tgccaaaaaa aaaa
                                                                   384
<210> 37
<211> 468
<212> DNA
<213> Homo sapiens
<400> 37
gcgatgctgg gtgtggcagg cctcctgagc cggctggagg aggacaggct gctgctgcta 60
ccgaaggagg atgkctgtcg ctgggccttg gctgtaggca gctgggctta ctgccgggcc 120
ctgcatacac agcgcctcca gtgggagtga cagttggata cagccaggca gggtttctgc 180
cctgccgaac actttccctc ccacctgcct gctcctggcg ccttctccct aggggtagac 240
tettetgeet actgaagtgg gtttgetgea cattgaetgg teaggggeag agtetgggtg 300
ctgtcctttg gccacgtgtg gggacttgtc tagaccagaa tgaaaggaca gggtcccaga 360
cacgttttggg ggtcctgatt ctgggctgga cacggttgtg gatccagaga agaggcctag 420
                                                                   468
tctccaataa atcttaggaa ttttgcagga aaaaaaaaa aaaaaaaa
<210> 38
<211> 1095
<212> DNA
<213> Homo sapiens
<400> 38
ggcacgagga taatgagcat aagcgttcac tgaccaagac tccagccaga aagtctgcac 60
atgtgaccgt gtctgggggc acccaaaaag gcgaggctgt gcttgggaca cacaaattaa 120
agaccatcac ggggaattot gotgotgtta ttaccocatt caagttgaca actgaggcaa 180
cgcagactcc agtctccaat aagaaaccag tgtttgatct taaagcaagt ttgtctcgtc 240
ccctcaacta tgaaccacac aaaggaaagc taaaaccatg ggggcaatct aaagaaaata 300
attatctaaa tcaacatgtc aacagaatta acttctacaa gaaaacttac aaacaacccc 360
atotocaqao aaaggaagag caacggaaga aacgcgagca agaacgaaag gagaagaaag 420
caaaggtttt gggaatgcga aggggcctca ttttggctga agattaataa tttttaaca 480
tottgtaaat attootgtat totcaacttt tttccttttg taaatttttt ttttttgctg 540
tcatccccac tttagtcacg agatcttttt ctgctaactg ttcatagtct gtgtagtgtc 600
catgggttct tcatgtgcta tgatctctga aaagacgtta tcaccttaaa gctcaaattc 660
```

```
tttgggatgg tttttactta agtccattaa caattcaggt ttctaacgag acccatccta 720
 aaattotgtt totagatttt taatgtoaag ttoocaagtt coccotgotg gttotaatat 780
 taacagaact gcagtcttct gctagccaat agcatttacc tgatggcagc tagttatgca 840
 agcttcagga gaatttgaac aataacaaga atagggtaag ctgggataga aaggccacct 900
 cttcactctc tatagaatat agtaaccttt atgaaacggg gccatatagt ttggttatga 960
 catcaatatt ttacctaggt qaaattgttt aggcttatgt accttcgttc aaatatcctc 1020
 atgtaattgc catctgtcac tcactatatt cacaaaaata aaactctaca actcatctaa 1080
                                                                    1095
 catgcttact taaaa
 <210> 39
 <211> 1757
 <212> DNA
 <213> Homo sapiens
 <220>
 <221> misc feature
 <222> (596)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (647)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (648)
 <223> n equals a,t,g, or c
 <400> 39
 gccagccacc attttatctc tctaaagtct ggtcccagta ttaaacctat tctttagtaa 60
 actcatatta ctgttctaaa ttgaagaaat tatttattac tctgtacttc tagactcaaa 120
 attetttate aaagatagte teaaagaggt agtacaagte etgtttaaet geaettttte 180
 acattcacag tgcttcctct gatatctttc cttacatcat tatacactgt tgatatcatt 240
 ttactcttct ttctcttcta catttcttaa attttggttc ttttcctgta catgtgtttt 300
 aggggggcc ttttctttga actttqtcta attagcctgt acatttttgt ttcttttaag 360
 gtagaacaga tottttttg tttctccttt taagtctact ggttttaaaa gaggtaaatg 420
 tatccataga ccacagtgcc ttgctttttc ctctgccagc acatggagca cgggattaga 480
 tgcacaaacc tatttaggga actattttgg tagatgtttg agtttataca gaaattgcag 540
 ctggtatttt attttgctgt acatttactc aacttgtcca ttagtattta actatntcca 600
 gagtttgttt aggagtaaga attgacccat tcgttagttt accatanntt ttcctggtat 660
 aaaaaggagc cagaaataag ccttattgct aaataattaa ttatgtaagc ccacctaggt 720
 cctgcataaq atcccctca catacttcac aatatatatg tgtgtgtgtg tgtgtgtgtg 780
 tgtgtgtgtg tgtgtgtgt tgtgtatktg gctaaaaaat tatactgcca aaattactga 840
 ttataaatac ttgactacac tgattgatgg gacaaaatga ttaaaagtatt ttcagggatc 900
 ttattccata tgtcaccacc aaagatttct acagtgttat aaagtatata aatattccaa 960
. atttctqtqq ttaaatattt ttttcttttt tttccttttt tagaataaca cagtctgtgc 1020
 tttccaaaaa tgcttgaact tttatgttgt taagaaatat ataatgatat cttacattaa 1080
 gcatgagtct aatttgtatt aattgggatg gactaaattt tcatttgatt atcaggaaaa 1140
 ttaaggagtt atatatttaa aagcaatttt ctgtgttttc ttctttgtaa gttgactcat 1200
 ttgtgaagca attaggcaaa ttttgagaag atcattgtta ttgtggtttg cagtatatat 1260
```

PCT/US00/05883 WO 00/55351 26

```
ttcttagtaa atatcactta agattaaatt tttcagaaag aaaattatag cttttttccc 1320
   aaaatatttt taagatttaa totttttgta gtatgotaca gatttaatta tattaactot 1380
   tttttaagac attgaccatg acttaacatt ttgccttcta acacctttta aatctatgta 1440
   ctttaatagt taagagaaaa taagtttgca gatttttaat aatctgtttg taaaaggcta 1500
   tctctaagcc tagtatgtgg gtaattttac aggtgtgttt tttgataact ttaatataaa 1560
   ataaactcat tttatttgtg gcaattcgcg tttctttttt tatgccagag tacatatgtt 1620
   ggattccatg aattggtatt acttattatt atgtgttgat taaatatatg cacacactta 1680
   ggattacaga tcacagagca aattatgaaa atcataaaca ttctggtatg gtcatccata 1740
                                                                     1757
   ggattatgaa aaagaaa
   <210> 40
   <211> 1945
   <212> DNA
   <213> Homo sapiens
<400> 40
   accgggaget ggtgacggat ggcggggccg ccagcccctg gcgctgcaac tgggaacagt 60
   tgttgaaccc gcgaccaagc gaggcggacc ctgaagcgga ccccgaggaa gccactgctg 120
   ccagggtgat tgacaggttt gatgaagggg aagatgggga aggtgatttc ctagtagtgg 180
   gtagcattag aaaactggca tcagcctccc tcttggacac ggacaaaagg tattgcggca 240
   aaaccacctc tagaaaagca tggaatgaag accattggga gcagactctg ccaggwtcgt 300
   ctgatgagga aatatctgat gaggaagggt ctggagatga agattcagag ggactgggtc 360
   tggaggaata tgatgaggac gacctgggtg ctgctgagga acaggagtgt ggtgatcaca 420
   gggagagcaa gaagagcaga agccactctg caaaaacacc gggcttcagt gtccagagta 480
   tcagtgactt tgagaaattt accaagggaa tggatgacct tgggagcagt gaggaggagg 540
   aagacgaaga gagtggcatg gaagaagggg atgacgcgga agactcccaa ggcgagagtg 600
   aggaagacag ggctggagat agaaacagtg aggatgatgg tgtggtgatg accttctcta 660
   gtgtcaaagt ttctgaggaa gtggagaaag gaagagccgt gaagaaccag atagcactgt 720
   gggaccaget ettggaagga aggateaaac tacaaaaage tetgttgaee accaaccage 780
   ttcctcaacc agatgttttc ccattgttca aggacaaagg tggcccagaa ttttccagtg 840
  ccctgaaaaa tagtcacaag gcacttaaag cattgttgag gtcattggta ggtcttcagg 900
  aagagttgct tttccagtac ccagacacta gatatctagt agatgggaca aagcccaatg 960
```

ccaaactggc ttctggaaaa ctggggaagg gttttggtgc ctttgaacgc tcaatcttga 1200 ctcagatcga ccatattctg atggacaaag agagattact tcgaaggaca cagaccaagc 1260 gctcygtcta tcgagttctt ggcaaacctg agccagcagc tcagcctgtc ccagagagtt 1320 tgccagggga accggagatc cttcctcaag cccctgctaa tgctcatctg aaggacttgg 1380

atgaagaaat ctttgatgat gatgactttt accaccagct ccttcgagaa ctcatagaac 1440 ggaagaccag ctccttggat cccaacgatc aggtggccat gggaaggcag tggcttgcaa 1500 tccagaagtt acgaagcaaa atccacaaaa aagtagatag gaaagccagc aaaggcagga 1560

caatgaatga tgatgccagg acagaactgt accgctctct ttttggccag ctccaccctc 1680 ccgacgaagg ccacggggat tgacatcgcc cacctccgac acccagtggg cgccttggct 1740 ggtgcggctg ctggtccaga tggaggaaac cagtgacttt atggggctga gctagtaggg 1800

ggccgcgaat taccggaccg gtaac

aagcccctgg aaagatgctg cgttccgaac ctgtgcctaa tacacgcaag ggcgctgtcc 1860 cgcccaaccc cgcctttaaa cgccacaaat aaagagcatt gttaccgcca agtacgacgc 1920

gargaagggt ccctgcaaag aggaagctgg agatggagga ctatcccagc ttcatggcaa 1080 agegetttge egaetttaea gtetaeagga acegeacaet teagaaatgg eaegataaga 1140 aactteggtt teatgteett ageaagetae tgagttteat ggeacetatt gaecataeta 1620

1945

```
<211> 588
<212> DNA
<213> Homo sapiens
<400> 41
aggogtatac caccatgact gaaaacaaaa gactttttt tgagactccc tctcaaaaac 60
aaaacaaaac aaaaaaatta gacaaatgct acattaatgt ttgggtggtc agattctact 120
ttgaatctga agtttgcaga tatgcctata gatttttgga gtttaccact ttcttattct 180
gtatcattaa tgtaatattt taaattacta tatatgttac catttttctg gatttagtaa 240
gaaatttgca gttttggttt gatgtaacaa gggttttaat gtaatttatg ttagattttg 300
catttttttc attactgtta tattttaacc tgactgactg atctaattgt attagtattg 360
tgaataatca tgtgaaatgt tttgagacag agtactatat ttgtgaatat aattttatgg 420
tttttttcac ttagaacctt tctgtgtgga aaactaagaa aattgctttc tgctgtataa 480
totggcatto attgtagatt aaagottatt tttotgtgaa taaaacgtat toaataaaat 540
                                                                   588
actattcttt aaaattawaw mawaaaaaaa aaaaaaaaa aaaaaaaa
<210> 42
<211> 1568
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (104)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (112)
<223> n equals a,t,g, or c
<400> 42 '
cattagattt cactttttta aaaaacccag tggacattgc tataaataag atttatttgg 60
ctacaaataa cctgggatgt tgcttattat gattgatgcc tgcnggtttg tncccaagct 120
gagtgaaatt gaacctcgtc ctccctactc attttgatga ctgaggctgg tttataagaa 180
aaggaagttt ggagaagaaa accgagatta gaaaatatca tgttttggtt ggagataaga 240
accagggatg gcaagtacca gtgtgtacaa atgtatttca cggagtttga aggaacgcat 300
aatcaagagg gaaaacaatt tgtccttcat tggacgtatt atttggattt gggtgagcaa 360
caaaatggaa tgtggtctgt taggagcatt ctgtttgttc ttttgtccct gatgtgatga 420
atcattgcca catgctagat ggactcttca tatccaggtt ttgtccctca gggctgagca 480
ctgtattaaa gagtttttgt tgagtcattt aaccttagtg tccacatcca gatcagctgt 540
aaaatgggga agacgtgtqc tqatttggaa tgaatgcaaa atatcactat cattttccta 600
attacagagg agcaaaggtt atcttcagcc ctttcagttc tatgctcaca tattcaaata 660
tcaaatgtaa tttagctgaa gttatttaat aatcaagtct ttcaatatct gttcaaagaa 720
aaagaacaca ctttgaaaat tctgcaaagc tgtctcccag tctttaaaat gtctggaagc 780
actotoctto titacaatac caacatoact ggoocagaat citocotgig ciaggitigta 840
aatataaata aattacttgt tttgtaaact tttgtaaaga atattttggt agaaatactt 900
caaacatatt ctttgggtta tatttataca tatgtgaaat aaatatacta tcaaaaggtt 960
atattttata caaaaagtaa attgctacct tttgtatgct aatatgcaaa gttttgtata 1020
atatgatggt ttatttttag ctctacactt aaaccatagg tggttgagtg ggaacttttg 1080
aaaactatca agaggcttqt tagacaaatt tatattctga aacctcaata agaaagcatt 1140
```

```
ccaggtttca atccttgttt tttgtcctgc tcccaaattc ttttttaaac ccatagttct 1200
 tgtgtcttat ttgattcttc tgctgtgcac attgtattgg tccttgttgc atgtagtcta 1260
 ctgtgtgttt tccgatttta taaggcagca tttctccata caaaaaraaa aaaaatgatg 1320
 tacatataaa cgcttttrtt gtatggctcc tccatgttac tgtatatatc tgccagcact 1380
 tcccagttac actcctgtga gtcagcttat ttttacccta acataaatag tatgttttgt 1440
 agtagttatc aaatttaaga gataaagcaa tcagaatgtt tggattttct tctatcttaa 1500
 tgtgaatttc ataattaatg tctatttatt cagctattca ttaaaataca ggattctttg 1560
 gggaaaaa
                                                                 1568
 <210> 43
 <211> 1060
 <212> DNA
<213> Homo sapiens
<400> 43
gcttgtcatg agaaggtggt aaatatccaa aaagaccccg gtgaatctct cggcatgacc 60
gtcgcagggg gagcatcaca tagaraatgg gatttgccta tctatgtcat cagtgttgag 120
cccggaggag tcataagcag agatggaaga ataaaaacag gtgacatttt gttgaatgtg 180
gatggggtcg aactgacaga ggtcagccgg agtgaggcag tggcattatt gaaaagaaca 240
tcatcctcga tagtactcaa agctttggaa gtcaaagagt atgagcccca ggaagmctgc 300
agcagcccag cagccctqqa ctccaaccac aacatqqccc cacccagtga ctggtcccca 360
tcctgggtca tgtggctgga attaccacgg tgcttgtata actgtaaaga tattgtatta 420
cgaagaaaca cagctggaag tctgggcttc tgcattgtag gaggttatga agaatacaat 480
ggaaacaaac cttttttcat caaatccatt gttgaaggaa caccagcata caatgatgga 540
agaattagat gtggtgatat tcttcttgct gtcaatggta gaagtacatc aggaatgata 600
catgottgot tggcaagact gotgaaagaa ottaaaggaa gaattactot aactattgtt 660
tcttggcctg gcacttttt atagaatcaa tgatgggtca gaggaaaaca gaaaaatcac 720
aaataggota agaagttgaa acactatatt tatottgtca gtttttatat ttaaagaaag 780
aatacattgt aaaaatgtca ggaaaagtat gatcatctaa tgaaagccag ttacacctca 840
gaaaatatga ttccaaaaaa attaaaacta ctagtttttt ttcagtgtgg aggatttctc 900
attactctac aacattgttt atattttttc tattcaataa aaagccctaa aacaacaaaa 960
ccaagettac gtacgegtge atgegacgte atagetette
<210> 44
<211> 1344
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (144)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (163)
<223> n equals a,t,g, or c
<400> 44
cccacgcgtc cggggccacc agggcctcct ggcccccctg ggcccccagc ccctgttggg 60
```

```
ccacccatg cccggatctc ccagcatgga gacccattgc tgtccaacac cttcactgag 120
 accaacaacc actggcccca gggnacccac tgggcctcca ggncytccag ggcccatggg 180
 tececetggg cetectggee ceaeaggtgt ecetgggagt cetggteaca taggaceece 240
 aggccccact ggacccaaag gaatctctgg ccacccagga gagaagggcg agagaggact 300
 9C9t9999ag cctggccccc aaggctctgc tggggcagcg gggggaactg gccctaaggg 360
 agaccetggt gagaagagee actgggetee tagettacag agetteetge ageageagge 420
 tcagctggag ctcctggcca gamgggtcam cctcctggaa gccatcatct ggccagaacc 480
 agagctgggg tctggggcgg gccctgccgg cacaggcacc cccagcctcc ttcggggcaa 540
 gaggggcgga catgcaacca actaccggat cgtggccccc aggagccggg acgagagagg 600
 ggccagctgc ctccagggac cgcccgtcca tatttattaa tgtcctcagg gtcccttctg 720
 ccatctaggc cttaggggta agcaggtctc agtcctggca ccatgcacat gtctgaggct 780
 gagcaagggc tgagaggaga ggcttgggcc tcagtttccc tctgtgaagt ggggggaggc 840
 aggccttcaa ggagggatag aggtacaagg cttcgtctca tctgctgtct gagcatccag 900
 gcccaaaggc actgagggag tcaggagctg gggctcggca catgcagaga tgacagggca 960
 99999cagtc ttcctcccc tccccgacca aacctcgggg agccctcctg tgcccctccc 1020
teettgttgt ccagtgetgg gyteeceace eegaggteag getgeecaat cetetgaetg 1080
gateaccggg ggettettge eteagttett ecetetgage eceeaggece teeegeatet 1140
caggttgggg atggggacat ggagaggaag gggccgccta ctcctgcaaa tgcttgtgac 1200
agatgccagg aggtagatgt gtgctggcca ataaaggccc ctacctgatt ccccgcaaaa 1260
aaaaaaaaa aaaaaaaaa aaaaaaaagg gcggccgctc tagaggatcc aagcttacgt 1320
acgcgtgcaa cgcgggtcat agct
                                                                 1344
<210> 45
<211> 892
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (890)
<223> n equals a,t,g, or c
<400> 45
ttgagaagtt ggatgaatat atatatagac acttctttgg tcacactttt tcccctccat 60
atggacccag tcgacctgat aaaaagcaac gtatggtaaa tattgaaaac tccaggcatc 120
gaaaacaaga gcagaagcac cttcagccac agccttataa aagggaaggt aaatggcata 180
aatatggtcg cactaatgga agacaaatgg caaatcttga aatagaattg gggcaattac 240
cttttgatcc tcaatactga ttcacaattg agttaaatta gacaactgta agagaaaaat 300
ttatgctttg tataatgttt ggtattgaaa ctaatgaaat taccaagatg acaatgtctt 360
ttcttttgtt tctaagtatc agtttgataa ctttatatta ttcctcagaa gcattagtta 420
aaagtctact aacctgcatt ttcctgtagt ttagcttcgt tgaatttttt ttgacactgg 480
aaatgttcaa ctgtagtttt attaaggaag ccaggcatgc aacagatttt gtgcatgaaa 540
tgagacttcc tttcagtgta agagcttaaa gcaagctcag tcatacatga caaagtgtaa 600
ttaacactga tgtttgtgtt aaatttgcag cagagcttga gaaaagtaca ttgttctgga 660
atttcatcat taacatttta taatettaca eteaettett gtetttttgt gggtteaaga 720
gccctctgac ttgtgaagaa tttgctgccc tcttaagagc ttgctgactt gttttcttgt 780
gaaatttttt gcacatctga atatcgtgga agaaacaata aaactacacc atgaggaaaa 840
aaaaaaaaa aaaaaaaaa aaaaaaaaaa aaaaccccgg ggggggcccn ga
                                                                892
```

```
<211> 496
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (496)
<223> n equals a,t,g, or c
<400> 46
aattoggoag agtoggagtg tggtacttot cotagttgoa gtoaggotto atacgotatt 60
gtcctgcccg taagttcccg ttttgtgtgt ggttagagca gccagcgggt acagaatgga 120
ttttggaaga gggagtcacc actggacctc caaggaagcc acgtgcagac atctacaacc 180
ttcgatctcc tgacgagttt attgttggcc aaaaccaggc tttgattgaa ccaggatgaa 240
tgcgggtgtt ggaagtagaa tatatatata catataaaat tgaaactggc gatggaatat 300
gagaggagcc ctctggaaag aaaaggacag accctgtgct ttcatgaaag tgaagatctg 360
gctgaaccag ttccacaagg ttactgtata catagcctga gtttaaaaagg ctgtgcccac 420
ttcaagaatg tcattgktag actttgaaat ttctaactgc ctacctgcat aaagaaaata 480
aaatctttta aatcan
<210> 47
<211> 1229
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (764)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (1165)
<223> n equals a,t,g, or c
<400> 47
attcggaacg agagctgata tggaagggtt atttctttct ggccaatact ttttggtatt 60
tctaaatatt gcaatcttga tttttactat taaatttgtt aattgtcagt tctggctttt 120
ttgcataaag agttggtcca ttaacttgcc aatttgaagc ttctaactag atattcccta 180
ctgaaagttt tggatttgtt tttagtttgt ggagcagtct tagctgggga caggtaattg 240
acaacggcag agatactttc ttttcctagg attctaagtc tgtaatccac atcctcaatg 300
tattcacagg actttaaaat tctctccaaa tgaggraggg aaatatcctg gtgctttcta 360
atgggttact aaaagttgtg tttagaacaa cagattttaa taggcatctt cctttgttat 420
gtgtcattag ccctttgccc gtttacctta gggctctttg aaggagaaat ggatgggaga 480
aaacctgtca cttggcgaaa gtaaaaggga taattaactg gctcagagct tatgtgcaga 540
gttccaagcc ccaaagttaa tctagaacca ctcgataaca ccaataaaaa tatttatttc 600
acatetgtta tatatetgga aaatgkteta ageatettae acatatttet eattaaatee 660
acaggtgacc attgtgaggt agawattttg ktctaawttt ccagatgagg aagctgagac 720
cctaaaaggt taggtgacag gttatacaac ttggagtgtg ggangaggag agaggaacct 780
gaacagggca agttggggat ctgacttttg tttgggtaga tgtaagcaca ttgtattttt 840
ggcttagatg ctttattcat catggctgaa ggtaatacca tttactcact caccgaaaat 900
```

B4 (contid)

PCT/US00/05883 WO 00/55351 31

```
tgtttacaat aatctagatg aatttgctgt ctttggacat ctgtcttttg actggacccc 960
agtatatagt ctgtggaagc tcacttaagg agaragctcc tttttgtttg gttagagaaa 1020
ttttctgtcc taaaagtaga aatagcccct tctaggtaag gatggagcat ttgatcatac 1080
tggtttcatt atattcctct aacaggttgg aaccgattgt ttttgagtac ttgtttcaaa 1140
cttctgagta ttttccttct ggaanatagc tcagtgtttt aaaatttaca tgaacttaaa 1200
                                                                   1229
aggttaattt ttttttaaaa gaatggtta
<210> 48
<211> 1411
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (1410)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (1411)
<223> n equals a,t,g, or c
<400> 48
catectgget cettgagtgg gagtratate acctetatee taactgteet tgteeeteet 60
ctccccacag ctggattatc accgaggect cttggtggac cgtccctctg aaactaagac 120
agaggagcag ggaataccac ggcccctgca ccccccaccc ccaccccgg tccagccacc 180
acagcacccc cgggcagagc agcgggagca ggaacgggca gtgcgggaac agtgggcaga 240
acgggaacgg gaaatggagc ggcgggagcg gactcgatca gagcgtgaat gggatcggga 300
caaagttcga gaagggcccc gttcccgatc aaggtcccgt gaccgccgcc gcaaggaacg 360
tgcgaagtct aaagaaaaga agagtgagaa gaaagagaaa gcccaggagg aaccacctgc 420
caagetgetg gatgaeettt teegaaagae caaggeaget eeetgeatet attggeteee 480
actgactgac agccagatcg ttcagaaaga ggcagagcgg gccgaacggg ccaaggagcg 540
ggagaagcgg cgaaaggagc aagaagaaga agagcaaaag gagcgggaga aggaagccga 600
gcgggaacgg aaccgacagc tggagcgaga gaaacgtcgg gagcacagtc gggagaggga 660
cagggagaga gagagagaaa gggagcggga caggggggac cgagatcggg atagggaaag 720
ggaccgagaa cgaggcaggg aaagggatcg cagggacacc aagcgccaca gcagaagccg 780
gagtoggago acacotgtgo gggacogggg tgggcgccgc tagotgggaa aacactagag 840
ctgcaggtac cagccactcg gccccagggg gttatggcca cagagggata ggcacagtct 900
ccaccaccct ggagccaagg gtctttcaca tcacctatcc ctacatacat accaaatgga 960
aaagtggcca tccttttccc cccaaacaca ccccttaac ctatctcttg ggacttagcc 1020
cgaccctccc tctcatttcc cattaagtct gagaggcaag agctaggtta ggcaaggagg 1080
tggttggcca gagatgggga acagccaggt gccccagtcc tctgattttt cctccatcct 1140
gcttaccacc tccctgggta cttacagcct tctcttggga acagccgggg ccaggactgg 1200
gtcacctatg agctgaatca gcatctcctc ctgagtccca gggcccctgc agttcccagt 1260
ctcttctgtc ctgcagccct tgcctctttc ccacaggttc cactttatat ccaccttttc 1320
cttttgttca atttttattt ttatttttt tattattaaa tgatgtggtc tatggaaaaa 1380
                                                                  1411
aaaataaaaa totgacttag ttttaaaaan n
<210> 49
<211> 1685
<212> DNA
```

```
<213> Homo sapiens
<220>
<221> misc feature
<222> (5)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (344)
<223> n equals a,t,q, or c
<220>
<221> misc feature
<222> (1606)
<223> n equals a,t,q, or c
<400> 49
egethtteec ecceacace gtgtggeeag ggateeege atggeeeate ttagaaacte 60
aactatttgg tggatgctaa acacttcact tcaggcaatc ccaaggcatt tgctccaggg 120
tatccgatga gattacagct gttaagcttg ctttccattt cataacttgc tgtgcagcta 180
gttaccaccc ccatgctgaa gagtaaagca aagtgccgtg gttcggcagt ggaatccacc 240
cccagcactc tgctcgcact ggagcgttca agtccggtta tgtgagaaca gactaggact 300
ctcttgctgc ctctaattgc atttcactgt caccctcccc agtnttctga tggtgtgcat 360
gtgaggagaa gatgaggtta ggactgagaa gtgcagaagt tggaacagtg gtaaggctgt 420
tttaaaaataa gatgttttgt tttaataata tgctcctggc acaaagctag gagtaaatgt 480
gactccaaag ggagttcagt taatctctga aatgcacaaa acctagctat tttctccctc 540
tcatcacagt ctgagtctgg tccattgcta ccccaattct ctggggacat aaaaccaggc 600
tggaaaggga ccaggaagtt tgaaatagtg acatatcatc cactagtccc aagggctaag 660
gaatagtgag tttattctgg aaggaactgg gaagcttagt ctaattagtg cctggggatg 720
acctatgcaa tcacaccgct tatgaccatc ctagagaggg ccctgagcac cagcttgatc 780
ttagggattt ccaaagtaac ctgctttttg cctggatagg gttaaaatag acctttcttg 840
cctatccttg ccttaaccta tctgcctgag gttggcctga gattgtgagt caacgacttt 900
gctatctttt cctcagtgtt gaactttcat taagaaataa agtcctagct tcttacagag 960
aggggtccaa atggtgaatg ctcatcctgc ctgggattca aggaattagc tcagagrttg 1020
gcccctagct tttctgcctt tgtaggggac agcaaaaggg gaaaatttgc tgcagaaaat 1080
tccaaaagat tgctgtagct ctcacaggga agtggtaaag atcagctaaa cctgggttgg 1140
ggtgctttct gcccagtggg tcttggcata agtagattaa tcctgctctt ttaagaaaaag 1200
gcaacttatt caggcagtct ggaaaggggg ttctcagaaa actcagtttc tttattcctt 1260
cttttctccc aactactgtt actggttata gaggtctttg gactctaaag accaatgttt 1320
ggccactaac tggactaata tgtatctttc tgtgatttca tcatagaggt ctgttttgtg 1380
agggtttggg gtgcagaaaa ctttgattaa atcttaatgg gaggctgggt gacctggatt 1440
atctacagtg agcagactta aatggaacag aagtttatgt gtccaaatga tggaatcatt 1500
aaacctgagt gacttgacct gtgtggttcc ttaatagtat ctatatatct agacaaaaat 1560
agattgtgaa tgtaaatggt gaatgaaaag gatggaaata atgttntcat atgttaatcc 1620
atgagettga atccagggag gaataceteg gtgetttaae cacettagtt ataacacatt 1680
tctta
                                                                  1685
```

<210> 50

WO 00/55351

<211> 660

<212> DNA

```
<213> Homo sapiens
<220>
<221> misc feature
<222> (515)
<223> n equals a,t,g, or c
<400> 50
eggeacgegt gggeetactt teaegettee teeeteece eteeteett atecettege 60
tttcgctctt ttccgtcgag gccgacccct gagttgtgag tctggggtct ggttggtgaa 120
aaagagccct tgaagctgga agacgggaga ggacaaaagc atgtcttccc ttcctgggtg 180
cattggtttg gatgcagcaa cagctacagt ggagtctgaa gagattgcag agctgcaaca 240
ggcagtggtt gaggaactgg gtatctctat ggaggaactt cggcatttca tcgatgagga 300
actggagaag atggattgtg tacagcaacg caagaagcag ctagcagagt tagagacatg 360
ggtaatacag aaagaatctg aggtggctca cgttgaccaa ctctttgatg atgcatccag 420
ggcagtgact aattgtgagt ctttggtgaa ggacttctac tccaagctgg gactacaata 480
ccgggacagt agctctgagg acgaatcttc ccggnctaca gaaataattg rgattcctga 540
tgaagatgat gatgtcctca gtattgattc aggtgatgct gggagcagaa ctccaaaaga 600
ccagaagctc cgtgaagcta tggctgcctt aagaaagtca gctcaagatg ttcagaagtt 660
<210> 51
<211> 1572
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (2)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (1555)
<223> n equals a,t,g, or c
<400> 51
tnagtgaaag aatgtgccat attacatatt gcaacctaat ttgttaaaac taactccagc 60
actaaagctg aaatgccaca aacactaaaa gtataaatat gtctgatttt tgaaacacat 120
aagetttget etttaggeag gaatgatett tteaaateat tageacaata tttaaatate 180
taaaaattta agagatccat actttctgta gctttacaat taatttaagt actaaaaaga 240
caaggatttc ttttaagaaa tttatagcat ttactgtgtt atttaaatgc taagccaaag 300
tatctgcact taggtatacc tctttatgcc aataatgatt ttaatgaagg ctcttttcag 360
atgtaacctt atgaaggaaa tatctgcttt gtgtatatgc cagttagaat actggtttct 420
aaagtctgtc aaattgtatt tcagtggcac aaaaaccagt tttgaggtct tagacttata 480
attotttgaa taaaactgat aacttatttg tataattgga gtggagacct acctccataa 540
ttagataaac totttttgga ttataatcag aattttgcct tttttcttct caaattatta 600
catatgtatg tattatatat ccacatatat agttttccct gattaaatgg atattaaaat 660
aattgegggt getteaggae tttttgette tatatttaag tatattgttt ttatageaag 720
aacatattot gaatgittia taaatotita ataattiata tgtaggiaat attitigtat 780
cacaatgcat tatttttttc ctcctttcct tccaaactat accactgtat ttaccacttc 840
taagagtgac tgacgacggg ccagatgacc cttgaagtag tcattatgta gcaataaatg 900
```

```
aagcctgaaa caggtttttt tacttccact ttaatcctta gaaatttctt ggcaacttcg 960
catattttca ttgacaccgg tgtataagta taaatttaaa tgaactaatt acttttgcat 1020
attttaaatt ctttatatgg tagttatttt ttataacagg atattaacat aagttaaatc 1080
ctatgtattt gåaattgtta cagagettte etetttaett caaacageaa aaaagtgggg 1140
ggcatattgt agtcctgtca tttaagttat gtwaaaaatt taatcattat tttgatgctt 1200
taaacattct catgtgtaat atatgttttt gtatcaaaaa cactcatata tttcaagaaa 1260
aagaaattat gttaaatagc cctgttttaa gaaaaatatt tatgaagcat ctcaacttga 1320
agatcaagtc aaagttataa ctcaggatct gargtctcaa gctaggagag actgagaatt 1380
ttaatcagtt tgggcatata rtttggactg aatcacatct gtagtactta gccaaagaca 1440
atttggarga raatatcagc cttctggaar tagctacttc ctgaacaatg taaagtgtcg 1500
gggggggccc cg
<210> 52
<211> 635
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (632)
<223> n equals a,t,g, or c
<400> 52
gctgctccag ctgttcgaag gtgatccaga cgcaagatgg ctgtcctctc taaggaatat 60
ggttttgtgc ttctaactqq tqctqccaqc tttataatqq tgqcccacct agccatcaat 120
gtttccaagg cccgcaagaa gtacaaagtg gagtatccta tcatgtacag cacggaccct 180
gaaaatgggc acatcttcaa ctgcattcag cgagcccacc agaacacgtt ggaagtgtat 240
cctcccttct tattttttct agctgttgga ggtgtttacc acccgcgtat agcttctggc 300
ctgggcttgg cctggattgt tggacgagtt ctttatgctt atggctatta cacgggagaa 360
cccagcaagc gtagtcgagg agccctgggg tccatcgccc tcctgggctt ggtgggcaca 420
actgtgtgct ctgctttcca gcatcttggt tgggttaaaa gtggcttggg cagtggaccc 480
aaatgctgcc attaaagaat tataggggtt taaaaactct cattcatttt aaatgactta 540
cctttatttc cakttacatt ttttttctaa atataataaa aacttacctg gcatcagcct 600
                                                                635
catacctaaa aaaaaaaaaa aaaaaaaaac tnggg
<210> 53
<211> 1367
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (106)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (958)
<223> n equals a,t,g, or c
```

```
<400> 53
ggccacgttg ttatctcttt gatcaagttg ttttacgtgt cacagtagag tctgaccagt 60
taccataacc aaacattttg tgcgtgtgct attgttgctg cgatantctc ctttgggtgg 120
aacacagtga agatcgacat gagtgcagcc cggagagatc ctcttccaat tgttccattt 180
ggattagctg catttgctac cactttgttt gccttgggat tagctttagg aacaaccata 240
gctgttggga tgttgttttt tatccagatg aaaataattc tcagaaacaa aacttctatt 300
gagtcatgga ttgaagagaa ggctaaagat cgaattcagt attatcaact agatgaagtc 360
tttgtttttc catatgatat gggaagtaga tggaggaact ttaaacaggt atttacgtgg 420
tcaggggtcc ctgaaggaga tggacttgag tggccagtaa gagaaggctg tcaccaatac 480
agottaacaa tagaacagtt gaaacaaaaa goagataaga gagtoagaag tgttogotat 540
aaagtaatag aagattatag tggtgcctgc tgccctctga ataaaggaat caaaaccttc 600
ttcacaagtc cctgcaccga agagcctcga atacagctgc aaaaagggga attcatttta 660
gccacaagag gtttacgata ctggttatat ggagacaaaa ttcttgatga ttcctttata 720
gaaggtgttt caagaataag gggttggttc cctagaaaat gtgtggaaaa gtgtccctgt 780
gatgctgaaa cagatcaagc cccagagggg gagaagaaaa atagatagct gctgttaaaa 840
caaaattatc ctttaagtct gcttaattac ttgaaaattg tacatattac taaagaatta 900
tgcaatgagc ctactctggt taagatgttc ttttcctcaa aggtgcccta gtgccatnga 960
tttaaatatt tttattacca ttttgaaatg gagaagccat tctgcatatg cctttgaatt 1020
ectgececte tttaccacet ettectecee etcaaaggaa aaacatttea tecaagtaag 1080
atacagttcc ccccttgcca ggagcatctg catgtggtac ttctcttttc cctcagttga 1200
tatttcttat atgatattct agatactata gaactcaatt tgtcagattc agtataacct 1260
cagattttgt tacctgtctt ttaaaaatgc agattttgtc aaatcaaata aagatcaatg 1320
gatgttgggt ataawmaaaa aaaaaaaaaa aaaaaaaaa aaaaaaa
<210> 54
<211> 378
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (14)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (29)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (363)
<223> n equals a,t,g, or c
<400> 54
ggcagtggta gggngtgaga accetgggne etgetgaaaa geeteetetg taggaggtea 60
cccagcagga caragaagca ggaggaggac agggccacar aggaagccaa gaacggtgaa 120
aaggccaggc ggwgttcara ggaggtggac ggccagcacc cggcccaaga ggaggtcccg 180
gaatcgcccc agacctctgg cccagagcag aaaataggtg tgggagcccc aggggaggaaa 240
agccarytgg agaggaagca gagwtggaaa aggctacaga ggtgaagggg gagagggtgc 300
```

```
aaaatgaaga ggtgggacct gaacatgaca gccaagaaac aaagaagctt gaggagggag 360
                                                                   378
ctncagtgaa ggcgaccc
<210> 55
<211> 1058
<212> DNA
<213> Homo sapiens
<400> 55
tcgggtatga ggctgggact aagccaaggg attcaggtgt ggtgccggtg ggaactgagg 60
aagcgcccaa gcttttttgt tctgaactcc cactgcgttg tggattcctg aggatgggat 120
gactgtatct tgattacccg gagttttcaa gatggcagca tctatgcatg gtcmgcccag 180
tccttctcta gaagatgcaa aactcagaag accaatggtc atagaaatca tagaaaaaaa 240
ttttgactat cttagaaaag aaatgacaca aaatatatat caaatggcga catttggaac 300
aacagctggt ttctctggaa tattctcaaa cttcctgttc agacgctgct tcaaggttaa 360
acatgatgct ttgaagacat atgcatcatt ggctacactt ccatttttgt ctactgttgt 420
tactgacaag ctttttgtaa ttgatgcttt gtattcagat aatataagca aggaaaactg 480
tgttttcaga agctcactga ttggcatagt ttgtggtgtt ttctatccca gttctttggc 540
ttttactaaa aatggacgcc tggcaaccaa gtatcatacc gttccactgc caccaaaagg 600
aagggtttta atccattgga tgacgctttg tcaaacacaa atgaaattaa tggcgattcc 660
tctagtcttt cagattatgt ttggaatatt aaatggtcta taccattatg cagtatttga 720
agagacactt gagaaaacta tacatgaaga gtaaccaaaa aaatgaatgg ttgctaactt 780
agcaaaatga agtttctata aagaggactc aggcattgct gaaagagtta aaagtaactg 840
tgaacaaata atttgttctg tgccttttgc ctggtatata gcaaatactc aaaaagtatt 900
caataattca atcaataaat ataagtttca tottacacgt aagatacagg tottatotoo 960
tgatggtgtg tccattttgc ctggtatata acagataata aatatccagt gtcaataaat 1020
                                                                   1058
gtaacaataa aagtttcatc tttcctcttt gtatgtgg
<210> 56
<211> 682
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (4)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (667)
<223> n equals a,t,g, or c
<400> 56
gggnccggaa catattccct tactcaaaag attgcatgac tgaatttgct taaggaaaaa 60
aaaaattgta tcaagtccat taatacaatt atacattaat tatattacat taatacaata 120
tatggtttgt gaattcagag acattaccag tttgcctcct tctctcaata gaacttgtat 180
tttcattttc ttggttaagc agttgtctcc taatattatc ccatatgcta cctagtttgc 240
tggtcccaaq cagtttactg tacttcacta gatttggtac ctgctctccc ctggacttct 300
ttttcaatat tctagccttt cctagatgta aatctttacc tccttgttag tgaaattaga 360
tataagccat gatttggaga gggaagaaat ctggaatact taatttcatt taattatcta 420
```

```
tgctgatgaa tgcctgtatc attgttaata aaggagaatt gaaaatactc atttctactt 480
tetgecetea aatttetgtt tetateteaa etaggeaaga ateageaggg tgeatgayge 540
cattttaagc tgcttcacat cagactgaaa tcctaattac agttcataag tgaaacagac 600
taattcmatg ggcaatacct ttkgtawagg tccygtgctt aaaggaggca agtataaatt 660
ttcccantaa ggaatccccg gt
<210> 57
<211> 644
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (5)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (27)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (458)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (619)
<223> n equals a,t,g, or c
<400> 57
ggagnctggg cctgtgcggc ggccgcngta gcgctttgga aggcgcacgg ggcgaagatg 60
geggeggaeg acaggaggeg etgagggagt tegtggeggt gaegggegee gaggaggaee 120
gggcccgctt ctttctcgag tcggccggct gggacttgca gatcgcgcta gagcttttta 180
tgaggacgga ggggatgaag acattgtgac catttcgcag gcaaccccca gttcagtgtc 240
cagaggcaca gccccagtg ataatagagt gacatccttc agagacctca ttcatgacca 300
agatgaagat gaggaggaag aggaaggcca gaggtgagtc ttctagaggg ggtcaggggg 360
acagttcaca gggaagtcca gggtaatgtg taaatcacct agaacaggac ctggtaaaac 420
atgtttggtt tattgttagc cattactact gtgggctngt ctgtgtgggt tatatcttag 480
gaagtetett etacteettg tagettagaa gtgaeeeetg tteegttaet taatgtattt 540
attgaggaat attaggggag ggaaaccaag gaaaagatct agcattccca ctttttggta 600
ttgactaaaa aggatttgna aatcagtttg taaaagaagg tgtc
<210> 58
<211> 766
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
```

```
<222> (760)
<223> n equals a,t,g, or c
<400> 58
gggtcgaccc acgcgtccgg aatgttttgg tgaataaatc tgttcttcag caaccctacc 60
tgcttctcca aactgcctaa agagatccag tactgatgac gctgttcttc catctttact 120
ccctggaaac taaccacgtt gtcttctttc cttcaccacc acccaggagc tcagagatct 180
aagctgcttt ccatcttttc tcccagcccc aggacactga ctctgtacag gatggggccg 240
testettges testeteat estaatees ettetesage tgateaacey ggggagtast 300
cagtgttcct tagactccgt tatggataag aagatcaagg atgttctcaa cagtctagag 360
tacagtccct ctcctataag caagaagctc tcgtgtgcta gtgtcaaaag ccaaggcaga 420
ccgtcctcct gccctgctgg gatggctgtc actggctgtg cttgtggcta tggctgtggt 480
tcgtgggatg ttcagctgga aaccacctgc cactgccagt gcagtgtggt ggactggacc 540
actgcccgct gctgccacct gacctgacag ggaggaggct gagaactcag ttttgtgacc 600
atgacagtaa tgaaaccagg gtcccaacca agaaatctaa ctcaaacgtc ccacttcatt 660
aaaactcgag ggggggcccg gaamcaattc gggctatagn agagcg
<210> 59
<211> 2361
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (1174)
<223> n equals a,t,g, or c
<400> 59
gttctagatc gcgagcggcc gccctttttt ttttttttt tttggaaagc aaggatcaca 60
cttccccctc cctgttcctt aatccctttt ctaaaaaggg gggaaaatcc ggatggattt 120
tagggattgg tctggtgtca gctgtgtttt attgcacacc taaatcctga ttataggctt 180
ttcatttctc cgcaaagcct ttattttggc agttaagcca aatgtgtttt ccagaaagtt 240
agttattttc teetetttet tteetttett teeteeettt tteeegtetg acceeaaacg 300
ttattgtcca aacatgactg gacagcagct tttgtttctt gaccctgtaa tatgacagtc 360
tgctaatatt gacagaaggt gcagtttttg ggttatagtc gtgattttcg ctaatcaatc 420
atattagcag gaaaaaaaat gacttgtttc tgttgtactt gagtcttaag aaaaagtgcc 480
catagtttag tgacaatttc caaaggcttt agtaccacct gtatttcaaa atgggggacc 540
caaactcccg gaagaaacaa gctctgaaca gactacgtgc tcagcttaga aagaaaaaag 600
aatctctagc tgaccagttt gacttcaaga tgtatattgc ctttgtattc aaggagaaga 660
agaaaaagtc agcacttttt gaagtgtctg aggttatacc agtcatgaca aataattatg 720
aagaaaatat cctgaaaggt gtgcgagatt ccagctattc cttggaaagt tccctagagc 780
ttttacagaa ggatgtggta cagctccatg ctcctcgata tcagtctatg agaagggatg 840
taattggctg tactcaggag atggatttca ttctttggcc tcggaatgat attgaaaaaa 900
tegtetgtet cetgttttet aggtggaaag aatetgatga geettttagg cetgtteagg 960
ccaaatttga gtttcatcat ggtgactatg aaaaacagtt tctgcatgta ctgagccgca 1020
aggacaagac tggaatcgtt gtcaacaatc ctaaccagtc agtgtttctc ttcattgaca 1080
gacagcactt gcagactcca aaaaacaaag ctacaatctt caagttatgc agcatctgcc 1140
totacotgoe acaggaacag otcaccoact gggncagttg gcaccataga ggatcaccto 1200
cgtccttata tgccagagta gagtactgac cagcaaaatg gagaagatca gagaatgcag 1260
cagcagtttt ttttcttgtt ttcttaccac tttattcttt cagagtttaa agaaaatgga 1320
```

```
ctcatgcaca gaacactatg cattttgaaa cttqttcatc ctggattttt ttaaatcatt 1380
 tttatctcag aacttaaaca aaaattagat gtcgtgcacg gactgtgtga aagaagatgc 1440
tttgcatatt tgctgcactg catcagtatc ttactaaaaa tgtgaaatga aaggactatt 1500
gtacactgaa atgcttaaat gtatctgaaa gcacaaggtg atactcattt ttatggtctt 1560
cccatttgtg ctggtttttg cctctttgac atctgtcatc agtatttaga gggtgagaag 1620
tgaatgtaac aggtataaat aacattttta aaaacaataa ctttgctata atcacagttg 1680
ttccagagca ctgtcagata cattctaatg accagaactg gtttaaaaaa agaaaataca 1740
accatgggaa rgaaatctta aatgaaaaac gcatctcatt gtaggcattt ttgcctcata 1800
ttttactggg ccatgtttgt ttcctggtac tcatgtattt ttttttcca gatctctttc 1860
cccaagttgc tattgtaaga gtattctgct gcgtgtggat gcagttatac acattaaagc 1920
agatctggag tctgaagtag ctataaagca gctataaaac agaaatacat gcatagctgc 1980
ttttggtttt acagagaaga gatttttatt acaaagaaaa aaattccagt gaattgtgca 2100
gaaatgctgg tttttacacc atcctaaaga aaaactttac aagggtgttt tggagtagaa 2160
aaaaggttat aaagttggaa tottaaattg taaaattaac cattgagtgt caaagttota 2220
aaagcagaac tcattttgtg caatgracat aaggraagac tactgtatag gtttttkttt 2280
totootttta aatgaaraaa arcttgotta agggttgoat acttttattg gagtaaatot 2340
gaatgatect actecettqq a
                                                                 2361
<210> 60
<211> 1472
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (129)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (130)
<223> n equals a,t,g, or c
<400> 60
aattoggoac gagoccagat ggogotggag gaccaggoog ccacactgga gtataagacc 60
atcaaggaac atctcagcag caagagteee aaccatgggg tgaacettgt ggagaacetg 120
gacageetnn eececaaagt tecacagegg gaggeeteee tgggteeeee gggageetee 180
ctgtctcaga ccggtctaag caagcggctg gaaatgcacc actcctcttc ctacggggtt 240
gactataaga ggagctaccc cacgaactcg ctcacgagaa gccaccaggc accactctca 300
aaagaaacaa cactaactcc tccaattcct ctcacctctc cagaaaccag agctttggca 360
ggggagacaa cccgccgccc gccccgcaga gggtggactc catccaggtg cacagctccc 420
agccatctgg ccaggoogtg actgtctcga ggcagoocag cctcaacgco tacaactcac 480
tgacaaggte ggggetgaag egtacgeeet egetaaagee ggaegtacee eecaaaceat 540
cctttgctcc cctttccaca tccatgaagc ccaatgatgc gtgtacataa tcccaggggg 600
agggggtcag gtgtcgaacc agcaggcaag gcgaggtgcc cgctcagctc agcaaggttc 660
tcaactgcct cgagtaccca ccagaccaag aargcctgcg gcagagccga ggacgctggg 720
tectectete tgggacacag gggtacteae gaaaactggg cegegtggtt tggtgaaggt 780
ttgcaacggc ggggactcac cttcattctc ttccttcact ttcccccaca ccctacaaca 840
ggtcggaccc acaaaagact tcagttatca tcacaaacat gagccaaaag cacataccta 900
```

ccccatecee cacecemea cacacaca catgeacaca acacatacae acacaegeae 960

agaggtgaac agaaactgaa acattttgtc cacaacttca cgggacgtgg ccagactggg 1020 tttgcgttcc aacctgcaaa acacaaatac attttttaaa atcaagaaaa tttaaaaaga 1080 caaaaaaaaa agaattcatt gataattcta actcagactt taacaatggc agaagtttac 1140 tatgcgcaaa tactgtgaaa tgcccgccag tgttacagct ttctgttgca gcagataaat 1200 gccatgttgg gcaactatgt catagatttc tgctcctcct ctcttttaat gaaataacgt 1260 ctcttccaaa tatcatccta tgaacagctc ttcagaaagc ccattgaaag ttaaactatt 1380 taacgtgaaa tccattaact ggaataattg agtttcttta tttttacaat aaattcactg 1440 agtaaataaa aaaaaaaaaa aa 1472 <210> 61 <211> 1672 <212> DNA <213> Homo sapiens <220> <221> misc feature <222> (884) <223> n equals a,t,g, or c <220> <221> misc feature <222> (1583) <223> n equals a,t,g, or c <220> <221> misc feature <222> (1645) <223> n equals a,t,g, or c <220> <221> misc feature <222> (1663) <223> n equals a,t,g, or c <400> 61 ccagcotoca ggcaccoggg atccagegco gccgctcata acaccegcga ccccgcagct 60 aagcgcaget eeegacgcaa tggaeeegge getggeagee cagatgageg aggetgtgge 120 cgagaagatg ctccagtacc ggcgggacac agcaggctgg aagatttgcc gggaaggcaa 180 tggagtttca gtttcctgga ggccatctgt ggagtttcca gggaacctgt accgaggaga 240 aggcattgta tatgggacac tagaggaggt gtgggactgt gtgaagccag ctgttggagg 300 cctacgagtg aagtgggatg agaatgtgac cggttttgaa attatccaaa gcatcactga 360 caccetgtgt gtaaqcagaa cetecactee etecgetgee atgaagetea ttteteecag 420 agattttgtg gacttggtgc tagtcaagag atatgaggat gggaccatca gttccaacgc 480 cacccatgtg gagcatccgt tatgtccccc gaagccaggt tttgtgagag gatttaacca 540 tecttgtggt tgettetgtg aacetettee aggggaacee accaagacea acetggteae 600 attottocat accqacetea qeggttacet eccacaqaac gtggtggact cettettece 660 CCgCagcatg acccggtttt atgccaacct tcagaaagca gtgaagcaat tccatgagta 720 atgctatcgt tacttcttgg caaagaactc ccgtgactca tcgaggagct ccagctgttg 780 ggacaccaag gagcctggga gcacgcagag gcctgtgttc actctttgga acaagctgat 840

ggactgcgca tctctgagaa tgccaaccag aggcggcagc ccanccettc ctgcctcctg 900

```
ccccactcag ggttggcgtg tgatgagcca ttcatgtgtt ccaaactcca tctgcctgtt 960
 acceaaacac geeteteetg geagggtaga eccaggeete taaccatetg acagagaete 1020
 ggcctggaca ccatgcgatg cactctqqca ccaaqqcttt atgtqcccat cactctcaga 1080
 gaccacgttt ccctgactgt catagagaat catcatcgcc actgaaaacc aggccctgtt 1140
gccttttaag catgtaccgc tccctcaqtc ctgtqctqca qccccccaaa tatatttttc 1200
tgatatagac cttgtatatg gctttaatgc cgcaaaatat ttatttttcc ttaaaaaaagg 1260
tgtcaacttg gaaataatgg tttaaaaaca ggataagcat taaggaaaaa cactttcaat 1320
gtgtcttcca tttgatgaat ttgtkttkct ctctttatcc ccgcaagtgg agtttcatgt 1380
cctcggtgaa accagacagt gtgaatctgt tccagcccaa atctgcagca ttagggatga 1440
gttctcrgaa gtgattctga actgagcacg cactcatgtc tgcatgggga actctgggga 1500
gaagagcctt ccttttcttt cccttgggcc atttgccttt ccttgtcgtc ttactgaggg 1560
cggaggcagg gagggtetet gtnettteea gggeeetggg eagggeeate etggeeatte 1620
agggaaagat gggaagagtt agggnctccg ttttaggcag ccntgggtgg ga
                                                                   1672
<210> 62
<211> 1540
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (1265)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (1468)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (1507)
<223> n equals a,t,g, or c
<400> 62
gcggacggtg ggtcgaccca cgcgtccgct actaacaact taccacagtg cggagactgc 60
tttctgaaaa ggccactcac gtgaacacta gggatgaaga tgagtrtacc cctcttcatc 120
gagcagccta cagtggacac ttagatattg ttcaggagct cattgcacag ggggccgatg 180
ttcatgcagt gactgtggat ggctggacgc ccctgcacag tgcttgtaag tggaataata 240
ccagagtggc ttctttctta ctgcagcatg atgcagatat caatgcccaa acaaaaggcc 300
tettgacece ettgeatett getgetggga acagagacag caaggatace etagaactee 360
tootgatgaa cogttacgto aaaccagggo tgaaaaacaa ottggaagaa actgcatttg 420
atattgccag gaggacaagt atctatcact acctctttga aattgtggaa ggctgtacaa 480
attetteace teagtettaa caattetagt aatttteeta agtttetaaa taccagtgee 540
tcctgtgtgt gagatgtatt cccataatca aagttgacgt caaacatctt actacaaaaa 600
ttcagtgaca ttcattataa cattcttcca aqtgaattgc ctgactttra tgtcaaaatg 660
tatttgaaag taatttgcat atatctttaa ttatttctgt ggagtttgtg attttttat 720
cagaaataat tttaatgtgt qtatacttaa aaacttgaca cgggttgtac agaaactggt 780
atttttggtg ctgatacaag agaaatgtat ttttaaatat cccacatcct ggatctttgt 840
tgggtattta gtatattgac atatattttt ataaggtgag gtaactcaga acttaattta 900
aaagtettaa atattetgat acaatteage tgtettetet acettaceat agecagttge 960
```

41

٠.,

```
tttcatttta aaccagagca agtaacatat tagtgacttg aatcttcata agttaaagta 1020
aaaaacagca aaaaacctag atctttgtct tttagaacac agaccatttt caggaaagca 1080
gttagctaag tgtttaattc atgaatattg tatactgcat cccctaccac aatttacaca 1140
atcctgtgga tagtcctacc tcaccctggt caacctacat gatccttaag ctaatggcga 1200
atcacgatga ccttgtagac atgcacacaa ctataccttt gtccaacaga tcataatata 1260
tetgnetate caactggttt tacetgeeta atectactga tttgggeact gettgtatar 1320
tctctcaagt tcacaggaaa tgttgatttt ctaaggtcct catttttaca gagtatacag 1380
gcaaagtgac aggggaaaag gaattagtct aagagtaagg ggatgattat tatrttgagg 1440
staaaaccac aaagtggctc aggctttnaa aaaaaaacac tgtggataat gacaaaaagc 1500
ataagtnaaa atatttgaga aaaataaagt acaagaaatg
<210> 63
<211> 1044
<212> DNA
<213> Homo sapiens
<400> 63
aacaccttca tecatgaaga tatetggaac attegtagta tetgeageac caccaatate 60
caatgcaaga acggcaagat gaactgccat gagggtgtag tgaaggtcac agattgcagg 120
gacacaggaa gttccagggc acccaactgc agatatcggg ccatagcgag cactagacgt 180
gttgtcattg cctgtgaggg taacccacag gtgcctgtgc actttgacgg ttagatgcca 240
ccatgtaggg attatcgcga gtggttgacc ttacacttac tccttaaata gcagtgagta 300
atgcatttga gctgtcccag gctctgtctc ctcagctcat ttcctactct ttttctctat 360
ataactcatt ctattaaata cattgcacca aagagatatg gagacataaa cctgtaatga 420
atgaggetgg gettttetgt aataagette ettttataat actggteage ttagetetet 480
cagatectat cetgtggaat ttagttatta tgtgtattta tgtagtattt caaacattte 540
aaaatgcttt catctatgtt tatcacattt taataccaca gcacttataa tgatgtcact 600
acatatagaa gctcaaagtt aagggatttg ctgaagactg taaagttaat ggaagaattg 660
agacaaaaat ccagtgtagc tggccactta tccagggctt tttctacttc atcacaagga 720
atgttttgaa agtgtctgct ttttttatcc ttaaaattca cctgtcaggg aggcattaaa 780
aatttggaaa tgtatgccag caaaatgtga gctctgtatt ttttggcatt cttatgtttg 840
ggtttaataa gattaagaaa atgatactgg gaattttctt tttcctgaaa ctttgaatca 900
ccctagtaag tcaaagtact aaaaaatgta ctagatcatt aagacttatg tgctcttact 960
gattgaaaga ttttttatgt tttccttgta ataaaggacc taaaccgaag gtacctgaaa 1020
                                                                  1044
aaaaaaaaa aaaaaaaact cgag
<210> 64
<211> 851
<212> DNA
<213> Homo sapiens
<400> 64
cacgagagaa ggtggttatt tatacaaaca tggacatact cactcccaag ggctgatgag 60
atgctgaatt ttctttgggg gcattcatta attgtcccag ctgcagcgac tggagcaagt 120
ctggaagetg cetgtgetaa gaccacceag etgtecetgg gtteteatee tagggeette 180
tttgcttcca ggtcagggga cctgcttcaa tgagaaagca actgaattga ggctaggaga 240
ggtaggaga gctgagttct gacttcacct gtgcagaact ctctgccccc atgttacctg 300
gactggaaca gactgtgaat atagcagaag gttccaagaa ctctggtgtc tgacctagaa 360
gaggcacagt totototact ggaaagaaaa cgatgtagcc gattgcacaa gggtgccaag 420
ggaagaccca ggatggccca tcaaaggaac ctgggggagg atgcaggagg ctgaagggat 480
```

gcacctggca tttctctcac tgtgctctta ccgcatcagc aacccccaac ttttgggcct 540

```
actetgeece ceatgegtga ataccetget tggatgetgt getttteegg tttgteteta 600
 ageceettte tecagggeat gttggtttee etggeetete agtgteetaa etggageeea 660
 gagtgccttg ttctgagcca ggagacggct gagcactggc cctccacacc taagcgtcct 720
 ttacattaac ttattggtct tgtataacac ctggtgccat tgccaagtgg ctgtgtcctc 780
 agctacagag ctggaattgt gtggggttta gtgctaaata cttcaataaa gtctgttttt 840
tgtgattggc t
                                                                   851
<210> 65
<211> 2793
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (2793)
<223> n equals a,t,q, or c
<400> 65
ccacgcgtcc ggattacatg tagttattga gaatcctttc gaattcagtg gcttaatcat 60
gaatgtctaa atattgttga cattaggatg atacatgtaa attaaagtta catttgttta 120
gcatagacaa gcttaacatt gtagatgttt ctcttcaaaa atcatcttaa acatttgcat 180
ttggaattgt gttaaataga atgtgtgaaa cactgtatta gtaaacttca tcacctttct 240
acttccttat agtttgaact tttcagtttt tgtagttccc aaacagttgc tcaatttaga 300
gcaaattaat ttaacacctg ccaaaaaaag gctgctgttg gcttatcagt tgtctttaaa 360
ttcaaatgct catgtgactt ttatcacatc aaaaaatatt tcattaatga ttcaccttta 420
gctctgaaaa ttaccgcgtt tagtaattat agtgggctta taaaaacatg caactctttt 480
tgatagttat ttgagaattt tggtgaaaaa tatttagctg agggcagtat agaacttata 540
aaccaatata ttgatatttt taaaacattt ttacatataa gtaaactgcc atctttgagc 600
ataactacat ttaaaaaataa agctgcatat ttttaaatca agtgtttaac aagaatttat 660
attttttatt ttttaaaatt aaaaataatt tatatttcct ctgttgcatg aggattctca 720
tctgtgctta taatggttag agattttatt tgtgtggaat gaagtgaggc ttgtagtcat 780
ggttctagtg tttcagtttg ccaagtctgt ttactgcagt gaaattcatc aaatgtttca 840
gtgtggtttt ctgtagccta tcatttactg gctatttttt tatgtacacc tttaggattt 900
tctgcctact ctatccagtt gtccaaatga tatcctacat tttacaaatg ccctttcagt 960
ttctattttc tttttccatt aaattgccct catgtcctaa tgtgcagttt gtaagtgtgt 1020
gtgtgtgtgt ctgtgtgtgt gtgaatttga ttttcaagag tgctagactt ccaatttgag 1080
agattaaata atttaattca ggcaaacatt tttcattgga atttcacagt tcattgtaat 1140
gaaaatgtta atcctggatg acctttgaca tacagtaatg aatcttggat attaatgaat 1200
ttgttagtag catcttgatg tgtgttttaa tgagttattt tcaaagttgt gcattaaacc 1260
aaagttggca tactggaagt gtttatatca agttccattt ggctactgat ggacaaaaaa 1320
tagaaatgcc ttcctatgga gagtattttt cctttaaaaa attaaaaagg ttaattattt 1380
tgaaaaaaaa aaatcgaccc acgcgtccgg attacatgta gttattgaga atcctttcga 1440
attcagtggc ttaatcatga atgtctaaat attgttgaca ttaggatgat acatgtaaat 1500
taaagttaca tttgtttagc atagacaagc ttaacattgt agatgtttct cttcaaaaat 1560
catcttaaac atttgcattt ggaattgtgt taaatagaat gtgtgaaaca ctgtattagt 1620
asacttcatc acctttctac ttccttatag tttgaacttt tcagtttttg tagttcccaa 1680
acagttgctc aatttagagc aaattaattt aacacctgcc aaaaaaaaggc tgctgttggc 1740
ttatcagttg tctttaaatt caaatgctca tgtgactttt atcacatcaa aaaatatttc 1800
attaatgatt cacctttagc totgaaaatt accgogttta gtaattatag tgggottata 1860
aaaacatgca actctttttg atagttattt gagaattttg gtgaaaaata tttagctgag 1920
ggcagtatag aacttataaa ccaatatatt gatattttta aaacattttt acatataagt 1980
```

```
aaactgccat ctttgagcat aactacattt aaaaataaag ctgcatattt ttaaatcaag 2040
 tgtttaacaa gaatttatat tttttatttt ttaaaattaa aaataattta tatttcctct 2100
 gttgcatgag gattctcatc tgtgcttata atggttagag attttatttg tgtggaatga 2160
agtgaggctt gtagtcatgg ttctagtgtt tcagtttgcc aagtctgttt actgcagtga 2220
aattcatcaa atgtttcagt gtgstyttct gtagyctatc atttactggc tatttttta 2280
tgtacacctt taggattttc tgcctactct atccagttgt ccaaatgata tcctacattt 2340
tacaaatgcc ctttcagttt ctatttctt tttccattaa attgccctca tgtcctaatg 2400
tgcagtttgt aagtgtgtgt gtgtgtgtct gtgtgtgtgt gaatttgatt ttcaagagtg 2460
ctagacttcc aatttgagag attaaataat ttaattcagg caaacatttt tcattggaat 2520
ttcacagttc attgtaatga aaatgttaat cctggatgac ctttgacata cagtaatgaa 2580
tcttggatat taatgaattt gttagtagca tcttgatgtg tgttttaatg agttattttc 2640
aaagttgtgc attaaaccaa agttggcata ctggaagtgt ttatatcaag ttccatttgg 2700
ctactgatgg acaaaaaata gaaatgcctt cctatggaga gtatttttcc tttaaaaaat 2760
taaaaaggtt aattattttg aaaaaaaaa acn
                                                                 2793
<210> 66
<211> 303
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (108)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (278)
<223> n equals a,t,g, or c
<400> 66
agattaagca tacttaacca ctccttattt gtagattcac tttcaacctt aaaaattaat 60
accagtttgc ataaaccaat atctgaaaag aacaggaaat gttaatgnca agcaacagct 120
attaatactg atgtgaatgg atgcatttgt tttgcagtgg tgactggcct aggcaggttt 180
gggatctgtg aaagaattga ttcattttca aaattattcc ataaagttaa aaagttacac 240
tttaaaggca acaggtcata cagttcttta aaatctgnat ccaactgtag ctttatttaa 300
aag
                                                                303
<210> 67
<211> 1410
<212> DNA
<213> Homo sapiens
<400> 67
ccacgcgtcc ggtccctagg agataagagt atcttgcaca gcaggtgcag gtttcccagc 60
agctcaggca agagtccgat gtttgtgcca tctgatcctg atgtctggag agatagccat 120
gtgtgagcct gaatttggca atgacaaggc cagggagccg agcgtgggtg gcaggtggcg 180
cttcatcttc atcgggtgcc tgtcggtcat tgagaatggg acggacactg ggctgctgca 300
gccggccctg gcccacgggc tggctttggg gctcgtgatt gccacgctgg ggaatatcag 360
tggtggacac ttcaaccctg cggtgtccct ggcagccatg ctgatcggag gcctcaacct 420
```

```
ggtgatgctc ctcccgtact gggtctcaca gctgctcggg gggatgctcg gggctgcctt 480
 ggccaaggcg gtgagtcctg aggagaggtt ctggaatgca tctggggcgg cctttgtgac 540
 agtccaggag caggggcagg tggcaggggc gttggtggca gagatcatcc tgacgacgct 600
 getggeeetg getgtatgea tgggtgeeat caatgagaag acaaagggee etetggeeee 660
 gttctccatc ggctttgccg tcaccgtgga tatcctggct gggggccctg tgtctggagg 720
 ctgcatgaat cccgcccgtg cttttggacc tgcggtggtg gccaaccact ggaacttcca 780
 ctggatctac tggctgggcc cactcctggc tggcctgctt gttggactgc tcattaggtg 840
cttcattgga gatgggaaga cccgcctcat cctgaaggct cagtgaagca gagctcgtgg 900
gatteetget getecaggtg teeteagete acctgteeca gactgaggae aggggagtte 960 -
ctgcatttcc tgccagggca gaggcccaga ggagcgaccc cctgcttcca ctgcttgggc 1020
ctgctttctc agatagactg actgctgagg aggctctagg ttcttggaat tcctttgtgc 1080
tcatcagaga ccccagcctg gggaacacgc tgcccgcact gcccagagag cagtgcaaac 1140
accacaacac gagcgtgttt cttgagagga atgtccccga gttggacaag gaggctgttt 1200
ctgcacatca geteatities egeaseceat trettgettg attgetttgt tgggggeetg 1260
gccacttcct tgcttctcaa gctgacaatt ctcactttgc aataaatagt ccagtgtttc 1320
aaaaaaaaa aaaaaaaaa aaaaaaaaa
                                                                 1410
<210> 68
<211> 1024
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (2)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (7)
<223> n equals a,t,g, or c
<400> 68
angggangga agggaaggga agggaagggg gggtcacgcg ggggcgcgcg cgcgcaccgg 60
gagccgctcg raggcgagtg gaactggatc gggtttgctg ccagcggcgt gagcttcggc 120
egecatttta caacagetee actegegeeg gacacaggga geagegagea egegttteee 180
gcaacccgat accateggae aggatttete egeeteagee caaeggggag atetetggaa 240
acatggctac agaacatgtt aatggaaatg gtactgaaga gcccatggat actacttctg 300
cagttatcca ttcagaaaat tttcagacat tgcttgatgc tggtttacca cagaaagttg 360
ctgaaaaact agatgaaatt tacgttgcag ggctagttgc acatagtgat ttagatgaaa 420
gagctattga agctttaaaa gaattcaatg aagacggtgc attggcagtt cttcaacagt 480
ttaaagacag tgatctctct catgttcaga acaaaagtgc ctttttatgt ggagtcatga 540
agacttacag gcagagaga aaacaaggga ccaaagtagc agattctagt aaaggaccag 600
atgaggcaaa aattaaggca ctcttggaaa gaacaggctc acacttgatg tgaccactgg 660
acagaggaag tatggaggac cacctccaga ttccgtttat tcaggtcagc agccttctgt 720
tggcactgag atatttgtgg gaaagatccc aagagatcta tttgaggatg aacttgttcc 780
attatttgag aaagcataag gttctcagag tgatagagct ggaaggatca taaaggtcat 840
ctagtctaat ggttctcaaa ctcgaaggaa cattagggtc atcctggaga gtttactggg 900
ccccqtctca gaggttctga tgctgtaaat caggcgggac ccctgaattt tcatttctaa 960
gaageteaca ggtgetaeta atgttgaaga gaacetatga tetagtteaa ettetgggat 1020
```

tctt 1024 <210> 69 <211> 1848 <212> DNA <213> Homo sapiens <220> <221> misc feature <222> (1761) <223> n equals a,t,g, or c <220> <221> misc feature <222> (1844) <223> n equals a,t,g, or c <220> <221> misc feature <222> (1847) <223> n equals a,t,g, or c <400> 69 agacteggat ggtagteege tgteeaacag ceareettee tteecagtgg agatettgee 60 cttcctctac ttgggctgtg ccaaagactc caccaacttg gacgtgttgg aggaattcgg 120 catcaagtac atcttgaacg tcacccccaa tttgccgaat ctctttgaga acgcaggaga 180 gtttaaatac aagcaaatcc ccatctcgga tcactggagc caaaacctgt cccagttttt 240 ccctgaggcc atttctttca tagatgaagc ccggggcaag aactgtggtg tcttggtaca 300 ttgcttggct ggcattagcc gctcagtcac tgtgactgtg gcttacctta tgcagaagct 360 caatctgtcg atgaacgatg cctatgacat tgtcaaaatg aaaaaatcca acatatcccc 420 taacttcaac ttcatgggtc agctgctgga cttcgagagg acgctgggac tcagcagccc 480 atgtgacaac agggttccag cacagcagct gtattttacc accccttcca accagaatgt 540 ataccaggtg gactototge aatotacgtg aaagaccoca caccotoot tgotggaatg 600 tgtctggccc ttcagcagtt tctcttggca gcatcagctg ggctgctttc tttgtgtgtg 660 gccccaggtg tcaaaatgac accagctgtc tgtactagac aaggttacca agtgcggaat 720 tggttaatac taacagagag atttgctcca ttctctttgg aataacagga catgctgtat 780 agatacagge agtaggtttg ctctgtacce atgtgtacag cctacccatg cagggactgg 840 gattcgagga cttccaggcg catagggtag aaccaaatga tagggtagga gcatgtgttc 900 tttagggcct tgtaaggctg tttccttttg catctggaac tgactatata attgtcttca 960 atgaagacta attcaatttt gcatatagag gagccaaaga gagatttcag ctctgtattt 1020 gtggtatcag tttggaaaaa aaaatctgat actccatttg attattgtaa atatttgatc 1080 ttgaatcact tgacagtgtt tgtttgaatt gtgtttgttt tttcctttga tgggcttaaa 1140 aaagaaaatt gtgctctttt ctaatccaaa gggtatattt gcagcatgct tgactttacc 1260 aattotgatg acatotttac ggacactatt atcactaaga cottgttatg gcgaagtott 1320 tagtcttttt catgtatttt cctcatgatt ttttctcttt atgtagtttg actatgcctt 1380 acctttgtaa atatttttgc ttgtgttgtc gcaaagggga taatctggga aagacaccaa 1440 atcatgggct cactttaaaa aaagaaagaa taaaaaaacc ttcagctgtg ctaaacagta 1500 tattacctct gtataaaatt cttcagggag tgtcacctca aatgcaatac tttgggttgg 1560 tttctttcct ttaaaaaaat ttgtataaaa ctggaagtgt gtgtgtgtga gcatgggtac 1620 ccatttgata agagaaatgc atttgattgt gaagaaggga gagttaaatt ctccattatg 1680

```
ttcgtggtgt aaagtttwga gctggaattt attataagaa tgtaaaacct taaattatta 1740
 aaaaaaaaa aaaaaaaaa aaaaaaaaa aaaaaaaggg gggnccnc
<210> 70
 <211> 2682
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (647)
<223> n equals a,t,g, or c
<400> 70
gaatacccca ggatttatgt ataaaaacct gcagtgtctg gttattgatg aagctgatcg 60
tatctttgat gtggggtttg aagaggaatt aaagcaaatt attaaacttt tgccaacacg 120
tagacagact atgctctttt ctgccaccca aactcgaaaa gttgaagacc tggcaaggat 180
ttctctgaaa aaggagccat tgtatgttgg cgttgatgat gataaagcga atgcaacagt 240
ggatggtctt gaacagaaga accgaaagaa gaagcttatg gtcttctttt catcttgtat 300
gtctgtgaaa taccactatg agttgctgaa ctacattgat ttgcccgtct tggccattca 360
tggaaagcaa aagcaaaata agcgtacaac cacattette cagttetgca atgcagatte 420
gggaacacta ttgtgtacgg atgtggcagc gagaggacta gacattcctg aagtcgactg 480
gattgttcag tatgaccctc cggatgaccc taaggaatat attcatcgtg tgggtagaac 540
agccagaggc ytaaatggga gagggcatgc cttgctcatt ttgcgcccag aagaattggg 600
ttttcttcgt tacttgaaac aatccaaggt tccattaagt gaatttngac ttttcctggt 660
ctaaaatttc tgacattcag tctcagcttg agaaattgat tgaaaagaat tactttcttc 720
ataagtcagc ccaggaagca tataagtcat acatacgagc ctatgattcc cattctctga 780
aacagatett taatgttaat aacetaaatt tgeeteaggt tgetetgtea tttggtttea 840
aggtgcctcc cttcgttgat ctgaacgtca acagtaatga aggcaagcag aaaaagcgag 900
gaggtggtgg tggatttggc taccagaaaa ccaagaaagt tgagaaatcc aaaatcttta 960
aacacattag caagaaatca tetgacagea ggeagttete teaetgaaca catgeettee 1020
tttcatcttg aataactttg tcctaaaatg aatttttttt ccccttgatt taacaggatt 1080
tttgtagact ttagaatttg gacttaccta acaagagtat aaattgactt gggttgcaag 1140
cactgagcac tgttacttct atcacgtctc tcttttattt ctgggatata aaacaggctt 1200
taagtttctt ggttgcccaa gggcagagca aggaatatct ggtgtttctt gtgatgataa 1260
tattttaatt ttaaatatcc ctccctcata caagtgtatg ttaccatttt aatataattc 1320
tttttgtacc tttccttctt gttttgtgaa gatttttgtg gcatggattg ctgtgctcac 1380
tgctgtaaaa ggtgacctag tgtactgggc agctggtggc ggtgcagaaa agagtctcag 1440
gttatttttt gtttttagtt atttcttgga ccttgacagt atctaatgac tcctcctgaa 1500
aatgctgcag tataaaagag caaagagctt tgggaaatac ctaagaagca ccttaagatt 1560
agggtggcat tgcttttata gattcttgat tttaaagcaa caggcctttc tcaggtgttg 1620
cattttttgg agcaaaaact atgggttgta atttgaataa agtgtcacta agcagttata 1680
acgtttgatg gctggggggt aggaagagga tggaattgag atgtttgagc ctcatttaca 1740
tcaatagagg tgtaatgtac tgcatttctt catttggtaa cataacaaag actttcatac 1800
aaagaacgat gatgctcctc attaagattt gtttaattca aggtggtttg gatttggtaa 1860
gcctttgcac tctgtagagt acttagaaga caagggcaac ttacttggag ttagagccaa 1920
gctgtcagac ggtgcccagc acacattaat gttagcttct ttctgagaaa aaaatacctc 1980
ttccaggccc tgaaacaaaa aatacatttg ctgtgaagat tgaaaatgaa caaagttaga 2040
aaaaaaaaca gcaaaatcag tgatttagtc agatgagttt ttcgttgtag gagcacttga 2100
tttctagtgt gttttgtaca gtatataact acaagatagt acattttgta gcagttcaaa 2160
```

```
gccaaagttg ctagcatcat tttgctgttg tgccagttaa tcataggatc ccattaaata 2220
 gaacaatctt ccatttctgg gcttggccac catcaccctg gtcggacctg tcctggactt 2340
 ccaaccttga ctgctgagct cctggcttag cttcttgggt tcctaattcc tggtgtttaa 2400
 taattototo cacgatoatg tittitotgat tittitito agaaataatg tittitaaaa 2460
 gacaaaaaca aagggaagaa tatttaatta ctgagcagaa gtaaatactg ttggtatttt 2520
 gtacataatc taatttttat atgcatgtty atgcttttta attttttat caaaaattaa 2580
 gtcatctacc tactacttgt aaccagettg tttcataaca tgttattttc ctgtgtcatt 2640
2682
<210> 71
<211> 412
<212> DNA
<213> Homo sapiens
<400> 71
ggcagagcca acagacaccc tccactctga ggtctcacct tcgcctttgc tgaagtctcc 60
ccgcagccct ctccacccag aggtctccct ataccgagac ccaccatssw wccatcctga 120
ggaccgcccc aaccctcgga gccccccact cagtaggtct gaaggcctcc atttgtaccg 180
aaacaccccg ctcacgctga cagcctccta ggytccctga ggtacctttc cacccagacc 240
ctccttcccc accccataag ccctgagact cccgcctttr acctgacgat cttccccctt 300
eccgeettea ggtteeteet aggegeteag aggeegetet ggggggttge etegagteee 360
cccacccctc cccacccacc accgctcccg cggcaagcca gcccgtgcag aa
<210> 72
<211> 1361
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (46)
<223> n equals a,t,g, or c
<400> 72
taagaacttt tgtccttccc ttcttgaggt ccttttttga ttgtgncttt agtatcaagt 60
tcagcagttg tttcaagagc agctgagata atwaattcaa ccaaatggcg ccttggttct 120
ttawggtatc tgawactcct ctaggacttg cgagggccgt gtcctgagta gtgtgtgmcc 180
cttggctcac gttgcctctg ttttcctcaa gttgccagac ttagaagmct tgatgaaaag 240
ggagaaccag aagattetga eteceetggt gageetggae aeceeaggga aageaacagt 300
acaggtggtc attctggccg accctgacgg acatgaaatt tgctttgtcg gggatgaagc 360
atttcgagaa ctttctaaga tggatccaga gggaagcaaa ttgttggatg atgcaatggc 420
agcagataaa agtgacgagt ggtttgccaa acacaataaa cccaaagctt caggttaacg 480
gaagacatga tgcagagcaa gcctctgtga ttcctgccca gcacctgtga ggcctgacgt 540
gtcagttccc aataaatgct cttctgattt gtttcccgta caggcaagga ggcttgggta 600
gtgcagattt gtgtatttca atctttgaaa gctctgatgt aatttagaaa tgaaatccaa 660
tcatgagtcc aggtagagaa cgcctgctgt aatctacact gttgctggga ctgcgcattc 720
tgtatataac tgtgttggat gagtgacaga tgattgtcca gactaggaca gcggcatgaa 780
catgactttg gttgggattg cggatagtta gggttacctc tgaatcgtgt agcttttatg 840
agagcagctg tgcaagtgaa tccacattaa tgccttgtcg tggtgccatt cccagcgcct 900
gacgatacgc tottotattg tottattctg gcaggttttg acgttttaaa ttttttaaag 960
```

```
aaattttatt ccttggacca aaaggtttgg ttaaccaccc ccctcttact tgctttcaca 1020
 ttttgagtgt ccagaggaaa cagaaaggaa tgagtgtgtg acgttgctgc acgcctgact 1080
 ctgtgcgagc ttcttctgt gtatatattt tgttttattt ttttccgtgt atatttttaa 1140
 tecegacaga acateatgtg agatttettt aaaatggatt aaaegattte tteageetga 1200
 aaaaaaaggt tttgaaaatg ttttcttgta gttttgtttg gttctaaaca acaaataggt 1260
 tttaatcact cgaaatggaa ttatattgtg tattcattga ataaattttt tttgaaagta 1320
 agcttctgaa atcaaaaaaa aaaaaaaaaa a aaaaaaaaa a
 <210> 73
 <211> 928
 <212> DNA
<213> Homo sapiens
<400> 73
cagcaatggc agcatctgcc ttgatatcct gcggtctcag tggtctccag cgttgactgt 60
gtcaaaagtt ctcttgtcca tctgctcgct gctctgcgac cccaaccccg atgaccccct 120
ggtgccagag atagcacaca cctacaaggc cgacagagag aagtacaaca gactagcaag 180
agagtggaca caaaaatatg ctatgtaagt gccttggagg ttttacatga gacactgtcc 240
aagagaaget ggeagagagg tetteeetta aaaetttggg etgttggetg ageeatteaa 300
agagcatcat ctgttcttca aacaaatgtt ggtcacccac tctctccagc tgcagcatgt 360
tggtgccatt ttcagcaatt acggctttga cagtgccacc tctttgatgc caaatcagca 420
accattgttg ttatgatetg eagtetteet ggtgacaetg gaatetetet etetgeegee 480
tcagtttgtc tgctggtctc ttggggggcc aggcctgcac gtctctccta cccggcctca 540
aatggtgctg ctgcccatga tggtaccaca ccagggcctc agcctggccc ctcaccacat 600
accetttgce ttttagaact cagtgecate etgggtgeee agggeagare aggetttgtt 660
egeaceteat etgetgeaga accaeateet gaggagtete agettateet ggagggaatt 720
gggaacagtg tcactgggaa gtgaaggcct agccctgtgg cttccaccag tctcctcctg 780
cagtgccacg tggtgaattt tctcgccttc acaccaagaa agcagcaaag tggaaaattt 840
tcaaggatac aaaggcacat aacamcccca taagragatg attaaggttt tttagaagca 900
agagcaaaat tttgaaaacc tctaggag
                                                                   928
<210> 74
<211> 1186
<212> DNA
<213> Homo sapiens
<400> 74
geggaegegt gggeageeeg ggeggetgee ettgggtget ecetteeetg eeegaeaeee 60
agaccgacct tgaccgccca cctggcagga gcaggacagg acggccggac gcggccatgg 120
ccgagetece ggggeeettt etetgegggg ceetgetagg etteetgtge etgagtggge 180
tggccgtgga ggtgaaggta cccacagagc cgctgagcac gcccctgggg aagacagccg 240
agctgacctg cacctacage acgtcggtgg gagacagett cgccctggag tggagetttg 300
tgcagcctgg gaaacccatc tctgagtccc atccaatcct gtacttcacc aatggccatc 360
tgtatccaac tggttctaag tcaaagcggg tcagcctgct tcagaacccc cccacagtgg 420
gggtggccac actgaaactg actgacgtcc acccctcaga tactggaacc tacctctgcc 480
aagtcaacaa cccaccagat ttctacacca atgggttggg gctaatcaac cttactgtgc 540
tggttccccc cagtaatccc ttatgcagtc agagtggaca aacctctgtg ggaggctcta 600
ctgcactgag atgcagctct tecgaggggg etectaagee agtgtacaae tgggtgegte 660
ttggaacttt tectacacet teteetggea geatggttea agatgaggtg tetggeeage 720
teatteteae caacetetee etgaceteet egggeaceta eegetgtgtg gecaceaace 780
```

agatgggcag tgcatcctgt gagctgaccc tstctgtgac cgaaccctcc caaggccgag 840

PCT/US00/05883 WO 00/55351 50

```
tggccggagc tctgattggg gtgctcctgg gcgtgctgtt gctgtcagtt gctgcgttct 900
 gcctggtcag gttccagaaa gagaggggga agaagcccaa ggagacatat gggggtagtg 960
accttcggga ggatgccatc gctcctggga tctctgagca cacttgtatg agggctgatt 1020
ctagcaaggg gttcctggaa agaccctcgt ctgccagcac cgtgacgacc accaagtcca 1080
agctccctat ggtcgtgtga cttctcccga tccctgaggg cggtgagggg gaatatcaat 1140
aattaaagtc tgtgggtacc aaaaaaaaaa aaaaaaagt cgacgc
                                                                   1186
<210> 75
<211> 933
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (791)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (794)
<223> n equals a,t,g, or c
<400> 75
gtctggatca tattgtagat aaagtaaaag aatgtgtgga tcatttaagt agagatgagg 60
atgaagagaa actggtagcc tcactatggg gagcagagag atgtttacga gttttagaaa 120
gtgtaactgt gcataatccc gaaaatcaaa gctacttgat agcatataaa gattcccaac 180
ttattgtttc atcagctaaa gcattacagc attgtgaaga actgattcag cagtacaacc 240
gtgctgagga cagcatatgc ttagctgaca gtaagcctct gcctcaccag aatgtaacta 300
accatgtagg caaagcagtg gaggactgca tgagggccat catcggggtg ttgcttaatt 360
taactaatga taatgagtgg ggcagcacca aaacaggaga gcaggacggt ctcataggca 420
cagcgctgaa ctgtgtgctt caggttccaa agtacctacc tcaggagcag agatttgata 480
ttcgagtgct gggcttaggt ctgctgataa atctagtgga gtatagtgct cggaatcggc 540
actgtcttgt caacatggaa acatcgtgct cttttgattc ttccatctgt agtggagaag 600
gggatgatag tttaaggata ggtggacaag ttcatgctgt ccagctttag tgcagctatt 660
ccttgagcga gagcgggcag cccagctagc agaaagtaaa acagatgagt tgatcaaaga 720
tgctcccacc actcagcatg ataagagtgg agagtggcaa gaaacaagtg gagaaataca 780
gtgggtgtca ntgnaaaaga ctgatggtac agaagagaaa cataagaagg aggaggagga 840
tgaagaactt gacctccaat aaaggtatat ttactttgaa tggtgtattt aaattgaaga 900
tagtggtttg attttgtttt tttcctccaa acc
                                                                  933
<210> 76
<211> 1964
<212> DNA
<213> Homo sapiens
<400> 76
ggtttggcag ggcggggcgc ctcgcgaaga tggtggcgcg cgtggcgtgt ggctcccgtc 60
gtotggccaa gtotcagogc agogcacogg coggogtoto gttggcotgg agoccacaco 120
caccgggtcc ctgaccccgc gcccccgcg cccggttccc ggcatgcctc gcgcccgtaa 180
999caacacg ctccggaagg gtggtcagcg ccgtggagga ggtgcccgga gcagtgccca 240
agctgactcg ggttccagtg acgatgaggc agccagtgag gcccgcagca ccgccagtga 300
```

```
atgccccage cttctcagca ccactgcaga ggacagcctt ggggggggatg tcgtggatga 360
gcagggccag caggaagacc ttgaggaaaa gctgaaggag tatgtggact gtctcacaga 420
caagagtgcc aagacccggc aggtgctctt gagagcctgc gcctggccct agcgtcccgc 480
ctactccccg acttcttgct ggagcgccgc ctcacgctag ccgatgccct ggaaaagtgc 540
ctcaagaaag ggaagggcga ggaacaagcc ctggctgctg ctgtgctagg cctgctctgc 600
gtgcagctgg gccctggacc taagggtgag gagctgtttc acagcctgca gcctctgctg 660
gtototgtgc toagtgacag cacagotage cotgotgeco ggotocactg tgcttotgcc 720
tgcttagaaa gtgttttcag ccggttctat ggcttggggg gcagctccac aagtcctgtg 840
gttcctgcca gcctgcacgg cctgctctct gctgccctgc aggcctgggc attgctgctc 900
accatctgcc ctagcaccca aatcagccac atccttgaca ggcagctgcc ccggctgccc 960
cagetettgt ceagtgaaag tgtgaacetg eggategetg eeggtgaaac cattgeactg 1020
ctctttgagc ttgcccggga ccttgaggag gagtttgttt acgaggacat ggaggcctc 1080
tgcagtgtcc tgcgcactct ggccactgac agtaacaagt accgtgccaa ggctgatcgt 1140
cggcgccagc gctctacttt ccgcgccgtg ctgcactccg tggagggcgg tgaatgcgaa 1200
gaagagatag tgcgcttcgg ctttgaggtg ctctacatgg acagctgggc tcggcaccgg 1260
atctacgctg ccttcaagga agtgctgggt tcgggcatgc accaccacct ccagaacaat 1320
gagetactee gtgaeatett tggeetggge eetgtgetgt tgetggatge eactgeeetg 1380
aaggeetgea aggtteeaeg etttgagaag cacetgtaca atgetgetge etteaaagee 1440
cggaccaagg ctcgaagccg tgtgcgggac aagcgggcag acatcctgtg aagcaggacc 1500
tgctgaagag gagactttct atgcccttgg tccgtatttt taacagaaga cagtgcaaca 1560
actggtctcc accagtattt gtcactttat tttttttaat gacaaaacca aaaacagaca 1620
tggggtgggt agctgggggc ccggacactt gggaccctga cccctttgtc cctgcactca 1680
gccctgtggc cccttcctgt cctgtctcag gccaggctaa atatgtgcct tcctcagggc 1740
ggatgaccca ctcttagggg ggtggtggca tctggacaaa tgccaccaca gcaggtgggg 1860
tggcaaagct acctggaatg gatttgtgtg ctgattttta aggattatta cagataatta 1920
                                                             1964
aacagaacgg tcagccttca aaaaaaaaaa aaaaaaaaa aaaa
```

```
<211> 1802
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (1680)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (1747)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (1757)
<223> n equals a,t,g, or c
<220>
<221> misc feature
```

<210> 77

```
<222> (1800)
<223> n equals a,t,g, or c
<400> 77
acgogtccgc ttccatctgc tctggaatta aatatgcatt tcaggtgatt ggagagctac 60
attcccaact cgatggatcc gaagtactgc tgctgactga tggggaggat aacactgcaa 120
gttcttgtat tgatgaagtg aaacaaagtg gggccattgt tcattttatt gctttgggaa 180
gagctgctga tgaagcagta atagagatga gcaagataac aggaggaagt catttttatg 240
tttcagatga agctcagaac aatggcctca ttgatgcttt tggggctytt acatcaggaa 300
atactgatct ctccsagaag tcccttcagc tcgaaagtaa gggattaaca ctgaatagta 360
atgcctggat gaacgacact gtcataattg atagtacagt gggaaaggac acgttctttc 420
tcatcacatg gaacagtctg cctcccagta tttctctytg ggatcccagt ggaacaataa 480
tggaaaattt cacagtggat gcaacttcca aaatggccta tctyagtatt ccaggaactg 540
saaaggtggg cacttgggca tacaatctty aagccaaagc gamcccagaa acmttaacta 600
ttacagtwac ttctcgagca kcaaaattct tctgtgcctc caatcacagt gaatgctaaa 660
atgaataagg acgtaaacag tttccccagc ccaatgattg tttacgcaga aattctacaa 720
ggatatgtac ctgttcttgg agccaatgtg actgctttca ttgaatcaca gaatggacat 780
acagaagttt tggaactttt ggataatggt gcaggcgctg attctttcaa gaatgatgga 840
gtctactcca ggtattttac agcatataca gaaaatggca gatatagctt aaaagttcgg 900
gctcatggag gagcaaacac tgccaggcta aaattacggc ctccactgaa tagagccgcg 960
tacataccag gctgggtagt gaacggggaa attgaagcaa acccgccaag acctgaaatt 1020
gatgaggata ctcagaccac cttggaggat ttcagccgaa cagcatccgg aggtkcattt 1080
gtggtatcac aagtcccaag ccttccttgc ctgaccaata cccaccaagt caaatcacag 1140
accttgatgc cacagttcat gaggataaga ttattcttac atggacagca ccaggagata 1200
attttgatgt tggaaaagtt caacgktata tyataagaat aagtgcaagt attcttgatc 1260
taagagacag ttttgatgat gctcttcaag taaatactac tgatctgtca ccaaaggagg 1320
ccaactccaa ggaaagcttt gcatttaaac cagaaaatat ctcagaagaa aatgcaaccc 1380
acatatttat tgccattaaa agtatagata aaagcaattt gacatcaaaa gtatccaaca 1440
ttgcacaagt aactttgytt atccctcaag caaatcctga tgacattgat cctactccta 1500
ctcctactcc tactcctgat aaaagtcata attctggagt taatatttct acgctggtat 1560
tgtctgtgat tgggtctgtt gkaattgkta actttatttt aagtaccacc atttgaacct 1620
taacgaagaa aaaaatcttc aagtagacct agaagagagt tttaaaaaac aaaacaatgn 1680
aagtaaagga tatttctgaa tcttaaaatt catcccatgt gtgatcataa actcataaaa 1740
ataattntaa gatgtengga aaaggataet ttgattaaaa taaaaacaet catggatatn 1800
                                                                   1802
ta
<210> 78
<211> 995
<212> DNA
<213> Homo sapiens
<400> 78
cggggtgcct ggggcagacg aggccggctt ctccgcggac agctagggag agtgtcctgg 60
gtgtcagcca gaacatgtct ttcaacctgc aatcatcaaa gaaactgttc attttcttag 120
gaaaatcact gtttagtctt ctggaggcta tgatttttgc cttactccca aagccacgga 180
agaacgttgc tggtgaaata gtcctcatca caggtgctgg aagtggactc ggaaggctct 240
tagcottgca gtttgcccgg ctgggatctg ttcttgttct ctgggatatc aataaggagg 300
ggaatgagga aacatgtaag atggctcggg aagctggagc cacaagagtg cacgcctata 360
cctgcgattg cagccaaaag gaaggagtgt atagagtasc cgaccaggtt aaaaaagaag 420
teggegatgt ttecatecta ateaacaatg eeggaategt aacaggeaaa aagtteettg 480
actgtccaga tgagcttatg gaaaagtcat ttgatgtgaa tttcaaagca catttatgga 540
```

52

```
cttataaagc ctttctacct gctatgattg ctaatgacca tggacatttg gtttgcattt 600
 caagttcagc tggattaagt ggagtaaatg ggctggcaga ttactgtgca agtaaatttg 660
 cagcetttgg gtttgetgaa tetgtatttg tagaaacatt tgtecaaaaa caaaagggga 720
 tcaaaaccac gattgtgtgc ccctttttta taaaaactgg aatgtktgaa ggttgtacta 780
 caggctgtcc ttctctgttg ccaattctgg aaccaaaata tgcagttgaa aaaatagtag 840
 aagctattct acaagaaaaa atgtacttgt atatgccaaa gttgttatac ttcatgatgt 900
 ttottaaaag gtaattacat cagottotat tacttoocta acatgocagt ctacagttta 960
 ctccaaatcc cmccaggaaa aaccactttt aaaaa
                                                                  995
 <210> 79
 <211> 1215
 <212> DNA
<213> Homo sapiens
<400> 79
gcaggaccgt cattgacgcc atgagcgcgc tgctgcggct gctgcgcacg ggtgccccag 60
ccgctgcgtg cctgcggttg gggaccagtg cagggaccgg gtcgcgccgt gctatggccc 120
tgtaccacac tgaggagcgc ggccagccct gctcgcagaa ttaccgcctc ttctttaaga 180
atgtaactgg tcactacatt tccccctttc atgatattcc tctgaaggtg aactctaaag 240
aggaaaatgg cattcctatg aagaaagcac gaaatgatga atatgagaat ctgtttaata 300
tgattgtaga aatacctcgg tggacaaatg ctaaaatgga gattgccacc aaggagccaa 360
tgaatcccat taaacaatat gtaaaggatg gaaagctacg ctatgtggcg aatatcttcc 420
cttacaaggg ttatatatgg aattatggta ccctccctca gacttgggaa gatccccatg 480
aaaaagataa gagcacgaac tgctttggag ataatgatcc tattgatgtt tgcgaaatag 540
gctcaaagat tctttcttgt ggagaagtta ttcatgtgaa gatccttgga attttggctc 600
ttattgatga aggtgaaaca gattggaaat taattgctat caatgcgaat gatcctgaag 660
cctcaaagtt tcatgatatt gatgatgtta agaagttcaa accgggttac ctggaagcta 720
ctcttaattg gtttagatta tataaggtac cagatggaaa accagaaaac cagtttgctt 780
ttaatggaga attcaaaaac aaggcttttg ctcttgaagt tattaaatcc actcatcaat 840
gttggaaagc attgcttatg aagaagtgta atggaggagc tataaattgc acaaacgtgc 900
agatatetga tagecettte egttgeacte aagaggaage aagateatta gttgaategg 960
tatcatcttc accaaataaa gaaagtaatg aagaagagca agtgtggcac ttccttggca 1020
agtgattgaa acatctgaaa ttctgctgtc aagattccca tctctaagga ctccaagtgc 1080
tagagacaag ggggtctatg agcatttact gacttcctgt taaaacttca ttttttcaaa 1140
agggcggccg ctcta
<210> 80
<211> 2660
<212> DNA
<213> Homo sapiens
<400> 80
gcagacttga ttagcctgcc taccactgta gagggacttc agaagagtgt agcttccatt 60
ggcaatactt taaacagcgt ccatcttgct gtggaagcac tacagaaaac tgtggatgaa 120
cacaagaaaa cgatggaatt actgcagagt gatatgaatc agcacttctt gaaggagact 180
Cctggaagca accagatcat tccgtcacct tcagccacat cagaacttga caataaaacc 240
cacagtgaga atttgaaaca ggatatcctg taccttcaca actctttaga ggaggtaaac 300
agtgccctag tggggtacca gagacagaat gatcttaaac tcgagggaat gaacgagaca 360
gtcagtaatc ttacccagag agtcaacctg atagaaagcg atgtggttgc tatgagcaag 420
gtagaaaaga aagcaaacct gtccttcagc atgatgggtg atagatctgc cactctgaaa 480
```

```
agacagtett tggwteaagt caccaacaga acagatacag taaaaateca aageataaag 540
aaagaagata gttcaaattc tcaggtatcc aagctaagag agaaactcca gctgatcagt 600
gctcttacaa acaaacctga gagcaacmgg cctccagaga ccgccgatga agagcaagta 660
gagagtttca catcaaagcc atcagcattg ccaaaatttt cacagtttct tggagaccca 720
gttgagaaag ctgcccaact aagacctatc tccctaccag gagtttctag cactgaagat 780
cttcaggatt tattccgcaa gactggccag gacgtggatg ggaagctgac ctaccaggaa 840
atctggacct ccctaggttc tgctatgcca gaaccagaga gcttgagagc atttgattcc 900
gatggagatg gaagatactc attcctggag ctaagggtag ctttaggtat ctagcttcat 960
caggcatatt ttagaaatgg actgcctaat atctatttac ctaacaacaa aacaaccctt 1020
acttacccat cagtcctcta gtcctccaaa ctactgtagc agatactttg ccacctttta 1080
acttgtttga agaagctata taaaagttat ttttttaaag aagaagacca ttttacttat 1140
gatgttcaga aatctatgat ttcctacaac cagtaagatc ttacatttta aaattgccag 1200
aaaaaaaatt aaagccctct ttttttctct ttcctttttt tgaggggagg agaccttatc 1260
ttttaaagct gggaaatgta tatagagaga gaataagcca cttttatatt tcacttaaat 1320
ttgccttaaa ttagctgcac tttatagaga ctcagaaaat gtcttttctt taaaagatag 1380
gccttttctg tttgtaaata tttaaatgaa agaaagcatt gtgcatattg tgtggaaagt 1440
aggaagaatg gttttgaaca ggatatgaac aaatgactta ttaaaaaattg ctgatctggt 1500
gtaggtggca gctgaaacta catccatgtc tccataaggy atccctcaaa ggcccaggcg 1560
ctgccagggg gtttgtcctg gtagctggag gaaccgattt cagggagtag acactggaga 1620
caatactgac tecaggeatg geteatggaa gtaggattet ggttetttgt tectattece 1680
tcagctaatc ccaacctggg aatcagagaa gtcttgggga tttttctcat ttttagtact 1740
atttcagggt ttatgagcat aaaaagttat ccattgggga gctccatttt ccctgctgag 1800
tgagctagat tgccttcccc acccacccac ttaagtctgt cttaaagccg tagctggctc 1860
ccaccaccag taccatctcc atttgaatgg cagggctaaa ttcccccagc cattatctca 1920
cactgaccac ccagagettt agaagagage tgtgetteta attttgacce agaaaaccat 1980
accccttgag attttaccta gaggctaacc aagagcctaa tatgtttctc tgggggatga 2040
ctaaagccaa aaaggctgtg agatgaaaca tgtgaaataa tattcagttt ccttaccatt 2100
accageteag aagtagetag aggettteta eecaaaggat gecaaagtat ageagggeag 2160
gcctggagct agggccttca catggtggta gcaagttttt caaatctaat acaatcaagt 2220
acaatacttc ctttaaatgc ttctgtggac ctggcatgaa agatccctag attgaaagga 2280
ataatacete catgteteet gtatgttgag tetagaattg etgtgttgtt ettagaagea 2340
gtctttgggc aacaacttga aaggggaaaa aaaaactaca aaaacttaac tttggtatag 2400
gccaagtcag ggagaaagta gagaaagctg tcatgccaca gacttcttta gtggagatca 2460
tttccttttt aactttgttc aggttgccct tcaccatgga tacagtccgg tacccttaaa 2520
catttaaggg ctgtttttt tttctttaca tgatgttcag cttggtatta accaaactta 2580
aatttttttt ccaqaaqtat taaaatttag ttaaagcaaa aaaaaaaaaa aaaaaaaaa 2640
                                                                  2660
aaaaaaaa gggcggccgc
```

<210> 81

<211> 1790

<212> DNA

<213> Homo sapiens

<400> 81

ccttgcccta tctgaccaca ctatttaatg tttttatctt aaatttaaaa aactgaaatc 60 tgaaactgta tgatagtcag taggcctaaa actcccctt gactttgaga atttgaaggg 120 attcccttcc atcctgaagt ctactttctt gtcatttaag ggtgagagaa gggaagcttc 180 tgtgcctttc tagaaattaa caaagaacct gttgggtcct agaccagaaa tccagcacgt 240 tatcctagca tgaaactccc ttttaaaaag tgaacaccca aagagatgtt acaaatgaag 300 atatagcccc ttcagcatct ctggagacca ataccacaat aaggaataat aacaacctag 360 gaataaaggc aggagtttt acataggatg cacgatatcc aaagggactt tataaacaca 420

```
agccattgag tettaagace tgacacatgg caaggrtagg acatgtgaga gaaaatggat 480
ggacggttga agaaaagagg ggaaaagacc atgcagttga actaacttct ttttaatttc 540
aaacaggtat tttttgcatc cgtgcgatct ggaggaagta gccaagtgtt tttcatgacc 600
ctcaacagaa attccatgat gaactggtaa cagaagagca cttggcactt atcttcatgg 660
cgttatttct aatttaaaag aacataactc atgtggactt atgccagtct agaggcagaa 720
tcagaagget tggttgaaca tategettte cettttteet etceeteege eceteecagt 780
acagtccatc tttcaatgtt gcagcctggt tgagaaggag agaaaaaggt ggcaggaatt 840
tccaggagat ccccaagaat gctgccttgt ctgtggacaa agatggacca tgtgcccttc 900
ggaattaggg atagaaacaa atattgtgtg ctcttaacga ttaagctgtg ttatggtggg 960
ttttcaggtt tttacctttt ttctttaccc ctttactctg caagaatggg gaaagaatgc 1020
atactgcgaa aatgagtett ttaaattetg tetgeetaet agttttaagt atatggtatg 1080
ttgtaaaatt tccaatgatg agagacagca caataaatgt accttatctc cttaggctga 1140
aggccataac tacatagtgg agtaatttaa gaactetett gccttcacca acccaaaagg 1200
ttgctttttg atagcaactg gctaatgaat ttttaaaaaga gaagaaaaat actagttttc 1260
ccctcttttg ggaaatagat tttaaatggc taaactacta gccttaaaac tactagtcta 1320
ataaaatcaa ctaccacttt tgtgaatctg acaggccaca tttttatatg gccctttaca 1380
gaatggagtg tgttgaacag gatactaacg ccattgagtt gagctggcct agcgatggag 1440
ggacactota acacaacttt cootcagota ttatgcaaca gatcagggaa aaagatggga 1500
tgacagatgg ggtcagacag aaagagcttc tgggaaacaa gcttacatag tcttttttaa 1560
aatgcacaaa gcctcccagc taagaggtca cttggtttgg gcttcattag gactgagact 1620
ttgttgagtt ctttctggga cttggagagt ggatgatatt caggctctga acattcccag 1680
cgctctcccg agggtgccac tttctcaaga tgaaaactgt gactgaaaaa attaataata 1740
1790
```

<210> 82

<211> 1350

<212> DNA

<213> Homo sapiens

<400> 82

agtgggcggg ccatttcttg ttctctctcc cgctctcgga agctttcgtc tcgtgggtgc 60 gaaaggtaac cgaagcggct caggaaggca gctgtcactg agcccctgga acagagcgag 120 agtategtaa gtaaccagge teageeggtt teteaggeeg etetagteaa ataaaccata 180 aagatcagac tegggettet teactteett eteteegtgg tttegeeatt agetteeggt 240 tccggggagg ggccgagttt tcttcgaaga tttggggctc cgcgatacag ttaggatggc 300 tgtagtacct ctgctgttgt tggggggttt gtggagcgct gtgggagcgt ccagcctggg 360 tgtcgttact tgcggctccg tggtgaagct actcaatacg cgccacaacg tccgactgca 420 ctcacacgac gtgcgctatg ggtcaggtag tgggcagcag tcagtgacag gtgtaacctc 480 tgtggatgac agcaacagtt actggaggat acgggggaag agtgccacag tgtgtgagag 540 gggaaccccc atcaagtgtg gccagcccat ccggctgaca catgtcaaca ctggccgaaa 600 cctccatagt caccacttca cttcacctct ttctggaaac caggaagtga gtgcttttgg 660 tgaggaaggt gaaggtgatt atctggatga ctggacagtg ctctgtaatg gaccctactg 720 ggtgagagat ggtgaggtgc ggttcaaaca ctcttccact gaggtactgc tgtctgtcac 780 aggagaacaa tatggtcgac ctatcagtgg gcaaaaagag gtgcatggca tggcccagcc 840 aagtcagaac aactactgga aagccatgga aggcatcttc atgaagccca gtgagttgtt 900 gaaggcagaa gcccaccatg cagagctgtg aatctagagg ctctgagcca ctgttaacgc 960 acaatgttca cagacatctg ttgctgcctc accttgggat ccctgccaca agttccttgg 1020 gcagtggcca tgtcaccatt gagatgaaga tatacaacag aaaatagtgg ctgtgtttgg 1080 aagetteage cetgeacatt tgaactagte acteteceag acttgegtgg gteagttett 1140 totgagtaga ggacttgctg gtaaaggggc agatgctttt tattagtact gataaaacaa 1200 actgagggaa acatecetet tagetgggaa acttttaete tteaggaget tggeateatg 1260

```
gactgttaat gtatgtgatt ttccccctat tttctctctc caaaatgata aaaacaataa 1320
                                                                 1350
ttttaaaaaa aaaaaaaaaa aaactcgagg
<210> 83
<211> 1746
<212> DNA
<213> Homo sapiens
<400> 83
ggcatcagta aggtctgtat ttaaatgtgg atgtagacat cataattacc aagacaagaa 60
attgttttga gaaattctct gatgtttttc ttcttcaggt ttcacgtgcc acgatcatgg 120
tgccacggta ctgcagtatg cacccaaaca gcaactccta atctcggggg gtaggaaaag 180
acacgtctgc atttttgaca tcargcaaag gcagctcatt cacacgttcc aggcccatga 240
ctcagctatt aaggctctgg ccttggatcc ctatgaggaa tattttacca caggttcagc 300
agaaggtaac ataaaggttt ggagattgac aggccatggc ctaattcatt catttaaaag 360
tgaacatgct aagcagtcca tatttcgaaa cattggggct ggagtcatgc agattgacat 420
catccagggc aatcggctct tctcctgtgg tgcagatggc acgctgaaaa ccagggtttt 480
gcccaatgct tttaacatcc ctaacagaat tcttgacatt ctataaagat tggggtttta 540
tttttatata catttcagtt aaaaggcaca ctacagtcat cactaggcaa ttctgctttc 600
taagcagttg tattgaaaac agagaatctc tgtgtagaat ttgaatatga cccaagctga 660
gtattatcta aacaggttgg tggaatgaat gcgcatgtac cttattatgc tgacatacta 720
aaaaaaataa aacctagtat tgtatgaagg atagctattc tttacagcat ttagcaaacc 780
tgattcagaa aacatttgag attagcaaat tagtaacttg aaataatgaa aaggacgttt 840
ataccaaatt aaggaagaaa atgttgctga tttgggtttt tcttcctgtt cttaccactg 900
actgaagcat qcctqcaqtc tcctcctctg ttgaatgaag gataatcata aggtgtttgt 960
taggageget agaceaeetg gaaaaettte ttagetgtgg ageagtgege agtgaeeagt 1020
tetetgetgt gagaggeegt tteeattett teetgetgaa tattttteet gttagtgttt 1080
atactgagct agtactgtaa cttgcaaatg agtgcaaatt taaatgcaat gttttactca 1140
caatttgcac attcacattt tttggactgc tagtttttct atttaaatat ttgccttcat 1200
gttaggaatg tactatgtga acatgacata tttgtagtta accaaacaca ccttcttagt 1260
ccagtttagt acttttctt ttcgtgtatt caaggttaaa cacccaaaca tttaaggata 1320
tgttgaaact acaccaatag agcatttcat atcataatta aaatgaatgt taggcttctt 1380
gtggccagtt aatagttgat gagattggtg acattattta ttgccacagc ctattgtata 1440
aactatgcag agttaaatat ttgcttgtaa aatattagcc aatgttgtca ttattttgat 1500
gtatttcctt ggttatgacc aaaaatatgt tgagatactg aaactaatgt ctgtgtgttt 1560
aaatgtttac cagcaaattg tcttatcatg ttaatgagaa tgttcaatgc ctgtgtggta 1620
aatagtaaat acaatggcat aaaagtaact ttctctgaag atgtgatgtt caggctgtga 1680
1746
ctcgta
<210> 84
<211> 1491
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (176)
<223> n equals a,t,g, or c
<220>
```

<221> misc feature <222> (711) <223> n equals a,t,g, or c <400> 84 cccacgcgtc cgaatcaaca aagaatctga agtttacaag atgcttcagg agaaacagga 60 gttgaatgaa cccctgaaac agtctacctc tttcctgatt ttgcaggaaa tcctggagtc 120 tgagataaaa ggggatetea acaaccetea ggatteagaa gtgttaaaac teetgnacee 180 traagtgrmt gcatcaattg gaaatgctca gaaggtgccc atgtgtgaca aatgtggtcc 240 tggcattgta qqcatqtttq taaaqctqcq qqqaccatca tcccctccct gaatgttacq 300 tgtgcactga ttgtgacamt cacccgaaag agaagggctt ttttttttt tttccatcaa 360 atctactgtg aagagcatgc ccaggagcaa gtcacaccac ttgagggtac gatgtgatca 420 tcatgttccc caagtgatcc agcagacctg cactgaccac cgttctccag ccagcctctg 480 ctgcagctag ttctctaaat gttctggcct tgtctcttga aagttctgta cttattcccc 540 cacccccaa cccgcttacc ttggttttat ccctgctcat tgaaccttga gtcccttgtc 600 ttggttaact gactcacact gactgtgtgg tgcccgccca cttttacaat gaatggcaaa 660 ctgtttttgt tcagtgtccc cttgccggca acactgtgta ccttcctccc ntcagttctt 720 ctctgctgca aatggacatc agccacattt gaaccaaatc aaatataata tgtctgacat 780 tgatttcatt tttgctccat ctatagactc ccagaaaaaa raaawaaaaa aaatgcaaag 840 aaaatttaaa tgaacaaaca gaccettetg gaacetaetg tgacatgaga tgtgtecaca 900 aggogaggtt toaggoacac actgaaggag catotgotgg acagocotco cogococcaa 960 gtccttacca acctgtgcca ctgcataccc tgtaaaaagt gtgtggtggt tggtaatgga 1020 ggagttttga agaataagac attrggrgaa aaaatcgacy cctatgatgt aataataaga 1080 atgaataatg gtcctgtttt aggacatgaa gaagaagttg ggagaaggac aaccttccga 1140 cttttttatc cagaatctgt tttttccaga tccctattca caatgaccct aatacgacag 1200 tgattcctca ctgcttttaa gccacatgat ttaaggtggc tgttggaatt gttgatgggt 1260 gacaaaataa acactaatgg tttttggaag aaaccagcct taaacctgat ttataaacct 1320 tatcaaatcc gaatattaga tcctttcatt atcagaacag cagcttatga actgcttcat 1380 tttccaaaag tgtttcccaa aaatcagaaa cctaaacacc caacaacagg aattattgcc 1440 atttttacat aacctctatg attttaataa aaaaaattat gtaaaaaaaa a 1491 <210> 85 <211> 968 <212> DNA <213> Homo sapiens <400> 85 ctgcagttaa gtgaaaagaa aatccagcct cccctccaa aaaaaaaaa aaaaaaaaa 60 atttaatttt taaaaattag tggtatggca ataagacact tcagaggcta tcttaacctc 120 tgaataccca tcttctagtt taaagacaga gacatcccat ctggaaaatg ttaacttgtg 180 ttgccatctc gttgccgqaq taagtagaca taagacagag tttaagaagt aaaaatatag 240 aaaaattttg atggtcacaa tgagataaat attagaatat tactattcca atgattaaat 300 gaggatettg aaataaatte tgaagtette caatttttae atttattgga ggggteeetg 360 agttctgtca actttttat ttaagtctct tgctcttatt ttgtgcataa atgttaaacc 420 ttccaaaaat gaaatgttag ctttctttct tttacttttt attaaattta atagaaaata 480 tgacctgagt agttaaaaag tattttgcat tattttgcagt aagatgtctc tagcactgct 540 caaagggcaa attttaaaac ttcagtctgg gtgaaagatt tgctagtttt acagaaagat 600 ttgctatctt aaactcaagc tggtttttct gttctcatgt aagtgactgg gatgctgtct 660

tatgaattet teeaaggtea tgtttgtgaa ataaacatta eatgagaget tteetgteat 720 etaeactata tgttgtetgg agtgttgaae aaatttattt tagtttetaa gttgtaatet 780 ateeteatat ggtetataeg attttgaatg tgtgeeacta eataetgaga tgataatget 840

gtacaatttt aagtggtagc agtttctgta tgcagtaggc tgaaatattt tgatgaactg 900 cttaattttt ggattttatt ttttaagttg tataatttat tttcttgcaa aataaaaatg 960 taatataa <210> 86 <211> 3068 <212> DNA <213> Homo sapiens <400> 86 cgacagaagg ggaggttgtt tttataagag gcgtcattgg cgcccgagct gtgaccgccg 60 ccactggggc agccagcaca atcgggcgga ggtggcgctg ccccttcaga cctgaaagat 120 gtctgaaaat tccagtgaca gtgattcatc ttgtggttgg actgtcatca gtcatgaggg 180 gtcagatata gaaatgttga attctgtgac ccccactgac agctgtgagc ccgcccaga 240 atgttcatct ttagagcaag aggagcttca agcattgcag atagagcaag gagaaagcag 300 ccaaaatggc acagtgctta tggaagaaac tgcttatcca gctttggagg aaaccagctc 360 aacaattgag gcagaggaac aaaagatacc cgaagacagt atctatattg gaactgccag 420 tgatgattct gatattgtta cccttgagcc acctaagtta gaagaaattg gaaatcaaga 480 agttgtcatt gttgaagaag cacagagttc agaagacttt aacatgggct cttcctctag 540 cagecagtat actttetgte agecagaaac tgtattttea teteageeta gtgaegatga 600 atcaagtagt gatgaaacca gtaatcagcc cagtcctgcc tttagacgac gccgtgctag 660 gaagaagacc gtttctgctt cagaatctga agaccggcta gttgctgaac aagaaactga 720 accttctaag gagttgagta aacgtcagtt cagtagtggt ctcaataagt gtgttatact 780 tgctttggtg attgcaatca gcatgggatt tggccatttc tatggcacaa ttcagattca 840 gaagcgtcaa cagttagtca gaaagataca tgaagatgaa ttgaatgata tgaaggatta 900 tctttcccag tgtcaacagg aacaagaatc ttttatagat tataagtcat tgaaagaaaa 960 tcttgcaagg tgttggacac ttactgaagc agagaagatg tcctttgaaa ctcagaaaac 1020 gaacettget acagaaaate agtatttaag agtatecytg gagaaggaag aaaaageett 1080 atcctcatta caggaagagt taaacaaact aagagaacag attagaatat tggaagataa 1140 agggacaagt actgaattag ttaaagaaaa tcagaaactt aagcagcatt tggaagagga 1200 aaagcagaaa aaacacagct ttcttagtca aagggagact ctgttgacag aagcaaagat 1260 gctaaagaga gaactggaga gagaacgact agtaactacg gctttaaggg gggaactcca 1320 gcagttaagt ggtagtcagt tacatggcaa gtcagattct cccaatgtat atactgaaaa 1380 aaaggaaata gcaatcttac gggaaagact cactgagctg gaacggaagc taaccttcga 1440 acagcagcgt tctgatttgt gggaaagatt gtatgttgag gcaaaagatc aaaatggaaa 1500 acaaggaaca gatggaaaaa agaaaggggg cagaggaagc cacagggcta aaaataagtc 1560 aaaggaaaca tttttgggtt cagttaagga aacatttgat gccatgaaga attctaccaa 1620 ggagtttgta aggcatcata aagagaaaat taagcaggct aaagaagctg tgaaggaaaa 1680 totgaaaaaa ttotoagatt cagttaaato cactttoaga cactttaaaag ataccaccaa 1740 gaatatettt gatgaaaagg gtaataaaag atttggtget acaaaagaag cagetgaaaa 1800 accaagaaca gtttttagtg actatttaca tecacagtat aaggeaceta eagaaaacea 1860 tcataataga ggccctacta tgcmaaatga tggaaggaaa gaaaagccag ttcactttaa 1920 agaattcaga aaaaatacaa attcaaagaa atgcagtcct gggcatgatt gtagagaaaa 1980 ttotcattot ttcagaaagg cttgttctgg tgtatttgat tgtgctcaac aagagtccat 2040 gagccttttt aacacagtgg tgaatcctat aaggatggat gaatttagac agataattca 2100 aaggtacatg ttaaaagaac tggatacttt ttgtcactgg aacgaacttg atcagttcat 2160 caataagttt ttcctaaacg gtgtctttat acatgatcag aagctcttca ctgactttgt 2220 taatgatgtt aaagattatc ttagaaacat gaaggaatat gaagtagata atgatggagt 2280 atttgagaag ttggatgaat atatatatag acacttcttt ggtcacactt tttcccctcc 2340 atatggaccc aggtcggttt acataaaacc gtgtcattac agtagtttgt aacatttgta 2400

gattggatag cattittatg atttgatgag titcttgtaa ggttaccgtt tctaagagtt 2460

```
gtgctttatg gccactgaga gaattcagaa taaattgaaa gatggagtct aaaaattatt 2520
agctgttaca aatggaacat ttcattataa cgtgatcact ttgacttgag caaatggttt 2580
aatttttatc ttaaaaatca gttaagaata tataaaatcc tactttggcc aagtttgttt 2640
cttttcatta tagtttatat gaaaagatca ccttaagtga aattattttc ctttaatctt 2700
ttatgtattt attcactttt ggaagctagg aatgagcaac acaaatttta ctctgaagtc 2760
agaagagete atatataata attetaatgt cecacetatt tteaettgte cattecatgt 2820
accagettag ttatgatact tagteacata attatetttg ataaaggtag aggeacaaag 2880
aggcaaacta agcaagtcaa attctaatgt gtgtacttca taataatttt ttatccattt 2940
tcatctttat attctgtaac atgaaactta cctaatcttc aaatgttagc ttcatttttt 3000
3068
aaaaaaa
<210> 87
<211> 2230
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (2227)
<223> n equals a,t,g, or c
<400> 87
ggcacagccg tgctccgggt aagatggcag cggacggaca gtgctcgctc cccgcttcat 60
ggcggccggt gaccctcacc cacgtcgaat atcctgcagg tgatctctcy ggccacctcc 120
ttgcctacct gagcctcagc cctgtatttg tcatcgtcgg tttcgtgacc ctcatcatat 180
ttaageggga gtgcacaega teteetteet tgggggeetg geaetgaaeg agggggteaa 240
ctggctgatc aaaaacgtca tccaqgagcc acggccctgt ggaggccccc acacagcagt 300
gggcaccaag tacgggatgc cctccagcca ttcccagttt atgtggttct tctccgtcta 360
ttocttoctt ttoctgtatt taagaatgca ccaaacaaac aacgccaggt tcctggactt 420
getgtggagg caegtgetet eeetgggaet eetegetgtg geetteetag teteetaeag 480
cagggtctac ctgctgtacc acacctggag ccaggtgctc tatggaggca tcgctggagg 540
cctcatggcc ategectggt teatetteac ceaggaggte etcaceeege tgtteeeeag 600
gatagcagec tggcctgtct ccgagttctt cctaatccga gacacaagcc tcattcccaa 660
cgtactctgg tttgagtaca cggtaacccg ggcagaagcc aggmacagac aacgcaagct 720
ggggacgaaa ctgcagtgac cagtgggtgt ggctgggtcc agcctccaga tctggcccgc 780
acgatgcctt gcaggatgga caggatgaca gacagggacg aagcagagac ctctacagac 840
ccaagtcacc aagtggagcc tttttttttc ttattttaat tttaatgaac aaggtggacc 900
aaagggotga accageeest caaccaggae eetgggggge etgetgeetg ggggeegtgg 960
ccagagaccc tcgctgtgct gctgccagcc cctggctggg gcagaaagtg ccctcggcat 1020
gggcacctgg gtgtggggtg gaggaggagg gctcgcgcct ctggtctcgg ggccaggaat 1080
tccaggtggc gtgagaagta cacactattt attttttggt tttktcagag gcaggcagga 1140
ttttggagct ggaagaatct gctctccggt ggctgccctg tgaacagagg gctcccggtc 1200
agetteecag geeettegee ctatgeecag aggeagactg ceteteectg ggeeggggtg 1260
gcctgggtgc caggaggagg ggagcatacc ccacaccctc cctgccaccg ttgccgttcc 1320
agaacctcgg tcagtgtttc cctgtctggg ggcagggccc agagcgagca cgcgtctggc 1380
ggctgctgtc gttgtgttct accccqtact gacccaacac cacaagggct ttctctggtc 1440
ccctgtccct aagacaataa tcgctttctg acaaaggagc ctgcacattt gggtgagcag 1500
acceaagetg tttacagete tttettgtee tgeeateeag tageagttag tetteateee 1560
cacgtgaaca aaatgggaag gagccgtgag gagaggagtg aggcaacagg cacccgaagt 1620
coctogtect tecetetgtg tgetetgaat atgteettgt cetteetgae ceatetetga 1680
```

```
ccagctggga acctgcttgg ggtcccctc aaacctgtgt ctggggtgtg ggctcacaga 1740
tccctatcag cctggttcgt gggagggctc ttcctaaagg gacccccatc tctaagtcac 1800
tctgaaaggg agttgtggag aggagacgcc tccagactct cagaagtttt gaggactgaa 1860
ctgggtcact cgggatctgt gttcgaatcc tccccacccc tttctttgtg gagtttccta 1920
caaaagccat tocagatgcc aagaccaggg gcttatttct agggaaggta ggtcggtttc 2040
catgtttccc tcccgttatt tttatttttt actttttgcc tgagacaagc cgagtatgag 2100
gtggtttgat ttaagaaaaa tcaatgaaat tgtttactac tgttttaaaa taaaaccgta 2160
aactctgaaa aaaaaaaaa aaaaaaaaa aaaaactcga gggggggccc ggtacccaat 2220
                                                                 2230
cgcatcncat
<210> 88
<211> 1163
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (159)
<223> n equals a,t,g, or c
<400> 88
actgcccaa gctcaaggag atcaatttcc gtgggaacaa gctgagggac aagcgcctgg 60
agaagatggt cagcggctgc cagaccagat ccatcctgga gtacctgcgc gtcggaggcc 120
gtggtggcgg gaaagggcaa gggccgtgcg agggctcgna gaaggaagag agccggagaa 180
gaggaggag aggaagcaga ggcgggaagg tggtgatggg gargagcagg acgtgggaga 240
tgccggccgg ctgctgctca gggtcctgca cgtctctgaa aaccccgtac ctctgacagt 300
cagagtgage eccgaggtee gggatgtgeg geectacatt gtgggggeeg tggtgegagg 360
catggacctg cagccaggga atgcactcaa gcgcttcctc acctcgcaga ccaagctcca 420
cgaagatoto tgtgagaaga ggacggotgo caccottgoo acccacgago toogtgcogt 480
caaagggccc ctgctgtact gcgcccggcc cccacaggac ctcaagattg tccccttggg 540
gcggaaagaa gccaaggcca aggagctggt gcggcagctg cagctggagg ccgaggagca 600
gaggaagcag aagaagcggc agagtgtgtc gggcctgcac agataccttc acttgctgga 660
tggaaatgaa aattacccgt gtcttgtgga tgcagacggt gatgtgattt ccttcccacc 720
aataaccaac agtgagaaga caaaggttaa gaaaacgact tetgatttgt ttttggaagt 780
aacaagtgcc accagtctgc agatttgcaa ggatgtcatg gatgccctca ttctgaaaat 840
ggcagaaatg aaaaagtaca ctttagaaaa taaagaggaa ggatcactct cagatactga 900
agccgatgca gtctctggac aacttccaga tcccacaacg aatcccagtg ctggaaagga 960
egggeeetee ettetggtgg tggageaggt eegggtggtg gatetggaag ggageetgaa 1020
ggtggtgtac ccgtccaagg ccgacctggc cactgccct ccccacgtga ctgtcgtgcs 1080
ctgacsccag ggccgcctgt ccgcgtttgt ttggccggtt ttgcggaggt ttctatgcgg 1140
                                                                1163
caatgctgaa ttatccgtta gat
<210> 89
<211> 1939
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (20)
```

```
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (31)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (33)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (1609)
<223> n equals a,t,g, or c
<400> 89
agcaacctat agatcatgan aggcaacggt nanctgacag taccggtcgg aattcccggg 60
tegacecacg egteergegg taacegeeac agetgeeage gacaggatgg agagegacte 120
agactcagac aagagtagcg acaacagtgg cctgaagagg aagacgcctg cgctaaagat 180
gtcggtctcg aaacgagccc gaaaggcctc cagcgacctg gatcaggcca gcgtgtcccc 240
atccgaagag gagaactcgg aaagctcatc tgagtcggag aagaccagcg accaggactt 300
cacacctgag aagaaagcag cggtccgggc gccacggagg ggccctctgg ggggacggaa 360
aaaaaagaag gegeegteag ceteegaete egaeteeaag geegattegg aeggggeeaa 420
gcctgagccg gtggccatgg cgcggtcggc gtcctcctcc tcctcttcct cctcctcc 480
cgactccgat gtgtctgtga agaagcctcc gaggggcagg aagccagcgg agaagcctct 540
cccgaagccg cgagggcgga aaccgaagcc tgaacggcct ccgtccagct ccagcagtga 600
cagtgacagc gacgaggtgg accgcatcag tgagtggaag cggcgggacg aggcgcggag 660
gcgcgagctg gaggcccggc ggcggcgaga gcaggaggag gagctgcggc gcctgcggga 720
gcaggagaag gaggagaagg agcggaggcg cgagcgggcc gaccgcgggg aggctgagcg 780
gggcagcggc ggcagcagcg gggacgagct cagggaggac gatgagcccg tcaagaagcg 840
gggacgcaag ggccggggcc ggggtccccc gtcctcctct gactccgagc ccgaggccga 900
gctggagaga gaggccaaga aatcagcgaa gaagccgcag tcctcaagca cagagcccgc 960
cgtgaaggtg gagcggaccc ggaagcggtc cgagggcttc tcgatggaca ggaaggtaga 1080
gaagaagaaa gagccctccg tggaggagaa gctgcagaag ctgcacagtg agatcaagtt 1140
tgccctaaag gtcgacagcc cggacgtgaa gaggtgcctg aatgccctag aggagctggg 1200
aaccctgcag gtgacctctc agatcctcca gaagaacaca gacgtggtgg ccaccttgaa 1260
gaagattcgc cgttacaaag cgaacaagga cgtaatggag aaggcagcag aagtctatac 1320
ccggctcaag tcgcgggtcc tcggcccaaa gatcgaggcg gtgcagaaag tgaacaaggc 1380
tgggatggag aaggagaagg ccgaggagaa gctggccggg gargagctgg ccggggagga 1440
rgcccccag gagaaaggcg gargacaagc ccagcaccga tctctcagcc ccagtgaatg 1500
gcgaggccac atcacagaag ggggagagcg cagaggacaa ggagcacgag gagggtcggg 1560
actoggagga ggggccaagg tgtggctcct ctgaagacct gcacgacanc gtacgggagg 1620
gtcccgacct ggacaggcct gggagcgacc ggcaggagcg cgagagggca cggggggact 1680
cggaggccct ggacgaggag agctgagccg cgggcagcca ggcccagccc ccgcccgagc 1740
traggetgee ceteteette eceggetege aggagageag ageagagaac tgtggggaac 1800
gctgtgctgt ttgtatttgt tcccttgggt ttttttttcc tgcctaattt ctgtgatttc 1860
caaccaacat gaaatgacta taaayggttt tttaatgaaa aaaaaaaaaa aaaagggcgg 1920
                                                                1939
ccgctctaga ggatccctc
```

```
<210> 90
 <211> 2032
 <212> DNA
<213> Homo sapiens
<400> 90
ggcacaggcg gccgccgcg cgccaagttc ctcagccctt ggctcctgcc cagtgtttag 60
ggtgttggcg gagaaaaggg gaagagtcat cgcctgtcgg ggctaggata tgatgggtga 120
gaggtgtcaa accaaattct ctcggtttgg aaacggagaa aatctaaaaa tgaggatgtg 180
aggaaagagt ccgctctcaa ggcgcgttgt ggtctatccg agccccgtcc cctgggctcc 240
ctcgggctgg ggtgaggcgg gcagctacgc gtggggtagg accatcttac gctgggaccc 300
egecaaggag ceceaggaag taggtgaaag ggeaggggeg tggetetegg ggegeeacce 360
acgetettga aatetgggtg attgegageg geegeteage gteeceaca ceacagacee 420
gegeegeega egaceeagea geegeeatgg etetgeteeg aggtgtgttt gtagttgetg 480
ctaagcgaac gccctttgga gcttacggag gccttctgaa agacttcact gctactgact 540
tgtctgaatt tgctgccaag gctgccttgt ctgctggcaa agtctcacct gaaacagttg 600
acagtgtgat tatgggcaat gtcctgcaga gttcttcaga tgctatatat ttggcaaggc 660
atgttggttt gcgtgtggga atcccaaagg agaccccagc tctcacgatt aataggctct 720
gtggttctgg ttttcagtcc attgtgaatg gatgtcagga aatttgtgtt aaagaagctg 780
aagttgtttt atgtggagga accgaaagca tgagccaagc tccctactgt gtcagaaatg 840
tgcgttttgg aaccaagctt ggatcagata tcaagctgga agattcttta tgggtatcat 900
taacagatca gcatgtccag ctccccatgg caatgactgc agagaatctt gctgtaaaac 960
acaaaataag cagagaagaa tgtgacaaat atgccctgca gtcacagcag agatggaaag 1020
ctgctaatga tgctggctac tttaatgatg aaatggcacc aattgaagtg aagacaaaga 1080
aaggaaaaca gacaatgcag gtagacgagc atgctcggcc ccaaaccacc ctggaacagt 1140
tacagaaact tcctccagta ttcaagaaag atggaactgt tactgcaggg aatgcatcgg 1200
gtgtagctga tggtgctgga gctgttatca tagctagtga agatgctgtt aagaaacata 1260
acttcacacc actggcaaga attgtgggct actttgtatc tggatgtgat ccctctatca 1320
tgggtattgg tcctgtccct gctatcagtg gggcactgaa gaaagcagga ctgagtctta 1380
aggacatgga tttggtagag gtgaatgaag cttttgctcc ccagtacttg gctgttgaga 1440
ggagtttgga tettgacata agtaaaacca atgtgaatgg aggagecatt getttgggte 1500
acceactggg aggatetgga teaagaatta etgeacacet ggtteacgaa ttaaggegte 1560
gaggtggaaa atatgccgtt ggatcagctt gcattggagg tggccaaggt attgctgtca 1620
tcattcagag cacagcctga agagaccagt gagctcactg tgacccatcc ttactctact 1680
tggccaggcc acagtaaaac aagtgacctt cagagcagct gccacaactg gccatgccct 1740
gccattgaaa cagtgattaa gtttgatcaa gccatggtga cacaaaaaatg cattgatcat 1800
gaataggagc ccatgctaga agtacattct ctcagatttg aaccagtgaa atatgatgta 1860
tttctgagct aaaactcaac tatagaagac attaaaagaa atcgtattct tgccaagtaa 1920
ccaccacttc tgccttagat aatatgatta taaggaaatc aaataaatgt tgccttaact 1980
2032
<210> 91
<211> 1788
<212> DNA
<213> Homo sapiens
<400> 91
ttcccaccgg cttccccaga ggtggaagaa acccgaracg ttccgaagtc aacgcaagca 60
aaggggagtg cgggtcgggg aggaatattc ttttggaaac gtaatattgg ccttggggct 120
ctccagccct ttgggacttc caatgggatc ttagaagcag ccgaagcagc gtgagggcgg 180
```

cagccagggc cagccacgat ttgaacgctc tgccttgcag ctcttctgga ccgaggagcc 240 caaagcccta ccctcaccat tcaccaggtt acagttctta tccgcgtgaa tacacatggc 300

```
tetgttaega aaaattaate aggtgetget gtteettetg ategtgaece tetgtgtgat 360
tctgtataag aaagttcata aggggactgt gcccaagaat gacgcagatg atgaatccga 420
gactcctgaa gaactggaag aagagattcc tgtggtgatt tgtgctgcag cagggaggat 480
gggtgccact atggctgcca tcaatagcat ctacagcaac actgacgcca acatcttgtt 540
ctatgtagtg ggactccgga atactctgac tcgaatacga aaatggattg aacattccaa 600
actgagagaa ataaacttta aaatcgtgga attcaacccg atggtcctca aagggaagat 660
cagaccagac tcatcgaggc ctgaattgct ccagcctctg aactttgttc gattttatct 720
ccctctactt atccaccaac acgaagaaag tcatctattt ggacgatgat gtaattgtac 780
aaggtgatat ccaagaactg tatgacacca ccttggccct gggccacgcg gcggctttct 840
cagatgactg cgatttgccc tetgeteagg acataaacag actegtggga etteagaaca 900
catatatggg ctatctggac taccggaaga aggccatcaa ggaccttggc atcagcccca 960
gcacctgctc tttcaatcct ggtgtgattg ttgccaacat gacagaatgg aagcaccage 1020
gcatcaccaa gcaattggag aaatggatgc aaaagaatgt ggaggaaaac ctctatagca 1080
gctccctggg aggagggtg gccacctccc cartgctgat tgtgtttcat gggaaatatt 1140
ccacaattaa ccccctgtgg cacataaggc acctgggctg gaatccagat gccagatatt 1200
cggagcattt tctgcaggaa gctaaattac tccactggaa tggaagacat aaaccttggg 1260
acttccctag tgttcacaac gacttatggg aaagctggtt tgttcctgac cctgcaggga 1320
tatttaaact caatcaccat agctgatata actctaccct taaaatattc cctgtataga 1380
aatgtggaat tgtccctttg tagccaacta taacattgtt ctttatgaat attacctttg 1440
atacatatga tocacaatat aaaaaccaaa aactactgtg tgcaaattat accttggacc 1500
atataggcat tgattaactt ctttaagtac atgtgataac tatggaaatc aagattatgt 1560
gactgaaaaa cataaaggaa gagacccatc tagataacag caatcaacct gcttaattct 1620
gaatgacaat tatatccaca aatttttaaa acttctacat gtatttttca catgaagatc 1680
tccttaacag gttgccaacc ttttctttta taaaactatt acatttaaaa tatggacgtc 1740
                                                                 1788
<210> 92
<211> 495
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (402)
<223> n equals a,t,g, or c
<400> 92
gggtcgaccc acgcgtccga ccacattcct cctctaaaga agcccctggg agcacagctc 60
atcaccatgg actggacctg gaggttcctc tttgtggtgg cagcagctac aggtgtccag 120
teccaggtge agetggtgea gtetgggget gaggtgaaga ageetgggte eteggtgaag 180
gtctcctgca aggcttctgg aggcaccttc agcagctatg ctatcagctg ggtgcgacag 240
gcccctggac aagggcttga gtggatggga gggatcatcc ctatctttgg tacagcaaac 300
tacgcacaga agttccaggg cagagtcacg attaccgcgg acgaatccac gagcacagcc 360
tacatggagc tgagcagcct gagatctgag gacacggcca tntattactg tgcgaraagk 420
ccctmagcgg gttatctatc ccaactacta ccacggtatg gacgtctggg gccaagggac 480
cacggtcacc gtctc
                                                                 495
<210> 93
```

<210> 93 <211> 1377

```
<212> DNA
 <213> Homo sapiens
 <220>
 <221> misc feature
 <222> (1367)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (1371)
 <223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (1376)
<223> n equals a,t,g, or c
<400> 93
ggacccacgc gtccgagact tttgaaggaa gaaatcaatt atgatgataa actacaggta 60
agagttgggt gttctaggtc ctgttcttca ggctttttat attcagaaat atgatacatg 120
tataacagct taggcagtca ttgcctagtt ggtcacatta gggtgacaac caaagattaa 180
caccaacatg tatttaattg tatgatttat agtgtccctt ttggcttaac actttcaaac 240
atttttctta tatttggctt tcctagttcc ctattatttt tttaaatctg gaagttgtca 300
ttttttaatt aatttctgtc gaactgaagt gattagaaat atcaacatct ctttcaggtt 360
aaaaatattt tgtatcatgc agtcaaagaa atggtgagag ccttgaagat acacgaggat 420
gaagtagasg atatggaaga aaattaagtg tgatccagtt tgatattttt aggttgttga 480
actgggatta cttaaccttq aatqatqata tqtatqcaca ctgactttaa qcttcataaa 540
accatcagtg ccaagaaatt ctctttgtag taattacttg ttactgacac cacagcagta 600
tagcatatgt cacageteet gtgatteaat gttataaaac aagcagaatt ttaaaagcag 660
cactatatag ctgttttgta ttatagtgta tatgatgttt gtgaaaatgc cagatttaaa 720
atgatgtatt tatttttggt aaaaaataaa aaattctatg ctatattgtt gatcaagtgt 780
aaatgtgacc ttgtacagtt tactaaaatt actgatattt ttcactacat tgagacagtt 840
actgtgagaa taggacacaa acaccagcta ttgcctgcat ctgggaaatt gctgaatcgc 900
acagcagtca tgtcataatc agaaaattac tgccaaataa ttgtaaaatt tgtaaagtat 960
aaagtatata aagtagatac taaatacaga cacttcaata ttttgttgaa gctattgact 1020
gtacaattaa acattttcaa aaggtgtaat ttatttaaaa ttgtctcatt ttggtaaaat 1080
ttatgtgaac ttttaaagct aaatattaaa cttaatatgc tatgtaaata tatacatata 1140
tacatttaat gatgtatttt tttaaaacat tggcttgctt ttgttaaagt gcaagtgtta 1200
catatggctt tgtacattaa agttgaaagg ggttttacat tttccattaa aaggacttta 1260
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaggggnggc nttttna
<210> 94
<211> 2819
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (82)
```

64

```
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (83)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (84)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (2816)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (2817)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (2818)
<223> n equals a,t,g, or c
<400> 94
ttttgtattt ttttttagta gagacagggt ttcactgtgt cagccaggat ggtcttgatc 60
totggcccaa gottttaaaa cnnnaaaacg gtggccaggc acggcagcac acacttgtaa 120
ttctagcact tcaggaggcc gagatagaag gatcactcga gcccaggaat tcgagaccag 180
ccctgacgat ataaataggg aaagagagag agagagagag agagcgcgtg cacgcgaggg 240
agaatgcctg cccctctcca gcctggccaa cagaaggaga tcctgtctca aagaaagtga 300
aaatgottoa gotagaatta taggataato otgkgtgaga taatttacat agygaotgga 360
agagttatta aatattgctt tettgytget aagttetgta gttgggttag atatetaatg 420
cgtaactatt gtgaaagtca agagattcta atttttccag aaaataatgt tgagtttcca 480
tgaagaacag gaagtactgc cagaaacttt ccttgctaat ttcccttctc tgataaagat 540
ggacattcac aaaaaagtaa ctgacccaag tgtggccaaa agcatgatgg cttgcctcct 600
gtcttcactg aaggctaatg gctcccgggg agctttctgt gaagtgagac cagatgataa 660
aagaattctg gaattttaca gcaagttagg atgttttgaa attgcaaaaa tggaaggatt 720
tccaaaggat gtggttatac ttggtcggag cctgtgacat ttgttgacac tgtgaactgt 780
ccaaaagtct cttaactgca ccttgtgaat ggtagttgag gtcttcatac agttcagcct 840
ctagaatggt aacaaatcag ccaattggat tcgaaacaaa gaagactatg taaaactcac 900
ccatcacact ttgagactac tcactggttg gaagaatata gtattgcagc aaatcctgta 960
tgaaagagag atgtgggctt cctttttgag tcttgtgtta ggtgctgaga ccttttacat 1020
gggcttatac agggagagag tcttcaataa atgtagtcag cactattttc tgcatccagt 1080
gtggttgcgt ttctcacctg agagtaatca agataacatc tgtcatcttc cttggtttat 1140
tgagtgaaat gcctctcagt cttaggggac atggcagaga tgaaagaaag aaagagtggg 1200
tttcagaagt gtcagggtgg agtgattcca agtgggatgg ttgtggcatt agtttaagct 1260
gaataaataa tttcaatttg gggcagttat tctgcttttt gtaaagccgt ggccaattgt 1320
ctcctgtaat gactgttggt tcaggcatgt tgtactttgt agggacaaat gtgcatttgt 1380
```

```
ttgtggcaaa agcctacaat tgacaaactt gtaaatttct ttgtatataa actagctgta 1440
acctgactat cctttgtgtt tactgttttt gtaaattttt ttcctctata aatgaaaggg 1500
tgttggttca gaatggcact ttgaataatg taaaccagtg aaaagtggat tttctttact 1560
tttgtctttg ggtttggggt tgtttttgtt ctttttgaag ttttattatt tttaaagtgc 1620
ctcccaccta ggcgtaggcc atgaccattt ggggtacgag agcctaattt tgtaggactt 1680
aatctgttga aaagtgcagt tacttctgga aattaacctc aatattaggt cagcatgtga 1740
aatgttggat ttgacatgtc aggtagggtt cagggactga ttggtcccat ttgccctcag 1800
gtcagttgtt taatctcaag acctgttact actgatttta ttaaatcaga gtctttaatt 1860
cttgcatgtt tgtatctaat ttctgaacga atgagcacac tttaaccagt tatttacagt 1920
tacctttttc ctttaaccgg attgtgaaag cttcatgtat tttaatttag attctgtgtt 1980
tttaagggtt ctgagcatga agctggcaga tagtcggcag gactcatttt ttcatcatgg 2040
ctggctgatt tctccataga ttgataacag tattttgtta tcttgcttct ctgtagtttt 2100
gcatcagctg tttaactttg agctgagtga ggggagaggg gtaaagagaa agaaacttaa 2160
gttttctttc acagaactcc accattgtgg gctttgagag agccctaaag cattgtacct 2220
agtggtacct agtgacttcc aaccaaagcc tttgagtatg cactaaatag gtgagaagaa 2280
aggagagaag gtttttaggt tagaaacctt taaccgatag aaggatatgg tatgttgtaa 2340
agetggaace aagtttgcat ttttgaggge ttgagatgaa gggaagacte ttaccagata 2400
gtaagacage tgagttttee teagttttet egtettaaca etagtggaca attetageat 2460
tttgtttgga ggatttcaga gttaacctca tggaattcag gattttttag caagtttgct 2520
tttggtttta tcttggcttt tagtaatcat gttggctggt ctggtcacag gtgactgtga 2580
aacagatqcc ctgqtcttqc tttcatcact ctaggatcat gaagtgctat gctatttcct 2640
ggttatgaat attaaggttg gaattacatt tttattgatt gtttggatca gagctcagtt 2700
cctgtagaaa acgaactgta aaagaccatg caagaggcaa aataaaactt gaagtgaatg 2760
<210> 95
<211> 705
```

66

```
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (488)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (682)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (684)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (687)
<223> n equals a,t,g, or c
```

<400> 95

```
geggeetgge taacteetge eaggeagtge cetteeegga gegtgeeete geegetggta 60
eggeteetae etggtetgga aagagetggg aggetteaea gagaaggetg tggtteecet 120
gggcctctac actgggcagc tggccctgaa ctgggcatgg ccccccatct tctttggtgc 180
ccgacaaatg ggctgggcct tggtggatct cctgctggtc agtggggcgg cggcagcact 240
acceptagect getaccaget gagecegete geogeoegee tectetacce etacctagee 300
tggctggcct tcgcgaccac actcaactac tgcgtatggc gggacaacca tggctggcgt 360
gggggacggc ggctgccaga gtgagtgccc ggcccaccag ggactgcagc tgcaccagca 420
ggtgccatca cgcttgtgat gtggtggccg tcacgctttc atgaccactg ggcctgctag 480
tetgteangg cettggeeca ggggteagea gagetteaga ggtggeecea cetgageece 540
caccogggag cagtgtootg tgctttotgc atgcttagag catgttottg gaacatggaa 600
cgtaaccaat tggccctaaa gngngtngtt taaaattaat ggccg
<210> 96
<211> 3472
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (55)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (69)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (3457)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (3466)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (3470)
<223> n equals a,t,g, or c
<400> 96
attaaagcca gaaccagatg atctcattga cgaagacctc aactttgtgc agganaatcc 60
cttatctcng aaaaaaccta cagtgacact tacatatggt tcttctcgcc cttctattga 120
aatttatcga ccacctgcaa gtagaaatgc agatagtggt gttcatttaa acaggttgca 180
atttcaacag cagcagaata gtattcatgc tgccaagcag cttgatatgc agagtagttg 240
ggtatatgaa acaggacgtt tgtgtgaacc agaggtgctt aacagcttag aagaaacgta 300
tagtccgttc tttagaaaca actcggagaa aatgagtatg gaggatgaaa actttcggaa 360
gagaaagttg cctgtggtaa gttcagttgt taaagtaaaa aaattcaatc atgatggaga 420
```

agaggaggaa	gaagatgat	g attacgggtc	tcgaacagg	a agcatctcc	a gcagtgtgtc	480
tgtgcctgca	aagcctgaaa	a ggagaccttc	tcttccacci	tctaaacaa	g ctaacaaga <u>a</u>	540
tctgattttg	aaggctatat	ctgaagctca	agaatccgta	a acaaaaaca	a ctaactacto	600
tacagttcca	cagaaacaga	a cacttccagt	tgctcccaga	a actcgaact	ctcaagaaga	660
attgctagca	gaagtggtco	agggacaaag	taggacccc	agaataagto	cccccattaa	720
agaagaggaa	acaaaaggag	, attctgtaga	aaaaaatcaa	ggaactcaac	agaggcaatt	780
attatcccga	ctgcaaatcg	, acccagtaat	ggcagaaact	ctgcagatga	a gtcaagatta	840
					a agaagccaaa	
gctgtctgag	gaagtagtag	, tggcaccaaa	ccaagagtc	, gggatgaaga	ctgcagattc	960
					: cagataaacc	
					gatacatgtc	
					ctgcagcctc	
					gcaggcagct	
					tggcacagaa	
					gggatgagtg	
					ttgctgaaaa	
					cagattgtcc	
					caccaccage	
					tggaatgtcc	
					actgcacatt	
					gacctcaaac	
					ttttcatgta	
					tattgctttc	
					tttgtaagtt	
					agacagctta	
					gttgtgagga	
					ggctacacgg	
					attgtactac	
					gcattggcca	
					tgaatttagt	
					agttcccagt	
					cagctggaat	
					taacataatg	
					ttttttaca	
					aatgtacata	
					acttagttac	
	•	•	_	_	taaatgacag	
		-			gatgaaactt tgttaaggca	
	_	-			cttggtgtat aaaggggtaa	
	_			-	aaagttcatt	
					ctcacgttta	
					ggagaagaaa	
					tcccacagga	
					gctgttgtct	
					tgaatttaag	
		_	-		ttattttaaa	
					tgttctcagt	
		-			gccattttac	
aaggaaataa						3472
		Laucetyyun	a			7416

```
<210> 97
<211> 1216
<212> DNA
 <213> Homo sapiens
<400> 97
ggagcgtgac ttcatctcaa aaaaaaaaaa aaaaaaatta ttctqtacca tcacarcttt 60
tcacaacgat ggcaagcctt atgtcttggg agcctgtttt gctaggcaaa gttacaagtg 120
acctaatggg ageteaaatg tgtgtgtgte tetetgtgtg tttgtgtgtg tgtgtgcaet 180
caagacetet aacageeteg aageetgggg tggeateeeg geettgeeat tageatgeet 240
catgcatcat cagatgacaa ggacaaccct catgacgaag caacatgaat tagggggcct 300
cttggccttg gtccaaaatt gtcaatcaga aatgaacata aaggactcca gagcagtggg 360
actgtctgtc aaaagactct gtatatcttt tgtggatgag ttttgtgaga gaacagagag 420
accattgtac ctggcacaag ggctsttcat gaaaagggag acttactggg aggtgcaaga 480
cagtggcatt tetectetee tettgetget cageacagee etggattgea geecegagge 540
tgagaccaga caaagcccgg gaggcagaaa gatgctccaa gaaccaacac tatcaatgtc 600
tttgcaaatc ctcacaggat tcctgtgggt ccagctttgg aactgggaaa cctttcttcg 660
gatecgcact cattecactg atgccagetg eceetgaagg atgccagtae tgtggtgtgt 720
gagteteage ageegeeeac aegeteetaa etetgetgea tggeagatge etaggtggaa 780
atagcaaaaa caaggcccag gctggggcca gggccagagg ggaaggccct ggattctcac 840
tcatgtgaga tcttgaatct ctttctttgt tctgtttgtt tagttagtat catctggtaa 900
aatagttaaa aaacaacaaa aaactctgta tctgtttcta gcatgtgctg cattgactct 960
attaatcaca tttcaaattc accetacatt ceteteetet teactageet etetgaaggt 1020
gtcctggcca gccctggaga agcactggtg tctgcagcac ccctcagttc ctgtgcctca 1080
gcccacaggc cactgtgata atggtctgtt tagcacttct gtatttattg taagaatgat 1140
tataatgaag atacacactg taactacaag aaattataaa tgtttttcac atcaaaaaaa 1200
aaaaaaaaa aaaaag
                                                                   1216
<210> 98
<211> 1186
<212> DNA
<213> Homo sapiens
<400> 98
ggcacgagaa ataatcacct ggagtttgtt aaaccatatg gattctcagg ctcctctctt 60
gaagattctg attcagtagg tctgggagtg gcgccctgga ttttgatcaa aattgtagag 120
cattttaagg tgagtacctg agggagaact taaagacatc ttagttgggg agtagtcctt 180
ttgaatttta cagctagata taatcttcag tcagataaaa tttatgggag ctggtgtctt 240
atgeetgaet ettagtaatt teataceggt ttgaagtaeg tgtgeecatg cetaaageet 300
tgactttcag aatgttgtct tttgattctt ctgtcttgat ttgattaggg gtgaaattta 360
gaagtettag taatgtaaet tgaagatgtt aaacaaaaat eteaagtaaa atgaaaagea 420
aatatgggct actgaattaa gaaactggca ttctagtatt aaatcctcac ttcaggagct 480
tttaaaaata ctgagacccc cccataacca gagattcaga ttcaaagact gaggatagga 540
cettageatt gtagetattt aaagttteta atgtgeacee agggttggga ateaceaatg 600
tgggtgtgaa aatgcctaca aagggtttta gtgccttaga agtcctaaga agcccaatct 660
gtatcaaagc agatccattt tgcaaggatc tttcttttag aactttctca gttctcttag 720
taagaacttt agaagtaatc ttgataataa gcacagacag cctaacagca gaggcaactt 780
aaataactcc tgagcagttg gcactagaac agaatacttg gaatgacacc aaagttaacc 840
aagtocagca tatgtocaaa gagttaagtg tttcatttac tgtagcattc tgggtgagaa 900
attggttgct gaaatcttaa gacagtggtc tcaaccttgg ctgcacattg gaatcacctg 960
```

```
tagggtttta aagcatccaa atggtaatta acaggcagca aaacttcaga actagttctg 1020
 catctactgt gcaaagatca tgattaactg tcaagacact ggtagaacag aacaagcaaa 1080
 agattaagag ttcaaaagta aatgcaacca wtttaacatg tagtgttatt aaaaaattac 1140
 aaaggcctag accagcctgg gcaacagaga ccatgcttaa aaaaaa
                                                                    1186
<210> 99
<211> 1120
<212> DNA
<213> Homo sapiens
<400> 99
aattoggcac gaggtgacca ggagtogacg tgtgcagaag tootggtaat ctggtoottg 60
ttcccgtctg gataccagct tccttcagca gcgcaggcgg tggtccctga ggcccgtgga 120
aggagtcaaa cttgcgggaa ttttgcagtt tatctgcagg gctgttgttt ccagcaagac 180
ccaaagctag aaaaggagga ggaagaaact gacccgatca gtgccagaag tcattgtatt 240
caaagaagaa taagcaagaa agaaaagaag gaaggaagag aggtagacag atacaagatg 300
aaatcctgtc aaaaaatgga aggaaaacca gaaaatgaga gtgaaccaaa gcatgaggaa 360
gagccaaagc ctgaggaaaa gccagaagag gaggagaagc tagaggagga ggccaaagca 420
aaaggaactt ttagagaaag gctgattcaa tctctccagg agtttaaaga agatatacac 480
aacaggcatt taagcaatga agatatgttt agagaagtgg atgaaataga tgagataagg 540
agagtcagaa acaaacttat agtgatgcgt tggaaggtta atcgaaacca tccttacccc 600
tatttaatgt agtttacctt gatttttatc tgatattaac aataccatat agcttgcttt 660
ttattagcat ttcctgatat tcctttqtcc atatttctac ttataacctg ttgctattaa 720
tggttttaga tgtatctctt gttatctgca tctcattgtt tattgtattt tgaaccaatc 780
tacaagtoto tgtottttaa taaaagaact ttacacattt gtaaaaaaaga ggttottggt 840
aagatataaa atggaaaaag gctaagtaat atgtgaatat catatttttg aaaggtaaaa 900
agtacatttg tatattacat atatggacat aacttgtgaa ggatgaaaga aagtacagcc 960
tctcggtggt gggattatga atgatttttc tccttttgct tgtttgtatt ttctatattc 1020
ctaaaattaa cacacattat tattgctaga ataataaaag ttttataaaa aagaagcaaa 1080
                                                                   1120
aaaaaaaaa aaaaaaaaa aaaaaaaaa aggggggga
<210> 100
<211> 1225
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (286)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (287)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (288)
<223> n equals a,t,q, or c
```

```
<220>
<221> misc feature
<222> (1213)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (1225)
<223> n equals a,t,g, or c
<400> 100
cttgctctgt cacccaggct gggagtgcag tggcatgatc tctgcaacct ctacctccca 60
ggttcaagca attcttgtgc ctcagcctcc caagtaactg ggactacagg tgcacgctac 120
cacacctggc tgatttttt tatgttttag tagagacagg gtttcaacca tgttgcccag 180
gttggtctca aactcctgag ctcaggcaat ccacccgcct tggcctccca aagtgctagg 240
attacaggtg tgagccacca cacccagcta tttttcttt cggttnnnaa ttttaaagtt 300
ggggggggtc tcaatttgtt taccctggct ggtctcgaac tcccggactt aagcgatcct 360
ctggctccaa gcccactacc agtctcaggt ttctttacta aaagatcact acctttttt 420
ctcttatctg ctgccatgtg agatgtggct ttcaccttcc gccatgattg tgaggccttc 480
ccagccacgt rgaactgtaa gtccaataaa cctcttttgt aaattaaaaa aaaaaaatca 540
ctatttaaga tactaggatg gattgtgact gttgaggagt acttacatat cctacatttg 600
actacattat ttccaaacca agtattccat ccaaaggaac atactgctat catagagacc 660
aaggagggac tgtttaaggt tgccaaggtg aagcgagctg agaggctttg tcctcgtgcc 720
agtaactctg aaatctctct taattcctgc tgtccaggca gcagaatgcc atggtttccc 780
caagtaggta gctgctttag cakttaaagc ccaaatgtct gttctgttga tcagaggtct 840
ctgaatttct gaagtggtgt ttcgtttctg gtgactgagt taatccttta caatccctct 900
tgtaaagtgt gctaatagaa agaatccacc tttcaaagct gcagaaccag accgtgccct 960
aaattgacca acgtarctga tgtgcctcag gaagtctctt gccagctgtc cctgtgaaga 1020
cccctcctc cccccagct gctgccttgc acactgaagc atctcagact gtgcaaagcc 1080
rtgtagtcat caagacagta aatcccaggg cttggttaag tgctgtgtga taacttgttt 1140
ggatgagact taacttaaaa ccacttacaa taaacttggg aaactaccgt caaaaaaaaa 1200
                                                                  1225
aaaaaaaat ttnggggggg cccgn
<210> 101
<211> 1213
<212> DNA
<213> Homo sapiens
<400> 101
ggtagataaa ttgactagct gataagtaaa attaaaagag gaattttctc tttcaggtag 60
gattattgac tgtgctttta ctgtcacttt taatcccaaa tatgatacgt tattaaaagc 120
tgtaaaagat gctactaaca ctggaataaa gtgtgctgga attgatgttc gtctgtgtga 180
tgttggtgag gccatccaag aagttatgga gtcctatgaa gttgaaatag atgggaagac 240
atatcaagtg aaaccaatcc gtaatctaaa tggacattca attgggcaat atagaataca 300
tgctggaaaa acagtgccga ttgtgaaagg aggggaggca acaagaatgg aggaaggaga 360
agtatatgca attgaaacct ttggtagtac aggaaaaggt gttgttcatg atgatatgga 420
atgttcacat tacatgaaaa attttgatgt tggacatgtg ccaataaggc ttccaagaac 480
aaaacacttg ttaaatgtca tcaatgaaaa ctttggaacc cttgccttct gccgcagatg 540
gctggatcgc ttgggagaaa gtaaatactt gatggctctg aagaatctgt gtgacttggg 600
cattgtagat ccatatccac cattatgtga cattaaagga tcatatacag cgcaatttga 660
acataccatc ctgttgcgtc caacatgtaa agaagttgtc agcagaggag atgactatta 720
```

```
aacttagtcc aaagccacct caacaccttt attttctgag ctttgttgga aaacatgata 780
ccagaattaa tttgccacat gttgtctgtt ttaacagtgg acccatgtaa tacttttatc 840
catgtttaaa aaagaaggaa tttggacaaa ggcaaaccgt ctaatgtaat taaccaacga 900
aaaagctttc cggactttta aatgctaact gtttttcccc ttcctgtcta ggaaaatgct 960
ataaagctca aattagttag gaatgactta tacgttttgt tttgaatacc taagagatac 1020
tttttqqata tttatattqc catattctta cttqaatgct ttgaatgact acatccagtt 1080
ctgcacctat accctctggt gttgcttttt aaccttcctg gaatccattt tctaaaaaat 1140
aaagacattt tcagatctga gaaaaaaaaa aaaaaaaaa aaaaaaacyc ggggggggcc 1200
                                                                 1213
ggtmcccaat tcg
<210> 102
<211> 1564
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (1509)
<223> n equals a,t,g, or c
<400> 102
ctgatgcagt aatatattca gtttatctat gcattgctgg ggtcttgata taagatggaa 60
acagtgtttc ttatctaaag ttttgattat cagcaagttg aatggacact ttagttattt 120
aaataaagat ttttgaccaa aatccagaaa atggtatgag agaaaaataa attccagcta 180
gtttaataga tttttaaatg tcaatctgat tttagctctt agagagtgct aactagctkg 240
taatgtttac ttttaattcc ttgttaaaat gaggcaataa tttgcaagat ttttgtatat 300
aagtgtaaat tetteatate tttttagate taatteaata ttttetgaet aettetgeea 360
tgtataatac catttttgtg catgcttgga tgtgacattc ataaattgta ccactatgac 420
tttatccatg taaaatagct atttattgaa ttttctttta aaagctggat ttactgggtt 480
tttttttttt ctcagtttaa acatcttaac agaraawttg ttactgttta ttaaaagaat 540
tgcatttgga agcaagaaaa caaccggatt tgcaatcatg tgaagaaaca ataatgcctt 600
tattatcaag tgttaagcac aattcttata acaaactgtg ataaattctt tttgtttttt 660
tttcctttgc cccattattt tcttatgaac aaaccaaaaa ttcatggtga gcagttgcag 720
tgttggctga tatatctttt atgtacaggg aatttgaaaa ggacagtgga ttcatttaga 780
agtgtaactg gtgctgtgat tatagcaata catttgttag ttgtacttca tctttttcat 840
qctagctttt taaatgttta gttttcctct tgtcatggtc agctgctgaa tttacttgaa 900
ggatgtagaa tactgtttaa aaaatactaa aatttgtaca attagatcaa agaattgtgc 960
aatcatttcc tttttaattt ttaaaatgtt gaggctcata aatatttgag aacatcagat 1020
ctaatagagc atagtgatac tatttaatta accaaagtct ctagtgaata tttcaacttt 1080
gaatgtaaac taacaaataa acctgaccac caaggagatt gtttgcccag agtttcaaag 1140
cacattgtct acaaatggaa attgaaataa tttataaaat attgacgtta ctatgttttt 1200
taaaaagttc ctaatttttt cactaaatgg aggaaactat tagttttatt gttaaatatg 1260
gtagatatta atattcctct tagatgacca gtgattccaa ttgtcccagt ttgaaataag 1320
taccctgtga gtatgagata aattagtgac aatcagaaca agtttcagta tcagatgttc 1380
aagaggaagt tgctattgca ttgattttaa tatttgtaca taaacactga tttttttgag 1440
cattattttg tatttgttgt actttaatac ctggtgtaca gttccagaaa taaaaatctg 1500
1564
tcta
<210> 103
```

<210> 103 <211> 1457

```
<212> DNA
<213> Homo sapiens
 <400> 103
aattoggcac gagcogttca agggototta gaggtggoca aagactcaat coccogaagt 60
cactggaaaa agaccccagt ggtcctaaag gcaacagcag gactacgctt actgccagaa 120
cacaaagcca aggctctgct ctttgaggta aaggagatct tcaggaagtc acctttcctg 180
gtaccaaagg gcagtgttag catcatggat ggatccgacg aaggcatatt agcttgggtt 240
actgtgaatt ttctgacagg tcagctgcat ggccacagac aggagactkt ggggaccttg 300
gacctagggg gagcctycac ccaaatcacg ttcctgcccc agtttgagaa aactctggaa 360
caaactccta kgggctacct cacttccttt gagatgttta acagcactta taakctctat 420
acacatagtt acttgggatt tggattgaaa gctgcaagac tagcaaccct gggagccctg 480
gagacagaag ggactgatgg gcacactttc cggagtgcct ktttaccgag atgkttggaa 540
gcagagtgga tctttggggg tgtgaaatac cagtatggtg scaaccaaga aggggaggtg 600
ggetttgage cetgetatge egaagtgetg agggtggtae gaggaaaact teaccageea 660
gaggaggtcc agagaggttc cttctatgct ttctcttact attatgaccg agctgttgac 720
gccagggaag tgtgtgataa cttggaaaac ttcacctcag gcagtccttt cctgtgcatg 840
gateteaget acateacage cetgttaaag gatggetttg getttgeaga cageacagte 900
ttacagctca caaagaaagt gaacaacata gagacgggct gggccttggg ggccaccttt 960
cacctgttgc agtctctggg catctcccat tgaggccacg tacttccttg gagacctgca 1020
tttgccaaca cctttttaag gggaggagag agcacttagt ttctgaacta gtctggggac 1080
atcctggact tgagcctaga gatttaggtt taattaattt tacacatcta atgtgaactg 1140
ctgcctaacc actcaagagt acacagctgg caccagagca tcacagagag ccctgtgagc 1200
caaaaagtat agttttggaa cttaaccttg gagtgagagc ccagggacag gtccctggaa 1260
accaaagaaa aatcgcattt caaccetttg agtgcctcat tccactgaat atttaaattt 1320
tectettaaa tggtaaaetg aettattgea ateceaagae eeateaatat eagtattttt 1380
ttcctcccta tacagtgccc tgcccaccct tatctgcacc cacctcccct gaaaaagaaa 1440
aaaaaaaaa ctcgtag
                                                                 1457
<210> 104
<211> 785
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (748)
<223> n equals a,t,g, or c
<400> 104
gtgctgatga aaatatggag gaaatgaaac tctcatgggt tttgcaggga atctaagtca 60
gtgctgtgtt gtgaatgtag gtgtaccctt tgaattcata tgttgaatcc taacccccaa 120
agcaatggca ttaagaggtg gggcctttgg ggctgggata caggagtgag ccactgcgcc 180
tggctgatcc cagcactttt caaatgatgc cgctcaaagc cgtgacttgg cctactttga 240
acagcaaact tgttgctgct gttgtcaacc tgaaggcctc tcaaatgcca gcttcaagca 300
999tgtgaat tggccagtgt cagateteag gagteetgtg ttgagagtgt ggettteage 360
tgcggggagc tgcacttggt ggggaaagcc aggcaggtca ccctcacagc cagataatgt 420
ggaggtcaga acccaaggaa gggagtgaga cctccactcc cagtggggga cctggccacc 480
catcottggg gacctgagaa agcgtacttc accttggggt gaaggctggg tggggccaga 540
gggaccagtg coetecteag tgettagggg cagageeace tgeageaatg gtatetgeat 600
```

```
attagement etccacette ttteteeege tgaateattt eeetcaaage eeaagagetg 660
 tractgette tttetecetg ggaagaatge gtggactetg cetggtgata gaetgaagee 720
 agaacagtgc cacaccctcg ccttaatncc ttgctaggtg tctcagattt atgagacttc 780
 ttagt
                                                                 785
 <210> 105
 <211> 921
 <212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (40)
<223> n equals a,t,g, or c
<400> 105
agggaaggac cctcccctag agtctctgga gggaactggn atacaattgc agagtgcact 60
aaacagttgc cccagaaaga catgtcttgt tttaaagccc agaacctgaa attattatag 120
attttattcg gtaataagga actttgcatg tgtaattact taaggatatg aagatgagat 180
tgtcctggat tattaagcac cctaaatgcc atgtacaggt gtccttccaa gagaacagaa 240
gaggagacac agacacagag caggaggaca cgtggagaca gaggcagact ggagtgatgc 300
ggccacaage ccagggacac ctggagecee caggagetgg gagaggeagg aaggateete 360
ccctagagcc tccaggggga actggaggat gcgtaagaga cccagaactt ccacagaagg 420
tgatacagaa gcatccaggc tgcaggagta caggtcgcaa gtgctgagcg tgggccttgg 540
gtgtgtctca tgggggaaaa aaaactgtga aaaacctcag agtagcatct tcacagtaac 600
gcacggacga tecetaaaet geettgtaaa caaaaatgag agettgagte agaggaagee 660
gagacaatat cetteetega caacgtgega gaaceetgae gteeeccage aaaggaagae 720
gttgcaagca ggcaaaatgc gtcgattttt tttttttgtc agtatgatga tttttgcagc 780
cacttggcta tggagagcag ccgacacccc ctcttacagc cgtggatgtt tcctggaagc 840
tgactcagtc tgttcactgg ttgagctttg agtgaaaaga taacacaggt ctattgactc 900
acacacatgt tttaagatgg a
                                                                 921
<210> 106
<211> 592
<212> DNA
<213> Homo sapiens
<400> 106
gtgatctgca tgtggcaggg ctgcgcagtg gagcggccag tgggcaggat gacgagccag 60
acceptetge cecagteece eeggeecagg eggeegaega tgtetaetgt tgtggagetg 120
aacgtcgggg gtgagttcca caccaccacc ctgggtaccc tgaggaagtt tccgggctca 180
aagctggcag agatgttete tagettagee aaggeeteea eggaegegga gggeegette 240
ttcatcgacc gccccagcac ctatttcaga cccatcctgg actacctgcg cactgggcaa 300
gtgcccacac agcacatccc tgaagtgtac cgtgaggctc agttctacga aatcaagcct 360
ttggtcaagc tgctggagga catgccacag atctttggtg agcaggtgtc tcggaagcag 420
tttttgctgc agtgccgggc tacagcgaga acctgggagc tcatggtgcg cctggcacgt 480
gcagaagcca taacagcacg gaaktccagg tgyttgtgtg cctggtgaaa cttgagggag 540
caggatgcat tattattcag aggtcctgtg tttttcttgc aggataagaa gg
<210> 107
```

<211> 2248 <212> DNA <213> Homo sapiens

<400> 107

totgggagta cgacatggcg cgcgagctgc gggcgctgct gctgtggggc cgccgcctgc 60 ggcctttgct gcgggcgccg gcgctggcgg ccgtgccggg aggaaaacca attctgtgtc 120 ctcggaggac cacageccag ttgggeecca ggegaaacce agectggage ttgcaggeag 180 gacgactgtt cagcacgcag accgccgagg acaaggagga acccctgcac tcgattatca 240 gcagcacaga gagcgtgcag ggttccactt ccaaacatga gttccaggcc gagacaaaga 300 agottttgga cattgttgcc cggtccctgt actcagaaaa agaggtgttt atacgggagc 360 tgatctccaa tgccagcgat gccttggaaa aactgcgtca caaactggtg tctgacggcc 420 aagcactgcc agaaatggag attcacttgc agaccaatgc cgagaaaggc accatcacca 480 tccaggatac tggtatcggg atgacacagg aagagctggt gtccaacctg gggacgattg 540 ccagatcggg gtcaaaggcc ttcctggatg ctctgcagaa ccaggctgag gccagcagca 600 agatcatcgg ccagtttgga gtgggtttct actcagcttt catggtggct gacagagtgg 660 aggtetatte eegeteggea geeeegggga geetgggtta eeagtggett teagatggtt 720 ctggagtgtt tgaaatcgcc gaagcttcgg gagttagaac cgggacaaaa atcatcatcc 780 acctgaaatc cgactgcaag gagttttcca gcgaggcccg ggtgcgagat gtggtaacga 840 agtacagcaa cttcgtcagc ttccccttgt acttgaatgg aaggcggatg aacaccttgc 900 aggccatctg gatgatggac cccaaggatg tcsgtgagtg gcaacatgag gagttctacc 960 gctacgtcgc gcaggctcac gacaagcccc gctacaccct gcactataag acggacgcac 1020 cgctcaacat ccgcagcatc ttctacgtgc ccgacatgaa accgtccatg tttgatgtga 1080 gccgggaget gggetecage gtttgeactg tacageegea aagteeteat ecagaceaag 1140 gccacggaca tcctgcccaa gtggctgcgc ttcatccgag gtgtggtgga cagtgaggac 1200 attcccctga acctcagccg ggagctgctg caggagagcg cactcatcag gaaactccgg 1260 gacgttttac agcagaggct gatcaaattc ttcattgacc agagtaaaaa agatgctgag 1320 aagtatgcaa agttttttga agattacggc ctgttcatgc gggagggcat tgtgaccgcc 1380 accgagcagg aggtcaagga ggacatagca aagctgctgc gctacgagtc ctcggcgctg 1440 ccctccgggc agctaaccag cctctcagaa tacgccagcc gcatgcgggc cggcacccgc 1500 aacatctact acctgtgcgc ccccaaccgt cacctggcag agcactcacc ctactatgag 1560 gccatgaaga agaaagacac agaggttctc ttctgctttg agcagtttga tgagctcacc 1620 ctgctgcacc ttcgtgagtt tgacaagaag aagctgatct ctgtggagac ggacatagtc 1680 gtggatcact acaaggagga gaagtttgag gacaggtccc cagccgccga gtgcctatca 1740 gagaaggaga cggaggagct catggcctgg atgagaaatg tgctggggtc gcgtgtcacc 1800 aacgtgaagg tgaccctccg actggacacc caccctgcca tggtcaccgt gctggagatg 1860 ggggctgccc gccacttcct gcgcatgcag cagctggcca agacccagga ggagcgcgca 1920 cageteetge ageceaeget ggagateaac eccaggeaeg egeteateaa gaagetgaat 1980 cagctgcgcg caagcgagcc tggcctggct cagctgctgg tggatcagat atacgagaac 2040 gccatgattg ctgctggact tgttgacgac cctagggcca tggtgggccg cttgaatgag 2100 ctgcttgtca aggccctgga gcgacactga cagccagggg gccagaagga ctgacaccac 2160 agatgacage eccaceteet tgagetttat ttacetaaat ttaaaggtat ttettaacee 2220 2248 gaaaaaaaa aaaaaaaaaa cctctgcc

<210> 108

<211> 785

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

```
76
```

```
<222> (769)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (771)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (785)
<223> n equals a,t,g, or c
<400> 108
cccagcccat aaagatctgt gaccggcagc cccagacctg cctgccttcc tgacttctgt 60
tccagagcaa aggtcattca gccgcttgaa tcagcctttt ccccccaccc ggtccccaac 120
tttgtttacc cgataaggaa ggtcagcatt caaagtcaag aagcgccatt tatcttcccg 180
tgcgctctac aaatagttcc gtgagaaaga tggccgggaa ctcgatcctg ctggctgctg 240
tototattot otoggootgt cagcaaagtt attitigotti gcaagttigga aaggcaagat 300
taaaatacaa agttacgccc ccagcagtca ctgggtcacc agagtttgag agagtatttc 360
gggcacaaca aaactgtgtg gagttttatc ctatattcat aattacattg tggatggctg 420
ggtggtattt caaccaagtt tttgctactt gtctgggtct ggtgtacata tatggccgtc 480
acctatactt ctggggatat tcagaagctg ctaaaaaacg gatcaccggt ttccgactga 540
gtctggggat tttggccttg ttgaccctcc taggtgccct gggaattgca aacagctttc 600
tggatgaata tctggacctc aatattgcca agaaactgag gcggcaattc taacttttc 660
tcttcccttt aatgcttgca gaagctgttc ccaccatgaa ggtaatatgg tatcatttgt 720
ccaan
<210> 109
<211> 611
<212> DNA
<213> Homo sapiens
<400> 109
ggcacagtgg tggaaggtgg gtgtgtagtc gtggtacttt acgcctcggt gtttagggag 60
gagcctaagg taaggagtca gaaacgggga gtaaccgagc tgcggctttt atataaggtc 120
agtggtaggt aaggaaggg ccttaacctc tgctggtgac cagaagcctg catttctgca 180
ttctgcttaa ttccctttcc ttagatttga aagaagccaa cactaaacca caaatataca 240
acaaggccat tttctcaaac gagagtcagc ctttaacgaa atgaccatgg ttgacacaga 300
gatgccattc tggcccacca actttgggat cagctccgtg gatctctccg taatggaaga 360
ccactcccac tcctttgata tcaagccctt cactactgtt gacttctcca gcatttctac 420
tccacattac gaagacattc cattcacaag aacagatcca gtggttgcag attacaagta 480
tgacctgaaa cttcaagagt accaaagtgc awtcaaagtg gagcctgcat ctccacctta 540
ttattctgag aagactcagy tctacaataa gcctcatgaa gagccttcca actccctcat 600
                                                                611
ggcaattgaa t
<210> 110
<211> 664
<212> DNA
<213> Homo sapiens
```

```
<220>
<221> misc feature
<222> (24)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (72)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (614)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (616)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (633)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (649)
<223> n equals a,t,g, or c
<400> 110
aattcggcac gagtttggtt tttncctcta tgtaggtatc tggtaaagta atgaatttat 60
cacaaatttt tnccaggccc tttctggtta ctgtggcttt atggcagcca rcctttatgc 120
tcgttccata tttggtgaag atgcacttgc aaatgtcagc attgagaagc caattcacca 180
gggaccagat gctgctgtta ccggccatat aagaattcgt gcaaagagcc agggaatggc 240
cttaagtctt ggagataaaa tcaacttgtc acagaagaaa actagtatat aaaaataaac 300
aaaaagtcct tgaagcttta cagttaattt aggtatgggc ttactggact ccaacatctt 360
ttgtactctt tcatgcttat atagaatctg agttcatgct gaatactttt cagccaataa 420
tttatagcct ttcccttaaa tcaagattga gtttaaaatt atagtttgtc ttttgtctta 480
acagttctga atgctgtcct caaagtatat aatgtttcat gtaccaagac ccttttcaca 540
cccaagetta eginenegig cattgegacg tentagetet titataggng teaccetaaa 660
                                                               664
tttc
<210> 111
<211> 4065
<212> DNA
<213> Homo sapiens
<400> 111
```

tcccgccgcc	gcccgctgcg	teegeecage	gccagtccgc	gtcccgaccg	gcccgcggca	60
					agtctcccac	
tcccaagtcg	cccccgtccc	gcaagaaaga	tgattccttc	: ttggggaaac	tcggagggac	180
cctggcccgg	aggaagaaag	ccaaggaggt	gtccgagctg	, caggaggagg	gaatgaacgc	240
catcaacctg	cccctcagcc	caattccctt	tgagctggac	cccgaggaca	cgatgctgga	300
ggagaatgag	gtgcgaacaa	tggtggatcc	aaactcacgo	agacscccaa	gcttcaagaa	360
ctgatgaagg	tattaattga	ctggattaat	gatgtgttgg	r ttggagaaag	aatcattgtg	420
aaagacctag	ctgaagattt	gtatgatgga	caagtcctgc	agaagctttt	cgagaaactg	480
gagagtgaga	agctaaatgt	ggctgaggtc	acccagtcag	agattgctca	gaagcaaaaa	540
ctgcagactg	tcctggagaa	gatcaatgaa	accctgaaac	ttcctcccag	gagcatcaag	600
tggaatgtgg	attctgttca	tgccaagagc	ctggtggcca	tcttacacct	gctcgttgct	660
ctgtctcagt	atttccgtgc	accaattcga	ctcccagacc	atgtttccat	ccaagtggtt	720
gtggtccaga	aacgagaagg	aatcctccag	tctcggcaaa	tccaagagga	aataactggt	780
aacacagagg	ctctttccgg	gaggcatgaa	cgtgatgcct	ttgacacctt	gttcgaccat	840
gccccagaca	agctgaatgt	ggtgaaaaag	acactcatca	ctttcgtgaa	caagcacctg	900
aataaactga	acctggaggt	cacagaactg	gaaacccagt	ttgcagatgg	ggtgtacctg	960
gtgctgctca	tggggctcct	ggagggctac	tttgtgcccc	tgcacagctt	cttcctgacc	1020
ccggacagct	ttgaacagaa	ggtcttgaat	gtctcctttg	cctttgagct	catgcaagat	1080
ggagggttgg	aaaagccaaa	accgcggcca	gaagacatag	tcaactgtga	cctgaaatct	1140
acactacgag	tgttgtacaa	cctcttcacc	aagtaccgta	acgtggagtg	aggggctgcc	1200
ctgggcccac	cactgcccaa	gagttcttgc	tgttggcgta	ctggaccctc	ctccgaactg	1260
ccttaccctg	cttattcctg	tctcttgcac	tgtgctctcc	cacaagtcca	gctgcaaccc	1320
agagatagtg	gaaactgaaa	ttaggaagga	aatcatcaat	aactcagtgg	gctgacccat	1380
ccctcccagg	cgctggggac	caacctagca	atgaaggttg	ggaaggttgt	tcccttcccg	1440
gtgccaggtc	cagatttccc	tccatgattt	gggaaccagc	ttaggcaaaa	gagtccccac	1500
aagatgaaaa	taaagatcct	agttaccatt	caaaggatgc	taactgtgtg	tcaggcccca	1560
cactaagtgc	tctgctctga	tatactcaag	gccattaatc	ttcaggactc	ccattgacgt	1620
aggtgtttca	ttcccctttt	acagatgagg	aaactaaggc	ttggaggtta	aatgacttgc	1680
cagaagttgg	aattttttc	ctctttgaac	ataacctctc	ccttctccct	aaaggtaacc	1740
actattctga	gtccaatcat	caaggttttg	cttttctttt	tagctaagta	tgcattcctc	1800
aatagtagac	agtacaacat	gtttataaca	agccaattac	attatgttct	ttgcatgttc	1860
		_			agccaaaaac	
					gattcacact	
gaaattggca	aattggattt	aacccaatta	atagtgtgtg	tgtggcagga	gtcatgtccc	2040
tcacatcctt	tgtacaaatg	aaaattactc	ttaattcctt	cagatttata	ataactctgt	2100
					agtggcacat	
					ctgcaaaata	
					cagagagctg	
					acccttgaac	
					ctggctaagt	
					tttagaccaa	
					atctcctcta	
					cctgtaagaa	
					ggaaaatatt	
					tgtagccatc	
					cgttatggaa	
					gtctgtgact	
					aattcatttt	
					ttcctttcag	
					aattgaggac	
ccataaaatt	tagataacta	catgtctttg	ctcttagaat	tgtcactcag	cataatgagc	3060

```
atttaacata caaaggcaat gtactgtttt gtgttgatct atgtaaaaga atacaattct 3120
 tttttacata attagtgaaa ttttatttt tattaggaaa cactaaatag tgtaatattt 3180
 cttttgcttt taaaaaaatt cctggtagca aatcaagata aataattgct tcattttctt 3240
 atgaattttg totottttt ggtototttt tottatatto aagttacaaa tgtacaagta 3360
 tccttactaa gagtgctcct tttgtatttt acatatatac agtatgaaaa tacattggaa 3420
 cactaggaaa gtttttaaat aacagttcta atttatcaga aaattgtgtt ttgggattga 3480
 gttctttgtc tcagcccaga atcccaggtc ctgggcctgg ttttctaatg ctgtcatctc 3540
 agttcgatat tttactttag aayctggaat ctcctactta atatatgacc atgactttga 3600
 aaggcaaaag aggaatcaag aataaataaa acaaacttaa tetteatett taaaaaaaaag 3660
 ctgttaattt aaactcagtt atttttaatg cttaatacat acatggtgca aaatttaaaa 3780
agegeaaata ggtatetagt ggaaaaeeta ageeteeete teteteegge acceattace 3840
totocotgga ggcaactgtt ttgatocatt tottacacac actgccagag atactctagg 3900
catgtaaagc acaaacatac atataaaatc tgcgggcttc aaaaaatata agtaggatgt 3960
catctatact gtcatacact ttgtttttta tcacttactt aatgttatat cttggatatt 4020
gtattaccct gggtattaaa aagaactcct ttcacatttt aaaat
                                                             4065
<210> 112
<211> 1492
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (8)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (1487)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (1491)
<223> n equals a,t,g, or c
<400> 112
attetetgnet egtateegee ttgeeteeae aagtgetggg attacaggtg tgageeaeca 60
caccoggoot atattgtttt gaaagcatac totatatata gttaygggca gaggcacagg 120
catcctcagc agctgattca ggagatgatg gtaaagctag ctaactatga attaaacatt 180
cacatatcca gtctacctgg tccagtaata atacaagcaa atcttgtatt tcaggaacaa 240
atcaaggttc tcttaatttt ttggcttata tacaatgaag taaaaacttg ataaacatgg 300
tttcaaattg aggaggagag tcttggatgt atgttttaat atgtatacct tataattctg 360
cctctagcca aatgctatgt ttgcaaaatg tggcatctgt tagtttttat tgtctgtgtc 420
gtaatgtcag acacacaaga aaagcaaatc agtgttgtaa gcttaaagta caatttcaaa 540
ggtcattacc aacagcaggg ttttttttat actttaaaaa cattatgcta catatcattg 600
ccattttcat attttggggt tttgctactc ttatacaatg gaatcaatgg aaatgtcatc 660
cagccactga attgccatta ttatatctaa aaagtttcta agatgacagt tatcactatt 720
```

```
ttgttttatc tccatgctga catttgaaag aaggtactag tatccctcta gccagattgc 780
ttagtttttc gttggtaatc aaacaacagt tgtactaaag gaaagtaaag ctaggaccta 840
aatcagaatc atagttgcct gcatatatgg taacaaggtc gtgtgcattt gctttcacag 900
tgatgagtga gaggatgaga agaaattatt tgacattttt ctgtggttga atagaagaca 960
cctttctttt gtctttaggt ttaggaggag atactaagat actggatgtt tatcctatct 1020
tagtttggtt ggagtaataa gagagaagaa gagggtggac tttggctttt cagtgttttt 1080
tecectaaag agtgatattg etgaegttte tateaatttt acacataata tgtggetatg 1140
aaaccatata totcacttaa gtaacaaagt aatcactttg totatcacta agtaatagac 1200
aaaaatcatt gtctattatt taaagccaac aaaacagtgt aacagtttta agttcaataa 1260
tgttaagtat tgtatagaaa tatattggag gcaaagttca gttgatgaca attgtgtata 1320
tgttactgat gctgtaaatt atttttaata aagaaaattg tattatcaaa aaaaaaaaa 1380
<210> 113
<211> 1482 . .
<212> DNA
<213> Homo sapiens
<400> 113
atttttttt ttttttttt tttttaagct caaattttta ttaaccttgg aacaaatgca 60
ataattcctt acagtcatat agcattttac aattctgaaa gaattttcac atataccaat 120
tgaaccctca caacagccct gtgaggtagg cagggtaggt gttactttcc tactgctagt 180
gaggagaaca aggctaagag gtgaagtaag gtcacacagt tggtaaatga tggagctagg 240
actagaacct aggeettetg acttgetgee teeetgagaa catteaagta ataatateet 300
atgctatata atgaatattt atctcctatg atgttgatca ggtctatttt tatacatttt 360
acctgttttt atattacctt tccctaatac tgaaaaacac taaaactgat acgagacatt 420
tgagacattt cttctctgtt actggacttt cttagatata tcaaacacta tcctaagatg 480
aaacttctgt tttgaggatc cttggctata aattctcaat tatgatacga acatttattt 540
tacaaattet acaaaagtat gttgaactta agaaaaacaa aacaggtgtg tttatattet 600
caaaagcttt gccatctttc ccaatatgac tttaatatgt gtataaatgg aaaacaggga 660
aaggtgttca gcaacattac agtattattg ggaaacctat gcagagtgca cataaatgca 720
agttacatca cattaatttg tittctttgt tggccttata gaggatgaac cattagtgtc 780
tttcaggttt gatcctgtct tatatgtgac atcctcagca acaagctaaa atgatctgaa 840
ttataccaat agcggggctc aagcagcagt gatcaaaaca taatatgtat gtggtaaaaa 900
ggaacacttg ttcttcagtg gttttgccta ggtccagtgt aattacttat caaaacatgt 960
tttaagctac agcatctctg ttaaatttag aaatgtgaaa catggaagag ttatcaactt 1020
ggaatacaat actaaaactg aatataactg acccaaaact acctgtcaaa agcacagtaa 1080
agottaacag gcataaaaac taaggggtaa aacccaactg ctctgacata agagtgaaaa 1140
acagcaaatg caaaccatca ggttaaagtg aatcacaaaa cattaggcat gtagagcatg 1200
ttttaaaaaat aggaaaatga cactgagctg tattaccagg aataatattt ttaaaattcc 1260
aggtatggcc ttctacattt aatagcaatg gagagaaaca agcctatggg ggaggtgcag 1320
aaaatgaatg ggatctagaa agggagttga gtttggaagt taaggaagtc aaagaaacaa 1380
atacatccaa aatggattta gaatctctcc tctaaatcca tcctttccaa aaaatgtttc 1440
ctatattgag agatttggta aaaaaaaaaa aaaaaaagtc ga
<210> 114
<211> 3731
<212> DNA
<213> Homo sapiens
```

```
<220>
<221> misc feature
<222> (652)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (3730)
<223> n equals a,t,g, or c
<400> 114
aaaaacttag tttagggtga cacgtataga aggtacgccg tgcaggtacc ggtccggaat 60
tocogggtog acceaegegt coggagetee atcecegect coccegecag cogaceegge 120
teetteacet teeeggggga cagegaetee eteeagegge agacaceeeg ceaegeggme 180
cctggcaagg atactgaccg catgagcacg tgctcctcgg ccagcgagca gtccgtgcag 240
tccacccaga gcaacgggag tgaaagcagc agcagtagca acatctccac catgttggtg 300
acacacgatt acacggcagt raaggaggat gagatcaacg tctaccaagg agaggtcgtt 360
caaattctgg ccagcaacca gcagaacatg tttctggtgt tccgagccgc cactgaccag 420
tgccccgcag ctgagggctg gattccaggc tttgtcctgg gccacaccag tgcagtcatc 480
gtggagaacc cggacgggac tctcaagaag tcaacatctt ggcacacagc actccgttta 540
aggaaaaaat ctgagaaaaa agataaagac ggcaaaaggg aaggcaagtt agagaacggt 600
tatcggaagt cacgggaagg actcagcaac aaggtatctg tgaaagcttc tncaatccca 660
actacattta tgaacgttcc ccccagaatt cgtcattcca ttgagtgagg tcacgtgtga 720
gacaggggag acceptigtic tragatetic agticitytegic cecccaaag cotcaattac 780
ctggaagggc cctgaacaca acaccttgaa caacgatggt cactacagca tctcctacag 840
tgacctggga gaggccacgc tgaagattgt gggcgtgacc acggaagatg acggcatcta 900
cacgtgyatc gctgtcaatg acatgggttc agcctcatcg tcggccagcc tgagggtcct 960
aggtccaggg atggatggga tcatggtgac ctggaaagac aactttgact ccttctacag 1020
tgaagtggct gagcttggca ggggcagatt ctctgtcgtt aagaaatgtg atcagaaagg 1080
aaccaagcga gcagtggcca ctaagtttgt gaacaagaag ttgatgaagc gcgaccaggt 1140
cacccatgag cttggcatcc tgcagagcct ccagcacccc ctgcttgtcg gcctcctcga 1200
cacctttgag accccacca gctacatcct ggtcttagaa atggctgacc agggtcgcct 1260
cctggactgc gtggtgcgat ggggaagcct cactgaaggg aagatcaggg cgcacctggg 1320
ggaggttctg gaagctgtcc ggtacctgca caactgcagg atagcacacc tggacctaaa 1380
tggagatgct gttcagctca acacgaccta ctacatccac cagttactgg ggaaccctga 1500
attogoagec cotgaaatca tootogggaa cootgtotoo otgacotogg atacgtggag 1560
tgttggagtg ctcacatacg tacttcttag tggcgtgtcc cccttcctgg atgacagtgt 1620
ggaagagacc tgcctgaaca tttgccgctt agactttagc ttcccagatg actactttaa 1680
aggagtgage cagaaggeea aggagttegt gtgettetee tgeaggagga ceeegeeaag 1740
cgtccctcgg ctgcgctggc cctccaggag cagtggctgc aggccggcaa cggcagaaag 1800
cacgggcgtc ctcgacacgt ccagactgac ttccttcatt gagcggcgca aacaccagaa 1860
tgatgttcga cctatccgta gcattaaaaa ctttctgcag agcaggcttc tgcctagagt 1920
ttgacctatc cagaagttct ttctcattct ctttcacctg ccaatcagct gttaatctga 1980
attttcaaga gaaaacaagc aaacataact gatcagctgc cggtatgttc atcgtgtgaa 2040
attgcattcc aagtgagctg tgctcagcag tgcttggaca cagagctgca agctgcgctg 2100
gggtggagga ccgtcactta cactctkccc aaggcagagg tcgcattgct gtatcacagt 2160
attitatica ggitticigca aaaaaataaa aagataacti tittaaacaa acatgaatag 2220
aattttgcaa atttaacgtt ttcaagattt attcaaggaa acaaaatgcc tatgttcaac 2280
cactggtgtt aatgaacaaa gatactgtgc gtctctgggg aagacgcacc taggtggcgg 2340
ccactcccat ggccttgtct aggactcaga gaccactcgg ctctgagctt ccaggcgcct 2400
```

```
egtetgtgtg cateteaege eegaegtgge ttetgaaaeg tgeatteaae eteaaaettt 2460
tgcataaaat agaatgaatc gttttgctct gatgaaatgt aggccttact tgtatataag 2520
actgttectg cetteggtet gteattttee cacetgeete ecetaceeae ececeaceea 2580
ccacctgggg cttcctctgg gggtccgagg gtcttcccat cacatgaaga catcaggttg 2640
ggtectgeec cactgeecet ecceetgtte etgeeceaag eegteaatea gattgtggag 2700
cagtacacag tcagatgaaa atactgtaaa tgcactcatt gggggttttt tggttttact 2760
tcatatcatg tgcaatgttg tggctttaac attttatgca actatttatg aagacctctg 2820
ttgtacctgt aataaatata tagaaaaagc acatacttcg tatggtgagc tttatggttt 2880
tgtgtgtgtgt ttggggttgg cgggtgggtg ggtagggtcg tagccctgtg ccatcggttc 2940
aaagagactt ttcgtgaaat ttgttggttt tgaggactgt aaaagtgatt tcatactctg 3000
aatataaaac tggataatag ggtaatgttt taaaatttat tatgctatta ttcagaatgc 3060
caaagtatta tttttttcc caaaatcagt ctggacattt actacttttt agactttttg 3120
acgttgaact ttctgtataa aaattggctg ggttttgagc ttttggtaag aaataaaagc 3180
cgattaagca ctggccgccc cgcggctggt acccaatgcc cgagtcactg tggcagcatt 3240
cgcactggtg tggggagtcc tttcaactca aggaggctgg gtttctgggc accctcgaag 3300
ttttctggat gtctttttat ctttctcgtg tgaactgcac tacaaaagag accagcccgc 3360
ttcccaagcc agccagacac ctgggtcttg agccataaac tggcgtagtt aagctttgca 3420
gcttccagtg tattttattt attcttttgt tgggtttttg tttgtttctt cttgtaaaat 3480
tgtacagaaa ctttttaaaa gaaattggat tcgaaactgg atgtgtattc gtaacctcat 3540
aattttatt tgtgtattgt ttcttttatt atttcagtta aatttttaca ttattttgca 3600
tgtatatttc tttgtacaga gaccttacat gtttacacag tatgatgtga tgtaaatatt 3660
ttattttgcc atcagttatt ttaaaaaaatt aaacatattt gcctgaaaaa aaaaaaaaa 3720
ggggggcgcn c
                                                                  3731
```

<210> 115

<211> 1315

<212> DNA

<213> Homo sapiens

<400> 115

agaggaaacg gcgtggaggc tttgcagttc aggcgaagaa gccaaaaaga aacgaaatag 120 atgcggagcc gccagctaag cggcacgcca cagcagagga ggtggaggaa gaagagaggg 180 accggatccc aggccccgtt tgcaagggaa agtggaaaaa taaggaacgg attctcatct 240 tttcttccag aggaataaat tttagaacaa gacatttaat gcaggacttg agaatgttga 300 tgcctcattc taaagcagat actaaaatgg atcgtaagga taagctattt gtgattaacg 360 aggtttgtga aatgaagaac tgtaataaat gcatctattt tgaagctaag aaaaaacagg 420 atctctatat gtggctttca aattcacctc acggaccatc tgctaaattc cttgttcaaa 480 atattcatac cctcgctgaa ctgaagatga ctggaaactg tttgaaaggt tctcggcccc 540 ttttgtcttt tgaccctgct tttgatgaat taccacatta tgctttgkta aaagaactct 600 taattcagat ctttagtaca ccacggtatc atcccaaaag ccaaccattt gtggaccacg 660 tgtttacttt caccattttg gataatagga tatggtttcg gaactttcag atcatagaag 720 aagatgctgc tcttgtagaa ataggacctc gttttgtctt aaatctcata aagattttcc 780 agggaagttt tggaggacca actttatatg aaaatcctca ctaccagtca ccaaacatgc 840 atcggcgtgt cataagatcc atcacagctg caaaatacag agagaaacag caagtgaaag 900 atgtgcaaaa actgagaaag aaagagccga agactcttct tccacatgat cccactgcag 960 atgtttttgt aacaccagct gaggagaaac caatagaaat acagtgggta aaaccagagc 1020 caaaagttga tttgaaagca agaaagaaac ggatttacaa aaggcaaaga aaaatgaaac 1080 agaggatgga cagtgggaaa acaaaataag tcaatggaaa cctgatttgt ttttcagtta 1140 ctttatattt attttgtatt caatgtgtaa atacttttat tatctaatac tatcttacgt 1200 ctaattagtg tagcatttac aagaaagaaa aattaagatc ttaaaatcag tgattatctt 1260

```
1315
 <210> 116
 <211> 1320
 <212> DNA
 <213> Homo sapiens
<400> 116
ggctggcttc tgcgtggtgc agctgcgcac gtgtttcagc cggcagcgct ttaagatttc 60
cggggatgga atccgaaatg gaaacgcaga gcgccrgggc agaggagggc tttacccagg 120
teaccegeaa gggtggeega egggegaaga aacgaeagge tgaacagetg teegeageag 180
gagagggcgg ggatgcgggc cgcatggaca cagaggaggc caggccggcg aagaggcccg 240
tetteccace cetetgtggg gaegggetee tgagtgggaa agaagaaaca aggaaaatte 300
cagtcccagc taacagatac acaccattga aagaaaactg gatgaagata tttactccta 360
ttgtggaaca tttgggactt cagatacgct ttaacttgaa atcaaggaat gtagaaatca 420
ggacttgtaa rgaaaccaag gatgttagtg ctctgacaaa agcagctgat tttgtgaaag 480
cttttattct cggctttcag gtggaggatg cacttgccct catcaggttg gatgacctct 540
tcctagagtc ttttgaaatt acagatgtta aacccctaaa gggagaccat ctatccaggg 600
caataggaag aatcgctggc aaaggaggaa aaaccaaatt caccatagag aatgtgacac 660
ggacaaggat agttttggct gatgtgaaag ttcacatcct tggctccttc caaaatatca 720
agatggcaag aactgccatt tgcaacctaa tcttgggaaa tcctccttcc aaggtttatg 780
gcaatattcg agctgtggct agcagatcag cagatcgatt ctgatttcaa gtcagagact 840
ttttatcttg cctttggact ctggtgaaaa atactttaca gtggtcggtc acaagaaacc 900
atctgaacaa tttcagtcat ttgaagcctc cgtcccttct tccattctca gccagaagca 960
taaacagaaa agaaagattt aagaggattc acactcaaca ggttttagga taatttaaat 1020
atcaaaaatt gattgttata cttacacatt aggtataatt tatcatttat ctgaaatcac 1080
atgtagcaga ttgcatagtc tgtaatcctc tcagagggaa acttcttgtt taaacagctc 1140
tatatggatt tatactttta tatttataaa tttataactt catacaaatt tataaacatt 1200
totttataaa ttgtaattta atagattato toagaaaaac otototgaat gatgaccott 1260
ccttaatact gggtgatgtg tgaatatttg tttgttggca gacagggtct cactttgtca 1320
<210> 117
<211> 2025
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (1339)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (1916)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (1944)
<223> n equals a,t,g, or c
```

```
<400> 117
 ttattttaca gcctcaaata tttctcatta tcttgtcact tagttcttca tgtttctcct 60
tctgactttt aataatggta ataggaaaac aaaacccaaa gcttttcaga acttcagtgt 120
gaggtttcct attttracaa gttaacttgt aaatactcag gttttacgat gtataattta 180
cctaatagac caaactaact catggagata ttttgaacta ttatttaggt acaaacttta 240
taaagaatgt tagtatgtca taaaatataa cattacagct tatttaaaac caaatatagt 300
tgaacatatt taaaatacat tttcacagaa tggatgaatt agttgtttct tcagagttac 360
ttatgaacag ttgaatgctt taaaatgttc tgtctgtagg taacatctaa aacacaagtg 420
ggtttattta aatttttaaa atttgaaatt ttttatttgc aaaaaattgt tttatgcttt 480
attatatcgc aaatgagtgt cagatttttg agtaccaatg atcatgcttc catttttttt 540
agttttaaac caccaaacca atatttttcc tttaaatttt aatcttataa tatagaaatc 600
ttatgtaaat gaaattttgt catgtttcaa ataaagagaa ctgaagtaga aaatagaaat 660
gccagtaaac aacataatgt ttaatttaca acttacatta ggggtttggg ggaatgctaa 720
ttatatattg agaatataca ttagaactct tcaaaatggg ctcttctaat gaggtcacta 780
ctgaacaaaa ttgttccctc ttctgttaaa tagaataggt ttaaatgact agtcaaatga 840
attattttct tcttgttaaa taaattaaat cttactttct tttaatgacc aaccttaggt 900
aaaacaaaaa tattgtaatc ctagaaatta tcctccagct ttctcacctg aaaatctatt 960
gaagtgatcc ctggtcatcc taataatggg atgagggaag tttccagcag atttcaggct 1020
gttcttaaag tttttgttgg tcattttctc aatagtacat gaaatcaaga tgcttatgag 1080
catggaaatg tatttaaagt ttttgcttgt gtcctcctca gtcagaatag aaaagtaact 1140
gaaatactct tacctttctg tccttgataa aatagtaaag aaaaccaaac aaacccaggc 1200
ctgatgggaa aaatgattcc tttattctag caacttactt tctgttggta tgggaaatgt 1260
tattaatttc tattactaaa gttcatatca caaaatgata tttaataata accttggggt 1320
aaatcatgaa ttttttttnc tacgtgtgag tataaaagac aaaagttgaa cagcatggaa 1380
totcattgcc aaattattag tgaatgtata gttcaggtat totttgagac acacagtato 1440
attaatttcc gaattgtatt tcagtgttat tttttgtttg tgaccactaa gcttctgtct 1500
taatacaaag ctgttacctt ctacagaatt taagtctgaa gatgtaaaga gagaacaggc 1560
cttgtgtaac agaagatact ctttttatg ctccttactg tgatcacaga aaaattaaaa 1620
atccaagtgc tctctagatt tgttgataaa cattttatgc ttgcatttaa acttgaaatg 1680
tatgagcaga atgagacaat cagttaaatc agaaatgaga agtattataa tgtaaaggcc 1740
ttgttttgct gtagcaataa aatgaccaag tgcaatgact tgatttaata aaatcatatt 1800
ttaaaaagtgc tgstatgaaw atttttggct ataaaatttt accctgactt gstttcaata 1860
actgttacgt aatgcagttt gatgttgtaa cctaacattc caaaaaaaaa attganaggg 1920
ggaatctcaa aatagtatat actncactaa cttgtttaca ggtgctgtat ttaaaagcat 1980
gcttctctct caaaaagaaa aattaaagga ttttattgcc aaacc
                                                                  2025
<210> 118
<211> 1295
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (1286)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (1292)
```

<223> n equals a,t,g, or c

```
<400> 118
ggcacgaggt gcagttacac gttttcctcc aaggagcctc ggacgttgtc acgggtttgg 60
ggtcggggac agagcggtga ccatggccag gctggcgttg tctcctgtgc ccagccactg 120
gatggtggcg ttgctgctgc tgctctcagc agctgagcca gtaccagcag ccagatcgga 180
ggaccggtac cggaatccca aaggtagtgc ttgttcgcgg atctggcaga gcccacgttt 240
catagccagg aaacggggct tcacggtgaa aatgcactgc tacatgaaca gcgcctccgg 300
caatgtgagc tggctctgga agcaggagat ggacgagaat ccccagcagc tgaagctgga 360
aaagggccgc atggaagagt cccagaacga atctctcgcc accctcacca tccaaggcat 420
ccggtttgag gacaatggca tctacttctg ccagcagaag tgcaacaaca cctcggaggt 480
ctaccagggc tgcggcacag agctgcgagt catgggattc agcaccttgg cwcagctgaa 540
gcagaggaac acgctgaagg atggtatcat catgatccag acgctgctga tcatcctctt 600
catcatcgtg cctatcttcc tgctgctgga caaggatgac agcaaggctg gcatggagga 660
agatcacacc twcgagggcc tggacattga ccagacagcc acctatgagg acatagtgac 720
aggtegeece atgaeetggg tgeaggetee etggeeteag tgaetgette ggagetgeet 840
ggctcatggc ccaacccctt tccyggaccc cccagctggc ctctgaagct ggcccaccag 900 🕟
agctgccatt tgtctccagc ccctggtccc cagctcttgc caaagggcct ggagtagaag 960
gacaacaggg cagcaacttg gagggagttc tctgggggatg gacgggaccc agccttctgg 1020
gggtgctatg aggtgatccg tccccacaca tgggatgggg gaggcagaga ctggtccaga 1080
gcccgcaaat ggactcggag cygagggcct cccagcagag cttgggaagg gccatggacc 1140
caactgggcc ccagaagagc cacaggaaca tcattcctct cccgcaacca ctcccacccc 1200
agggagccct ggcctccagt gccttccccc gtggaataaa cggtgtgtcc tgagaaacca 1260
maaaaaaaaa aaaaaaaaa aaaaangggg gnccc
                                                                1295
<210> 119
<211> 1257
<212> DNA
<213> Homo sapiens
<400> 119
tggacagacc tcagcaacac agcaatgtgc actttgtagt aaagaaatac caacttgagt 60
ttttaaaaaa cctagttagt cctacattcc cttttcttta aaaaaacttt attgttcaca 120
ttattttaat gactatgaga taatgtatat gacagcactt tgagaaaata tcaactgtaa 180
tataactata aggitgiagi attgictgit taaaagataa gacagitgai tcaatgigga 240
tggaccctgt ggggtacctg aaaatgtaga tacgtaagaa tcacctctgt catttatcac 300
atttagaaat atgaaactgc ttaacaggta tgagcaggta tagcaagtgt ttgctaaagt 360
tgtagttcag agctgaatta cttcaggaaa ctagggacca actttttggt ttaattccga 420
totttaaaaa gtaagaatgt gtactcacto cagaacacag aagctcttoo aaggacottg 480
actcaagaag gatgaggtcc tcttactctt ctccatttat ccactatatg cttggccatt 540
tatectaaat giggigggaa cagaciigti aicigiigai giigacagig iciiittitaa 600
```

cctatgtcct gcatagttt gttaggttta cagggggagg tggatggcca taaaaccagt 660 gcactttggg aattacttt ctaggattc ctaccagtta taaatgacat tgacatttgt 720 catcttttt ttcttttct aaaaagaata gctgaattta attcacctat tataaaatac 780 tcaaaagtaa attgcmttgg tggccacttc tgaattatag ctacatttca ttatgacccc 840 ttctgctcwc ttccatttg ctactgatgt cattctgtt atcaggctgt gcccctacca 900 ggagttcata ttgggttgac agggttatct atattttgt tcttgatttt tgagttttat 960 catcttgcat taaattgtc cacctggatt tggggttcat ctctgtgccc taaggatctg 1020 ctatgaccaa tcctctttt gtaggtggt ctctggctta agtattgata ggcttcagcg 1080 gtttgtgct ctgtcttagc ttgtatcaag ccagtagtag ctcacttcct ttgtaaattc 1140 ctgcttcagt ctgggatccg taggagtatg tgagaacttc tgaaacgtct ccaactctta 1200

acagtcaaga tatctatatc atttggawag agttctggkt ttccaactac taagacc

<210> 120

```
<211> 397
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (325)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (378)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (395)
<223> n equals a,t,g, or c
<400> 120
ccccaggaaa ataccaaacc taggtttaaa aatagggaag ggaagggaga gaagaaaggg 60
aagataaaga aagcccaacc tccttccaaa atgtcatgag aatcttgagc acatatggtc 120
cttggcatga ccacatgacc tgcagagccc ctgttataga actcattttt atattttcct 180
tagtataaca gttaatataa tatgtcattt ttgttaatag tgtctttttg tcattttact 240
ttttaaaaga ttttattgaa atatacatac aggaaagtgc atctatcata agtgtgccaa 300
attgatggaa ttctaaaatc tttantggta cctgtttagc acatagattg gacacggaac 360
                                                                   397
ataactaaca accagaantc tccgtgtact ccctncc
<210> 121
<211> 876
<212> DNA
<213> Homo sapiens
<400> 121
cccacgcgtc cgggaagtgc ttactcgtcg tctccatgcg ccggttcctg ggcgtcttag 60
agccaaggcg cgaggctcgg agtgagaggt agagctggag gggaccctaa gcgccctccg 120
cccgggacgt gagccgctgc gcccaccggg ctagacccgg cgccatcatg ctgcttctgc 180
caagegeege ggaeggeegg ggeaeegeea teaeceaege tetgaeetet geetetaeae 240
tctgtcaagt tgaacctgtg ggaagatggt ttgaagcttt tgttaagagg agaaacagaa 300
atgettetge etettteag gaactggagg ataagaaaga gttateegag gaateagaag 360
atgaagaatt gcagttggaa gagtttccca tgctgaaaac acttgatccc aaagactgga 420
agaaccaaga tcattatgca gttcttggac ttggccatgt gagatacaag gctacacaga 480
gacagatcaa agcagctcat aaagcaatgg ttttaaaaaca tcacccagac aaacggaaag 540
cagctggtga accaataaaa gaaggagata atgactactt cacttgcata actaaagctt 600
atgaaatgtt atctgatcca gtgaaaagac gagcatttaa cagtgtagat cctacttttg 660
ataactcagt tccttctaaa agtgaagcaa aggataattt cttcgaagtg tttaccccag 720
tgtttgaaag gaattccaga tggtcaaata aaaaaaatgt tcctaaactt ggtgatatga 780
attcatcatt tgaagatgta gatatatttt attctttctg gtataatttt gattcttgga 840
gagaattttc ttatttagat gaagaagaaa aaaaaa
                                                                   876
```

PCT/US00/05883

```
<210> 122
<211> 1278
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (107)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (128)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (149)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (1228)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (1231)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (1262)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (1269)
<223> n equals a,t,g, or c
<400> 122
ccaggaaggc ctttggaatg caaacatttt tggtccccat cgaaatgttc gaaagactaa 60
ggaagataaa aagagttgac gggcgccgac ctgaaggact gcgtcanaca acagcctgag 120
cagcaatnca gcctccccag cgtgcaganc tgccggcgcc tgcgtgagag gagggtcgcc 180
agetgggeeg tgteetttga gegeetgetg caggacceeg teggtgteeg etaettetet 240
gattttctaa ggaaagaatt cagtgaagaa aacattttat tctggcaggc ctgtgaatat 300
tttaatcatq ttcctqcaca tqacaaaaag gagctttcct acagggcccg ggagattttc 360
agtaagtttc tctgcagcaa agccaccacc ccggtcaaca tcgacagcca ggcccagcta 420
gcagacgacg tecteegege aceteaceca gacatgttea aggageagea getseagate 480
ttcaatctca tgaagtttga tagctacact cgctttctga agtccccgct gtaccaggga 540
```

```
atgcatcctg ggcggaagtg gagggcegtg cactcccgga ctcgcagcag gtccccagca 600 gcccggcttc caagcacagc ctcggttcag accactccag tgtgtccacg ccaaaaaagt 660 taagtggaaa atcaaaatcc ggccgatccc ttgaatgaag agctggggga tgaggacagc 720 gagaagaaga gggagcacgg gtttttctcg tggtcgcgga ccaggagcac cgggaggtcc 780 cagaaaaaaga gggagcacgg ggaccacgca gacgacgcc tgcatgccaa tggaggcctg 840 tgtcgccgag agtcgcaggg ctctgtgtcc tctgcgggga gcctggacct gtcggaggcc 900 tgcaggactt tggacccga gaaggacaag gccaccaagc actgctgat tcatctcccg 960 gatgggacat cctggtgt ggctgtcaag gcgggcttct ccatcaaaga catcctgtcc 1020 ggactctgtg agcggcatgg catcaacggg gcggccgcgg acctcttcct ggtgggcggg 1080 gacaagcctc tggtgcttg accaagacag tagcatcttg ggagtcaagg gacctgcgcc 1140 ttaggaaaag cggcacctt gtttcgggt tggatctttg tttccgatt aaccggttca 1200 tggggattca aggccaagcc caccaagnc nttacggagg tgctgcgcc ctggtggcca 1260 gntacggcnt ggactcat
```

<210> 123 <211> 3115 <212> DNA

<213> Homo sapiens

<400> 123

ggcacgagcg cgggcagcga gcgcactcgg cggacgcaag ggcggcgggg agcacacgga 60 gcactgcagg cgccgggttg ggacagcgtc ttcgctgctg ctggatagtc gtgttttcgg 120 ggatcgagga tactcaccag aaaccgaaaa tgccgaaacc aatcaatgtc cgagttacca 180 ccatggatgc agagctggag tttgcaatcc agccaaatac aactggaaaa cagctttttg 240 atcaggtggt aaagactate ggeeteeggg aagtgtggta etttggeete cactatgtgg 300 ataataaagg atttcctacc tggctgaagc tggataagaa ggtgtctgcc caggaggtca 360 ggaaggagaa tcccctccag ttcaagttcc gggccaagtt ctaccctgaa gatgtggctg 420 aggageteat ecaggaeate acceagaaae ttttetteet ecaagtgaag gaaggaatee 480 ttagcgatga gatctactgc ccccctgaga ctgccgtgct cttggggtcc tacgctgtgc 540 aggccaagtt tggggactac aacaaagaag tgcacaagtc tgggtacctc agctctgagc 600 ggctgatccc tcaaagagtg atggaccagc acaaacttac cagggaccag tgggaggacc 660 ggatccaggt gtggcatgcg gaacaccgtg ggatgctcaa agataatgct atgttggaat 720 acctgaagat tgctcaggac ctggaaatgt atggaatcaa ctatttcgag ataaaaaaca 780 agaaaggaac agacctttgg cttggagttg atgcccttgg actgaatatt tatgagaaag 840 atgataagtt aaccccaaag attggctttc cttggagtga aatcaggaac atctctttca 900 atgacaaaaa gtttgtcatt aaacccatcg acaagaaggc acctgacttt gtgttttatg 960 ecceacgtet gagaateaac aageggatee tgeagetetg catgggeaac catgagttgt 1020 atatgcgccg caggaagcct gacaccatcg aggtgcagca gatgaaggcc caggcccggg 1080 aggagaagca tcagaagcag ctggagcggc aacagctgga aacagagaag aaaaggagag 1140 aaaccgtgga gagagagaaa gagcagatga tgcgcgagaa ggaggagttg atgctgcggc 1200 tgcaggacta tgaggagaag acaaagaagg cagagagaga gctctcggag cagattcaga 1260 gggccctgca gctggaggag gagaggaagc gggcacagga ggaggccgag cgcctagagg 1320 ctgaccgtat ggctgcactg cgggctaagg aggagctgga gagacaggcg gtggatcaga 1380 taaagagcca ggagcagctg gctgcggagc ttgcagaata cactgccaag attgccctcc 1440 tggaagaggc gcggaggcgc aaggaggatg aagttgaaga gtggcagcac agggccaaag 1500 aagcccagga tgacctggtg aagaccaagg aggagctgca cctggtgatg acagcacccc 1560 egececeace acceeegtg tacgageegg tgagetacca tgtccaggag agettgcagg 1620 atgagggcgc agagcccacg ggctacagcg cggagctgtc tagtgagggc atccgggatg 1680 accycaatga ggagaagcgc atcactgagg cagagaagaa cgagcgtgtg cagcggcagc 1740 tgctgacgct gagcagcgag ctgtcccagg cccgagatga gaataagagg acccacaatg 1800 acatcatcca caacgagaac atgaggcaag gccgggacaa gtacaagacg ctgcggcaga 1860

teeggeaggg caacaceaag cagegeateg aegagttega ggeeetgtaa cageeaggee 1920

```
aggaccaagg gcagagggt gctcatagcg ggcgctgcca gccccgccac gcttgtcttt 1980
agtgctccaa qtctaqqaac tccctcaqat cccaqttcct ttagaaagca gttacccaac 2040
agaaacattc tgggctggga accagggagg cgccctggtt tgttttcccc agttgtaata 2100
gtgccaagca ggcctgattc tcgcgattat tctcgaatca cctcctgtgt tgtgctggga 2160
gcaggactga ttgaattacg gaaaatgcct gtaaagtctg agtaagaaac ttcatgctgg 2220
cctgtgtgat acaagagtca gcatcattaa aggaaacgtg gcaggacttc catctgtgcc 2280
atacttgttc tgtattcgaa atgagctcaa attgattttt taatttctat gaaggatcca 2340
tctttgtata tttacatgct tagaggggtg aaaattattt tggaaattga gtctgaagca 2400
ctctcgcaca cacagtgatt ccctcctcc gtcactccac gcagctggca gagagcacag 2460
tgatcaccag cgtgagtggt ggaggaggac acttggatat ttttttagtt tttttttt 2520
tggcttaaca gttttagaat acattgtact tatacacctt attaatgatc agctatatac 2580
tatttatata caagtgataa tacagatttg taacattagt tttaaaaaagg gaaagttttg 2640
ttctgtatat tttgttacct tttacagaat aaaagaatta catatgaaaa accctctaaa 2700
ccatggcact tgatgtgatg tggcaggagg gcagtggtgg agctggacct gcctgctgca 2760
gtcacgtgta aacaggatta ttattagtgt tttatgcatg taatggacta tgcacacttt 2820
taattttgtc agattcacac atgccactat gagctttcag actccagctg tgaagagact 2880
ctgtttgctt gtgtttgttt ggcagtctct ctctgccatg gccttggcag gctgctggaa 2940
ggcagcttgt ggaggccgtt ggttccgccc actcattcct tctcgtgcac tgctttctcc 3000
ttcacagcta agatgccatg tgcaggtgga ttccatgccg cagacatgaa ataaaagctt 3060
tgcaaaggca aaaaaaaaaa aaaaaraaaa maaaaaaaaa maaaraaaaa aaaaa
<210> 124
<211> 379
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (340)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (344)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (366)
<223> n equals a,t,g, or c
<400> 124
atcttgtgct gtttaaaaag cagattttat tctttgcctt ttgcatgact gatagctgta 120
actcacagtt aacatgcttt cagtcaagta cagattgtgt ccactggaaa ggtaaatgat 180
tgctttttta tattgcatca aacttggaac atcaaggcat ccaaaacact aagaattcta 240
tcatcacaaa aataattcqt ctttctaqqt tatqaaqaqa taattatttg kctggtaagc 300
atttttataa acccacycat tttatattta graaaatccn aaangggtgg gggacgccct 360
                                                                379
tgtagngacc ttccaatac
```

```
<210> 125
<211> 1267
<212> DNA
<213> Homo sapiens
<400> 125
ggcacagttg aggctggtga ctgtggccgg ctgggagtag gcggcagtga gtttccctgg 60
gagggeageg egettggege ttetececte ecceegatet geetecagte teggaettgg 120
ttgttgcgcg ctccggctcc ggctgagctg ggagagttgg aggaggtggc ggcgggcaga 180
ggtgatgtct gggagccctt ccttgacagc ccgggccgag aagagtccct gcaggaagca 240
tcacccagge tggcagatca tggtagcage agegggggtg getgggaagt gaaacggage 300
cageggetga ggaggggeee cageageeee egaaggeeet ateaggaeat ggagtatgaa 360
agacgtggtg gtcgtggtga caggactggc cgctatggag ccactgaccg ctcgcaggat 420
gatggtgggg agaaccgcag ccgagaccac gactaccggg acatggacta ccgttcatat 480
cctcgcgagt atggcagcca ggagggcaag catgactatg acgactcatc tgaggagcag 540
agtgcggagg attcctacga ggcctccccg ggctccgaga ctcagcgtag gcggcggcgg 600
cggcacaggc acagccccac cggcccgcca ggcttccccc gagacggcga ctatcgggac 660
caggactatc ggaccgagca agggaggagg aggaggagga rgaggatgag gaggaggagg 720
agaaggccag taacatcgtc atgctgagga tgctgccaca ggcasccact gaggatgaca 780
tccgtggcca gytgcagtcg cacggcgtgc aagcacggga rgttcggytg atgcggaaca 840
aatcttcagg tcagagccgg ggcttcgcct tcgtcgagtt tagtcacttg caggacgctc 900
acgatggatg gaagccaatc agcactccct caacatcctg ggccagaagg tgtcgatgca 960
ctacagtgac cccaagccca agatcaatga ggactggctg tgcaataagt gtggcgtcca 1020
gaacttcaaa cgccgagaga agtgcttcaa atgtggcgtg cccaagtcag aggcagagca 1080
gaagetgeee eteggmacga ggytggatea geagaeaetg eeaetgggtg keegggaget 1140
gagecaggge etgettyeee tgeegeagee etaccaggee cagggagtee tggeeteeca 1200
agecetgtea cagggetegg agecaagete agagaaegee aatgacaeca teattttgeg 1260
caacctg
                                                                 1267
<210> 126
<211> 841
<212> DNA
<213> Homo sapiens
<400> 126
gcgttacsat cgtccgtgcg caccgcccgg cgtccaggtg agtctcccat ctgcagagac 60
geggaegege eggeeegeag ttggeetgeg gagegeggtg gaeggtttgg egeeeaceag 120
gcgatcaata ctttggattt ttaatttcta gatttggcaa ttcttcgctg aagtcatcat 180
gagettttte caacteetga tgaaaaggaa ggaacteatt eeettggtgg tgtteatgae 240
tgtggcggcg ggtggagcct catctttcgc tgtgtattct ctttggaaaa ccgatgtgat 300
ccttgatcga aaaaaaaatc cagaaccttg ggaaactgtg gaccctactg tacctcaaaa 360
gcttataaca atcaaccaac aatggaaacc cattgaagag ttgcaaaatg tccaaagggt 420
gaccaaatga cgagccctcg cctctttctt ctgaagagta ctctataaat ctagtggaaa 480
cattlctgca caaactagat tctggacacc agtgtgcgga aatgcttctg ctacattttt 540
agggtttgtc tacatttttt gggctctgga taaggaatta aaggagtgca gcaataactg 600
cactgtctaa aagtttgtgc ttattttctt gtaaatttga atattgcata ttgaaatttt 660
tgtttatgat ctatgaatgt ttttcttaaa atttacaaag ctttgtaaat tagattttct 720
gatecetega ggggeecaag ettacgegtg catgegaegt catagetetg teectacgaa 840
                                                                 841
g
```

```
<210> 127
<211> 1172
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (119)
<223> n equals a,t,g, or c
<400> 127
tactatttat agetttagat agggeeteee tteeeetett ettetttgt tetettteat 60
taaacccctt ccccagtttt tttttatact ttaaaccccg ctcctcatgg ccttggccnt 120
ttctgaagct gcttcctctt ataaaatagc ttttgccgaa acatagtttt tttttagcag 180
atcccaaaat ataatgaagg ggatggtggg atatttgtgt ctgtgttctt ataatatatt 240
attattette ettegetteta gaaaaataga taaatatatt ttttteagga aatagtgtgg 300
tgtttccagt ttgatgttgc tgggtggttg agtgagtgaa ttttcatgtg gctgggtggg 360
tttttgcctt tttctcttgc cctgttcctg gtgccttctg atggggctgg aatagttgag 420
gtggatggtt ctaccettte tgcettetgt ttgggaccea getggtgtte tttggtttge 480
tttcttcagg ctctagggct gtgctatcca atacagtaac cacatgcggc tgtttaaagt 540
taagccaatt aaaatcacat aagattaaaa atteetteet cagttgcact aaccaegttt 600
tgttggacag cactattcta gagaactaaa ctggcttaac gagtcacagc ctcagctgtg 720
ctgggacgac ccttgtctcc ctgggtagga ggggggggaa tggggggggg ctgatgaggc 780
cccagctggg gcctgttgtc tgggaccctc cctctcctga gaggggaggc ctggtggctt 840
agcctgggca ggtcgtgtct cctcctgacc ccagtggctg cggtgagggg aaccaccctc 900
ccttgctgca ccagtggcca ttagctcccg tcaccactgc aacccagggt cccagctggc 960
tgggtcctct tctgccccca gtgcccttcc ccttgggctg tgttggagtg agcacctcct 1020
ctgtaggcac ctctcacact gttgtctgtt actgattttt tttgataaaa agataataaa 1080
1172
aaaaagggcg gccgctcgcg atctagaact ag
<210> 128
<211> 891
<212> DNA
<213> Homo sapiens
<400> 128
acceaegegt cegtgagatt eteteceagg ceaeaagaca ttteetgete ggaacettgt 60
ttactaattt ccactgcttt taaggccctg cactgaaaat gcaagctcag gcgccggtgg 120
tegttgtgac ccaacetgga gteggteeeg gteeggeeec ccagaactee aactggeaga 180
caggcatgtg tgactgtttc agcgactgcg gagtctgtct ctgtggcaca ttttgtttcc 240
cgtgccttgg gtgtcaagtt gcagctgata tgaatgaatg ctgtctgtgt ggaacaagcg 300
tegeaatgag gaetetetae aggaecegat atggeatece tggatetatt tgtgatgaet 360
atatggcaac tetttgetgt ceteattgta etetttgeca aateaagaga gatateaaca 420
gaaggagagc catgcgtact ttctaaaaac tgatggtgaa aagctcttac cgaagcaaca 480
aaattcagca gacacctctt cagcttgagt tcttcaccat cttttgcaac tgaaatatga 540
tggatatgct taagtacaac tgatggcatg aaaaaaatca aatttttgat ttattataaa 600
tgaatgttgt ccctgaactt agctaaatgg tgcaacttag tttctccttg ctttcatatt 660
atogaattto otggottata aactttttaa attacatttg aaatataaac caaatgaaat 720
attttactga taagattett catgettett tgeteteett aaaatgtett ttteactagt 780
```

```
tagttccaag ggtcagtctc ataattttgt tcttatactt tgatttcctt tttcttttt 840
tttttttta atagagttgg gggatcyttc yttcttttt tttttttt t
<210> 129
<211> 2461
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (14)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (1164)
<223> n equals a,t,g, or c
<400> 129
tttcaattct tggntttctg ttcccttcta ccaaaaccca gcataggact cagtgtacac 60
ttactttaaa acaaaaactc acatttctta gctgcaggtg atggcctcag tcattttaat 120
acagoctgga atgagtttgc ttattaccca gtcactttcg tagtgaatgt tcaaacccca 180
aagcaaatgt ttgcatctcc ttgtccataa aggagaaagc caggttatag gagaaagaga 240
gagaaaggeg catgtetgtt tgeacagaga gaggeaattt tgtetacett tegagaatea 300
gttataaaca gaagggcctc ttaggatttt gagctctcct gacaatgaag gaaaagctct 360
cttgagtata caagttccac actcattacc tttcagtggt gacccatcac ccactacaat 420
ttgttgaagg aagggagtgt cagagatatg ctttaaagtt gtactttagg ctgaaattct 480
ctctgtattt ggacctgcag atgttgtgta cagaaccgat gcatggcagg gtcaggaagc 540
taggagagtg aaggcgettg tggagacage tetgtageaa atgaaacaeg gaageeteeg 600
ggaatgtgtt tgtgtcacca gcagcaggca tttccctgtc ctccccaccc ccagtctcca 660
catococago agootottoo agaagoatgt cagggagaog gacaggtgot otcottotog 720
tgcaccacat ccaagtccac ccaccgtgga cgcagtgtga ctaaatgctg gccttgaaga 780
gaaaccctca gccagcttgt ctgttgtcca ggtccctcag tgtctctggt ttccctgccc 840
tgcataattt aagcattagt gccaaataca tetgteatat teeteteeet ggagaetgeg 900
aaatgtccag actttttcag actagtggag ggaaggaatg ttacataact aagtggaggc 960
ctggaactgt caggatttga cagggctgga ccagagaccc ttccgcctct gcctagtgtg 1020
tctgtcaggc aggcagcagc catcaatcca agaatgagcc atggcggcaa gcactktgtg 1080
gagaaaggaa cccagccgag gtctgagttt cagacagaaa ctggggagtt gggacatctt 1140
ctctgtgcca ggcttcattg acancatcgg tccttcattg asctgagccc aagccctcag 1200
tggaacctgt caagagcatc agcagcatgg agctgaagac cgagcccttt gatgacttcc 1260
tgttcccagc atcatccagg cccagtggct ctgagacagc ccgctccgtg ccagacatgg 1320
acctatctgg gtccttctat gcagcagact gggagcctct gcacagtggc tccctgggga 1380
tggggcccat ggcacagagc tggagcccct gtgcactccg gtggtcacct gtactcccag 1440
ctgcactgct tacacgtctt ccttcgtctt cacctacccc gaggctgact ccttccccag 1500
ctgtgcagct gcccaccgca agggcagcag cagcaatgag ccttcctctg actcgctcag 1560
ctcacccacg ctgctggccc tgtgaggggg cagggaaggg gaggcagccg gcacccacaa 1620
gtgccactgc ccgagctggt gcattacaga gaggagaaac acatcttccc tagagggttc 1680
ctgtagacct agggaggacc ttatctgtgc gtgaaacaca ccaggctgtg ggcctcaagg 1740
acttgaaagc atccatgtgt ggactcaagt cettacetet teeggagatg tagcaaaacg 1800
catggagtgt gtattgttcc cagtgacact tcagagagct ggtagttagt agcatgttga 1860
gccaggcctg ggtctgtgtc tcttttctct ttctccttag tcttctcata gcattaacta 1920
```

```
atctattggg ttcattattg gaattaacct ggtgctggat attttcaaat tgtatctagt 1980
gcagctgatt ttaacaataa ctactgtgtt cctggcaata gtgtgttctg attagaaatg 2040
accaatatta tactaagaaa agatacgact ttattttctg gtagatagaa ataaatagct 2100
atatccatgt actgtagttt ttcttcaaca tcaatgttca ttgtaatgtt actgatcatg 2160
cattgttgag gtggtctgaa tgttctgaca ttaacagttt tccatgaaaa cgttttattg 2220
tgtttttaat ttatttatta agatggatto tcagatattt atatttttat tttattttt 2280
tctaccttga ggtcttttga catgtggaaa gtgaatttga atgaaaaatt taagcattgt 2340
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaagggcggc cgctcgcgat ctagaactag 2460
t
                                                                 2461
<210> 130
<211> 2197
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (1381)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (2194)
<223> n equals a,t,g, or c
<400> 130
gacgagatet gtgtcagaac gtgcgtgtga gcggatacaa aacccgagag aggcgtgagc 60
agcgctgtgt ttgcgagcgg kagcgaggrg cgccggctgr ggtgtgtgct cctgagctct 120
tcagaaacca ggctgctttc aggaacattg ctgtggattc ccagggccta ttccactaga 180
agcaagatgg ctgaactcaa tactcatgtg aatgtcaagg aaaagatcta tgcagttaga 240
tcagttgttc ccaacaaaag caataatgaa atagtcctgg tgctccaaca gtttgatttt 300
aatgtggata aagccgtgca agcctttgtg gatggcagtg caattcaagt tctaaaagaa 360
tggaatatga caggaaaaaa gaagaacaat aaaagaaaaa gaagcaagtc caagcagcat 420
caaggcaaca aagatgctaa agacaaggtg gagaggcctg aggcagggcc cctgcagccg 480
cagecaceae agatteaaaa eggeeecatg aatggetgeg agaaggacag etegteeaca 540
gattetgeta acgaaaaacc agccettate cetegtgaga aaaagatete gataettgag 600
gaaccttcaa aggcacttcg tggggtcaca ggcccaaata ttgagaaatc agtgaaggat 660
ttgcaacgct gcaccgtttc tctaactaga tatcgcgtca tgattaagga agaagtggat 720
agtteegtga aqaaqateaa agetgeettt getgaattae acaactgeat eattgacaaa 780
gaagtttcat taatggcaga aatggataaa gttaaagaag aagccatgga aatcctgact 840
gctcgtcaga agaaagcaga agaactaaag agactcactg accttgccag tcagatggca 900
gagatgcagc tggccgaact cagggcagaa attaagcact ttgtcagcga gcgtaaatat 960
gacgaggagc tcgggaaagc tgcccggttt tcctgtgaca tcgaacagct gaaggcccaa 1020
atcatgetet qeqqaqaaat tacacateca aagaacaact atteeteaag aacteeetge 1080
agetecetge tgeetetget gaatgegeae geageaacet etgggaaaca gagtaacttt 1140
tecegaaaat catecaetea caataageee tetgaaggea aageggeaaa ceecaaaatg 1200
gtgagcagtc tccccagcac cgccgacccc tctcaccaga ccatgccggc caacaagcag 1260
aatggatett etaaccaaag aeggagattt aatecaeagt ateataacaa eaggetaaat 1320
gggcctgcca agtcgcaggg cagtgggaat gaagccgagc cactgggaaa gggcaacagc 1380
ngccacgaac acagaagaca gccgcacaac ggcttccggc ccaaaaacaa aggcggtgca 1440
```

```
aaaatcaaga ggcttccttg gggatgaaga cccccgaggc cccggcccat tctgaaaagc 1500
cccggcgaag gcagcacgct gcagacacct cggaggccag gcccttccgg ggtagtgtcg 1560
gtagggtttc acagtgcaat ctctgcccca cgagaataga agtttccaca gatgcagcag 1620
ttctctcagt cccggctgtg acgttggtgg cctgagctag gaggaaaaag agcagttttc 1680
actcagtttt ggttccctgc ccgaggtgct gacccaattc gctgccaaaa gagtgtcaat 1740
cagaatatac aaatcccgta tggttgtgtc atcctctctt aatcattttt actaattcta 1800
ataatcagct ctagcttgct tcataatttt catggctttg cttgatctgt tgatgctttc 1860
totcatcaag actitgcago attitagoca ggoagtatti actoattati aggaaaatca 1920
agatgtggct gaagatcaga ggctcagtta gcaacctgtg ttgtagcagt gatgtcagtc 1980
cattgattgt ctttagagag ttaatgttac aaaaaagaat tcttaataat cagacaaaca 2040
tgatctgctg aggacacatg cgcttttgta gaatttaaca tctggtgttt ttctgaaaaa 2100
atatatatac atatattgct ttatttgaaa caaattaaaa tatgctgcat ttgaaaaaaa 2160
                                                                   2197
aaaaaaaaa aaaaaaaaa aaaaaaaaa aaanaaa
<210> 131
<211> 464
<212> DNA
<213> Homo sapiens
<220> .
<221> misc feature
<222> (397)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (405)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (420)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (449)
<223> n equals a,t,g, or c
<400> 131
atteateteg tteattgeta caeceegtta gateetegge ggtgeeaggt ttegtegaat 60
ggaaacccaa atgggtataa gcgttccact ttggcagcgt tgctaaagca accaccacca 120
gcgttggaac ggttggctac taccaattta tggaccgcct attaagtggc atggttacag 180
ccaatacgat agtgagaaaa ccaaaacgca gcctagtgag agtagaaagt gtaacaccat 240
tgcccacaac tggttgctgc ctactgtcgc taaggcggct taggcaaaat ttgctgcagc 300
gtacgcggag agttgtttac caaagatgcc ttacaaccct gcgctgaaag ggggctgctg 360
cttatgccaa ttatgtttta aggctggctt ctggtanttt tgccnaatgg ttttgatttn 420
                                                                   464
aggittacca titgittice ceaaattane eetitgegeg eeeg
<210> 132
```

<211> 1950

PCT/US00/05883

95

```
<212> DNA
 <213> Homo sapiens
 <220>
 <221> misc feature
 <222> (1941)
 <223> n equals a,t,g, or c
 <400> 132
 ggggtggctt gccacccaca gcaattgtga ctttgaaagg ccattccacc gttctatcaa 60
 tccagctgct tcaggatgat gggcaacgtg gtaagaccag tgaattccac gaacatgagc 120
 ccactgctgc acttctatgg ccgtaaatta acttgagaaa gtggaatcga attccgatgt 180
 tgaattttcc ttctggcccc attcatgtgg caggtggtga ttcaggattg tcctcccggg 240
 ctggcagcag ggccccagcg gcaccatgtc tgccctcgga gtcaccgtgg ccctgctggt 300
 gtgggcggcc ttcctcctgc tggtgtccat gtggaggcag gtgcacagca gctggaatct 360
 gcccccaggc cctttcccgc ttcccatcat cgggaacctc ttccagttgg aattgaagaa 420
 tattcccaag tccttcaccc ggttggccca gcgcttcggg ccggtgttca cgctgtacgt 480
 gggctcgcag cgcatggtgg tgatgcacgg ctacaaggcg gtgaaggaag cgctgctgga 540
 ctacaaggac gagttctcgg gcagaggcga cctccccgcg ttccatgcgc acagggacag 600
 gggaatcatt tttaataatg gacctacctg gaaggacatc cggcggtttt ccctgaccac 660
cctccggaac tatgggatgg ggaaacaggg caatgagagc cggatccaga gggaggccca 720
 cttcctgctg gaagcactca ggaagaccca aggccagcct ttcgacccca ccttcctcat 780
 eggetgegeg ceetgeaacg teatageega cateetette egeaageatt ttgaetacaa 840
 tgatgagaag tttctaaggc tgatgtattt gtttaatgag aacttccacc tactcagcac 900
 tecetggete cagetttaca ataattttee cagettteta caetaettge etggaageea 960
 cagaaaagtc ataaaaaatg tggctgaagt aaaagagtat gtgtctgaaa gggtgaagga 1020
 gcaccatcaa tototggaco ccaactgtoo cogggacoto accgactgoo tgotogtgga 1080
 aatggagaag gaaaagcaca gtgcagagcg cttgtacaca atggacggta tcaccgtgac 1140
 tgtggccgac ctgttctttg cggggacaga gaccaccagc acaactctga gatatgggct 1200
 cctgattctc atgaaatacc ctgagatcga agagaagctc catgaagaaa ttgacagggt 1260
 gattgggcca agccgaatcc ctgccatcaa ggataggcaa gagatgccct acatggatgc 1320
 tgtggtgcat gagattcagc ggttcatcac cctcgtgccc tccaacctgc cccatgaagc 1380
 aacccgagac accattttca gaggatacct catccccaag ggcacagtcg tagtgccaac 1440
 tctggactct gttttgtatg acaaccaaga atttcctgat ccagaaaagt ttaagccaga 1500
 acactteetg aatgaaaatg gaaagtttaa gtacagtgae tattteaage catttteeae 1560
 aggaaaacga gtgtgtgctg gagaaggcct ggctcgcatg gagttgtttc ttttgttgtg 1620-
 tgccattttg cagcatttta atttgaagcc tctcgttgac ccaaaggata tcgacctcag 1680
 ccctatacat attgggtttg gctgtatccc accacgttac aaactctgtg tcattccccg 1740
ctcatgagtg tgtggaggac accctgaacc ccccgctttc aaacaagatt tcgaattgtt 1800
 tgaggtcagg atttctcaaa ctgattcctt tctttgcata tgagtatttg aaaataaata 1860
 ttttcccaga atataaataa atcatcacat gattatttta actawaaaaa aaaaaaaaaa 1920
aaaaaaaaa naaaaaaaa
                                                                   1950
<210> 133
<211> 2093
<212> DNA
<213> Homo sapiens
<400> 133
cacgcgttcg cccacgcgts sgctgggttt ctgaactgct gggtttctgc ttgctcctct 60
ggagatgcag cgtctgttga ctccagtgaa gcgcattctg caactgacaa gagcggtgca 120
```

```
ggaaacetee eteacacetq eteqeetqet eccagtagee caccaaaggt titetacage 180
ctctgctgtc cccctgqcca aaacaqatac ttggccaaag qacgtgggca tcctggccct 240
ggaggtctac ttcccagccc aatatgtgga ccaaactgac ctggagaagt ataacaatgt 300
ggaagcagga aagtatacag tgggcttggg ccagacccgt atgggcttct gctcagtcca 360
agaggacatc aactccctgt gcctgacggt ggtgcaacgg ctgatggagc gcatacagct 420
cccatgggac tctgtgggca ggctggaagt aggcactgag accatcattg acaagtccaa 480
agotgtoaaa acaqtqotoa tqqaactott coaggattoa ggoaatactg atattgaggg 540
catagatacc accaatgcct gctacggtgg tactgcctcc ctcttcaatg ctgccaactg 600
gatggagtcc agttcctggg atggtcgtta tgccatggtg gtctgtggag acattgccgt 660
ctatcccagt ggtaatgctc gtcccacagg tggggccgga gctgtggcta tgctgattgg 720
gcccaaggcc tctggccctg gagcgagggc tgaggggaac ccatatggag aatgtgtatg 780
acttctacaa accaaatttg gcctcggagt acccaatagt ggatgggaag ctttccatcc 840
agtgctactt gcgggccttg gatcgatgtt acacatcata ccgtaaaaaa atccagaatc 900
agtggaagca agctggcagc gatcgaccct tcacccttga cgatttacag tacatgatct 960
ttcatacacc cttttgcaag atggtccaga agtctctggc tcgcctgatg ttcaatgact 1020
tcctgtcagc cagcagtgac acacaaacca gcttatataa ggggctggag gctttcgggg 1080
ggctaaagct ggaagacacc tacaccaaca aggacctgga taaagcactt ctaaaggcct 1140
ctcaggacat gttcgacaag aaaaccaagg cttcccttta cctctccact cacaatggga 1200
acatgtacac ctcatccctg tacgggtgcc tggcctcgct tctgtcccac cactctgccc 1260
aagaactggc tggctccagg attggtgcct tctcttatgg ctctggttta gcagcaagtt 1320
tetttteatt tegagtatee caggatgetg etceaggete teecetggae aagttggtgt 1380
ccagcacatc agacctgcca aaacgcctag cctcccgaaa gtgtgtgtct cctgaggagt 1440
tcacagaaat aatgaaccaa agagagcaat tctaccataa ggtgaatttc tccccacctg 1500
gtgacacaaa cagcetttte ecaggtaett ggtacetgga gegagtggae gagcageate 1560
gccgaaagta tgcccggcgt cccgtctaaa ggtgttctgc agatccatgg aaagcttcct 1620
gggaaacgta tgctagcaga gcttctcccc gtgaatcata tttttaagat cccactctta 1680
gctggtaaat gaatttgaat cgacatagta gccccataag catcagccct gtagagtgag 1740
gagecatete tagegggeee tteatteete teeatgetge aateaetgte etgggettat 1800
ggtgctatgg actaggggtc ctttgtgaaa gagcaagatg gagcaatgga gagaagacct 1860
cttcctgaat cactggactc cagaaatgtg catgcagatc agctgttgcc ttcaagatcc 1920
agataaactt teetgteatg tgttagaact ttattattat taatattgtt aaacttetgt 1980
gctgttcctg tgaatctcca aattttgtac cttgttctaa gctaatatat agcaattaaa 2040
aagagagaaa gaggaaaaaa aaaaaaactt tggggggggc ccggacccca att
<210> 134
<211> 729
<212> DNA
```

<211> 729
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (646)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (665)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (665)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (665)
<223> n equals a,t,g, or c

```
<222> (725)
<223> n equals a,t,g, or c
<400> 134
gctcgtgccg aattcggcac gagtcggcac gaggtccaag ggggtgtgtg ttcacgggaa 60
tgctgagtac cagcccggtt ctccagttta ttcctccaag tgccaggact gcgtgtgcac 120
ggacaaggtg gacaacaaca ccctgctcaa cgtcatcgcc tgcacccacg tgccctgcaa 180
cacctcctgc agccctggct tcgaactcat ggaggccccc ggggagtgct gtaagaagtg 240
tgaacagacg cactgtatca tcaaacggcc cgacaaccag cacgtcatcc tgaagcccgg 300
ggacttcaag agcgacccga agaacaactg cacattcttc agctgcgtga agatccacaa 360
ccagctcatc tcgtccgtct ccaacatcac ctgccccaac tttgatgcca gcatttgcat 420
cccgggctcc atcacattca tgcccaatgg atgctgcaag acctgcaccc ctcgcaatga 480
gaccagggtg ccctgctcca ccgtccccgt caccacggag gtttcgtacg ccggctgcac 540
caagaccgtc ctcatgaatc attgctccgg gtcctgcggg acatttgtca tgtamtcggc 600
caaggccagg ccctggacca cagcttgctc ctgctgcaaa gaaganaaaa ccagccagcg 660
tgagntggtc ctgactgccc aatggcggtc gctaacacac acctacacca catcgagact 720
gccantgcc
                                                                    729
<210> 135
<211> 1189
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (5)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (8)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (17)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (1160)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (1175)
<223> n equals a,t,g, or c
<400> 135
gtaanacnga cagtacngta cggaattccc gggtcgaacc cacgcgtcct ggggtgagag 60
ggtgacgcat gtgccctctg gcagtctgct gctgtgtcca gagtccgact ccagctgggc 120
```

```
tgtaactggg cttggccccc gccttaggcc ccgccagcag gcgaagcagg gagatgtcag 180
 actgctacac ggagctggag aaggcagtca ttgtcctggt ggaaaacttc tacaaatatg 240
 tgtctaagta cagcctggtc aagaacaaga tcagcaagag cagcttccgc gagatgctcc 300
agaaagagct gaaccacatg ctgtcggaca cagggaaccg gaaggctgcg gataagctca 360
 tccagaacct ggatgccaat catgatgggc gcatcagctt cgatgagtac tggaccttga 420
taggcggcat caccggcccc atcgccaaac tcatccatga gcaggagcag cagagcagca 480
gctagagacc cctttggcca caccttccag gcactggcct gatgccccgc cctggtgctc 540
tecceagget ecetecteag ectectgece acceagggee etttactete ttetecetee 600
agacetteet etgaceettg etgaactggg gteeetttgt gagtgtetea gtetagaggt 660
acctecetee etggggggte teageteetg gagtegeagg eeettgggge eeetetgtga 720
gateteaatg etgtetgggg accetaagag tttteteace tgtteagtet catetaacet 780
tccaatgtct gatgttcctg ccaaattcct gcctgattct gggtccgtcc tgacctccaa 840
aggtcagett ggtgettgag gtetecetge tettggtgge agtggtagea geaacageag 900
cagcagcage agcagcagea geagagaeet etecaettte cettageeee tetgetgggt 960
agagaggcac tttcagggac ttccctccag ctgcctcttc atctgggaat gagctaagca 1020
aggctgagcc tcctcctgtt gcttgaaata atgatgatat aaaggctgga tttggagttt 1080
aaaaaargcg ggsggtttan aggatccaac ttacntaccc gtgcattgc
                                                               1189
<210> 136
<211> 1466
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (2)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (1291)
<223> n equals a,t,g, or c
<400> 136
engettagtt ettecattte accettgeag ceagetgttg gecaeggeee tgeeetetgg 60
tetgeegtge atetecetgt gecetettge tgeetgeetg tetgetgagg taaggtggga 120
ggagggctac agccacatcc cacccctcg tccaatccca taatccatga tgaaaggtga 180
ggtcacgtgg cctcccaggc tgacttccca acctacagca ttgacgccaa cttggctgtg 240
aaggaagagg aaaggatetg geettgtggt caetggeate tgageeetge tgatggetgg 300
ggcaagtgct ggggctcatg gtgctctgag ctggcctgga ccctgtcagg atgggcccca 420
cctcagaacc aaactcactg tccccactgt ggcatgaggg cagtggagca ccatgtttga 480
gggcgaaggg cagagcgttt gtgtgttctg gggagggaag gaaaaggtgt tggaggcctt 540
aattatggac tgttgggaaa agggttttgt ccagaaggac aagccggaca aatgagcgac 600
ttctgtgctt ccagaggaag acgagggagc aggagcttgg ctgactgctc agagtctgtt 660
ctgacgccct gggggttcct gtccaacccc agcaggggcg cagcgggacc agccccacat 720
tccacttgtg tcactgcttg gaacctattt attttgtatt tatttgaaca gagttatgtc 780
ctaactattt ttatagattt gtttaattaa tagcttgtca ttttcaagtt catttttat 840
tcatatttat gttcatggtt gattgtacct tcccaagccc gcccagtggg atgggaggag 900
gaggagaagg ggggccttgg gcgctgcagt cacatctgtc cagagaaatt ccttttggga 960
```

```
ggaagggctt gcccccagcc ttaggatttc agggtttgac tgggggcgtg gagagagagg 1080
gaggaacctc aataaccttg aaggtggaat ccagttattt cctgcgctgc gagggtttct 1140
ttatttcact cttttctgaa tgtcaaggca gtgaggtgcc tctcactgtg aatttgtggt 1200
gggcgggggc tggaggagag ggtggggggc tggctccgtc cctcccagcc ttctgctgcc 1260
cttgcttaac aatgccggcc aactggcgac ntcacggttg cacttccatt ccaccagaat 1320
gacctgatga ggaaatcttc aatasgacgc aaagatcaat gcaaaaattg ttctatctga 1380
acatataact ggagctcgtc caaaaagcac actacgacag aactggacgt tcgcagcgtc 1440
cattcaaagc agcctcctca tcaagt
                                                               1466
<210> 137
<211> 140
<212> DNA
<213> Homo sapiens
<400> 137
ggttcaccta cggaaacctt gttacgactt ttacttcctc tagatagtca agttcgaccg 60
tetteteage geteegeeak ggeegtggge egacecegge ggggeegate egarggeete 120
actaaaccat ccaatcggta
<210> 138
<211> 4142
<212> DNA
<213> Homo sapiens
<400> 138
gaggggagcg agcggcgctt tggggggaggg gtcgcgtagg cgcctcacct gaccctgcgg 60
ccgtgcggtt gctgctccgg ggcaggtctc cttccaggcc aggggcccgg aatcatgtac 120
ataaagcagg tgattatcca gggttttcga agttacagag atcaaacaat tgtagatccc 180
ttcagttcaa aacataatgt gattgtgggc agaaatggat ctggaaaaag taactttttt 240
tatgcaattc agtttgttct cagtgatgag tttagtcatc ttcgtccaga acagcggttg 300
gctttattgc atgaaggtac tggtcctcgt gttatttctg cttttgtgga gattattttt 360
gataattcag acaaccggtt accaatcgat aaagaggaag tttcacttcg aagagttatt 420
aacctccttg aaagcgctgg tttttctcga agcaatcctt attatattgt taaacaagga 540
aagatcaacc agatggcaac agcaccagat tctcagagat taaagctatt aagagaagta 600
gctggtacta gagtgtatga cgaacgaaag gaagaaagca tctccttaat gaaagaaaca 660
gagggcaaac gggaaaaat caatgagttg ttaaaataca ttgaagagak attacatact 720
ctmgaggaag aaaaggaaga actagctcag tatcagaagt gggataaaat gagacgagcc 780
ctggaatata ccatttacaa tcaggaactt aacgagactc gtgccaaact tgatgagctt 840
tctgctaagc gagagactag tggagaaaaa tccagacaat taagagatgc tcagcaggat 900
gcaagagata aaatggagga tatcgaacgc caagttagag aattgaaaac aaaaatttca 960
gctatgaaag aagaaaaaga acagcttagt gctgaaagac aagagcagat taagcagagg 1020
actaagttgg agcttaaagc caaggattta caagatgaac tagcaggcaa tagtgaacaa 1080
aggaaacgtt tattaaaaga gaggcagaag ctgcttgaaa aaatagaaga aaagcagaaa 1140
gaactggcag aaacagaacc caaattcaac agtgtgaaag agaaagaaga acgaggaatt 1200
gctagattgg ctcaagctac ccaggaaaga acggatcttt atgcaaagca gggtcgagga 1260
agccagttta catcaaaaga agaaagggat aagtggatta aaaaggaact caagtcttta 1320
gatcaggota ttaatgacaa gaaaagacag attgotgota tacataagga tttggaagac 1380
actgaagcaa ataaagagaa aaatctggag cagtataata aactggacca ggatcttaat 1440
gaagtcaaag ctcgagtaga agaactggac agaaaatatt acgaagtaaa aaataagaaa 1500
```

```
gatgaactmc aaagtgaaag aaactacttg tggagagaag agaatgcaga acagcaagca 1560
 cttgctgcta aaagagaaga tcttgaaaag aagcaacaac ttcttagagc agcaacagga 1620
 aaggccattt taaatggaat agacagcata aacaaagtgc tagaccactt ccgtcgaaaa 1680
 ggaataaacc agcatgttca aaatggctat catggtattg taatgaataa ctttgaatgt 1740
 gaaccagett tetacacatg egtggaagte actgetggaa acaggttatt ttatcacatt 1800
 gttgattcag atgaagtcag cacgaagatt ttaatggagt ttaataaaat gaatcttcct 1860
 ggagaggtta cttttctgcc tcttaacaag ttagatgtca gggatacagc ctatcctgaa 1920
 accaatgatg ctattcctat gatcagcaaa ctgaggtaca atcccagatt tgacaaagct 1980
 ttcaaacatg tgtttggaaa gactcttatt tgtcgtagca tggaagtttc aacccagctg 2040
 gcccgtgctt tcactatgga ctgtattact ttggaaggtg accaagtcag ccatcggggt 2100
gctctaactg ggggttatta tgacacaagg aagtctcgac ttgaattgca aaaagatgtt 2160
agaaaagcag aagaagaact aggtgaactt gaagcaaagc tcaatgaaaa cctgcgcaga 2220
aatattgaaa ggattaataa tgaaattgat cagttgatga accaaatgca acagatcgag 2280
acccagcaaa ggaaatttaa agcatctaga gatagcatat tatcagaaat gaagatgcta 2340
aaagagaaga ggcagcagtc agagaaaacc ttcatgccta agcaacgtag cttacagagt 2400
ttggaggcaa gcttgcatgc tatggagtct accagagagt cattgaaagc agaactggga 2460
actgattigc titcicaact gagittiggaa gaicagaaga gagiagaigc actgaatgat 2520
gagattogic aacttoagoa ggaaaacaga cagttgotaa atgaaagaat taaattagaa 2580
ggtattatta ctcgagtaga gacttatctc aatgagaatc tgagaaaacg cttggaccaa 2640
gtagaacagg aacttaatga gctgagagag acagaagggg gtactgttct cacagccaca 2700
acatcagaac ttgaagccat caataaaaga gtaaaagaca ctatggcacg atcagaagat 2760
ttggacaatt ccattgataa aacagaagct ggaattaagg agcttcagaa gagtatggag 2820
cgctggaaaa atatggaaaa agaacatatg gatgctataa atcatgatac taaagaactg 2880
gaaaagatga caaatcggca aggcatgcta ttgaagaaga aagaagagtg tatgaagaaa 2940
attcgagaac ttggatcact tccccaggaa gcatttgaaa agtaccagac actgagcctc 3000
aaacagttgt ttcgaaaact tgagcagtgc aacacagaat taaagaagta cagccatgtt 3060
aacaaaaagg ctttggrtca gtttgtaaat ttctccgagc agaaagaaaa gttaataaag 3120
cgtcaagaag agttagatak gggttacaaa tcgatcatgg aactgatgaa tgtacttgaa 3180
cttcggaaat atgaagctat tcagttaact ttcaaacagg tatctaagaa cttcagtgaa 3240
gtattccaga agttagtacc tggtggcaaa gctactttgg tgatgaagaa aggagatgtg 3300
gagggcagtc agtctcaaga tgaaggagaa qqqaqtqqtq aqaqtqaqaq qqqttctqqc 3360
tcacaaagca gtgtcccatc agttgaccag tttactggag ttggaattag ggtgtcattt 3420
acaggaaaac aaggtgaaat gagagaaatg caacagcttt caggtggaca gaaatccttg 3480
gtagcccttg ctctgatttt tgccattcag aaatgtgacc cggctccatt ttacttgttt 3540
gatgaaattg accaggetet ggatgeteag cacagaaagg etgtgteaga tatgattatg 3600
gaacttgctg tacatgctca gtttattaca actactttta ggcctgaact gcttgagtca 3660
gctgacaaat tctatggtgt aaagttcaga aataaggtta gtcatattga tgtgatcaca 3720
gcagagatgg ccaaagactt tgtagaagat gataccacac atggttaatt ggaaaatact 3780
acctactggt ttgggagatg tatatagtaa tatgattctc atacccagga actgtaaatt 3840
taaacctaaa tatttggcca atagttttca gacttaaagc atcatagtcc ttttatattt 3900
gtctttgtat tttataagat actctgtaat gtcatgtttg tactgatagt ttaagaattt 3960
aatttcctgt acaacttttt gtaaaatgtt ctgctcctat tttaaatgtt ttgaaacatg 4020
Ctaaatattc tttcctaatt attttatcac ttatactacc ttttttatag cttcaattaa 4080
ataatcggtt ttatgactaa aaaaaaaaa aaaaaacysg gsggggggcc cggtacccaa 4140
tt
                                                                  4142
```

<210> 139

<211> 1747

<212> DNA

```
<220>
<221> misc feature
<222> (1659)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (1704)
<223> n equals a,t,g, or c
<400> 139
aagactccat ttcaaaaaaa aaaaaaaaaa aaaatccact catataaaag gtgagctcag 60
ctcactggtc catttctcag tggcttctcc atcctcattt gcaaacctca gagggataag 120
gcagttgaac ctgatgagca agaattataa cagcaaggaa acattaatgc ttagaattct 180
gagatocago acaactoagt otgtgggago toagotogot goocagggat aggtatgaco 240
tatgtctgcc ttaggctgct gggagatgcc attctccagt ttcagaagca ggcagggcaa 300
aggtcaagac tgtggtattg gggtcttttg gctctgaagg atcctggaac cactgatttt 360
ggtttattcc ctccagggtc taaagagaac aagaggtgct agctcttacc aaaacagatg 420
gtagagagag ttgctggcta tttaaaaagc tctttcatct kttaattcac ytcttctttt 480
cacctcttta accactcctc aggaacagaa cacttctagg actgggggtc ttttagctcc 540
ataagcaagt gagcagatgg gacaagttag tettttetee etagaaacaa aggggatgee 600
cagtggtttc cctttgcttc ccaacctaaa atttcaagtt taataaaata gcaattagca 660
gaagtgacca aattgggaga taattatcag tcatgaggaa agacacagat ttcggtcata 720
aagaatgtaa gggctataag tagaaacttt ctataaccta aatgatgtta tagaattatt 780
tttgagcagg agcagaaaga ttaaatatga tcacttcata cttctaaatc agaaatagga 840
agattaaaac cacagaacag tttgtgattt ctattgctgt agctaggtat cttactctgt 900
ccactcttgt tcaagtatct aactcttctg gaaaccaaat aggctttaga agagattatc 960
ctatattcct atcagtataa tactaaaatg taacttttta atcatctggt ttttaaaaga 1020
taaacagttt agcccatctc tccagagagc aaacatagga atatgactca ggagcctcct 1080
agggettate ateageeete acaecegett ceceetecaa eccacageet ttgettecag 1140
gtggcaggat tactactttg cctcttcagc agcatctact ctaggcatat tgatcatttt 1200
agacactggg agaagagaac ctcaaactag gaggaaaaga cagagcctcc acttagtttt 1260
gggaggggat ggcagacagt caaggagatg agcgtcctaa ggcatgttgg gatagggtca 1320
gatgcaccac ccatggagag gtttgtcaac acaaagacat ggaaggttag aggtttgtca 1380
acaaaaagac atggaaggtt aggtttgtca acacaagac atggaagatt agaggtttgt 1440
caacacaaag acacaggaag aatgggctgc agaagattta gatgttttcc atttgggcac 1500
attttactta gctggagaac taggtttaaa acagcctggg taggaaaatt agaascaagc 1560
tggatgcagt gggctccatg cctgttaatc ccaacacttt tgggaggttc caggcaggaa 1620
agatcacttg ggcccaagaa gtccaacctg ccagcgganc ttaagattca caccacttgc 1680
actcccaccc tggggtttaa ttanaaccaa aacccttttc tccgaaaaaa aaaaaaaaa 1740
                                                                  1747
aaaaaa
<210> 140
<211> 1240
<212> DNA
<213> Homo sapiens
<400> 140
gcggacgcgg ctggaggcgc ggcggcaggg ctgggcggcg gcggcggcgg cggtcatgga 60
acgccaagag gagtctctgt ccgcgcggcc ggccctggag accgaggggc tgcgcttcct 120
gcacaccacg gtgggctccc tgctggccac ctatggctgg tacatcgtct tcagctgcat 180
```

```
cettetetac gtggtettte agaagettte egeceggeta agageettga ggeagaggea 240
gctggaccga gctgcggctg ctgtggaacc tgatgttgtt gttaaacgac aagaagcttt 300
agcagctgct cgactgaaaa tgcaagaaga actaaatgcg caagttgaaa agcataagga 360
aaaactgaaa caacttgaag aagaaaaaag gagacagaag attgaaatgt gggacagcat 420
gcaagaagga aaaagttaca aaggaaatgc aaagaagccc caggaggaag acagtcctgg 480
gccttccact tcatctgtcc tgaaacggaa atcggacaga aagcctttgc ggggaggagg 540
ttataacccg ttgtctggtg aaggaggcgg agcttgctcc tggagacctg gacgcagagg 600
cccgtcatct ggcggatgag gctaagaatc ttgttagtgt cacttttgac attagcaaga 660
tgaaccctta accctcgatt caattgcctt acgcacgctt ttcacagtga ctagccaagg 720
ggaggtgggg ttgatttctg ttcctaacta cacctgcata tgtcagggct ccagtcagca 780
aaaggtatag atgttgcctc taggcatgag gtcattggtc acattctact tggagacagt 840
gattgcattc attgatttca tggttaattg ctagttggta ggtaaaggcc tctagatgat 900
tagcaatctt gataaaagag gcctagtaat gttcttttga ggttagaaat ccttgctgct 960
aggacagtot ctgtgacagg ttgcgttgaa tgatgtotto ottatcaatg gtgagcccac 1020
cagtgaggat tactgatgtg gacagttgat ggggtttgtt tctgtatatt tatttttatg 1080
tacagaactt tgtaaaaacg aaactattta aaaaacaaga ataacatttt tagcatcttt 1140
attcaaggag atttatggac ttcaatttgt ctatcaaaca ttaaatagct ttttattaca 1200
acctccaaaa aaaaaaaaaa aaaaaaaaaa aaawaaacaa
                                                                   1240
<210> 141
<211> 671
<212> DNA
<213> Homo sapiens
<400> 141
gtatectgca ggteceggte eggaatteee gggtetacee aegegteege gtgcgcaayg 60
tgccctggga atttggcgac gtaattcccg actatgtgct gggccagagc acctgtgccc 120
tgttcctcag cctccqctac cacaacctqc acccaqacta catccatggg cggctgcaga 180
gcctggggaa gaacttcgcc ttgcgggtcc tgcttgtcca ggtggatgtg aaagatcccc 240
agcaggccct caaggagctg gctaagatgt gtatcctggc cgactgcaca ttgatcctcg 300
cctggagccc cgaggaagct gggcggtacc tggagaccta caaggcctat gagcagaaac 360
cagcggacct cctgatggag aagctagagc aggacttcgt ctcccgggtg actgaatgtc 420
tgaccaccgt gaagtcagtc aacaaaacgg acagtcagac cctcctgacc acatttggat 480
ctctggaaca gctcatcgcc gcatcaagag aagatctggc cttatgccca ggcctgggcc 540
ctcagaaagc ccggaggctg tttgatgtcc tgcacgagcc cttcttgaaa gtaccctgat 600
gaccccagct gccaaggaaa cccccagtgt aataataaat cgtcctccca ggccaggcaa 660
aaaaaaaaa a
                                                                   671
<210> 142
<211> 3265
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (3234)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (3256)
```

<223> n equals a,t,g, or c

<400> 142 ggcaccgtgg acattgagag cctgacgggc taccgcacct accgctgtgc ccacccctg 60 gccacactet teaagateet ggegteette tacateagee tagteatett etaeggeete 120 atctgcatgt atacactgtg gtggatgcta cggcgctccc tcaagaagta ctcgtttgag 180 tegateegtg aggagageag etaeagerae ateeeegaeg teaagaaega ettegeette 240 atgctgcacc tcattgacca atacgacccg ctctactcca agcgcttcgc cgtcttcctg 300 teggargtga gtgagaacaa getgeggeag etgaacetea acaaegagtg gaegetggae 360 aagctccggc agcggctcac caagaacgcg caggacaagc tggagctgca cctgttcatg 420 ctcagtggca tccctgacac tgtgtttgac ctggtggagc tggaggtcct caagctggag 480 ctgateceeg aegtgaeeat eeegeeeage attgeeeage teaegggeet caaggagetg 540 tggctctacc acacagcggc caagattgaa gcgcccgcgc tggccttcct gcgcgagaac 600 ctgcgggcgc tgcacatcaa gttcaccgac atcaaggaga tcccgctgtg gatctatagc 660 ctgaagacac tggaggagct gcacctgacg ggcaacctga gcgcggagaa caaccgctac 720 atcgtcatcg acgggctgcg ggagctcaaa cgcctcaagg tgctgcggct caagagcaac 780 ctaagcaagc tgccacaggt ggtcacagat gtgggcgtgc acctgcagaa gctgtccatc 840 aacaatgagg gcaccaagct catcgtcctc aacagcctca agaagatggc gaaacctgac 900 tgagctggag ctgatccgct gtgacctgga gcgcatcccc cactccatct tcagcctcca 960 caacctgcag gagattgacc tcaaggacaa caacctcaag accatcgagg agatcatcag 1020 cttccagcac ctgcaccgcc tcacctgcct taagctgtgg tacaaccaca tcgcctacat 1080 ccccatccag ateggcaace teaceaacet ggagegeete tacetgaace gcaacaagat 1140 cgagaagatc cccacccagc tettetactg ccgcaagetg cgctacctgg aceteagcca 1200 caacaacctg accttcctcc ctgccgacat cggcctcctg cagaacctcc agaacctage 1260 catcacggcc aaccggateg agacgeteee teeggagyte tteeagtgee ggaagetgeg 1320 ggccctgcac ctgggcaaca acgtgctgca gtcactgccc tccagggtgg gcgagctgac 1380 caacctgacg cagategage tgeggggeaa ceggetggag tgeetgeetg tggagetggg 1440 cgagtgccca ctgctcaagc gcaggcttgg tggtggagga ggacctgttc aacacactgc 1500 cacccgaggt gaaggagcgg ctgtggaggg ctgacaagga gcaggcctga gcgaggccgg 1560 cccagcacag caagcagcag gaccgctgcc cagtcctcag gcccggaggg caggcctagc 1620 ttctcccaga actcccggac agccaggaca gcctcgtggc tgggcaggag cctggggccg 1680 cttgtgagtc aggccagagc gagaggacag tatctgtggg gctggcccct tttctccctc 1740 tgagactcac gtcccccagg gcaagtgctt gtggaggaga gcaagtctca agagcgcagt 1800 atttggataa tcagggtctc ctccctggag gccagctctg ccccaggggc tgagctgcca 1860 ccagaggtcc tgggaccctc actttagttc ttggtattta tttttctcca tctcccacct 1920 ccttcatcca gataacttat acattcccaa gaaagttcag cccagatgga aggtgttcag 1980 ggaaaggtgg gctgcctttt ccccttgtcc ttatttagcg atgccgccgg gcatttaaca 2040 eccaectgga etteageaga gtggteeggg gegaaceage eatgggaegg teacceagea 2100 gtgccgggct gggctctgcg gtgcggtcca cgggagagca ggcctccagc tggaaaggcc 2160 aggcctggag cttgcctctt cagtatttgt ggcagtttta gttttttgtt ttttttttt 2220 taatcaaaaa acaatttttt taaaaaaaaa aagctttgaa aatggatggt ttgggtatta 2280 aaaagaaaaa aaaaacttaa aaaaaaaaag acactaacgg ccagtgagtt ggagtctcag 2340 ggcagggtgg cagtttccct tgagcaaagc agccagacgt tgaactgtgt ttcctttccc 2400 tgggcgcagg gtgcagggtg tcttccggat ctggtgtgac cttggtccag gagttctatt 2460 tgttcctggg gagggaggtt tttttgtttg ttttttgggt ttttttggtg tcttgttttc 2520 tttctcctcc atgtgtcttg gcaggcactc atttctgtgg ctgtcggcca gagggaatgt 2580 totggagotg ccaaggaggg aggagactog ggttggctaa toccoggatg aacggtgcto 2640 cattegeace tecestecte gtgcctgeee tgccteteca egeacagtgt taaggageea 2700 agaggageca cttegeceag actttgttte cecacegeet geggeatggg tgtgtecagt 2760 gccaccgctg gcctccgctg cttccatcag ccytgtcgcc acctggtcct tcatgaagag 2820 cagacactta gaggctggtc gggaatgggg aggtcgcccc tgggagggca ggcgttggtt 2880

```
ccaagccggt tcccgtccct ggcgcctgga gtgcacacag cccagtcggc acctggtggc 2940
tggaagccac cctgctttag atcactcggg tccccacctt agaagggtcc ccgccttaga 3000
tcaatcacgt ggacactaag gcacgtttta gagtctcttg tcttaatgat tatgtccatc 3060
cgtctgtccg tccatttgtg ttttctgcgt cgtgtcattg gatataatcc tcagaaataa 3120
tgcacactag cctctgacaa ccatgaaqca aaaatccgtt acatgtgggt ctgaacttgt 3180
taaagatcaa cttctncctt gatca
<210> 143
<211> 765
<212> DNA
<213> Homo sapiens
<400> 143
gcccacgcgt ccgcccacgc gtccqcggac gcgtgqgggg tgacattgag ctcaccagcg 60
ccaccgtccc cggcgaagtt ctgcgctggt cggcggagta gcaagtggcc atggggagcc 120
tcagcggtct gcgcctggca gcaggaagct gttttaggtt atgtgaaaga gatgtttcct 180
catctctaag gcttaccaga agctctgatt tgaagagaat aaatggattt tgcacaaaac 240
cacaggaaag teeeggaget eeateeegea ettacaacag agtgeettta cacaaaceta 300
cggattggca gaaaaagatc ctcatatggt caggtcgctt caaaaaggaa gatgaaatcc 360
cagagactgt ctcgttggag atgcttgatg ctgcaaagaa caagatgcga gtgaagatca 420
gctatctaat gattgccctg acggtggtag gatgcatctt catggttatt gagggcaaga 480
aggetgeeca aagacaegag aetttaacaa gettgaaett agaaaagaaa getegtetga 540
aagaggaagc agctatgaag gccaaaacag agtagcagag gtatccgtgt tggctggatt 600
ttgaaaatcc aggaattatg ttataacgtg cctgtattaa aaaggatgtg gtatgaggat 660
ccatttcata aagtatgatt tgcccaaacc tgtaccattt ccgtatttct gctgtagaag 720
tagaaataaa ttttcttaaa taaaaaaaaa aaaaaaaaac tcgag
                                                                 765
<210> 144
<211> 1694
<212> DNA
<213> Homo sapiens
<400> 144
gcccacgcgt ccgggttgct ctattattat tattattatt atttgccttt ttttaatcac 60
catttatttg tgtaatcttt ctccattgat tggctgtcat tcttataata tctgaactac 120
cccataaaat aattototga ottaaaggca tttagotttt gottatogtt tttacatoot 180
ctattcaact aagacactgt cttgagagtt atttttcca gatggatcgt tggcctaaat 240
tttcacactt ctcccctgtt catccttttt cctcttccct gcttcctggg aataaaagga 300
acttttttaa aaaaattaat tagtccacag gwctmattat ctttctttat gattaatcta 360
tgactttttg gtacaagaac aatggaaaaa gtgaattaag gtaatgaaca aaacctttca 420
cccacttaaa cattttccag ttttgagatt cctcttcgtg tttgtggtgt cttccccttg 480
ttaccccttc tgcccttttt ctctgactat ggtaatttgg tctttaggct catatcagtc 540
tccccgagac attctgcagt cattatcacc tttttgggtg gattttattt tgttttattt 600
tgtttttttt aaaaaaataa ctttttaaca ttggtgcata tttgcttggg atagagcttg 660
tgtaatttac caatcgtatt gattgtaagt gattgtgccc tgcagaggta tatttaacaa 720
gacaaaaata atcttggtta ataaaggagc ccatgagatt tgagtcaggt tgtaagtgaa 780
atcacttaca cttttggata gaatttatac tcctgctctt ataaatcagt ggtagactta 840
ccatttttta aagttttctt gcattttttt gtttttttat tgccacagct ccctattctt 900
tettgeetge etceacece etgtteagga aaaaaaaaa ttgageetta aagtgacage 960
tgatttttta attgctgaat tttgtgaaat tttacttttt ccaagtgttt ccaactttaa 1020
```

```
aaagagaagt gaagacaaat aggttggaat ggtgaagaca aatggrttgg ratttcacag 1080
gctgtgaata attccttagg atctggcaaa ccgtgaagtc ttatttgaag accttatctc 1140
ctgagagttc ttttggagta ggaaaaagaa ccctatttga aatagaccgt ttttctcttg 1200
tttttaatct gtttaatatt tctgattttt aagcagcttt caaaacaagt gtggtggaaa 1260
aaaagaaata gtagtaggaa gatgtttagg gcagcagaac tctgggtcta aataagtaca 1320
tgttcccact tgttgccgat ttttgagagt actagggcca tctttctcaa ttttgtatta 1380
tttgtgtgca tgtttatatc aaagatgccc attttgttaa aatgctattt cctttattac 1440
cttggaaact gactcagcct catgttgctc ctaattagtg tttaaggctc ccatgagttg 1500
cagataaaat gatttatttt aacaagtaga aggaggtgat tcaccttttg gattgtaaat 1560
atatgaaaat gtctacaagg tctttatctg ctttctgtca gcatttatat taaatgataa 1620
1694
aaaaaagggc ggcc
<210> 145
<211> 823
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (182)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (731)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (743)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (749)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (755)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (817)
<223> n equals a,t,g, or c
<220>
<221> misc feature
```

<222> (821)

```
<223> n equals a,t,g, or c
<400> 145
tgtcacagac tacttcatca gtcgcttatc tggagctggg accaaggttt ctgccaggcc 60
ttgggatcag ctcttggggg tcagagcagc cttcccacat cctctggcac tgctgaactt 120
ttgcagcagc tctttcctcc tctyttggat gcccttcgag agcccaggtt acgacggatt 180
tnctgccagc ctgcagatcc tgcgcctgtc gccctgcagg tctctgtacc cttcagacca 240
ccttgctctg gttcctgggc agagctcagc agtacttggc agcatgggac ccagcttcct 300
tectgeteet gatecaaaag gaettaeete etetgttgea tgaggeagaa getttgtata 360
gcctggcctc agaggaaagc ttagctctgg aagtggagca gcagctgggc ctggagatcc 420
agaagctgac tgcacagatc cagctcctgc ctgaagagtc actaagtgtc ttttctcaag 480
aatgtcataa acaagccatg caaggtttca agctctacat gccacggggt cggtactggc 540
ggcttcgtct ctgtcctgaa cctcccagtg ctcctagtga gtatgctggt ttagtggtcc 600
gcaccgtact ggagcctgtg ttgcaaggat tgcaagggtt gcacctcaag cccaggcccc 660
tgcccttggt caggctctga cggscatcgt gggtgcctgg cttgaccaca ttcttaccca 720
tgggattcgg nttcaacctg canggagene tkcanettaa acaagaettt ggaatggtea 780
ggagtttgtg gaaaagagca tggacctgtc cctgatntcg nca
<210> 146
<211> 1134
<212> DNA
<213> Homo sapiens
<400> 146
caaaagcata gagaaattat aaaattcaag aacagatgtt agaatggaaa ctgatctaga 60
ggttataata aaggataata gtcttgtgct gacaccatca cacatcaaag cctacatgtt 120
gatgactett caaggattag aatatttaca teaacattgg atectacata gggatetgaa 180
accaaacaac ttgttgctag atgaaaatgg agttctaaaa ctggcagatt ttggcctggc 240
caaatctttt gggagccca atagagctta tacacatcag gttgtaacca ggtggtatcg 300
ggcccccgag ttactatttg gagctaggat gtatggtgta ggtgtggaca tgtgggctgt 360
tggctgtata ttagcagagt tacttctaag ggttcctttt ttgccaggag attcagacct 420
tgatcagcta acaagaatat ttgaaacttt gggcacacca actgaggaac agtggccgga 480
catgtgtagt cttccagatt atgtgacatt taagagtttc cctggaatac ctttgcatca 540
catcttcagt gcagcaggag acgacttact agatctcata caaggcttat tcttatttaa 600
tccatgtgct cgaattacgg ccacacaggc actgaaaatg aagtatttca gtaatgcgcc 660
agggccaaca cctggatgtc agctgccaag accaaactgt ccagtggaaa ccttaaagga 720
gcaatcaaat ccagctttgg caataaaaag gaaaagaaca gaggccttag aacaaggagg 780
attgcccaag aaactaattt tttaaagaga acactggaca acattttact actgagggaa 840
atagccaaaa aggcaaataa tggaaaaata gtaaacatta agtaaatgct gtagaagtga 900
gtttgtaaat attctacaca tgtaaaatat gtaaaactat gggttatttt tattaaatgt 960
attttaaaat aaaaatttaa ttctggtttt tctgattaga gtgcmaaagt gagaaaagtt 1020
caatactctt gaatgtagaa ttgaaaatgc attagggaaa acttaataaa aattattacc 1080
agttatttgg aagatctgac ccatatagta tcacaaatct gtagtagcat gggt
<210> 147
<211> 1486
<212> DNA
<213> Homo sapiens
<400> 147
gcggacqcgt qqqqqcqqq gtgtcgtttc ctttcgctga tgcaagagcc tagtgcggtg 60
```

```
gtgggagagg tatcggcagg ggcagcgctg ccgccggggc ctggggctga cccgtctgac 120
ttcccgtccg tgccgagccc actcgagccg cagccatgtc tggggacgag atgatttttg 180
atcctactat gagcaagaag aaaaagaaga agaagaagcc ttttatgtta gatgaggaag 240
gggataccca aacagaggaa acccagcctt cagaaacaaa agaagtggag ccagagccaa 300
ctgaggacaa ggatttggaa gctgatgaag aggacactag gaaaaaagat gcttctgatg 360
atctagatga cttgaacttc tttaatcaaa agaaaaagaa gaaaaaaact aaaaagatat 420
ttgatattga tgaagctgaa gaaggtgtaa aggatcttaa gattgaaagt gatgttcaag 480
aaccaactga accagaggat gaccttgaca ttatgcttgg caataaaaag aagaaaaaga 540
agaatgttaa gttcccagat gaggatgaaa tactagagaa agatgaagct ctagaagatg 600
aagacaacaa aaaagatgat ggtatctcat tcagtaatca gacaggccct gcttgggcag 660
gctcagaaag agactacaca tacgaggagc tgctgaatcg agtgttcaac atcatgaggg 720
aaaagaatcc agatatggtt gctggggaga aaaggaaatt tgtcatgaaa cctccacaag 780
tcgtccgagt aggaaccaag aaaacttctt ttgtcaactt tacagatatc tgtaaactat 840
tacatcgtca gcccaaacat ctccttgcat ttttgttggc tgaattgggt acaagtggtt 900
ctatagatgg taataaccaa cttgtaatca aaggaagatt ccaacagaaa cagatagaaa 960
atgtettgag aagatatate aaggaatatg teaettgtea cacatgeega teaeeggaea 1020
caatcctgca gaaggacaca cgactctatt tcctacagtg cgaaacttgt cattctagat 1080
gttctgttgc cagtatcaaa accggcttcc aggctgtcac gggcaagcga gcacagctcc 1140
gtgccaaagc taactaattt gctaatcact gattttgcaa agcttgttgt ggagatgtgg 1200
ctggacaggt ttgccatcag agtggatata ccgttgtatt aaaaacaaga taaaaagct 1260
gccaagattt ttggcgagtg gttggtctga agtccttgca agacgctgat gctcaagctg 1320
ttgacatact cattgcctac tttaacacct gtcagagaaa cgtgatatgg ggtaaggagg 1380
tgctttttta aaatcgttca tagacttctg taaaatgcaa gataaattaa agttattata 1440
                                                                 1486
<210> 148
<211> 153
<212> DNA
<213> Homo sapiens
<400> 148
egectgtgea gegeaagate gaggeteget eggeagagga etectteaca ggettegtee 60
ggaccotgta otttgotgac acotacotga aggagtgoca aggotgagog gocaggooto 120
                                                                 153
cagaacatgg agctggcgcc tgtgcagcgc aag
<210> 149
<211> 882
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (14)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (25)
<223> n equals a,t,g, or c
<220>
```

```
<221> misc feature
 <222> (870)
 <223> n equals a,t,g, or c
 <400> 149
acgaagggca aagntggtgt caccncggtg cgccgtctag actagtggat cccggctcag 60
gattcgcacg tgcctcctgg tctcagtatg gcgctgtcct gggttcttac agtcctgagc 120
ctcctacctc tgctggaagc ccagatccca ttgtgtgcca acctagtacc ggtgcccatc 180
accaacgcca ccctggaccr gatcactggc aagtggtttt atatcgcatc ggcctttcga 240
aacgaggagt acaataagtc ggttcaggag atccaagcaa ccttcttta cttcaccccc 300
aacaagacag aggacacgat ctttctcaga gagtaccaga cccgacagga ccagtgcatc 360
tataacacca cctacctgaa tgtccagcgg gaaaatggga ccatctccag atacgtggga 420
ggccaagagc atttcgctca cttgctgatc ctcagggaca ccaagaccta catgcttgct 480
tttgacgtga acgatgagaa gaactggggg ctgtctgtct atgctgacaa gccagagacg 540
accaaggage aactgggaga gttctacgaa gctctcgact gcttgcgcat tcccaagtca 600
gatgtcgtgt acaccgattg gaaaaaggat aagtgtgagc cactggagaa gcagcacgag 660
aaggagagga aacaggagga gggggaatcc tagcaggaca cagccttgga tcaggacaga 720
gacttggggc catcctgccc ctccaacccg acatgtgtac ctcagctttt tccctcactt 780
actcgagggg gggcccgkaa cccaatcgcn tgatattatt ag
                                                                 882
<210> 150
<211> 1508
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (126)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (155)
<223> n equals a,t,g, or c
<400> 150
ctaaggaggg gtgaaccggc ccaggtcgga aacggagcag gtcaaaactc ccgtgctgag 60
gtgggaggat cgcttgagcc caggagttct gggctgtagt gcgctatgcc gatcgggtgt 120
ecgcanteta geettggeaa cagtgeaaga etgtnteaaa aacageaaca garageagga 180
cgtgagactt ctacctgctc actcagaatc atttctgcac caaccatggc cacgtttgtg 240
gageteagta ecaaageeaa gatgeeeatt gtgggeetgg geaettggaa gteteetete 300
ggcaaagtga aagaagcagt gaaggtggcc attgatgcag gatatcggca cattgactgt 360
gcctatgtct atcagaatga acatgaagtg ggggaagcca tccaagagaa gatccaagag 420
aaggotgtga agogggagga cotgttoato gtoagoaagt tgtggcocao tttotttgag 480
agaccccttg tgaggaaagc ctttgagaag accctcaagg acctgaagct gagctatctg 540
gacgtctatc ttattcactg gccacaggga ttcaagtctg gggatgacct tttccccaaa 600
gatgataaag gtaatgccat cggtggaaaa gcaacgttct tggatgcctg ggaggccatg 660
gaggagetgg tggatgaggg getggtgaaa geeettgggg teteeaattt cageeactte 720
cagatcgaga agctcttgaa caaacctgga ctgaaatata aaccagtgac taaccaggtt 780
gagtgtcacc catacctcac gcaggagaaa ctgatccagt actgccactc caagggcatc 840
```

```
accyttacgy cctacagece cetgggetet ceggatagae ettgggecaa gecagaagae 900
ccttccctgc tggaggatcc caagattaag gagattgctg caaagcacaa aaaaaccgca 960
gcccaggttc tgatccgttt ccatatccag aggaatgtga ttgtcatccc caagtctgtg 1020
acaccagcac gcattgttga gaacattcag gtctttgact ttaaattgag tgatgaggag 1080
atggcaacca tactcagctt caacagaaac tggagggcct gtaacgtgtt gcaatcstct 1140
catttggaag actatccctt cgatgcagaa tattgaggtt gaatctcctg gtgagattat 1200
acaggagatt ctctttcttc gctgaagtgt gactacctcc actcatgtcc cattttagcc 1260
aagcttattt aagatcacag tgaacttagt cctgttatag acgagaatcg aggtgctgtt 1320
ttagacattt atttctgtat gttcaactag gatcagaata tcacagaaaa gcatggcttg 1380
aataaggaaa tgacaatttt ttccacttat ctgatcagaa caaatgttta ttaagcatca 1440
gaaactctgc caacactgag gatgtaaaga tcaataaaaa aaataataat cataaaaaaa 1500
aaaaaaa
                                                                 1508
<210> 151
<211> 1232
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (1)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (7)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (1213)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (1217)
<223> n equals a,t,g, or c
<400> 151
naactgngct agcatgccca gcccacagag agcctccact agagtgatgc taagtggaaa 60
tgtgaggtgc agctgccaca gagggccccc accagggaaa tgtctagtgt ctagtggatc 120
caggccacag gagagagtgc cttgtggagc gctgggagca ggacctgacc accaccagga 180
ctccagcctg ggtgacaggg tgaacgccat ctcaaaaaat aaaaattaaa aaataaaaaa 240
agaacctgga tctcaattta atttttcata ttcttgcaat gaaatggact tgaggaaqct 300
aagatcatag ctagaaatac agataattcc acagcacatc tctagcaaat ttagcctatt 360
cctattctct agcctattcc ttaccacctg taatcttgac catatacctt ggagttgaat 420
attgttttca tactgctgtg gtttgaatgt tccctccaac actcatgttg agacttaatc 480
cctaatgtgg caatactgaa aggtggggcc tttgagatgt gattggatcg taaggctgtg 540
ccttcattca tgggttaatg gattaatggg ttatcacagg aatgggactg gtggctttat 600
gatgotaagt ggaaatgtga ggtgcagctg ccacagaggg cccccaccag ggaaatgtct 720
```

```
agtgtctagt ggatccaggc cacaggagag agtgccttgt ggagcgctgg gagcaggacc 780
tgaccaccac caggacccca gaactgtgga gtcagtggca gcatgcagcg cccccttggg 840
asagetttag geaceageet geacecatt egageageea egtaggetge acceageaaa 900
gccacaggca cggggctacc tgaggccttg ggggcccaat ccctgctcca gtgtgtccgt 960
gaggcagcac acgaagtcaa aagagattat tetetteeca cagatacett tteteteeca 1020
tgaccettta acagcatetg etteatteee etcacettee caggetgate tgaggtaaac 1080
1232
aaaaaaaaa aangggnggc cgttttaaag ga
<210> 152
<211> 999
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (917)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (951)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (995)
<223> n equals a,t,g, or c
<400> 152
gegeagetee geeggegeet ggteeeageg eeegggege egegteeeeg geeeaaceat 60
ggcrtcctcc gcggccggct gcgtggtgat cgttggcagt ggagtcattg ggygaagctg 120
ggccatgctg tttgccagtg gaggcttcca ggtgaaactc tatgacattg agcaacagca 180
gataaggaay gccctggaaa acatcagaaa ggagatgaag ttgctggagc aggcaggttc 240
tetgaaagge teeetgagtg tggaagagea getgteacte ateagtggtt gteeeaatat 300
ccaagaagca gtagagggyg ccatgcwcat ycwgtgaatc cgccatacta catcccgctg 360
gttgagctgg tcccccaccc ggagacggcc cctacgacag tggacagaac ccacgccctg 420
atgaagaaga ttggacagtg ccccatgcga gtccagaagg aggtggccgg cttcgttctg 480
aaccgcctgc aatatgcaat catcagcgag gcctggcggc tagtggagga aggaatcgtg 540
tetectagtg acctggaeet tgteatgtea gaagggttgg geatgeggta tgeatteatt 600
ggacccctgg aaaccatgca tctcaatgca gaaggtatgt taagctactg cgacagatac 660
agegaaggea taaaacatgt cetacagact tttggaceca ttccagagtt ttccagggec 720
actgctgaga aggttaacca ggacatgtgc atgaaggtcc ctgatgaccc ggagcactta 780
gctgccagga ggcagtggag ggacgagtgc ctcatgagac tcgccaagtt gaaragtcaa 840
gtgcagmyaa sctggaratt tccacctttt cttttcagct tgattgcatt tgactatatt 900
ttacagccag tgattgnagt ttcatggtaa tatgtggcaa aatatttttg naattatttt 960
                                                              999
ctaatccctt tcttaagtac tctggggccc tgcanttat
<210> 153
```

<210> 153 <211> 1212

```
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (794)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (1047)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (1146)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (1176)
<223> n equals a,t,g, or c
<400> 153
cacgcccacc tototoctgg agogctgggc ottogctggc ogcaccggca gccatgagct 60
cggagatgga gccgctgctc tgggcctgga gctattttag gcgcaggaag ttccagctct 120
ggccgatcta tgcacgcaga tgctggagaa gtccccttat gaccaggcgg ctgctgcaga 180
tgggcattta taacggccag ctttttaaca atctggggct gtgttgcttc tatgcccagc 240
agtatgatat gactotgaco toatttgaac gtgccctttc tttggctgaa aatgaagaag 300
aggcagetga tgtetggtae aacttgggae atgtagetgt gggaatagga gatacaaatt 360
tggcccatca gtgcttcagg ctggctctgg tcaacaacaa caaccacgcc gaggcctaca 420
acaacctggc tgtgctgqag atgcggaagg gccacgttga acaggcaagg gcactattac 480
aaactgcatc atcattagca ccccatatgt atgaaccgca ttttaatttt gcaacaatct 540
ctgataagat tggagatctg cagagaagct atgttgctgc gcagaagtct gaagcagcat 600
ttccagacca tgtggacaca caacatttaa ttaaacaatt aaggcagcat tttgctatgc 660
totgattgtt cottagacca catatgttct tatgaagcmg cattatgcaa ggggaaaaaa 720
gcactatgtc tgtgtatgta tgtatatagt gtaatacgta tattttaaca aacctgtcct 780
tgatattagt taanggtgac acataagggt gacacagaat gtgtaatgca aatttcatag 840
taatagtaac tttataaaat aatattataa aatacaggat ttaaaccttt ctaaatagat 900
cctgaaactg tctctcacat tatatagtag atgtttgttt ataatgttta caaaacattt 960
tggtgaattt cctcaatgtt ttataaatgt acatttttta agtccttaag ctgactctta 1020
gccatcatgt agcttaagga gtctggnaat ctggccattg aaaactggca cctttgaagc 1080
caggtgtggt tagcatgtgc ctatagtccc agcttacttg gggaggtggg aggtggggag 1140
ggattnatga aattaggagg acttttccct ttaagnactt ttaaaaaaaat ggtattttga 1200
aaacctattt tt
                                                                   1212
<210> 154
<211> 2361
<212> DNA
<213> Homo sapiens
```

```
<220>
<221> misc feature
<222> (92)
<223> n equals a,t,g, or c
<400> 154
ggagccttgc cttgctgctc tacctccacc atgccaagtg gtcccaggct gcacccatgg 60
cagaaggagg agggcagaat catcacgaag gntgaagttc atggatgtct atcagcgcat 120
actgccatcc aatcgagacc ctggtggaca tcttccagga gtaccctgat gagatcgagt 180
acatetteaa gecateetgt gtgeeeetga tgegatgegg gggetgetge aatgaegagg 240
gcctggagtg tgtgcccact gaggagtcca acatcaccat gcagattatg cggatcaaac 300
ctcaccaagg ccagcacata ggagagatga gcttcctaca gcacaacaaa tgtgaatgca 360
gaccaaagaa agatagagca agacaagaaa aatgtgacaa gccgaggcgg tgagccgkgc 420
aggaggaagg agcctccctc agggtttcgg qaaccagatc tctcaccagg aaagactgat 480
acagaacgat cgatacagaa accacgctgc cgccaccaca ccatcaccat cgacagaaca 540
gtccttaatc cagaaacctg aaatgaagga agaggagact ctgcgcagag cactttgggt 600
ccggagggcg agactccggc ggaagcattc ccgggcgggt gacccagcac ggtccctctt 660
ggaattggat tcgccatttt attttcttg ctgctaaatc accgagcccg gaagattaga 720
gagttttatt tetgggatte etgtagaeae acceaeceae atacataeat ttatatatat 780
ctttttttaa attaacagtg ctaatgttat tggtgtcttc actggatgta tttgactgct 900
gtggacttga gttgggaggg gaatgttccc actcagatcc tgacagggaa gaggaggaga 960
tgagagactc tggcatgatc ttttttttgt cccacttggt ggggccaggg tcctctcccc 1020
tgcccaggaa tgtgcaaggc cagggcatgg gggcaaatat gacccagttt tgggaacacc 1080
gacaaaccca gccctggcgc tgagcctctc taccccaggt cagacggaca gaaagacaga 1140
tcacaggtac agggatgagg acaccggctc tgaccaggag tttggggagc ttcaggacat 1200
tgctgtgctt tggggattcc ctccacatgc tgcacgcgca tctcgccccc aggggcactg 1260
cctggaagat tcaggagcct qqqcqqcctt cgcttactct cacctgcttc tgagttgccc 1320
aggagreeac tggcaqatgt cccggcgaag agaagagaca cattgttgga agaagcagcc 1380
catgacaget eccetteetg ggaetegeec teateetett eetgeteece tteetggggt 1440
gcagcctaaa aggacctatg tcctcacacc attgaaacca ctagttctgt cccccagga 1500
ttcccgaggc acagagagac agggcaggat ccacgtgccc attgtggagg cagagaaaag 1620
agaaagtgtt ttatatacgg tacttattta atatcccttt ttaattagaa attaaaacag 1680
ttaatttaat taaagagtag ggttttttt cagtattctt ggttaatatt taatttcaac 1740
tatttatgag atgtatcttt tgctctctct tgctctctta tttgtaccgg tttttgtata 1800
taaaattcat gtttccaatc tctctctccc tgatcggtga cagtcactag cttatcttga 1860
acagatattt aattttgcta acactcagct ctgccctccc cgatcccctg gctccccagc 1920
acacattcct ttgaaataag gtttcaatat acatctacat actatatata tatttggcaa 1980
cttqtatttq tqtqtatata tatatatata tqtttatqta tatatqtgat tctgataaaa 2040
acatactaaa teteteteet tiittaatti taatattigt tateatitat tiattiggige 2160
tactgtttat ccgtaataat tgtggggaaa agatattaac atcacgtctt tgtctctagt 2220
gcagtttttc gagatattcc gtagtacata tttatttta aacaacgaca aagaaataca 2280
gatatatett aaaaaaaaa aageattttg tattaaagaa tttaattetg ateteaaaa 2340
                                                             2361
aaaaaaaaa aaaaaggggg g
<210> 155
<211> 1831
<212> DNA
```

```
<400> 155
 aaaggtgaga atgcacaaag acagctctgg gttgggtacc acagttttgc ttggtagaaa 60
 gaaaccagtg taggaaagga gacgccacca gacatettca acagacaaga ttettetge 120
 ctttttcaaa agatgctctc tgcagcagta agactataga tagagttgat tggaatatca 180
 tgtgacccag tatgctactg ctaggcataa ttatcaaaaa ttcatttttc tcattaaata 240
 ttgttaattg ctcgccacat aaagagaagc tagagctcac cagtcttggt ggtgtcctag 300
 accttcctct aaagcagtct tgggaagctg gatcatcagw tctttagcct agacagagtg 360
 tegetggtaa ataaaggaga cacaggtaac ccaqagtgga cagtgatttg cqtggggagw 420
cacagtggat ctggggcctc tgatactttg yttcckaaaa cagcccccag ttttcggctt 480
gcctatgaga tgatgttcat gtgcttcctt gaaaccaggt ggaaagaaag gggaagaatt 540
aattttctca ttctgttgct gttgaacgta atgtaatctt aatactgtag ccttcctaga 600
agcccttccc tctttttcat gctgtaaagt caaatatttg atatccttaa cataaatttt 660
aaaaattaag gtcattaggr agcaaatgtc tatttccaaa qcaatqagct tqttqtqact 720
gtgattttat tcttctatag tattttttc ctcattttaa ctgagaggag aaaataatac 780
tettttgcaa tateettagg tteteceett eeeettggtg eeeettetag tgtettaaga 840
ctttgtctta acaagtataa cattacattt tgttgttaaa acctttcgaa actgtattca 900
gtgattcttc caagtttatc tgctctgcac tatttcacta ataaaccctg gctaccacgt 960
agcccttgat ctccaagtag tttacctatg caagacctgt gacactctga attcacttct 1020
ctttctttca gaaagtagtc ataaatggag cttaattata aaggtaaaac ttgtctccaa 1080
ccagtttcat tittggccatt tctttttcaa aatgtcagct gttttcctcc aagatttttc 1140
accaaaacaa tgatcataag tgctggaata tataatactt tgcaggcata aaataaccca 1200
gacatactct catatttctt tggtgtattt tggttggtaa aacttaccag cattaaatgt 1260
aaaatataat gaggagttaa ttccttacct agaactattt cttcctttta agattcataa 1320
gtaacctttt atttttacag agctacgtat aacttccaca ttacagtcag ggacctgagg 1380
tgtaacttac taagtgaacc ccaaggttat tttatcttgc aaaagaaacc taaaccaaac 1440
taagggcctt acagtttatg gttagactga atcaaaagct ataacctcaa tttttccaaa 1500
aacagcttct gactgcaaaa gcaagtcata cagttgttag gtatgaaata gcactgatca 1560
ggaaatgcat cttcgcagat ggtatttcct tcagaaaaga cttttctact tttaatataa 1620
attaagccat aacagtttca tgctgtggaa agagggtgaa aaggttcatt ttaagagatt 1680
atataatatg aactttcaca tttactgtga aatgtctaac tttgccagtg cttcagcaag 1740
tttttttggg ggggtgatgg gggaggggta gtattgggtt ttwggaggkt ttccaaatct 1800
gtggaacttt gggagagggg acagttgttg g
<210> 156
<211> 1186
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (1045)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (1078)
<223> n equals a,t,g, or c
<220>
<221> misc feature
```

```
<222> (1118)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (1134)
<223> n equals a,t,g, or c
<400> 156
ggcacgagcg ggcctggccg aggttcgggc tccgttggcc gaggggggcg tacggaggtg 60
gcagctgtgg gaggaggcgg cgtggaaggc cgaggagctc aagcccggac caatccccac 120
gttccgggcc gcgaccctga ccctgcagcg taccgggaag cgaaaccggc cggatgggcc 180
gctgagcccg aatcgggcac tgtgtggagc cccctggagc tgagatcagg atgttccgct 240
tcatgaggga cgtggagcct gaggatccca tgttcctgat ggatcccttt gctattcacc 300
gtcagcatat gagccgtatg ttgtcaggtg gctttggata tagccccttc ctcagcatca 360
cagatggcaa catgccaggg accaggcctg ccagccgccg gatgcagcag gctggagctg 420
tctccccctt tgggatgctg ggaatgtcgg gtggtttcat ggacatgttt gggatgatga 480
atgacatgat tggaaacatg gaacacatga cagctggagg caattgccag accttctcat 540
cttccactgt catctcctac tccaatacgg gtgatggtgc ccccaaggtc taccaagaga 600
catcagagat gcgctcggca ccaggcggga tccgggagac acggaggact gttcgggatt 660
cagacagtgg actggagcag atgtccattg ggcatcacat ccgggacagg gctcacatcc 720
tecagegete eegaaaceat egeaegggg accaggagga geggeaggae tatateaace 780
tggatgagag tgaggccgca gcgtttgatg acgagtggcg gcgggagacc tcccgattcc 840
ggcagcagcg tcccctggag tttcggcggc ttgagtcctc aggggctggg ggacgaaggc 900
ggaggggcct ccccgcctgg ccatccaggg acctgaggay tcccctttcc cgacaktccc 960
gccgytatga ctggtgaggg ccccgggcct caagcctctt ctttgtaaca ggctgagagg 1020
ctgagaaatc aatcccctga ataanttttc cctctccgat tccccatccc ccaatttnat 1080
aattaaattt aaacagggaa agccgggccc ccaactgntt ccttgggggt cttnagggga 1140
gaacttttaa cgggaccttt ttccctaact ttttccttct ttaaaa
                                                                   1186
<210> 157
<211> 1448
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (456)
<223> n equals a,t,g, or c
<400> 157
ggcctgaacc cggggctggt gggcctttct gtgtcctact ccttgcaggt gacatttgct 60
ctgaactgga tgatacgaat gatgtcagat ttggaatcta acatcgtggc tgtggagagg 120
gtcaaggagt actccaagac agagacagag gcgccctggg tggtggaagg cagccgccct 180
cccgaaggtt ggcccccacg tggggaggtg gagttccgga attattctgt gcgctaccgg 240
ccgggcctag acctggtgct gagagacctg agtctgcatg tgcacggtgg cgaraaggtg 300
gggatcgtgg gccgcactgg ggctggcaak tcttccatga ccytttgcct gttccgcatc 360
ctggaggcgg caaagggtga aatccgcatt gatggcctca atgtggcaga catcggcctc 420
catgacetge geteteaget gaccateate eegeangace ceateetgtt eteggggace 480
ctgcgcatga acctggaccc cttcggcagc tactcagagg aggacatttg gtgggctttg 540
gagetgtece acctgeacae gtttgtgage teecageegg cageetggga etteeagtge 600
```

```
teagagggeg gggagaatet cagegtggge cagaggeage tegtgtgeet ggeeegagee 660
ctgctccgca agasccgcat cctggtttta gacgaggcca cagctgccat cgacctggag 720
actgacaacc tcatccaggc taccatccgc acccagtttg atacctgcac tgtcctgacc 780
atcgcacacc ggcttaacac tatcatggac tacaccaggg tcctggtcct ggacaaagga 840
gtagtagctg aatttgattc tccagccaac ctcattgcag ctagaggcat cttctacggg 900
atggccagag atgctggact tgcctaaaat atattcctga gatttcctcc tggcctttcc 960
tggttttcat caggaaggaa atgacaccaa atatgtccgc agaatggact tgatagcaaa 1020
cactgggggc accttaagat tttgcacctg taaagtgcct tacagggtaa ctgtgctgaa 1080
tgctttagat gaggaaatga tccccaagtg gtgaatgaca cgcctaaggt cacagctagt 1140
ttgagccagt tagactagtc cccggtctcc cgattcccaa ctgagtgtta tttgcacact 1200
gcactgtttt caaataacga ttttatgaaa tgacctctgt cctccctctg atttttcata 1260
ttttctaaag tttcgtttct gttttttaat aaaaagcttt ttcctcctgg aacagaagac 1320
agctgctggg tcaggccacc cctaggaact cagtcctgta ctctggggtg ctgcctgaat 1380
ccattaaaaa tqqqaqtact qatqaaataa aactacatqq tcaacagtaa aaaaaaawaa 1440
aaaaaaa
                                                                   1448
<210> 158
<211> 1004
<212> DNA
<213> Homo sapiens
<400> 158
ggcagagctc cagactactt taaatgtctc tsctctgact gaattgaagg aattgtaagt 60
ttcagttgct gaatatatca gtatatctga actccggatc tttttatttc ctatttttgg 120
cttcctacat aaattaataa agtctgtcta tatttaaggt ttctgggagt agttttgtct 180
atatttaatc catagatgtg ctcctagtca tcagtcttat ttcagtaaaa ccatctttct 240
ggccaaatct ctaacacgtt ttttacttca gtagtgaggg caatgagaag ctttattaag 300
aaagatccta tttaaagggc taatttggta ttgaaagcat gctgatataa agtccagtat 360
ttgaggatat aaagaggatg tgcactgagc tgtgctgatg ttcagcattt attatacttt 420
aatgggatag tgcttcttga ccattataga acaacaaact gtcaaagggt taatacagat 480
gacccagacc tgacattaaa tcctcttgat tagaaataat taaatgaatt atttattcat 540
ttototocto tgccaaatot acttageecc acaaaaatge cecageteag ttaacatttt 600
tttgtttttc actttaggta tctcttaggc aaatagagat ataaattgta ataggaaaca 660
gtctctaaat gtgaggctga atacagcttc agtctggctc tctaatagga caaaagccag 720
tecatgtgtt gtetetmaet gatttagett tttettttet ttgaacaatt eggeatgaat 780
tgaaaccagg ttttcctgtg gaaagttata gcttgattgg gagatagaag ttgaattgag 840
ttctttcttg caactcttag tgtttatttt tatatctcag taagacgagg ataccttcag 900
tttgaatctg cataatgttc actgccaaac tccttctcat ttaatgctta tggccttcac 960
atttctgtat aataaagatc aattatcagc tmaaaaaaaa waaa
                                                                  1004
<210> 159
<211> 1509
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (1420)
<223> n equals a,t,q, or c
<400> 159
```

```
agagagagag actagttctc tcttactcct aggcctttcg gtttgcgcga cgggcaggaa 60
agcgtgcgtg cggctaagag agtgggcgct ctcgcggccg ctgacgatgg aagaactgga 120
gcaaggcctg ttgatgcagc catgggcgtg gctacagctt gcagagaact ccctcttggc 180
caaggttttt atcaccaagc agggctatgc cttgttggtt tcagatcttc aacaggtgtg 240
gcatgaacag gtggacacta gtgtggtcag ccagcgagcc aaggagctga acaagcggct 300
cactgotoot cotgoagott toototgtoa tittggataat otoottogoo cattgttgaa 360
ggacgctgct caccctagcg amgctacctt ctcctgtgat tgtgtggcag atgcactgat 420
totacgggtg cgaagtgage tetetggeet eceettetat tggaatttee actgeatget 480
agetagteet teeetggtet eccaacattt gattegteet etgatgggea tgagtetgge 540
attacagtgc caagtgaggg agctagcaac gktacttcat atgaaagacc tagagatcca 600
agactaccag gagagtgggg ctacgctgat tcgagatcga ttgaagacag aaccatttga 660
agaaaattcc ttcttggaas aatttatgat agagaaactg ccagaggcat gcagcattgg 720
tgatggaaag ccctttgkca tgaatctgca ggatctgtat atggcagtca csacacaaga 780
ggtccaagtg ggacagaagc atcaaggcgc tggagateet cataceteaa acagtgette 840
cctgcaagga atcgatagcc aatgtgtaaa ccagccagaa caactggtct cctcagcccc 900
aaccetetea geacetgaga aagagteeae gggtaettea ggeeetetge agagacetea 960
gctgtcaaag gtcaagagga agaagccaag gggtctcttc agttaatctg ttgtggcctc 1020
agctgctgag gatggacttg gagaayagct tccaagcttc accttgaaag aagcttacat 1080
ggcagcaata tttctaaaat agtgatacag tcagaggcct cctgtaaggg cgagagaact 1140
gaagttgatg ttgacaggcc cacagggaat tggccttccc tgttcaagtg gaagccagtc 1200
totgagaato cogtgototo ototottttg gtggaggtto tgtaggttoa ggtttotaco 1260
atggacttta ggtatatagg gcaagtcagc aagaaagcac cacacactca ggaagccttg 1320
totacctttc cctagcgtct ctagccagcc agcccagat actcctcaga gacccacttc 1380
totottttgc atggaataaa aagcactcac agtgccctgn cttttgggat tacttatggc 1440
tgtggaactt catgaaccca atttcacttt ccttcactgg gttcccaccc cattgttgtc 1500
                                                                  1509
tctgggatg
<210> 160
<211> 2160
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (470)
<223> n equals a,t,g, or c
<400> 160
gctcgtgccg tggatgcggc tctgcaggat gaagatgaga tacaggtgga tgcatcatca 60
tttgaaagca ctgcaaataa gaaatcctcc tcctcttcct caggaacccc tgcatctcag 120
ctttatccac agtctcgggg gctggttcca aagtaaagcc agcttctcct ctcccagggc 180
ggaaacagca tttgccttct gagagaagag actagcaaaa agctgcagag aggattcggc 240
ccaaactcag aactgttccc ctgaggagaa gcggtggcct ctttgcagat caaccaactt 300
aatotggttg aacgtgctgt tootaatotg goactcagco cototgggaa acatotttta 360
attagcatct cagaaatgca tgggtaaggt aaagtgcgat agttcaagtg gaaagcaaga 420
gaatgaccag tgaccttgct tccttccccc ttgccttctt ctcccccttn ccctgtgctc 480
cetttetete eteteteett ttetageetg ttettwacat ggggeteeet tettgttgaa 540
caatagggca gaatcaggrg tcaccttagc aggaccacat ctttggagcc tcgggataaa 600
atgacagtga ggttgaaaag tgaaaaccct aggaacttga ataggtgcct gttcttgtag 660
ggagaaatga gaaatcgcat ttggatccag gccccaggtg ggcaccatca gcagtcttgc 720
```

ttccatgcac ctcagtaaga agtggatctg cctttgggac ctgctcagtg aggaaatctc 780

```
ttccaatttc tgcttctgaa tgattcaatg ttgggagcaa tagaaataac attccctttg 840
ccttctctga gtgtttaggg aaatagcttc tttaaaacct caaaaccatg accatcctgt 900
caaagaccta agtotgtaag otggtgocat gtocatacac catgtoactt tactottoat 960
ttgtcaccat cttttcccat gcacgcatac tctgaacatc cttgtgtggg cccatcctct 1020
gcatccagag catgctctgc agtgggcctg ttttgtggaa gaaaggaggc tgtctctgcc 1080
ttctctgatg ggactggagt tgagggaagg agctgtattg tggcacttct gaattccccg 1140
ttttgttcca tattggtata gagagcagaa gagtagctag gcagatgcag agatggagac 1200
atgagactca gtgcagtggg cagggaagac ataacagatg gaagcaaagg aatcctgcct 1260
geetteagea gagaatteae egaateetag aactgtgget eeeteeagge agageetaag 1320
atgctggtga agaatagctg tgtgattgaa taggctcaaa ggagagttca gaattcccat 1380
ttacatatta ctagtttggt ttgtaagttt tagttccttg tattattgag attcagagct 1440
tcattttatg ttggtcatta ggtgaatatt actcattttc cctcaagaga agctcataag 1500
tgtgtgtggg tgtgagagca cgatggtgcc tgtgttctgt gaatgtgtcc atatgtgtct 1560
gtaagagaga cagagaccaa gaacttgccc aattttagaa atacactaat gtgcagttgt 1620
tgccttttgt ctgtattgaa ggcccattga atgactaatc caggctggaa gcattcccat 1680
gtgggtgtct gagtccatga gccaagcctg aggggacagt gagtctccag gtctgccaca 1740
ctggtgcacc ttgctggcac ggtgcctcag gaaggtggcg actcargtgg gccttgagtt 1800
atattttaac tcagctgctc agttcccagg gcacatttct ggatcagaac ccatgggaaa 1860
caggaggtac taagtgcaat gtcttagcat tctgcaaaat ggagatctgt tgtccagcgg 1920
cttatctcct ttttagtaac ccttctttct gaacccaggg cccttttcag ccttccctca 1980
tattttcttg agatcaaact ttacttcttt cttatttact aagaatttgc ctgtttgaat 2040
aagaacaaaa cgctaaggtg ggtagcctaa gctgattttc tgctggttac acgtgtctct 2100
cacaccacat ttcctcaaag ctaatctgaa ttctgtaggc taaaaatatt catgtagcaa 2160
```

<210> 161

<211> 3609

<212> DNA

<213> Homo sapiens

<400> 161

ctggtaatcg aaaatgttaa catgcctgag sagattgtta ttcacgcact gcagtgtact 60 cactatgtaa tcctttggca acttgctaag ataactgaaa gcagctctac aaaggaggac 120 ttgctgcgtt taaagaaaca aatgagagta ttttgtcaga tatgtcaaca ttacctgacc 180 aacgtgaata ctactgttaa ggaacaggcc ttcactattc tgtgtgatat tttgatgatc 240 ttcagccatc agattatgtc aggagggcgt gacatgttag agccattagt gtatacccct 300 gattetteat tgeagtetga gttgeteage tttattttgg ateatgtett cattgaacag 360 gatgatgata ataatagtgc agatggtcag caagaggatg aagccagtaa aattgaagct 420 ctgcacaaga gaagaaattt acttgcagca ttttgtaagc taattgtata tactgtggtg 480 gagatgaata cagctgcaga tatcttcaaa cagtatatga agtattataa tgactatgga 540 gatatcatca aagaaacaat gagtaaaaca aggcagatag acaaaattca gtgtgctaag 600 accettatte teagtetgea acagetttta atgaaatgat acaagaaaat ggetataatt 660 ttgatagatc atcctctaca tttagtggca taaaagaact tgctcgacgt tttgctttaa 720 cttttggact tgatcagttg aaaacaagag aagccattgc catgctacac aaagatggca 780 tagaatttgc ttttaaagag cctaatccgc aaggggagag ccatccacct ttaaatttgg 840 cattlcttga tattctgagt gaattttctt ctaaactact tcgacaagac aaaagaacag 900 tgtatgttta cttggaaaag ttcatgacct ttcagatgtc actccgaaga gaggatgtgt 960 ggcttccact gatgtcttac cgaaattctt tgctagctgg tggtgatgat gacaccatgt 1020 cagtcattag tggaatcagc agccgggggt caacagtacg gagtaaaaaa tcaaaaccat 1080 ctacaggaaa acggaaagtg gttgagggca tgcagctttc actcactgaa gaaagtagta 1140 gtagtgacag tatgtggtta agcagagaac aaacactgca cacccctgtt atgatgcaga 1200 caccacact cacctccact attatgagag agcccaaaag attacggcct gaggatagct 1260

```
tcatgagtgt ttatccaatg cagactgaac atcatcaaac acctcttgat tataatcggc 1320
gtggcacaag cctaatggaa gatgatgaag agccaattgt ggaagatgtt atgatgtcct 1380
cagaagggag gattgaggat cttaatgagg gaatggattt tgacaccatg gatatagatt 1440
tgccaccatc aaagaacaga cgagagagaa cagaactgaa gcctgatttc tttgatccag 1500
cttcaattat ggatgaatca gttcttggag tgtcaatgtt ttaataccag tacacaatta 1560
aatctgtggt gaagtcattt tctaagtgga agaggaaatt ttaaagtgtg gtagatacag 1620
tgaaattctg tacagatttt tctctaagga gaatatgaca tgcttatgct taccaagatc 1680
aagtgcattg aggggcagtt ttgtttgcct gaataaacgt aaaggacaag taaacaattt 1740
gatgataagc tacagttttt cttagaaagt aaatatttta tttatgcgct gttagttggc 1800
agaggcattt ggtacagata tgaattctct tacatttatt tactggttgt actaaataat 1920
gatgacctct gctggatttc tgtttacatc cagaaaacaa tgttaaggat gtatttattc 1980
ccctaccctg aagaaagtgt aggatagaat tgtttttagc attctaaatt taaatgctta 2040
aaacgtcaat caacaaaact ttgttttaaa tattgtaatt gtggagaaaa gtaaacttat 2100
aagcagaact tttacaattt tttcatctaa aagtatttta agatattttt aaaatccaag 2160
agottotota taottitoag aaatatooag atgoagtgaa otgooagaag gtaaccagto 2220
tcaaacatgc ttatcccatt atcaaccctg aaagtttgct tgtcctttaa gataaaaatg 2280
taatgttgtg atattccttc cagtaatgcc actgtatttt gtctccaaat aaaagaagct 2340
tattgtagta tgtttgcaga aaaattctaa acaaaaatta tacagcttat tagagtgtgg 2400
gaatagggat ctaaatttta aataaaatta tatatata taaattggtg ctgattttat 2460
aattgcgcag tttgtttagt tttttcttac ttttaaattc caacttaaaa ttatgaggtt 2520
tcagaaatat attgaaagtt taacaatgtt taaaaataga aaagcatgag tgttcatgct 2580
ttaaaatgat ttttaaattt gtattttata ttgttttatc tatctgtctt tgcaaqcagt 2640
cttcaggtta aagatacttc taacaggtta cagtacattt cctctgtatg taaattagat 2700
gggataatag aattcataac ccataatatt ctttgaaagc taagctttaa acttcatttt 2760
atgtcctttc acaaataaat tagtttaaaa cagaaagtgg ctacttgcca ttttgacatc 2820
aactcatttt gcgaggctta ggcagctaga catcgtttaa aacaaaatat taacttatat 2880
tacatgtgta totatotatt gtoagtogto totoagttot tgaggtatat tattttaato 2940
attccatgcc ttaatatgct tgcaatacaa gaatatcttc agatgggtga ataccaaaag 3000
gettteagtt tttagteaga aateaageat tgggetgtgg tageeaaaaa ceataggtta 3060
gctaaaaaga tcatgataca attatttat taagtcatgg ttaataacaa atgaatccag 3120
acttgtctaa cagattttcc atcaacaaat attgttatgt gcaaaagtat tgcctatgtt 3180
gttttacaca ccactgcatt aactagaact gctgagagga ctgtatatat gattttaaac 3240
ctaagttgat ttttttctc actcttgaaa ggagtacttc tttgtgaaag cagttcttac 3300
agetttgttt teaaccaget aaaaatgttt tatatattae tetaacetgt tgtcctccae 3360
attctattgt cctaattgta ctgttttctg atttgtattt atgtcttgag acagtaactt 3420
tttgaataaa aataaaccta cagtatgttg tatgttttct cttgtactca aagggggagg 3480
gtggctataa atggtttgca aatttatatc tattatcaca tcttttaatg tgtttgggga 3540
ataatttata gagaatacca tcagtttata tttttaataa atcatatgta tttacaatga 3600
aaaaaaaa
                                                                3609
```

<210> 162

<211> 1603

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (1600)

<223> n equals a,t,g, or c

```
<400> 162
 gttcaggaga gatcacgctg ctgccctccc gggacaaccc ccgtcgcctg cgcgtgctgc 60
 tgcgctacaa agtgggagac caggaggaga agaccaaaga ctttgccatg gaggactgag 120
 cgttgccttt tctcccagct acctcccaaa gcagcctgac ctgcgtggga gaggcgtagm 180
 gagtcggagg ggaaagggag atcccacgtg caagtagggg gaatatctcc cccttttccc 240
 tcatagcctc tagggaggga gagtgacttc attctccatt tkaagagatt cttctggtga 300
 tgtttactta aaaagtgatc cccctcaaca acggatacag cgtgcttatt attgggcatt 360
 tagcctcaaa agcatgtagt accaagcact tgtatttccg tatattttgt ttcgcggggg 420
 agtgaggggg aagaacacgg atgaaaatgt cagtttttga agggtccatg cacatccctg 480
acacctcaca ccttatctaa gtctgaagct ggggagaaag gggttcattt agacttcata 540
catttccagt acgactttag tatctctcca gagccatatt ttctcagtcc gaattaattc 600
cccctcccta ggtgcctgta ggctatggta cttcttcctc attgttttct aggtaaactt 660
cactactggt aattaagggg aaggatatga ggaagcagtt taaatagccc tgttctcatt 720
actctgacca catacatcat agggtgctaa agttgatgaa cacattaatc cgttaagtaa 780
aatggacttt gtaattgtac agcataccta agaaactcag aaggtgcatt taagagagag 840
acctgaaaga aatagtatgg atttttaaaa attcttgtct ctactattat aaccaaaaaa 900
tatttcttgt atgtcccata aaaatatttg kgtaattctt atgaaacagg ctggtagagg 960
aggtttctga gcctagccca agggcttatt catcaccatg ggtaaattat ttaaactcac 1020
ttaattaagg aaaatatttt cccagctaga aaagtatact cattctcatt taaactctct 1080
catttggagg gatcatgtga gttggcctac ttacaagtag tgaaagttcc cttttcagtt 1140
ttgttttgtt ttgttttgtt tttctctttc actcagccaa atgtgaaagt tgtgaattta 1200
ggaaaatcac ttgtaatgaa gtgtgaatct tgttatcaaa tttatttctc tgatgtttcc 1260
ttccttatcc ttgtagccaa taaaacattg acattctcac gttttataga tgaggtaaaa 1320
agtcttgtgt gctgtgagtt ataatgcttt tgccttttta atattattag ttcttaagtg 1380
ttacagcccc ttcagaatat aacttcagga caattcaaac tatgcttaat gtatgatttt 1440
cgagcttctg tatgctaaga aaataggtgt gaaaaactgg tgttctgaaa tagcctaaca 1500
tttattgtaa ttctgaattt tctgcccttt tattcattgc atattaaagt attagagtat 1560
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa ccc
                                                                   1603
<210> 163
<211> 853
<212> DNA
<213> Homo sapiens
<400> 163
gaataaaccc aacctacaga gcatcatagc ttagcctagc ctgctttaaa tgtgctcaga 60
aaacttccat tagcctgcaa ttaggcaaaa tcatcaaaca taaaaccatc aaacataaaa 120
tatttataaa gtgttgaata tctcatatag tttattgaat acctgcatcc aaaagatgct 180
ggcaacacag cacactttag agcattggtt gtttactctc ttgatggtat ggctgcccag 240
catcaagagt tatcatactg caaatcgata gcccaggaaa agagcaaaat tcaaagttca 300
aagtagagtt tttactgaat gettgetttt geaeegtegt aaagttgaaa agaatttaaa 360
ttgaaccatc ataagctgca gactgtgcat tttatattga aaagttaata tttttaattt 420
ttaatgcaga gaagtaccca aagcataaga acacaacac ttttcacaaa gcaaacacag 480
ccatggaacc agcacccata tcaactaaca aaatactagt ttgggctttt ttgtacttta 540
tacaaatgga ctcatataat gttcatcttt tgggtctgcc tgctttcatt caatattagg 600
tttgtgggtt catctctgct gtgtgtagtt ctttcctgtt ctttatacag tgttccaaag 660
tatagtatat tacagtttac ccattctact cttgatagta aatgttttca catttgggct 720
attacaaata gtgctgcagt gaacattcac atacacatct tttggtgaac atgtgttaca 780
tttccaagta caattgctgg gtgatgagta tgcatactct taaaacatgg ttgtaccaat 840
ttacacctct acg
                                                                  853
```

```
<210> 164
 <211> 1917
 <212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (1433)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (1856)
<223> n equals a,t,g, or c
<400> 164
gcccacgcgt ccgcggacgc gtgggaaact tttgtaaaaa aagtttattc ttaaatgtac 60
aacagctcca agacaacatt aattccagct atacgagaag tttcttcaca ggtataagat 120
gatetetgaa tteaectgge ceaaccatga eetteettea gacaaagagg etgteaagaa 180
actaattgaa cggtgtggtt ttcaggatga tgtagcttat gggaagacca aaattttcat 240
tegaacacce egaacattgt ttacettgga agaacteegt geecagatge teataaggat 300
tgtcctcttt ctacaaaasg tgtggcgggg caccckggcc cgcatgcggt acaaaagaac 360
caaggcagct ctgacaataa tcaggtacta ccggcgctac aaagtgaagt cgtacatyca 420
cgargtggcc agacgcttcc atggcgtcaa gaccatgcga gactacggga agcacgtgaa 480
gtggccaagc cetectaaag ttettegeeg ttttgaggag geeetgeaga egatttteaa 540
tagatggaga gcateceage teateaagag catteeggee teagacetge eeeaggteag 600
ggcaaaggtt gcagccgtgg aaatgttgaa gggtcaaagg gctgacctcg ggctccagag 660
ggcctgggag ggcaactatc ttgcttcaaa gccagataca cctcagacct caggcacttt 720
tgtccctgtt gctaatgaat tgaaacggaa ggacaaatac atgaatgtcc tcttttcctg 780
tcacgtccgt aagtaaatcg atttagtaag gtggaagaca gagcaatttt tgtcactgac 840
cgtcacctgt ataaaatgga tcccactaaa cagtacaagg tgatgaagac tatccctcta 900
tacaatttga ctggtctgag tgtctccaat ggaaaggacc aacttgtagt gttccatacg 960
amagacaaca amagacctcat tgtctgcctc ttcagcammac agccmmcccm tgmgagtcgm 1020
attggagaac ttgttggagt gctggtgaat catttcaaga gtgagaagcg ccaccttcaa 1080
gtgaacgtca ccaacccagt acagtgcagc ctgcacggga agaagtgcac cgtctccgtg 1140
gagacgcggc tcaaccagcc ccagcccgac ttcaccaaga atcgctcggg cttcatcctc 1200
agcgtgcccg ggaactgacg ccccgcggag gcctggcccg gagcccggcc acactccgag 1260
tectgggtee cagtecaget getgeeteec aacceatgee egetagaaac etgetgegag 1320
ggcccctccc agaggagccc cgcccctgta agatttcctt cctggttttc tgcctttggt 1380
atcatcttcc tetgteetta etgteeacgg tecetgttea ataageeaaa ganeetggtg 1440
eccegeceag acceetggge tgaegteeag accaatetea ecceararge aactggatgg 1500
tgcctttagt tggtgcggat gccccgtggc aggtcaagtc agagcacctg gacaggtgtc 1560
ctccctgctg ctgaccctgc agagggaagg ggtggggatg caggaccccg ctctgcggga 1620
gccccatagc cacctctytt gcccaaggtg agccagccct ggggacccag ctcagggagg 1680
ctctgctcag agttcggcgg acceaccca acceaactcc cagccgccag ccaaagccac 1740
tgggtgagca gagtcaccca cagggccagc ccctcagcca ggagccagtg gaggagcgga 1800
acageceate cageagagtg agtecateet teecaggtte teecetggga gaetenettt 1860
gccaccaagg cccccaccag ggctctgacc accgctctgg agaggacagt gtggcat
```

<210> 165 <211> 2420

PCT/US00/05883

<212> DNA <213> Homo sapiens

<400> 165 gcacctccgt gcgcccggtt gcagcgtgga cgccggatga gttgctttta ggcttgctgg 60 cccgcggggc tgtccaggca cgcgaggccc ctcagcaaca aaatgcttca acaagttcca 120 gaaaacataa attttcctgc tgaagaagag aaaatcttgg agttttggac tgaatttaat 180 tgttttcagg aatgcttaaa gcaatcaaaa cataaaccaa aatttacctt ctatgatggt 240 cctccttttg caactggact gcctcactat ggacatatac ttgcgggtac aattaaagat 300 atagttacaa gatatgctca ccagagtggg tttcatgttg acagaagatt tggatgggat 360 tgccatggct tacctgtgga atatgaaatt gataagacac tgggaatcag aggaccagag 420 gatgtggcca aaatggggat tacagagtat aacaatcagt gccgagcaat tgtgatgaga 480 tattctgctg agtggaagtc tactgttagc agacttggcc gatggattga ctttgacaat 540 gactataaaa ctctgtatcc acaattcatg gaatcagtct ggtgggtctt caaaccaactc 600 tatgataaag gccttgttta tagaggtgtg aaagtcatgc ccttctctac ggcatgtaac 660 actccacttt ccaacttcga gtcacaccag aattataagg atgttcaaga tccttcagta 720 tttgtaactt tccctttgga agaagatgaa actgtatctt tagttgcttg gacaaccact 780 ccctggactc tacctagtaa ccttgctgtg tgtgttaatc cagaaatgca atatgtgaaa 840 attaaagatg ttgccagagg acgattactc attttaatgg aagccagatt gtcagccctc 900 tataaattgg agagtgacta tgagatcctt gaaagatttc ctggtgccta tcttaaaggc 960 aagaagtaca ggcccctgtt tgactatttc ctgaagtgta aagagaatgg cgctttcact 1020 gtgcttgttg acaactatgt gaaggaagaa gaaggcacag gggttgtcca ccaagctcct 1080 tacttcggtg ctgaggacta tcgggtctgt atggacttta acattattcg gaaagactca 1140 ctccctgttt gccctgtgga tgcttcaggc tgcttcacaa cggaggtgac agatttcgca 1200 ggacagtatg tgaaggatgc tgacaaaagt atcatcagga ctttgaagga acaaggccga 1260 cttctggttg ccaccacctt cactcacage taccettttt getggagate agacacteet 1320 ctaatttaca aagcagtgcc cagctggttt gtgcgagtgg agaacatggt ggaccagctc 1380 ctaaggaaca atgacctgtg ctactgggtc ccagagttgg tacgagaaaa acgatttgga 1440 aattggctga aagatgcacg tgactggaca atttccagaa acagatactg gggcaccccc 1500 atcccactgt gggtcagcga tgactttgag gaggtggtat gcattgggtc agtggcggaa 1560 cttgaagaac tgtcaggagc aaagatctca gatctccaca gagagagtgt tgaccacctg 1620 accatteett cacgetgtgg gaagggatee ttgcaccgca tetetgaagt gtttgaetgt 1680 tggtttgaga gtggcagcat gccctatgct caggttcatt acccgtttga aaacaagagg 1740 gagtttgagg atgcttttcc tgcagatttc attgccgagg gcatcgacca aaccagagga 1800 tggttttata ccctgctggt gctggccacg gccctctttg gacaaccgcc tttcaagaac 1860 gtaattgtga atgggcttgt cctggcaagt gatggccaaa aaatgagcaa acggaaaaag 1920 aattatccag atccagtttc catcatccag aagtatggtg ctgatgccct cagattatat 1980 ctgattaact cccctgtggt gagagcagaa aacctccgct ttaaagaaga gggtgtgcgg 2040 gacgtcctta aggatgtact gctcccatgg tacaatgcct atcgcttctt aatccagaac 2100 gttctgaggc tccagaagga ggaagaaata gaatttctct acaatgagaa cacggttaga 2160 gaaagcccca acattacaga ccggtggatc ctgtccttca tgcagtctct cattggcttc 2220 tttgagactg aaatggcagg tgagtctctc ttggtctgtc ctcccaggaa taaggactat 2280 tototttgta ackgcccttt tgatatttaa tagtggaaat attgagagat acagamaatt 2340 aaataattgt ttccttttac ctctcatata gttttgttaa ggcttgttaa ttgtcgtgat 2400 atctttgttt aagacctggg 2420

<210> 166

<211> 2061

<212> DNA

```
<400> 166
geoggeaceg cageageeeg aggaggege gggeregrgg ceeggtgegt geageetgea 60
cctcagcgag cgcgccgact ggcagtactc gcagcgcgag ctggacgccg tcgaggtctt 120
cttctcgcgc acggcccggg acaaccggct cggctgcatg ttcgtgcgct gcgcgcctc 180
cageegetae aegetgetet tetegeaegg caaegeegtg gaeetgggee agatgtgeag 240
cttctacatt ggcctcggct cccgcatcaa ctgcaacatc ttctcctacg actactcggg 300
atacggcgtc agtcgggcaa gccctccgag aagaacctct acgccgacat cgacgccgcg 360
tggmaggcgc tgcgcacccg gtatggcgtg agtcccgaga acattatcct ctatggtcag 420
agcattggga ctgtccccac ggtagacttg gcctcgaggt atgaatgcgc agggtaattc 480
tecattecee tetgatgtet ggtttgegtg tggettttee ggataceagg aaaacatact 540
gctttgatgc tttccccagc attgacaaga tatctaaagt cacctctcct gtgttggtca 600
ttcatggtac agaggatgag gtcatcgatt tctcccatgg cctagcgatg tacgagcgct 660
gtccccgagc cgtggagccc ctttggkttg aaggggctgg gcataatgac atagagcttt 720
atgcacaata cctagaaaga ctaaaacagt tcatatctca cgaacttcct aattcctgaa 780
gacaacaact tgatcttacc tcatttactg tgaacagaag agtcctctgt tttgcacatg 840
ctttaactgg gtagctgtaa aggcttgata accatgaaga agtgcccaac ctttagggtg 900
ttctaatcaa agagctgatg aaatctcagt cttttgtatc tagaggtggt tctgctaatt 960
cacacaacac gttaaactga acagtcgtga ttcccagctt cattaccttg caggaatggg 1020
aatgagaget gaatgtaggg acaattttet agtgetgtat aaagtageet egeatetgtt 1080
tctcaacctt atccatcatt tctgacattc atgcaggact tgccctgttg ccaccaatgt 1140
teteggtatt teacatgeag etetettet gecaetggat acatgggtte aatecatttg 1200
tgaagctgtg atagtgtaac tggaaagcta gtgtggtgaa aattccttta ttattttttg 1260
ttaacatgct gatctttccc ggacaaatga actgaagggt aatttactgg aactctcgtg 1320
tacagettea teaactgtaa ecatataaat ataactggaa tattettaaa caaaaagaaa 1380
ctaggggttt ttttaagtgt aaatttatta ctagccaaca gagttttact attttgattg 1440
tctggttggt ttaacaaaga gcctagctga ctttccttct gtaaagtcct ccttgtaggc 1500
ttttttaaag tactgtacat atttgcaatc acattgtgca tagattctta atggtagata 1560
tgatttcttt tgtcaggcta caacaatgaa ctgcagattc cttgtttgta atgtaaatga 1620
ttgaatacat tttgttaata tgtttttatt cctatgtttt gctattaaaa attttataac 1680
atttccaaga caaaaattcc aagtttatgc tttgaagaat ttatgtaatt aaaatttcac 1740
taaactaatc tttttagttt aggaattatt tgggttttga cactggaagt tgcgccaaat 1800
aagcatcaga aataggagat gcttaacatt gctatactac ttgtgttggt taggggtttg 1860
gatttggggg ttctttggtt ttaatttttt tttccacatt taaaaqcctt aaatqtactq 1920
taagcctcag atcgttgtac aactggactg cggttgattg ccagtttgtg tactgttgct 1980
ааааааааа ааааааааа а
                                                                2061
<210> 167
```

```
<211> 2567
<212> DNA
<213> Homo sapiens

<220>
<221> misc feature
<222> (16)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (55)
<223> n equals a,t,g, or c
```

```
<220>
 <221> misc feature
 <222> (74)
 <223> n equals a,t,g, or c
 <400> 167
 ggagaaggcg gcggtnggcg gcgtggacgg cccgcagcgg gacggccgcg gcganggcgg 60
 acageeggge geaneggegg yacaggggee eeeggeggeg ceteagetea cagagaeget 120
gggcttctac gagagcgacc ggcggcggga gaggcgscgg gccgcacaga gctttcattg 180
ttgaggttcc tcagtgctga actaacaaga gggtacttcc ttgaacataa tgaggccaag 240
tatacagaaa gaagagaaag agtatacact tgtttgcgaa taccaagaga attggaaaag 300
ctgatggttt ttggaatctt tctgtgcctg gatgcgtttt tgtatgtgtt caccctgctt 360
cctttaagag ttttcctggc actattcagg ctcctcactt tgccttgcta tggcttaagg 420
gacagacgtt tgcttcagcc tgcccaggtg tgtgacattt tgaagggtgt cattttggta 480
atctgctatt ttatgatgca ctatgttgac tactccatga tgtaccacct gataaggggg 540
cagtccgtca tcaagctcta catcatctac aacatgctgg aggtagctga tcgtctgttt 600
tcatcttttg gacaagacat attagatgct ctctattgga cagcaacaga gcctaaagaa 660
agaaaaagag cccacattgg ggtgattcct cactttttca tggctgttct ctatgtcttt 720
ttgcatgcaa ttcttataat gsttcaagca acaactctca atgtagcttt taactcacac 780
aacaagtett tgtetaetat catgatgtet aataatyttg ttgaaattaa aggaagtgtt 840
ttcaagaagt ttgaaaagaa caatctcttt caaatgtcaa atagcgatat taaggaacga 900
ttcacaaayt atgtgctytt actgatagtg tgtctaagaa acatggaaca gttttcttgg 960
aatccasatc atctctgggt gttgtttcca gatgtctgta tggtaattgc atcagaaatt 1020
gccgtggata ttgtaaaaca tgcctttatt actaaattca atgacattac tgcagatgtc 1080
tacagtgaat atagagccag tcttgctttt gaccttgtta gcagccgaca gaaaaatgca 1140
tacactgatt acagtgactc tgtagcacgg aggatgggct ttattcctct cccactagct 1200
gttttactca tcagagttgt aacaagctca attaaagtgc aaggaatcct gtcttatgcc 1260
tgtgtcatac tcttctattt tgggttgata tccctgaaag tacttaatag catcgtgctg 1320
ttggggaaat cgtgccagta tgtgaaggaa gccaaaatgg aagagaagct gtcgaatcct 1380
cccgcaacct gcactccagg caagccgtcc agtaaatcac agaacaaatg taaaccctct 1440
caaggcottt ccacagaaga aaacctgtot gootcoatca ccaaacaacc tattoatcaa 1500
aaggaaaata tcataccatt acttgtgaca agcaattctg atcagttttt gacaactcca 1560
gatggtgacg agaaggacat aacgcaggac aattctgaat taaaacacag atcctcaaag 1620
aaagatttgt tagagataga caggttcaca atttgtggaa accgaattga ctgaatctgt 1680
ggcttcatgc gctgaagaag ctgggtcctg gggcaacaag tgctgtgttg ccaggacaaa 1740
tagatgctaa acatggcact taaatattta tttaaaaact taaattatta ttggcaagca 1800
gcgacctccg gccttgactg tctgggaagc ttgatggatt ataaaacttc ctcctgcctg 1920
gccaagcagc agcatcattt ccaggaccca acaaaggcaa catcaaaatc tgttttgctt 1980
tgtcagtctg ggcttccaga atgttgaatt tgcctcaagg cctcttcagt ataaggaaat 2040
acctggaaaa ctgtgaaact tttaccacga cgtaatcttt ccagtctcat actattttca 2100
caaacagttt tcaaacgtta cttcatctgc caaagcatta aaaaaattaa acataagtca 2160
agataaatgt tettaccace agaataacce ttaaagatgt atettaatta ateagaataa 2220
aaggctacct taaataagac atgatgaata gtagcatttt gtagggttaa aaaaaaaatg 2280
ctaaactagt ttatttatta aaaaaataat taatgaaggc tatgcattac tgggaaaaat 2340
ccttcataat ttttcagttt actctttaaa gcaaaatgtg agctgtatgt catttaattg 2400
gtggataaaa caaatttcct tacaaaaggg cactttttac accaaggaag cagagcagtg 2460
ttaactttaa ggtatactta actgattttg ctttaaaact aattacytcc mtaaattatt 2520
acmgctaaag ggttycgrtg ttggarccgg gcyggaaaat tgtccat
                                                                 2567
```

```
<210> 168
 <211> 2324
 <212> DNA
 <213> Homo sapiens
 <400> 168
 eccaegegte eggteettee ggtategegt tgeteagggg etttteaace etetgteagt 60
 cggcgatcgc aagcaggctc ttctaagttc ccgacgcctc ttggcccgga aaactccggg 120
 aaccccacac tgctttcctc tgcccagccc gagactcggg tcagttactg gacgaaactg 180
 ctctcccagc teettgegee geteecegga ttgetteaga aggtgetaat ttggagecaa 240
 cttttcggtg gaatgtttcc gaccagatgg ctagattttg ctggagtcta cagcgccctg 300
 agagecetga agggaeggga gaaaceagee geceeeacag egeagaaate tttgagtteg 360
 ctgcagctcg actcctcaga cccctcggtc accagtcccc ttgattggct agaggagggg 420
 atccactggc aatactcgcc cccagaccta aaattggagc ttaaggccaa gggaagtgct 480
 ttggaccctg cagcacaggc ttttctctta gagcagcagc tgtggggagt ggagctgttg 540
 cccagtagcc ttcaatcccg tctgtactct aaccgggaac ttggctcttc gccctctggg 600
 cttctaaaca ttcaacgcat agacaatttc agtgtggtat cctatttgct gaacccttcc 660
 tacctggact gctttcctag gctagaagtc agctatcaga acagtgatgg aaatagcgag 720
 gtagtcggct tccagacact aaccccagag agcagctgcc tgagagagga ccattgtcat 780
 ccccagccgy tgartgcaga actcattccg gsctcgtggc agggatgtcc acctctttct 840
 acggaaggcc taccagaaat tcaccatctt cgcatgaaac ggctggaatt ccttcaacag 900
 gctagcaagg ggcaagatwt acccaccect gaccaggata atggctaeca cagcetggag 960
 gaggaacaca gccttctccg gatggatcca aaacactgca gagataaccc aacacagttt 1020
gttcctgctg ctggagacat tcctggaaac acccaggaat ccactgaaga aaaaatagaa 1080
ttattaacta cagaggttcc acttgctttg gaagaagaga gcccttctga gggctgtcca 1140
tctagtgaga tacctatgga aaaggagcct ggagagggcc gaataagtgt agttgattac 1200
tratacrtag aaggtgacrt trecatttet geragacrag ettgtagtaa raaactgata 1260
gattatattt tgggaggtgc atccagtgac ctggaaacaa gttctgatcc agaaggtgag 1320
gattgggatg aggaagctga ggatgatggt tttgatagtg atagctcact gtcagactca 1380
gacettgaac aagaceetga agggetteac etttggaact etttetgeag tgtagateet 1440
tataatcccc agaactttac agcaacaatt cagactgctg ccagaattgt tcctgaagag 1500
ccttctgatt cagagaagga tttgtctggc aagtctgatc tagagaattc ctcccagtct 1560
ggaagcette etgagaceee tgageatagt tetggggagg aagatgaetg ggaatetagt 1620
gcagatgaag cagagagtet caaactgtgg aactcattet gtaattetga tgacccetac 1680
aaccetttaa attttaagge teetttteaa acateagggg aaaatgagaa aggetgtegt 1740
gactcaaaga coccatotga gtocattgtg gocatttotg agtgtcacac ottactttot 1800
tgtaaggtgc agctgttggg gagccaagaa agtgaatgtc cagactcggt acagcgtgac 1860
gttctttctg gaggaagaca cacacatgtc aaaagaaaaa aggtaacctt ccttgaagaa 1920
gttactgagt attatataag tggtgatgag gatcgcaaag gaccatggga agaatttgca 1980
agggatggat gcaggttcca gaaacgaatt caagaaacag aagatgctat tggatattgc 2040
ttgacatttg aacacagaga aagaatgttt aatagactcc agggaacatg cttcaaagga 2100
cttaatgttc tcaagcaatg ttgagttggc agcctgtagt cctagctagc atacactacc 2160
tottacctga gaggtgtctt ttaaaaacaa atottggcag ctgtcctttg acatttttt 2220
tttagrggaa tgtaactggm ctrgtaattt ttttttttgc aacatatccc cactccagaa 2280
acattccagg tttgaagcca gccctggata atgaaggatg aact
                                                                  2324
<210> 169
<211> 1784
<212> DNA
```

```
<220>
 <221> misc feature
 <222> (200)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (215)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (1759)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (1778)
<223> n equals a,t,g, or c
<400> 169
gagaattacc ttcagctgta tcaattacag tacacaggaa ttgttacgat ttcctaaact 60
tcatgatgcc atagttgaag tggtgacttg tcttcttcgt aaaaggttgc ctgttacaaa 120
tgaaatggtc cataacttag tggcaattga actggcttat atcaacacaa aacatccaga 180
ctttgctgat gcttgtgggn taatgaacaa taatntagag gaacaaagga gaaacaggct 240
agccagagaa ttaccttcag ctgtatcacg agacaaggtt gcatctggag gtggtggggt 300
tggagatggt gttcaagaac caaccacagg caactggaga ggaatgctga aaacttcaaa 360
agctgaagag ttattagcag aagaaaaatc aaaacccatt ccaattatgc cagccagtcc 420
acaaaaaggt catgccgtga acctgctaga tgtgccagtt cctgttgcac gaaaactatc 480
tgctcgggaa cagcgagatt gtgaggttat tgaacgactc attaaatcat attttctcat 540
tgtcagaaag aatattcaag acagtgtgcc aaaggcagta atgcattttt tggttaatca 600
tgtgaaagac actcttcaga gtgagctagt aggccagctg tataaatcat ccttattgga 660
tgatcttctg acagaatctg aggacatggc acagcgcagg aaagaagcag ctgatatgct 720
aaaggcatta caaggagcca gtcaaattat tgctgaaatc cgggagactc atctttggtg 780
aagagaacta tgtaatactg agactttgtt gactcaaaac ttgctagtta ctgcctacct 840
gagtagaatc ttatttatga actcctgtgt attgcaatgg tatgaatctg ctcatgtgga 900
gactggctat aaactgaaaa gtgtattcca aattgcagaa cacatcacac atttaatcca 960
aataataaat ggctgtttct aaagtttccc agtatatata aaatacatca agtctgtctt 1020
gtgacagttt catctgaact taacttaaaa acaactgtta atgttctagt tgtgcaaagc 1080
agtttgcctg tggataagat gacctgtgta ataatctttg ttagtagtct taaagctgct 1140
gccatagtcc tccaagaaga aagcaccaag acaacatttc atatgactat aatgcatgta 1200
ctatataagc tgatctggct ttgaaagatg tgagttggca agttcctcac atagagtcat 1260
tgtattccac ctgtccttca atttagtttt ttctgagctt ctttgcagcc tttgatgtgt 1320
ttttaagaaa gctgaatgca caagaggatc tgtgacactg acatggctgt ggtgtgcata 1380
ctgtgtagtt acatagccct tccaattctg ggtccatttg cactagcaaa ttaaaatatg 1440
ctttgattca tacttaaacc tgaaagcagg aatgcctaca ttaattccta cattaaaaac 1500
agccatctac ccttgattat ctagwaagac ttggtaatga tggtcagttc cttttagatt 1560
tcagaaaatc aaatgatgac ctaaatttcc cttaatttgc aaatacagta gtaattaagg 1620
tacatctcta aagtggagca cttacaccag gctctaagat tcactttgag gtggaactta 1680
aaaccagtgt actgtatgta tgcattggta atagctactt tkgcttcata gcttccatac 1740
caacmaaata tattrttna gratagtatg aaagtcangg gagg
                                                                  1784
```

```
<210> 170
 <211> 1296
 <212> DNA
 <213> Homo sapiens
 <220>
 <221> misc feature
 <222> (1261)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (1276)
<223> n equals a,t,g, or c
<400> 170
ggcggtgcag aggcggcagg aagatggagt tggggagttg cctggagggc gggagggagg 60
cggcggagga agagggcgag cctgaggtga aaaagcggcg acttctgtgt gtggagtttg 120
cctcggtcgc aagctgcgat gccgcagtgg ctcagtgctt cctggccgag aacgactggg 180
agatggaaag ggctctgaac tectactteg ageeteeggt ggaggagage geettggaac 240
geegaeetga aaccatetet gageecaaga eetatgttga eetaaccaat gaagaaacaa 300
ctgattccac cacttctaaa atcagcccat ctgaagatac tcagcaagaa aatggcagca 360
tgttctctct cattacctgg aatattgatg gattagatct aaacaatctg tcagagaggg 420
ctcgaggggt gtgttcctac ttagctttgt acagcccaga tgtgatattt ctacaggaag 480
ttattccccc atattatagc tacctaaaga agagatcaag taattatgag attattacag 540
gtcatgaaga aggakatttc acagctataa tgttgaagaa atcaagagtg aaattaaaaa 600
gccaagagat tattcctttt ccaagtacca aaatgatgag aaacctttta tgtgtgcatg 660
tgaaygtgtc aggaaatgag ctttgcctta tgacatccca tttggagagc accagagggc 720
atgctgcgga acgaatgaat cagttaaaaa tggttttaaa gaaaatgcaa gaggctccag 780
agtcagctac agttatattt gcaggagata caaatctaag ggatcgagag gttaccagat 840
gtggtggttt acccaacaac attgtggatg tctgggagtt tttggggyaaa cctaaacatt 900
gccagtatac atgggataca caaatgaact ctaatcttgg aataactgct gcttgtaaac 960
ttcgttttga tcgaatattt ttcagagcag cagcagaaga gggacacatt attccccgaa 1020
gtttggacct tettggatta gaaaaactgg actgtggtag attteetagt gateactggg 1080
gtcttctgtg caacttagat ataatattgt aaaatgcttt tcaagtgtgg gttttgccct 1140
gattgttgca aatacaattt ccaccttctg gaaaggtagg tttgctgtgg aggaaataat 1200
gwactagatc attgtcacag aaaaaccaac tatgatttat ggkkgtgttt tcmccaryat 1260
nagacggaaa gacconcccc ttcttccccc cccct
                                                                   1296
<210> 171
<211> 1897
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (952)
<223> n equals a,t,g, or c
<400> 171
```

```
tggtttctta taaccctact ccacgtctgg atgtgtctag tccgaatgaa gcaggaaggc 120
cggagtggga agtacatgtg tcgtatcata gttcatttta tgtgggagga tgttcagcag 180
cgcgcagagt catgggggtt aatccctata tcctgaagaa gaacatgatc ctcatgacaa 240
atcatttcta tgcagcgatc ttgggatatg atgaggggat cctttcagat gatcatgggc 300
tggccgctgc cctctggaga accttcttca accggaaatg tgaagaccct cgacatcttg 360
aattgctggt agagtatgtg aggaaacaga tacagtacct ggactccatg aacggggagg 420
atctgcttct gacaggggag gtgagctggc gccctctagt ggagaagaat cctcagagca 480
teetgaagee ceatteteeg aettaeaaeg aegagggaet ttgatggget gggeeteege 540
acggcccgcc agctggcttc gaggaacctc caggagagaa gtgcctgttg gtccaggacc 600
ctgcagaaag tggcctgaac tgacctctga acagcatctg tcaaatacct ggccccattt 660
gtgttgagtt tcctcttagt gtgcccagga gtctgatctg ctggggtaca gggctgggag 720
aacccctagc tetecegggg tgteetetee ettaggggaa geeeegagtg agagteeeee 780
agcacacact ccccaaccc ctccagcaac tacatgtgac tgatagcttt tcccaaaaggc 840
caaggaaggg atggtgtagg ttcaaaaggg aaacccccca gggcctgctg tggcctagga 900
gcagattgta atgctgccga gtccggtcgg tgaccacgcg ttgtccctcg gntttcagcc 960
atggggttga gttggccatt aaaagaaaca gagacttctc tctgccatgg cccttcttta 1020
ttccagggac ttagaaactt gcctgagatg gtggacgcag taatgagggc accgcgcast 1080
cagttagaga cggagaaagg gaagaggctg ggatggtctc tgctgctctt gcctctagtt 1140
catggagatg tgtctctgtt caggccaaga tacagccagc caggcctgtc gtctgggacc 1200
caggaggeet etgatgacea agggetttea cateetaagt catttggaag gaggeettga 1260
gaacaaagtc acctttgtca ctcccagtga actgaatgag gaacatgctg tctcctgtct 1320
tggcctcccc tttcatgaga tactggggag aagagaacat tcctcctggc ttagttgtag 1380
cagacccaga cetgtgeeca getttggtee ecetteecaa ettetgaage aegtgetgea 1440
gagccacett ggtetgagea cetgaggace ageceeteet ceetcagtge gggteatete 1500
ttgggggatt ttcttaaagt gaagaaaggg ggtggggaac catattgccc ctccctcccc 1560
catcaaactt ccttcattta acttgctata aaatgagtca tataaagaaa ctctatatgg 1620
gtgaggtata tcccacttct gtgaaaacat tacaaatcaa accgcttctc tcagtttatt 1680
taagatgctt ttgttgcgag cggagctcta gagtgaagcc tcctgtgtgt gtgtgagata 1740
ataacacctt gtaactcatt acagctgggc actatttaca taaaccagag ctgagccagg 1800
caggaatttg ctgattaatt tatttttaat ggagtgaagt ataccatgca ccaaaataaa 1860
ctttactgtg tgtacctaaa aaaaaaaaa aaaaaaa
                                                                1897
```

<210> 172

<211> 1723

<212> DNA

<213> Homo sapiens

<400> 172

cggggagttc acctccgcc gtcacctct ccccttgtcg cctaggtcca cccgagccc 60 ctccccggg ccgccccga gcacgaagtt ggcgggagcc tataaaagct ggtgccggcg 120 cgacccgsgg acacacagtg caggcgcca agccgccgc gccagatcgg tgccgattcc 180 tgccctgcc cgaccgcag cgcgaccatg tcccatcact gggggtacgg caaacacaac 240 ggacctgagc actggcataa ggacttccc attgccaagg gagagcgcca gtccctgtt 300 gacatcgaca ctcatacagc caagtatgac ccttccctga agcccctgtc tgtttcctat 360 gatcaagcaa cttccctgag gatcctcaac aatggtcatg ctttcaacgt ggagtttgat 420 gactctcagg acaagcagt gctcaaggga ggaccctgg atggcactta cagattgatt 480 cagtttcact tcactgggg ttcactggt ggacaaggtt cagagcatac tgtggataaa 540 aagaaatatg ctgcagaact tcacttggt cactggaaca ccaaatatgg ggattttggc 600 gctaaaccgg gccttcagaa agttgttgat gtgctggatt ccattaaaac aaagggcaag 720

```
agtgctgact tcactaactt cgatcctcgt qqcctccttc ctgaatccct ggattactgg 780
acctacccag geteactgac caccetect ettetggaat gtgtgacetg gattgtgete 840
aaggaaccca tcagcgtcag cagcgagcag gtgttgaaat tccgtaaact taacttcaat 900
ggggagggtg aacccgaaga actgatggtg gacaactggc gcccagctca gccactgaag 960
aacaggcaaa tcaaagcttc cttcaaataa gatggtccca tagtctgtat ccaaataatg 1020
aatcttcggg tgtttccctt tagctaagca cagatctacc ttggtgattt ggaccctggt 1080
tgctttgtgt ctagttttct agacccttca tctcttactt gatagactta ctaataaaat 1140
gtgaagacta gaccaattgt catgcttgac acaactgctg tggctggttg gtgctttgtt 1200
tatggtagta gtttttctgt aacacagaat ataggataag aaataagaat aaagtacctt 1260
gactttgttc acaqcatgta qqgtgatgaq cactcacaat tgttgactaa aatgctgctt 1320
ttaaaacata ggaaagtaga atggttgagt gcaaatccat agcacaagat aaattgagct 1380
agttaaggca aatcaggtaa aatagtcatg attctatgta atgtaaacca gaaaaaataa 1440
atgttcatga tttcaagatg ttatattaaa gaaaaacttt aaaaattatt atatatttat 1500
agcaaagtta tottaaatat gaattotgtt gtaatttaat gaottttgaa ttacagagat 1560
ataaatgaag tattatctgt aaaaattgtt ataattagag ttgtgataca gagtatattt 1620
ccattcagac aatatatcat aacttaataa atattgtatt ttagatatat tctctaataa 1680
                                                               1723
```

<210> 173 <211> 1416

<212> DNA

<213> Homo sapiens

<400> 173

ccagtagctt ggaaagtaga gatgactaat gttttagcct tttcttggag aaaaggaaga 60 actittettg aatattitea cagatgattg tgattgettt aaatgacete tgtggcaatt 120 taaattagat ggatttaatc tcagtaatgt gctggtcgca taaatgtcat gttttaatag 180 gaaaagttac ttgtaaatct ttagaccttt gttgtcactt aggctgggga gtcactaccc 240 tatttggcat cttactagtt ggggggacct tttccgtgta cagtgatggg acttttgtga 300 cctttactct cactatgcaa tagagggttt catgtagtta atctgacatg tcaaaattgg 360 qaaqactgta acctttttt tttttttta aqatttctct tttttgtgtc cctcaatact 420 tagcagatgt tcatttggtg gaaattctta ttacttacat gaatgagttt gaatttagtg 480 gcaaggaaga aaaaaaaac tcaaattatt gttttaaaag aagaaaactt gcaaagtaca 540 taagtatttt ttaaaaatca atcgaacaga aaggaatgca tgctgttttt caatggctta 600 gacatgettt ttatteactg actagtatte acttttttae aacttgtate aaaacaaatg 660 atctttgttt ttgtcacagg caaaaacagg ttgacactgg tgggttggct ttattaatta 720 attititit tattaggitt totttaataa igitaaatti otaaattata goataigitt 780 tagttaattc tgaaatcagt tacttcattt gttaatttat ccctcatatc atgaatattg 840 ttttttaaat kttcctatac maatttgcat cacttctttt cttacagctt ttgcagttwa 900 tatattotaa acttgaaaat gtggtatoaa toaataatag aagtatoact ggaggattta 960 tttagctttg tatttcttaa ttttagtcct agctactaaa gtatgtaagc cttaaagttt 1020 aaaatgtttt tottaaatta gotttataca caaacatttt catttacttt atgaaatggg 1080 aggagatagt ccactgtgct tatgtttttt tgtttaattt ctatattctg aagcagtgca 1140 gatatagggt atgctaatca agtgagcaag gtggaacatg tacaatataa ggagaagctg 1200 taaaaatcac agtataaaat tatgaagttt ggtaactgta aaatgtactg tatttatatg 1260 taactctcat tctaaaagtt gccacaaaag ctgaattgga agcttcatgt ctgcatgaaa 1320 tttcctatat ttttaatgtg tatgatgaaa ttaatttttc ttgaatatta aagtctgcca 1380 1416 attgctatga aamaaaaaaa aaaaaaaaa actcga

<210> 174

<211> 1956

```
<212> DNA
 <213> Homo sapiens
 <220>
 <221> misc feature
 <222> (1)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (4)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (6)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (24)
<223> n equals a,t,g, or c
<400> 174
nctnantaag ggaacaaagc tggngctcca ccgcggtgcc gaccgctcta gaactagtgg 60
atcccccggg ctgcaggaat tcggcacgag gatcaaccgg atttttagga tatgcaatct 120
aacaagacca caggaaggtt atctgatggt gcaacagttt cagtacctag gatgggcttc 180
tcatcgagaa gtgcctggtt ccaaaaggtc attcttgaaa ctgatacttc aggtggaaaa 240
gtggcaggag gaatgcgagg aaggggaagg ccggacgatt atccactgcc taaatggtgg 300
cgggcgaagt ggcatgttct gtgctatagg catcgttgtt gaaatggtga aacgggcaaa 360
atgttgtcga tgttttccat gcagtaaagr cactgaggga acagcaagcc aaacatggtg 420
ggaagccccg gagcaatacc gtttctgcta tgatgtagct ttggagtacc tgggaatcat 480
cttagttggg tgagactctt taaagtgcat ccatgaagra acctgtccat ctattgagcc 540
agcagctgtt gtacctgtta cacttgtgca gaaagatttt aatgtggggg gtggqagact 600
tttacatttg agaggtaaaa gtatttttt tatgaagttg tgtatcttaa taaaaaggac 660
tgaattagtt tttattacta tattaaagca tcaacatttc atgccacata aattatatt 720
aataagaacc agattgaaat gagaacgtat tggtgtttgt acagtgaaca tgccaccttt 780
tttctcatgg tttcagtaga gcagctacca catgttgcat gagttcatac tttctacqtq 840
agctgtgcaa attcatagta aagttcgttt tttatatgtt tccagtgtag cagatctcta 960
tataaatata taaatatata taactggctt attttctttt aatgtgcaat gatggctgga 1020
tcattttaaa aaaaaagggt tctttttaga aaataacata agccaaagac tcaagtgtaa 1080
atatgtetat atggagaaag cacattatat ttattggtta ettacattee ttttttgatg 1140
gctaaaatac taccaccaca caatcatctt ttttttcctg aagaaagctt tttctttagc 1200
taaaatcaat tgtaaacgat ttttgtagat tattttttgt atgttttagt gtaagtagaa 1260
gataaacttt ttattcataa accaggaagc aatgttcttt atagtgattc tcttgtgtac 1320
atgcttgtga attaaatttg tgtaaaatcc cttggcaatt gggtctttta atataggacc 1380
aaattaaaac attttgctga atatgtatag tttttcacaa tttcattagg taaataatgg 1440
tttggtgatc atacatgaga aatgtacaca ttaaaaggcc ttgctgacaa cttgcacaat 1500
gttgaacata gcctttaagc atcatttaaa ttttaaagga atggagtttt tcagcctgtg 1560
gcccagcact ggtcaagaaa acaagatggc aacatatatg ctttcagggt caaatttgag 1620
```

```
caaactgtaa actgtcaggg tgataaaatg tttctcttga tgtttacatg cacaagcttt 1680
 gcgttctgac tataaaaagt gtgaacaaat caatgccaga ttcctgtttt gcgcattgtc 1740
 atgggattet taagtgaace tttetaaatg tggtettgtt cacatgetee acgtagetgt 1800
 aacttcacat catcagettg cagtttgtaa ttgactaaag cattecagtg teetetttet 1860
 agattgccag ctcatgacat ggtgcttata aaqatttaat taaagtaaga atgaaataaa 1920
 gtttttataa ttataaaaaa aaaaaaaaa aaactc
                                                                 1956
<210> 175
<211> 1689
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (1688)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (1689)
<223> n equals a,t,g, or c
<400> 175
ggctgcaggt cgacactagt ggatccaaag aattcggcas akctcttatt cctcactttc 60
caccccgta ttttgtaatg accatgagca atgtttttac tttttgtata atggggtggg 120
gtggagtggg ggcttctgag agtcagcctg aggtctttag aggaccagct attgtagcac 180
cttggatact tgaagtttaa tgctcagttg ggtcgggtgg cagttgactt ggtggctggc 240
atgttcagca gtgcctgggg ccctgtttct gggcagcctt tgaggatttt ctatgatatt 300
gaatgacagt tttaagtggc aactcaggcc cagctcatgc ccttttttgc ctggacatgt 360
gctattttta ttcacttata tatcaattac ttgtaagggt taaactttca aacaggaagt 420
atattgggac aaaagggctc ttggggatta gatatccctt taatctgtga ccattgggca 480
aaaaatttto otgoagoaaa agtotgaggo tgttgggaco atttttgcag otttaatoot 540
tagcctcttt tgactgtata tttgtgttta aaatgcagag ctcaactgaa tatttccttt 600
tttgttttgt tttgttttgt tttaagaagt aggttgtttt cctgaaccgt aaacttgtat 660
cattttaact tgcacaaagg aagtotgtto ttggtattgc tottgcactt gggttttttg 720
ttattgtttt gtgtggattt tttaaagctt ttctgttcac cctcctgcca ggaaaatccc 780
agaaagetta atgataceee aaaatgatta caceeaggga ggaaaaaaaag gagegettte 840
tagggtcaga atcgtggaga gaatactcag aaatgaacct ctttaaagcc ttgcaggaat 900
gagtcactct tacttaatga aatgttaaag ccaattaaaa agcatgctgt gatgcccagc 960
ttccctttcc acagggtgca tgcgtctcct gctggtgaat cacatgcggc aagaggcaac 1020
tggctccaca gcctgggatg ctgccgtacc aagaggaaag aagcagcaaa atgcctttac 1080
gttgttctaa acccccgacg cataaagtgt agaggaggga tggccaaggg tggqtqqtaq 1140
aaagtgtgtt caggctgaca ctggcaatga gtacagataa tttcactttc ctcttccaqq 1200
ggcaaaggct gatggcctct acctttgtat ccaggagaaa ctgcagagca gccctgtgac 1260
tttacaaaat atgctacctc aaagtgctac cgataaacct ttctaattgt aagkscctta 1320
ctaagggcac atgtcttaat caaagttagt tttttgtttt ctggtttgtt ttttttttt 1380
tgtatattga tgaatgagat cttacctatt aaatatatta ttggattatg gttcctgaag 1440
gtcattagag tgtgtgtgtg tgtgtgtgt tgtgtgtgtg ttttatgact taaatatctt 1500
tacgtgtgtt ttttagagct tggttcttta aagatttgga gaagatatgt aaattaccaa 1560
ggcacttggt ttttctgttt tatatactaa taatcagggc ctaagttaaa taaaaatatg 1620
```

1689

aaaaaaann

```
<210> 176
<211> 1016
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (895)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (928)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (970)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (992)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (1001)
<223> n equals a,t,g, or c
<400> 176
taagagagct ttgcaaaaaa aaaaagaaaa aagaaaaaaa aaaaaccacg tttctttgtt 60
gagctgtgtc ttgaaggcaa aagaaaaaaa atttctacag tagtctttct tgtttctagt 120
tgagctgcgt gcgtgaatgc ttatttctt ttgtttatga taatttcact taactttaaa 180
gacatatttg cacaaaacct ttgtttaaag atctgcaata ttatatatat aaatatatat 240
aagataagag aaactgtatg tgcgagggca ggagtatttt tgtattagaa gaggcctatt 300
aaaaaaaaa gttgttttct gaactagaag aggaaaaaaa tggcaatttt tgagtgccaa 360
gtcagaaagt gtgtattacc ttgtaaagaa aaaaattaca aagcaggggt ttagagttat 420
ttatataaat qttgagattt tgcactattt tttaatataa atatgtcagt gcttgcttga 480
tggaaacttc tcttgtgtct gttgagactt taagggagaa atgtcggaat ttcagagtcg 540
cctgacggca qagggtgagc ccccgtggag tctgcagaga ggccttggcc aggagcggcg 600
ggctttcccg aggggccact gtccctgcag agtggatgct tctgcctagt gacaggttat 660
caccacgtta tatatteect accgaaggag acacetttte ecceetgace cagaacagee 720
tttaaatcac aagcaaaata ggaaagttaa ccacggaggc accgagttcc aggtagtggt 780
tttgcctttc ccaaaaatga aaataaactg ttaccgaagg aattagtttt tcctcttctt 840
ttttccaact gtgaaggtcc ccgtggggtg gagcatggtg cccctcacaa gccgnacggc 900
tggtgcccgg gctaccaggg acatgccnga gggctcgatg acttgtctct gcagggcgct 960
ttggtggtgn ttaactggct aaaggttacc gntgaaggca ngtgcggtaa ctggcc
```

WO 00/55351 PCT/US00/05883

```
<210> 177
 <211> 1364
 <212> DNA
 <213> Homo sapiens
 <400> 177
 gaatcccact cocttctccc acttgttaat tagttacata cttttttgta attgtttatt 60
 tggttgctgt ctccctctca agaatgcagg gaccatgtct gcattctgca gtaatcacta 120
 ctgcacaccc agaatctatt acagatcctg gcatgtagct gatgcataaa tatttgttga 180
 atgaaagtct gtacattgta tttatgctat tggtattgct atgacctgaa actaaaagga 240
gttgtggaaa agatttctta tggaacagaa atatcccttt tgattaatat cacaatctcg 300
 taaattgaga aaacaaawaa tatatactac tggagcattc atgtatagtt ggagattatg 360
actcatttat tggtgtgttt ttggactcag aacaaagatg agggaatatt ccttaaagct 420
ctgtattgaa ataacgaaaa gcagtcacat tttaataata gaagcttcct agcttactct 480
ttctgtaatc ttcttttcct aaatgtaaga gagcctcata attatgaggc ttattactag 540
agtaaggctg tcaaaggcag caaaatgtct ttctgtttgg aagaataaca taaacttgac 600
atgtatggtg ggggacagaa ggtttcaaaa gtttaagaat ctgtgttgtc ttaacaaata 660
gatgcttctc aaggasstta cgytagtggt tactctgtcc agtcagggtt ttttcttctt 720
taacttgggt tcatttcctg atggcacaca tgaagtttgg atcatatggt ttgactttag 780
ctatggtcct tagctatggg gagcagcatc agcgacctgt gacatgtaaa ttaaaaatac 840
aatgccaggg cccttcccca gcccctctga tagagaacct cttggccatc tgtattttta 900
gatgttccag gttagtctga ttaacaccct tggttaagaa ccattgggag gatctgattg 960
CCagtttaag gggaccttca agcctgtagg tctttatagt taaaaaaaaa aaaagatttt 1020
aaaaatcatg catatgttgt ggctgaawtc tggtttagca catactgctt ttaatggcct 1080
gaaatgtttt tcccaaataa attstcttgt tatagctttc atgtgtgatt tggtccagct 1140
tcttgttttg aagatactta cgggggggaa cactttgtga tttctcttag taacatatta 1200
acccacttaa aaaccctttc tattacaggt cttcacattt aggcttaatg tgcttaattc 1260
aaatgtaaaa atacacctgc ctttgttctc agtgaaagta tgtaataaat aaatgagggg 1320
ttggcaaact actgcccacc atctgttttt ttatggccta tgaa
                                                                   1364
<210> 178
<211> 740
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (38)
<223> n equals a,t,q, or c
<220>
<221> misc feature
<222> (171)
<223> n equals a,t,g, or c
<400> 178
tggctgggac tccaggcgca taccaccatg actggctnat ttttgtgttt ttagtagaga 60
cggggtttca ccatgttggc caggctggtc ttgaacttct ggccccaagt catctgcctg 120
cctcagcctc ccaaggtgct gggattacaa gtgtgagcca ctgtgtacag nctttgtgtt 180
aacttacttt gaattagccc cttattccaa agctgcctcc tgaaaggasg cttcctaaaa 240
99t9ttgctt tggggtaaat aagaggtgct ggtgaagtga gactagcttg cgcatctctc 300
```

WO 00/55351

```
tgccatgaag gaaactagct ccgcagacgt tttactaacc acagcagacc ccctccttga 360
 ggaacccaga agggcagaga gcatcagatg aaatcaactg ctgagagagg gaagtgagtg 420
 ctgtgttggc accgctgcca gaaactcttg agaatgagca tcgtgtgcca cttatccact 480
 gcttgccgac ttcagtagca agagcctcca gaatgctcat ggataaacat catctttgtg 540
 gccacacatt gttttatgag ctgagtcatc agactggctg gctccttaaa tgctgctgtg 600
 tgattctcta ggcagcagaa aacaaggaga gaagatatga agtgtatctc atcgagcttt 660
 gtagagggcc agtatcgatt caccaaaggt gatgggggat ttaccattat ggagtttgct 720
 tgtgataaaa aattattgat
                                                                 740
<210> 179
<211> 1410
<212> DNA
<213> Homo sapiens
<400> 179
gaaaatgtat ataataggca aggaaagaaa tacagtactg tttctggacc cttataaaat 60
cctgtgcaat agacacatac atgtcacatt tagctqtqct cagaagggct atcatcaycc 120
tacaactcac attagagaac atcctggctt ttgagcactt ttcaaacaat caagttgact 180
cacgtgggtc ctgaggcctg cagcacgtcg gatgctaccc cactatgaca gaggattgtg 240
gtcacaactt gatggctgcg aagacctacc ctccgttttt ctactagata ggaggatggt 300
agaagtttgg ctgctgtcat aacatccaga gcyttgtcgt atttggcaca cagcagaggc 360
ccagatatta gaaaggctct attccaataa actatgagga ctgccttatg gatgatttaa 420
gtgtctcact aaagcatgaa atgtgaattt ttattgttgt acatacgatt taaggtattt 480
aaagtatttt cttctctgtg agaaggttta ttgttaatac aaggtataat aaaattatcg 540
caacccctct ccttccagta taaccagctg aagttgcaga tgttagatat ttttcataaa 600
caagttcgag tcaaagttga aaattcatag taagattgat atctataaaa tagatataaa 660
tttttaagag aaagaattta gtattatcaa agggataaag aaaaaaatac tatttaagat 720
gtgaaaatta cagtccaaaa tactgttctt tccaggctat gtataaaata catagtgaaa 780
attgtttagt gatattacat ttatttatcc agaaaactgt gatttcagga gaacctaaca 840
aattttttga agtctttaat aaataaccca taattgaagt gtataatata aaaaatttta 960
aaaatctaag cagcttattg tttctctgaa agtgtgtgta gttttacttt cctaaggaat 1020
taccaagaat atcctttaaa atttaaaagg atggcaagtt gcatcagaaa gctttatttt 1080
gagatgtaaa aagattccca aacgtggtta cattagccat tcatgtatgt cagaagtgca 1140
gaattggggc acttaatggt caccttgtaa cagttttgtg taactcccag tgatgctgta 1200
cacatatttg aagggtettt eteaaagaaa tattaageat gttttgttge teagtgtttt 1260
tgtgaattgc ttggttgtaa ttaaattctg agcctgatat tgatatggtt ttaagaagca 1320
gttgtaccaa gtgaaattat tttggagatt ataataaata tatacattca aaaaaaaaa 1380
aaaaaaaaa aaaaaaaaa aaraaaaaaa
                                                                 1410
<210> 180
<211> 1493
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (1328)
<223> n equals a,t,g, or c
<220>
```

```
<221> misc feature
<222> (1352)
<223> n equals a,t,q, or c
<220>
<221> misc feature
<222> (1376)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (1406)
<223> n equals a,t,q, or c
<220>
<221> misc feature
<222> (1436)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (1484)
<223> n equals a,t,g, or c
<400> 180
ggccaaatct tcccgggctg ctgtgggcaa caagatgttt gtcaagggtg cccctgaggg 60
cgtcatcgac cgctgtaact atgtgcgagt tggcaccacc cgggtgccac tgacggggcc 120
ggtgaaggaa aagatcatgg cggtgatcaa ggagtggggc actggccggg acaccctgcg 180
ctgcttggcc ctggccaccc gggacacccc cccgaagcga gaggaaatgg tcctggatga 240
ctctgccagg ttcctggagt atgagacgga cctgacattc gtgggtgtag tgggcatgct 300
ggaccetecg egeaaggagg teaegggete catecagetg tgeegtgaeg eegggateeg 360
ggtgatcatg atcactgggg acaacaaggg cacagccatt gccatctgcc ggcgaattgg 420
catctttggg gagaacgagg aggtggccga tcgcgcctac acgggccgag agttcgacga 480
cctgccctg gctgaacagc gggaagcctg ccgacgtgcc tgctgcttcg cccgtgtgga 540
gccctcgcac aagtccaaga ttgtggagta cctgcagtcc tacgatgaga tcacagccat 600
gacaggtgat ggcgtcaatg acgcccctgc cctgaagaag ctgagattgg cattgccatg 660
ggatctggca ctgccgtggc caagactgcc tctgagatgg tgctggctga cgacaacttc 720
tecaccateg taretgetgt ggaggargge egegecatet acaacaacat gaagcagtte 780
atcogctace teattteete caacgtggge gaggtggtet gtatetteet gacegetgee 840
ctggggctgc ctgaggccct gatcccqqtq caqctgctat gggtgaactt ggtgaccgac 900
gggctcccag ccacagccct gggcttcaac ccaccagacc tggacatcat ggaccgcccc 960
ccccggagcc ccaaggagcc cctcatcagt ggctggctct tcttccgcta catggcaatc 1020
gggggctatg tgggtgcagc caccgtggga gcagctgcct ggtggttcct gtacgctgag 1080
gatgggcctc atgtcaacta cagccagctg actcacttca tgcagtgcac cgaggacaac 1140
acceaetttg agggeataka etgtqaggte ttegaggeee eegageeeat gaeeatggee 1200
ctgtccgtgc tggtgaccat cgagatgtgc aatgcactga acagcctgtc cgaraaccag 1260
tccctgctgc ggaattgcma cccctggggt traacaattc ttgggctggc tgggsttcca 1320
ttcttggnct tcttccaatg ttcccctggc ancttccctc aattccctcc taatgnttga 1380
accecettg eeegaatgaa tetttnaagg etteegggge eettggaace tteaaneeaa 1440
gttgggttaa tggttcctcc aagattttca attggccagt taantggggg ttc
```

```
<210> 181
 <211> 2040
 <212> DNA
 <213> Homo sapiens
 <400> 181
 gcatgagctc atgcaagagg caggggatga gtgtgagccc gagtggtgtg atgccgagga 60
 cccactcttc atcctgtaca ccagtggctc cacaggcaaa cccaagggtg tggttcacac 120
 agttgggggc tacatgctct atgtagccac aaccttcaag tatgtgtttg acttccatgc 180
 agaggatgtg ttctggtgca cggcagacat tggttggatc actggtcatt cctacgtcac 240
 ggacgtgaac cgcctgtgga gcattgtgga caaatacaag gtgaccaagt tctacacagc 360
 acceacagee atcegtetge teatgaagtt tggagatgag cetgteacea ageatageeg 420
 ggcatccttg caggtgttag gcacagtggg tgaacccatc aaccctgagg cctggctatg 480
 gtaccaccgg gtggtaggtg cccagcgctg ccccatcgtg gacaccttct ggcaaacaga 540
gacaggtggc cacatgttga eteceettee tggtgecaca eccatgaaac eeggttetge 600
tactttccca ttctttggtg tagctcctgc aatcctgaat gagtccgggg aagagttgga 660
aggtgaagct gaaggttatc tggtgttcaa gcagccctgg ccagggatca tgcgcacagt 720
ctatgggaac cacgaacgct ttgagacaac ctactttaag aagtttcctg gatactatgt 780
tacaggagat ggctgccagc gggaccagga tggctattac tggatcactg gcaggattga 840
tgacatgctc aatgtatctg gacacctgct gagtacagca gaggtggagt cagcacttgt 900
ggaacatgag gctgttgcag aggcagctgt ggtgggccac cctcatcctg tgaagggtga 960
atgectetae tgetttgtea cettgtgtga tggecacaee tteageceea ageteaeega 1020
ggagctcaag aagcagatta gagaaaagat tggccccatt gccacaccag actacatcca 1080
gaatgcacct ggcttgccta aaacccgctc agggaaaatc atgaggcgag tgcttcggaa 1140
gattgctcag aatgaccatg acctcgggga catgtctact gtggctgacc catctgtcat 1200
cagtcacctc ttcagccacc gctgcctgac catccagtga acatgatcct gacctttacc 1260
taggatteet cetgeteeaa aetttgeeea teetetttge eeeeteagga gtgetgaggg 1320
ccagtgttga cccacactac cctcccttga ccagctgtct gggaccggaa accagctttg 1380
tctccaggta gagacaacat cctgtgactg ccaggcagaa aggacagggc ccaggtcagc 1440
ctcagtctgc tgtgcctcca gactgcagag ctctcagaac ccagaacaga gacgaaaagg 1500
ctacctctcc tacccaagtt aagtgttcaa aggggatgtg agggcctcca ctgaagcagg 1560
gaggcagctg tgtaatccta tgtcagctct cttaggaagc cccagtactt atattgggca 1620
tgcacttgcc cttaaaaaca atgatttgtg agtccaggaa caatttacta tttttaaaat 1680
attttgctgc ttctgttctg ggtctgaatt cccttttgtg ccagatgcca gtactgtctg 1740
cccattggct ccaggggctg tatgggcaga ttcagtctcc agagggtatt cagatcatct 1800
gcttctttga aggagtaaat gtgttttgtt cctagggcca gaggagcttg tcttccttgt 1860
cctctgttcc caccetecee tgaacagaac ccageecata agagacatte tcagatgaaa 1920
ctctgttttc ttgccccagt caggctcaag ccctgtggtt gtaggaataa agcctgtgat 1980
<210> 182
<211> 969
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (11)
<223> n equals a,t,g, or c
```

```
<220> ·
 <221> misc feature
 <222> (128)
 <223> n equals a,t,g, or c
 <400> 182
 agacagttct nattctcccc agggcaggga gcaggttatg accaggacta aggtcccaaa 60
 gtccccaccc tgaacccctc cctgctgttc caccgctccc tcatatccac ccctgcccca 120
 tetectgnae titiggicaeg etageatett etgetgatee tgaaattgta eeageggeaa 180
gatgtggcct ggaaggggac tttaagttct ccacaactgc cagcaatcct tccaccaggc 240
aaaacacatc atctaaggaa aagaagtgag gtttgcttag ggcgtggcag cttcggataa 300
acgcaggact cogcotggca goodgattto tocoggaaco totgotcago otggtgaaco 360
acacaggcca gcgctctgac atgcagaagg tgaccctggg cctgcttgtg ttcctggcag 420
gctttcctgt cctggacgcc aatgacctag aagataaaaa cagtcctttc tactatgact 480
ggcacagcct ccaggttggc gggctcatct gcgctggggt tctgtgcgcc atgggcatca 540
tcatcgtcat gagtgagtgg aggagctcgg gggagcaggc gggccggggc tggggctccc 600
ctcccctgac cactcagete tececaacag gtgcaaaatg caaatgcaag tttggccaga 660
agtccggtca ccatccaggg gagactccac ctctcatcac cccaggctca gcccaaagct 720
gatgaggaca gaccagctga aattgggtgg aggaccgttc tctgtcccca ggtcctgtct 780
ctgcacagaa acttgaactc caggatggaa ttcttcctcc tctgctggga ctcctttgca 840
tggcagggcc tcatctcacc tctcgcaaga gggtctcttt gttcaatttt ttttwatcta 900
aaaaaaaga
                                                                 969
<210> 183
<211> 1452
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (17)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (18)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (1430)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (1441)
<223> n equals a,t,q, or c
<400> 183
gtcgacccac gcgtccnncc acggtccggt ggggagaagc cgggaggact gggtgcgcct 60
```

```
gcagggatcg gaagccggtt ggggtgtgag aggttttctc gctctaggga gattcttcaa 120
 gcaatcacta tgtcaacaga cacaggtgtt tcccttcctt catatgagga agatcaggga 180
 tcaaaactca ttcgaaaagc taaagaggca ccattcgtac ccgttggaat agcgggtttt 240
 gcagcaattg ttgcatatgg attatataaa ctgaagagca ggggaaatac taaaatgtcc 300
 attcatctga tccacatgcg tgtggcagcc caaggctttg ttgtaggagc aatgactgtt 360
 ggtatgggct attccatgta tcgggaattc tgggcaaaac ctaagcctta gaagaagaga 420
 tgctgtcttg gtcttgttgg aggagcttgc tttagttaga tgtcttatta ttaaagttac 480
 ctattattgt tggaaataaa ctaatttgta tgggtttaga tggtaacatg gcattttgaa 540
 tattggcttc ctttcttgca ggcttgattt gcttggtgac cgaattacta gtgactagtt 600
 tactaactag gtcattcaag gaagtcaagt taacttaaac atgtcaccta aatgcacttg 660
 atggtgttga aatgtccacc ttcttaaatt tttaagatga acttagttct aaagaagata 720
 acaggccaat cctgaaggta ctccctgttt gctgcagaat gtcagatatt ttggatgttg 780
 cataagagtc ctatttgccc cagttaattc aacttttgtc tgcctgtttt gtggactggc 840
 tggctctgtt agaactctgt ccaaaaagtg catggaatat aacttgtaaa gcttcccaca 900
 attgacaata tatatgcatg tgtttaaacc aaatccagaa agcttaaaca atagagctgc 960
 ataatagtat ttattaaaga atcacaactg taaacatgag aataacttaa ggattctagt 1020
 ttagtttttt gtaattgcaa attatatttt tgctgctgat atattagaat aatttttaaa 1080
 tgtcatcttg aaatagaaat atgtatttta agcactcacg caaaggtaaa tgaacacgtt 1140
ttaaatgtgt gtgttgctaa ttttttccat aagaattgta aacattgaac tgaacaaatt 1200
acctataatg gatttggtta atgacttatg agcaagctgg tttggccaga cagtataccc 1260
aaacttttat ataatataca gaaggctatc acacttgtga aattctcttg tctaatctga 1320
atttgcattc catggtgtta acatggtata tgtattgtta ttaaagtaag tgacccatgt 1380
naaaaaaaa aa
                                                                 1452
<210> 184
<211> 2119
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (2090)
<223> n equals a,t,g, or c
<400> 184
aaattgaaac ttctaataaa aatgatatga ctatagatat attacatgct gatggtgaaa 60
gacctaatgt tctagaaaac ctagacaact caaaggaaaa gactgttgga tcagaagcag 120
caaaaactga agatacagtt ctctgcagca gtgatacaga tgaggagtgt ttaatcattk 180
wtacagaatg taaaaataat agtgatggaa agacagctgt tgtgggttct aacttaagtt 240
ccagaccage tagtecaaat tetteeteag gacaggette tgtaggaaac cagactaata 300
ctgcttgtwg tcctgaagag tcatgtgttt taaaaaaaacc tatcaaacga gtatataaaa 360
aatttgatcc agttggagag attttaaaaa tgcaggatga gctcttwaag ccaatttcca 420
gaaaagtacc agaattgccc ttaatgaatt tagaaaattc taaacagcct tctgtttctg 480
agcaattgtc tggtccttca gactcctcta gttggccgaa atctggatgg ccttctgcat 540
ttcagaagcc aaaaggacga ttgccatatg aacttcagga ctatgttgaa gatacatcgg 600
aatacctagc tcctcaggaa ggaaattttg tttataagtt atttagcctg caagacctgt 660
tgttactcgt acgctgcagt gtccagagga tagagacaag accacgttct aaaaaacgga 720
agawwatyag aagacaattt ccagtttatg tactaccaaa agtagagtat caagcttgtt 780
atggagttga agctctgact gaaagtgaac tttgtcgctt atggactgaa agtttattgc 840
```

attccaacag ctcattttat gttgggcata tcgatgcatt tacttcaaaa ctttttctac 900

```
tggaagaaat tacctcagaa gaattaaaag aaaagctttc agcactcaag atttccaatt 960
 tatttaacat cctccaacac attctaaaga aactaagtag cttgcaggag ggttcctact 1020
 tgttatctca tgcagcagaa gattcttcac tcctgattta taaggcctct gatggaaaag 1080
 ttactaggac agcatacaat ttgtataaaa cacattgcgg ccttcctggt gtaccttcca 1140
 gtctctcagt tccctgggtc ccattagatc ccagcctgtt attaccatat catatccatc 1200
atggaagaat accttgtact tttccaccga aatcactgga taccacaaca caacaaaaga 1260
 ttggtggaac gagaatgcct acacgcagcc acaggaatcc agtttccatg gaaaccaaaa 1320
gcagttgctt gcctgctcag caagttgaaa ctgaaggagt ggctccacat aaaagaaaaa 1380
taacttgagg actgtaccat ggaaaactaa atttaaaaaa mcagttataa cagtgtttaa 1440
tttagataag tttgagggaa aataatcagt aggcaagagg aacatttttc ctgtagtagc 1500
tagagtgcct tgaaaaaatg tgttggctat gtgaaggaat atttcaacta aaatggaatg 1560
gtatgctttt cacccttraa gtttgaggag gatcttgata tgttttaaca ttatcatggc 1620.
agggaaatat ataaagaaga aaaatatttt tacattaaac cttttctaaa aattgtaaat 1680
agaaaaataa tttggttttt tatcaagaac aacacttatc gttatgtatt gtgttagtta 1740
tattgccagt ctgttgcgac tgactcaaaa agttaaatgt tgccactgct gaagatgatt 1800
atgagcatcg caaactttgt ttctgaccca ttttgacagt ttttatatac tcctttaaaa 1860
tgatgaatgt tacaggttaa taaagttaat acctttaaaa acttggtgaa attccattac 1920
agaagccaaa aataaaaact ccctgcctct gaaaagtcag attactgact tcttgtttgg 1980
caaccatcag titigittaat aaaagaaaaa attiggiggi ataacatgit tgatgacaga 2040
tgcctctatc tctagattca agctgagtgt tgaaatacac tgctgaaagn aagagatagg 2100
tatgttttcc agaaaaaa
                                                                   2119
<210> 185
<211> 1325
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (21)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (1319)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (1320)
<223> n equals a,t,g, or c
<400> 185
atgactgggg agcgacccag ncacggcgct cccgggacag acgctggggg ccscggaatc 60
totocotgga tattggcact gaagtgtttg cocotggaco gggctctggt attcagaaac 120
agcgggagcc acggaagggc cgcctcatcg tgtgtggcca tgggacgctg gagcgggacg 180
gagtettetg tetecteage gatgateatg gtgeeteetg gegetaegga agtggggtea 240
9C99Catccc ctacggtcag cccaagcagg aaaatgattt caatcctgat gaatgccagc 300
cctatgaget eccagatgge teagtegtea teaatgeeeg aaaceagaac aactaceact 360
gccactgccg aattgtcctc cgcagctatg atgcctgtga tacactaagg ccccgtgatg 420
tgaccttcga ccctgagctc gtggaccctg tggtagctgc aggagctgta gtcaccagct 480
```

```
eeggeattgt ettettetee aacceageae atceagagtt eegagtgaae etgaeeetge 540
 gatggagctt cagcaatggt acctcatggc ggaaagagac agtccagcta tggccaggcc 600
 ccagtggcta ttcatccctg gcaaccctgg agggcagcat ggatggagag gagcaggccc 660
 cccagctcta cgtcctgtat gagaaaggcc ggaaccacta cacagagagc atctccgtgg 720
 ccaaaatcag tgtctatggg acactctgag ctgtgccact gccacagggg tattctgcct 780
 tcaggactct gccttcagga acacgggtct gtagagggtc tgctggagac gcctgaaaga 840
 cagttccatc ttcctttaga ctccagcctt ggcaaaatca ccttcccttt accagggaaa 900
 tracttrott taggartgaa agrtaggregt retererar aaaaaagter tgeetrate 960
 tgagaatact gtctttccat atggctaagt gtggccccac caccetetet gcctcccggg 1020
 acattgattg gtcctgtctt gggcaggtct agtgagctgt agaattgaat caatgtgaac 1080
 tcagggaact ggggaaggct gagcctcctc tttggtgttg cggtaagata accgacaggg 1140
 ctggtgaaag tccccagatg gcaggatatt tggtttcaga gtaaggacta ggtgcaccac 1200
 catgactgac tatcaatcaa aatgtttgta acttaaaaatt tttaatgaag gataatgaat 1260
 aaaaa
                                                                 1325
<210> 186
<211> 433
<212> DNA
<213> Homo sapiens
<400> 186
aattcggcac gagggcgcag gccccagcca gctcaggcta cactatccca ggatcagcat 60
ggccgtccgc cagtgggtaa tcgccctggc cttggctgcc ctccttgttg tggacaggga 120
agtgccagtg gcagcaggaa agctcccttt ctcaagaatg cccatctgtg aacacatggt 180
agagteteca acctgttece agatgteeaa cetggtetge ggeactgatg ggeteacata 240
tacgaatgaa tgccagctct gcttggcccg gataaaaacc aaacaggaca tccagatcat 300
gaaagatggc aaatgctgat cccacaggag cacctcaagc catgaagtgt cagctggaga 360
acagtggtgg gcatggagag gatatgacat gaaataaaag atccagccca aaaaaaaaa 420
aaaaaaaaa aaa
                                                                433
<210> 187
<211> 859
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (803)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (853)
<223> n equals a,t,g, or c
<400> 187
cccacgcgtc cgcccacgcg tccgcccacg cgtccgaccg gggcttttcg tgagctcqtc 60
tctgatctcg cgcaagagtg acacacaggt gttcaaagac gcttctgggg agtgagggaa 120
gcggtttacg agtgacttgg ctggagcctc aggggcgggc actggcacgg aacacacct 180
gaggccagcc ctggctgccc aggcggagct gcctcttctc ccgcgggttg gtggacccgc 240
```

```
tcagtacgga gttggggaag ctctttcact tcggaggatt gctcaacaac catgctgggc 300
 atctggaccc tectacetet ggttettaeg tetgttreta gattategte caaaagtgtt 360
 aatgoccaag tgactgacat caactccaag ggattggaat tgaggaagac tgttactaca 420
gttgagactc agaacttgga aggectgcat catgatggcc aattetgcca taagccctgt 480
cctccaggtg aaaggaaagc tagggactgc acagtcaatg gggatgaacc agactgcgtg 540
ccctgccaag aagggaagga gtacacagac aaagcccatt tttcttccaa atgcagaaga 600
tgtagattgt gtgatgaagg acatggctta kaagtggaaa taaactgcac ccggacccag 660
aatmccaagt gcagatgtaa accaaacttt ttttgkaact ctactgtatg tgaacactgt 720
gaccettgea ceaaatgtga acatggaate ateaaggaat geacacteae cageaacace 780
aagtgcaaag aggaaggatc canatctaac ttggggtggc tttggcttct tcttttgcca 840
attccctaat tgnttgggt
                                                                   859
<210> 188
<211> 833
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (65)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (798)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (803)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (809)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (812)
<223> n equals a,t,g, or c
<400> 188
tegeagagat tacaceactg caacgagact egggeecaga egagatetge etgggegaca 60
cagtnagact ctgtctcaaa ataaataaat aagtaaatag aacctcctga gctaccctgg 120
cttataagga ttcagattac tttaggaaat taggcattag cactaggagg ggggaagatg 180
gctggcaaaa cttctagcta gcaacctatg tctagcacat gggtaactaa ccatagcgag 240
attetgaaca catateetet aggtgeaggt ggagggaacg atgteeaata cetgaageag 300
aatctcacat ggacggaacg totgtattto cototootgc acgaatcact catcattott 360
ggagggette tetgeattee teettttett eteteeeete eeetgeettt tgtettttet 420
aaagagtotg aactoogatt tocatgotot cotgotacat taataagcaa aacctgottg 480
```

```
tgtgtacggt tctttactgg aaacatgact ttttgtttct gtattggttt tactgtcatc 540
cagttttcta gtttaatatc tagcaaaact aaatctgaat gtactcgctt tttccgttaa 600
gtatgccaag cacctcggtt gaaaggcttg actcaaacca gaagtcttgc tggaattcgt 660
ctctgaacac ttgaaaaaca gaaaccctga gccgcaacaa acatgcctct gtgtgtcggg 720
attgcctttg tctctgcttc catgtggctt ttccttttgt agctatgctt agtgacataa 780
tottccctct tcaagcantc tgngttggnc cnttcccgtt ccccccccg tgc
<210> 189
<211> 2211
<212> DNA
<213> Homo sapiens
<400> 189
ggcacgagga gtacagggcc cgcgcatgcg tggattgtcg tcttctgtcc aagttggtcg 60
cttccctgcg ccaaagtgag cagtagccaa catgtcaggg tgggagtcat attacaaaac 120
cgagggcgat gaagaagcag aggaagaaca agaagagaac cttgaagcaa gtggagacta 180
taaatattca ggaagagata gtttgatttt tttggttgat gcctccaagg ctatgtttga 240
atctcagagt gaagatgagt tgacaccttt tgacatgagc atccagtgta tccaaagtgt 300
gtacatcagt aagatcataa gcagtgatcg agatctcttg gctgtggtgt tctatggtac 360
cgagaaagac aaaaattcag tgaattttaa aaatatttac gtcttacagg agctggataa 420
tccaggtgca aaacgaattc tagagcttga ccagtttaag gggcagcagg gacaaaaacg 480
tttccaagac atgatgggcc acggatctga ctactcactc agtgaagtgc tgtgggtctg 540
tgccaacctc tttagtgatg tccaattcaa gatgagtcat aagaggatca tgctgttcac 600
caatgaagac aacccccatg gcaatgacag tgccaaagcc agccgggcca ggaccaaagc 660
cggtgatete cgagatacag geatetteet tgaettgatg caectgaaga aacetggggg 720
ctttgacata tccttgttct acagagatat catcagcata gcagaggatg aggacctcag 780
ggttcacttt gaggaatcca gcaagctaga agacctgttg cggaaggttc gcgccaagga 840
gaccaggaag cgagcactca gcaggttaaa gctgaagctc aacaaagata tagtgatctc 900
tgtgggcatt tataatctgg tccagaaggc tctcaagcct cctccaataa agctctatcg 960
ggaaacaaat gaaccagtga aaaccaagac ccggaccttt aatacaagta caggcggttt 1020
gcttctgcct agcgatacca agaggtctca gatctatggg agtcgtcaga ttatactgga 1080
gaaagaggaa acagaagagc taaaacggtt tgatgatcca ggtttgatgc tcatgggttt 1140
caageegttg gtactgetga agaaacacca ttacetgagg ceeteeetgt tegtgtacee 1200
agaggagtcg ctggtgattg ggagctcaac cctgttcagt gctctgctca tcaagtgtct 1260
ggagaaggag gttgcagcat tgtgcagata cacaccccgc aggaacatcc ctccttattt 1320
tgtggctttg gtgccacagg aagaagagtt ggatgaccag aaaattcagg tgactcctcc 1380
aggettecag etggtetttt taccetttge tgatgataaa aggaagatge eetttactga 1440
aaaaatcatg gcaactccag agcaggtggg caagatgaag gctatcgttg agaagcttcg 1500
cttcacatac agaagtgaca gctttgagaa ccccgtgctg cagcagcact tcaggaacct 1560
ggaggccttg gccttggatt tgatggagcc ggaacaagca gtggacctga cattgcccaa 1620
ggttgaagca atgaataaaa gactgggctc cttggtggat gagtttaagg agcttgttta 1680
cccaccagat tacaatcctg aagggaaagt taccaagaga aaacacgata atgaaggttc 1740
tggaagcaaa aggcccaagg tggagtattc agaagaggag ctgaagaccc acatcagcaa 1800
gggtacgctg ggcaagttca ctgtgcccat gctgaaagag gcctgccggg cttacgggct 1860
gaagagtggg ctgaagaagc aggagctgct ggaagccctc accaagcact tccaggactg 1920
accagaggee gegegteeag etgecettee geagtgtgge caggetgeet ggeettgtee 1980
tragcragtt aaaatgtgtt teteetgage taggaagagt etaceegaca taagtegagg 2040
gactttatgt tittgagget tietgitgee atggigatgg tgtageeete eeacttiget 2100
2211
aaaaaaaaa aaagtcgacc ggccgttaat ttagtagtag taggcggccg c
```

PCT/US00/05883

<210> 190 <211> 1659 <212> DNA <213> Homo sapiens <220> <221> misc feature <222> (1582) <223> n equals a,t,g, or c <400> 190 atcgggttca agaagaaaat gctaggctta agaagaaaaa agagcagttg cagcaggaaa 60 ctcagaaaga tttggaagta gctcttactc acaaggatga taatattaat gctttgacta 180 actgcattac acagttgaat ctgttagagt gtgaatctga atctgagggt caaaataaag 240 gtggaaatga ttcagatgaa ttagcaaatg gagaagtggg aggtgaccgg aatgagaaga 300 tgaaaaatca aattaagcag atgatggatg tctctcggac acagactgca atatcggtag 360 ttgaagagga tctaaagctt ttacagctta agctaagagc ctccgtgtcc actaaatgta 420 acctggaaga ccaggtaaag aaattggaag atgaccgcaa ctcactacaa gctgccaaag 480 ctggactgga agatgaatgc aaaaccttga ggcagaaagt ggagattctg aatgagctct 540 atcagcagaa ggagatggct ttgcaaaaga aactgagtca agaagagtat gaacggcaag 600 aaagagagca caggctgtca gctgcagatg aaaaggcagt ttcggctgca gaggaagtaa 660 aaacttacaa gcggagaatt gaagaaatgg aggatgaatt acagaagaca gagcggtcat 720 ttaaaaacca gatcgctacc catgagaaga aagctcatga aaactggctc aaagctcgtg 780 ctgcagaaag agctatagct gaagagaaaa gggaagctgc caatttraga cacaaattat 840 tagawttaac acaaaagatg gcaatgctgc aagaagaacc tgtgattgta aaaccaatgc 900 Caggaaaacc aaatacacaa aaccctccac ggagaggtcc tctgagccag aatgtctttt 960 ggcccatccc ctgtgagtgg tggagaatgc tcccctccat tgacagtgga gccacccgtg 1020 agacctctct ctgctactct caatcgaaga gatatgccta gaagtgaatt tggatcagtg 1080 gacgggcctc tacctcatcc tcgatggtca gctgaggcat ctgggaaacc ctctccttct 1140 gatccaggat ctggtacagc taccatgatg aacagcagct caagaggete ttcccctacc 1200 agggtactcg atgaaggcaa ggttaatatg gctccaaaag ggcccctcc tttcccaqqa 1260 gtccctctca tgagcacccc catgggaggc cctgtaccac cacccattcg atatggacca 1320 ccacctcage tetgeggace ttttgggeet eggeaettee tecaccettt ggeeetggta 1380 tgcgtccacc actaggetta agagaatttg caccaggegt tecaccagga agacgggace 1440 tgcctctcca ccctcgggga tttttacctg gacacgcacc atttagacct ttaggttcac 1500 ttggcccaag agagtacttt attcctggta cccgattacc acccccaacc catggtcccc 1560 aggaataccc accamcacct gnttgttaar gagratttat kgcgttcagt gttagagatg 1620 aggcctcaac tggcttctta gaggcattag ccagggatt 1659 <210> 191 <211> 3894 <212> DNA <213> Homo sapiens <400> 191 cacacttgaa gctgaaaaag aaagaagaaa atctgggcta tcctcaagag ttcagtttcg 60 aaaccaaggt totgagcoca aatatactca agaactaact otgaagaggo agaaacagaa 120 agtgtgcatg gaggaaaccc tgtggctaca ggataatatc agagataaac tgcgtcccat 180 tcccataact gcctcagtgg agatccaaga gccaagctct cgtaggcgag tgaattcact 240 tccagaagtt cttccaattc tgaattcaga tgaacccaag acagctcata ttgatgttca 300

WO 00/55351 PCT/US00/05883 143

cttcttaaaa						
taaattttgc						
tgtaccagaa						
cagcccttcc						
gattgcaacg ·	tttccagaca	a ctttaaccta	ttctgcatat	t agagaactga	gggctttcc	600
tgagaaacag ·	ttgagttgtg	g ttgccaacca	a gaatggctcq	g caagctgact	gtgagctcg	660
aaatcctttt a	aaaagaaatt	caaatgtcac	tttttattt	g gttttaagta	caactgaagt	720
cacctttgac a	accccagato	: tggatattaa	tctgaagtta	a gaaacaacaa	gcaatcaaga	1 780
taatttggct o	ccaattacaç	, ctaaagcaaa	agtggttatt	gaactgcttt	tatoggtoto	840
gggagttgct a						
gaaatctgaa q						
taaacctctt a						
caatgggaaa t						
ttgtgagcca d						
gaaacgggaa a						
aagaaaatac d						
sctgcggggg c						
atttctagag g						
tgtgactgct g						
tgtgtttccc t						
ggctattctc g						
tttcttcaag a						
tgctcagcca t						
aattgtgtgg a						
taaggatccg g						
aaaaacagtg g						
aaaaaaagct t						
aaagcctgct c						
gttttaactg t						
aactgttgga a						
tttggcgtgg c						
acatecteca g						
cgtcctaacc t						
actatgccat t						
tagaaggtga t						
tcacgtcaaa t						
cttgaatgct a						
attttgttat to						
aatcagaatt a						
aatctttata aa						
tccttcatga ca						
aaagatgttt at						
gatttcatac to						
gtgcggttta c						
cctatggtgg at						
atcagtgagt co						
ttactttggg go						
gggtggaatt at						
tttaattacc at						
tttgttttgg at						
gtgccactgt tg						
	,	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	Julia	a co coddaco	ccaayacact	2200

```
aaggacgttg ttttggttgt actttggaat tcttagtcac aaaatatatt ttgtttacaa 3420
 aaatttctgt aaaacaggtt ataacagtgt ttaaagtctc agtttcttgc ttggggaact 3480
 tgtgtcccta atgtgtttag attgctagat tgctaaggag ctgatacttt gacagtgttt 3540
 ttagacctgt gttactaaaa aaaagatgaa tgtcctgaaa agggtgttgg gagggtggtt 3600
 caacaaagaa acaaagatgt tatggtgttt agatttatgg ttgttaaaaa tgtcatctca 3660
 agtcaagtca ctggtctgtt tgcatttgat acatttttgt actaactagc attgtaaaat 3720
 tatttcatga ttagaaatta cctgtggata tttgtataaa agtgtgaaat aaatttttta 3780
 taaaagtgtt cattgtttcg taacacagca ttgtatatgt gaagcaaact ctaaaattat 3840
 3894
 <210> 192
 <211> 695
 <212> DNA
 <213> Homo sapiens
<220>
<221> misc feature
<222> (2)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (3)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (11)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (23)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (28)
<223> n equals a,t,g, or c
<400> 192
annotataca noatacaggg aanggtanac tgacagtacg gtcggattcc cgggtcgacc 60
cacgogtccg ctgagccatt agaaaatcca tttaaaaaga tgaaaaacaa cattgttgat 120
gctgcaaaca atcacagtgc cccagaagta ctgtatgggt ccttgcttaa ccaggaagag 180
ctgaaattta gcagaaatga tcttgaattt aaatatcctg ctggtcatgg ctcagccagc 240
graagtgaac acaggagttg ggccagagag agcaaaagct ttaatgttct gaaacagctg 300
cttctctcag aaaactgtgt gcgagatttg tccccgcaca gaagtaactc tgtggctgac 360
agtaaaaaga aaggacacaa aaataatgtg accaacagca aacctgaatt tagcatttct 420
totttaaatg gactgatgta cagttocact cagcocagca gttgcatgga taacaggaca 480
ttttcatacc caggtgtagt aaaaactcct gtgagtccta ctttccctga gcacttgggc 540
tgtgcagggt ctagaccaga atctgggctt ttgaatgggt gttccatgcc cagtgagaaa 600
```

WO 00/55351

ggacccatta agtgggttat cactgatgcg gaqaaqatga gtatqaaaag cctctccaga 660 ttgaccaaac cacccatac twtattacat gcttc <210> 193 <211> 3131 <212> DNA <213> Homo sapiens <220> <221> misc feature <222> (4) <223> n equals a,t,g, or c<220> <221> misc feature <222> (5) <223> n equals a,t,g, or c <220> <221> misc feature <222> (10) <223> n equals a,t,g, or c <220> <221> misc feature <222> (26) <223> n equals a,t,g, or c <220> <221> misc feature <222> (3128) <223> n equals a,t,q, or c <400> 193 gggnncaaan getggagete cacegnggtg egteegetet agaactagtg gateeeegg 60 getgeaggat teggeaegag gecaetteet ggggeegeeg geggggeege tggetgeaet 120 cagcgccgga gccgggagct agcggccgcc gccatgtccc accagaccgg catccaagca 180 agtgaagatg ttaaagagat ctttgccaga gccagaaatg gaaagtacag acttctgaaa 240 atatctattg aaaatgagca acttgtgatt ggatcatata gtcagccttc agattcctgg 300 gataaggatt atgatteett tgttttaece etgttggagg acaaacaace atgetatata 360 ttattcaggt tagattctca gaatgcccag ggatatgaat ggatattcat tgcatggtct 420 ccagatcatt ctcatgttcg tcaaaaaatg ttgtatgcag caacaagagc aactctgaag 480 aaggaatttg gaggtggcca cattaaagat gaagtatttg gaacagtaaa ggaagatgta 540 tcattacatg gatataaaaa atacttgctg tcacaatctt cccctgcccc actgactgca 600 gctgaggaag aactacgaca gattaaaatc aatgaggtac agactgacgt gggtgtggac 660 actaagcatc aaacactaca aggagtagca tttcccattt ctcgagaarc ctttcaggct 720 ttggaaaaat tgaataatag acagctcaac tatgtgcagt tggaaataga tataaaaaat 780 gaaattataa ttttggccaa cacaacaaat acagaactga aagatttgcc aaagaggatt 840 cccaaggatt cagctcgtta ccatttcttt ctgtataaac attcccatga aggagactat 900 ttagagtcca tagtttttat ttattcaatg cctggataca catgcagtat aagagagegg 960 atgctgtatt ctagctgcaa gagccgtctg ctagaaattg tagaaagaca actacaaatg 1020

```
gatgtaatta gaaagatcga gatagacaat ggggatgagt tgactgcaga cttcctttat 1080
gaagaagtac atcccaagca gcatgcacac aagcaaagtt ttgcaaaacc aaaaggtcct 1140
gcaggaaaaa qaggaattcg aagactaatt aqqqqccag cggaaactga agctactact 1200
gattaaagtc atcacattaa acattgtaat actagttttt taaaagtcca gcttttagta 1260
caggagaact gaaatcattc catgttgata taaagtaggg aaaaaaattg tactttttgg 1320
aaaatagcac ttttcacttc tgtgtgtttt taaaattaat gttatagaag actcatgatt 1380
totatttttg agttaaagct agaaaagggt toaacataat gtttaatttt gtoacactgt 1440
tttcatagcg ttgattccac acttcaaata cttcttaaaa ttttatacag ttgggccagt 1500
tctagaaagt ctgatgtctc aaagggtaaa cttactactt tcttgtggga cagaaagacc 1560
ttaaaaatatt catattactt aatgaatatg ttaaggacca ggctagagta ttttctaagc 1620
tggaaactta gtgtgccttg gaaaaggccg caagttgctt actccgagta gctgtgctag 1680
ctctgtcaga ctgtaggatc atgtctgcaa cttttagaaa tagtgcttta tattgcagca 1740
gtcttttata tttgactttt ttttaatagc attaaaattg cagatcagct cactctgaaa 1800
ctttaagggt accagatatt ttctatactg caggatttct gatgacattg aaagacttta 1860
aacagootta gtaaattato tttotaatgo totgtgaggo caaacattta tgttoagatt 1920
gaaatttaaa ttaatatcat tcaaaaggaa acaaaaaatg ttgagtttta aaaatcagga 1980
ttgacttttt tctccaaaac catacattta tgggcaaatt gtgttcttta tcacttccga 2040
gcaaatactc agatttaaaa ttactttaaa gtcctggtac ttaacaggct aacgtagata 2100
aacaccttaa taatctcagt taatactgta tttcaaaaca catttaactg ttttctaatg 2160
ctttgcatta tcagttacaa cctagagaga ttttgagcct catatttctt tgatacttga 2220
aatagaggga gctagaacac ttaatgttta atctgttaaa cctgctgcaa gagccataac 2280
tttgaggcat tttctaaatg aactgtgggg atccaggatt tgtaatttct tgatctaaac 2340
tttatgctgc ataaatcact tatcggaaat gcacatttca tagtgtgaag cactcatttc 2400
taaaccttat tatctaaggt aatatatgca cctttcagaa atttgtgttc gagtaagtaa 2460
agcatattag aataattgtg ggttgacaga tttttaaaat agaatttaga gtatttgggg 2520
ttttgtttgt ttacaaataa tcagactata atatttaaac atgcaaaata actgacaata 2580
atgttgcact tgtttactaa agatataagt tgttccatgg gtgtacacgt agacagacac 2640
acatacaccc aaattattgc attaagaatc ctggagcaga ccatagctga agctgttatt 2700
ttcagtcagg aagactacct gtcatgaagg tataaaataa tttagaagtg aatgtttttc 2760
tgtaccatct atgtgcaatt atactctaaa ttccactaca ctacattaaa gtaaatggac 2820
attocagaat atagatgtga ttatagtott aaactaatta ttattaaacc aatgattgot 2880
gaaaatcagt gatgcatttg ttatagagta taactcatcg tttacagtat gttttagttg 2940
gcagtatcat acctagatgg tgaataacat attcccagta aatttatata gcagtgaaga 3000
attacatgcc ttctggtgga cattttataa gtgcatttta tatcacaata aaaatttttt 3060
3131
aaaaaanaa a
```

<210> 194 <211> 2058

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (2045)

<223> n equals a,t,g, or c

<400> 194

gccactcegg gtttatttgt ttacaagcgg attacgtcag ctcctccctc tcttccctat 60 ctctggaccc gcctcctgaa ctcttttccc gcccctttcg gctccgaacc ggcttgcgtc 120 acaatggtgc gatattcgga ttggctggag tcggccatca cgctccacgt acgccacttc 180

```
cttttcgtgg cactataaag ggtgctgcac ggcgcttgca tctcttcgcc tctcggagct 240
ggaaatgcag ctattgagrt cttcgaatgc tgcggagctg gaggcggagg cagctgggga 300
ggtccgagcg atgtgaccag gccgccatcg ctcgtctctt cctctctcct gccgcctcct 360
gtctcgaaaa taactttttt agtctaaaga aagaaagaca aaagtagtcg tccgccctc 420
acgccctctc ttcctctcag ccttccgccc ggtgaggaag cccggggtgg ytgctccgcc 480
gteggggeeg egeegeegag eeeeggeege eeegggeege eeeegeaege egeeeeeatg 540
catecettet acaceggge egecaceatg ataggegaga tegeogeege egtgteette 600
atotocaagt ttotocgcac caaggggoto acgagogago gacagotgca gacottoago 660
cagageetge aggagetget ggeagaacat tataaacate actggtteee aggaaaageea 720
tgcaagggat cgggttaccg ttgtattcgc atcaaccata aaatggatcc tctgattgga 780
caggcagcac agoggattgg actgagcagt caggagctgt tcaggcttct cccaagtgaa 840
ctcacactct gggttgaccc ctatgaagtg tcctacagaa ttggagagga tggctccatc 900
tgtgtgctgt atgaagcctc accagcagga ggtagcactc aaaacagcac caacgtgcaa 960
atggtagaca gccgaatcag ctgtaaggag qaacttctct tgggcagaac gagcccttcc 1020
aaaaactaca atatgatgac tgtatcaggt taagatatag tctgtggatg gatcatctga 1080
tgatgatgga taaatttgat ttttgctttg ggtgggctcc tcttggggat ggattatgga 1140
aaattttaag tgacagtgcc atagtttgga cagtaccttt caatgattaa ttttaatagc 1260
ctgtgagtcc aagtaaatga tcactttatt tgctagggag ggaagtccta gggtggtttc 1320
agtttctccc agacatacct aaatttttac atcaatcctt ttaaagaaaa tctgtatttc 1380
aaagaatett tetetgeagt aaatetegea ggggaatttg cactattaca ettgaaagtt 1440
gttattgtta accttttcgg cagcttttaa taggaaagtt aaacgtttta aacatggtag 1500
tactggaaat tttacaagac ttttacctag cacttaaata tgtataaatg tacataaaga 1560
caaactagta agcatgacct ggggaaatgg tcagaccttg tattgtgttt ttggccttga 1620
aagtagcaag tgaccagaat ctgccatggc aacaggcttt aaaaaagacc cttaaaaaga 1680
cactgtetea actgtggtgt tagcaccage cagetetetg tacatttget agettgtagt 1740
tttctaagac tgagtaaact tcttatttt agaaagtgga ggtctggttt gtaactttcc 1800
ttgtacttaa ttgggtaaaa qtcttttcca caaaccacca tctattttgt gaactttgtt 1860
agtcatcttt tatttggtaa attatgaact ggtgtaaatt tgtacagttc atgtatattg 1920
attgtggcaa agttgtacag atttctatat tttggatgag aaatttttct tctctctata 1980
tctanaagat ccaagctt
                                                              2058
```

```
<211> 831
<212> DNA
<213> Homo sapiens

<220>
<221> misc feature
<222> (2)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (28)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (28)
<221> misc feature
<222> (28)
<221> misc feature
<222> (44)
```

<210> 195

```
<223> n equals a,t,g, or c
 <220>
<221> misc feature
<222> (791)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (793)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (806)
<223> n equals a,t,g, or c
<400> 195
ancecteact aagggaacaa aagetggnag etceacegeg gtgnegaeeg etctagaact 60
agtggatccc ccgggctgca ggaattcggc agagttcgac ctctgctgca gcccgtgccg 120
ccgccgcctc ctgggaagag aggaagcggg agaggagccc acgtcgcctg tcacccaata 180
tetecageeg egeagteeeg aagagtgtaa gatgttegee tgegeeaage tegeetgeae 240
cccctctctg atccgagctg gatccagagt tgcatacaga ccaatttctg catcagtgtt 300
atotogacca gaggotagta ggactggaga gggototacg gtatttaatg gggoocagaa 360
tggtgtgtct cagctaatcc aaagggagtt tcagaccagt gcaatcagca gagacattga 420
tactgctgcc aaatttattg gtgcaggtgc tgcaacagta ggagtggctg gttctggtgc 480
tggtattgga acagtetttg geageettat cattggttat geeagaaace ettegetgaa 540
gcagcagctg ttctcatatg ctatcctggg atttgccttg tctgaagcta tgggtctctt 600
ttgtttgatg gttgctttct tgattttgtt tgccatgtaa caaattactg cttgacatgt 660
tggcattcat attaattacg gatgtaattc tgtgtatctt actgtgactc cgaaaactgt 720
agtattggtg tcatgggaat gtacgttatt tccaaagtca tttcattaaa gatgaaaact 780
ttaattcctc ngngattgga ctacanaagt tagattaccc caagagacgg c
                                                                   831
<210> 196
<211> 961
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (31)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (32)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (923)
```

```
<223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (947)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (953)
 <223> n equals a,t,g, or c
 <220>
<221> misc feature
<222> (954)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (960)
<223> n equals a,t,g, or c
<400> 196
tagatagaac agatgttttg tgtgaaattt nntatcttta acttaatwaa ccagcaggaa 60
ctgtatgaac acaacacacc caactgacaa acagagagaa ctaacatgtt tatttagctg 120
tatgtatata tgcttaacta cacccgagga agctgtagag ttagaaaaac atgaaccatt 180
aacagatgtg gcctccctgc agaactttta ctttgaaaaa gaagtacgtc tgaaccagat 240
tcacatgttt gatatttgga tgcagagaaa atggggcaga aagcatcgca acagttggct 300
ctgaaggaca gcaaagaggt gcccgtcgtc tgtgargtgg tcagtgaagc tatagtccat 360
gcagctcaga aactgaagga gtaccttgga tttgaatatc ctccaagtaa actctgccca 420
gctgcaaata ctctgaatga gatcttctta atccatttca tcactttctg ccaagaaaag 480
ggagttgatg agtggctgac caccaccaag atgaccaagc accaagcctt cctgtttggt 540
gcagactgga tttggacctt ttggggatcy gacaagcaaa taaagcttca gctcqcaqta 600
cagactetge agatgtette accteeteet gtggaateta ageettgtga cettteeaat 660
ccagaatcaa rggtaragga rtcttcctgg aagaaaagta gatttgataa gctggaagaa 720
ttctgtaact taataggaga ggattgcctg ggtctgttta tcatctttgg tatgccagga 780
aagcctaaag acatcagggg agttgtcctg gacagtgtca aaagtcagat ggtgaggagc 840
catctgccag gagggaaggc tgtggctcas tttgtcctgg aaactgaaga ttgtgtgttc 900
atcaaagagc tgctcaaaat tgnctgagta agaaagacgg gctgganaga agnnggcaan 960
<210> 197
<211> 606
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (488)
<223> n equals a,t,g, or c
```

```
<220>
 <221> misc feature
 <222> (500)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (603)
<223> n equals a,t,g, or c
<400> 197
gcttgggtct gtcccgggtg gacgacgccg tggctgccaa cacccgccag tgygcccaga 60
ggagggacag gagaggcggt gaaggaagag ggcaggggat cgagccttca cccgcctctg 120
ccaccccagg gactegggga gtatgccgca tgccagtcac acgccttcat gaagggcgtt 180
ttcaccttcg tcacaggcac cggcatggcc tttggcttgc agatgttcat tcagaggaag 240
tttccatacc ctttgcagtg gagcctccta gtggccgtgg ttgcaggctc tgtggtcagc 300
tacggggtga cgagagtgga gtcggagaaa tgcaacaacc tctggctctt cctggagacc 360
gggcagctcc ccaaagacag gagcacagat cagagaagct aggagagctc cagcaggggc 420
acagaggatt gggggcagga ggagtetgga acacagcett catgececet gaccecagge 480
egaccetnee cacaccetan ggtaccecag tegtateete tgteegeatg tgtggeeagg 540
cctgacaaac acctgcagat ggctgctgcc caacctggga ccttgcccag gaggttggag 600
                                                                   606
canaaa
<210> 198
<211> 393
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (253)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (354)
<223> n equals a,t,g, or c
<400> 198
cccacgcgtc cgcccacgcg tcctggacct cctgtgcaag aacatgaaac acctgtggtt 60
cttcctcctg ctggtggcag ctcccagatg ggtcctgtcc caggtgcagc tgcaggagtc 120
gggcccagga ctggtgaagc cttcacagac cctgtccctc acctgcactg tctctggtgg 180
ctccatcage agtggtgctt actactggag ctggatccge cagcacccag ggaagggcct 240
ggagtggatt ggntwcatct attacagtgg gascacctac tacaayccgt ccctcaarag 300
totagttasc atatcastag acacgtotaa gaaccastto tocotgaasc tganototgt 360
                                                                   393
gackgccgcg gacacggmcg tgtattactg tgc
<210> 199
<211> 1061
<212> DNA
<213> Homo sapiens
```

```
<220>
<221> misc feature
<222> (1035)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (1056)
<223> n equals a,t,g, or c
<400> 199
gccccacgct gaccaccggc gtggagggaa ggcctctgag actctgcact gagcaccatt 60
ttggacttgt gtgtccagga gtcatgtccc ccgacgagta ccaytcaggg gtcaacaact 120
ctgtgtacac caacgtcctg gtccagaaca ggtcagacac aagatcccct cacctcaccc 180
caccecegee ecagetggag acetgeeeeg gtgeeeecac taggeaggea geagetggaa 240
gtgtaggggt tgcagcetec eccametace tecaceteca geetgegett tgetgetgee 300
ctggcccagg acctgggtct tcccatcccc agccaktggc tggcggtggc tgacaagatc 360
aaggtaccct ttgacqtkga gcaqaacttc cacccggagt tcgatgggta tgagcctggt 420
gaktggaccc cttcaagggy tcctcccctg ccgtcgagac cctcgagtct gtcctggaac 480
accttccagt cagcggcacc tccctgtagg agaggtggtg aagcaggcag acgtcgtgct 540
cctgggatac cmagtcccct tctccctgag tcctgatgtt cgcaggaaaa atctggagat 600
ttacgagget gtgacgtccc cccagggecc cgccatgacc tggagcatgt ttgctgtggg 660
ctggatggag ctgaaggacg cagtgcgggc ccggggcctc ctggacagga gctttgccaa 720
catggctgaa cccttcaagg tgtggacgga gaatgcagac gggtcaggcg ctgtgaactt 780
cctgacaggc atggggggct tctgcaggcg gtggtcttcg ggtgcacggg gttcagggtc 840
accogagogg gtgtgacctt tgaccotgtg tgtctgtcgg ggatctccag artgagogty 900
teeggeatet tetaceaggg gaacaagete aacttetett titeegagga eteegtgace 960
gtgqaggtca cagctcgagc agggccctgg gctcctcacc tggaggctga gctgtggcca 1020
ttccagtccc ggmtnttcct tgtkcmggam macaangggc t
<210> 200
<211> 1359
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (1005)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (1128)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (1342)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
 <222> (1343)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (1344)
 <223> n equals a,t,q, or c
 <400> 200
tcacgcgtcc ggggctgcag taggtcccgg caaccgcagg ctcgcggcgg gcgctgggcg 60
cgggatccga ctctagtcgt aatggaggcg ggcggctttc tggactcgct catttacgga 120
gcatgcgtgg tcttcaccct tggcatgttc tccgccggcc tctcggacct caggcacatg 180
cgaatgaccc ggagtgtgga caacgtccag ttcctgccct ttctcaccac ggaagtcaac 240
aacctgggct ggctgagtta tggggctttg aagggagacg ggatcctcat cgtcgtcaac 300
acagtgggtg ctgcgcttca gaccctgtat atcttggcat atctgcatta ctgccctcgg 360
aagcgtgttg tgctcctaca gactgcaacc ctgctagggg tccttctcct gggttatggc 420
tacttttggc tcctggtacc caaccctgag gcccggcttc agcagttggg cctcttctgc 480
agtgtcttca ccatcagcat gtacctctca ccactggctg acttggctaa ggtgattcaa 540
actaaatcaa cccaatgtct ctcctaccca ctcaccattg ctacccttct cacctctqcc 600
tectggtgcc tetatgggtt tegacteaga gatecetata teatggtgte caacttteea 660
ggaatcgtca ccagctttat ccgcttctgg cttttctgga agtaccccca ggagcaagac 720
aggaactact ggctcctgca aacctgaggc tgctcatctg accactgggc accttagtgc 780
caacctgaac caaagagacc teettgttte agetgggeet getgteeage tteecaggtg 840
cagtgggttg tgggaacaag agatgacttt gaggataaaa ggaccaaaga aaaagcttta 900
cttagatgat tgattggggc ctaggagatg aaatcacttt ttatttttta gagatttttt 960
tttttaattt tggaggttgg ggtgcaatct ttagaatatg ccttnaaagg ccgggcgcqg 1020
tgctcacgcc tgtaatccca gcactttggg aggccaaggt gggcggatcg cctgaggtca 1080
ggagttcaag accaacctga ctaacatggt gaaaccccat ctctactnaa aatacaaaat 1140
tagccaggca tgatggcaca tgcctgtaat cccagatact tgggaggctg aggcaggaga 1200
attgcttgaa cccaggaggt ggaggttgca gtgagctgag atcgtgccat tgtgatatga 1260
atatgcctta tatgctgata tgaatatgcc ttaaaataaa gtgttcccca cccctgaaaa 1320
aaaaaaaaa annnaaaaag ggcggccgc
                                                                  1359
<210> 201
<211> 726
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (7)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (30)
<223> n equals a,t,q, or c
<220>
```

```
<221> misc feature
 <222> (179)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (724)
 <223> n equals a,t,g, or c
 <400> 201
 ttcgaantta cccttcatta aagggaacan aagttggagc ttccaccgcg gtggcggccg 60
 ctctagaact agtggatccc ccgggctgca ggaattcggc acgaggagag aactagtctc 120
 gcgcagagcg cagcgmacgg ccacagacag ccctgggcat ccaccgacgg cgcacggang 180
 ccagcagage eggaaggege geeeegggea gagaaageeg ageagagetg ggtggegtet 240
cogggeogec getocgacgg gecagegee tecceatgte cetgeteeca egeogegee 300
ctccggtcag catgaggctc ctggcggccg cgctgctcct gctgctgctg gcgctgtaca 360
ccgcgcgtgt ggacgggtcc aaatgcaagt gctcccggaa ggacccaaga tccgctacag 420
cgacgtgaag aagctggaaa tgaagccaaa gtacccgcac tgcgaggaga agatggttat 480
catcaccacc aagagcgtgt ccaggtaccg aggtcaggag cactgcctgc accccaagct 540
gcagagcacc aagcgcttca tcaagtggta caacgcctgg aacgagaagc gcagggtcta 600
cgaagaatag ggtgaaaaac ctcagaaggg aaaactccaa accagttggg agacttgtgc 660
ggcnta
                                                                 726
<210> 202
<211> 2714
<212> DNA
<213> Homo sapiens
<400> 202
gctttgtttg ccatttccta caggtgaaac gccatcatta ggattcactg taacgttagt 60
gctattaaac tcactagcat ttttattaat ggccgttatc tacactaagc tatactgcaa 120
cttggaaaaa gaggacctct cagaaaactc acaatctagc atgattaagc atgtcgcttg 180
gctaatcttc accaattgca tcttttctg ccctgtggcg ttttttcat ttgcaccatt 240
gatcactgca atctctatca gccccgaaat aatgaagtct gttactctga tatttttcc 300
attgcctgct tgcctgaatc cagtcctgta tgttttcttc aacccaaagt ttaaagaaga 360
ctggaagtta ctgaagcgac gtgttaccaa gaaaagtgga tcagtttcag tttccatcag 420
tagccaaggt ggttgtctgg aacaggattt ctactacgac tgtggcatgt actcacattt 480
gcagggcaac ctgactgttt gcgactgctg cgaatcgttt cttttaacaa agccagtatc 540
atgcaaacac ttgataaaat cacacagctg teetgeattg geagtggett ettgeeaaag 600
acctgagggc tactggtccg actgtggcac acagtssgcc cactctgatt atgcagatga 660
agaagattoo tttgtotoag acagttotga coaggtgoag gootgtggao gagootgott 720
ctaccagagt agaggattcc ctttggtgcg ctatgcttac aatctaccaa gagttaaaga 780
ctgaactact gtgtgtgtaa ccgtttcccc cgtcaaccaa aatcagtgtt tatagagtga 840
accetattet catettteat etgggaagea ettetgtaat caetgeetgg tgteaettag 900
aagaaggaga ggtggcagtt tatttctcaa accagtcatt ttcaaagaac aggtgcctaa 960
attataaatt ggtgaaaaat gcaatgtcca agcaatgtat gatctgtttg aaacaaatat 1020
atgacttgaa aaggatctta ggtgtagtag agcaatataa tgttagtttt ttctgatcca 1080
taagaagcaa atttatacct atttgtgtat taagcacaag ataaagaaca gctgttaata 1140
ttttttaaaa atctatttta aaatgtgatt ttctataact gaagaaaata tcttgctaat 1200
tttacctaat gtttcatcct taatctcagg acaacttact gcagggccaa aaaagggact 1260
```

```
gtcccagcta gaactgtgag agtatacata ggcattactt tattatgttt tcacttgcca 1320
 tccttgacat aagagaacta taaattttgt ttaagcaatt tataaatcta aaacctgaag 1380
 atgtttttaa aacaatatta acagctgtta ggttaaaaaa atagctggac atttgttttc 1440
 agtcattata cattgctttg gtccaatcag taattttttc ttaagtgttt tgtgattaca 1500
 ctactagaaa aaaagtaaaa ggctaattgc tgtgtgggtt tagtcgattt ggctaaacta 1560
Ctaactaatg tgggggttta atagtatctg agggatttgg tggcttcatg taatgttctc 1620
attaatgaat acttcctaat atcgttggct ctactaatat tttccaattt gctgggatgt 1680
cacctagcaa tagcttggat tatatagaaa gtaaactgtg gtcaatactt gcatttaatt 1740
agacgaaacg gggagtaatt atgacacgaa gtacttatgt ttatttctta gtgagctgga 1800
ttatcttgaa cctgtgctat taaatggaaa tttccataca tcttccccat actattttt 1860
ataaaagagc ctattcaata gctcagaggt tgaactctgg ttaaacaaga taatatgtta 1920
ttaataaaaa tagaagaaga aagaataaag cttagtcctg tgtctttaaa aattaaaaat 1980
tttacttgat tcccatctat gggctttaga cctattactg ggtggagtct taaagttata 2040
attgttcaat atgttttttg aacagtgtgc taaatcaata gcaaacccac tgccatatta 2100
gttattctga atatactaaa aaaatccagc tagattgcag tttaataatt aaactgtaca 2160
tactgtgcat ataatgaatt tttatcttat gtaaattatt tttagaacac aagttgggaa 2220
atgtggcttc tgttcatttc gtttaattaa agctacctcc taaactatag tggctgccag 2280
tagcagactg ttaaattgtg gtttatatac tttttgcatt gtaaatagtc tttgttgtac 2340
attgtcagtg taataaaaac agaatctttg tatatcaaaa tcatgtagtt tgtataaaat 2400
gtgggaagga tttatttaca gtgtgttgta attttgtaag gccaactatt tacaagtttt 2460
aaaaattgct atcatgtata tttacacatc tgataaatat taaatcataa cttggtaaga 2520
aactcctaat taaaaggttt tttccaaaat tcaggttatt gaaaaytttt cattttattc 2580
atttaaaaac tagaataaca gatatataaa agtgttaatc tttgtgctat atggtatgaa 2640
atacaatatt gtactcagtg ttttgaatta ttaaagtttc tagaaagcaa aaaaaaaaa 2700
aaaaaaactc gtag
                                                                 2714
<210> 203
<211> 422
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (419)
<223> n equals a,t,g, or c
<400> 203
gacggagccg gaagcaggaa gcagcctgtk ctccccagga cctgcctggt tgggggaatt 60
ggaggcttct aggaggtggc acggtgcacg ccaagatggc tgtgtccaca gaggagctgg 120
aggccacggt tcaggaagtc ctggggagac tgaagagcca ccagtttttc cagtccacat 180
gggacactgt tgccttcatt gttttcctca ccttcatggg caccgtgctg ctcctgctgc 240
tgctggtcgt cgcccactgc tgctgctgca gctcccccgg gccccgcagg gaaagcccca 300
ggaaggaaag acccaaggga qtggataact tggccctgga accctgaccc tgtgtctcct 360
gg
                                                                 422
<210> 204
<211> 2339
<212> DNA
<213> Homo sapiens
```

```
<220>
 <221> misc feature
 <222> (2)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (18)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (19)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (47)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (91)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (125)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (199)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (2238)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (2321)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (2329)
<223> n equals a,t,g, or c
<220>
```

PCT/US00/05883 WO 00/55351 156

```
<221> misc feature
 <222> (2334)
 <223> n equals a,t,g, or c
 <400> 204
 anacatggcc aatcaatnnt ctttcagcgt caagaatacg ggacatncac caggaccctg 60
 tgaactgacc gctgtgcctg cccttcaagt ncaaggccaa ggattgcact gtgcccatca 120
 acacntgcat ccagaacccc tgtcagcatg aggcacctgc cacctgagtg acagccccaa 180
 ggatgggttc agctgytcnt gccctctggg ctttragggg cagcggtgtg agatcaaccc 240
 agatgactgt gaggacaacg actgcgaaam caatgccacc tgcgtggacg ggatcaacaa 300
 ctacgtgtgt atctgtccgc ctaactacac aggtgagcta tgcgacgagg tgattgacca 360
 ctgtgtgcct gagctgaacc tctgtcagca tgaggccaag tgcatccccc tggacaaagg 420
attcagctgc gagtgtgtcc ctggctacag cgggaagctc tgtgagacag acaatgatga 480
ctgtgtggcc cacaagtgcc gccacggggc ccagtgcgtg gacacaatca atggctacac 540
atgcacctgc ccccagggct tcagtggacc cttctgtgaa cacccccac ccatggtcct 600
actgcagacc agcccatgcg accagtacga gtgccagaac ggggcccagt gcatcgtggt 660
gcagcaggag cccacctgcc gctgcccacc aggcttcgcc ggccccagat gcgagaagct 720
catcactgtc aacttcgtgg gcaaagactc mtacgtggaa ctggcctccg ccaaggtccg 780
accccaggcc aacatctccc tgyaggtggc cctgacaagg acaacggmat ccttctctac 840
aaaggagaca atgacccct ggcactggag ctgtaccagg gccacgtgcg gctggtctat 900
gacagcctga gttcccctcc aaccacagtg tacagtgtgg agacagtgaa tratgggcag 960
tttcacagtg tggagctggt gacgctaaac cagaccctga acctagtagt ggacaaagga 1020
actccaaaga gcctggggaa gctccagaag cagccagcag tgggcatcaa cagcccctc 1080
tacettggag geateceeae etecacegge eteteegeet tgegeeaggg eaeggaeegg 1140
cctctaggcg gcttccacgg atgcatccat gaggtgcgca tcaacaacga gctgcaggac 1200
ttcaaggccc tcccaccaca gtccctgggg gtgtcaccag gctgcaagtc ctgcaccgtg 1260
tgcaagcacg gcctgtgccg ctccgtggag aaggacagcg tggtgtgcga gtgccgccca 1320
ggctggaccg gcccactctg cgatcaggag gcccgggacc cctgcctcgg ccacagatgc 1380
caccatggaa aatgtgtggc aactgggacc tcatacatgt gcaagtgtgc cgagggctat 1440
ggaggggact tgtgtgacaa caagaatgac tctgccaatg cctgctcagc cttcaagtgt 1500
caccatgggc agtgccacat ctcagaccaa ggggagccct actgcctgtg ccagcccggc 1560
tttagcggcg agcactgcca acaagagaat ccgtgcctgg gacaagtagt ccgagaggtg 1620
atccgccgcc agaaaggtta tgcatcatgt gccacagcct ccaaggtgcc catcatggaa 1680
tgtcgtgggg gctgtgggcc ccagtgctgc cagcccaccc gcagcaagcg gcggaaatac 1740
gtcttccagt gcacggacgg ctcctcgttt gtagaagagg tggagagaca cttagagtgc 1800
ggctgcctcg cgtgttccta agcccctgcc cgcctgcctg ccacctctcg gactccaqct 1860
tgatggagtt gggacagcca tgtgggaccc cctggtgatt cagcatgaag gaaatgaagc 1920
tggagaggaa ggtaaagaag aagagaatat taagtatatt gtaaaataaa caaaaaatag 1980
aacttatttt tattatggaa agtgactatt ttcatctttt attataaaa tatattacac 2040
catctgcgta tatgtaccat atagtgagtt atttttacca agttttgtgt tgtgtatttg 2100
ttgtgttttt aaaaatagct gtttaaaaat ttaagaaaaa aatagactaa taaaaatgct 2160
ttaaaacaaa aggataagaa taaagaatga tagcctgtct gaggaaggag gaagatgttt 2220
tcatgtttat gaaacggnat tatgtcggca gtagaccaag agctgctcat gagatcagaa 2280
aaaggaataa gaggaagaga gaggagggaa aagaccttgt ntctgtttnt taantccct 2339
<210> 205
<211> 1655
<212> DNA
<213> Homo sapiens
```

<220>

```
<221> misc feature
 <222> (1548)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (1559)
 <223> n equals a,t,g, or c
<220>
 <221> misc feature
<222> (1564)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (1623)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (1643)
<223> n equals a,t,g, or c
<400> 205
ttcggggcta gcgtcggcga ggcttgagct tgcagcgcgc ggcttccctg ctttctcgcg 60
gccaccccgg ctccggcggc ctcggcgcgc gaggggctgg aggtgcggga gccgctctcc 120
gccggtcggt ccccgcgcgg ctgagcccag gccgccagcg ccgcggccmc gtgcggtgtc 180
cotgagetee tgeteeeege egggetgete egageaaegg tgetteggag eteeaaaete 240
gggctgccgg ggcaagtgtc ttcatgaacc cagaggatgt ccgggaagca ctacaagggt 300
cctgaagtca gttgttgcat caaatacttc atatttggct tcaatgtcat attttggttt 360
ttgggaataa catttcttgg aattggactg tgggcatgga atgaaaaagg agttctgtcc 420
aacatetett eeateacega teteggegge tttgaceeag tttggetett eettgtggtg 480
ggaggagtga tgttcatttt gggatttgca gggtgcattg gagcgctacg ggaaaacact 540
ttccttctca agtttttttc tgtgttcctg ggaattattt tcttcctgga gctcactgcc 600
ggagttctag catttgtttt caaagactgg atcaaagacc agctgtattt ctttataaac 660
aacaacatca gagcatatcg ggatgacatt gatttgcaaa acctcataga cttcacccag 720
gaatattggc agtgctgtgg ggcttttgga gctgatgatt ggaacctaaa tatttacttc 780
aattgcacag attccaatgc aagtcgagag cgatgtgggg ttccattctc ctgctgcact 840
aaagatcccg cagaagatgt catcaacact cagtgtggct atgatgccag gcaaaaacca 900
gaagttgacc agcagattgt aatctacacg aaaggctgtg tgccccagtt tgagaagtgg 960
tttgggatat gcctggccca gaatttggtt agcgatatcg aagctgtcag ggcgagctgg 1080
tagaccccct gcaaccgctg ctgcaagaca ctggacagac ccagctttcg ggaccctccc 1140
gcgtgccgaa ctgatcttcg agctgcatgg acctaatcac agatgcagcc tgcagtctcg 1200
cctaatggag ctgccattag gggagtgtaa aactgggaaa tgctgctcac tgacagaatt 1260
aaaaaaaaa ataaccagta tgaaagtcgt tgcgccgtga atctctactg tagccatgaa 1320
tttatggaca gttagatgct taccaaaaaa gaaaaaaagg gagggtaggg gacccagatg 1380
tacttgaatg tgcagaaaat acattettgt ceteatette egtaattgga gggetgggag 1440
argeagettt getetteace acacettgga eggaceacet tetttetgtt ceatggeetg 1500
aaggagtggc atctcctcaa aggactcagc ccctcacctg ggagggancg agtttctgnc 1560
```

```
ccenettaga tttttaatcc agettggtgg tecaccegtt tgttetgeec ecceetgggg 1620
 agncaagatt atcaagcctt gcncgcactt cttgt
 <210> 206
 <211> 5145
 <212> DNA
 <213> Homo sapiens
 <220>
 <221> misc feature
 <222> (4)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (17)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (5126)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (5143)
<223> n equals a,t,g, or c
<400> 206
gtcngattcg cggccgnatc ggaggtttcg gctaagttgg aggtactggc cacgactgca 60
tgcccgcgcc cgccaggtga tacctccgcc ggtgacccag gggctctgcg acacaaggag 120
tetgeatgte taagtgetag acatgeteag etttgtggat acgeggaett tgttgetget 180
tgcagtaacc ttatgcctag caacatgcca atctttacaa gaggaaactg taagaaaggg 240
cccagccgga gatagaggac cacgtggaga aaggggtcca ccaggccccc caggcagaga 300
tggtgaagat ggtcccacag gccctcctgg tccacctggt cctcctggcc cccctggtct 360
cggtgggaac tttgctgctc agtatgatgg aaaaggagtt ggacttggcc ctggaccaat 420
gggcttaatg ggacctagag gcccacctgg tgcagctgga gccccaggcc ctcaaggttt 480
ccaaggacct gctggtgagc ctggtgaacc tggtcaaact ggtcctgcag gtgctcgtgg 540
tecagetgge cetectggea aggetggtga agatggteae cetggaaaae eeggaegaee 600
tggtgagaga ggagttgttg gaccacaggg tgctcgtggt ttccctggaa ctcctggact 660
tcctggcttc aaaggcatta ggggacacaa tggtctggat ggattgaagg gacagcccgg 720
tgctcctggt gtgaagggtg aacctggtgc ccctggtgaa aatggaactc caggtcaaac 780
aggagecegt gggetteetg gtgagagagg aegtgttggt geceetggee cagetggtge 840
ccgtggcagt gatggaagtg tgggtcccgt gggtcctgct ggtcccattg ggtctgctgg 900
ccctccaggc ttcccaggtg cccctggccc caagggtgaa attggarctg ttggtaacgc 960
tggtcctgct ggtcccgccg gtccccgtgg tgaagtgggt cttccaggcc tctccggccc 1020
cgttggacct cctggtaatc ctggagcaaa cggccttact ggtgccaagg gtgctgctgg 1080
cetteeegge gttgetgggg etceeggeet eeetggace egeggtatte etggeeetgt 1140
tggtgctgcc ggtgctactg gtgccagagg acttgttggt gagcctggtc cagctggctc 1200
caaaggagag agcggtaaca agggtgagcc cggctctgct gggccccaag gtcctcctgg 1260
teccagtggt gaagaaggaa agagaggeee taatggggaa getggatetg eeggeeetee 1320
```

aggacctcct	gggctgagag	g gtagtcctg	ttctcgtggt	cttcctggaq	g ctgatggcag	1380
agctggcgtd	atgggccctc	ctggtagtcg	g tggtgcaagt	ggccctgctg	g gagtccgagg	1440
acctaatgga	gatgctggtc	gccctgggg	a gcctggtctc	: atgggaccca	gaggtcttcc	1500
tggttcccct	ggaaatatcg	gccccgctg	g aaaagaaggt	cctgtcggcd	tccctggcat	1560
cgacggcagg	cctggcccaa	ttggcccmgc	tggagcaaga	ggagagcctg	g gcaacattgg	
			tcctggcaaa			
tggtcttgct	ggtgctcggg	gtgctccagg	, tcctgatgga	aacaatggtg	r ctcagggacc	1740
			ı aggtgaacag			
			: cgctggtgaa			
			tcctgctggt			
			: tggtcctatt			
			acctggtgtg			
			agagagggt			
			aggtgaaatt			
			ccctggtcct			
			cctgctggtc			
			ggatttgctg			
			aaagggccta			
			ccagctggtc			
			ggtatgactg			
			tctggccctc			
			gaccaaggtc			
			ggtgagaagg			
			cagggtcttc			
			ctaccaggtg			
			ggggcccgtg			
			gctggtcgtg			
			cacaagggag			
			ggtcctcatg			3060
			tctggtcctg			3120
			attcgtggcg			
			ggacacaatg			
			cctggctccg			3300
			aaagatggtc			
			ggtcaccaag			
			agcggtggtg			
			tcagcacctt			
			aaccagattg cgtgacttga			
			caaggatgca			
			atccgggccc			
			aaacacgtct			
			ggagtgactt			
			gcctctcaga			
			ggcaacctga			
			ggcaacagca			
			tggggaaaga			
			attgcacctt			
			tgtttcaaat			
			ctttgccatt			
			catctacttg			
J						

```
gaaaaagaag gattgatcag agcattgtgc aatacagttt cattaactcc ttcccccgct 4440
 CCCCCaaaaa tttgaatttt tttttcaaca ctcttacacc tgttatggaa aatgtcaacc 4500
 tttgtaagaa aaccaaaata aaaattgaaa aataaaaacc ataaacattt gcaccacttg 4560
 tggcttttga atatcttcca cagagggaag tttaaaaccc aaacttccaa aggtttaaac 4620
 tacctcaaaa cactttccca tgagtgtgat ccacattgtt aggtgctgac ctagacagag 4680
 atgaactgag gtccttgttt tgttttgttc ataatacaaa ggtgctaatt aatagtattt 4740
 cagatacttg aagaatgttg atggtgctag aagaatttga gaagaaatac tcctgtattg 4800
 agttgtatcg tgtggtgtat tttttaaaaa atttgattta gcattcatat tttccatctt 4860
 attcccaatt aaaagtatgc agattatttg cccaaatctt cttcagattc agcatttgtt 4920
ctttgccagt ctcattttca tcttcttcca tggttccaca gaagetttgt ttcttgggca 4980
agcagaaaaa ttaaattgta cctattttgt atatgtgaga tgtttaaata aattgtgaaa 5040
ggggcccggw acccaattgg ccccangggg ggccgtttac atnca
                                                                 5145
<210> 207
<211> 487
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (470)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (483)
<223> n equals a,t,g, or c
<400> 207
teegecetee egtegeteee etgetegggg teagetagtg teeketetge teggeegegg 60
gctcccggag gactgcaggc aggatgacgc aaaacacggt gattgtgaat ggagttgcta 120
tggcctctag gccatcccag cccacccacg tcaacgtcca catccaccag gagtcagctt 180
tgacacaact gctgaaagct ggaggttctc tgaagaagtt tctttttcac cctggggaca 240
ctgtgccttc cacagccagg attggttatg agcagctggc tctagqggtg actcagatat 300
tgctgggggt tgtgagttgt gttcttggag tgtgtctcag cttggggccc tggactgtgc 360
tgagtgcctc agctgtgcct tctgggcggg gtctgtggtg atcgcarcar gastkgggcc 420
attgtccatg araarcaccc gggcaaactk gytggctata ttscagccgn tcacccggca 480
agntttg
                                                                487
<210> 208
<211> 2296
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (202)
<223> n equals a,t,g, or c
<220>
```

```
<221> misc feature
 <222> (252)
 <223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (2258)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (2285)
<223> n equals a,t,g, or c
<400> 208
gaagaattag gettggttte aggttacata aataatagag cagatggttg cetttgggte 60
ttgaaccaaa ataagactta ctaaaggaag agtgagtttt tagaagagaa ctttacgagc 120
gtgacattat gcattactcc acatccaccc tttaagaatt gatttattac aaaattatgt 180
totattttaa agtocactoo oncaaaatao tgatttotto catggattat ttttatatga 240
tttgtacaaa tnttttctga aatttaaatt gacaagcaat gttataaaaa tattgctaat 300
cttctgctta tttttcagcc tttaaagtct gaaatactat aaaacactga gagtatctat 360
gtctttctga atttaaaatg aaaattcatg tccatatgga gacttacata ttccccaatc 420
tttccatgaa ttgcattttt ttctaatact tatctctgtt aagactccat tgaaagttaa 480
acaaaaagcc gatataatag tttgggtttt ttttttttgc ttattttagt attttgaatc 540
agagaatact tggccaagct cgtatttgta aactaaaacc ccttgttatt tgtatcttct 600
gcatttcagt tttactgtaa gaacatacat yttgaaatta tgaacatttt tttcataaaa 660
attaaatgct ttaagaaatg gagaaggaaa aatagctttt atcaattttt ttctcctcaa 720
gattetgtaa taaacetcaa agtetggtgt agaatggtat ttteeegttt gaggtettgg 780
tagttttttt tttttttta aacatggtgc cacttttaat taactaaatg ttacaaaatt 840
ctcagcattt gtttttgtct ggtagtatta ttgagtcttt tcatacactt cttaaaatgt 900
gaaaatctat gttttcagta ttatgacagt atctgcagat actataataa tatgctttgg 960
ccaaatttgc tktttataga gtgaaccaag atgtcagttt tgtattgggg atatgtttta 1020
cataaataga actcatttaa aagtatggtt caagtactgc tcttcttttt atggggaaat 1080
tgatttttaa ggagcgattc ttttcctata taaaagctat tgaggcttag ctttattcat 1140
acatgagtga tttggttata actcaatcaa aatttttatc tttaaatctg agacaagtat 1200
tatatttaaa actagatcta ttaatacatt catcactgcc tgaaaatttg ctgttctaat 1260
gwttgtgaat tttcactcat tacctagagt aaacttattg catattttca taatcagtca 1320
aaataataaa actaaaaaca aaaagtaaaa attagttccc aagtaaatat atcagtgttt 1380
cctgtgtttg ggcagaagtg caaagtagtt ttaatttctc acgttgtaga aaaagaggcc 1440
aaaaaggtca ccttagttta tttttccaaa acataacttt aggtattcta atgtattttg 1500
ttagttgctt agaaatggaa ataaaatata tgtgcttatt aaataatgca cagtacacta 1560
gattatagag tttatttttg cttttatgct ttaaaqaatg catgcccaaa acactactac 1620
caacaagagg attttttaaa atcacagaat tgatatttat ctcaagacta tcttaagcta 1680
atgtacttct gttacataat taaactattt ctgctattat ttttaaagca gtattatttt 1740
ataaccaatt ctaaaattca gctttaaaaa tattgracat accttcctac cacttacgct 1800
tcaagtttca tttattgaat accagggtca tatcttagaa ttgtatataa aacaacatgt 1860
aacccattca tgaaaaacgt ttttaagtat tgctttttgc tgctatgttc tgcattgagc 1920
ctagttttgc cattgtcccc tgaatgtagt attatctata gattatacat aactacatct 1980
attgcttttg gtggtaaatc aagatttagt tgtaattttc cagctgtgaa aatgttgcct 2040
tgtatttaaa agggtttcat gaatggaaac ctaagtaaaa ctaagctcat tagtgacaga 2100
cttgttttct tcttgttatt cctccagcaa ctccctcacc accacgcctc cctgcctacc 2160
```

```
atccccggaa gggtgcttat tctttaacaa agagaatcta aaaaaaaaac aaaaaactgt 2220
 tgtctatatt cacgtaatgt cctggcttta ttccctgngt ttagagagca ttcctggttg 2280
 tacantgact ttgatg
                                                                    2296
 <210> 209
 <211> 625
 <212> DNA
 <213> Homo sapiens
<220>
<221> misc feature
<222> (1)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (10)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (25)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (26)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (600)
<223> n equals a,t,g, or c
<400> 209
ntctcattcn acacceaacc ttcannttca actacaactt ctccgctttg ggcaaacacc 60
gtcactcttg ctggaggcaa gcttcattcc aaagggttga aatacttcca tcactttacc 120
ctcagtctct gtggaaacca gggtaggaaa atgtctgtgt gcaccgacaa tgtcactgac 180
ctccggattc ctgagggtga gtcagggttc tccaaatcta tcacagccta cgtctgccag 240
gcagtcatca tccccccaga ggtgacaggc tacaaggccg gggtttcctc acagcctgtc 300
agcettgetg ategaettat tggggtgaea acagatatga etetggatgg aateacetee 360
ccagctgaac ttttccacct ggagtccttg ggaataccgg acgtgatctt cttttatagg 420
tccaatgatg tgacccagtc ctgcagttct gggagatcaa ccaccatccg cgtcaggtgc 480
agtccacaga aaactgtccc tggaagtttg ctgctgccag gaacgtgctc agatgggamc 540
tgtgatgget geaactteea etteetgtgg gaaaamgsgs tgsttgeeeg etetgetean 600
tggctgacta ccatgctatc gtcac
                                                                   625
<210> 210
<211> 1551
<212> DNA
<213> Homo sapiens
```

<220>

```
<221> misc feature
<222> (760)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (1543)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (1544)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (1545)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (1546)
<223> n equals a,t,g, or c
<400> 210
ttaaggetgt cegetetggg eteegeggee teggeeeget geacteeace teegeeecet 60
eggacteect eccetetget tetacteete etgeteeagt geggategtt tegeaactge 120
ttgccactcg tcccgtgcct ggctgtttty ccatttcccg gcccctctt cttgagtact 180
ttaccccctg catttgggga cagggactgg aaaaggggcg ggtggagcgt ccagtggaga 240
agaaggaage gaggeeegea gaggaggagg ateggeggae tgtggggagg agaeeeeaeg 300
ccaccettte tggteatete ccctccegee ecgeceetge geacacteee tegegggega 360
gctactttcg gaccaggaaa gtaagagcgg ccctgggtga cagcgccgcg gggccagtcc 420
cggggttagc cgcgcgtctg ctcgcttctg gtccgtcgcg ctcccagcca gggcacagcg 480
gaccgaggat qqcttcqacc acaacctqca ccaggttcac ggacgagtat cagcttttcg 540
aggagettgg aaagggggea tteteagtgg tgagaagatg tatgaaaatt cetactggae 600
aagaatatgc tgccaaaatt atcaacacca aaaagctttc tgctagggat catcagaaac 660
tagaaagaga agctagaatc tgccgtcttt tgaagcaccc taatattgtg cgacttcatg 720
atagcatate agaagagge ttteactact ttggtggttn gattaagtta etggaggtga 780
actgtttgaa gacatagtgg caagagaata ctacagtgaa gctgatgcca gtcattgcat 840
tcagcagatc ctggaggctg tgctacactg ccatcagatg ggcgtggtcc atcgggacct 900
gaagcctgag aatttgcttt tagctagcaa atccaaggga gcagctgtga aattggcaga 960
acctggatat ctttctycar aagttttacg taaagatcct tatggaaagc cagtggatat 1080
gtgggcatgt ggtgtcattc tctatattct acttgtgggg tatccaccct tctgggatga 1140
agaccaacac agactetate ageagateaa ggetggaget tatgatttte cateaccaga 1200
atgggacacg gtgactcctg aagccaaaga cctcatcaat aaaatgctta ctatcaaccc 1260
tgccaaacgc atcacagcct cagaggcact gaagcaccca tggatctgtc aacgttctac 1320
tgttgcttcc atgatgcaca gacaggagac tgtagactgc ttgaagaaat ttaatgctag 1380
aagaaaacta aagggtgcca tottgacaac tatgctggct acaaggaatt totcagcagc 1440
```

```
caagagtttg ttgaagaaac cagatggagt aaaggagtca actgagagtt caaatacaac 1500
aattgaggat gaattcagct tggacttaac caggttgact cannnngggg g
<210> 211
<211> 1011
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (309)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (801)
<223> n equals a,t,g, or c
<400> 211
tcgacccacg cgtccgggag aatggcggcg gaaggctgga tttggcgttg gggctggggc 60
eggeggtgee tgggaaggee tgggettete ggeeceggee etggeeceae tacacetete 120
tttcttcttt tgttgttggg gtctgtgact gcggatataa ctgacggcaa cagtgaacat 180
ctcaagcggg agcattcgct cattaagccc taccaagggg tcggttccag ctctatgccc 240
ctctgggact tccagggcag cactatgctc acgagccagt acgtacgtct gacccctgac 300
gagogoagna aagagggoto tatotggaac caccagoogt gottootcaa agactgggaa 360
atgcacgtcc acttcaaagt ccacggcaca gggaagaaga acctccatgg agacggcatc 420
gccttgtggt acacccggga ccgcctcgtg ccagggcctg tgtttggaag caaagataac 480
ttccacggct tagccatctt cctggacacc taccccaatg atgagaccac tgagcgcgtg 540
ttcccgtaca tctcggtgat ggtgaacaat ggctccctgt cctacgacca cagcaaggat 600
gggcgctgga ccgagctggc gggctgcacg gctgacttcc gcaaccgcga tcacgacacc 660
tteetggetg tgegetacte eeggggeegt etgaeggtga tgaeegaeet ggaggaeaag 720
aacgagtgga agaactgcat tgacatcacg ggagtgcgcc tgcccaccgg ctactacttc 780
ggggcctccg ccggcaccgg nracctgtct gacaatcatg acatcatctc catgaaagct 840
gttccaagct gatggtggaa gcacacgccc gacgaggaga agcatcgact tggaccaaga 900
tegageceag egteaaette teaagtegee caaagacaac gtggaegaee ceaeggggaa 960
ctttcgcagc gggcccctga mggggtggcg ggtgtttcct gctgctgctg t
<210> 212
<211> 1639
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (1630)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (1637)
<223> n equals a,t,g, or c
```

```
<400> 212
ggcacgagga cgcgccgagg tactaggcag agccgtggaa ccgccgccag gtcgctgttg 60
gtccacgccg cccgtcgcgc cgcccgcccg ctcagcgtcc gccgccgcca tgggagtgca 120
ggtggaaacc atctccccag gagacgggcg caccttcccc aagcgcggcc agacctgcgt 180
ggtgcactac accgggatgc ttgaagatgg aaagaaattt gattcctccc gggacagaaa 240
caagcccttt aagtttatgc taggcaagca ggaggtgatc cgaggctggg aagaaggggt 300
tgcccagatg agtgtgggtc agagagccaa actgactata tctccagatt atgcctatgg 360
tgccactggg cacccaggca tcatcccacc acatgccact ctcgtcttcg atgtggagct 420
totaaaactg gaatgacagg aatggcotco tooottagot cootgttott ggatotgcor 480
tggagggatc tggtgcctcc agacatgtgc acatgartcc atatggagct tttcctgatg 540
ttccactcca ctttgtatag acatctgccc tgactgaatg tgttctgtca ctcagctttg 600
cttccgacac ctctgtttcc tcttcccctt tctcctcgta tgtgtgttta cctaaactat 660
atgccataaa cctcaagtta ytcattttat tttgttttca ttttggggtg aagattcagt 720
ttcagtcttt tggatatagg tttccaatta agtacatggt caagtattaa cagcacaagt 780
ggtaggttaa cattagaata ggaattggtg ttgggggggg gtttgcaaga atattttatt 840
aaagccatag cagatttgag gcgctgttga ggactgaatt actctccaag ttgagagatg 960
tctttgggtt aaattaaaag ccctacctaa aactgaggtg gggatgggga gagcctttgc 1020
ctccaccatt cccacccacc ctccccttaa accetetgec tttgaaagta gateatgtte 1080
actgcaatgc tggacactac aggtatctgt ccctgggcca gcagggacct ctgaagcctt 1140
ctttgtggcc ttttttttt ttcatcctgt ggtttttcta atggactttc aggaattttg 1200
taatctcata actttccaag ctccaccact tcctaaatct taagaacttt aattgacagt 1260
ttcaattgaa ggtgctgttt gtagacttaa cacccagtga aagcccagcc atcatgacaa 1320
atccttgaat gttctcttaa gaaaatgatg ctggtcatcg cagcttcagc atctcctgtt 1380
ttttgatgct tggctccctc tgctgatctc agtttcctgg cttttcctcc ctcagcccct 1440
tctcacccct ttgctgtcct gtgtagtgat ttggtgagaa atcgttgctg cacccttccc 1500
ccagcaccat ttatgagtct caagttttat tattgcaata aaagtgcttt atgccggctt 1560
aaaaaaan ggggggncc
                                                              1639
<210> 213
<211> 2127
<212> DNA
<213> Homo sapiens
<400> 213
ttgaggttct gggggtcctg gagacttacc attgagccat gcaatctggg aagcacagga 60
tggctctctc atgtccttgg cttgctcctc tattctacct ctctttctcc agcaataata 180
tgcaaatgaa gacatgtatc cataagaagg agtgctcttc atcaactaat agagcaccta 240
ccacagtgtc atacctggta gaggtgagca attcatattc aaaggttgca aagtgtttgt 300
aatatattca tgaggctgga akkaagaaga attaaaaatt tgtcctaatt acaatgagaa 360
ccattctagg tagtgatctt ggagcacaca tgaataactt tctgaaggtg caaccaaatc 420
catttttatt tctgcctggc ttggtcacct ctgtaaaggt ttaacttagt gttgtcaagt 480
aacagttact gaaagagctg agaaaaagaa caatgaacag caacgatctt gactgtgcaa 540
ctcagacatt cctgcagaaa agacatatgt tgctttacaa gaaggccaaa gaactatggg 600
gccttcccag catttgactg ttcattgcat agaatgaatt aaatatccag ttacttgaat 660
gggtataacg catgaatatt tgtgtgtctg tgtgtgtgtc tgagttgtgt gattttatta 720
ggggcatctg ccaattetet cactgtggtt cettetetga etttgcetgt tcatcateta 780
```

aggaggetag atectteget gaetteacea tteeteaaae etgtaagttt eteaettett 840

```
ccaaattggc tttggctctt tcttcaacct ttccattcaa gagcaatctt tgctaaggag 900
taagtgaatg tgaagagtac caactacaac aattctacag ataattagtg gattgtgttg 960
tttgttgaga gtgaaggttt cttggcatct ggtgcctgat taaggcttga gtattaagtt 1020
ctcagcatat ctctctattg tcttgacttg agtttgctgc attttctatg tgctgttcgt 1080
gacttggaga acttaaagta atcgagctat gccaacttgg ggtggtaaca gagtacttcc 1140
caccacagtg ttgaaaggga gagcaaagtc ttatggataa accctccttt cttttgggga 1200
cacatggctc tcacttgaga agctcacctg tgctgaatgt ccacatggtc actaaacatg 1260
ttatccttaa accccccgta tgcctgagtt gaaagggctc tctcttatta ggttttcatg 1320
ggaacatgag gcagcaaatc tattgctaag actttaccag gctcaaatca tctgaggctg 1380
atagatattt gacttggtaa gacttaagta aggctctggc tcccaggggc ataascaaca 1440
gtttcttgaa tgtgccatct garaagggag acccaggtta tgagttttcc tttgaacaca 1500
ttggtctttt ctcaaagttc ctgccttgct agactgttag ctctttgagg acagggacta 1560
tgtcttatca atcactatta ttttcctgtt acctagcatg ggacaagtac acaacacata 1620
tttgttcaat gaatgaatga atgtcttcta aaagactcct ctgattggga gaccatatct 1680
ataattggga tgtgaatcat ttcttcagtg gaataagagc acaacggcac aaccttcaag 1740
gacatattat ctactatgaa cattttactg tgagactctt tattttgcct tctacttgcg 1800
ctgaaatgaa accaaaacag gccgttgggt tccacaagtc aatatatgtt ggatgaggat 1860
tctgttgcct tattgggaac tgtgagactt atctggtatg agaagccagt aataaacctt 1920
tgacctgttt taaccaatga agattatgaa tatgttaata tgatgtaaat tgctatttaa 1980
gtgtaaagca gttctaagtt ttagtatttg ggggattggt ttttattatt tttttccttt 2040
ttgaaaaata ctgagggatc ttttgataaa gttagtaatg catgttagat tttagttttg 2100
cagagcatgt tgtttaacaa ataaagg
                                                                   2127
<210> 214
<211> 1166
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (1163)
<223> n equals a,t,g, or c
<400> 214
gcggacgcgt gggcggacgc gtgggcggac gcgtgggcgg gtcgcttggt ggctccgtct 60
gtctgtccgt ccgcccgcgg gtgccatcat ggcggacgcg gccagtcagg tgctcctggg 120
ctccggtctc accatcctgt cccagccgct catgtacgtg aaagtgctca tccaggtggg 180
atatgageet etteeteeaa caataggaeg aaatattttt gggeggeaag tgtgteaget 240
tectggtete tttagttatg etcageacat tgecagtate gatgggagge gegggttgtt 300
cacaggetta actecaagae tgtgtteggg agteettgga actgtggtee atggtaaagt 360
tttacagcat taccaggaga gtgacaaggg tgaggagtta ggacctggaa atgtacagaa 420
agaagtotca tottootttg accaogttat caaggagaca actogagaga tgatogotog 480
ttctgctgct acceteatea cacatecett ceatgtgate actetgagat etatggtaca 540
gttcattggc agagaatcca agtactgtgg actttgtgat tccataataa ccatctatcg 600
ggaagagggc attctaggat ttttcgcggg tcttgttcct cgccttctag gtgacatcct 660
ttctttgtgg ctgtgtaact cactggccta cctcgtcaat acctatgcac tggacagtgg 720
ggtttctacc atgaatgaaa tgaagagtta ttctcaagct gtcacaggat tttttgcgag 780
tatgttgace tatecetttg tgettgtete caatettatg getgteaaca actgtggtet 840
tgctggtgga tgccctcctt actccccaat atatacgtct tggatagact gttggtgcat 900
gctacaaaaa gaggggaata tgagccgagg aaatagctta tttttccgga aggtcccctt 960
tgggaagact tattgttgtg acctgaaaat gttaatttga agatgtgggg cagggacagt 1020
```

```
gacatttctg tagtcccaga tgcacagaat tatgggagag aatgttgatt tctatacagt 1080
 1166
 aacgggggg gcccggaacc canttc
<210> 215
 <211> 3323
<212> DNA
<213> Homo sapiens
<400> 215
ggggcaaaaa ggccgagggg gcccagaatc agggcaaaaa ggccgagggg gcccagaacc 60
agggcaagaa ggcmgagggg gcccagaacc agggcargaa ggccgagggg gcccagaacc 120
aggrcaagaa ggccgagggg rcccmkaacc agggcargaa ggccgagggg gcccmgaacc 180
agggcargaa ggccgagggg gcccagaacc agggcaagaa ggccgagggg gcccagaayc 240
agggcaagaa ggccgagggg gcccagaayc agggcaagaa ggccgagggg gcccagaayc 300
agggcaagaa ggccgagggg gcccagaacc agggcaagaa ggccgagggk gctcagaacc 360
agggcaaaaa agtakaaggg gcccagaacc agggcaagaa ggctgagggg gcccagaacc 420
agggcaagaa ggccgagggg gctcagaacc agggcaaaaa ggccgaggga gcccagaacc 480
agggccaaaa aggagaggga gcccagaatc agggtaaaaa gacagaaggg gctcagggca 540
aaaaggcaga aaggagtccc aaccaaggca aaaaaggaga gggagctccc atccagggca 600
aaaaggcaga ttcggttgct aatcagggca caaaggtaga gggtattaca aaccagggga 660
aaaaagcaga agggtccccc agtgaaggca aaaaggcaga agggtccccc aaccaaggca 720
aaaaggcaga cgcagctgcc aatcagggta aaaagacaga gtcagcttct gtccagggca 780
gaaatacaga tgtggcccag agcccagagg caccaaagca agaggctcct gccaagaaga 840
agtotggtto aaagaaaaaa ggtgagootg ggoococaga tgoogaoggo cotototaco 900
tcccctacaa gacgctggtc tccacggttg ggagcatggt gttcaacgag ggcgaggccc 960
aggggeteat egagateetg tetgagaagg etggeateat teaggacace tggeacaagg 1020
ccactcagaa gggtgaccct gtggcgattc tgaaacgcca gytggaagag aaggaaaaac 1080
tgctggccac agaacaggaa gatgcggctg tcgccaagag caaaytgagg gagctcaaca 1140
aggagatggc agcagaaaag gccaaagcag cagccgggga ggccaaagtg aaaaagcagc 1200
tggtggcccg ggagcaggag atcacggctg tgcaggcacg catgcaggcc agctaccggg 1260
agcacgtgaa ggaggtgcag cagctgcagg gcaagatccg gactcttcag gagcagctgg 1320
agaatggccc caacacgcag ctggcccgcc tgcagcagga gaactccatc ctgcgggatg 1380
ccttgaacca ggccacgagc caggtggaga gcaagcagaa cgcagagctg gccaagcttc 1440
ggcaggagct cagcaaggtc agcaaagagc tggtggagaa gtcagaggct gtgcggcaag 1500
atgagcagca gcggaaagct ctggaagcca aggcagctgc cttcgagaag caggtcctgc 1560
agctgcaggc gtcccacagg gagagtgagg aggccctgca gaagcgcctg gacgaggtca 1620
gccgggaget gtgccacaeg cagageagee aegeeageet eegggeggat geegagaagg 1680
cccaggagca acagcagcag atggccgagc tgcacagcaa gttacagtcc tccgaggcgg 1740
aggtgcgcag caaatgcgag gagctgagtg gcctccacgg gcagctccag gaggccaggg 1800
eggagaacte ecageteaca gagagaatee gtteeattga ggeeetgetg gaggegggee 1860
aggcgcggga tgcccaggac gtccaggcca gccagscgga ggctgaccag cagcagactc 1920
gcctcaagga gctggagtcc caggtgtcgg gtctggagaa ggaggccatc gagctcaggg 1980
aggccgtcga gcagcagaaa gtgaagaaca atgacctccg ggagaagaac tggaaggcca 2040
tggaggcact ggccacggcc gagcaggcct gcaaggagaa gctgcactcc ctgacccagg 2100
ccaaggagga atcggagaag cagctctgtc tgattgaggc gcagaccatg gaggccctgc 2160
tggctctgct cccagaactc tctgtcttgg cacaacagaa ttacaccgag tggctgcagg 2220
atctcaaaga gaaaggcccc acgctgctga agcacccgcc agctcccgcg gagccctcct 2280
cggacctggc ctccaagttg agggaggccg aggagacgca gagcacactg caggccgagt 2340
gtgaccagta eegeageate etggeggaga eggagggeat geteagagae etgeagaaga 2400
gcgtggagga ggaggagcag gtgtggaggg ccaaggtggg cgccgcagag gaggagctcc 2460
```

```
agaagtcccg ggtcacagtg aagcatctcg aagagattgt agagaagcta aaaggagaac 2520
 ttgaaagttc ggaccaggtg agggagcaca cgtygcattt ggaggcagag ctggaaaagc 2580
acatggcggc cgccagcgcc gagtgccaga actacgccaa ggaggtggca gggctgaggc 2640
aacttctcct agaatctcaa tctcagctcg atgccgccaa gagcgaagcc agaaacagag 2700
cgatgagett gecetggtea ggeageagtt gagtgaaatg aagagecaeg tagaggatgg 2760
tgacataget ggggeeceag ettecteece agaggegeec ceageegage aggaeceegt 2820
tcagctgaag acgcagctgg agtggacaga agccatcctg gaggatgagc agacacagcg 2880
gcagaagctc acggccgagt ttgaggaggc tcagacctcg gcatgtcggt tacaagaaga 2940
attggagaag ctccgcacag ccggccccct agagtcttca gaaacagagg aggcctcaca 3000
gctgaaggag agactagaaa aagagaagaa gttaacaagt gacctggggc gcgccgccac 3060
gagactgcag gagcttctga agacgaccca ggagcagctg gcaagggaga aggacacggt 3120
gaagaagctg caggaacagc tggaaaaggc agaggacggc agcagctcaa aggagggcac 3180
ctctgtctga gtttcctctt tggaaaaaga agttactgtt caacttacca aaatgcctta 3240
ggggcccggt acccaattcg ccc
                                                                 3323
<210> 216
<211> 1408
<212> DNA
<213> Homo sapiens
<400> 216
taaactattt atcttgtgtg tgtacatttg tgggtggagt ttgtgcgcct ggtttttttg 60
tttggaaaac actgcgtggt caatgtggtt atggggggga gtgatgcatt tttttctagt 120
cttaaaacta aaaacttgag tctaccattt cttggttgca ctgaaaatac cgcccagcct 180
gatggtgttc ccgtgctgtc cctccccctt cccttctccc cgcgtctacc tccccacccc 240
gttctgttcc ccctccctcc ttctccctct ccctcaaatc cgtgagtttt ggaagcccca 300
gggcctctct cccccgcccc tectggatga ggccaccatc ccccaaaccg gcttgttttg 360
cagtttcccc aggatcctgg aagctcgctg gcgctcgagg gtggcgggga cacggggggg 420
tgggtgaagg ttcgttacct tttctagtgc gttctatcat agttaacggt tgcacacttt 480
tttaaaaaaa gtaaatggat ttgccacaat taaatgtcat aacatttatg acagaatata 540
aaatattaac atattttaag ccaagtttta ggtgtatttt ttgaatcttg gttataaacc 600
caattttaaa gggcgatgta tccagcgttg tgaaggcaac agagtgtacc catatttata 660
tttttataaa atacctataa gactgtgaat ctcttgtgct aatggctgag ttaattgaag 720
gategttttg cecettttta geeteecaga gettegagga eteaattega accegaaate 780
ctgccgtggg ggaggggttg cgtcgagacc tgggcccggg gaggttctcc tgcgtcactt 840
tetgteetga aaggegeeet teetggttte tgtggeteea attttetatg cageeceaca 900
ccccttgttg ttttgatcct gagaaataaa agggaggctg aattattcaa atttaaatga 960
ggtttcccct tcatggaagt gctgctgacc cttcgtgcag aaatggggag cacttgagga 1020
cacaggtggg tggaggccct ttgtgcgtgg ctggtcgtat tcgggcagcc ctccgtcgct 1080
ttttataaaa ctttgtgtga gaagaatata ttgataatgt cagtgaaaca agcagacatt 1140
gaaatggagg cacagattac tccacaagga gttcttctgt atattttttc tagatgcaaa 1200
taccttttta attatgttaa ttaatgttaa gactttctag gcttatatcg aagctgtgtg 1260
tgggtcacgg ggtgatcact gctaactgga taaagtttgt gcagcacatt cctgagtgta 1320
cgatattgac ctgtagccca gcgtgaaaaa tttataaata aatttttcat tgatcttttt 1380
atattaaaaa aaaaaaaaa aaaaaaaa
                                                                 1408
<210> 217
<211> 2111
```

<212> DNA

<213> Homo sapiens

```
<220>
<221> misc feature
<222> (2102)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (2104)
<223> n equals a,t,q, or c
<400> 217
ggcacgagga gcattccata tagaaactgc tgaaactgcc acaggtgctt ctccgaaaac 60
cttacagttg tggcattgaa tgttcagtat cgcttccttt ctgcacacga ggcatactgt 120
tgagcctgag aaatgccagt ggcctgacag cagcagacat tgcacaaacc cagggtttcc 180
aagagtgtgc ccagtttctc ttgaacctcc agaattgtca tctgaaccat ttctataaca 240
atggcatctt aaatgggggt catcagaatg tatttcctaa tcatattagt gtgggaacaa 300 🗀
atcgaaagag atgcttggga agactcagaa gactttggag taaagaaagc tagaactgaa 360
gctcaaagct tggattctgc cgtgccactc acgaatggcg acacagaaga cgatgctgac 420
aaaatgcacg ttgataggga gtttgctgtt gtaacagata tgaaaaacag tagctccgta 480
togaatacat tgacaatgga tgtgtcatca atggacattt ggacttcccc tccacgaccc 540
cgctcagtgg gatggaaagc aggaatggcc agtgcttgac aggaactaac ggaattagca 600
gtggattagc cccaggacag ccgtttccga gtagccaggg ttctctctgc attagtggga 660
ctgaggagcc agagaagacc ctgagagcta accetgagtt gtgeggttet ctgeacctga 720
acgggagtcc aagtagctgc atagccagta ggccttcctg ggtggaagac attggggata 780
acctgtacta tggacactac cacgggtttg gggacactgc tgaaagcatg cccagaactg 840
aacagtgtgg tcgagcattc caagtccgtg aaggtgcagg agcggtacga cagtgccgtg 900
ctgggcacca tgcacctgca ccacggctcc tagagacgct gacctggctc tcggaaacgc 960
aggagteett cetggtagee ageteagaat acceatgtag cageaacttg aacgaatgte 1020
acaacttgta ctttttttat atacttcaac tttctgaaaa agtaaacttc gacaagttcc 1080
cagcaactgc ttgtttgtgc atgagtaggg cttactaagt gcatagatgt ttctacagtg 1140
aggtgtcctt tttataaggt gcacttttgg agtttttctg atgccaatct caacattgtc 1200
tttttaatac tgtcaccaga tattgccatt tttctttttg ttaaaagatt atatgatcaa 1260
gataaattgg ggtggtaaat caggtgcctg gtaatttatc tctttgcaca tgggcatcat 1320
tttaaaaagc ttgcttccac tcttttctgt agaatttgac ggaacacagc tatttcccta 1380
tgcaaggtac agccttacaa agatttctqc agtgatttgt gtgaagaaga gaatgtttgt 1440
ctttttcaat gaagetttge agateaceat gtggttgaag gttttagttg tggacacagt 1500
ggtccctcct taatgatgaa gatcactgcc ttgggcttca tggaaaacag gcccagcctg 1560
gggctgcgtt tggatttatt gtttttattc cacacttcct acttggtctc tggaagtttt 1620
accacatgta acagattcct ttatatgtag tgaaaatcac tatttgtaga aactgtcagg 1680
tcaaaatatt taactgactg ttgacatgta ttttcttttt tccttgtttt tgttttttgg 1740
ggttttctgc tttaagatat ataccactat gtatatccag ttaactgaga gaattttgac 1800
tetettaata aaactgeatt aagtttttga ttttgtagaa attagetttt gtetaggeaa 1860
ctagtggtta tactctgcaa atattgtaat gaatttttac ttttttgatt tttgtaataa 1920
aaattggtgc agataaaatg tcaaatgaac aaaccagtgt tctaagagtg ttactaacat 1980
ananaaaaaa a
                                                              2111
```

<210> 218 <211> 2493

<212> DNA <213> Homo sapiens

<400> 218

ggcccggtgg ggccggccgg gactcgccgc tcgcacgccc ttgggccgcg gccgggcgcc 60 cgctcttcct tccgcttgcg ctgtgagctg aggcggtgta tgtgcggcaa taacatgtca 120 accecgetge cegecategt gecegeegee eggaaggeea eegetgeggt gatttteetg 180 catggattgg gagatactgg gcacggatgg gcagaagcct ttgcaggtat cagaagttca 240 catatcaaat atatctgccc gcatgcgcct gttaggcctg ttacattaaa tatgaacgtg 300 gctatgcctt catggtttga tattattggg ctttcaccag attcacagga ggatgaatct 360 gggattaaac aggcagcaga aaatataaaa gctttgattg atcaagaagt gaagaatggc 420 attectteta acagaattat tttgggaggg ttttctcagg gaggagettt atetttatat 480 actgccctta ccacacagca gaaactggca ggtgtcactg cactcagttg ctggcttcca 540 cttcgggctt cctttccaca gggtcctatc ggtggtgcta atagagatat ttctattctc 600 cagtgccacg gggattgtga ccctttggtt cccctgatgt ttggttctct tacggtgqaa 660 aaactaaaaa cattggtgaa tccagccaat gtgaccttta aaacctatga aggtatgatg 720 cacagttcgt gtcaacagga aatgatggat gtcaagcaat tcattgataa actcctacct 780 ccaattgatt gacgtcacta agaggccttg tgtagaagta caccagcatc attgtagtag 840 agtgtaaacc ttttcccatg cccagtcttc aaatttctaa tgttttgcag tgttaaaatg 900 ttttgcaaat acatgccaat aacacagatc aaataatatc tcctcatgag aaatttatga 960 tcttttaagt ttctatacat gtattcttat aagacgaccc aggatctact atattagaat 1020 agatgaagca ggtagcttct tttttctcaa atgtaattca gcaaaataat acagtactgc 1080 caccagattt tttattacat catttgaaaa ttagcagtat gcttaatgaa aatttgttca 1140 ggtataaatg agcagttaag atataaacaa tttatgcatg ctgtgactta gtctatggat 1200 ttattccaaa attgcttagt caccatgcag tgtctgtatt tttatatatg tgttcatata 1260 tacataatga ttataataca taataagaat gaggtggtat tacattattc ctaataatag 1320 ggataatgct gtttattgtc aagaaaaagt aaaatcgttc tcttcaatta atggcccttt 1380 tattttggga ccaggetttt attttccctg atattatttc tatttaatac tetttetet 1440 caagaaaaaa aaaaaagttt gttttttctt tattgtcctt catagcaggc caagtattgc 1500 ctctctgcaa tagacagcta ctgtcaatac atgctgtaat ttgacattct gggtcacaga 1560 tataaggtat ttaaaatcta tttatgcttt atagagaaac cagacattaa aacttcatgc 1620 actacttatt togaattact gtaccttatc caaatttaca cctagctatt aggatcttca 1680 acccaggtaa caggaataat totgtggttt catttttotg taaacaactg aaagaataat 1740 tagatcatat totagtatgt totgaaatat otttaagact gatottaaaa actaacttot 1800 aagatgattt catcttctca tagtatagag tttactttgt acacgtttga aaccaactac 1860 tgtagaagat gaggaatcta ttgtaatttt ttgctttatt ttcatctgcc agtggactta 1920 tttgaaattt tcactttagt caaattattt tttgtattag tttttgatgc agacataaaa 1980 atagcaatca ttttaaattg tcaaaatttc cagattactg gtaaaaatta tttgaaaaca 2040 aacttatggg taataaaggc tagtcagaac cctataccat aaagtgtagt taccatacag 2100 attaatatgt agcaaaaatg tatgcttgat atttctcaac tgtgttaatt tttctgctgt 2160 attccagctg accaaaacaa tattaagaat gcatctttat aaatgggtgc taattgataa 2220 tggaaataat ttagtaatgg actatacagg atgttaataa tgaagccata tgtttatgtc 2280 tggatttaaa aattttaaac aatcatttac tatgtcattt ttctttacct tgaagaacat 2340 aaactgttat ttcacttcta caaatcagca agatattatt tatggcaaga aatattccat 2400 tgaaatattg tgctgtaaca tgggaaagtg taaatgtttt tcatggtttc tatcaatgtg 2460 aaataaaatt taattotgaa aaaaaaaaaa aaa 2493

<210> 219

<211> 1259

<212> DNA

<213> Homo sapiens

```
<400> 219
gcgccgcgt gccggaaccg ctgggcggga gcgaggcggt gcggctgcag ctgcagggcg 60
aggagetgeg getgeaggag gagagegtge ggetgeacea gattaacate tacetcageg 120
accycatete actycaccyc cycetycecy wycyctygaa cecyctytyc aaagagaaga 180
aatatgatta tgataatttg cccaggacat ctgttatcat agcattttat aatgaagcct 240
ggtcaactct ccttcggaca gtttacagtg tccttgagac atccccggat atcctgctag 300
aagaagtgat cettgtagat gactacagtg atagagagca cetgaaggag egettggeea 360
atgagettte gggaetgeec aaggtgegee tgateegege caacaagaga gagggeetgg 420
tgcgagcccg gctgctgggg gcgtctgcgg cgargggcga tgttctgacc ttcctggact 480
gtcactgtga gtgccacgaa gggtgctgga gccgctgctg cagaggatcc atgaagagga 540
gtcggcagtg gtgtgcccgg tgattgatgt satcgactgg aacacettcg aatacetggg 600
gaactccggg gagccccaga tcggcggttt cgactggagg ctggtgttca cgtggcacac 660
agttcctgag agggagagga tacggatgca atcccccgtc gatgtcatca ggtctccaac 720
aatggctggt gggctgtttg ctgtgagtaa gaaatatttt gaatatctgg ggtcttatga 780
tacaggaatg gaagtttggg gaggagaaaa cctcgaattt tcctttagga tctggcagtg 840
tggtggggtt ctggaaacac acccatgttc ccatgttggc catgttttcc ccaagcaagc 900
tecetactee egcaacaagg etetggeeaa eagtgttegt geagetgaag tatggatgga 960
tgaatttaaa gagetetaet aecategeaa eeceegtgee egettggaae ettttgggga 1020
tgtgacagag aggaagcagc tccgggacaa gctccagtgt aaagacttca agtggttctt 1080
ggagactgtg tatccagaac tgcatgtgcc tgaggacagg cctggcttct tcgggatgct 1140
ccagaacaaa ggactaacag actactgctt tgactwtaac cctcccgatg aaaaccagat 1200
tgtgggacac caggtcattc tgtacctctg tcatgggatg ggccagaatg acctggtgc 1259
<210> 220
<211> 1849
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (920)
<223> n equals a,t,g, or c
<400> 220
ctgttgtatg gagcagggtg tgtgggtttt ctgggcccat cattatggct gcttcagagt 60
cagaagaaag ccatagggca gtaggggagc tcctattgcc tagcccctct ccctttgtgg 120
ctcccactct agetgcctat ttttgctcat cagetggtga gtcagtatgg gccagcagtt 180
ctccctccct aagcccttgc tactttatgg gttagctttg caggtttggt ggcttgaggg 240
gtgggggcaa ctcaccactg ccaggtaact ccctgaaggg tgggagtgga ttatcttcta 300
ggctcttacc cgcggtaggg aagggcatca acactgtctt ccttccattc tcctttcccc 360
catcccattt agtgctgcca cagggcagaa gcacacaaac caaccacaca gtctctgact 420
totoctaago actttgagtt gttgaatggg gotoaggggo aagagttttt gotgoootoo 480
ccagcgtggt cacagggtta ttgaactgcc tgcacttgtt tctcatgcaa ctccagcatt 540
ttccccagaa gttgaactat ggatagcagc ttggtatgga tttcctaaat cttaacattt 600
gaagcagctt cttgaggctg gcaactatcc tggtttctgt cttggagggg gtggtttgtt 660
tgctggggcc caacgtctgt cccaagtggt ggggtgagag taagttaact ttggtgccag 720
gtgagaggtg ggggctcttt gcttagactc cctatcatgg aaagattgga gttttctatg 780
cagggcactg gggaaaagga ttgctgattc tgactgaccc tgatcagaga gattaggatt 840
gtattttgac ataggatttg gaacccatct aaatgttgaa gttccctgag acagctctcc 900
agetgetgag cetgegeean gggetaagea geecetaatg agaggetetg etecetttee 960
```

```
cacctcgcca atgttgttgt tgctgccttt ttgatttgta tcctctgtta tagacatttt 1020
 ttaaaaaacga tttcctcttt cattgtgcac aagtgctgag agtctgaggc cccatttctg 1080
ctgtgtatat atatcctgac tcggggcttt tattcagcaa actgttcatt cttctgtcag 1140
acaatgtcat attcaactct gttcatatta aaccactgtg aagcaagcct ctgttttcct 1200
gcttaagttg taaatttagt attctttagt gtctaggata tgctgggtat tatgcagaaa 1260
tcatacagtg tggccagtgt cctgaggtaa tgttttgcat ttaaattttt ttagaaagca 1320
gaatcttaac ttatcttaat gatatttacc tatccttttt gcaactcaca actgactttg 1380
tcacagaggt aatgcatctg cttgcaggaa gtarctgtag gctcagtacc tgttgkttga 1440
gtcagattta gcagatttgg tttttaagct tgtgggtttg kgctaatttg ggcagaatat 1500
atttattata tatgtgtgtg tgtatgtktg tatgtgtgtg tctgcatatg taatacatgt 1560
acataaacac acatgcatgt gttcatcctc tgacacaccc acacaacacc aacaaacatt 1620
tottotatag gotttttato toaactgaca ctgtttttt toocaaataa atttgacaca 1680
ggcagaaagg tgggtgaact ctcagaactt ttggtgggtg gatattcatc tgaccagtga 1740
gctctgaaat ggtttcccta cacagagtgg gttttggcaa gggttggaat gaggggaggt 1800
agcagtcttg tcatttagaa aatcaaagct agttttgatg tagctcaac
<210> 221
<211> 1267
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (11)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (17)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (26)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (1244)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (1252)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (1264)
<223> n equals a,t,g, or c
```

```
<400> 221
cggattatgc ngamacnccc cagggnttrt gctatgacgt cgcatgcacg cgtaagcttg 60
ggcccctcga gggatcctct agagcggccg ccgcggcatt cggggaatct gcagggcaga 120
 tgagtaacga aagaggcttt gaaaatgtag aactgggagt cataggaaaa aagaagaaag 180
 tcccaaggag agtcatccac tttgttagtg gtgaaacaat ggaagaatat agcacagatg 240
aagacgaagt tgatggcctg gagaagaaag atgttttgcc tactgttgat ccgacaaaac 300
ttacctgggg tccctactta tggttttaca tgcttcgggc tgctacatca actctctcag 360
 tgtgtgactt ccttggagag aagattgcat ctgttttggg tatcagcacc ccaaagtacc 420
aatatgccat tgatgaatat tatcggatga agaaggagga agaagaagaa gaagaagaaa 480
acaggatgtc tgaagaagca gaaaaacaat atcaacagaa taaattgcag actgattcca 540
ttgttcagac agatcaacca gagacagtga tatccagctc atttgtgaat gtcaattttg 600
aaatggaggg agacagtgaa gtaattatgg aaagcaagca aaatccagtc tctgtcccac 660
cataaaatga aatgactatc aagcttcaaa ctcttaagtt ttttttttt aatacaaaaa 720
ctttcacatt ctttattcag tgggacttaa tacaattatt tatattttaa attattaaag 780
tatctggaaa gggaaaatgt tttcttcatt tttaggatct atctagcaaa agccagatct 840
gaaattcaga tatttgtact gtttttactg tgtatagaaa ttagtgcttt ggttttaaaa 900
tgatctttta aaaaagttaa ggacatccta gagccttaat agttaagaag agttaaatta 960
tcaagcctat ttgtgcattt gctttttttg aaaaaggtaa gttgctgatt aagtctaatt 1020
ggaattgata attocatagt cttagattaa aatgaggata ttttctccta gattttctca 1080
tgttatgcca tgcatttata tatctaacca ttaatttcac actaaggatg cttcaccata 1140
aaaaggggcg gacgcgtggg tccgacccgg gaattcccgg atcngtcact gncgggctga 1260
cttntct
                                                                 1267
<210> 222
<211> 754
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (702)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (710)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (754)
<223> n equals a,t,g, or c
<400> 222
cagagaactg agatgaaagc aatgatgaag ggaccctggg accctgcctt tcctctccct 60
acteageagg agettatgaa gteateteae tttetettet gteeceeete teetetteat 120
gcaggtataa agaaatatga ggccccaatt ggaacagcag catggagggt cccagttggg 180
tccccaacgt gctccccatg ggcaagacaa tggaaacttc cacaagcagg gaaggcaaac 240
cctctttatt gaacattagc cagcccagcc cagaccccag ggctgctaag gacacagaga 300
ttctccatgg gaaggggact gccaagcatg aggaaataga agattcaggg gcctgarctc 360
```

```
tggaagctgc aagcaaaagg gatgggacta gggctgagtt gtgtctycat tttgataagg 420
 aaaggatatg ctcacactct tgcttgttca gattccaaga cagaaggctt cacaaggcca 480
 acgcctggaa aatgggcatc tctccctccc atgttaagct ttaacctctg taatctgcct 540
 gtatctatag gtgggcatct cactccatca aaggagccca gcctcttttg tcctctacca 600
 tgcacagtct ttctgtgcat ttccccaagc tgggccctct tctactctca tttaggcctg 660
 tgataactca ttacccaccc atcacttgtg tcttcagggc anacttggcn aagcagggaa 720
 ttgccttgga cataaattga agggcactcc tttn
<210> 223
<211> 1258
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (41)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (1205)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (1241)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (1247)
<223> n equals a,t,g, or c
<400> 223
aacgatacag ccaaggmgat caccatcaac aagattctkt nccaacgwga gccttgtgca 60
ggagaacctg tacttccagc gctgcctaga ctggaaccgt gacatcctca agaaggagct 120
gggactgaca gagcaggaca tcattgacct gcccgctctg ttcaagatgg acgaggacca 180
ccgtgccaga gccttcttcc caaacatggt gaacatgatc gtgctggaca aggacctggg 240
catccccaag ccattcgggc cacaggttga ggaggaatgc tgcctggaga tgcacgtgcg 300
tggcctcctg gagcccctgg gcctcgaatg caccttcatc gacgacattt ctgcctacca 360
caaatttctg ggggaagtcc actgtggcac caacgtccgc aggaagccct tcaccttcaa 420
gtggtggcac atggtgccct gaccctccag gggccctggc gtttgcctcc ttmgcttart 480
tetecagace etyecteaca ygeecagage ettetgetga catggactgg acageecege 540
tgggagacct ttgggacgtg gggtggaatt tggggtatct gtgccttgcc ctccctgaga 600
ggggcctcag tgwcctctga agccatcccc agtgagcctc gactctgtcc ctgctgaaaa 660
tagctgggcc agtgtctctg tagccctgac ataaggaaca gaacacaaca aaacacagca 720
aaccatgtgc ccaaactgct ccccaaaraa ttttgagtct ctaatctgac actgaatgag 780
gggagaaggg aaggagattc tgggattgcc agttcttcca gcagccatgc tctgaaaatc 840
aaggtagaat ccatggaaag ggaccccagg accccgggac cctagacgta tcttgaactg 900
ccatcgtcat ttcaaataca tctccctcag ggtttccagg tggccacccc caatwattca 960
ttccttacca acctctcaaa tcctcttggc tttctctctg cagtgtgqac actgttggct 1020
```

```
agtcctcccc actccctgag ggtccagtaa gttaccttag aaccttcctg ggaaacattt 1080
catctggagg caggkttccc cacgtgtggg atgctccttt ttgcctcatc tgtcttcagg 1140
ggatggcagg ctcccccgca ttgcatgggg gattttttcc ccagaccagg cataatttgt 1200
ggacntgagg agtttcaatg tgttaaagat ggccctgggt naagccntat tccatctt
<210> 224
<211> 584
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (494)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (495)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (577)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (583)
<223> n equals a,t,g, or c
<400> 224
cttacccaga aggcaacgct tctctttctg gtcaaaatgg ctggtaagca ggccgtttca 60
gcatcaggca agtggctgga tggtattcga aaatggtatt acaatgctgc aggattcaat 120
aaactggggt taatgcgaga tgatacaata tacgaggatg aagatgtaaa agaagccata 180
agaagacttc ctgagaacct ttataatgac aggatgtttc gcattaagag ggcactggac 240
ctgaacttga agcatcagat cttgcctaaa gagcagtgga ccaaatatga agaggaaaat 300
ttctaccttg aaccgtatct gaaagaggtt attcgggaaa gaaaagaaag agaagaatgg 360
gcaaagaagt aatcatgtag ttgaagtctg tggatgcagc tgttatgaag atggttaaac 420
ttgaaacaaa caattttaag aattatttgg tctgaagatg ttttacttta aataaatgtc 480
aaaaaaaaa aaaaaaaaa aaaaaaaaa aaggggnggc cgnt
                                                               584
<210> 225
<211> 3449
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (2330)
<223> n equals a,t,g, or c
```

```
<220>
 <221> misc feature
 <222> (3434)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (3443)
 <223> n equals a,t,g, or c
 <400> 225
 gcgagcacgt tagaaagcct gacatggcct gactcgggac agctcagagc agggcagaac 60
 tggggacact ctgggccggc cttctgcctg catggacgct ctgaagccac cctgtctctg 120
 gaggaaccac gagcgaggga agaaggacag ggactcgtgt ggcaggaaga actcagagcc 180
gggaagcccc cattcactag aagcactgag agatgcggcc ccctcgcagg gtctgaattt 240
cctgctgctg ttcacaaaga tgctttttat ctttaacttt ttgttttccc cacttccgac 300
conggingting atothering the transfer of the confidence of the confidence of the confidence of the confidence of the confidence of the confidence of the confidence of the confidence of the confidence of the confidence of the confidence of the confidence of the confidence of the confidence of the confidence of the confidence of the confidence of the confidence of the confidence of the confidence of the confidence of the confidence of the confidence of the confidence of the confidence of the confidence of the confidence of the confidence of the confidence of the confidence of the confidence of the confidence of the confidence of the confidence of the confidence of the confidence of the confidence of the confidence of the confidence of the confidence of the confidence of the confidence of the confidence of the confidence of the confidence of the confidence of the confidence of the confidence of the confidence of the confidence of the confidence of the confidence of the confidence of the confidence of the confidence of the confidence of the confidence of the confidence of the confidence of the confidence of the confidence of the confidence of the confidence of the confidence of the confidence of the confidence of the confidence of the confidence of the confidence of the confidence of the confidence of the confidence of the confidence of the confidence of the confidence of the confidence of the confidence of the confidence of the confidence of the confidence of the confidence of the confidence of the confidence of the confidence of the confidence of the confidence of the confidence of the confidence of the confidence of the confidence of the confidence of the confidence of the confidence of the confidence of the confidence of the confidence of the confidence of the confidence of the confidence of the confidence of the confidence of the confidence of the confidence of the confidence of the confidence of the confidence of the confidence of the confidence of the confidence of the confidence of the confidence of the conf
acctcaaccc gtcttacctc ttcttgacct gaacaatcag tctgtgggaa ttgagggagg 420
agcacggaag ggggtttccc agaagaacaa tgacctaaca agttgctgct tctcagatgc 480
caagactatg tatgaggttt tccaaagagg actcgctgtg tctgacaatg ggccctgctt 540
gggatataga aaaccaaacc agccctacag atggctatct tacaaacagg tgtctgatag 600
agcagagtac ctgggttcct gtctcttgca taaaggttat aaatcatcac cagaccagtt 660
tgtcggcatc tttgctcaga ataggccaga gtggatcatc tccgaattgg cttgttacac 720
gtactctatg gtagctgtac ctctgtatga caccttggga ccagaagcca tcgtacatat 780
tgtcaacaag gctgatatcg ccatggtgat ctgtgacaca ccccaaaagg cattggtgct 840
gatagggaat gtagagaaag gcttcacccc gagcctgaag gtgatcatcc ttatggaccc 900
ctttgatgat gacctgaagc aaagagggga gaagagtgga attgagatct tatccctata 960
tgatgctgag aacctaggca aagagcactt cagaaaacct gtgcctccta gcccagaaga 1020
cctgagcgtc atctgcttca ccagtgggac cacaggtgac cccaaaggag ccatgataac 1080
ccatcaaaat attgtttcaa atgctgctgc ctttctcaaa tgtgtggagc atgcttatga 1140
geocactect gatgatgtgg coatatecta ectecetetg geteatatgt ttgagaggat 1200
tgtacaggct gttgtgtaca gctgtggagc cagagttgga ttcttccaag gggatattcg 1260
gttgctggct gacgacatga agactttgaa gcccacattg tttcccgcgg tgcctcgact 1320
ccttaacagg atctacgata aggtacaaaa tgaggccaag acacccttga agaagttctt 1380
gttgaagetg getgttteea gtaaatteaa agagetteaa aagggtatea teaggeatga 1440
tagtttctgg gacaagctca tctttgcaaa gatccaggac agcctgggcg gaagggttcg 1500
tgtaattgtc actggagctg cccccatgtc cacttcagtc atgacattct tccgggcagc 1560
aatgggatgt caggtgtatg aagcttatgg tcaaacagaa tgcacaggtg gctgtacatt 1620
tacattacct ggggactgga catcaggtca cgttggggtg cccctggctt gcaattacgt 1680
gaagctggaa gatgtggctg acatgaacta ctttacagtg aataatgaag gagaggtctg 1740
catcaagggt acaaacgtgt tcaaaggata cctgaaggac cctgagaaga cacaggaagc 1800
cctggacagt gatggctggc ttcacacagg agacattggt cgctggctcc cgaatggaac 1860
tctgaagatc atcgaccgta aaaagaacat tttcaagctg gcccaaggag aatacattgc 1920
accagagaag atagaaaata totacaacag gagtoaacca gtgttacaaa tttttgtaca 1980
cggggagagc ttacggtcat ccttagtagg agtggtggtt cctgacacag atgtacttcc 2040
ctcatttgca gccaagcttg gggtgaaggg ctcctttgag gaactgtgcc aaaaccaagt 2100
tgtaagggaa gccattttag aagacttgca gaaaattggg aaagaaagtg gccttaaaac 2160
ttttgaacag gtcaaagcca tttttcttca tccagagcca ttttccattg aaaatgggct 2220
cttgacacca acattgaaag caaagcgagg agagctttcc aaatactttc ggacccaaat 2280
tgacagcctg tatgagcaca tccaggatta ggataaggta cttaagtacn tgccggccca 2340
```

```
ctgtgcactg cttgtgagaa aatggattaa aaactattct tacatttgtt ttgcctttcc 2400
 tcctattttt ttttaacctg ttaaactcta aagccatagc ttttgtttta tattgagaca 2460
 tataatgtgt aaacttagtt cccaaataaa tcaatcctgt ctttcccatc ttcgatgttg 2520
 ctaatattaa ggcttcaggg ctacttttat caacatgcct gtcttcaaga tcccagttta 2580
 tgttctgtgt ccttcctcat gatttccaac cttaatacta ttagtaacca caagttcaag 2640
 ggtcaaaggg accetetgtg cettettett tgttttgtga taaacataac ttgccaacag 2700
 tctctatgct tatttacatc ttctactgtt caaactaaga gatttttaaa ttctgaaaaa 2760
ctgcttacaa ttcatgtttt ctaqccactc cacaaaccac taaaatttta gttttaqcct 2820
atcactcatg tcaatcatat ctatgagaca aatgtctccg atgctcttct gcgtaaatta 2880
aattgtgtac tgaagggaaa agtttgatca taccaaacat ttcctaaact ctctagttag 2940
atatctgact tgggagtatt aaaaattggg tctatgacat actgtccaaa aggaatgctg 3000
ttcttaaagc attatttaca gtaggaactg gggagtaaat ctgttcccta cagtttgctg 3060
ctgagctgga agctgtgggg gaaggagttg acaggtgggc ccagtgaact tttccagtaa 3120
atgaagcaag cactgaataa aaacctcctg aactgggaac aaagatctac aggcaagcaa 3180
gatgcccaca caacaggctt attttctgtg aaggaaccaa ctgatctccc ccacccttgg 3240
attagagttc ctgctctacc ttacccacag ataacacatg ttgtttctac ttgtaaatgt 3300
aaaaaaaaa aaangggggg ccnttttaa
                                                                3449
<210> 226
<211> 1866
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (1859)
<223> n equals a,t,g, or c
<400> 226
caccaatgtt gataaactgg tgaaggacat ttacggagga gactatgaac gatttggcct 60
tcaaggatct gctgtagcat caagctttgg caacatgatg agtaaagaaa agcgagattc 120
catcagcaag gaagacctcg cccgggccac attggtcacc atcaccaaca acattggctc 180
cattgctcgg atgtgtgcgt tgaatgagaa catagacaga gttgtgtttg ttggaaattt 240
tctcagaatc aatatggtct ccatgaagct gctggcatat gccatggatt tttggtccaa 300
aggacaactg aaagctctgt ttttggaaca tgagggttat tttggagccg ttggggcact 360
gttggaactg ttcaaaatga ctgatgayaa gtagagacga gcagtggagg aaacagcctc 420
ccaaaaggac agagaactaa aaaattgctg ctggagaagg tgaaagtcgc tttgggacgg 480
aagccaagcc attatggcag atgaacctgc tggatttgta aataatttaa aatccttcca 540
gatgatettt taetettagg ttttgageta atgatteaaa aegggggaat ataaaaggtt 600
ttttttctgt atactgtatt tttttaaaaa aatggtgcag cgtggccaaa cctaccaatt 660
gtatgcatta actttgaaaa gttgtttgat gtttaagaag gacctgatat gtaagcqctg 720
gtcatttttc ttctggggtt tactgatcag tgtggtgatt ttaacttcat ttagtaatta 780
ctctaggaga ttttaccttg acttatattt ttcatgacgt ttcatgattt gctgttggtt 840
tcaaatgaaa ctacaaatct ggcatgtttt actgtgaaca cttttgttat ttgttttgta 900
cccttttttg tcttgktttt ctgktttagt tgkcttctga aaaaagagtc gttccctctg 960
tttctgtcct cagatgatgt ccctcccct acctgtaacc tttctttgac ataattgttc 1020
atatcaatga aggtgctgac cagctcaata caaagttaag cacaagatct aaagctcttg 1080
aaaatgcccg tgaagagaag actgaatgtg ttaatgaatt taatgagtct ggcaaaagtt 1140
gcaaattata tgcaagtttg tcctatcgct tataaatgta gtgtttcatt ggatttattt 1200
```

```
tatgctaggt tatattaagt tgaaatagtc tgtgattaaa tgtcctcatc catgcacaga 1260
atatgaatgg cagcaaatct ttgtgcaaga aatttgaaac ttattgggaa aagcctccca 1320
gtagattaat tgttcatatc aggagattta gggtaagtca tgggttgagg tgtcagatag 1380
taatatotat ttgttttgta catgtatata totaggaact ttgtaacaac acatotttaa 1440
taatgttaaa ggttttttca tttttaatat tttaaactaa aaactgtact tcaatctcag 1500
tttctaaaat taaaaataat ttatactgat ctatatattt tttctttttg aaagatttca 1560
ttaagactga tgggtaactt tcaaatgagg gtcatgtaca aatattggga tgcatgagat 1620
cccatgatct tgtgtattga gcttattgtt gaaagggatt tttgaaggac agaacaatta 1680
ctccatgatg aatcttcctt tctctgcctt ctgagcaccg tctttaattt ccatatcttc 1740
aagtottgaa gaagttgatg ttaattgaag aattoacttg totggttgaa ataaagcotg 1800
tttctgttgt gaaaaaaaa aaaaaaaact sgtggggggc ccggacccaa ttgccctang 1860
ggagcc
<210> 227
<211> 1064
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (209)
<223> n equals a,t,g, or c
<400> 227
ggcaacagca tggccacaat tttatagcag caaaatgaag caaaaatcaa aggagttagc 60
aaaggcagaa acatatgtgt agtgtgctgc cagcataaga tggaagaact taaagaaggc 120
ctgcggcaaa gaqatgagct tattgaggag aagcagcgca tgcagcagaa aatagacacc 180
atgacaaaag aggtgtttga cctccaggng acacttcttt ggaaagataa aaaaattgrg 240
aaacatggct tagttataat ccccgatggc actcccaatg gtgatgtcag tcatgaacca 300
gtggctggag ccatcactgt tgtgtctcag gaagctgctc aggtcttgga gtcagcagga 360
gaagggccat tagatgtaag gctacgaaaa cttgctggag agaaggaaga actactgtca 420
cagattagaa aactgaagct tcagttagag gaggaacgac agaaatgctc caggaatgat 480
ggcacagtgg gtgacctggc aggactgcag aatggctcag acttgcagtt catcgaaatg 540
cagagagatg ccaatagaca aattagcgaa tacaaattta agctttcaaa agcagaacag 600
gatataacta ccttggagca aagtattagc cggcttgagg gacaggttct gagatataaa 660
actgctgctg agaatgctga gaaagttgaa gatgaattga aagcagaaaa acggaagcta 720
caacgagagt tacgaacagc actggacaag attgaggaga tggagatgac caacagccac 780
ctggccaagc ggctggagaa gatgaaggcc aataggacag cacttctggc ccagcagtag 840
gaaaaccacc cttcaacctg ggtgatgctc cttggggccc tacctagagg gactgacttt 900
tgtccattga cacaaacccc ttttagtact gttttgagtt ttgtcattaa aacagccacc 960
tttgtatttt ataatttatg acagratgaa gtcattttga atctacatga atgaacactt 1020
                                                                  1064
tggatttttg ttggagtttg attctagggt agaaccagtc catg
<210> 228
<211> 373
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (329)
```

```
<223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (332)
 <223> n equals a,t,g, or c
 <400> 228
 gctgcactct caggtattcc ctgctcttac tccaaaaaga tggacccagg tccgaagggg 60
 cactgccact gtggggggca tggccatcct ccaggtcact gcgggccacc ccctggccat 120
 ggcccagggc cctgcgggcc accccccac catggcccag ggccctgcgg gccacccccc 180
caccatggtc cagggccetg cgggccaccc cctggccatg gcccagggcc ctgcgggcca 240
ecceccace atggtecagg geoetgeggg cetecceetg gecatggees aggteaceca 300
ccccctggtc cacatcactg aggaagtana anaaaacagg acacaagatg gcaagcctga 360
gagaaattgc cca
                                                                   373
<210> 229
<211> 2844
<212> DNA
<213> Homo sapiens
<400> 229
tcgacccacg cgtccgcagg tgttcaagat ggcggtagct gaggggttga ccgagagacc 60
cagttgamgg cctttacgaa gtgaaagagg ccgggaatcg cccctaccc gcttctcgta 120
gtcctgggag cacagcagaa gtgtttttct ttttttaatg aacaagtaaa ccatacaaat 180
tgtcaacatg ggacggagat ctacatcatc caccaagagt ggaaaattta tgaaccccac 240
agaccaagcc cgaaaggaag cccggaagag agaattaaag aagaacaaaa aacagcgcat 300
gatggttcga gctgcagttt taaagatgaa ggatccaaaa cagataatcc gagacatgga 360
gaaattggat gaaatggagt ttaacccagt gcaacagcca caattaaatg agaaagtact 420
gaaagacaag cgtaaaaagc tgcgtgaaac ctttgaacgt attctacgac tctatgaaaa 480
agagaatcca gatatttaca aagaattgag aaagctagaa gtagaatatg aacagaagag 540
ggctcaactt agccaatatt ttgatgctgt caagaatgct cagcatgtgg aagtggagag 600
tattcctttg ccagatatgc cacatgctcc ttccaacatt ttgatccagg acattccact 660
tectggtgee cagecaceet etateetaaa gaaaacetea geetatggae etecaacteg 720
ggcagtttct atcettcete ttettggaca tggtgtteca egtttgeece etggcagaaa 780
acctectgge cetececetg gtecacetee teeteaagte gtgeagatgt atggeegtaa 840
agtgggtttt gccctagatc ttccccctcg taggcgagat gaagacatgt tatatagtcc 900
tgaacttgcc cagcgaggtc atgatgatga tgtttctagc accagtgaag atgatggcta 960
tcctgaggac atggatcaag ataagcatga tgacagtact gatgacagtg acaccgacaa 1020
atcagatgga gaaagtgacg gggatgaatt tgtgcaccgt gataatggtg agagagacaa 1080
caatgaagaa aagaagtcag gtctgagtgt acggtttgca gatatgcctg gaaaatcaag 1140
gaagaaaaag aagaacatga aggaactgac teetetteaa geeatgatge ttegtatgge 1200
aggtcaagaa atccctgagg agggacggga agtagaggaa ttttcagagg acgatgatga 1260
agatgattot gatgactotg aagcagaaaa gcaatcacaa aagcagcata aagaggaato 1320
ccattctgat ggcacatcca ctgcttcttc acagcagcag gctccgccgc agtctgttcc 1380
teetteteag atacaageae eteecatgee aggaceacea cetettggae caccacetge 1440
tecaccatta eggeeteetg ggeeacetae aggeetteet eetggteeae etccaggage 1500
testecatte etgagaceae etggaatgee aggacteega gggeeettae eeegaetttt 1560
acetecagga ccaccaccag geogaecece tggecetece ecaggtecae etecaggtet 1620
gcetcctggt ccccctcctc gtggaccccc accaaggcta cctccccttg cacctccagg 1680
tattectoca cetegteetg geatgatgeg eccacetttg gtgeeteece ttggaeetge 1740
```

```
ccccctggg ctgttcccac cagctccctt gccaaaccct ggggttttaa gtgccccacc 1800
 caacttgatt cagcgaccca aggcggatga tacaagtgca gccaccattg agaagaaagc 1860
 cacagcaacc atcagtgcca agccacagat cactaatccc aaggcagaga ttactcgatt 1920
 tgtgcccact gcactgagag tacgtcggga gaataaaggg gctactgctg ctccccaaag 1980
 aaagtcagag gatgattotg otgtgootot tgocaaagca gcacccaaat otggtootto 2040
 tgttcctgtc tcagtacaaa ctaaggatga tgtctatgag gctttcatga aagagatgga 2100
 agggctactg tgacagcttt tgatgccaga aaaggcttct gttcacaaca gtggcccatg 2160
 gagaaagagg ctcttattaa acttagatga aagagctgct tccattgtca gggtattttc 2220
 taatttcagt tcaaggaata tcctaaaatt tagccttgtt cagaatttac tgcacataaa 2280
 aaagggtatt tcatccagaa tagatcagtt attgaagcag tgctgctaac atccattccc 2340
 tttcatacca ccattttcac cctgtttctt cccctcctcc agttctttgg aaatttgtga 2400
 tcgggggatc ttagttgctt atttgttttg actcttgtgt gctgtgggca ctggagtaga 2460
 gatttctgga gaaaaaaaa cagtttattt catcttgcct tttgtgtttg agttattttt 2520
 aatattttcc tgtaaatatt ttgtaatatt ttacttgtaa tgaaatggat cacaatgtca 2580
 tttcctaata caaggcagga tatgtgggaa gaatatgtac aattatttga ttaaaattat 2640
 ttcccactga cctaaacttt cagtgatttg tgggaaaaat aaataaatgt tctacaccaa 2700
 gatactctgt gttactgata atatgtaaac ataataccta ttttatggga caggaaaaag 2760
ttaaaatatt taaaaacttg gggtttttaa gggaactgcc tttctgggta cagatgagga 2820
tcttactgga aaactgggta aaaa
<210> 230
<211> 1798
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (1)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (15)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (24)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (31)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (501)
<223> n equals a,t,g, or c
```

<220>

```
<221> misc feature
 <222> (1798)
<223> n equals a,t,g, or c
<400> 230
ngcaaatata cgtgnacact tatnaaaagt nacgcctgac acgtgaccgg ttccgggaat 60
tecegggteg acceaegegt eeggeeeage actagaagte ggeggtgttt ceatteggtg 120
atcagcactg aacacagagg actcaccatg gagtttgggc tgagctgggt tttcctcqtt 180
gctcttttaa gaggtgtcca gtgtcaggtg cagctggtgg agtctggggg aggcgtggtc 240
cagcctggga ggtccctgag actctcctgt gcagcstctg gattcacctt cagtagctat 300
ggcatgcact gggtccgcca ggctccaggc aaggggctgg agttgggtggc agttatatsr 360
tatgatggaa gtaataaata ctatgcagac tccgtgaagg gccgattcac catctccaga 420
gacaattcca agaacacgct gtatctgcaa atgaacagcc tgagagctga ggacacggct 480
gtktattact gtgcgaraga ngttactatg gttcggaaag catctactac tactttgact 540
ctggggccag ggaacmctgg tcaccgtctc ctcagcctcc accaagggcc catcggtctt 600
ccccctggca ccctcctcca agagcacctc tgggggcaca gcggccctgg gctgcctggt 660
caaggactac ttccccgaac cggtgacggt gtcgtggaac tcaggcgccc tgaccagcgg 720
cgtgcacacc ttcccggctg tcctacagtc ctcaggactc tactccctca gcagcgtggt 780
gaccgtgccc tccagcagct tgggcaccca gacctacatc tgcaacgtga atcacaagcc 840
cagcaacacc aaggtggaca agaragttga gcccaaatct tgtgacaaaa ctcacacatg 900
cccaccgtgc ccagcacctg aactcctggg gggaccgtca gtcttcctct tccccccaaa 960
acccaaggac accctcatga tctcccggac ccctgaggtc acatgcgtgg tggtggacgt 1020
gagccacgaa gaccctgagg tcaagttcaa ctggtacgtg gacggcgtgg aggtgcataa 1080
tgccaagaca aagccgcggg aggagcagta caacagcacg taccgtgtgg tcagcgtcct 1140
caccetcctg caccaggact ggctgaatgg caaggagtac aagtgcaagg tctccaacaa 1200
agecetecea geceecateg agaaaaceat etecaaagee aaagggeage eeegagaace 1260
acaggtgtac accetgeece cateeeggga kgagmtgace aagaaccagg teageetgae 1320
ctgcctggtc aaaggcttct atcccagcga catcgccgtg gagtgggaga gcaatgggca 1380
gccggagaac aactacaaga ccacqcctcc cgtqctggac tccgacggct ccttcttcct 1440
ctayagcaag ctcaccgtgg acaagagcag gtggcagcag gggaacgtct tctcatgctc 1500
cgtgatgcat gaggetetge acaaccacta cacgeagaag ageeteteee tgteyeeggg 1560
taaatgagtg cgacggccgg caagcccccg ctccccgggc tetcgcggtc gcacgaggat 1620
gcttggcacg taccccgtst acatacttcc crggcrccca gcatggaaat aaagcaccca 1680
aaaaaaaaa aaaaaaaaaa aaaaaaaaaaa 1798
<210> 231
<211> 1823
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (82)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (1593)
<223> n equals a,t,q, or c
```

```
<220>
 <221> misc feature
 <222> (1714)
 <223> n equals a,t,g, or c
 <400> 231
 gtegeetgee acceptteg gecaeggeea gacgeeegeg geetteetea gegetetget 60
 gccctcgcag ccgccgcgg gncggtcaac gccctggggc tgcccaaggg tgtcacccc 120
 gcagatttcc aaagaaggcc agtagaactg ctagaatagc ctccgatgag gaaattcaag 180
gcacaaagga tgctgttatt caagacctgg aacgaaaact tcgcttcaag gaggacctcc 240
 tgaacaatgg ccagccgagg ttaacatacg aagaaagaat ggctcgtcga ctgctaggtg 300
ctgacagtgc aactgtcttt aatattcagg agccagaaga ggaaacagct aatcaggaat 360
acaaagtctc cagctgtgaa cagagactca tcagtgaaat agagtacagg ctagaaaggt 420
ctcctgtgga tgaatcaggt gatgaagttc agtatggaga tgtgcctgtg gaaaatggaa 480
tggcaccatt ctttgagatg aagctgaaac attacaagat ctttgaggga atgccagtaa 540
ctttcacatg tagagtggct ggaaatccaa agccaaagat ctattggttt aaagatggga 600
agcagatete tecaaagagt gateactaea ceatteaaag agatetegat gggacetget 660
ccctccatac cacagectec accetagatg atgatgggaa ttatacaatt atggetgeaa 720
acceteaggg eegeateagt tgtaetggae ggetaatggt acaggetgte aaccaaagag 780
gtcgaagtcc ccggtctccc tcaggccatc ctcatgtcag aaggcctcgt tctagatcaa 840
gggacagtgg agacgaaaat gaaccaattc aggagcgatt cttcagacct cacttcttgc 900
aggctcctgg agatctgact gttcaagaag gaaaactctg cagaatggac tgcaaagtca 960
gtgggttacc aaccccagat ctaagctggc aactagatgg aaagcccgta cgccctgaca 1020
gtgctcacaa gatgctggtg cgtgagaacg gggtgcactc tctgatcata gagccagtca 1080
cgtcacgtga tgccggcatc tacacatgta tagctaccaa ccgagcagga cagaactcat 1140
tcagcctgga gcttgtggtt gctgctaaag aagcacaaa accccctgtg tttattgaga 1200
agctccaaaa cacaggagtt gctgatgggt acccagtgcg gctggaatgt cgtgtattgg 1260
gagtgccacc acctcagata ttttggaaga aagaaaatga atcactcact cacagcactg 1320
accgagtgag catgcaccag gacaaccacg gctacatctg cctgctcatt cagggagcca 1380
caaaagaaga tgctgggtgg tatactgtgt cagccaagaa tgaagcaggg attgtgtcct 1440
gtactgccag gctggacgtt tacacccagt ggcatcagca gtcacagagc accaagccaa 1500
aaaaagtacg gccctcagcc agtcgctatg cagcactttc ggaccaggga ctagacatca 1560
aagcagcgtt ccaacctgag gccaacccat ctnacctgac actgaatact gccttggtag 1620
aaagtgagga cctgtaatcc agcattcttg ktaaagctga aacacttgaa acagscattg 1680
scttgaccaa catatteett tgteacatta tgtnaaagge agaameatae etttgetatt 1740
agaaattaaa aaaacaccaa aatatatttt ctacttgaat accaacttag tttaagtaga 1800
taatgctaat acaaatatac aca
                                                                   1823
<210> 232
<211> 970
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (936)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (960)
```

WO 00/55351 PCT/US00/05883

```
<223> n equals a,t,g, or c
 <400> 232
 aattogggao gagggoagoo ogottgooaa toagagogoo gotgagoggo coogoagooa 60
 acceccgagg ageggeegge tggegteege egegeeeagg agttggggat gteetacaaa 120
 cccatcgccc ctgctcccag cagcacccct ggctccagca cccctgggcc gggcaccccg 180
 gtccctacag gaagegteec gtegeegteg ggeteagtge caggageegg egeteettte 240
 agaccgctgt ttaacgactt tggaccgcct tccatgggct acgtgcaggc gatgaagcca 300
 eccggegeee agggeteeea gageaeetae aeggaeetge tgteagteat agaggagatg 360
 ggcaaagaga tccggcctac ctatgctggc agcaagagcg ccatggagcg cytgaagaga 420
ggaagegeet eggeeteage gtetggaeet ateeggeeae tgeagageae eegettetee 480
ctggccttca tcccgagttg cactaaccat cctgggcttc ctgtcctgtg tcccttggtg 540
ggtcccctcc aggaaccaag gagtggccct ccaggtggca gcactaagga cacccccca 600
caacaagagt tagcagcgag gtccccatga gtcccaccca tgacctgccg acagtgttgc 660
ccaccggaac ttttgtggcc cctaccgctc agcccttccc agcacttctc ccactttgtc 720
ccgagcctcc ttctccccca gcaggggcac aggcctggca cctccctgcc ttgtgtcctg 780
agccatagtg actetttat etgtgtgtet tttgetaaat atgeeetttt tatattaata 840
aaaaaaaggg cggccgctct agaggatcca tgcttnacgt acgcgtgcat gcgtacgtcn 960
ttgctcttct
                                                                 970
<210> 233
<211> 967
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (923)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (926)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (955)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (957)
<223> n equals a,t,g, or c
<400> 233
ggcagagcac ttcctggcca ggaaacctga gcggtgagac tcccagctgc ctacatcaag 60
gccccaggac atgcagaacc ttcctctaga acccgaccca ccaccatgag gtcctgcctg 120
tggagatgca ggcacctgag ccaaggcgtc cagtggtcct tgcttctggc tgtcctggtc 180
ttetttetet tegeettgee etettttatt aaggageete aaacaaagee tteeaggeat 240
```

```
caacgcacag agaacattaa agaaaggtct ctacagtccc tggcaaagcc taagtcccag 300
 gcacccacaa gggcraggag gacaaccatc tatgcagagc cagygccaga gaacaatgcc 360
 ctcaacacac aaacccagcc caaggcccac accaccggag acagaggaaa ggaggccaac 420
 caggcaccgc cggaggagca ggacaaggtg ccccacacag cacagagggc agcatggaag 480
 agcccagaaa aagagaaaac catggtgaac acactgtcac ccagagggca agatgcaggg 540
 atggcctctg gcaggacaga ggcacaatca tggaagagcc aggacacaaa gacgacccaa 600
 99aaat9999 gccagaccag gaagctgacg gcctccagga cggtgtcaga gaagcaccag 660
 ggcaaagcgg caaccacagc caagacgstc attyccaaaa gtcagcacag aatgctggct 720
yccacaggag cagtgtcaac aaggacgaga cagaaaggar tkaccacagc agtcatccca 780
cctaaggaga agaaacctca ggccacccca cccctgccc ctttccagag ccccacgacg 840
cagagaaacc aaagactgaa gggcggcaac ttcaaatctg agcctcggtg ggattttgag 900
gaaaaataca agcttcgaaa tanganggct tcagacgact tggccttgac tctgngnaga 960
tcaaaag
<210> 234
<211> 2163
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (1140)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (1157)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (1158)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (1166)
<223> n equals a,t,g, or c
<400> 234
gcccgagcct gcgatggctc ttccccaccg gaggctcagt ccgtggctgc gtcaaaggca 60
tcaaggccct gggcaagtat gtggacctca agcggctgaa cacgacaggc gtgacgccgg 120
etgeacygee gacetgetgg tggggegege catgacttte catggecacg getteetteg 180
ectggegete tegaacgtgg cacegeteae tggeaacgte tacteegget teggetteea 240
cagegeecag gacagtgeec tgetetaeta eegggegtee eeggatggge tatgeeaggt 300
gtccctgcag cagggccgtg tgagcctaca gctcctgagg actgaagtga aaactcaagc 360
gggcttcgcc gatggtgccc cccattacgt cgccttctac agcaatgcca cgggagtctg 420
gctgtatgtc gatgaccagc tccagcagat gaagccccac cggggaccac cccccgagct 480
ecageegeag cetgagggge ceeegagget ceteetggga ggeetgeetg agtetggeae 540
catttacaac ttcagtggct gcatcagcaa cgtcttcgtg cagcggctcc tgggcccaca 600
gcgcgtattt gatctgcagc agaacctggg cagcgtcaat gtgagcacgg gctgtgcacc 660
```

```
egecetgeaa geceagaeee egggeetggg geetagagga etgeaggeea eegeceggaa 720
 ggcctcccgc cgcagccgtc agcccgcccg gcatcctgcc tgcatgctgc ccccacacct 780
 caggaccacc cgagactcct accagtttgg gggttccctg tccagtcacc tggagtttgt 840
 gggcatcctg gcccgacata ggaactggcc cagtctctcc atgcacgtcc tcccgcgaag 900
 ctcccgaggc ctcctcctct tcactgcccg tctgaggccc ggcagcccct ccctggcgct 960
 cttcctgagc aatggccact tcgttgcaca gatggaaggc ctcgggactc ggctccgcgc 1020
 ccagagccgc cagcgctccc ggcctggcgc tggcacaagg tctccgtgcg ctgggagaag 1080
 aaccggatcc tgctggtgac ggacggggcc cgggsctgga gccaggaggg gccgcaccgn 1140
 agcaccaggg ggcagannac ccccangccc cacaccctct ttgtgggcgg cctcccggcm 1200
 agcagecaca getecaaact teeggtgace gtegggttea geggetgtgt gaagagaetg 1260
aggetgeacg ggaggeeeet gggggeeeee acaeggatgg caggggteae accetgeate 1320
ttgggccccc tggaggcggg cctgttcttc ccaggcagcg ggggagttat cactttagac 1380
ctcccaggag ctacactgcc tgatgtgggc ctggaactgg aggtgcggcc cctggcagtc 1440
accegactga tettecaett gegeeaggee eggacgeece cetaettgea gttgeaggtg 1500
accgagaagc aagteetget gegggeggat gaeggageag gggagttete caegteataa 1560
cccgcccctc agtgctgtgt gatggccagt ggcaccggct agcggtgatg aaaagcggga 1620
atgtgctccg gctggaggtg gacgcgcaga gcaaccacac cgtgggcccc ttgctggcgg 1680
ctgcagctgg tgccccagcc cctctgtacc tcgggggcct gcctgagccc atggccgtgc 1740
agecetggee eccegeetae tgeggetgea tgaggagget ggeggtgaac eggteeeeeg 1800
tegecatgae tegetetgtg gaggteeacg gggeagtggg ggeeagtgge tgeecageeg 1860
cctaggacac agccaaccc ggccctggt caggccctg cagctgcctc acaccgcccc 1920
ttgtgctcgc ctcataggtg tctatttgga ctctaagctc tacgggtgac agatcttgtt 1980
tctgaagatg gtttaagtta tagcttctta aacgaaagaa taaaatactg caaaatgttt 2040
ttatatttgg cccttccacc catttttaat tgtgagagat ttgtcaccaa tcatcactgg 2100
aaa
                                                                 2163
<210> 235
<211> 1321
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (1313)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (1320)
<223> n equals a,t,g, or c
<400> 235
gegegaegee gecaecteeg gaacaageea tggtggegge gaeggtggea geggegtgge 60
tgctcctgtg ggctgcggcc tgcgcgcagc aggagcagga cttctacgac ttcaaggcgg 120
tcaacatccg gggcaaactg gtgtcgctgg agaagtaccg cggatcggtg tccctggtgg 180
tgaatgtggc cagcgagtgc ggcttcacag accagcacta ccgagccctg cagcagctgc 240
agcgagacct gggcccccac cacttcaacg tgctcgcctt cccctgcaac cagtttggcc 300
aacaggagee tgacagcaac aaggagattg agagetttge eegeegcace tacagtgtet 360
cattccccat gtttagcaag attgcagtca ccggtactgg tgcccatcct gccttcaagt 420
acctggccca gacttctggg aaggagccca cctggaactt ctggaagtac ctagtagccc 480
```

```
cagatggaaa ggtggtaggg gcttgggacc caactgtgtc agtggaggag gtcagacccc 540
agatcacage getegtgagg aageteatee taetgaageg agaagaetta taaccacege 600
gtotoctcct ccaccacctc atcccgccca cctgtgtggg gctgaccaat gcaaactcaa 660
atggtgcttc aaagggagag acccactgac tetecttect ttactettat gccattggtc 720
ccatcattct tgtgggggaa aaattctagt attttgatta tttgaatctt acagcaacaa 780
ataggaactc ctggccaatg agagctcttg accagtgaat caccagccga tacgaacgtc 840
ttgccaacaa aaatgtgtgg caaatagaag tatatcaagc aataatctcc cacccaaggc 900
ttctgtaaac tgggaccaat gattacctca tagggctgtt gtgaggatta ggatgaaata 960
cctgtgaaag tgcctaggca gtgccagcca aataggaggc attcaatgaa cattttttgc 1020
atataaamca aaaaataact tgttatcaat aaaaacttgc atccaacatg aatttccagc 1080
cgatgataat ccaggccaaa ggtttagttg ttgttatttc ctctgtatta ttttcttcat 1140
С
                                                             1321
<210> 236
<211> 683
<212> DNA
<213> Homo sapiens
<400> 236
tegacecaeg egteegagea getgetgeag ggeecatgge ggacaeceag tacateetge 60
ccaatgacat cggcgtgtct agcctggact gccgtgaggc cttccgcctg ctgtcaccca 120
cagagegeet ctatgeetae cacetgteee gtgeegeetg gtaeggagge etggetgtge 180
tgcttcagac ctcccctgag gccccctaca tctatgctct gctcagccgc ctcttccgcg 240
cccaggaccc cgaccagctg cgccaacatg ccctggctga aggccttacc gaggaggagt 300
atcaggogtt cotggtotat googoggtg tttactocaa catgggcaac tacaagtoot 360
ttggtgacac caaqtttgtt cccaacttgc ccaaggaaaa gctggaacgg gtgatcctag 420
ggagtgaggc tgctcagcag cacccagaag aagtcagggg cctctggcak acctgcgggg 480
agcttatgtt ctctctggag ccaaggette gacacetegg aetggggaag gagggaatea 540
ccacctattt ctctgggaat tgtaccatgg aagatgccaa attggccmag atttctggac 600
tcacagaacc tyartgccta caacaaccgg stcttyaaag aagtcsatgg garaaaggaa 660
rccctamtac gaaggtgcgg gtt
                                                            683
<210> 237
<211> 2115
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (2112)
<223> n equals a,t,g, or c
<400> 237
attoccgggt cqacccacgc gtccgggctc cggcaaccgc tccggcaacg ccaaccgctc 60
cgctgcgcgc aggctgggct gcaggctctc ggctgcagcg ctggggtctt gctttgtctc 120
ccaggctggt gtgcagtggt gcgaccacgg ctcacggcag cctcagccac ccagatgtaa 180
gcgatctggt tcccacctca gcctcccgag tagtggatct aggatccggc ttccaacatg 240
tggcagetet gggcetecet etgetgeetg etggtgttgg ecaatgeeeg gagcaggeee 300
```

```
tetttecate cestgtegga tgagetggte aactatgtea acaaacggaa taccaegtgg 360
caggeeggge acaactteta caacgtggae atgagetact tgaagagget atgtggtace 420
ttcctgggtg ggcccaagcc accccagaga gttatgttta ccgaggacct gaagctgcct 480
gcaagetteg atgeaeggga acaatggeea eagtgteeea eeateaaaga gateagagae 540
cagggeteet gtggeteetg etgggeette ggggetgtgg aagceatete tgaceggate 600
tgcatccaca ccaatgcgca cgtcagcgtg gaggtgtcgg cggaggacct gctcacmtgc 660
tgtggcagca tgtgtgggga cggctgtaat ggtggctatc ctgctgaagc ttggaacttc 720
tggacaagaa aaggeetggt ttetggtgge etetatgaat eecatgtagg gtgeagaeeg 780
tactccatcc ctccctgtga gcaccacgtc aacggctccc ggcccccatg cacgggggag 840
ggagataccc ccaagtgtag caagatctgt gagcctggct acagcccgac ctacaaacag 900
gacaagcact acggatacaa ttcctacagc gtctccaata gcgagaagga catcatggcc 960
gagatotaca aaaacggccc cgtggaggga gotttototg tgtattogga ottootgctc 1020
tacaagtcag gagtgtacca acacgtcacc ggagagatga tgggtggcca tgccatccgc 1080
atcctgggct ggggagtgga gaatggcaca ccctactggc tggttgccaa ctcctggaac 1140
actgactggg gtgacaatgg cttctttaaa atactcagag gacaggatca ctgtggaatc 1200
gaatcagaag tggtggctgg aattccacgc accgatcagt actgggaaaa gatctaatct 1260
gccgtgggcc tgtcgtgcca gtcctggggg cgagatcggg gtagaaatgc attttattct 1320
ttaagttcac gtaagataca agtttcagrc agggtctgaa ggactggatt ggccaaacat 1380
cagacctgtc ttccaaggag accaagtect ggctacatec cageetgtgg ttacagtgca 1440
gacaggccat gtgagccacc gctgccagca cagagggtcc ttccccctgt agactagtgc 1500
cgtagggagt acctgctgcc ccagctgact gtggccccct ccgtgatcca tccatctcca 1560
gggagcaaga cagagacgca ggaatggaaa gcggagttcc taacaggatg aaagttcccc 1620
catcagttcc cccagtacct ccaagcaagt agctttccac atttgtcaca gaaatcagag 1680
gagagatggt gttgggagcc ctttggagaa cgccagtctc ccaggccccc tgcatctatc 1740
gagtttgcaa tgtcacaacc tctctgatct tgtgctcagc atgattcttt aatagaagtt 1800
ttattttttc gtgcactctg ctaatcatgt gggtgagcca gtggaacagc gggagacctg 1860
tgctagtttt acagattgcc tcctaatgac gcggctcaaa aggaaaccaa gtggtcagga 1920
gttgtttctg acccactgat ctctactacc acaaggaaaa tagtttagga gaaaccagct 1980
tttactgttt ttgaaaaatt acagcttcac cctgtcaagt taacaaggaa tgcctgtgcc 2040
2115
cccattggcc tntgg
<210> 238
<211> 1642
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (1633)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (1638)
<223> n equals a,t,g, or c
<400> 238
taagcaggca ctagaggacc tggagcgcac atcaggccgt ggcaccctga tgtcgccacc 60
atgctcaaca tccttgcttt ggtgtatcgt gaccagaata agtataagga agctgcccac 120
```

ctgctgaatg atgcccttag catccgggag agcaccttgg gacctgacca tcctgctgtg 180

```
gctgccacac tcaacaattt ggctgtgctc tatggcaaaa ggggcaagta caaggaggca 240
 gagcctctgt gccagcgggc actggagatt cgagaaaagg tcctgggcac gaatcatcca 300
 gatgtggcaa aacagctgaa caacctggcc ctcttgtgcc aaaaccaggg caagtatgag 360
 gccgtggaac gctactacca gcgagcactg gccatctacg aggggcagct ggggccggac 420
 aaccctaatg tagcccggac caagaacaac ctggcttcct gttacctgaa acagggcaaa 480
 tatgctgagg ctgagacact atacaaagag atcctgaccc gtgcccatgt acaggagttt 540
 999tct9t99 atgatgacca caagcccatc tggatgcatg cagaggagcg ggaggaaatg 600
 agcaaaagcc ggcaccatga gggtgggaca ccctatgctg agtatggagg ctggtacaag 660
 gcctgcaaag tgagcagccc cacagtgaac actactctga gaaacctggg agctctgtat 720
 aggcgccagg gaaagctgga ggctgctgag accctggagg aatgtgccct gcggtcccqq 780
 agacagggca ctgaccctat cagccagacg aaggtggcag agctgcttgg ggagagtgat 840
 ggtagaagga cctcccagga gggccctgga gacagtgtga aattcgaggg aggtgaagat 900
gcttctgtgg ctgtggagtg gtccggggat ggcagtggga ccctgcagag gagtggctct 960
cttggcaaga tccgggatgt gctccgcaga agcagtgaac tcttggtgag gaagctccar 1020
gggactgagc ctcggccctc cagcagcaac atgaagcgag cagcctcctt gaactatctg 1080
aaccaaccta gtgcagcacc cctccaggtc tcccggggcc tcagtgccag caccatggac 1140
etetetteaa geagetgaca tteaaccegg ecceeaggte tgetgggtee ecceaecee 1200
acagecetea cageatteee cattgeteet ggetetteee cacecetagg tgggacagtg 1260
aaggggagca gtttaaccag aagattgctg ctgcccttag ggtctcagct ccctcctcag 1320
gaatccctct taggaaggac cctcaggaca ccctctctgc accctgtggt cctctagagt 1380
agctagctct gaggccccaa ggtgggtaca aagcaggtat ggccctcaga gatgcagcct 1440
getgetgget titeagteag agggitgggg getggeeage caagetgeet tgeeetggee 1500
getettacte cetecetetg etgeteteact teaggteeat gtattteact tttettaaat 1560
caatttgccc canagggngg cg
                                                                 1642
<210> 239
<211> 468
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (461)
<223> n equals a,t,g, or c
<400> 239
geggaegegt gggeetggte teagtatgge getgteetgg gttettaeag teetgageet 60
cctacctctg ctggaagcca gatcccattg tgtgccaacc tagtaccggt gcccatcacc 120
aacgccaccc tggaccggat cactggcaag tggttttata tcgcatcggc ctttcgaaac 180
gaggagtaca ataagteggt teaggagate caageaacet tettttaett taececcaae 240
aagacagagg acacgatett teteagagag taccagaeee geeagaaeea gtgettetat 300
aactccagtt acctgaatgt ccagcgggag aatgggaccg tctccagata cgagggaggc 360
cgagaaacat gttgctcacc tgctgttcct tagggacacc aagaccttga tgtttggtty 420
ctacctggac gatgagaaga actgggggtg tctttctatg ntgacaag
                                                                468
<210> 240
<211> 1329
<212> DNA
<213> Homo sapiens
```

```
<400> 240
 tacatcttat aaaacctaac tggcatttaa aaaatactgt ggccgggcgt ggtggctcat 60
gcctgtaatc ccagcacttt gggaggccga ggtgggagga ttgcttgagt ccaggaattt 120
gagaccagee tggacaacae agtgagaeet catetetate aaaaaataaa aattagetag 180
atgtggtggc atgagcctgt gttcccagct gcttaggagg ctgaagcagg aggattgatt 240
gagcctgcga ggccaaggct gcagcaggct gtgattgcac cactgcactt cagcttgggc 300
aacagagcaa gaccctgtct ccgaaacaaa taaaaaatac tgtaataaaa gtacttataa 360
acatactaat cctctttcag gaccctaaag ttgcaggtta gtaggtcttc aaggacaaat 420
ctgtaagttt cttatttctg tagtgcaagt aaaatttcac tttttgaaac tatagagaga 480
tecetttetg attageetae agaaettaaa gtgagggaae cattteetet cacagacaaa 540
gaggcctggg atattaggac tttggggttt gagagcatca tggggcagac agatggtgga 600
tggtctggac aagaagcgag taagccactg cggttggtca tactgaaggg aattgatggc 660
aagaggatcc cctgagcaag tcagaagtta ctctcatcag tcgttcatgg tcacaacctg 720
aggtactetg etgagtggge aaggetgaag aagaggeetg tggaatgeag cattacetge 780
tggacagage agggcaggea gttetatgee ttggagetee tgactgeagg gactetgtee 840
ccacactcar aaagactcag ctcactcaat gagagaatgt gatttacttt atagaacgta 900
taatcaactt tgttgaataa tttgttctat taaggctgtc taaagtatgt gatgtcttca 960
tcatagtatg aagtgttgaa aattaataac gagcctagtt taggaaaaag ctgcttaaaa 1020
ctgtggctct aagagagtaa tcataaaata ccttagataa aattgcacta tggaattttc 1080
attgagtatg tttaaattat tggcttgtct actaatacac atctgcttca aaatgaacat 1140
atttcataaa attggcatca attttaatga cgctcctggt atggaacctc agatataccc 1200
tattggagac aatcetttga teataaatte teeceaacta taaateattt tatgtettta 1260
tcawaaaaaa aaaaaggaat tcgatatcaa gcttatcgat accgtcgacc tcgagggggg 1320
gcccgtacc
                                                                   1329
<210> 241
<211> 1652
<212> DNA
<213> Homo sapiens
<400> 241
gagcayttcg gcaactggca aaaattaggt gtacagggat ctaggtaata ctgtttattt 60
gagcaataat atattgtgct aacgttcagg catcctatta ctgagaaata agggaaaatg 120
agtgtaaagt acaactaaga gtctcggcta cagggaaaaa taccatcagt taaatatcca 180
tagtcctaga gcatttatgt aaaactgcaa tttgaatcct gcaatacatt ttggcttttt 240
cctcagtgat accatgtgtg ggaagttgtt ctgtcaaggt gggtcggata atttgccctg 300
gaaaggacgg atagtgactt tootgacatg taraacattt gatootgaag acacaagtoa 360
agaaatargc atggtggcca atggaactaa gtgtggcgat aacaaggttt gcatkaatgc 420
agaatgtgtg gatattgaga aagcctacaa atcaaccaat tgctcatcta agtgcaaagg 480
```

acatgctgtg tgtgaccatg agctccagtg tcaatgtgag gaaggatgga tccctcccga 540 ctgcgatgay tcctcagtgg tcttccactt ctccattgtg gttggggtgc tgttccaat 600 ggcggtcatt tttgtggtgg ttgctatggt aatccggcac cagagctcca gagaaaagca 660 gaagaaagat cagaggccay tatctaccac tggcaccagg ccacacaaac agaagaggaa 720 accccagatg gtaaaggctg ttcaacccca agagatgagt cagatgaagc cccatgtgta 780 tgatctgcca gtagaaggca atgagcccc agcctcttt cataaagaca caaacgcact 840 tccccctact gtttcaagg ataatccaat gtctacacct aaggactcaa accaaaagg 900 atgaagcaac agctaagcaa gaactaatgg ctaaattatc aacttggaaa actggaaaat 960 ctggatggca gagaaatata ctatccacc agtatttgct ctcgactcaa gaaggttaac 1020 attttctgat tcatgtaga ctttgaagag actaaagaa attttcaaga ggaacatatg 1080 cctgagaacc tttgcatgaa tttaaaatt caattacca ttcttataag aaggaagatg 1140 attgtaaaga aatatctccg aagttaaaa ctgtaatagg aattgatca ttctcaatg 1200

```
aaaacaaaac ataaaaacat cacactaatc ttggaggaat aagaaaaatt gtacatccat 1260
 taaatgtaca attgattgca acatcttgat tgttttaacc attaacttgt caaattacaa 1320
 tcacagttaa gaaaatgatg taaaattctg ttttgtggat ctctttccta gattagcttc 1380
 tgaaatcatt attagctata tcatttgagg ttttctacaa tttggtataa ctaagaattt 1440
 aaaaatgttt tatcatatat atttgtataa ttaattactg gcatggttaa agtggttttc 1500
 actttttaaa tggagaaaat ttcagttaaa ttaataggat aaaccaggtt gcgaactggt 1560
 gacctgtagg ccatgtttgc actgcaaata tatttggtct gaatgatatt gaaaaaaaaa 1620
 aaaaaaaaa ctcgagggg ggcccgtacc ca
                                                                   1652
 <210> 242
 <211> 1946
 <212> DNA
 <213> Homo sapiens
<220>
<221> misc feature
<222> (84)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (538)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (1932)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (1941)
<223> n equals a,t,g, or c
<400> 242
ggcacgagta caaggtggcg gcgctgggmc tggccaccgg cwtcgtcttg gtgctgctgc 60
tgctctgcct ctaccgcgtg ctangcccgc gcaactacgg gcagctgggt ggtgggcccg 120
ggcggcggag gcgcggggag ctgccctgcg acgactacgg ctatgcgcca cccgagacgg 180
agategtgee gettgtgetg egeggeeace teatggaeat egagtgeetg geeagegaeg 240
gcatgctgct ggtgagctgc tgcctggcag gccacatctg cgtgtgggac gcgcaqaccq 300
gggattgcct aacgcgcatt ccgcgcccag gcaggcagcg ccgggacagt ggcgtgggca 360
gcgggcttga ggctcaggag agctgggaac gactttcaga tggtgggaag gctggtccag 420
aggageetgg ggacageest coeetgagas accgeeceeg gggeesteeg eegeettees 480
tcttcgggga ccagcctgac ctcacctgct taattgacac caacttttca gcgcagcntc 540
ggtcctcaca gcccactcag cccgagcccc ggcaccgggc ggtctgtggc cgctctcqqq 600
actecccagg ctatgacttc agetgeetgg tgcagegggt gtaccaggag gaggggetgg 660
eggeegtetg cacaccagee etgegeecac cetegeetgg geeggtgetg teecaggeee 720
ctgaggacga gggtggctcc cccgagaaag gctccccttc cctcgcctgg gcccccagtg 780
ccgagggttc catctggagc ttggagctgc agggcaacct catcgtggtg gggcggagca 840
gcggccggct ggaggtgtgg gacgccattg aaggggtgct gtgctgcagc agcgaggagg 900
totoctcagg cattacogot otggtgttot tggacaaaag gattgtggot gcacggotca 960
```

```
acggttccct tgatttcttc tccttggaga cccacactgc cctcagcccc ctgcagttta 1020
 gagggacccc agggcggggc agttcccctg cctctccagt gtacagcagc agcgacacag 1080
 tggcctgtca cctgacccac acagtgccct gtgcacacca aaaacccatc acagccctga 1140
 aagccgctgc tgggcgcttg gtgactggga gccaagacca cacactgaga gtgttccgtc 1200
 tggaggactc gtgctgcctc ttcacccttc agggccactc aggggccatc acgaccgtgt 1260
 acattgacca gaccatggtg ctggccagtg gaggacaaga tggggccatc tgcctgtggg 1320
 atgtactgac tggcagccgg gtcagccatg tgtttgctca ccgtggggat gtcacctccc 1380
 ttacctgtac cacctcctgt gtcatcagca gtggcctgga tgacctcatc agcatctggg 1440
 accgcagcac aggcatcaag ttctactcca ttcagcagga cctgggctgt ggtgcaagct 1500
 tgggtgtcat ctcagacaac ctgctggtga ctggcggcca gggctgtgtc tccttttggg 1560
 acctamacta cggggacctg ttacagacag tctacctggg gaagaacagt gaggcccagc 1620
 ctgcccgcca gatcctggtg ctggacaacg ctgccattgt ctgcaacttt ggcagtgagc 1680
 tcagcctggt gtatgtgccc tctgtgctgg agaagctgga ctgagcgcag ggcctccttg 1740
 cccaggcagg aggctggggt gctgtgtggg ggccaatgca ctgaacctgg acttggggga 1800
 aagagccgag tatcttccag ccgctgcctc ctgactgtaa taatattaaa cttttttaaa 1860
 aaaaaaaaa anaaaaaaaa nggggg
                                                                 1946
<210> 243
 <211> 518
 <212> DNA
 <213> Homo sapiens
 <220>
 <221> misc feature
 <222> (298)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (472)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (494)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (500)
 <223> n equals a,t,g, or c
<220>
 <221> misc feature
 <222> (507)
```

<223> n equals a,t,q, or c

<221> misc feature

<220>

<222> (513)

```
<223> n equals a,t,g, or c
 <400> 243
 ggacgcgtgg gcagctgcag aaatccaaaa atattgacct tataagctca agatgctgta 60
 tgctgggttt ttacaaggat attcggtatt tgatgaaacc cagttaggca tgacatattc 120
 cccttctccc cattcctacc tctctttat taaaaatttt atagttacag tgtctatgtt 180
 gcccagcctg gtcttgaacc ctttggctca agtgatccac ctgccttggc ctcccaaagt 240
 gctgggatta cagatgggag ccatcgtgtc tggcccattc ctgcctctta aagccctnca 300
 cccaacaggc agacttgaga ctcaaaccgt ggtcccagct cttgcatcag gggtagtttg 360
 ggaattcaaa atctttcaaa ctggggtaaa aaccaggccc agaattcaga gttcaaccaa 420
 caagetttee aagaatgeeg geecaaagga aaaaagtggg ttettggaaa aneeggggaa 480
 aaggggggtg caancetttn gggagtnaca agngettg
 <210> 244
 <211> 621
 <212> DNA
 <213> Homo sapiens
 <220>
 <221> misc feature
<222> (460)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (569)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (593)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (609)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (612)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (621)
<223> n equals a,t,g, or c
<400> 244
gggaaggtcc atgggttgat acctcaggtc aaaaatgtgt ttactctgtt gattgctgtt 60
tcactttact tgtatatcag atatataagc tatgaacaca agtttgtagt aaaagtatct 120
```

```
tctgtctggg caatggctca cacctgtaat tccaacactt tgggggggctc aggtgggagg 180
 atttctagtc cccaggagtt tgagaccagc ctgggcaata aactagaccc catgtctcta 240
 aaaaatgtaa aaaacatcaa gaggctgagt caggaggatc atttgagctt aggagttcaa 300
 ggctgcagta agttatgatt gtgccactgc attccagcct gggtgacaag agtgagaccc 360
 tgacccaaaa aaagtatctt ctgataaagt ggcatttgaa aattgcagaa aattttaata 420
 ttttttttt taatattaag aactttattg atctctctan gacaccttgg tgaggaaatt 480
 aatggcactt ttcttgacat tcaacctggg actttgggtg attctgggtt ctggtgaatt 540
 taaagtttca acatttcttt ggggcaccnt ttacaagggg tttggccctt ggnaccttat 600
 gaccggtcna anggtccaaa n
                                                                    621
 <210> 245
 <211> 480
 <212> DNA
 <213> Homo sapiens
<220>
 <221> misc feature
<222> (340)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (366)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (431)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (447)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (458)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (460)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (469)
<223> n equals a,t,g, or c
<400> 245
```

```
ggcacgaggt gaaaccctgt ctctactaaa aatacaaaaa ttagctgggt gtggtggtgg 60
 gcgcctgtag tcccagctac tcgggaggct gaggcgggag tatgacttga acctgggagg 120
 cggaggttgc agtgagctga gattgtgcca ctgcactcca gcctgggtga cagagcaaga 180
 ctccgtttca gaaaaaaaa aaaactgtgt ctcatcattg cactgttctt ttaaaattgt 240
 atatatatat ttttcttgca gatacactct ggaaatgatt aaactagtac cacataatga 300
 aagtgcatgg aactatttga aagggatttt gcaggatcgn ggtctttcca aatatcccaa 360
 tctgtnaaat caattacctt gatttacaac caagtcaaag ttccccctac ctaattgcct 420
 ttcttgggga naccatgaag acatgcnaga aaaccagngn gacaataang gagacatcct 480
 <210> 246
 <211> 451
 <212> DNA
 <213> Homo sapiens
<220>
<221> misc feature
<222> (102)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (107)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (110)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (135)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (198)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (287)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (309)
<223> n equals a,t,g, or c
<220>
<221> misc feature
```

```
<222> (314)
 <223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (319)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (324)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (328)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (330)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (332)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (342)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (349)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (379)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (434)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (438)
```

```
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (439)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (451)
<223> n equals a,t,g, or c
<400> 246
aggcgaccca ccaccatgcc ccggctaaat ttagttgtat ttttagtaga gatggggttt 60
caccgtatta gccaggatgg tetegatete etgacetegt gnteegngen ceteggeete 120
ccaaagtgct ggganttaca ggcgtgagcc accgtgcccg gcctgattct cttaaaattg 180
aagaggtgct gccaaggnct tcagatctaa cgcagatgca tagaccttgt tcatggtact 240
tgttcagcct gtgctgggga gccgtggttc cgagtttcct gggaggntga cagggtgaag 300
ccaccgtanc cacnaccenc cganttenen thegetttet thteageant aggattaaag 360
ggattttgaa tgaagcaant tttaaggggt aggaggtgtt ggggaaaata aataattatt 420
caagtaaggc cttngggnnt ttagggggtt n
<210> 247
<211> 530
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (7)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (8)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (13)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (29)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (40)
<223> n equals a,t,g, or c
```

```
<220>
 <221> misc feature
 <222> (404)
 <223> n equals a,t,g, or c
<400> 247
aggaaannag tanctgacag taacggtong aattocoggn togaccoacg cgtccgctgg 60
aactteteet ggteteteag etggggeeae tgteggeate atgattggag tgetggttgg 120
ggttgctctg atatagcagc cctggtgtag tttcttcatt tcaggaagac tgacagttgt 180
tttgcttctt ccttaaagca tttgcaacag ctacagtcta aaattgcttc tttaccaagg 240
atatttacag aaaagactct gaccagagat cgagaccatc ctagccaaca tcgtgaaacc 300
ccatctctac taaaaataca aaaatgagct gggcttggtg gcgcacacct gtagtcccag 360
ttactcgggg aagctgaggc aggagaatcg cttgaacccg ggantggaga ttgcagtgag 420
cccagatcgc accactgcac tccagtctgg ccaacagagc aagactccat ctcaaaaaaag 480
aaaagaaaag gagactctga cctggtactc ttgaatacaa gtttctgata
                                                                    530
<210> 248
<211> 635
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (217)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (224)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (235)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (408)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (437)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (484)
<223> n equals a,t,g, or c
```

<220>

<211> 360

```
<221> misc feature
 <222> (513)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (516)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (560)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (568)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (576)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (603)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (635)
<223> n equals a,t,g, or c
<400> 248
ggtggcaggt gcttataatc ccagctactc tgggggccaa ggcaggagaa ttgcttgagc 60
ctgggagatg gaggttgcag tgagctgaga tcatgccact gcactccagc ctgggcaaca 120
gagcaagact ctgcctcaaa aaaaaattaa aataaattta aatacaaaaa aaaatagcca 180
99tgtggggt gcatgcctgg aatcccagct acttganaag gctnaaggca ccaanaattg 240
cttgaaccca ggaggtggag gttgcagtga gccaagatca caggagccac tgcactccag 300
cctgggtgac agagtgagac tctgtctcaa aaaaaaaatt aaataaatta ttataacctt 360
tcaaaaatgc tgtgtgcatt ttcatgttct tttttttaac attactgnca ctctccctaa 420
tgaaatggac ttcaaanaag cagtattttg ttaaataaat acataacctc attctgaata 480
atgnccctca ttttgactat aactgggctt ggnttnaaaa gcaaaattta acaaaaattt 540
aatccccttc caaaggaacn ttgggtancc tgggtnaaaa aatgccaaat ggggtacttt 600
tanttaaaat ttggaattta acatcttttt tggan
                                                                   635
<210> 249
```

```
<212> DNA
 <213> Homo sapiens
 <220>
 <221> misc feature
 <222> (118)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (280)
 <223> n equals a,t,g, or c
<220>
<221> misc feature
 <222> (282)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (305)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (360)
<223> n equals a,t,g, or c
<400> 249
ctcaggaaac catgtccaaa accctagcag cggtacagca tgctgtctcc aacccttatc 60
cccaggttta agggtggttt atggccatac gtggaggttt tttgttgttg tttttganac 120
tgagtttcac tettgttgee caggetggag tgeaatggea ceatetegge teactgeaac 180
ctccacctcc tggttcaagc gatctcaggc ctcagcttcc caagtagttg ggattacagg 240
cgcctgccac cacacctggc taattttgta tttttagtan anatggggtt ctccatgttg 300
gtcangctgg tctcaaactc ccgaactcaa gtgatctgcc cgccttgggc tcccaaaatn 360
<210> 250
<211> 464
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (397)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (436)
<223> n equals a,t,g, or c
```

```
<220>
 <221> misc feature
 <222> (446)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (459)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (460)
 <223> n equals a,t,g, or c
 <400> 250
 gctgtgagga aggggaatcg cttgaacccg ggaggcggag gttgcggtga gccgagatag 60
cgccattgca ctccagcctg ggcaacaaga gcgaaaccct gtctcaaaaa aaaaacaaaa 120
 aaccccacaa aaactaggag cctggaaggc cggactgggt ctccgtggga ggggcctggg 180
tctggagagc agggcagggt ctcctgggcc taggggatgg ggatggggct gggtctcaga 240
ggaggcaggg tttacgtgca gaagagcgga cttggtctcc ggggtcccga gtgggtgacg 300
cggcccgcca caggtgcttc ctgaaggtga gccggctgga ggcacaactg ctcctggagc 360
gctaccccga gtgcgggaac ctgctgctgc ggcccancgg ggacggcgcc gacggcgtgt 420
cggtcaccac tcggcngatg ccaacnggaa cgcacgtgnn ccgg
<210> 251
<211> 315
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (24)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (28)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (37)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (77)
<223> n equals a,t,g, or c
<220>
```

```
<221> misc feature
<222> (113)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (202)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (210)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (220)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (265)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (302)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (305)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (311)
<223> n equals a,t,g, or c
<400> 251
aaagtaaaca tcggggaagg tttncggnaa cgctccnagg taccggtccg gaattcccgg 60
gtcgacccac gcgtttngct ccttgttcag gctggtctgg aactggcgac ttngggtgat 120
ecgecegect eggeeteeca aagtggtggg attacaggtg tgagecaceg tgeceagece 180
tgaaatagtc ttaattgctt gnttttcttn tttgtctgan gtgtgctttt taaaatctct 240
atggagatgg agaagactga cattntctgg cctgatgtga aaaacctctc attaaaaacc 300
                                                                   315
gngtntgtag ntttg
<210> 252
<211> 333
<212> DNA
```

<213> Homo sapiens

```
<220>
<221> misc feature
<222> (51)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (79)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (141)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (196)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (200)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (233)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (253)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (254)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (302)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (303)
<223> n equals a,t,g, or c
```

```
<220>
 <221> misc feature
 <222> (325)
 <223> n equals a,t,g, or c
 <400> 252
 999ctaattt gtgtattttt agtggaaacg gggttttgcc acgttggcca ngctggtctc 60
 gaactcctga cctcaggtna tccacccacc ccagcctccc aaagtgctgg gattacaggc 120
 gtgagccact gagcccagcc nacttttcag tttttaacat aatttttgtt ttatccacaa 180
cttttcaagt attganagtn caataaaaaa catgggttct tagtctgtaa ctntctgtta 240
aagcctatga atnncttctg aaaatcatgt ttttaaatgc ataaaatata tacgattacg 300
anngaatott attattgtcg aaatncagtt att
<210> 253
<211> 307
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (7)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (42)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (48)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (250)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (260)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (281)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (299)
```

```
<223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (302)
<223> n equals a,t,g, or c
<400> 253
gaaaaanttt taaaggaaga agggaaggca ggctggggag gntggggnaa ggaagcaggg 60
agtgcagatc actoccotto catgagttgt tttottaaga tgctagaact tggccaggca 120
tggtggctca cccctgtaat cccagcactt tgggaggctg aggctggcag atcacttgag 180
gtcaggagtt ccagaccagc ctggccaaca tggtgaaacc ccatctctac taataataca 240
aaatttagcn gggtgtgggn ggtgtgcacc tgtggcccta nctacttggg aaggctgana 300
cnaggag
                                                                    307
<210> 254
<211> 401
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (256)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (340)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (350)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (359)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (378)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (379)
<223> n equals a,t,g, or c
<400> 254
```

```
gtataaatgt tacttaaaaa aaatatattt ggccgagcac agtggctcac gcctgtaatc 60
cccacacttt gggaggccga ggcgggcaga ttgcctgagg tcaggaattt gagatcagcc 120
tggccaacat gatgaaaccc cgtctctact aaaaatacaa aaattagccg ggcatggtgg 180
caggeacetg taateeegge taetegggag getgaggeag gaaaateget tgaaceeggg 240
agtoggaagt tgcagngago caaggtoatg toatcattgo actocagott gggcaacaag 300
agtgaagact tcgtctcaaa aaaaaaactt acagactttn ttttcctttn gtaaattgnt 360
agtttaactt tgaattonng atgaaggatt tattcttatc t
<210> 255
<211> 406
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (149)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (243)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (369)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (370)
<223> n equals a,t,q, or c
<220>
<221> misc feature
<222> (376)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (390)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (392)
<223> n equals a,t,g, or c
<400> 255
gcttatcatt tgtattaaaa tatggtttaa tgtaaagagt tgcctttctc cattccccc 60
toccctcccc toccctcctc toccctcctc tettaccccc aattaaaaaa tagcacatcc 120
```

<210> 257

```
ctaatgtggg aaacagtaag aaagcatana ttacatttta ggcagggcac agtggctcac 180
gcctgtaatc ccagcacttt cggaggctga ggtgggtgga tcacttgagg tcaggagttt 240
ganaccagoc tggccaacat ggtgaaaccc tgtctctact aaaagtacaa aaattagcca 300
ggcatggagg cgggtgcctg taatcccagc tacttgggag gctgaggcag gagaattgct 360
tgagcccann aggcanaggt tgcagtgagn anagatcggg ccattg
                                                                   406
<210> 256
<211> 415
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (27)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (324)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (378)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (379)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (411)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (412)
<223> n equals a,t,g, or c
<400> 256
gacatgaatt ccttaatgat gggagangat aaaatcaagt tcaaacacat caccccctg 60
caggagcaga gcaaagaggt ggccatccgc atctttcagg gctgccagtt tcgctccgtg 120
gaggetgtgc aggagateae agagtatgcc aaaagcatte etggttttgt aaatettgae 180
ttgaacgacc aagtaactct cctcaaatat ggagtccacg agatcattta cacaatgctg 240
gcctccttga tgaataaaga tggggttctc atatccgagg ggccaagctt catgacaagg 300
gagtttctaa agagcctgcg aaancttttg gtgactttat gggagcccag tttgagtttg 360
ccgtgaaatt ccatggcnng ggattatatg gacagcggct tgggcaaatt nnagc
```

```
<211> 414
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (102)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (297)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (375)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (380)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (384)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (397)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (411)
<223> n equals a,t,g, or c
<400> 257
cgcagaggaa accccgcacc cctggcagaa gttccggacc aagccccagg gggaccagga 60
caccggcaag gaggctgatg acggatgtgc ccttgggggc angtgatggg agcacagctg 120
gaacaatgtg ctcggccccc agtgctctgt gggagcccca ggacaagtga gctggtgtca 180
cctcctgcct gggggaagag ccaggccctg aagaacagcc gcagcgtgtc acaggtgttg 240
gtgaggacac acactaggcc caaggtgcct gtgctcccag caggttccaa gtgcaanttc 300
aagccaactt tgcgtgttaa cttcaacggg gacttccaag cttccaagct aacttttgtg 360
gtgttaacct tcaanaaaan caanaaaggg gggcttnggg gcattttggt ncct
<210> 258
<211> 373
```

<212> DNA

```
<213> Homo sapiens
<220>
<221> misc feature
<222> (321)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (324)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (328)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (351)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (361)
<223> n equals a,t,g, or c
<400> 258
ctccgagtca gggcccaggt gcagctctcc ggtggacaca gaatgcagcc atgctgaggg 60
cagcoggago caaggoootg agaaagoott cagcooggot totocatgtg cotggaacgt 120
gtgtgtcacc aggaaggccc ccctgctggc ctctgacagt agctcctctg ggggctccca 180
cagcgaggat ggcgaccaga aggcagcgag tgccatggat gcggtgagca ggggtcccgg 240
ccgggaggcc ccccgctgcc cacagtggcc aagacagaag aagcttttgg caaggttcgg 300
ttttctgaca accggctttt naancetnee ttgeeceege gecaaaagga nttaatttet 360
ngcccaagcg ttg
<210> 259
<211> 529
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (287)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (377)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (438)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (443)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (444)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (495)
<223> n equals a,t,g, or c
<400> 259
aaactaacag atgaagaagt agatgaaatg atcagagaag cagatattga tggagacgga 60
caagtcaact atgaagaatt cgtacagaat gatgactgca aaatgaagac ctactttcaa 120
ctcctttttc cccctctta gaaagaatca aatttgaatc ttttacttac ctccttgcaa 180
aaaaaagaaa aaagaaaaaa ttccatttat tcatccttgt ttcctatata gccaaactga 240
atgttcaaaa gtaccttcct tgtcccacac acacaaatct gcatgtntgg ttgggggggt 300
ccctgtcccc ctaaagatca agctacactt cccattttta caatataata cttgttctac 360
cttatgatag atccctnaaa agtttcccct ttgctaatga ttatacctgt ttgggtggcc 420
agttttccct gcttgcantt gannaatgac ccagccggcc tttgttttaa attgaaatga 480
aaacaattcc aaccntccat ggttcccgtc cattgttaat taatggcca
                                                                   529
<210> 260
<211> 566
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (361)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (413)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (437)
<223> n equals a,t,g, or c
```

```
<220>
 <221> misc feature
 <222> (460)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (473)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (509)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (562)
<223> n equals a,t,g, or c
<400> 260
actgtctgta tattacggaa gctcttttca cataatatga ctcgtctgcg aaagtttatg 60
gtttactttg gaaagaacca aagtttgcag aagatacaga aaactcctct ctttgtggcg 120
gcgatctgtg ctcattggtt tcagtatcct tttgacccat cctttgatga tgtggctgtt 180
ttcaagtcct atatggaacg cctttcctta aggaacaaag cgacactgaa aattctcaaa 240
gcaactgtgt cctcctgtgg tgagctggcc ttgaaagggt ttttttcatg ttgctttgag 300
tttaatggat ggatggatct cgcagaagca gggggtggat ggaagatgaa gatctaacca 360
ngtgcttgga tgagcaaatt ttacagccca gagactaaga ccattctacc ggntttttaa 420
gttccggcct tccaagnaat tcttggcggg ggatgaggcn ggattgaact ccngggatcc 480
agataggcag gaacatcaag attggggang gtaaccattg gaacaaacca ctcacccagg 540
tgacggtaag cgcctacaac antttt
<210> 261
<211> 502
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (14)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (25)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (44)
<223> n equals a,t,g, or c
```

```
<220>
 <221> misc feature
 <222> (47)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (61)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (72)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (75)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (89)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (98)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (126)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (146)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (149)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (151)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (157)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (169)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (176)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (180)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (186)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (190)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (194)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (211)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (224)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (231)
<223> n equals a,t,g, or c
```

<220>

```
<221> misc feature
<222> (235)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (246)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (247)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (262)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (273)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (315)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (334)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (339)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (362)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (375)
<223> n equals a,t,g, or c
<220>
<221> misc feature
```

```
<222> (376)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (446)
 <223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (454)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (477)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (484)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (497)
<223> n equals a,t,g, or c
<400> 261
ggttaaaagt ggantgtatg ttgtnataga agttaaagtt gcanctnatt atggaataga 60
nataacctgt cnaanttatc tgatgacana ttaccaangt gctcccccat ccccacagta 120
tagaangatt atttgcatgg gtgcanaana naatggnttg ccgctggant atcaanagan 180
gttaanagen ttanaaccaa atgactatac ntgaaaggte teanaagaaa ntgangacat 240
catcannaag ggggaaacac anactettta gancataaca gaatatatet aagggtatte 300
tatgtgctaa tatanaatat tattaacact tganaacang gatctggggg atctccacgt 360
tngatccatt ttcannagtg ctctgagagg agtatcttac ttggggtgac tccttgtttt 420
tagactatac tcagaaactg ggatanggag ttanaccatt taaaacgggt gtatganggc 480
ctgnaatatg tgacaantga at
                                                                   502
<210> 262
<211> 489
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (2)
<223> n equals a,t,g, or c
<220>
<221> misc feature
```

```
<222> (3)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (387)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (440)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (464)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (477)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (483)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (486)
<223> n equals a,t,g, or c
<400> 262
gnngacgcgt gggtccggga tgaggagtgg ggtggccact cccccggag tcccagggga 60
tgggaccagg agcccgccag ggagcaggca ggcgggggct ggcgggccag gcggccccgg 120
geoegeteeg tggaegeeet ggaegaeete acceegeega geaeegeega gteagggage 180
aggtetecca egagtaatgg tgggaggaga ageegggeet acatgeeece geggageege 240
ageogggacg acctetatga ccaagacgae tegagggaet teccaegete eegggaceec 300
cactacgacg actteaggte tegggagege ceteetgeeg acceeaggte ceaceaceac 360
cgtacccggg acctcggga caacggntcc aggtccgggg acctccccta tgatgggcgg 420
ctactggagg aggctgtgan gaagaagggg tcggacgaga ggangagacc ccacaangag 480
                                                                   489
gangangaa
<210> 263
<211> 93
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
```

```
<222> (22)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (51)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (75)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (76)
 <223> n equals a,t,g, or c
 <220>
<221> misc feature
 <222> (93)
 <223> n equals a,t,g, or c
 <400> 263
 gaggatgace gactagagag thittacatga caggatataa tagatgaaga ngacagatgac 60
 acaccatggc cttcnncacc aggcagttca tgn
 <210> 264
 <211> 389
 <212> DNA
 <213> Homo sapiens
 <220>
 <221> misc feature
 <222> (9)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (24)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (45)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (72)
<223> n equals a,t,g, or c
```

<220>

```
<221> misc feature
<222> (106)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (178)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (241)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (249)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (309)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (327)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (333)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (344)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (358)
<223> n equals a,t,g, or c
<400> 264
ggcagagtnt gctcttggga agtncaggct cggttgtctt ttggnagcca tggagagtga 60
ctttaatctg cnttactacg tggggcacaa gggcaagtcc ggccangagt tcctggagtt 120
tgaagtttcg accggacgga gcttgaaatc gtcattggag atgaacacat ttcttttnac 180
aacatcaaaa attggttccc ttattgatgt caatcatgcc aaggatccag aaggcttacg 240
```

```
nagtatttna ttatcttgtc caggacctga agtgtttggt cttcagtctt attgggttac 300
acttcaagnt taaaccatct agactgnata ttngtgtggg acangggggt gggtgggngt 360
aggaaatttt gtgtattttc aggggcatt
                                                                    389
<210> 265
<211> 400
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (296)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (308)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (342)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (343)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (389)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (390)
<223> n equals a,t,g, or c
<400> 265
tttgeecacg egteegeeca egegteegee caegegteeg eccaegegte egeaeceeca 60
toccagtocc agoctactto ogccacgoag aacotggatt otocotcaag aggcccaggg 120
ggctcaqccq qaqcctccca cctccqcccc ctqccaaggg cagcattccc atcaqccqcc 180
tettecetee teggaececa ggetggeace agetgeagee eegegggtgt catteeggge 240
gaaggcctag agactctgca gagccctggg tatgacccaa gccgcaaaag tctttnttca 300
agcaaagntt caaaaggtta agccgcttgg gcaatggttt annggaaagg ttttaagggg 360
                                                                   400
gcctccaagg gaggacggcc ggttttttnn ggaaaagggt
<210> 266
<211> 382
<212> DNA
```

WO 00/55351 219 PCT/US00/05883

```
<213> Homo sapiens
 <220>
 <221> misc feature
 <222> (10)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (42)
 <223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (44)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (49)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (88)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (103)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (109)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (162)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (166)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (185)
<223> n equals a,t,g, or c
```

<220>

```
<221> misc feature
<222> (186)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (220)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (248)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (278)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (301)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (326)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (341)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (350)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (362)
<223> n equals a,t,g, or c
<400> 266
ggacctggan cggaggggg aagaaagtca tacccagatc cnanatccnc acgcagaatg 60
cacaqqtqaq ctqccqctqq gcccgganca tgctgggcgt tcncacctng cagactgcac 120
gctccaaccg cccgctccac ctactctttc caggcccggc ancttntgga gaaggaattc 180
agcannetta teteettagg cacagacagg etgetggaen aggacatgeg ecaagtettt 240
```

```
cagttcgntc cccatcctgg cggaagatgt tccggganga aggacctccg aggcgtaact 300
ngccgactca ctgagatgtt gccccncaac tttcgttcgg ntgcagcggn attcctgggc 360
                                                                    382
tnttccgggg ctcccttttc cc
<210> 267
<211> 449
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (374)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (433)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (446)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (447)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (448)
<223> n equals a,t,g, or c
<400> 267
gggcgatggc tgaaggacca ggagctgagc cctcgggagc cggtgctgcc cccacagaag 60
atggggccta tggagaaatt ctggaataaa tttttggaga ataaatcccc ttggaggaaa 120
atggtccatg gggtatacaa aaagagtatc tttgttttca ctcatgtact tgtacctgtc 180
tggattattc attattacat gaagtatcat gtttctgaaa aaccatatgg catagttgaa 240
aagaagtcca gaatattccc tggtgataca attctggaga ctggagaagt aattccacca 300
atgaaagaat ttcctgatca acatcattaa agattatgta aaaaggtaaa aggcttatga 360
gcctaagttt ggtnctatat taccatattt actggaattt tcttggaaaa gtactttaat 420
                                                                   449
aaagtttaat ctnagaaaaa aaaaannna
<210> 268
<211> 594
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
```

```
<222> (1)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (8)
<223> n equals a,t,g, or c
<400> 268
ngcaagenga caccaaccet cactaaaggg aacaaaaget ggagetecac cgcggtgcgg 60
ccgctctaga actagtggat cccccgggct gcaggaattc ggcacgaggt cagtgtcggg 120
cgcagacggc ggcagtgcgg cttgctcttg gaagttcagg ctcggttgtc ttttgggagc 180
catggagagt gacttttatc tgcgttacta cgtggggcac aagggcaagt tcggccacga 240
gttcctggag tttgagtttc gaccggacgg gaagttaaga tatgccaaca acagcaatta 300
caagaatgat gtcatgatca gaaaagaggc ttatgtacat aaaagcgtga tggaggaact 360
gaagagaata attgacgaca gtgaaattac caaagaggat gatgcattgt ggcctcctcc 420
tgaccgagtg ggccggcagg agcttgaaat cgtcattgga gatgaacaca tttcttttac 480
aacatcaaaa attggttccc ttattgatgt caatcaatcc aaggatccag aaggcttacg 540
agtattttat tatcttgtcc aggacctgaa gtgtttggtc ttcagtctta ttgg
<210> 269
<211> 332
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (19)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (240)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (275)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (296)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (321)
<223> n equals a,t,g, or c
<220>
```

WO 00/55351 223 PCT/US00/05883

```
<221> misc feature
<222> (332)
<223> n equals a,t,g, or c
<400> 269
gcgggatttg ggtcgcagnt cttgtttgtg gattgctgtg atcgtcactt gacaatgcag 60
atcttcgtga agactctgac tggtaagacc atcaccctcg aggttgagcc cagtgacacc 120
atcgagaatg tcaaggcaaa gatccaagat aaggaaggca tccctcctga ccagcagagg 180
ctgatctttg ctggaaaaca gctggaagat gggcgcaccc tgtctgacta caacatccan 240
aaagagtcca ccctgcacct ggtgctccgt ctcanaggtg ggatgcaaat cttcgngaag 300
accetgactg geaagaceat naccettgag gn
<210> 270
<211> 515
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (3)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (4)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (7)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (10)
<223> n equals a,t,g, or c
<400> 270
gennganaen aacceteact aaagggaaca aaagetggag etecacegeg gtgeggeege 60
tctagaacta gtggatcccc cgggctgcag gaattcggca cgagggatgt tgatgtcctg 120
catctaacgc ggtgtaaccc ccgaagccga gcgagctccg gaggaatttc agtatctgct 180
acggtaactt catcagcccg ccaagatggc gatgcaagcg gccaagaggg cgaacattcg 240
acttccacct qaaqtaaatc qgatattgta tataaqaaat ttgccataca aaatcacaqc 300
tgaagaaatg tatgatatat ttgggaaata tggacctatt cgtcaaatca gagtggggaa 360
cacacctgaa actagaggaa cagcttatgt ggtctatgag gacatctttg atgccaagaa 420
tgcatgtgat cacctatcgg gattcaatgt ttgtaacaga taccttgtgg ttttgtacta 480
taatgccaac agggcatttc agaagatgga cacaa
<210> 271
<211> 141
<212> DNA
```

```
<213> Homo sapiens
 <220>
 <221> misc feature
 <222> (12)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (13)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (14)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (25)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (39)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (141)
<223> n equals a,t,g, or c
<400> 271
cactccatgg gnnnctctgt gtggnatttg gggcccctnc atacttcatt tattatatta 60
tcaaaactga gagggatagg aaagtaaaaa cttatccagg taggaaaatt ggatcgaaca 120
tttcacctct catattaagg n
                                                                    141
<210> 272
<211> 433
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (32)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (49)
<223> n equals a,t,g, or c
```

```
<220>
 <221> misc feature
 <222> (52)
 <223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (94)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (139)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (166)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (177)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (187)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (198)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (244)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (248)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (259)
<223> n equals a,t,g, or c
```

PCT/US00/05883 WO 00/55351 226

```
<220>
<221> misc feature
<222> (274)
 <223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (276)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (288)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (355)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (364)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (396)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (402)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (427)
<223> n equals a,t,g, or c
<400> 272
gagcggcggc ggaccgcagc gaagtggcga gntagtggca aacgttgant tntgaagggg 60
ggcccaagat gaccggttct aacgaagttc aagntgaacc agccacccgg aggatagcat 120
ctcctccgta aagttcagnc ccaacacctc ccagttcctg cttgtntcct cctgggncac 180
gtccgtncga ctctacgnat gtgccggcca actccatgcg gctcaagtac cagcacaccg 240
gagnogtnet ggactgcgne ttetacggte caangnatge etggagtnga ggactagate 300
atcagttgaa aatgcatgat ttgacactga tcaagaaaat ttcttggacc catgntgccc 360
tatnagatgt gttgaatact gtcagaagtg aattanaatg gnactggaag ttggggttag 420
ccagttnacc tgt
                                                                   433
```

<210> 273

```
<211> 432
 <212> DNA
 <213> Homo sapiens
 <220>
 <221> misc feature
 <222> (187)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (190)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (332)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (371)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (373)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (380)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (430)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (432)
<223> n equals a,t,g, or c
<400> 273
ggttcatctc cgtctcagaa aagagcaagg atcgcggcag caacacgatc ggcgcccgcc 60
tgaaccgagt agaagacaag gtgacgcagc tggaccagag gctggcactc atcaccgaca 120
tgcttcacca gctgctctcc ttgcacggtg gcagcacccc tgagcccact gtgcgtgggg 180
ctcccgnctn caacccctcg cccagtccca gcagccagcc aaacacacag aaggggactg 240
ccaccttccc ttgccagctg ctgagccgca gagaagtgac ggttcctaca caggacaggg 300
gttccttctg ggcattacat cgcatagaaa tnaataattt gtggtgattt ggatctgggt 360
```

```
tttaatgaat ntnacagtgn gactttgatt attaattgag caagcttttc ctaataaacg 420
tggagaattn cn
                                                                    432
<210> 274
<211> 276
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (95)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (234)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (255)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (264)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (265)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (269)
<223> n equals a,t,g, or c
<400> 274
gategettet etgggteeaa gtetgeeage aeggeeteee tgaecatete tgggeteeag 60
gctgaggacg aggctgatta ttactgcagc tcatntacaa gtagtatctc ttatgtcttc 120
ggaactggga ccaaggtcac cgtcctagtc cagcccaagg ccaaccccac tgttcactcc 180
tgtttccccc cctcctctt aagaacttcc aagcccaaca aaggcaacta tgtnttttgg 240
                                                                   276
aaccattact tctanccggg aaanntttna aaatgc
<210> 275
<211> 351
<212> DNA
<213> Homo sapiens
<220>
```

```
<221> misc feature
 <222> (48)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (78)
 <223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (87)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (117)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (150)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (154)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (174)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (178)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (206)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (219)
<223> n equals a,t,g, or c
<220>
```

<221> misc feature

```
<222> (241)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (248)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (288)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (292)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (303)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (329)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (349)
<223> n equals a,t,g, or c
<400> 275
ccgcagacta gggcgcctcg ggccagggga acgcggaaga gccatggnca ccggctaacg 60
gggccgtgga aaacgggnac cggacangaa gccgccggcc ctgccgcgcc ccatccncaa 120
cctggaagtc gagttcacca agatatttan caanaatgga atgggacgaa tccnagantg 180
ggaaaaagtg tgctacatgt tacccntcaa ctccggganc aaatatgtga agtggaagaa 240
ngagatangg ccgacgtggg acgaaggctg tggaagctgc acagggtngc tnccaaaaag 300
ggntccccca tgggcgcccg gtgggatgnc ctgaattcct tggccggtng c
<210> 276
<211> 463
<212> DNA
<213> Homo sapiens
<400> 276
gctgaattct ggctgaccag ggcagtcacc agagctccag acaatgtctg tctccttcct 60
catcttcctg cccgtgctgg gcctcccatg gggtgtcctg tcacaggtgc agctgcagca 120
gtcaggtcca ggactggtga agccctcgca gaccctctca ctcacctgtg ccatctccgg 180
ggacactgtc tctaggaaca gtgctggttg gaactggatc aggcagtccc catcgagagg 240
```

```
ccttgagtgg ctgggaagga catactacag gtccaaatgg tataatgatt atgccgtatc 300
tgtgaaaagt cgaataacca tcaacgcaga ttcaaccaag aatcagttct ctctgcagct 360
gaactctgtg actcccgagg acacggctct gtattactgt gcaagagatc ggggcagctg 420
gtccgatgaa gccgaggggc tcccgccgcg ttacttctac tac
<210> 277
<211> 463
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (392)
<223> n equals a,t,g, or c
<400> 277
ctgtcctcta gagaaaaccc tgtgagcaca gctcctcacc atggactgga cctggaggat 60
cctcttcttg gtggcagcag ctacaagtgc ccactcccag gtgcagctgg tgcagtctgg 120
tgctgaggtg aagaagcctg gggcctcagt gaaggtctcc tgcaaggctt ctggatacac 180
cttcaccagt tatgatatca actgggtgcg acaggccact ggacaggggc ttgagtgggt 240
gggatggatg aaccctaaca gtgctaacac aggctatgca cagaagttcc agggcagagt 300
caccatgacc aggaacacct ccataagcac agcctacatg gagctgagca gcctgagatc 360
tgaggacacg gccgtctatt actgtgcgag anggaggcgg tgggagctgc tcgggatgat 420
gtgggacttt gactactggg gccagggaac cctggtcacc gtc
<210> 278
<211> 343
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (172)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (271)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (284)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (293)
<223> n equals a,t,g, or c
<220>
```

```
<221> misc feature
<222> (294)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (315)
<223> n equals a,t,g, or c
<400> 278
ggcagaggga totcagggct tottttctg toctccacca toatggggtc aaccgccate 60
ctcgccctcc tcctggctgt tctccaagga gtctgtggcg aggtgcagct ggtacatgct 120
ggaggagaga tgaggaaagc ccggggagtc tctgaagatc tcctgtgaag gntgttggga 180
tacacctttg aacatctact gggatcggct gggtgcgcca gatgcccggg gaaggcctgg 240
gagtgggtgg ggcatcatat gtcctggtga ntctgatggc cagngatagc cannottttc 300
gagggccaga tgcancatgt gcagtcgaca agtgccacca aca
<210> 279
<211> 436
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (121)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (151)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (211)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (326)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (362)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (373)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (384)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (392)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (403)
<223> n equals a,t,g, or c
<400> 279
geaccatgge ttggacccca ctcctcttcc tcaccctcct cctccactge acagggtctc 60
teteccaget tgtgetgaet caategeeet etgeetetge etecetggga geeteggtea 120
ngctcacctg cactctgagc agtgggcaca ncgactacgc catcgcatgg catcagcagc 180
agccagagaa gggccctcgg tacttgctga ngcttaacac tgatggcagc cacaggaagg 240
gggacgggat ccctgatcgc ttctcaggct ccagctctgg ggctgagcgc tacctcacca 300
tctccagcct ccagtctgag gatgangctg actattactg tcagaactgg ggctttggga 360
tngtattcgg cgnaagggac caanctgaac gncctaagtc agnccaaggc tgcccctcg 420
gtcaatctgt tcccgg
                                                                    436
<210> 280
<211> 315
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (76)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (138)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (224)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (246)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
 <222> (280)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (308)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (315)
<223> n equals a,t,g, or c
<400> 280
ggcacgagct cccccagcct tgctgaagat ccgttccaag gagggcaggt gtgcgcacca 60
tcccgggcta tacagnccat ctgcctgccc tcgatgtata acgatcccca gtttggcaca 120
agctgtgaga tcactggnct ttggaaaaag gaattctagt gaagtgaaca attgcgaact 180
gaacttagga aggtcctgga ggagtgtttt gacctggaaa atgnagccca gtgtggttca 240
agggtnagac tgcagagttt agaggtgggg agcactgagn cggtggcaga ttgggtccca 300
gggttggntt gaagn
<210> 281
<211> 411
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature ·
<222> (305)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (339)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (358)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (376)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (403)
```

```
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (411)
<223> n equals a,t,g, or c
<400> 281
ggcaggttgg agccgctgcc gtcgccatga cccgcggtaa ccagcgtgag ctcgcccgcc 60
agaagaatat gaaaaagcag agcgactcgg ttaagggaaa gcgccgagat gacgggcttt 120
ctgctgccgc ccgcaagcag agggactcgg agatcatgca gcagaagcag aaaaaggcaa 180
acgagaagaa ggaggaaccc aagtagcttt gtggcttcgt gtccaaccct cttgcccttc 240
gcctgtgtgc ctggagccag tcccaccacg ctcgcgtttc ctcctgtagt gctcacaggt 300
cccancaccg atggcattcc ctttgccctg agtctgcanc gggtcccttt tgtgcttnct 360
tcccctcaag tacctntttc cccctgggcc acttccgggg gtnagggggg n
<210> 282
<211> 570
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (6)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (7)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (12)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (217)
<223> n equals a,t,g, or c
<400> 282
gcaagnngaa antaaccctc actaaaggga acaaaagctg gagctccacc gcggtgcggc 60
cgctctagaa ctagtggatc ccccgggctg caggaattcg gcacgagtag agacagcgcc 120
ggggcaagtg agaqccggac gggcactggg cgactctgtg cctcgctgag gaaaaataac 180
taaacatggg caaaggagat cctaagaagc cgagagnaaa atgtcatcat atgcattttt 240
tgtgcaaact tgtcgggagg agcataagaa gaagcaccca gatgcttcag tcaacttctc 300
agagttttct aagaagtgct cagagaggtg gaagaccatg tctgctaaag agaaaggaaa 360
atttgaagat atggcaaaag cggacaaggc ccgttatgaa agagaaatga aaacctatat 420
ccctcccaaa gggqaqacaa aaaagaagtt caaggatccc aatgcaccca agaggcctcc 480
ttoggootto ttootottot gototgagta togoocaaaa atcaaaggag aacatootgg 540
```

```
570
 gctgtccatt ggtgatgttg cgaagaaact
<210> 283
<211> 366
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (2)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (4)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (10)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (32)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (39)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (327)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (333)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (337)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (348)
<223> n equals a,t,g, or c
```

```
<220>
 <221> misc feature
 <222> (357)
 <223> n equals a,t,g, or c
 <400> 283
 gntnatgtgn aattaagaca aataaaaacg tnaagcggna caaatcacag agagccacaa 60
 ageggattte acacatgeet ageagaceag aactetegge agttgetaca agggaagaaa 120
ggactatgtg gatcccttgt ggctatgcag atacctacct cacagagttg ttgtagaaga 180
ctggtggttt ggttcaaacc ttgtgattaa agagtttgtc aagcatttta ttcttttgaa 240
aaaaaaaaaa aaaaaaaaa aaagggnggc cgntttnaag gatccaanct tacgaancgt 360
gcatgc
<210> 284
<211> 414
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (389)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (394)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (395)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (398)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (407)
<223> n equals a,t,g, or c
<400> 284
ggaagctgag acaggcattc caaggggact ccatcccggt tttcgacctg ctgatcctgg 60
gggtgggccc cgatggtcac acctgctcac tcttcccaga ccaccccctc ctacaggagc 120
gggagaagat tgtggctccc atcagtgact ccccgaagcc accgccacaq cqtqtqaccc 180
tcacgctacc tgtcctgaat gcagcacgaa ctgtcatctt tgtggcaact ggagaaggca 240
aggcagetgt tetgaagege attttggagg accaggagga aaaccegetg eeegeegeet 300
```

ggtccagccc cacaccggga aactgtgctg gtcttggacg aggcggccgc cgcttctgac 360 cgtgcccttc gagaaacatt ccactttgna actnngcnca aaggacnccc aaat <210> 285 <211> 551 <212> DNA <213> Homo sapiens <220> <221> misc feature <222> (5) <223> n equals a,t,g, or c <220> <221> misc feature <222> (8) <223> n equals a,t,g, or c <220> <221> misc feature <222> (22) <223> n equals a,t,g, or c <220> <221> misc feature <222> (24) <223> n equals a,t,g, or c <220> <221> misc feature <222> (64) <223> n equals a,t,g, or c <220> <221> misc feature <222> (180) <223> n equals a,t,g, or c <220> <221> misc feature <222> (186) <223> n equals a,t,g, or c <220> <221> misc feature <222> (225) <223> n equals a,t,g, or c <220> <221> misc feature

<222> (234)

```
<223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (271)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (296)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (298)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (319)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (322)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (324)
 <223> n equals a,t,g, or c
. <220>
 <221> misc feature
 <222> (325)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (365)
 <223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (368)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (410)
<223> n equals a,t,g, or c
```

```
<220>
 <221> misc feature
 <222> (482)
 <223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (526)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (528)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (536)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (545)
<223> n equals a,t,g, or c
<400> 285
gtcongentg ageogeacgg engnaegete gtcttegece gecatggeeg agagegactg 60
gganacggtg acggtgctgc gcaagaaggg ccctacggac gcccagcaac atccaagcag 120
gctatcttag cggcacaaag actaggagaa gatgtggaga cttccaataa atgggctgcn 180
ggccanaaca aacaacattc tattaccaag aacacggcca agctngaccg gganacagag 240
tgctgcacca tgacaggtga ccctgaagtg ngtcaagtga tccagcaagt cggcananca 300
agggettaca cataacgane tngnnacgaa aateatgata agecacagtg ategeagaet 360
atganagngg tacggccata cccaataacc agtgcttggc aaaatcgacn ggaccattgg 420
ctccaagctc cgggaaagac attggaaaac ccatcgagaa gggcctaggc gaaatgaaca 480
cnaagcoteg aaatcatgag etecagetga tetetteege egttementg geegenatte 540
cgttntcctc a
                                                                   551
<210> 286
<211> 615
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (3)
<223> n equals a,t,g, or c
<400> 286
gengacacca acceteacta aagggaacaa aagetggage tecacegegg tgeggeeget 60
ctagaactag tggatccccc gggctgcagg aattcggcac gagtattgcc tctgagggag 120
```

```
tocaactgta tacctgcatc agtgtcattc ctttgtgtga tttcttaatg ctgtatttgt 180
 tcatctcaaa cctagatgta tacagctctg agttataaat ggttataaag ctcctgttac 240
tcatattagt tatttacatc aaaaagcttt tagaaaatgg tacgaggtaa ccaattcttg 300
tcatggtgaa atctgattga gtaaccaagc agttttacta ttctggtgct gcttcataac 360
aaaaatgaaa agctgcatgc atctacagca ggcatggatt gtttatgtcg tatgatatcc 420
tttattaagt aagttcactt atagtatttc tataatttga ttcattgccg taatagagcc 480
atgtaggaaa tgcactgatt gcatgttatt gtggcaagaa tatcctaaat gtcattaaaa 540
tectecaaca tgatggatet acttatggte ttgtttgttg acatgacaaa ttaacattet 600
tatagttaca tctgg
                                                                    615
<210> 287
<211> 302
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (221)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (226)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (237)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (286)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (296)
<223> n equals a,t,g, or c
<400> 287
gcggaatgtc acacacattg atcaggcact ccaggaagct catcgggtgc tgaaaccagg 60
aggacggttt ctctqtctqq aatttagcca agtgaacaat cccctcatat ccaggcttta 120
tgatetatat agettecagg teatecetgt cetgggagag gteategetg gagaetggaa 180
gtcctatcag taccttgtag agagtatccg aaggtttccg nctcangaag agttcangga 240
catgatagaa gatgcaggct ttcacaaggt gacttacgaa agtctnacat caggcnttgt 300
                                                                   302
gg
<210> 288
<211> 414
```

<212> DNA

```
<213> Homo sapiens
 <220>
 <221> misc feature
 <222> (53)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
<222> (57)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (63)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (83)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (86)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (91)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (95)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (96)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (100)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (107)
<223> n equals a,t,g, or c
```

<220> <221> misc feature <222> (116) <223> n equals a,t,g, or c <220> <221> misc feature <222> (147) <223> n equals a,t,g, or c <220> <221> misc feature <222> (153) <223> n equals a,t,g, or c <220> <221> misc feature <222> (157) <223> n equals a,t,g, or c <220> <221> misc feature <222> (158) <223> n equals a,t,g, or c <220> <221> misc feature <222> (168) <223> n equals a,t,g, or c <220> <221> misc feature <222> (201) <223> n equals a,t,g, or c <220> <221> misc feature <222> (205) <223> n equals a,t,g, or c <220> <221> misc feature <222> (208) <223> n equals a,t,g, or c <220> <221> misc feature <222> (212)

<223> n equals a,t,g, or c

```
<220>
<221> misc feature
<222> (216)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (221)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (227)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (233)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (253)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (275)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (281)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (292)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (298)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (299)
<223> n equals a,t,g, or c
<220>
```

```
<221> misc feature
<222> (315)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (318)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (332)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (341)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (348)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (354)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (359)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (363)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (364)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (372)
<223> n equals a,t,g, or c
<220>
```

<221> misc feature

```
<222> (379)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (385)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (390)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (402)
<223> n equals a,t,g, or c
<400> 288
aattoggcac gagagagaga gagagagaga gagagagaga gagagagaga gtngcgntag 60
ttngtgtgtc ctcggtttct cgnctnctgg ntcgnncccn cccacanctg gggcgntcta 120
tgtcgagtgg cgcccatggc gaagagntct canctonnat gtggaagnct ctcaccttct 180
tegtegeget eeeeggggtg neagneanea thetgnatgt ntacethaag teneaceaeg 240
gagagcacga ganacccgag ttcatcgtct accontatct ncgtatcagg ancaagcnnt 300
ttccctgggg agatngtnac catacttttt tncataaccc ntatgtgnat ccanttccnc 360
ttnntacgga gntgtatana gagantttgn ccattaccgg gncaacaggg ccca
<210> 289
<211> 184
<212> DNA
<213> Homo sapiens
<220> -
<221> misc feature
<222> (7)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (9)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (14)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (25)
<223> n equals a,t,g, or c
```

```
<220>
 <221> misc feature
 <222> (35)
 <223> n equals a,t,g, or c
<220>
 <221> misc feature
<222> (101)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (142)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (159)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (175)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (176)
<223> n equals a,t,g, or c
<400> 289
ggacttnant tetntggaat gcatngaatg gcagngacgc attggccetg ccettggcet 60
gcattgatga cgagatggac tgtgagcctc agggccccgc ncctggccca gctctccgat 120
gtggccatgc acagcctggg tntggctttc atctatganc agactgacga catcnnggat 180
gttc
<210> 290
<211> 207
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (9)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (15)
<223> n equals a,t,g, or c
```

<220>

```
<221> misc feature
 <222> (21)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (45)
 <223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (63)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (107)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (133)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (149)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (160)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (176)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (200)
<223> n equals a,t,g, or c
<400> 290
ggacgtacng tectnetagt ngaggaatat gtegagttte tetanggetg ceccageaat 60
ggnccacttt tgctaaaata tggtatatct tagatgggaa aatgcancca cctggcaaac 120
ttgctgctat ggnatctata agacttcang gattacatan acctgcgtac catgcnctga 180
Ctgactgtgg ggatcatgtn tgttata
                                                                    207
```

```
<210> 291
 <211> 492
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (33)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (437)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (448)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (472)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (474)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (477)
<223> n equals a,t,g, or c
<400> 291
gaagagacat tgaacctgga gaagaaattt ctngttatta tggagatggg ttctttggag 60
aaaataatga gttctgcgag tgttacactt gcgaaagacg gggcactggt gcttttaaat 120
ccagagtggg actgcctgcg cctgctcctg ttatcaatag caaatatgga ctcagagaaa 180
cagataaacg tttaaatagg cttaaaaagt taggtgacag cagcaaaaat tcagacagtc 240
aatctgtcag ctctaacact gatgcagata ccactcagga aaaaaacaat gcaacttcta 300
accgaaaatc ttcagttggc gtaaaaaaga atagcaagag cagaacgtta acgaggcaat 360
ctatgtcaag aattccagct tcttccaact ctacctcatc taagcttaac tcatataaat 420
aattccaggg taccaanaga aactgaanaa agtctgcaaa gcctttactt tnanagntaa 480
acattgagaa at
                                                                   492
<210> 292
<211> 237
<212> DNA
<213> Homo sapiens
```

```
<220>
 <221> misc feature
 <222> (16)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (19)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (42)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (65)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (79)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (110)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (111)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (123)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (129)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (167)
<223> n equals a,t,g, or c
```

```
<220>
 <221> misc feature
 <222> (186)
 <223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (192)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (210)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (226)
<223> n equals a,t,g, or c
<400> 292
gggggacatg ccatancent cettggggge ctatggaace theaaagegg cegtggeget 60
tactnatgga cacattcane tgtaaactce tteeetgggg ggteaaggtn naccateate 120
cancetggnt getteaagae agagteagtg aagaaaegtg ggtteantgg gaaaagegee 180
aacaanttgc tnctggccca accttgtctn aagagcttct gcaggnctta cgggaaa
<210> 293
<211> 630
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (2)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (580)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (588)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (594)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (608)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (609)
<223> n equals a,t,g, or c
<400> 293
gnttggaaag acaccacttg gagtttggca aaacactgct cagagacgag agcctgaata 60
tettteaaaa ceteaategt egacageatg ageatgeeat ceacatgatg gacattgeaa 120
tcattgccac agacctcgcc ctgtatttca agaagaggac gatgttccaa aagatcgtgg 180
atcagtctaa gacatatgag agttaacagg agtggacaca gtacatgatg ctggagcaga 240
cacggaagga aatcgttatg gccatgatga tgaccgcctg tgatctctca gccatcacca 300
aaccctggga ggtgcagagc caggtagctc tgctggtggc tgctgaattc tgggaacaag 360
gtgacctgga gcgcacggtg ctgcaacaga atcccattcc catgatggac agaaacaaag 420
cagatgaact coctaagctt caagtegget teattgactt tgtttgcace ttegtetaca 480
aggaattete cegttteeae gaggagatea ecceaatgtt ggaegggate accaacaate 540
gcaaggagtg gaaggccgct tgctgatgaa tacgatgccn agatgaangt gcangaagag 600
aagaaacnna aaccagcaag tcggccaagt
                                                                   630
<210> 294
<211> 346
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (1)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (2)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (12)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (24)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (83)
```

```
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (113)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (205)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (206)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (207)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (220)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (249)
<223> n equals a,t,g, or c
<400> 294
nnagcgctcg cnagtggaac actnattgga atccaaaaaa ttcggacagt gggaaatact 60
ggggtaaatc ctggttaccc canaactata ccctggttga tatgaagatt gantttggtg 120
ttgatataac caccaaagaa atggttcttg ctgatgattc ctggagactg gccattacga 180
gtattgaagc caacagtaaa gacannnagt cttactgggn gctcaaagaa gtaactcctg 240
aagggctcna aatggtaaag aaaagctttg aggccgggca cggtgactca tgcctgtaat 300
                                                                   346
cccagcactt tgggaggcca aggcaggcag atcacccaag gtcagg
<210> 295
<211> 531
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (206)
<223> n equals a,t,g, or c
<220>
```

```
<221> misc feature
<222> (209)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (277)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (286)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (311)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (319)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (320)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (345)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (353)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (365)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (374)
<223> n equals a,t,g, or c
<220>
<221> misc feature
```

```
<222> (383)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (421)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (423)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (425)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (427)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (430)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (432)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (438)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (441)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (444)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (448)
```

```
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (462)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (463)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (464·)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (471)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (495)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (508)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (519)
<223> n equals a,t,g, or c
<400> 295
gttctgtctc gctgatgtca gacctggagg gcaacaccaa gtcacgtgtc cgcctgttgg 60
tectegtgee accetecaaa ecagaatgeg geategaggg agagaceata attgggaaca 120
acatecaget gacetgecaa teaaaggagg geteaceaac eeetecagta cagetggaaa 180
gaagttacaa catcctgaat caagancanc ccctggcccc acccacctca ggttcaacct 240
gttctccctt aaaaaatatc tcccacagaa cacatcnggt ttatantctt gttcctccca 300
gcaataagaa nggaaaccnn tttctgcaac ttcacggtgg ccttncaaat ctncccccca 360
taaantttgg cccntttttt tgnctccccg ggggggtttt ttttttcacc ccccttatcc 420
ntngngncan cnccttangg ngcngccncc caggggaaag annnaacccc naaaaaaagg 480
gaaaaccggg caccnggacc ctttgaanac cccacactnt aaaatttcca a
<210> 296
<211> 572
<212> DNA
```

```
<213> Homo sapiens
 <220>
 <221> misc feature
 <222> (435)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (446)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (451)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (465)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (489)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (501)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (539)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (546)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (570)
<223> n equals a,t,g, or c
<400> 296
ggttctgccc ccactgctta taatgctggt gatctacatt aagatcttcc tggtggcctg 60
caggcagett cagegcactg agetgatgga ceactegagg accaecetee agegggagat 120 .
ccatgcagcc aagtcactgg ccatgattgt ggggattttt gccctgtgct ggttacctgt 180
```

```
gcatgctgtt aactgtgtca ctcttttcca gccagctcag ggtaaaaata agcccaagtg 240
 ggcaatgaat atggccattc ttctgtcaca tgccaattca gttgtcaatc ccattgtcta 300
 tgcttaccgg aaccgagact tccgctacac ttttcacaaa attatctcca ggtatcttct 360
 ctgccaagca gatgtcaaga gtgggaatgg tcaggctggg gtacagcctg ctctcggtgt 420
 gggcctatga tctangctct cgcctnttca ngagaagatc aaatncacaa gaaacaaaga 480
 ggacacggnt ggttttattg ngaaagatag ctacacctta caaggaaatg gactggctnt 540
 tttgancact tcctggaact accacgtatn ta
 <210> 297
<211> 334
 <212> DNA
 <213> Homo sapiens
<220>
<221> misc feature
<222> (44)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (67)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (74)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (84)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (90)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (106)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (108)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (118)
```

```
<223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (131)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (167)
 <223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (176)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (177)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (219)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (227)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (263)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (292)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (293)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (315)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (316)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (317)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (319)
<223> n equals a,t,g, or c
<400> 297
ggcagaaaga aaggccctgc tcctccaggg ctccaacgag atcnaaatcc gcgcccgagg 60
gcaacanccg cttnacctac agenteactn tegatggetg cacgantnac accggagnec 120
tggggcaaga nagtgaattg aattacaaaa ccaccaagac ctcccgnttg cccatnnatc 180
gatgtggccc ccttggaacg ttggtgcccc aaaccaggna attcggnttc gaacgttggg 240
ccctgtttgg tttcctgtaa aantcccttc cattcccaac ctgggttccc tnnccaaccc 300
                                                                    334
aaccaaattt ttccnnncna acccgggaaa cagg
<210> 298
<211> 293
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (23)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (165)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (199)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (237)
<223> n equals a,t,g, or c
<400> 298
atggaggccg ctgactaccg agnggccagc agccagcagg gcctggccta tgccacagag 60
```

```
gctgtctatg aaagcgcaga ggccccgggc cactatcccg cagaggacag cacctacgat 120
gagtacgaga acgatctggg gatcacagcc gtcgccctgt acgantacca ggctgcgggc 180
gatgatgaga totoatttna cootgatgac atcatcacca acatcgagat gattgangac 240
ggctggtggc gcggggtgtg caagggccgc ttcagggagc tcgcattctc ttg
<210> 299
<211> 418
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (29)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (59)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (71)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (76)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (78)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (114)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (154)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (168)
<223> n equals a,t,g, or c
```

<220>

```
<221> misc feature
 <222> (213)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (221)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (241)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (260)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (269)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (278)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (284)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (292)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (294)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (313)
<223> n equals a,t,g, or c
<220>
<221> misc feature
```

PCT/US00/05883

```
<222> (330)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (334)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (346)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (347)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (352)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (354)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (355)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (358)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (373)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (377)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (379)
```

```
<223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (383)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (392)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (393)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (408)
<223> n equals a,t,g, or c
<400> 299
aatteggeae gaggggeetg ggegttttnt tgttggtett egtgetgggt etgggtetna 60
ccccaccgac nttggntnag gataactcca ggtacacaca cttcctgacc cagnactatg 120
atgccaaacc acagggccgg gatgacagat actntgaaag catcatgngg agacggggcc 180
tgacctgacc ctgcaaagac atcaacacat ttnttcatgg naacaagcgc agattcaagg 240
ncatctgtga aaacaaggan tggaaaccnt tacagggnaa cctnaggttt angnaagttt 300
tttttttcca ggnaaccatt tggaaagttn aatngggggt ttcccnnggg tntnnaanga 360
ctttcccggg gcnaaangng ggnttaaaaa anntttttt tttttttnga aaaaggtt 418
<210> 300
<211> 346
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (41)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (97)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (107)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (277)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (296)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (317)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (320)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (330)
<223> n equals a,t,g, or c
<400> 300
ccacaaacag tttgcatccc tagaacatgg cattgtgcca nttaccagtg attgccagta 60
cctcttccct gccaaggttg tctctcgcct ggtgaantgg gtgacanttg cccatgagga 120
ttacatggag ctgcacttca ccaaagacat tgtggatgcg ggactggctg gggacaccaa 180
tetetactac atggegetea tegaaagggg cacagecaaa etgeaggeeg etgtggtgtt 240
gaaccotggc tactcctcca teccaectgt tttccanete tgtttgaact ggaaanggga 300
                                                                    346
gaaaaccaac agcaacnatn acaacatton gggccatgga gggcga
<210> 301
<211> 213
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (19)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (46)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (60)
```

```
<223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (66)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (80)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (119)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (130)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (165)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (170)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (202)
<223> n equals a,t,g, or c
<400> 301
gctttataat ctgctcatnt ttgcctaata aatgcaacat ccacangaac tgaatttctn 60
aaaaanttgg tactaccagn tattggttcg tttacaatta ttgatggaaa tcaagtcanc 120
ggacaaaatn ctggaaacaa tttcttcctt caaaaaatct tatcngcaan aaccgactga 180
agctgccata gatttcctta cnagaattaa ata
                                                                    213
<210> 302
<211> 440
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (121)
```

```
<223> n equals a,t,g, or c
 <220>
 <221> misc feature
<222> (324)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (342)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (363)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (382)
<223> n equals a,t,g, or c
<400> 302
ggcacgagcg agaccccagc aggcaccatc ctttaccacg ctcatttaga catcgaggcc 60
ttcaccatgg accgggaagt gcgcaaaatc aaacaaggcc tgggcttgaa atttgctgag 120
ntggtgtata ccggtttctg gcacagccct gagtgtgaat ttgtccgcca ctgcatcgcc 180
aagtcccagg agcgagtgga agggaaagtg caggtgtccg tcctcaaggg ccaggtgtac 240
atcctcggcc gggagtcccc actgtctctc tacaatgagg agctggtgag catggatgag 300
aacctcatgc acatcagcta cgangctgga atcctggaga ancccaagaa ccaagcgctc 360
cangtottaa acgaagacco angacccago caaagcccca acaaccctga catotccgag 420
atcgagttca aaaaagggtc
                                                                   440
<210> 303
<211> 495
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (22)
<223> n equals a,t,g, or c
<400> 303
ctcataaggg accaaagctg gngctccacc gcggtggcgg ccgctctagc actagtggat 60
ccccgggct gcaggacgcc atgttggggt ttgtgggtcg ggtggccgct gctccggcct 120
ccggggcctt gcggagactc acccettcag cgtcgctgcc cccagetcag ctettactgc 180
gggccgtccg acggcggtcc atcctggtga gagcacagta aggactattg ctatggatgg 240
tacagaaggc ttggttagag gccagaaagt actggattct ggtgcaccaa tcaaaattcc 300
tgttggtcct gagactttgg gcagaatcat gaatgtcatt ggagaaccta ttgatgaaag 360
aggtcccatc aaaaccaaac aatttgctcc cattcatgct gaggctccag agttcatgga 420
aatgagtgtt gagcaggaaa tottgtgact ggtatcaagg ttgtcgatot gctagottoc 480
```

```
tatgccaagg gtggc
                                                               495
 <210> 304
 <211> 293
 <212> DNA
 <213> Homo sapiens
 <220>
 <221> misc feature
 <222> (284)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
<222> (286)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (287)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (289)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (292)
<223> n equals a,t,g, or c
<400> 304
ggtcagggac aagatggtgc caccggtgca ggtctctccg ctcatcaaga ttacctaaaa 60
cctcgggcag aagaggagag gaggatagca gcagaagaga agaagaagca ggatgaactg 120
aaacggattg ccagagaatt ggcagaagat gacagcatat taaagtgagt gaccctgcga 180
aaaaaaaaa aaaaaaaaa aaaaaaaaaa aaaaaagggg cggncnntnt tna
<210> 305
<211> 261
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (17)
<223> n equals a,t,g, or c
<220>
<221> misc feature
```

```
<222> (36)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (181)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (190)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (205)
<223> n equals a,t,g, or c
<400> 305
ccggaatcgg ccctgtngcc cccgcccgca ctccanagcc ggctgagaac ggcagcggcg 60
agggetecae gtgeagegte teteegggea cettegggte eaggactaca acteeeggea 120
gggtgcgcaa aacgaccgcc caaggcaacg gaggctcacg agaatcagca tgattcttca 180
naggetettn aggtteteet etgtnatteg gteageegte teagteeatt tgeggaggaa 240
cattggtgtt acagcagttg g
                                                                    261
<210> 306
<211> 502
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (41)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (147)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (165)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (173)
<223> n equals a,t,g, or c
<220>
```

```
<221> misc feature
 <222> (186)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (213)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (253)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (260)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (270)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (274)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (293)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (316)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (324)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (346)
<223> n equals a,t,g, or c
<220>
<221> misc feature
```

```
<222> (423)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (436)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (462)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (468)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (488)
<223> n equals a,t,g, or c
<400> 306
gcaacactaa aggacgaacc tgatctctta tactagtatc nttaatcatt tttattgcca 60
caactaacct cctcggactc ctgcctcact catttacacc aaccacccaa ctatctataa 120
tcctagccat ggccatcccc ttatgancgg gcgcagtgat tatangcttt cgntctaaga 180
ttaaanatgc cctagcccac ttcttatcaa aangcacacc tacacccctt atccccatac 240
tagttattat ggnaaacatn atcctactcn ttcnaccaat agccctgggc gtnagcctaa 300
tegettacat tactgnaggg caentactea tgcaecteat tggaanegte cectacaata 360
tcaatcatta aacttccctc tacacttatc tcttcacatt ctattctaac ttaatatcct 420
aanaaattcc ttttcncttt attccaagcc caactttttc cnactttntt cttaaacccc 480
                                                                   502
ttactttncg aaaaaccttt tt
<210> 307
<211> 119
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (14)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (33)
<223> n equals a,t,g, or c
<220>
<221> misc feature
```

```
<222> (40)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (67)
<223> n equals a,t,g, or c
<220>
<221> misc feature
· <222> (76)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (113)
<223> n equals a,t,g, or c
<400> 307
aaccgactat gganttacag ccacaaagca agnggtgaan gctggaacat tcttttggtc 60
tgttgtnatc cctcanttgc ggagaatatt aaccatattg cagtggctca ccntaccag 119
<210> 308
<211> 403
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (9)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (11)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (13)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (344)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (368)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (375)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (388)
<223> n equals a,t,q, or c
<220>
<221> misc feature
<222> (389).
<223> n equals a,t,g, or c
<400> 308
gcggacggnc ngngaaggtg cttaagcggc tgcgacttca gaagcgaggc acaggcggtg 60
tggacacggc tgcggtgggc ggggtcttcg acgtctccaa cgctgaccgc ctgggcttct 120
cagaggtgga gctggtgcag atggtggtgg acggagtgaa gctgctcatc gagatggagc 180
ageggetgga geagggeeag geeategaeg aceteatgee tgeecagaaa tgaageeegg 240
cecacacecg acaceageee tgetgettee taacttattg cetgggeagt geceaceatg 300
cacccctgat gttcgccgtc tggcgagccc ttagccttgc tgtnagagat tccgttcaac 360
                                                                   403
cttggtanaa tttanttttt tgatgggnna agatatgctg atg
<210> 309
<211> 559
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (5)
<223> n equals a,t,g, or c
<400> 309
aagengacae cacceteact aaagggaaca aaagetggag etecacegeg gtgeggeege 60
tctagaacta gtggatcccc cgggctgcag gaattcggca cgaggtttat ctcaaggcct 120
gagtagcegg taacaaacga gggtteeegg gattggaeeg acgeageeat geetetgega 180
cttgatatca aaagaaagct aactgctaga tctgatcgag ttaagagtgt ggatctgcat 240
cctacagagc catggatgtt ggcaagtctt tacaatggca gtgtgtgtgt ttggaatcat 300
gaaacacaga cactggtgaa gacatttgaa gtatgtgatc ttcctgttcg agctgcaaag 360
tttgttgcaa ggaagaattg ggttgtgaca ggagcggatg acatgcagat tagagtgttc 420
aattacaata ctctggagag agttcatatg tttgaagcac actcagacta cattcgctgt 480
attgctgttc atccaaccca gcctttcatt ctaactagca gtgatgacat gcttattaag 540
                                                                   559
ctctgggact gggataaaa
<210> 310
<211> 521
<212> DNA
<213> Homo sapiens
```

```
<220>
<221> misc feature
<222> (9)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (227)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (245)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (494)
<223> n equals a,t,g, or c
<400> 310
ggagatgtnt cgctccgtgg ccttagctgt gctcgcgcta ctctctctt ctggcctgga 60
ggctatccag cgtactccaa agattcaggt ttactcacgt catccagcag agaatggaaa 120
gtcaaatttc ctgaattgct atgtgtctgg gtttcatcca tccgacattg aagttgactt 180
actgaagaat ggagagagaa ttgaaaaagt ggagcattca gacttgnctt tcagcaagga 240
ctggnctttc tatctcttgt actacactga attcacccc actgaaaaag atgagtatgc 300
ctgccgtgtg aaccatgtga ctttgtcaca gcccaagata gttaagtggg atcgagacat 360
gtaagcagca tcatggaggt ttgaagatgc cgcatttgga ttggatgaat tccaaattct 420
gcttgcttgc tttttaatat tgatatgctt atacacttac actttatgca caaaatgtag 480
ggttataata atgntaacat ggacatgatc ttctttataa t
                                                                   521
<210> 311
<211> 591
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (51)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (52)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (528)
<223> n equals a,t,g, or c
```

```
<220>
 <221> misc feature
 <222> (537)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (557)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (563)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (571)
 <223> n equals a,t,g, or c
 <400> 311
 ggcccctgc aggtaccggt ccggaattcc cgggtacggc tgcgagaaga nnacagaagg 60
 ggattcctga agctgacagc attcgggccg agatgtctcg ctccgtggcc ttagctgtgc 120
 tegegetact etetettet ggeetggagg etatecageg tactecaaag atteaggttt 180
 actcacgtca tccagcagag agtggaaagt caaatttcct gaattgctat gtgtctgggt 240
 ttcatccatc cgacattgaa gttgacttac tgaagaatgg agagagaatt gaaaaagtgg 300
 agcattcaga cttgtctttc agcaaggact ggtctttcta tctcttgtac tacactgaat 360
 tcacccccac tgaaaaagat gagtatgcct gccgtgtgaa ccatgtgact ttgtcacagc 420
 ccaagatagt taagtgggat cgagacatgt aagcagcatc atggaggttt gaagatgccc 480
 gcatttggat tggatgaatt caaattctgc ttgcttggtt tttaatantg atatgcntat 540
 acacttacct ttatgcncaa aanggtaggg ntataataat ggtaacatgg g
                                                                    591
<210> 312
 <211> 584
 <212> DNA
 <213> Homo sapiens
<220>
<221> misc feature
<222>(4)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (14)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (20)
```

```
<223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (33)
 <223> n equals a,t,g, or c
 <220>
<221> misc feature
 <222> (35)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (119)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (259)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (262)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (299)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (310)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (327)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (329)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (330)
<223> n equals a,t,g, or c
```

```
<220>
 <221> misc feature
 <222> (350)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (365)
 <223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (400)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (424)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (437)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (508)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (527)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (535)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (553)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (576)
<223> n equals a,t,g, or c
```

```
<400> 312
 gagnttcccg ggtncgacgn cacgcgtccg aantnaaaat ttttaaaaaaa aaaaaaaaaa 60
 aaaaaaaaa aaaagggcgg ccgttctaga ggatccaagc ttacgtacgc gtgcatgcna 120
 cgtcatagct cttctatagt gtcacctaaa ttcaattcac tggccgtcgt tttacaacgt 180
 cgtgactggg aaaaccctgg cgttacccaa cttaatcgcc ttgcagcaca tccccctttc 240
 gccagctggc gtaatagcna anaggcccgc accgatcgcc cttcccaaca gttgcgcanc 300
 ctgaatggcn aatgggacgc gccctgnann ggcgcattaa gcgcggcggn tgaggtggtt 360
 acgencageg tgacegetae acttgecagt geectagegn eegeteettt egetttette 420
 cctncctttc tcgccangtt cgccggcttt ccccgtcaag ctctaaatcg ggggctccct 480
 ttagggttcc gatttagtgc tttacggnac cttcgacccc aaaaaanttg attanggtga 540
 tggttcacgt aantgggcca tcgcccttga tagacnggtt tttc
                                                                    584
<210> 313
<211> 763
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (11)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (12)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (52)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (54)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (264)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (297)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (331)
<223> n equals a,t,g, or c
```

```
<220>
 <221> misc feature
 <222> (372)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (431)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (496)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (528)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (530)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (588)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (641)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (657)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (676)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (714)
<223> n equals a,t,g, or c
```

```
<220>
 <221> misc feature
 <222> (730)
 <223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (731)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (744)
<223> n equals a,t,g, or c
<400> 313
atccaagett acgtacgegt geatgegacg teatagetet tetatagtgt cacetaaatt 120
caattcactg gccgtcgttt tacaacgtcg tgactgggaa aaccctggcg ttacccaact 180
taatcgcctt gcagcacatc cccctttcgc cagctggcgt aatagcgaag aggcccgcac 240
cgatcgccct tcccaacagt tgcncagcct gaatggcgaa tgggacgcgc cctgtancgg 300
cgcattaagc gcggcggtg tggtggttac ncgcagcgtg accgttacac ttgccagcgc 360
cctagcgccc gntcctttcg ctttcttccc ttcctttctc gccacgttcg ccggctttcc 420
ccgtcaagct ntaaatcggg ggctcccttt agggttccga tttagtgctt tacggcacct 480
cgaccccaaa aaactngatt agggtgatgg ttcacgtagt gggccatngn cctgatagac 540
ggtttttcgc cctttgacgt tggagtccac gttcttaata gtggactntt gttccaaact 600
ggaacaacac ttaaccctat ctcgggctat tcttttgatt nataagggat ttttccnatt 660
tcgggcctat tggttnaaaa aatgaagctt gttttaacaa aaaatttaac gcgnaatttt 720
accaaaaatn nttaaacggc ttanaattta agggggggcc ctt
                                                                763
<210> 314
<211> 761
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (76)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (103)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (109)
<223> n equals a,t,g, or c
<220>
```

```
<221> misc feature
 <222> (119)
 <223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (126)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (155)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (225)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (248)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (251)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (255)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (257)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (297)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (339)
<223> n equals a,t,g, or c
<220>
```

<221> misc feature

```
<222> (345)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (367)
 <223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (371)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (386)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (397)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (437)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (441)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (447)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (460)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (467)
<223> n equals a,t,g, or c
<220>
<221> misc feature
```

<222> (483)

PCT/US00/05883

```
<223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (510)
 <223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (526)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (527)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (528)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (535)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (545)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (557)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (567) ·
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (581)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (596)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (611)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (632)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (644)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (651)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (653)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (657)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (660)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (664)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (675)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (678)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (692)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (723)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (744)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (756)
<223> n equals a,t,g, or c
<400> 314
aaaaaaaaaa aagggnggcc gctctaaagg atccaagctt acntacgcnt gcatgcaang 120
tcatanctct cctatagtgt cacctaaatt caatncactg gccgtcgttt tacaacgtcg 180
tgactgggaa aaccctggcg ttacccaact taatcgcctt gcaanacatc cccctttcgc 240
cagctggngt natancnaaa aggcccgcac cgatcgccct tcccaacagt tgcgcancct 300
gaatggcaaa tgggacgcc cctgttacgg cgcattaanc ccggngggtg tggtggttac 360
ccccaangtt naccgctaca cttgcnageg ccctagngcc cgctcctttc gctttcttcc 420
cttcctttct cgccaanttc ngccggnttt ccccgtcaan ctctaantcg ggggcccctt 480
tanggttcca atttatgctt tacggcaccn caacccaaaa aacttnnnta aggtnatggt 540
ccacntatgg gccatchect aataaanggt tttccccctt ngaaattgga atccanttct 600
taaaagggaa nctgttccaa atggaaaaaa anccaaccct atcncgggct ntncctngan 660
ttanaaaggg aattnggnca attccggcct antgggttta aaaaattgaa actgaattta 720
                                                               761
aanaaaaatt taaacgcaaa attntaaaaa aaattnttta a
<210> 315
<211> 540
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (40)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (46)
<223> n equals a,t,g, or c
<220>
```

```
<221> misc feature
 <222> (47)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (109)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (252)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (367)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (376)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (394)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (422)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (432)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (478)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (484)
<223> n equals a,t,g, or c
<220>
```

<221> misc feature

```
<222> (488)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (504)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (528)
<223> n equals a,t,g, or c
<400> 315
gattttttat aaaccacggt tqcaqccaaa aaaaaaaaan aaaaannaaa aaaaaaaaa 60
aaaagggcgg ccgctctaga ggatccaagc ttacgtacgc gtgcatgcna cgtcatagct 120
cttctatagt gtcacctaaa ttcaattcac tggccgtcgt tttacaacgt cgtgactggg 180
aaaaccctgg cgttacccaa cttaatcgcc ttgcagcaca tccccctttc gccagctggc 240
gtaatagega anaggeeege acegategee etteecaaca gttgegeage etgaatggeg 300
aatgggacgc gccctgtagc ggcgcattaa gcgcggcggg tgtggttggtt acgcgcagcg 360
tgaccgntac acttgnaagc gccctaacgc ccgntccttt cgctttcttc ccttcctttc 420
the cacette greegette cegteaaget etaaateggg ggeteettta agggteenaa 480
ttantggntt tacgggacct tgancccaaa aaaacttgat ttaggggnga agggttcacg 540
<210> 316
<211> 513
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (265)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (420)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (468)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (478)
<223> n equals a,t,g, or c
<220>
<221> misc feature
```

```
<222> (483)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (496)
<223> n equals a,t,g, or c
<400> 316
gtctttctgt taatttccct ctgcctaaag actacatgac agaaatgacc tatcactact 60
tattatttct gaagcctaac tgcaagactg atttctgaga acaagtaaag aactggaata 120
cttatttttc atataaaaat ctaaatgtgt taataaatca tttcatacaa aagtacatta 180
ccaagettae gtaegegtge atgenaegte atagetette tatagtgtea cetaaattea 300
attcactggg ccgtcgtttt acaacgtcgg tgactgggaa aaccctggcg ttacccaact 360
taatccgcct tgcagcacat ccccctttcg ccagctggcg taatagcgaa gaggcccgcn 420
ccgatcgccc ttcccaacag ttgcgcatgc tgaatggcga atgggacncg ccctgtancg 480
ggngcattaa agcgcngcgg gtgtggttggt tac
                                                                513
<210> 317
<211> 389
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (9)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (31)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (60)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (70)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (72)
<223> n equals a,t,g, or c
<220>
<221> misc feature
```

```
<222> (75)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
<222> (105)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (111)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (126)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (248)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (282)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (296)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (342)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (349)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (351)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (357)
```

```
<223> n equals a,t,g, or c
 <400> 317
 gggcggccgn thtanaggat ccaagettac gtacgcgtgc atgenacgtc ntagetette 120
 tatagngtca cctaaattca attcactggc cgtcgtttta caacgtcgtg actgggaaaa 180
 ccctggcgtt acccaactta atcgccttgc agcacatccc cctttcgcca gctggcgtaa 240
 tagcgaanag gcccgcaccg atcgcccttc ccaacagttg cncagcctga atggcnaatg 300
 ggacgcgccc tgtagcggcg cattaagcgc ggcgggtgtg gnggttacnc ncagcgngac 360
 cgttacactt gccagcgccc tagcgcccg
                                                               389
 <210> 318
 <211> 388
 <212> DNA
 <213> Homo sapiens
 <220>
 <221> misc feature
<222> (1)
 <223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (2)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (3)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (14)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (143)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (144)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (146)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (150)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (154)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (159)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (160)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (163)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (168)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (171)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (174)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (196)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (198)
<223> n equals a,t,g, or c
<220>
```

```
<221> misc feature
 <222> (223)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (226)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (227)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (234)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (240)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (242)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (255)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (280)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (314)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (359)
<223> n equals a,t,g, or c
<220>
<221> misc feature
```

```
<222> (366)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (368)
 <223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (377)
<223> n equals a,t,g, or c
<400> 318
nnnatototo tggnggacco aatttacata ggaaacagot atgaccatga ttacgccaag 60
ctctaatacg actcactata gggaaagctg gtacgcctgc aggtaccggt ccggaattcc 120
cgggtcgacc cacgcgtccg gtnnanaccn atgnggggnn agntctcngg nggnaaggaa 180
aatcgtgcaa agaggnanta atgaatgtgg atcacgagga tanccnntta gtgnaggaan 240
tncatcgttt gggtntaaaa aatgctgatg gaaagttaan tgtgaaaatt ggggtcctct 300
ttcgtgatga taantgagcc aacctctttg aagcattggt aggaactctt aaagctgtna 360
aacgananaa gaatgtncat atccagga
<210> 319
<211> 418
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (235)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (240)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (285)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (380)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (391)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (392)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (396)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (401)
<223> n equals a,t,g, or c
<400> 319
gatatttgtt acttttagtt ctataagtga ggaagagttt atggcaaaga tttttggcac 60
tttgttttca agatggtgtt atcttttgaa ttcttgataa atgactgttt ttttctgcct 120
aatagtaact ggttaaaaaa caaatgttca tatttattga ttaaaaaatgt ggttgcttaa 180
aggatecaag ettaegtaeg egtgeatgeg aegteatage tettntatag tgteacetaa 300
attcaattca ctggccgtcg ttttacaacg tcgtgactgg gaaaaccctg gcgttaccca 360
acttaatcgc cttgcagcan atcccccttt nnccanctgg ngaataccaa aaggcccg
<210> 320
<211> 684
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (11)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (41)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (71)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (251)
<223> n equals a,t,g, or c
<220>
```

```
<221> misc feature
 <222> (570)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (594)
 <223> n equals a,t,g, or c
 <220>
<221> misc feature
 <222> (596)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (606)
 <223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (670)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (684)
<223> n equals a,t,g, or c
<400> 320
cgggaaattc ncaaagctgt ttccgcctgc aggtcccggt ncggaattcc cgggtcgacc 60
cacgcgtccg natccccagt gtgaggttaa tgagcaaaat tggtctttgg ggcccttttt 120
gtccaagccc cactgaaagg cctcttcaga aaactattat ctttaaagcc ctactttaac 180
tccttaattc cagcatacag ctaaaactgg atgtatattc tggcaagtaa aggctgagga 240
ctcctcttta ntcctcagat ctagataact catgacattt tatttgacca acatagcaca 300
tgatgagata tcaaggtaat taaaatagca tgcttgaaaa aaaatacgta atctgtttca 360
cctgtaactg tttaagccaa taaacttttc aaaatttaaa aaaaaaaaa aagggcggcc 420
gctctagagg atccaagctt acgtacgcgt gcatgcgacg tcatagctct tctatagtgt 480
cacctaaatt caattcactg gccgtcgttt tacaacgtcg tgactgggaa aaccctggcg 540
ttacccaact taatcgcctt gcagcacatn cccctttcgc agctggcgta atancnaaga 600
ggcccnaccg atcgcccttt ccaacagttg cgcagcctga atggcgaatg ggacgcgccc 660
tgtagccggn cattaagcgc cggn
                                                                   684
<210> 321
<211> 216
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (2)
```

```
<223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (4)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (10)
 <223> n equals a,t,q, or c
 <220>
 <221> misc feature
 <222> (11)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (25)
<223> n equals a,t,g, or c
 <220>
<221> misc feature
<222> (108)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (155)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (183)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (190)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (192)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (202)
<223> n equals a,t,g, or c
```

```
<400> 321
 cncnagacon nottiggaaa ogcongacta tagggaaago tggtacgcot gcaggtaccg 60
 gtccggaatt cccgggtcga cccacgcgtc cgcccggctg gaggctgnca gaaggatgct 120
 ggggataagc ccttaggcac cagcttagac acctncaaga accaggcccc gctgatgcaa 180
 ganggcagan engataceca tnagageece gagaat
                                                                     216
 <210> 322
 <211> 557
 <212> DNA
 <213> Homo sapiens
 <220>
 <221> misc feature
 <222> (40)
 <223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (98)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (286)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (394)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (415)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (509)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (545)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (546)
```

<223> n equals a,t,g, or c

```
<220>
 <221> misc feature
 <222> (550)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (555)
<223> n equals a,t,g, or c
<400> 322
ggtccagaag cctccccgac cccccaagct atttgctcan attaacaaat taaagtgcct 60
gaagcataat tcatttttgt atctgtggta acaaaacntt aaccaaaaga ttttctgtcc 120
agaagcctcc ccgaccccc aagctatttg ctcacattaa caaattaaag tgcctgaagc 180
ataattcatt ctttacctgt atactaaaaa ccctgttgta ttgatttttt tataataagc 240
ctttttacct ctgtgtaaaa aatatatata caagtgtatg atgtanattt tagttcttaa 300
ctttttttta tggtttctaa tatgtatgac caatgtagcc attgctttaa aatgtaccgt 360
gtaaatataa acacatccta tcagaaaaaa aaanaaaaaa gggcggccgc tctanaggat 420
ccaagettae gtaegegtge atgegaegte atagetette tatagtgtea cetaaattea 480
attcactggc cgtcgtttta caacgtcgng actgggaaaa accctgggcg ttacccaact 540
taatnnggcn ttgcngg
                                                                    557
<210> 323
<211> 145
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (5)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (7)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (15)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (19)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (56)
```

```
<223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (139)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (140)
 <223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (142)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (145)
<223> n equals a,t,q, or c
<400> 323
ggtancngca gtacngtcng aattcccggc tctagagatc caagcttacg tactgngcat 60
gcacgtcata gctcttctat agtgtcacct aaattcaatt cactggccgt cgttttacaa 120
cgtcgtgact gggaaaacnn tntan
<210> 324
<211> 353
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (1)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (2)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (3)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (28)
<223> n equals a,t,g, or c
```

```
<220>
 <221> misc feature
 <222> (43)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (110)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (133)
 <223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (146)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (216)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (219)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (225)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (232)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (235)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (263)
<223> n equals a,t,g, or c
```

```
<220>
 <221> misc feature
 <222> (332)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (334)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
<222> (349)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (353)
<223> n equals a,t,g, or c
<400> 324
nnnattcatc atagccacca tcaccctnct taacctctac ttntacctac gcctaatcta 60
ctccacctca atcacactac tccccatatc tagcaacgta aaaataaaan gacagtttga 120
acatacaaaa conaceccat tectonecae acteategee ettaceaege tacteetace 180
tatctccccc tttatactaa taatcttata aaaaanaana aaaangggcg gncgntctag 240
aggatccaag cttacgtacg cgngcatgcg acgtcatagc tcttctatag ggtcacctaa 300
attcaattca ctggccgtcg ttttacaacg tngngactgg gaaaacccng gcn
<210> 325
<211> 553
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (359)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (381)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (406)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (448)
```

```
<223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (461)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (481)
 <223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (513)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (524)
<223> n equals a,t,g, or c
<400> 325
ggcacgagga caaagccttg ctctgttccc caggctggag tgcattggtg caatcatggc 60
tcactgcagt ctcaaccttc cggactcaag tgatggtccc gcttcagcta cttgggaggc 120
tgaggcagga gaatcgcttg aacccgggag gcggaggttg cggggagccg ggattgtgcc 180
actgcactcc accctagagt gagactccct ctcaaaaaaa aaaaaaaaa actcgagggg 240
gggcccggta cccaattcgc cctatagtga gtcgtattac aattccactg gccgtcgttt 300
tacaacgtcg tgactgggaa aaccctgggc gttacccaac ttaaatcgcc ttgcagcana 360
teccettteg ceagetgggt naattagega agaggeeege acegantege etteceaaca 420
gttgcgcagt ggaatggcga atggcaantg taagcttaaa ntttgtttaa aattcgcgtt 480
naaatttttg gttaaatcag ctcattttt aancataagg ccgnaatcgg gaaaatccct 540
tattaaatcc aaa
<210> 326
<211> 628
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (3)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (7)
<223> n equals a,t,g, or c
<220>
<221> misc feature
```

```
<222> (434)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (435)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (437)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (464)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (592)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (602)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (613)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (622)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (625)
<223> n equals a,t,g, or c
<400> 326
gentgentee aagtecatag gteetgeete tteaateetg getttetagg geetgggatg 60
atcattgcta gaactgagag accagcctgg ctagaacttc agggcgttcc attcattctt 120
tcagtaaatg tttgcagcac atgtgttaca tgtcaggcag tgaaaccccc cacagcagcc 180
treceterea gaggatacat trgtaaccat tacacagrea teagaggaat aarttrttt 240
aatcaccagt gtgcacacag tcatggagtt gggtattccc agctaccagg gaggctgagg 300
tgggaggatt gcttgatgcc aggagttagg gaatatagtg caccgtgatt ggacttgcga 360
atagccactg cactgcggcc tggacgacgt agtgataccc tgactcttat aaataaataa 420
```

```
atgaataaac acannanaaa aaaaaaaggg cggccgctct agangatcca agcttacgta 480
 cgccgtgcat gcgacgtcat aactcttcta taggggcacc taaattcaat tcactggccc 540
 gccgtttaca acgtctgact gggaaaaccc tggcgttacc caacttaatc gncttgcaga 600
 anatcccctt ttnccaactg gnggnata
 <210> 327
 <211> 416
 <212> DNA
 <213> Homo sapiens
 <220>
 <221> misc feature
 <222> (22)
 <223> n equals a,t,g, or c
 <220>
<221> misc feature
<222> (254)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (258)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (260)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (265)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (285)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (297)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (299)
<223> n equals a,t,g, or c
```

<220>

```
<221> misc feature
 <222> (300)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (305)
 <223> n equals a,t,g, or c
 <220>
<221> misc feature
<222> (334)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (349)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (416)
<223> n equals a,t,g, or c
<400> 327
gatgactgat gttattatac antatggtaa atacaaagtt gtagtattat ggttcttgat 60
ggtgtgattt acttatgtaa attatgtaca aatttaagtt caatgaaaca ctgatttaat 120
gtactgaaag gtaaatagta ccatagtgaa ttattttctg tcttgcctta ggtttatttt 180
aaaaaaaaa gggnggangn totanaggat ccaagottac gtacnogtgo atgcaangnn 300
atagntette tatagtgtea cetaaattea attnactgge egtegattna caacgtegtg 360
actgggaaaa ccctggcgtt acccaactta atcgccttgc agcacatccc cctttn
<210> 328
<211> 629
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (227)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (228)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (229)
```

```
<223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (233)
 <223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (242)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (243)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (244)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (257)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (271)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (275)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (284)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (301)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (394)
<223> n equals a,t,g, or c
```

```
<220>
 <221> misc feature
 <222> (469)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (484)
 <223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (512)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (544)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (554)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (573)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (598)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (619)
<223> n equals a,t,g, or c
<400> 328
ttttttttt tttttteggc gctgccgtat cgttccgcct gggcgggatt ctgacttaga 60
ggcgttcagt cataatccca cagatggtag cttcgcccca ttggctcctc agccaaqcac 120
atacaccaaa tgtctgaacc tgcggttcct ctcgtactga gcaggattac catggcaaca 180
acacatcatc agtagggtaa aactaacctg tctcacgacg gtctaannna aanaaaaaa 240
annnaaaaaa gaattcnaaa agcttctcga nagtncttct aaancggccg cgggcccatc 300
nattttccac ccgggtgggg taccaggtaa gtgtacccaa ttcgccctat agtgagtcgt 360
attacaattc actggccgtc gttttacaac gtcntgactg ggaaaaccct ggcgttaccc 420
aacttaatcg ccttgcagca catccccctt tcgccagctg gcgtaatanc gaaaaaggcc 480
gcancgatcg cccttcccaa cagtttgcgc ancctgaaat ggcgaatgga aatcaatttt 540
```

```
taantgttta atgntgttaa actactgaat ccnaattgtt tggtgttttt taaaatcnca 600
 gtcccaaggg tcatttcang gccctcaat
 <210> 329
 <211> 458
 <212> DNA
 <213> Homo sapiens
 <220>
 <221> misc feature
 <222> (4)
 <223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (20)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (31)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (86)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (96)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (194)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (226)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (238)
<223> n equals a,t,g, or c
<220>
<221> misc feature
```

<222> (262)

```
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (267)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (277)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (280)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (285)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (295)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (332)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (333)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (339)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (346)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (352)
<223> n equals a,t,g, or c
```

```
<220>
 <221> misc feature
 <222> (356)
 <223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (372)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (380)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (405)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (414)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (452)
<223> n equals a,t,g, or c
<400> 329
tccaagetta cgtacgegtg catgenacgt catagntetg ctatagtgtc acctaaattc 120
aattcactgg ccgtcgtttt acaacgtcgt gactgggaaa accctggcgt tacccaactt 180
aatcgccttg cagnacatcc ccctttcgcc agatggcgta atagcnaaaa ggcccgcncc 240
gategeeett cecaacagtt gngcagnetg aatggenaan gggangegee etgtngegge 300
gcattaagcg cggcgggtgt ggtggttacg cnnagggtna ccgctncact tnccancgcc 360
ctagcgcccg gncctttcgn tttcttccct tcctttctcg ccacnttcgc cggntttccc 420
cgtcaagctc taaatcgggg ggtccctttt anggttcc
                                                               458
<210> 330
<211> 453
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (78)
```

<223> n equals a,t,g, or c

```
<220>
 <221> misc feature
 <222> (83)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (113)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (134)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (323)
 <223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (327)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (391)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (418)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (427)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (428)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (453)
<223> n equals a,t,g, or c
<400> 330
```

```
aaaaaaaagg gcggccgntc tanaggatcc aagcttacgt acgcgtgcat gcnacgtcat 120
  agetetteta tagngteace taaatteaat teactggeeg tegttttaca aegtegtgae 180
  tgggaaaacc ctggcgttac ccaacttaat cgccttgcag cacatccccc tttcgccagc 240
  tggcgtaata gcgaaaaggc ccgcaccgat cgcccttccc aacagttgcg cagcctgaat 300
  ggcgaatggg acgcgccctg tancggngca ttaagcgcgg cgggtgtggt ggttacgcgc 360
  agcgtgaccg ttacacttgc cagcgcccta negcccgctc ctttcgtttc ttcccttnct 420
  ttctcgnnac gttcgccggt ttccccgtta agn
  <210> 331
  <211> 498
  <212> DNA
  <213> Homo sapiens
  <220>
  <221> misc feature
  <222> (356)
  <223> n equals a,t,g, or c
  <220>
  <221> misc feature
  <222> (361)
  <223> n equals a,t,g, or c
<220>
  <221> misc feature
  <222> (381)
  <223> n equals a,t,g, or c
  <220>
  <221> misc feature
  <222> (393)
  <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (424)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (433)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (452)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
```

```
<222> (469)
 <223> n equals a,t,g, or c
 <220>
<221> misc feature
<222> (483)
<223> n equals a,t,g, or c
<400> 331
gagaaagctg actaatccaa agggcaaggt ggtttacctt aaagaaaaaa aaaaaaaaag 60
ggcggccgct ctagaggatc caagcttacg tacgcgtgca tgcgacgtca tagctcttct 120
atagtgtcac ctaaattcaa ttcactggcc gtcgttttac aacgtcgtga ctgggaaaac 180
cctggcgtta cccaacttaa tcgccttgca gcacatccc ctttcgccag ctggcgtaat 240
agegaagagg cccgcaccga tcgcccttcc caacagttgc gcagcctgaa tggcgaatgg 300
gacgcgccct gtacggcgca ttaagcgcgg cgggtgtggt ggttacgccc agcgtnaccg 360
ntacacttgc cagcgcccta ncgccccgct contttcgct ttctttccct ttcctttct 420
tggncacgtt tcnccgggtt tttcccccgt tnaaagcctt ttaaaatcng ggggggcttc 480
ccntttaaag gggttccc
                                                                    498
<210> 332
<211> 450
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (278)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (317)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (328)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (335)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (338)
<223> n equals a,t,g, or c
<220>
<221> misc feature
```

```
<222> (347)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
<222> (353)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (358)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (368)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (373)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (374)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (377)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (378)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (384)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (386)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (392)
```

```
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (395)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (397)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (415)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (417)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (426)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (428)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (430)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (446)
<223> n equals a,t,g, or c
<400> 332
aattcggcag aggtactcct ggcttatcaa tggaacattc cagcaaagca cacaagagct 60
ctttatccct aacatcactg tgaataatag tggatcctat acctgccacg ccaataactc 120
agtcactggc tgcaacaggg ccacagtcaa gacgatgcat agtcactgag ctaagtccag 180
tagtagcaaa gccccaaatc aaagccagca agaccacagt cacaggagat taaggactct 240
gtggaacctg gacctggttc cacaaaatgg acactggnat cttccatccc gttggttctt 300
tcaaaaaacc aggggtnttc ccgtcctngg ggggnttnga aggtttntcc ccnggggnaa 360
aaaaccancc ttnnggnntt aaancncttt tnaangnggg ggggtttttt gggangngtt 420
ttgggntntn ggggttttta aaccontttg
                                                                   450
```

```
<210> 333
 <211> 434
 <212> DNA
 <213> Homo sapiens
 <220>
 <221> misc feature
 <222> (2)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (58)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (119)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (195)
 <223> n equals a,t,g, or c
<220>
 <221> misc feature
 <222> (214)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (218)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (269)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (291)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (296)
<223> n equals a,t,g, or c
```

```
<220>
 <221> misc feature
 <222> (316)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (333)
 <223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (337)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (382)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (399)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (405)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (425)
<223> n equals a,t,g, or c
<400> 333
gntgaacgta aactataatg ctctaccaca agaaaatggc ctctcacctg gggccatngc 60
tggcattgtg attggagtag tggccctggt tgctctgata gcagtagccc tggcatgtnt 120
tctgcatttc gggaagaccg gcagctcagg accactccaa tgacccacct aacaagatga 180
atgaagttac ttatnctacc ctgaactttg aagnccanca acccacacaa ccaacttcag 240
cctccccatc cctaacagcc acagaaatna tttattccag aagtaaaaaa ncagtnatga 300
aacetggtee tgetenetge agtgeetgat gtntttneaa gteteteace ecceateact 360
aggaaattcc tttcccctgt tngggtaaag ggtggggana gaaancaatt tctcctactc 420
tcctncctat agga
                                                                   434
<210> 334
<211> 612
<212> DNA
<213> Homo sapiens
```

```
<221> misc feature
  <222> (365)
  <223> n equals a,t,g, or c
  <220>
  <221> misc feature
  <222> (437)
  <223> n equals a,t,g, or c
  <220>
  <221> misc feature
  <222> (455)
  <223> n equals a,t,g, or c
  <220>
  <221> misc feature
  <222> (474)
  <223> n equals a,t,g, or c
<220>
  <221> misc feature
  <222> (482)
  <223> n equals a,t,g, or c
  <220>
  <221> misc feature
  <222> (493)
  <223> n equals a,t,g, or c
  <220>
 <221> misc feature
 <222> (497)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (525)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (540)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (565)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
```

```
<222> (583)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (606)
<223> n equals a,t,g, or c
<400> 334
ggtctagcca caacagggtc aatgctcgcc ttgcaggtgc ccccagcgag gacccccagt 60
tccccaaggt gcagtggcca ccccgtgaac tttgttctgc ctgccacaat gaacgcctgg 120
atgtgcccgt gtgggacgtg gaagccaccc tcaacttcct caaggcccac ttctccccaa 180
gcaacatcat cctggacttc cctgcagctg ggtcaacttg cccgagggat gtgcagaatg 240
tggcaagccg ccccaaactg gcgatgggag ccctggagct ggaaagccgg aattcaactc 300
tggaccctgg gaagcctgag atgatgaagt cccccacaaa caccaccca catgtgccgg 360
ctganggacc tgaggcaagt cgacccccga agcttgcacc ctggcctaaa acttgaccag 420
gccaggaacc ctctgancac aatggcaaaa gcttnaaagg aatgaaccag gaancaagcc 480
gntttgggca atngggnact ttgagccaaa gccgaagaac accanggggc ttggatttgn 540
tttggcttta atttccaagg ggttnaaaaa aaaaaacccg gcnttttttg gggggccccc 600
tttttnggaa gg
                                                                    612
<210> 335
<211> 462
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (287)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (337)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (358)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> .(373)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (428)
<223> n equals a,t,g, or c
```

```
<220>
  <221> misc feature
  <222> (456)
  <223> n equals a,t,g, or c
  <400> 335
  gcccacgcgt ccgcatgttt ccaggagggg ccatgggggt cagggtggtt ttgagagagc 60
  agggtaagga aggaatgtgc tagaagtgct cctagtttct tgtaaaggaa gccagagttg 120
  acagtacaaa gggtcgtggc cagccctgca gcttcagcac ctgccccacc cagagtggga 180
  gtcaggtgga gccacctgct gggctccccc agaactttgc acacatcttg ctatgtatta 240
  gccgatgtct ttagtgttga gcctctggat tctggggtct gggccantgg ccatagtgaa 300
  acctgggaat gaatggtact tgaacatctg ggcttgncag ccacaaggaa aggccaancc 360
  catgtacccc aancattett gccaaccett getetgggca tteceggaag ggtegateet 420
  taggettngc tttaaaagee ettgeeettg cetttntett gg
  <210> 336
  <211> 336
  <212> DNA
  <213> Homo sapiens
  <220>
  <221> misc feature
  <222> (170)
  <223> n equals a,t,g, or c
  <220>
  <221> misc feature
  <222> (175)
  <223> n equals a,t,g, or c
  <220>
  <221> misc feature
  <222> (177)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (183)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (196)
 <223> n equals a,t,g, or c
 <220>
<221> misc feature
 <222> (204)
 <223> n equals a,t,g, or c
 <220>
```

```
<221> misc feature
 <222> (208)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (230)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (262)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (275)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (293)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (318)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (335)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (336)
<223> n equals a,t,g, or c
<400> 336
gcagattttg atcgttttaa agttatgaag gcaaagaaaa tgaggaacag aataatcaag 60
aatgaattaa gaagetteaa aaggeagete teetgaaage tteteecaaa aaacacetgg 120
tactaagggt actgctgctg ctgctgctgc tgctgctgct gctgctaaan tccancnaaa 180
aanatcaccg cccganttaa aagntccncc caaaagtcct gcccaaaaan cccaggccaa 240
aaacacgctg ctccaaactc anaggtcaaa actcncccaa aaccctctcc aangctctgc 300
aaaaagctta ttgcatcnta aaattataag gtctnn
                                                                   336
<210> 337
<211> 303
<212> DNA
<213> Homo sapiens
```

```
<220>
 <221> misc feature
 <222> (21)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (25)
 <223> n equals a,t,g, or c
 <220>
<221> misc feature
 <222> (28)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (37)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (49)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (50)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (51)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (64)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (66)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (67)
<223> n equals a,t,g, or c
```

```
<220>
 <221> misc feature
 <222> (70)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
<222> (120)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (168)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (189)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (190)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (192)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (223)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (249)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (256)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (257)
<223> n equals a,t,g, or c
```

```
<221> misc feature
 <222> (267)
 <223> n equals a,t,g, or c
 <400> 337
 agacaatcct taccatgtga naggnggnat gactgtnatg gcatgagann ngcatcacta 60
 tgananngan aactcagtag aagataatgg caagtccaga ctggggatat gatgacaaan 120
atggtcctga acaatggagc aagctgtatc ccattgccaa tggaaatnac cagtcccctg 180
ttgatattnn gnccagtgaa accaaacatg acacctctct ganacctatt agtgtctcct 240
acaacccanc cacagnnaaa gaaattntcc aatgtggggg cattccttcc atgtaaattt 300
ttg
                                                                    303
<210> 338
<211> 460
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (13)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (315)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (409)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (423)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (424)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (433)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (454)
<223> n equals a,t,g, or c
```

```
<400> 338
gatttaaggc atntcctgca tgcacagttg cagttagtta ttccaggtat tatttttgtt 60
ttcagaaaaa gaaaactcag tagaagataa tggcaagtcc agactgggga tatgatgaca 120
aaaatggtcc tgaacaatgg agcaagctgt atcccattgc caatggaaat aaccagtccc 180
ctgttgatat taaaaccagt gaaaccaaac atgacacctc tctgaaacct attagtgtct 240
cctacaaccc agccacagcc aaagaaatta tcaatgtggg gcattccttc catgtaaatt 300
ttgaggacaa cgatnaccga tcaagtgctg aaaggtggtc ctttctctga cagctcaggc 360
tctttcagtt ccattttcac tggggcagtc aaaatgagca tgggttaana acattccagt 420
                                                                    460
ggnntgggag tcnaaatatt ctggccgagc tttnacgtaa
<210> 339
<211> 416
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (30)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (33)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (42)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (51)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (126)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (137)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (147)
```

<223> n equals a,t,g, or c

```
<220>
 <221> misc feature
 <222> (161)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (173)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (258)
 <223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (267)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (268)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (378)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (403)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (407)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (411)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (415)
<223> n equals a,t,g, or c
<400> 339
```

```
ggtgccgatt cctgccctgc cccgaccgcn agncggacca tntcccatca ntgggggtac 60
 ggcaaacaca acggacctaa gcactggcat aaggacttcc ccattgccaa gggaagaqcq 120
 ccagtncccc tgttganatc gacactncat acagccaagt ntgaaccctt ccntgaaagc 180
 ccctgtttgt ttcctatgaa tcaagcaact tccctgagga tcctcaacaa tggtcatgct 240
 ttcaacgtgg gagtttgnat gactctnnag gacaaagcag tgcttcaagg gaaggacccc 300
 tgggttgggc actttacaga ttggttttca ttttttcaat tttcaatggg ggtttcaatt 360
 tgatgggaca aggtttcnga ggcataattg tgggttaaaa agnaatntgg ntgcng
 <210> 340
 <211> 362
 <212> DNA
 <213> Homo sapiens
 <220>
 <221> misc feature
 <222> (5)
 <223> n equals a,t,g, or c
 <220>
<221> misc feature
<222> (76)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (117)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (136)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (170)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (201)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (204)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (233)
```

```
<223> n equals a,t,q, or c
<220>
<221> misc feature
 <222> (310)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (331)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (332)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (335)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (338)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (339)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (357)
<223> n equals a,t,g, or c
<400> 340
ggcanagtga atgttgctgg agaacaaggc cagcattttt ggaggaggac tgcctgcccc 60
ataccaggic aaacantige accigeactig gicegactig ccatataagg geteggngea 120
cagcetegaa tggggngcae tttgccatgg gagatgcaca tagtacatgn gaaaagagaa 180
ggggacatcg aggaatgtga naanagggcc caggaaccct gaagacgaaa ttncggtgct 240
gggccttttt ggtgggaggc tgggaaccca ggtgaaacga gggctttcca gccactggtg 300
ggaggcactn tcttaatatt ccccaaacct nnggntgnng cattacgatt ggcaganagg 360
ca
                                                                   362
<210> 341
<211> 328
<212> DNA
```

<213> Homo sapiens

```
<220>
<221> misc feature
<222> (63)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (98)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (152)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (171)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (184)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (186)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (195)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (276)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (280)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (303)
<223> n equals a,t,g, or c
```

```
<221> misc feature
 <222> (311)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (325)
 <223> n equals a,t,g, or c
 <400> 341
 aagcetttea agatgateee eggagtggtg gatggggtet teetgeeeag geaceeceag 60
 ganctgctgg cctctgccga ctttcagcct gtccctanca ttgttggtgt caacaacaat 120
 gaattcggct ggctcatccc caaggtcatg angatctatg atacccagaa ngaaatggac 180
 aganangeet eccangetge tetgeagaaa atgttaaege tgetgatttg ceteetacat 240
 ttggtgacct gctgaaggaa gaattcattt gggganaatn gggatcccca aaacccccaa 300
 acncatttcc nggaaaataa ttgcngaa
                                                                    328
<210> 342
<211> 140
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (3)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (11)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (33)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (70)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (73)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (129)
<223> n equals a,t,g, or c
```

```
<220>
 <221> misc feature
 <222> (130)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (140)
 <223> n equals a,t,g, or c
 <400> 342
 aangggactt nccagtgatg cacccaagag ctntttatcc ccaacatcac tgtgaataat 60
 aggggatcon atnogtgoca agcocataac totacactgg cottaatagg agcacagtca 120
 cgaatatcnn agtctatgcn
 <210> 343
 <211> 477
 <212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (396)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (421)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (435)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (459)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (463)
<223> n equals a,t,g, or c
<400> 343
gggacagcag agctgacagt cacagcagcc ctgacaagag agttcctgga gcccaagctc 60
ttctccacag aggacaagca ggcagcagag accatggggt ccccttcagc ctgtccatac 120
agagtgtgca ttccctggca ggggctcctg ctcacagcct cgcttttaac cttctggaac 180
ctgccaaaca gtgcccagac caatattgat gtcgtgccgt tcaatgtcgc agaagggaag 240
```

```
gaggtccttc tagtagtcca taatgagtcc cagaatcttt atggctacaa ctggtacaaa 300
 ggggaaaggg tgcatgccaa ctatcgaatt ataggatatt gtaaaaaata taagtcaaga 360
 aaatgcccaa ggcccgacac aacgtcgaga gacaintacc caatggaacc ttgtgttcca 420
 nacgtaccac atgcncagga tttttcctca ctataaaana aanttggatg agaatac
 <210> 344
 <211> 389
 <212> DNA
 <213> Homo sapiens
 <220>
 <221> misc feature
 <222> (1)
 <223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (2)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (3)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (4)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (5)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (6)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (7)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (8)
<223> n equals a,t,g, or c
```

```
<221> misc feature
 <222> (9)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (11)
 <223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (19)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (21)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (22)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (32)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (35)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (144)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (145)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (159)
<223> n equals a,t,g, or c
<220>
<221> misc feature
```

```
<222> (201)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (379)
 <223> n equals a,t,g, or c
 <400> 344
 nnnnnnnnt ntegeacgne nngecageca ancenteact aaagggaaca aaagetggag 60
 ctccaccgcg gtgcgaccgc tctagaacta gtggatcccc cgggctgcag gaattcggca 120
 cgaggccggc cggggctggc acgnncgccg cggcggggnc tggaggcgcg accgggcgcc 180
 cccgagcggg aatcagaacg ncgccgaggg gaccagatca acgccagcaa gaacgaggag 240
 gacgcgggaa aaatgttcgt tggtggcctg agctgggata ctagcaaaaa agatttaaaa 300
 gactatttta ctaaatttgg agaggtcgtt gactgtacaa taaaaatgga tcccaacact 360
 ggacggtcaa gagggtttng gtttatcct
 <210> 345
 <211> 152
 <212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (11)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (34)
<223> n equals a,t,q, or c
<220>
<221> misc feature
<222> (42)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (48)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (61)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (64)
<223> n equals a,t,g, or c
```

```
<220>
 <221> misc feature
 <222> (84)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (87)
 <223> n equals a,t,g, or c
<220>
 <221> misc feature
<222> (122)
<223> n equals a,t,g, or c
<400> 345
tcgacccacg ngtccggggc gcaccatggc ccgnggggct gngctggngc tgctgctctt 60
nggnctgctg ggtgttctgg tcgncgnccc ggatggtggt ttcgatttat ccgatgccct 120
tnctgacaat gaaaacaaga aacccactgc aa
                                                                    152
<210> 346
<211> 634
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (2)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (32)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (38)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (284)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (491)
<223> n equals a,t,g, or c
```

```
<220>
 <221> misc feature
 <222> (586)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (588)
 <223> n equals a,t,g, or c
 <220>
<221> misc feature
<222> (598)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (613)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (621)
<223> n equals a,t,g, or c
<400> 346
tntgtctgaa tgtaaatcac cttctgagcc gntgattncc aagagggttg gtcttattca 60
catatcccaa gtcatctcag aaattgatgg taacaggatg accttgagcc aagaaggagc 120
acaagattcc ttccctcttc agcagaagat cttggtttgc tctttgatgc tcttgatcag 180
gcagttgaaa atcaaagagg tcactctggg gaagttatat gaagcctaca gtaaagtctg 240
tegeaaacag caggtggegg etgtggacca gteagagtgt ttgneaettt cagggetett 300
ggaagccagg ggcattttag gattaaagag aaacaaggaa acccgtttga caaaggtgtt 360
tttcaagatt gaagagaaag aaatagaaca tgctctgaaa gataaagctt taattggaaa 420
tatcttagct actggattgc cttaaattct tctcttacac cccacccgaa agtattcaag 480
ctggcattta nagagctaca ggcttcattt taaggcttta cacattcggg cctgaaaaca 540
aatatgacct tttttacttg aagccaatga attttaatct atagancntt aaaattanca 600
cagaataata tenttgggge ntactatttt acce
                                                                   634
<210> 347
<211> 363
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (228)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (233)
```

```
<223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (242)
 <223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (268)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (319)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (322)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (323)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (324)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (325)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (328)
<223> n equals a,t,g, or c
<400> 347
ggcacgagag gaatatggag aggctgactc ttgcttgtgg tggggtggcc ctgaattctt 60
ttgaggacct aagtcctgac tgcttgggac atgcaggact tgtatatgag tatacattgg 120
gagaagttca cctttattga gaagtgtaac aaccctcgtt ctatcacatt attgatcaaa 180
ggaccaaata agcccacact tagatcaaag atgcagtaaa gggatggnct tgnagggctg 240
thcaaaaatg ctgttgatga tggctgthtg gttccgggtg ctggtgctgt ggaagtggca 300
atggcagaag ccctggatna annnnaantc catgtaaagg gcaaggcaca gttggggtcc 360
agc
                                                                   363
```

```
<210> 348
 <211> 388
 <212> DNA
 <213> Homo sapiens
 <220>
<221> misc feature
<222> (205)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (339)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (344)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (364)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (382)
<223> n equals a,t,g, or c
<400> 348
aattcggcac gagctgaagg ctagcaaacc gagcgatcat gtcgcacaaa caaatttact 60
attoggacaa atacgacgac gaggagtttg agtatoggtt agtgctggcg cgggagcaat 120
agcgagggtc gtgagctttg gccgctgagg gcacaaggaa ttagtaacag gaactgaggc 180
gatagaattg gcgcatgcgt atganacatg tcatgctgcc caaggacata gccaagctgg 240
tecetaaaac ceatetgatg tetgaatetg aatggaggaa tettggegtt cageagagte 300
agggatgggt ccattatatg atccatgaac cagaacctna aatnttgctg ttccggggcc 360
attnccagga accaaggaat tnagtttc
                                                                    388
<210> 349
<211> 194
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (38)
<223> n equals a,t,g, or c
<220>
<221> misc feature
```

```
<222> (51)
 <223> n equals a,t,g, or c
 <220>
<221> misc feature
<222> (57)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (60)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (67)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (69)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (74)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (83)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (91)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (124)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (127)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (140)
```

```
<223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (180)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (191)
 <223> n equals a,t,g, or c
<400> 349
gagttgttgc ctgggctgga cgtggttttg tctgctgngc ccgctcttag ngctctngtn 60
taatttnang cagngcgcca genggatggt neacaageag atatactaet eggacaagta 120
cttngangaa cactacgagn accgggatgg tatgttaccc agagaacttg acaaacaagn 180
acctaaaact natc
                                                                    194
<210> 350
<211> 524
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (9)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (11)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (14)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (17)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (29)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (85)
```

```
<223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (98)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (101)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (148)
 <223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (240)
<223> n equals a,t,q, or c
<220>
<221> misc feature
<222> (258)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (484)
<223> n equals a,t,g, or c
<400> 350
ttaaccttnt naanggnaca aagtctggnt ctccaccagg tggaggaccg ctcctagcaa 60
ctagtgggtc ccccgggcct gcagnaattc ggcagtgncg naaagcccta cggcgtcact 120
gcaatgtgct ggaactggga gcaagtgnca gcggctggac ggcatcctga gtcgagacca 180
ttccgattca cgggcgcggc aacttcccca cgctcgagct gcagccgagc ctgtatcgtn 240
aaggtggtgc ggcggcgnct tgccgagaag cgcatcggcg tccgcgacgt gcgcctcaac 300
ggctcggcag ccagccatgt cctgcaccag gacagcggcc tgggctacaa ggacctggac 360
ctcatcttct gcgccgacct gcgcggggaa ggggagtttc agactgtgaa ggacgtcgtg 420
ctggactgcc tgttggactt cttacccgag ggggtgaaca aagagaagat cacaccactc 480
acgntcaagg aagcttatgt gcagaaaatg gttaaagtgt gcaa
                                                                    524
<210> 351
<211> 352
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (21)
```

```
<223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (261)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (291)
 <223> n equals a,t,g, or c
 <220>
<221> misc feature
<222> (295)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (328)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (348)
<223> n equals a,t,g, or c
<400> 351
gccaaatcct ttgaatactg ngccaggatt tttaagcaac actttatgga cagcagaata 60
ccttgcttaa tcgtagctgc aaagtcagac ctgcatgaag ttaaacaaga atacagtatt 120
tcacctactg atttctgcag gaaacacaaa atgcctccac cacaagcctt cacttgcaat 180
actgctgatg cccccagtaa ggatatcttt ggtaaattga caacaatggc catgtatccc 240
catgcccggt tacgctgtat ntgcacctgc aacaggtgta cattttgcat ntgtnaaaac 300
ttcctcaact tatactttgc tgcaaatntg gtaaaagaac aaaaatcntt tc
                                                                    352
<210> 352
<211> 632
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (3)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (4)
<223> n equals a,t,g, or c
<220>
```

```
<221> misc feature
 <222> (8)
 <223> n equals a,t,g, or c
 <400> 352
 agnnaganac caacceteae taaagggaac aaaagetgga getecacege ggtgeggeeg 60
 ctctagaact agtggatccc ccgggctgca ggaattcggc acgaggtgtg tcagaacaat 120
 cttgaatcat gaagctacta accagagccg gctctttctc gagattttat tccctcaaag 180
 ttgcccccaa agttaaagcc acagctgcgc ctgcaggagc accgccacaa cctcaggacc 240
 ttgagtttac caagttacca aatggcttgg tgattgcttc tttggaaaac tattctcctg 300
 tatcaagaat tggtttgttc attaaagcag gcagtagata tgaggacttc agcaatttag 360
 gaaccaccca tttgctgcgt cttacatcca gtctgacgac aaaaggagct tcatctttca 420
 agataacccg tggaattgaa gcagttggtg gcaaattaag tgtgaccgca acaagggaaa 480
acatggctta tactgtggaa tgcctgcggg gtgatgttga tattctaatg gagttcctgc 540
tcaatgtcac cacagcacca gaatttcgtc gttgggaagt agctgacctt cagcctcagc 600
taaagattga caaagctgtg gcctttcaga at
<210> 353
<211> 440
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (435)
<223> n equals a,t,g, or c
<400> 353
ctttaactcc accattagca cccaaagcta agattctaat ttaaactatt ctctgttctt 60
tcatggggaa gcagatttgg gtaccaccca agtattgact cacccatcaa caaccqctat 120
gtatttcgta cattactgcc agccaccatg aatattgtac ggtaccataa atacttgacc 180
acctgtagta cataaaaacc caatccacat caaaaccccc tccccatgct tacaagcaag 240
tacagcaatc aaccctcaac tatcacacat caactgcaac tccaaagcca cccctcaccc 300
actaggatac caacaaacct acccaccctt aacagtacat agtacataaa gccatttacc 360
gtacatagca cattacagtc aaatcccttc tcgtccccat ggatgacccc cctcagatag 420
gggtcccttg accancatcc
                                                                   440
<210> 354
<211> 609
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (3)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (5)
<223> n equals a,t,g, or c
```

```
<220>
 <221> misc feature
 <222> (8)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (11)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (139)
 <223> n equals a,t,g, or c
 <400> 354
 aancnganac naaccctcac taaagggaac aaaagctgga gctccaccgc ggtgcggccg 60
 ctctagaact agtggatccc ccgggctgca ggaattcggc acgagccgga gggtgtgtgt 120
 tgggcaaagc cggaggagna ggaggacgat tgttttacgg atcccgtgat cggcccgtcc 180
 ttctcccctt tcccccctcc ctaccgcccc tgtcccgccg gggagcggcg gcggccttgg 240
actttgctgt ctttcctcgc ggagacagat ttcaacacta cacttgcaca atgtctttga 300
aaccaagagt agtagatttt gatgaaacat ggaacaaact tttgacgaca ataaaagccg 360
tggtcatgtt ggaatacgtc gaaagagcaa catggaatga ccgtttctca gatatctatg 420
ctttatgtgt ggcctatcct gaaccccttg gagaaagact ttatacagaa actaagattt 480
ttttggaaaa tcatgttcgg catttgcata agagagtttt ggagtcagaa gaacaagtac 540
ttgttatgta tcataggtac tgggaagaat acagcaaggg tgcagactat atggactgct 600
tatataggt
<210> 355
<211> 466
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (348)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (368)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (450)
<223> n equals a,t,g, or c
<220>
<221> misc feature
```

```
<222> (451)
 <223> n equals a,t,g, or c
<400> 355
gctccattat tgatcggttc atgcagaata attgtgtgcc caagaagatg ctgcagctgg 60
ttggtgtcac tgccatgttt attgcaagca aatatgaaga aatgtaccct ccagaaattg 120
gtgactttgc ttttgtgact gacaacactt atactaagca ccaaatcaga cagatggaaa 180
tgaagattct aagagcttta aactttggtc tgggtcggcc tctacctttg cacttccttc 240
ggagagcatc taagattgga gaggttgatg tcgagcagca tactttggcc aaatacctga 300
tggaactaac tatgttggac tatgacatgg tgcactttcc tccttctnaa attgcagcag 360
gagetttntg ettageactg aaaattetgg gataatggtg aatggttatg cageacetgg 420
ctaagaatgt agtcatgggt aaatcaaggn nttacaaagc acatgc
                                                                    466
<210> 356
<211> 447
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (269)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (375)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (380)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (436)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (440)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (446)
<223> n equals a,t,g, or c
<400> 356
ggtgatgagg aggcttgtcc agaggacaag ggaccccagg acccacaggc actggcgctg 60
gacacccaga tccctgcaac ccctggaccc aaacccctgg tccgcaccag ccgggagcca 120
```

```
gggaaggacg teacgacete agggtactee teegteagea eegeaagtee cacaagetee 180
  gtggacggtg gcttgggggc cctgcccaa cctacctcag tgctgtccct ggacagtgac 240
  tegeacacac agecetgeea ceateaggne aggaagteat gtttacagtg tegteecca 300
  agtcccccgg agagcagtgt tccccagcaa caggtgaagc ggataaacta tgcatacaca 360
  gtgaagagga ggacntgaan ctgggcttgt gaagctgtaa gtgtgtcagc acatttgcgc 420
  agtggatttt actgangggn tgaagng
  <210> 357
  <211> 510
  <212> DNA
  <213> Homo sapiens
  <220>
  <221> misc feature
  <222> (2)
  <223> n equals a,t,g, or c
  <220>
  <221> misc feature
  <222> (453)
  <223> n equals a,t,g, or c
  <220>
  <221> misc feature
  <222> (486)
  <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (491)
 <223> n equals a,t,g, or c
 <220>
<221> misc feature
 <222> (496)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (500)
 <223> n equals a,t,g, or c
 <400> 357
 tnecacgegt eegeceacge gteegeceac gegteegeag atteceteeg tegeegecaa 60
 gatgatgtgc ggggcgccct ccgccacgca gccggccacc gccgagaccc agcacatcgc 120
 cgaccaggtg aggtcccagc ttgaagagaa agaaaacaag aagttccctg tgtttaaggc 180
 cgtgtcattc aagagccagg tggtcgcggg gacaaactac ttcatcaagg tgcacgtcgg 240
 cgacgaggac ttcgtacacc tgcgagtgtt ccaatctctc cctcatgaaa acaagccctt 300
 gacettatet aactaceaga eeaacaaage caageatgat gagetgacet atttetgate 360
 ctgactttgg acaaggccct tcagccagaa gactgacaaa gtcatcctcc gtctaccaga 420
 gcgtgcactt gtgatcctaa aataagcttc atntccgggc tgtgcccctt ggggtggaag 480
```

```
gggcangatt ntgcanctgn ttttgcattt
                                                                     510
  <210> 358
  <211> 240
  <212> DNA
  <213> Homo sapiens
  <400> 358
  ggtcttgcac tcatgagctg tccccacatt aggcttaaaa acagatgcaa ttcccggacg 60
  totaaaccaa accaetttea eegetacaeg acegggggta tactaeggte aatgetetga 120
  aatctgtgga gcaaaccaca gtttcatgcc catcgtccta gaattaattc ccctaaaaat 180
  ctttgaaata gggcccgtat ttaccctata gcaccccctc tacctcctct agagccaaaa 240
  <210> 359
  <211> 340
  <212> DNA
  <213> Homo sapiens
  <220>
  <221> misc feature
  <222> (320)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (331)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (334)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (335)
 <223> n equals a,t,g, or c
 <220>
<221> misc feature
 <222> (338)
 <223> n equals a,t,g, or c
 <400> 359
 ggcacgagct cataaggaaa tctaccccta tqtcatccag gaacttagac caactttaaa 60
 tgaactggga atctccactc cggaggaact gggccttgac aaagtgtaaa ccgcatggat 120
 gggcttcccc aaggatttat tgacattgct acttgagtgt gaacagttac ctggaaatac 180
 tgatgataac atattacctt atttgaacaa gttttccttt attgagtacc aagccatgta 240
 atggtaactt ggactttaat aaaaaggaaa tgagtttgaa ccggaaaaaa aaaaaaaaa 300
 aaaaaaaaa aaaagaaaan aaagaaggga nagnnaanaa
                                                                    340
```

```
<210> 360
<211> 501
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (147)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (148)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (192)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (242)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (244)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (348)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (364)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (384)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (455)
<223> n equals a,t,g, or c
```

<220>

```
<221> misc feature
 <222> (465)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (469)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
<222> (474)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (491)
<223> n equals a,t,g, or c
<400> 360
cccacgcgtc cgcccacgcg tccgatgcct atcatatagt aaaacccagc ccatgacccc 60
taacaggggc cctctcagcc ctcctaatga cctccggcct agccatgtga tttcacttcc 120
actecataaa geteeteata etaaggnnta etaaceaaca eactaaceat ataceaatga 180
tggcgcgatg tnacacgaag aaagcacata ccaagggcac cacaccac ctgtccaaaa 240
angnettega taegggataa teetatttat taeeteagaa gttttttet tegeaggatt 300
ttctgagctt ttacactcca gcctagccct acccccaact aagaaggnac tggccccaac 360
aagnatcacc cgctaaatcc ctanaatcca ctcctaaaca ctccgtatat cgatcaggat 420
atcatcactg actcacatat ctaatagaaa aaacngaaac aatantcanc atgnttatta 480
aatttatggt ntctatttac c
                                                                    501
<210> 361
<211> 393
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (357)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (359)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (364)
<223> n equals a,t,g, or c
<220>
```

```
<221> misc feature
 <222> (367)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (390)
 <223> n equals a,t,g, or c
 <400> 361
 gccccattat tcctagaacc aggcgacctg cgactccttg acgttgacaa tcgagtagta 60
ctcccgattg aagcccccat tcgtataata attacatcac aagacgtctt gcactcatga 120
gctgtcccca cattaggctt aaaaacagat gcaattcccg gacgtctaaa ccaaaccact 180
ttcaccgcta cacgaccggg ggtatactac ggtcaatgct ctgaaatctg tggagcaaac 240
cacagtttca tgcccatcgt cctagaatta attcccctaa aaatctttga aatagggccc 300
aagnttnaaa aaactgaaaa tcagaaaagn ttt
                                                               393
<210> 362
<211> 664
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (308)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (535)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (551)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (567)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (642)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (660)
```

```
<223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (662)
<223> n equals a,t,g, or c
<400> 362
gagtaggtct acaagacgct acttccccta tcatagaaga gcttatcacc tttcatgatc 60
acgccctcat aatcattttc cttatctgct tcctagtcct gtatgccctt ttcctaacac 120
tcacaacaaa actaactaat actaacatct cagacgctca ggaaatagaa accgtctgaa 180
ctatcctgcc cgcatcatcc tagtcctcat cgccctccca tccctacgca tcctttacat 240
aacagacgag gtcaacgatc cctcccttac catcaaatca attggccacc aatggtactg 300
aacctacnaa gtacaccgac tacggcggac taatcttcaa ctcctacata cttccccatt 360
attoctagaa ccaggogacc tgcgactcct tgacgttgac aatcgagtag tactcccgat 420
tgaagccccc attcgtataa taattacatc acaagacgtc ttgcactcat gagctgtccc 480
tacacgaacc nggggtatta ctacggncaa tgctctgaaa tctggggagc aaaaccacag 600
gttcatgccc atcgtcctag aaataaattc ccctaaaaat cnttgaaaaa aggggcccgn 660
antt
                                                                664
<210> 363
<211> 595
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (466)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (467)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (485)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (515)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (552)
<223> n equals a,t,g, or c
```

```
<220>
 <221> misc feature
 <222> (557)
 <223> n equals a,t,q, or c
 <220>
 <221> misc feature
 <222> (559)
 <223> n equals a,t,g, or c
 <220>
<221> misc feature
<222> (568)
<223> n equals a,t,g, or c
<400> 363
gcgcaagtag gtctacaaga cgctacttcc cctatcatag aagagcttat cacctttcat 60
gatcacgccc tcataatcat tttccttatc tgcttcctag tcctgtatgc ccttttccta 120
acactcacaa caaaactaac taatactaac atctcagacg ctcaggaaat agaaaccgtc 180
tgaactatcc tgcccgccat catcctagtc ctcatcgccc tcccatccct acgcatcctt 240
tacataacag acgaggtcaa cgatccctcc cttaccatca aatcaattgg ccaccaatgg 300
tactgaacct acgagtacac cgactacggc ggactaatct tcaactccta catacttccc 360
ccattattcc tagaaccagg cgacctgcga ctccttgacg tttgacaatc gagtagtact 420
cccgattgaa gcccccattc gtataataat tacatcacaa gacgtnnttg cactcatgag 480
ctgtncccac attaagctta aaaacagatg cattnccgga cgtctaaacc aaaccacttt 540
caccgataca cnaaccngng ggtatacnac cggtcaatgc ttctgaaatc ttgtg
<210> 364
<211> 441
<212> DNA
<213> Homo sapiens
<400> 364
acaagacget actteceeta teatagaaga gettateace ttteatgate acgeeeteat 60
aatcattttc cttatctgct tcctagtcct gtatgccctt ttcctaacac tcacaacaaa 120
actaactaat actaacatct cagacgctca ggaaatagaa accgtctgaa ctatcctgcc 180
cgccatcatc ctagtcctca tcgccctccc atccctacgc atcctttaca taacagacga 240
ggtcaacgat coctcocttt accatcaaat caattgggcc accaatggta ctgaacctac 300
gagtacaccg actacggcgg actaatcttc aactcctaca tacttccccc attattccta 360
gaaccaggcg acctgcgact cettgacgtt gacaatcgag tagtactccc gattgaagcc 420
cccattcgta taataattaa c
                                                                   441
<210> 365
<211> 367
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (347)
<223> n equals a,t,g, or c
```

```
<220>
 <221> misc feature
 <222> (362)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (363)
 <223> n equals a,t,g, or c
<220>
 <221> misc feature
<222> (366)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (367)
<223> n equals a,t,g, or c
<400> 365
catacttccc ccattattcc tagaaccagg cgacctgcga ctccttgacg ttgacaatcq 60
agtagtactc ccgattgaag cccccattcg tataataatt acatcacaag acgtcttgca 120
ctcatgagct gtccccacat taggcttaaa aacagatgca attcccggac gtctaaacca 180
aaccactttc accgctacac gaccgggggt atactacggt caatgctctg aaatctgtgg 240
agcaaaccac agtttcatgc ccatcgtcct agaattaatt cccctaaaaa tctttggaaa 300
tagggcccgt atttacccta tagcaccccc tctaccccct ctagagncaa aaaaaaaaa 360
annagnn
                                                                    367
<210> 366
<211> 460
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (51)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (154)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (211)
<223> n equals a,t,g, or c
<220>
```

```
<221> misc feature
 <222> (322)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (336)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (340)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (355)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (356)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (378)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (411)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (413)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (415)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (453)
<223> n equals a,t,g, or c
<400> 366
ttttcgaggc caacgatccc tcccttacca tcaaatcaat tggccaccaa nggtaccgaa 60
```

```
cctacgagta caccgactac ggcggactaa tcttcaactc ctacatactt cccccattat 120
 toctagaacc aggogacctg cgactcottg acgntgacaa togagtagta otoccgattg 180
aaacccccat toggataata attacataca nggacgtott goactcatga gotgooccac 240
attaggetta aaaacagatg caatteegg acgtetaaac caaaccacta teacegetac 300
acgaccgggg gtatactacg gncaatgctc tgaaanctgn ggagcaaacc acagnntcat 360
gcccatcggc ctagaatnaa ttcccctaaa aatctttgaa atagggcccg nantnaccct 420
atagcacccc ctctaccccc tctagagcca aanaaaaaaa
<210> 367
<211> 610
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (6)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (13)
<223> n equals a,t,g, or c
<400> 367
gcaagntgac acnaaccete actaaaggga acaaaagetg gagetecace geggtgegge 60
cgctctagaa ctagtggatc ccccgggctg caggaattcg gcacgaggga atggcggctt 120
ccatctctga ggcgagcgac gctatggatc ccacagtggt ttgctaagaa ggccattttc 180
aactotocac tggaggotgo tatggogtto cotoacetgo agcageccag ctttotaetg 240
gctagcctga aagctgactc tataaataag ccctttgcac agcagtgcca agacttggtt 300
aaagtcattg aggactttcc agcaaagtct gaaccaatca gagtccttgt gactggagca 360
gctggtcaaa ttgcatattc actgctgtac agtattggaa atggatctgt ctttggtaaa 420
gatcagatgt catcgcaaca gataaagaag acgttgcctt caaagacctg ggatgtggcc 480
attottgtgg gctccatgcc aagaagggaa ggcatggaga gaaaagattt actgaaagca 540
aatgtgaaaa tottcaaato coagggtgca goottagata aatacggcaa gaagtcagtt 600
aaaggttatt
                                                                   610
<210> 368
<211> 548
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (370)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (378)
<223> n equals a,t,q, or c
```

WO 00/55351

```
<220>
 <221> misc feature
 <222> (384)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (412)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (429)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (449)
 <223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (471)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (490)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (495)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (528)
<223> n equals a,t,g, or c
<400> 368
ggcacgagga gcactctatt tattgtactg tgaataatga tgaaggagag tggagtgqcc 60
caccacctga atgcagagga aaatctctaa cttccaaggt cccaccaaca gttcagaaac 120
ctaccacagt aaatgttcca actacagaag tctcaccaac ttctcagaaa accaccacaa 180
aaaccaccac accaaatgct caaggtacag agactccatc agttcttcaa aaacacacca 240
cagaaaatgt ttcagctaca agaaccccac caactcctca gaaacccacc acagtaaatg 300
tcccagctac aatagtcaca ccaacacctc agaaacccac cacattaatg ttccagttac 360
aggagteten teaacaente aagneacaee tagtaatgtt teagttacag gneetaceae 420
ttttcgganc ccaccggggc aatgttcgnc accattcccg cgcgttcggc ntttctttca 480
aaaccttttn caagnocttt tgcgttagat cctgtggcat gttttgtnca cggcccttac 540
ggccaggt
                                                                   548
```

```
<210> 369
 <211> 538
 <212> DNA
 <213> Homo sapiens
<220>
<221> misc feature
<222> (12)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (423)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (449)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (466)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (521)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (531)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (538)
<223> n equals a,t,g, or c
<400> 369
gatggcgcgg anccgggacg cgcgtacgcc ctgctgcttc tcctgatctg ctttaacgtt 60
ggaagtggac ttcacttaca ggtcttaagc acaagaaatg aaaataagct gcttcctaaa 120
catcctcatt tagtgcggca aaagcgcgcc tggatcaccg cccccgtggc tcttcgggag 180
ggagaggatc tgtccaagaa gaatccaatt gccaagatac attctgatct tgcagaagaa 240
agaggactca aaattactta caaatacact ggaaaaggga ttacagagcc accttttggt 300
atatttgtct ttaacaaaga tactggagaa ctgaatgtta ccagcattct tgatcgagaa 360
gaaacaccat tttttctgct aacaggttta cgctttggat gcaagaggga acaatgtaga 420
ganaccettt agagetaege attaagggnt ettgatatee aattgneaae ggaaccagtg 480
gttcacacag ggatgtcttt gttggggcct gttgaagagt ngaggtgcag nacatacn 538
```

```
<210> 370
 <211> 538
 <212> DNA
 <213> Homo sapiens
 <220>
 <221> misc feature
 <222> (401)
 <223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (492)
<223> n equals a,t,q, or c
<220>
<221> misc feature
<222> (500)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (536)
<223> n equals a,t,g, or c
<400> 370
gageteagte eccatecega ageacaggge aggacgtege ggeggagtgg ggaagegagg 60
agtccgtggc cgggagcttg gaggctgagt ttgagaaagc tgcagaggag gttaggcacc 120
ttaagaccaa gccatcggat gaggagatgc tgttcatcta tggccactac aaacaagcaa 180
ctgtgggcga cataaataca gaacggcccg ggatgttgga cttcacgggc aaggccaagt 240
gggatgcctg gaatgagctg aaagggactt ccaaggaaga tgccatgaaa gcttacatca 300
acaaagtaga agagctaaag aaaaaatacg ggatatgaga gactggattt ggttactgtg 360
ccatgtgttt atcctaaact gagacaatgc cttgtttttt nctaataccg tggatggtgg 420
gaatccggga aaataaccag ttaaaccagc tactcaaggc tgctcaccat acggctctaa 480
cagattaggg gntaaaacgn ttactgactt ccttgagtag ttttacctga aaccantt 538
<210> 371
<211> 224
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (21)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (26)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (48)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (59)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (68)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (90)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (108)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (113)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (123)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (141)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (171)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (192)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (204)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (215)
<223> n equals a,t,g, or c
<400> 371
gcctgtgcct acacaccacc ntcgcngaaa gctgtgcagc gcattgcnga gtctcaccng 60
cagtctanca gcaatttgaa tgagaaccan gcctcagagg aggagganga gcngggggag 120
ctncgggagc tgggttatcc nagagaggaa gatgaggagg aagaggagga ngatgaagaa 180
gaggaagact angaggacag ccangctgaa gaccngagcg gaga
                                                                    224
<210> 372
<211> 459
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (6)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (52)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (90)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (105)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (139)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (140)
<223> n equals a,t,g, or c
```

```
<220>
 <221> misc feature
 <222> (176)
 <223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (208)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (328)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (394)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (429)
<223> n equals a,t,g, or c
<400> 372
aacttnocca atgccgaact gggaggcccc tttaaccaga tgaacggagt gnccggaaat 60
ggcatgaaca acattgacat gactggagan aagaagtcgt tgganctccc atatcccagc 120
agetttgete eegtetetnn acetagaaac eagacettea ettacatggg eaagtnetee 180
attgaccetc agtaccetgg tgccagenge tacceagaag gcataatcaa tattgtgagt 240
gcaggcatct tgcaaggggt cacttcccca gcttcaacca cagcctcatc cagcgtcacc 300
totgoctoco coaaccoact ggocacanga cocotgggtg tgtgcaccat gtcccagaco 360
cagootgaco tggaccacot gtactotocg coanogooto otoctoctta ttotggotgt 420
gcaggaganc tctaccagga cccttctgcg ttcctgtta
                                                                    459
<210> 373
<211> 422
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (27)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (47)
<223> n equals a,t,g, or c
<220>
```

```
<221> misc feature
 <222> (60)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (66)
 <223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (70)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (78)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (87)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (105)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (267)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (331)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (351)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (359)
<223> n equals a,t,g, or c
<220>
<221> misc feature
```

```
<222> (393)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (401)
<223> n equals a,t,g, or c
<400> 373
ggcagacctg aggcccatcc ccaaggngcc cagccgtagc ttcaggntct ccgccagggn 60
coctonoggn tgottotngt ttttaanact tocagatoga tootntooto ggtacogtgg 120
gctttgggtc tggcctccac gggtgggcct tcaccctgaa agcagtttgc cgagaatgta 180
tgtgagccaa gttcgccgcc aagggggagg gccagttggg agcctgccga gcgggccaag 240
aaagtagagg acatgatgaa gaagctntgg ggtgacaggt gagccccggg gaatatggtg 300
ggggattcct gaaaactggg ggtagtggca ncaacgtagg ggcgtggtgt nctattcana 360
attggttcaa gcccacaagt tttgcccaaa atnttccctt ngggaccaac ttcccaagta 420
at
                                                                    422
<210> 374
<211> 342
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (4)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (16)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (17)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (20)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (24)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (292)
```

```
<223> n equals a,t,g, or c
  <220>
  <221> misc feature
  <222> (301)
  <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (305)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (325)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (332)
 <223> n equals a,t,g, or c
 <400> 374
 gcanaacatc agcgcnnacn gganataaaa agattatcca cagagcattc cagtgtatca 60
 gagtatcatc cagccgatgg ctatgcgttc agtagcaaca tttacacaag aggatcccac 120
 ctggaccaag gggaagctgc tgttgctttt aagccaactt ctaatcgcca tattagattg 180
 aaattatgaa ccactccaaa acacaaccca agaaatatgc ccaatcccag ttatgacttt 240
 gtttgccagg ggaaacaaca gttgagctct ccgggttcct taaggaatga tntttttaga 300
 naatnoottg aaatgaatcg gaaancatgg tngaaaaagt tt
                                                                     342
 <210> 375
 <211> 387
 <212> DNA
 <213> Homo sapiens
 <220>
 <221> misc feature
 <222> (19)
 <223> n equals a,t,g, or c
<220>
 <221> misc feature
 <222> (162)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (305)
 <223> n equals a,t,g, or c
 <220>
```

```
<221> misc feature
<222> (335)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (365)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (366)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (374)
<223> n equals a,t,g, or c
<400> 375
ggcagagctc tgcgcgcant ccgcttgact cagctcaccg agattctgtc agggggtgtt 60
tatattgaga agaacgataa gctttgtcac atggacacaa ttgactggag ggacatcgtg 120
agggaccgag atgctgagat agtggtgaag gacaatggca gnaagctgtc cccctgtca 180
tgaggtttgc aaggggcgat gctggggtcc tggatcagaa gactgccaga cattgaccaa 240
gaccatctgt gcttcctcag tgtaattggt cactgctttg gggcccaacc ccaaccagtg 300
gttgncatga tgagtgtggc cgggggttgt ttcanggccc cttcagggac acagactgtt 360
tttgnntggc cggnatttca atggaca
                                                                   387
<210> 376
<211> 492
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (110)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (203)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (318)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (333)
```

```
<223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (336)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (405)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (416)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (440)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (444)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (448)
<223> n equals a,t,g, or c
<400> 376
ggcacgagaa gcaaactcaa agcatttggg tcaaaacatc ctgattgttt tatacatggt 60
ttggatgata aattcagtaa agatacaggc ataatcctta tatgcaaatn agttgatggg 120
tattttctat ggtgatttca gacaaggaac ctgcaggtca ctctggaaga tggttacatt 180
gaattgagca ccagcgatag ggncggccca atttttaaat ctccacagac gtatatggat 240
ggtttactgc attatgtatc tgtaataagc gacaactctg ggtgagtcga ataaatactt 300
ctgtcagagc tgtgagtnga gttttactct ctnttngttt taatggaatt ttctggtgtc 360
tttttgcaaa aaatttgtcc ttgattacca aaaatacttt cactnataag tcttgncctt 420
ctttcctttt ttcccatatn caantttnct tcataaaaaa aataaacttg ccacacatgg 480
gtgggcttca tt
                                                                   492
<210> 377
<211> 336
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (4)
```

```
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (15)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (36)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (66)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (70)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (116)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (163)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (197)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (227)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (229)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (231)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (249)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (280)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (292)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (308)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (325)
<223> n equals a,t,g, or c
<400> 377
gacngtaccg tcccnaatcc cgggtcgacc cacgentecg aagcagcagt tageccgccg 60
cccgcntgtn tgtccccaga gccatggaga gagccagtct gatccagaag gccaanctgg 120
cagagcaggc cgaacgctat gaggacatgg cagccttcat ganaggcgcc gtggagaagg 180
gcgaggagtc tcctgcnaag agcgaaacct gctctcagta gcctatnana ncgtggtggg 240
cggccagang gctgcctgga gggtgctgtc cagtattgan cagaaaagca angaggaggg 300
gttcgganag gagaaggggc ccgangtgcg ttgaat
                                                                    336
<210> 378
<211> 488
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (2)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (9)
<223> n equals a,t,g, or c
<220>
```

<221> misc feature

```
<222> (20)
  <223> n equals a,t,g, or c
  <220>
  <221> misc feature
  <222> (35)
  <223> n equals a,t,g, or c
  <220>
  <221> misc feature
  <222> (43)
  <223> n equals a,t,g, or c
  <400> 378
  cngtcagtna cggtaccggn aattcccggg tgcgnaccca cgncgtgccg ccgagaccgc 60
  tgccttgctc ggaaggggc gagcggctgc tgcccaccca gaagcagccc gggggcggcc 120
  aggtcaactc cagccgctac aagacggagc tgtgccgccc ctttgaggaa aacggtgcct 180
  gtaagtacgg ggacaagtgc cagttcgcac acggcatcca cgagctccgc agcctgaccc 240
  gccaccccaa gtacaagacg gagctgtgcc gcaccttcca caccatcggc ttttgcccct 300
  acgggccccg ctgccacttc atccacaacg ctgaagagcg ccgtgccctg gccggggccc 360
  gggacctete egetgacegt eeeegeetee ageatagett tagtttgetg ggttteeeag 420
  488
cctatttt
  <210> 379
  <211> 398
  <212> DNA
  <213> Homo sapiens
  <220>
  <221> misc feature
  <222> (46)
  <223> n equals a,t,g, or c
 <220>
  <221> misc feature
 <222> (124)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (344)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (384)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
```

```
<222> (385)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (386)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (394)
<223> n equals a,t,g, or c
<400> 379
ggcacgaggg ggcctcccgc tgtggccacc tctgccgcgg ccgcgncgcc gcgtcctacc 60
ctgccctccg tgcctctctg ctgccgcagt cgctggcggc ggcggccgcg ttcccgacgc 120
gcantaacag ccaggagtcc aaaactactt acctggaaga ccttccacca ccccctgagt 180
atgaattggc cccgtccaag ttagaagagg aagtggatga tgtctttctc attcgagctc 240
aaggactgcc ctgggtcatg gcactatggg aagatgtggc tttaactttt tttttccaga 300
cttgcagaat ccggcaacgg ttgagtaatg ggaattacat tttnctccct aaaaacaaga 360
gatgggggaa aacgtaaggg ggtnnntggc cttnaatt
<210> 380
<211> 455
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (315)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (365)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (421)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (442)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (447)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (448)
<223> n equals a,t,g, or c
<400> 380
atgccatggt geggetggte aagtgegaeg tetacecetg ceceaacaca gtggaetget 60
tegtgteeg ceccaeegag aaaaeegtet teaeegtett catgetaget geetetggea 120
tetgeateat ceteaatgtg geegaggtgg tgtaceteat cateegggee tgtgeeegee 180
gageccageg cegetecaat ceacetteec geaagggete gggettegge cacegeetet 240
cacctgaata caagcagaat gagatcaaca agctgctgag tgagcaggat ggctccctga 300
aagacatact gcgcncaacc ctggcacggg ggctgggctg gctgaaaaaa acgaccgtgc 360
teggntgtga tgccacatac caggcaacct cccatcccac cccgaccttg cctgggcgaa 420
necetectte teeetgeegg tneceanngg eteac
<210> 381
<211> 421
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (1)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (3)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (4)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (8)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (23)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (156)
<223> n equals a,t,g, or c
```

```
<220>
 <221> misc feature
 <222> (191)
 <223> n equals a,t,g, or c
<220>
 <221> misc feature
<222> (387)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (398)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (410)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (413)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (421)
<223> n equals a,t,g, or c
<400> 381
ntnngcgnct gcaggtcgaa cantagtgga tccaaagaat tcggcacgag tgggaacgag 60
gggtgaagcg gcccaggtga ggctcgccat ggccaaacag ctgcaggccc gaagctagac 120
gggatcgact acaacccctg ggtggagttt gtgaantggc cagtgagcat gacgtcgtga 180
acttgggcca nggcttcccg gatttcccac caccagactt tgccgtggaa gcctttcagc 240
acgctgtcag tggagacttc atgcttaacc agtacaccaa gacatttggt tacccaccac 300
tggacgagga tcctggcaat ttctttgggg gagctgctgg gtcaaggata agacccgttc 360
agggatgtgc tggtgactgt tggtggntat gggggccngt ttcaaaagcn ttnccaggcc 420
n
                                                                    421
<210> 382
<211> 545
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (5)
<223> n equals a,t,g, or c
<220>
```

```
<221> misc feature
 <222> (14)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (57)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (466)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (505)
 <223> n equals a,t,g, or c
<400> 382
aaggnagaca caanceteac taaagggaac aaaagetgga getecacege ggtgegneeg 60
ctctagaact agtggátccc ccgggctgca ggaattcggc acgagcggcg gcggcggcgg 120
eggeecagte ggtgtatgee tteteggege geeegetgge eggeggggag cetgtgagee 180
tgggctccct gcggggcaag gtactactta tcgagaatgt ggcgtccctc tgaggcacca 240
cggtccggga ctacacccag atgaacgagc tgcagcggcg cctcggaccc cggggcctgg 300
tggtgctcgg cttcccgtgc aaccagtttg ggcatcagga gaacgccaag aacgaagaga 360
ttctgaattc cctcaagtac gtccggcctg gtggtgggtt cgagcccaac ttcatgctct 420
tcgagaagtg cgaggtgaac ggtgcggggg cgcaccctct cttcgncttc ctgcgggagg 480
ccctgccagc tcccagcgac gacgncaccg cgcttatgac cgaccccaag ctcatcacct 540
ggtct
<210> 383
<211> 375
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (224)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (242)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (264)
<223> n equals a,t,g, or c
```

```
<220>
 <221> misc feature
 <222> (282)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (329)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (333)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (348)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (368)
<223> n equals a,t,g, or c
<400> 383
gctttcattg ccaagtcctt ctatgacctc agtgccatca gcctggatgg ggagaaagta 60
gatttcaata cgtctcgggg cagggccgtg ctgattgaga atgtggcttc gctctgaggc 120
acaaccaccc gggacttcac ccagctcaac gagctgcaat gccgctttcc caggcgcctg 180
gtggtccttg ggcttccctt gcaaccaatt tgggacatca gganaactgt caaaatgagg 240
anatectgaa cagteteaat tatntteegt eetggggtgg gnataceaac eeceetteee 300
cctttttcca aaaattttaa ggttaaatng gcnaaaaaaa acatcctntt tttcccccta 360
ccttaaanga aaaac
                                                                    375
<210> 384
<211> 530
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (178)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (354)
<223> n equals a,t,g, or c
<220>
<221> misc feature
```

```
<222> (361)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (382)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (386)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (415)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (426)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (436)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (449)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (515)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (527)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (529)
<223> n equals a,t,g, or c
<400> 384
gctcgtgccg tgagacacaa ccacccggga cttcacccag ctcaacgagc tgcaatgccg 60
ctttcccagg cgcctggtgg tccttggctt cccttgcaac caatttggac atcagagcag 120
```

```
gagagacaga agtagcaaac cctctttcga gatgtccctc cagccccaga agtacctnca 180
gcctcacacc atctcttcag cctagcaagt tgctggaggg agtctataac ctaccaggag 240
ccagccagcc atttgtatca agaaatagaa atctgcaggg tacagtggct cacacctata 300
atcccagcgc tttgggaggc taagttctag gacaaaggca aggaagaaaa gcangaactt 360
naaaatccaa ttccttttgg gncttnaaat ttaaccttca agttcaaggg agctnaagta 420
aggcanaagg ccaaanggct ttttacttna acaacaacgg tgccaatttg gaaaggcaag 480
gccaaggcaa aaaacccagg ggcaagaagg aaaangggaa aaggggntnt
<210> 385
<211> 465
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (151)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (287)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (310)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (312)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (329)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (338)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (347)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (351)
```

```
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (354)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (373)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (383)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (438)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (449)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (450)
<223> n equals a,t,g, or c
<400> 385
cacactcaag ttctttcctg ccagtgccga caggacggtc atcgattaca acggggaacg 60
cacgctggat ggttttaaga aattcctgga gagcggtggc caggatgggg caggggatga 120
tgacgatete gaggacetgg aagaageaga ngageeagae atggaggaag acgatgatea 180
gaaagctgtg aaagatgaac tgtaatacgc aaagccagac ccgggcgctg ccgagacccc 240
tegggggget geacaaceag cageagegea aggetteega geettgnggg eteggtttga 300
aaagaagggn tngccgggaa acccagggna actctctnga agttganact ncanccctag 360
aaaacgtccg ttnaaccccg ttnctttctt ctgcttttcg ggtttttgga aaagggattc 420
atttccaggc aggccaanct tgttggggnn tgttcctgaa accat
                                                                   465
<210> 386
<211> 733
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (606)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (621)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (689)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (703)
<223> n equals a,t,g, or c
<400> 386
gcggtgatca tgggggcccc gggctcgggc aagggcaccg tgtcgtcgcg catcactaca 60
cacttegage tgaageacet etecageggg gacetgetee gggacaacat getgegggge 120
acagaaattg gcgtgttagc caaggctttc attgaccaag ggaaactcat cccagatgat 180
gtcatgactc ggctggccct tcatgagctg aaaaatctca cccagtatag ctggctgttg 240
gatggttttc caaggacact tccacaggca gaagccctag atagagctta tcagatcgac 300
acagtgatta acctgaatgt gccctttgag gtcattaaac aacgccttac tgctcgctgg 360
atteateceg ceagtggeeg agtetataac attgaattea acceteceaa aactgtggge 420
attgatgacc tgactgggga gcctctcatt cagcgtgagg atgataaacc agagacggtt 480
atcaagagac taaaggetta tgaagaccaa acaaageeag teetggaata ttaccagaaa 540
aaaggggtgc tggaaacatt ctccggaaca gaaaccaaca agatttggcc ctatgtatat 600
gctttnctac aactaaagtt ncacaaagaa gccagaaagc tttaattact tcatgaggag 660
aaatgtgtgt aactattaat agtaagaang gcaaaccttc tantccttgg atttaaaact 720
ggttttctaa aac
<210> 387
<211> 180
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (1)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (6)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (11)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (43)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (61)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (123)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (133)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (151)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (153)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (159)
<223> n equals a,t,g, or c
<400> 387
netttnatet ntgaagtgga tetacaatgg etteageagt gtneteeagt teetaggaet 60
ntacaagaaa totggaaaac ttgtattott caggottggt taatgtcagg caaaaccact 120
gtngttgcac atngcttcaa aggtgcgcag ntngtgggnc aacattgttt cccaacactt 180
<210> 388
<211> 428
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (49)
<223> n equals a,t,g, or c
<220>
```

```
<221> misc feature
<222> (84)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (90)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (197)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (263)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (285)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (286)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (306)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (366)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (395)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (414)
<223> n equals a,t,g, or c
<220>
<221> misc feature
```

```
<222> (418)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (427)
<223> n equals a,t,g, or c
<400> 388
gggaacagta agaccgagga ccagcgcaac gaggagaagg cgcacgtgna ggccaacaaa 60
aagatcgaga agcagctgca gaangacaan caggtctacc gggccacgca ccgcctgctg 120
ctgctgggtg ctggagaatc tggtaaaagc accattgtga agcagatgag gatcctgcat 180
gttaatgggt ttaatgnaga cagtgagaag gcaaccaaag tgcaggacat caaaaacaac 240
ctgaaagagg cgattgaaac cantgtggcc gccatgagca acctnngtgc cccccgtgga 300
gctggncaac cccgagaaac cagttcagag tggactacat cctggagtgt tatgaacgtg 360
cctggntttt gacttccctc cggattctat gagcnggcaa ggtctgtgga ggtnaagntt 420
                                                                    428
ctgctgna
<210> 389
<211> 454
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (181)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (184)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (209)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (240)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (283)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (287)
```

```
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (292)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (309)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (316)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (319)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (369)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (402)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (424)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (426)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (437)
<223> n equals a,t,g, or c
<400> 389
acceaegegt eegeceaege gteeegaget caaagacete eaggageece aggageeeag 60
ggttgggaaa ctcaggaact ttgcacccat ccctggtgaa cctgtggttc ccatcctctg 120
tagcaacccg aactttccag aagaactcaa geetetetge aagageecaa tgeecaggag 180
```

```
ntanttcaga ggctggagga aatcgctgna ggacccgggg cacatgtgga aatctgtgcn 240
tacgctggcc tgtaccggat gctaaggggg cttgccactg gcnggcntcc cntccgcagc 300
aggggaagnc ttttcntcnt gcagaaaggg ccacccatga tattccattc cccagcagtt 360
caactaacnt ggttccattc gggaaggagc agccggggaa gnattgggtt gattggaagg 420
cttngnccca aatggtnctt tccctggcaa tttt
<210> 390
<211> 553
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (7)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (29)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (30)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (58)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (77)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (414)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (417)
<223> n equals a,t,g, or c
<400> 390
gcaaganaaa attaccctca ctaaagggnn caaaagctgg agctccaccg cggtgcgncc 60
gctctagaac tagtggntcc cccgggctgc aggaattcgg cacgagcagg gacgctaaga 120
ttgctacctg gactttcgtt gaccatgctg tcccgggtgg tactttccgc cgccgccaca 180
gcgccccctc tctgaagaat gcagccttcc taggtcCagg gaccctatgt actcggaact 240
```

```
gggcttatct tgtacgcttt atccaaagaa atatatgtga ttagcgcaga gaccttcact 300
gccctatcag tactaggtgt aatggtctat ggaattaaaa aatatggtcc ctttgttgca 360
gactttgctg ataaactcaa tgagcaaaaa cttgcccaac tagaagaggc gaanagngct 420
tccatccaac acatccagaa tgcaattgat acggagaagt cacaacaggc actggttcag 480
aagogocatt acctttttgg atgtgcaaag gaataacatt gctatggctt tggaagttac 540
ttacccggga acg
                                                                    553
<210> 391
<211> 632
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (12)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (586)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (613)
<223> n equals a,t,g, or c
<400> 391
cagtttcgaa antaaccctc actaaaggga acaaaagctg gagctccacc gcggtgcggc 60
cgctctagaa ctagtggatc ccccgggctg caggaattcg gcacgaggtc ctgtgcggtc 120
acttagccaa gatgcctgag gaaacccaga cccaagacca accgatggag gaggaggagg 180
ttgagacgtt cgcctttcag gcagaaattg cccagttgat gtcattgatc atcaatactt 240
tctactcgaa caaagagatc tttctgagag agctcatttc aaattcatca gatgcattgg 300
acaaaatccg gtatgaaagc ttgacagatc ccagtaaatt agactctggg aaagagctgc 360
atattaacct tataccgaac aaacaagatc gaactctcac tattgtggat actggaattg 420
gaatgaccaa ggctgacttg atcaataacc ttggtactat cgccaagtct gggaccaaag 480
cgttcatgga agctttgcag gctggtgcag atatctctat gattggccag ttcggtgttg 540
gtttttattc tgcttatttg gttgctgaga aagtaactgt gatcancaaa cataacgatg 600
atgagcagta cgnttgggag tcctcagcag gg
                                                                   632
<210> 392
<211> 600
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (6)
<223> n equals a,t,g, or c
<220>
```

```
<221> misc feature
<222> (162)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (518)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (571)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (572)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (587)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (590)
<223> n equals a,t,g, or c
<400> 392
gctcanatct gccttctgga gactgcgccg tcctcccggg agagccagaa agaggacatg 60
gctgctgqqc agcgggaagc gaggccccag gtgtcactga cattcgagga cgtggctgtg 120
ctctttacct gggatgagtg gagaaagctg gctccttctc anagaaactt gtaccgggat 180
gtgatgctgg agaactatag gaacctggtc tcactgggac tctcatttac caaaccaaaa 240
gtcatctccc tgttgcagca aggagaagat ccctgggagg tggagaaaga cagttctggt 300
gtctcctctc taggatgtaa gagcacacct aaaatgacaa agtcaactca aactcaggat 360
tcatttcagg agcagataag gaaaagattg aaaagggatg aaccctggaa cttcatatca 420
gaaagatcct gcatatatga agagaaatta aagaaacagc aggacaaaaa tgaaaattta 480
caaataattt caqttqccca tacaaaaatc cttactgnag atagaagcca taaaaatgtt 540
gaatttgccc aaaacttcta cctgaaatca nncttcatta agcaccngan aattgcctaa 600
<210> 393
<211> 531
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (63)
<223> n equals a,t,g, or c
```

```
<220>
  <221> misc feature
  <222> (267)
  <223> n equals a,t,g, or c
  <220>
  <221> misc feature
  <222> (352)
  <223> n equals a,t,g, or c
  <220>
  <221> misc feature
  <222> (376)
  <223> n equals a,t,g, or c
  <220>
  <221> misc feature
  <222> (394)
  <223> n equals a,t,g, or c
  <220>
  <221> misc feature
  <222> (395)
  <223> n equals a,t,g, or c
  <220>
  <221> misc feature
  <222> (400)
<223> n equals a,t,g, or c
  <220>
  <221> misc feature
  <222> (451)
  <223> n equals a,t,g, or c
  <220>
  <221> misc feature
  <222> (464)
  <223> n equals a,t,g, or c
  <220>
  <221> misc feature
  <222> (471)
  <223> n equals a,t,g, or c
  <220>
  <221> misc feature
  <222> (476)
  <223> n equals a,t,g, or c
  <220>
```

```
<221> misc feature
<222> (512)
<223> n equals a,t,g, or c
<400> 393
tgcagctctt ttcattttgc catccttttc cagctccatg atggttctgc aggtttctgc 60
ggncccccg gacagtggct ctgacggcgt tactgatggt gctgctcaca tctgtggttc 120
cagggcaggg ccactccaga gaattacctt ttccagggac ggcaggaatg ctacgcgttt 180
aatggtaaca gccagaagga catcctggag gagaaagcgg gcagtgccgg aacaggatgt 240
gcagacacaa cttacggagc tgggcgngcc catggaccct gcagcgccga gttccagcct 300
agggtggaat gttttccccc tccaagtagg gggcccttgg cagcaacaca anctgcttgt 360
ttggccaagt gacggntttt tacccaggca gcannggtan tcctgtcaac tggattggag 420
gcacatttga ttttgcccgg ttagacatga nggggttggg ttcngttggt naaatntggg 480
ttgggaattt taatgaaaaa ggggggcaaa gnaattttaa aggggggttt t
<210> 394
<211> 404
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (269)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (295)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (330)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (382)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (387)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (390)
<223> n equals a,t,g, or c
<220>
```

```
<221> misc feature
 <222> (399)
 <223> n equals a,t,g, or c
 <400> 394
 gggactctaa ttctgtaata tatcaaggaa tctcgtaaaa ccgacactaa aacgtccctg 60
 cctacaaatc atccggccaa attatgagtt cattgtatta tgcgaatgct ttattttcta 120
 aatatccagc ctcaagttcg gttttcgcta ccggagcctt cccagaacaa acttcttgtg 180
cgtttgcttc caacccccag cgcccgggct atggagcggg ttcgggcgct tccttcgccg 240
cctcgatgca gggcttgtac cccggcggng ggggcatggc gggccagagc gcggncggcg 300
tctacgcggc cggctatggg ctcgagccgn gttccttcaa catgcactgc gcgccctttg 360
 agcagaaacc tctccggggt gngcccnggn gaattccgnc aagg
<210> 395
<211> 499
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (10)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (89)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (90)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (93)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (95)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (98)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (112)
```

```
<223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (115)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (119)
 <223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (120)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (125)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (149)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (172)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (211)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (223)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (225)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (299)
<223> n equals a,t,g, or c
```

```
<220>
 <221> misc feature
 <222> (426)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (442)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (443)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (445)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (457)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (470)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (477)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (484)
<223> n equals a,t,g, or c
<400> 395
ggcacgaggn gcggcgggtc tggagccccc atcctcctgc ggcagatgtt cgagcctgta 60
agetgeacet teaegtacet getgggtgnn agngngtnee gggaggeegt tntgntegnn 120
ccagnectgg aaacagegee tegggatgne cagetgatea aggagetggg gntteggetg 180
ctctatgctg gcgttggaga ccagggccag ncctggccac aantnaggct gtgtcacctt 240
cgttctgaat gaccacagca tggccttcac tggagatgcc ctgttgatcc gtgggtgtng 300
gcggacagac tttcagcaag gctgttgcca agaccttgta accattcggt ccatgaaaag 360
atctttcaaa atttccagga gactgtcttg atctaacctg gttcaaggtt accatggggt 420
ttaaantgtt caacgtggag gnngnggagg acttttnaaa cccttggttn aaccttnaat 480
                                                                   499
tttnaggagt ttttcaaaa
```

```
<210> 396
<211> 526
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (445)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (502)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (508)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (519)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (523)
<223> n equals a,t,g, or c
<400> 396
ggtccccgtc acgctgactt tccgtgcagt gctgtggtgc gaaaatgcct cgccgctcct 60
ggtagacgaa gaggaagaca aacctacagt cgcttccaaa ctctagagtt ggaaaaggaa 120
tttcttttta acccctatct gaccaggaaa agaagaatcg aggtttccca cgccctagcc 180
ctcaccgaga gacaggtaaa aatctggttc cagaacagga gaatgaaatg gaaaaaggaa 240
aacaacaagg acaaatttcc cgtttcccgg caggaggtga aggacgggga aacgaaaaag 300
gaagcccaag agctggagga agacagagcc gaaggcctga caaattaact tctaccttta 360
aaatttacca cagactatta aaactaataa tcaccatatg ctgtggacac cacctatttt 420
ctttggtgga aaggacctta cctgngtttc aagctacctt catgtcactg gtcttgaggg 480
                                                                   526
tttctgggct tttgagaggg antttggngg tttaaaaang ttntag
<210> 397
<211> 443
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (94)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (443)
<223> n equals a,t,g, or c
<400> 397
gcccacgcgt ccgggtgctc cttacctccc cggtggtcgg gcgcgaatta ctggaaattg 60
getttteeeg ttggggeega agtacettee etgnggegge gaeteagegg ggtgtegtte 120
ggccggcgtg acgcagccgg atcggcgcca gacggaaacc tagcggtgac tgtatctgaa 180
ttttgcagct gcagaatgtg tagtacctta aaaggttggc aacaatgagt aaaccagaat 240
taaaggaaga caagatgctg gaggttcact ttgtgggaga tgatgatgtt cttaatcaca 300
ttctagatag agaaggagga gctaaattga agaaggagcg agcgcacttt tggtcaaccc 360
caaaaaaata ataaagaagc cagaatatga tttggaggaa gatgaccagg aggtcttaaa 420
                                                                    443
agatcagaac tatgtggaaa ttn
<210> 398
<211> 652
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (14)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (16)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (21)
<223> n equals a,t,q, or c
<220>
<221> misc feature
<222> (31)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (64)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (68)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (78)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (88)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (91)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (100)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (103)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (111)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (116)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (134)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (261)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (325)
<223> n equals a,t,g, or c
<220>
```

```
<221> misc feature
<222> (383)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (387)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (397)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (549)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (579)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (594)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (606)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (620)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (639)
<223> n equals a,t,g, or c
<400> 398
gcccacgcgt ccgnanacgc ntccgtttgg nccaagatgg catggaatga ggaaggcgct 60
teentggnga etggtggnet tggegtenet negggetgtn agnaceteat ntatgngeae 120
tttaccaaag cggntgaaaa ttgtggaagt tggtccccga gatggactac aaaatgaaaa 180
gaatatcgta tctactccag tgaaaatcaa gctgatagac atgctttctg aagcaggact 240
ctctgttata gaaaccacca nctttgagtc tcctaagtgg gttccccaga tgggtgacca 300
cactgaagtc ttgaagggca ttcanaagtt tcctggcatc aactacccag tcctgacccc 360
```

```
aaatttgaaa ggcttcgagg cancggnacc atgactnctg tgaggatgca gcactccctg 420
qcaqqtcaqa cctatgccgt gcccttcatc cagccagacc tgcggcgaga ggaggccgtc 480
caqcaqatqq cqqatqccct gcaqtacctg caqaaqgctc tggaqacatc ttcagcaagt 540
gggtgctgnc actcaccccc acctgatgag agggccatnc ctgtctgggc aatnccagca 600
acacancett tgggagcaan eceettgggg aateeeggne tggggaacee at
<210> 399
<211> 341
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (39)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (84)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (137)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (153)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (302)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (310)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (332)
<223> n equals a,t,g, or c
<400> 399
ggcacgagag gacctggata aagcacttct aaaggcctnt caggacatgt tcgacaagaa 60
aaccaaggct tocotttacc totnoactca caatgggaac atgtacacct catcootgta 120
cgggtgcctg gcctcgnttc tgtcccacca ctntgcccaa gaactggctg gctccaggat 180
```

tggtgccttc tcttatggct ctggtttagc agcaagtttc ttttcatttc gagtatcccg 240

```
tctaaaggtg ttctgcagat ccatggaaag cttctgggaa acgtatgcta gcagagcttc 300
tncccgtgan tcatatttt aagatcccac tnttagctgg a
<210> 400
<211> 604
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (392)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (484)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (502)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (509)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (559)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (593)
<223> n equals a,t,g, or c
<400> 400
gcctccgcat aggcctgcgt cagattaaaa cactgaactg acaattaaca gcccaatatc 60
tacaatcaac caacaagtca ttattaccct cactgtcaac ccaacacagg catgetcata 120
aggaaaggtt aaaaaaagta aaaggaactc ggcaaatctt accccgcctg tttaccaaaa 180
acatcacctc tagcatcacc agtattagag gcaccgcctg cccagtgaca catgtttaac 240
ggccgcggta ccctaaccgt gcaaaggtag cataatcact tgttccttaa atagggacct 300
gtatgaatgg cttcacgagg gttcagctgt ctcttacttt taaccagtga aattgacctg 360
cccgtgaaga ggcggcatga cacagcaaga cnaagaagac cctatggagc tttaatttat 420
taatgcaaac agtacctaca aacccacagg tcctaactac caaacctgca ttaaaaaatt 480
cggntggggc gacctcggac anaaccaanc tccagcagta catgctaaac ttaccagcaa 540
acgactatat ctaattganc atacttgaca aggacaagta cctaggaaca ggnaatcttt 600
ttaa
                                                                   604
```

```
<210> 401
<211> 519
<212> DNA
<213> Homo sapiens
<400> 401
cataatcact tqttccttaa ttagggacct gtatgaatgg ctccacgagg gttcagctgt 60
ctcttacttt taaccagtga aattgacctg cccgtgaaga ggcgggcata acacagcaag 120
acgagaagac cctatggagc tttaatttat taatgcaaac agtacctaac aaacccacag 180
gtcctaaact accaaacctg gcattaaaaa tttcggttgg ggcgacctcg gagcagaacc 240
caacctccga gcagtacatg ctaagacttc accagtcaaa gcgaactact atactcaatt 300
gatccaataa cttgaccaac ggaacaagtt accctaggga taacagcgca atcctattct 360
agagtccata tcaacaatag ggtttacgac ctcgatgttg gatcaggaca tcccgatggt 420
gcagccgcta ttaaaggttc gtttgttcaa cgattaaagt cctacgtgat ctgagttcag 480
accggagtaa tccaggtcgg tttctatcta ctttcaaat
<210> 402
<211> 265
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (23)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (213)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (218)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (233)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (255)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (264)
<223> n equals a,t,g, or c
```

```
<400> 402
gctgccagta gcatatgctt gtntcaaaga ttaagccatg catgtctaag tacgcacggc 60
eggtacagtg aaactgegaa tggeteatta aatcagttat ggtteetttg gtegeteget 120
cctctcctac ttggataact gtggtaattc tagagctaat acatgccgac gggcgctgac 180
ccccttcgcg ggggggatgc gtgcatttat canatcanaa ccaacccggt canccctct 240
                                                                    265
ccggccccgg ccggngggcg gcgnc
<210> 403
<211> 325
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (137)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (138)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (172)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (173)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (200)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (263)
<223> n equals a,t,g, or c
<400> 403
gcaggtactt ggttctccag tgggagctgc cctctcgaag gcaggacagc ggtggcggca 60
gatataaaga cctgaagata gtctttctg tccaaagatg gaaaacagta ctactaccat 120
ttctcgggag gagcttnnag aactacaaga ggcatttaat aaaatagata tnnacaatag 180
tgggtatgtc agtgactatn aacttcaaga cctgtttaag gaagcaagcc ttcctctgcc 240
tggctacaag gtgcgcgaga ttntggagaa aattctatca gttgctgaca gcaacaaaga 300
                                                                   325
tggcaaaatc aattttgaag agttt
```

```
<211> 540
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (469)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (473)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (489)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (526)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (537)
<223> n equals a,t,g, or c
<400> 404
ataactatat ctttcttcct ctgtctccgc ccaccacat ttttctcttt ccctttctct 60
ctttggggac cetececat geteecetge eccateceet ttteecette eegtettete 120
atccctccat tcccatcttt ccccaqcaat taccagctct ggctgggtcg ccacaacttg 180
tttgacgacg aaaacacagc ccagtttgtt catgtcagtg agagcttccc acaccctggc 240
ttcaacatga gcctcctgga gaaccacacc cgccaagcag acgaggacta cagccacgac 300
ctcatgctgc tccgcctgac agagcctgct gataccatca cagacgctgt gaaggtcggg 360
aagttgccca cccaggaacc cgaagtgggg gagcacctgg ttggcttccg gctggggcaa 420
gcattgaacc agaagaattt cttaatttca gaagatcttc aaatggtgng ganccttcaa 480
aaatcctgnc taaaggaata aatggcgaaa aaagcccaac gttcanaaag gtggacngga 540
<210> 405
<211> 319
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (5)
<223> n equals a,t,g, or c
<220>
```

```
<221> misc feature
<222> (94)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (296)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (298)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (301)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (309)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (313)
<223> n equals a,t,g, or c
<400> 405
ctgcnccgcc gegggcccca gctgcgcgct gaaggccggc aagacagcga gcggtgcggg 60
cgaggtggtg cgctgtctgt ctgagcagag cgtnggccat ctcgcgctgc gccgggggcc 120
eggggegege etgeetgeee tgetggaega geageaggta aaegtgetge tetacgaeat 180
gaacggctgt tactcacgcc tcaaggagct ggtgcccacc ctgccccaga accgcaagtg 240
aagcaaggtg gagattttcc agcacgtcat cgactacatc agggacttta atttgnantt 300
                                                                   319
naatcggant ccnaatttg
<210> 406
<211> 355
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (5)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (10)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (23)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (27)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (41)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (46)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (57)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (86)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (121)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (124)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (141)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (145)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (150)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (171)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (216)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (251)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (253)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (266)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (283)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (304)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (321)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (325)
<223> n equals a,t,g, or c
<400> 406
```

```
ggcanaggtn cagctgaccc tgncggncac acagtgccca nagggnaagt ccgtaanatg 60
ccacgtgaaa gcactacacg attccnagcc aggatgtaac tgtgcccctg cccagttccc 120
ncancttece catgetgeca necengattn tggetgaaac gaceggeeet ngaggaeetg 180
gtcttaggtt cagaagcgaa gcatcacgtg acacantgac cggcctgaga gaatgcctct 240
ggtgaccact ntnacctggg acgccnttaa agtgggaaga gcnctgtttc aaggaccacc 300
tggngcgtga cctgtgtggg nttgntacag gtgttccagt gtgctgactg gttgt
<210> 407
<211> 437
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (5)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (110)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (272)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (296)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (370)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (389)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (412)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (430)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (435)
<223> n equals a,t,g, or c
<400> 407
ggcanagcac aagcccagca acaccaaggt ggacaagaga gttgagtcca aatatggtcc 60
cccatgccca tcatgcccag cacctgaatt tcctgggggg accatcagtn ttcctgttcc 120
ccccaaaacc caaggacact ctcatgaatc tcccggaccc ctgaaggtca cgtgcgtggt 180
ggtggacgtg aagccaggga agaccccgag gtccagttca actggtacgt ggatggcgtg 240
gaggtgcata atgccaagac aaagccgcgg gnggagcagt tcaacagcac gtaccngtgg 300
ttcagcgtcc ttcaccgtcc tgcaccagga tggcttgaac ggcaagggag ttacaagtgg 360
caaggttttn caacaaaggg cttcccgtnc ttccttgggg aaaacctttt tncaaaggcc 420
                                                                    437
aaggggcagn cccgngg
<210> 408
<211> 310
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (102)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (137)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (277)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (289)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (294)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (298)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (303)
<223> n equals a,t,g, or c
<400> 408
gggggatatt gtagtggtgg tagctgctct aatttctact tctaccacat ggacgtctgg 60
ggcgaaagga ccacggtcac cgtctcctca gcctccacca anggcccatc ggtcttcccc 120
ctggcgccct gctccangaa cacctccgaa aacacagcgg ccctgggctg cctggtcaag 180
gactacttcc ccgaaaccgg tgacggtgtc ttggaactca gggggctctg accagcgggg 240
tgcacacctt cccagctgtc ctacagtcct caggaancta ctccctcanc accntggnga 300
cgntgcctcc
<210> 409
<211> 421
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (52)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (74)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (235)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (246)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (279)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (346)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (382)
```

```
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (384)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (405)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (417)
<223> n equals a,t,g, or c
<400> 409
gctcagttag gacccatacg gaaccatgga agccccagcg cagcttctct tnctcctgct 60
actotggctc ccanatacca ctggagaaat actgatgacg cagtotccag ccaccotgtc 120
tgtgtctcca ggggaaagag tcaccctctc ctgcagggcc gggcagagtg tttacagcaa 180
cttagectgg tateageaga aacetggeea ggeteecagg etecteatgt atggnteate 240
caccanggcc actgatgtcc cagtcaggtt cagtggcant gggtctggga cagagttcac 300
tctcaccatc agcagcctgc agtctgacga ttctgcagtc tatttntgtc agcagtatat 360
tatgtggcct ggaaccttcg gncnagggac caagggggaa atcanacgaa ctggggntgc 420
<210> 410
<211> 448
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (8)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (9)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (11)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (13)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (14)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (342)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (361)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (384)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (421)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (424)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (443)
<223> n equals a,t,g, or c
<400> 410
gtacggcnng ntnntttcgg gtcgaccgcg ccttccgcgg acgcgtgggt tcggacgcgt 60
gggcggacgc gtggggccga ggctgccaag atgcttggag aagcactgag caagaaccct 120
ggctacatca aacttegeaa gattegagea geceagaata tetecaagae gategeeaca 180
tcacagaatc gtatctatct cacagctgac aaccttgtgc tgaacctaca ggatgaaagt 240
ttcaccaggg gaagtgacag cctcatcaag ggtaagaaat gagcctagtc accaagaact 300
ccaccccag aggaagtgga tctgcttctc cagttttgga gnaccaccag gggtccagaa 360
nagocotaco cogococatt atentgoaat ggtccccaca cogggttccc tgaaccctct 420
nggnttaagg aaaatgaaaa tanccctt
<210> 411
<211> 141
<212> DNA
<213> Homo sapiens
```

```
<220>
<221> misc feature
<222> (67)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (95)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (101)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (120)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (138)
<223> n equals a,t,g, or c
<400> 411
gattgatctc atgtgcaaga aaatgaagca cctgtggttc ttcctcctgc tggtggcagt 60
ctcccanatg cgtcctgtcc caggtgcagc tgcangagtc ngggccagga ctggtgaagn 120
                                                                   141
cttcggagac cctgtccntc a
<210> 412
<211> 473
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (253)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (403)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (461)
<223> n equals a,t,g, or c
<220>
```

```
<221> misc feature
<222> (469)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (471)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (472)
<223> n equals a,t,g, or c
<400> 412
ggaaaggagc cccagccctg agattcccag gtgtttccat tcggtgatca gcactgaaca 60
cagaactcac catggagttt ggactgagct gggttttcct tgttgttatt ttaaaaggtg 120
tccagtgtga agtgcagctg gtggagtctg ggggagccgt agtacagcct ggggggtccc 180
ttagactete etgtgaagee tetggattea eetttgacaa ttatgeeatg caetgggtee 240
gtcaagctcc ggngaagggt ctggagtggg tctgtctcat cagtcgggat ggtcgtaaga 300
catattttgc agactctatg aagggtcggt tcaccatctc cagagacaac agcaaaaact 360
gcctgtatct ccaagtgaac agtctgagag ttgaggacac cgncttgtat tactgtgcaa 420
aagatateee ggggtegteg gtatggaegt etggggtaaa nggaeaceng nna
<210> 413
<211> 328
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (183)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (187)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (188)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (228)
<223> n equals a,t,g, or c
<220>
<221> misc feature
```

```
<222> (241)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (242)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (288)
<223> n equals a,t,g, or c
<400> 413
ggtcctggac tccaaggcct ttccacttgg tgatcagcac tgagcacaga ggactcacca 60
tggaattggg gctgagctgg gttttccttg ttgctatttt agaaggtgtc cagtgtgagg 120
tgcagctggt ggagtctgg ggaggcttgg tccaagccgg gggggtccct gagactctcc 180
tgngcannet etggettece cetttataac catgggatga cetgggtneg ecaggeteca 240
nngaaggggc tggaatgggt ggccaccata cagtgagatg aaactganaa atactatgtg 300
                                                                    328
gactctgtga agggccgatt caccatct
<210> 414
<211> 575
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (14)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (361)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (470)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (511)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (527)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (539)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (544)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (573)
<223> n equals a,t,g, or c
<400> 414
ggccgtgaga ttcncaggag tttccacttg gtgatcagca ctgaacacag accaccaacc 60
atggagtttg ggcctagctg ggttttcctt gttgctattt taaaaggtgt ccactgtgag 120
gtgcagctgg tggagtctgg gggaggcttg gtacagccag ggcggtccct gagactctcc 180
tgtacaactt ctggattcac ctttggagat tattctatga gctgggtccg ccaggctcca 240
gggaaggggc tggagtgggt aggtttcatt agaagcaaag cgcatggtgg gacaacagaa 300
tacgccgcgt ctgtgaaaag gcagattcac catctcaaag agatgattcc acaggcatcg 360
nctatctggc aaatgaacag cctgaaaccg aggacacaga cattattact gtctagacat 420
gactacaggc acaccctgg ctactggggg cagggaaccc tggtcaccgn cttctctggc 480
ttccaccaag ggccatcgtc ttccccctgg ngcccttgtt ccaggancac ttccgaaanc 540
                                                                   575
cagnggcctg ggcttgctgg gcaagggctc ttncc
<210> 415
<211> 438
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (37)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (65)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (105)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (139)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (157)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (190)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (201)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (269)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (281)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (296)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (297)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (301)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (303)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (312)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (323)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (330)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (331)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (333)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (350)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (351)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (356)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (371)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (385)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (397)
<223> n equals a,t,g, or c
<220>
```

```
<221> misc feature
<222> (422)
<223> n equals a,t,g, or c
<400> 415
gtccagtgtg aggtgcagct ggtggagtct gggggangct tggtacagcc tggggggtct 60
ctganactct cctgtgcagc ctctggattc accttcagta gttangacat gcattgggtc 120
cgccaagttg caggaaaang tctggaatgg gtctcangta ttgatcctgc tggtaacaca 180
aactatccan gctccgtgaa nggccgattc atcatctcca gagaaaatga caagagctcc 240
tcgtatcttc aaaatgaatg ggctgacanc cggggaaaac ngtgtgtaat attgtnnaaa 300
nanaaattgc anttcctggt aantgggtan ntncgatctc ttggggccgn nggaancctt 360
ggttaaatgt nttcctcaag aattncccga accaagnccc caaaggtttt tcccgcttaa 420
ancctttgaa aaagaaac
<210> 416
<211> 502
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (22)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (48)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (105)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (135)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (145)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (312)
<223> n equals a,t,g, or c
<220>
```

<221> misc feature

```
<222> (367)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (428)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (451)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (455)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (474)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (480)
<223> n equals a,t,g, or c
<400> 416
ggcacgagca acgctggcaa tnataacaca aaatattcac agaagttnca ggacagagtc 60
accattacca gggacacatc cacgaacaca gcctacatgg atctnagcag cctgagatct 120
gaagacacgg ctgtntatta ttgtncgagg ggattttttg gggaccgtga ttactactac 180
tactactaca tggacgtctg gggcaaaggg accacggtca ccgtctcctc agcatccccg 240
accageccea aggtettece getgagecte tgeageacce agecagatgg gaacgtggte 300
ategoetget tngtecaggg ettetteece caggageeac tteagtgtgg acetggageg 360
aaagggnaca gggcgtgacc gccagaaaat tcccacccag ccaggatgcc tccgggggac 420
ctgtacanca cgagcagcca gctgaccctg ncggncacaa gtgccttagc cggnaagttn 480
                                                                   502
cgttgacatt gccacgtgga ag
<210> 417
<211> 427
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (230)
<223> n equals a,t,g, or c
<220>
<221> misc feature
```

```
<222> (233)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (325)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (352)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (363)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (388)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (411)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (427)
<223> n equals a,t,g, or c
<400> 417
gatcatgagt atctatgtga attggtatcg gcagaaagca ggaaaagccc ctgagctcct 60
gatccacggt ggcatccagc ttacaaagtg gagtccccgg aaggttcagt ggcaggggga 120
tetgggacag attteactet caccattage agtetgeaac etgaagattt tggcacttae 180
ttctqtcaac agaattacaa tqtcccqtgg aacqttcggc caggggaacn aangtggaaa 240
atgaaaccga actgtggctg caccatctgt cttcatcttc ccgccatctg atgagcagtt 300
gaaatctgga actgcctctg ttgtnttgcc tgctgaataa cttctatccc anaaaaggcc 360
aanttcattg gaaggtggat aacccccncc atcggttact cccggaaaat ntcccaaacc 420
ggacgcn
<210> 418
<211> 308
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (126)
```

```
<223> n equals a,t,g, or c
 <220>
  <221> misc feature
  <222> (132)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (182)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (254)
. <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (262)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (270)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (282)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (297)
 <223> n equals a,t,g, or c
 <400> 418
 gctccaactc tggcaacaca gccactttga ccatcagcgg gactcaggct atggatgagg 60
 ctgactatta ctgtcaggcg tgggacagta gcgctgtggt cttcggcgga gggaccaggc 120
 tgacentect angteageec aaggetgeec ceteggteac tetgtteeeg ceeteetetg 180
 angagettea agecaacaag gecacaetgg tgtgteteat aaatgaette taccegggaa 240
 gccgtgacag tggnctgqaa angcagatan caaccccgtt cnaggcggaa ttggganaaa 300
 caaccaca
 <210> 419
 <211> 482
 <212> DNA
 <213> Homo sapiens
```

<220>

```
<221> misc feature
<222> (370)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (441)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (449)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (462)
<223> n equals a,t,g, or c
<400> 419
tcgacccacg cgtccgcagc tgtgggcaca agaggcagca ctcaggacaa tctccagcat 60
ggcctggtct cctctcctcc tcactctcct cgctcactgc acagggtcct gggcccagtc 120
tgtgctgacg cagccgccct cagtgtctgg ggccccaggg cagagggtca ccatctcctg 180
cactgggage agetecaaca teggggeagg ttatgatgta cactggtace ageagettee 240
aggaacagcc cccaaagtcc tcatctatgg taacagcaat cggccctcag gggtccctga 300
ccgattctct ggctccaagt ctggcacctc agcctccctg gccatcactg ggctccaggc 360
tgaagatgan gttgattatt actgccagtc ctatgacagc agcctgggtg gttcggtgtt 420
cggcggaagg accaagctga ncgtcctang tcagcccaaa gntgccccct cggtaactct 480
                                                                   482
gt
<210> 420
<211> 462
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (21)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (71)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (85)
<223> n equals a,t,g, or c
<220>
```

```
<221> misc feature
<222> (86)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (100)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (110)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (438)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (446)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (452)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (456)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (459)
<223> n equals a,t,g, or c
<400> 420
gacaggattc aggacaatct ncaccatggc cggcttccct ctcctcctca ccctcctcac 60
teactgtgca nggteetggg eccannetgt getgactean ecaecetean egtetgggae 120
ccccgggcag agggtcacca tctcttgttc tggaagcagc tccaacatcg gaactaatta 180
tgtatactgg taccagcagc tcccaggaac ggcccccgaa gtcctcatct ataagaatga 240
tcagcggccc tcaggggtcc ctgaccgatt ctctggctcc aagtctggca cctcagcctc 300
cctggccatc ggtgggctcc ggtccgagga tgaggctgat tattactgtg catcatggga 360
tgacagcctg agtggtccqq tcttcggcgg agggaccaag ctgaccgtct tgggtcagcc 420
caaggetgee eccteggnea etetgnteee gneetnetnt ga
                                                                   462
<210> 421
```

<211> 435

```
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (324)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (351)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (391)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (416)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (423)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (431)
<223> n equals a,t,g, or c
<400> 421
ggaggcagag ctctgggaat ctcaccatgg cctggacccc tctcctgctc cccctcctca 60
ctttctgcac agcggaagag aggccaggcc cctgtggtgg tcatctatga ggacaacaaa 120
cgaccetecg ggatecetga gagattetet ggetecacet cagggacatt ggecacegtg 180
attatcagtg gggcccaggt ggacgatgat actgacttct actgtcagtc aacacacagt 240
agtaataatg gtaggtccgt atgtcttcgg aactgggacc aaggtcaccg tccttggtca 300
gcccaaggcc aaccccaatg tcantctgtt cccggcctcc tctgaaggag nttcaagcca 360
aacaaaggca cactaagtgt gtctgatcag ngagttttaa ccgggaagtg tgaaantggg 420
                                                                    435
ctnggaagca nattg
<210> 422
<211> 334
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (11)
```

```
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (101)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (122)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (135)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (145)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (310)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (323)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (324)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (326)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (331)
<223> n equals a,t,g, or c
<400> 422
gcagaactct nggtgtctca ccatggcctg gatccctcta cttctccccc tcctcactct 60
ctgcacagac tctgaggcct cccatgaatt gagacaacca ntttcggtgt cagtgtcccc 120
angacagacg gccangatca cctgntctgg agatgcattg ccagaacaat ctattttttg 180
```

```
gtatcaacag aagccaggcc aggcccctgt attggtgatt tataaagtcc atgagaggcc 240
gtcagatgcc ctgaacgatt ctctggctcc aggtcacaga caacagtcac gttgaccatc 300
                                                                    334
agtggagccn agggcaaaaa atnngngggg ngtg
<210> 423
<211> 597
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (1)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (8)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (26)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (61)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (81)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (115)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (117)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (118)
<223> n equals a,t,g, or c
<220>
<221> misc feature
```

```
<222> (126)
  <223> n equals a,t,g, or c
  <220>
  <221> misc feature
  <222> (132)
  <223> n equals a,t,g, or c
  <220>
  <221> misc feature
  <222> (168)
  <223> n equals a,t,g, or c
  <220>
  <221> misc feature
  <222> (174)
  <223> n equals a,t,g, or c
<220>
  <221> misc feature
  <222> (176)
  <223> n equals a,t,g, or c
  <220>
  <221> misc feature
  <222> (189)
  <223> n equals a,t,g, or c
  <220>
  <221> misc feature
  <222> (199)
  <223> n equals a,t,g, or c
  <220>
  <221> misc feature
  <222> (201)
  <223> n equals a,t,g, or c
  <220>
  <221> misc feature
  <222> (204)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (209)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (217)
```

```
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (230)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (257)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (259)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (272)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (277)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (296)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (333)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (344)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (393)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (412)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (413)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (414)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (427)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (457)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (492)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (511)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (513)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (550)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (552)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (580)
<223> n equals a,t,g, or c
```

```
<400> 423
 nggatttngc caagctctga atcaanctca ctaaagggaa caaaaggtgg agctccaccg 60
 nggtggcggc cgctctagaa ntactggatc ccccgggttg cccgggttcg gcgananngg 120
 acaatntagg cnatgtaggg tctggtcccc caaatccaga tctgtcgnaa acantnttgg 180
atcaatacnt tgccatggnc ncanaaaanc atgggtncaa catggaacan gctcttggga 240
tgctcttctg gcataancnt aatatccaaa antcatnggc tgatttgccc aacttnaccc 300
ctttcccaga taagtggact gtggaagata aantcttatt tgancaagcc tttacttttc 360
atgggaaaac ttttcataca atccaaccaa tgnttccaca taaatctata gnnngtctgg 420
tgaaatntta ctattcttgg aaaaaagacg aagactnaaa ctattgtgat ggatcgccat 480
gccccggaaa cnaaacggga cgggaagaga ncnacgatga actggaacaa gcaaatggaa 540
caatcccatn gnacttgaag ttggatccaa accaagaaan ccaaagggaa gtcccct
<210> 424
<211> 143
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (42)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (92)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (96)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (99)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (131)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (138)
<223> n equals a,t,g, or c
<400> 424
gaacacatat aagagcaaaa totggatogg caggtgttac anacacaatg tatacgactg 60
gaggeeeggt actacageet cageetgaeg gnacaneane teteceaeat egtggeggag 120
ttgaggaacc ngaaacanaa aat
                                                                   143
```

```
<210> 425
<211> 323
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (7)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (291)
<223> n equals a,t,g, or c
<400> 425
gggcagngga gctctattgc caccatgagt ttctccggca agtaccaact gccagagcca 60
ggaaaacttt gaagccttca tgaaggcaat cggtctgccg gaagagctca tccagaaggg 120
gaaggatatc aagggggtgt cggaaatcgt gcagaatggg aagcacttca agttcaccat 180
caccgctggg tccaaagtga tccaaaacga attcacggtg ggggaggaat gtgagctgga 240
gacaatgaca ggggagaaag tcaagacagt ggttcagttg gaaggtgaca ntaaactggt 300
gacaactttc aaaaacatca agt
<210> 426
<211> 683
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (79)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (94)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (105)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (112)
<223> n equals a,t,g, or c
<220>
<221> misc feature
```

```
<222> (114)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (120)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (124)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (129)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (134)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (136)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (139)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (158)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (163)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (188)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (195)
```

```
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (206)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (232)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (234)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (241)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (251)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (262)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (264)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (275)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (286)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (291)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (301)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (324)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (326)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (338)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (348)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (370)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (387)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (395)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (399)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (409)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (418)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (487)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (536)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (558)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (578)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (601)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (607)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (633)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (648)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (662)
<223> n equals a,t,g, or c
<400> 426
```

```
aaaaaaaaaa aaaaaaaang ggcggccgtt ttanaggatc caagnttacg tncncgtgcn 120
tgcnacgtna tagntnttnt atagggtcac ctaaattnaa ttnactggcc gtcgttttac 180
aacgtcgnga ctggnaaaac cctggngtta cccaacttaa tcgccttgca gnanatcccc 240
ntttcgccaq ntqqcqtaat anchaaaaqq cccqnaccqa tcqccnttcc naacagttqc 300
ncagcctgaa tggcaaatgg gacnenecet gtagcggngc attaageneg gegggtgtgg 360
gggttaccon cagogtgaco gttacanttg coagngcont agogcocgnt cotttogntt 420
tettecette ettttegee acgttegeeg gtttteeeeg taaagettta aatgggggge 480
tcccttnagg gttccgattt agggctttac gggaccttga ccccaaaaaa ctttgnttag 540
ggggatggtt cacqtagnqq qqccattqcc cttgatanac gggtttttcg cccttttgac 600
nttggantcc cacgtttttt aaataggggg gcntttttgt tccaaaantg gggaacaaac 660
antttaaccc ctttttttgg ggg
                                                                683
<210> 427
<211> 369
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (323)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (337)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (344)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (349)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (350)
<223> n equals a,t,g, or c
<400> 427
tgggcctgag atgcaggtaa aactgctcca gtccctgggc ctgaaatcaa ccctcatcac 60
cgatggctcc actcccatca acctcttcaa cacagccttt gggctgctgg ggatggggcc 120
cgagggtcca gccctgggc agaaaggttg gcattgggcc cagccctgga agggggatat 180
cccccagtc ttgctcaagc ccctcaagct cctggaaaac accactttgt gcctgttctg 240
cgcttactcc tgattaatac aatgaatttt cttgggcatt ttacaatttc caacacttta 300
aaaaaaaaa aaaaaaattc aanggggggg ccggttncca attnccccnn ttttatttct 360
                                                                369
tttaaaatc
```

```
<210> 428
<211> 299
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (1)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (79)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (121)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (295)
<223> n equals a,t,g, or c
<400> 428
nectaatote ggaateetaa gtggtegeet gaggacegge eggaatteee gggcacecae 60
gcgtcggcgg tagctgctnt tcctggggcc cgtgggcctc atcatgtacc tcgggggcgt 120
nttcttcatc aaccggcage getctageac tgccatgaca gtgatggccg acctgggcga 180
gcgcatggtc agggagaacc tcaaagtgtg gatctatccc gagggtactc gcaacgacaa 240
tggggacctg ctgcctttta agaagggcgc cttctacctg gcagtccagg cacangtgc 299
<210> 429
<211> 538
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (124)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (133)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (325)
```

```
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (374)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (376)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (394)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (397)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (414)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (432)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (435)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (440)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (460)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (472)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (473)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (482)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (484)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (498)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (499)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (529)
<223> n equals a,t,g, or c
<400> 429
gaagcagaga totgaagaca qoatgtacac agocattooc cagagtggot otocattooc 60
aggeteagtg caggatecag geetgeatgt gtggegggtg gagaagetga ageeggtgee 120
tgtngcgcaa ganaaccagg gcatcttctt ctcgggggac tcctacctag tgctgcacaa 180
tggcccagaa gaggtttccc atctgcacct caacacactg ctgggagagc ggcctgtgca 240
gcaccgcgag gtaaggggca atgagtctga cctcttcatg agctacttcc cacggggctt 300
caagtaccag gaaggtggtt tggantcagc atttcacaag acttccacag gagccccagt 360
tgccatcaag aaantntacc aggtgaaggg gaanaanaaa tccgtccaac gagngggcat 420
gaattgggaa anttnaaatn ggggttgttt acctggaatn ggcaaaaatt tnnctggttt 480
gngnaatcaa atttgganna aaagggggga ttgcctggat cgggatttnc aaggaagc
<210> 430
<211> 552
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (434)
<223> n equals a,t,g, or c
```

. ;

```
<220>
<221> misc feature
<222> (449)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (505)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (508)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (514)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (523)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (535)
<223> n equals a,t,g, or c
<400> 430
gcggacacgg acaggattga cagattgata gctctttctc gattccgtgg gtggtggtgc 60
atggccgttc ttagttggtg gagcgatttg tctggttaat tccgataacg aacgagactc 120
tggcatgcta actagttacg cgacccccga gcggtcggcg tcccccaact tcttagaggg 180
acaagtggcg ttcagccacc cgagattgag caataacagg tctgtgatgc ccttagatgt 240
ccggggctgc acgcgcgcta cactgactgg ctcagcgtgt gcctacccta cgccggcagg 300
cgcgggtaac ccgttgaacc ccattcgtga tggggatcgg ggattgcaat tattccccat 360
gaacgaggaa ttcccagtaa gtgcgggtca taagcttgcg ttgattaagt ccctgcccct 420
tcaacccttc tggnccttcg gaccactgng acttttccat ctttcttaaa cggaggctgg 480
gccttggggg gggggctggc ctggnttntg ttgnccccaa ganggtgctt tcaanggtga 540
ggaacttttt tt
<210> 431
<211> 218
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (31)
```

```
<223> n equals a,t,g, or c
<220>
 <221> misc feature
<222> (36)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (37)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (43)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (56)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (60)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (83)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (104)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (105)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (107)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (136)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (143)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (159)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (168)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (171)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (181)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (196)
<223> n equals a,t,g, or c
<400> 431
ccccggcct gcaggaaatt cgagcagagt ncacanngag ggnaccaccg tcctgntctn 60
ccagttcggg ttgaatgcaa gtnctagccg atttttccta caannantcc agttgattac 120
aattetteet gtacgneaga ganceetgee tttaaaagnt gecaaegntt neetgaegag 180
                                                                    218
ncctgcagcc acagtncggc aattcctaca agtgccaa
<210> 432
<211> 610
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (401)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (587)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (590)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (592)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (593)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (604)
<223> n equals a,t,g, or c
<400> 432
gcacacccct gggcgtcccc gtcatccagc cgtatcgcct ggactccaag gtcaagcaaa 60
taggaggtgg aattcagagc atcacctaca cccacaacgg agacatcagc cgaaagccca 120
acacacgtaa gcagaagaac ggcttcccgc ccaacttcat ccactcgctg gactcctccc 180
acatgatgct caccgccctq cactgctaca ggaagggcct gaccttcgtc tctgtgcacg 240
actgttactg gactcacgca gctgatgtct ccgtcatgaa ccaggtgtgc cgggagcagt 300
ttgtccgctt gcacagcgag cccatcctgc aggacctgtc cagattcctg gtcaagcggt 360
tetgetetga gececagaag atettggagg ceagecaget naaggagaea etgeaggegg 420
tgcccaagcc aggggccttc gacctggagc aggtgaagcg ttccacctac ttcttcagct 480
gacaccccqt gaqccttqtc aqtqtqtaaa taaagctctt ttqccacccc aaaaaaaaaa 540
aaaaaaaact tggggggggg gcccgggacc caattgccct atagggnggn gnnttacaat 600
                                                                    610
tcantggccg
<210> 433
<211> 328
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (26)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (123)
<223> n equals a,t,g, or c
<220>
<221> misc feature
```

```
<222> (131)
 <223> n equals a,t,g, or c
 <220>
<221> misc feature
<222> (132)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (141)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (222)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (223)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (225)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (244)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (249)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (266)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (291)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (314)
```

```
<223> n equals a,t,q, or c
<400> 433
caaatgtatg gaactaacaa gatggntcca tatcgagatt caaagttaac ccatctgttc 60
aagaactact ttgatgggga aggaaaagtg cggatgatcg tgtatgtgaa ccccaaggct 120
gangattatg nngaaaactt ncaagtcatg agatttgcgg aagtgactca agaagttgaa 180
gtagcaagac ctgtagacaa ggtaatatgt ggtttaacgc cnngnaggag atacagaaac 240
cagnetegng gtecagttgg aaatgnacca ttgggtactg acgtggtttt ncagagtttt 300
ccacctttgc cgtncatgcg aaattttt
<210> 434
<211> 535
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (76)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (77)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (274)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (351)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (405)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (454)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (491)
<223> n equals a,t,g, or c
```

<220>

```
<221> misc feature
 <222> (504)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (512)
 <223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (517)
<223> n equals a,t,g, or c
<400> 434
gggttcgacc cacgcgtccg aggctgaaca ggacagaaag atagaagaag tcagagatgc 60
catggaaaat gaaatnngaa actctctgaa caagaattac aatttcgtcg tctcagtcaa 120
gagcaagttg acaactttac tctggatata aatactgcct atgccagact cagaggaatc 180
gaacaggctg ttcagagcca tgcagttgct gaagaggaag ccagaaaagc ccaccaactc 240
tggctttcag tggaggcatt aaagtacagc atgnaagacc tccatctggc agaaacacct 300
actatecege tgggtagtgg cagttgaage ceatecaaag ceaactgtte nggataatga 360
atttcaccca agetttaacc geagetatte cettecagag ttcenggace egtggggtgg 420
ttacatggaa gagaaccctt agggcccgtt ttcncatggt ggtttccaaa aattgggccc 480
cgagggtagg nccaatggat tggnttggaa ancccgnaat tagcttgtta cccgt
<210> 435
<211> 524
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (110)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (138)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (154)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (157)
<223> n equals a,t,g, or c
<220>
```

```
<221> misc feature
 <222> (238)
 <223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (258)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (259)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (262)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (269)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (279)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (308)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (337)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (338)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (339)
<223> n equals a,t,g, or c
<220>
<221> misc feature
```

```
<222> (340)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (341)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (342)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (343)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (344)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (345)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (347)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (348)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (350)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (354)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (375)
```

```
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (380)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (498)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (500)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (518)
<223> n equals a,t,g, or c
<400> 435
ccctgctcca ccgtccccgt caccacggag gtttcgtacg ccggctgcac caagaccgtc 60
ctcatgaatc attgctccgg gtcctgcggg acatttgtca tgtactcggn ccaagcccag 120
gccctggacc acagcttnct cctgctgcaa aganganaaa accagccagc gtgaggttgg 180
tectgagett gecceaatgg eggetegett gacacacace tacacecaca tegaaganet 240
gecagtgeca agaacaennt entgggggnt teeccaaeng gaaetteeeg eeggggeegg 300
ggggcttncc ccttagcatc tggaacgtag gtttttnnnn nnnnngnnan aaanccccct 360
ttcaattqcc cttcnaaaan ttttacctcc ccccgaacct ctttaaactc cttaaactcg 420
ggttcctctt cttccaaata ttatgttcta atttttttt tcatccctgc tttcccaata 480
                                                                   524
taaactcagg gggaaatncn aaaaaaaaaa aaatccangg gggg
<210> 436
<211> 384
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (5)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (79)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (124)
```

```
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (177)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (191)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (215)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (320)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (341)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (349)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (366)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (374)
<223> n equals a,t,g, or c
<400> 436
ggcanaggat caggctggag aagtggatca caccttgttg ggacaatgca caggtggcgg 60
ttacttcatg cagttcagna ccagctcggg gtccgcggaa gaggcagccc tactggagtc 120
tcgnattctt tacccaaaga ggaagcagca gtgcctgcaa tttttctata aaatgancgg 180
ggaagtcctt ncagacagac ttcgttgtct gggtncagga ggggatgaca gcacaggcaa 240
tgttcgcaat tggtgaaggt gcagactttt caaggagatg atgaccacaa tttggaaaat 300
tggcccatgt gggtgcttcn aagaggaaca gaatttcggt naccttttnc caggggcaca 360
                                                                   384
aaaggnggac cttnagagct tcaa
```

```
<210> 437
<211> 390
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (304)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (317)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (372)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (385)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (386)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (390)
<223> n equals a,t,g, or c
<400> 437
cttgctcaat gacgccqtca ctgtggtcct gtatcacctc tttgaggagt ttgccaacta 60
cgaacacgtg ggcatcgtgg acatcttcct cggcttcctg agcttcttcg tggtggccct 120
gggcggggtg cttgtgggcg tggtctacgg ggtcatcgca gccttcacct cccgatttac 180
ctcccacatc cgggtcatcg agccgctctt cgtcttcctc tacagctaca tggcctactt 240
gtcagecgag ctcttccacc tgtcaggcat catggcgctc atagcctcag gagtggtgat 300
gegneectat gtgggangee aacaetteea caagtteeca caacaacate aaataattte 360
                                                                   390
ctggaagatg tnggagcagc gtcannaagn
<210> 438
<211> 234
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
```

```
<222> (1)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (21)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (24)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (47)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (82)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (114)
<223> n equals a,t,g, or c
<400> 438
neceeggact tttagtgtaa ngenectace eeetgeaggt aceggtnegg aatteeeggg 60
tttgactcca cgcgttttgc tncattaaca acataaaacc ctcatggaca cganaaaaca 120
contrate catacaccta toccocatto tectectate ceteaacce garateatta 180
234
<210> 439
<211> 144
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (1)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (2)
<223> n equals a,t,g, or c
<220>
<221> misc feature
```

```
<222> (36)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (43)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (105)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (114)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (135)
<223> n equals a,t,g, or c
<400> 439
nnctatcgat ggggagcaag agtcttttaa ataagnccat ttnagtccct ggttaacaag 60
ggtttaaagt ggagcgaatg cacatcacag acatgaaatt ggctnacctg cctngcttag 120
                                                                   144
aagcccttgg tgttnaggtc aaca
<210> 440
<211> 411
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (69)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (86)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (132)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (209)
```

```
<223> n equals a,t,q, or c
<220>
<221> misc feature
<222> (230)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (246)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (276)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (340)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (346)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (390)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (404)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (410)
<223> n equals a,t,g, or c
<400> 440
gccaaggtcc accccaactc tgtgcacatc tgtgcggtgg ttgtggagta cgagaccaag 60
gctggccgna tcaacaaggg cgtggncacc aactggctgc gggccaagga gcctgccggg 120
gagaacggcg gncgcgcgct ggtgcccatg ttcgtgcgca agtcccagtt ccgcctgccc 180
ttcaaggcca ccacgcctgt catcatggng ggccccggca ccggggtgtn acccttcata 240
ggcttnatcc aggagcgggc ctggctgcga cagcanggca aggaggtggg ggagacgctg 300
ctgaactacg gctgccgccg ctcggatgag gactacctgn accggnagga gctggcgcag 360
ttccacaggg acggtgcgct cacccagctn aacgtggcct tctnccgggn a
                                                                   411
```

```
<210> 441
<211> 623
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (9)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (73)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (141)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (162)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (232)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (252)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (289)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (360)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (365)
<223> n equals a,t,g, or c
<220>
```

```
<221> misc feature
<222> (407)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (435)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (449)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (472)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (495)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (502)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (504)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (509)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (538)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (560)
<223> n equals a,t,g, or c
<220>
<221> misc feature
```

```
<222> (586)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (587)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (619)
<223> n equals a,t,g, or c
<400> 441
gccagcagne accacagege etgetteete ggeeetgaaa teatgeeeet aggteteetg 60
tggctgggcc tanccetgtt gggggctctg catgcccagg cccaggactc cacctcagac 120
ctgateccag ecceaectet nageaaggte ectetgeage anaactteca egacaaccaa 180
ttccacggga agtggtatgt ggtacgcctg gcacggaatg caattctcag anaacacaaa 240
gaccegcaaa anatgtatge caccatetat gagetgaagg aaacaagane tacaatgtee 300
ctccgcctgt ttaagaaaaa aaaatgtgac tacttggatc aggaattttg gtccaaggtn 360
gccancegge gaattecace ttggggacet ttaaaattge ettggantaa ecaattteet 420
ccttccaatt gttancacca attacaacng ccttcttttg gttttcttcc anaaaatttc 480
tccaaacaag gaatnettee ananeeene tteeggaaaa acaaggaatt aatteegnae 540
ttaaaggaaa aattotoogn totoocattt ottgggooco otaaannoaa attogtotto 600
ccttttccaa ccaacattnt ttt
                                                                    623
<210> 442
<211> 211
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (47)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (58)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (77)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (93)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (121)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (131)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (178)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (195)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (207)
<223> n equals a,t,g, or c
<400> 442
tgggcagcca cactgcacgc aggctgggcc gactgagggg ctcagangcc aggctctnag 60
gcccacgcag ggcctanggt gggaagatgg cangtggggg cggcgacctg agcaccagga 120
ngctgaatga ntgtatttca ccagtagcaa atgagatgaa ccatcttcct gcacacancc 180
                                                                    211
acgatttgca aaggntgttc acggaanacc a
<210> 443
<211> 399
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (316)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (347)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (358)
<223> n equals a,t,g, or c
```

```
<220>
 <221> misc feature
 <222> (376)
 <223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (391)
<223> n equals a,t,g, or c
<400> 443
gtctgagtgg atggacactg cctcttagaa ctagaactta gaactttatc ttgaaaatgt 60
accactgttg cagaagetee teacagagta tgtgteagge atttttaace tgetaaagge 120
aagaagaagt gttcaccaca tagttgcaaa ggtcttcaac ttgccacagc caacagaaaa 180
aaatgctttt qaqqaaaatc ataaaaaqac aqqaaqacat cataaqacat ttctqqatca 300
tctcaaagtg tgttgnaact gttccccaca aaaggcaaga gaattgncct ctctttgntt 360
cccatagcat tttggntgcc agcataccgg nttaaagaa
<210> 444
<211> 465
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (376)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (390)
<223> n equals a,t,g, or c
<400> 444
gcgggactcc aaatgggtcg cagtcgcagc cgctctccac ggagggaacg taggcgttcc 60
cggtccacat cccgggagag agaacgcagg cgccgagaaa ggtccaggtc tcgggagaga 120
gatoggagaa ggagoogoto gogatocoog cacogaagao gotocogato tocaagaoga 180
catagatcca catctccttc cccttctcga ctgaaagaaa gaagagatga ggaaaagaaa 240
gaaacaaaag aaacaaagag caaagaacgg cagattactg aggaagactt agagggcaaa 300
acagaggaag aaatagaaat gatgaagtta atgggatttg cctcctttga ctccacaaaa 360
ggtaagaagg tggatngctc tgtaaatqcn tatgccataa atgtctctca gaagaggaag 420
tacaggtatg catagccccc atttttgttt gaactaataa atcag
                                                                465
<210> 445
<211> 297
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
```

```
<222> (7)
<223> n equals a,t,g, or c
<400> 445
ggcagtntct ctgccaggct ggggatgatt ccaatagtaa taagaagaat gctgacctcc 60
aagtgctaaa gcccgagccc gagctggttt atgaagacct gaggggctca gtgaccttcc 120
actgtgccct gggccctgag gtggcaaacg tggccaaaat tctgtctggc agagagtggg 180
gaaaagacgc ggtttccagc ttgcagattt gttaagtttc tcaggcagat tttgactttc 240
agcctttcat acttgtttaa gcaactattt gtattaaatg aagttttttg aaaaaca
<210> 446
<211> 448
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (21)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (22)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (24)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (306)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (366)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (369)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (435)
<223> n equals a,t,g, or c
<220>
```

```
<221> misc feature
<222> (440)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (448)
<223> n equals a,t,g, or c
<400> 446
tcgacccacg cgtccgccga nnanagtttg gttttgcgga ttgccaccga tgattccaaa 60
gcagtctgtc gcctcagtgt taaattcggg gccacactca aaatcagcag gcttctcttg 120
gaacgggcga gagagctgaa tattgacatc atcggtgtca gcttccacgt gggaagtggc 180
tgcaccgatc ctggagacct tcgtgcaagc catctccgat gcccgctgtg tcttcgacat 240
ggggagctga ggttggtttc aacatgtatc tgcttgatat cggtggtggg ctttcctggg 300
atctgnagga tgtgaaactt aaatttggaa gagatcacca tgttatcaac ccagccctgg 360
gacaantant tocogggoog aattogggog tggacattoa tagoogagoo cgggoaggat 420
aattaagttg gcttncagcn ttcaagcn
<210> 447
<211> 268
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (10)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (21)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (36)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (43)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (45)
<223> n equals a,t,g, or c
<220>
<221> misc feature
```

```
<222> (60)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (99)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (132)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (135)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (140)
<223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (141)
 <223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (159)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (183)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (192)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (206)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (222)
```

```
<223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (243)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (260)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (262)
 <223> n equals a,t,g, or c
<400> 447
ggcacgaggn agtgtcccag ncgggttcgt gtcgcnatgg ggnanatcga gtgggccatn 60
tgggccaacg agcaggcgct ggcgtccggc ctaatcctna tcaccggggg catcgtggcc 120
acagctgggc gnttnacccn ntggtacttt ggtgcctant ccattgtggc gggcgtgttt 180
gtntgcctgc tngagtaccc ccgggnaaag aggaagaagg gntccaccat ggtgcgatgg 240
ggncagaagt acatgaccgn cntggtga
<210> 448
<211> 425
<212> DNA
<213> Homo sapiens
<400> 448
gacaccttca teegteacat egecetgetg ggetttgaga agegettegt acceagecag 60
cactatgtac atgttcctgg tgaaatggca ggacctgtcg gagaaggtgg tctaccggcg 120
cttcaccgag atctacgagt tccatctccc aagtggtttg acgggcagcg ggccgccgag 180
aaccaccagg gcacacttac cgagtactgc ggcacgctca tgagcctgcc caccaagatc 240
tecegetyte eccacetect egacttette aaggtgegee etgatgacet caageteece 300
acggacaacc agacaaaaa gccagagaca tacttgatgc ccaaagatgg caagagtacc 360
gcgacagaca tcaccggccc catcatcctg cagacgtacc gcgccattgc caactacgag 420
aagac
                                                                   425
<210> 449
<211> 88
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (25)
<223> n equals a,t,g, or c
<220>
<221> misc feature
```

```
<222> (26)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (71)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (73)
<223> n equals a,t,g, or c
<400> 449
tcgttgccct gttactgtct gtggnnatgt gcatggtcaa tttcatgatc ttatggaact 60
ctttagaatt ngnggaaaat caccggat
<210> 450
<211> 214
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (8)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (26)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (31)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (49)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (53)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (68)
<223> n equals a,t,g, or c
```

```
<220>
 <221> misc feature
 <222> (71)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (75)
 <223> n equals a,t,g, or c
<220>
<221> misc feature
 <222> (89)
 <223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (91)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (102)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (108)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (113)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (114)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (141)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (154)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (193)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (204)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (205)
<223> n equals a,t,g, or c
<400> 450
atctccantg gaaccacgtt gtggcngatg ntggggcttt cctgcggtnc aangagccct 60
taccgganta ngtgnggatg gtgactgant nttcaaataa antacganac tgnnccaacc 120
tototgocac ggacatocaa ntgottgoac gcanatacca gttggaagca gagtttgttg 180
                                                                   214
gggtgtctca acnaaaagtt gagnnaagca acgt
<210> 451
<211> 473
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (370)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (444)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (469)
<223> n equals a,t,g, or c
<400> 451
gcggacgcgt ggggcaagac ttttgcccgg tacctttcat tccggcgtga caacaatgag 60
ctgttgctct tcatactgaa gcagttagtg gcagagcagg tgacatatca gcgcaaccgc 120
tttggggccc agcaggacac tattgaggtc cctgagaagg acttggtgga taaggctcgt 180
cagatcaaca tocacaacot ototgoattt tatgacagtg agotottcag gatgaacaag 240
ttcagccacq acctqaaaaq qaaaatqatc ctgcagcagt tctgaggccc tatgccatcc 300
ataaggattc cttgggattc tggtttgggg tggtcagtgc cctctgtgct ttatggacac 360
aaaaccagan cacttgatga actcggggta ctagggtcag ggcttatagc aggatgtctg 420
                                                                  473
gctgcacctg gcatgactgt ttgnttctcc aacctgcttt gtgcttctna cct
```

```
<210> 452
<211> 397
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (29)
<223> n equals a,t,g, or C
<220>
<221> misc feature
<222> (225)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (330)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (376)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (385)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (387)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (389)
<223> n equals a,t,g, or c
<400> 452
gggtcgaccc acgcgtccgc ccacgctcnc gcttgcttgg acatcaggta ccaactgcac 60
togttttggc attgcagcta aatatcagtt ggatcccact gcttccattt ctgcaaaagt 120
caacaactet agettaattg gagtaggeta tactcagact etgaggeetg gtgtgaaget 180
tacactctct ggctctggta gatgggaaga gcattaaatg ctggnaggcc acaaggttgg 240
ggctcgccct gggagttggg aggcttaatc cagctgaaag aaacctttgg ggaatgggat 300
atccagaaga tttgggcctt aatataattn ccattgtgga ccagcagcag gctttttttc 360
                                                                    397
ccccaagaa gattgntcca aaccnangnt gatctcc
<210> 453
```

<211> 463

```
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (315)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (393)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (404)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (426)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (435)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (453)
<223> n equals a,t,g, or c
<400> 453
ggcaagatgg tgttgcagac ccaggtcttc atttctctgt tgctctggat ctctggtgcc 60
tacggggaca tcgtgatgac ccagtctcca gactccctgg ctgtgtctct gggcgagagg 120
gccaccatca actgcaagtc cagccagagt gttttataca gctccaacaa taagaactac 180
ttaacttggt accagcagaa accaggacag cctcctaagc tgctccttta ctgggcatct 240
accogggaat coggggtoco tgacogatto agtggcagog ggtotgggao agatttoact 300
ctcaccatca gcagnctgca ggctgaagat gtggcagatt attactgtca gcaatattat 360
actactccct ggacgttcgg ccactggacc aangtggaaa tcanacgaaa ctgtggctgc 420
accatntgcc tcatntttcc gccatctggt gancagttga aat
                                                                   463
<210> 454
<211> 332
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (95)
```

```
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (332)
<223> n equals a,t,g, or c .
<400> 454
tggctcatct tggctgtgat ttcagtatat gatttagtgg ctgttttgtg tccgaaaggt 60
ccacttcgta tgctggttga aacagctcag gaganaaatg aaacgctttt tccagctctc 120
atttactcct caacaatggt gtggttggtg aatatggcag aaggagaccc ggaagctcaa 180
aggagagtat ccaaaaattc caagtataat gcagaaagca cagaaaggag tcacaagaca 240
ctgttgcaga gaatgatgat ggcgggttca gtgaggaatg ggaagcccag aaggacagtc 300
atctagggcc tcatcgctct acacctgaat cn
<210> 455
<211> 429
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (4)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (11)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (12)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (99)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (105)
<223> n equals a,t,q, or c
<220>
<221> misc feature
<222> (107)
<223> n equals a,t,g, or c
```

<220>

```
<221> misc feature
<222> (109)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (143)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (148)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (158)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (172)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (243)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (271)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (274)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (292)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (314)
<223> n equals a,t,g, or c
<220>
```

<221> misc feature

```
<222> (346)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (382)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (392)
<223> n equals a,t,g, or c
<400> 455
ggcnagtagt nnggggtccc agggtttgtt tttaaagtag tgacttctac caacatgtcc 60
cgtggttcca gagagcggtt ttgaccgcca cattaccant ttttnancng agggtcggct 120
ctaccaagta ggaatatgct ttnaaggnta ttaaccangg tggacttaca tnagtagctg 180
atcagcggga aagactgtgc agtaattgtc acacagaaga aagtacctga caaattattg 240
gantocagoa cagtgactoa ottattoaag ntanotggaa acattggttg tntgaagaco 300
ggaatgtcag ctgncagcag atcccaggta cagagggcac gctatnaggc agctaacttg 360
gaatacaagt atggctatga gnttcctgtg gncatgcctg tgtaaaagga tttccggtat 420
ttctcaggt
                                                                    429
<210> 456
<211> 623
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (38)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (352)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (482)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (516)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (540)
```

```
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (554)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (570)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (588)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (604)
<223> n equals a,t,g, or c
<400> 456
tggcggcttc cttcacccgc aacccgagag acgacccncc gggcccgccc cgcggaagcc 60
gccggttgcc aggccaagga gtggactagg gtcgccgggg aagcggtttg ggagagccca 120
tggtgactgc gtgagtggag cccagctgtg tggatgcccc agcatggatg actacatggt 180
cctgagaatg attggggagg gctcgttcgg cagagctctt ttggttcaac atgaaagcag 240
taatcaagat gtttgccatg aaagaaataa ggcttccaag tctttctcta atacacagaa 300
ttctaggaag gaggctgttc ttttagccaa aatgaaacac cctaatattg gngccttcaa 360
agaatcattt gaaagctgca ggacacttgt atattgtgat ggaatactgt gatggacggg 420
atctaatgca aaagattaaa cagcagaaaa ggaaaagtta tttcctgaag acatgatact 480
tnaatggttt acccaaatgt gccttggagt aaaatnacat ttaccaagaa acgtgtgctn 540
cccaagagat tttnaaagtc ccaaaaaatn tttttcctta acctcaanaa ttgggaaaaa 600
                                                                   623
gttnaaaatt ggggaaaaac ttt
<210> 457
<211> 441
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (5)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (13)
<223> n equals a,t,g, or c
<220>
```

```
<221> misc feature
<222> (16)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (20)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (28)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (185)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (223)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (233)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (250)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (391)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (399)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (417)
<223> n equals a,t,g, or c
<220>
```

<221> misc feature

```
<222> (432)
<223> n equals a,t,g, or c
<400> 457
atcongaaac tgnaancogn tgtgtcanct gaaaaaccat toggtgtgtc tgcacttgga 60 -
ggctgcactt gcttgcttcc acttatgctt gttctcagaa cacaaacaaa acctgtgaag 120
agtgcctgaa aaacgtctcc tgtctttggt gcaacactaa caagcttgtc ttggactacc 180
agttncaaag tottgccacc ggottccctt tgttaattaa ctncttgcac ctngggaatt 240
ttgttgggtn aaacttagaa gcgctgaatc atcacatgtt cggtagtccg gggaaccctc 300
ctcctggggc attggcatct gctgcttgct tgcttgctgc aagaagaaaa aaagaacccg 360
aaacccggac aggaattaaa gaaaaaaggc nttgcgttna accggaaaga aaaagcngaa 420
taccggccgg angaacggaa a
<210> 458
<211> 419
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (1)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (8)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (252)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (278)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (306)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (402)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (404)
```

```
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (408)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (409)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (410)
<223> n equals a,t,g, or c
<400> 458
netteetnta ggageaggag ggatgageaa gggteteeca gegegaeagg acatggagaa 60
agagcgagag actctgcagg cctggaagga gcgcgtgggg caggagctgg accgcgtggt 120
ggctttctgg atggagcact cccacgacca ggagcacggg ggcttcttca cgtgccttgg 180
ccgcgagggg cgggtgtatg atgacctcaa gtatgtgtgg ctgcagggga ggcaggtatg 240
gatgtattgt engeetgtae egeaettteg agegettneg ecatgeteag ettetggaeg 300
cagcanaagc aggtggtgag ttcttgctgc ggtatgcccg ggtggcacct tctggcaaga 360
agtgtgcctt tgtgctgact cggtgacggc cgcccggtca angngcannn aaccatctt 419
<210> 459
<211> 509
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (21)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (40)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (284)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (308)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (331)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (369)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (377)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (393)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (405)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (410)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (414)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (419)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (424)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (440)
<223> n equals a,t,g, or c
<220>
```

```
<221> misc feature
<222> (472)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (485)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (490)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (493)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (499)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (502)
<223> n equals a,t,g, or c
<400> 459
aattoggcac gagotgaagt nactgatgag tataaaaaatn atgtaaaaaa cagatotgtt 60
tatattaaag gcttcccaac tgatgcaact cttgatgaca taaaagaatg gttagaagat 120
aaaggtcaag tactaaatat tcagatgaga agaacattgc ataaagcatt taagggatca 180
atttttgttg tgtttgatag cattgaatct gctaagaaat ttgtagaggc ccctggccag 240
aagtacaaag aaccagacct gctaatactt ttcaaggccg gttnctttgc caaaaaatga 300
ggaagaanca aataagtgga gctaattagg nttacagggc agagcaacca agttgaggag 360
tcctgatgna ctctggngaa gttggtcctt ctnatttcgg ggttngtgcn gccntgggng 420
tteneacttt teateagggn taatgtgete eeaggeeagg gtttttttag aneeggettg 480
                                                                   509
tacongtoan tgncccotng enggtottg
<210> 460
<211> 468
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (20)
<223> n equals a,t,g, or c
<220>
```

```
<221> misc feature
<222> (445)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (450)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (459)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (465)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (468)
<223> n equals a,t,g, or c
<400> 460
cgccttttgg taccggtccn gaattcccgg ggcttccctc ctcttccttt cttcgccatc 60
gtggtgtgtt cttgactccg ctgctcgcca tgtcttctca caagactttc aggattaagc 120
gatteetgge caagaaacaa aagcaaaate gteecattee eeagtggatt eggatgaaaa 180
ctggaaataa aatcaggtac aactccaaaa ggagacattg gagaagaacc aagctgggtc 240
tataaggaat tgcacatgag atggcacaca tatttatgct gtctgaaggt cacgatcatg 300
ttaccatatc aagctgaaaa tgtcaccact atctggagat ttcgacgtgt tttcctctct 360
gaatctgtta tgaacacgtt ggttggctgg attcagtaat aaatatgtaa ggcctttctt 420
tttaaaaaaa aaaaaaaaa aaaanaaaan acaaaaaana tcaanaan
                                                                   468
<210> 461
<211> 580
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (9)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (18)
<223> n equals a,t,g, or c
<220>
<221> misc feature
```

```
<222> (54)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (249)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (340)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (427)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (433)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (452)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (462)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (466)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (470)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (472)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (478)
```

```
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (509)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (510)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (556)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (567)
<223> n equals a,t,q, or c
<220>
<221> misc feature
<222> (575)
<223> n equals a,t,q, or c
<400> 461
gggggggng ggggggtntt aggtttgcct aaaaatattt aggtgacact atanaaggta 60
cgcctgcagg taccggtccg gaattcccgg gtcgacccac gcgtccgtcg acccacgcgt 120
cogoccacgo gtocgoccac gogtocgocc acgogtocgo tgtgtogtaa aatgggggto 180
ccttactgca ttatcaaggg aaaggcaaga ctgggacgtc tagtccacag gaagacctgc 240
accactging ccttcacaca ggigaactcg gaaagacaaa ggcgcttigg ctaagciggt 300
ggaagctatc aggaccaatt acaatgacag atacgatgan atccgcccgt ccactggggt 360
tggcaatgtt ccctgggtcc ctaattcttg ttgctccgta tcgcccaact ccgaaaaagg 420
caaaagntta aanaactttg ccacttaaac tngggttaaa tnttcnctgn tnaatttncc 480
580
ggggggccc ttaaanattc cccccnaag gggcnaatta
<210> 462
<211> 549
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (3)
<223> n equals a,t,g, or c
<220>
<221> misc feature
```

```
<222> (5)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (8)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (11)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (13)
<223> n equals a,t,g, or c
<400> 462
acngnganac nanceteact aaagggaaca aaagetggag etecacegeg gtgeggeege 60
tctagaacta gtggatcccc cgggctgcag gaattcggca cgaggcgccg ccacaatggt 120
gcgcatgaat gtcctggcag atgctctcaa gagtatcaac aatgccgaaa agagaggcaa 180
acgccaggtg cttattaggc cgtgctccaa agtcatcgtc cggtttctca ctgtgatgat 240
gaagcatggt tacattggcg aatttgaaat cattgatgac cacagagctg ggaaaattgt 300
tgtgaacctc acaggcaggc taaacaagtg tggggtgatc agccccagat ttgacgtgca 360
actcaaagac ctggaaaaat ggcagaataa tctgcttcca tcccgccagt ttggtttcat 420
tgtactgaca acctcagctg gcatcatgga ccatgaagaa gcaagacgaa aacacacagg 480
agggaaaatc ctgggattct ttttctaggg atgtaataca tatatttaca aataaaatgc 540
ctcatggac
                                                                   549
<210> 463
<211> 480
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (7)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (130)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (320)
<223> n equals a,t,g, or c
<220>
```

```
<221> misc feature
<222> (410)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (416)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (450)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (455)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (456)
<223> n equals a,t,g, or c
<400> 463
gcctctngcg ggccctgttc aagcggaatc ctgccaaccg gctcggctcc ggccctgatg 60
gggcagagga aatcaagcgg catgtcttct actccaccat tgactggaat aagctatacc 120
qtcqtqaqan cacqccaccc ttcaaqccag cagtggctca gcctgatgac accttctact 180
ttgacaccga gttcacgtcc cgcacaccca aggattcccc aggcatcccc cccagcgctg 240
gggcccatca gctgttccgg ggcttcagct tcgtggccac cggcctgatg gaagacgacg 300
gcaagcctcg tgccccgcan gcacccctgc actcggtggt acagcaactc catgggaaga 360
acctggtttt tagtgacggc tacgtggtaa aggagacaat tggtgtgggn tcctantctg 420
agtgcaagcg ctgtgtccac aaagggccan aacannaata atgcaatagg ggaggtaaca 480
<210> 464
<211> 220
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (16)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (17)
<223> n equals a,t,g, or c
<220>
<221> misc feature
```

```
<222> (18)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (30)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (42)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (58)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (63)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (67)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (72)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (105)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (129)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (147)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (157)
```

```
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (170)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (213)
<223> n equals a,t,g, or c
<400> 464
agggacacgt cccatnnngt ggcgggcgcn ctgcggccct tngtgcaggc cacggtgncc 60
genacengaa gneageetgt tttggaceta aageggeeet teetnageeg ggagtegetg 120
ageggeeang cetgegateg acttgtngte gacteentgg gtgeteaatn teeetgette 180
                                                                    220
tttttgttaa ttcccacaca gacatcaagg tgnctgattt
<210> 465
<211> 438
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (330)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (366)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (383)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (403)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (414)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (428)
```

```
<223> n equals a,t,g, or c
<400> 465
ataggcatga gccaccacgc caggccggga atgccctatt ctaattcaca taaagactcc 60
atgtgggcta gcaggcatgt gaaatgtctg ccagtgcatc aacagctata taactaagaa 120
gttatctttt tcactgtctt ctggtactct tcatttcact tgggtttttt agcaattcag 180
gaagetggaa tgtttgaatg ggttttaget tgatacette ttetttttee catttggeag 240
ataataccac tagtctgacg gataaacacc tggacccaat cagggaaaat ctgggaaagc 300
actgggaaaa actgtgcccg taaactgggn ttcacacagt ctcagattga tgaattgacc 360
atgacnatga gcgagatgga tgnaagaaag gttaccagat gcnccaaaat gggngatgag 420
gaaggctnaa ggggcccg
<210> 466
<211> 127
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (21)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (53)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (87)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (94)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (118)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (122)
<223> n equals a,t,g, or c
<400> 466
gcacgattca tgcaaaaagg naactaagca ctatgagatg cttgctaatc gancagctgc 60
aaatggtcac tgcattgata tttatgnttg tgcncctgat caaactggac ttttgganct 120
```

127

gnagtgt

```
<210> 467
<211> 439
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (40)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (194)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (295)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (409)
<223> n equals a,t,g, or c
<400> 467
gctggaatct ttacaggaga accacttcca agaagatgan cagtttctgg gagccgttat 60
gccaaggett ggcattggaa tggatacttg tgtcatteet ttgaageaeg gtgggettte 120
cttggttcaa accacagatt acatttaccc gatcgtagac gacccttaca tgatgactcc 180
tgcagttgct gaantcaggc ctgtcccctg cccacacttg gcactgggca taaagcaatt 240
agggaggaag caggaaagcc ctctgctgct gttgcaactg aatacatgct ggcangataa 300
catgtgccaa tgtcctcagt gactctatgc aatgggggtc acggaatgtg acaatatgct 360
gatgctcctt ggaatcataa taaaatgacc gacaggaaaa ggataaatna tcctctgatt 420
atccaaggtt ttaaaacca
<210> 468
<211> 484
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (350)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (399)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (412)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (415)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (449)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (463)
<223> n equals a,t,g, or c
<400> 468
gagcaggece gttggaagtg gttgtgacaa ceceageaat gtggagaage etggggettg 60
cctggctctc tgtctcctcc catcgggagg aacagagagc caggaccaaa gctccttatg 120
taagcaaccc ccagctggac ataagagatc aagatcaatg ctaaactcca atggttcagt 180
gactgtggtt gtcttcttca agccagctga tacctgtcat actgcaggca tctaaattag 240
aaacctgcga qtaaaactga agaaagaagg atattctaat attcttatat tgtgtaatat 300
taaggaatct cttctcgata aaatcacaca tctaagaata aggttaaaan atatttctgt 360
tataccagaa gaaacaacaa tgctgactct ttaatgaana aatactctat antanatggg 420
cgctgaatac tgttgctttc tcacttcang aaaacataat gtntgaaaat ggacgtttca 480
                                                                    484
ttaa
<210> 469
<211> 489
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (308)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (348)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (368)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (371)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (387)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (417)
<223> n equals a,t,g, or c
<220> ·
<221> misc feature
<222> (420)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (458)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (468)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (477)
<223> n equals a,t,g, or c
<400> 469
cgcctggcga ttaccggtct caccatggag cggaaagtgc ttgcgctcca ggcccgaaag 60
aaaaggacca aggccaagaa ggacaaagcc caaaggaaat ctgaaactca gcaccgaggc 120
tetgeteece actetgagag tgatetaeca gageaggaag aggagattet gggatetgat 180
gatgatgagc aagaagatcc taatgattat tgtaaaggag gttatcatct tgtgaaaatt 240
ggagatctat tcaatgggag ataccatgtg atccgaaagt taggctgggg acacttttca 300
acagtatngg ttatcatggg gtattccagt taagttttaa ttggttcntg taaaaagatt 360
agttaganga ngtotaaaag ggtttgnotg agttocatgg tggacocagg ttcaacnacn 420
ctagccggtc cattaccaga atttgttgtt ggcaaagncc cgatcctngg ggaaccnttt 480
                                                                    489
ctttcggaa
<210> 470
<211> 318
<212> DNA
<213> Homo sapiens
```

```
<220>
<221> misc feature
<222> (2)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (12)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (21) -
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (32)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (73)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (102)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (103)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (106)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (114)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (151)
<223> n equals a,t,g, or c
```

<220>

. 1

```
<221> misc feature
<222> (188)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (223)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (258)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (264)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (280)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (281)
<223> n equals a,t,g, or c
<400> 470
cntcactata tntgaggagc nggtaccct gnaggtaccg gtccggaatt cccgggtcga 60
cccacgcgtc cgntatgaca acctgatcac accagccatg annggngccg gctncctgca 120
ggggaacgtc gattcttgcc agggtgacag nggagggcct ctggtcactt cgaagaacaa 180
tatctggngg ctgatagggg atacaagctg gggttctggc tgngccaaag cttacagacc 240
aggagtgtac gggaatgnga tggnattcac ggactggatn natcgacaaa tgagggcaga 300
                                                                    318
cggctaatcc acatggct
<210> 471
<211> 455
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (306)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (417)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (426)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (431)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (440)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (446)
<223> n equals a,t,g, or c
<400> 471
ggagtataca ccatgagcaa agctcaccct cccgagttga aaaaatttat ggacaagaag 60
ttatcattga aattaaatgg tggcagacat gtccaaggaa tattgcgggg atttgatccc 120
tttatgaacc ttgtgataga tgaatgtgtg gagatggcga ctagtggaca acagaacaat 180
attggaatgg tggtaatacg aggaaatagt atcatcatgt tagaagcctt ggaacgagta 240
taaataatgg ctgttcagca agagaaaccc atgtcctctc tccatagggc ctgttttact 300
atgatnttaa aaattaagto atgtacattt toatattaaa otttttgtta aataaacttt 360
tgtaataatc aaaaaaaaa aaaaaaaaa aaacccaagg gggggcccgg tccccantcc 420
                                                                   455
cccctntttt nattcctttn aaaatnccct ggccc
<210> 472
<211> 676
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (605)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (669)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (672)
<223> n equals a,t,g, or c
```

```
<400> 472
gctccaggag tgggacggag ggagctggcc gggatgaagt ctgagactat gtcctgagaa 60
gaaagagtgt atcgtattgg ttgaaaagtt ggtggggtcg ggcttaagcg gaggaggggg 120
ctctctggcc cttactcggc agatgggccc ggagagaga cgggaggtgc cgggagaaca 180
tcgagggacc ggtggaggaa gggtagctgg atgagttttg attcatcatg gataatctgt 240
catcagaaga aattcaacag agagctcacc agattactga tgagtctctg gaaagtacga 300
ggagaatcct gggtttagcc attgagtctc aggatgcagg aatcaagacc atcactatgc 360
tggatgaaca aaaggaacaa ctaaaccgca tagaagaagg cttggaccaa ataaataagg 420
acatgagaga gacagagaag actttaacag aactcaacaa atgctgtggc ctttgtgtct 480
gcccatgtaa tagaacaaag aactttgagt ctggcaaggc ttataagaca acatggggag 540
atggtggaga aaactcacct tgcaatgtag tatctaaaca gccaggcccg gtgacaaatg 600
gtcancttta gcaaccaaca acaggagcag ccagtggtgg atacattaaa cccataacta 660
                                                                   676
atgateceng anaaga
<210> 473
<211> 512
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (1)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (403)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (457)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (487)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (495)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (500)
<223> n equals a,t,g, or c
<220>
```

<221> misc feature

```
<222> (506)
<223> n equals a,t,g, or c
<400> 473
ntcgacagaa gggtacggct gcgagaagac gacagaaggg tacggctgcg agaagacgac 60
agaagggggc agcatggcgt acccggggca tcctggcgcc ggcggcgggt actacccagg 120
cgggtatgga ggggctcccg gagggcctgc gtttcccgga caaactcagg atccgctgta 180
tggttacttt gctgctgtag ctggacagga tgggcagata gatgctgatg aattgcagag 240
atgtctgaca cagtctggca ttgctggagg atacaaacct tttaacctgg agacttgccg 300
gcttatggtt tcaatgctgg atagagatat gtctggcaca atgggtttca atgaatttaa 360
agaactctgg gctgtactga atggctggag acaacacttt atnaattttt gacactgcag 420
gaatggaaca agtagaccca caagaattgg ataaagnccc tgacaacaat gggatttaag 480
gtttgantcc ccaanctggn gaattnaatt gc
<210> 474
<211> 272
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (18)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (59)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (69)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (74)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (104)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (122)
<223> n equals a,t,g, or c
<220>
```

<221> misc feature

```
<222> (129)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (150)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (185)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (186)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (191)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (234)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (249)
<223> n equals a,t,g, or c
<400> 474
ggcacagogg cgggccongt cgtccggcgg ttgcggatgt cgggctgggc ggacgagcnc 60
ggcgtcgang gccnacgggc gcatctacgt ggggaacttc cgancgacgt gcgcgagaag 120
gnacttggna ggacctgttc tacaagtacn gccgcatccg cgagatcgag ctcaagaacc 180
ggcanncctc ntcctgtcgg ccttcgtgcg cttcgaggaa cccccgagat gcanaggatg 240
                                                                   272
ctatttatng gaagaaatgg ttatgattat gg
<210> 475
<211> 338
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (1)
<223> n equals a,t,g, or c
```

```
<221> misc feature
<222> (8)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (15)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (16)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (36)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (119)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (127)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (170)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (173)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (204)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (250)
<223> n equals a,t,g, or c
<220>
<221> misc feature
```

```
<222> (284)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (298)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (308)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (318)
<223> n equals a,t,g, or c
<400> 475
naatetengt ttggnnggee egecegeagg teeggneegg aacteeeggg tegaceeaeg 60
cgtccggcta ccattctgaa acaaatgcaa gtattacatc cagcagccag aatgctggng 120
gagctgncta aggctcaaga tatagaagca ggagatggca ccacatcagn agncatcatt 180
gctggctccc tcttagattc ttgnaccaag cttcttcaga aagggattca tccaaccatc 240
atttctgagn cattccagaa ggccctggaa aagggcattg aaancttgac tgacatgnct 300
                                                                   338
cgacctgngg aactgagnga cagagaaact ttggtaaa
<210> 476
<211> 424
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (330)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (378)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (381)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (388)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (424)
<223> n equals a,t,g, or c
<400> 476
ttaagttcat gaattccaga gttttcaaga aaattcaagc tttgaaggct tcaccgtcta 60
agaaacggtg caattcaatc gccgccctaa aggccacttc acaggagatt gtgtcctcaa 120
ttagccagga atggaaggat gagaagcggg atttgctgac tgaaggacaa agttttagca 180
gccttgatga agaagccctg ggatcccgac acaggccaga cctggtccct agcactccat 240
cactgtttga agctgcttcc ttggcaacca caatttcact tcttcctata cgtcaatggg 300
cattatccac aagacaaggc ctacaatttn ttcaaaccag gtaatatttt ggtgcaattc 360
aaattaaccc ttcaaggntt nttaaccnca atcaaccatt agggcctgaa cccgtttttt 420
ttgn
<210> 477
<211> 228
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (6)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (71)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (110)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (111)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (153)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (157)
<223> n equals a,t,g, or c
```

```
<221> misc feature
<222> (165)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (207)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (223)
<223> n equals a,t,q, or c
<400> 477
ggcatncatg tetteagaaa catecataag accaatetet gtgatettat caccageett 60
ttgtgccttt nggttctttt gccaaccaaa gaactcaatg aacacttctn ntccaagctt 120
aaggcaccga ttcctattga acttgttgtt gtngtancag ccacnttaac ctctcatttt 180
                                                                    228
ggaaaactac atgaaaatta taattcnagt attgctggac atnttccc
<210> 478
<211> 486
<212> DNA
<213> Homo sapiens
<400> 478
aactagtoto gaacggccco goggacacgo tggatotgao otactggatt gaoggcacco 60
ggcatgtggt ctccctggag gacgtcggcc tggctgactc gcagtggaag aacgtcaccg 120
tgcaggtggc tggcgagacc tacagcttgc acgtgggctg cgacctcata gacagcttcg 180
ctctggacga gcccttctac gagcacctgc aggcggaaaa gagccggatg tacgtggcca 240
aaggetetge cagagagagt cactteaggg gtttgettea gaacgteeac ctagtgtttg 300
aaaactctqt qqaaqatatt ctaaqcaaqa agggttgcca gcaaggccag ggaggtaggt 360
gtgttgtgaa aaatgcattt tatatactgg cttggatgga tttctattgt gacatggtgt 420
atgtgtgtgt gtgtatgtgt gtgcattcat gcttgtaaaa atttaagtaa aaatatttgg 480
gtaact
<210> 479
<211> 524
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (70)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (369)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (409)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (432)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (471)
<223> n equals a,t,g, or c
<400> 479
ggtgcctgct gcctcaaacc accttgtgta aaatctgcaa tacggcttct tccatgtacc 60
tgtgcctgan ctgtctgcaa taaagaagaa tttgtaaaaa aacggcacct cgctttgctt 120
ttcctccgca accatgtctg acaaacccga tatggctgag atcgagaaat tcgataagtc 180
gaaactgaag aagacagaga cgcaagagaa aaatccactg ccttccaaag aaacgattga 240
acaggagaag caagcaggcg aatcgtaatg aggcgtgcgc cgccaatatg cactgtacat 300
tccacaagca ttgccttctt attttacttc ttttagctgt ttaactttgt aagatgcaaa 360
gaggttggnt caagtttaaa tgactgtgct gcccctttca catcaaagna ctactgacaa 420
cgaaggccgc gnctgccttt cccatctgtc tatctatctg gctggcaggg naggaaagaa 480
                                                                   524
cttgcatgtt ggtgaaggaa gaagtggggt ggaagaagtg gggt
<210> 480
<211> 306
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (15)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (19)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (34)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (52)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (64)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (66)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (76)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (97)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (126)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (129)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (130)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (133)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (134)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (145)
<223> n equals a,t,g, or c
```

```
<221> misc feature
<222> (146)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (161)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (166)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (181)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (186)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (194)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (200)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (233)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (253)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (267)
<223> n equals a,t,g, or c
<220>
<221> misc feature
```

```
<222> (275)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (304)
<223> n equals a,t,g, or c
<400> 480
ggcagagggc ccgcnagcng ccgccctcct cctnagcctg ctgctgttcg gnttcaccct 60
agtntnaggc acaggngcag agaagactgg cgtgtgnccc gagctccagg ctgcaccagc 120
aactgncann cannagtgcg tcctnnggaa cagcgaaatg ncccgnacaa cctccaagtg 180
nctgcnaggc gggnctgtgn caccttctgc ctctctgccc caatgatgaa ggngggttcc 240
tgcccccagg tgnaacatta aactttnccc aggtngggcc tctgttcggg caccatgcca 300
                                                                   306
ggtngt
<210> 481
<211> 473
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (364)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (411)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (418)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (431)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (445)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (459)
<223> n equals a,t,g, or c
```

```
<400> 481
gcctttagct gccatcttqc qtccccqcqt gtqtqcqcct aatctcaqqt ggtccacccq 60
agaccccttg agcaccaacc ctagtccccc gcgcggcccc ttattcgctc cgacaagatg 120
aaagaaacaa tcatgaacca ggaaaaactc gccaaactgc aggcacaagt gcgcattggt 180
gggaaaggaa ctgctcgcag aaagaagaag gtggttcata gaacagccac agcagatgac 240
aaaaaaacttc agttctcctt aaagaagtta ggggtaaaca atatctctgg tattgaagag 300
gtgaatatgt ttacaaacca aggaacagtg atccacttta acaaccctaa agttcaggca 360
tctntggcag cgaacacttt caccattaca ggccatgctg agacaaagca nctgacanaa 420
atgctaccca ncatcttaaa ccagnttggt gcggatagnc tgactaagtt taa
<210> 482
<211> 571
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (3)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (4)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (13)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (70)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (92)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (297)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (307)
<223> n equals a,t,g, or c
```

```
<221> misc feature
<222> (494)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (550)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (565)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (569)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (571)
<223> n equals a,t,g, or c
<400> 482
gannacttct ctngaaacgc ccgtaccggt cttgaattcc cggctcgacc cacgcgtccg 60
gatgacggtn ccgggcgcct ctcccgagga cncttgggtc aaggtggagt atgcctacag 120
cgacaacagc ctggaccccg ggctttttgt agaaagcacc cgcaagggga gtgtagtgtc 180
cagagetaat ageateggtt ceaecagtge etettetgte eccaacacag atgatgagga 240
cagtgattac caccaggagg cctacaagga gtcctacaaa gaccggcggc ggcgcgnaac 300
acacttnagg cttgagcaga agaggagga cgccatcaag agaggctatg atgaccttca 360
gaccategte eccaettgee ageageagga ettetecatt ggeteecaaa ageteageaa 420
agccatcgtc tacaaaagac cattgactac attcagtttt tgcacaagga gaagaaaaag 480
caggaggagg aggngtcacg ttacgcaagg atgtaccggc ctaaagatca tgaaagtgaa 540
ctatgagcan attgtgaagg cacantagna n
                                                                   571
<210> 483
<211> 220
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (16)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (69)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (71)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (99)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (136)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (179)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (183)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (185)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (215)
<223> n equals a,t,g, or c
<400> 483
aatacaacgg gaatcnctaa ctgccttgcg tgaaggtccc ggtccggaat tcccgggtcg 60
acceaegent negggeeagg atgetgaate tgetgetgnt ggegetggee gteetggega 120
geogegeeta egeggneet geoceaggee aggeeetgea gegagtggge ategteggng 180
                                                                   220
gtnangaggc ccccaggagc aagtggccct ggcangtgag
<210> 484
<211> 439
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (5)
<223> n equals a,t,g, or c
```

<222> (18)

<221> misc feature

```
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (31)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (35)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (36)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (394)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (406)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (414)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (434)
<223> n equals a,t,g, or c
<400> 484
gggangggag gggaaatnet teteggtate nggtnnetgg agetecaceg eggtggegge 60
cgctctagaa ctagtggatc ccccgggctg caggaattcg gcacgagcag cccagcagcg 120
gctgaccctc tgcctgcggg gaagggagtc gccaggcggc cgtcatggcg gtgtcggaga 180
gccagctcaa gaaaatggtg tccaagtttt taacgatggc agttccaggg aactaatgaa 240
cctcactgga acaatccctg tgccttatag aggtaataca tacaatattc caatatgcct 300
atggctactg gacacatacc catataatcc ccctatctgt tttgttaagc ctactagttc 360
aatgactatt aaaacaggaa agcatgttga ttgnccaaaa aaattngggg gggnaaaaaa 420
ggggaaaatt ttanttttt
                                                                   439
<210> 485
```

```
<211> 115
 <212> DNA
  <213> Homo sapiens
 <220>
 <221> misc feature
 <222> (11)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (69)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (71)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (87)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (89)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (104)
 <223> n equals a,t,g, or c
 <400> 485
 gacaaagtaa ngcatccctc ctgaccatca gacgttgatc tttgctggga aacatctgga 60
 aaatggache neeetgtetg actaeanent ceacaaagaa teeneeetge acetg
 <210> 486
 <211> 558
 <212> DNA
 <213> Homo sapiens
 <220>
 <221> misc feature
 <222> (1)
<223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (8)
```

```
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (12)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (151)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (159)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (255)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (270)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (353)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (402)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (404)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (410)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (416)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (469)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (488)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (495)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (517)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (539)
<223> n equals a,t,g, or c
<400> 486
ntctctgngg tntagctgaa cgccgaggac cggccgaatt cccggtcgac cccgcgttcg 60
ttcttttagc atcaaggaat ctgatgagaa agcaggaaag atcttttcac agatgaacaa 120
tattatgagt aaaagtttgc atgatgatgg ntttactgnt ccacagatta ttgaaatgga 180
gctggatagt caggagcaag ttgttgttgc aggatcctcc tgtgacttac attcagcaat 240
ttgcagatgc agcanccaac cttacctctn cggattctga gaagtggaac tctgtgtttc 300
ccaagcctgg gactttggtt caagtgcttg aggctgcaaa gtttgcatag gangagaatc 360
tttgtataac tcaataactc cttgtgctga cggaattcat tngntggtan gactgnggac 420
atgccctgtt gaatccttga gtgcaataaa tcaaagtaga aggccttgna taatttaaat 480
taaattanac totgnactat gtaataaccg gaaaggnaac tgcaatcaaa tttgcttgna 540
tggaatgggg caaaatta
                                                                    558
<210> 487
<211> 354
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (13)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (15)
```

```
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (18)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (21)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (79)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (114)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (115)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (120)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (127)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (155)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (195)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (203)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (229)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (239)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (307)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (315)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (339)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (343)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (346)
<223> n equals a,t,g, or c
<400> 487
getetgetea aengngangg nteggeacaa catteagaag gaattatgte tteatgetge 60
tcaaggtctc gctcagctna aggcatgtac ctacaaaaggt cacaagacag gtgnnactgn 120
agagcanata tgggagatcc agaaggatca acttntatac tatccattct taaaaatgtg 180
cctttcagca aatgntgagc atncaagctt agtggatgca acccatcana accactccna 240
aaatggatac ttagccaaaa tgattaagcg ttccttaaaa ttaacttgac caaggaaata 300
tcctttntca taaanctgtg actaggcata cactgtagnt gtnganaatt atgc
<210> 488
<211> 508
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
```

```
<222> (134)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (236)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (242)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (258)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (275)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (288)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (298)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (300)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (314)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (349)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (351)
```

```
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (375)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (387)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (400)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (407)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (412)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (413)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (424)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (429)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (434)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (440)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (441)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (450)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (456)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (458)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (462)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (469)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (475)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (478)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (485)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (493)
<223> n equals a,t,g, or c
```

```
<400> 488
aattcggcac gagaaagcgc atggagacta agggagctgg agtgaccctg aatgttctgg 60
aaatgacttc tgaagattta gaaaatgctc taaaagcagt catcaatgac aaaagttaca 120
aggagaacat catnogcoto tocagootto acaaggacog cocggtggag cogotggaco 180
tggccgtgtt ctgggtggag tttgtgatga ggcacaaggg cgcgccacac ctgcgncccg 240
cncccacgg acctcacntg gtaccagtac cattnccttg gccgtgantt ggtttccntn 300
ttggcccttg gtcntgaaat tggccttaat aacctttaaa attttgctnt natggttacc 360
cgaaaatttt ggggnaaaaa agggccnttt aagaaagccn caaaatnaga cnnccttttg 420
aaangggtng gganaaaggn naaaattttn accttncncg gnatttccna atttnaanag 480
                                                                   508
atagngttta aanatttttt tttttagg
<210> 489
<211> 425
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (3)
<223> n equals a,t,q, or c
<400> 489
concegetege atettegaet gagecegeae gagaagtage agtegetege agageaeaca 60
ggctgctctg ggggatgagc tggtgcgttt aaggaacagg ccagcactgg cattcgcaag 120
cagtggggaa ggggagagat gccgaggtgg tcagtatcct gactttcaga ggcctttttt 180
tgtttgtttt aatttttgct agattgatat taaaaactca tgtggaggaa ctcaaggaat 240
gtttagaaga ccaaaagtcc ccaatgacag gaacaaaagc aaccaatttt taactttctc 300
ttctcattcc tgttttcatt gatttcccac atgtagtcct tttgctcagg aagtctttgg 360
ggaaattaag gatotttgaa gototgaaat aggtgatoag gttagtggtg totgtoagot 420
                                                                   425
gtctg
<210> 490
<211> 607
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (2)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (5)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (6)
<223> n equals a,t,g, or c
```

```
<221> misc feature
<222> (8)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (9)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (58)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (443)
<223> n equals a,t,g, or c
<400> 490
ancannonna caccacctca ctaaagggaa caaaagctgg agctccaccg cggtgcgncc 60
getetagaac tagtggatee eeegggetge aggaattegg cacgagaage egteaaggag 120
tagaaattgg tatgcttaga agcagattct aaaagcagtt tctcttcaga acatcttttt 180
tcataccact tgataagcat cttgaaacac catggctgta gctgcagtaa aatgggtgat 240
gtcaaagaga actatcttga aacatttatt tccagtccaa aatggagctt tatattgtgt 300
ttgtcataaa tctacgtatt ctcctctacc agatgactat aattgcaacg tagagcttgc 360
totgacttot gatggcagga caatagtatg ctaccaccot totgtggaca ttocatatga 420
acacacaaaa cctatccctc ggncagatcc tgtgcataat aatgaagaaa cacatgatca 480
agtgctgaaa accagattgg aagaaaaagt tgaacacctt gaggaaggac ctatgataga 540
acaacttagc aaaatgtttc tttactacta agcaccgttg gtatcctcat ggacggtatc 600
                                                                   607
acagatg
<210> 491
<211> 371
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (81)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (265)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (336)
```

```
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (339)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (353)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (364)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (368)
<223> n equals a,t,g, or c
<400> 491
aaactgtaat tgcaatgttg aggggtgact tgctaaccag tcagttgaat tccaggcaca 60
gattgagttg cttctggagt nggcagggtc actgtgaacg cctacgtgag cctcttctac 120
accataaagc gggcacaagt ggtcagtcct gaaagagtcg gaagctggca tatcggccgc 180
ccaagtgacc ctgtccagtg tctgcttgcc atcctgccag aacaggccct caagcccaag 240
agccatccca ggcctgtttc agctncagct aaagcctctc tttcatctgg aagaagaggc 300
aagggggcag gagaccaggc tctagctctg gggccntcnt tcagccccca tcnggggaat 360
aaanttantt t
<210> 492
<211> 440
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (347)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (353)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (397)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (402)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (434)
<223> n equals a,t,g, or c
<400> 492
ttgagtcgtg ttaatgtaag aatgactcct atcattagga gtgctgctcg gaggttactc 60
acctttggga gtaatactga agagagggt ctgcagaaag gatgtgtatg aagcttagat 120
aataatggct gtttcgtaaa ctgtttgaga cctattaatg aaaatgacta tttcttgctg 180
tttttatcca acgtctgcat tttccccctt taaagctgcg gtctcctgtt tgataaaaga 240
atattggcca gtattgcaga ttttaactgg atttggctga tcctccaggg gaccagtttc 300
tgtgggcgtg tattggagca ggtttgtctt taactcttaa atggttnggt ccnaattttt 360
aaaaaggaag ggcccaagt agcccagatt taaaggngta tncccattcc caaagttcct 420
tggaacaatt accnaaagga
<210> 493
<211> 90
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (1)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (20)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (27)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (49)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (56)
<223> n equals a,t,g, or c
<400> 493
```

```
ngggagetgg cetggagegn atgggeneeg tgatggateg catggeeane ggetgneage 60
gcatgggccc atcaatctgg agcggatcgg
<210> 494
<211> 218
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (28)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (30)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (40)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (46)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (47)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (53)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (78)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (87)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (95)
```

```
<223> n equals a,t,g, or c
 <220>
 <221> misc feature
<222> (135)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (163)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (167)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (192)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (216)
<223> n equals a,t,g, or c
gggtcgaccc acgcggtccg tttttttntn tttttttagn tcccannttt tantcaagaa 60
ctcatacaaa attttccnga taaatgnaat ttaancctcg tcttcctcct cttcttcgtc 120
ctggttaatc tgggnagtaa cgtaattcgt aactctcttt ggntgtnagc aactgacgcg 180
caaccagttc angtagatta ttcttcttca aatatngt
                                                                    218
<210> 495
<211> 148
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (26)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (83)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (96)
```

```
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (111)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (116)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (122)
<223> n equals a,t,g, or c
<400> 495
gtttttaaaa aaaacatgtc atgtangttg tctaaaaata aaatgcattt aaactcaaaa 60
gntttgaaga agggaagggg ggcccccc
<210> 496
<211> 536
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (355)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (382)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (412)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (444)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (460)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (484)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (534)
<223> n equals a,t,g, or c
<400> 496
atgacccaca ctgccagaag agaattcagt atttttact tttcacactg tcttcccgat 60
gagggaagga gcccagccag aaagcactac aatcatggtc aagttcccaa ctgagtcatc 120
ttgtgagtgg ataatcagga aaaatgagga atccaaaaga caaaaatcaa agaacagatg 180
gggtctgtga ctggatcttc tatcattcca attctaaatc cgacttgaat attcctggac 240
ttacaaaatg ccaagggggt gactggaagt tgtgggatat cagggtataa attatatccg 300
tgagttgggg gagggaagac cagaattccc ttggaattgt gtattgatgc cattntaagc 360
ctaaaagatc accttgtatt cnctttacct tctaaaagcc attatttatg gngttagaag 420
aagaggaaga aattcaggta ccgnaaaaca cttttgttcn ggggggggcc cgtacccaat 480
tognocoata gtgagtogta ttacaatcac gggccgtcgt ttacacggcg gacngg
<210> 497
<211> 93
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (84)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (85)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (88)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (89)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (91)
<223> n equals a,t,g, or c
```

```
<400> 497
aaaaaaaaa aaaaaaaaa aaannaanna nat
<210> 498
<211> 392
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (8)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (50)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (104)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (106)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (113)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (160)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (180)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (181)
<223> n equals a,t,g, or c
```

```
<221> misc feature
<222> (245)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (248)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (334)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (351)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (363)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (377)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (390)
<223> n equals a,t,g, or c
<400> 498
cgggaccnaa ggaggagctg cgtggcggcg gtggcgacat ggcggacctn ccgaggcggg 60
tgacgcgccc cctgatgatg ggcctccagg ggagctcggg cctnanggcc tgnacggtcc 120
agaggaaaag ggccgggatc gtgaccggga gcgacggcgn acaccggagc gagcgcgagn 180
ncgccgggac cgggatcgtg accgtgaccg tgaccgcgag cacaaacggg gggagcgggg 240
cattnaancg gggcagggat gaagcccgaa gttggggggg gtggccagga caacgggttg 300
gaaggtttgg gcaacgacag ccgagaattt tacntgaatt ttaaggcggc nacgttactt 360
                                                                   392
gtnccggaaa ttggttnttt attgaagttn cc
<210> 499
<211> 262
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (23)
```

```
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (40)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (60)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (76)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (78)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (104)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (114)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (160)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (209)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (212)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (218)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (219)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (226)
<223> n equals a,t,g, or c
<400> 499
ggtaagagca acgtgctttg ggngcagaga agagggagan agcagcatct tgcctggatn 60
agccagggga cacagnanag aagcccacct ggacacaaca ccanaaaggc ttcntattcg 120
ggtgtggagt cttttcagca acccggtcca gtactgggcn gatacagcca tccaccttac 180
agatgtgtct acgtgacgct ctgccattnc anctcggnna ctatangtaa ttctcaagaa 240
                                                                    262
agccctcatt tttataacct gg
<210> 500
<211> 437
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (309)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (317)
<223> n equals a,t,q, or c
<220>
<221> misc feature
<222> (384)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (398)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (405)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (406)
```

```
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (418)
<223> n equals a,t,g, or c
<400> 500
accacaaagc ccccctggag catcttcccg gctggcagga ccatgccatc tctgtggaga 60
aggtgctggg gagggaagtc cttccagtgc cacatggagt gaggccctgc ccatgctggg 120
gactttgggg aggaatttgg tattctggtg gccttgctca gctctcattg agatcttttc 180
ctatcagaat gttagtgaat atacttcgca gctctttgtt cagcaataag gaatattctt 240
tcaattcctg ctcttcaagc caatttacta cacccatttg tctttccaaa attcatccca 300
acggtatant tggtttnggt cctccttgga ttcaatctgt ttcctggtaa aattgaacct 360
gtccattgtg aatcctctta attncctcct cccaaaanaa ccagnncttg taaatttntg 420
                                                                    437
gccaactcca ggggcca
<210> 501
<211> 180
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (162)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (165)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (166)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (174)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (177)
<223> n equals a,t,g, or c
<400> 501
gagaactagt ctcgagtttt ttttttttt ttttttttt ttttttgtt ttttggctct ttcaaaggta 60
atggcccatc gatgagcatt tttaacatac tccatagtct tttcctgtgg tgttaggtct 120
ttatttttat tttttcctg ggggctgggt gggtttgggg gncanngggg gaantgncct 180
```

```
<210> 502
<211> 436
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (101)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (174)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (197)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (199)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (222)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (225)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (229)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (262)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (266)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (276)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (287)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (290)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (297)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (327)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (328)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (330)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (336)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (343)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (364)
<223> n equals a,t,g, or c
<220>
```

```
<221> misc feature
<222> (385)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (390)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (436)
<223> n equals a,t,g, or c
<400> 502
tacaaactgt cctttattca gagtgagact gcggaacatt aataatttat cacgcgggga 60
gtccccagaa gccctgtgcc cacgaacccc tgtgggcgga nggagagaag cggggactcc 120
gggagcttcc tgagagggcc gtgtcttggg agcaaggtga catatccagt ccangcacgc 180
ggaacatgac tcagaantng ggaaacaaaa aaccatcccc cnccngaang ggggggcca 240
ggcccctaaa aagcacaatg gnggcnggtg gaattngggt taaaatntcn gggttcnaaa 300
aagaccatat tttttttcc cagttcnntn gccccncctt ttnttgttaa gggggggggt 360
taanatteec eceteeegg gaaanaaaan taeetttett aggaagaagg geeeeceee 420
                                                                   436
ccttcccgcc tttttn
<210> 503
<211> 418
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (41)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (50)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (55)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (56)
<223> n equals a,t,g, or c
<220>
<221> misc feature
```

```
<222> (57)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (61)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (62)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (72)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (94)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (97)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (106)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (109)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (110)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (111)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (112)
```

PCT/US00/05883

528

```
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (116)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (125)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (126)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (127)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (130)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (179)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (210)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (212)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (221)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (226)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (237)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (239)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (245)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (253)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (256)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (257)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (289)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (337)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (350)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (351)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (367)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (375)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (379)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (404)
<223> n equals a,t,g, or c
<400> 503
gctcttttaa ataaatgagc aagtgtccta agctatgtca nccaaagatn gtccnnncca 60
nnctcaaatc engtgactgg gatcactcaa cagnaengtg atgtangann nncaangagg 120
tgccnnnctn aactgaccaa atgctgcctt gtttggcccc taaatcaata aaatatgtna 180
aaatttgtat cccctgttgt ggcatttttn tnagataatc naagcnagaa aaatganang 240
gaatnotgga conggnnggg aaggaaaaga accotttott gtogotggna actgtgttgg 300
taaggaagtc caaatttgtg catatgaaat aagccgnaac cgctggaacn ncactcctat 360
gcagctnctc ttganccana aacaaggagc ttggtctaat gganatacac tgtgcttg 418
<210> 504
<211> 202
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (99)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (126)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (143)
<223> n equals a,t,g, or c
<220>
<221> misc feature
```

By (contid)

```
<222> (161)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (182)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (183)
<223> n equals a,t,g, or c
<400> 504
gctgggttta taccgtcgtg agacaagtta gttttaccct actgatgatg tgttgttgcc 60
atggtaatcc tgctcagtac gagaggaacc gcaggttcng acatttggtg tatgtgcttg 120
gctgangaac caatggggcg aanctaccat ctgtgggatt ntgactgaac gcctctaatt 180
                                                                    202
cnnaatcccg cccatgcgga ac
<210> 505
<211> 568
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (258)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (334)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (342)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (393)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (395)
<223> n equals a,t,g, or c
<220>
<221> misc feature
```

```
<222> (404)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (422)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (423)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (425)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (459)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (482)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (503)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (511)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (538)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (561)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (565)
```

<220>

```
<223> n equals a,t,g, or c
<400> 505
gggtagctct ttgaaggtgg ataagacttc agaagaggaa aggccagact ttgcttacca 60
tragraticty caatgggcca aacacacete aaattggety agttgagaaa gcageeccay 120
tagttccatt cttgcccagc actttctgca ttccaaacag catcctacct gggtttttta 180
tccacaaagg ttagcggcca catggttttt aaattatgaa gaaacacatt tgtcctctcc 240
ttttatccaa gcaggaanat cctatatccc tgatggttaa aaacaaatcc aggccaccct 300
gaatttgcta ccccaaaaaa gagatttggt taanctgttt cnccggtttg ttccctaagg 360
ccatatttta aaattaccac tctgggggtc ccntnaaaac cccngccggg gaccatcttg 420
cnntntggtt aaaaccccct gtttcaatct ctaaatttnc ccctaaggag ggggttggct 480
tnaaaatttg ggggaactta teneeettea ngttttttee gggtaeceee eeettggngg 540
                                                                    568
gggaaaccct ggctcgggga ntganaaa
<210> 506
<211> 187
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (8)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (99)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (140)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (178)
<223> n equals a,t,g, or c
<400> 506
aatteggnac gagecaaaat ggtggaaaca geettaacce caaatgeetg caateetaac 60
taatttaagt aattgctgac tgcatagctc ttttccttna gaggctctcc attttaattc 120
aaaaagttag catatttatn aaccatgaaa tttgaaaacc agggcttttt tttttttngg 180
                                                                   187
ggggttg
<210> 507.
<211> 68
<212> DNA
<213> Homo sapiens
```

```
<221> misc feature
<222> (53)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (54)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (64)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (65)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (66)
<223> n equals a,t,g, or c
<400> 507
68
cccnnncc
<210> 508
<211> 366
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (3)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (7)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (25)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (46)
```

PCT/US00/05883

```
<223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (50)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (70)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
· <222> (95)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (118)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (160)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (161)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (172)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (241)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (302)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (303)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (314)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (332)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (339)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (348)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (364)
<223> n equals a,t,g, or c
<400> 508
ggnaganctg aaggacacct gcctnaaagc agagatggag gccttntgtn cacggcggat 60
tctttgtttn aatcttgcaa tgtgctttcc ttgtngctgg gcggatgaat gtttactnaa 120
cgatgaaatt ttaacatcca aagggggata ggcacttggn ncccccattc tnccaaggcc 180
cgggggggcg gtttcccatg ggaatgtgaa aaggctggcc attattaagt ccctgtaaat 240
naatgtgaaa ccccaccggg gcaccccccg tcccccaaag ttttggttgt ttaaaaataa 300
gnnttccatg gggnagtttt aaaaacctgg tngccccgnt tttttttnaa ttaaaataag 360
                                                                   366
ggtnag
<210> 509
<211> 496
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (53)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (62)
<223> n equals a,t,g, or c
<220>
```

```
<221> misc feature
<222> (75)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (99)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (111)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (146)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (148)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (201)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (242)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (282)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (320)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (346)
<223> n equals a,t,g, or c
<220>
```

<221> misc feature

```
<222> (353)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (374)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (382)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (413)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (450)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (486)
<223> n equals a,t,g, or c
<400> 509
ggcacgagcc agcctccctg tctccagctg cctgggcccg gaaggtgtgt ggntccttct 60
engggtetga ttttntcact gaactecace gaccaactne cetaageece nagggeetee 120
agggaccagg ttcgagaccc aaaccncnaa aatccaaaac ttctcttgaa aagttcaggg 180
accetccage geagategege negagatate eatgactcca gaagatecca 240
gnttctctct ccagggtgct tagttggctt tgaccacccc tnactcccca gggagctctg 300
gggcacaget teetgeacan ecetgtgeee aaceacacag etgeentage tgnaceeega 360
gaagtgetet tggntgacce tntggtgtgt ggtgaggggt ttgtgtteee ttnctgttte 420
agaccetega tttteegtaa tggtttgggn gagttgggga ggtteaagea gagtgtttta 480
                                                                   496
ttattntcgg tttatg
<210> 510
<211> 363
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (3)
<223> n equals a,t,g, or c
<220>
<221> misc feature
```

```
<222> (25)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (282)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (339)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (352)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (354)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (361)
<223> n equals a,t,g, or c
<400> 510
gcnagaggaa ccgcaggttc agacntttgg tgtatgtgct tggctgagga gccaatgggg 60
cgaagctacc atctgtggga ttatgactga acgcctctaa gtcagaatcc cgcccaggcg 120
gaacgatacg gcagcgccgc ggagcctcgg ttggcctcgg atagccggtc ccccgcctgt 180
ccccgccggc gggccgccc cccctccacg cgccccgcgc gcgcgggagg gcgcgtgccc 240
cgccgcgcgc cgggaccggg gtccggtgcg gagtgccctt cntcctggga aacggggccc 300
ggctggaaag gcggccgttt agaggatcca agcttacgna cgcgtgcatg cnangccata 360
                                                                   363
nct
<210> 511
<211> 331
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (1)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (9)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (15)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (66)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (90)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (276)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (301)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (312)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (318)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (330)
<223> n equals a,t,g, or c
<400> 511
naggaatang ccggnaaagc ttctacgcct gcaggtaccg gtccggaatt cccgggtcta 60
cccacntttc cgcataggtg ttcatactgn tacatgcaga acatttgtca ggctctctgt 120
cagettteat gtacatatgg tatagaaace atggagttag geaetteetg gattttttt 180
nttaaaaaac anaaaatnaa aaaaaaaaan a
```

<210> 512 <211> 754

```
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (572)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (667)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (724)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (748)
<223> n equals a,t,g, or c
<400> 512
ggtgatctcc ccaccttggc cttccaaagt gctaggatta caggcgccta gcctaggcag 60
tcattttcaa aaaacaaqca tgactcacca aaagttttaa gattttctgt gataatgttc 120
ttattgaggc ttacattata ttacagtttc ttgaatetaa aatgatgtac cctcttagga 180
tatatacatc atgcttcatt ggtctcaggg ggctgatttt tataaggaga gatttgctag 240
ttttcacaat atgtcctcta agttggcatg tatagctaaa caggctttca taaaaatata 300
caatttagtt aatgaaattt gggatatagt cttttatgat tgaaataatt ttgctaaata 360
gactgtctct gatttattag gtaatcacca ctcttatttt gttttacttc cttaatgtct 420
acatagaaag gaaatgagaa aaatccagag gttgtcattt gacttatgag tctgtttgac 480
ttcaggattt ggtacatgaa atttcactta atctttttga tatgtataaa acaaatattc 540
tgggtaatta tttttatcct tttggttttg antccttttt attcctatca tattgaaatt 600
ggtaagttaa ttttcctttg aaatattcct tatagccagg tctaaaattc aatgggccca 660
caaccgncaa ccqccaacaa caaccaaccc cactttacta tcatggctgg gtgcctccaa 720
                                                                   754
tttnccttct gggaaccacc cagttaantt aaaa
<210> 513
<211> 245
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (7)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (67)
```

```
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (76)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (81)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (131)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (179)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (207)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (232)
<223> n equals a,t,g, or c
<400> 513
taaatgntcc tttcctttgt agactctggc aaaaggcttt aggaagataa aagtttgagg 60
agaacanaca ggaatnotga nttaagcaca gagttgaagt ttatacccga ttcacatgct 120
tttcaagaat ntcgcaatta ctaagaagca gataatggtg ttttttagaa acctaattna 180
ggtatattca accaaatact tttaaangta taaaataaat attatacaat anacttgtgt 240
                                                                   245
agcag
<210> 514
<211> 393
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (29)
<223> n equals a,t,g, or c
<220>
<221> misc feature
```

```
<222> (60)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (89)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (97)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (104)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (118)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (124)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (126)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (141)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (162)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (174)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (192)
```

```
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (194)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (196)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (234)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (262)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (297)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (302)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (312)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (317)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (319)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (327)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (333)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (334)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (341)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (359)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (362)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (382)
<223> n equals a,t,g, or c
<400> 514
aattcggcac gagttttaat atgaaaganc ctcatgaatt aaatagttga tgcaattttn 60
aacgttaatt gatataaaaa aaaaaacanc aaaattnggc ttgnaaaact gacttttnca 120
ttangngggt tttgaaatct ngccccagac atactgtgtt gngagatact tagngggagg 180
gagtaggttt tnangnggtt gatggtggtg gggagggaag gcctcctgaa ttgngtttga 240
tgcagagctt tttagccatg angaatcttt cagtcatagt actaataatt aaatttncag 300
tntttaaaaa gncaagntnt ttgtccnttt tgnntttctg nactccctgg aaagttccnt 360
                                                                   393
tnggcggtgg ggcccaaagc tnttggtttt cct
<210> 515
<211> 231
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (87)
<223> n equals a,t,g, or c
<220>
```

```
<221> misc feature
<222> (114)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (121)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (200)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (206)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (208)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (223)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (230)
<223> n equals a,t,g, or c
ggacaaatgt taatcttttg tctccagaaa aagttgggct ttcccaagca gttctattac 60
ccggttcaca attccttcac ccaaaantca tctcatggta tacatggctc ctantccttt 120
aaaaaaaaaa aaaaaagggn ggccgntnta gaggatccaa gtntacgtan g
                                                              231
<210> 516
<211> 82
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (14)
<223> n equals a,t,g, or c
<220>
```

```
<221> misc feature
<222> (22)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (36)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (67)
<223> n equals a,t,g, or c
<400> 516
ggcacgtacg gcangagcga angaaggagt aaggtngtgg gatctcaccg tgggtccgat 60
tagcctnttc tctgccttac tt
<210> 517
<211> 237
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (173)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (223)
<223> n equals a,t,g, or c
<400> 517
aatteggeac gageceacet ceacetgeec caeteaceae etetgetagt tecagacace 60
tccacqccca cctqqtcctc tcccatcqcc cacaaaaggg ggggcacgag ggacgagctt 120
agctgagctg ggaggagcag ggtgagggtg ggcgacccag gattccccct ccncttccca 180
<210> 518
<211> 281
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (35)
<223> n equals a,t,g, or c
<220>
<221> misc feature
```

```
<222> (116)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (134)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (230)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (243)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (259)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (263)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (265)
<223> n equals a,t,g, or c
<400> 518
gctcacgccg gccggggccg cgaggcctgg tctgngcctc agggaggggc cccgggtcct 60
ctcagtcttt cccctccccc aacgatgtag cgtttttcgt tgtttgcttt aggttnttga 120
aacagccccg gcgncgcctc tattggctct cggccttggc aacggccgtc gtcatggtta 180
ctggccctaa cagccgatgg ccgaagccga cctgccaccg ggcggggtcn ctggttggcc 240
                                                                   281
ggncccaggc gcgcggggnc gcngnagccg agcattcttt t
<210> 519
<211> 443
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (372)
<223> n equals a,t,g, or c
<220>
```

```
<221> misc feature
<222> (373)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (396)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (411)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (441)
<223> n equals a,t,g, or c
<400> 519
tgaagccagc tcacagtgct gtgtgccccg gtcacctagc aagctgccga accaaaagaa 60
tttgcacccc gctgcgggcc cacgtggttg gggccctgcc ctggcagggt catcctgtgc 120
teggaggeca tetegggeae aggeceaece egeceeaece etecagaaea eggeteaege 180
ttacctcaac catectggct geggegtetg tetgaaceac gegggggeet tgagggaege 240
tttgtctgtc gtgatggggc aagggcacaa gtcctggatg ttgtgtgtat cgagaggcca 300
aaggctggtg gcaagtgcac gggggcacaag cggagtctgt cctgtgacgc gcaagtctta 360
aggtctggcc gnnggccggc tgggtctggg catttntggg tgcaccgcgg ngctttccag 420
                                                                    443
accaacatgt aaccggcatg ntt
<210> 520
<211> 129
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (27)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (56)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (67)
<223> n equals a,t,g, or c
<220>
<221> misc feature
```

```
<222> (81)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (89)
<223> n equals a,t,g, or c
<220> .
<221> misc feature
<222> (104)
<223> n equals a,t,g, or c
<400> 520
tggttccccc acagtaggtg ttttaanata agaattaggg tccttttgga aagaantagt 60
tgcagtnttt ataggatagt ngtggtaana ttctagttta tttnccattt ggctaattgg 120
tctgtgctg
<210> 521
<211> 113
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (9)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (56)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (64)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (70)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (89)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (112)
```

```
<223> n equals a,t,g, or c
<400> 521
ggggggccng gtacccaatt gcccctatag tgagtgcgta ttacaattga ctggancgtg 60
gtgntacaan gtggtggact gggaaaaanc ctggggttac ccaacttgaa tng
<210> 522
<211> 393
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (116)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (132)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (136)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (159)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (165)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (186)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (228)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (235)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (248)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (266)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (290)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (329)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (340)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (349)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (389)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (392)
<223> n equals a,t,g, or c
<400> 522
tttcagtttg caaatagaac taatactggt gaaaatttac ctaaaacctt ggttatcaaa 60
tacateteca gtacatteeg ttetttttt ttttgggaet etgteteaaa taaatneata 120
aaaattaaat gngganttca ctttgcagtt gctgctgtnc aacgnacatt actcaatctt 180
tatgtnegge attetatget etaetgggga aatttgggta ggagtgangt atttngtata 240
catatothca tttaataatg gcaatngctg ggtctatott actattttan ctattggata 300
aatattttgt ttcccccagg tgctggggnt gcaggcgtgn ccccactgng gcccggccac 360
atteagttet tatecaaggg ataacceeng ent
                                                                   393
```

<210> 523 <211> 146

WO 00/55351 PCT/US00/05883

```
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (5)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (13)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (18)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (46)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (74)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (102)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (112)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (114)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (120)
<223> n equals a,t,g, or c
<400> 523
ttcantaaat gtngtggnac ttccatttgt caaagcacca aaacanagga accccaacct 60
tacatgtaat acanacttaa ctcaaaatgg atcatatatc tnactgtaaa angnaaagcn 120
```

146

```
ataaaactga aaacagacta tcttta
<210> 524
<211> 346
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (59)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (61)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (63)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (119)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (120)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (278)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (319)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (329)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (342)
```

<223> n equals a,t,g, or c

PCT/US00/05883

```
<400> 524
 tggggcacgg acaccgacgg gttgcgactg tgacgtgagg tgttctcgcg cgcgctagnt 60
 nentgeeggg tgeegetgae gggegtgege gettgtgegg accggaggtg ggggeegann 120
 cagccaaggt tgcggggcc gcagagccgg acgaagacgg agggcggagc ggcttcggga 180
 ctgcggagac tacacaccga gcgagcgct gggcccgaag gagcgatgct gtggttccag 240
 ggcgccattc cggccgccat cgcgacggcc aaaaagancg gcgcgtcttc gttgtgttcg 300
 tggcagtgat gatgaacant ctacacagnt ggcttcaagt tnggaa
                                                                    346
 <210> 525
 <211> 470
 <212> DNA
 <213> Homo sapiens
· <220>
 <221> misc feature
 <222> (189)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (192)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (203)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (274)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (300)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (335)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
<222> (381)
 <223> n equals a,t,g, or c
<220>
<221> misc feature
```

```
<222> (415)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (418)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (425)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (427)
 <223> n equals a,t,g, or c
 <400> 525
 gettaetttt aaccagtgaa attgaeetge eegtgaagag gegggeataa cacagcaaga 60
 cgagaagacc ctatggagct ttaatttatt aatgcaaaca gtacctaaca aacccacagg 120
 toctaaacta ccaaacctgc attaaaaatt toggttgggg cgacctogga gcagaaccca 180
 gcctccganc antacatgct aanacttcac cagtcaaagc gaactactat actcgattga 240
 tccaataact tgaccaacgg aacaagttac cctngggata acagcgcaat cctattctan 300
 agtocatate aacaataggg tttacgacet cgatnttgga teatgacate cegatggtge 360
 agcogotatt aaaggttogt ntgttcaaca attaaagtoo tacgtgatot gagtnoanac 420
 cggantnatc caagtcggtt tctatctact tcaaattcct ccctgttcga
 <210> 526
 <211> 299
 <212> DNA
 <213> Homo sapiens
 <220>
 <221> misc feature
 <222> (7)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (21)
\cdot <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (48)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (66)
```

```
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (68)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (70)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (71)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (75)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (77)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (111)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (124)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (136)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (141)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (198)
<223> n equals a,t,g, or c
```

WO 00/55351

```
<220>
<221> misc feature
<222> (220)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (241)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (251)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (274)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (285)
<223> n equals a,t,g, or c
<400> 526
cgtacgngtc aaggagaagg ncaaagaaga agaccgtgca aaagcttngt gaaaaagaag 60
aaacantngn ngccngntta tagattagaa gaggtcaagg ataaagatgg naagccactc 120
ctgncaaaag agtctnaagg nacagcttcc acccatggag tggaagactt ccttctgggg 180
tggctttgtg tgtagggnct tctgctggtt ccacaaaatn gcttcatctg cttaaaattt 240
naaggatgct naaacttgct ggctggccca tctnctgaag tgggnttccc aaaacccca 299
<210> 527
<211> 323
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (5)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (23)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (39)
```

558

PCT/US00/05883 WO 00/55351

```
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (64)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (131)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (191)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (291)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (293)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (295)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (317)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (323)
<223> n equals a,t,g, or c
<400> 527
ggcanaaaat tagattataa ctnatagtat gtagagttna gagctttatg gtctagattt 60
tccnatttgt atttaagtta cctaatttaa gaaggtttta aaaatggaaa ttcagtatat 120
aatatttgtg nggttttttt ccacagtgaa aaatgaaatt atgcagaaaa tgttccccac 180
aacatgacag ngaaaggaat tetgggacac gttttttece agteecatta ttttcacagg 240
gateggetgg aatacagggt caaaggatet etttgeeaga atgtgeeaaa ntngntgaaa 300
aaggtaactg tttatcnctg atn
                                                                   323
```

<210> 528

560

```
<211> 220
 <212> DNA
 <213> Homo sapiens
<220>
<221> misc feature
<222> (9)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (13)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (15)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (37)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (54)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (59)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (94)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (106)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (124)
<223> n equals a,t,g, or c
<220>
```

<221> misc feature

```
<222> (147)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (150)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (171)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (176)
<223> n equals a,t,g, or c
<400> 528
actettgtne agngngtagt atetggggeg agtgttnggg gtaaaagece acentacana 60
aagtggaaca gcccggagcc tgtatgtgaa aggnccacgg gtgttntaag ctagggacac 120
ggangtccaa acttggaatc aaacggncgn actgttaaat tatatcttat naactnatta 180
aatgaaaaca ttttgctccg taaaaaagaat ataaaaaagt
                                                                    220
<210> 529
<211> 285
<212> DNA
<213> Homo sapiens
<400> 529
ccaagaagaa gctttacata ttctgggctt tcaacctcca tttgaagata ttaggtttgg 60
tcctttcacg gggaatacaa cacttatgag gtggtttaga caaattaatg accacttcca 120
tgtaaaagga tgctcttatg ttctatataa gcctcatggg aagaataaaa cagcaggaga 180
aactgcttca ggggccctgt caaagttaac ccgtgggatt gaaagatgaa tcgctggctt 240
atatctatca ttgccaaaat cattattttt gtccaattgg cttcc
<210> 530
<211> 79
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (5)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (8)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (25)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (28)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (33)
<223> n equals a,t,g, or c
<400> 530
ggcanagntg caccacccat gggantgnct ggnctgggaa cgcttccgat gcaacattaa 60
                                                                    79
ctgtgatgag gacccaaag
<210> 531
<211> 236
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (15)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (19)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (33)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (38)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (46)
<223> n equals a,t,g, or c
<220>
<221> misc feature
```

```
<222> (49)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (50)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (51)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (54)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (91)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (125)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (134)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (174)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (197)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (201)
<223> n equals a,t,g, or c
<221> misc feature
<222> (221)
```

```
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (223)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (226)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (229)
<223> n equals a,t,g, or c
<400> 531
ggcagagtaa aatantttnc aggagctcca ggnaatgngg cggacncann nttntttaga 60
acacaaatga tggatttaga attggcaatg ntgcgtcaaa accatggttt atcatcatat 120
gactnaggag gagnggtttg aagttgatca gctccagggt ttgtgaaaat tcantccgca 180
atggtaactt tcaggtncct nggaactgca gctggaggag ngnctnctng gccctt
<210> 532
<211> 341
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (17)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (20)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (66)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (74)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (81)
```

```
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (101)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (109)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (142)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (181)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (220)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (222)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (224)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (228)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (229)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (238)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (241)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (255)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (279)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (285)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (288)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (292)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (321)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (332)
<223> n equals a,t,g, or c
<400> 532
ggcagaaacg agcactnctn aattaatatc tgtatcctgg aacaatattt aatggttatg 60
tttttntgtg tgtnagtttt natagtatcc atattttaat nactgtttnt tacttccatg 120
aaattttaaa aatctgaagg gnaaatgttt tgtgaaacat ttatttttt aaaggaaaag 180
ntgaaaggca ggcctatttc atcacaggac cacacacatn tncncggnnt agggcatnca 240
nactcaatgg ctttntttgt gaaatttggg tgttttttna atttnttnct gntcaaatgg 300
                                                                   341
atgtggccaa aaacctttta nctgggttgg cntgggaaat t
<210> 533
```

<211> 208

```
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (26)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (33)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (72)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (103)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (124)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (143)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (161)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (163)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (171)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (190)
```

```
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (192)
<223> n equals a,t,g, or c
<400> 533
ggcagagcat ctttgccagt acaggngctt gtnccgtggc ccacagccca cagcccacag 60
ccatgggctg anacctgacg gtgaaagatg ctggcgggca acnaattcca ggtgtccctg 120
aagncagctg ccatgtgggt gtnaaagctg aaggcgcgag ntncacccag naagatcggg 180
gtgcacgctn tnttagccag gcgtttgg
<210> 534
<211> 252
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (49)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (101)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (152)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (163)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (203)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (240)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (246)
```

```
<223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (247)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (250)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (251)
 <223> n equals a,t,g, or c
 <400> 534
 ggcagagcac tagagcagag tacgagtcta aggcggaggg agtaatggna ggacaagcgt 60
 ttagaaagtt tcaacagggt gctgctggca acatgaaagg natgatggga attcaatgaa 120
 tatgtgaaag gaaaatgccc ttgaatatga anctgaactg canttgaaat gacctgaatt 180
 tgcctgagaa cctgcagcgt ttncccttcc tttttgccga aattgggcgg ggaaagtgtn 240
 attttnnctn ng
                                                                    252
 <210> 535
 <211> 380
 <212> DNA
 <213> Homo sapiens
 <220>
 <221> misc feature
 <222> (1)
 <223> n equals a,t,g, or c
 <220>
<221> misc feature
 <222> (2)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (10)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (11)
 <223> n equals a,t,g, or c
<220>
<221> misc feature
```

```
<222> (46)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (95)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (98)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (135)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (149)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (157)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (167)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (181)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (205)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (213)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (215)
```

```
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (232)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (256)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (302)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (307)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (309)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (313)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (317)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (326)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (328)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (331)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (333)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (343)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (344)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (346)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (350)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (379)
<223> n equals a,t,g, or c
<400> 535
nnttcggcan ngggggttta aaactttgct gcttttttac ataaangact gtgcctttcc 60
tagagagtta agatgtaaat gtgttctcac atgtnaantt tgagagttca ggggtctatt 120
atggaatgat acacnttttt aatgaacent aaaatantte actaagntgt ttgcctteca 180
nagtgtttac ccttaagcct taacntgtat ctncnttcag aaaaccgtta tnttgtgcaa 240
accatagtag gaaganaaac ctttatttgg gatataacac tactgtaagt tatgttacag 300
angetanane canecenetg tgttananta nangageeaa aannaneaan agaaaaaagg 360
ggaaaagaaa aactaatang
                                                                    380
<210> 536
<211> 91
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (15)
<223> n equals a,t,g, or c
<220>
```

```
<221> misc feature
 <222> (34)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (39)
<223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (55)
<223> n equals a,t,g, or c
<220>
. <221> misc feature
<222> (68)
<223> n equals a,t,g, or c
<400> 536
ggcacgaggt ctctngaaca cgctgcgggg ctcncgggnc tgagccaggt ctgtnctcca 60
cgcaggtntt ctgcgcgccc cgttcagcca t
                                                                    91
<210> 537
<211> 316
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (164)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (232)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (277)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (288)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (290')
```

```
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (314)
<223> n equals a,t,g, or c
<400> 537
atcgacccac gcgtccgcca agattaatca tataaccatg ggacaaagaa ttttatagaa 60
atttttaaac atctgataaa acttaagctt ctttttcaga tgtttaaatt ttatcatcct 120
ttttttctc atgaattctt aaaggattat gctttaatgc tgtnatctat cttattgttc 180
ttgaaaatac ctggcatttt ttggtatcat gttcaaccaa catcattatg anattaatta 240
gattcccatg gccataaaaa tggctttaaa agaatanata tatatttntn aagtagctga 300
gaagcaaatg ggcngt
<210> 538
<211> 374
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (6)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (11)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (13)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (16)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (31)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (272)
<223> n equals a,t,g, or c
```

<220>

```
<221> misc feature
<222> (303)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (306)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (335)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (352)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (354)
<223> n equals a,t,g, or c
<400> 538
ggaaanctgg nencenteag gtaceggtee ngaatteegg gtegaeeeae gegteegtge 60
tgatccccat cgctgtgggt ggtgccctgg cggggctggt cctcatcgtc ctcatcgcct 120
acctcgtcgg caggaagagg agtcacgcag gctaccagac tatctagcct ggtgcacgca 180
ggcacagcag etgcagggge etetgtteet ttetetggge ttagggteet gtegaaggga 240
gggcacactt totggcaaac gtttotcaaa tntggttoat coaatgtgaa gttocatott 300
ggnaancatt tgactatgca caacagatta attancgaaa tggacggtgt tnantttggc 360
                                                                   374
taaatgggtt aaat
<210> 539
<211> 109
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (9)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (46)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (47)
```

```
<223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (62)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (82)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (108)
<223> n equals a,t,g, or c
<400> 539
gtgggattnc tgtgcaggag ggtcgtggtc tggctgtggc ggaggnncat aagaaggtaa 60
cncgacctgg cgcggcagac anggctcgaa gacctcatct ttattaana
                                                                    109
<210> 540
<211> 396
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (268)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (340)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (353)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (366)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (390)
<223> n equals a,t,g, or c
```

```
<220>
  <221> misc feature
  <222> (393)
  <223> n equals a,t,g, or c
  <400> 540
  tctgaccttt tgggttttaa gcaggaggtg tcagaaaagt taccacaggg ataactggct 60
  tgtggcggcc aagcgttcat agcgacgtcg ctttttgatc cttcgatgtc ggctcttcct 120
  atcattgtga agcagaattc accaagcgtt ggattgttca cccactaata gggaacgtga 180
 gctggggttt agaccgtcgt gagacaggtt agttttaccc tactgatgat gtgttgttgc 240
 catggtaatc ctgctcagta cgagaggnac cgcagttcag acattggtgt atgtgctggg 300
 ctgaggagcc aatggggcga aactacccat ctgtggggan tatgactgaa cgncttctaa 360
                                                                     396
 gtcagnatcc cgcccaagcg gaaacgatan ggnagc
 <210> 541
 <211> 429
 <212> DNA
 <213> Homo sapiens
 <220>
 <221> misc feature
 <222> (314)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (353)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (382)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (414)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (418)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (419)
 <223> n equals a,t,g, or c
 <400> 541

    ttgggtttta agcaggaggt gtcagaaaag ttaccacagg gataactggc ttgtggcggc 60
```

```
caagegttea tagegaegte getgtttgat cettegatgt eggetettee tateattgtg 120
aagcagaatt caccaagcgt tggattgttc acccactaat agggaacgtg agctgggttt 180
agaccgtcgt gagacaggtt agttttaccc tactgatgat gtgttgttgc catggtaatc 240
ctgctcagta cgagaggaac cgcagttcag acatttggtg tatgtgcttg gctgaggagc 300
caatggggcg aacnaccatc tgtgggatta tgactgaacg cctctaagtc agnatcccgc 360
ccaggcggaa cgatacggcc ancgccgcgg agcctcggtt ggcctcggat agancggnnc 420
cccgcctgt
<210> 542
<211> 617
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (11)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (18)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (25)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (49)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (52)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (552)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (588)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (601)
```

```
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (609)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (612)
<223> n equals a,t,g, or c
<400> 542
cacgtagtag nggaaacntg gtacnccgtg caggtaccgg tccggaatnc cngggtcgac 60
ccacgcgtcc gagtttccct caggatagct ggcgctctcg cagacccgac gcacccccgc 120
cacgcagttt tatccggtaa agcgaatgat tagaggtctt ggggccgaaa cgatctcaac 180
ctattctcaa actttaaatg ggtaagaagc ccggctcgct ggcgtggagc cgggcgtgga 240
atgcgagtgc ctagtgggcc acttttggta agcagaactg gcgctgcggg atgaaccgaa 300
cgccgggtta aggcgcccga tgccgacgct catcagaccc cagaaaaggt gttggttgat 360
atagacagca ggacggtggc catggaagtc ggaatccgct aaggagtgtg taacaactca 420
cctgccgaat caactagecc tgaaaatgga tggcgctgga gcgtcgggcc catacccggc 480
cgtcgccggc agtcgagagt ggacgggagc ggcgggggcg gcgcgcgcgcgcgtgtt 540
ggtgttcgcc gncttcccag tgggcaagcg ccccaacccc cttccttntt ggttcctctt 600
                                                                   617
nccccaatng gnaacaa
<210> 543
<211> 302
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (134)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (135)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (148)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (156)
<223> n equals a,t,g, or c
<220>
```

```
<221> misc feature
<222> (281)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (282)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (293)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (295)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (299)
<223> n equals a,t,g, or c
<400> 543
acccacgcgt ccgaaatact taaaatgagg aataagaatg gagatgttac atctggtaga 60
tgtacattgc taccagatta tggatggact gatctgaaaa tcaacctcaa ctcaagggtg 120
gtcagctcaa tggnncacag agcacggnct tttggnttct ttgcagtact ttgaatttat 180
ttttctacct atatatgttt tatatgctgc tggtgctcca ttaaagtttt actctgtgtt 240
gcaaaaaaaa aaaaaaaaaa aaaaaaaaag gggggccccc nntaaggggc ccnantttng 300
                                                                    302
ga
<210> 544
<211> 534
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (99)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (141)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (142)
<223> n equals a,t,g, or c
```

```
<220>
   <221> misc feature
   <222> (174)
  <223> n equals a,t,g, or c
  <220>
  <221> misc feature
  <222> (252)
  <223> n equals a,t,g, or c
  <220>
  <221> misc feature
  <222> (281)
  <223> n equals a,t,g, or c
  <220>
  <221> misc feature
  <222> (283)
  <223> n equals a,t,g, or c
  <220>
  <221> misc feature
  <222> (290)
  <223> n equals a,t,g, or c
  <220>
  <221> misc feature
  <222> (296)
  <223> n equals a,t,g, or c
  <220>
  <221> misc feature
  <222> (317)
  <223> n equals a,t,g, or c
<220>
  <221> misc feature
  <222> (318)
  <223> n equals a,t,g, or c
  <220>
  <221> misc feature
  <222> (320)
  <223> n equals a,t,g, or c
  <220>
  <221> misc feature
  <222> (327)
  <223> n equals a,t,g, or c
```

```
<220>
 <221> misc feature
 <222> (332)
 <223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (336)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (338)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (348)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (352)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (384)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (386)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (393)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (419)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (426)
<223> n equals a,t,g, or c
```

<220>

```
<221> misc feature
<222> (436)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (461)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (483)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (493)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (498)
<223> n equals a,t,g, or c
<400> 544
gcaagggaaa gatgaaaaat tataaccaag cataatatag caaggactaa cccctatacc 60
ttctgcataa tgaattaact agaaataact ttgcaaggna gagccaaagc taagaccccc 120
gaaaccaaac gagctacctt nnagaacgct aaaagagcac acccgtctat gttngccaaa 180
tagtggaaaa aatttatagg ttgaaggcga acaaacctac cgacctggta atactggttt 240
gttccaaaat anatcttaat ttccactttt aattttgccc ncnaaacccn ctaatncccc 300
tttttaattt actgttnngn tcccaanaag gnaacnenet ttgggaenet tngaaaaacc 360
tttttaaaa aaattttaaa tttntncccc ttntgggggc cctaaacccc cccctttna 420
aaaggntttt teaceneece eeeceeeg aaaceeece nttttttt eeeceeece 480
ctnggaccct ttnccccnaa aaaaattttt tttttttta aaaacccccc cccc
<210> 545
<211> 355
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (1)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (14)
<223> n equals a,t,g, or c
<220>
```

```
<221> misc feature
<222> (38)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (43)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (82)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (94)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (169)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (247)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (279)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (281)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (299)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (337)
<223> n equals a,t,g, or c
<220>
```

<221> misc feature

```
<222> (355)
<223> n equals a,t,g, or c
<400> 545
ngcaacagga aagnccagga ggacctctga ggccacgnct ganccttctt ggctggggca 60
aactactctt caagtggtgg cncagtccca gcanggcagt ccgcctctcc ccctgctgag 120
actttaatct ccaccagece ttaaagtgte ggeegetetg tgaetggant tatgetettt 180
tgaaatgtca caaggccgcc tcccatctct gggggtattg ttacaaattc ttcctctcc 240
tgaaatngcc tttcctgctt tcctccgtgg gtaagttcna ncaaatttcc tctagcttnc 300
ctggaaggaa tcactcccc caaggaaacc tcccttncct tttcctgggg tgttn
<210> 546
<211> 269
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (178)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (232)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (252)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (267)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (268)
<223> n equals a,t,g, or c
<400> 546
gtttttcatc aagttcctaa gagctgactt ggagatttta ttcccagggc tccactgcta 60
ggattcttct cactagttct aacaaaatct gtgatgttaa atgactgatg ctctcaattg 120
tgatccagag ttttaaataa atgaaatcaa ggtgggattt tgggaatata tcctgaantt 180
taacatcttg atgttccttc ttgtttgtta aaaaaaaaa aaaaaactcg anggggggcc 240
cggtacccaa tnccccctaa tagtgannc
<210> 547
<211> 82
<212> DNA
```

```
<213> Homo sapiens
<220>
<221> misc feature
<222> (38)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (40)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (54)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (56)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (63)
<223> n equals a,t,g, or c
<400> 547
ggaaaacatg gaaaaggatc tggaaagtgg gcttgcanan gcttgggacg gaanancctg 60
                                                                    82
atnccggccc tgatggtcac gg
<210> 548
<211> 362
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (284)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (311)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (338)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (344)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (360)
<223> n equals a,t,g, or c
<400> 548
caatcaccta ttcacttctc atgcacccgg atgctctgga agagcctgat gaccagaacc 60
gtatttagtc tccattgtct tgcattggga tttgagaaga aaatcagaga gggaagatct 120
ggtatttcct ggcctaaatt ccccttgggg aggacaggga gatgctgcag ttccaaaaga 180
gaaggtttct tccagagtca tctacctgag tcctgaagct ccctgtcctg aaagccacag 240
acaatatggt ccccaataac cgaatgcacc ttctgtgctt ccancttctt ccttgaaatt 300
caagggtott neegttteec catteecece caggecante caanttatte caaaccetgn 360
tt
                                                                    362
<210> 549
<211> 448
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (159)
<223> n equals a,t,q, or c
<220>
<221> misc feature
<222> (239)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (251)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (259)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (281)
<223> n equals a,t,g, or c
<220>
<221> misc feature
```

PCT/US00/05883

<222> (284) <223> n equals a,t,g, or c <220> <221> misc feature <222> (299) <223> n equals a,t,g, or c <220> <221> misc feature <222> (301) <223> n equals a,t,g, or c <220> <221> misc feature <222> (319) <223> n equals a,t,g, or c <220> <221> misc feature <222> (343) <223> n equals a,t,g, or c <220> <221> misc feature <222> (374) <223> n equals a,t,g, or c <220> <221> misc feature <222> (396) <223> n equals a,t,g, or c <220> <221> misc feature <222> (437) <223> n equals a,t,g, or c <220> <221> misc feature <222> (446) <223> n equals a,t,g, or c <400> 549 ggatggcagg agagcitgtc attgagcctg gcaatttagc aaactgatgc tgaggatgat 60 tgaggtgggt ctacctcatc tctgaaaatt ctggaaggaa tggaggagtc tcaacatgtg 120 tttctgacac aagatccgtg gtttgtactc aaagcccana atccccaagt gcctgctttt 180 gatgatgtct acagaaaatg ctggctgact gaacacattt gcccaattcc aggtgtgcnc 240 agaaaaccga naatattcna aattcccaat ttttttctta ngancaagaa aaaaatgtng 300 ncctaaaagg ggttaattna aggggttagg ggttatgaaa gancttgatt tggatctctt 360

tttattttaa tttnaatttc acttttgaca tccaanaaaa actttgttga aatacttctg 420

448

```
ttctcaatgt tttgganaaa aatcancc
<210> 550
<211> 502
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (13)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (25)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (153)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (158)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (207)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (296)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (318)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (327)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (329)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (342)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (381)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (412)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (427)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (463)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (493)
<223> n equals a,t,g, or c
<400> 550
aattcggcag agnaaaccat ttacncaaat aaagtatagg cgatagaaat tgaaacctgg 60
cgcaatagat atagtaccgc aaggagaaga tgaaaaatta taaccaagca taatatagca 120
aggacttaac ccctatacct tctggcataa tgnaattnaa ctaggaaatg aactttgcaa 180
gggggagcca aagcttaaga cccccgnaaa ccagacggag cttaccttaa ggaacagctt 240
aaaagaggca cacccgtctt atgtaggcaa aatagtgggg aaggtttttt aggttngagg 300
cggaccaaac cttaccgngg cctggtngnt agcttggttg tnccaggtta ggatctttta 360
gtttccaact ttaaattttg ncccacagga accettttaa atccccttgt tnaattttaa 420
ccgtttngtc cccagggggg accagttttt tggccattgg ggnaaaacct tttggggggg 480
gttaaaaatt ttnccccct gg
                                                                   502
<210> 551
<211> 119
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (35)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (57)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (98)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (104)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (107)
<223> n equals a,t,g, or c
<400> 551
aaaaaggaaa ttaagagaag gtagaaattt aaatntttta atgaaaataa tgctttnaat 60
cattaaaaca ggatatgaat actccaatcc tttttaanat tatnacngtt ttcaaaatt 119
<210> 552
<211> 396
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (209)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (357)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (370)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (373)
<223> n equals a,t,g, or c
<220>
```

```
<221> misc feature
<222> (379)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (389)
<223> n equals a,t,g, or c
<400> 552
gtagtaaatt gaaacctggc gcaatagata tagtaccgca agggaaagat gaaaaattat 60
aaccaagcat aatatagcaa ggactaaccc ctataccttc tgcataatga attaactaga 120
aataactttg caaggagagc caaagctaag acccccgaaa ccagacgagc tacctaagaa 180
acagctaaaa gagcacaccc gtctatgtng caaaatagtg ggaagattta taggttgagg 240
cgacaaacct accgagcctg gtgatagctg gttgtccaag ataaatctta gttcaacttt 300
aatttgccca cagaacctct aatccccttg ttaatttact gtttgtccaa agaagancac 360
tctttggacn ctnggaaanc cttgtaaana aattaa
                                                                    396
<210> 553
<211> 253
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (4)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (96)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (100)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (203)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (216)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (218)
```

```
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (221)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (230)
<223> n equals a,t,g, or c
<400> 553
gaanatcgaa aggagaaaaa aagccgagat gtagtctcta agaaagagga acgtaagcgt 60
acaaaaaaga aaaggaacaa agccaagaaa ggacanagan gaaatgcttt gggaccagtc 120
tattettgga ttttgaactt teaaattggt teteceaagt taaattgaaa aatagtgaga 180
cttggtttta tgaatcgtgt tentacaett tettantnat nggteetttn etectaceaa 240
                                                                    253
ggctattaac aat
<210> 554
<211> 431
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (277)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (306)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (354)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (383)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (395)
<223> n equals a,t,g, or c
<220>
<221> misc feature
```

```
<222> (399)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (417)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (430)
<223> n equals a,t,g, or c
<400> 554
gcccaaaccc actccacctt actaccaqac aaccttagcc aaaccattta cccaaataaa 60
gtataggcga tagaaattga aacctggcgc aatagatata gtaccgcaag ggaaagatga 120
aaaattataa ccaagcataa tatagcaagg actaacccct ataccttctg cataatgaat 180
taactagaaa taactttgca aggagagcca aagctaagac ccccgaaacc agacgagcta 240
cctaagaaca gctaaaagag cacacccgtc tatgttngca aaatagtggg aaaaatttat 300
aggttngaag cgacaaacct acgagcctgg tgatactggt tgttcccaga atanaatctt 360
agtiticacti tiaattitigg concagaaco occinaatno octiggitaa tittacintit 420
agttccaaan a
                                                                    431
<210> 555
<211> 489
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (13)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (17)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (24)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (97)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (109)
```

```
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (113)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (127)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (137)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (138)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (163)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (164)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (179)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (184)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (186)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (198)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
 <222> (232)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (246)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (276)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (322)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (332)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (346)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (350)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (368)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (382)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (411)
<223> n equals a,t,g, or c
```

```
<220>
 <221> misc feature
 <222> (413)
 <223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (459)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (486)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (488)
<223> n equals a,t,g, or c
<400> 555
gacccactcc acntgcnaaa gctnaaacta ctctgctttc tcacttacct acacttttga 60
cttaccacat acatetetet etteggatat gagetgnaaa eteettatnt canegeteta 120
actctgnagt cctaatnntt ctagttggac caaaaaaaat ccnnattgtt tgatctaang 180
agangnaatt taccaatnet gtatacgeat gtgtgtgtgt egettaaaeg anetgteegg 240
ttatanaaaa tootgatogt cataaatoat gtotanacat catgtaatga attgcacgat 300 .
ttaatattgt ccctattagc antcactaca anctattct caaatntacn tatttctccg 360
taaacaanca ttcagtactc cntcggatct ctaaaaatcc tctatgatct ntncacatca 420
ctgataaaga ccaattcgta tatacatgac tgtccttanc acatattcac tatcagtaga 480
aaagcnanc
                                                                   489
<210> 556
<211> 77
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (13)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (26)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (66)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (75)
<223> n equals a,t,g, or c
<400> 556
ggaaaatatt atncagtaaa caatantgtg tgaactttta aaatggataa tagggcatgg 60
                                                                     77
actgantgct gctanct
<210> 557
<211> 506
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (221)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (228)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (270)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (286)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (293)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (294)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (333)
<223> n equals a,t,g, or c
<220>
<221> misc feature
```

```
<222> (339)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (343)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (350)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (369)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (402)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (466)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (471)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (480)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (482)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (501)
<223> n equals a,t,g, or c
<400> 557
gcccactcca ccttactacc agacaacctt agccaaacca tttacccaaa taaagtatag 60
gcgatagaaa ttgaaacctg gcgcaataga tatagtaccg cagggaaaga tgaaaaatta 120
```

```
taaccaagca taatatagca aggactaacc cctatacctt ctgcataatg aattaactag 180
  aaataacttt gcaaggagag ccaaagctaa gacccccgaa nccagacnag ctaccttaga 240
  acagettaaa gageaeaeee gtetatgttn caaaatagtg ggaaanattt atnngttgaa 300
  gcgacaaacc taccgacctg gtgatactgg ttntccaana tanatcttan ttcactttaa 360
  tttgccacng aacctcttaa tcccttgtta atttactgtt antccaaaaa agacactctt 420
  tggacctagg aaaaaacctt tttaaaaaat taaaaattta cacccntttt nggctaaaan 480
  cngccccat tttaaaaaag nttcaa
  <210> 558
  <211> 298
  <212> DNA
  <213> Homo sapiens
  <220>
<221> misc feature
  <222> (65)
  <223> n equals a,t,g, or c
  <220>
  <221> misc feature
  <222> (150)
  <223> n equals a,t,g, or c
  <220>
 <221> misc feature
  <222> (166)
  <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (252)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (263)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (269)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (286)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (291)
```

```
<223> n equals a,t,g, or c
<400> 558
gtattatcaa taacaataaa aataaagcaa atacattaga cattaccctc ccatcaggtg 60
cacanaagaa agtcaaggct ggaatttcat totottatot aaatototot gttotototo 120
agggaatatt ttcagagaat aggtggaatn aagtgaggct gtgganaatg ttatctataa 180
taggatagac tttcttctgt gcacctgatg ggagggtaat gtctaatgta ttatcagtaa 240
cagtaaaaat anagcaaata congaaaant aaataagggg gggconttot naaaaato
<210> 559
<211> 295
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (10)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (19)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (29)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (51)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (76)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (109)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (128)
<223> n equals a,t,g, or c
<220>
<221> misc feature
```

```
<222> (177)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (183)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (186)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (187)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (201)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (234)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (276)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (286)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (290)
<223> n equals a,t,g, or c
<400> 559
acaaagtgan cggtctggna agtcccggnc cggaaattcc cgggtcgacc ngaaccgtcc 60
ggataaatac tgtcantcca ttgatttatc tcctcctgtc ccccatctna aatacccatg 120
ctgctttnct gagtgttgat gggggttacc atcttgatcc actgttgctc ttagaangcc 180
canaanntct ttgggcattg ncaaggaaat cccggattat ctggaaaacc ctcnctttct 240
cttcacggct gtaccagaaa atccctaaga cagatnttgc ggtggncgan caata
```

<210> 560

```
<211> 371
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (4)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (41)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (45)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (114)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (127)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (161)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (265)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (299)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (311)
<223> n equals a,t,g, or c
<220>
```

<221> misc feature

```
<222> (341)
 <223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (350)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (360)
<223> n equals a,t,g, or c
<400> 560
gctnttttct gccgccaagc gcccggccgc gcgccggccg ncgcnacccg ctccggggac 60
agtgccaggt ggggagtttg actggggcgg tacacctgtc aaacggtaac gcangtgtcc 120
taaggcnagc tcagggagga cagaaacctc ccgtggagca naagggcaaa agctcgcttg 180
atcttgattt tcagtacgaa tacaagaccg tgaaagcggg gcctcacgat ccttctgacc 240
ttttgggttt taagcaggag gtgtnagaaa agttaccaca gggataactg gcttgtggng 300
gccaagcgta natagcgacg tcctttttga tccttcgatg ncggctcttn ctatcattgn 360
gaagcataat t
<210> 561
<211> 205
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (2)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (35)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (67)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (186)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (193)
<223> n equals a,t,g, or c
```

```
<220>
 <221> misc feature
 <222> (200)
 <223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (201)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (202)
<223> n equals a,t,g, or c
<400> 561
tnaaagcccc cgcgaggggc ccggggggg gtccnttaaa cctgcgggcc gccggtgaaa 60
taccacnact ctgatcgttt tttcactgac ccggtgaggc ggggggggga gccccgaggg 120
getetegett etggegecaa gegeeegge gegegegge egggegegae eegeteeggg 180
gacagngcca ggnggggagn nngac
<210> 562
<211> 580
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (3)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (4)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (19)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (21)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (23)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (108)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (114)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (131)
<223> n equals a,t,g, or c
<220>
<221> misc feature.
<222> (383)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (386)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (448)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (480)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (511)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (515)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (542)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (561)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (569)
<223> n equals a,t,g, or c
<400> 562
ttnngactat agttttagnt nanacccctg caggtaccgg tccggaattc ccgggtcgac 60
ccacgcgtcc gcccattttt ccggttgata atgcaataga taatgggnaa gaanttcaag 120
ttgcattgcc natcttaatg gcagcttatg caatggcgga agcgtttatg tcaacaggag 180
ttggagcttc tcttatccta attgcattaa aagtaggaat tactgctaaa actgttgcag 240
ttataggagc tattgtcaca tcaatattat caatagcaac tgggacaagt tggggaacat 300
ttgcagcctg tgcacctatt tttttatggc taaatcatat agttggcgga aatattttat 360
ttgacaacaa gcagctattg cangangagc atgttttgga agataatata ggactatttc 420
agatactaca atagtaaagt ctggtatnca aaaaagtttg aaagttgtaa gaaagaattn 480
gacacccaag gtggtatggg caagcattag ntttnataat tcaaggaatt aataggcatt 540
tncttaatgg gtgggattta ncaatgggna tttaaccctt
<210> 563
<211> 198
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (2)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (4)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (39)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (78)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (91)
<223> n equals a,t,g, or c
```

```
<220>
 <221> misc feature
 <222> (130)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (132)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (164)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (173)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (197)
 <223> n equals a,t,g, or c
 <400> 563
 gngngcccta ggcctcgcgc tgcccggccg gctcctcgng tcccactccc ggcgcacgcc 60
 ctecegegag tecegggnee etecegegee netatacteg gegegegege ageatggege 120
 cccegcaggn enteacgtte gggettetga ttgccgcgge gaengegaet ttngccgcag 180
 ctcaggaaga atggagna
                                                                    198
 <210> 564
 <211> 176
 <212> DNA
 <213> Homo sapiens
 <220>
 <221> misc feature
 <222> (7)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (22)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (25)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (36)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (70)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (104)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (121)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (133)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (139)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (144)
<223> n equals a,t,g, or c
<400> 564
caactgnage teattetgtt anagnteete atteanetgg teaetgtgga cagagggtgt 60
tggcctgctn ccttctaagt attcttaaag ccatggattt ttgnggacca ttttcttctg 120
ntcttccttg agntatttnc tttntttgct atcttgggac tcttctttgt gcttga
<210> 565
<211> 264
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (4)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (23)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (30)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (47)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (139)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (246)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (253)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (254)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (255)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (257)
<223> n equals a,t,g, or c
<400> 565
gcangtattc tacctaaatc ttncaatttn ctttaaatgg taagagnttc taaaacagac 60
aataatttaa caagctcagc tctgctttat ctgagtttag tggtcctaat atatatgtag 120
agaaagatgg tggggttgnt cacctctgta cagaccatct gtatgttagg tgacattgat 180
tatgggttat aatcagggaa actaattgga tttagtgaca aaaataaaaa gtttttttt 240
tatganaaaa aannnanggg ggac
                                                                    264
```

```
<210> 566
  <211> 411
  <212> DNA
  <213> Homo sapiens
  <220>
  <221> misc feature
  <222> (1)
  <223> n equals a,t,g, or c
  <220>
  <221> misc feature
  <222> (96)
  <223> n equals a,t,g, or c
  <220>
  <221> misc feature
  <222> (101)
  <223> n equals a,t,g, or c
  <220>
  <221> misc feature
  <222> (110)
  <223> n equals a,t,g, or c
  <220>
  <221> misc feature
  <222> (142)
  <223> n equals a,t,g, or c
<220>
  <221> misc feature
  <222> (178)
  <223> n equals a,t,g, or c
  <220>
  <221> misc feature
  <222> (206)
  <223> n equals a,t,g, or c
  <220>
  <221> misc feature
  <222> (291)
  <223> n equals a,t,g, or c
  <220>
  <221> misc feature
 <222> (295)
 <223> n equals a,t,g, or c
```

```
<220>
 <221> misc feature
 <222> (335)
 <223> n equals a,t,g, or c
<220>
 <221> misc feature
 <222> (382)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (385)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (387)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (393)
<223> n equals a,t,g, or c
<400> 566
nggacattga agccaaacca agccactatc agctggtgag tggaagcagc acggaggact 60
cgctccatgt tcatgctcag atggcagaga atgaanaaga nggtagtggn ggcggaggca 120
gtgaagagga tccccctgc anacaccaaa gctgtgaaca gaaagactgc ctggccanca 180
aaccttggga catcagcctg gcccancctg aaagcatccg cagtgaccta gagagttctt 240
gatgcacagt ctgacgatgt gccagacatc accttcagaa tgaaatgtgg nttcncccgc 300
teccatactg cageetgeec etegaceec agagneeaag gtgcaeegag cecaagtgee 360
catatgaacc tctctgccct ancenangga canactgtct tgaagccaga a
<210> 567
<211> 208
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (28)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (181)
<223> n equals a,t,g, or c
<220>
<221> misc feature
```

```
<222> (194)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (201)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (202)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (206)
<223> n equals a,t,g, or c
<400> 567
ggggaaaggg acctttccga aaaacatntt ttggggaaat aaaaatgtgg actgtgaaaa 60
208
nggggggcct tttnaaaaaa nnaaantt
<210> 568
<211> 322
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (1)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (11)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (191)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (204)
<223> n equals a,t,g, or c
<220>
<221> misc feature
```

```
<222> (291)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (300)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (306)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (320)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (321)
<223> n equals a,t,g, or c
<400> 568
ncttggtcta ncctggctgc tcagaaagag cagtcaggac ttgagggaag catcaaattc 60
tatacccata aactgcagtt ggaagtcagc tttttgaaat gtccagcctt tgcccaattg 120
tttcagatca tctcattcct caggctttgg caggtatcct gccctccatc ttattccagt 180
gtgttcacct natcaaggca gcanagtgga tgaaggagta agtctgccct ttgccatact 240
gaacagctgt ggaccccgat tggtgagggc tctgcatatg cctgtatgaa ngagatacan 300
                                                                   322
gtgtgngtgc acatgccggn nt
<210> 569
<211> 594
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (285)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (487)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (499)
<223> n equals a,t,g, or c
```

```
<220>
 <221> misc feature
 <222> (541)
 <223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (575)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (588)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (591)
<223> n equals a,t,g, or c
<400> 569
gggaacccga tcctaattca gagaatattg ctgcaatctc tcagtcttca gtgggttcag 60
acttgtttgt atttaaacct agtgagccaa ggccattgta tattcaaaag ggtatctcca 120
gagagaaagt ccagtgggga gtgtttgttc cacgagatgt ccctgaatcc ttcacctcag 180
aagcttacca gtggctaaat agatcccagt tttacttcct aacaaaatca cagagtttat 240
tgacattcag tacaaagtct ccagaagaaa aactcacacc aacanagcaa acagctgcta 300
gcagaagaaa gtcttcccac aaccccattt tatttcatat tgggaaaaca caggcaacag 360
caggatgaaa aactaaacga aactttagag aatgagctgg tacaactacc cttaacagaa 420
aacatacccg caattagtga gcttcttcac actccaccca tgtcctgcca tctgctgctt 480
tectgtnete catgtttgna aatteattge tgetgtetaa aggagaetaa gaagtgetaa 540
ngaaattcct gaaaaatgta gatatgggaa gaagnaaaac ggaaagtnaa natt
<210> 570
<211> 310
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (274)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (286)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (288)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (290)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (305)
<223> n equals a,t,g, or c
<400> 570
gcggacgcgt gggaaataat tgcattaaaa4 tacaaaaggt gatagggaag aattaaaaga 60
tttgcagtat tgtacacaaa agctaataat tttgtgtact ttttatttat tttggaggtt 120
ttatatgatc ttcaattgag tattaaataa tttgcctaga ttaagcctaa aatgatgacc 180
agctaattaa agaagatatt ttqaatctgg ttctgagcta aagttgagta aattcttagc 240
taagaaaaaa ttggaaatcc atcatctata ttancaacag attctnanan taaattggta 300
acttntatga
                                                                    310
<210> 571
<211> 109
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (46)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (64)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (94)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (97)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (108)
<223> n equals a,t,g, or c
<400> 571
gggcggttgc ggttagtgga ccgggaccgg taggggtgct gttganatta tggttgaccc 60
```

```
ctancccgg taccctgaat gatagatcga ggangantta actatagna
                                                                    109
 <210> 572
<211> 429
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (295)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (322)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (374)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (392)
<223> n equals a,t,q, or c
<220>
<221> misc feature
<222> (399)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (419)
<223> n equals a,t,q, or c
<220>
<221> misc feature
<222> (420)
<223> n equals a,t,g, or c
<400> 572
gtgtatttta caatttttt aaaggaaaat ttaaaaatatg aaatgtttgt tttgtcttaa 60
cagggtatec ettetecete cettgteage etteetteet tetttgaaag gagaagteat 120
acgttaagta gatctacaac tcatttgata tgaagcgtta ccaaaatctt aaattataga 180
aatgtataga cacctcatac tcaaataaga aactgactta aatggtactt gtaattagca 240
cttggtgaaa gctggaagga agataaataa cactaaacta tgctatttga ttttncttct 300
tgaaagagta aggtttacct gntacatttt caagttaatt catgtaaaaa atgatagtga 360
ttttgatgta attnatctct tgatcgaatc tngcattcna aaggccaata atttaaagnn 420
ggctatcaa
                                                                   429
```

```
<210> 573
<211> 202
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (33)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (45)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (152)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (158)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (173)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (189)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (194)
<223> n equals a,t,g, or c
<400> 573
gggctggggc tgaccgagga ggtggagggt ggnagaggct ggggntgata aatctattga 60
202
aaaaaaaana aatntaatat gc
<210> 574
<211> 229
<212> DNA
```

<213> Homo sapiens

```
<220>
 <221> misc feature
 <222> (30)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (53)
 <223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (72)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (148)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (163)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (172)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (191)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (220)
<223> n equals a,t,g, or c
<400> 574
gcccacgcgt ccgtctagat cgcgagcggn cgcccttttt ttttttttt canaagagct 60
acattgtgtc antggacatt tttaaaaact gtgattttta ataatgtcca atgactgcaa 120
gtcggcctgg attttcactt gcaaaggnta cagctgcatt gtnaggtctc cnagccctgc 180
agagagetee ntecactggt tageagtgtg ttgtgttttn catteattt
                                                                   229
<210> 575
<211> 260
<212> DNA
<213> Homo sapiens
```

```
<220>
<221> misc feature
<222> (196)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (215)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (217)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (250)
<223> n equals a,t,q, or c
<220>
<221> misc feature
<222> (257)
<223> n equals a,t,g, or c
<400> 575
gaaaagctta aagaaggttt tactgatcca gatgttgtcc agagacttcg agccttgagg 60
gttcttggtg ctgatgttgg tgaaggtgtg cgcgggggatc agtaaaagct taaagaaggt 120
tttcacaggt cactgggctg tggtgagaga aggcctcacg aacccttgga ttccggataa 180
ctggtcttgg ggcggngtgg cttctgaaca ctgcnantgc taccgagttc tacactgaaa 240
                                                                    260
aggactggan caagaangac
<210> 576
<211> 263
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (208)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (212)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (233)
```

```
<223> n equals a,t,g, or c
   <220>
   <221> misc feature
   <222> (251)
  <223> n equals a,t,g, or c
  <220>
  <221> misc feature
  <222> (255)
  <223> n equals a,t,g, or c
  <400> 576
  ggtttttgtcc ttgtgttagg cagtctgagc agcgagtgat ccagagcgca gccaacaaag 60
  cagcagatag cagtgtacag aaagcaaaaa aggaactgta tgtgaggcac ttgtttctgt 120
  taatatccat attcctgtta acacacacc tttctcatgt aaaaagaaaa ataaataaat 180
  ggtctgaact ttgaaaactt tgtgctgnta ancatagatt ttggagacaa atnaatagat 240
  gctatgctgt ntcantttca tag
                                                                      263
  <210> 577
  <211> 366
  <212> DNA
  <213> Homo sapiens
  <220>
  <221> misc feature
  <222> (297)
  <223> n equals a,t,g, or c
  <220>
  <221> misc feature
  <222> (361)
  <223> n equals a,t,g, or c
  <220>
  <221> misc feature
. <222> (364)
  <223> n equals a,t,g, or c
  <220>
  <221> misc feature
  <222> (365)
  <223> n equals a,t,g, or c
  <220>
  <221> misc feature
  <222> (366)
  <223> n equals a,t,g, or c
  <400> 577
  gaggaaacac tgtctatgat aggatttcca aaagtatttg tggacagtta aatgctaatt 60
```

```
aatatacatc tgtagttatt ctacattttc ttgaaatttg ggaggttaat accaagtatt 120
catttcatga tgtaaagaaa ctgaacagtg aagtggcttg attgcttaaa ctattgactt 180
ggtaagtcta ctgtatataa catctaatat atatattaca ggccaaatga actaaacatt 240
gccttgctat attcaccaaa aggacttaat tcttgttttt ttcccagttt tatatanagg 300
aaacactatg ataggatttc ctaaagtatt tgtggacagt taaatgctaa ttatatacat 360
ntgnnn
<210> 578
<211> 595
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (4)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (5)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (14)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (158)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (212)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (376)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (414)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (419)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (483)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (564)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (565)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (570)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (572)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (576)
<223> n equals a,t,g, or c
<400> 578
gganngctgg attnggccca ggcaaagacc agcaggaaga agaaatttgg gaaaaaaaac 60
aaggaccagg gaggtgagta ctgagggcca gggaagagga gtaggggtgt ctcagggtga 120
tetetggece acceptttgg coeettetee caggietnac ccaggeacag tacattgact 180
gettecagaa gateaagtae agetteaace tnetggtagg tggeteecca caagtteace 240
aggeotetec tetteccett cetecceagt aatectetge tgtetggaet caaccatece 300
aagcettttt ettetteate tacteeect agaaceteee etteeetett gggaettttg 360
ggaagtgcca gccttncagc caaggcataa aacaattatg gtgacctggt gaanatggng 420
tggtgtgaag ggtggtgaca ggcattgctc tttgtcccca agggaaaggc tggcccacct 480
ggnttgaagg agacaagtgc cccctgagct cgtacacatt cctctttaag tcccttgaac 540
tttcgtgaag ttaagggacg acannggtgn tnaaanacgg acaggcttga agtca
<210> 579
<211> 132
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (2)
```

```
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (17)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (64)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (77)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (79)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (110)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (115)
<223> n equals a,t,g, or c
<400> 579
cnaccttcta agagatntaa tgggtcacta tgtgtggtta ttctacatta agcctacaac 60
attnttcagg gttgganana tgaactaata ctggtgaaaa tttacctaan acctnggtta 120
                                                                    132
tcaaaaacat ct
<210> 580
<211> 558
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (1)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (9)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (14)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (42)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (236)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (269)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (353)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (370)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (374)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (410)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (411)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (428)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (507)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (529)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (543)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (547)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (553)
<223> n equals a,t,g, or c
<400> 580
ntcggaatna accntcactt aagggaacaa aagctggagg angcgcgcct gcaggtcgac 60
actagtggat ccaaagaatt cggcacgagg ccgcgttgac cactggcgtc tcgctggtgg 120
tettegagae eggegttggt tgaaaatege eeceggettt ggeegtggee gegggtgaga 180
tteggegeee agageeeeeg ggggeeteag eteacegege getgeeeeat gtgegneggt 240
gaaacccagg ccccgacagg cgctgccgnc ttcccccccg ggtgcggttc gttcgcgagg 300
tgttggcccc tgattccttg accccgattg cagaccctta accttgttct ttnttccgca 360
gacaatggtn cttncccacg gctgtacaac cgacggtcgg ccaaggaccn nggggttttg 420
gggggaantt tggtttttcc caaggttttt caaattaaag ttgtttttgt tttaaaaaaa 480
aaaaaaaaa aaaaattggg ggggtanttt ttgggggggg cccgggggnc ccatggtttt 540
                                                                   558
ttncaanccg ggnggggt
<210> 581
<211> 120
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (62)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (65)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (70)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (99)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (103)
<223> n equals a,t,g, or c
<400> 581
ggggacccgg cccaattccc gggtcgacca cgcgtccgca cgattggaag aagaagcttt 60
tnccnttggn ctaattcgca ctttcctcac gaggaaatna aantagggca aaaaccaaac 120
<210> 582
<211> 260
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (5)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (211)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (240)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (245)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (259)
<223> n equals a,t,g, or c
<220>
```

```
<221> misc feature
<222> (260)
<223> n equals a,t,g, or c
<400> 582
ggcanagctc agaatgctta tttccaatta aaacgcctac agctgcctcc tagaatatag 60
actgtctgta ttattattca cctataatta gtcattatga atgctttaaa gctgtacttg 120
catttcaaag cttattaaga tataaatgga gattttaaag tagaaataaa tatgtattcc 180
atgttttaa aaaaaaaaa aaaaaaaaa nccccggggg gggccccggt ccccatttgn 240
cccantgggg ggccgtttnn
                                                                    260
<210> 583
<211> 469
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (162)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (423)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (460)
<223> n equals a,t,g, or c
<400> 583
gggaggcccc cggcgccccc ccggtgtccc cgcgaggggc ccggggcggg gtccgccggc 60
cctgcgggcc gccggtgaaa taccactact ctgatcgttt tttcactgac ccggtgaggc 120
gggggggcga gccccgaggg gctctcgctt ctggcgccaa gngcccggcc gcgcgccggc 180
cgggcgcgac ccgctccggg gacagtgcca ggtggggagt ttgactgggg cggtacacct 240
gtcaaacggt aacgcaggtg tcctaaggcg agctcaggga ggacagaaac ctcccgtgga 300
gcagaagggc aaaagctcgc ttgatcttga ttttcagtac gaatacagac cgtgaaagcg 360
gggcctcacg atccttctga ccttttgggt tttaagcagg aggtgtcaga aaagttacca 420
canggataac tggcttgtgg cggccaaacg ttatagcgan gtcgctttt
<210> 584
<211> 361
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (253)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (265)
<223> n equals a,t,g, or c
<400> 584
ggttagtttt accetactga tgatgtgttg ttgccatggt aatcetgete agtacgagaa 60
gaaccgcagt tcagacattt ggtgtatgtg cttggctgag gagccaatgg ggcgaactac 120
catctgtggg attatgactg aacgcctcta agtcagaatc ccgcccaggc ggaacgatac 180
ggcagegeeg eggageeteg gttggeeteg gatageeggt eeceegeetg teecegeegg 240
egggeegeee ceneeteeae gegeneegeg egegegggag ggegegtgee eegeegegeg 300
ccgggaccgg ggtccggtgc ggagtgccct tcgtcctggg aaacggggcg cggccggaaa 360
                                                                    361
g
<210> 585
<211> 482
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (32)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (148)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (165)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (169)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (176)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (203)
<223> n equals a,t,g, or c
<220>
<221> misc feature
```

```
<222> (207)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (224)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (236)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (275)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (319)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (363)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (370)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (380)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (405)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (426)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (441)
```

```
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (445)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (450)
<223> n equals a,t,g, or c
<400> 585
ggtacctaac aaacccacag gtcctaaact ancaaacctg cattaaaaat ttcggttggg 60
gcgacctcgg agcagaaccc aacctccgag cagtacatgc taagacttca ccagtcaaag 120
cgaactacta tactcaattg atccaatnac ttgaccaacg gaacnagtna ccctanggat 180
aacagcgcaa tectatteta tanteentat caacaatagg gttnacgace tegatnttgg 240
atcaggacat cocgatggtg cagoogotat aaaangttog tttgttcaac cattaaagtc 300
ctacgtgatc tgaattcana ccggagtaat ccaggtcggt ttctatctac ttcaaattcc 360
tenetgtaen acaggacatn aagatataag geetaettet caaanegeet teeceegtaa 420
atgatntcat ctcaacttaa ntatnatacn cacaccctcc caataaaagg gtctgttggg 480
tt
                                                                    482
<210> 586
<211> 492
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (5)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (11)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (15)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (19)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (79)
```

```
<223> n equals a,t,g, or c
 <220>
. <221> misc feature
<222> (447)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (458)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (463)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (480)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (491)
<223> n equals a,t,g, or c
<400> 586
ccganttcta nattnaggna cacctgccgg taccgggtcc ggaattcccg ggtcgaccca 60
egegteeggt cettteeent teeceecee caegeeteet ecceteetee egeceaegee 120
ccgctccccg cccccggagc cccgcggacg ctacgccgcg acgagtagga gggccgctgc 180
ggtgagcctt gaagcctagg gcgcgggccc gggtggagcc gccgcaggtg cagatcttgg 240
tggtagtagc aaatattcaa acgagaactt tgaaggccga agtggagaag ggttccatgt 300
gaacagcagt tgaacatggg tcagtcggtc ctgagagatg ggcgagcgcc gttccgaagg 360
gacgggcgat ggcctccgtt gccctcggcc gatcgaaagg gagtcgggtt cagatccccg 420
aatccggagt ggcggagatg gcgccgngag gcgtcagngc ggnaacgcga ccgatcccgn 480
agaagcccgg ng
                                                                    492
<210> 587
<211> 248
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (65)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (122)
```

```
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (124)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (205)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (210)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (211)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (220)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (242)
<223> n equals a,t,g, or c
<400> 587
ccacgcgtcc ggttaacaac aagaaaggtg taattagaat tgggatgtgg atatttactg 60
tatgnacaac acatttacag ttctgtaatg caaggatgca gtttaaaaat gtgaagtagt 120
gnanggtttt tgaaaataag ctttaaaata tagggatctt gaaaggcccc cgggggtact 180
attttataac ttagaataaa tgggnaatcn naactgtgtn tttggtaaat taatttttta 240
antatttt
                                                                   248
<210> 588
<211> 653
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (1)
<223> n equals a,t,g, or c
<220>
<221> misc feature
```

```
<222> (2)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (3)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (11)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (24)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (475)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (510)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (544)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (575)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (578)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (604)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (626)
```

```
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (653)
<223> n equals a,t,g, or c
<400> 588
nnncttccta ntggaaattc ccgngacact attgaaggta cgcctgcagg taccggtccg 60
gaattcccgg gtcgacccac gcgtccgcgg acgcgtgggg actgcttaga aatatagctg 120
aagtgatcac cacagccata aaattgttta agaaagattt atataatgtt tacaaatctg 180
gaatcaagga ttttagctga aatcctttaa gagatattag agcaagtatt taattcaggt 240
attiticaagt titaaaactt aacctgttta cctactaaaa ataaaatagc tagtittitt 300
ctgcatataa aagttcattg aaatgatatg cccttatttg caatactttt cccataaagt 360
tttaagtgtg aaagaattgt aatttactag atatgtttgg tatggggatat tttgttaggc 420
aagttttctt ttttcttctt aaattgcaat aggcttccaa aaagagtata attgnttcag 480
aacaaattaa ctcttggcat tatacgtctn cctttttctt tacagtatta gtaaaatgaa 540
aaantggaca ctttctgatt taacttcact aatgnaanta ctctctcaag gaagctttta 600
aaanttaaat taccatcaca caaccntttt atagtaaggc aacatttggt ttn
<210> 589
<211> 625
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (3)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (364)
<223> n equals a,t,q, or c
<220>
<221> misc feature
<222> (375)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (398)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (400)
<223> n equals a,t,q, or c
<220>
```

```
<221> misc feature
<222> (521)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (522)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (525)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (560)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (562)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (563)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (603)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (618)
<223> n equals a,t,g, or c
<400> 589
gengaaacet eeegtggage agaaqqqeaa aagetegett gatettgatt tteagtaega 60
atacagaccg tgaaagcggg gcctcacgat ccttctgacc ttttgggttt taagcaggag 120
gtgtcagaaa agttaccaca gggataactg gcttgcggcg gccaagcgtt catagcgacg 180
tegetttttg atcettegat gteggetett cetateattg tgaageagaa tteaceaage 240
gttggattgt tcacccacac gagccctgtg cttttggtgt aaataatgta caatttgtgg 300
atgtcattga atctagagga ctttcccctt tttatatttg tattaacttt aacttattaa 360
aaanaaaaaa agaanaagaa aaacaattta taaaaaanan aaaaagcaac caaccccaac 420
aacaaaaaag aatggtttgg tattggagaa gggatggtca gttaagcctg ctggcacacg 480
acggaatgga tctgggcccg gggaccactt tcatactacg nnctnatctt tggataccca 540
gggaggggca acceptttcgn tnngggctgt acceagaagg tggaacggag tttggacaga 600
                                                                   625
ctntccatta ggcgtggntc tttat
```

```
<210> 590
<211> 365
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (71)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (177)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (205)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (264)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (300)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (305)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (341)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (346)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (349)
<223> n equals a,t,g, or c
```

```
<400> 590
ggcagagttt tcaaaaccaa gtgcacaaac gtttattaag catttaggaa atattatgta 60
aagaacetet nateettgea tgeeaggeae tettteaate aetteagtga eeatttttee 120
aaaattctga aacatccaca cttagggttt tctttgaatt tgggggtgcc ctccccncac 180
ccggcagcct tctgtgtcag ggggntacgg tcttgatata gacaccattt tttggaccta 240
ggggcagttt tgggattcta gctncagggg tacctgggtc ttaagggcaa ggtttgggan 300
ccggnacttt ttgcaaaacg tgggggcagt ttcaattttg nccctnaang aggccctaga 360
                                                                    365
cggga
<210> 591
<211> 65
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (48)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (53)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (55)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (56)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (57)
<223> n equals a,t,g, or c
<400> 591
gccctatagt gagtcgtatt acaattcact ggccgtcgtt ttacaacntc gtnannngga 60
aaacc
<210> 592
<211> 269
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (8)
```

```
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (28)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (96)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (123)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (127)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (129)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (132)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (134)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (138)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (152)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (161)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (198)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (212)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (221)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (234)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (252)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (256)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (267)
<223> n equals a,t,g, or c
<400> 592
ggcagagngt gaaggctaga cccggttnac tggaattccc ctggcgatca aggggtccta 60
gtacaccgca atcatgtcta taatgtccta taacgnaggg gccgtaatgg ccatgaaagg 120
ggnaagnanc thintggncc atcgctgcag anaggcgctt ngggaatcca ggcccagaat 180
ggtgaaccac gggacttnca gaaagatctt tncccatggg ntgaaccggt tgtnaatggg 240
                                                                    269
tttgggccgg gnttgncaat taaggtnca
<210> 593
<211> 307
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (8)
```

```
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (160)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (172)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (267)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (268)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (278)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (282)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (302)
<223> n equals a,t,g, or c
<400> 593
ggcagagnag cattetetaa etetaceeca ceetacaaaa tgcatatgga ggtaggetga 60
aaagaatgta atttttattt totgaaatac agatttgago tatcagacca acaaacotto 120
cccctggaaa agtgagcagc aacgtaaaaa cgtatgtgan agcctctctt gnaatttcta 180
gttagcaatc ttaaggctct ttaaggtttt ctccaatatt aaaaaatatc accaaagaag 240
tcctgctatg ttaaaaacaa acaacannaa acaaacanca gnaaaaaatt taaaaaaaaa 300
                                                                    307
ancgggg
<210> 594
<211> 128
<212> DNA
<213> Homo sapiens
```

<220>

```
<221> misc feature
 <222> (48)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (72)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (94)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (123)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (124)
 <223> n equals a,t,g, or c
 <400> 594
 tatccacact gtcaaacagg ttggtgtggg ttcattggca ttctttgnaa tactgcttaa 60
 ttgctgatac cntatgaatg aaacatgggc tgtnattact gcaatcactg tgcctatcgg 120
                                                                     128
 canntaat
 <210> 595
 <211> 598
 <212> DNA .
 <213> Homo sapiens
 <220>
 <221> misc feature
 <222> (214)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
. <222> (234)
 <223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (236)
<223> n equals a,t,g, or c
<220>
<221> misc feature
```

```
<222> (252)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (279)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (303)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (306)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (328)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (361)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (367)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (384)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (391)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (407)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (426)
```

PCT/US00/05883

```
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (552)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (560)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (562)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (591)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (593)
<223> n equals a,t,g, or c
<400> 595
gtggtttttg gctctttcag agaggtctca ggttctttcc atgcagactc ctcagatctg 60
aacacagttt agtgctttac atqctgtqct ctttgaagag atttcaacaa gaatattgta 120
tgttaaagca tcagagatgg taatctacag ctcacctctg aaggcaaata taagctggga 180
aaaaagtttt gatgaaattc ttgaagttca tggngatcag tgcaattgac cttntncctc 240
actoctgoca gntgaaaatg gatttttaaa ttatactgna gctgatgaaa ctcctgattt 300
tgnagntaat ttattaagtc tgggatgnag aacttcaaga agtaagagct aagttctaag 360
ntcatgnttg gaaattaata cttnatttgg ngctgggcta ttttganttt gggggggaat 420
cagcantatt cttcagaagg ggacctggtt tcttcaaggg aaagaaacac tcttattcca 480
aactacagaa taatggggta aacatgctaa ataggtctat aaggaaacca aatactggat 540
tatctcggag gntattggtn anaagggcct tgggtaaaaa taagggtaaa nanaaagg
<210> 596
<211> 465
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (11)
<223> n equals a,t,g, or c
<220>
<221> misc feature
```

```
<222> (423)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (438)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (465)
<223> n equals a,t,g, or c
<400> 596
gaaaaaaaat ncattgtaaa taacctcagc tgggatgagg agtgacagaa tatcaaaata 60
atttgtggct gtggattttt ttaactgcta gtagtggaat actggaaaag cttcatttct 120
gaagatgaat tttattttta aaaaatacat gcacactcaa aacttttagc tttgatcaca 180
agtggacaaa tttctgaaac caaaggcaac taagttgctg tgttagctct tgctggattt 240
tgagcctagg tcctactgtc tgccagtact catgtgagtt gtatgtgccc ccagtgctac 300
atacgcaggt atgcgtaagt gtgtatgctt gttttaaaca aacactcaac gtacatatgt 360
acataatcta cacatattta tatcacatat ctagctttat tactatagac tatacgaatt 420
ggnggtaaca tgaaatgnta ccttttacag actgttttta aaaan
<210> 597
<211> 320
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (45)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (98)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (104)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (105)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (123)
```

```
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (132)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (147)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (159)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (175)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (187)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (236)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (240)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (259)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (313)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (319)
<223> n equals a,t,g, or c
```

```
<400> 597
 gcacgagcat accttctggt tgcttcaaac ctgacaccgt ccctnagtga atacgtacag 60
 ccaaaaagga ccaactggct tctgtgcact agcctgtnaa ttannttgct tagtatggtt 120
ctnagatctt gnacagtata tttaaanctg taaatatgnt tgtgccttaa aaggngagaa 180
gaaagtntag atagttaaaa gactgcagct gctggaagtt ctgagccggg caagtngtgn 240
 ggggctgttg ggacacttnc ttgtggggcc cggggtaatc agggcagcct ttcatagggc 300
                                                                    320
ggggtccatg tgntggcant
<210> 598
<211> 688
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (343)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (471)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (507)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (582)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (584)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (604)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (637)
<223> n equals a,t,g, or c
<220>
```

<221> misc feature

```
<222> (642)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (650)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (673)
<223> n equals a,t,g, or c
<400> 598
gcccaaaccc actccacctt actaccagac aaccttagcc aaaccattta cccaaataaa 60
gtataggcga tagaaattga aacctqqcqc aatagatata gtaccgcaag ggaaagatga 120
aaaattataa ccaagcataa tatagcaagg actaacccct ataccttctg cataatgaat 180
taactagaaa taactttgca aggagagcca aagctaagac ccccgaaacc agacgagcta 240
cctaagaaca gctaaaagag cacacccgtc tatgtagcaa aatagtggga agatttatag 300
gtagaggcga caaacctacc gagcctggtg atagctggtt gtncaagata gaatcttagt 360
tcaactttaa atttgcccac agaaccctct aaatcccctt gtaaatttaa ctgttagtcc 420
aaagaggaac agctctttgg acactaggaa aaaacctttg tagagagagt naaaaattta 480
acaccccata gtaggcctaa aaqcaqncac caattaaaga aagcgttcaa gcttcaacac 540
ccacttccta aaaaattcca aacatataac tggaacttcc tnanacccaa ttgggaccaa 600
tttntcaccc ctattagaaa gaaactaatg gttagtntta angtaaccan tgaaaaacat 660
ttttccttcc ggnattaaag ccctggcg
                                                                   688
<210> 599
<211> 748
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (543)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (613)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (657)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (707)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (727)
<223> n equals a,t,g, or c
<400> 599
gctccacctt actaccagac aaccttagcc aaaccattta cccaaataaa gtataggcga 60
tagaaattga aacctgqcqc aatagatata qtaccqcaag ggaaagatga aaaattataa 120
ccaagcataa tatagcaagg actaacccct ataccttctg cataatgaat taactagaaa 180
taactttgca aggagagcca aagctaagac ccccgaaacc agacgagcta cctaagaaca 240
gctaaaagag cacacccgtc tatgtagcaa aatagtggga agatttatag gtagaggcga 300
caaacctacc gagcctggtg atagctggtt gtccaagata gaatcttagt tcaactttaa 360
atttgcccac agaaccctct aaatcccctt gtaaatttaa ctgttagtcc aaagaggaac 420
agctctttgg acactaggaa aaaaccttgt agagagagta aaaaatttaa cacccatagt 480
aggectaaaa geageeacea attaagaaag egtteaaget eaacaceeac tacetaaaaa 540
atnocaaaca tataactgac teettacace caaattggac ecaatetate acceetatag 600
aaagaactaa tgntagtatt aagtaaccat gaaaaaccat tcttcctccg gattaanccc 660
tgcgtcagga ttaaaacccc tgaactggcc atttaacagg cccaatntct taccattcaa 720
cccaccnagg tcattattac ccttactt
                                                                   748
<210> 600
<211> 253
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (80)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (85)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (91)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (94)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (193)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (197)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (204)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (250)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (251)
<223> n equals a,t,g, or c
<400> 600
cctgaccaca cgctggggca tcaacaaatg atcacttgac ttaatctgcc cctatgaacg 60
ccccgggaaa aaccgcttgn atgcnccaaa nctngtggaa ctttgcccca gcagtgatgc 120
ctgccaggaa agggttgaac cgcgaacctt gacgaagggg gggcccggtt acccaattgc 180
ggccctatag tgnagtngtg attnacaatt gcactgggcc gtcgtttttg acaagttcgt 240
gatgtttggn nat
<210> 601
<211> 524
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (41)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (280)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (325)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (338)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (411)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (480)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (494)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (500)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (507)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (524)
<223> n equals a,t,g, or c
<400> 601
ggcacgagcg gaagatcccc acatcgatga aagcaaagcg nagcaccaag ccatcatcat 60
gtccacgtcg ctacgagtca gcccatccat ccatggctac cacttcgaca cagcctctcg 120
taagaaagcc gtgggcaaca tctttgaaaa cacagaccaa gaatcactag aaaggctctt 180
cagaaactct ggagacaaga aagcagagga gagagccaag atcattttg ccatagatca 240
agatgtggag gagaaaacgc gtgccctgat ggccttgaan gaagaggaca aaagacaagc 300
ttttccattt ctgaaactgc ggaanttttc cttcaaantt cattgaagag aagaggttgg 360
ttaaggacgt tttccaggat tggacattca aagaccagtg ggtttttggg nttttacagt 420
tgcagctttg tttttacctt acagtttttt tttttcaggt tccaggtttg aagggcccgn 480
ttgaaaggcc cggnttacan ttgtttnaag gttcccacat tttn
                                                                   524
<210> 602
<211> 397
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (309)
<223> n equals a,t,g, or c
```

```
<220>
 <221> misc feature
 <222> (343)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (363)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (379)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (386)
<223> n equals a,t,g, or c
<400> 602
ggcacgaget acgcgggcca cgctgctggc tggcctgacc taggcgcgcg gggtcgggcg 60
gccgcgcggg cgggctgagt gagcaagaca agacactcaa gaagagcgag ctgcgcctgg 120
gtcccggcca ggcttgcacg cagaggcggg cggcagacgg tgcccggcgg aatctcctga 180
gctccgccgc ccagctctgg tgccagcgcc cagtggccgc cgcttcgaaa gtgactggtg 240
cctcgccgcc tcctcttcgg tgcgggacca tgaagtgctg ccgtcggtgg tgctgaaact 300
ctttctggnt tcattctctt cggcactggt tactggcgaa aancctggaa acggctttcg 360
ganaaggcta actgctggna acaagnaaac cggaacc
                                                                    397
<210> 603
<211> 76
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (32)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (45)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (55)
<223> n equals a,t,g, or c
<220>
```

```
<221> misc feature
<222> (59)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (64)
<223> n equals a,t,g, or c
<400> 603
tegacecacg egteegeeca egegteeggt gnttagtate ecegneetgt gggengeene 60
                                                                    76
agtntcccct cctaag
<210> 604
<211> 127
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (9)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (20)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (67)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (95)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (98)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (126)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (127)
```

```
<223> n equals a,t,g, or c
<400> 604
ttttcacgnt taattcactn tatttttctt gtataaaaac cctatgttgt agccacagct 60
ggagccntag tccgctgcac ggagactgtg gtgtnggnct tgacgaggtg ggtcagtgaa 120
ctcctnn
<210> 605
<211> 138
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (6)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (15)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (36)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (68)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (88)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (119)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (134)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (137)
<223> n equals a,t,g, or c
```

```
<400> 605
tttaanaaaa ggggnccctc cagcccagtg gcggangttc tagaactact ggatcccccg 60
ggttgcanga attcggcacg agagggancc gtgggccggg cgcgccggtt cccggcacnt 120
gtctcggcac gtgncanc
<210> 606
<211> 102
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (10)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (18)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (41)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (81)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (85)
<223> n equals a,t,g, or c
<400> 606
ctcttgaaan agacgtgnag ctgctcctac ccaccactcc nggctgagcc ttgcctgata 60
                                                                   102
cagcagcccg gaggcaccac negenacccg agteteacce te
<210> 607
<211> 80
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (45)
<223> n equals a,t,g, or c
<220>
```

```
<221> misc feature
<222> (56)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (61)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (72)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (78)
<223> n equals a,t,g, or c
<400> 607
cacaggcatg ctcataagga aaggttaaaa aaaaaaaaa aaaantcgag gggggncccg 60
                                                                    80
naaaccaaat tngccccnaa
<210> 608
<211> 398
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (132)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (137)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222>. (138)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (139)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (360)
```

```
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (373)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (377)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (386)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (394)
<223> n equals a,t,g, or c
<400> 608
agacgcggag ggtcgccctg agggaagact cttcgggatg acaggagcgg gcctcggaag 60
ggactcgggg cgctggaggg aagtttcgtt cttcggagaa acagaacgcg ctcgaggggg 120
caccgtgggg cnaaggnnnc actcggttgc ggcggcagga gtgagggaca gtcccccgat 180
ttcctgctcc ctggggccct ggggacgttc cggccaccgg agcgactgtc acgccgacgg 240
ggatcaccgg cgcgagttgg ggggtcggaa agcgcctcct cccgccggtc gcggtccgct 300
aaccacttct cgcttgcctg ttccgctcct taagagcaac tgttgccctt ttgaagcagn 360
                                                                   398
ataagtgtgc tgngctngaa gcttancggg ttgnttgt
<210> 609
<211> 275
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (28)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (234)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (261)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (262)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (266)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (274)
<223> n equals a,t,g, or c
<400> 609
tttttaagtg ctccatttta atgccganga ataagtcttt tggcaacaca aactggtcaa 60
taataggtaa tgcaggtatg ttcaggttaa gccaacaatg ttttgcattt ttatgcttat 120
tttctgtcaa cactaatgaa gtcaacattg cctgaatgtc tgaataatga aacacatccc 180
aaaaaaaaa nncccncggg gggnc
                                                              275
<210> 610
<211> 433
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (329)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (358)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (391)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (396)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (422)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (429)
<223> n equals a,t,g, or c
<400> 610
ggcagagcgc ggctctccca cctgtcaccc tggcccttct ctgcttggat ggtgtcttcc 60
tetecteage egagaatgae ttegteeace ggateeagga ggtggaagag gatggeecea 120
gcagctgctc ggaggacgat tacagtgagc tgctgcagga gatcacagac aacctgacga 180
ggaaggagat teagatagag aagateeatt tggacaegte eteetteatg gaggagetge 240
ctggagagaa ggaccttgcc cacgtggtag agatcttatg actttggaac cagcgttcaa 300
gacggaggac ctgcttggca acgtttttnt gagtttccaa gaggaagggg tttcaagntt 360
caattgggtt ggatgataat tcaaggaatt nggcantttt tccctgcccg ggccttaatt 420
tncggaagnc ctg
                                                                    433
<210> 611
<211> 497
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (340)
<223> n equals a,t,q, or c
<220>
<221> misc feature
<222> (405)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (422)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (459)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (481)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (487)
<223> n equals a,t,g, or c
```

```
<400> 611
ggcacgagtg ggaccccagg cagcagcagc agcggcagct aaagcagcag caaagttcgg 60
tgctggagca gccggagtcc tccctggtgt tggaggggct ggtgttcctg gcgtgcctgg 120
ggcaattcct ggaaaaccac cccacactgg gaatagccac cttgcccttg tagaatccat 180
cogoccatco qtocatteat coateqqtee qtocatecat gtocccagtt gaccgcccgg 240
caccactage tggetgggtg cacccaccat caacctggtt gacctgtcat ggccgcctgt 300
gccctgcctc caaccccatc ctaaactccc ccaaggcgtn cggggctgtg cagactgggg 360
tgccaagcat cttctcccca accggggtgt tcccacatgc agtantgtat aacccccatt 420
entteetegg tecaatgaae tteagageag ttecattent geeeggeeat ettttgtgte 480
                                                                    497
ngctgtnaaa ataaata
<210> 612
<211> 503
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (1)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (28)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (33)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (41)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (47)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (52)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (64)
<223> n equals a,t,g, or c
```

PCT/US00/05883

<220> <221> misc feature <222> (69) <223> n equals a,t,g, or c <220> <221> misc feature <222> (71) <223> n equals a,t,g, or c <220> <221> misc feature <222> (90) <223> n equals a,t,g, or c <220> <221> misc feature <222> (111) <223> n equals a,t,g, or c <220> <221> misc feature <222> (116) <223> n equals a,t,g, or c <220> <221> misc feature <222> (129) <223> n equals a,t,g, or c<220> <221> misc feature <222> (141) <223> n equals a,t,g, or c <220> <221> misc feature <222> (156) <223> n equals a,t,g, or c <220> <221> misc feature <222> (162) <223> n equals a,t,g, or c <220> <221> misc feature <222> (166) <223> n equals a,t,g, or c

<220>

```
<221> misc feature
<222> (181)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (192)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (211)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (224)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (250)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (265)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (268)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (284)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (287)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (290)
<223> n equals a,t,g, or c
<220>
```

<221> misc feature

PCT/US00/05883

```
<222> (324)
  <223> n equals a,t,g, or c
  <220>
  <221> misc feature
  <222> (336)
  <223> n equals a,t,g, or c
  <220>
  <221> misc feature
  <222> (347)
  <223> n equals a,t,g, or c
  <220>
  <221> misc feature
  <222> (355)
  <223> n equals a,t,g, or c
  <220>
  <221> misc feature
  <222> (374)
  <223> n equals a,t,g, or c
  <220>
 <221> misc feature
  <222> (385)
 <223> n equals a,t,g, or c
<220>
 <221> misc feature
 <222> (388)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (398)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (408)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (423)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (442)
```

```
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (447)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (450)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (460)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (462)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (491)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (493)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (494)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (497)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (498)
<223> n equals a,t,g, or c
<400> 612
naatteggea gagttttttt ttttttnaa ggntcaaatg ngatetnttt tnaatataaa 60
gatnttttnt naaaatctct gtatgaaatn atctccgggg agatagattc nccatntttc 120
ccctgaagnt ttaggggcct ntgcctgcca ctccanaccc tntttntgaa gggcccaagt 180
```

```
nactcactat gnaaagaagt cattccctct ngttagtgtt aaanccagtt atgggtcttc 240
ctggaatggn ggataatcca cacgnggnta aatccaaggg ttgnttnatn tgggttcctc 300
cctccctcc ccttccacca gggnttccct gacagnggcc acagggngac ttttnagggg 360
ttttaggtca ttgnggggat gggtnccngg aaatgggncc agatctgnat tgggggcccc 420
contggttgt cocatggggt tnttagnggn ttttaggggn tngtgggggt aaaggggttt 480
                                                                    503
ttttaacaaa ntnnttnncc agg
<210> 613
<211> 197
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (15)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (39)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (44)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (45)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (90)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (120)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (152)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (165)
```

<223> n equals a,t,g, or c

```
<220>
<221> misc feature
<222> (181)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (185)
<223> n equals a,t,g, or c
<400> 613
aaaatctcaa gttgntgggc agaaaaactg acagggcant acanngtaac aaacagaatc 60
caagtggggt ggcccttgtg cacagagctn caggtgacct ctggagagac atgggcattn 120
acatggaaag ctaaaacgga agcttaagct tntattactc aacanaaact tctgtgagac 180
                                                                    197
naaangacaa gccatgt
<210> 614
<211> 435
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (307)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (384)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (388)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (390)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (396)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (419)
<223> n equals a,t,g, or c
```

```
<400> 614
cattttaatc ttttataaag ttttgaatgt tcatgtatga atgctgcagc tgtgaagcat 60
acataaataa atgaagtaag ccatactgat ttaatttatt ggatgttatt ttccctaaga 120
cctgaaaatg aacatagtat gctagttatt tttcagtgtt agccttttac tttcctcaca 180
caatttggaa tcatataata taggtacttt gtccctgatt aaataatgtg acggatagaa 240
tgcatcaagt gtttattatg aaaagagtgg aaaagtatat agctttagcc aaaggtgttg 300
cccatcnaag aaatgagcga tatatagaat agtgtgggca ttctcctgta agtggagtga 360
aggggtgaca ttctccccac tctnccancn ggttcncccc atattgaata aaggacgcng 420
agagacttga accta
                                                                    435
<210> 615
<211> 272
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (7)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (18)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (33)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (64)
<223> n equals a,t,q, or c
<220>
<221> misc feature
<222> (94)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (141)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (143)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (145)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (151)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (162)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (193)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (194)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (228)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (253)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (267)
<223> n equals a,t,g, or c
<400> 615
ggggcangca cgtaagtncg acgcacgtat agngaaagct tgggtacgcc gtgcaggtac 60
cggntccggg aattcccggg gtcgacccac gcgntccgga ataatggaat ataatatgtc 120
ttcataatat aacaacacta ntncnctaat ngtaagatta anttaggcag tcttctacca 180
aatgtggtaa tgnngattgc ctcaaaattg tggtccacat aatccacnct catcttgcaa 240
                                                                   272
agcgctattt cangcacatc attggantac ag
<210> 616
<211> 160
<212> DNA
```

<213> Homo sapiens

```
<220>
<221> misc feature
<222> (37)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (47)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (53)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (75)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (83)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (110)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (134)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (148)
<223> n equals a,t,g, or c
<400> 616
ggtatggtcc catattaaga ggcctgttgt ctatganatt gtctagnatt ctngtgcagg 60
totttgctgg ttaantcagg acnaacgagg aggcacgtca gtccacccon ctcctctccc 120
attttccgtg ttgntccctt gcttaacngg caaagacctg
                                                                   160
<210> 617
<211> 205
<212> DNA
<213> Homo sapiens
```

```
<220>
  <221> misc feature
  <222> (6)
  <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (30)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (180)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (188)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (189)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
<222> (190)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (194)
<223> n equals a,t,g, or c
<400> 617
ggactntgta catttgggag tttttatgan aaacttaaat gttattatct gggcttatat 60
ctggcctctg ctttctcctt taattgtaaa gtagaagcta taaagcagta ttttcttga 120
савававава авававався вывывания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выстубликания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выстубликания выпубликания выпубликания выпубликания выпубликания выпубликания выпубликания выстубликания выпубликания выстубликания выстубликания выстубликания выстубликания выстубликания выстубликания выстубликания выстубликания выстубликания выстубликания выстубликания выстубликания выстубликания выстубликания выстубли
ggggggnnn cccngaaaaa aaaac
<210> 618
<211> 450
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (222)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (344)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (405)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (419)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (423)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (428)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (445)
<223> n equals a,t,g, or c
<400> 618
cgacaaagtc cttaatgggc ccagaaggtg aggggagtcc ggcaatgagg ggtggtaggg 60
ttageggcca tegeceaget egtetteett etaceagaeg etggtgetgg aaaagagaag 120
tgtaagaata acttgcgcca ttaggcccat cggaaaggcc caccaccctt taggaagatt 180
actggctgtt tatagaaggc ccgtgtatat cctatgaaga angctggctc tcaacttccc 240
ccccagcctt ttaaaagaaa acatttgcta catcgagccg ttctaggtgt aaagaggttg 300
ttgacttatg atagagttag aaaatcacac atccttgtaa attncccatt tggtttaaaa 360
aaaaaaaaa aaaactcgag gggggggccc gggtacccaa tttgncccta aaagggagnc 420
                                                                   450
ggnattanaa ttcactggcc ggcgntttta
<210> 619
<211> 294
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (122)
<223> n equals a,t,g, or c
<220>
```

```
<221> misc feature
<222> (183)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (279)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (283)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (285)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (289)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (290)
<223> n equals a,t,g, or c
<400> 619
tacctttgtt ggtcctttct tccttaagtg ccaagtgctg agctaaagga ggataacttt 60
ttggggaagt catgctgagg gtggtagtgt gaccctgcct gaaaaaaggg tctcttaccc 120
tnccagccct ggctcaactc tgaagaagga tcttgctaca gaaggagccc ttgggctccc 180
ttnctctttg gatagcagtt ataaatgccc ttgttcccaa taaaactggg cagatgggaa 240
aaaaaaaaa aaaaaaaaa aaaaaacccc ggggggggnc ccngncccnn tttg
<210> 620
<211> 127
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (9)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (10)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (25)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (90)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (95)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (99)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (117)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (125)
<223> n equals a,t,g, or c
<400> 620
ggcagagenn cageegeagg ecegnegeee getgetggeg eegtggeete etatgaetae 60
ctggtgatcg ggggggctc gggcgggctn gccancgtng tggagagcca caagctnggt 120
                                                                    127
ggcantt
<210> 621
<211> 115
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (27)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (86)
<223> n equals a,t,g, or c
<220>
```

```
<221> misc feature
<222> (111)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (112)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (115)
<223> n equals a,t,g, or c
<400> 621
ggcacgaggc tcagtacagc tcagctnagc ccagcccagt ccaacccagc ccagcccagt 60
ccaacccage ccagetcage teagencage ccagetcage teagetcage nnagn
<210> 622
<211> 507
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (300)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (358)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (380)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (451)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (466)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (485)
```

```
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (504)
<223> n equals a,t,g, or c
<400> 622
gaaattaaaa aaacactttt taaagggtgc attgataaaa tctgaggttt tttggttgtc 60
gtttttttttt gtgtacattt ttttcctaag tttatggcac agggtagacc ttaagtattc 120
ctcctccatc cttcattctt caccctccat tggatcctca agttttaatg aattccaatt 180
ataccttaca tcagcaagtt aaaaaaagta ctttaaaata aagcaaaggg agactgttgc 240
teaaccatea ggaaacagtt gteagaagae ateattggtt etgtgtttee taeggaaatn 300
agaaacgata aatattgcac tgaatgtttg tggtttggag tccctgaata ataaagangc 360
aatatatttg cagaaagtcn catagggttt tttaatgcag aattttgtca gaagacaatg 420
gcgctgcatg tttttctttg aattgcaaat nttcattgct aaagantttt tttaagatgg 480
gcatnttgct ttgaaaaaga aaanatt
                                                                    507
<210> 623
<211> 340
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (286)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (290)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (302)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (308)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (340)
<223> n equals a,t,g, or c
<400> 623
aattcggcag aggtcattaa aaaactagag aattagccat attaaggatt tttcttgact 60
gcaaattact totaaagaat catcagtgta tagattagaa gtgctcatta cctgcaactt 120
```

```
ttaaaaaaaa ttcagttata gctgcttttg aagaggtttc catttttatt taaattacta 180
atggatcaaa gaacaattgt ttattttttc tctttggttt tagatattaa tgataacctt 240
gttgggaatt tttttccaa agaaaatatt tttatgaatt gaaatnaatn ttgaatgttt 300
tncttccntt tcatttacct actcttggca gtgttagggn
<210> 624
<211> 223
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (202)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (204)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (212)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (222)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (223)
<223> n equals a,t,g, or c
<400> 624
ggcacgaget aagtteggea teaatatggt gaceteeegg gageggggga ceaceaggtt 60
gcctggcctg ataatgtcct ttttaaatgg agttcagact attaacattt aatgtaatta 120
tcaatatagt tggatttaag tgtactgtct tgctatttgt ttcctattta tgccaacttt 180
tttttaatgt cttttgttct tntngttttc tnttctttcc tnn
<210> 625
<211> 541
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (265)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (337)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (398)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (442)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (456)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (468)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (482)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (491)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (495)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (502)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (507)
<223> n equals a,t,g, or c
<400> 625
```

```
gttgtaataa gtaaatgcct taagagtatt taaaatatgc ttccacattt caaaatataa 60
aatgtaacat gacaagagat tttgcgtttg acattgtgtc tgggaaggaa gggccagacc 120
ttggaacctt tggaacctgc tgtcaacagg tcttacaggg ctgcttgaac cctcataggc 180
ctaggctttg gtctaaaagg aacatttaaa aagttgccct gtaaagttat ttggtgttca 240
tttgaccaat tgcatcccca gcttnaaaag caagaagcat ccgtttccct ggaattataa 300
agaatttgtt tcccacccct aaaattttta cagtttnaaa aacttgggtt tcccattgaa 360
cattcctcct tttttcccca gtttccccca aattcctntt ttttattttt ttggggaaat 420
aaggtttgcc ccattttta ancctacact actttnggaa atgccccncc cctggaatga 480
anggaaaggt ncccnattac gnctttnagg ttaattacag ttccctcccc ttccccttgc 540
С
<210> 626
<211> 483
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (231)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (342)
<223> n equals a,t,q, or c
<220>
<221> misc feature
<222> (344)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (355)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (371)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (385)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (451)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (479)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (480)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (481)
<223> n equals a,t,g, or c
<400> 626
aacccactcc accttactac cagacaacct tagccaaacc atttacccaa ataaagtata 60
ggcgatagaa attgaaacct ggcgcaatag atatagtacc gcaagggaaa gatgaaaaat 120
tataaccaag cataacatag caaggactaa cccctatacc ttctgcataa tgaattaact 180
agaaataact ttgcaaggag agccaaagct aagacccccg aaaccagacg nagctacctg 240
agaacagcta aaagagcaca cccqtctatq ttaqcaaaat aatqqqaaqa tttatagggt 300
tgaagcgaca aacctaccga cctgggtgat actggttgtc cnanataaat cttanttcac 360
tttaaatttg nccacagaac ctctnaatcc cttgttaatt taatgttatc caaaaaagaa 420
cagctcttgg gacctaagaa aaaacttgtt naaaaattaa aatttacacc atgtagctnn 480
nac
                                                                   483
<210> 627
<211> 221
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (109)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (116)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (158)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (161)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (189)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (191)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (221)
<223> n equals a,t,g, or c
<400> 627
actictagect aggattitige aaaaagetat ttaegtaaca etatagaagg taegeetgea 60
ggtaccggtc cggaattccc gggtcgaccc acgcgtccgg tcttggggnc cacganccag 120
actcaggaca gagtggactc tgcctgtgat ggggtggnct ncctgctggc ccccctccac 180
cagtgcctnt ngcatatata tatttggtgt gcacaggaag n
                                                                    221
<210> 628
<211> 122
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (30)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (55)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (58)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (70)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (71)
<223> n equals a,t,g, or c
```

```
<400> 628
aaggctgaaa aacgcaagag gatattggtn gatatcgagc tatgaggaaa gatcnaanag 60
catgaaggan nagggaagga agatgagcta agatgaagat gaagaaagaa agatgatgat 120
ga
<210> 629
<211> 252
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (6)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (12)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (17)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (40)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (60)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (140)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (169)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (174)
<223> n equals a,t,g, or c
<220>
```

```
<221> misc feature
<222> (175)
 <223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (182)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (243)
<223> n equals a,t,g, or c
<400> 629
ctactnatgg angtgtngtt gccatggtaa tcctgctcan tacgacatga accgcaggtn 60
cagacatttg gtgtatgtgc ttggctgagg agccaatggg gcgaagctac catctgtggg 120
attatgactg aacgcctctn agtcagaatc ccgcccaggc ggaacgatnc ggcnncgccg 180
engatecteg gttggcetet gatatecggt ecceegeetg teeegeegg egggeggga 240
congggtoco gt
                                                                    252
<210> 630
<211> 619
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (4)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (17)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (18)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (19)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (22)
<223> n equals a,t,g, or c
```

WO 00/55351 683 PCT/US00/05883

```
<220>
<221> misc feature
<222> (64)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (86)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (93)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (94)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (104)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (251)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (484)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (528)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (558)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (581)
<223> n equals a,t,g, or c
<220>
```

```
<221> misc feature
. <222> (605)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (613)
 <223> n equals a,t,g, or c
 <400> 630
 gtentagtaa gattaennnt gnaageatee ceatteeagt gagtteacee tetaaateae 60
 cacnatcaaa agggacaagc atcaancacg cannaatgca gctnaaaacg cttagcctag 120
 ccacaccccc acgggaaaca gcagtgatta acctttagca ataaacgaaa gtttaactaa 180
 gctatactaa ccccagggtt ggtcaatttc gtgccagcca ccgcggtcac acgattaacc 240
 caagtcaata naagccggcg taaagagtgt tttagatcac cccctccca ataaagctaa 300
 aactcacctg agttgtaaaa aactccagtt gacacaaaat agactacgaa agtggcttta 360
 acatatotga acacacaata gotaagacco aaactgggat tagataccco actatgotta 420
 gccctaaacc tcaacagtta aatcaacaaa actgctcgcc acaacactac gagccacagc 480
 ttanaactca aaggaactgg cggtgcttca tatccctcta aaaagaanct gttctgttat 540
 cgataaaccc cgatcaanct ccccactctt gctcacctat ntccaaaaaa aaaaaaaaaa 600
 ctcanggggg gcngggtcc
                                                                    619
 <210> 631
 <211> 210
 <212> DNA
 <213> Homo sapiens
 <220>
 <221> misc feature
 <222> (3)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (5)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (16)
 <223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (42)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (46)
<223> n equals a,t,g, or c
```

```
<220>
 <221> misc feature
<222> (49)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (53)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (63)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (64)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (80)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (102)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (130)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (136)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (162)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (165)
<223> n equals a,t,g, or c
```

```
<220>
 <221> misc feature
 <222> (206)
<223> n equals a,t,g, or c
<400> 631
ggncntaaca cccacncaaa gagtccccac ttaacaatac cncccnccna cgncaagaat 60
gcnnaaatcc gaatgacccn agttttccta ttgagtaaac angatcccag ttgtgcccca 120
ctagcatgan gcctgnagtt ccggtttcat gcatgaaatt gnttntggag agttttgtaa 180
gttgtaaagc caattactgg cttttnacat
                                                                210
<210> 632
<211> 359
<212> DNA
<213> Homo sapiens
<400> 632
caagetgetg etecaaggee tggecacatg cagacaggag gaagetgage tegacattag 60
gcctcaaggc tgccatctgt cttgtagggc ctggccttgt gggcaggggg cagtcctgtg 120
ccttgtgggc cctcagcctc tgagggcaga gatgctgtca gtgccgcagg gtaagggacg 180
agtettetgg aaggetetge catggacatt tgteeteggg eteagaggee ceaccetgee 240
ccacacctgc ccctaatcac tgcagtgtcc agcccagtgt tgaacagatt gtagcgttct 300
<210> 633
<211> 328
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (221)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (223)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (246)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (256)
<223> n equals a,t,g, or c
<220>
<221> misc feature
```

```
<222> (286)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (319)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (323)
<223> n equals a,t,g, or c
<400> 633
cttttggggg ataagaaagc ctgggagggg cctgtgccaa aaccctctct gcctggggac 60
tgggcggtga ttccgcttct gcctgggctc ctgccatggc ccccgagagg ggctgacact 120
ttagctcccg gtgcaggtga gaacccgccc ggaggaagaa ggaaggcgcg ggccggggat 180
taggagacgg aggcggactc ggagccaggg aaccaggggt nenggctaga getggagteg 240
tgagenegeg ecegeneege tetgggagga eegegagatg ecegtnetga ageagetggg 300
ccccgcgtca cccaagaanc ggnctgat
                                                                   328
<210> 634
<211> 330
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (324)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (325)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (326)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (327)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (329)
<223> n equals a,t,g, or c
```

```
<400> 634
cagaatcotc tttcctcccc atttggccct gggctcaggg gaccaggtgg ggcgggtggg 60
gagetgteeg gtgetaccae accgtgeeet cagtggacta accaeageag cageeaggga 120
tgggccctgg aggttcccgg ccggagagtg cctctccct ctgccatcca cgtcaggtct 180
ttggtggggg gaccccaaag ccattctggg aagggctcca gagtccagcc gtccagctgc 240
tootttooca gittgattto aataaatotg tooactooco tittgigggg gigaacgitt 300
taacagccaa aaaaaaaaaa aaannnnana
<210> 635
<211> 111
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (11)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (19)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (24)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (35)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (38)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (109)
<223> n equals a,t,g, or c
<400> 635
caatcccggt ntacccagng tccnttttcc ccccncanga aaagaaacaa caacttgggg 60
111
<210> 636
<211> 298
<212> DNA
<213> Homo sapiens
```

```
<220>
<221> misc feature
<222> (198)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (211)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (220)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (225)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (288)
<223> n equals a,t,g, or c
<400> 636
aattoggcac agottaatca coottgotoo tootgggtgo otggaagatg gactggcaga 60
gacctgtttg ttgcgttttg tgctttgatg ccaggaatgc cgcctagttt atgtccccgg 120
tgggggcaca cagcggggg cgccaggttt tccttgtccc ccagctgctc tgcccctttt 180
ccccttcttc cctgactnca ggcctgaacc ngtcccgtgn ctgtnaataa atctttgtga 240
aattaaaaaa aaaaaaaaa aaaactcggg ggggggcccg gtaccaantt gggccctt
<210> 637
<211> 491
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (58)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (64)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (70)
```

```
<223> n equals a,t,g, or c
  <220>
  <221> misc feature
  <222> (114)
  <223> n equals a,t,g, or c
  <220>
  <221> misc feature
  <222> (119)
  <223> n equals a,t,g, or c
  <220>
  <221> misc feature
  <222> (133)
  <223> n equals a,t,g, or c
  <220>
  <221> misc feature
  <222> (139)
  <223> n equals a,t,g, or c
  <220>
  <221> misc feature
  <222> (157)
  <223> n equals a,t,g, or c
  <220>
  <221> misc feature
  <222> (221)
  <223> n equals a,t,g, or c
  <220>
  <221> misc feature
  <222> (255)
  <223> n equals a,t,g, or c
  <220>
  <221> misc feature
  <222> (298)
  <223> n equals a,t,g, or c
  <220>
<221> misc feature
 <222> (365)
  <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (367)
 <223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (371)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (381)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (390)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (414)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (428)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (469)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (473)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (474)
<223> n equals a,t,g, or c
<400> 637
ggcagagccc cagaagagca ggacgccctg tacctgcaga gaagggaagc agcctctnta 60
cctnatctgn ggctaccaga gagcagaaag gacccaccct gggactcttc tgtntgttng 120
aaagatgcgc cancectgne ecceggette ecetetntee gecacagaac ecagtttet 180
agaccagggg gacgggcacc catcactccg caggcgaaat naaagccccc ctgccccggc 240
cctaaacccc tgtgncctcc tttcccatgg tttccccgag agccagttac aaccctgncc 300
cgggccttaa cccccatggc ttctttctg tggttttccc ccagaggcca gttagttccc 360
aactngnaaa nccgtttggg nttccccatn aaaaaaaatt ttggtttcat tttnaaaaaa 420
aaaagggnag gaggggggg gcccggttaa ccatttgggc tttaagtgng tgnnttttaa 480
                                                                  491
aattaattgg c
```

```
<210> 638
 <211> 331
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (4)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (17)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (29)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (55)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (79)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (111)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (135)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (142)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (148)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (163)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (206)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (218)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (257)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (277)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (286)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (309)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (321)
<223> n equals a,t,g, or c
<400> 638
ccgnagctgg gtatctnaaa tctcctttna tccagccact gcccaaagcc atctncctgc 60
ctactggatg cttacagtna ctgtggatac gggggttccc tttccccatt nagtgacatg 120
tectetetge ttggngtaaa enattetngg gaggacaett ttnecaataa actettteee 180
cagctgatta gtgtctaagg aatganccaa tacttgtntg cccttttcct tggactatta 240
acaattgcct gggaggntta gcaagaggaa gcctgtntgt aatttnattt caaaaaggca 300
aaatagagng ttttacagtc ntaggggaat t
                                                                   331
<210> 639
```

<211> 444 <212> DNA

```
<213> Homo sapiens
<220>
<221> misc feature
<222> (235)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (236)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (237)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (426)
<223> n equals a,t,g, or c
<400> 639
ccgagttcca gagcatgggg tctcggttgt cccagccttt tgagtcctat atcactgcgc 60
ctcccggtac cgccgccgcg cccgccaaac ctgcgcccc agctacaccc ggagcgccga 120
cctccccagc agaacaccgc ctgttgaaga cctgctggag ctgtcgcgtg ctttctgggt 180
tggggctgat gggggcgggc gggtacgtgt actgggtggc acggaagccc atgannntgg 240
gatacccccc gagtccatgg accattacgc agatggtcat cggcctcagt gagaatcaag 300
gcattgccac ctggggtatc gttgtcatgg cagaccccaa agggaaggcc taaccgcgtt 360
gtttgaaagt accaccagtg aatctgtctt ctgtctctgt ccctttcccc gtgacacaca 420
gagcangcat ggaatttaat gggt
                                                                   444
<210> 640
<211> 598
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (205)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (397)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (469)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (484)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (518)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (520)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (543)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (557)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (568)
<223> n equals a,t,g, or c
<400> 640
gacccactcc accttactac cagacaacct tagccaaacc atttacccaa ataaagtata 60
ggcgatagaa attgaaacct ggcgcaatag atatagtacc gcaagggaaa gatgaaaaat 120
tataaccaag cataatatag caaggactaa cccctatacc ttctgcataa tgaattaact 180
agaaataact ttgcaaggag agccnaaggt taagaccccc gaaaccagac gagctaccta 240
agaacagcta aaagagcaca cccgtctatg tagcaaaata gtgggaagat ttataggtag 300
aggogacaaa cotacogago otggtgatag otggttgtoo aagatagaat ottagttoaa 360
ctttaaattt gccacagaac cctctaaatc cccttgnaaa tttaactgta gtccaaagag 420
gaacagctct ttggacacta ggaaaaaacc ttgtagagag aggaaaaant tacacccata 480
gtangcctaa aagcagcacc aattaagaaa gggtcaantn acaccatact aaaatccaac 540
ctntactgac tctacancca ttggccantt tcctttaaac caggggtatc cgaacttc
<210> 641
<211> 466
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (17)
```

```
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (18)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (19)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (258)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (280)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (314)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (337)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (376)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (443)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (464)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (465)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (466)
<223> n equals a,t,g, or c
<400> 641
ggtcctaaac tactaannnt gcattaaaaa tttcggttgg ggcgacctcg gagcagaacc 60
caacctccga gcagtacatg ctaagacttc accagtcaaa gcgaactact atactcaatt 120
gatecaataa ettgaceaac ggaacaagtt accetaggga taacagegca atectattet 180
agagtccata tcaacaatag ggtttacgac ctcgatgttg gatcaggaca tcccgatggt 240
gcagccgcta ttaaaggntc gtttggtcaa cgattaaagn cctacgtgat ctgagttcag 300
accggagtaa tcanggcggg ttctatctac ttcaaantct tcctgtacga aaggacaaga 360
gaaataaggc tacttnacaa agcgccttcc ccgtaatgat atcatcttaa cttagtatta 420
                                                                   466
tacccacacc cacccaagaa cangggttgg taagaaaaaa aaannn
<210> 642
<211> 575
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (5)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (7)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (20)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (30)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (116)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (123)
<223> n equals a,t,g, or c
```

```
<220>
 <221> misc feature
 <222> (127)
 <223> n equals a,t,g, or c
 <220>
<221> misc feature
 <222> (130)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (134)
<223> n equals a,t,g, or c .
<220>
<221> misc feature
<222> (140)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (143)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (150)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (173)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (193)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (238)
<223> n equals a,t,g, or c
·<220>
<221> misc feature
<222> (309)
<223> n equals a,t,g, or c
```

<220>

```
<221> misc feature
<222> (327)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (424)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (491)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (492)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (497)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (532)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (543)
<223> n equals a,t,g, or c
<400> 642
gttgnancag tccactctgn ctttaaaacn tagtgattac aatatttaga aagttttgag 60
cacttgctat aagtttttta attaacatca ctagtgacac taataaaatt aacttnttag 120
aangcangan gtgnttgtgn gtnacaaatn cagaaagtga actgcagtgc tgnaatacac 180
atgttaatac tgnttttctt ctatctgtag ttagtacagg atgaatttaa atgtgctntt 240
cctgagagac aaggaagact tgggtatttc ccaaaacagg taaaaatctt aaatgtgcac 300
caagagcang aggatcaact tttaggncat tgatgatctg taaagacaac aaatcccttt 360
ttttttctca attgacttaa ctgcatgagt tctggtttat ctacctctaa agcaaatctg 420
cagngttcca aagactttgg tatggattaa gcgctgccag taacaaaatg aagtctcaaa 480
acagagetea nntgeanaaa ageatatttt etgeggttet ggaetgeact gntgeettge 540
                                                                   575
ctnacataga cactcagaca cccttacaaa cacag
<210> 643
<211> 492
<212> DNA
<213> Homo sapiens
```

```
<220>
<221> misc feature
<222> (40)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (125)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (310)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (461)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (492)
<223> n equals a,t,g, or c
<400> 643
gaccttctgc ataatgaatt aactagaaat aactttgcan ggagagccaa agctaagacc 60
cccgaaacca gacgagctac ctaagaacag ctaaaagagc acacccgtct atgtagcata 120
atagngggaa gatttatagg tagaggcgac aaacctaccg agcctggtga tagctggttg 180
tccaagatag aatcttagtt caactttaaa tttgcccaca gaaccctcta aatccccttg 240
taaatttaac tgttagtcca aagaggaaca gctctttgga cactaggaaa aaaccttgta 300
gagagagtan aaaatttaac acccatagta ggcctaaaag cagccaccaa ttaagaaagc 360
gtcaagctca acacccacta cctaaaaaaat cccaaacata taactgaact cctacaccca 420
attggaccaa tctatcaccc tatagaagaa ctaatggtag nataagtaac atgaaaacat 480
tctccttcgc an
<210> 644
<211> 68
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (6)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (10)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (41)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (58)
<223> n equals a,t,g, or c
<400> 644
gatacntcan tgggaacagg gcccatggaa atgtacagga ntttccctat tttggtgntc 60
agcttgaa
<210> 645
<211> 488
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (265)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (290)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (302)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (336)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (342)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (365)
<223> n equals a,t,g, or c
<220>
<221> misc feature
```

```
<222> (385)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (420)
<223> n equals a,t,g, or c
<400> 645
ggcacagogc togtocacgg tottotgcat cactggtata cacactogtt agogtocatt 60
tottatttaa ttagaatgga taagatgatg ttaaatgcct tggtttgatt tctagtatct 120
attgtgttgg ctttacaaat aattttttgc agtcttttgc tgtgctgtta cattactgta 180
tgtataaatt atgaaggacc tggaaataag gtataaggat cttttgtaaa tggagacaca 240
tacaaaaaaa atctttgaat ggttnaatag ggatggaatg gggaaagtgn ttttggaaag 300
anattcccat tttgccgggg agactatttg aagtgnccat cnttgtccca aacaaggtaa 360
atttnttttt gtaaagtgcc aagtnccggc aggcagaagg aaccgtttac agtgtgattn 420
aagaaaggga aaccgtgccc tttttagcct ccaaacccaa ttgaccataa tttacaggcc 480
                                                               488
ccggtttg
<210> 646
<211> 302
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (287)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (288)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (290)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (297)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (302)
<223> n equals a,t,g, or c
<400> 646
```

```
tgaaaagtac caaagcttct ttctgttgtg tttgatttta ctataggggt tttgcttttt 120
ctagagatac ttttcattta acagcttttg ttaagtgtca ggctgcactt tgctccatat 180
aattattgtt ttcagatttc aacttgtatg tgtttgtctc ttaaagcatt ggtgaaatca 240
catattttat attcagcata aaggagaata aattccagaa aacacannan aaaaaanaaa 300
<210> 647
<211> 137
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (13)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (15)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (112)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (114)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (115)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (117)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (132)
<223> n equals a,t,g, or c
<400> 647
gggcggggg gentnecceg aggggetete gettetggeg ccaagegeee ggtegegege 60
cggccgggcg ctacccgctc cggggacagt gccaggtggg gagtatgact gngnngnaac 120
acctgttaaa cnggaac
```

```
<210> 648
<211> 432
<212> DNA
<213> Homo sapiens
<400> 648
ggcacgagct gcagcgggt gagcggcggc agcggccggg gatcctggag ccatggggcg 60
cgcgcgcgac gccatcctgg atgcgctgga gaacctgacc gccgaggagc tcaagaagtt 120
caagetgaag etgetgtegg tgeegetgeg egagggetae gggegeatee egeggggege 180
gctgctgtcc atggacgcct tggacctcac cgacaagctg gtcagcttct acctggagac 240
ctacggcgcc gagctcaccg ctaacgtgct gcgcgacatg ggcctgcagg agatggccgg 300
gcagctgcag gcggccacgc accagggctc tggagccgcg ccactgggat ccaggcccct 360
cctcagtcgg cagccaagcc aagcctgcac tttaatagac cagcaccggg cttcgttatc 420
gcgaaggtca aa
<210> 649
<211> 544
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (395)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (438)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (459)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (505)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (519)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (531)
<223> n equals a,t,g, or c
```

<220>

```
<221> misc feature
<222> (540)
<223> n equals a,t,g, or c
<400> 649
ctcctgcctc ttctcagggg acctgctctt cctctctggc tgtgggcgga cctttgaggg 60
caatgcagag accatgctga gctcactgga cactgtgctg gggctagggg atgacaccct 120
tctgtggcct caagtgtgat gccttacaaa agcaccactc agatgggcag ctggactctg 180
gtgtcctgag actctgccct cttcccacag cctccctgcc ccacccatcc ctgcaaagcc 240
atttttcaga cagagecatt cctaagaaca etgaaggget ggaatgetgg etggecaete 300
totgootcag tggootcoot aaagootgga agaaggaggg tootgattgo caaggaaacc 360
tcctcattgg gctaaggaga cactggagtc tggantgtgg agccccacag tcttgcaggt 420
caaatgctct ccttgcanat ctggcctggt tgtaaccant gggctctggc tctgccctgg 480
gggcaaaagg ggcctcctt gccangggag aaaagccang gtctctttgg ncgatggtgn 540
aatc
<210> 650
<211> 406
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (234)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (272)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (374)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (393)
<223> n equals a,t,g, or c
<400> 650
ctccacctta ctaccagaca accttaacca aaccatttac ccaaataaag tataggcgat 60
agaaattgaa acctggcgca atagatatag taccgcaagg gaaagatgaa aaattataac 120
caagcataat atagcaagga ctaaccccta taccttctgc ataatgaatt aactagaaat 180
aactttgcaa ggaagagcca aagctaagac ccccgaaacc agacgagcta cctnagaaca 240
gcttaaagag cacacccctc tatttttgcc anaatagtgg gaaagattta taggtttgaa 300
ggcgaacaaa cctaccgagc ctggttgatt agcttgtttg tcccaagatt agaatcttta 360
tttcccactt tttnattttt gccccaccag aanccctcct tttaaa
```

```
<211> 444
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (196)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (237)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (275)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (299)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (313)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (322)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (361)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (388)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (412)
<223> n equals a,t,g, or c
<220>
```

<221> misc feature

```
<222> (420)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (444)
<223> n equals a,t,g, or c
<400> 651
ggaaagatga aaaattataa ccaagcataa tatagcaagg actaacccct ataccttctg 60
cataatgaat taactagaaa taactttgca agggagagcc aaagctaaga cccccgaaac 120
cagacgaget acetaagaaa cagetaaaag ageacaceeg tetatgtage aaaatagtgg 180
gaagatttat aggtanaggc gacaaaccta ccgagcctgg tgatagctgg tttcccnaag 240
aatagaatct tagttcaact ttaaatttgc ccacngaacc ctctaaatcc cccttgttna 300
atttaactgt tingtoccaa anaaggaaca gotoottitg ggaccotagg aaaaaacott 360
nttaaaaaaa agtttaaaaa attttacncc ccttgtttgg ccttaaaacc cnccccccan 420
                                                                    444
ttaaaaaagg tttcaaactc ccan
<210> 652
<211> 69
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (20)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (24)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (32)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (40)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (57)
<223> n equals a,t,g, or c
<400> 652
ctttttttt ttttaaatan gtanctccat tntttttctn ttttccaaga tggccgntgt 60
tatggtttt
                                                                   69
```

```
<210> 653
<211> 649
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (232)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (235)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (240)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (253)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (268)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (270)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (275)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (283)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (284)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (310)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (313)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (324)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (344)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (351)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (352)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (354)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (364)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (367)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (374)
<223> n equals a,t,g, or c
```

<220>

```
<221> misc feature
<222> (384)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (393)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (396)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (398)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (417)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (420)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (424)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (429)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (433)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (444)
<223> n equals a,t,g, or c
<220>
<221> misc feature
```

```
<222> (457)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (477)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (497)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (504)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (513)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (525)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (532)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (568)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (591)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (605)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (617)
```

```
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (646)
<223> n equals a,t,g, or c
<400> 653
ccagtagatt tgtattaaaa gaaaaaaaa tggggcctta gcttctggct tttaattttg 60
ccagctaagg acataaaaca aaaataaaca aacaaaaaca aatagccatc tgctatcagc 120
atcattatgt aaaagaaaat atattttagc ccctaaaatt aggaagaatg taatctcaga 180
ataaaggttg tcatttaagt tgaataaata tatagcttta tgaaaaacat anaanaaaan 240
aaaaaaaaa aangccccga aaggaccntn ttaancaaaa ccnnattgaa aaggcttgga 300
aaaacaaagn cgnttgaaag ctgnttccag taaaccaaac caanccagta nngnggggca 360
attngtngcc ttancagtac ccantcaaaa aanagngntt tgggaaaaagg gggaaanaan 420
aggnaatcng aancttaagc ttanactttt gggaaanatt cccccttgga aattganaag 480
ttttttgggg aaaaggnaaa aggnacaacc ttnttgaaaa tttanggggg gnattaaact 540
taaatttgcc taattggggg gaaccccntt taaaaaaaaa ttggacttgg ngactaaagt 600
tgcantgaaa tttttnccc ttaaaaaagg ggccttgtta cccttnagg
<210> 654
<211> 598
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (251)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (343)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (433)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (455)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (517)
<223> n equals a,t,g, or c
<220>
```

```
<221> misc feature
<222> (522)
<223> n equals a,t,q, or c
<220>
<221> misc feature
<222> (561)
<223> n equals a,t,q, or c
<220>
<221> misc feature
<222> (590)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (592)
<223> n equals a,t,g, or c
<400> 654
gegggeetea cettgeegte geactgeete ttgeceaget tggteteete agggtggtag 60
aaccacttga ccttgaccac catgttgctg ccccacgact cccacatgct ctcgatgcgg 120
ccgatgtagg ggaggttggg ccgcccagct gacaggaaga cggcacagtc cccgacacgc 180
agggtetect egeceegeac gatggeettg taaaacaget teegggeett ecectteatg 240
ccacgccgct ntgggggaca tgggcagggt ggctctgaaa agccgggggg ctgtggggac 300
agattgcggc caggaagcat ggaaggtgtg gtgtgggtgt gantgtgaat ctgaatgtga 360
gtgtgcaggg cgcccacaag ggcaggaagc cgcagcaccg cggcttaagg ccatggcagc 420
catggatctg gancaagggc cacgcctcca cggancccgc acatggaatc atgactctgg 480
acactggatc tggggacagg gacatgtgga caagacnttc ancacagtgt tttttacgaa 540
ggcggaagaa ccacgaatgg ncccccatgc gccccccaac aattgccctn gnttaaga
<210> 655
<211> 433
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (298)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (312)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (347)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (401)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (415)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (416)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (431)
<223> n equals a,t,g, or c
<400> 655
aaaagctata ttttgaagac tggggttatt tcagaaaaaa ctacagccct ttttgtctta 60
cctgcctttt actttcgtgt ggatatgtga agcattgggt cgggaactag ctgtagaaca 120
caactaaaaa ctcatgtctt ttttcacaga ataatgtgcc agttttttgt agcaatgata 180
tttctcttgg aaagccagaa atgctttgta ccagagcacc tccaaactgc attgagaaaa 240
aattcccaga accatcccct ttttccattt ttatattatt tataaagaaa gattaaanct 300
gttttgacta tnttacagcc ctggaattta ctacctccct gtttctntct ccccggaaaa 360
aatgaaacca acgattgggt teetttgaat teeegtteee neeteeegtt atttnnaaaa 420
tcccccctt ntt
                                                                   433
<210> 656
<211> 450
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (7)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (123)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (135)
<223> n equals a,t,g, or c
<220>
```

```
<221> misc feature
<222> (136)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (336)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (350)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (355)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (395)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (414)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (428)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (435)
<223> n equals a,t,g, or c
<400> 656
tegacenggg ctteegeatg getgeteetg taegtateae ggtettgtge tetaaggaaa 60
acgacagcac gtgttctttt tcactagtag aagtgacgtt ggtttcatgt tggggggggg 120
ggngccattt ttttnntgtt tcagtggaga gcaaaatgaa taacaaagcg ggctcctttt 180
tctggaacct tagacaattc agtacattag tttcaacaag cagaactatg aggctatgtt 240
gtttgggact ttgcaaacca aaaatagttc cattcaaact ggaacatttt gaaataactt 300
tcataacaga atgcaatcaa cggatgatca ttgagngagc gcttgcaggn tgccntcatt 360
tttgaaatca gatgttggcc ttgcaaacaa agggncataa agcactccaa cagnccctta 420
gaaattgnaa agacnacctt tatgctaaaa
                                                                   450
<210> 657
```

<211> 434

```
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (6)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (80)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (412)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (427)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (433)
<223> n equals a,t,g, or c
<400> 657
ttttangttg ttaaatacct gtaggtttct tttaatcata aagaaggaaa atgaaagact 60
tgaggatcac ctacatagan cgaaaacaga aaaaaacccc gaatcccatt actttgacag 120
tgtttttaga cctgtgttac taaaaaaaag atgaatgtcc tgaaaagggt gttggggaggg 180
tggttcaaca aagaaacaaa gatgttatgg tgtttagatt tatggttgtt aaaaatgtca 240
teteaagtea agteaetggt etgtttgeat ttgatacatt tttgtaetaa etageattgt 300
aaaattattt catgattaga aattacctgt ggatatttgt ataaaagtgt ggaataattt 360
tttataaaag ggtccatggt tcgtaacccg ccttgtatat ggggagccaa cncccaaatt 420
ataatgnccc ccna
                                                                   434
<210> 658
<211> 397
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (7)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (10)
```

```
<223> n equals a,t,g, or c
<220>
 <221> misc feature
<222> (15)
 <223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (17)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (28)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (360)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (377)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (383)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (392)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (395)
<223> n equals a,t,g, or c
<400> 658
gacagtnach gtccngnatt cccgggtncg accctcggcg tccggaagag tcttcatgtg 60
gacagtetea gggacaccat gtagagaatt ttggtetega tteagaaaaa agaaagagee 120
agtggttgtt gagacagtag aagagaaaaa ggaacctatc ctagtgtgtc cacctttacg 180
aagccgagca tacacaccac ctgaagatct ccagagtcgt ttggaatctt acgttaaaga 240
agtttttggt tcatctcttc ctagtaattg gcaagacatc tccctggaag atagtcgtct 300
aaagttcaat cttctggctc atttagctga tgacttgggt catgtagtcc ctaaactccn 360
gactccacca gatgtgnagg gtnagagatg tnctnga
                                                                   397
```

```
<210> 659
<211> 156
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (2)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (7)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (10)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (12)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (90)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (94)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (98)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (130)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (150)
<223> n equals a,t,g, or c
<400> 659
```

```
gnageenttn gnaaegttet tggeggaate ageggggaaa gaagaeeetg ttgagettga 60
ctctagtctg gcacggtgaa gagacatgan aggngtanaa taagtgggag gcccccggcg 120
ccccccggn gtccccgcga ggggcccggn gcgggg
                                                                    156
<210> 660
<211> 276
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (242)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (255)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (258)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (261)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (267)
<223> n equals a,t,g, or c
<400> 660
gragtttagt tttaccctac tgatgatgtg ttgttgccat ggtaatcctg ctcagtacga 60
gaggaaccgc aggttcagac atttggtgta tgtgcttggc tgaggagcca atggggcgaa 120
gctaccatct gtgggattat gactgaacgc ctctaagtca gaatcccgcc caggcggaac 180
gatacggcag cgccgcggag cctcggttgg cctcggatag ccggtccccc cgctgtcccc 240
gncggcggc agconconct ntacgangcc caccgc
<210> 661
<211> 275
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (4)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (5)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (14)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (25)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (33)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (186)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (225)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (250)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (259)
<223> n equals a,t,g, or c
<400> 661
cgtnncctac tgangatgtg ttgangccat ggnaatcctg ctcagtacga gaggaaccgc 60
aggttcagac atttggtgta tgtgcttggc tgaggagcca atggggcgaa gctaccatct 120
gtgggattat gactgaacgc ctctaagtca gaatcccgcc caggcggaac gatacggcag 180
cgccgnggag cctcggatgg ctcggatagc cggtcccccg cctgnccccg ccggcgggcc 240
                                                                   275
gcccccctn cacgcgccnc gcgcgcgcgg gaaag
<210> 662
<211> 506
<212> DNA
<213> Homo sapiens
```

```
<220>
<221> misc feature
<222> (51)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (69)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (183)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (191)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (345)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (363)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (383)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (432)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (445)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (466)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (481)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (487)
<223> n equals a,t,g, or c
<400> 662
gtgcctttca tttttatatt accacagata ctttcctcat agtcttgcca ntgcttgtag 60
aatgcttana aaaagcttga taaaccactg ggctaagtac acagagggag aggctagcag 120
tatttttaaa ttggtttcta aattttttat agcttgatgg tagataacac atttgcttca 180
atnaaggtaa neeggaaaaa acaaateete aaaaagaeet eteaattaga attettaaat 240
gacaatgttt tctttatcat atatttgaga gattgattta aagaaaaata tgcttgacta 300
tetgaaataa tattttaace etateataaa atetetgeet ggtanaacag etgaetgtgg 360
aanggtaaaa tgcagagaac cantcattgg atctcccttc tctactttgt tactgaaatc 420
ttgaacctgt anaacaatta cttancactg gggttccttt cctaanggga aaataatact 480
                                                                    506
naacacntgc agagtaattt ttaaaa
<210> 663
<211> 550
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (420)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (480)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (501)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (510)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (528)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (532)
<223> n equals a,t,g, or c
<400> 663
gagttggtgg agcgatttgt ctggttaatt ccgataacga acgagacaac cttagccaaa 60
ccatttaccc aaataaagta taggcgatag aaattgaaac ctggcgcaat agatatagta 120
ccgcaaggga aagatgaaaa attatagcca agcataatat agcaaggact aacccctata 180
ccttctgcat aatgaattaa ctagaaataa ctttgcaagg agagccaaag ctaagacccc 240
cgaaaccaga cgagctacct aagaacagct aaaagagcac acccgtctat gtagcaaaat 300
agtgggaaga tttataggta gaggcgacaa acctaccgag cctggtgata gctgggttgt 360
ccaagataga atcttaagtt caactttaaa tttgccacag aaccctctaa atccccttgn 420
aaatttaact ggtagtccca agaggaacag ctctttggac actaggaaaa aaccttgtan 480
agagagtaaa aaaattaaca nccatagtan gcctaaaagc agcaccanta anaaagcggt 540
caagctcaca
<210> 664
<211> 542
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (486)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (499)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (504)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (514)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (530)
<223> n equals a,t,g, or c
<400> 664
gcgtctatgt agcaaaatag tgggaagatt tataggtaga ggcgacaaac ctaccgagcc 60
tggtgatagc tggttgtcca agatagaatc ttagttcaac tttaaatttg cccacagaac 120
cctctaaatc cccttgtaaa tttaactgtt agtccaaaga ggaacagctc tttggacact 180
```

```
aggaaaaaac cttgtagaga gagtaaaaaa tttaacaccc atagtaggcc taaaagcagc 240
caccaattaa gaaagcgttc aagctcaaca cccactacct aaaaaatcca acatataact 300
gaactcctac acccaattgg accaatctat caccctatag aagaactaat gttagtataa 360
gtaacatgaa aacattetee teegeataag cetgegteag attaaaacae tgaactgaca 420
attaacagcc caatatctac aatcaaccaa caagtcatta ttaccctcac tgtcaaccca 480
acacangcat gctcataang gaanggttaa aaanaaaaaa aaaaactttn gggggggccc 540
gg
<210> 665
<211> 712
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (310)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (324)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (370)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (429)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (431)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (525)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (549)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (600)
```

```
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (627)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (635)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (650)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (687)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (692)
<223> n equals a,t,g, or c
<400> 665
ggatggtggg agctccqtgc aaagtgaagc tgaggcctct gtggatccca gtttgtcgtg 60
gggtcagagg aaaaaacttt actatgacac ggactatggt tccaagtccc gaggccggca 120
gagtcaacag gaggcagagg aggaggaaag agaggaggag gaggaggcac agatcattca 180
gcggcgccta gcccaagcgc tgcaagagga tgattttggt gtcgcctggg ttgaggcctt 240
tgcaaaacca gtgcctcagg tagatgaggc tgagacacgg gtcgtgaagg atttggctaa 300
aggttcagtn gaaagaaaaa cctnaaaatg ttgcaaaagg aatcaccaga actcttggag 360
cttatagaan accttgaaag tcaagttgac agaagttaag gatgagctgg agccattggt 420
agaagttgnt nggaacaagg ggatcattcc acccggaaaa aggaagccaa tactttgagg 480
accaagtaca acctctactt gaattaattg ctcgaacatc agttnttatt tgatcctgaa 540
agctaggana gtcccagcac atggacatct tgtcatagaa aggcttgttc ctaccgaaan 600
ttgatcaaca agctgtccgt tgggatnaaa actgncctaa aaatcgcatn tgttgcactt 660
aggttatctt taaagaagac tgtttcnaag cnaatcacca agccaaacca ag
<210> 666
<211> 381
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (1)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (12)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (18)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (20)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (29)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (344)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (357)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (361)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (380)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (381)
<223> n equals a,t,g, or c
<400> 666
ncacgcgtcc gngggcancn aagtcgatna atgtaaagaa gaaatgaaag cctggtgtat 60
tgtacttcaa gatgcctccc tgatgtatag aatctccttg taaaataaat aattgcattg 120
tatatcagtc ttcccatcaa tattaattat taaatatttt agaatttttt tatagttggt 180
atttaaaaaa aaaaaaaaa agggcggccg ctctagagga tccctcgagg ggcccaagct 240
ttacgcgtgc atgcgacgtc catagctctc tccctatagt gagtcgtatt attaagctag 300
```

```
gcactggccg tgcggtttac aacgtccgtg gactggggag atcngctagc ttggggncct 360
  nggttgaagg aaccttactn n
  <210> 667
  <211> 437
  <212> DNA
  <213> Homo sapiens
  <220>
  <221> misc feature
  <222> (71)
  <223> n equals a,t,g, or c
 <220>
  <221> misc feature
 <222> (78)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (261)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (302)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (314)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (334)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (371)
^{\circ} <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (373)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (392)
```

```
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (403)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (408)
<223> n equals a,t,g, or c
<400> 667
tttgtgtgcc ttctctgctc ctttctctgg ctgccctacc cttcccctcc acgctgcctg 60
ggcagcaagg nacagggnac caacaggtag caagtgtgcc ttcctcaggg cccttcctga 120
gagetecaca geocaccetg tggeecectg ettggettgg cetggeetge eeggeeceag 180
ccttccaatg ctgctgcacg tcctcatttt cctttttggt cccctcctgc cccctctggc 240
tgttctgcct ttgggcctca nccccagctg cctgaatttg ggcaaggttc tttctctgtg 300
gnottcaago toanococaa gggttottga acongggoto ttoccaacgg gcccaaccot 360
aacttaaaaa ntngaacccc tggttttcaa antctttctt aantggtnaa aaaccccaat 420
                                                                   437
cccaagggta aaatttc
<210> 668
<211> 365
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (8)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (172)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (239)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (243)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (244)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (329)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (330)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (353)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (358)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (362)
<223> n equals a,t,g, or c
<400> 668
ggcagagnat ctctgcaccc tggggcctgg aacagaactg gcaaagaggc aagaggtcac 60
tgagggcctc tgtcacccag gacctgcctc ctgcctgccc ctctcccgcc agactgttag 120
aaaatggaca ctgtgcccag cccggacctt gggcagccca ggccggggtg gngcatgggc 180
ctgggccacc ttctcttcct ttgctgaggc ctccagcttt caggcaggcc aaggccttnt 240
tennececae cegecetece cagggggeet egggagetea ggtgggeece agttteaate 300
ttcccgttgt tgttgttggg gcccttaann ttccccagcg ttcccatttt ttnggcantt 360
tntgg
                                                                   365
<210> 669
<211> 474
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (405)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (454)
<223> n equals a,t,g, or c
<220>
```

```
<221> misc feature
<222> (456)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (458)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (472)
<223> n equals a,t,g, or c
<400> 669
gtccacctta ctaccagaca accttagcca aaccatttac ccaaataaag tataggcgat 60
agaaattgaa acctggcgca atagatatag taccgcaagg gaaagatgaa aaattataac 120
caagcataat atagcaagga ctaaccccta taccttctgc ataatgaatt aactagaaat 180
aactttgcaa ggagagccaa agctaagacc cccgaaacca gacgagctac ctaagaacag 240
ctaaaagagc acacccgtct atgtagcaaa atagtgggaa gatttatagg tagaggcgac 300
aaacctaccg agcctggtga tagctggttg tccaagatag aatcttagtt caactttaaa 360
tttgcccaca gaacctccta aatccccttg ttaatttaac ttgtnagtcc aaagaagaac 420
agctctttgg acactaagaa aaaaccttgt aganananta aaaaatttaa cncc
<210> 670
<211> 467
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (5)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (12)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (82)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (110)
<223> n equals a,t,g, or c
<220>
<221> misc feature
```

```
<222> (148)
 <223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (169)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (171)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (188)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (211)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (215)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (217)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (219)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (227)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (229)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (254)
```

```
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (282)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (287)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (300)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (305)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (313)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (318)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (325)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (327)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (332)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (335)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (336)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (337)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (343)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (348)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (359)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (361)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (367)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (371)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (386)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (398)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (405)
<223> n equals a,t,q, or c
<220>
<221> misc feature
<222> (441)
<223> n equals a,t,q, or c
<400> 670
gaccgctctg agctaaacct anccccaaac ccactccacc ttactaccan acaaccttag 120
ccaaaccatt tacccaaata aagtatangc gatacaaatt gaaacctgnc ncaatacata 180
tactacence agggaaacat gaaaaattat nacenanent aatatanena ggactaacce 240
ctataccttc tgcntaatga attaactaca aataactttg cnacganagc ccaagctaan 300
acconceasa concacanot acothanasc anothnnaga acnoceonto tatgtacona 360
ntactgngaa nattatacgt aaaggnacca acctaccnaa cctgntgata ctggttgtcc 420
acataaatct tattcccttt naatttgccc ccaaacctct taatccc
                                                                467
<210> 671
<211> 360
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (292)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (316)
<223> n equals a,t,g, or c
<400> 671
gtggtttacc tccacgtatt tatttcacct tagcagatgg aaacaaagta ttttgctgga 60
taagaaagac cctaaaatgg atatagaagt gtgtgtgtat ccataaaatg catatgtaaa 120
tttttttttg tttttaagca ttcacccaaa caaaaaaatc acaggtaaac ccatgtttct 180
gagatgccat tattccaagc aaaataagag ataatccctt caagttaaat tgaaaatttt 240
cctgaaacca tacatttcaa gtgaaataag taattctaga tagggcaatt tnaattggat 300
aattttaaag tgtctnttat tgcagtggtt tatttgcaaa ttcctaaaag ggaaaatttt 360
<210> 672
<211> 237
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (63)
```

```
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (75)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (112)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (168)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (170)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (210)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (213)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (227)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (228)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (236)
<223> n equals a,t,g, or c
<400> 672
ggcagaggtt cgtctgggct catgctggga tgtcgcagtg ctcctgttgc aactcctccc 60
agneagecag gtttnetggg ggccaggetg ggtgteetea caggagtagg gnetacaece 120
aattccaaaa gcctgagaaa gagagaagtg gagggggagg cgagtttntn aataaaggct 180
```

```
237
cccatcaggt caaaaaaaaa aaaaaaaaan ttnggggggg gccccgnncc caattng
<210> 673
<211> 429
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (240)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (385)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (387)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (426)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (427)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (429)
<223> n equals a,t,g, or c
<400> 673
tttgcctgct cccggcgagg ggtggctttg atttcggcga tgagctccca gaaaggcaac 60
gtggctcgtt ccagacctca gaagcaccag aatacgttta gcttcaaaaa tgacaagttc 120
gataaaagtg tgcagaccaa gaaaattaat gcaaaacttc atgatggagt atgtcagcgc 180
tgtaaagaag ttcttgagtg gcgtgtaaaa tacagcaaat acaaaccatt atcaaaaccn 240
aaaaagtgtg ttaaatgttt acaaaagaca gtgaaggatt cttatcacgt aatgtgcagg 300
ccatgtgccc tgtgaacttg aagtttgcgc aaaatgttgg aagaaaggag accttgtatt 360
ccaatcctgg gccaaagaat ccagnoncaa gagttggaag cttagaaagg agttccactc 420
                                                                   429
aggggnntn
<210> 674
<211> 134
<212> DNA
<213> Homo sapiens
```

```
<220>
<221> misc feature
<222> (8)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (14)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (41)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (48)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (70)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (124)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (127)
<223> n equals a,t,g, or c
<400> 674
cttccccntg ccangtttgt aaacagcgtg atacccgaga nctctcgnct gccatagggt 60
agetcaggen tgtccageta caccecgaat cactetgtgg cettcageaa gtggcatgag 120
cagncgntgg agca
<210> 675
<211> 274
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (9)
<223> n equals a,t,g, or c
```

PCT/US00/05883

```
<220>
<221> misc feature
<222> (13)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (20)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (22)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (37)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (39)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (48)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (50)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (57)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (76)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (79)
<223> n equals a,t,g, or c
<220>
```

```
<221> misc feature
<222> (97)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (108)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (128)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (148)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (207)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (222)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (225)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (235)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (266)
<223> n equals a,t,g, or c
<400> 675
ggcacgagna aancccagen gnctatactt agcattntnt aaatccantn tcaaatncca 60
aatatcacag acaccnctna cacaaggaat ataaaancca ccaccctnca gcctgggaga 120
acgtcgtnga gaacctacat ctatacanga ttttaaaaat gaagctgggc gtggtggtac 180
acacctgtgg tcccagctta ctagggnggc tgcagccagg tntgnacgct ccaanccagg 240
gcttagtggc tgcaatgagc tcttanttgg catc
```

<210> 676

```
<211> 416
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (99)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (102)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (306)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (322)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (344)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (369)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (387)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (393)
<223> n equals a,t,g, or c
<400> 676
ggcacagtct atttagaact gaggggtttc ccaaggacta tgggcatggc caagaataag 60
ctggtgaaat cagatccagg gactcaacaa ctgattctnt gnttctttct ttctctctcc 120
agagtettet teccaceetg ggeagggatg caeaeggetg cagegetggt gtegggeeaa 180
gcagatgggc ttggagcctc ccccagaggt gtggcaggtg ctgaagaccc accccggagg 240
acccccgctt ccagtgcagg tcagagacag gccgggaggg ctttcagggg agccagggcc 300
```

```
tttttncagg catgttcacc engetgttee tgacetgagg gagnaatggt tggagggttt 360
ggaagggcnt tgtttgaaca ggcaagnagt ttnttttgag gtggcctggt ttcagg
<210> 677
<211> 507
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (2)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (38)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (40)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (41)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (98)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (106)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (112)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (172)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (197)
```

```
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (214)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (287)
<223> n equals a,t,g, or c
<220>
<221> misc feature ·
<222> (291)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (322)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (362)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (380)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (385)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (386)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (394)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (395)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (400)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (404)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (409)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (411)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (414)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (419)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (436)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (438)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (439)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (448)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (455)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (456)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (457)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (464)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (472)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (473)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (479)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (487)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (495)
<223> n equals a,t,g, or c
<400> 677
anatteggea gageacttte ategeetace eegaegengn neceagetge gggaegtgea 60
tcacggctgg gcccccagag gagagaggag gccgacgnca gcggtncccg tncgggaacg 120
ggagggtttt eggggggtte ggegtegeae ettggggeee eeegeageeg thtaceggge 180
ctcccatctg ctaagenttt ttccgttgag ccgntccaaa aacactaage tggggacgee 240
aagtgeeece ecaceeegge teeetggeee tateeacaae tteaacneea neceaggate 300
```

```
gccatctttt aggggaggcc tnggaagggg gtgttaaggt gtttttaggg ccaacgaggt 360
tnaaacaaaa aggaccttn cccannccaa ccannccaan cccnaattna nctncatgnc 420
ttaggggaaa aatttncnna acaatttncc ctttnnngga accngggcaa anncaaggna 480
agttttnggg gtttnaattg tttctta
                                                                    507
<210> 678
<211> 122
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (1)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (4)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (38)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (95)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (102)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (104)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (114)
<223> n equals a,t,g, or c
<400> 678
ncanaaactc tggtccttct gtctggtggc acttaaantc ttttgtgcca taatgcaaca 60
atatggaggg aagattttat ggaaaaatgg ggatnotott ontnaacccc aatnaattaa 120
                                                                   122
gg
```

<210> 679

```
<211> 121
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (9)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (18)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (50)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (55)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (62)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (101)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (106)
<223> n equals a,t,g, or c
<400> 679
acttcgtcng gaactcgnga tctccctttg ggatggcccg cccgcaggtn ccggnccgga 60
antcccgggt cgacccacgc gtccgctata ttattggaag naattntcct ctcacctcct 120
                                                                    121
a
<210> 680
<211> 475
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
```

```
<222> (5)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (83)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (122)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (130)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (137)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (178)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (203)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (271)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (301)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (330)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (333)
```

```
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (340)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (343)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (390)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (399)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (441)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (458)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (463)
<223> n equals a,t,g, or c
<400> 680
ggcanagtgc aacacaggaa gtgaggatac ttctggcgag cgccggttgc tgtttcttct 60
caggetcagg gaceggeege ggneeegtag tgtatttaac tcaaatgggt gatgaaaagg 120
tnctcttggn aaagtgnaaa actttagatg gaaattcttc agggaaaaga aacgaggnaa 180
ggaacaagag gagaaagcag agntaaaacg cttaaaaaat tctgatgacc gggattccaa 240
gcgggattcc cttgaggagg gggagctgag ngattcactg ccatggagat cacaataagg 300
nactccccgt atagaagaga agacttcatn ggnagacagn ggnggaagaa gttggtttct 360
ttggccatca aaccaccccg gcaaatgttn ttggaaagna aaagttcctt cccggaaagt 420
tgaaaagggg aaaggaaaat ntqqqcttct ggcctttngc cgngggttcc agggg
<210> 681
<211> 421
<212> DNA
<213> Homo sapiens
```

```
<220>
<221> misc feature
<222> (349)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (377)
<223> n equals a,t,g, or c
<400> 681
gtagaattct gagcactcaa ctcatgtttg gcattttaaa gtaaaaacaa gtgtgacttc 60
gaggaccaaa gaaattgtca gctatacatt tatctttatg aactcattta tattcctttt 120
taatgactcg ttgttctaac atttcctaga agtgttctta taaaggtcta atgtatccac 180
aggotgttgt cttattagta aatgcaaaga aatgactttg totgttttac totagtottt 240
agtacttcaa aattaccttt catatccatg atctgagtcc attgggggat tttaagaatt 300
gatgtattca atacacgttc aaaataaatg tttaatttag tatgagtang tagttcccga 360
agtggtccca ttaaatnata aaccatgtaa cttgtctgtg aaaaaaaaaa aaaaaacccg 420
                                                                    421
g
<210> 682
<211> 118
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (1)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (54)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (57)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (59)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (62)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (101)
<223> n equals a,t,g, or c
<400> 682
nacctccacg tcctggtgtg tgagcctgac tggggtcgaa gaccagacag gacntgnant 60
ancetgetet gagegagtga gateetactg gateateatt nacetaaace ccaageag
<210> 683
<211> 485
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (164)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (245)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (313)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (332)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (337)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (339)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (363)
<223> n equals a,t,g, or c
<220>
<221> misc feature
```

```
<222> (367)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (376)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (378)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (412)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (445)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (455)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (479)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (481)
<223> n equals a,t,g, or c
<400> 683
cctctccgcc ccctccgggc ttggctctcc caggaggcta cgactggagc cactggtccc 60
geaggatece egegteeteg gtegeegegt ceaegteet etegegteee egeceggege 120
cacgccgcct cctctgggtt cggcctccgc gcggtgcagc gcantctcag gccgcgggac 180
aagcccgact taaatctctg caatggctaa cgaacttatc cttgtccgtg ttgacttggc 240
cacanattga ttatggaagg ctaggcgtga attcaattcc aacaatcaag gttatttcac 300
aatccccttt gangcaggca actgtaatgt cntccanant atttggtggc attgcccata 360
canattntac tgaatnantc cggaatgata ccaacatgtc ccaatctttt tngggaaact 420
tggacccctg gaatgtcttc tcctnatggt gaaanaaatc caaaaaaaaa aaaatgttnt 480
                                                                   485
naatt
<210> 684
```

<211> 527

```
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (308)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (401)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (457)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (479)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (506)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (512)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (520)
<223> n equals a,t,g, or c
<400> 684
tttcggccgg cgccgccagt tcctggggca cacccagagg tccccttctc gccgccgcct 60
gcaactgcga gggtagcccg gggccgcttg gagtcgcccg gacctgagag gctgctgcac 120
tgggcctcag ccagccctcc ggatgctggt gctgccatcc ccctgccctc agcctctggc 180
attttcctcc gttgagacca tggagggccc tccccgtcgg acttgccgct ccccagaacc 240
tgggaccttc ctcctccatc ggattctccc caggctttca tcttcttcca agggcccaac 300
cactaacntg ctttattgga cattcagggt gttccctgac acagtggttg gtgggacgag 360
gagtcacaga ggggagccag gggccagtgg gggttccagg ncagaaaaat tggttacagt 420
tgcccgtgtg gtcaagggtc tttcgagtaa atgttcntaa ttttaaggga cacagcatna 480
                                                                   527
accaattggg agttaaaagc cttcgnatgt gnaatttgtn gggaagg
```

<210> 685 <211> 125

```
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (1)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (19)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (24)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (33)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (36)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (105)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (124)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (125)
<223> n equals a,t,g, or c
<400> 685
nccacctcgg tgcagccgnt ctanaactag tgnatncccg ggctgcagga attcggcacg 60
agcgtgcaag acagctgggt gtacagcgtc ctcgaaacca cgagnaagtg agcagatcct 120
ccgnn
<210> 686
<211> 534
```

<212> DNA

```
<213> Homo sapiens
<220>
<221> misc feature
<222> (7)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (88)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (122)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (199)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (273)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (276)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (308)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (322)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (369)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (375)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (378)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (410)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (423)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (433)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (436)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (454)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (502)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (508)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (509)
<223> n equals a,t,g, or c
<400> 686
togagtnttt ttttttttt tttttttct ggatggaatt tttaatttat ttatcatgtt 60
tgtaagttac agacatttat gttttcanca acagtttata atagttacat ctcatacttc 120
anctattaca acagagagaa cattaaagta caaagaaaga cttcaaaaaat gaggttactg 180
tgatgtatca taaaaggant taaaattcaa aatatcaaag acctcaccta tcggactaaa 240
```

```
cataaatctt aaaacctcct atggtcctct ganccnaaaa ttacaaaact tagcaactgc 300
ttaaaccnta ggaattaacg gntctgtgtt ttccaggtaa gaaaaacaaa aaatgctttg 360
gtaaactanc ccatnatnta gtttaaatgt ttctgccccg ttttgtatcn ctccttgaaa 420
ganagtatat aanttncagg ccagcatata tttnaaaaaa catctcccaa atttcattta 480
ctataggttt ctccaataat cntttacnnt tttaatccaa tgaaaaaaat tgat
<210> 687
<211> 308
<212> DNA
<213> Homo sapiens
<400> 687
gccacagaac cctctaaatc cccttgtaaa tttaactgtt agtccaaaga ggaacagctc 60
tttggacact aggaaaaaac cttgtagaga gagtaaaaaa tttaacaccc atagtaggcc 120
taaaagcagc caccaattaa gaaagcgttc aagctcaaca cccactacct aaaaaatccc 180
aaacatataa ctgaactcct cacacccaat tggaccaatc tatcacccta tagaaagaac 240
taatgttagt ataagtaaca tgaaaacatt ctcctccgca taagcctgcg tcagattaaa 300
                                                                   308
acactgaa
<210> 688
<211> 676
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (26)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (27)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (140)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (150)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (151)
<223> n equals a,t,g, or c
<220>
<221> misc feature
```

```
<222> (155)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (157)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (159)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (160)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (161)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (162)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (165)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (167)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (168)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (169)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (176)
```

```
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (177)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (180)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (193)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (207)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (219)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (223)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (237)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (246)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (262)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (291)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (292)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (300)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (307)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (310)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (316)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (339)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (361)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (368)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (394)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (413)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (414)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (415)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (428)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (429)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (432)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (448)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (454)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (471)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (481)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (514)
<223> n equals a,t,g, or c
```

<220>

```
<221> misc feature
<222> (518)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (520)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (523)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (524)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (534)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (553)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (562)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (582)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (589)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (593)
<223> n equals a,t,g, or c
<220>
```

<221> misc feature

```
<222> (609)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (629)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
<222> (640)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (643)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (656)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (664)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (670)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (673)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (675)
<223> n equals a,t,g, or c
<400> 688
ggttttagag aaaacaaatt gaagcnnatc aaatttgtaa aatcaaatta catatatata 60
aaaaaaccta tctgtattag acaaaaactg tttttattta tttctgtaag atatccatta 120
aataaatatt ttagtggaan aaaaaaaaan naaantnann nnaanannna aaatannaan 180
aagggcggcc gcnctaaagg atccaanctt acgttcgcnt gcntgcaacg tcatacntct 240
cctatnttgt cacctaattt cnatcccctg gccgtctttt tacaaccttc nngactgggn 300
aaatconctn gogttnooca acttaaacog cottgoaant acatcocott ttogocagot 360
nggcgttntt tctaaaaaag cccgcatccg atcncccttc ccaattagtt gcnnnccctt 420
```

```
taattggnna antggggacc cccctgtntt cggntccttt taatcttcgg nggggtggtg 480
nttgggttta ccctccacct ttgaaccttt atanttgncn atnnccccaa atcncccgct 540
cottteeget theetteect theetteete ectetette eneeggent conceptet 600
aatttttant cggggggctc cttttaggnt tccaattttn tgnttatcgg gtcccnccaa 660
cccnttaatn tcntnt
<210> 689
<211> 195
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (14)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (154)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (159)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (160)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (194)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (195)
<223> n equals a,t,g, or c
<400> 689
ggcacgaggc tgcnccagag tttggaagga agatcgaggc agaagatgta gaaggaagct 60
gtgggggtgg gagtgatgcc tcaggaacaa aactgaggaa ttccctaacg gacccagtcc 120
ctagggaaag aggeteect caggetetee ttgnetagnn ccacacetgg cagageetgt 180
                                                                   195
cacccagect agenn
<210> 690
<211> 283
<212> DNA
```

<213> Homo sapiens

```
<220>
 <221> misc feature
 <222> (7)
 <223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (34)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (42)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (105)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (139)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (183)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (224)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (257)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (265)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (266)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (279)
<223> n equals a,t,g, or c
<400> 690
ctcattnatt tgcaactgtc atggatgttt acangaaccc anccagagtt tgcctccctg 60
cacttcatcc caaagcgcac ctgcttcctc cacttcacct tcggnagaag acacttcaaa 120
ctgcggacac acgcaaaanc aactcccagc tctgtttgat gttactcgtt tcctcaacaa 180
gtnggcaaaa cagatatcat gctgaattcc gggggccctg tgantcaaaa tcacttcttt 240
tttaagcaat tgaaaanctg caggnnggtg ctctttgcna ctg
<210> 691
<211> 494
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (140)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (163)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (200)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (234)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (238)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (272)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (286)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (290)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (311)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (325)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (332)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (336)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (343)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (346)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (348)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (361)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (368)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (385)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (387)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (390)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (407)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (437)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (438)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (478)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (490)
<223> n equals a,t,g, or c
<400> 691
gtggaaacgt gctatttgga ggttattttc ctagtcgaca tccaggagat ctccagagat 60
ctatttcagc cccacctgtt gatttcatca tgaaaaggag gaagctcaaa ctgaagtgag 120
ttaaaaaactt catctcctan agaggactgt ggctcggcct ganttgagtt tttttatgtt 180
tatgtgcaag cgcaatgaan aagaacaccc gccagactac catgaggatc aatnagcnag 240
atgetetetg caccecacae teccatgaae enaagaagat etteenaatn tittigatga 300
aggaaaaatt ntgccccctt tggtntcttc enceentgtt ttnaanance attttattee 360
ngcttccncc ccccaaaaac ccccntnttn aatgcttcct ggcccancct taaaacctgg 420
tggcccaaaa aaaaaannaa acccctttta aaattttccc taaatctccc cccggggnaa 480
                                                                   494
aaaatttggn cccc
```

```
<210> 692
<211> 138
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (11)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (26)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (33)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (60)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (74)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (109)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (133)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (138)
<223> n equals a,t,g, or c
<400> 692
gtggtagagt nctgttaaat gaatgntctg ggntagatac agcttggaga acctgctggn 60
cttgttagac agenettggg cetttgccag cagcaagagg tgaagcganc cactetteec 120
ccttccctc ccncctgn
```

<210> 693

```
<211> 456
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (17)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (22)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (42)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (43)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (45)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (46)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (47)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (53)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (62)
<223> n equals a,t,g, or c
<220>
<221> misc feature
```

```
<222> (64)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (74)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (123)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (138)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (168)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (175)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (187)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (193)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (236)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (246)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (255)
```

```
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (257)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (276)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (282)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (291)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (292)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (303)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (305)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (316)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (319)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (338)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (340)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (356)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (382)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (392)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (406)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (425)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (428)
<223> n equals a,t,g, or c
<400> 693
gcacagtect geeettnatg encageeeca tgggacaeec gnngnnnttt eenaaaeete 60
engnaaaaca caentggage cagageette tgeegeeage eetgeeeetg aattggaage 120
agnoctytyc tegatygnag gygeteccag geeggeagee ettgecanet teetntycea 180
agcctgntgc tgnagaacgg ttattgctga ggtgcccctg tccaggcctg ctaacnttgg 240
ccacanacac atatnangcc cttggcttac agcctnaacc tnggcttcac nnctgctggc 300
canchagact gettentine ageattgate ttgtgttnan caagteteae tggcanaget 360
ggcattggag ggtgcttgtc cntggacttt gntcagaggc ctgtgncaga gtcagtttga 420
                                                                   456
actentinat geatgetetg ggeetgagtt geagea
<210> 694
<211> 104
<212> DNA
<213> Homo sapiens
```

```
<220>
<221> misc feature
<222> (11)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (53)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (78)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (92)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (98)
<223> n equals a,t,g, or c
<400> 694
ggaaatttgt nggggggctg ccaaaacctg aacaagaaga tggcgccaac aangcattct 60
cagactcctt tgtggatnct tgccctgaag gngaaggnca gagg
<210> 695
<211> 426
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (5)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (7)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (54)
<223> n equals a,t,g, or c
<220>
<221> misc feature
```

```
<222> (68)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (85)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (132)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (137)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (188)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (219)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (227)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (281)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (300)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (369)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (370)
```

```
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (396)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (414)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (422)
<223> n equals a,t,g, or c
<400> 695
ggaancnotg gttttaaata ttttgacttg ttgagggtat gttttatata gcangacatt 60
atatagengt aaaaaatggt gtttnatett etatataatt eetgttttta ttattaacaa 120
aacagtccta antagcngcc ctcaattgtg aaaaaattta ctttaaacta cattaggttg 180
tgaatgengg ttttateaga actatgtttt ttgtteagnt tatetgntea tatggataaa 240
tattggttgg gatgacttgg tgtctaatgt gtagtgctac ncacctaact tatggggccn 300
aaatagcatg tootaatgot tgotgotgat ttaaacacat taaaggtact ttgcaggaaa 360
aaaaaattnn taagggcggc cgctctagag gatccnagct tacgtacgcg tgcntgcgac 420
                                                                   426
qncata
<210> 696
<211> 196
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (130)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (139)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (157)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (184)
<223> n equals a,t,q, or c
```

```
<220>
<221> misc feature
<222> (196)
<223> n equals a,t,g, or c
<400> 696
tcgacccacg cgtccgattt aatgcactaa ctttaaatgt tttccaaata taattacctg 60
tcagtctttt tatagatata aatcaagtag gcattatgtt ttaaaaagact gacaggtaat 120
tatatttggn aaacatttna tgcactaact ttaaagnaat tgaaaattca ggtggataaa 180
                                                                    196
tagnottaca aaagan
<210> 697
<211> 263
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (43)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (210) ·
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (211)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (225)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (237)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (253)
<223> n equals a,t,g, or c
<400> 697
gaacttcccc ttcccgcaag tgtgaggaac cccaggctca ctnatgctcc tctgccccct 60
ctttaacatt ttcccctgga caagtgtgta tctgttctct ccattggcat ttctacttcc 120
agcctctggg ctcctgcttc tgcctcctgc ttaggaacct gtccccctgg ggtagcttca 180
```

```
caacacette aaacatagge agteagaggn neaceegaga agggneette ceaegtneag 240
 gaccaaattt ctnccgggaa ttt
 <210> 698
<211> 508
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (358)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (449)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (480)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (496)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (499)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (505)
<223> n equals a,t,g, or c
<400> 698
gcggacgcgt gggtaaagct gcacttggga tttttaccta acgctttact gattctctca 60
agcacatggc aaagtttgat ttgcactccg ttcatttctg acacgttttg ctgcctccta 120
cctttctaag cgtcatgcaa attcgagaat ggagaaggac gctgccggtc cctgagcggt 180
gtggagaggg cggaaggtgg actccagcgc agcttgaggg gctgaggacg gaggctgcag 240
catctgtgtc gttctactga gcacgcttct ctgcctcgct cctgactcag cactttgttc 300
actggctcag cagttatgtt tacacatcat ttttatggtc ctgctttgta attcatgntt 360
gagatgggtg gccactgtac agatatttat tacgcttttc agactttctg aatagatttt 420
tttgaataaa catgggttta tgaaagtgna aaaaaaaaaa aaaaaggggg gcccttttan 480
aggatccaag tttacnacnc gggcntgg
                                                                   508
<210> 699
```

<211> 651

```
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (499)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (502)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (550)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (588)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (596)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (611)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (614)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (643)
<223> n equals a,t,g, or c
<400> 699
gcaataaagc taaaactcac ctgagttgta aaaaactcca gttgacacaa aatagactac 60
gaaagtggct ttaacatatc tgaacacaca atagctaaga cccaaactgg gattagatac 120
cccactatgc ttagccctaa acctcaacag ttaaatcaac aaaactgctc gccagaacac 180
tacgagccac agettaaaac teaaaggaee tggeggtget teatateeet etagaggage 240
ctgttctgta atcgataaac cccgatcaac ctcaccacct cttgctcagc ctatataccg 300
ccatcttcag caaaccctga tgaaggctac aaagtaagcg caagtaccca cgtaaagacg 360
ttaggtcaag gtgtagccca tgaggtggca agaaatgggc tacattttct accccagaaa 420
```

```
actacgatag cccttatgaa acttaagggt cgaaggtgga tttagcagta aactgagagt 480
agagtgctta gttgaacang gncctgaacg cgacacaccg ccgtaccctt ctcaggatac 540
ttcaaggacn ttactaaacc cctacgcatt atttgaggag acagtcgnaa catggnagtg 600
acctggaaag ngcncttgga caaccaaaaa aaaaaaaaa aanggggggc c
<210> 700
<211> 787
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (5)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (33)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (58)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (99)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (109)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (116)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (126)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (127)
<223> n equals a,t,g, or c
<220>
```

```
<221> misc feature
 <222> (130)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (147)
 <223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (152)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (163)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (181)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (184)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (186)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (211)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (215)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (233)
<223> n equals a,t,g, or c
<220>
<221> misc feature
```

```
<222> (236)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (248)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (252)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (260)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (267)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (271)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (284)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (288)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (301)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (304)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (305)
```

```
<223> n equals a,t,g, or c
<220>
 <221> misc feature
<222> (351)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (364)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (373)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (408)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (416)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (446)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (504)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (525)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (534)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (536)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (589)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (601)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (608)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (614)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (626)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (628)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (649)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (653)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (665)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (726)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (737)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (747)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (758)
<223> n equals a,t,q, or c
<220>
<221> misc feature
<222> (777)
<223> n equals a,t,q, or c
<400> 700
taaanggggg ggggggggg ggggaaattt gantttgaaa aggggggggg gggggaanct 60
tttttttaag gggggggg gggggaaaaa aaagtaaang gggggggng gggaancttt 120
tttttnnccn ccatcaaggg ggggaanttt antttttggg gtnaacaaac ccttgccccc 180
nggntnaccc cggggttccc cggggaaaaa ntttnccccc ggggggttcc ggnaanccct 240
tattgcongt tncccggggn ttttttnccc naaaaaaaac aaantttntt tccccttttg 300
nccnntttta acttgggccg cctttgccca aaagggcttt ggggggggcc naaagggtca 360
attroccttg aancttgaaa ccggggaaaa gcttcaactt tggcattrgg cccttnccgt 420
ggtccccact tgcaaacgtg gtcaantggg tgggaacctg aacttgccgt ctaaaaaaaa 480
acttgccaaa tattgaatga acantcaaaa aaaggtgggt gaaancaagc ctcngnaagg 540
cccccttcaa aaggcaatct tggcttacac ttaacaccaa ggtggtctnc ttttgacttt 600
naacaagnga acanccactt cttcancntt taacgcttgg ggcttgcant tgnccttcaa 660
ccaancactt ttgtcaaagc tcaattttct tgggtattaa caaaaccaaa attttggctt 720
acagenaaca aagggtnggg tgggaaneet caatgggnee ecaacaattg ggeeetneea 780
aagggaa
                                                                   787
<210> 701
<211> 133
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (109)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (119)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (125)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (126)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (128)
<223> n equals a,t,g, or c
<400> 701
ggaagaggat gacaccatca tggaagaatt ggtagataat catggcaaaa aaatcaagtc 60
tttanngnac cca
<210> 702
<211> 447
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (4)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (7)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (382)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (413)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (424)
<223> n equals a,t,g, or c
<220>
```

```
<221> misc feature
<222> (439)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (445)
<223> n equals a,t,g, or c
<400> 702
gcgnatncgt gggctgaagc ataaagaatt aatgacttac tttaattact ggaattcttc 60
tgcaacattt gacaaaacta accttgaata aggcccactg taatacgtag ctctcttaaa 120
tataacactt aggactagaa gattagaaac taccaatccc aactacgtaa taggaaaatg 180
taggatcaaa aggcccatgt atataagtac tgaccactgg gccataatgt tgcttctcag 240
gctatatgca gtcctttagt cagaagtcaa taggcctatt tattaatatt ttacagacca 300
tattacctgg attaccaggg actatctttg ctgcagagat caagggttaa gatctatggg 360
aagatactta tttttctgag gnccttatgc ctggcatata attaaagact cangagaatt 420
atgngaaatg ctttctggnt gcccnaa
                                                                    447
<210> 703
<211> 349
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (117)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (214)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (225)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (272)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (295)
<223> n equals a,t,g, or c
<220>
<221> misc feature
```

```
<222> (311)
 <223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (322)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (328)
<223> n equals a,t,g, or c
<400> 703
ccctaatgta aaatatggac tttggtgata gcgatgtgtc agtgtatgtt catcaattgt 60
aataaacatt cctttctggt ggggaggttg taaatggggg agggtgtgca tgtgtanggg 120
cacgagttat atgggaattc tctgtacctt ctgttcaatt ttgctatgaa cctaaaactg 180
ctctaaaaaa taacctctgc tttaaaaagg tatntgtact ctatnatctt ttattagaaa 240
totttgttgc tatttttaca tggaaaaata enggatgaag teettattee eetanaataa 300
attatggaaa ntcaccattc cnagtttntg atggaatcct ggatgctcc
                                                                    349
<210> 704
<211> 328
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (160)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (228)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (263)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (276)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (302)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (305)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (310)
<223> n equals a,t,g, or c
<400> 704
cgcaccggac cccggtcccg gcgcgcggcg gggcacgcgc cctcccgcgc gcgcggggcg 60
cgtggagggg ggggcggccc gccggcgggg acaggcgggg gaccggctat ccgaggccaa 120
ccgaggetcc geggegetge egtategtte egeetgggen ggattetgae ttagaggegt 180
tcagtcataa tcccacagat ggtagcttcg ccccattggc tcctcagnca agcacataca 240
ccaaatgtct gaacctgcgg ttnctctcgt actgancagg attaccatgg caacaacaca 300
                                                                   328
tnatnagtan ggtaaaacta acctgtct
<210> 705
<211> 666
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (395)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (437)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (443)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (456)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (468)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (473)
```

```
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (478)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (484)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (494)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (497)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (505)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (506)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (512)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (541)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (548)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (562)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (578)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (589)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (617)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (618)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (652)
<223> n equals a,t,g, or c
<400> 705
gttttgtcca atcatttaaa acttattata taaaaatttg ttttaaatga ttggacaaaa 60
aggtatggtc taatggtaat aaacaaattt ttatataata agttttattt gtatgtaata 120
taatatatta tttaatatga taaaacttat attaaatgaa attttatgct gttctcttgt 240
caatctgtct tttgttatct tgctggtgtg cctgtcatgt gagggactgc aatctgatat 300
gcctattttc cacagtcaaa gcaattacaa gagaattgtt acaattaccc agttatgtca 360
agagattttt tttaattcac taaggtagag ataangagaa tgtattaaaa ataggatatt 420
ttaattataa atgcatnact ggngaagggg tattgntttt gaataaanat atngaggnta 480
tttngccatg accncanaaa aaacnnaagt tngaaaaaat cccctgggaa aatttaatgt 540
ntccttcnaa ctttttaaaa antaccctaa aaaaaatntt aatttggant taaaatcaat 600
atctccaatt aatcccnnaa ttctctttaa ataatccccc ttaaaataag gntacccctt 660
                                                               666
gaaata
<210> 706
<211> 267
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (6)
<223> n equals a,t,g, or c
<220>
```

```
<221> misc feature
<222> (24)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (28)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (36)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (43)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (62)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (75)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (78)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (79)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (95)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (130)
<223> n equals a,t,g, or c
<220>
<221> misc feature
```

```
<222> (147)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (155)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (156)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (192)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (208)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (222)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (256)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (258)
<223> n equals a,t,g, or c
<400> 706
cccgtncccc cctcctcctc ggcncgcngc ggcggnggcg ggnggcggag gggccgcggg 60
enggteece cegenggnne egeceeggg geegnggtte eggeggegee tegeetegge 120
eggegeetan cageegaett agaactngtg eggannaggg gaateegaet gtttaattaa 180
aacaaagcat cncgaaggcc cgcggcgngt gttgacgcga tntgatttct gcccagtgct 240
ctgaatgtca agttgnanaa attcaat
                                                                   267
<210> 707
<211> 300
<212> DNA
<213> Homo sapiens
```

<220>

```
<221> misc feature
<222> (64)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (79)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (105)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (113)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (161)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (171)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (172)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (227)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (238)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (251)
<223> n equals a,t,g, or c
<220>
<221> misc feature
```

```
<222> (257)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (274)
<223> n equals a,t,g, or c
<400> 707
cctccaccca cggccgggcc ttgacgtcat gggctgcggc cccctcccgg ctgaacctat 60
aaancggcag gtgcgcgcng ccctacagac gttcgcacac ctggntgcca gcnccccaaa 120
agtcccggga cagcccgaag cgccgcgcc gcagccccga nctccccaag nnttcgaaag 180
cggcgcacac teceggtete caetegetet tecaacacee getegtnttg geggcagnte 240
gtgtcccaga naccganttg ccccagaaaa cganacgccg ccgctgcgaa ggaccaatga 300
<210> 708
<211> 282
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (1)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (5)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (6)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (30)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (50)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (239)
<223> n equals a,t,g, or c
```

<220>

```
<221> misc feature
<222> (262)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (272)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (275)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (279)
<223> n equals a,t,g, or c
<400> 708
ntttnnatag tccccaagct taatacgaan ccctataggg aaagctgaan acgcctgcag 60
gtaccgggtc cgggaattcc cgggtcgacc cacgcgtccg attacaagct gtagaccacc 120
taatatcaat ttgtaggtaa tgttcctgaa aattgcaata catttcaatt atactaaacc 180
tcacaaagta gaggaatcca tgtaaattgc aaataaacca ctttctaatt ttaaaaaana 240
                                                                  282
aaaaaaaaaa anggggggc cnccntaang gt
<210> 709
<211> 399
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (4)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (20)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (42)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (58)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (72)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (123)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (138)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (143)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (346)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (364)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (388)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (395)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (399)
<223> n equals a,t,g, or c
<400> 709
gctnttttat acgaagggen cctaataggg gtttaaagct gnaaaacccc cctggcangg 60
tagccgcgaa ancgggaaat tcccgggggt cgaacccacg cgttccggga aaaagcttgc 120
canaaacagg gagaaganag ganagaaaaa gggggattag ttatatcaaa aagcctggaa 180
aggtgggaat ggaccaaaaa gatggggact cctcctttat tccaagcatg ggagggggtt 240
ttaaatggga gggatttcct ttttcctgcg acaaaacgtc ttttcacaac ttaccctgtt 300
```

```
aagtcaaaat ttattttcca ggaatttaat atgtacttta gttggnatta tctatgtcaa 360
tganttttaa gctatgaaaa tatatatnaa cttanagan
<210> 710
<211> 302
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (294)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (300)
<223> n equals a,t,g, or c
<400> 710
ggtgtaattc tgttagtttc agatttctct cctgtttttg caaattgtgg gaaagattga 60
caatgcaaat gtgtcaaaga catactgttg ggtgcaatat taacaatttt aaatgcaaat 120
ttctttggat aaattatttc tatattctgt aaatctgaga tttaatgtat attttgttta 180
aa
                                                          302
<210> 711
<211> 489
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (3)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (70)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (110)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (116)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (287)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (402)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (439)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (465)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (466)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (483)
<223> n equals a,t,g, or c
<400> 711
tangggaaat ttgaagctgg ttccctgcag gtcccctgca ggtaccggtc cggaattccc 60
gggtcgaccn acgcgtccgg gctccacgag ggttcagctg tctcttactn ttaacnagtg 120
aaattgacct gcccgtgaag aggcgggcat aacacagcaa gacgagaaga ccctatggag 180
ctttaattta ttaatgcaaa cagtacctaa caaacccaca ggtcctaaac taccaaacct 240
gcattaaaaa tttcggttgg ggcgacctcg gagcagaacc caacctncga gcagtacatg 300
ctaagacttc accagtcaaa gcgaactact atactcaatt gatccaataa cttgaccaac 360
ggaacaagtt accctaggga taacagcgca atcctattct anagtccata tcaacaataa 420
ggggttacga cotogatgnt ggatcaagac attocgatgg tgcannogct attaaagggt 480
cgnttggtt
                                                                   489
<210> 712
<211> 121
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (2)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (74)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (88)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (93)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (94)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (119)
<223> n equals a,t,g, or c
<400> 712
gnattggggc ttcctttcga gggggccggg gactagggat cctgaccaca atgactgagc 60
ctgctacatg aagngcccca cgtaggtncg gannactttg acatcttggt acctaggana 120
                                                                   121
C
<210> 713
<211> 476
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (337)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (420)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (436)
<223> n equals a,t,g, or c
<220>
```

```
<221> misc feature
<222> (450)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (458)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (463)
<223> n equals a,t,g, or c
<400> 713
ggagcaaaca tgttttttga accttgtcat ttttgtgaag aattgcctag attccttctc 60
tcatcaacgg gaaagtactt cctctgagag tgcgagtgca ccatgctcac tgttgctgcg 120
tgggagagtc acaagccact ggcaagcaag tggtatagtc tgtgaagcac tgcagcgagc 180
agcacctgga tcttgccttt ataagaacat tttactacct gcagctttga gtcttgccct 240
acattttggg catgacataa gatgtgtctt tattcagctc gtcgtgaaga tgctgctgct 300
gaatgggtca gcatatotot gtttgcatgg tttgcangaa gtcggttttc atggtcattc 360
agtttccaca gatcttgaat gattactggc tggctgggtc tttttttcca tgagaaaatn 420
actggtgcaa aattgnccta taaaattggn ctttactnaa atnaccaatg gtttaa
<210> 714
<211> 527
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (9)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (16)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (79)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (80)
<223> n equals a,t,g, or c
<220>
<221> misc feature
```

```
<222> (414)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (415)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (419)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (462)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (469)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (483)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (497)
<223> n equals a,t,q, or c
<220>
<221> misc feature
<222> (516)
<223> n equals a,t,g, or c
<400> 714
ccctttgant ataccngaaa gctggttcgc ctgcaggtac cggtccggaa ttcccgggtc 60
gacccaegeg teegeeeann eccaeteeae ettaetaeea gacaaeeetta gecaaaeeat 120
ttacccaaat aaagtatagg cgatagaaat tgaaacctgg cgcaatagat atagtaccgc 180
aagggaaaga tgaaaaatta tagccaagca taatatagca aggactaacc cctatacctt 240
ctgcataatg aattaactag aaataacttt gcaaggagag ccaaagctaa gacccccgaa 300
accagacgag ctacctaaga acagctaaaa gagcacaccc gtctatgttg caaaatagtg 360.
ggaaagattt ataggtagag gcgacaaacc tacccgagcc tggtgatagc tggnntgtnc 420
aagataagaa tettagttea acetttaaat tttggeecae anaaceetnt aaatteeett 480
                                                                   527
ggnaaattaa ccggtangtc caagagggac caggtnttgg gacccct
```

<210> 715 <211> 511

```
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (23)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (54)
<223> n equals a,t,g, or c
<400> 715
gaaacccact ccaccttact acntgacaac cttagccaaa ccatttaccc aagntaaagt 60
ataggcgata gaaattgaaa cctggcgcaa tagatatagt accgcaaggg aaagatgaaa 120
aattatagcc aagcataata tagcaaggac taacccctat accttctgca taatgaatta 180
actagaaata actttgcaag gagagccaaa gctaagaccc ccgaaaccag acgagctacc 240
taagaacagc taaaagagca cacccgtcta tgtagcaaaa tagtgggaag atttataggt 300
agaggcgaca aacctaccga gcctggtgat agctggttgt ccaagataga atcttagttc 360
aactttaaat ttgcccacag aaccctctaa atccccttgt aaatttaact gttagtccaa 420
agaggaacag tetttggcae taggaaaaac ettgtagaag agagtaaaaa attaacacee 480
                                                                   511
atagtaggcc taaaagcagc accaattaag a
<210> 716
<211> 81
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (15)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (39)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (74)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (77)
<223> n equals a,t,g, or c
<400> 716
gggtggcatg aggangtccc acttgcaact tctttctgnt gagagaacct taggtacgga 60
```

81

```
gaagaataga gggnctnatg g
<210> 717
<211> 208
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (2)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (6)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (20)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (71)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (72)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (104)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (115)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (127)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (175)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (195)
<223> n equals a,t,q, or c
<220>
<221> misc feature
<222> (201)
<223> n equals a,t,g, or c
<400> 717
tnggtncata agcatcttcn tggaatcgta ttataaaatt gaaattagat atagagaatg 60
ttttaacact nntttaactc aaaatttgta atcattctta atancatctt tcttnatcaa 120
aagaaanagg aatttaatga caggcagaca ctcttttaaa acttattcac aaaanccaat 180
aactgcacaa aatgntatta nctgcctg
<210> 718
<211> 562
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (557)
<223> n equals a,t,q, or c
<400> 718
gcccacgcgt ccggcccagg ctgctcccta ccaggtgacg gagcgcgccg gggctgtggg 60
tgccaggggc tgagtgctag ggactcgtca tgagtgggga tccccacgtt cctgtcactg 120
ctgtcaaaca gaaggtaaac agtcttatga atgtatttcc ttaggaaaac ttgtaaaaac 180
ttttattagg atatctattt aatactgaac tttggcctac tttgtgatag actataaaca 240
aattgaggaa atcactattt ctcacttctg tattttctca aaaataattt tgttacagag 300
ttcaatatac tgtgtaccat tgatcttcta ttgtgaaagc aaagaatttc atcaaaatat 360
tttaaattat gagtgaaaat tgtgtatgtt aattttgcag ctataatatt aatcaaattt 420
tgtgtaattc taatcacaaa atgacgtgcc ttaagtgccc ctccagctgt gggttggcag 480
tgtccggaca gggagggccc atcaccgaaa tcctgaatga ttactagacc aattctatta 540
                                                                   562
aaaacatttc aaggcanaaa aa
<210> 719
<211> 579
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (400)
<223> n equals a,t,g, or c
<220>
<221> misc feature
```

```
<222> (470)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (501)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (530)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (534)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (555)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (578)
 <223> n equals a,t,g, or c
 <400> 719
 gcaaacccac tccaccttac taccagacaa ccttagccaa accatttacc caaataaagt 60
 ataggcgata gaaattgaaa cctggcgcaa tagatatagt accgcaaggg aaagatgaaa 120
 aattatagcc aagcataata tagcaaggac taacccctat accttctgca taatgaatta 180
 actagaaata actttgcaag gagagccaaa gctaagaccc ccgaaaccag acgagctacc 240
 taagaacagc taaaagagca cacccgtcta tgtagcaaaa tagtgggaag atttataggt 300
agaggegaca aacctacega geetggtgat agetggttgt ecaagataga atettagtte 360
aactttaaat ttgcccacag aaccctctaa atccccttgn aaatttaact ggtagtccaa 420
agaggaacag gtttttggac ctaggaaaaa ccttgtgaag agagtaaaan tttaacaccc 480
 tagtaggeet aaaageagee necaattaag aaageggtea agettaacan eeantaceta 540
aaaaatccca acttntactg gacttcttac acccattng
                                                                    579
<210> 720
<211> 403
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (19)
<223> n equals a,t,g, or c
<400> 720
```

```
gctttaaatt tgcccacana accetetaaa tcccettgta aatttaactg ttagtccaaa 60
 gaggaacagc tctttggaca ctaggaaaaa accttgtaga gagagtaaaa aatttaacac 120
 ccatagtagg cctaaaagca gccaccaatt aagaaagcgt tcaagctcaa cacccactac 180
 ctaaaaaatc ccaaacatat aactgaactc ctacacccaa ttggaccaat ctatcaccct 240
 atagaagaac taatgttagt ataagtaaca tgaaaacatt ctcctccgca taagcctgcg 300
 tcagattaaa acactgaact gacaattaac agcccaatat ctacaatcaa ccaacaagtc 360
 attattaccc tcactgtcaa cccaacacag gcatgctcat aag
<210> 721
<211> 327
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (311)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (316)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (320)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (322)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (323)
<223> n equals a,t,g, or c
<400> 721
ggacacttet teateteace ecceeegee eccetetagg agagetgget etgeagtggg 60
ggagggatgc agggacattt actgaaggag ggacatggac aaaacaacat tgaattccca 120
gccccattgg ggagtgatct cttggacaca gagcccccat tcaaaatggg gcagggcaag 180
ggtgggagtg tgcaaagccc tgatctggag ttacctgagg ccatagctgc cctattcact 240
totaagggcc ctgttttgag attgtttgtt ctaatttatt ttaagctagg taaggctggg 300
                                                                   327
gggagggtgg ngccgnggtn cnnttag
<210> 722
<211> 202
<212> DNA
<213> Homo sapiens
```

```
<220>
 <221> misc feature
 <222> (48)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (54)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (63)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (65)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (73)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (139)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (165)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (176)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (182)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (201)
<223> n equals a,t,g, or c
<400> 722
```

```
gctcgcgccc caggccggtg tacccccgca ctccgcgccc cggcctanaa gctntctctc 60
congnitocc ggneeggee eegteeege eegeecaga teegetggge egecatggag 120
cgctggcctt gaccgtaang gcggcgcctg gctgctcgtg gctgnccgcg cgctgntgca 180
antgctgagc tcagacctgc nt
<210> 723
<211> 354
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (39)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (43)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (50)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (66)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (72)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (94)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (113)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (125)
<223> n equals a,t,g, or c
```

<220>

```
<221> misc feature
<222> (154)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (155)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (203)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (246)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (274)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (295)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (298)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (333)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (335)
<223> n equals a,t,g, or c
<400> 723
gggagaatcc atctaaagta aacagcccag cattggganc canctctttn gcaagttgga 60
ggcttnctgt ancgttaatt tcaggaaatc ctangcaaat atgcagttac tgntctagaa 120
gatanatagg tagtgtgtac tgtgatggaa attnnaatgt cactgttaaa aggtttgcat 180
tttgtgggct tggaagggcc tanaacttcc ttcttaggct ttctcttcac taagtgggct 240
cttgcnttat attacttcca gagaaaggca ggcnggatta gaggcatggt aaggnganca 300
atttggggaa atacctatac tgtgcaaaag agncnaagga caacctttta atgg
```

```
<210> 724
<211> 310
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (22)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (151)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (171)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (204)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (217)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (239)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (248)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (296)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (297)
<223> n equals a,t,g, or c
```

```
<400> 724
gctacctcgg tgcgccccg gntcgcaggc cccgccagaa ggcccgtggc cacggcgaat 60
acggcgcgtg cgtcccggcc ccagggtccg gcagccccgc cggccgagcg cctccctgcg 120
gcctagccgg gcccggccgg gccggagcag nttcccacgg cccccacccg ntcgcctgcc 180
egeogeoteg egggtggggg eggngegegg getecanece ettttgaaat ttgagtetng 240
caaccagnaa gttcggaatc ccgagatacc ggatcctctg cgcaaaatgt tttctnncga 300
aggtgaaagg
<210> 725
<211> 99
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (10)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (41)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (49)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (65)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (90)
<223> n equals a,t,g, or c
<400> 725
geggaegen gggeggegg gegggeggee atgaggeteg ngeggeggng gegggeggg 60
                                                                   99
taggncggcg ggcccgggga ggggggggn agggcatgt
<210> 726
<211> 208
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (44)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (64)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (91)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (137)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (179)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (185)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (187)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (204)
<223> n equals a,t,g, or c
<400> 726
agtgagtcat ctgctggccg gcttctgtgt gtgggtcgtc ttgngctggg tagggggctc 60
agtncccaac ctgggccctg ctgagcagga ncagaaccat tacctgccca gctgtttggc 120
tgtacggcga gaatggnacg ctgactgcaa ggggcttggc gcggttttcc acaacctgng 180
                                                                    208
gctangncaa gttcaagggc ttcnactg
<210> 727
<211> 441
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (321)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (394)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (405)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (422)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (433)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (438)
<223> n equals a,t,g, or c
<400> 727
ggaagacaag ttcttgactc tatgttgagg ccagttgaaa aatgagggag aataaaacca 60
tgaacgaaac aagaaagaaa caaaacagaa gaggaatgaa aaagacataa tgatgtcatc 120
caagccaaca agccatgctg aagtaaatga aaccataccc aacccttacc caccaagcag 180
ctttatggct cctggatttc aacagcctct gggttcaatc aacttagaaa accaagctca 240
gggtgctcag cgtgctcagc cctacggcat cacatctccg ggaatctttg ctagcagtca 300
accgggtcaa ggaaatatac naatgataaa tccaagtgtg ggaacagcag taatgaactt 360
taaaagaaag aagcaaaggc actagggggt gatncagatc atggntggat tgatgccatt 420
gntttggaat tgntttgngt t
<210> 728
<211> 429
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (95)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (99)
<223> n equals a,t,g, or c
```

```
<220>
 <221> misc feature
 <222> (149)
 <223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (231)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (243)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (264)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (284)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (290)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (311)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (317)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (327)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (357)
<223> n equals a,t,g, or c
<220>
```

```
<221> misc feature
<222> (363)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (397)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (403)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (416)
<223> n equals a,t,g, or c
<400> 728
ctcaagtctc ttttctgccc aaaaagggaa aagtgataga aatgggggtg gcaagtgggg 60
tgagtggatg aaggtgggta ttgggggtgg ctgtnaaana aaataatgga gaatcacttt 120
tctatacatc tacctatact taatctaana aacaaagtaa tctactgtaa agtactctgc 180
cccttgaaag aagtattaaa aagagtgagg atggatttaa aaaaaaacat naatttagaa 240
atnttcaaaa tggtttttgt gggnagattc ctattatgaa ttcncacatn tttaaagaat 300
gagaaacata nttattngtt aaaaatncca aaaacagttc ctgggttcct cttgttnttt 360
ganaactaaa aaaaatacca gagtgttgga atctccnaaa ccnatgaaat cccccnaaat 420
tttaaggac
<210> 729
<211> 260
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (40)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (53)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (54)
<223> n equals a,t,g, or c
<220>
<221> misc feature
```

```
<222> (57)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (89)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (103)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (104)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (120)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (150)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (188)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (195)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (251)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (256)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (259)
```

```
<223> n equals a,t,g, or c
<400> 729
tggtacccct gcaggtaccg gtccggaatt cccgggtcgn tccacgcgtc cgnnctntat 60
caaatgtttg ccagaattca cagtttagng catctaaatc canntatata gaaagcgctn 120
tttttctttt ctttctttc ttttttttt ttttttta agatggactc cacgttgcca 180
aggotggnaa titgnttoot ottgatoaat ataaagaogt ticaacatta tigatotott 240
tagagtttgg ntatantant
                                                                   260
<210> 730
<211> 136
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (6)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (15)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (49)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (51)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (75)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (123)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (131)
<223> n equals a,t,g, or c
<400> 730
gegganeace atatngaacg ggagacetgg tgactagaca teaagcaang nactatgeac 60
```

```
aanaaaaaa naaaaa
<210> 731
<211> 110
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (1)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (25)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (34)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (61)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (83)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (110)
<223> n equals a,t,g, or c
<400> 731
necetagaac cecagecagg acegnggagg ceengaagac ceceateaag gaggagetgg 60
nggcagggaa aacctacagg cgntgagaga gaggccgcag caagaagcan
                                                            110
<210> 732
<211> 639
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (222)
<223> n equals a,t,g, or c
```

```
<220>
  <221> misc feature
  <222> (247)
  <223> n equals a,t,g, or c
  <220>
  <221> misc feature
  <222> (361)
  <223> n equals a,t,g, or c
  <220>
  <221> misc feature
  <222> (387)
  <223> n equals a,t,g, or c
  <220>
  <221> misc feature
  <222> (457)
  <223> n equals a,t,g, or c
  <220>
  <221> misc feature
  <222> (514)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (577)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (579)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
. <222> (588)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (607)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (639)
 <223> n equals a,t,g, or c
```

```
<400> 732 -
gataaacaat aaaatattgt gaacatcttc attagaatat ttttgtcagc tttggaggta 60
ggatctagat aaaagttttt aggctaaccc aaaatattta tcttcagtaa tgatatgcct 120
tttgctgtgt atgacatctg aaatgtggat aatactgaaa cgctctcagt cttaaactta 180
taagctacac taaaatctaa ttaatgaatt gctgtaaaag tngttgatta ttaatataag 240
ctgtagnttt taacttttta tctgctgcct cttgtgttca tttcctttta aaggtgattg 300
gtttctgttt gtcatcaaaa cataaaaacc ttaaaggagt cttacagatt ttttgtgctg 360
ntaggtggct tttcccttct ggctctnttt ttttaaacaa taattaataa ctaaaatatt 420
tatgtcttat tgaatatctt atggtataat aacatanttt atcttaaaat aatcaaatag 480
gatattcatg gatttttaga tctgtcttgt gagntgtgac agatttattc aataaacatt 540
tattgagtcc cctatcaact acttggtacc aaagaanana gatgaatnaa tcttggtctt 600
tcaaaangct ataggctatt ggggggaaat agggatggn
<210> 733
<211> 380
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (12)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (40)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (44)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (58)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (306)
<223> n equals a,t,g, or c
<400> 733
gaattcattt tnttcttatt aaggaaatac tttgcataan gggnatcatt cccagagngc 60
tttaccaaaa ttctcttaaa taaaaataat agactcgcta gtcagtaaag atatttgaat 120
atgtatcgtg ccccctccgg tgtctttgat caggatgaca tgtgccattt ttcagaggac 180
gtgcagacag gctggcattc tagattactt ttcttactct gaaacatggc ctgtttggga 240
gtgcgggatt caaaggtggt cccaccgctg ccctactgc aaatggcagt tttaatctta 300
tettingget tetgeagatg gitgeaattg atcettaace aataatggie agiceteate 360
tctgtcctgc ttcataggtg
                                                                   380
```

```
<210> 734
<211> 311
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (8)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (13)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (27)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (61)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (92)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (128)
<223> n equals a,t,g, or c
<400> 734
ttaactgnaa tcntctacta taggttnagc tggtacgcct gcaggtaccg gtccggaatt 60
nccgggtcga cccacgcgtc cgcggacgct tnggttggtg gccaaggaaa ggtatatagt 120
aaaagttnta aaccatgtca actgaagtga gtgtaatctc agatatcaac attattatat 180
tttaaaatca cgctatggaa atatcacctg aattctgtca tttgtcagat ttacagtacc 240
311
aaaaaaaaa a
<210> 735
<211> 361
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
```

```
<222> (173)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (219)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (308)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (314)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (327)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (331)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (343)
<223> n equals a,t,g, or c
<400> 735
gtaccgctgc cgccgtctct aaggtcgccc gggtcccacc gccgccacca tgcctcgggg 60
egegeaccea eegecetegg cageegeeee ageeceegee eettegggee agneggget 180
catggctcag atggcgacca cggccgcagg ggtagccgng ggctcggctg tgggacacgt 240
catgggcagc geoctgaccg gagcetteag eggggggage teggageeet eccageetge 300
tgtccagnag gccnccaccc ccgctgnccc ncagcccctg canatggggc cctgcgccta 360
                                                              361
t
<210> 736
<211> 388
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (38)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (43)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (49)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (53)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (64)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (85)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (109)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (148)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (153)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (161)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (164)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (169)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (170)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (187)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (231)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (237)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (265)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (296)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (332)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (345)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (378)
<223> n equals a,t,g, or c
```

<220>

<221> misc feature

<223> n equals a,t,g, or c

<222> (384)

```
<400> 736
gtatccatag ttgctgctca gatgtttctt tttttcanag ttntgctgnt aanaatatct 60
cctnaacatt tgacttcatt gtggncaata atggtctctg aattgattna gacattcaca 120
cagcttgaag aaaatctaaa agatgaanat gantcattga naancaccnn caaagtaaac 180
agaattnaag tttcagtccc ggatgcaaat ggaccctcag tgggggagat nccccanagt 240
gaactcatct tgtatttatc agctngcaaa ttcttggaca cagcagcttt cttttncacc 300
tgacaagatg ccattatttc aaatttatac gngggcattt attcnagaag tggacacata 360
                                                                   388
gggccctgtc ttctgttnat gtanagga
<210> 737
<211> 146
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (32)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (70)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (96)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (102)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (124)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (133)
<223> n equals a,t,g, or c
<400> 737
ggtaaatcaa agttttgggt ggaagtgttg anaagtatga gttttttgtt gtttttgtt 60
tacttaaaan ttttaattta tccagaatgg cagtancttt ancaagcaga tggtcacaat 120
```

```
146
ctgntttcta aancattttt tattaa
<210> 738
<211> 101
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (9)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (46)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (67)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (99)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (101)
<223> n equals a,t,g, or c
<400> 738
ggtgagagnc tcatttctat gcacagtgtt tctgaggagg atgganctag atagctgtct 60
gttgtcntgt agcccaagct tgataatgga actatccang n
<210> 739
<211> 542
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (3)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (10)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (15)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (23)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (30)
<223> n equals a,t,q, or c
<220>
<221> misc feature
<222> (458)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (485)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (494)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (530)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (541)
<223> n equals a,t,g, or c
<400> 739
tanggteten agggnettet aenggaaaen eteaetatat tgaaagetgg tacceetgea 60
ggtaccggtc cggaattccc gggctaaata tgaaaataag tcatttgaaa aaaatacagt 120
atgtaaaatt tgttcattcg ttgaggtaat ggtgctatgt ttttacaaaa ttgttcctac 180
acctttttc tacttcaggt attttatttc aaccatttcc atcaattgaa ctgttaccat 240
tgcctttttc tgttgagaaa ttgcctctga aaaatagtgc tatttttcag cttaagtgtt 300
cttaagtgaa tgaaattttc aaagtactag atcaccttaa aattatttca cgtactgaag 360
acaattaagt ccgttatgtt tagagtagaa aatgtttagg ttaaagagca tctgtcaaca 420
gaatctacaa aaaagattcc cttgcatttg aattaagntc tctattctcc tattgctaaa 480
tgtgngatat atanagagga tgtataaaag gaaatggaaa tagactatgn acttggctgg 540
nt
                                                                   542
```

```
<210> 740
<211> 184
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (8)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (13)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (24)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (77)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (78)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (107)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (122)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (138)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (171)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (175)
<223> n equals a,t,g, or c
<400> 740
aattoccnac tonagtttag gotngtacco otgoaggtac oggtocggaa ttoccgggto 60
gacccacgcg teegtennge teegetgegg egeceeaet getgatngag etgetgggee 120
tnagcgctct gctgcagnga gatcccagga agctggcaca tcttggaagg nccgncctgc 180
tcgg
<210> 741
<211> 231
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (9)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (167)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (170)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (173)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (176)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (225)
<223> n equals a,t,g, or c
<400> 741
gcccacgent ccgggccaga cgagcagagg acggcatcgg cctggacttg cctctttatc 60
cagcccaccc ccaggacttc catgaagtag aggacttgat aaagactgcc ataggcaaca 120
cactggtcca ggacatctga tattctccag atacccaaaa gctcctngtn cgnctnagtg 180
acgattacaa caggacgttt ctggagaacc tgaaagtgaa caccngagaa t
```

```
<210> 742
<211> 119
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (66)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (92)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (97)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (103)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (116)
<223> n equals a,t,g, or c
<400> 742
ttttcnttta tacttttgtt tatttttcct gnttatnaaa acngccaaca attgcnttt 119
<210> 743
<211> 580
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (264)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (338)
<223> n equals a,t,g, or c
<220>
```

```
<221> misc feature
  <222> (366)
  <223> n equals a,t,g, or c
  <220>
  <221> misc feature
  <222> (369)
  <223> n equals a,t,g, or c
  <220>
  <221> misc feature
  <222> (385)
  <223> n equals a,t,g, or c
  <220>
  <221> misc feature
  <222> (396)
  <223> n equals a,t,g, or c
  <220>
  <221> misc feature
  <222> (443)
  <223> n equals a,t,g, or c
  <220>
  <221> misc feature
  <222> (458)
  <223> n equals a,t,g, or c
  <220>
  <221> misc feature
  <222> (499)
  <223> n equals a,t,g, or c
  <220>
  <221> misc feature
  <222> (515)
  <223> n equals a,t,g, or c
. <220>
  <221> misc feature
  <222> (540)
  <223> n equals a,t,g, or c
  <220>
  <221> misc feature
  <222> (562)
  <223> n equals a,t,g, or c
  <220>
  <221> misc feature
```

```
<222> (563)
<223> n equals a,t,g, or c
<400> 743
gtcggttttt tatttttta caatttcact tagtctgtac ttcatcattt tgacagcatc 60
ttcctccctc ctttaattaa tggaatcttc tgaattttcc ctgaatgttt aaagatcatg 120
acatatgact tgatcttctg ggagcaggaa caatgactac tttttctggt gtgttaacat 180
gtcgctagcc agtgctccag gcacccagct ttgtctgtgg gttagtattg gtgtatgtat 240
gagtatctgt atgtatatat acanggtatt tatagagaga gactatcctg gagaagcctc 300
gttttgatgc cattcttcct tgcaaggtta agcaaggngg gtggaaacta agacacctga 360
accotnoang gccttccgca tcaangtcag catgangaca gaccacagag ctgcactttt 420
gctccgaagc tactttcac tgncccgttc aatctgantg ctgccacaac cagtcagggc 480
cgtcacagag agggagagnt gagaaagaag tcttnctctt tattgagttc caagactacn 540
accaattaca ctggcttttg annccgtgat cctgatccaa
<210> 744
<211> 225
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (21)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (210)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (213)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (217)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (220)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (224)
<223> n equals a,t,g, or c
<400> 744
```

```
cgaacaagac atgaaaagag nggtgacaaa tcaagaataa acactggttg tagtcagttt 60
225
aaaaaaaaa aaaaaaaaa aaagggggn ccngttnaan gggnc
<210> 745
<211> 338
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (1)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (49)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (56)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (58)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (62)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (175)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (316)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (321)
<223> n equals a,t,g, or c
```

<220>

```
<221> misc feature
<222> (334)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (336)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (338)
<223> n equals a,t,g, or c
<400> 745
nagetggtac geetgeaggt accggteegg aatteeeggg tegaceeang egteentnaa 60
antaaagggg ctacagaaac actcattttt atgctgttcc ctcttgggct tcatgcaaag 120
acaattctgt gtaaatgtac agttgactct gatttggaaa tatgaaaatc agtcnatcct 180
tgttataaaa aatttttta caattgtaat tatattgatg ttcatattgt gtaaaataac 240
aaaaaaaaa aaaaanaaaa naaaaaaaaa aggnangn
<210> 746
<211> 160
<212> DNA
<213> Homo sapiens
<400> 746
ggtttcagtt gagccctgga actcctaaac ctttgcccct ggggcttcca tcccaaccag 60
tgccaaggac etectettee ecettecaaa taataaagte tatggacagg getgtetetg 120
                                                            160
<210> 747
<211> 218
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (178)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (198)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (204)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (213)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (218)
<223> n equals a,t,g, or c
<400> 747
ggaaaaaatg cattgtcaac ggaatctttt atgtttgttt gtcttccttt aagcaacatt 60
gcggccgttt taaaggancc aagnttacgt acncgtgn
<210> 748
<211> 265
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (12)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (28)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (41)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (52)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (53)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (77)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (80)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (82)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (106)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (107)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (121)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (127)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (150)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (153)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (159)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (161)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (175)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (186)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (207)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (208)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (258)
<223> n equals a,t,g, or c
<400> 748
gctgttactt angaaaatgg aacacaanaa aagtaaagaa naaagaatga cnnacacatt 60
taagatetga ttggaenegn angataatee tgagaattge taatanntea etgggtttgg 120
nccttantgt tgacttcagt atgctgagan ggngaccanc ncgcctagag ctaangcttg 180
atgacnttga agagtttgag aacattnnaa aggacctgga gacccgtaag aaacagaagg 240
aagatgtgga agttgtanga ggcaa
                                                                   265
<210> 749
<211> 156
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (92)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (107)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (132)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (146)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (156)
<223> n equals a,t,g, or c
<400> 749
gtctgaaagg aggaattttc attttccttt aaagtgaaaa ggtaaaaact gcatttacta 60
aaccaggoog gtgggggctc tgtgagcccc tntgcacagg aagcctnaga gactctgcat 120
ggtgttcccg gngcatcctg gccaangtgg gagaan
                                                         156
<210> 750
<211> 174
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (155)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (159)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (164)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (165)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (173)
<223> n equals a,t,g, or c
<400> 750
aaaaaaaaa aaaaaaaaa aaaaaaaaa aaaangggng gccnntttaa agna
```

```
<210> 751
<211> 74
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (42)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (43)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (44)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (67)
<223> n equals a,t,g, or c
<400> 751
ccagtcctca cccatggcat gcccctgcg atcaggccat tnnnctcctc gtggtcatct 60
tccacangta ctcc
<210> 752
<211> 210
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (88)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (155)
<223> n equals a,t,g, or c
<400> 752
gctctaagtc acgggaactg cccttgctac ttgtgacctg ccctttactc agcagttttt 60
gttctgggaa gccctgggat tctgctanta cctatcactg taggtgctga agggaaacag 120
atgaaaacat gacctcaagg agcttctgta atganaaacc aagctgcgct ggaaagattt 180
aaaggacctg aactgtcttg actctttgat
                                                                   210
```

```
<211> 313
  <212> DNA
<213> Homo sapiens
  <220>
  <221> misc feature
  <222> (310)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (312)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (313)
 <223> n equals a,t,g, or c
 <400> 753
 ggtgagtgtc atttttaaga acagttgtag cccttctgat tattgcagta gctgtagaag 60
 tatgtaagaa tatgtgatgg gtgtagtcat tagcaaagca tttaaatcac ttgagtattt 120
 tgtcatggtt cattattatt aaagcacaaa ataacctatt gttagaaaat atgtgttttt 180
 ataaatgaat gtaaaataat taaatgaatt gtgaaatgga tgtttaagaa aatataggct 240
 taaaaagtaa atctataaaa tgatgtctta aaacagccat atcatgaaaa attctactta 300
 gctatattan tnn
                                                                     313
 <210> 754
 <211> 445
 <212> DNA
 <213> Homo sapiens
 <220>
. <221> misc feature
 <222> (2)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (4)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (9)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (26)
 <223> n equals a,t,g, or c
```

WO 00/55351 841 PCT/US00/05883

```
<220>
<221> misc feature
<222> (83)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (84)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (86)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (93)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (96)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (97)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (102)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (108)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (113)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (116)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (126)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (128)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (142)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (157)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (160)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (165)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (181)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (198)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (210)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (211)
<223> n equals a,t,g, or c
```

<220>

```
<221> misc feature
<222> (214)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (248)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (283)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (299)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (344)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (345)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (355)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (364)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (421)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (429)
<223> n equals a,t,g, or c
<220>
```

<221> misc feature

```
<222> (444)
<223> n equals a,t,g, or c
<400> 754
engnggeang ggggaaacce aggganeage gatgggetge atggttgeat eagggeteet 60
gacaggattg gccgaggtcc tcnngntgct gtngcnnacc cnacagenag gcnacnttca 120
ataccnangg tttcgggtcc anctggaatc catgaanaan ctgantgacc tggaggcaca 180
ntgggcaccc agccccence tggaagccen naanettetg geegeegtgt gecaccacce 240
tgctctgnct ctgagatage cctgggtace ctgageceae canggacace tegecettna 300
geocaecaec etggeagget tteateceeg tecatgetea agannggtee etggneaeca 360
tggncattac caccettcag ggcctgagca gctggatctg gtacaaagca atcggacata 420
nagttggang gggaagcccc tgang
<210> 755
<211> 531
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (527)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (528)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (529)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (530)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (531)
<223> n equals a,t,g, or c
<400> 755
ggagccaaag ctaagaccc cgaaaccaga cgagctacct aagaacagct aaaagagcac 60
acccgtctat gtagcaaaat agtgggaaga tttataggta gaggcgacaa acctaccgag 120
cctggtgata gctggttgtc caagatagaa tcttagttca actttaaatt tgcccacaga 180
accetetaaa teecettgta aatttaactg ttagteeaaa gaggaacage tetttggaca 240
ctaggaaaaa accttgtaga gagagtaaaa aatttaacac ccatagtagg cctaaaagca 300
gccaccaatt aagaaagcgt tcaagctcaa cacccactac ctaaaaaaatc ccaaacatat 360
aactgaactc ctcacaccca attggaccaa tctatcaccc tatagaagaa ctaatgttag 420
```

tataagtaac atgaaaacat tctcctccgc ataagcctgc gtcagattaa aacactgaac 480 tgacaattaa cagcccaata tctacaatca accaacaaga aaaacannnn n <210> 756 <211> 540 <212> DNA <213> Homo sapiens <220> <221> misc feature <222> (1) <223> n equals a,t,g, or c <220> <221> misc feature <222> (493) <223> n equals a,t,g, or c <220> <221> misc feature <222> (496) <223> n equals a,t,g, or c <220> <221> misc feature <222> (497) <223> n equals a,t,g, or c <220> <221> misc feature <222> (498) <223> n equals a,t,g, or c <220> <221> misc feature <222> (532) <223> n equals a,t,g, or c <400> 756 ngttgcgttg cggaccgcga gctgcactgc ttcctgccca agcccaagct cctcgcagca 60 gtaggggaca agatgccaac tggcaagcag ctagctgaca ttggctataa gaccttctct 120 acctccatga tgcttctcac tgtgtatggg gggtacctct gcagtgtccg agtctaccac 180 tatttccagt ggcgcagggc ccagcgccag gccgcagaag aacagaagac ctcaggaatc 240 atgtagaact ggggggcttt ttctcctgag cagagaggcc caaggcatgc tgtggagaga 300 cttcacctgc caccatttcc aggtcaacag gactagagcg ttgatggttt tcaaaccctg 360 ttggaagaaa gtgcccatgg tttctctggt tctgccagtt tgacaagttt atggaggctt 420 ttgaatcgta atagcaatgt gagggtgagg gacaccctac agacattaaa taatttgctg 480 gtgaaaaaa aanaannnaa aaaggggcgg gccggtttta aaagatccaa anttacgtac 540 <210> 757

<211> 560

```
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (414)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (435)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (505)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (528)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (539)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (549)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (553)
<223> n equals a,t,g, or c
<400> 757
ctcaaatcag acttctgggc aagatgttct ttagagtaag caaacctaca acctaaaaat 120
ctcttcaaga ggcatctctg gtcttgtgac gagacctctt caaaaaccca cagtaaaact 180
ccctcctc cagttggcca ccagtctgcc accaaacatg aacaaattct gctgctaatc 240
ggtttccctt gtgatctggt tcctgaggtc ttcggatctg tgcaatgaat tatttattgt 300
tttattaaac cgacagtggt gtcccagaga ggaaccataa ataaaatgga aatctggtgc 360
tgtgataaag taataactag cattaatgag acctggtttt cctttcagaa aggncagtat 420
acctgtaaca aaggntaaag caatttatat ttaatttgca ttctgatggt aacatttaaa 480
cagcaattct aacaaaaatg catcnagtct aattcttacc tctatcanaa aacaactgna 540
                                                               560
taaaatttnt ganccacctt
```

<210> 758

gattentana agtatgagaa gaattatnet tattgaceat taatgteatg tneattttaa 60

```
<211> 155
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (6)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (9)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (28)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (52)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (84)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (117)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (140)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (143)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (149)
<223> n equals a,t,g, or c
<400> 758
```

```
tgtaatataa ttgagatgaa atgntctctg gttggaacag actctctctt tattttnttg 120
caatctttaa gaatacatan atntaaaant catta
<210> 759
<211> 80
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (40)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (45)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (49)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (52)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (58)
<223> n equals a,t,g, or c
<400> 759
ggcggtaagt gcggtgcagt attcaactga ccggtggacn cagancttna gncatgangg 60
                                                                    80
taacaggcat ctttcttctc
<210> 760
<211> 286
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (2)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (26)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (60)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (61)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (80)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (124)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (131)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (148)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (151)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (160)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (164)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (180)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (184)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (189)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (220)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (240)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (259)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (282)
<223> n equals a,t,g, or c
<400> 760
tntggaaagc tgttccgcct gcaggnaccg gtccggaatt cccgggtcga cccacgcgtn 60
ntaactctgt cttgacgcgn ggactgcctg gcacatagta ttcattctct tccctttaac 120
atanaagtgt ncagctgcgt acagtctntc naccagcaan tgtnaacgaa cctgtgcctn 180
taanaagcna ttctaaacca cctatgagta tttcttttan ggctcactta aatacatgtn 240
                                                                   286
tgtatattct gtattctant cagaataatc tatatctgat cnaggt
<210> 761
<211> 207
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (24)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (30)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (55)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (89)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (91)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (96)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (122)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (171)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (188)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (198)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (204)
<223> n equals a,t,g, or c
<400> 761
ggaactttag tattaaatca gttntcaatn tcattgttta tgtattgttt tactnctttt 60
tattcatacg taaaattttg gattaattng ngaaantgta attataagct gagaccggtg 120
207
aaaaaaanaa atgnaaa
```

```
<210> 762
<211> 162
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (21)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (23)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (61)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (78)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (82)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (123)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (132)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (140)
<223> n equals a,t,g, or c
<400> 762
catgggaccc ctctcagccc ntncctgcag attgcatgtc ccctggaagg aggtcctgct 60
nacagootta ottgtaanot tntggaacco accoaccact gocaagotca otattgaato 120
cangccattc antgtcgcan aggggaagga ggttcttcta ct
                                                                   162
```

```
<210> 763
<211> 340
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (2)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (50)
<223> n equals a,t,g, or c
<400> 763
tntaataatc aacaccctcc tagccttact actaataatt attacatttn gactaccaca 60
actcaacggc tacatagaaa aatccaccc ttacgagtgc ggcttcgacc ctatatcccc 120
egecegegte cettteteca taaaattett ettagtaget attacettet tattatttga 180
totagaaatt goodtoottt taccootacc atgagoodta caaacaacta acctgooact 240
aatagttatg tcatccctct tattaatcat catcctagcc ctaagtctgg cctatgagtg 300
                                                                 340
<210> 764
<211> 354
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (318)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (343)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (344)
<223> n equals a,t,g, or c
<400> 764
aatcaacacc ctcctagcct tactactaat aattattaca ttttgactac cacaactcaa 60
cggctacata gaaaaatcca ccccttacga gtgcggcttc gaccctatat cccccgcccg 120
cgtccctttc tccataaaat tcttcttagt agctattacc ttcttattat ttgatctaga 180
aattgccctc cttttacccc taccatgagc cctacaaaca actaacctgc cactaatagt 240
tatgtcatcc ctcttattaa tcatcatcct agccctaagt ctggcctatg agtgactaca 300
aaaaggatta gactgaancc gaataaaaaa aaaaaaaaaa ccnngggggg gggc
```

```
<210> 765
<211> 443
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (1)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (99)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (160)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (298)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (306)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (317)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (357)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (377)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (386)
<223> n equals a,t,g, or c
```

<220>

```
<221> misc feature
<222> (390)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (398)
<223> n equals a,t,g, or c
<400> 765
nttttaataa tcaacacct cctagcctta ctactaataa ttattacatt ttgactacca 60
caactcaacg gctacataaa aaaatccacc ccttacgant gcggcttcga ccctatatcc 120
cccgcccgcg tccctttctc cataaaattc ttcttagtan ctattacctt cttattattt 180
gatetaaaaa ttgccctcct tttaccccta ccatgagccc tacaaacaac taacctgcca 240
ctaatagtta tgtcatccct cttattaatc atcatcctac cctaattctg gctatgantg 300
actacnaaaa ggattanact gaaccgaata aaaaaaaaaa aaaaaaaaaa atcccanggg 360
gggcccggtc cccattnccc cctatnttan ttttttnaa aatccctggc cgcgttttaa 420
actttttat tggaaaaaaa aca
                                                                   443
<210> 766
<211> 351
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (29)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (337)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (345)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (347)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (348)
<223> n equals a,t,g, or c
<220>
<221> misc feature
```

```
<222> (350)
<223> n equals a,t,g, or c
<400> 766
gattttaata atcaacaccc tcctagccnt actactaata attattacat tttgactacc 60
acaactcaac ggctacatag aaaaatccac cccttacgag tgcggcttcg accctatatc 120
ccccgcccgc gtccctttct ccataaaatt cttcttagta gctattacct tcttattatt 180
tgatctagaa attgccctcc ttttacccct accatgagcc ctacaaacaa ctaacctgcc 240
actaatagtt atgtcatccc tcttattaat catcatccta gccctaagtc tggcctatga 300
                                                                    351
gtgactacaa aaaggattag actgaaccga ataaaanaaa aaaanannan a
<210> 767
<211> 511
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (389)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (398)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (421)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (435)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (447)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (455)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (508)
<223> n equals a,t,g, or c
```

```
<400> 767
ggtttctcgc agaccctata acataatcca taattccttt tatggctcct attaattacc 60
tcattatttt aagtatgttt taaaggactg tatttgacta atgggttccc tttaactgaa 120
cttgttttta tttctgatct aacacccctt ttaaatggat caagccaaga cagaatgttt 180
gtgacaacgg tgcttgagat tgaacaactt ttggcaaggg taggtgtttt aaaggactct 240
atttaagtaa tgggtttcct ttaactgaac tttttagttc tgatctaaca ccccttttaa 300
atggatotgo caagacagaa tgtttttgac aatggtgatt gatactgaac agotttttggg 360
caagegttaa gtgetteetg etaaatggnt attttgenaa ttaatgtgtt eteettaaat 420
ngateetgga ttatnttaaa aegaetnttt aattnattta eeateeatee aaaattteee 480
cccagccct aatttgataa acctcccngt c
                                                                    511
<210> 768
<211> 490
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (4)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (9)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (66)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (338)
<223> n equals a,t,g, or c
<400> 768
ctgnaagcna gacaccaacc ctcactaaag ggaacaaaag ctggagctcc accgcggtgc 60
ggccgntcta gaactagtgg atcccccggg ctgcaggaat tcggcacgag ggcagctcgg 120
actggtcata cggccttgag aagggtagtc tcgggatgcc gtccgaagtc ggcgacaggg 180
ccggggcgca ggcgcccgtg cggaatggca gatatttagc ttcctgtggt atactgatga 240
gcagaactct tocactacat acctcaattt tgcctaagga gatatgtgca cgaactttct 300
tcaaaatcac tgcaccatta ataaacaaaa ggaaaganta ttcagagaga agaattttag 360
gatattcaat gcaggaaatg tatgatgtag tatcgggagt ggaggattac aagcattttg 420
ttccttggtg caaaaaatca gatgttatat caaagagatc tggatattgt aaaacaagat 480
                                                                   490
tagaaattgg
<210> 769
<211> 399
<212> DNA
<213> Homo sapiens
```

```
<220>
<221> misc feature
<222> (137)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (225)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (242)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (246)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (261)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (276)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (329)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (332)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (353)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (358)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (362)
<223> n equals a,t,g, or c
<400> 769
ggcacgagag cgcttgggga tggatgccct ggttgctgaa gaggaggcgg aagccaaggg 60
gaatgaagtg aggcccagtg gccgggtctt cttgagttcc gcagcactta gacttacgtg 120
caccttttca tcaggtncag gccccagttg tcaacccttc cagaacattt tcccatggat 180
tttgcggtat ttgacttttc aagattcaag agtcttaata atccngttgg gcaatttttg 240
gnaaanttgg acccagtcaa ngtttttaaa attccntccc caaggccttc cagccttggg 300
gggttccaag gttttcccga agggcccant cntaccagct ccttttttta aanggcgnat 360
                                                                    399
anccagttga gcatatgact attgtttccc aattaccag
<210> 770
<211> 582
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (7)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (529)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (553)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (573)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (578)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (579)
<223> n equals a,t,g, or c
<400> 770
gtecacnegt eegeceacge gteegeceac gegteeggeg gagttgeage geetggtgge 60
```

```
cgccgagcag cagaaggcgc agtttactgc acaggccacg tgcccgtaga aaagatactc 120
atccactgtg ggttttggtt tcgccgtcac cccactgcct cactggattg tgaggatcat 180
atgcgacaat gtatttgaaa acgactagaa cattatcgga ggaaggtgga ctctgaagta 240
gtcgctgtag actatggatg tagaacaagg gtttggagcc cttcggacat ggttctaacg 300
cggcctgact tcttgctggc tacatgacct tggactacat aatcacgcct cttaaatggg 360
aggtgatgac agctatcctt gaggacctta gagagaactg atttcttagt acccagcctc 420
acaaatagtg catcacttca tggagttatg ttgggataaa tgtgtggaga agccagggaa 480
tegectagae tetegeactg aaaattgtet etceagetgt gtagacegnt teattgacae 540
cactettgcc atnacccagt eggtttgccc canattgnnc ca
<210> 771
<211> 452
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (15)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (66)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (389)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (395)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (432)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (438)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (450)
<223> n equals a,t,g, or c
```

<400> 771

```
gtggaggaat tgcanaagct ggaagtggtc atatgaacta cattcaagta acacctcagg 60
aaaaanaagc tatagaaagg ttaaaggcat taggatttcc tgaaggactt gtgatacaag 120
cgtattttgc ttgtgaaaaa aatgagaatt tggctgccaa ttttcttcta cagcagaact 180
ttgatgaaga ttgaaaggga ctttttata tctcacactt cacaccagtg cattacacta 240
acttgttcac tggattgtct gggatgactt gggctcatat ccacaatact tggtataagg 300
taataaattg ttgggggtgg ggaaggaagg atctaggata caggcaggat aatacatgca 360
ttctctccat tacaatccgc actcccacnt gtgtnaatat tacaccaaat cactttgcag 420
                                                                    452
tcttattctc tntaaacnta gtacttcctn gt
<210> 772
<211> 631
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (298)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (380)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (451)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (552)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (559)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (610)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (611)
<223> n equals a,t,g, or c
<220>
<221> misc feature
```

```
<222> (614)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
<222> (631)
<223> n equals a,t,g, or c
<400> 772
ggagggacta acccccagg agatctgcga caagtaccac atcatccaga gccttggtct 60
ctgttgctgt accatactca tctgtcccac acagatagag ggtgttccac tggcggaggg 120
actaaccccc caggagatct gcgacaagta ccacatcatc catgctgaca tctaccgctg 180
gtttaacatt togtttgata tttttggtcg caccaccact ccacagcaga ccaaaatcac 240
ccaggacatt ttccagcagt tgctgaaacg aagttttgtg ctgcaagata ctgtgganca 300
actgcgatgt gagcactgtg ctcgcttcct ggctgaccgc tttcgtggaa ggcgtgtgtc 360
ccttctgtgg ctatgaagan gctcggggtg accagtgtga caagtgtggc aagctcatca 420
atgctgtcga gcttaagaag cctcagtgtt nagtctgccg atcatgccct gtggtgcagt 480
cgagccagca cctgtttctg gaactgccta agctggagaa gcgactggag gaatggttgg 540
ggaggacatt gnctggcant gatggacacc aatgcccagt ttatcacccg ttcttggctt 600
ccggatggcn ncanccacct gcttaaccga n
                                                                    631
<210> 773
<211> 631
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (1)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (501)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (583)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (589)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (595)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (596)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (631)
<223> n equals a,t,g, or c
<400> 773
ngtggattta cttgtcgaca aaaggcatct cttaattggc acatgaagaa acatgatgca 60
gactccttct accagttttc ttgcaatatc tgtggcaaaa aatttgagaa gaaggacagc 120
gtagtggcac acaaggcaaa aagccaccct gaggtgctga ttgcagaagc tctggctgcc 180
aatgcaggcg ccctcatcac cagcacagat atcttgggca ctaacccaga gtccctgacg 240
cagcetteag atggteaggg tetteetett etteetgage eettgggaaa eteaacetet 300
ggagagtgcc tactgttaga agctgaaggg atgtcaaagt catactgcag tgggacggaa 360
cgggtgagcc tgatggctga tgggaagatc tttgtgggaa gcggcagcag tggaggcact 420
gaagggctgg ttatgaactc agatatactc ggtgctacca cagaggttct gattgaagat 480
tcagactctg ccggacctta ntggacagga agacttgggg catgggacag ctcagacttt 540
gtatttaaaa gttaaaaagg acaaataaaa aaaaaaaggg gcnggccgnt tctannagga 600
tccaagcttt acgtaccccg ttgcaatgcc n
                                                                   631
<210> 774
<211> 101
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (69)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (98)
<223> Xaa equals any of the naturally occurring L-amino acids
Gln Asp Glu Leu Gln Glu Glu Ser Glu Met Ser Glu Lys Lys Ser Cys
  1
                  5
                                     10
Ser Ser Ser Pro Thr Gln Ser Glu Ile Ser Thr Ser Leu Pro Pro Asp
             20
                                 25
Arg Gln Arg Arg Lys Arg Glu Leu Arg Thr Phe Ser Phe Ser Asp Asp
                             40
Glu Asn Lys Pro Pro Ser Pro Lys Glu Ile Arg Ile Glu Val Ala Glu
                         55
     50
                                             60
```

Gly Phe Thr Trp Xaa Ser Asn Pro Leu Lys Trp Ser Val Ala Asp Val 65 70 75 80

Val Arg Phe Ile Arg Ser Thr Asp Cys Ala Ser Ile Ser Lys Asn Ile 85 90 95

Pro Xaa Pro Gly Asn 100

<210> 775

<211> 97

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (49)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 775

Ala Ala Arg Ala Ala Arg Glu Ala Leu Leu Gly Trp Gly Thr Asp Cys

1 5 10 15

Pro Pro Phe Leu Met Cys Val Val Ser Leu Cys Cys Gly Ile Asp Met 20 25 30

Asp Ala Arg Thr Thr Leu Glu Thr Gly Val Ala Ser Arg Ala His Arg
35 40 45

Xaa Arg Glu Glu Gly Ala Ile Thr Gly Cys Gln Pro Leu Pro Gly Leu 50 55 60

Gly Ala Leu Ser His Gly Pro Ala Pro Ser Trp Val Phe Ile Leu Tyr 65 70 75 80

Leu Leu Gly Asp Arg Arg Gly Ile Leu Pro Gly Trp Asp Lys Pro
85 90 95

Leu

<210> 776

<211> 146

<212> PRT

<213> Homo sapiens

<220>

```
<221> SITE
<222> (21)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (22)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (77)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (88)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (104)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (121)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (125)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (126)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (140)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (143)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 776
Phe Gly Arg Glu Ser Cys Ser Val Arg Thr Gln Arg Glu Pro Trp Lys
```

1 10 15 Pro Gln Arg Ile Xaa Xaa Pro Pro Ala Thr Leu Ala Pro Arg Tyr Tyr 20 25 Arg Arg Asn Cys Val Asp Ala Phe Pro Asp Thr Leu Ser Leu Ser Pro 40 Gly Glu Arg Ala Thr Leu Ser Cys Arg Thr Ser Gln Ser Val Gly Ser 50 55 Asn Phe Leu Thr Trp Tyr Glu Gln Lys Ser Gly Gln Xaa Pro Arg Leu 70 Leu Met Phe Gly Asn Ser Arg Xaa Pro Leu Ala Ser Gln Thr Gly Ser 90 Val Ala Val Gly Leu Gly Gln Xaa Ser Leu Ser Pro Ser Ala Asp Trp 105 Arg Leu Lys Ile Leu Gln Cys Ile Xaa Val Gln Gln Xaa Xaa Phe Arg 115 120 Ser Thr Met Phe Gln Phe Trp Ala Arg Gly Pro Xaa Leu Glu Xaa Lys 135 140 Asp Cys 145 <210> 777 <211> 201 <212> PRT <213> Homo sapiens <220> <221> SITE <222> (12) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (21) <223> Xaa equals any of the naturally occurring L-amino acids. <220> <221> SITE

<223> Xaa equals any of the naturally occurring L-amino acids

<222> (47)

<220> <221> SITE <222> (175) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (186) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (187) <223> Xaa equals any of the naturally occurring L-amino acids <400> 777 Arg Ser Gly Ser Gly Ser Lys Ile Lys Ser Arg Xaa Leu Gly Val Pro Arg Arg Ser Gln Kaa Ser Glu Gly Cys Pro Ala Thr Pro Ala Gly Ala 25 Pro Pro Gly Gln Gly His Thr Thr Gly Ser Val Lys Pro Leu Xaa Arg Ser Asp Ala Met Glu Leu Asp Leu Ser Pro Pro His Leu Ser Ser Ser 50 55 Pro Glu Asp Leu Cys Pro Ala Pro Gly Thr Pro Pro Gly Thr Pro Arg 70 Pro Pro Asp Thr Pro Leu Pro Glu Glu Val Lys Arg Ser Gln Pro Leu 90 Leu Ile Pro Thr Thr Gly Arg Lys Leu Arg Glu Glu Glu Arg Arg Ala 100 105 Thr Ser Leu Pro Ser Ile Pro Asn Pro Phe Pro Glu Leu Cys Ser Pro 120 Pro Ser Gln Ser Pro Ile Leu Gly Gly Pro Ser Ser Ala Arg Gly Leu Leu Pro Ala Asn Ala Ser Arg Pro His Val Val Lys Val Tyr Ser Glu 150 155 Asp Gly Ala Cys Ser Leu Trp Arg Trp Gln Gln Val Pro Gln Xaa Ala 170 165

Thr Cys Val Lys Cys Trp Cys Thr Ser Xaa Xaa Leu Ser Asp Glu Thr

185

Trp Gly Phe Val Glu Cys His Pro Asn 195 200

<210> 778

<211> 120

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (81)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 778

Asn Gln Cys Ser Gly Glu Arg His Leu Arg Val Thr Gln Gly Leu Gly
1 5 10 15

Thr Gly Ala Phe Leu Gly Gly Leu Arg Pro Val Leu Gln Pro Arg Gln 20 25 30

Gly Gln Asp Phe Arg Lys Tyr Glu Glu Gly Phe Asp Pro Tyr Ser Met
35 40 45

Phe Thr Pro Glu Gln Ile Met Gly Lys Asp Val Arg Leu Leu Arg Ile
50 60

Lys Lys Glu Gly Ser Leu Asp Leu Ala Leu Glu Gly Gly Val Asp Ser 65 70 75 80

Xaa Ile Gly Lys Val Val Val Ser Ala Val Tyr Glu Arg Gly Ala Ala 85 90 95

Glu Arg His Gly Gly Ile Val Lys Gly Asp Glu Ile Met Ala Ile Asn 100 105 110

Gly Lys Ile Val Thr Asp Tyr Thr 115 120

<210> 779

<211> 111

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (88)

```
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (91)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (94)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (98)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (101)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (103)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (106)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (107)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (108)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 779
His Gln Glu Glu Leu Arg Leu Leu Gly Arg Lys Ala Arg Arg Asn Thr
                  5
                                      10
Arg Leu Arg Asp Glu Phe Ser Thr Glu Ala Ala Lys Leu Trp Thr Leu
             20
                                                      30
                                 25
Ala Arg Pro Phe Cys Pro Pro Leu Leu Ala Thr Leu Leu Gln Met Gln
         35
                             40
```

Met Val Val Leu Pro Cys Leu Gly Phe Thr Leu Leu Leu Trp Ser Gln 50 55 60

Val Ser Gly Ala Gln Gly Gln Glu Phe His Phe Gly Pro Cys Gln Val 65 70 75 80

Lys Gly Val Val Pro Gln Lys Xaa Trp Glu Xaa Phe Trp Xaa Val Lys 85 90 95

Asp Xaa Met Gln Xaa Gln Xaa Asn Ile Xaa Xaa Xaa Arg Leu Leu 100 105 110

<210> 780

<211> 110

<212> PRT

<213> Homo sapiens

<400> 780

Ile Arg His Glu Phe Asn Thr Lys Cys Pro Ser Gly Ser Cys Val Met

1 5 10 15

Asn Gln Tyr Leu Ser Ser Lys Phe Pro Lys Asp Phe Ser Thr Ser Cys
20 25 30

Arg Ala His Phe Glu Arg Tyr Leu Leu Ser Gln Lys Pro Lys Cys Leu 35 40 45

Leu Gln Ala Pro Ile Pro Thr Asn Ile Met Thr Thr Pro Val Cys Gly
50 55 60

Asn His Leu Leu Glu Val Gly Glu Asp Cys Asp Cys Gly Ser Pro Lys 65 70 75 80

Glu Cys Thr Asn Leu Cys Cys Glu Ala Leu Thr Cys Lys Leu Lys Pro 85 90 95

Gly Thr Asp Cys Gly Gly Asp Ala Pro Asn His Thr Thr Glu 100 105 110

<210> 781

<211> 124

<212> PRT

<213> Homo sapiens

<400> 781

Gly Gln Pro Ala Arg Val Trp Ser Leu Asp Thr Met Gly Thr Arg Leu

1 5 10 15

Leu Pro Ala Leu Phe Leu Val Leu Val Leu Gly Phe Ala Pro Arg
20 25 30

Ala Leu Leu Thr His Ser Pro Pro Ala Glu Val Gln Gly Thr Gln Gln 35 40 45

Pro Gln Gln Asp Glu Met Pro Ser Pro Thr Phe Leu Thr Gln Val Lys 50 55 60

Glu Ser Leu Ser Ser Tyr Trp Glu Ser Ala Lys Thr Ala Ala Gln Asn 65 70 75 80

Leu Tyr Glu Lys Thr Tyr Leu Pro Ala Val Asp Glu Lys Leu Arg Asp 85 90 95

Leu Tyr Ser Lys Ser Thr Ala Ala Met Ser Thr Tyr Thr Gly Ile Phe 100 105 110

Thr Asp Gln Val Leu Ser Val Leu Lys Gly Glu Glu 115 120

<210> 782

<211> 86

<212> PRT

<213> Homo sapiens

<400> 782

Asn Arg Asp Val Ser Arg Asp Pro Gln Phe Trp Arg Leu Arg Ser Leu 1 5 10 15

Lys Ser Arg His Gln Gln Ile Pro His Leu Val Lys Ala His Ser Leu 20 25 30

Leu His Arg Trp His Cys Leu Ala Val Phe Ser His Gly Arg Arg Gly
35 40 45

Lys Gln Ala Pro Leu Gly Leu Phe Tyr Lys Gly Thr Asn Ser Met Pro 50 55 60

Lys Gly Arg Ala Leu Met Thr Leu Ser Pro Thr Lys Arg Leu His Phe 65 70 75 80

Phe Ile Leu Leu Glu Gly

```
<210> 783
<211> 102
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (66)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (73)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (86)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (98)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 783
Gly Gln Ser Pro Asp Ala Gly Phe Leu Val Phe Pro Ala Gly Ile Lys
Gln Lys Gly Leu Leu Ser Ser Ser Leu Met His Ser Glu Ser Glu
             20
                                 25
                                                      30
Leu Asp Ser Asp Asp Ala Ile Phe Thr Trp Pro Asp Arg Glu Lys Gly
         35
                             40
                                                  45
Lys Leu Leu Ala Trp Ser Glu Trp Leu Cys Thr Gln Arg Ala Asp Pro
                         55
Ser Xaa Arg Pro Gly Ala Arg Gly Xaa Arg Ser Cys Ser His Leu Val
                                         75
Cys Leu Leu Arg Ala Xaa Pro Gly Thr Ile Ala Arg Pro Val Leu Leu
                 85
```

Thr Xaa Arg Val Leu Arg 100

<210> 784 <211> 44

```
<212> PRT
<213> Homo sapiens
<400> 784
Ile Tyr Ile Thr Gly Tyr Val Asn Ile Phe Lys Tyr Trp Gly Asn Cys
                  5
Phe Thr Val Leu Glu Pro Ser Lys Ile His Leu Cys Phe Val Phe Met
                                  25
Phe Ile Cys Leu Leu Lys Ala Arg Val Glu Asp Lys
                              40
<210> 785
<211> 47
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (39)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 785
Ala Gly Ile Thr Pro Leu His Ser Ser Leu Gly Asp Lys Ser Glu Ser
Val Ser His Gln Lys Lys Lys Glu Lys Glu Arg Cys Leu Thr Lys Val
                                                      30
Thr Ile Ser His Lys Phe Xaa Thr Thr Tyr Pro Ser Ser Phe Lys
         35
                             40
<210> 786
<211> 301
<212> PRT
<213> Homo sapiens
<400> 786
Leu Arg Val Phe Leu Cys Val Phe Phe Tyr Phe Ala Trp Leu Phe Glu
                 5
```

His Asn Leu Ile Ala Leu Phe Glu His Ala Lys Lys Pro Gly Leu Ala 35 40 45

His Tyr Trp Thr Leu Val Leu Glu Gly Lys Thr Phe Gln Leu Tyr Ser

25

Ala	His 50	Ile	Gln	Thr	His	Arg 55	Phe	Pro	Asp	Arg	Ile 60	Leu	Pro	Arg	Lys
Phe 65	Ala	Leu	Thr	Thr	Lys 70	Ile	Pro	Asp	Thr	Lys 75	Gly	Cys	His	Lys	Cys 80
Cys	Ile	Val	Arg	Asn 85	Pro	Tyr	Thr	Gly	His 90	Lys	Tyr	Leu	Cys	Gly 95	Ala
Leu	Gln	Ser	Gly 100		Val	Leu	Leu	Gln 105	Trp	туr	Glu	Pro	Met 110	Gln	Lys
Phe	Met	Leu 115	Ile	Lys	His	Phe	Asp 120	Phe	Pro	Leu	Pro	Ser 125	Pro	Leu	Asn
Val	Phe 130	Glu	Met	Leu	Val	Ile 135	Pro	Glu	Gln	Glu	Tyr 140	Pro	Met	Val	Cys
Val 145	Ala	Ile	Ser	Lys	Gly 150	Thr	Glu	Ser	Asn	Gln 155	Val	Val	Gln	Phe	Glu 160
Thr	Ile	Asn	Leu	Asn 165	Ser	Ala	Ser	Ser	Trp 170	Phe	Thr	Glu	Ile	Gly 175	Ala
Gly	Ser	Gln	Gln 180	Leu	Asp	Ser	Ile	His 185	Val	Thr	Gln	Leu	Glu 190	Arg	Asp
Thr	Val	Leu 195	Val	Cys	Leu	Asp	Lys 200	Phe	Val	Lys	Ile	Val 205	Asn	Leu	Gln
Gly	Lys 210	Leu	Lys	Ser	Ser	Lys 215	Lys	Leu	Ala	Ser	Glu 220	Leu	Ser	Phe	Asp
Phe 225	Arg	Ile	Glu	Ser	Val 230	Val	Cys	Leu	Gln	Asp 235	Ser	Val	Leu	Ala	Phe 240
Trp	Lys	His	Gly	Met 245	Gln	Gly	Lys	Ser	Phe 250	Lys	Ser	Asp	Glu	Val 255	Thr
Gln	Glu	Ile	Ser 260	Asp	Glu	Thr	Arg	Val 265	Phe	Arg	Leu	Leu	Gly 270	Ser	Asp

Arg Val Val Leu Glu Ser Arg Pro Thr Glu Asn Pro Thr Ala His

295 300

280

Ser Asn Leu Tyr Ile Leu Ala Gly His Glu Asn Ser Tyr

275

<210> 787 <211> 141

<212> PRT

<213> Homo sapiens

<400> 787

Asn Lys Phe Gln Gly Phe Ser Leu Pro Leu Val Arg Lys Phe Ala His 1 5 10 15

Ser Ile Leu Gln Cys Leu Asp Ala Leu His Lys Asn Arg Ile Ile His
20 25 30

Cys Asp Leu Lys Pro Glu Asn Ile Leu Leu Lys Gln Gln Gly Arg Ser 35 40 45

Gly Ile Lys Val Ile Asp Phe Gly Ser Ser Cys Tyr Glu His Gln Arg
50 55 60

Val Tyr Thr Tyr Ile Gln Ser Arg Phe Tyr Arg Ala Pro Glu Val Ile 65 70 75 80

Leu Gly Ala Arg Tyr Gly Met Pro Ile Asp Met Trp Ser Leu Gly Cys
85 90 95

Ile Leu Ala Glu Leu Leu Thr Gly Tyr Pro Leu Leu Pro Gly Glu Asp 100 105 110

Glu Gly Asp Gln Leu Ala Cys Met Ile Glu Leu Leu Gly Met Pro His 115 120 125

Arg Asn Cys Trp Met His Pro Asn Glu Pro Lys Ile Leu 130 135 140

<210> 788

<211> 75

<212> PRT

<213> Homo sapiens

<400> 788

Glu Lys Arg Ser Ser Ser Phe Glu Ala Arg Gly Leu Ile Trp Arg Ser
1 5 10 15

Lys Thr Leu His Val His Phe Gln Thr Trp Ser Gly Thr Tyr Ile Val 20 25 30

Asn Tyr Asn Gln Ser Trp Glu Leu His Lys Asp Asn Glu Ala Gln Leu 35 40 45

Lys Pro Ser Phe Ser Leu Pro Tyr Leu Tyr Pro Ser Leu Arg Thr Ala

50 55 60

Val Gln Glu Asn Gln Ala Val Cys Gly Leu Leu 65 70 75

<210> 789

<211> 59

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (53)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 789

Met Gly Trp Ala Lys His Cys Cys Arg Phe Ile Leu Leu Pro Thr Gln
1 5 10 15

Leu Leu His Asn Lys Ala Leu Leu Ser Leu Lys Lys Lys Lys Lys Lys Lys Lys 20 25 30

Lys Lys Lys Asn Xaa Gly Gly Gly Pro Pro Pro 50 55

<210> 790

<211> 111

<212> PRT

<213> Homo sapiens

<400> 790

Asp Glu Lys Gly Thr Val Pro Gln Arg Tyr Thr Phe Gly Thr Ser Ile
1 5 10 15

Met Lys Ala Ser Leu Ala Trp Gln Val Glu Tyr Arg Gln Phe Trp Ile 20 25 30

Phe Asn Ala Trp His Gly Ala Gly Val Lys Tyr Leu Ala Arg Ala Cys

Leu Pro Tyr Asn Gly Arg Glu Pro Gly Leu Trp Met Ile Arg Tyr Gln 50 55 60

Thr Leu Leu Leu Ser Val Phe Phe Cys Gly Lys Gly Arg Arg Ile

65 70 75 80 Glu Trp Arg Gly Ile Ser Gly Ser Leu Gly Glu Val Gln Asn Lys Glu Thr Val Lys Ser Ser Thr Ser Lys Leu Gly Leu His Gln Asp Ser 105 <210> 791 <211> 245 <212> PRT <213> Homo sapiens <400> 791 Glu Tyr Leu Thr Ser Ser Gly Gly Arg Arg Met Glu Tyr Ile Leu Thr Asp Ile Arg Lys Gly His Met Cys Asn Ala Lys Leu Leu Arg Asn Met Pro Glu Phe Ser Gly Val Leu His Gln Cys His Ile Leu Ala Ser Glu 35 40 Met Val His Phe Ile His Gln Met Gln Tyr Tyr Ile Thr Phe Glu Val 55 Leu Glu Cys Ser Trp Asp Glu Leu Trp Asn Lys Val Gln Gln Ala Gln Asp Leu Asp His Ile Ile Ala Ala His Glu Val Phe Leu Asp Thr Ile 90 Ile Ser Arg Cys Leu Leu Asp Ser Asp Ser Arg Ala Leu Leu Asn Gln 100 105 Leu Arg Ala Val Phe Asp Gln Ile Ile Glu Leu Gln Asn Ala Gln Asp 120 Ala Ile Tyr Arg Ala Ala Leu Glu Glu Leu Gln Arg Arg Leu Gln Phe 135 Glu Glu Lys Lys Gln Arg Glu Ile Glu Gly Gln Trp Gly Val Thr 145 150 155 Ala Ala Glu Glu Glu Glu Asn Lys Arg Ile Gly Glu Phe Lys Glu

170

Ser Ile Pro Lys Met Cys Ser Gln Leu Arg Ile Leu Thr His Phe Tyr

185

165

Gln Gly Ile Val Gln Gln Phe Leu Val Leu Leu Thr Thr Ser Ser Asp 195 200 205

Glu Ser Leu Arg Phe Leu Ser Phe Arg Leu Asp Phe Asn Glu His Tyr 210 215 220

Lys Ala Arg Glu Pro Arg Leu Arg Cys Val Ser Gly Tyr Gln Gly Ala 225 230 235 240

Ala His Ser His Thr 245

<210> 792

<211> 108

<212> PRT

<213> Homo sapiens

<400> 792

Phe Trp Ala Tyr Thr Lys Lys Ser Arg Tyr Gly Lys Ile Tyr Cys Gln
1 5 10 15

Gly Ile Leu Glu Phe Pro Thr Arg Val Gly Glu Arg Cys Pro Asn Ser 20 25 30

Leu Arg Met Val Phe Met Met Val Pro Tyr Leu Ser Pro Gly Leu Phe
35 40 45

Ser Tyr Ser Val Pro Gln Lys Cys Cys Arg Gly Gln Asp Ser Thr Phe 50 55 60

Thr Ala Cys Ser Ile Tyr Glu Ile Phe Gln Met Leu Leu Val Val Asp
65 70 75 80

Ile Pro Asn Ser Trp Tyr Leu Ala Thr Arg Asp His Asp Gly Met Ser 85 90 95

Gly Trp Leu Phe Tyr Leu Pro Phe Pro Gln Asn Ser 100 105

<210> 793

<211> 128

<212> PRT

<213> Homo sapiens

<400> 793

Glu Ala Ala Asn Met Ile Leu Val Asp Asp Asp Phe Ser Ala Ile Met

1 5 10 15

Asn Ala Val Glu Glu Gly Lys Gly Ile Phe Tyr Asn Ile Lys Asn Phe 20 25 30

Val Arg Phe Gln Leu Ser Thr Ser Ile Ser Ala Leu Ser Leu Ile Thr
35 40 45

Leu Ser Thr Val Phe Asn Leu Pro Ser Pro Leu Asn Ala Met Gln Ile 50 55 60

Leu Trp Ile Asn Ile Ile Met Asp Gly Pro Pro Gly Arg Gly Glu Ala
65 70 75 80

Gly Arg Leu Gly Ala Leu Cys Leu Phe Thr Tyr Leu Arg Gly Phe Leu 85 90 95

Gln Gly Leu Leu Ala Val Pro Lys Ala Ile Gly Met Asn Lys Tyr Ser 100 105 110

His Phe Pro Ser Gly Val Pro Arg Lys Leu Lys Cys Val Ala Leu Glu 115 120 125

<210> 794

<211> 262

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (38)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 794

Ser Ser Val Pro Gly Gly Tyr Pro Gly Thr Glu His Ser His Arg Cys
1 5 10 15

Arg Arg Phe Tyr Gln Leu Ala Leu Gly Trp Thr Thr Leu Ala Lys Thr 20 25 30

Ser Trp Leu Glu Asp Xaa Ser Pro Asp Leu Val Pro Arg Gly Ser Gln
35 40 45

Leu Ala Gly Gly Val Ile Leu Gly Val Ala Leu Trp Leu Arg His Asp 50 55 60

Pro Gln Thr Thr Asn Leu Leu Tyr Leu Glu Leu Gly Asp Lys Pro Ala 65 70 75 80

Pro Asn Thr Phe Tyr Val Gly Ile Tyr Ile Leu Ile Ala Val Gly Ala 85 90 95

Val Met Met Phe Val Gly Phe Leu Gly Cys Tyr Gly Ala Ile Gln Glu 100 105 110

Ser Gln Cys Leu Leu Gly Thr Phe Phe Thr Cys Leu Val Ile Leu Phe 115 120 125

Ala Cys Glu Val Ala Ala Gly Ile Trp Gly Phe Val Asn Lys Asp Gln 130 135 140

Ile Ala Lys Asp Val Lys Gln Phe Tyr Asp Gln Ala Leu Gln Gln Ala 145 150 155 160

Val Val Asp Asp Asp Ala Asn Asn Ala Lys Ala Val Val Lys Thr Phe 165 170 175

His Glu Thr Leu Asp Cys Cys Gly Ser Ser Thr Leu Thr Ala Leu Thr 180 185 190

Thr Ser Val Leu Lys Asn Asn Leu Cys Pro Ser Gly Ser Asn Ile Ile 195 200 205

Ser Asn Leu Phe Lys Glu Asp Cys His Gln Lys Ile Asp Asp Leu Phe 210 215 220

Ser Gly Lys Leu Tyr Leu Ile Gly Ile Ala Ala Ile Val Val Ala Val 225 230 235 240

Ile Met Ile Phe Glu Met Ile Leu Ser Met Val Leu Cys Cys Gly Ile 245 250 255

Arg Asn Ser Ser Val Tyr 260

<210> 795

<211> 45

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (44)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (45)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 795

Ser Gln Leu Leu Gly Arg Leu Arg Gln Glu Asn Gly Val Asn Pro Gly
1 5 10 15

Gly Gly Ala Cys Ser Glu Pro Arg Ser Cys His Cys Thr Pro Ala Trp
20 25 30

Ala Thr Glu Arg Asp Phe Arg Leu Lys Lys Lys Xaa Xaa 35 40 45

<210> 796

<211> 178

<212> PRT

<213> Homo sapiens

<400> 796

Phe Arg Ala Leu His Arg Gly Ala Ala Leu Asp Leu Ser Pro Leu His

1 5 10 15

Arg Ser Pro His Pro Ser Arg Gln Ala Ile Phe Cys Trp Met Ser Phe 20 25 30

Ser Ala Tyr Gln Thr Ala Phe Ile Cys Leu Gly Leu Leu Val Gln Gln 35 40 45

Ile Ile Phe Phe Leu Gly Thr Thr Ala Leu Ala Phe Leu Val Leu Met $50 \hspace{1cm} 55 \hspace{1cm} 60$

Pro Val Leu His Gly Arg Asn Leu Leu Leu Phe Arg Ser Leu Glu Ser 65 70 75 80

Ser Trp Pro Phe Trp Leu Thr Leu Ala Leu Ala Val Ile Leu Gln Asn 85 90 95

Met Ala Ala His Trp Val Phe Leu Glu Thr His Asp Gly His Pro Gln
100 105 110

Leu Thr Asn Arg Arg Val Leu Tyr Ala Ala Thr Phe Leu Leu Phe Pro 115 120 125

Leu Asn Val Leu Val Gly Ala Met Val Ala Thr Trp Arg Val Leu Leu 130 135 140

Ser Ala Leu Tyr Asn Ala Ile His Leu Gly Gln Met Asp Leu Ser Leu

145 150 155 160

Leu Pro Pro Arg Ala Ala Leu Ser Thr Pro Ala Thr Thr Arg Thr Glu 165 170 175

Thr Ser

<210> 797

<211> 219

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (66)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 797

Ala Gly Leu Cys Ser Ala Asp Trp Arg Pro Pro Gly Thr Glu Val Thr
1 5 10 15

Ser Gln Gly Pro Arg Gln Pro Ser Ser Ser Gly Ala Lys Arg Arg Arg 20 25 30

Leu Arg Ala Ala Leu Gly Pro Gln Pro Thr Arg Ser Ala Leu Arg Phe 35 40 45

Pro Ser Ala Ser Pro Gly Ser Leu Lys Ala Lys Gln Ser Met Ala Gly 50 55 60

Ile Xaa Gly Arg Glu Ser Asn Ala Pro Ser Val Pro Thr Val Ser Leu 65 70 75 80

Leu Pro Gly Ala Pro Gly Gly Asn Ala Ser Ser Arg Thr Glu Ala Gln
85 90 95

Val Pro Asn Gly Gln Gly Ser Pro Gly Gly Cys Val Cys Ser Ser Gln
100 105 110

Ala Ser Pro Ala Pro Arg Ala Ala Ala Pro Pro Arg Ala Ala Arg Gly
115 120 125

Pro Thr Pro Arg Thr Glu Glu Ala Ala Trp Ala Ala Met Ala Leu Thr 130 135 140

Phe Leu Leu Val Leu Leu Thr Leu Ala Thr Leu Cys Thr Arg Leu His 145 150 155 160

Arg Asn Phe Arg Arg Gly Glu Ser Ile Tyr Trp Gly Pro Thr Ala Asp 165 170 175

Ser Gln Asp Thr Val Ala Ala Val Leu Lys Arg Arg Leu Leu Gln Pro 180 185 190

Ser Arg Arg Val Lys Arg Ser Arg Arg Pro Leu Leu Pro Pro Thr 195 200 205

Pro Asp Ser Gly Pro Glu Gly Glu Ser Ser Glu 210 215

<210> 798

<211> 137

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (8)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 798

Tyr Gln Leu Lys Pro Tyr Thr Xaa His Leu Ile Lys Asp Leu His Phe 1 5 10 15

Phe Leu Arg Val Leu Ile Gln Leu Tyr His Arg Ile Pro His Lys Leu 20 25 30

His Ile Ile Pro Leu Trp Asp Arg Asp Pro Ser Thr Ser Leu Leu Glu 35 40 45

Gln Gly His Ile Val His Tyr Leu Ser Gln Val Leu Ile Ser Ser Pro 50 55 60

Lys Asp Gln Thr Val Phe Gln His Leu Leu Leu Gln Gly Ser Val Leu 65 70 75 80

Ile Leu Ala Leu Trp Pro Cys His Met Gly Phe Lys Asp Leu Ser Arg 85 90 95

His Leu Gln Cys Leu Asp Arg Phe Gln Phe Thr Glu His Arg Cys His
100 105 110

Gln His Phe Lys Thr Ile Thr Met Gly Gln Gly Gly Ile Lys Met Asp 115 120 125

Ser Lys Asn Ile Phe Leu Asn Val Leu 130 135

```
<210> 799
<211> 119
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (49)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 799
Cys Phe Gly Ala Gly Gln Ser Val Ala Gly Arg Gly His Met Pro Lys
                                     10 .
Ser His His Glu Leu Pro Gly Ala Ser Arg Gln Gly Pro Ser Ile Pro
                                 25
His Gln Val Phe Gln His Asp Val Pro Asp Gly Arg Gln Leu Gly Leu
                             40
                                                 45
Xaa Ala Glu Ile Lys Ala Gly Lys Ser Leu Lys Pro Thr Pro Gln Ser
Lys Gly Leu Thr Thr Val Phe Ser Gly Ile Gly Gln Pro Ala Phe Gln
                     70
                                         75
Val Gly Gly Pro Ser Arg Ser Leu Arg Pro Gly Phe Pro Gly Pro Arg
                                     90
Pro Pro Gly Ala Gln Pro His Arg Phe Ser Leu Gln Pro Asp Ser Pro
            100
                                105
Leu Pro Ser Val Ser Pro Ala
```

<210> 800
<211> 148
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (93)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 800

115

Gly Ser Thr His Ala Ser Gly Trp Ser Cys Val Tyr Lys Asn Asp Gln
1 10 15

Ala Ala Lys Asp Asn Pro Thr Lys Ser Leu Gln Glu Glu Pro Cys
20 25 30

Pro Arg Phe Ala His Gln Leu Val Tyr Asp Glu Leu His Lys Val His
35 40 45

Tyr Leu Phe Gly Gly Asn Pro Gly Lys Ser Cys Ser Pro Lys Met Arg
50 55 60

Leu Asp Asp Phe Trp Ser Leu Lys Leu Cys Arg Pro Ser Lys Asp Tyr 65 70 75 80

Leu Leu Arg His Cys Lys Tyr Leu Ile Arg Lys His Xaa Phe Glu Glu 85 90 95

Lys Ala Gln Val Asp Pro Leu Ser Ala Leu Lys Tyr Leu Gln Asn Asp 100 105 110

Leu Tyr Ile Thr Val Asp His Ser Asp Pro Glu Glu Thr Lys Glu Phe 115 120 125

Gln Leu Leu Ala Ser Ala Leu Phe Lys Ser Gly Ser Arg Phe Tyr Ser 130 135 140

Ser Gly Leu Phe 145

<210> 801

<211> 214

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (214)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 801

Ser His Ile Gln Gly Glu Gly Ser Cys Thr Leu Phe Arg Lys Tyr Asp 1 5 10 15

His Met Arg Ala Ala Ile Leu Glu Lys Met Pro Leu Val Glu Arg Asp 20 25 30

Gly Pro Gln Ala Asp Glu Glu Ala Lys Glu Ser Lys Glu Ala Ala Gln
35 40 45

Leu Ser Glu Ala Ala Pro Val Pro Thr Glu Pro Gln Ala Ser Gln Leu 50 55 60

Leu Asp Leu Leu Asp Leu Leu Asp Gly Ala Ser Gly Asp Val Gln His
65 70 75 80

Pro Pro His Leu Asp Pro Ser Pro Gly Gly Ala Leu Val His Leu Leu 85 90 95

Asp Leu Pro Cys Val Pro Pro Pro Pro Ala Pro Ile Pro Asp Leu Lys
100 105 110

Val Phe Glu Arg Glu Gly Val Gln Leu Asn Leu Ser Phe Ile Arg Pro 115 120 125

Pro Glu Asn Pro Ala Leu Leu Leu Ile Thr Ile Thr Ala Thr Asn Phe 130 135 140

Ser Glu Gly Asp Val Thr His Phe Ile Cys Gln Ala Ala Val Pro Lys 145 150 155 160

Ser Leu Gln Leu Gln Ala Pro Ser Gly Asn Thr Val Pro Ala 165 170 175

Arg Gly Gly Leu Pro Ile Thr Gln Leu Phe Arg Ile Leu Asn Pro Asn 180 185 190

Lys Ala Pro Leu Arg Leu Lys Leu Arg Ser Leu Arg Pro Leu Ser Pro 195 200 205

Val Gly Ala Gly Asp Xaa 210

<210> 802

<211> 51

<212> PRT

<213> Homo sapiens

<400> 802

Lys Phe Ala Asn Leu Lys Arg Gly Val Ser Glu Asp His Tyr Leu Leu 1 5 10 15

Arg Thr Leu Lys Asn Lys Cys Leu Gln Leu Cys Met Gly Thr Ile Leu 20 25 30

Tyr Ser Leu His Phe Tyr Gly Pro Thr Ala Thr Ser Tyr Pro Cys Lys
35 40 45

Tyr Ile Asn 50

<210> 803

<211> 167

<212> PRT

<213> Homo sapiens

<400> 803

Ala Arg Leu Pro Gly Ser Gly Cys Cys Arg Pro Pro Val Ser Ala Arg

1 5 10 15

Val Ala Pro Gly His Gln Gly Ala Val Gly Gly Ser Gly Arg Arg Pro 20 25 30

Ala Arg Val Glu Val Val Asp Ala Ala Ala Arg Pro Ser Ser Arg Pro
35 40 45

Phe Ser Leu Pro Ala Ala Ile Met Leu Ala Leu Ile Ser Arg Leu Leu 50 55 60

Asp Trp Phe Arg Ser Leu Phe Trp Lys Glu Glu Met Glu Leu Thr Leu 65 70 75 80

Val Gly Leu Gln Tyr Ser Gly Lys Thr Thr Phe Val Asn Val Ile Ala 85 90 95

Ser Gly Gln Phe Ser Glu Asp Met Ile Pro Thr Val Gly Phe Asn Met 100 105 110

Arg Lys Val Thr Lys Gly Asn Val Thr Ile Lys Ile Trp Asp Ile Gly 115 120 125

Gly Gln Pro Arg Phe Arg Ser Met Trp Glu Arg Tyr Cys Arg Gly Val 130 135 140

Ala Ser Arg Asn Glu Leu Thr 165

<210> 804

<211> 361

<212> PRT

<213> Homo sapiens

<400> 804

Ala Arg Ser Arg Asp Gly Ala Pro Glu Arg Arg Glu Pro Gly Leu Gly
1 5 10 15

Val Leu Leu Arg Glu Glu Glu Trp Ser Arg Gly Asp Ala Ala Ala Ala 20 25 30

Leu Thr Met Ser Phe Leu Gly Gly Phe Phe Gly Pro Ile Cys Glu Ile 35 40 45

Asp Ile Val Leu Asn Asp Gly Glu Thr Arg Lys Met Ala Glu Met Lys
. 50 55 60

Thr Glu Asp Gly Lys Val Glu Lys His Tyr Leu Phe Tyr Asp Gly Glu 65 70 75 80

Ser Val Ser Gly Lys Val Asn Leu Ala Phe Lys Gln Pro Gly Lys Arg 85 90 95

Leu Glu His Gln Gly Ile Arg Ile Glu Phe Val Gly Gln Ile Glu Leu
100 105 110

Phe Asn Asp Lys Ser Asn Thr His Glu Phe Val Asn Leu Val Lys Glu 115 120 125

Leu Ala Leu Pro Gly Glu Leu Thr Gln Ser Arg Ser Tyr Asp Phe Glu 130 135 140

Phe Met Gln Val Glu Lys Pro Tyr Glu Ser Tyr Ile Gly Ala Asn Val 145 150 155 160

Arg Leu Arg Tyr Phe Leu Lys Val Thr Ile Val Arg Arg Leu Thr Asp 165 170 175

Leu Val Lys Glu Tyr Asp Leu Ile Val His Gln Leu Ala Thr Tyr Pro 180 185 190

Asp Val Asn Asn Ser Ile Lys Met Glu Val Gly Ile Glu Asp Cys Leu 195 200 205

His Ile Glu Phe Glu Tyr Asn Lys Ser Lys Tyr His Leu Lys Asp Val 210 215 220

Ile Val Gly Lys Ile Tyr Phe Leu Leu Val Arg Ile Lys Ile Gln His 225 230 235 240

Met Glu Leu Gln Leu Ile Lys Lys Glu Ile Thr Gly Ile Gly Pro Ser 245 250 255

Thr Thr Thr Glu Thr Glu Thr Ile Ala Lys Tyr Glu Ile Met Asp Gly 260 265 270

Ala Pro Val Lys Gly Glu Ser Ile Pro Ile Arg Leu Phe Leu Ala Gly 275 280 285

Tyr Asp Pro Thr Pro Thr Met Arg Asp Val Asn Lys Lys Phe Ser Val 290 295 300

Arg Tyr Phe Leu Asn Leu Val Leu Val Asp Glu Glu Asp Arg Ser Ser 305 310 315 320

Phe Lys Gln Gln Glu Ile Ile Leu Trp Arg Lys Ala Pro Glu Lys Leu 325 330 335

Arg Lys Gln Arg Thr Asn Phe His Gln Arg Phe Glu Ser Pro Glu Ser 340 345 350

Gln Ala Ser Ala Glu Gln Pro Glu Met 355 360

<210> 805

<211> 92

<212> PRT

<213> Homo sapiens

<400> 805

Ala Ala Pro Pro Ala Leu Arg Thr Trp Pro Arg Lys Ala Glu Trp Pro 1 5 10 15

Ala Gly Ala Pro Gln Gly Trp Arg Pro Arg Ser Leu Ser Val Thr His
20 25 30

Ser Thr Thr Arg Cys Pro Leu Val Gly Val Arg Ala Glu Gly Leu Arg
35 40 45

His Ala Thr Ala Pro Leu Glu Leu Gly Thr Thr Asp Trp Thr Gly Ser 50 55 60

Leu His Ala Gln Pro Pro Glu Thr Gly Thr Pro Ser Leu Lys Gly Pro 65 70 75 80

Arg Arg Gln Val Asp Lys Lys Val Glu Lys Gly Val 85 90

<210> 806

<211> 271

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (1)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 806

Xaa Gly Phe Pro Ala Pro Leu Pro Pro Thr Arg Met Met Glu Ser Lys

1 10 15

Met Ile Ala Ala Ile His Ser Ser Ser Ala Asp Ala Thr Ser Ser Ser Ser 20 25 30

Asn Tyr His Ser Phe Val Thr Ala Ser Ser Thr Ser Val Asp Asp Ala
35 40 45

Leu Pro Leu Pro Leu Pro Val Pro Gln Pro Lys His Ala Ser Gln Lys
50 55 60

Thr Val Tyr Ser Ser Phe Ala Arg Pro Asp Val Thr Thr Glu Pro Phe 65 70 75 80

Gly Pro Asp Asn Cys Leu His Phe Asn Met Thr Pro Asn Cys Gln Tyr 85 90 95

Arg Pro Gln Ser Val Pro Pro His His Asn Lys Leu Glu Gln His Gln
100 105 110

Val Tyr Gly Ala Arg Ser Glu Pro Pro Ala Ser Met Gly Leu Arg Tyr 115 120 125

Asn Thr Tyr Val Ala Pro Gly Arg Asn Ala Ser Gly His His Ser Lys 130 135 140

Pro Cys Ser Arg Val Glu Tyr Val Ser Ser Leu Ser Ser Ser Val Arg 145 150 155 160

Asn Thr Cys Tyr Pro Glu Asp Ile Pro Pro Tyr Pro Thr Ile Arg Arg 165 170 175

Val Gln Ser Leu His Ala Pro Pro Ser Ser Met Ile Arg Ser Val Pro 180 185 190

Ile Ser Arg Thr Glu Val Pro Pro Asp Asp Glu Pro Ala Tyr Cys Pro 195 200 205

Arg Pro Leu Tyr Gln Tyr Lys Pro Tyr Gln Ser Ser Gln Ala Arg Ser 210 220

Asp Tyr His Val Thr Gln Leu Gln Pro Tyr Phe Glu Asn Gly Arg Val 225 230 235 240 His Tyr Arg Tyr Ser Pro Tyr Ser Ser Ser Ser Ser Ser Tyr Tyr Ser 245 250 255

Pro Asp Gly Ala Leu Cys Asp Val Asp Ala Tyr Gly Gln Ser Ser 260 265 270

<210> 807

<211> 56

<212> PRT

<213> Homo sapiens

<400> 807

Asn Asn Thr Phe His Asn Gln Asn Phe Asn Ser Lys Tyr Lys Ile Lys

1 10 15

Phe Ile Leu Asn Asn Glu Asn Val Phe Val Leu Asn Leu Val Thr Arg
20 25 30

Glu His Arg Asn Lys Ile His Glu Thr Lys Val Ala Arg Asn Val Arg
35 40 45

Thr Gly Gly Asn Val Tyr Ile Ile 50 55

<210> 808

<211> 182

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (4)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (106)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 808

Val Cys Ala Xaa His Gly His Gly Arg Glu Leu Phe Gln Tyr Met Leu 1 5 10 15

Gln Lys Glu Arg Val Glu Pro His Gln Leu Ala Ile Asp Arg Pro Ser 20 25 30 Gln Lys Leu Leu Lys Phe Leu Asn Lys His Tyr Asn Leu Glu Thr Thr
35 40 45

Val Pro Gln Val Asn Asn Phe Val Ile Phe Glu Gly Phe Phe Ala His 50 55 60

Gln His Pro Pro Ala Arg Lys Leu Pro Pro Lys Arg Ala Glu Gly Asp
65 70 75 80

Ile Lys Pro Tyr Ser Ser Ser Asp Arg Glu Phe Leu Lys Val Ala Val
85 90 95

Glu Pro Pro Trp Pro Leu Asn Arg Ala Xaa Arg Arg Ala Thr Pro Pro 100 105 110

Ala His Pro Pro Pro Arg Ser Ser Leu Gly Asn Ser Pro Glu Arg 115 120 125

Gly Pro Leu Arg Pro Phe Val Pro Glu Gln Glu Leu Leu Arg Ser Leu 130 135 140

Arg Leu Cys Pro Pro His Pro Thr Ala Arg Leu Leu Leu Ala Ala Asp 145 150 155 160

Pro Gly Gly Ser Pro Ala Gln Arg Arg Thr Ser Ser Leu Pro Arg 165 170 175

Ser Glu Glu Ser Arg Tyr 180

<210> 809

<211> 119

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (72)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 809

Pro Ala Gly Glu Ser Ser Pro Ala Pro Trp Leu Lys Gly Pro Gly Ala 1 5 10 15

His Leu Pro Glu Ala Arg Cys Gly Gly Gly Pro Arg Gly Arg Ser Gln 20 25 30

Ala Gln Ser Pro Gln Ser Ser Gly Pro Val Gly Gly Arg Gly Arg Ser 35 40 45

Gly Ser Lys Ala Arg Thr Pro Gln Leu Phe Arg Leu Gln Gln Gln Leu 50 55 60

Gln Arg Phe Gly His Gly Cys Xaa Val Pro Arg Cys Trp Leu Gln Ala 65 70 75 80

Ala Arg Glu His Pro Gly Gln Gly Gln Glu Ala Gln Ser Glu Glu Glu 85 90 95

Gly Glu Gly Gln Glu Gly Glu Glu Glu Glu Gly Gly Ser Pro Leu
100 105 110 .

Lys Gly Leu Asp Lys Ala His

<210> 810

<211> 144

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (24)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 810

Asp Ala Gly Cys Gly Arg Pro Pro Glu Pro Ala Gly Gly Gln Ala 1 5 10 15

Ala Ala Ala Thr Glu Gly Gly Xaa Leu Ser Leu Gly Leu Gly Cys Arg
20 25 30

Gln Leu Gly Leu Pro Gly Pro Ala Tyr Thr Ala Pro Pro Val Gly
35 40 45

Val Thr Val Gly Tyr Ser Gln Ala Gly Phe Leu Pro Cys Arg Thr Leu
50 60

Ser Leu Pro Pro Ala Cys Ser Trp Arg Leu Leu Pro Arg Gly Arg Leu 65 70 75 80

Phe Cys Leu Leu Lys Trp Val Cys Cys Thr Leu Thr Gly Gln Gly Gln 85 90 95

Ser Leu Gly Ala Val Leu Trp Pro Arg Val Gly Thr Cys Leu Asp Gln 100 105 110

Asn Glu Arg Thr Gly Ser Gln Thr Arg Leu Gly Val Leu Ile Leu Gly

115 120 125

Trp Thr Arg Leu Trp Ile Gln Arg Arg Gly Leu Val Ser Asn Lys Ser 130 135 140

<210> 811

<211> 154

<212> PRT

<213> Homo sapiens

<400> 811

His Glu Asp Asn Glu His Lys Arg Ser Leu Thr Lys Thr Pro Ala Arg 1 5 10 15

Lys Ser Ala His Val Thr Val Ser Gly Gly Thr Gln Lys Gly Glu Ala 20 25 30

Val Leu Gly Thr His Lys Leu Lys Thr Ile Thr Gly Asn Ser Ala Ala 35 40 45

Val Ile Thr Pro Phe Lys Leu Thr Thr Glu Ala Thr Gln Thr Pro Val 50 55 60

Ser Asn Lys Lys Pro Val Phe Asp Leu Lys Ala Ser Leu Ser Arg Pro 65 70 75 80

Leu Asn Tyr Glu Pro His Lys Gly Lys Leu Lys Pro Trp Gly Gln Ser 85 90 95

Lys Glu Asn Asn Tyr Leu Asn Gln His Val Asn Arg Ile Asn Phe Tyr
100 105 110

Lys Lys Thr Tyr Lys Gln Pro His Leu Gln Thr Lys Glu Glu Gln Arg 115 120 125

Lys Lys Arg Glu Gln Glu Arg Lys Glu Lys Lys Ala Lys Val Leu Gly 130 135 140

Met Arg Arg Gly Leu Ile Leu Ala Glu Asp 145 150

<210> 812

<211> 86

<212> PRT

```
<213> Homo sapiens
<220>
<221> SITE
<222> (78)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 812
Asn Arg Ser Phe Phe Val Ser Pro Phe Lys Ser Thr Gly Phe Lys Arg
                                                          15
                  5
                                     10
Gly Lys Cys Ile His Arg Pro Gln Cys Leu Ala Phe Ser Ser Ala Ser
             20
                                 25
Thr Trp Ser Thr Gly Leu Asp Ala Gln Thr Tyr Leu Gly Asn Tyr Phe
Gly Arg Cys Leu Ser Leu Tyr Arg Asn Cys Ser Trp Tyr Phe Ile Leu
                                        60
                        55
Leu Tyr Ile Tyr Ser Thr Cys Pro Leu Val Phe Asn Tyr Xaa Gln Ser
 65
                                         75
                     70
Leu Phe Arg Ser Lys Asn
                 85
<210> 813
<211> 566
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (341)
<223> Xaa equals any of the naturally occurring L-amino acids
Arg Glu Leu Val Thr Asp Gly Gly Ala Ala Ser Pro Trp Arg Cys Asn
                                     10
                                                         15
Trp Glu Gln Leu Leu Asn Pro Arg Pro Ser Glu Ala Asp Pro Glu Ala
                                 25
             20
Asp Pro Glu Glu Ala Thr Ala Ala Arg Val Ile Asp Arg Phe Asp Glu
Gly Glu Asp Gly Glu Gly Asp Phe Leu Val Val Gly Ser Ile Arg Lys
```

55

60

50

Leu 65		Ser	Ala	Ser	Leu 70		Asp	Thr	Asp	Lys 75	Arg	Tyr	Cys	Gly	Lys 80
Thr	Thr	Ser	Arg	Lys 85	Ala	Trp	Asn	Glu	Asp 90		Trp	Glu	Gln	Thr 95	Leu
Pro	Gly	Ser	Ser 100	Asp	Glu	Glu	Ile	Ser 105		Glu	Glu	Gly	Ser 110	Gly	Asp
Glu	Asp	Ser 115	Glu	Gly	Leu	Gly	Leu 120	Glu	Glu	Tyr	Asp	Glu 125	Asp	Asp	Leu
Gly	Ala 130	Ala	Glu	Glu	Gln	Glu 135	Cys	Gly	Asp	His	Arg 140	Glu	Ser	Lys	Lys
Ser 145	Arg	Ser	His	Ser	Ala 150	Lys	Thr	Pro	Gly	Phe 155	Ser	Val	Gln	Ser	11e 160
Ser	Asp	Phe	Glu	Lys 165	Phe	Thr	Lys	Gly	Met 170	Asp	Asp	Leu	Gly	Ser 175	Ser
Glu	Glu	Glu	Glu 180	Asp	Glu	Glu	Ser	Gly 185	Met	Glu	Glu	Gly	Asp 190	Asp	Ala
Glu	Asp	Ser 195	Gln	Gly	Glu	Ser	Glu 200	Glu	Asp	Arg	Ala	Gly 205	Asp	Arg	Asn
Ser	Glu 210	Asp	Asp	Gly	Val	Val 215	Met	Thr	Phe	Ser	Ser 220	Val ·	Lys	Val	Ser
Glu 225	Glu	Val	Glu	Lys	Gly 230	Arg	Ala	Val	Lys	Asn 235	Gln	Ile	Ala	Leu	Trp 240
Asp	Gln	Leu	Leu	Glu 245	Gly	Arg	Ile	Lys	Leu 250	Gln	Lys	Ala	Leu	Leu 255	Thr
Thr	Asn	Gln	Leu 260	Pro	Gln	Pro	Asp	Val 265	Phe	Pro	Leu	Phe	Lys 270	Asp	Lys
Gly	Gly	Pro 275	Glu	Phe	Ser	Ser	Ala 280	Leu	Lys	Asn	Ser	His 285	Lys	Ala	Leu
Lys	Ala 290	Leu	Leu	Arg	Ser	Leu 295	Val	Gly	Leu	Gln	Glu 300	Glu	Leu	Leu	Phe
Gln 305	Tyr	Pro	Asp	Thr	Arg 310	Tyr	Leu	Val	Asp	Gly 315	Thr	Lys	Pro	Asn	Ala 320
Gly	Ser	Glu	Glu	Ile 325	Ser	Ser	Glu	Asp	Asp 330	Glu	Leu	Val	Glu	Glu 335	Lys

Lys Gln Gln Arg Xaa Arg Val Pro Ala Lys Arg Lys Leu Glu Met Glu
340 345 350

Asp Tyr Pro Ser Phe Met Ala Lys Arg Phe Ala Asp Phe Thr Val Tyr 355 360 365

Arg Asn Arg Thr Leu Gln Lys Trp His Asp Lys Thr Lys Leu Ala Ser 370 375 380

Gly Lys Leu Gly Lys Gly Phe Gly Ala Phe Glu Arg Ser Ile Leu Thr 385 390 395 400

Gln Ile Asp His Ile Leu Met Asp Lys Glu Arg Leu Leu Arg Arg Thr
405 410 415

Gln Thr Lys Arg Ser Val Tyr Arg Val Leu Gly Lys Pro Glu Pro Ala 420 425 430

Ala Gln Pro Val Pro Glu Ser Leu Pro Gly Glu Pro Glu Ile Leu Pro
435 440 445

Gln Ala Pro Ala Asn Ala His Leu Lys Asp Leu Asp Glu Glu Ile Phe 450 455 460

Asp Asp Asp Phe Tyr His Gln Leu Leu Arg Glu Leu Ile Glu Arg 465 470 475 480

Lys Thr Ser Ser Leu Asp Pro Asn Asp Gln Val Ala Met Gly Arg Gln
485 490 495

Trp Leu Ala Ile Gln Lys Leu Arg Ser Lys Ile His Lys Lys Val Asp
500 505 510

Arg Lys Ala Ser Lys Gly Arg Lys Leu Arg Phe His Val Leu Ser Lys 515 520 525

Leu Leu Ser Phe Met Ala Pro Ile Asp His Thr Thr Met Asn Asp Asp 530 535 540

Ala Arg Thr Glu Leu Tyr Arg Ser Leu Phe Gly Gln Leu His Pro Pro 545 550 555 560

Asp Glu Gly His Gly Asp 565

<210> 814

<211> 66

<212> PRT

<213> Homo sapiens

<400> 814

Ala Tyr Thr Thr Met Thr Glu Asn Lys Arg Leu Phe Phe Glu Thr Pro 1 5 10 15

Ser Gln Lys Gln Asn Lys Thr Lys Lys Leu Asp Lys Cys Tyr Ile Asn 20 25 30

Val Trp Val Val Arg Phe Tyr Phe Glu Ser Glu Val Cys Arg Tyr Ala 35 40 45

Tyr Arg Phe Leu Glu Phe Thr Thr Phe Leu Phe Cys Ile Ile Asn Val 50 55 60

Ile Phe 65

<210> 815

<211> 79

<212> PRT

<213> Homo sapiens

<400> 815

Glu Lys Glu Val Trp Arg Arg Lys Pro Arg Leu Glu Asn Ile Met Phe 1 5 10 15

Trp Leu Glu Ile Arg Thr Arg Asp Gly Lys Tyr Gln Cys Val Gln Met 20 25 30

Tyr Phe Thr Glu Phe Glu Gly Thr His Asn Gln Glu Gly Lys Gln Phe 35 40 45

Val Leu His Trp Thr Tyr Tyr Leu Asp Leu Gly Glu Gln Gln Asn Gly 50 55 60

Met Trp Ser Val Arg Ser Ile Leu Phe Val Leu Leu Ser Leu Met 65 70 75

<210> 816

<211> 227

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (29)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (99)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 816

Ala Cys His Glu Lys Val Val Asn Ile Gln Lys Asp Pro Gly Glu Ser
1 5 10 15

Leu Gly Met Thr Val Ala Gly Gly Ala Ser His Arg Xaa Trp Asp Leu 20 25 30

Pro Ile Tyr Val Ile Ser Val Glu Pro Gly Gly Val Ile Ser Arg Asp 35 40 45

Gly Arg Ile Lys Thr Gly Asp Ile Leu Leu Asn Val Asp Gly Val Glu
50 55 60

Leu Thr Glu Val Ser Arg Ser Glu Ala Val Ala Leu Leu Lys Arg Thr 65 70 75 80

Ser Ser Ser Ile Val Leu Lys Ala Leu Glu Val Lys Glu Tyr Glu Pro 85 90 95

Gln Glu Xaa Cys Ser Ser Pro Ala Ala Leu Asp Ser Asn His Asn Met
100 105 110

Ala Pro Pro Ser Asp Trp Ser Pro Ser Trp Val Met Trp Leu Glu Leu 115 120 125

Pro Arg Cys Leu Tyr Asn Cys Lys Asp Ile Val Leu Arg Arg Asn Thr 130 135 140

Ala Gly Ser Leu Gly Phe Cys Ile Val Gly Gly Tyr Glu Glu Tyr Asn 145 150 155 160

Gly Asn Lys Pro Phe Phe Ile Lys Ser Ile Val Glu Gly Thr Pro Ala 165 170 175

Tyr Asn Asp Gly Arg Ile Arg Cys Gly Asp Ile Leu Leu Ala Val Asn 180 185 190

Gly Arg Ser Thr Ser Gly Met Ile His Ala Cys Leu Ala Arg Leu Leu 195 200 205

Lys Glu Leu Lys Gly Arg Ile Thr Leu Thr Ile Val Ser Trp Pro Gly 210 215 220

Thr Phe Leu

225

```
<210> 817
<211> 200
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (48)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (55)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (150)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 817
Pro Arg Val Arg Gly His Gln Gly Leu Leu Ala Pro Leu Gly Pro Gln
Pro Leu Leu Gly His Pro Met Pro Gly Ser Pro Ser Met Glu Thr His
                                                     30
             20
                                 25
Cys Cys Pro Thr Pro Ser Leu Arg Pro Thr Thr Gly Pro Arg Xaa
         35
                             40
Pro Thr Gly Pro Pro Gly Xaa Pro Gly Pro Met Gly Pro Pro Gly Pro
                       55
Pro Gly Pro Thr Gly Val Pro Gly Ser Pro Gly His Ile Gly Pro Pro
65
                     70
                                         75
Gly Pro Thr Gly Pro Lys Gly Ile Ser Gly His Pro Gly Glu Lys Gly
                                     90
                 85
Glu Arg Gly Leu Arg Gly Glu Pro Gly Pro Gln Gly Ser Ala Gly Ala
            100
                                105
Ala Gly Gly Thr Gly Pro Lys Gly Asp Pro Gly Glu Lys Ser His Trp
                           120
Ala Pro Ser Leu Gln Ser Phe Leu Gln Gln Ala Gln Leu Glu Leu
    130
                      135
                                            140
```

Leu Ala Arg Arg Val Xaa Leu Leu Glu Ala Ile Ile Trp Pro Glu Pro 145 150 155 160

Glu Leu Gly Ser Gly Ala Gly Pro Ala Gly Thr Gly Thr Pro Ser Leu 165 170 175

Leu Arg Gly Lys Arg Gly Gly His Ala Thr Asn Tyr Arg Ile Val Ala 180 185 190

Pro Arg Ser Arg Asp Glu Arg Gly 195 200

<210> 818

<211> 85

<212> PRT

<213> Homo sapiens

<400> 818

Glu Lys Leu Asp Glu Tyr Ile Tyr Arg His Phe Phe Gly His Thr Phe 1 5 10 15

Ser Pro Pro Tyr Gly Pro Ser Arg Pro Asp Lys Lys Gln Arg Met Val 20 25 30

Asn Ile Glu Asn Ser Arg His Arg Lys Gln Glu Gln Lys His Leu Gln
35 40 45

Pro Gln Pro Tyr Lys Arg Glu Gly Lys Trp His Lys Tyr Gly Arg Thr
50 55 60

Asn Gly Arg Gln Met Ala Asn Leu Glu Ile Glu Leu Gly Gln Leu Pro 65 70 75 80

Phe Asp Pro Gln Tyr

<210> 819

<211> 67

<212> PRT

<213> Homo sapiens

<400> 819

Leu Gln Ser Gly Phe Ile Arg Tyr Cys Pro Ala Arg Lys Phe Pro Phe 1 5 10 15

Cys Val Trp Leu Glu Gln Pro Ala Gly Thr Glu Trp Ile Leu Glu Glu 20 25 30

```
Gly Val Thr Thr Gly Pro Pro Arg Lys Pro Arg Ala Asp Ile Tyr Asn
         35
                              40
                                                  45
Leu Arg Ser Pro Asp Glu Phe Ile Val Gly Gln Asn Gln Ala Leu Ile
                          55
Glu Pro Gly
 65
<210> 820
<211> 60
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (38)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (57)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (60)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 820
Leu Thr Gly Ser Glu Leu Met Cys Arg Val Pro Ser Pro Lys Val Asn
Leu Glu Pro Leu Asp Asn Thr Asn Lys Asn Ile Tyr Phe Thr Ser Val
             20
                                 25
Ile Tyr Leu Glu Asn Kaa Leu Ser Ile Leu His Ile Phe Leu Ile Lys
        35
                             40
Ser Thr Gly Asp His Cys Glu Val Xaa Ile Leu Xaa
     50
                         55
```

<210> 821 <211> 259 <212> PRT <213> Homo sapiens <400> 821

Leu Ser Leu Ser Leu Leu Ser Pro Gln Leu Asp Tyr His Arg Gly Leu 1 5 10 15

Leu Val Asp Arg Pro Ser Glu Thr Lys Thr Glu Glu Gln Gly Ile Pro
20 25 30

Arg Pro Leu His Pro Pro Pro Pro Pro Pro Val Gln Pro Pro Gln His
35 40 45

Pro Arg Ala Glu Gln Arg Glu Gln Glu Arg Ala Val Arg Glu Gln Trp
50 55 60

Ala Glu Arg Glu Arg Glu Met Glu Arg Arg Glu Arg Thr Arg Ser Glu 65 70 75 80

Arg Glu Trp Asp Arg Asp Lys Val Arg Glu Gly Pro Arg Ser Arg Ser 85 90 95

Arg Ser Arg Asp Arg Arg Lys Glu Arg Ala Lys Ser Lys Glu Lys
100 105 110

Lys Ser Glu Lys Lys Glu Lys Ala Gln Glu Glu Pro Pro Ala Lys Leu 115 120 125

Leu Asp Asp Leu Phe Arg Lys Thr Lys Ala Ala Pro Cys Ile Tyr Trp 130 135 140

Leu Pro Leu Thr Asp Ser Gln Ile Val Gln Lys Glu Ala Glu Arg Ala 145 150 155 160

Glu Arg Ala Lys Glu Arg Glu Lys Arg Arg Lys Glu Glu Glu Glu 165 170 175

Glu Gln Lys Glu Arg Glu Lys Glu Ala Glu Arg Glu Arg Asn Arg Gln 180 185 190

Leu Glu Arg Glu Lys Arg Arg Glu His Ser Arg Glu Arg Asp Arg Glu 195 200 205

Arg Glu Arg Glu Arg Glu Arg Asp Arg Gly Asp Arg Asp Arg Asp Arg 210 215 220

Glu Arg Asp Arg Glu Arg Gly Arg Glu Arg Asp Arg Asp Thr Lys
225 230 235 240

Arg His Ser Arg Ser Arg Ser Arg Ser Thr Pro Val Arg Asp Arg Gly
245 250 255

Gly Arg Arg

```
<210> 822
<211> 59
<212> PRT
<213> Homo sapiens
<400> 822
Ile Asn Pro Ala Leu Leu Arg Lys Gly Asn Leu Phe Arg Gln Ser Gly
            5 ·
Lys Gly Val Leu Arg Lys Leu Ser Phe Phe Ile Pro Ser Phe Leu Pro
             20
                                 25
Thr Thr Val Thr Gly Tyr Arg Gly Leu Trp Thr Leu Lys Thr Asn Val
                             40
                                                 45
Trp Pro Leu Thr Gly Leu Ile Cys Ile Phe Leu
<210> 823
<211> 175
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (128)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (133)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 823
Ser Trp Lys Thr Gly Glu Asp Lys Ser Met Ser Ser Leu Pro Gly Cys
Ile Gly Leu Asp Ala Ala Thr Ala Thr Val Glu Ser Glu Glu Ile Ala
Glu Leu Gln Gln Ala Val Val Glu Glu Leu Gly Ile Ser Met Glu Glu
        35
                             40
```

Leu Arg His Phe Ile Asp Glu Glu Leu Glu Lys Met Asp Cys Val Gln

60

55

50

Gln Arg Lys Lys Gln Leu Ala Glu Leu Glu Thr Trp Val Ile Gln Lys
65 70 75 80

Glu Ser Glu Val Ala His Val Asp Gln Leu Phe Asp Asp Ala Ser Arg 85 90 95

Ala Val Thr Asn Cys Glu Ser Leu Val Lys Asp Phe Tyr Ser Lys Leu 100 105 110

Gly Leu Gln Tyr Arg Asp Ser Ser Ser Glu Asp Glu Ser Ser Arg Xaa 115 120 125

Thr Glu Ile Ile Xaa Ile Pro Asp Glu Asp Asp Val Leu Ser Ile 130 135 140

Asp Ser Gly Asp Ala Gly Ser Arg Thr Pro Lys Asp Gln Lys Leu Arg 145 150 155 160

Glu Ala Met Ala Ala Leu Arg Lys Ser Ala Gln Asp Val Gln Lys 165 170 175

<210> 824

<211> 90

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (36)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 824

His Lys Leu Asn Pro Met Tyr Leu Lys Leu Leu Gln Ser Phe Pro Leu 1 5 10 15

Tyr Phe Lys Gln Gln Lys Ser Gly Gly His Ile Val Val Leu Ser Phe 20 25 30

Lys Leu Cys Xaa Lys Phe Asn His Tyr Phe Asp Ala Leu Asn Ile Leu 35 40 45

Met Cys Asn Ile Cys Phe Cys Ile Lys Asn Thr His Ile Phe Gln Glu 50 55 60

Lys Glu Ile Met Leu Asn Ser Pro Val Leu Arg Lys Ile Phe Met Lys 65 70 75 80

His Leu Asn Leu Lys Ile Lys Ser Lys Leu

85 90

<210> 825

<211> 156

<212> PRT

<213> Homo sapiens

<400> 825

Ser Arg Arg Lys Met Ala Val Leu Ser Lys Glu Tyr Gly Phe Val Leu 1 5 10 15

Leu Thr Gly Ala Ala Ser Phe Ile Met Val Ala His Leu Ala Ile Asn 20 25 30

Val Ser Lys Ala Arg Lys Lys Tyr Lys Val Glu Tyr Pro Ile Met Tyr 35 40 45

Ser Thr Asp Pro Glu Asn Gly His Ile Phe Asn Cys Ile Gln Arg Ala
50 55 60

His Gln Asn Thr Leu Glu Val Tyr Pro Pro Phe Leu Phe Phe Leu Ala 65 70 75 80

Val Gly Gly Val Tyr His Pro Arg Ile Ala Ser Gly Leu Gly Leu Ala 85 90 95

Trp Ile Val Gly Arg Val Leu Tyr Ala Tyr Gly Tyr Tyr Thr Gly Glu
100 105 110

Pro Ser Lys Arg Ser Arg Gly Ala Leu Gly Ser Ile Ala Leu Leu Gly
115 120 125

Leu Val Gly Thr Thr Val Cys Ser Ala Phe Gln His Leu Gly Trp Val 130 135 140

Lys Ser Gly Leu Gly Ser Gly Pro Lys Cys Cys His 145 150 155

<210> 826

<211> 259

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (20)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 826															
Ser	Leu	Thr	Ser	Tyr	His	Asn	Gln	Thr	Phe	Cys	Ala	Cys	Ala	Ile	Va
1				5					10			_		15	

Ala Ala Ile Xaa Ser Phe Gly Trp Asn Thr Val Lys Ile Asp Met Ser

Ala Ala Arg Arg Asp Pro Leu Pro Ile Val Pro Phe Gly Leu Ala Ala 35 40 45

Phe Ala Thr Thr Leu Phe Ala Leu Gly Leu Ala Leu Gly Thr Thr Ile 50 55 60

Ala Val Gly Met Leu Phe Phe Ile Gln Met Lys Ile Ile Leu Arg Asn 65 70 75 80

Lys Thr Ser Ile Glu Ser Trp Ile Glu Glu Lys Ala Lys Asp Arg Ile 85 90 95

Gln Tyr Tyr Gln Leu Asp Glu Val Phe Val Phe Pro Tyr Asp Met Gly 100 105 110

Ser Arg Trp Arg Asn Phe Lys Gln Val Phe Thr Trp Ser Gly Val Pro 115 120 125

Glu Gly Asp Gly Leu Glu Trp Pro Val Arg Glu Gly Cys His Gln Tyr 130 135 140

Ser Leu Thr Ile Glu Gln Leu Lys Gln Lys Ala Asp Lys Arg Val Arg 145 150 155 160

Ser Val Arg Tyr Lys Val Ile Glu Asp Tyr Ser Gly Ala Cys Cys Pro 165 170 175

Leu Asn Lys Gly Ile Lys Thr Phe Phe Thr Ser Pro Cys Thr Glu Glu
180 185 190

Pro Arg Ile Gln Leu Gln Lys Gly Glu Phe Ile Leu Ala Thr Arg Gly 195 200 205

Leu Arg Tyr Trp Leu Tyr Gly Asp Lys Ile Leu Asp Asp Ser Phe Ile 210 215 220

Glu Gly Val Ser Arg Ile Arg Gly Trp Phe Pro Arg Lys Cys Val Glu 225 230 235 240

Lys Cys Pro Cys Asp Ala Glu Thr Asp Gln Ala Pro Glu Gly Glu Lys
245 250 255

Lys Asn Arg

```
<210> 827
<211> 88
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (4)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (19)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (28)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (39)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (41)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (82)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 827
Glu Pro Trp Xaa Leu Leu Lys Ser Leu Leu Cys Arg Arg Ser Pro Ser
Arg Thr Xaa Lys Gln Glu Glu Asp Arg Ala Thr Xaa Glu Ala Lys Asn
             20
                                  25
                                                      30
Gly Glu Lys Ala Arg Arg Xaa Ser Xaa Glu Val Asp Gly Gln His Pro
         35
                             40
                                                  45
Ala Gln Glu Glu Val Pro Glu Ser Pro Gln Thr Ser Gly Pro Glu Gln
     50
                         55
```

Lys Ile Gly Val Gly Ala Pro Gly Arg Lys Ser Gln Leu Glu Arg Lys
65 70 75 80

Gln Xaa Trp Lys Arg Leu Gln Arg 85

<210> 828

<211> 206

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (14)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 828

Leu Pro Gly Val Phe Lys Met Ala Ala Ser Met His Gly Xaa Pro Ser

1 10 15

Pro Ser Leu Glu Asp Ala Lys Leu Arg Arg Pro Met Val Ile Glu Ile 20 25 30

Ile Glu Lys Asn Phe Asp Tyr Leu Arg Lys Glu Met Thr Gln Asn Ile
35 40 45

Tyr Gln Met Ala Thr Phe Gly Thr Thr Ala Gly Phe Ser Gly Ile Phe 50 55 60

Ser Asn Phe Leu Phe Arg Arg Cys Phe Lys Val Lys His Asp Ala Leu 65 70 75 80

Lys Thr Tyr Ala Ser Leu Ala Thr Leu Pro Phe Leu Ser Thr Val Val 85 90 95

Thr Asp Lys Leu Phe Val Ile Asp Ala Leu Tyr Ser Asp Asn Ile Ser 100 105 110

Lys Glu Asn Cys Val Phe Arg Ser Ser Leu Ile Gly Ile Val Cys Gly
115 120 125

Val Phe Tyr Pro Ser Ser Leu Ala Phe Thr Lys Asn Gly Arg Leu Ala 130 135 140

Thr Lys Tyr His Thr Val Pro Leu Pro Pro Lys Gly Arg Val Leu Ile 145 150 155 160

His Trp Met Thr Leu Cys Gln Thr Gln Met Lys Leu Met Ala Ile Pro

165 170 175

Leu Val Phe Gln Ile Met Phe Gly Ile Leu Asn Gly Leu Tyr His Tyr 180 185 190

Ala Val Phe Glu Glu Thr Leu Glu Lys Thr Ile His Glu Glu
195 200 205

<210> 829

<211> 78

<212> PRT

<213> Homo sapiens

<400> 829

Tyr Asn Ile Trp Phe Val Asn Ser Glu Thr Leu Pro Val Cys Leu Leu 1 5 10 15

Leu Ser Ile Glu Leu Val Phe Ser Phe Ser Trp Leu Ser Ser Cys Leu 20 25 30

Leu Ile Leu Ser His Met Leu Pro Ser Leu Leu Val Pro Ser Ser Leu 35 40 45

Leu Tyr Phe Thr Arg Phe Gly Thr Cys Ser Pro Leu Asp Phe Phe Phe 50 55 60

Asn Ile Leu Ala Phe Pro Arg Cys Lys Ser Leu Pro Pro Cys 65 70 75

<210> 830

<211> 101

<212> PRT

<213> Homo sapiens

<400> 830

Arg Phe Gly Arg Arg Thr Gly Arg Arg Trp Arg Arg Thr Thr Gly Gly
1 5 10 15

Ala Glu Gly Val Arg Gly Gly Asp Gly Arg Arg Gly Gly Pro Gly Pro
20 25 30

Leu Leu Ser Arg Val Gly Arg Leu Gly Leu Ala Asp Arg Ala Arg Ala 35 40 45

Phe Tyr Glu Asp Gly Gly Asp Glu Asp Ile Val Thr Ile Ser Gln Ala 50 55 60

Thr Pro Ser Ser Val Ser Arg Gly Thr Ala Pro Ser Asp Asn Arg Val 65 70 75 80

Thr Ser Phe Arg Asp Leu Ile His Asp Gln Asp Glu Asp Glu Glu Glu 85 90 95

Glu Glu Gly Gln Arg 100

<210> 831

<211> 155

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (64)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 831

Arg Cys Ser Ser Ile Phe Thr Pro Trp Lys Leu Thr Thr Leu Ser Ser 1 5 10 15

Phe Leu His His His Pro Gly Ala Gln Arg Ser Lys Leu Leu Ser Ile 20 25 30

Phe Ser Pro Ser Pro Arg Thr Leu Thr Leu Tyr Arg Met Gly Pro Ser 35 40 45

Ser Cys Leu Leu Leu Ile Leu Ile Pro Leu Leu Gln Leu Ile Asn Xaa 50 55 60

Gly Ser Thr Gln Cys Ser Leu Asp Ser Val Met Asp Lys Lys Ile Lys 65 70 75 80

Asp Val Leu Asn Ser Leu Glu Tyr·Ser Pro Ser Pro Ile Ser Lys Lys 85 90 95

Leu Ser Cys Ala Ser Val Lys Ser Gln Gly Arg Pro Ser Ser Cys Pro 100 105 110

Ala Gly Met Ala Val Thr Gly Cys Ala Cys Gly Tyr Gly Cys Gly Ser 115 120 125

Trp Asp Val Gln Leu Glu Thr Thr Cys His Cys Gln Cys Ser Val Val 130 135 140

Asp Trp Thr Thr Ala Arg Cys Cys His Leu Thr 145 150 155

<210> 832 <211> 238 <212> PRT <213> Homo sapiens <220> <221> SITE <222> (221) <223> Xaa equals any of the naturally occurring L-amino acids <400> 832 Tyr His Leu Tyr Phe Lys Met Gly Asp Pro Asn Ser Arg Lys Lys Gln 10 Ala Leu Asn Arg Leu Arg Ala Gln Leu Arg Lys Lys Glu Ser Leu Ala Asp Gln Phe Asp Phe Lys Met Tyr Ile Ala Phe Val Phe Lys Glu Lys Lys Lys Ser Ala Leu Phe Glu Val Ser Glu Val Ile Pro Val Met Thr Asn Asn Tyr Glu Glu Asn Ile Leu Lys Gly Val Arg Asp Ser 70 Ser Tyr Ser Leu Glu Ser Ser Leu Glu Leu Leu Gln Lys Asp Val Val Gln Leu His Ala Pro Arg Tyr Gln Ser Met Arg Arg Asp Val Ile Gly 100 Cys Thr Gln Glu Met Asp Phe Ile Leu Trp Pro Arg Asn Asp Ile Glu 115 120 Lys Ile Val Cys Leu Leu Phe Ser Arg Trp Lys Glu Ser Asp Glu Pro 135 Phe Arg Pro Val Gln Ala Lys Phe Glu Phe His His Gly Asp Tyr Glu 145 150 155 160 Lys Gln Phe Leu His Val Leu Ser Arg Lys Asp Lys Thr Gly Ile Val . 165 Val Asn Asn Pro Asn Gln Ser Val Phe Leu Phe Ile Asp Arg Gln His

Leu Gln Thr Pro Lys Asn Lys Ala Thr Ile Phe Lys Leu Cys Ser Ile

195 200 205

Cys Leu Tyr Leu Pro Gln Glu Gln Leu Thr His Trp Xaa Ser Trp His 210 215 220

His Arg Gly Ser Pro Pro Ser Leu Tyr Ala Arg Val Glu Tyr 225 230 235

<210> 833

<211> 146

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (44)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 833

Asn Ser Ala Arg Ala Gln Met Ala Leu Glu Asp Gln Ala Ala Thr Leu 1 5 10 15

Glu Tyr Lys Thr Ile Lys Glu His Leu Ser Ser Lys Ser Pro Asn His
20 25 30

Gly Val Asn Leu Val Glu Asn Leu Asp Ser Leu Xaa Pro Lys Val Pro 35 40 45

Gln Arg Glu Ala Ser Leu Gly Pro Pro Gly Ala Ser Leu Ser Gln Thr
50 55 60

Gly Leu Ser Lys Arg Leu Glu Met His His Ser Ser Ser Tyr Gly Val 65 70 75 80

Asp Tyr Lys Arg Ser Tyr Pro Thr Asn Ser Leu Thr Arg Ser His Gln 85 90 95

Ala Pro Leu Ser Lys Glu Thr Thr Leu Thr Pro Pro Ile Pro Leu Thr 100 105 110

Ser Pro Glu Thr Arg Ala Leu Ala Gly Glu Thr Thr Arg Arg Pro Pro 115 120 125

Arg Arg Gly Trp Thr Pro Ser Arg Cys Thr Ala Pro Ser His Leu Ala 130 135 140

Arg Pro

145

<210> 834

<211> 239

<212> PRT

<213> Homo sapiens

<400> 834

Gln Pro Pro Gly Thr Arg Asp Pro Ala Pro Pro Leu Ile Thr Pro Ala 1 5 10 15

Thr Pro Gln Leu Ser Ala Ala Pro Asp Ala Met Asp Pro Ala Leu Ala 20 25 30

Ala Gln Met Ser Glu Ala Val Ala Glu Lys Met Leu Gln Tyr Arg Arg
35 40 45

Asp Thr Ala Gly Trp Lys Ile Cys Arg Glu Gly Asn Gly Val Ser Val 50 55 60

Ser Trp Arg Pro Ser Val Glu Phe Pro Gly Asn Leu Tyr Arg Gly Glu 65 70 75 80

Gly Ile Val Tyr Gly Thr Leu Glu Glu Val Trp Asp Cys Val Lys Pro 85 90 95

Ala Val Gly Gly Leu Arg Val Lys Trp Asp Glu Asn Val Thr Gly Phe
100 105 110

Glu Ile Ile Gln Ser Ile Thr Asp Thr Leu Cys Val Ser Arg Thr Ser 115 120 125

Thr Pro Ser Ala Ala Met Lys Leu Ile Ser Pro Arg Asp Phe Val Asp 130 135 140

Leu Val Leu Val Lys Arg Tyr Glu Asp Gly Thr Ile Ser Ser Asn Ala 145 150 155 160

Thr His Val Glu His Pro Leu Cys Pro Pro Lys Pro Gly Phe Val Arg 165 170 175

Gly Phe Asn His Pro Cys Gly Cys Phe Cys Glu Pro Leu Pro Gly Glu 180 185 190

Pro Thr Lys Thr Asn Leu Val Thr Phe Phe His Thr Asp Leu Ser Gly 195 200 205

Tyr Leu Pro Gln Asn Val Val Asp Ser Phe Phe Pro Arg Ser Met Thr 210 215 220

Arg Phe Tyr Ala Asn Leu Gln Lys Ala Val Lys Gln Phe His Glu

225 230 235

<210> 835

<211> 154

<212> PRT

<213> Homo sapiens

. <220>

<221> SITE

<222> (24)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 835

Gln Leu Thr Thr Val Arg Arg Leu Leu Ser Glu Lys Ala Thr His Val

Asn Thr Arg Asp Glu Asp Glu Xaa Thr Pro Leu His Arg Ala Ala Tyr
20 25 30

Ser Gly His Leu Asp Ile Val Gln Glu Leu Ile Ala Gln Gly Ala Asp 35 40 45

Val His Ala Val Thr Val Asp Gly Trp Thr Pro Leu His Ser Ala Cys
50 55 60

Lys Trp Asn Asn Thr Arg Val Ala Ser Phe Leu Leu Gln His Asp Ala 65 70 75 80

Asp Ile Asn Ala Gln Thr Lys Gly Leu Leu Thr Pro Leu His Leu Ala 85 90 95

Ala Gly Asn Arg Asp Ser Lys Asp Thr Leu Glu Leu Leu Met Asn 100 105 110

Arg Tyr Val Lys Pro Gly Leu Lys Asn Asn Leu Glu Glu Thr Ala Phe 115 120 125

Asp Ile Ala Arg Arg Thr Ser Ile Tyr His Tyr Leu Phe Glu Ile Val 130 135 140

Glu Gly Cys Thr Asn Ser Ser Pro Gln Ser 145 150

<210> 836

<211> 77

<212> PRT

<213> Homo sapiens

<400> 836

Asn Thr Phe Ile His Glu Asp Ile Trp Asn Ile Arg Ser Ile Cys Ser 1 5 10 15

Thr Thr Asn Ile Gln Cys Lys Asn Gly Lys Met Asn Cys His Glu Gly
20 25 30

Val Val Lys Val Thr Asp Cys Arg Asp Thr Gly Ser Ser Arg Ala Pro 35 40 45

Asn Cys Arg Tyr Arg Ala Ile Ala Ser Thr Arg Arg Val Val Ile Ala 50 55 60

Cys Glu Gly Asn Pro Gln Val Pro Val His Phe Asp Gly 65 70 75

<210> 837

<211> 84

<212> PRT

<213> Homo sapiens

<400> 837

Arg Asp Ala Pro Gly Ile Ser Leu Thr Val Leu Leu Pro His Gln Gln 1 5 10 15

Pro Pro Thr Phe Gly Pro Thr Leu Pro Pro Met Arg Glu Tyr Pro Ala
20 25 30

Trp Met Leu Cys Phe Ser Gly Leu Ser Leu Ser Pro Phe Leu Gln Gly 35 40 45

Met Leu Val Ser Leu Ala Ser Gln Cys Pro Asn Trp Ser Pro Glu Cys 50 55 60

Leu Val Leu Ser Gln Glu Thr Ala Glu His Trp Pro Ser Thr Pro Lys 65 70 75 80

Arg Pro Leu His

<210> 838

<211> 96

<212> PRT

<213> Homo sapiens

<400> 838

Cys Phe Ser Leu Pro Ser Leu Phe Thr Ala Val Lys Phe Ile Lys Cys
1 5 10 15

Phe Ser Val Val Phe Cys Ser Leu Ser Phe Thr Gly Tyr Phe Phe Met 20 25 30

Tyr Thr Phe Arg Ile Phe Cys Leu Leu Tyr Pro Val Val Gln Met Ile 35 40 45

Ser Tyr Ile Leu Gln Met Pro Phe Gln Phe Leu Phe Ser Phe Ser Ile 50 55 60

Lys Leu Pro Ser Cys Pro Asn Val Gln Phe Val Ser Val Cys Val Cys 65 70 75 80

Val Cys Val Cys Val Asn Leu Ile Phe Lys Ser Ala Arg Leu Pro Ile 85 90 95

<210> 839

<211> 64

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (1)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (58)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 839

Xaa Gln Ala Thr Ala Ile Asn Thr Asp Val Asn Gly Cys Ile Cys Phe 1 5 10 15

Ala Val Val Thr Gly Leu Gly Arg Phe Gly Ile Cys Glu Arg Ile Asp 20 25 30

Ser Phe Ser Lys Leu Phe His Lys Val Lys Lys Leu His Phe Lys Gly 35 40 45

Asn Arg Ser Tyr Ser Ser Leu Lys Ser Xaa Ser Asn Cys Ser Phe Ile 50 55 60

<210> 840

<211> 288

<212> PRT

<213> Homo sapiens

<400> 840

Glu Ile Arg Val Ser Cys Thr Ala Gly Ala Gly Phe Pro Ala Ala Gln
1 5 10 15

Ala Arg Val Arg Cys Leu Cys His Leu Ile Leu Met Ser Gly Glu Ile 20 25 30

Ala Met Cys Glu Pro Glu Phe Gly Asn Asp Lys Ala Arg Glu Pro Ser 35 40 45

Val Gly Gly Arg Trp Arg Val Ser Trp Tyr Glu Arg Phe Val Gln Pro
50 60

Cys Leu Val Glu Leu Leu Gly Ser Ala Leu Phe Ile Phe Ile Gly Cys
65 70 75 80

Leu Ser Val Ile Glu Asn Gly Thr Asp Thr Gly Leu Leu Gln Pro Ala 85 90 95

Leu Ala His Gly Leu Ala Leu Gly Leu Val Ile Ala Thr Leu Gly Asn 100 105 110

Ile Ser Gly Gly His Phe Asn Pro Ala Val Ser Leu Ala Ala Met Leu 115 120 125

Ile Gly Gly Leu Asn Leu Val Met Leu Leu Pro Tyr Trp Val Ser Gln 130 135 140

Leu Leu Gly Gly Met Leu Gly Ala Ala Leu Ala Lys Ala Val Ser Pro 145 150 155 160

Glu Glu Arg Phe Trp Asn Ala Ser Gly Ala Ala Phe Val Thr Val Gln 165 170 175

Glu Gln Gly Gln Val Ala Gly Ala Leu Val Ala Glu Ile Ile Leu Thr 180 185 190

Thr Leu Leu Ala Leu Ala Val Cys Met Gly Ala Ile Asn Glu Lys Thr 195 200 205

Lys Gly Pro Leu Ala Pro Phe Ser Ile Gly Phe Ala Val Thr Val Asp

210 215 220

Ile Leu Ala Gly Gly Pro Val Ser Gly Gly Cys Met Asn Pro Ala Arg 225 230 235 240

Ala Phe Gly Pro Ala Val Val Ala Asn His Trp Asn Phe His Trp Ile
245 250 255

Tyr Trp Leu Gly Pro Leu Leu Ala Gly Leu Leu Val Gly Leu Leu Ile 260 265 270

Arg Cys Phe Ile Gly Asp Gly Lys Thr Arg Leu Ile Leu Lys Ala Gln 275 280 285

<210> 841

<211> 216

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (2)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 841

Gly Xaa Glu Gly Lys Gly Arg Glu Gly Gly Val Thr Arg Gly Arg Ala
1 5 10 15

Arg Ala Pro Gly Ala Ala Arg Arg Arg Val Glu Leu Asp Arg Val Cys
20 25 30

Cys Gln Arg Arg Glu Leu Arg Pro Pro Phe Tyr Asn Ser Ser Thr Arg
35 40 45

Ala Gly His Arg Glu Gln Arg Ala Arg Val Ser Arg Asn Pro Ile Pro 50 55

Ser Asp Arg Ile Ser Pro Pro Gln Pro Asn Gly Glu Ile Ser Gly Asn 65 70 75 80

Met Ala Thr Glu His Val Asn Gly Asn Gly Thr Glu Glu Pro Met Asp 85 90 95

Thr Thr Ser Ala Val Ile His Ser Glu Asn Phe Gln Thr Leu Leu Asp 100 105 110 Ala Gly Leu Pro Gln Lys Val Ala Glu Lys Leu Asp Glu Ile Tyr Val 115 120 125

Ala Gly Leu Val Ala His Ser Asp Leu Asp Glu Arg Ala Ile Glu Ala 130 135 140

Leu Lys Glu Phe Asn Glu Asp Gly Ala Leu Ala Val Leu Gln Gln Phe 145 150 155 160

Lys Asp Ser Asp Leu Ser His Val Gln Asn Lys Ser Ala Phe Leu Cys 165 170 175

Gly Val Met Lys Thr Tyr Arg Gln Arg Glu Lys Gln Gly Thr Lys Val 180 185 190

Ala Asp Ser Ser Lys Gly Pro Asp Glu Ala Lys Ile Lys Ala Leu Leu 195 200 205

Glu Arg Thr Gly Ser His Leu Met 210 215

<210> 842

<211> 189

<212> PRT

<213> Homo sapiens

<400> 842

Asp Ser Asp Gly Ser Pro Leu Ser Asn Ser Gln Pro Ser Phe Pro Val 1 5 10 15

Glu Ile Leu Pro Phe Leu Tyr Leu Gly Cys Ala Lys Asp Ser Thr Asn 20 25 30

Leu Asp Val Leu Glu Glu Phe Gly Ile Lys Tyr Ile Leu Asn Val Thr 35 40 45

Pro Asn Leu Pro Asn Leu Phe Glu Asn Ala Gly Glu Phe Lys Tyr Lys
50 55 60

Gln Ile Pro Ile Ser Asp His Trp Ser Gln Asn Leu Ser Gln Phe Phe 65 70 75 80

Pro Glu Ala Ile Ser Phe Ile Asp Glu Ala Arg Gly Lys Asn Cys Gly 85 90 95

Val Leu Val His Cys Leu Ala Gly Ile Ser Arg Ser Val Thr Val Thr

Val Ala Tyr Leu Met Gln Lys Leu Asn Leu Ser Met Asn Asp Ala Tyr

115 120 125

Asp Ile Val Lys Met Lys Lys Ser Asn Ile Ser Pro Asn Phe Asn Phe 130 135 140

Met Gly Gln Leu Leu Asp Phe Glu Arg Thr Leu Gly Leu Ser Ser Pro 145 150 155 160

Cys Asp Asn Arg Val Pro Ala Gln Gln Leu Tyr Phe Thr Thr Pro Ser 165 170 175

Asn Gln Asn Val Tyr Gln Val Asp Ser Leu Gln Ser Thr 180 185

<210> 843

<211> 220

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (216)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 843

Asn Thr Pro Gly Phe Met Tyr Lys Asn Leu Gln Cys Leu Val Ile Asp 1 5 10 15

Glu Ala Asp Arg Ile Phe Asp Val Gly Phe Glu Glu Glu Leu Lys Gln
20 25 30

Ile Ile Lys Leu Leu Pro Thr Arg Arg Gln Thr Met Leu Phe Ser Ala 35 40 45

Thr Gln Thr Arg Lys Val Glu Asp Leu Ala Arg Ile Ser Leu Lys Lys 50 55 60

Glu Pro Leu Tyr Val Gly Val Asp Asp Asp Lys Ala Asn Ala Thr Val 65 70 75 80

Asp Gly Leu Glu Gln Lys Asn Arg Lys Lys Lys Leu Met Val Phe Phe 85 90 95

Ser Ser Cys Met Ser Val Lys Tyr His Tyr Glu Leu Leu Asn Tyr Ile 100 105 110

Asp Leu Pro Val Leu Ala Ile His Gly Lys Gln Lys Gln Asn Lys Arg . 115 120 125 WO 00/55351

Thr Thr Thr Phe Phe Gln Phe Cys Asn Ala Asp Ser Gly Thr Leu Leu 130 135 140

Cys Thr Asp Val Ala Ala Arg Gly Leu Asp Ile Pro Glu Val Asp Trp 145 150 155 160

Ile Val Gln Tyr Asp Pro Pro Asp Asp Pro Lys Glu Tyr Ile His Arg 165 170 175

Val Gly Arg Thr Ala Arg Gly Leu Asn Gly Arg Gly His Ala Leu Leu 180 185 190

Ile Leu Arg Pro Glu Glu Leu Gly Phe Leu Arg Tyr Leu Lys Gln Ser 195 200 205

Lys Val Pro Leu Ser Glu Phe Xaa Leu Phe Leu Val 210 215 220

<210> 844

<211> 83

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (40)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 844

Arg Pro Pro Phe Val Pro Lys His Pro Ala His Ala Asp Ser Leu Leu 1 5 10 15

Gly Ser Leu Arg Tyr Leu Ser Thr Gln Thr Leu Leu Pro His Pro Ile
20 25 30

Ser Pro Glu Thr Pro Ala Phe Xaa Leu Thr Ile Phe Pro Leu Pro Ala 35 40 45

Phe Arg Phe Leu Leu Gly Ala Gln Arg Pro Leu Trp Gly Val Ala Ser 50 55 60

Ser Pro Pro Thr Pro Pro His Pro Pro Pro Leu Pro Arg Gln Ala Ser 65 70 75 80

Pro Cys Arg

```
<210> 845
<211> 114
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (1)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (15)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (32)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 845
Xaa Ser Ser Arg Thr Cys Glu Gly Arg Val Leu Ser Ser Val Xaa Pro
                                     10
Leu Ala His Val Ala Ser Val Phe Leu Lys Leu Pro Asp Leu Glu Xaa
                                25
Leu Met Lys Arg Glu Asn Gln Lys Ile Leu Thr Pro Leu Val Ser Leu
         35
                             40
Asp Thr Pro Gly Lys Ala Thr Val Gln Val Val Ile Leu Ala Asp Pro
     50
                         55
Asp Gly His Glu Ile Cys Phe Val Gly Asp Glu Ala Phe Arg Glu Leu
                                         75
Ser Lys Met Asp Pro Glu Gly Ser Lys Leu Leu Asp Asp Ala Met Ala
Ala Asp Lys Ser Asp Glu Trp Phe Ala Lys His Asn Lys Pro Lys Ala
           100
                                105
```

Ser Gly

<210> 846 <211> 68 <212> PRT

<213> Homo sapiens

<400> 846

Ser Asn Gly Ser Ile Cys Leu Asp Ile Leu Arg Ser Gln Trp Ser Pro 1 5 10 15

Ala Leu Thr Val Ser Lys Val Leu Leu Ser Ile Cys Ser Leu Leu Cys
20 25 30

Asp Pro Asn Pro Asp Asp Pro Leu Val Pro Glu Ile Ala His Thr Tyr 35 40 45

Lys Ala Asp Arg Glu Lys Tyr Asn Arg Leu Ala Arg Glu Trp Thr Gln
50 55 60

Lys Tyr Ala Met 65

<210> 847

<211> 365

<212> PRT

<213> Homo sapiens

<400> 847

Gly Arg Val Gly Ser Pro Gly Gly Cys Pro Trp Val Leu Pro Ser Leu
1 5 10 15

Pro Asp Thr Gln Thr Asp Leu Asp Arg Pro Pro Gly Arg Ser Arg Thr
20 25 30

Gly Arg Pro Asp Ala Ala Met Ala Glu Leu Pro Gly Pro Phe Leu Cys $35 \hspace{1cm} 40 \hspace{1cm} 45$

Gly Ala Leu Leu Gly Phe Leu Cys Leu Ser Gly Leu Ala Val Glu Val
50 55 60

Lys Val Pro Thr Glu Pro Leu Ser Thr Pro Leu Gly Lys Thr Ala Glu 65 70 75 80

Leu Thr Cys Thr Tyr Ser Thr Ser Val Gly Asp Ser Phe Ala Leu Glu 85 90 95

Trp Ser Phe Val Gln Pro Gly Lys Pro Ile Ser Glu Ser His Pro Ile 100 105 110

Leu Tyr Phe Thr Asn Gly His Leu Tyr Pro Thr Gly Ser Lys Ser Lys 115 120 125

Arg Val Ser Leu Leu Gln Asn Pro Pro Thr Val Gly Val Ala Thr Leu 130 135 140

Lys Leu Thr Asp Val His Pro Ser Asp Thr Gly Thr Tyr Leu Cys Gln 145 150 155 Val Asn Asn Pro Pro Asp Phe Tyr Thr Asn Gly Leu Gly Leu Ile Asn Leu Thr Val Leu Val Pro Pro Ser Asn Pro Leu Cys Ser Gln Ser Gly 185 Gln Thr Ser Val Gly Gly Ser Thr Ala Leu Arg Cys Ser Ser Ser Glu 195 Gly Ala Pro Lys Pro Val Tyr Asn Trp Val Arg Leu Gly Thr Phe Pro Thr Pro Ser Pro Gly Ser Met Val Gln Asp Glu Val Ser Gly Gln Leu 230 Ile Leu Thr Asn Leu Ser Leu Thr Ser Ser Gly Thr Tyr Arg Cys Val 245 250 Ala Thr Asn Gln Met Gly Ser Ala Ser Cys Glu Leu Thr Leu Ser Val 260 265 Thr Glu Pro Ser Gln Gly Arg Val Ala Gly Ala Leu Ile Gly Val Leu 280 Leu Gly Val Leu Leu Ser Val Ala Ala Phe Cys Leu Val Arg Phe 295 Gln Lys Glu Arg Gly Lys Lys Pro Lys Glu Thr Tyr Gly Gly Ser Asp 310 315 Leu Arg Glu Asp Ala Ile Ala Pro Gly Ile Ser Glu His Thr Cys Met 325 330 Arg Ala Asp Ser Ser Lys Gly Phe Leu Glu Arg Pro Ser Ser Ala Ser Thr Val Thr Thr Lys Ser Lys Leu Pro Met Val Val

360

<210> 848

<211> 215

<212> PRT

<213> Homo sapiens

355

<400> 848

Leu Asp His Ile Val Asp Lys Val Lys Glu Cys Val Asp His Leu Ser
1 5 10 15

Arg Asp Glu Asp Glu Glu Lys Leu Val Ala Ser Leu Trp Gly Ala Glu
. 20 25 30

Arg Cys Leu Arg Val Leu Glu Ser Val Thr Val His Asn Pro Glu Asn 35 40 45

Gln Ser Tyr Leu Ile Ala Tyr Lys Asp Ser Gln Leu Ile Val Ser Ser 50 55 60

Ala Lys Ala Leu Gln His Cys Glu Glu Leu Ile Gln Gln Tyr Asn Arg
65 70 75 80

Ala Glu Asp Ser Ile Cys Leu Ala Asp Ser Lys Pro Leu Pro His Gln 85 90 95

Asn Val Thr Asn His Val Gly Lys Ala Val Glu Asp Cys Met Arg Ala 100 105 110

Ile Ile Gly Val Leu Leu Asn Leu Thr Asn Asp Asn Glu Trp Gly Ser 115 120 125

Thr Lys Thr Gly Glu Gln Asp Gly Leu Ile Gly Thr Ala Leu Asn Cys 130 135 140

Val Leu Gln Val Pro Lys Tyr Leu Pro Gln Glu Gln Arg Phe Asp Ile 145 150 155 160

Arg Val Leu Gly Leu Gly Leu Leu Ile Asn Leu Val Glu Tyr Ser Ala 165 170 175

Arg Asn Arg His Cys Leu Val Asn Met Glu Thr Ser Cys Ser Phe Asp 180 185 190

Ser Ser Ile Cys Ser Gly Glu Gly Asp Asp Ser Leu Arg Ile Gly Gly
195 200 205

Gln Val His Ala Val Gln Leu 210 215

<210> 849

<211> 368

<212> PRT

<213> Homo sapiens

<400> 849

Gly Lys Ala Glu Gly Val Cys Gly Leu Ser His Arg Gln Glu Cys Gln

	1				5				1	0				1	5
Ası	p Pro	o Al	a Gl;		a Le	u Gl	u Se	r Le		g Le	u Ala	a Le	u Ala		r Arq
Le	ı Le	a Pro		p Pho	e Le	u Lei	u Glu 40		g Ar	g Le	u Thi	r Lei		a Ası	o Ala
Le	1 Glu 50		s Cy	s Lei	ı Ly:	5 Lys		γ Ly:	s Gly	y Gli	ı Glu		n Ala	a Lei	ı Ala
Ala		a Vai	l Lei	ı Gly	7 Let 70		ı Cys	s Val	l Gli	n Lei 75		Pro	Gly	Pro	Lys 80
Gly	/ Glu	ı Glı	ı Let	1 Phe 85		s Ser	Leu	ı Glr	Pro 90		ı Lev	ı Val	Ser	Val 95	. Leu
Ser	Asp	Sei	Thr 100		Ser	Pro	Ala	Ala 105		j Lev	His	Cys	Ala 110		Ala
Leu	Gly	Leu 115		' Cys	Туг	· Val	. Ala 120		Ala	Asp	Ile	Gln 125		Leu	Val
Ser	Cys 130		Ala	Cys	Leu	Glu 135		Val	. Phe	e Ser	Arg 140		Tyr	Gly	Leu
Gly 145		Ser	Ser	Thr	Ser 150		Val	Val	Pro	Ala 155		Leu	His	Gly	Leu 160
Leu	Ser	Ala	Ala	Leu 165	Gln	Ala	Trp	Ala	Leu 170		Leu	Thr	Ile	Cys 175	Pro
Ser	Thr	Gln	Ile 180		His	Ile	Leu	Asp 185	Arg	Gln	Leu	Pro	Arg 190	Leu	Pro
Gln	Leu	Leu 195	Ser	Ser	Glu	Ser	Val 200	Asn	Leu	Arg	Ile	Ala 205	Ala	Gly	Glu
Thr	Ile 210	Ala	Leu	Leu	Phe	Glu 215	Leu	Ala	Arg	Asp	Leu 220	Glu	Glu	Glu	Phe
Val 225	Tyr	Glu	Asp	Met	Glu 230	Ala	Leu	Cys	Ser	Val 235	Leu	Arg	Thr	Leu	Ala 240
Thr	Asp	Ser	Asn	Lys 245	Tyr	Arg	Ala	Lys	Ala 250	Asp	Arg	Arg	Arg	Gln 255	Arg
Ser	Thr	Phe	Arg 260	Ala	Val	Leu	His	Ser 265	Val	Glu	Gly	Gly	Glu 270	Cys	Glu
Glu	Glu	110	Val	Ara	Dha	Gly	Pho	C1	17 - 1	T 0	m	Mot	N	C	m

275 280 285

Ala Arg His Arg Ile Tyr Ala Ala Phe Lys Glu Val Leu Gly Ser Gly 290 295 300

Met His His Leu Gln Asn Asn Glu Leu Leu Arg Asp Ile Phe Gly 305 310 315 320

Leu Gly Pro Val Leu Leu Leu Asp Ala Thr Ala Leu Lys Ala Cys Lys 325 330 335

Val Pro Arg Phe Glu Lys His Leu Tyr Asn Ala Ala Ala Phe Lys Ala 340 345 350

Arg Thr Lys Ala Arg Ser Arg Val Arg Asp Lys Arg Ala Asp Ile Leu 355 360 365

<210> 850 <211> 218 <212> PRT <213> Homo sapiens <220> <221> SITE <222> (96) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (105) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (180) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (190) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (194)

<223> Xaa equals any of the naturally occurring L-amino acids

<22	0>														
<221> SITE															
<222> (207)															
<22	3> X	aa e	qual	s an	y of	the	nat	ural	ly o	ccur	ring	L-a	mino	aci	ds
			-		•		•		•						
<400> 850															
Ala	Ser	Ala	Ser	Ile	Cys	Ser	Gly	Ile	Lys	Tyr	Ala	Phe	Gln	Val	Ile
1				5	-		-		10					15	
Gly	Glu	Leu	His	Ser	Gln	Leu	Asp	Gly	Ser	Glu	Val	Leu	Leu	Leu	Thr
-			20				•	25					30		
Asp	Gly	Glu	Asp	Asn	Thr	Ala	Ser	Ser	Cvs	Ile	Asp	Glu	Val	Lys	Gln
		35					40		-1 -			45			
Ser	Glv	Ala	Ile	Val	His	Phe	Ile	Ala	Leu	Glv	Ara	Ala	Ala	Asp	Glu
	50					55				1	60				
											• •				
Ala	Va 1	Tle	Glu	Met	Ser	T.vs	Ile	Thr	Glv	Glv	Ser	His	Phe	Tvr	Val
65			0.0		70	D, J	110	****	017	75				-1-	80
0.5					, 0					, ,					•
Ser	Aen	Glu	Δla	Gln	λen	Aen	Gly	T.011	Tla	Aen	Δla	Phe	Glv	Δla	Yaa
JCI	w	OIU	nια	85	ASII	A311	GLY	Deu	90	nop	71.2.0	1	01	95	nuu
				0.5					30					,,	
ጥኮሎ	Sar	G1v	Acn	Th.∽	N.c.n	Tan	Ser	V = =	Tue	Sar	Leu	Gln	T.011	Glu	Sor
1111	Ser	Gly	100	1111	vah	Dea	261	105	пåэ	261	Dea	GIII	110	Olu	361
			100					105					110		
T	C1	7 011	mb =	T 011	200	Co-	200	77-	m	Wot	700	700	mb-	Val	Tla
гÃа	Gry	115	THE	Leu	ASII	Set	Asn	Ala	тър	Met	ASII	125	1111	Val	116
		113					120					123			
T1.	>	C	m h	*** 1	G3	T		mh	Dho	Dho	T 011	т10	mh.∽	m~~	N a n
TTE		ser	Thr	vai	GIY		Asp	THE	Pne	Pne	140	116	THI	пр	ASII
	130					135					140				
C	•	D	n	~	-1-	C	T	m	×	D	C	~1··	mb	T10	14
	Leu	PIO	Pro	ser		ser	Leu	тгр	Asp		ser	GIY	Int	116	
145					150					155					160
a 3	•				•	- 1 -		a	-			m	T		- 1-
GIU	Asn	Pne	rnr		Asp	ATA	Thr	ser	_	met	Ala	туг	Leu		iie
				165					170					175	
.						-1					•	•			-
Pro	GLY	Thr		гåг	vaı	GIY	Thr		Ala	Tyr	Asn	Leu		ATA	гаг
			180					185					190		
		_			_			_,			_	_			
ALA	хаа		Glu	Thr	Leu	Thr	Ile	Thr	val	Thr	ser	-	Ala	xaa	гÀг
		195					200					205			

Phe Phe Cys Ala Ser Asn His Ser Glu Cys

215

210

<210> 851 <211> 303 <212> PRT <213> Homo sapiens <220> <221> SITE <222> (133) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (255) <223> Xaa equals any of the naturally occurring L-amino acids <400> 851 Gly Cys Leu Gly Gln Thr Arg Pro Ala Ser Pro Arg Thr Ala Arg Glu Ser Val Leu Gly Val Ser Gln Asn Met Ser Phe Asn Leu Gln Ser Ser 25 Lys Lys Leu Phe Ile Phe Leu Gly Lys Ser Leu Phe Ser Leu Glu 40 45 Ala Met Ile Phe Ala Leu Leu Pro Lys Pro Arg Lys Asn Val Ala Gly Glu Ile Val Leu Ile Thr Gly Ala Gly Ser Gly Leu Gly Arg Leu Leu 70 Ala Leu Gln Phe Ala Arg Leu Gly Ser Val Leu Val Leu Trp Asp Ile Asn Lys Glu Gly Asn Glu Glu Thr Cys Lys Met Ala Arg Glu Ala Gly 100 Ala Thr Arg Val His Ala Tyr Thr Cys Asp Cys Ser Gln Lys Glu Gly 115 120 Val Tyr Arg Val Xaa Asp Gln Val Lys Lys Glu Val Gly Asp Val Ser 135 Ile Leu Ile Asn Asn Ala Gly Ile Val Thr Gly Lys Lys Phe Leu Asp 150 145 155 160 Cys Pro Asp Glu Leu Met Glu Lys Ser Phe Asp Val Asn Phe Lys Ala His Leu Trp Thr Tyr Lys Ala Phe Leu Pro Ala Met Ile Ala Asn Asp

185

180

His Gly His Leu Val Cys Ile Ser Ser Ser Ala Gly Leu Ser Gly Val 195 200 205

Asn Gly Leu Ala Asp Tyr Cys Ala Ser Lys Phe Ala Ala Phe Gly Phe 210 215 220

Ala Glu Ser Val Phe Val Glu Thr Phe Val Gln Lys Gln Lys Gly Ile.
225 230 235 240

Lys Thr Thr Ile Val Cys Pro Phe Phe Ile Lys Thr Gly Met Xaa Glu 245 250 255

Gly Cys Thr Thr Gly Cys Pro Ser Leu Leu Pro Ile Leu Glu Pro Lys 260 265 270

Tyr Ala Val Glu Lys Ile Val Glu Ala Ile Leu Gln Glu Lys Met Tyr 275 280 285

Leu Tyr Met Pro Lys Leu Leu Tyr Phe Met Met Phe Leu Lys Arg 290 295 300

<210> 852

<211> 340

<212> PRT

<213> Homo sapiens

<400> 852

Arg Thr Val Ile Asp Ala Met Ser Ala Leu Leu Arg Leu Leu Arg Thr
1 5 10 15

Gly Ala Pro Ala Ala Ala Cys Leu Arg Leu Gly Thr Ser Ala Gly Thr 20 25 30

Gly Ser Arg Arg Ala Met Ala Leu Tyr His Thr Glu Glu Arg Gly Gln
35 40 45

Pro Cys Ser Gln Asn Tyr Arg Leu Phe Phe Lys Asn Val Thr Gly His
50 60

Tyr Ile Ser Pro Phe His Asp Ile Pro Leu Lys Val Asn Ser Lys Glu 65 70 75 80

Glu Asn Gly Ile Pro Met Lys Lys Ala Arg Asn Asp Glu Tyr Glu Asn 85 90 95

Leu Phe Asn Met Ile Val Glu Ile Pro Arg Trp Thr Asn Ala Lys Met 100 105 110

Glu Ile Ala Thr Lys Glu Pro Met Asn Pro Ile Lys Gln Tyr Val Lys 115 120 125

Asp Gly Lys Leu Arg Tyr Val Ala Asn Ile Phe Pro Tyr Lys Gly Tyr 130 135 140

Ile Trp Asn Tyr Gly Thr Leu Pro Gln Thr Trp Glu Asp Pro His Glu
145 150 155 160

Lys Asp Lys Ser Thr Asn Cys Phe Gly Asp Asn Asp Pro Ile Asp Val 165 170 175

Cys Glu Ile Gly Ser Lys Ile Leu Ser Cys Gly Glu Val Ile His Val
180 185 190

Lys Ile Leu Gly Ile Leu Ala Leu Ile Asp Glu Gly Glu Thr Asp Trp
195 200 205

Lys Leu Ile Ala Ile Asn Ala Asn Asp Pro Glu Ala Ser Lys Phe His 210 215 220

Asp Ile Asp Asp Val Lys Lys Phe Lys Pro Gly Tyr Leu Glu Ala Thr 225 230 235 240

Leu Asn Trp Phe Arg Leu Tyr Lys Val Pro Asp Gly Lys Pro Glu Asn
245 250 255

Gln Phe Ala Phe Asn Gly Glu Phe Lys Asn Lys Ala Phe Ala Leu Glu 260 265 270

Val Ile Lys Ser Thr His Gln Cys Trp Lys Ala Leu Leu Met Lys Lys 275 280 285

Cys Asn Gly Gly Ala Ile Asn Cys Thr Asn Val Gln Ile Ser Asp Ser 290 295 300

Pro Phe Arg Cys Thr Gln Glu Glu Ala Arg Ser Leu Val Glu Ser Val 305 310 315 320

Ser Ser Ser Pro Asn Lys Glu Ser Asn Glu Glu Glu Gln Val Trp His 325 330 335

Phe Leu Gly Lys

<210> 853

<211> 317

<212> PRT

<213> Homo sapiens

<220> <221> SITE <222> (165) <223> Xaa equals any of the naturally occurring L-amino acids <400> 853 Ala Asp Leu Ile Ser Leu Pro Thr Thr Val Glu Gly Leu Gln Lys Ser Val Ala Ser Ile Gly Asn Thr Leu Asn Ser Val His Leu Ala Val Glu 25 Ala Leu Gln Lys Thr Val Asp Glu His Lys Lys Thr Met Glu Leu Leu 40 Gln Ser Asp Met Asn Gln His Phe Leu Lys Glu Thr Pro Gly Ser Asn Gln Ile Ile Pro Ser Pro Ser Ala Thr Ser Glu Leu Asp Asn Lys Thr 70 75 His Ser Glu Asn Leu Lys Gln Asp Ile Leu Tyr Leu His Asn Ser Leu 85 90 Glu Glu Val Asn Ser Ala Leu Val Gly Tyr Gln Arg Gln Asn Asp Leu 105 Lys Leu Glu Gly Met Asn Glu Thr Val Ser Asn Leu Thr Gln Arg Val Asn Leu Ile Glu Ser Asp Val Val Ala Met Ser Lys Val Glu Lys Lys 130 135 Ala Asn Leu Ser Phe Ser Met Met Gly Asp Arg Ser Ala Thr Leu Lys 145 150 155 Arg Gln Ser Leu Xaa Gln Val Thr Asn Arg Thr Asp Thr Val Lys Ile 165 170 Gln Ser Ile Lys Lys Glu Asp Ser Ser Asn Ser Gln Val Ser Lys Leu 185 Arg Glu Lys Leu Gln Leu Ile Ser Ala Leu Thr Asn Lys Pro Glu Ser 195 200 205 Asn Arg Pro Pro Glu Thr Ala Asp Glu Glu Gln Val Glu Ser Phe Thr 210

Ser Lys Pro Ser Ala Leu Pro Lys Phe Ser Gln Phe Leu Gly Asp Pro

235

230

225

Val Glu Lys Ala Ala Gln Leu Arg Pro Ile Ser Leu Pro Gly Val Ser
245 250 255

Ser Thr Glu Asp Leu Gln Asp Leu Phe Arg Lys Thr Gly Gln Asp Val 260 265 270

Asp Gly Lys Leu Thr Tyr Gln Glu Ile Trp Thr Ser Leu Gly Ser Ala 275 280 285

Met Pro Glu Pro Glu Ser Leu Arg Ala Phe Asp Ser Asp Gly Asp Gly 290 295 300

Arg Tyr Ser Phe Leu Glu Leu Arg Val Ala Leu Gly Ile 305 310 315

<210> 854

<211> 34

<212> PRT

<213> Homo sapiens

<400> 854

Leu Leu Phe Asn Phe Lys Gln Val Phe Phe Ala Ser Val Arg Ser Gly
1 5 10 15

Gly Ser Ser Gln Val Phe Phe Met Thr Leu Asn Arg Asn Ser Met Met 20 25 30

Asn Trp

<210> 855

<211> 232

<212> PRT

<213> Homo sapiens

<400> 855

Leu Pro Val Pro Gly Arg Gly Arg Val Phe Phe Glu Asp Leu Gly Leu
1 5 10 15

Arg Asp Thr Val Arg Met Ala Val Pro Leu Leu Leu Gly Gly 20 25 30

Leu Trp Ser Ala Val Gly Ala Ser Ser Leu Gly Val Val Thr Cys Gly
35 40 45

Ser Val Val Lys Leu Leu Asn Thr Arg His Asn Val Arg Leu His Ser

50 55 60

His Asp Val Arg Tyr Gly Ser Gly Ser Gly Gln Gln Ser Val Thr Gly 65 70 75 80

Val Thr Ser Val Asp Asp Ser Asn Ser Tyr Trp Arg Ile Arg Gly Lys 85 90 95

Ser Ala Thr Val Cys Glu Arg Gly Thr Pro Ile Lys Cys Gly Gln Pro 100 105 110

Ile Arg Leu Thr His Val Asn Thr Gly Arg Asn Leu His Ser His His 115 120 125

Phe Thr Ser Pro Leu Ser Gly Asn Gln Glu Val Ser Ala Phe Gly Glu 130 135 140

Glu Gly Glu Gly Asp Tyr Leu Asp Asp Trp Thr Val Leu Cys Asn Gly 145 150 155 160

Pro Tyr Trp Val Arg Asp Gly Glu Val Arg Phe Lys His Ser Ser Thr
165 170 175

Glu Val Leu Ser Val Thr Gly Glu Gln Tyr Gly Arg Pro Ile Ser 180 185 190

Gly Gln Lys Glu Val His Gly Met Ala Gln Pro Ser Gln Asn Asn Tyr 195 200 205

Trp Lys Ala Met Glu Gly Ile Phe Met Lys Pro Ser Glu Leu Leu Lys 210 220 .

Ala Glu Ala His His Ala Glu Leu 225 230

<210> 856

<211> 147

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (41)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 856

Cys Phe Ser Ser Ser Gly Phe Thr Cys His Asp His Gly Ala Thr Val 1 5 10 15 Leu Gln Tyr Ala Pro Lys Gln Gln Leu Leu Ile Ser Gly Gly Arg Lys
20 25 30

Arg His Val Cys Ile Phe Asp Ile Xaa Gln Arg Gln Leu Ile His Thr 35 40 45

Phe Gln Ala His Asp Ser Ala Ile Lys Ala Leu Ala Leu Asp Pro Tyr
50 55 60

Glu Glu Tyr Phe Thr Thr Gly Ser Ala Glu Gly Asn Ile Lys Val Trp
65 70 75 80

Arg Leu Thr Gly His Gly Leu Ile His Ser Phe Lys Ser Glu His Ala 85 90 95

Lys Gln Ser Ile Phe Arg Asn Ile Gly Ala Gly Val Met Gln Ile Asp 100 105 110

Ile Ile Gln Gly Asn Arg Leu Phe Ser Cys Gly Ala Asp Gly Thr Leu 115 120 125

Lys Thr Arg Val Leu Pro Asn Ala Phe Asn Ile Pro Asn Arg Ile Leu 130 135 140

Asp Ile Leu 145

<210> 857

<211> 96

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (59)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (61)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (63)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 857

Pro Arg Val Arg Ile Asn Lys Glu Ser Glu Val Tyr Lys Met Leu Gln

1 5 10 15

Glu Lys Gln Glu Leu Asn Glu Pro Leu Lys Gln Ser Thr Ser Phe Leu 20 25 30

Ile Leu Gln Glu Ile Leu Glu Ser Glu Ile Lys Gly Asp Leu Asn Asn 35 40 45

Pro Gln Asp Ser Glu Val Leu Lys Leu Leu Xaa Pro Xaa Val Xaa Ala 50 55 60

Ser Ile Gly Asn Ala Gln Lys Val Pro Met Cys Asp Lys Cys Gly Pro 65 70 75 80

Gly Ile Val Gly Met Phe Val Lys Leu Arg Gly Pro Ser Ser Pro Pro 85 90 95

<210> 858

<211> 45

<212> PRT

<213> Homo sapiens

<400> 858

Asp Thr Ser Glu Ala Ile Leu Thr Ser Glu Tyr Pro Ser Ser Ser Leu 1 5 10 15

Lys Thr Glu Thr Ser His Leu Glu Asn Val Asn Leu Cys Cys His Leu 20 25 30

Val Ala Gly Val Ser Arg His Lys Thr Glu Phe Lys Lys 35 40 45

<210> 859

<211> 758

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (590)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 859

Lys Met Ser Glu Asn Ser Ser Asp Ser Asp Ser Ser Cys Gly Trp Thr

1				5					10					15	
Val	Ile	Ser	His 20		Gly	Ser	Asp	Ile 25		Met	Leu	Asn	Ser 30	Val	Thr
Pro	Thr	Asp 35		Cys	Glu	Pro	Ala 40	Pro	Glu	Cys	Ser	Ser 45	Leu	Glu	Gln
Glu	Glu 50	Leu	Gln	Ala	Leu	Gln 55	Ile	Glu	Gln	Gly	Glu 60	Ser	Ser	Gln	Asn
Gly 65	Thr	Val	Leu	Met	Glu 70	Glu	Thr	Ala	Tyr	Pro 75	Ala	Leu	Glu	Glu	Thr 80
Ser	Ser	Thr	Ile	Glu 85	Ala	Glu	Glu	Gln	Lys 90	Ile	Pro	Glu	Asp	Ser 95	Ile
Tyr	Ile	Gly	Thr 100	Ala	Ser	Asp	Asp	Ser 105	Asp	Ile	Val	Thr	Leu 110	Glu	Pro
Pro	Lys	Leu 115	Glu	Glu	Ile	Gly	Asn 120	Gln	Glu	Val	Val	Ile 125	Val	Glu	Glu
Ala	Gln 130	Ser	Ser	Glu	Asp	Phe 135	Asn	Met	Gly	Ser	Ser 140	ser	Ser	Ser	Gln
Tyr 145	Thr	Phe	Cys	Gln	Pro 150	Glu	Thr	Val	Phe	Ser 155	Ser	Gln	Pro	Ser	Asp 160
Asp	Glu	Ser	Ser	Ser 165	Asp	Glu	Thr	Ser	Asn 170	Gln	Pro	ser	Pro	Ala 175	Phe
Arg	Arg	Arg	Arg 180	Ala	Arg	Lys	Lys	Thr 185	Val	Ser	Ala	Ser	Glu 190	Ser	Glu
Asp	Arg	Leu 195	Val	Ala	Glu	Gln	Glu 200	Thr	Glu	Pro	Ser	Lys 205	Glu	Leu	Ser
Lys	Arg 210	Gln	Phe	Ser	Ser	Gly 215	Leu	Asn	Lys	Cys	Val 220	Ile	Leu	Ala	Leu
Val 225	Ile	Ala	Ile	Ser	Met 230	Gly	Phe	Gly	His	Phe 235	Tyr	Gly	Thr	Ile	Gln 240
Ile	Gln	Lys	Arg	Gln 245	Gln	Leu	Val	Arg	Lys 250	Ile	His	Glu	Asp	Glu 255	Leu
Asn	Asp	Met	Lys 260	Asp	туr	Leu	Ser	Gln 265	Cys	Gln	Gln	Glu	Gln 270	Glu	Ser
Phe	Ile	Asp	Tyr	Lys	Ser	Leu	Lys	Glu	Asn	Leu	Ala	Arg	Cys	Trp	Thr

275 280 285

Leu Thr Glu Ala Glu Lys Met Ser Phe Glu Thr Gln Lys Thr Asn Leu 290 295 300

Ala Thr Glu Asn Gln Tyr Leu Arg Val Ser Leu Glu Lys Glu Glu Lys 305 310 315 320

Ala Leu Ser Ser Leu Gln Glu Glu Leu Asn Lys Leu Arg Glu Gln Ile 325 330 335

Arg Ile Leu Glu Asp Lys Gly Thr Ser Thr Glu Leu Val Lys Glu Asn 340 345 350

Gln Lys Leu Lys Gln His Leu Glu Glu Glu Lys Gln Lys Lys His Ser 355 360 365

Phe Leu Ser Gln Arg Glu Thr Leu Leu Thr Glu Ala Lys Met Leu Lys 370 375 380

Arg Glu Leu Glu Arg Glu Arg Leu Val Thr Thr Ala Leu Arg Gly Glu 385 390 395 400

Leu Gln Gln Leu Ser Gly Ser Gln Leu His Gly Lys Ser Asp Ser Pro 405 410 415

Asn Val Tyr Thr Glu Lys Lys Glu Ile Ala Ile Leu Arg Glu Arg Leu 420 425 430

Thr Glu Leu Glu Arg Lys Leu Thr Phe Glu Gln Gln Arg Ser Asp Leu 435 440 445

Trp Glu Arg Leu Tyr Val Glu Ala Lys Asp Gln Asn Gly Lys Gln Gly 450 460

Thr Asp Gly Lys Lys Gly Gly Arg Gly Ser His Arg Ala Lys Asn 465 470 475 480

Lys Ser Lys Glu Thr Phe Leu Gly Ser Val Lys Glu Thr Phe Asp Ala 485 490 495

Met Lys Asn Ser Thr Lys Glu Phe Val Arg His His Lys Glu Lys Ile 500 505 510

Lys Gln Ala Lys Glu Ala Val Lys Glu Asn Leu Lys Lys Phe Ser Asp 515 520 525

Ser Val Lys Ser Thr Phe Arg His Phe Lys Asp Thr Thr Lys Asn Ile 530 535 540

Phe Asp Glu Lys Gly Asn Lys Arg Phe Gly Ala Thr Lys Glu Ala Ala

555

560

Glu Lys Pro Arg Thr Val Phe Ser Asp Tyr Leu His Pro Gln Tyr Lys 565 570 Ala Pro Thr Glu Asn His His Asn Arg Gly Pro Thr Met Xaa Asn Asp 585 Gly Arg Lys Glu Lys Pro Val His Phe Lys Glu Phe Arg Lys Asn Thr 595 600 Asn Ser Lys Lys Cys Ser Pro Gly His Asp Cys Arg Glu Asn Ser His 615 Ser Phe Arg Lys Ala Cys Ser Gly Val Phe Asp Cys Ala Gln Glu Ser Met Ser Leu Phe Asn Thr Val Val Asn Pro Ile Arg Met Asp Glu 645 650 Phe Arg Gln Ile Ile Gln Arg Tyr Met Leu Lys Glu Leu Asp Thr Phe 660 665 Cys His Trp Asn Glu Leu Asp Gln Phe Ile Asn Lys Phe Phe Leu Asn 680 Gly Val Phe Ile His Asp Gln Lys Leu Phe Thr Asp Phe Val Asn Asp 695

550

Gly Val Phe Glu Lys Leu Asp Glu Tyr Ile Tyr Arg His Phe Phe Gly 730

Val Lys Asp Tyr Leu Arg Asn Met Lys Glu Tyr Glu Val Asp Asn Asp

715

710

725

His Thr Phe Ser Pro Pro Tyr Gly Pro Arg Ser Val Tyr Ile Lys Pro 740 745

Cys His Tyr Ser Ser Leu 755

<210> 860

<211> 184

<212> PRT

<213> Homo sapiens

<220>

705

545

<221> SITE

<222> (174)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 860

Ala Gly Val His Thr Ile Ser Phe Leu Gly Gly Leu Ala Leu Asn Glu
1 5 10 15

Gly Val Asn Trp Leu Ile Lys Asn Val Ile Gln Glu Pro Arg Pro Cys 20 25 30

Gly Gly Pro His Thr Ala Val Gly Thr Lys Tyr Gly Met Pro Ser Ser 35 40 45

His Ser Gln Phe Met Trp Phe Phe Ser Val Tyr Ser Phe Leu Phe Leu 50 55 60

Tyr Leu Arg Met His Gln Thr Asn Asn Ala Arg Phe Leu Asp Leu Leu 65 70 75 80

Trp Arg His Val Leu Ser Leu Gly Leu Leu Ala Val Ala Phe Leu Val 85 90 95

Ser Tyr Ser Arg Val Tyr Leu Leu Tyr His Thr Trp Ser Gln Val Leu 100 105 110

Tyr Gly Gly Ile Ala Gly Gly Leu Met Ala Ile Ala Trp Phe Ile Phe 115 120 125

Thr Gln Glu Val Leu Thr Pro Leu Phe Pro Arg Ile Ala Ala Trp Pro 130 135 140

Val Ser Glu Phe Phe Leu Ile Arg Asp Thr Ser Leu Ile Pro Asn Val 145 150 155 160

Leu Trp Phe Glu Tyr Thr Val Thr Arg Ala Glu Ala Arg Xaa Arg Gln 165 170 175

Arg Lys Leu Gly Thr Lys Leu Gln 180

<210> 861

<211> 360

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (53)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (360)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 861

Leu Pro Gln Ala Gln Gly Asp Gln Phe Pro Trp Glu Gln Ala Glu Gly
1 5 10 15

Gln Ala Pro Gly Glu Asp Gly Gln Arg Leu Pro Asp Gln Ile His Pro 20 25 30

Gly Val Pro Ala Arg Arg Pro Trp Trp Arg Glu Arg Ala Arg Ala
35 40 45

Val Arg Gly Leu Xaa Glu Gly Arg Glu Pro Glu Lys Arg Arg Glu Arg
50 55 60

Lys Gln Arg Arg Glu Gly Gly Asp Gly Glu Glu Gln Asp Val Gly Asp
65 70 75 80

Ala Gly Arg Leu Leu Leu Arg Val Leu His Val Ser Glu Asn Pro Val 85 90 95

Pro Leu Thr Val Arg Val Ser Pro Glu Val Arg Asp Val Arg Pro Tyr 100 105 110

Ile Val Gly Ala Val Val Arg Gly Met Asp Leu Gln Pro Gly Asn Ala 115 120 125

Leu Lys Arg Phe Leu Thr Ser Gln Thr Lys Leu His Glu Asp Leu Cys 130 135 140

Glu Lys Arg Thr Ala Ala Thr Leu Ala Thr His Glu Leu Arg Ala Val 145 150 155 160

Lys Gly Pro Leu Leu Tyr Cys Ala Arg Pro Pro Gln Asp Leu Lys Ile 165 170 175

Val Pro Leu Gly Arg Lys Glu Ala Lys Ala Lys Glu Leu Val Arg Gln 180 185 190

Leu Gln Leu Glu Ala Glu Glu Gln Arg Lys Gln Lys Lys Arg Gln Ser 195 200 205

Val Ser Gly Leu His Arg Tyr Leu His Leu Leu Asp Gly Asn Glu Asn 210 215 220

Tyr Pro Cys Leu Val Asp Ala Asp Gly Asp Val Ile Ser Phe Pro Pro 225 230 235 240

Ile Thr Asn Ser Glu Lys Thr Lys Val Lys Lys Thr Thr Ser Asp Leu 245 250 255

Phe Leu Glu Val Thr Ser Ala Thr Ser Leu Gln Ile Cys Lys Asp Val 260 265 270

Met Asp Ala Leu Ile Leu Lys Met Ala Glu Met Lys Lys Tyr Thr Leu 275 280 285

Glu Asn Lys Glu Glu Gly Ser Leu Ser Asp Thr Glu Ala Asp Ala Val 290 295 300

Ser Gly Gln Leu Pro Asp Pro Thr Thr Asn Pro Ser Ala Gly Lys Asp 305 310 315 320

Gly Pro Ser Leu Leu Val Val Glu Gln Val Arg Val Val Asp Leu Glu 325 330 335

Gly Ser Leu Lys Val Val Tyr Pro Ser Lys Ala Asp Leu Ala Thr Ala 340 345 350

Pro Pro His Val Thr Val Val Xaa 355 360

<210> 862

<211> 518

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (476)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 862

Gln Tyr Arg Ser Glu Phe Pro Gly Arg Pro Thr Arg Pro Ala Val Thr
1 5 10 15

Ala Thr Ala Ala Ser Asp Arg Met Glu Ser Asp Ser Asp Ser Asp Lys
20 25 30

Ser Ser Asp Asn Ser Gly Leu Lys Arg Lys Thr Pro Ala Leu Lys Met 35 40 45

Ser Val Ser Lys Arg Ala Arg Lys Ala Ser Ser Asp Leu Asp Gln Ala 50 55 60

Ser Val Ser Pro Ser Glu Glu Glu Asn Ser Glu Ser Ser Ser Glu Ser 65 70 75 80

Glu	Lys	Thi	r Sei	Asp 85		AS _I	o Ph∈	Thi	Pro 90		ı Lys	5 Lys	s Ala	Ala 95	
Arg	Ala	Pro	100		g Gly	Pro	o Leu	Gly 105	-	y Arg	J Lys	. Lys	110		s Ala
Pro	Ser	Ala 115		Asp) Ser	Asp) Ser 120	_	a Ala	a Asp	Ser	125	Gly	Ala	Lys
Pro	Glu 130		Val	. Ala	Met	135	-	Ser	Ala	Ser	Ser 140		Ser	Ser	Ser
Ser 145		Ser	Ser	Asp	Ser 150	_	Val	Ser	Val	Lys 155	_	Pro	Pro	Arg	Gly 160
Arg	Lys	Pro	Ala	Glu 165		Pro	Leu	Pro	Lys 170		Arg	Gly	Arg	Lys 175	
Lys	Pro	Glu	180		Pro	Ser	Ser	Ser 185		Ser	Asp	Ser	Asp 190	Ser	Asp
Glu	Val	Asp 195	_	Ile	Ser	Glu	Trp 200	Lys	Arg	Arg	Asp	Glu 205	Ala	Arg	Arg
Arg	Glu 210	Leu	Glu	Ala	Arg	Arg 215	-	Arg	Glu	Gln	Glu 220		Glu	Leu	Arg
Arg 225	Leu	Arg	Glu	Gln	Glu 230	Lys	Glu	Glu	Lys	Glu 235	Arg	Arg	Arg	Glu	Arg 240
Ala	Asp	Arg	Gly	Glu 245	Ala	Glu	Arg	Gly	Ser 250	Gly	Gly	Ser	Ser	Gly 255	Asp
Glu	Leu	Arg	Glu 260	Asp	Asp	Glu	Pro	Val 265	Lys	Lys	Arg	Gly	Arg 270	Lys	Gly
Arg	Gly	Arg 275	Gly	Pro	Pro	Ser	Ser 280	Ser	Asp	Ser	Glu	Pro 285	Glu	Ala	Glu
Leu	Glu 290	Arg	Glu	Ala	Lys	Lys 295	Ser	Ala	Lys	Lys	Pro 300	Gln	Ser	Ser	Ser
Thr 305	Glu	Pro	Ala	Arg	Lys 310	Pro	Gly	Gln	Lys	Glu 315	Lys	Arg	Val	Arg	Pro 320
Glu	Glu	Lys	Gln	Gln 325	Ala	Lys	Pro	Val	Lys 330	Va1	Glu	Arg	Thr	Arg 335	Lys
Arg	Ser	Glu	Gly 340	Phe	Ser	Met	Asp	Arg 345	Lys	Val	Glu	Lys	Lys 350	Lys	Glu

Pro Ser Val Glu Glu Lys Leu Gln Lys Leu His Ser Glu Ile Lys Phe 355 360 365

Ala Leu Lys Val Asp Ser Pro Asp Val Lys Arg Cys Leu Asn Ala Leu 370 375 380

Glu Glu Leu Gly Thr Leu Gln Val Thr Ser Gln Ile Leu Gln Lys Asn 385 390 395 400

Thr Asp Val Val Ala Thr Leu Lys Lys Ile Arg Arg Tyr Lys Ala Asn 405 410 415

Lys Asp Val Met Glu Lys Ala Ala Glu Val Tyr Thr Arg Leu Lys Ser 420 425 430

Arg Val Leu Gly Pro Lys Ile Glu Ala Val Gln Lys Val Asn Lys Ala 435 440 445

Gly Met Glu Lys Glu Lys Ala Glu Glu Lys Leu Ala Gly Glu Glu Leu 450 455 460

Ala Gly Glu Glu Ala Pro Gln Glu Lys Gly Gly Xaa Gln Ala Gln His 465 470 475 480

Arg Ser Leu Ser Pro Ser Glu Trp Arg Gly His Ile Thr Glu Gly Gly
485 490 495

Glu Arg Arg Gly Gln Gly Ala Arg Gly Gly Ser Gly Leu Gly Gly Gly 500 505 510

Ala Lys Val Trp Leu Leu 515

<210> 863

<211> 438

<212> PRT

<213> Homo sapiens

<400> 863

Val Lys Gly Gln Gly Arg Gly Ser Arg Gly Ala Thr His Ala Leu Glu

1 5 10 15

Ile Trp Val Ile Ala Ser Gly Arg Ser Ala Ser Pro Thr Pro Gln Thr
20 25 30

Arg Ala Ala Asp Asp Pro Ala Ala Ala Met Ala Leu Leu Arg Gly Val 35 40 45

Phe	• Val		l Ala	A Ala	a Lys	Arq 55		r Pro	Phe	e Gly	Ala 60		Gly	Gly	Leu
Leu 65	-	Asp	Phe	Thr	70		: Asp	Leu	ı Ser	75		Ala	Ala	Lys	Ala 80
Ala	Leu	Ser	Ala	Gly 85	-	Va]	. Ser	Pro	90		· Val	. Asp	Ser	Val 95	
Met	Gly	Asn	Val 100		. Gln	Ser	Ser	Ser 105	_	Ala	Ile	Tyr	Leu 110		Arg
His	Val	Gly 115		Arg	Val	Gly	11e	Pro	Lys	Glu	Thr	Pro 125		Leu	Thr
Ile	Asn 130	-	Leu	Cys	Gly	Ser 135	_	Phe	Gln	ser	11e		Asn	Gly	Cys
Gln 145	Glu	Ile	Cys	Val	Lys 150		Ala	Glu	Val	Val 155		Cys	Gly	Gly	Thr 160
Glu	Ser	Met	Ser	Gln 165		Pro	Tyr	Суѕ	Val 170	_	Asn	Val	Arg	Phe 175	Gly
Thr	Lys	Leu	Gly 180	Ser	Asp	Ile	Lys	Leu 185	Glu	Asp	Ser	Leu	Trp 190	Val	Ser
Leu	Thr	Asp 195	Gln	His	Val	Gln	Leu 200	Pro	Met	Ala	Met	Thr 205	Ala	Glu	Asn
	210				_	215		Arg			220			_	
Leu 225	Gln	Ser	Gln	Gln	Arg 230	Trp	Lys	Ala	Ala	Asn 235	Asp	Ala	Gly	Tyr	Phe 240
				245				Val	250		-		-	255	
			260					Arg 265					270		
		275					280	Lys		_		285			
	290					295		Gly		F	300				
Ser 305	Glu	Asp	Ala	Val	Lys 310	Lys	His	Asn	Phe	Thr	Pro	Leu	Ala	Arg	11e 320

Val Gly Tyr Phe Val Ser Gly Cys Asp Pro Ser Ile Met Gly Ile Gly 330 Pro Val Pro Ala Ile Ser Gly Ala Leu Lys Lys Ala Gly Leu Ser Leu 340 345 Lys Asp Met Asp Leu Val Glu Val Asn Glu Ala Phe Ala Pro Gln Tyr 355 360 Leu Ala Val Glu Arg Ser Leu Asp Leu Asp Ile Ser Lys Thr Asn Val 375 Asn Gly Gly Ala Ile Ala Leu Gly His Pro Leu Gly Gly Ser Gly Ser Arg Ile Thr Ala His Leu Val His Glu Leu Arg Arg Arg Gly Gly Lys 410 405 Tyr Ala Val Gly Ser Ala Cys Ile Gly Gly Gln Gly Ile Ala Val 420 425 Ile Ile Gln Ser Thr Ala 435 <210> 864 <211> 214 <212> PRT <213> Homo sapiens <220> <221> SITE <222> (138) <223> Xaa equals any of the naturally occurring L-amino acids <400> 864 Thr Leu Phe Asp Phe Ile Ser Leu Tyr Leu Ser Thr Asn Thr Lys Lys 10 Val Ile Tyr Leu Asp Asp Val Ile Val Gln Gly Asp Ile Gln Glu 25 Leu Tyr Asp Thr Thr Leu Ala Leu Gly His Ala Ala Ala Phe Ser Asp 35 40 45 Asp Cys Asp Leu Pro Ser Ala Gln Asp Ile Asn Arg Leu Val Gly Leu 50 55

Gln Asn Thr Tyr Met Gly Tyr Leu Asp Tyr Arg Lys Lys Ala Ile Lys

75

70

Asp Leu Gly Ile Ser Pro Ser Thr Cys Ser Phe Asn Pro Gly Val Ile 85 90 Val Ala Asn Met Thr Glu Trp Lys His Gln Arg Ile Thr Lys Gln Leu 100 105 Glu Lys Trp Met Gln Lys Asn Val Glu Glu Asn Leu Tyr Ser Ser Ser 120 Leu Gly Gly Val Ala Thr Ser Pro Xaa Leu Ile Val Phe His Gly 130 135 Lys Tyr Ser Thr Ile Asn Pro Leu Trp His Ile Arg His Leu Gly Trp 145 150 155 Asn Pro Asp Ala Arg Tyr Ser Glu His Phe Leu Gln Glu Ala Lys Leu 165 170 Leu His Trp Asn Gly Arg His Lys Pro Trp Asp Phe Pro Ser Val His 185 Asn Asp Leu Trp Glu Ser Trp Phe Val Pro Asp Pro Ala Gly Ile Phe 195 200 205 Lys Leu Asn His His Ser 210 <210> 865 <211> 165 <212> PRT <213> Homo sapiens <220> <221> SITE <222> (134) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (139) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (140) <223> Xaa equals any of the naturally occurring L-amino acids <220>

WO 00/55351 949 PCT/US00/05883

<221> SITE <222> (142) <223> Xaa equals any of the naturally occurring L-amino acids <400> 865 Gly Ser Thr His Ala Ser Asp His Ile Pro Pro Leu Lys Lys Pro Leu 5 Gly Ala Gln Leu Ile Thr Met Asp Trp Thr Trp Arg Phe Leu Phe Val 20 Val Ala Ala Ala Thr Gly Val Gln Ser Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys 55 Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln 65 70 Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr 105 Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg 115 120 Ser Glu Asp Thr Ala Xaa Tyr Tyr Cys Ala Xaa Xaa Pro Xaa Ala Gly 130 135 Tyr Leu Ser Gln Leu Leu Pro Arg Tyr Gly Arg Leu Gly Pro Arg Asp 155

His Gly His Arg Leu 165

<210> 866

<211> 87

<212> PRT

<213> Homo sapiens

<400> 866

Lys Gln His Tyr Ile Ala Val Leu Tyr Tyr Ser Val Tyr Asp Val Cys
1 5 10 15

Glu Asn Ala Arg Phe Lys Met Met Tyr Leu Phe Leu Val Lys Asn Lys
20 25 30

Lys Phe Tyr Ala Ile Leu Leu Ile Lys Cys Lys Cys Asp Leu Val Gln 35 40 45

Phe Thr Lys Ile Thr Asp Ile Phe His Tyr Ile Glu Thr Val Thr Val 50 55 60

Arg Ile Gly His Lys His Gln Leu Leu Pro Ala Ser Gly Lys Leu Leu 65 70 75 80

Asn Arg Thr Ala Val Met Ser 85

<210> 867

<211> 101

<212> PRT

<213> Homo sapiens

<400> 867

Phe Phe Gln Lys Ile Met Leu Ser Phe His Glu Glu Glu Glu Val Leu 1 5 10 15

Pro Glu Thr Phe Leu Ala Asn Phe Pro Ser Leu Ile Lys Met Asp Ile 20 25 30

His Lys Lys Val Thr Asp Pro Ser Val Ala Lys Ser Met Met Ala Cys 35 40 45

Leu Leu Ser Ser Leu Lys Ala Asn Gly Ser Arg Gly Ala Phe Cys Glu
50 55 60

Val Arg Pro Asp Asp Lys Arg Ile Leu Glu Phe Tyr Ser Lys Leu Gly
65 70 75 80

Cys Phe Glu Ile Ala Lys Met Glu Gly Phe Pro Lys Asp Val Val Ile 85 90 95

Leu Gly Arg Ser Leu 100

<210> 868

<211> 82

<212> PRT

<213> Homo sapiens

<400> 868

Leu Leu Pro Gly Ser Ala Leu Pro Gly Ala Cys Pro Arg Arg Trp Tyr

WO 00/55351 951 PCT/US00/05883

```
1
                  5
                                                          15
                                      10
Gly Ser Tyr Leu Val Trp Lys Glu Leu Gly Gly Phe Thr Glu Lys Ala
                                  25
Val Val Pro Leu Gly Leu Tyr Thr Gly Gln Leu Ala Leu Asn Trp Ala
                              40
Trp Pro Pro Ile Phe Phe Gly Ala Arg Gln Met Gly Trp Ala Leu Val
                         55
Asp Leu Leu Val Ser Gly Ala Ala Ala Leu Pro Trp Pro Gly
                     70
                                          75
Thr Arg
<210> 869
<211> 562
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (18)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (23)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 869
Leu Lys Pro Glu Pro Asp Asp Leu Ile Asp Glu Asp Leu Asn Phe Val
Gln Xaa Asn Pro Leu Ser Xaa Lys Lys Pro Thr Val Thr Leu Thr Tyr
             20
                                 25
Gly Ser Ser Arg Pro Ser Ile Glu Ile Tyr Arg Pro Pro Ala Ser Arg
         35
                             40
Asn Ala Asp Ser Gly Val His Leu Asn Arg Leu Gln Phe Gln Gln
                         55
Gln Asn Ser Ile His Ala Ala Lys Gln Leu Asp Met Gln Ser Ser Trp
                    70
                                         75
Val Tyr Glu Thr Gly Arg Leu Cys Glu Pro Glu Val Leu Asn Ser Leu
```

				85					90					95	
Gl	u Gli	ı Thi	100		Pro	Phe	Phe	105		Asn	Ser	Glu	Lys 110		Ser
Me	t Gl	ASE 115		. Asn	Phe	Arg	Lys 120	_	Lys	Leu	Pro	Val 125		Ser	Ser
Va	1 Va:		s Val	. Lys	Lys	Phe 135		His	Asp	Gly	Glu 140	Glu	Glu	Glu	Glu
As 14	p Asi	Asp	Tyr	Gly	Ser 150		Thr	Gly	Ser	Ile 155		Ser	Ser	Val	Ser 160
	l Pro		-	165		_			170					175	
	a Ası		180					185					190		
۷a	l Thi	195		Thr	Asn	Tyr	Ser 200	Thr	Val	Pro	Gln	Lys 205	Gln	Thr	Leu
	0 Val)				215					220				
22			_		230					235					240
G1	u Glu	ı Glu	Thr	Lys 245	Gly	Asp	Ser	Val	Glu 250	Lys	Asn	Gln	Gly	Thr 255	Gln
	n Arg		260			-		265					270		
	r Leu	275				-	280	-				285			
	290		-			295		_			300				
30					310					315	-			_	320
	1 Arg			325	•				330		-	-		335	
	Asp		340					345					350		
Pro) Ser	Pro	Pro	Gly	Tyr	Met	Ser	Asp	Gln	Glu	Glu	Asp	Met	Cys	Phe

WO 00/55351 953 PCT/US00/05883

355 360 365 Glu Gly Met Lys Pro Val Asn Gln Thr Ala Ala Ser Asn Lys Gly Leu 380 375 Arg Gly Leu Leu His Pro Gln Gln Leu His Leu Leu Ser Arg Gln Leu 395 385 390 Glu Asp Pro Asn Gly Ser Phe Ser Asn Ala Glu Met Ser Glu Leu Ser 405 410 Val Ala Gln Lys Pro Glu Lys Leu Leu Glu Arg Cys Lys Tyr Trp Pro 425 420 Ala Cys Lys Asn Gly Asp Glu Cys Ala Tyr His His Pro Ile Ser Pro 440 Cys Lys Ala Phe Pro Asn Cys Lys Phe Ala Glu Lys Cys Leu Phe Val 460 450 455 His Pro Asn Cys Lys Tyr Asp Ala Lys Cys Thr Lys Pro Asp Cys Pro 465 470 Phe Thr His Val Ser Arg Arg Ile Pro Val Leu Ser Pro Lys Pro Val 490 Ala Pro Pro Ala Pro Pro Ser Ser Ser Gln Leu Cys Arg Tyr Phe Pro 500 505 Ala Cys Lys Lys Met Glu Cys Pro Phe Tyr His Pro Lys His Cys Arg 515 520 Phe Asn Thr Gln Cys Thr Arg Pro Asp Cys Thr Phe Tyr His Pro Thr 530 535 Ile Asn Val Pro Pro Arg His Ala Leu Lys Trp Ile Arg Pro Gln Thr 555

Ser Glu

<210> 870

<211> 191

<212> PRT

<213> Homo sapiens

<400> 870

Pro Asn Gly Ser Ser Asn Val Cys Val Ser Leu Cys Val Phe Val Cys

1 10 15

Val Cys Ala Leu Lys Thr Ser Asn Ser Leu Glu Ala Trp Gly Gly Ile 20 25 Pro Ala Leu Pro Leu Ala Cys Leu Met His His Gln Met Thr Arg Thr 40 Thr Leu Met Thr Lys Gln His Glu Leu Gly Gly Leu Leu Ala Leu Val Gln Asn Cys Gln Ser Glu Met Asn Ile Lys Asp Ser Arg Ala Val Gly 70 75 Leu Ser Val Lys Arg Leu Cys Ile Ser Phe Val Asp Glu Phe Cys Glu 85 90 Arg Thr Glu Arg Pro Leu Tyr Leu Ala Gln Gly Leu Phe Met Lys Arg 105 Glu Thr Tyr Trp Glu Val Gln Asp Ser Gly Ile Ser Pro Leu Leu 120 Leu Leu Ser Thr Ala Leu Asp Cys Ser Pro Glu Ala Glu Thr Arg Gln 130 135 Ser Pro Gly Gly Arg Lys Met Leu Gln Glu Pro Thr Leu Ser Met Ser 155 145 150 Leu Gln Ile Leu Thr Gly Phe Leu Trp Val Gln Leu Trp Asn Trp Glu 170 165

<210> 871

<211> 75

<212> PRT

<213> Homo sapiens

180

<400> 871

Leu Phe Lys Val Ser Asn Val His Pro Gly Leu Gly Ile Thr Asn Val

Thr Phe Leu Arg Ile Arg Thr His Ser Thr Asp Ala Ser Cys Pro

185

190

Gly Val Lys Met Pro Thr Lys Gly Phe Ser Ala Leu Glu Val Leu Arg

Ser Pro Ile Cys Ile Lys Ala Asp Pro Phe Cys Lys Asp Leu Ser Phe 35 40 45

Arg Thr Phe Ser Val Leu Leu Val Arg Thr Leu Glu Val Ile Leu Ile 50 55 60

Ile Ser Thr Asp Ser Leu Thr Ala Glu Ala Thr 65 70 75

<210> 872

<211> 203

<212> PRT

<213> Homo sapiens

<400> 872

Asn Ser Ala Arg Gly Asp Gln Glu Ser Thr Cys Ala Glu Val Leu Val 1 5 10 15

Ile Trp Ser Leu Phe Pro Ser Gly Tyr Gln Leu Pro Ser Ala Ala Gln
20 25 30

Ala Val Val Pro Glu Ala Arg Gly Arg Ser Gln Thr Cys Gly Asn Phe
35 40 45

Ala Val Tyr Leu Gln Gly Cys Cys Phe Gln Gln Asp Pro Lys Leu Glu 50 55 60

Lys Glu Glu Glu Glu Thr Asp Pro Ile Ser Ala Arg Ser His Cys Ile 65 70 75 80

Gln Arg Arg Ile Ser Lys Lys Glu Lys Lys Glu Gly Arg Glu Val Asp 85 90 95

Arg Tyr Lys Met Lys Ser Cys Gln Lys Met Glu Gly Lys Pro Glu Asn 100 105 110

Glu Ser Glu Pro Lys His Glu Glu Glu Pro Lys Pro Glu Glu Lys Pro 115 120 125

Glu Glu Glu Lys Leu Glu Glu Glu Ala Lys Ala Lys Gly Thr Phe 130 135 140

Arg Glu Arg Leu Ile Gln Ser Leu Gln Glu Phe Lys Glu Asp Ile His 145 150 155 160

Asn Arg His Leu Ser Asn Glu Asp Met Phe Arg Glu Val Asp Glu Ile 165 170 175

Asp Glu Ile Arg Arg Val Arg Asn Lys Leu Ile Val Met Arg Trp Lys 180 185 190

Val Asn Arg Asn His Pro Tyr Pro Tyr Leu Met

WO 00/55351 956 PCT/US00/05883

195 200

<210> 873

<211> 66

<212> PRT

<213> Homo sapiens

<400> 873

Ser Leu Gln Pro Leu Pro Pro Arg Phe Lys Gln Phe Leu Cys Leu Ser 1 5 10 15

Leu Pro Ser Asn Trp Asp Tyr Arg Cys Thr Leu Pro His Leu Ala Asp
20 25 30

Phe Phe Tyr Val Leu Val Glu Thr Gly Phe Gln Pro Cys Cys Pro Gly 35 40 45

Trp Ser Gln Thr Pro Glu Leu Arg Gln Ser Thr Arg Leu Gly Leu Pro 50 55 60

Lys Cys 65

<210> 874

<211> 231

<212> PRT

<213> Homo sapiens

<400> 874

Val Lys Leu Lys Glu Glu Phe Ser Leu Ser Gly Arg Ile Ile Asp Cys
1 5 10 15

Ala Phe Thr Val Thr Phe Asn Pro Lys Tyr Asp Thr Leu Leu Lys Ala
20 25 30

Val Lys Asp Ala Thr Asn Thr Gly Ile Lys Cys Ala Gly Ile Asp Val 35 40 45

Arg Leu Cys Asp Val Gly Glu Ala Ile Gln Glu Val Met Glu Ser Tyr 50 55 60

Glu Val Glu Ile Asp Gly Lys Thr Tyr Gln Val Lys Pro Ile Arg Asn 65 70 75 80

Leu Asn Gly His Ser Ile Gly Gln Tyr Arg Ile His Ala Gly Lys Thr 85 90 95 WO 00/55351 957 PCT/US00/05883

Val Pro Ile Val Lys Gly Gly Glu Ala Thr Arg Met Glu Glu Gly Glu 100 105 110

Val Tyr Ala Ile Glu Thr Phe Gly Ser Thr Gly Lys Gly Val Val His
115 120 125

Asp Asp Met Glu Cys Ser His Tyr Met Lys Asn Phe Asp Val Gly His 130 135 140

Val Pro Ile Arg Leu Pro Arg Thr Lys His Leu Leu Asn Val Ile Asn 145 150 155 160

Glu Asn Phe Gly Thr Leu Ala Phe Cys Arg Arg Trp Leu Asp Arg Leu 165 170 175

Gly Glu Ser Lys Tyr Leu Met Ala Leu Lys Asn Leu Cys Asp Leu Gly
180 185 190

Ile Val Asp Pro Tyr Pro Pro Leu Cys Asp Ile Lys Gly Ser Tyr Thr
195 200 205

Ala Gln Phe Glu His Thr Ile Leu Leu Arg Pro Thr Cys Lys Glu Val 210 215 220

Val Ser Arg Gly Asp Asp Tyr 225 230

<210> 875

<211> 88

<212> PRT

<213> Homo sapiens

<400> 875

Cys Leu Tyr Tyr Gln Val Leu Ser Thr Ile Leu Ile Thr Asn Cys Asp 1 5 10 15

Lys Phe Phe Leu Phe Phe Pro Leu Pro His Tyr Phe Leu Met Asn 20 25 30

Lys Pro Lys Ile His Gly Glu Gln Leu Gln Cys Trp Leu Ile Tyr Leu 35 40 45

Leu Cys Thr Gly Asn Leu Lys Arg Thr Val Asp Ser Phe Arg Ser Val 50 60

Thr Gly Ala Val Ile Ile Ala Ile His Leu Leu Val Val Leu His Leu 65 70 75 80

Phe His Ala Ser Phe Leu Asn Val

85

```
<210> 876
<211> 330
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (97)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (106)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (124)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (138)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (174)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (178)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (194)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 876
Asn Ser Ala Arg Ala Val Gln Gly Leu Leu Glu Val Ala Lys Asp Ser
                  5
                                                          15
Ile Pro Arg Ser His Trp Lys Lys Thr Pro Val Val Leu Lys Ala Thr
             20
                                 25
                                                      30
```

- Ala Gly Leu Arg Leu Leu Pro Glu His Lys Ala Lys Ala Leu Leu Phe 35 40 45
- Glu Val Lys Glu Ile Phe Arg Lys Ser Pro Phe Leu Val Pro Lys Gly
 50 55 60
- Ser Val Ser Ile Met Asp Gly Ser Asp Glu Gly Ile Leu Ala Trp Val 65 70 75 80
- Thr Val Asn Phe Leu Thr Gly Gln Leu His Gly His Arg Gln Glu Thr
 85 90 95
- Xaa Gly Thr Leu Asp Leu Gly Gly Ala Xaa Thr Gln Ile Thr Phe Leu 100 105 110
- Pro Gln Phe Glu Lys Thr Leu Glu Gln Thr Pro Xaa Gly Tyr Leu Thr 115 120 125
- Ser Phe Glu Met Phe Asn Ser Thr Tyr Xaa Leu Tyr Thr His Ser Tyr 130 135 140
- Leu Gly Phe Gly Leu Lys Ala Ala Arg Leu Ala Thr Leu Gly Ala Leu 145 150 155 160
- Glu Thr Glu Gly Thr Asp Gly His Thr Phe Arg Ser Ala Xaa Leu Pro 165 170 175
- Arg Xaa Leu Glu Ala Glu Trp Ile Phe Gly Gly Val Lys Tyr Gln Tyr 180 185 190
- Gly Xaa Asn Gln Glu Gly Glu Val Gly Phe Glu Pro Cys Tyr Ala Glu 195 200 205
- Val Leu Arg Val Val Arg Gly Lys Leu His Gln Pro Glu Glu Val Gln 210 215 220
- Arg Gly Ser Phe Tyr Ala Phe Ser Tyr Tyr Tyr Asp Arg Ala Val Asp 225 230 235 240
- Thr Asp Met Ile Asp Tyr Glu Lys Gly Gly Ile Leu Lys Val Glu Asp
 245 250 255
- Phe Glu Arg Lys Ala Arg Glu Val Cys Asp Asn Leu Glu Asn Phe Thr 260 265 270
- Ser Gly Ser Pro Phe Leu Cys Met Asp Leu Ser Tyr Ile Thr Ala Leu 275 280 285
- Leu Lys Asp Gly Phe Gly Phe Ala Asp Ser Thr Val Leu Gln Leu Thr 290 295 300

Lys Lys Val Asn Asn Ile Glu Thr Gly Trp Ala Leu Gly Ala Thr Phe 305 310 315 320

His Leu Leu Gln Ser Leu Gly Ile Ser His 325 330

<210> 877

<211> 102

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (100)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 877

Asp Leu His Ser Gln Trp Gly Thr Trp Pro Pro Ile Leu Gly Asp Leu 1 5 10 15

Arg Lys Arg Thr Ser Pro Trp Gly Glu Gly Trp Val Gly Pro Glu Gly
20 25 30

Pro Val Pro Ser Ser Val Leu Arg Gly Arg Ala Thr Cys Ser Asn Gly 35 40 45

Ile Cys Ile Leu Ala Pro Leu His Leu Leu Ser Pro Ala Glu Ser Phe
50 60

Pro Ser Lys Pro Lys Ser Cys His Cys Phe Phe Leu Pro Gly Lys Asn 65 70 75 80

Ala Trp Thr Leu Pro Gly Asp Arg Leu Lys Pro Glu Gln Cys His Thr 85 90 95

Leu Ala Leu Xaa Pro Cys 100

<210> 878

<211> 135

<212> PRT

<213> Homo sapiens

<400> 878

Thr Leu Glu Ser Lys Ala Asp Thr Glu Ala Ser Arg Leu Gln Glu Tyr
1 5 10 15

Arg Ser Gln Val Leu Ser Val Gly Leu Gly Cys Val Ser Trp Gly Lys
20 25 30

Lys Asn Cys Glu Lys Pro Gln Ser Ser Ile Phe Thr Val Thr His Gly
35 40 45

Arg Ser Leu Asn Cys Leu Val Asn Lys Asn Glu Ser Leu Ser Gln Arg
50 55 60

Lys Pro Arg Gln Tyr Pro Ser Ser Thr Thr Cys Glu Asn Pro Asp Val 65 70 75 80

Pro Gln Gln Arg Lys Thr Leu Gln Ala Gly Lys Met Arg Arg Phe Phe
85 90 95

Phe Phe Val Ser Met Met Ile Phe Ala Ala Thr Trp Leu Trp Arg Ala 100 105 110

Ala Asp Thr Pro Ser Tyr Ser Arg Gly Cys Phe Leu Glu Ala Asp Ser 115 120 125

Val Cys Ser Leu Val Glu Leu 130 135

<210> 879

<211> 175

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (168)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 879

Val Ile Cys Met Trp Gln Gly Cys Ala Val Glu Arg Pro Val Gly Arg
1 5 10 15

Met Thr Ser Gln Thr Pro Leu Pro Gln Ser Pro Arg Pro Arg Pro
20 25 30

Thr Met Ser Thr Val Val Glu Leu Asn Val Gly Gly Glu Phe His Thr 35 40 45

Thr Thr Leu Gly Thr Leu Arg Lys Phe Pro Gly Ser Lys Leu Ala Glu 50 55 60

Met Phe Ser Ser Leu Ala Lys Ala Ser Thr Asp Ala Glu Gly Arg Phe
65 70 75 80

Phe Ile Asp Arg Pro Ser Thr Tyr Phe Arg Pro Ile Leu Asp Tyr Leu 85 90 95

Arg Thr Gly Gln Val Pro Thr Gln His Ile Pro Glu Val Tyr Arg Glu
100 105 110

Ala Gln Phe Tyr Glu Ile Lys Pro Leu Val Lys Leu Leu Glu Asp Met
115 120 125

Pro Gln Ile Phe Gly Glu Gln Val Ser Arg Lys Gln Phe Leu Leu Gln 130 135 140

Cys Arg Ala Thr Ala Arg Thr Trp Glu Leu Met Val Arg Leu Ala Arg 145 150 155 160

Ala Glu Ala Ile Thr Ala Arg Xaa Ser Arg Cys Leu Cys Ala Trp 165 170 175

<210> 880

<211> 397

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (311)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 880

Trp Glu Tyr Asp Met Ala Arg Glu Leu Arg Ala Leu Leu Trp Gly
1 5 10 15

Arg Arg Leu Arg Pro Leu Leu Arg Ala Pro Ala Leu Ala Ala Val Pro
20 25 30

Gly Gly Lys Pro Ile Leu Cys Pro Arg Arg Thr Thr Ala Gln Leu Gly
35 40 45

Pro Arg Arg Asn Pro Ala Trp Ser Leu Gln Ala Gly Arg Leu Phe Ser 50 55 60

Thr Gln Thr Ala Glu Asp Lys Glu Glu Pro Leu His Ser Ile Ile Ser 65 70 75 80

Ser Thr Glu Ser Val Gln Gly Ser Thr Ser Lys His Glu Phe Gln Ala 85 90 95

Glu Thr Lys Lys Leu Leu Asp Ile Val Ala Arg Ser Leu Tyr Ser Glu

Lys Glu Val Phe Ile Arg Glu Leu Ile Ser Asn Ala Ser Asp Ala Leu Glu Lys Leu Arg His Lys Leu Val Ser Asp Gly Gln Ala Leu Pro Glu Met Glu Ile His Leu Gln Thr Asn Ala Glu Lys Gly Thr Ile Thr Ile Gln Asp Thr Gly Ile Gly Met Thr Gln Glu Glu Leu Val Ser Asn Leu Gly Thr Ile Ala Arg Ser Gly Ser Lys Ala Phe Leu Asp Ala Leu Gln Asn Gln Ala Glu Ala Ser Ser Lys Ile Ile Gly Gln Phe Gly Val Gly Phe Tyr Ser Ala Phe Met Val Ala Asp Arg Val Glu Val Tyr Ser Arg Ser Ala Ala Pro Gly Ser Leu Gly Tyr Gln Trp Leu Ser Asp Gly Ser Gly Val Phe Glu Ile Ala Glu Ala Ser Gly Val Arg Thr Gly Thr Lys Ile Ile Ile His Leu Lys Ser Asp Cys Lys Glu Phe Ser Ser Glu Ala Arg Val Arg Asp Val Val Thr Lys Tyr Ser Asn Phe Val Ser Phe Pro Leu Tyr Leu Asn Gly Arg Arg Met Asn Thr Leu Gln Ala Ile Trp Met Met Asp Pro Lys Asp Val Xaa Glu Trp Gln His Glu Glu Phe Tyr Arg Tyr Val Ala Gln Ala His Asp Lys Pro Arg Tyr Thr Leu His Tyr Lys Thr Asp Ala Pro Leu Asn Ile Arg Ser Ile Phe Tyr Val Pro Asp Met Lys Pro Ser Met Phe Asp Val Ser Arg Glu Leu Gly Ser Ser Val Cys Thr Val Gln Pro Gln Ser Pro His Pro Asp Gln Gly His Gly His Pro

370 375 380

Ala Gln Val Ala Ala Leu His Pro Arg Cys Gly Gln 385 390 395

<210> 881

<211> 187

<212> PRT

<213> Homo sapiens

<400> 881

Ile Ser Leu Phe Pro Pro Pro Gly Pro Gln Leu Cys Leu Pro Asp Lys
1 5 10 15

Glu Gly Gln His Ser Lys Ser Arg Ser Ala Ile Tyr Leu Pro Val Arg
20 25 30

Ser Thr Asn Ser Ser Val Arg Lys Met Ala Gly Asn Ser Ile Leu Leu 35 40 45

Ala Ala Val Ser Ile Leu Ser Ala Cys Gln Gln Ser Tyr Phe Ala Leu 50 55 60

Gln Val Gly Lys Ala Arg Leu Lys Tyr Lys Val Thr Pro Pro Ala Val 65 70 75 80

Thr Gly Ser Pro Glu Phe Glu Arg Val Phe Arg Ala Gln Gln Asn Cys
85 90 95

Val Glu Phe Tyr Pro Ile Phe Ile Ile Thr Leu Trp Met Ala Gly Trp
100 105 110

Tyr Phe Asn Gln Val Phe Ala Thr Cys Leu Gly Leu Val Tyr Ile Tyr 115 120 125

Gly Arg His Leu Tyr Phe Trp Gly Tyr Ser Glu Ala Ala Lys Lys Arg 130 135 140

Ile Thr Gly Phe Arg Leu Ser Leu Gly Ile Leu Ala Leu Leu Thr Leu 145 150 155 160

Leu Gly Ala Leu Gly Ile Ala Asn Ser Phe Leu Asp Glu Tyr Leu Asp 165 170 175

Leu Asn Ile Ala Lys Lys Leu Arg Arg Gln Phe 180 185

<210> 882 <211> 128 <212> PRT <213> Homo sapiens <220> <221> SITE <222> (96) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (112) <223> Xaa equals any of the naturally occurring L-amino acids Thr Thr Asn Ile Gln Gly His Phe Leu Lys Arg Glu Ser Ala Phe 5 10 Asn Glu Met Thr Met Val Asp Thr Glu Met Pro Phe Trp Pro Thr Asn 20 25 Phe Gly Ile Ser Ser Val Asp Leu Ser Val Met Glu Asp His Ser His 40 Ser Phe Asp Ile Lys Pro Phe Thr Thr Val Asp Phe Ser Ser Ile Ser 50 Thr Pro His Tyr Glu Asp Ile Pro Phe Thr Arg Thr Asp Pro Val Val 70 75 Ala Asp Tyr Lys Tyr Asp Leu Lys Leu Gln Glu Tyr Gln Ser Ala Xaa Lys Val Glu Pro Ala Ser Pro Pro Tyr Tyr Ser Glu Lys Thr Gln Xaa 105 100

Tyr Asn Lys Pro His Glu Glu Pro Ser Asn Ser Leu Met Ala Ile Glu

120

125

<210> 883 <211> 81 <212> PRT

115

<213> Homo sapiens

<220>

<221> SITE <222> (9) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (22) <223> Xaa equals any of the naturally occurring L-amino acids <400> 883 Ser Asn Glu Phe Ile Thr Asn Phe Xaa Gln Ala Leu Ser Gly Tyr Cys Gly Phe Met Ala Ala Xaa Leu Tyr Ala Arg Ser Ile Phe Gly Glu Asp 20 25 30 Ala Leu Ala Asn Val Ser Ile Glu Lys Pro Ile His Gln Gly Pro Asp 35 40 Ala Ala Val Thr Gly His Ile Arg Ile Arg Ala Lys Ser Gln Gly Met 55 Ala Leu Ser Leu Gly Asp Lys Ile Asn Leu Ser Gln Lys Lys Thr Ser 70 75 Ile <210> 884 <211> 293 <212> PRT <213> Homo sapiens <400> 884 Gly Ala Asn Asn Gly Gly Ser Lys Leu Thr Gln Thr Pro Lys Leu Gln 5 10 Glu Leu Met Lys Val Leu Ile Asp Trp Ile Asn Asp Val Leu Val Gly 20 25 Glu Arg Ile Ile Val Lys Asp Leu Ala Glu Asp Leu Tyr Asp Gly Gln 40 Val Leu Gln Lys Leu Phe Glu Lys Leu Glu Ser Glu Lys Leu Asn Val

55

70

Ala Glu Val Thr Gln Ser Glu Ile Ala Gln Lys Gln Lys Leu Gln Thr

Val Leu Glu Lys Ile Asn Glu Thr Leu Lys Leu Pro Pro Arg Ser Ile 85 90 95

Lys Trp Asn Val Asp Ser Val His Ala Lys Ser Leu Val Ala Ile Leu 100 105 110

His Leu Leu Val Ala Leu Ser Gln Tyr Phe Arg Ala Pro Ile Arg Leu 115 120 125

Pro Asp His Val Ser Ile Gln Val Val Val Gln Lys Arg Glu Gly 130 135 140

Ile Leu Gln Ser Arg Gln Ile Gln Glu Glu Ile Thr Gly Asn Thr Glu 145 150 155 160

Ala Leu Ser Gly Arg His Glu Arg Asp Ala Phe Asp Thr Leu Phe Asp 165 170 175

His Ala Pro Asp Lys Leu Asn Val Val Lys Lys Thr Leu Ile Thr Phe 180 185 190

Val Asn Lys His Leu Asn Lys Leu Asn Leu Glu Val Thr Glu Leu Glu 195 200 205

Thr Gln Phe Ala Asp Gly Val Tyr Leu Val Leu Leu Met Gly Leu Leu 210 215 220

Glu Gly Tyr Phe Val Pro Leu His Ser Phe Phe Leu Thr Pro Asp Ser 225 230 235 240

Phe Glu Gln Lys Val Leu Asn Val Ser Phe Ala Phe Glu Leu Met Gln 245 250 255

Asp Gly Gly Leu Glu Lys Pro Lys Pro Arg Pro Glu Asp Ile Val Asn 260 265 270

Cys Asp Leu Lys Ser Thr Leu Arg Val Leu Tyr Asn Leu Phe Thr Lys 275 280 285

Tyr Arg Asn Val Glu 290

<210> 885

<211> 116

<212> PRT

<213> Homo sapiens

<400> 885

Tyr Val Tyr Leu Ile Ile Leu Pro Leu Ala Lys Cys Tyr Val Cys Lys

1 5 10 15

Met Trp His Leu Leu Val Phe Ile Val Cys Val Phe Phe Val Tyr Tyr
20 25 30

Thr Leu Gly Asn Phe Val Leu Pro Lys Lys Lys Lys Gly Ser Val
35 40 45

Met Ser Asp Thr Gln Glu Lys Gln Ile Ser Val Val Ser Leu Lys Tyr
50 60

Asn Phe Lys Gly His Tyr Gln Gln Gly Phe Phe Tyr Thr Leu Lys 65 70 75 80

Thr Leu Cys Tyr Ile Ser Leu Pro Phe Ser Tyr Phe Gly Val Leu Leu 85 90 95

Leu Leu Tyr Asn Gly Ile Asn Gly Asn Val Ile Gln Pro Leu Asn Cys
100 105 110

His Tyr Tyr Ile 115

<210> 886

<211> 80

<212> PRT

<213> Homo sapiens

<400> 886

Tyr Glu His Leu Phe Tyr Lys Phe Tyr Lys Ser Met Leu Asn Leu Arg

1 5 10 15

Lys Thr Lys Gln Val Cys Leu Tyr Ser Gln Lys Leu Cys His Leu Ser 20 25 30

Gln Tyr Asp Phe Asn Met Cys Ile Asn Gly Lys Gln Gly Lys Val Phe 35 40 45

Ser Asn Ile Thr Val Leu Leu Gly Asn Leu Cys Arg Val His Ile Asn 50 55 60

Ala Ser Tyr Ile Thr Leu Ile Cys Phe Leu Cys Trp Pro Tyr Arg Gly
65 70 75 80

<210> 887 <211> 416 <212> PRT

<213> Homo sapiens

<400> 887

Thr Phe Pro Pro Glu Phe Val Ile Pro Leu Ser Glu Val Thr Cys Glu l 5 10 15

Thr Gly Glu Thr Val Val Leu Arg Cys Arg Val Cys Gly Arg Pro Lys
20 25 30

Ala Ser Ile Thr Trp Lys Gly Pro Glu His Asn Thr Leu Asn Asn Asp 35 40 45

Gly His Tyr Ser Ile Ser Tyr Ser Asp Leu Gly Glu Ala Thr Leu Lys
50 55 60

Ile Val Gly Val Thr Thr Glu Asp Asp Gly Ile Tyr Thr Cys Ile Ala
65 70 75 80

Val Asn Asp Met Gly Ser Ala Ser Ser Ser Ala Ser Leu Arg Val Leu 85 90 95

Gly Pro Gly Met Asp Gly Ile Met Val Thr Trp Lys Asp Asn Phe Asp 100 105 110

Ser Phe Tyr Ser Glu Val Ala Glu Leu Gly Arg Gly Arg Phe Ser Val 115 120 125

Val Lys Lys Cys Asp Gln Lys Gly Thr Lys Arg Ala Val Ala Thr Lys 130 135 140

Phe Val Asn Lys Lys Leu Met Lys Arg Asp Gln Val Thr His Glu Leu 145 150 155 160

Gly Ile Leu Gln Ser Leu Gln His Pro Leu Leu Val Gly Leu Leu Asp 165 170 175

Thr Phe Glu Thr Pro Thr Ser Tyr Ile Leu Val Leu Glu Met Ala Asp 180 185 190

Gln Gly Arg Leu Leu Asp Cys Val Val Arg Trp Gly Ser Leu Thr Glu 195 200 205

Gly Lys Ile Arg Ala His Leu Gly Glu Val Leu Glu Ala Val Arg Tyr 210 215 220

Leu His Asn Cys Arg Ile Ala His Leu Asp Leu Lys Pro Glu Asn Ile 225 230 235 240 Leu Val Asp Glu Ser Leu Ala Lys Pro Thr Ile Lys Leu Ala Asp Phe 245 250 255

Gly Asp Ala Val Gln Leu Asn Thr Thr Tyr Tyr Ile His Gln Leu Leu 260 265 270

Gly Asn Pro Glu Phe Ala Ala Pro Glu Ile Ile Leu Gly Asn Pro Val 275 280 285

Ser Leu Thr Ser Asp Thr Trp Ser Val Gly Val Leu Thr Tyr Val Leu 290 295 300

Leu Ser Gly Val Ser Pro Phe Leu Asp Asp Ser Val Glu Glu Thr Cys 305 310 315 320

Leu Asn Ile Cys Arg Leu Asp Phe Ser Phe Pro Asp Asp Tyr Phe Lys 325 330 335

Gly Val Ser Gln Lys Ala Lys Glu Phe Val Cys Phe Ser Cys Arg Arg 340 345 350

Thr Pro Pro Ser Val Pro Arg Leu Arg Trp Pro Ser Arg Ser Ser Gly 355 360 365

Cys Arg Pro Ala Thr Ala Glu Ser Thr Gly Val Leu Asp Thr Ser Arg 370 375 380

Leu Thr Ser Phe Ile Glu Arg Arg Lys His Gln Asn Asp Val Arg Pro 385 390 395 400

Ile Arg Ser Ile Lys Asn Phe Leu Gln Ser Arg Leu Leu Pro Arg Val 405 410 415

<210> 888

<211> 368

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (196)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 888

Arg Gln Arg Arg Lys Gly Gln Glu Arg Gly Arg Arg Gly Lys Met
1 5 10 15

Ala	Ala	Thr	Lys 20	_	Lys	Arg	Arg	Gly 25	_	Phe	Ala	Val	. Glr 30		Lys
Lys	Pro	Lys 35	Arg	Asn	Glu	Ile	Asp 40	Ala	Glu	Pro	Pro	Ala 45	-	Arg	His
Ala	Thr 50		. Glu	Glu	Val	Glu 55	Glu	Glu	Glu	Arg	Asp 60	Arg	Ile	Pro	Gly
Pro 65	Val	Cys	Lys	Gly	Lys 70	Trp	Lys	Asn	Lys	Glu 75	Arg	Ile	Leu	Ile	Phe 80
Ser	Ser	Arg	Gly	Ile 85	Asn	Phe	Arg	Thr	Arg 90	His	Leu	Met	Gln	Asp 95	Leu
Arg	Met	Leu	Met 100	Pro	His	Ser	Lys	Ala 105	Asp	Thr	Lys	Met	Asp 110	Arg	Lys
Asp	Lys	Leu 115	Phe	Val	Ile	Asn	Glu 120	Val	Cys	Glu	Met	Lys 125	Asn	Cys	Asn
Lys	Cys 130	Ile	Tyr	Phe	Glu	Ala 135	Lys	Lys	Lys	Gln	Asp 140	Leu	Туг	Met	Trp
Leu 145	Ser	Asn	Ser	Pro	His 150	Gly	Pro	Ser	Ala	Lys 155	Phe	Leu	Val	Gln	Asn 160
Ile	His	Thr	Leu	Ala 165	Glu	Leu	Lys	Met	Thr 170	Gly	Asn	Суѕ	Leu	Lys 175	Gly
Ser	Arg	Pro	Leu 180	Leu	Ser	Phe	Asp	Pro 185	Ala	Phe	Asp	Glu	Leu 190	Pro	His
туг	Ala	Leu 195	Xaa	Lys	Glu	Leu	Leu 200	Ile	Gln	Ile	Phe	ser 205	Thr	Pro	Arg
Tyr	His 210	Pro	Lys	Ser	Gln	Pro 215	Phe	Val	Asp	His	Val 220	Phe	Thr	Phe	Thr
Ile 225	Leu	Asp	Asn	Arg	11e 230	Trp	Phe	Arg	Asn	Phe 235	Gln	Ile	Ile	Glu	Glu 240
Asp	Ala	Ala	Leu	Val 245	Glu	Ile	Gly	Pro	Arg 250	Phe	Val	Leu	Asn	Leu 255	Ile
Lys	Ile	Phe	Gln 260	Gly	Ser	Phe	Gly	Gly 265	Pro	Thr	Leu	Tyr	Glu 270	Asn	Pro
	_		_	_							_			_	_

His Tyr Gln Ser Pro Asn Met His Arg Arg Val Ile Arg Ser Ile Thr

285

280

275

Ala Ala Lys Tyr Arg Glu Lys Gln Gln Val Lys Asp Val Gln Lys Leu 290 295 300

Arg Lys Lys Glu Pro Lys Thr Leu Leu Pro His Asp Pro Thr Ala Asp 305 310 315 320

Val Phe Val Thr Pro Ala Glu Glu Lys Pro Ile Glu Ile Gln Trp Val
325 330 335

Lys Pro Glu Pro Lys Val Asp Leu Lys Ala Arg Lys Lys Arg Ile Tyr 340 345 350

Lys Arg Gln Arg Lys Met Lys Gln Arg Met Asp Ser Gly Lys Thr Lys 355 360 365

<210> 889

<211> 273

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (32)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 889

Leu Ala Ser Ala Trp Cys Ser Cys Ala Arg Val Ser Ala Gly Ser Ala 1 5 10

Leu Arg Phe Pro Gly Met Glu Ser Glu Met Glu Thr Gln Ser Ala Xaa 20 25 30

Ala Glu Glu Gly Phe Thr Gln Val Thr Arg Lys Gly Gly Arg Arg Ala 35 40 45

Lys Lys Arg Gln Ala Glu Gln Leu Ser Ala Ala Gly Glu Gly Gly Asp
50 55 60

Ala Gly Arg Met Asp Thr Glu Glu Ala Arg Pro Ala Lys Arg Pro Val 65 70 75 80

Phe Pro Pro Leu Cys Gly Asp Gly Leu Leu Ser Gly Lys Glu Glu Thr
85 90 95

Arg Lys Ile Pro Val Pro Ala Asn Arg Tyr Thr Pro Leu Lys Glu Asn

Trp Met Lys Ile Phe Thr Pro Ile Val Glu His Leu Gly Leu Gln Ile
115 120 125

Arg Phe Asn Leu Lys Ser Arg Asn Val Glu Ile Arg Thr Cys Lys Glu 130 135 140

Thr Lys Asp Val Ser Ala Leu Thr Lys Ala Ala Asp Phe Val Lys Ala 145 150 155 160

Phe Ile Leu Gly Phe Gln Val Glu Asp Ala Leu Ala Leu Ile Arg Leu 165 170 175

Asp Asp Leu Phe Leu Glu Ser Phe Glu Ile Thr Asp Val Lys Pro Leu 180 185 190

Lys Gly Asp His Leu Ser Arg Ala Ile Gly Arg Ile Ala Gly Lys Gly
195 200 205

Gly Lys Thr Lys Phe Thr Ile Glu Asn Val Thr Arg Thr Arg Ile Val 210 215 220

Leu Ala Asp Val Lys Val His Ile Leu Gly Ser Phe Gln Asn Ile Lys 225 230 235 240

Met Ala Arg Thr Ala Ile Cys Asn Leu Ile Leu Gly Asn Pro Pro Ser 245 .250 255

Lys Val Tyr Gly Asn Ile Arg Ala Val Ala Ser Arg Ser Ala Asp Arg 260 265 270

Phe

<210> 890

<211> 60

<212> PRT

<213> Homo sapiens

<400> 890

Val Thr Ser Lys Thr Gln Val Gly Leu Phe Lys Phe Leu Lys Phe Glu
1 5 10 15

Ile Phe Tyr Leu Gln Lys Ile Val Leu Cys Phe Ile Ile Ser Gln Met
20 25 30

Ser Val Arg Phe Leu Ser Thr Asn Asp His Ala Ser Ile Phe Phe Ser 35 40 45 Phe Lys Pro Pro Asn Gln Tyr Phe Ser Phe Lys Phe 50 55 60

<210> 891

<211> 257

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (224)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 891

Ala Arg Gly Ala Val Thr Arg Phe Pro Pro Arg Ser Leu Gly Arg Cys
1 5 10 15

His Gly Phe Gly Val Gly Asp Arg Ala Val Thr Met Ala Arg Leu Ala 20 25 30

Leu Ser Pro Val Pro Ser His Trp Met Val Ala Leu Leu Leu Leu Leu 45

Ser Ala Ala Glu Pro Val Pro Ala Ala Arg Ser Glu Asp Arg Tyr Arg
50 55 60

Asn Pro Lys Gly Ser Ala Cys Ser Arg Ile Trp Gln Ser Pro Arg Phe
65 70 75 80

Ile Ala Arg Lys Arg Gly Phe Thr Val Lys Met His Cys Tyr Met Asn 85 90 95

Ser Ala Ser Gly Asn Val Ser Trp Leu Trp Lys Gln Glu Met Asp Glu 100 105 110

Asn Pro Gln Gln Leu Lys Leu Glu Lys Gly Arg Met Glu Glu Ser Gln 115 120 125

Asn Glu Ser Leu Ala Thr Leu Thr Ile Gln Gly Ile Arg Phe Glu Asp 130 135 140

Asn Gly Ile Tyr Phe Cys Gln Gln Lys Cys Asn Asn Thr Ser Glu Val 145 150 155 160

Tyr Gln Gly Cys Gly Thr Glu Leu Arg Val Met Gly Phe Ser Thr Leu 165 170 175

Ala Gln Leu Lys Gln Arg Asn Thr Leu Lys Asp Gly Ile Ile Met Ile

180 185 190

Gln Thr Leu Leu Ile Ile Leu Phe Ile Ile Val Pro Ile Phe Leu Leu 195 200 205

Leu Asp Lys Asp Asp Ser Lys Ala Gly Met Glu Glu Asp His Thr Xaa 210 215 220

Glu Gly Leu Asp Ile Asp Gln Thr Ala Thr Tyr Glu Asp Ile Val Thr 225 230 235 240

Leu Arg Thr Gly Glu Val Lys Trp Ser Val Gly Glu His Pro Gly Gln 245 250 255

Glu

<210> 892

<211> 52

<212> PRT

<213> Homo sapiens

<400> 892

Cys His Ser Cys Tyr Gln Ala Val Pro Leu Pro Gly Val His Ile Gly
1 5 10 15

Leu Thr Gly Leu Ser Ile Phe Leu Phe Leu Ile Phe Glu Phe Tyr His
20 25 30

Leu Ala Leu Asn Cys Ser Thr Trp Ile Trp Gly Ser Ser Leu Cys Pro 35 40 45

Lys Asp Leu Leu 50

<210> 893

<211> 50

<212> PRT

<213> Homo sapiens

<400> 893

Gly Arg Glu Gly Arg Glu Glu Arg Glu Asp Lys Glu Ser Pro Thr Ser

1 5 10 15

Phe Gln Asn Val Met Arg Ile Leu Ser Thr Tyr Gly Pro Trp His Asp 20 25 30

His Met Thr Cys Arg Ala Pro Val Ile Glu Leu Ile Phe Ile Phe Ser $35 \hspace{1cm} 40 \hspace{1cm} 45$

Leu Val

<210> 894

<211> 255

<212> PRT

<213> Homo sapiens

<400> 894

Ala Pro Ser Ala Arg Asp Val Ser Arg Cys Ala His Arg Ala Arg Pro 1 5 10 15

Gly Ala Ile Met Leu Leu Pro Ser Ala Ala Asp Gly Arg Gly Thr 20 25 30

Ala Ile Thr His Ala Leu Thr Ser Ala Ser Thr Leu Cys Gln Val Glu 35 40 45

Pro Val Gly Arg Trp Phe Glu Ala Phe Val Lys Arg Arg Asn Arg Asn 50 55 60

Ala Ser Ala Ser Phe Gln Glu Leu Glu Asp Lys Lys Glu Leu Ser Glu 65 70 75 80

Glu Ser Glu Asp Glu Glu Leu Gln Leu Glu Glu Phe Pro Met Leu Lys 85 90 95

Thr Leu Asp Pro Lys Asp Trp Lys Asn Gln Asp His Tyr Ala Val Leu 100 105 110

Gly Leu Gly His Val Arg Tyr Lys Ala Thr Gln Arg Gln Ile Lys Ala 115 120 125

Ala His Lys Ala Met Val Leu Lys His His Pro Asp Lys Arg Lys Ala 130 135 140

Ala Gly Glu Pro Ile Lys Glu Gly Asp Asn Asp Tyr Phe Thr Cys Ile 145 150 155 160

Thr Lys Ala Tyr Glu Met Leu Ser Asp Pro Val Lys Arg Arg Ala Phe 165 170 175

Asn Ser Val Asp Pro Thr Phe Asp Asn Ser Val Pro Ser Lys Ser Glu 180 185 190

Ala Lys Asp Asn Phe Phe Glu Val Phe Thr Pro Val Phe Glu Arg Asn

195 200 205

Ser Arg Trp Ser Asn Lys Lys Asn Val Pro Lys Leu Gly Asp Met Asn 210 215 220

Ser Ser Phe Glu Asp Val Asp Ile Phe Tyr Ser Phe Trp Tyr Asn Phe 225 230 235 240

Asp Ser Trp Arg Glu Phe Ser Tyr Leu Asp Glu Glu Glu Lys Lys 245 250 255

<210> 895

<211> 149

<212> PRT

<213> Homo sapiens

<400> 895

Val Glu Asn Gln Asn Pro Ala Asp Pro Leu Asn Glu Glu Leu Gly Asp 1 5 10 15

Glu Asp Ser Glu Lys Lys Arg Lys Gly Ala Phe Phe Ser Trp Ser Arg
20 25 30

Thr Arg Ser Thr Gly Arg Ser Gln Lys Lys Arg Glu His Gly Asp His 35 40 . 45

Ala Asp Asp Ala Leu His Ala Asn Gly Gly Leu Cys Arg Arg Glu Ser

Gln Gly Ser Val Ser Ser Ala Gly Ser Leu Asp Leu Ser Glu Ala Cys 65 70 75 80

Arg Thr Leu Ala Pro Glu Lys Asp Lys Ala Thr Lys His Cys Cys Ile 85 90 95

His Leu Pro Asp Gly Thr Ser Cys Val Val Ala Val Lys Ala Gly Phe 100 105 110

Ser Ile Lys Asp Ile Leu Ser Gly Leu Cys Glu Arg His Gly Ile Asn 115 120 125

Gly Ala Ala Ala Asp Leu Phe Leu Val Gly Gly Asp Lys Pro Leu Val 130 135 140

Leu Ala Pro Arg Gln 145 <210> 896

<211> 635

<212> PRT

<213> Homo sapiens

<400> 896

His Glu Arg Gly Gln Arg Ala His Ser Ala Asp Ala Arg Ala Ala Gly
1 5 10 15

Ser Thr Arg Ser Thr Ala Gly Ala Gly Leu Gly Gln Arg Leu Arg Cys
20 25 30

Cys Trp Ile Val Val Phe Ser Gly Ile Glu Asp Thr His Gln Lys Pro 35 40 45

Lys Met Pro Lys Pro Ile Asn Val Arg Val Thr Thr Met Asp Ala Glu 50 55 60

Leu Glu Phe Ala Ile Gln Pro Asn Thr Thr Gly Lys Gln Leu Phe Asp 65 70 75 80

Gln Val Val Lys Thr Ile Gly Leu Arg Glu Val Trp Tyr Phe Gly Leu 85 90 95

His Tyr Val Asp Asn Lys Gly Phe Pro Thr Trp Leu Lys Leu Asp Lys
100 105 110

Lys Val Ser Ala Gln Glu Val Arg Lys Glu Asn Pro Leu Gln Phe Lys 115 120 125

Phe Arg Ala Lys Phe Tyr Pro Glu Asp Val Ala Glu Glu Leu Ile Gln 130 135 140

Asp Ile Thr Gln Lys Leu Phe Phe Leu Gln Val Lys Glu Gly Ile Leu 145 150 155 160

Ser Asp Glu Ile Tyr Cys Pro Pro Glu Thr Ala Val Leu Leu Gly Ser 165 170 175

Tyr Ala Val Gln Ala Lys Phe Gly Asp Tyr Asn Lys Glu Val His Lys 180 185 190

Ser Gly Tyr Leu Ser Ser Glu Arg Leu Ile Pro Gln Arg Val Met Asp 195 200 205

Gln His Lys Leu Thr Arg Asp Gln Trp Glu Asp Arg Ile Gln Val Trp 210 215 220

His Ala Glu His Arg Gly Met Leu Lys Asp Asn Ala Met Leu Glu Tyr 225 230 235 240

Leu	Lys	Ile	e Ala	Glr 245		Leu	ı Glu	Met	Tyr 250	_	, Ile	e Asn	Туг	255	Glu
Ile	Lys	Asn	Lys 260		Gly	Thr	Asp	265	-	Leu	Gly	Val	. Asp 270		Leu
Gly	Leu	Asn 275		Туг	Glu	Lys	280		Lys	Leu	Thr	Pro 285	-	Ile	Gly
Phe	Pro 290	Trp	Ser	Glu	Ile	Arg 295		Ile	s Ser	Phe	Asn 300	_	Lys	Lys	Phe
Val 305	Ile	Lys	Pro	Ile	Asp 310		Lys	Ala	. Pro	Asp 315		Val	Phe	Tyr	Ala 320
Pro	Arg	Leu	Arg	Ile 325	Asn	Lys	Arg	Ile	Leu 330		Leu	Cys	Met	Gly 335	Asn
His	Glu	Leu	туг 340	Met	Arg	Arg	Arg	Lys 345		Asp	Thr	Ile	Glu 350	Val	Gln
Gln	Met	Lys 355		Gln	Ala	Arg	Glu 360	Glu	Lys	His	Gln	Lys 365	Gln	Leu	Glu
Arg	Gln 370	Gln	Leu	Glu	Thr	Glu 375	Lys	Lys	Arg	Arg	Glu 380	Thr	Val	Glu	Arg
Glu 385	Lys	Glu	Gln	Met	Met 390	Arg	Glu	Lys	Glu	Glu 395	Leu	Met	Leu	Arg	Leu 400
Gln	Asp	Tyr	Glu	Glu 405	Lys	Thr	Lys	Lys	Ala 410	Glu	Arg	Glu	Leu	Ser 415	Glu
Gln	Ile	Gln	Arg 420	Ala	Leu	Gln	Leu	Glu 425	Glu	Glu	Arg	Lys	Arg 430	Ala	Gln
Glu	Glu	Ala 435	Glu	Arg	Leu	Glu	Ala 440	Asp	Arg	Met	Ala	Ala 445	Leu	Arg	Ala
Lys	Glu 450	Glu	Leu	Glu	Arg	Gln 455	Ala	Val	Asp	Gln	Ile 460	Lys	Ser	Gln	Glu
Gln 465	Leu	Ala	Ala	Glu	Leu 470	Ala	Glu	Tyr	Thr	Ala 475	Lys	Ile	Ala	Leu	Leu 480
Glu	Glu	Ala	Arg	Arg 485	Arg	Lys	Glu	Asp	Glu 490	Val	Glu	Glu	Trp	Gln 495	His
Arg	Ala	Lys	Glu	Ala	Gln	Asp	Asp	Leu	Val	Lys	Thr	Lys	Glu	Glu	Leu

His Leu Val Met Thr Ala Pro Pro Pro Pro Pro Pro Pro Val Tyr Glu 515 520 525

Pro Val Ser Tyr His Val Gln Glu Ser Leu Gln Asp Glu Gly Ala Glu 530 535 540

Pro Thr Gly Tyr Ser Ala Glu Leu Ser Ser Glu Gly Ile Arg Asp Asp 545 550 555 560

Arg Asn Glu Glu Lys Arg Ile Thr Glu Ala Glu Lys Asn Glu Arg Val 565 570 575

Gln Arg Gln Leu Leu Thr Leu Ser Ser Glu Leu Ser Gln Ala Arg Asp 580 585 590

Glu Asn Lys Arg Thr His Asn Asp Ile Ile His Asn Glu Asn Met Arg 595 600 605

Gln Gly Arg Asp Lys Tyr Lys Thr Leu Arg Gln Ile Arg Gln Gly Asn 610 615 620

Thr Lys Gln Arg Ile Asp Glu Phe Glu Ala Leu 625 630 635

<210> 897

<211> 41

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (12)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (21)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (26)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (29)

<223> Xaa equals any of the naturally occurring L-amino acids

```
<220>
<221> SITE
<222> (30)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (37)
<223> Xaa equals any of the naturally occurring L-amino acids
Phe Val Phe Leu Gly Tyr Glu Glu Ile Ile Ile Xaa Leu Val Ser Ile
Phe Ile Asn Pro Xaa Ile Leu Tyr Leu Xaa Lys Ser Xaa Xaa Gly Gly
                                 25
Gly Arg Pro Cys Xaa Asp Leu Pro Ile
         35
<210> 898
<211> 128
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (83)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (92)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 898
Ser Leu Ala Gly Arg Ser Arg Trp Met Glu Ala Asn Gln His Ser Leu
Asn Ile Leu Gly Gln Lys Val Ser Met His Tyr Ser Asp Pro Lys Pro
                                 25
                                                     30
             20
Lys Ile Asn Glu Asp Trp Leu Cys Asn Lys Cys Gly Val Gln Asn Phe
                    40
         35
Lys Arg Arg Glu Lys Cys Phe Lys Cys Gly Val Pro Lys Ser Glu Ala
                         55
```

Glu Gln Lys Leu Pro Leu Gly Thr Arg Leu Asp Gln Gln Thr Leu Pro

65 70 75 80

Leu Gly Xaa Arg Glu Leu Ser Gln Gly Leu Leu Xaa Leu Pro Gln Pro 85 90 95

Tyr Gln Ala Gln Gly Val Leu Ala Ser Gln Ala Leu Ser Gln Gly Ser 100 105 110

Glu Pro Ser Ser Glu Asn Ala Asn Asp Thr Ile Ile Leu Arg Asn Leu 115 120 125

<210> 899

<211> 92

<212> PRT

<213> Homo sapiens

<400> 899

Ile Trp Gln Phe Phe Ala Glu Val Ile Met Ser Phe Phe Gln Leu Leu 1 5 10 15

Met Lys Arg Lys Glu Leu Ile Pro Leu Val Val Phe Met Thr Val Ala 20 25 30

Ala Gly Gly Ala Ser Ser Phe Ala Val Tyr Ser Leu Trp Lys Thr Asp 35 40 45

Val Ile Leu Asp Arg Lys Lys Asn Pro Glu Pro Trp Glu Thr Val Asp 50 55 60

Pro Thr Val Pro Gln Lys Leu Ile Thr Ile Asn Gln Gln Trp Lys Pro 65 70 75 80

Ile Glu Glu Leu Gln Asn Val Gln Arg Val Thr Lys 85 90

<210> 900

<211> 73

<212> PRT

<213> Homo sapiens

<400> 900

Gly Gly Trp Phe Tyr Pro Phe Cys Leu Leu Phe Gly Thr Gln Leu Val 1 5 10 15 Phe Phe Gly Leu Leu Ser Ser Gly Ser Arg Ala Val Leu Ser Asn Thr
20 25 30

Val Thr Thr Cys Gly Cys Leu Lys Leu Ser Gln Leu Lys Ser His Lys 35 40 45

Ile Lys Asn Ser Phe Leu Ser Cys Thr Asn His Val Ser Arg Gly Val 50 55 60

Thr Val Cys Ser Ser Trp Leu Leu Tyr
65 70

<210> 901

<211> 120

<212> PRT

<213> Homo sapiens

<400> 901

Gly Pro Ala Leu Lys Met Gln Ala Gln Ala Pro Val Val Val Thr
1 5 10 15

Gln Pro Gly Val Gly Pro Gly Pro Ala Pro Gln Asn Ser Asn Trp Gln 20 25 30

Thr Gly Met Cys Asp Cys Phe Ser Asp Cys Gly Val Cys Leu Cys Gly
35 40 45

Thr Phe Cys Phe Pro Cys Leu Gly Cys Gln Val Ala Ala Asp Met Asn 50 55 60

Glu Cys Cys Leu Cys Gly Thr Ser Val Ala Met Arg Thr Leu Tyr Arg
65 70 75 80

Thr Arg Tyr Gly Ile Pro Gly Ser Ile Cys Asp Asp Tyr Met Ala Thr 85 90 95

Leu Cys Cys Pro His Cys Thr Leu Cys Gln Ile Lys Arg Asp Ile Asn 100 105 110

Arg Arg Arg Ala Met Arg Thr Phe 115 120

<210> 902

<211> 163

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (1)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 902

Xaa Glu Pro Lys Pro Ser Val Glu Pro Val Lys Ser Ile Ser Ser Met
1
5
10
15

Glu Leu Lys Thr Glu Pro Phe Asp Asp Phe Leu Phe Pro Ala Ser Ser 20 25 30

Arg Pro Ser Gly Ser Glu Thr Ala Arg Ser Val Pro Asp Met Asp Leu 35 40 45

Ser Gly Ser Phe Tyr Ala Ala Asp Trp Glu Pro Leu His Ser Gly Ser 50 55 60

Leu Gly Met Gly Pro Met Ala Gln Ser Trp Ser Pro Cys Ala Leu Arg
65 70 75 80

Trp Ser Pro Val Leu Pro Ala Ala Leu Leu Thr Arg Leu Pro Ser Ser 85 90 95

Ser Pro Thr Pro Arg Leu Thr Pro Ser Pro Ala Val Gln Leu Pro Thr
100 105 110

Ala Arg Ala Ala Ala Met Ser Leu Pro Leu Thr Arg Ser Ala His
115 120 125

Pro Arg Cys Trp Pro Cys Glu Gly Ala Gly Lys Gly Arg Gln Pro Ala 130 135 140

Pro Thr Ser Ala Thr Ala Arg Ala Gly Ala Leu Gln Arg Gly Glu Thr 145 150 155 160

His Leu Pro

<210> 903

<211> 478

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (20)

<223> Xaa equals any of the naturally occurring L-amino acids

<220> <221> SITE <222> (24) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (451) <223> Xaa equals any of the naturally occurring L-amino acids Ala Asp Thr Lys Pro Glu Arg Gly Val Ser Ser Ala Val Phe Ala Ser 10 Gly Ser Glu Xaa Arg Arg Leu Xaa Cys Val Leu Leu Ser Ser Ser Glu 25 Thr Arg Leu Leu Ser Gly Thr Leu Leu Trp Ile Pro Arg Ala Tyr Ser 40 Thr Arg Ser Lys Met Ala Glu Leu Asn Thr His Val Asn Val Lys Glu 50 55 Lys Ile Tyr Ala Val Arg Ser Val Val Pro Asn Lys Ser Asn Asn Glu 75 70 Ile Val Leu Val Leu Gln Gln Phe Asp Phe Asn Val Asp Lys Ala Val 90 Gln Ala Phe Val Asp Gly Ser Ala Ile Gln Val Leu Lys Glu Trp Asn 100 105 Met Thr Gly Lys Lys Asn Asn Lys Arg Lys Arg Ser Lys Ser Lys 115 125 Gln His Gln Gly Asn Lys Asp Ala Lys Asp Lys Val Glu Arg Pro Glu 135 140 Ala Gly Pro Leu Gln Pro Gln Pro Pro Gln Ile Gln Asn Gly Pro Met 155 150 Asn Gly Cys Glu Lys Asp Ser Ser Ser Thr Asp Ser Ala Asn Glu Lys 165 Pro Ala Leu Ile Pro Arg Glu Lys Lys Ile Ser Ile Leu Glu Glu Pro . 180 185 Ser Lys Ala Leu Arg Gly Val Thr Gly Pro Asn Ile Glu Lys Ser Val

200

Lys Asp Leu Gln Arg Cys Thr Val Ser Leu Thr Arg Tyr Arg Val Met

	210					215					220				
Ile 225	Lys	Glu	Glu	Val	Asp 230	Ser	Ser	Val	Lys	Lys 235	Ile	Lys	Ala	Ala	Phe 240
Ala	Glu	Leu	His	Asn 245	Cys	Ile	Ile	Asp	Lys 250	Glu	Val	Ser	Leu	Met 255	Ala
Glu	Met	Asp	Lys 260	Val	Lys	Glu	Glu	Ala 265	Met	Glu	Ile	Leu	Thr 270	Ala	Arg
Gln	Lys	Lys 275	Ala	Glu	Glu	Leu	Lys 280	Arg	Leu	Thr	Asp	Leu 285	Ala	Ser	Gln
Met	Ala 290	Glu	Met	Gln	Leu	Ala 295	Glu	Leu	Arg	Ala	Glu 300	Ile	Lys	His	Phe
Val 305	Ser	Glu	Arg	Lys	Tyr 310	Asp	Glu	Glu	Leu	Gly 315	Lys	Ala	Ala	Arg	Phe 320
Ser	Cys	Asp	Ile	Glu 325	Gln	Leu	Lys	Ala	Gln 330	Ile	Met	Leu	Суз	Gly 335	Glu
Ile	Thr	His	Pro 340	Lys	Asn	Asn	Tyr	Ser 345	Ser	Arg	Thr	Pro	Cys 350	Ser	Ser
Leu	Leu	Pro 355	Leu	Leu	Asn	Ala	His 360	Ala	Ala	Thr	Ser	Gly 365	Lys	Gln	Ser
Asn	Phe 370	Ser	Arg	Lys	Ser	Ser 375	Thr	His	Asn	Lys	Pro 380	Ser	Glu	Gly	Lys
Ala 385	Ala	Asn	Pro	Lys	Met 390	Val	Ser	Ser	Leu	Pro 395	Ser	Thr	Ala	Asp	Pro 400
Ser	His	Gln	Thr	Met 405	Pro	Ala	Asn	Lys	Gln 410	Asn	Gly	Ser	Ser	Asn 415	Gln
Arg	Arg	Arg	Phe 420	Asn	Pro	Gln	Tyr	His 425	Asn	Asn	Arg	Leu	Asn 430	Gly	Pro
Ala	Lys	Ser 435	Gln	Gly	Ser	Gly	Asn 440	Glu	Ala	Glu	Pro	Leu 445	Gly	Lys	Gly
Asn	Ser 450	Xaa	His	Glu	His	Arg 4:55	Arg	Gln	Pro	His	Asn 460	Gly	Phe	Arg	Pro
Lys 465	Asn	Lys	Gly	Gly	Ala 470	Lys	Ile	Lys	Arg	Leu 475	Pro	Trp	Gly		

<210> 904

<211> 88

<212> PRT

<213> Homo sapiens

<400> 904

Ala Phe His Phe Gly Ser Val Ala Lys Ala Thr Thr Thr Ser Val Gly
1 5 10 15

Thr Val Gly Tyr Tyr Gln Phe Met Asp Arg Leu Leu Ser Gly Met Val 20 25 30

Thr Ala Asn Thr Ile Val Arg Lys Pro Lys Arg Ser Leu Val Arg Val
35 40 45

Glu Ser Val Thr Pro Leu Pro Thr Thr Gly Cys Cys Leu Leu Ser Leu
50 60

Arg Arg Leu Arg Gln Asn Leu Leu Gln Arg Thr Arg Arg Val Val Tyr 65 . 70 . 75 . 80

Gln Arg Cys Leu Thr Thr Leu Arg 85

<210> 905

<211> 508

<212> PRT

<213> Homo sapiens

<400> 905

Phe Arg Ile Val Leu Pro Gly Trp Gln Gln Gly Pro Ser Gly Thr Met

1 5 10 15

Ser Ala Leu Gly Val Thr Val Ala Leu Leu Val Trp Ala Ala Phe Leu 20 25 30

Leu Leu Val Ser Met Trp Arg Gln Val His Ser Ser Trp Asn Leu Pro 35 40 45

Pro Gly Pro Phe Pro Leu Pro Ile Ile Gly Asn Leu Phe Gln Leu Glu 50 55 60

Leu Lys Asn Ile Pro Lys Ser Phe Thr Arg Leu Ala Gln Arg Phe Gly
65 70 75 80

Pro Val Phe Thr Leu Tyr Val Gly Ser Gln Arg Met Val Val Met His 85 90 95

Gly	Туг	Lys	Ala 100		Lys	Glu	Ala	Leu 105		ı Asp	Туг	Lys	110		Phe
Ser	Gly	Arg 115		Asp	Leu	Pro	120		His	: Ala	. His	125		Arg	Gly
Ile	Ile 130	Phe	Asn	Asn	Gly	Pro 135		Trp	Lys	Asp	140	-	Arg	Phe	Ser
Leu 145	Thr	Thr	Leu	Arg	Asn 150	_	Gly	Met	Gly	Lys 155		Gly	Asn	Glu	Ser 160
Arg	Ile	Gln	Arg	Glu 165		His	Phe	Leu	Leu 170		Ala	Leu	Arg	Lys 175	Thr
Gln	Gly	Gln	Pro 180		Asp	Pro	Thr	Phe 185		Ile	Gly	Cys	Ala 190	Pro	Cys
Asn	Val	11e 195	Ala	Asp	Ile	Leu	Phe 200	-	Lys	His	Phe	Asp 205	Tyr	Asn	Asp
Glu	Lys 210	Phe	Leu	Arg	Leu	Met 215	Tyr	Leu	Phe	Asn	Glu 220	Asn	Phe	His	Leu
Leu 225	Ser	Thr	Pro	Trp	Leu 230	Gln	Leu	Tyr	Asn	Asn 235	Phe	Pro	Ser	Phe	Leu 240
His	Tyr	Leu	Pro	Gly 245	Ser	His	Arg	Lys	Val 250	Ile	Lys	Asn	Val	Ala 255	Glu
Val	Lys	Glu	Туг 260	Val	Ser	Glu	Arg	Val 265	Lys	Glu	His	His	Gln 270	Ser	Leu
Asp	Pro	Asn 275	Cys	Pro	Arg	Asp	Leu 280	Thr	Asp	Cys	Leu	Leu 285	Val	Glu	Met
Glu	Lys 290	Glu	Lys	His	Ser	Ala 295	Glu	Arg	Leu	Tyr	Thr 300	Met	Asp	Gly	Ile
Thr 305	Val	Thr	Val	Ala	Asp 310	Leu	Phe	Phe	Ala	Gly 315	Thr	Glu	Thr	Thr	Ser 320
Thr	Thr	Leu	Arg	туг 325	Gly	Leu	Leu	Ile	Leu 330	Met	Lys	Tyr	Pro	Glu 335	Ile
Glu	Glu	Lys	Leu 340	His	Glu	Glu	Ile	Asp 345	Arg	Val	Ile	Gly	Pro 350	Ser	Arg
Ile	Pro	Ala	Ile	Lys	Asp	Arg	Gln	Glu	Met	Pro	Tyr	Met	Asp	Ala	Val

Val His Glu Ile Gln Arg Phe Ile Thr Leu Val Pro Ser Asn Leu Pro 370 375 380

His Glu Ala Thr Arg Asp Thr Ile Phe Arg Gly Tyr Leu Ile Pro Lys 385 390 395 400

Gly Thr Val Val Pro Thr Leu Asp Ser Val Leu Tyr Asp Asn Gln
405 410 415

Glu Phe Pro Asp Pro Glu Lys Phe Lys Pro Glu His Phe Leu Asn Glu
420 425 430

Asn Gly Lys Phe Lys Tyr Ser Asp Tyr Phe Lys Pro Phe Ser Thr Gly
435 440 445

Lys Arg Val Cys Ala Gly Glu Gly Leu Ala Arg Met Glu Leu Phe Leu
450 455 460

Leu Leu Cys Ala Ile Leu Gln His Phe Asn Leu Lys Pro Leu Val Asp 465 470 475 480

Pro Lys Asp Ile Asp Leu Ser Pro Ile His Ile Gly Phe Gly Cys Ile 485 490 495

Pro Pro Arg Tyr Lys Leu Cys Val Ile Pro Arg Ser 500 505

<210> 906

<211> 290

<212> PRT

<213> Homo sapiens

<400> 906

Leu Gly Pro Arg Pro Leu Ala Leu Glu Arg Gly Leu Arg Gly Thr His

Met Glu Asn Val Tyr Asp Phe Tyr Lys Pro Asn Leu Ala Ser Glu Tyr 20 25 30

Pro Ile Val Asp Gly Lys Leu Ser Ile Gln Cys Tyr Leu Arg Ala Leu 35 40 45

Asp Arg Cys Tyr Thr Ser Tyr Arg Lys Lys Ile Gln Asn Gln Trp Lys 50 55 60

Gln Ala Gly Ser Asp Arg Pro Phe Thr Leu Asp Asp Leu Gln Tyr Met 65 70 75 80

Ile Phe His Thr Pro Phe Cys Lys Met Val Gln Lys Ser Leu Ala Arg

85 90 95

Leu Met Phe Asn Asp Phe Leu Ser Ala Ser Ser Asp Thr Gln Thr Ser 100 105 110

Leu Tyr Lys Gly Leu Glu Ala Phe Gly Gly Leu Lys Leu Glu Asp Thr 115 120 125

Tyr Thr Asn Lys Asp Leu Asp Lys Ala Leu Leu Lys Ala Ser Gln Asp 130 135 140

Met Phe Asp Lys Lys Thr Lys Ala Ser Leu Tyr Leu Ser Thr His Asn 145 150 155 160

Gly Asn Met Tyr Thr Ser Ser Leu Tyr Gly Cys Leu Ala Ser Leu Leu 165 170 175

Ser His His Ser Ala Gln Glu Leu Ala Gly Ser Arg Ile Gly Ala Phe 180 185 190

Ser Tyr Gly Ser Gly Leu Ala Ala Ser Phe Phe Ser Phe Arg Val Ser 195 200 205

Gln Asp Ala Ala Pro Gly Ser Pro Leu Asp Lys Leu Val Ser Ser Thr 210 215 220

Ser Asp Leu Pro Lys Arg Leu Ala Ser Arg Lys Cys Val Ser Pro Glu 225 230 235 240

Glu Phe Thr Glu Ile Met Asn Gln Arg Glu Gln Phe Tyr His Lys Val 245 250 255

Asn Phe Ser Pro Pro Gly Asp Thr Asn Ser Leu Phe Pro Gly Thr Trp 260 265 270

Tyr Leu Glu Arg Val Asp Glu Gln His Arg Arg Lys Tyr Ala Arg Arg 275 280 285

Pro Val 290

<210> 907

<211> 242

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (198)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (215)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (222)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (242)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 907

Leu Val Pro Asn Ser Ala Arg Val Gly Thr Arg Ser Lys Gly Val Cys

1 5 10 15

Val His Gly Asn Ala Glu Tyr Gln Pro Gly Ser Pro Val Tyr Ser Ser 20 25 30

Lys Cys Gln Asp Cys Val Cys Thr Asp Lys Val Asp Asn Asn Thr Leu 35 40 45

Leu Asn Val Ile Ala Cys Thr His Val Pro Cys Asn Thr Ser Cys Ser 50 55 60

Pro Gly Phe Glu Leu Met Glu Ala Pro Gly Glu Cys Cys Lys Lys Cys 65 70 75 80

Glu Gln Thr His Cys Ile Ile Lys Arg Pro Asp Asn Gln His Val Ile 85 90 95

Leu Lys Pro Gly Asp Phe Lys Ser Asp Pro Lys Asn Asn Cys Thr Phe 100 105 110

Phe Ser Cys Val Lys Ile His Asn Gln Leu Ile Ser Ser Val Ser Asn 115 120 125

Ile Thr Cys Pro Asn Phe Asp Ala Ser Ile Cys Ile Pro Gly Ser Ile 130 135 140

Thr Phe Met Pro Asn Gly Cys Cys Lys Thr Cys Thr Pro Arg Asn Glu
145 150 155 160

Thr Arg Val Pro Cys Ser Thr Val Pro Val Thr Thr Glu Val Ser Tyr 165 170 175 Ala Gly Cys Thr Lys Thr Val Leu Met Asn His Cys Ser Gly Ser Cys 180 185 190

Gly Thr Phe Val Met Xaa Ser Ala Lys Ala Arg Pro Trp Thr Thr Ala 195 200 205

Cys Ser Cys Cys Lys Glu Xaa Lys Thr Ser Gln Arg Glu Xaa Val Leu 210 215 220

Thr Ala Gln Trp Arg Ser Leu Thr His Thr Tyr Thr Thr Ser Arg Leu 225 230 235 240

Pro Xaa

<210> 908

<211> 119

<212> PRT

<213> Homo sapiens

<400> 908

Leu Gly Leu Ala Pro Ala Leu Gly Pro Ala Ser Arg Arg Ser Arg Glu
1 5 10 15

Met Ser Asp Cys Tyr Thr Glu Leu Glu Lys Ala Val Ile Val Leu Val 20 25 30

Glu Asn Phe Tyr Lys Tyr Val Ser Lys Tyr Ser Leu Val Lys Asn Lys 35 40 45

Ile Ser Lys Ser Ser Phe Arg Glu Met Leu Gln Lys Glu Leu Asn His 50 55 60

Met Leu Ser Asp Thr Gly Asn Arg Lys Ala Ala Asp Lys Leu Ile Gln 65 70 75 80

Asn Leu Asp Ala Asn His Asp Gly Arg Ile Ser Phe Asp Glu Tyr Trp 85 90 95

Thr Leu Ile Gly Gly Ile Thr Gly Pro Ile Ala Lys Leu Ile His Glu 100 105 110

Gln Glu Gln Gln Ser Ser Ser 115

<210> 909

<211> 171

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (162)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 909

Leu Ile Ala Cys His Phe Gln Val His Phe Leu Phe Ile Phe Met Phe 1 5 10 15

Met Val Asp Cys Thr Phe Pro Ser Pro Pro Ser Gly Met Gly Gly 20 25 30

Gly Glu Gly Pro Trp Ala Leu Gln Ser His Leu Ser Arg Glu Ile 35 40 45

Pro Phe Gly Thr Gly Gly Arg Lys Ala Ala Arg Arg Gln Gln Pro Trp 50 55 60

Leu Leu Ser Phe Gly Arg Leu Gly Lys Gly Leu Pro Pro Ala Leu Gly 65 70 75 80

Phe Gln Gly Leu Thr Gly Gly Val Glu Arg Glu Gly Gly Thr Ser Ile 85 90 95

Thr Leu Lys Val Glu Ser Ser Tyr Phe Leu Arg Cys Glu Gly Phe Phe 100 105 110

Ile Ser Leu Phe Ser Glu Cys Gln Gly Ser Glu Val Pro Leu Thr Val 115 120 125

Asn Leu Trp Trp Ala Gly Ala Gly Gly Glu Gly Gly Leu Ala Pro 130 135 140

Ser Leu Pro Ala Phe Cys Cys Pro Cys Leu Thr Met Pro Ala Asn Trp 145 150 155 160

Arg Xaa His Gly Cys Thr Ser Ile Pro Pro Glu 165 170

<210> 910

<211> 46

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

```
<222> (27)
<223> Xaa equals any of the naturally occurring L-amino acids
Gly Ser Pro Thr Glu Thr Leu Leu Arg Leu Leu Pro Leu Asp Ser
                  5
                                      10
Gln Val Arg Pro Ser Ser Gln Arg Ser Ala Xaa Ala Val Gly Arg Pro
                                  25
Arg Arg Gly Arg Ser Glu Gly Leu Thr Lys Pro Ser Asn Arg
                             40
<210> 911
<211> 1242
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (224)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (1013)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (1034)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 911
Ala Pro His Leu Thr Leu Arg Pro Cys Gly Cys Cys Ser Gly Ala Gly
                 5
                                     10
Leu Leu Pro Gly Gln Gly Pro Gly Ile Met Tyr Ile Lys Gln Val Ile
           20
                                                     30
Ile Gln Gly Phe Arg Ser Tyr Arg Asp Gln Thr Ile Val Asp Pro Phe
         35
                             40
Ser Ser Lys His Asn Val Ile Val Gly Arg Asn Gly Ser Gly Lys Ser
Asn Phe Phe Tyr Ala Ile Gln Phe Val Leu Ser Asp Glu Phe Ser His
```

65

70

Leu	Arg	Pro	Glu	Glr 85	-	, Leu	ı Ala	. Leu	Let 90		Glu	Gly	Thr	Gly 95	Pro
Arg	Val	Ile	Ser 100		Phe	e Val	. Glu	Ile 105		Phe	a Asp	Asn	Ser 110	_	Asn
Arg	Leu	Pro		Asp	Lys	Glu	120		. Ser	Leu	Arg	125		Ile	Gly
Ala	Lys 130	Lys	Asp	Gln	Tyr	Phe		Asp	Lys	Lys	Met 140		Thr	Lys	Asn
Asp 145	Val	Met	Asn	Leu	Leu 150		Ser	Ala	Gly	Phe 155		Arg	Ser	Asn	Pro 160
Tyr	Tyr	Ile	Val	Lys 165		Gly	Lys	Ile	170		Met	Ala	Thr	Ala 175	Pro
Asp	Ser	Gln	Arg 180		Lys	Leu	Leu	Arg 185		Val	Ala	Gly	Thr 190	Arg	Val
Tyr	Asp	Glu 195	Arg	Lys	Glu	Glu	Ser 200	Ile	Ser	Leu	Met	Lys 205	Glu	Thr	Glu
Gly	Lys 210	Arg	Glu	Lys	Ile	Asn 215	Glu	Leu	Leu	Lys	Туг 220	Ile	Glu	Glu	Xaa
Leu 225	His	Thr	Leu	Glu	Glu 230	Glu	Lys	Glu	Glu	Leu 235	Ala	Gln	Tyr	Gln	Lys 240
Trp	Asp	Lys	Met	Arg 245	Arg	Ala	Leu	Glu	Туг 250	Thr	Ile	Tyr	Asn	Gln 255	Glu
Leu	Asn	Glu	Thr 260	Arg	Ala	Lys	Leu	Asp 265	Glu	Leu	Ser	Ala	Lys 270	Arg	Glu
Thr	Ser	Gly 275	Glu	Lys	Ser	Arg	Gln 280	Leu	Arg	Asp	Ala	Gln 285	Gln	Asp	Ala
Arg	Asp 290	Lys	Met	Glu	Asp	Ile 295	Glu	Arg	Gln	Val	Arg 300	Glu	Leu	Lys	Thr
Lys 305	Ile	Ser	Ala	Met	Lys 310	Glu	Glu	Lys	Glu	Gln 315	Leu	Ser	Ala	Glu	Arg 320
Gln	Glu-	Gln	Ile	Lys 325	Gln	Arg	Thr	Lys	Leu 330	Glu	Leu	Lys	Ala	Lys 335	Asp
Leu	Gln	Asp	Glu	Leu	Ala	Gly	Asn	Ser	Glu	Gln	Arg	Lys	Arg	Leu	Leu

Lys Glu Arg	Gln Lys Leu	Leu Glu Lys	Ile Glu Glu Lys Gln Lys	Glu
355		360	365	

- Leu Ala Glu Thr Glu Pro Lys Phe Asn Ser Val Lys Glu Lys Glu Glu 370 375 380
- Arg Gly Ile Ala Arg Leu Ala Gln Ala Thr Gln Glu Arg Thr Asp Leu 385 390 395 400
- Tyr Ala Lys Gln Gly Arg Gly Ser Gln Phe Thr Ser Lys Glu Glu Arg
 405 410 415
- Asp Lys Trp Ile Lys Lys Glu Leu Lys Ser Leu Asp Gln Ala Ile Asn 420 425 430
- Asp Lys Lys Arg Gln Ile Ala Ala Ile His Lys Asp Leu Glu Asp Thr 435 440 445
- Glu Ala Asn Lys Glu Lys Asn Leu Glu Gln Tyr Asn Lys Leu Asp Gln 450 455 460
- Asp Leu Asn Glu Val Lys Ala Arg Val Glu Glu Leu Asp Arg Lys Tyr 465 470 475 480
- Tyr Glu Val Lys Asn Lys Lys Asp Glu Leu Gln Ser Glu Arg Asn Tyr 485 490 495
- Leu Trp Arg Glu Glu Asn Ala Glu Gln Gln Ala Leu Ala Ala Lys Arg 500 505 510
- Glu Asp Leu Glu Lys Lys Gln Gln Leu Leu Arg Ala Ala Thr Gly Lys 515 520 525
- Ala Ile Leu Asn Gly Ile Asp Ser Ile Asn Lys Val Leu Asp His Phe 530 540
- Arg Arg Lys Gly Ile Asn Gln His Val Gln Asn Gly Tyr His Gly Ile 545 550 555 560
- Val Met Asn Asn Phe Glu Cys Glu Pro Ala Phe Tyr Thr Cys Val Glu 565 570 575
- Val Thr Ala Gly Asn Arg Leu Phe Tyr His Ile Val Asp Ser Asp Glu
 580 585 590
- Val Ser Thr Lys Ile Leu Met Glu Phe Asn Lys Met Asn Leu Pro Gly 595 600 605
- Glu Val Thr Phe Leu Pro Leu Asn Lys Leu Asp Val Arg Asp Thr Ala 610 615 620

_				_				_			_	_	_	_	_
Tyr 625		Glu	Thr	Asn	Asp 630		Ile	Pro	Met	635		Lys	Leu	Arg	Tyr 640
Asn	Pro	Arg	Phe	Asp 645		Ala	Phe	Lys	His 650		Phe	Gly	Lys	Thr 655	Leu
Ile	Cys	Arg	Ser 660		Glu	Val	Ser	Thr 665		Leu	Ala	Arg	Ala 670	Phe	Thr
Met	Asp	Cys 675	Ile	Thr	Leu	Glu	Gly 680	Asp	Gln	Val	Ser	His 685	Arg	Gly	Ala
Leu	Thr 690	Gly	Gly	Туг	Tyr	Asp 695	Thr	Arg	Lys	Ser	Arg 700	Leu	Glu	Leu	Gln
Lys 705	Asp	Val	Arg	Lys	Ala 710	Glu	Glu	Glu	Leu	Gly 715	Glu	Leu	Glu	Ala	Lys 720
Leu	Asn	Glu	Asn	Leu 725	Arg	Arg	Asn	Ile	Glu 730	Arg	Ile	Asn	Asn	Glu 735	Ile
Asp	Gln	Leu	Met 740	Asn	Gln	Met	Gln	Gln 745	Ile	Glu	Thr	Gln	Gln 750	Arg	Lys
Phe	Lys	Ala 755	Ser	Arg	Asp	Ser	Ile 760	Leu	Ser	Glu	Met	Lys 765	Met	Leu	Lys
Glu	Lys 770	Arg	Gln	Gln	Ser	Glu 775	Lys	Thr	Phe	Met	Pro 780	Lys	Gln	Arg	Ser
Leu 785	Gln	Ser	Leu	Glu	Ala 790	Ser	Leu	His	Ala	Met 795	Glu	Ser	Thr	Arg	Glu 800
Ser	Leu	Lys	Ala	Glu 805	Leu	Gly	Thr	Asp	Leu 810	Leu	Ser	Gln	Leu	Ser 815	Leu
Glu	Asp	Gln	Lys 820	Arg	Val	Asp	Ala	Leu 825	Asn	Asp	Glu	Ile	Arg 830	Gln	Leu
Gln	Gln	Glu 835	Asn	Arg	Gln	Leu	Leu 840	Asn	Glu	Arg	Ile	Lys 845	Leu	Glu	Gly
Ile	Ile 850	Thr	Arg	Val	Glu	Thr 855	Tyr	Leu	Asn	Glu	Asn 860	Leu	Arg	Lys	Arg
Leu 865	Asp	Gln	Val	Glu	Gln 870	Glu	Leu	Asn	Glu	Leu 875	Arg	Glu	Thr	Glu	Gly 880
Gly	Thr	Val	Leu	Thr 885	Ala	Thr	Thr	Ser	Glu 890	Leu	Glu	Ala	Ile	Asn 895	Lys

Arg	Val	Lys	Asp	Thr	Met	Ala	Arg	Ser	Glu	Asp	Leu	Asp	Asn	Ser	Ile
			900					905					910		

- Asp Lys Thr Glu Ala Gly Ile Lys Glu Leu Gln Lys Ser Met Glu Arg 915 920 925
- Trp Lys Asn Met Glu Lys Glu His Met Asp Ala Ile Asn His Asp Thr 930 935 940
- Lys Glu Leu Glu Lys Met Thr Asn Arg Gln Gly Met Leu Leu Lys Lys 945 950 955 960
- Lys Glu Glu Cys Met Lys Lys Ile Arg Glu Leu Gly Ser Leu Pro Gln
 965 970 975
- Glu Ala Phe Glu Lys Tyr Gln Thr Leu Ser Leu Lys Gln Leu Phe Arg 980 985 990
- Lys Leu Glu Gln Cys Asn Thr Glu Leu Lys Lys Tyr Ser His Val Asn 995 1000 1005
- Lys Lys Ala Leu Xaa Gln Phe Val Asn Phe Ser Glu Gln Lys Glu Lys 1010 1015 1020
- Leu Ile Lys Arg Gln Glu Glu Leu Asp Xaa Gly Tyr Lys Ser Ile Met 025 1030 1035 1040
- Glu Leu Met Asn Val Leu Glu Leu Arg Lys Tyr Glu Ala Ile Gln Leu 1045 1050 1055
- Thr Phe Lys Gln Val Ser Lys Asn Phe Ser Glu Val Phe Gln Lys Leu 1060 1065 1070
- Val Pro Gly Gly Lys Ala Thr Leu Val Met Lys Lys Gly Asp Val Glu 1075 1080 1085
- Gly Ser Gln Ser Gln Asp Glu Gly Glu Gly Ser Gly Glu Ser Glu Arg 1090 1095 1100
- Gly Ser Gly Ser Gln Ser Ser Val Pro Ser Val Asp Gln Phe Thr Gly
 105 1110 1115 1120
- Val Gly Ile Arg Val Ser Phe Thr Gly Lys Gln Gly Glu Met Arg Glu 1125 1130 1135
- Met Gln Gln Leu Ser Gly Gly Gln Lys Ser Leu Val Ala Leu Ala Leu 1140 1145 1150
- Ile Phe Ala Ile Gln Lys Cys Asp Pro Ala Pro Phe Tyr Leu Phe Asp 1155 1160 1165

Glu Ile Asp Gln Ala Leu Asp Ala Gln His Arg Lys Ala Val Ser Asp 1170 1175 1180

Met Ile Met Glu Leu Ala Val His Ala Gln Phe Ile Thr Thr Phe 185 1190 1195 1200

Arg Pro Glu Leu Leu Glu Ser Ala Asp Lys Phe Tyr Gly Val Lys Phe 1205 1210 1215

Arg Asn Lys Val Ser His Ile Asp Val Ile Thr Ala Glu Met Ala Lys 1220 1225 1230

Asp Phe Val Glu Asp Asp Thr Thr His Gly 1235 1240

<210> 912

<211> 172

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (109)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (143)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (158)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 912

Glu Glu Lys Thr Glu Pro Pro Leu Ser Phe Gly Arg Gly Trp Gln Thr
1 5 10 15

Val Lys Glu Met Ser Val Leu Arg His Val Gly Ile Gly Ser Asp Ala
20 25 30

Pro Pro Met Glu Arg Phe Val Asn Thr Lys Thr Trp Lys Val Arg Gly
35 40 45

Leu Ser Thr Lys Arg His Gly Arg Leu Gly Leu Ser Thr Gln Arg His 50 55 60

Gly Arg Leu Glu Val Cys Gln His Lys Asp Thr Gly Arg Met Gly Cys

65 70 75 80

Arg Arg Phe Arg Cys Phe Pro Phe Gly His Ile Leu Leu Ser Trp Arg 85 90 95

Thr Arg Phe Lys Thr Ala Trp Val Gly Lys Leu Glu Xaa Ser Trp Met 100 105 110

Gln Trp Ala Pro Cys Leu Leu Ile Pro Thr Leu Leu Gly Gly Ser Arg 115 120 125

Gln Glu Arg Ser Leu Gly Pro Lys Lys Ser Asn Leu Pro Ala Xaa Leu 130 135 140

Lys Ile His Thr Thr Cys Thr Pro Thr Leu Gly Phe Asn Xaa Asn Gln 145 150 155 160

Asn Pro Phe Leu Arg Lys Lys Lys Lys Lys Lys Lys Lys 165 170

<210> 913

<211> 205

<212> PRT

<213> Homo sapiens

<400> 913

Arg Thr Arg Leu Glu Ala Arg Arg Gln Gly Trp Ala Ala Ala Ala 1 5 10 15

Ala Val Met Glu Arg Gln Glu Glu Ser Leu Ser Ala Arg Pro Ala Leu 20 25 30

Glu Thr Glu Gly Leu Arg Phe Leu His Thr Thr Val Gly Ser Leu Leu $35 \hspace{1cm} 40 \hspace{1cm} 45$

Ala Thr Tyr Gly Trp Tyr Ile Val Phe Ser Cys Ile Leu Leu Tyr Val
50 55 60

Val Phe Gln Lys Leu Ser Ala Arg Leu Arg Ala Leu Arg Gln Arg Gln 65 70 75 80

Leu Asp Arg Ala Ala Ala Ala Val Glu Pro Asp Val Val Lys Arg 85 90 95

Gln Glu Ala Leu Ala Ala Ala Arg Leu Lys Met Gln Glu Glu Leu Asn 100 105 110

Ala Gln Val Glu Lys His Lys Glu Lys Leu Lys Gln Leu Glu Glu Glu 115 120 125

Lys Arg Arg Gln Lys Ile Glu Met Trp Asp Ser Met Gln Glu Gly Lys 130 135 140

Ser Tyr Lys Gly Asn Ala Lys Lys Pro Gln Glu Glu Asp Ser Pro Gly
145 150 155 160

Pro Ser Thr Ser Ser Val Leu Lys Arg Lys Ser Asp Arg Lys Pro Leu 165 170 175

Arg Gly Gly Tyr Asn Pro Leu Ser Gly Glu Gly Gly Ala Cys
180 185 190

Ser Trp Arg Pro Gly Arg Arg Gly Pro Ser Ser Gly Gly 195 200 205

<210> 914

<211> 198

<212> PRT

<213> Homo sapiens

<400> 914

Ile Leu Gln Val Pro Val Arg Asn Ser Arg Val Tyr Pro Arg Val Arg

1 5 10 15

Val Arg Asn Val Pro Trp Glu Phe Gly Asp Val Ile Pro Asp Tyr Val 20 25 30

Leu Gly Gln Ser Thr Cys Ala Leu Phe Leu Ser Leu Arg Tyr His Asn 35 40 45

Leu His Pro Asp Tyr Ile His Gly Arg Leu Gln Ser Leu Gly Lys Asn 50 55 60

Phe Ala Leu Arg Val Leu Leu Val Gln Val Asp Val Lys Asp Pro Gln 65 70 75 80

Gln Ala Leu Lys Glu Leu Ala Lys Met Cys Ile Leu Ala Asp Cys Thr 85 90 95

Leu Ile Leu Ala Trp Ser Pro Glu Glu Ala Gly Arg Tyr Leu Glu Thr
100 105 110

Tyr Lys Ala Tyr Glu Gln Lys Pro Ala Asp Leu Leu Met Glu Lys Leu 115 120 125

Glu Gln Asp Phe Val Ser Arg Val Thr Glu Cys Leu Thr Thr Val Lys 130 135 140 Ser Val Asn Lys Thr Asp Ser Gln Thr Leu Leu Thr Thr Phe Gly Ser 145 150 155 160

Leu Glu Gln Leu Ile Ala Ala Ser Arg Glu Asp Leu Ala Leu Cys Pro 165 170 175

Gly Leu Gly Pro Gln Lys Ala Arg Arg Leu Phe Asp Val Leu His Glu 180 185 190

Pro Phe Leu Lys Val Pro 195

<210> 915

<211> 300

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (70)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 915

Gly Thr Val Asp Ile Glu Ser Leu Thr Gly Tyr Arg Thr Tyr Arg Cys
1 5 10 15

Ala His Pro Leu Ala Thr Leu Phe Lys Ile Leu Ala Ser Phe Tyr Ile
20 25 30

Ser Leu Val Ile Phe Tyr Gly Leu Ile Cys Met Tyr Thr Leu Trp Trp 35 40 45

Met Leu Arg Arg Ser Leu Lys Lys Tyr Ser Phe Glu Ser Ile Arg Glu 50 55 60

Glu Ser Ser Tyr Ser Xaa Ile Pro Asp Val Lys Asn Asp Phe Ala Phe 65 70 75 80

Met Leu His Leu Ile Asp Gln Tyr Asp Pro Leu Tyr Ser Lys Arg Phe 85 90 95

Ala Val Phe Leu Ser Glu Val Ser Glu Asn Lys Leu Arg Gln Leu Asn 100 105 110

Leu Asn Asn Glu Trp Thr Leu Asp Lys Leu Arg Gln Arg Leu Thr Lys
115 120 125

Asn Ala Gln Asp Lys Leu Glu Leu His Leu Phe Met Leu Ser Gly Ile 130 135 140 Pro Asp Thr Val Phe Asp Leu Val Glu Leu Glu Val Leu Lys Leu Glu 145 150 155 160

Leu Ile Pro Asp Val Thr Ile Pro Pro Ser Ile Ala Gln Leu Thr Gly
165 170 175

Leu Lys Glu Leu Trp Leu Tyr His Thr Ala Ala Lys Ile Glu Ala Pro 180 185 190

Ala Leu Ala Phe Leu Arg Glu Asn Leu Arg Ala Leu His Ile Lys Phe 195 200 205

Thr Asp Ile Lys Glu Ile Pro Leu Trp Ile Tyr Ser Leu Lys Thr Leu 210 215 220

Glu Glu Leu His Leu Thr Gly Asn Leu Ser Ala Glu Asn Asn Arg Tyr 225 230 235 240

Ile Val Ile Asp Gly Leu Arg Glu Leu Lys Arg Leu Lys Val Leu Arg
245 250 255

Leu Lys Ser Asn Leu Ser Lys Leu Pro Gln Val Val Thr Asp Val Gly
260 265 270

Val His Leu Gln Lys Leu Ser Ile Asn Asn Glu Gly Thr Lys Leu Ile 275 280 285

Val Leu Asn Ser Leu Lys Lys Met Ala Lys Pro Asp 290 295 300

<210> 916

<211> 157

<212> PRT

<213> Homo sapiens

<400> 916

Gln Val Ala Met Gly Ser Leu Ser Gly Leu Arg Leu Ala Ala Gly Ser
1 5 10 15

Cys Phe Arg Leu Cys Glu Arg Asp Val Ser Ser Ser Leu Arg Leu Thr
20 25 30

Arg Ser Ser Asp Leu Lys Arg Ile Asn Gly Phe Cys Thr Lys Pro Gln

Glu Ser Pro Gly Ala Pro Ser Arg Thr Tyr Asn Arg Val Pro Leu His 50 55 60

Lys Pro Thr Asp Trp Gln Lys Lys Ile Leu Ile Trp Ser Gly Arg Phe 65 70 75 80

Lys Lys Glu Asp Glu Ile Pro Glu Thr Val Ser Leu Glu Met Leu Asp 85 90 95

Ala Ala Lys Asn Lys Met Arg Val Lys Ile Ser Tyr Leu Met Ile Ala 100 105 110

Leu Thr Val Val Gly Cys Ile Phe Met Val Ile Glu Gly Lys Lys Ala 115 120 125

Ala Gln Arg His Glu Thr Leu Thr Ser Leu Asn Leu Glu Lys Lys Ala 130 135 140

Arg Leu Lys Glu Glu Ala Ala Met Lys Ala Lys Thr Glu 145 150 155

<210> 917

<211> 77

<212> PRT

<213> Homo sapiens

<400> 917

Ile Lys Val Met Asn Lys Thr Phe His Pro Leu Lys His Phe Pro Val
1 5 10 15

Leu Arg Phe Leu Phe Val Phe Val Val Ser Ser Pro Cys Tyr Pro Phe 20 25 30

Cys Pro Phe Ser Leu Thr Met Val Ile Trp Ser Leu Gly Ser Tyr Gln 35 40 45

Ser Pro Arg Asp Ile Leu Gln Ser Leu Ser Pro Phe Trp Val Asp Phe 50 55 60

Ile Leu Phe Tyr Phe Val Phe Phe Lys Lys Ile Thr Phe 65 70 75

<210> 918

<211> 187

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (10)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (22)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 918

Thr Phe Ala Ala Ala Leu Ser Ser Ser Xaa Gly Cys Pro Ser Arg Ala 1 5 10 15

Gln Val Thr Thr Asp Xaa Leu Pro Ala Cys Arg Ser Cys Ala Cys Arg 20 25 30

Pro Ala Gly Leu Cys Thr Leu Gln Thr Thr Leu Leu Trp Phe Leu Gly 35 40 45

Arg Ala Gln Gln Tyr Leu Ala Ala Trp Asp Pro Ala Ser Phe Leu Leu
50 55 60

Leu Ile Gln Lys Asp Leu Pro Pro Leu Leu His Glu Ala Glu Ala Leu 65 70 75 80

Tyr Ser Leu Ala Ser Glu Glu Ser Leu Ala Leu Glu Val Glu Gln Gln 85 90 95

Leu Gly Leu Glu Ile Gln Lys Leu Thr Ala Gln Ile Gln Leu Leu Pro 100 105 110

Glu Glu Ser Leu Ser Val Phe Ser Gln Glu Cys His Lys Gln Ala Met 115 120 125

Gln Gly Phe Lys Leu Tyr Met Pro Arg Gly Arg Tyr Trp Arg Leu Arg 130 135 140

Leu Cys Pro Glu Pro Pro Ser Ala Pro Ser Glu Tyr Ala Gly Leu Val 145 150 155 160

Val Arg Thr Val Leu Glu Pro Val Leu Gln Gly Leu Gln Gly Leu His
165 170 175

Leu Lys Pro Arg Pro Leu Pro Leu Val Arg Leu 180 185

<210> 919

<211> 260

<212> PRT

<213> Homo sapiens

<400> 919
Asn Ser Arg Thr Asp Val Arg Met Glu Thr Asp Leu Glu Val Ile Ile

sh Ser Arg Thr Asp val Arg Met Glu Thr Asp Leu Glu val IIe II

1 10 15

Lys Asp Asn Ser Leu Val Leu Thr Pro Ser His Ile Lys Ala Tyr Met 20 25 30

Leu Met Thr Leu Gln Gly Leu Glu Tyr Leu His Gln His Trp Ile Leu
35 40 45

His Arg Asp Leu Lys Pro Asn Asn Leu Leu Leu Asp Glu Asn Gly Val 50 55 60

Leu Lys Leu Ala Asp Phe Gly Leu Ala Lys Ser Phe Gly Ser Pro Asn 65 70 75 80

Arg Ala Tyr Thr His Gln Val Val Thr Arg Trp Tyr Arg Ala Pro Glu
85 90 95

Leu Leu Phe Gly Ala Arg Met Tyr Gly Val Gly Val Asp Met Trp Ala 100 105 110

Val Gly Cys Ile Leu Ala Glu Leu Leu Leu Arg Val Pro Phe Leu Pro 115 120 125

Gly Asp Ser Asp Leu Asp Gln Leu Thr Arg Ile Phe Glu Thr Leu Gly
130 135 140

Thr Pro Thr Glu Glu Gln Trp Pro Asp Met Cys Ser Leu Pro Asp Tyr 145 150 155 160

Val Thr Phe Lys Ser Phe Pro Gly Ile Pro Leu His His Ile Phe Ser 165 170 175

Ala Ala Gly Asp Asp Leu Leu Asp Leu Ile Gln Gly Leu Phe Leu Phe
180 185 190

Asn Pro Cys Ala Arg Ile Thr Ala Thr Gln Ala Leu Lys Met Lys Tyr 195 200 205

Phe Ser Asn Ala Pro Gly Pro Thr Pro Gly Cys Gln Leu Pro Arg Pro 210 215 220

Asn Cys Pro Val Glu Thr Leu Lys Glu Gln Ser Asn Pro Ala Leu Ala 225 230 235 240

Ile Lys Arg Lys Arg Thr Glu Ala Leu Glu Gln Gly Gly Leu Pro Lys 245 250 255

Lys Leu Ile Phe

<210> 920 <211> 345 <212> PRT <213> Homo sapiens <400> 920

Leu Pro Val Arg Ala Glu Pro Thr Arg Ala Ala Ala Met Ser Gly Asp 1 5 10 15

Lys Pro Phe Met Leu Asp Glu Glu Gly Asp Thr Gln Thr Glu Glu Thr 35 40 45

Gln Pro Ser Glu Thr Lys Glu Val Glu Pro Glu Pro Thr Glu Asp Lys
50 55 60

Asp Leu Glu Ala Asp Glu Glu Asp Thr Arg Lys Lys Asp Ala Ser Asp 65 70 75 80

Asp Leu Asp Asp Leu Asn Phe Phe Asn Gln Lys Lys Lys Lys Lys S Lys Lys S S 90 95

Thr Lys Lys Ile Phe Asp Ile Asp Glu Ala Glu Glu Gly Val Lys Asp 100 105 110

Leu Lys Ile Glu Ser Asp Val Gln Glu Pro Thr Glu Pro Glu Asp Asp 115 120 125

Leu Asp Ile Met Leu Gly Asn Lys Lys Lys Lys Lys Lys Asn Val Lys 130 135 140

Phe Pro Asp Glu Asp Glu Ile Leu Glu Lys Asp Glu Ala Leu Glu Asp 145 150 155 160

Glu Asp Asn Lys Lys Asp Asp Gly Ile Ser Phe Ser Asn Gln Thr Gly
165 170 175

Pro Ala Trp Ala Gly Ser Glu Arg Asp Tyr Thr Tyr Glu Glu Leu Leu 180 185 190

Asn Arg Val Phe Asn Ile Met Arg Glu Lys Asn Pro Asp Met Val Ala 195 200 205

Gly Glu Lys Arg Lys Phe Val Met Lys Pro Pro Gln Val Val Arg Val 210 215 220

Gly Thr Lys Lys Thr Ser Phe Val Asn Phe Thr Asp Ile Cys Lys Leu 225 230 235 240

Leu His Arg Gln Pro Lys His Leu Leu Ala Phe Leu Leu Ala Glu Leu 245 250 255

Gly Thr Ser Gly Ser Ile Asp Gly Asn Asn Gln Leu Val Ile Lys Gly
260 265 270

Arg Phe Gln Gln Lys Gln Ile Glu Asn Val Leu Arg Arg Tyr Ile Lys 275 280 285

Glu Tyr Val Thr Cys His Thr Cys Arg Ser Pro Asp Thr Ile Leu Gln 290 295 300

Lys Asp Thr Arg Leu Tyr Phe Leu Gln Cys Glu Thr Cys His Ser Arg 305 310 315 320

Cys Ser Val Ala Ser Ile Lys Thr Gly Phe Gln Ala Val Thr Gly Lys 325 330 335

Arg Ala Gln Leu Arg Ala Lys Ala Asn 340 345

<210> 921

<211> 34

<212> PRT

<213> Homo sapiens

<400> 921

Pro Val Gln Arg Lys Ile Glu Ala Arg Ser Ala Glu Asp Ser Phe Thr 1 5 10 15

Gly Phe Val Arg Thr Leu Tyr Phe Ala Asp Thr Tyr Leu Lys Glu Cys
20 25 30

Gln Gly

<210> 922

<211> 215

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (52)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 922

Trp Ile Pro Ala Gln Asp Ser His Val Pro Pro Gly Leu Ser Met Ala 1 5 10 15

Leu Ser Trp Val Leu Thr Val Leu Ser Leu Leu Pro Leu Leu Glu Ala 20 25 30

Gln Ile Pro Leu Cys Ala Asn Leu Val Pro Val Pro Ile Thr Asn Ala 35 40 45

Thr Leu Asp Xaa Ile Thr Gly Lys Trp Phe Tyr Ile Ala Ser Ala Phe 50 55 60

Arg Asn Glu Glu Tyr Asn Lys Ser Val Gln Glu Ile Gln Ala Thr Phe
65 70 75 80

Phe Tyr Phe Thr Pro Asn Lys Thr Glu Asp Thr Ile Phe Leu Arg Glu 85 90 95

Tyr Gln Thr Arg Gln Asp Gln Cys Ile Tyr Asn Thr Thr Tyr Leu Asn 100 105 110

Val Gln Arg Glu Asn Gly Thr Ile Ser Arg Tyr Val Gly Gln Glu 115 120 125

His Phe Ala His Leu Leu Ile Leu Arg Asp Thr Lys Thr Tyr Met Leu 130 135 140

Ala Phe Asp Val Asn Asp Glu Lys Asn Trp Gly Leu Ser Val Tyr Ala 145 150 155 160

Asp Lys Pro Glu Thr Thr Lys Glu Gln Leu Gly Glu Phe Tyr Glu Ala 165 170 175

Leu Asp Cys Leu Arg Ile Pro Lys Ser Asp Val Val Tyr Thr Asp Trp 180 185 190

Lys Lys Asp Lys Cys Glu Pro Leu Glu Lys Gln His Glu Lys Glu Arg 195 200 205

Lys Gln Glu Glu Gly Glu Ser 210 215

<210> 923

<211> 358

<212> PRT

<213> Homo sapiens

<220> <221> SITE <222> (9) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (19) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (25) <223> Xaa equals any of the naturally occurring L-amino acids <400> 923 Cys Ala Met Pro Ile Gly Cys Pro Xaa Ser Ser Leu Gly Asn Ser Ala Arg Leu Xaa Gln Lys Gln Gln Gln Xaa Ala Gly Arg Glu Thr Ser Thr Cys Ser Leu Arg Ile Ile Ser Ala Pro Thr Met Ala Thr Phe Val Glu 40 Leu Ser Thr Lys Ala Lys Met Pro Ile Val Gly Leu Gly Thr Trp Lys Ser Pro Leu Gly Lys Val Lys Glu Ala Val Lys Val Ala Ile Asp Ala 70 Gly Tyr Arg His Ile Asp Cys Ala Tyr Val Tyr Gln Asn Glu His Glu 90 Val Gly Glu Ala Ile Gln Glu Lys Ile Gln Glu Lys Ala Val Lys Arg 100 105 Glu Asp Leu Phe Ile Val Ser Lys Leu Trp Pro Thr Phe Phe Glu Arg 120 Pro Leu Val Arg Lys Ala Phe Glu Lys Thr Leu Lys Asp Leu Lys Leu 130 135 Ser Tyr Leu Asp Val Tyr Leu Ile His Trp Pro Gln Gly Phe Lys Ser 145 150 Gly Asp Asp Leu Phe Pro Lys Asp Asp Lys Gly Asn Ala Ile Gly Gly. 170 165

Lys Ala Thr Phe Leu Asp Ala Trp Glu Ala Met Glu Glu Leu Val Asp

180 185 190

Glu Gly Leu Val Lys Ala Leu Gly Val Ser Asn Phe Ser His Phe Gln 195 200 205

Ile Glu Lys Leu Leu Asn Lys Pro Gly Leu Lys Tyr Lys Pro Val Thr 210 215 220

Asn Gln Val Glu Cys His Pro Tyr Leu Thr Gln Glu Lys Leu Ile Gln 225 230 235 240

Tyr Cys His Ser Lys Gly Ile Thr Val Thr Ala Tyr Ser Pro Leu Gly 245 250 255

Ser Pro Asp Arg Pro Trp Ala Lys Pro Glu Asp Pro Ser Leu Leu Glu 260 265 270

Asp Pro Lys Ile Lys Glu Ile Ala Ala Lys His Lys Lys Thr Ala Ala 275 280 285

Gln Val Leu Ile Arg Phe His Ile Gln Arg Asn Val Ile Val Ile Pro 290 295 300

Lys Ser Val Thr Pro Ala Arg Ile Val Glu Asn Ile Gln Val Phe Asp 305 310 315 320

Phe Lys Leu Ser Asp Glu Glu Met Ala Thr Ile Leu Ser Phe Asn Arg 325 330 335

Asn Trp Arg Ala Cys Asn Val Leu Gln Ser Ser His Leu Glu Asp Tyr 340 345 350

Pro Phe Asp Ala Glu Tyr 355

<210> 924

<211> 75

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (2)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 924

Asn Xaa Ala Ser Met Pro Ser Pro Gln Arg Ala Ser Thr Arg Val Met

1 5 10 15

```
Leu Ser Gly Asn Val Arg Cys Ser Cys His Arg Gly Pro Pro Pro Gly
Lys Cys Leu Val Ser Ser Gly Ser Arg Pro Gln Glu Arg Val Pro Cys
                             40
Gly Ala Leu Gly Ala Gly Pro Asp His His Gln Asp Ser Ser Leu Gly
     50
                         55
Asp Arg Val Asn Ala Ile Ser Lys Asn Lys Asn
                     70
<210> 925
<211> 252
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (7)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (50)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (54)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (226)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (227)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE'
<222> (229)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
```

<222> (249) <223> Xaa equals any of the naturally occurring L-amino acids

The rate offices any of the naturally bootstring a small document

<400> 925

Ala Thr Ala Asp Lys Glu Xaa Pro Gly Lys His Gln Lys Gly Asp Glu
1 5 10 15

Val Ala Gly Ala Gly Arg Phe Ser Glu Arg Leu Pro Glu Cys Gly Arg
20 25 30

Ala Ala Val Thr His Gln Trp Leu Ser Gln Tyr Pro Arg Ser Ser Arg.
35 40 45

Gly Xaa His Ala His Xaa Val Asn Pro Pro Tyr Tyr Ile Pro Leu Val
50 55 60

Glu Leu Val Pro His Pro Glu Thr Ala Pro Thr Thr Val Asp Arg Thr
65 70 75 80

His Ala Leu Met Lys Lys Ile Gly Gln Cys Pro Met Arg Val Gln Lys 85 90 95

Glu Val Ala Gly Phe Val Leu Asn Arg Leu Gln Tyr Ala Ile Ile Ser 100 105 110

Glu Ala Trp Arg Leu Val Glu Glu Gly Ile Val Ser Pro Ser Asp Leu 115 120 125

Asp Leu Val Met Ser Glu Gly Leu Gly Met Arg Tyr Ala Phe Ile Gly 130 135 140

Pro Leu Glu Thr Met His Leu Asn Ala Glu Gly Met Leu Ser Tyr Cys 145 150 155 160

Asp Arg Tyr Ser Glu Gly Ile Lys His Val Leu Gln Thr Phe Gly Pro 165 170 175

Ile Pro Glu Phe Ser Arg Ala Thr Ala Glu Lys Val Asn Gln Asp Met 180 185 190

Cys Met Lys Val Pro Asp Asp Pro Glu His Leu Ala Ala Arg Arg Gln 195 200 205

Trp Arg Asp Glu Cys Leu Met Arg Leu Ala Lys Leu Lys Ser Gln Val 210 215 220

Gln Xaa Xaa Trp Xaa Phe Pro Pro Phe Leu Phe Ser Leu Ile Ala Phe 225 230 235 240

Asp Tyr Ile Leu Gln Pro Val Ile Xaa Val Ser Trp 245 250 <210> 926 <211> 220 <212> PRT

<213> Homo sapiens

<400> 926

Arg Pro Pro Leu Ser Trp Ser Ala Gly Pro Ser Leu Ala Ala Pro Ala 1 5 10 15

Ala Met Ser Ser Glu Met Glu Pro Leu Leu Trp Ala Trp Ser Tyr Phe 20 25 30

Arg Arg Arg Lys Phe Gln Leu Trp Pro Ile Tyr Ala Arg Arg Cys Trp 35 40 45

Arg Ser Pro Leu Met Thr Arg Arg Leu Leu Gln Met Gly Ile Tyr Asn 50 55

Gly Gln Leu Phe Asn Asn Leu Gly Leu Cys Cys Phe Tyr Ala Gln Gln 65 70 75 80

Tyr Asp Met Thr Leu Thr Ser Phe Glu Arg Ala Leu Ser Leu Ala Glu 85 90 95

Asn Glu Glu Ala Ala Asp Val Trp Tyr Asn Leu Gly His Val Ala 100 105 110

Val Gly Ile Gly Asp Thr Asn Leu Ala His Gln Cys Phe Arg Leu Ala 115 120 125

Leu Val Asn Asn Asn Asn His Ala Glu Ala Tyr Asn Asn Leu Ala Val 130 135 140

Leu Glu Met Arg Lys Gly His Val Glu Gln Ala Arg Ala Leu Leu Gln 145 150 155 160

Thr Ala Ser Ser Leu Ala Pro His Met Tyr Glu Pro His Phe Asn Phe 165 170 175

Ala Thr Ile Ser Asp Lys Ile Gly Asp Leu Gln Arg Ser Tyr Val Ala 180 185 190

Ala Gln Lys Ser Glu Ala Ala Phe Pro Asp His Val Asp Thr Gln His 195 200 205

Leu Ile Lys Gln Leu Arg Gln His Phe Ala Met Leu 210 215 220

<210> 927 <211> 105 <212> PRT <213> Homo sapiens <400> 927 Ser Ser Trp Met Ser Ile Ser Ala Tyr Cys His Pro Ile Glu Thr Leu 5 10 Val Asp Ile Phe Gln Glu Tyr Pro Asp Glu Ile Glu Tyr Ile Phe Lys Pro Ser Cys Val Pro Leu Met Arg Cys Gly Gly Cys Cys Asn Asp Glu 40 Gly Leu Glu Cys Val Pro Thr Glu Glu Ser Asn Ile Thr Met Gln Ile 55 Met Arg Ile Lys Pro His Gln Gly Gln His Ile Gly Glu Met Ser Phe 65 70 75 Leu Gln His Asn Lys Cys Glu Cys Arg Pro Lys Lys Asp Arg Ala Arg 90 85 Gln Glu Lys Cys Asp Lys Pro Arg Arg 105 100 <210> 928 <211> 87 <212> PRT <213> Homo sapiens <220> <221> SITE

<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (36)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (47)
<223> Xaa equals any of the naturally occurring L-amino acids

<222> (10)

Cys Val Gly Xaa His Ser Gly Ser Gly Ala Ser Asp Thr Leu Xaa Pro 35 40 45

Lys Thr Ala Pro Ser Phe Arg Leu Ala Tyr Glu Met Met Phe Met Cys 50 55 60

Phe Leu Glu Thr Arg Trp Lys Glu Arg Gly Arg Ile Asn Phe Leu Ile
65 70 75 80

Leu Leu Leu Asn Val Met 85

<210> 929

<211> 263

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (252)

<223> Kaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (257)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 929

Ala Arg Ile Gly His Cys Val Glu Pro Pro Gly Ala Glu Ile Arg Met

1 5 10 15

Phe Arg Phe Met Arg Asp Val Glu Pro Glu Asp Pro Met Phe Leu Met 20 25 30

Asp Pro Phe Ala Ile His Arg Gln His Met Ser Arg Met Leu Ser Gly 35 40 45

Gly Phe Gly Tyr Ser Pro Phe Leu Ser Ile Thr Asp Gly Asn Met Pro 50 55 60

Gly Thr Arg Pro Ala Ser Arg Arg Met Gln Gln Ala Gly Ala Val Ser
65 70 75 80

Pro Phe Gly Met Leu Gly Met Ser Gly Gly Phe Met Asp Met Phe Gly 85 90 95

Met Met Asn Asp Met Ile Gly Asn Met Glu His Met Thr Ala Gly Gly
100 105 110

Asn Cys Gln Thr Phe Ser Ser Ser Thr Val Ile Ser Tyr Ser Asn Thr 115 120 125

Gly Asp Gly Ala Pro Lys Val Tyr Gln Glu Thr Ser Glu Met Arg Ser 130 135 140

Ala Pro Gly Gly Ile Arg Glu Thr Arg Arg Thr Val Arg Asp Ser Asp 145 150 155. 160

Ser Gly Leu Glu Gln Met Ser Ile Gly His His Ile Arg Asp Arg Ala 165 170 175

His Ile Leu Gln Arg Ser Arg Asn His Arg Thr Gly Asp Gln Glu Glu 180 185 190

Arg Gln Asp Tyr Ile Asn Leu Asp Glu Ser Glu Ala Ala Ala Phe Asp 195 200 205

Asp Glu Trp Arg Arg Glu Thr Ser Arg Phe Arg Gln Gln Arg Pro Leu 210 215 220

Glu Phe Arg Arg Leu Glu Ser Ser Gly Ala Gly Gly Arg Arg Arg 225 230 235 240

Gly Leu Pro Ala Trp Pro Ser Arg Asp Leu Arg Xaa Pro Leu Ser Arg 245 250 255

Xaa Ser Arg Arg Tyr Asp Trp 260

<210> 930

<211> 308

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (110)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (115) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (152) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (225) <223> Xaa equals any of the naturally occurring L-amino acids Gly Leu Asn Pro Gly Leu Val Gly Leu Ser Val Ser Tyr Ser Leu Gln Val Thr Phe Ala Leu Asn Trp Met Ile Arg Met Met Ser Asp Leu Glu 25 Ser Asn Ile Val Ala Val Glu Arg Val Lys Glu Tyr Ser Lys Thr Glu 35 40 45 . Thr Glu Ala Pro Trp Val Val Glu Gly Ser Arg Pro Pro Glu Gly Trp 50 55 Pro Pro Arg Gly Glu Val Glu Phe Arg Asn Tyr Ser Val Arg Tyr Arg Pro Gly Leu Asp Leu Val Leu Arg Asp Leu Ser Leu His Val His Gly 90 Gly Glu Lys Val Gly Ile Val Gly Arg Thr Gly Ala Gly Xaa Ser Ser 110 100 105 Met Thr Xaa Cys Leu Phe Arg Ile Leu Glu Ala Ala Lys Gly Glu Ile 115 120 Arg Ile Asp Gly Leu Asn Val Ala Asp Ile Gly Leu His Asp Leu Arg 135 Ser Gln Leu Thr Ile Ile Pro Xaa Asp Pro Ile Leu Phe Ser Gly Thr 160 145 150 155 Leu Arg Met Asn Leu Asp Pro Phe Gly Ser Tyr Ser Glu Glu Asp Ile 165 170 Trp Trp Ala Leu Glu Leu Ser His Leu His Thr Phe Val Ser Ser Gln 180 185

Pro Ala Ala Trp Asp Phe Gln Cys Ser Glu Gly Gly Glu Asn Leu Ser

195 200 205

Val Gly Gln Arg Gln Leu Val Cys Leu Ala Arg Ala Leu Leu Arg Lys 210 215 220

Xaa Arg Ile Leu Val Leu Asp Glu Ala Thr Ala Ala Ile Asp Leu Glu 225 230 235 240

Thr Asp Asn Leu Ile Gln Ala Thr Ile Arg Thr Gln Phe Asp Thr Cys 245 250 255

Thr Val Leu Thr Ile Ala His Arg Leu Asn Thr Ile Met Asp Tyr Thr 260 265 270

Arg Val Leu Val Leu Asp Lys Gly Val Val Ala Glu Phe Asp Ser Pro 275 280 285

Ala Asn Leu Ile Ala Ala Arg Gly Ile Phe Tyr Gly Met Ala Arg Asp 290 295 300

Ala Gly Leu Ala 305

<210> 931

<211> 46

<212> PRT

<213> Homo sapiens

<400> 931

Arg Gly Cys Ala Leu Ser Cys Ala Asp Val Gln His Leu Leu Tyr Phe

Asn Gly Ile Val Leu Leu Asp His Tyr Arg Thr Thr Asn Cys Gln Arg 20 25 30

Val Asn Thr Asp Asp Pro Asp Leu Thr Leu Asn Pro Leu Asp 35 40 45

<210> 932

<211> 334

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (127)

<223> Xaa equals any of the naturally occurring L-amino acids

<220> <221> SITE <222> (191) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (227) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (246) <223> Xaa equals any of the naturally occurring L-amino acids <400> 932 Glu Arg Glu Thr Ser Ser Leu Leu Leu Leu Gly Leu Ser Val Cys Ala Thr Gly Arg Lys Ala Cys Val Arg Leu Arg Glu Trp Ala Leu Ser Arg 25 Pro Leu Thr Met Glu Glu Leu Glu Gln Gly Leu Leu Met Gln Pro Trp 35 40 Ala Trp Leu Gln Leu Ala Glu Asn Ser Leu Leu Ala Lys Val Phe Ile 55 Thr Lys Gln Gly Tyr Ala Leu Leu Val Ser Asp Leu Gln Gln Val Trp 75 70 His Glu Gln Val Asp Thr Ser Val Val Ser Gln Arg Ala Lys Glu Leu 95 85 Asn Lys Arg Leu Thr Ala Pro Pro Ala Ala Phe Leu Cys His Leu Asp 100 105 Asn Leu Leu Arg Pro Leu Leu Lys Asp Ala Ala His Pro Ser Xaa Ala 120 115 Thr Phe Ser Cys Asp Cys Val Ala Asp Ala Leu Ile Leu Arg Val Arg 135 Ser Glu Leu Ser Gly Leu Pro Phe Tyr Trp Asn Phe His Cys Met Leu 160 145 150 Ala Ser Pro Ser Leu Val Ser Gln His Leu Ile Arg Pro Leu Met Gly 170 175 165

Met Ser Leu Ala Leu Gln Cys Gln Val Arg Glu Leu Ala Thr Xaa Leu

180 185 190

His Met Lys Asp Leu Glu Ile Gln Asp Tyr Gln Glu Ser Gly Ala Thr 195 200 205

Leu Ile Arg Asp Arg Leu Lys Thr Glu Pro Phe Glu Glu Asn Ser Phe 210 215 220

Leu Glu Xaa Phe Met Ile Glu Lys Leu Pro Glu Ala Cys Ser Ile Gly 225 230 235 240

Asp Gly Lys Pro Phe Xaa Met Asn Leu Gln Asp Leu Tyr Met Ala Val 245 250 255

Thr Thr Gln Glu Val Gln Val Gly Gln Lys His Gln Gly Ala Gly Asp 260 265 270

Pro His Thr Ser Asn Ser Ala Ser Leu Gln Gly Ile Asp Ser Gln Cys 275 280 285

Val Asn Gln Pro Glu Gln Leu Val Ser Ser Ala Pro Thr Leu Ser Ala 290 295 300

Pro Glu Lys Glu Ser Thr Gly Thr Ser Gly Pro Leu Gln Arg Pro Gln 305 310 315 320

Leu Ser Lys Val Lys Arg Lys Lys Pro Arg Gly Leu Phe Ser 325 330

<210> 933

<211> 89

<212> PRT

<213> Homo sapiens

<400> 933

Pro Ser Cys Gln Arg Pro Lys Ser Val Ser Trp Cys His Val His Thr 1 5 10 15

Pro Cys His Phe Thr Leu His Leu Ser Pro Ser Phe Pro Met His Ala 20 25 30

Tyr Ser Glu His Pro Cys Val Gly Pro Ser Ser Ala Ser Arg Ala Cys
35 40 45

Ser Ala Val Gly Leu Phe Cys Gly Arg Lys Glu Ala Val Ser Ala Phe 50 55 60

Ser Asp Gly Thr Gly Val Glu Gly Arg Ser Cys Ile Val Ala Leu Leu 65 70 75 80

Asn Ser Pro Phe Cys Ser Ile Leu Val 85

<210> 934

<211> 314

<212> PRT

<213> Homo sapiens

<400> 934

Asp Pro Tyr Ser Gln Ser Ala Thr Ala Phe Asn Glu Met Ile Gln Glu
1 5 10 15

Asn Gly Tyr Asn Phe Asp Arg Ser Ser Ser Thr Phe Ser Gly Ile Lys
20 25 30

Glu Leu Ala Arg Arg Phe Ala Leu Thr Phe Gly Leu Asp Gln Leu Lys 35 40 45

Thr Arg Glu Ala Ile Ala Met Leu His Lys Asp Gly Ile Glu Phe Ala 50 55 60

Phe Lys Glu Pro Asn Pro Gln Gly Glu Ser His Pro Pro Leu Asn Leu 65 70 75 80

Ala Phe Leu Asp Ile Leu Ser Glu Phe Ser Ser Lys Leu Leu Arg Gln 85 90 95

Asp Lys Arg Thr Val Tyr Val Tyr Leu Glu Lys Phe Met Thr Phe Gln 100 105 110

Met Ser Leu Arg Arg Glu Asp Val Trp Leu Pro Leu Met Ser Tyr Arg 115 120 125

Asn Ser Leu Leu Ala Gly Gly Asp Asp Asp Thr Met Ser Val Ile Ser 130 135 140

Gly Ile Ser Ser Arg Gly Ser Thr Val Arg Ser Lys Lys Ser Lys Pro 145 150 155 160

Ser Thr Gly Lys Arg Lys Val Val Glu Gly Met Gln Leu Ser Leu Thr 165 170 175

Glu Glu Ser Ser Ser Ser Asp Ser Met Trp Leu Ser Arg Glu Gln Thr

Leu His Thr Pro Val Met Met Gln Thr Pro Gln Leu Thr Ser Thr Ile 195 200 205 Met Arg Glu Pro Lys Arg Leu Arg Pro Glu Asp Ser Phe Met Ser Val 210 215 220

Tyr Pro Met Gln Thr Glu His His Gln Thr Pro Leu Asp Tyr Asn Arg 225 230 235 240

Arg Gly Thr Ser Leu Met Glu Asp Asp Glu Glu Pro Ile Val Glu Asp 245 250 255

Val Met Met Ser Ser Glu Gly Arg Ile Glu Asp Leu Asn Glu Gly Met 260 265 270

Asp Phe Asp Thr Met Asp Ile Asp Leu Pro Pro Ser Lys Asn Arg Arg 275 280 285

Glu Arg Thr Glu Leu Lys Pro Asp Phe Phe Asp Pro Ala Ser Ile Met 290 295 300

Asp Glu Ser Val Leu Gly Val Ser Met Phe 305 310

<210> 935

<211> 109

<212> PRT

<213> Homo sapiens

<400> 935

Thr His Leu Ile Lys Glu Asn Ile Phe Pro Ala Arg Lys Val Tyr Ser 1 5 10 15

Phe Ser Phe Lys Leu Ser His Leu Glu Gly Ser Cys Glu Leu Ala Tyr 20 25 30

Leu Gln Val Val Lys Val Pro Phe Ser Val Leu Phe Cys Phe Val Leu 35 40 45

Phe Phe Ser Phe Thr Gln Pro Asn Val Lys Val Val Asn Leu Gly Lys 50 55 60

Ser Leu Val Met Lys Cys Glu Ser Cys Tyr Gln Ile Tyr Phe Ser Asp 65 70 75 80

Val Ser Phe Leu Ile Leu Val Ala Asn Lys Thr Leu Thr Phe Ser Arg 85 90 95

Phe Ile Asp Glu Val Lys Ser Leu Val Cys Cys Glu Leu 100 105

```
<210> 936
<211> 82
<212> PRT
<213> Homo sapiens
<400> 936
Phe Gly Leu Phe Cys Thr Leu Tyr Lys Trp Thr His Ile Met Phe Ile
                                     10
Phe Trp Val Cys Leu Leu Ser Phe Asn Ile Arg Phe Val Gly Ser Ser
                                 25
Leu Leu Cys Val Val Leu Ser Cys Ser Leu Tyr Ser Val Pro Lys Tyr
                             40
         35
Ser Ile Leu Gln Phe Thr His Ser Thr Leu Asp Ser Lys Cys Phe His
     50
Ile Trp Ala Ile Thr Asn Ser Ala Ala Val Asn Ile His Ile His Ile
                                         75
                     70
Phe Trp
<210> 937
<211> 237
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (79)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (85)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 937
Phe Gln Leu Tyr Glu Lys Phe Leu His Arg Tyr Lys Met Ile Ser Glu
                                     10
Phe Thr Trp Pro Asn His Asp Leu Pro Ser Asp Lys Glu Ala Val Lys
                                 25
             20
```

Lys Leu Ile Glu Arg Cys Gly Phe Gln Asp Asp Val Ala Tyr Gly Lys 40

35

Thr Lys Ile Phe Ile Arg Thr Pro Arg Thr Leu Phe Thr Leu Glu Glu 50 55 60

Leu Arg Ala Gln Met Leu Ile Arg Ile Val Leu Phe Leu Gln Xaa Val 65 70 75 80

Trp Arg Gly Thr Xaa Ala Arg Met Arg Tyr Lys Arg Thr Lys Ala Ala 85 90 95

Leu Thr Ile Ile Arg Tyr Tyr Arg Arg Tyr Lys Val Lys Ser Tyr Ile 100 105 110

His Glu Val Ala Arg Arg Phe His Gly Val Lys Thr Met Arg Asp Tyr 115 120 125

Gly Lys His Val Lys Trp Pro Ser Pro Pro Lys Val Leu Arg Arg Phe 130 135 140

Glu Glu Ala Leu Gln Thr Ile Phe Asn Arg Trp Arg Ala Ser Gln Leu 145 150 155 160

Ile Lys Ser Ile Pro Ala Ser Asp Leu Pro Gln Val Arg Ala Lys Val 165 170 175

Ala Ala Val Glu Met Leu Lys Gly Gln Arg Ala Asp Leu Gly Leu Gln 180 185 190

Arg Ala Trp Glu Gly Asn Tyr Leu Ala Ser Lys Pro Asp Thr Pro Gln
195 200 205

Thr Ser Gly Thr Phe Val Pro Val Ala Asn Glu Leu Lys Arg Lys Asp 210 215 220

Lys Tyr Met Asn Val Leu Phe Ser Cys His Val Arg Lys 225 230 235

<210> 938 -

<211> 752

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (748)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 938

Ala Cys Trp Pro Ala Gly Leu Ser Arg His Ala Arg Pro Leu Ser Asn

PCT/US00/05883 WO 00/55351

Lys Met Leu Gln Gln Val Pro Glu Asn Ile Asn Phe Pro Ala Glu Glu Glu Lys Ile Leu Glu Phe Trp Thr Glu Phe Asn Cys Phe Gln Glu Cys Leu Lys Gln Ser Lys His Lys Pro Lys Phe Thr Phe Tyr Asp Gly Pro Pro Phe Ala Thr Gly Leu Pro His Tyr Gly His Ile Leu Ala Gly Thr Ile Lys Asp Ile Val Thr Arg Tyr Ala His Gln Ser Gly Phe His Val Asp Arg Arg Phe Gly Trp Asp Cys His Gly Leu Pro Val Glu Tyr Glu Ile Asp Lys Thr Leu Gly Ile Arg Gly Pro Glu Asp Val Ala Lys Met Gly Ile Thr Glu Tyr Asn Asn Gln Cys Arg Ala Ile Val Met Arg Tyr Ser Ala Glu Trp Lys Ser Thr Val Ser Arg Leu Gly Arg Trp Ile Asp Phe Asp Asn Asp Tyr Lys Thr Leu Tyr Pro Gln Phe Met Glu Ser Val Trp Trp Val Phe Lys Gln Leu Tyr Asp Lys Gly Leu Val Tyr Arg Gly Val Lys Val Met Pro Phe Ser Thr Ala Cys Asn Thr Pro Leu Ser Asn Phe Glu Ser His Gln Asn Tyr Lys Asp Val Gln Asp Pro Ser Val Phe Val Thr Phe Pro Leu Glu Glu Asp Glu Thr Val Ser Leu Val Ala Trp Thr Thr Thr Pro Trp Thr Leu Pro Ser Asn Leu Ala Val Cys Val Asn Pro Glu Met Gln Tyr Val Lys Ile Lys Asp Val Ala Arg Gly Arg Leu Leu Ile Leu Met Glu Ala Arg Leu Ser Ala Leu Tyr Lys Leu Glu Ser

275		280		285
Asp Tyr Glu 290	Ile Leu Glu	Arg Phe P	Pro Gly Ala Tyr 300	Leu Lys Gly Lys
Lys Tyr Arg 305	Pro Leu Phe 310	Asp Tyr P	Phe Leu Lys Cys 315	Lys Glu Asn Gly 320
Ala Phe Thr	Val Leu Val 325	Asp Asn T	Tyr Val Lys Glu 330	Glu Glu Gly Thr 335
Gly Val Val	His Gln Ala 340		Phe Gly Ala Glu 345	Asp Tyr Arg Val
Cys Met Asp 355	Phe Asn Ile	Ile Arg L 360	Lys Asp Ser Leu	Pro Val Cys Pro 365
Val Asp Ala 370	Ser Gly Cys	Phe Thr T	Thr Glu Val Thr 380	Asp Phe Ala Gly
Gln Tyr Val 385	Lys Asp Ala 390	Asp Lys S	Ser Ile Ile Arg 395	Thr Leu Lys Glu 400
Gln Gly Arg	Leu Leu Val 405	Ala Thr T	Thr Phe Thr His	Ser Tyr Pro Phe 415
Cys Trp Arg	Ser Asp Thr 420		ile Tyr Lys Ala 125	Val Pro Ser Trp 430
Phe Val Arg 435	Val Glu Asn	Met Val A 440	asp Gln Leu Leu	Arg Asn Asn Asp 445
Leu Cys Tyr 450	Trp Val Pro	Glu Leu V 455	val Arg Glu Lys 460	Arg Phe Gly Asn
Trp Leu Lys 465	Asp Ala Arg 470	Asp Trp T	thr Ile Ser Arg 475	Asn Arg Tyr Trp 480
Gly Thr Pro	Ile Pro Leu 485	Trp Val S	er Asp Asp Phe 490	Glu Glu Val Val 495
Cys Ile Gly	Ser Val Ala 500		lu Glu Leu Ser 05	Gly Ala Lys Ile 510
Ser Asp Leu 515	His Arg Glu	Ser Val A 520	sp His Leu Thr	Ile Pro Ser Arg 525
Cys Gly Lys 530	Gly Ser Leu	His Arg I 535	le Ser Glu Val 540	Phe Asp Cys Trp
Phe Glu Ser	Gly Ser Met	Pro Tyr A	la Gln Val His	Tyr Pro Phe Glu

545					550					555					560
Asn	Lys	Arg	Glu	Phe 565	Glu	Asp	Ala	Phe	Pro 570	Ala	Asp	Phe	Ile	Ala 575	Glu
Gly	Ile	Asp	Gln 580	Thr	Arg	Gly	Trp	Phe 585	Tyr	Thr	Leu	Leu	Val 590	Leu	Ala
Thr	Ala	Leu 595	Phe	Gly	Gln	Pro	Pro 600	Phe	Lys	Asn	Val	11e 605	Val	Asn	Gly
Leu	Val 610	Leu	Ala	Ser	Asp	Gly 615	Gln	Lys	Met	Ser	Lys 620	Arg	Lys	Lys	Asn
Tyr 625	Pro	Asp	Pro	Val	Ser 630	Ile	Ile	Gln	Lys	Туг 635	Gly	Ala	Asp	Ala	Leu 640
Arg	Leu	Tyr	Leu	Ile 645	Asn	Ser	Pro	Val	Val 650	Arg	Ala	Glu	Asn	Leu 655	Arg
Phe	Lys	Glu	Glu 660	Gly	Val	Arg	Asp	Val 665	Leu	Lys	Asp	Val	Leu 670	Leu	Pro
Trp	Tyr	Asn 675	Ala	Tyr	Arg	Phe	Leu 680	Ile	Gln	Asn	Val	Leu 685	Arg	Leu	Gln
Lys	Glu 690	Glu	Glu	Ile	Glu	Phe 695	Leu	Tyr	Asn	Glu	Asn 700	Thr	Val	Arg	Glu
Ser 705	Pro	Asn	Ile	Thr	Asp 710	Arg	Trp	Ile	Leu	Ser 715	Phe	Met	Gln	Ser	Leu 720
Ile	Gly	Phe	Phe	Glu 725	Thr	Glu	Met	Ala	Gly 730	Glu	Ser	Leu	Leu	Val 735	Cys
Pro	Pro	Arg	Asn 740	Lys	Asp	Tyr	Ser	Leu 745	Cys	Asn	Xaa	Pro	Phe 750	Asp	Ile

<210> 939

<211> 104

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (75)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 939

Met Arg Arg Val Ile Leu His Ser Pro Leu Met Ser Gly Leu Arg Val 1 5 10 15

Ala Phe Pro Asp Thr Arg Lys Thr Tyr Cys Phe Asp Ala Phe Pro Ser 20 25 30

Ile Asp Lys Ile Ser Lys Val Thr Ser Pro Val Leu Val Ile His Gly 35 40 45

Thr Glu Asp Glu Val Ile Asp Phe Ser His Gly Leu Ala Met Tyr Glu 50 55 60

Arg Cys Pro Arg Ala Val Glu Pro Leu Trp Xaa Glu Gly Ala Gly His 65 70 75 80

Asn Asp Ile Glu Leu Tyr Ala Gln Tyr Leu Glu Arg Leu Lys Gln Phe 85 90 95

Ile Ser His Glu Leu Pro Asn Ser 100

<210> 940

<211> 557

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (6)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (19)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (25)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (53)

<223> Xaa equals any of the naturally occurring L-amino acids

```
<220>
<221> SITE
<222> (248)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (273)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (323)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 940·
Gly Glu Gly Gly Xaa Arg Arg Gly Arg Pro Ala Ala Gly Arg Pro
Arg Arg Xaa Arg Thr Ala Gly Arg Xaa Gly Gly Thr Gly Ala Pro Ala
Gly Ala Ser Ala His Arg Asp Ala Gly Leu Leu Arg Glu Arg Pro Ala
                             40
Ala Gly Glu Ala Xaa Gly Arg Thr Glu Leu Ser Leu Leu Arg Phe Leu
     50
                         55
Ser Ala Glu Leu Thr Arg Gly Tyr Phe Leu Glu His Asn Glu Ala Lys
                                        75
                    70
Tyr Thr Glu Arg Arg Glu Arg Val Tyr Thr Cys Leu Arg Ile Pro Arg
Glu Leu Glu Lys Leu Met Val Phe Gly Ile Phe Leu Cys Leu Asp Ala
                              105
Phe Leu Tyr Val Phe Thr Leu Leu Pro Leu Arg Val Phe Leu Ala Leu
        115
                           120
                                                125
Phe Arg Leu Leu Thr Leu Pro Cys Tyr Gly Leu Arg Asp Arg Leu
    130
                        135
Leu Gln Pro Ala Gln Val Cys Asp Ile Leu Lys Gly Val Ile Leu Val
                                       155
                    150
Ile Cys Tyr Phe Met Met His Tyr Val Asp Tyr Ser Met Met Tyr His
                                   170
Leu Ile Arg Gly Gln Ser Val Ile Lys Leu Tyr Ile Ile Tyr Asn Met
                              185
                                                   190
            180
```

By (contd)

Leu	Glu	Val 195	Ala	Asp	Arg	Leu	Phe 200	Ser	Ser	Phe	Gly	Gln 205	Asp	Ile	Leu
Asp	Ala 210	Leu	Tyr	Trp	Thr	Ala 215	Thr	Glu	Pro	Lys	Glu 220	Arg	Lys	Arg	Ala
His 225	Ile	Gly	Val	Ile	Pro 230	His	Phe	Phe	Met	Ala 235	Val	Leu	туг	Val	Phe 240
Leu	His	Ala	Ile	Leu 245	Ile	Met	Xaa	Gln	Ala 250	Thr	Thr	Leu	Asn	Val 255	Ala
Phe	Asn	Ser	His 260	Asn	Lys	Ser	Leu	Ser 265	Thr	Ile	Met	Met	Ser 270	Asn	Asn
Xaa	Val	Glu 275	Ile	Lys	Gly	Ser	Val 280	Phe	Lys	Lys	Phe	Glu 285	Lys	Asn	Asn
Leu	Phe 290	Gln	Met	Ser	Asn	ser 295	Asp	Ile	Lys	Glu	Arg 300	Phe	Thr	Asn	Tyr
Val 305	Leu	Leu	Leu	Ile	Val 310	Cys	Leu	Arg	Asn	Met 315	Glu	Gln	Phe	Ser	Trp 320
Asn	Pro	Xaa	His	Leu 325	Trp	Val	Leu	Phe	Pro 330	Asp	Val	Cys	Met	Val 335	Ile
Ala	Ser	Glu	Ile 340	Ala	Val	Asp	Ile	Val 345	Lys	His	Ala	Phe	Ile 350	Thr	Lys
Phe	Asn	Asp 355	Ile	Thr	Ala	Asp	Val 360	Tyr	Ser	Glu	Tyr	Arg 365	Ala	Ser	Leu
Ala	Phe 370	Asp	Leu	Val	Ser	Ser 375	Arg	Gln	Lys	Asn	Ala 380	Tyr	Thr	Asp	Tyr
Ser 385	Asp	Ser	Val	Ala	Arg 390	Arg	Met	Gly	Phe	Ile 395	Pro	Leu	Pro	Leu	Ala 400
Val	Leu	Leu	Ile	Arg 405	Val	Val	Thr	Ser	Ser 410	Ile	Lys	Val	Gln	Gly 415	Ile
Leu	Ser	Tyr	Ala 420	Cys	Val	Ile	Leu	Phe 425	Tyr	Phe	Gly	Leu	Ile 430	Ser	Leu .
Lys	Val	Leu 435	Asn	Ser	Ile	Val	Leu 440	Leu	Gly	Lys	Ser	Cys 445	Gln	Tyr	Val
Lys	Glu	Ala	Lys	Met	Glu	Glu	Lys	Leu	Ser	Asn	Pro	Pro	Ala	Thr	Cys

460

Thr Pro Gly Lys Pro Ser Ser Lys Ser Gln Asn Lys Cys Lys Pro Ser 465 470 475 480

Gln Gly Leu Ser Thr Glu Glu Asn Leu Ser Ala Ser Ile Thr Lys Gln 485 490 495

Pro Ile His Gln Lys Glu Asn Ile Ile Pro Leu Leu Val Thr Ser Asn 500 505 510

Ser Asp Gln Phe Leu Thr Thr Pro Asp Gly Asp Glu Lys Asp Ile Thr 515 520 525

Gln Asp Asn Ser Glu Leu Lys His Arg Ser Ser Lys Lys Asp Leu Leu 530 540

Glu Ile Asp Arg Phe Thr Ile Cys Gly Asn Arg Ile Asp 545 550 555

<210> 941

<211> 707

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (265)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (271)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (307)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 941

Pro Thr Arg Pro Val Leu Pro Val Ser Arg Cys Ser Gly Ala Phe Gln
1 5 10 15

Pro Ser Val Ser Arg Arg Ser Gln Ala Gly Ser Ser Lys Phe Pro Thr 20 25 30

Pro Leu Gly Pro Glu Asn Ser Gly Asn Pro Thr Leu Leu Ser Ser Ala 35 40 45

Gln	Pro 50	Glu	Thr	Arg	Val	Ser 55	Tyr	Trp	Thr	Lys	Leu 60	Leu	Ser	Gln	Leu
Leu 65	Ala	Pro	Leu	Pro	Gly 70	Leu	Leu	Gln	Lys	Val 75	Leu	Ile	Trp	Ser	Gln 80
Leu	Phe	Gly	Gly	Met 85	Phe	Pro	Thr	Arg	Trp 90	Leu	Asp	Phe	Ala	Gly 95	Val
Tyr	Ser	Ala	Leu 100	Arg	Ala	Leu	Lys	Gly 105	Arg	Glu	Lys	Pro	Ala 110	Ala	Pro
Thr	Ala	Gln 115	Lys	Ser	Leu	Ser	Ser 120	Leu	Gln	Leu	Asp	Ser 125	Ser	Asp	Pro
Ser	Val 130	Thr	Ser	Pro	Leu	Asp 135	Trp	Leu	Glu	Glu	Gly 140	Ile	His	Trp	Gln
Tyr 145	Ser	Pro	Pro	Asp	Leu 150	Lys	Leu	Glu	Leu	Lys 155	Ala	Lys	Gly	Ser	Ala 160
Leu	Asp	Pro	Ala	Ala 165	Gln	Ala	Phe	Leu	Leu 170	Glu	Gln	Gln	Leu	Trp 175	Gly
Val	Glu	Leu	Leu 180	Pro	Ser	Ser	Leu	Gln 185	Ser	Arg	Leu	Tyr	Ser 190	Asn	Arg
Glu	Leu	Gly 195	Ser	Ser	Pro	Ser	Gly 200	Leu	Leu	Asn	Ile	Gln 205	Arg	Ile	Asp
Asn	Phe 210	Ser	Val	Val	Ser	Tyr 215		Leu	Asn	Pro	Ser 220	Tyr	Leu	Asp	Cys
Phe 225	Pro	Arg	Leu	Glu	Val 230	Ser	Tyr	Gln	Asn	Ser 235	Asp	Gly	Asn	Ser	Glu 240
Val	Val	Gly	Phe	Gln 245	Thr	Leu	Thr	Pro	Glu 250	Ser	Ser	Cys	Leu	Arg 255	Glu
Asp	His	Cys	His 260	Pro	Gln	Pro	Leu	Xaa 265	Ala	Glu	Leu	Ile	Pro 270	Xaa	Ser
Trp	Gln	Gly 275	Cys	Pro	Pro	Leu	Ser 280	Thr	Glu	Gly	Leu	Pro 285	Glu	Ile	His
His	Leu 290	Arg	Met	Lys	Arg	Leu 295	Glu	Phe	Leu	Gln	Gln 300	Ala	Ser	Lys	Gly
Gln 305	Asp	Xaa	Pro	Thr	Pro 310	Asp	Gln	Asp	Asn	Gly 315	Tyr	His	Ser	Leu	Glu 320

Glu	Glu	His	Ser	Leu 325	Leu	Arg	Met	Asp	Pro 330	Lys	His	Cys	Arg	Asp 335	Asn
Pro	Thr	Gln	Phe 340	Val	Pro	Ala	Ala	Gly 345	Asp	Ile	Pro	Gly	Asn 350	Thr	Gln
Glu	Ser	Thr 355	Glu	Glu	Lys	Ile	Glu 360	Leu	Leu	Thr	Thr	Glu 365	Val	Pro	Leu
Ala	Leu 370	Glu	Glu	Glu	Ser	Pro 375	Ser	Glu	Gly	Cys	Pro 380	Ser	Ser	Glu	Ile
Pro 385	Met	Glu	Lys	Glu	Pro 390	Gly	Glu	Gly	Arg	Ile 395	Ser	Val	Val	Asp	Tyr 400
Ser	туr	Leu	Glu	Gly 405	Asp	Leu	Pro	Ile	Ser 410	Ala	Arg	Pro	Ala	Cys 415	Ser
Asn	Lys	Leu	11e 420	Asp	Tyr	Ile	Leu	Gly 425	Gly	Ala	Ser	Ser	Asp 430	Leu	Glu
Thr	Ser	Ser 435	Asp	Pro	Glu	Gly	Glu 440	Asp	Trp	Asp	Glu	Glu 445	Ala	Glu	Asp
Asp	Gly 450	Phe	Asp	Ser	Asp	Ser 455	Ser	Leu	Ser	Asp	Ser 460	Asp	Leu	Glu	Gln
Asp 465	Pro	Glu	Gly	Leu	His 470	Leu	Trp	Asn	Ser	Phe 475	Cys	Ser	Val	Asp	Pro 480
Tyr	Asn	Pro	Gln	Asn 485	Phe	Thr	Ala	Thr	Ile 490	Gln	Thr	Ala	Ala	Arg 495	Ile
Val	Pro	Glu	Glu 500	Pro	Ser	Asp	Ser	Glu 505	Lys	Asp	Leu	Ser	Gly 510	Lys	Ser
Asp	Leu	Glu 515	Asn	Ser	Ser	Gln	Ser 520	Gly	Ser	Leu	Pro	Glu 525	Thr	Pro	Glu
His	Ser 530	Ser	Gly	Glu	Glu	Asp 535	Asp	Trp	Glu	Ser	Ser 540	Ala	Asp	Glu	Ala
Glu 545	Ser	Leu	Lys	Leu	Trp 550	Asn	Ser	Phe	Cys	Asn 555	Ser	Asp	Asp	Pro	Туг 560
Asn	Pro	Leu	Asn	Phe 565	Lys	Ala	Pro	Phe	Gln 570	Thr	Ser	Gly	Glu	Asn 575	Glu
Lys	Gly	Cys	Arg 580	Asp	Ser	Lys	Thr	Pro 585	Ser	Glu	Ser	Ile	Val 590	Ala	Ile

Ser Glu Cys His Thr Leu Leu Ser Cys Lys Val Gln Leu Leu Gly Ser 600 595

Gln Glu Ser Glu Cys Pro Asp Ser Val Gln Arg Asp Val Leu Ser Gly 615 620

Gly Arg His Thr His Val Lys Arg Lys Lys Val Thr Phe Leu Glu Glu 630 635

Val Thr Glu Tyr Tyr Ile Ser Gly Asp Glu Asp Arg Lys Gly Pro Trp 650

Glu Glu Phe Ala Arg Asp Gly Cys Arg Phe Gln Lys Arg Ile Gln Glu 665 660

Thr Glu Asp Ala Ile Gly Tyr Cys Leu Thr Phe Glu His Arg Glu Arg 680

Met Phe Asn Arg Leu Gln Gly Thr Cys Phe Lys Gly Leu Asn Val Leu 700 695

Lys Gln Cys 705

<210> 942

<211> 259

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (67)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (72)

<223> Xaa equals any of the naturally occurring L-amino acids

Arg Ile Thr Phe Ser Cys Ile Asn Tyr Ser Thr Gln Glu Leu Leu Arg 5 10

Phe Pro Lys Leu His Asp Ala Ile Val Glu Val Val Thr Cys Leu Leu 20 25

Arg Lys Arg Leu Pro Val Thr Asn Glu Met Val His Asn Leu Val Ala 45 40 35

65 70 75 80

Ala Arg Glu Leu Pro Ser Ala Val Ser Arg Asp Lys Val Ala Ser Gly 85 90 95

Gly Gly Gly Val Gly Asp Gly Val Gln Glu Pro Thr Thr Gly Asn Trp 100 105 110

Arg Gly Met Leu Lys Thr Ser Lys Ala Glu Glu Leu Leu Ala Glu Glu 115 120 125

Lys Ser Lys Pro Ile Pro Ile Met Pro Ala Ser Pro Gln Lys Gly His 130 135 140

Ala Val Asn Leu Leu Asp Val Pro Val Pro Val Ala Arg Lys Leu Ser 145 150 155 160

Ala Arg Glu Gln Arg Asp Cys Glu Val Ile Glu Arg Leu Ile Lys Ser 165 170 175

Tyr Phe Leu Ile Val Arg Lys Asn Ile Gln Asp Ser Val Pro Lys Ala 180 185 190

Val Met His Phe Leu Val Asn His Val Lys Asp Thr Leu Gln Ser Glu 195 200 205

Leu Val Gly Gln Leu Tyr Lys Ser Ser Leu Leu Asp Asp Leu Leu Thr 210 215 220

Glu Ser Glu Asp Met Ala Gln Arg Arg Lys Glu Ala Ala Asp Met Leu 225 230 235 240

Lys Ala Leu Gln Gly Ala Ser Gln Ile Ile Ala Glu Ile Arg Glu Thr 245 250 255

His Leu Trp

<210> 943

<211> 369

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (185) <223> Xaa equals any of the naturally occurring L-amino acids <400> 943 Arg Cys Arg Gly Gly Arg Lys Met Glu Leu Gly Ser Cys Leu Glu Gly 5 Gly Arg Glu Ala Ala Glu Glu Glu Gly Glu Pro Glu Val Lys Lys Arg 25 20 Arg Leu Leu Cys Val Glu Phe Ala Ser Val Ala Ser Cys Asp Ala Ala 40 Val Ala Gln Cys Phe Leu Ala Glu Asn Asp Trp Glu Met Glu Arg Ala 55 Leu Asn Ser Tyr Phe Glu Pro Pro Val Glu Glu Ser Ala Leu Glu Arg 65 70 75 Arg Pro Glu Thr Ile Ser Glu Pro Lys Thr Tyr Val Asp Leu Thr Asn 85 Glu Glu Thr Thr Asp Ser Thr Thr Ser Lys Ile Ser Pro Ser Glu Asp 105 Thr Gln Gln Glu Asn Gly Ser Met Phe Ser Leu Ile Thr Trp Asn Ile 115 120 Asp Gly Leu Asp Leu Asn Asn Leu Ser Glu Arg Ala Arg Gly Val Cys 130 135 Ser Tyr Leu Ala Leu Tyr Ser Pro Asp Val Ile Phe Leu Gln Glu Val 145 150 Ile Pro Pro Tyr Tyr Ser Tyr Leu Lys Lys Arg Ser Ser Asn Tyr Glu 170 Ile Ile Thr Gly His Glu Glu Gly Xaa Phe Thr Ala Ile Met Leu Lys 180 185 Lys Ser Arg Val Lys Leu Lys Ser Gln Glu Ile Ile Pro Phe Pro Ser 195 200 Thr Lys Met Met Arg Asn Leu Cys Val His Val Asn Val Ser Gly 215 220 Asn Glu Leu Cys Leu Met Thr Ser His Leu Glu Ser Thr Arg Gly His 235 230

Ala Ala Glu Arg Met Asn Gln Leu Lys Met Val Leu Lys Lys Met Gln

250

Glu Ala Pro Glu Ser Ala Thr Val Ile Phe Ala Gly Asp Thr Asn Leu 260 265 270

Arg Asp Arg Glu Val Thr Arg Cys Gly Gly Leu Pro Asn Asn Ile Val 275 280 285

Asp Val Trp Glu Phe Leu Gly Lys Pro Lys His Cys Gln Tyr Thr Trp 290 295 300

Asp Thr Gln Met Asn Ser Asn Leu Gly Ile Thr Ala Ala Cys Lys Leu 305 310 315 320

Arg Phe Asp Arg Ile Phe Phe Arg Ala Ala Ala Glu Glu Gly His Ile 325 330 335

Ile Pro Arg Ser Leu Asp Leu Leu Gly Leu Glu Lys Leu Asp Cys Gly 340 345 350

Arg Phe Pro Ser Asp His Trp Gly Leu Leu Cys Asn Leu Asp Ile Ile 355 360 365

Leu

<210> 944

<211> 158

<212> PRT

<213> Homo sapiens

<400> 944

Tyr Ile Gln Phe Met Val Ser Tyr Asn Pro Thr Pro Arg Leu Asp Val 1 5 10 15

Ser Ser Pro Asn Glu Ala Gly Arg Pro Glu Trp Glu Val His Val Ser 20 25 30

Tyr His Ser Ser Phe Tyr Val Gly Gly Cys Ser Ala Ala Arg Arg Val
35 40 45

Met Gly Val Asn Pro Tyr Ile Leu Lys Lys Asn Met Ile Leu Met Thr 50 55 60

Asn His Phe Tyr Ala Ala Ile Leu Gly Tyr Asp Glu Gly Ile Leu Ser 65 70 75 80

Asp Asp His Gly Leu Ala Ala Ala Leu Trp Arg Thr Phe Phe Asn Arg 85 90 95

Lys Cys Glu Asp Pro Arg His Leu Glu Leu Leu Val Glu Tyr Val Arg 100 105 110

Lys Gln Ile Gln Tyr Leu Asp Ser Met Asn Gly Glu Asp Leu Leu 115 120 125

Thr Gly Glu Val Ser Trp Arg Pro Leu Val Glu Lys Asn Pro Gln Ser 130 135 140

<210> 945

<211> 294

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (8)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 945

Lys Leu Val Pro Ala Arg Pro Xaa Asp Thr Gln Cys Arg Arg Pro Ser

1 5 10 15

Arg Arg Gln Ile Gly Ala Asp Ser Cys Pro Ala Pro Thr Ala Ser
20 25 30

Ala Thr Met Ser His His Trp Gly Tyr Gly Lys His Asn Gly Pro Glu
35 40 45

His Trp His Lys Asp Phe Pro Ile Ala Lys Gly Glu Arg Gln Ser Pro 50 55 60

Val Asp Ile Asp Thr His Thr Ala Lys Tyr Asp Pro Ser Leu Lys Pro 65 70 75 80

Leu Ser Val Ser Tyr Asp Gln Ala Thr Ser Leu Arg Ile Leu Asn Asn 85 90 95

Gly His Ala Phe Asn Val Glu Phe Asp Asp Ser Gln Asp Lys Ala Val 100 105 110

Leu Lys Gly Gly Pro Leu Asp Gly Thr Tyr Arg Leu Ile Gln Phe His 115 120 125

Phe His Trp Gly Ser Leu Asp Gly Gln Gly Ser Glu His Thr Val Asp 130 135 140 Lys Lys Lys Tyr Ala Ala Glu Leu His Leu Val His Trp Asn Thr Lys 145 150 155 160

Tyr Gly Asp Phe Gly Lys Ala Val Gln Gln Pro Asp Gly Leu Ala Val 165 170 175

Leu Gly Ile Phe Leu Lys Val Gly Ser Ala Lys Pro Gly Leu Gln Lys 180 185 190

Val Val Asp Val Leu Asp Ser Ile Lys Thr Lys Gly Lys Ser Ala Asp 195 200 205

Phe Thr Asn Phe Asp Pro Arg Gly Leu Leu Pro Glu Ser Leu Asp Tyr 210 215 220

Trp Thr Tyr Pro Gly Ser Leu Thr Thr Pro Pro Leu Leu Glu Cys Val 225 230 235 240

Thr Trp Ile Val Leu Lys Glu Pro Ile Ser Val Ser Ser Glu Gln Val 245 250 255

Leu Lys Phe Arg Lys Leu Asn Phe Asn Gly Glu Gly Glu Pro Glu Glu 260 265 270

Leu Met Val Asp Asn Trp Arg Pro Ala Gln Pro Leu Lys Asn Arg Gln 275 280 285

Ile Lys Ala Ser Phe Lys 290

<210> 946

<211> 69

<212> PRT

<213> Homo sapiens

<400> 946

Lys Ser Ile Glu Gln Lys Gly Met His Ala Val Phe Gln Trp Leu Arg

1 5 10 15

His Ala Phe Tyr Ser Leu Thr Ser Ile His Phe Phe Thr Thr Cys Ile
20 25 30

Lys Thr Asn Asp Leu Cys Phe Cys His Arg Gln Lys Gln Val Asp Thr
35 40 45

Gly Gly Leu Ala Leu Leu Ile Asn Phe Phe Ser Ile Arg Phe Ser Leu 50 55 60

Ile Met Leu Asn Phe 65 <210> 947 <211> 163 <212> PRT <213> Homo sapiens <220> <221> SITE <222> (2) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (8) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (130) <223> Xaa equals any of the naturally occurring L-amino acids <400> 947 Leu Xaa Lys Gly Thr Lys Leu Xaa Leu His Arg Gly Ala Asp Arg Ser Arg Thr Ser Gly Ser Pro Gly Leu Gln Glu Phe Gly Thr Arg Ile Asn 25 Arg Ile Phe Arg Ile Cys Asn Leu Thr Arg Pro Gln Glu Gly Tyr Leu 40 Met Val Gln Gln Phe Gln Tyr Leu Gly Trp Ala Ser His Arg Glu Val 50 55 Pro Gly Ser Lys Arg Ser Phe Leu Lys Leu Ile Leu Gln Val Glu Lys 75 Trp Gln Glu Glu Cys Glu Glu Gly Glu Gly Arg Thr Ile Ile His Cys 90

Lys Xaa Thr Glu Gly Thr Ala Ser Gln Thr Trp Trp Glu Ala Pro Glu

Leu Asn Gly Gly Gly Arg Ser Gly Met Phe Cys Ala Ile Gly Ile Val

Val Glu Met Val Lys Arg Ala Lys Cys Cys Arg Cys Phe Pro Cys Ser

120

105

100

130 135 140

Gln Tyr Arg Phe Cys Tyr Asp Val Ala Leu Glu Tyr Leu Gly Ile Ile 145 150 155 160

Leu Val Gly

<210> 948

<211> 87

<212> PRT

<213> Homo sapiens

<400> 948

Thr Ser Leu Lys Pro Cys Arg Asn Glu Ser Leu Leu Leu Asn Glu Met
1 5 10 15

Leu Lys Pro Ile Lys Lys His Ala Val Met Pro Ser Phe Pro Phe His
20 25 30

Arg Val His Ala Ser Pro Ala Gly Glu Ser His Ala Ala Arg Gly Asn 35 40 45

Trp Leu His Ser Leu Gly Cys Cys Arg Thr Lys Arg Lys Glu Ala Ala 50 55 60

Lys Cys Leu Tyr Val Val Leu Asn Pro Arg Arg Ile Lys Cys Arg Gly 65 70 75 80

Gly Met Ala Lys Gly Gly Trp

85

<210> 949

<211> 88

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (49)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (60)

<223> Xaa equals any of the naturally occurring L-amino acids

```
<220>
<221> SITE
<222> (74)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (81)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (84)
<223> Xaa equals any of the naturally occurring L-amino acids
Pro Arg Arg His Arg Val Pro Gly Ser Gly Phe Ala Phe Pro Lys Asn
                  5
Glu Asn Lys Leu Leu Pro Lys Glu Leu Val Phe Pro Leu Leu Phe Ser
             20
Asn Cys Glu Gly Pro Arg Gly Val Glu His Gly Ala Pro His Lys Pro
                             40
Xaa Gly Trp Cys Pro Gly Tyr Gln Gly His Ala Xaa Gly Leu Asp Asp
                         55
Leu Ser Leu Gln Gly Ala Leu Val Val Xaa Asn Trp Leu Lys Val Thr
                     70
 65
Xaa Glu Gly Xaa Cys Gly Asn Trp
                 85
<210> 950
<211> 77
<212> PRT
<213> Homo sapiens
```

Phe Leu Met Ala His Met Lys Phe Gly Ser Tyr Gly Leu Thr Leu Ala 20 25 30

Trp Leu Leu Cys Pro Val Arg Val Phe Ser Ser Leu Thr Trp Val His

10

15

<400> 950

Met Val Leu Ser Tyr Gly Glu Gln His Gln Arg Pro Val Thr Cys Lys 35 40 45 Leu Lys Ile Gln Cys Gln Gly Pro Ser Pro Ala Pro Leu Ile Glu Asn 50 55 60

Leu Leu Ala Ile Cys Ile Phe Arg Cys Ser Arg Leu Val 65 70 75

<210> 951

<211> 42

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (26)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 951

Thr Ser Gly Pro Lys Ser Ser Ala Cys Leu Ser Leu Pro Arg Cys Trp
1 5 10 15

Asp Tyr Lys Cys Glu Pro Leu Cys Thr Xaa Phe Val Leu Thr Tyr Phe 20 25 30

Glu Leu Ala Pro Tyr Ser Lys Ala Ala Ser 35 40

<210> 952

<211> 58

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (34)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 952

Ala Arg Lys Glu Ile Gln Tyr Cys Phe Trp Thr Leu Ile Lys Ser Cys
1 5 10 15

Ala Ile Asp Thr Tyr Met Ser His Leu Ala Val Leu Arg Arg Ala Ile 20 25 30

Ile Xaa Leu Gln Leu Thr Leu Glu Asn Ile Leu Ala Phe Glu His Phe 35 40 45

Ser Asn Asn Gln Val Asp Ser Arg Gly Ser

50 55

<210> 953 <211> 223 <212> PRT <213> Homo sapiens <220> <221> SITE <222> (38) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (180) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (220) <223> Xaa equals any of the naturally occurring L-amino acids <400> 953 Arg Pro Cys Pro Glu Glu Ala Glu Ile Gly Ile Ala Met Gly Ser Gly 5 Thr Ala Val Ala Lys Thr Ala Ser Glu Met Val Leu Ala Asp Asp Asn 20 Phe Ser Thr Ile Val Xaa Ala Val Glu Glu Gly Arg Ala Ile Tyr Asn 40 Asn Met Lys Gln Phe Ile Arg Tyr Leu Ile Ser Ser Asn Val Gly Glu 55 Val Val Cys Ile Phe Leu Thr Ala Ala Leu Gly Leu Pro Glu Ala Leu 75 65 70 Ile Pro Val Gln Leu Leu Trp Val Asn Leu Val Thr Asp Gly Leu Pro Ala Thr Ala Leu Gly Phe Asn Pro Pro Asp Leu Asp Ile Met Asp Arg Pro Pro Arg Ser Pro Lys Glu Pro Leu Ile Ser Gly Trp Leu Phe Phe 120

Arg Tyr Met Ala Ile Gly Gly Tyr Val Gly Ala Ala Thr Val Gly Ala

140

135

Ala Ala Trp Trp Phe Leu Tyr Ala Glu Asp Gly Pro His Val Asn Tyr 145 150 155 160

Ser Gln Leu Thr His Phe Met Gln Cys Thr Glu Asp Asn Thr His Phe 165 170 175

Glu Gly Ile Xaa Cys Glu Val Phe Glu Ala Pro Glu Pro Met Thr Met 180 185 190

Ala Leu Ser Val Leu Val Thr Ile Glu Met Cys Asn Ala Leu Asn Ser 195 200 205

Leu Ser Glu Asn Gln Ser Leu Leu Arg Asn Cys Xaa Pro Trp Gly 210 215 220

<210> 954

<211> 412

<212> PRT

<213> Homo sapiens

<400> 954

His Glu Leu Met Gln Glu Ala Gly Asp Glu Cys Glu Pro Glu Trp Cys
1 10 15

Asp Ala Glu Asp Pro Leu Phe Ile Leu Tyr Thr Ser Gly Ser Thr Gly 20 25 30

Lys Pro Lys Gly Val Val His Thr Val Gly Gly Tyr Met Leu Tyr Val 35 40 45

Ala Thr Thr Phe Lys Tyr Val Phe Asp Phe His Ala Glu Asp Val Phe 50 55 60

Trp Cys Thr Ala Asp Ile Gly Trp Ile Thr Gly His Ser Tyr Val Thr 65 70 75 80

Tyr Gly Pro Leu Ala Asn Gly Ala Thr Ser Val Leu Phe Glu Gly Ile 85 90 95

Pro Thr Tyr Pro Asp Val Asn Arg Leu Trp Ser Ile Val Asp Lys Tyr 100 105 110

Lys Val Thr Lys Phe Tyr Thr Ala Pro Thr Ala Ile Arg Leu Leu Met 115 120 125

Lys Phe Gly Asp Glu Pro Val Thr Lys His Ser Arg Ala Ser Leu Gln 130 135 140

Val 145		Gly	Thr	Val	Gly 150		Pro	Ile	Asn	Pro 155	Glu	Ala	Trp	Leu	Trp 160
Tyr	His	Arg	Val	Val 165	Gly	Ala	Gln	Arg	Cys 170		Ile	Val	Asp	Thr 175	Phe
Trp	Gln	Thr	Glu 180		Gly	Gly	His	Met 185	Leu	Thr	Pro	Leu	Pro 190	Gly	Ala
Thr	Pro	Met 195	Lys	Pro	Gly	Ser	Ala 200	Thr	Phe	Pro	Phe	Phe 205	Gly	Val	Ala
Pro	Ala 210	Ile	Leu	Asn	Glu	Ser 215	Gly	Glu	Glu	Leu	Glu 220	Gly	Glu	Ala	Glu
Gly 225	Tyr	Leu	Val	Phe	Lys 230	Gln	Pro	Trp	Pro	Gly 235	Ile	Met	Arg	Thr	Val 240
Tyr	Gly	Asn	His	Glu 245	Arg	Phe	Glu	Thr	Thr 250	Tyr	Phe	Lys	Lys	Phe 255	Pro
Gly	Tyr	Tyr	Val 260	Thr	Gly	Asp	Gly	Cys 265	Gln	Arg	Asp	Gln	Asp 270	Gly	Tyr
Tyr	Trp	Ile 275	Thr	Gly	Arg	Ile	Asp 280	Asp	Met	Leu	Asn	Val 285	Ser	Gly	His
Leu	Leu 290	Ser	Thr	Ala	Glu	Val 295	Glu	Ser	Ala	Leu	Val 300	Glu	His	Glu	Ala
Val 305	Ala	Glu	Ala	Ala	Val 310	Val	Gly	His	Pro	His 315	Pro	Val	Lys	Gly	Glu 320
Cys	Leu	Tyr	Cys	Phe 325	Val	Thr	Leu	Cys	Asp 330	Gly	His	Thr	Phe	Ser 335	Pro
Lys	Leu	Thr	Glu 340	Glu	Leu	Lys	Lys	Gln 345	Ile	Arg	Glu	Lys	11e 350	Gly	Pro
Ile	Ala	Thr 355	Pro	Asp	Tyr	Ile	Gln 360	Asn	Ala	Pro	Gly	Leu 365	Pro	Lys	Thr
Arg	Ser 370	Gly	Lys	Ile	Met	Arg 375	Arg	Val	Leu	Arg	Lys 380	Ile	Ala	Gln	Asn
Asp 385	His	Asp	Leu	Gly	Asp 390	Met	Ser	Thr	Val	Ala 395	Asp	Pro	Ser	Val	11e 400
Ser	His	Leu	Phe	Ser 405	His	Arg	Cys	Leu	Thr 410	Ile	Gln				

<400> 956

<210> 955 <211> 150 <212> PRT <213> Homo sapiens <400> 955 Gly Leu Leu Arg Ala Trp Gln Leu Arg Ile Asn Ala Gly Leu Arg Leu Ala Ala Arg Phe Leu Pro Glu Pro Leu Leu Ser Leu Val Asn His Thr 25 20 Gly Gln Arg Ser Asp Met Gln Lys Val Thr Leu Gly Leu Leu Val Phe 40 35 Leu Ala Gly Phe Pro Val Leu Asp Ala Asn Asp Leu Glu Asp Lys Asn Ser Pro Phe Tyr Tyr Asp Trp His Ser Leu Gln Val Gly Gly Leu Ile 70 Cys Ala Gly Val Leu Cys Ala Met Gly Ile Ile Ile Val Met Ser Glu 85 90 Trp Arg Ser Ser Gly Glu Gln Ala Gly Arg Gly Trp Gly Ser Pro Pro 105 100 Leu Thr Thr Gln Leu Ser Pro Thr Gly Ala Lys Cys Lys Cys Lys Phe 120 115 Gly Gln Lys Ser Gly His His Pro Gly Glu Thr Pro Pro Leu Ile Thr 135 Pro Gly Ser Ala Gln Ser 145 <210> 956 <211> 136 <212> PRT <213> Homo sapiens <220> <221> SITE <222> (6)

<223> Xaa equals any of the naturally occurring L-amino acids

Val Asp Pro Arg Val Xaa Pro Arg Ser Gly Gly Glu Lys Pro Gly Gly
1 5 10 15

Leu Gly Ala Pro Ala Gly Ile Gly Ser Arg Leu Gly Cys Glu Arg Phe 20 25 30

Ser Arg Ser Arg Glu Ile Leu Gln Ala Ile Thr Met Ser Thr Asp Thr 35 40 45

Gly Val Ser Leu Pro Ser Tyr Glu Glu Asp Gln Gly Ser Lys Leu Ile 50 55 60

Arg Lys Ala Lys Glu Ala Pro Phe Val Pro Val Gly Ile Ala Gly Phe 65 70 75 80

Ala Ala Ile Val Ala Tyr Gly Leu Tyr Lys Leu Lys Ser Arg Gly Asn 85 90 95

Thr Lys Met Ser Ile His Leu Ile His Met Arg Val Ala Ala Gln Gly . 100 105 110

Phe Val Val Gly Ala Met Thr Val Gly Met Gly Tyr Ser Met Tyr Arg 115 120 125

Glu Phe Trp Ala Lys Pro Lys Pro 130 135

<210> 957

<211> 461

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (60)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (103)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (135)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (241) <223> Xaa equals any of the naturally occurring L-amino acids

<400> 957

Ile Glu Thr Ser Asn Lys Asn Asp Met Thr Ile Asp Ile Leu His Ala 1 5 10 15

Asp Gly Glu Arg Pro Asn Val Leu Glu Asn Leu Asp Asn Ser Lys Glu 20 25 30

Lys Thr Val Gly Ser Glu Ala Ala Lys Thr Glu Asp Thr Val Leu Cys 35 40 45

Ser Ser Asp Thr Asp Glu Glu Cys Leu Ile Ile Xaa Thr Glu Cys Lys 50 55 60

Asn Asn Ser Asp Gly Lys Thr Ala Val Val Gly Ser Asn Leu Ser Ser 65 70 75 80

Arg Pro Ala Ser Pro Asn Ser Ser Ser Gly Gln Ala Ser Val Gly Asn 85 90 95

Gln Thr Asn Thr Ala Cys Xaa Pro Glu Glu Ser Cys Val Leu Lys Lys 100 105 110

Pro Ile Lys Arg Val Tyr Lys Lys Phe Asp Pro Val Gly Glu Ile Leu 115 120 125

Lys Met Gln Asp Glu Leu Xaa Lys Pro Ile Ser Arg Lys Val Pro Glu 130 135 140

Leu Pro Leu Met Asn Leu Glu Asn Ser Lys Gln Pro Ser Val Ser Glu 145 150 155 160

Gln Leu Ser Gly Pro Ser Asp Ser Ser Ser Trp Pro Lys Ser Gly Trp 165 170 175

Pro Ser Ala Phe Gln Lys Pro Lys Gly Arg Leu Pro Tyr Glu Leu Gln 180 185 190

Asp Tyr Val Glu Asp Thr Ser Glu Tyr Leu Ala Pro Gln Glu Gly Asn 195 200 205

Phe Val Tyr Lys Leu Phe Ser Leu Gln Asp Leu Leu Leu Leu Val Arg 210 215 220

Cys Ser Val Gln Arg Ile Glu Thr Arg Pro Arg Ser Lys Lys Arg Lys 225 230 235 240

Xaa Ile Arg Arg Gln Phe Pro Val Tyr Val Leu Pro Lys Val Glu Tyr
245 250 255

Gln Ala Cys Tyr Gly Val Glu Ala Leu Thr Glu Ser Glu Leu Cys Arg 260 265 270

Leu Trp Thr Glu Ser Leu Leu His Ser Asn Ser Ser Phe Tyr Val Gly 275 280 285

His Ile Asp Ala Phe Thr Ser Lys Leu Phe Leu Leu Glu Glu Ile Thr 290 295 300

Ser Glu Glu Leu Lys Glu Lys Leu Ser Ala Leu Lys Ile Ser Asn Leu 305 310 315 320

Phe Asn Ile Leu Gln His Ile Leu Lys Lys Leu Ser Ser Leu Gln Glu 325 330 335

Gly Ser Tyr Leu Leu Ser His Ala Ala Glu Asp Ser Ser Leu Leu Ile 340 345 350

Tyr Lys Ala Ser Asp Gly Lys Val Thr Arg Thr Ala Tyr Asn Leu Tyr 355 360 365

Lys Thr His Cys Gly Leu Pro Gly Val Pro Ser Ser Leu Ser Val Pro 370 380

Trp Val Pro Leu Asp Pro Ser Leu Leu Leu Pro Tyr His Ile His His 385 390 395 400

Gly Arg Ile Pro Cys Thr Phe Pro Pro Lys Ser Leu Asp Thr Thr Thr 405 410 415

Gln Gln Lys Ile Gly Gly Thr Arg Met Pro Thr Arg Ser His Arg Asn 420 425 430

Pro Val Ser Met Glu Thr Lys Ser Ser Cys Leu Pro Ala Gln Gln Val 435 440 445

Glu Thr Glu Gly Val Ala Pro His Lys Arg Lys Ile Thr 450 455 460

<210> 958

<211> 248

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (7)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 958 Asp Trp Gly Ala Thr Gln Xaa Arg Arg Ser Arg Asp Arg Arg Trp Gly Pro Arg Asn Leu Ser Leu Asp Ile Gly Thr Glu Val Phe Ala Pro Gly 25 20 Pro Gly Ser Gly Ile Gln Lys Gln Arg Glu Pro Arg Lys Gly Arg Leu 40 Ile Val Cys Gly His Gly Thr Leu Glu Arg Asp Gly Val Phe Cys Leu Leu Ser Asp Asp His Gly Ala Ser Trp Arg Tyr Gly Ser Gly Val Ser 75 70 Gly Ile Pro Tyr Gly Gln Pro Lys Gln Glu Asn Asp Phe Asn Pro Asp Glu Cys Gln Pro Tyr Glu Leu Pro Asp Gly Ser Val Val Ile Asn Ala 105 Arg Asn Gln Asn Asn Tyr His Cys His Cys Arg Ile Val Leu Arg Ser 115 120 Tyr Asp Ala Cys Asp Thr Leu Arg Pro Arg Asp Val Thr Phe Asp Pro 135 130 Glu Leu Val Asp Pro Val Val Ala Ala Gly Ala Val Val Thr Ser Ser 155 Gly Ile Val Phe Phe Ser Asn Pro Ala His Pro Glu Phe Arg Val Asn 170 165 Leu Thr Leu Arg Trp Ser Phe Ser Asn Gly Thr Ser Trp Arg Lys Glu 180 185 Thr Val Gln Leu Trp Pro Gly Pro Ser Gly Tyr Ser Ser Leu Ala Thr 200 195 Leu Glu Gly Ser Met Asp Gly Glu Glu Gln Ala Pro Gln Leu Tyr Val 215

Leu Tyr Glu Lys Gly Arg Asn His Tyr Thr Glu Ser Ile Ser Val Ala

235

240

Lys Ile Ser Val Tyr Gly Thr Leu 245

1053

<210> 959

<211> 105

<212> PRT

<213> Homo sapiens

<400> 959

Ile Arg His Glu Gly Ala Gly Pro Ser Gln Leu Arg Leu His Tyr Pro
1 5 10 15

Arg Ile Ser Met Ala Val Arg Gln Trp Val Ile Ala Leu Ala Leu Ala 20 25 30

Ala Leu Leu Val Val Asp Arg Glu Val Pro Val Ala Ala Gly Lys Leu 35 40 45

Pro Phe Ser Arg Met Pro Ile Cys Glu His Met Val Glu Ser Pro Thr 50 55 60

Cys Ser Gln Met Ser Asn Leu Val Cys Gly Thr Asp Gly Leu Thr Tyr 65 70 75 80

Thr Asn Glu Cys Gln Leu Cys Leu Ala Arg Ile Lys Thr Lys Gln Asp 85 90 95

Ile Gln Ile Met Lys Asp Gly Lys Cys 100 105

<210> 960

<211> 237

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (68)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (166)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (177)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE <222> (187) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (223) <223> Xaa equals any of the naturally occurring L-amino acids <400> 960 Leu Gly Trp Ser Leu Arg Gly Gly His Trp His Gly Thr His Pro Glu Ala Ser Pro Gly Cys Pro Gly Gly Ala Ala Ser Ser Pro Ala Gly Trp Trp Thr Arg Ser Val Arg Ser Trp Gly Ser Ser Phe Thr Ser Glu Asp 40 Cys Ser Thr Thr Met Leu Gly Ile Trp Thr Leu Leu Pro Leu Val Leu 55 Thr Ser Val Xaa Arg Leu Ser Ser Lys Ser Val Asn Ala Gln Val Thr 75 70 Asp Ile Asn Ser Lys Gly Leu Glu Leu Arg Lys Thr Val Thr Thr Val 85 90 Glu Thr Gln Asn Leu Glu Gly Leu His His Asp Gly Gln Phe Cys His 100 Lys Pro Cys Pro Pro Gly Glu Arg Lys Ala Arg Asp Cys Thr Val Asn 120 125 Gly Asp Glu Pro Asp Cys Val Pro Cys Gln Glu Gly Lys Glu Tyr Thr 135 Asp Lys Ala His Phe Ser Ser Lys Cys Arg Arg Cys Arg Leu Cys Asp 145 155 150 Glu Gly His Gly Leu Xaa Val Glu Ile Asn Cys Thr Arg Thr Gln Asn 165 Xaa Lys Cys Arg Cys Lys Pro Asn Phe Phe Xaa Asn Ser Thr Val Cys Glu His Cys Asp Pro Cys Thr Lys Cys Glu His Gly Ile Ile Lys Glu 200 Cys Thr Leu Thr Ser Asn Thr Lys Cys Lys Glu Glu Gly Ser Xaa Ser

215

220

1055

Asn Leu Gly Trp Leu Trp Leu Leu Leu Leu Pro Ile Pro 225 230 235

<210> 961

<211> 132

<212> PRT

<213> Homo sapiens

<400> 961

Gln Pro Met Ser Ser Thr Trp Val Thr Asn His Ser Glu Ile Leu Asn
1 5 10 15

Thr Tyr Pro Leu Gly Ala Gly Gly Gly Asn Asp Val Gln Tyr Leu Lys
20 25 30

Gln Asn Leu Thr Trp Thr Glu Arg Leu Tyr Phe Pro Leu Leu His Glu 35 40 45

Ser Leu Ile Ile Leu Gly Gly Leu Leu Cys Ile Pro Pro Phe Leu Leu 50 55 60

Ser Pro Pro Leu Pro Phe Val Phe Ser Lys Glu Ser Glu Leu Arg Phe 65 70 75 80

Pro Cys Ser Pro Ala Thr Leu Ile Ser Lys Thr Cys Leu Cys Val Arg 85 90 95

Phe Phe Thr Gly Asn Met Thr Phe Cys Phe Cys Ile Gly Phe Thr Val 100 105 110

Ile Gln Phe Ser Ser Leu Ile Ser Ser Lys Thr Lys Ser Glu Cys Thr 115 120 125

Arg Phe Phe Arg

<210> 962

<211> 613

<212> PRT

<213> Homo sapiens

<400> 962

Ala Val Ala Asn Met Ser Gly Trp Glu Ser Tyr Tyr Lys Thr Glu Gly
1 5 10 15

Asp Glu Glu Glu Glu Glu Glu Glu Glu Asn Leu Glu Ala Ser Gly

20 25 30 Asp Tyr Lys Tyr Ser Gly Arg Asp Ser Leu Ile Phe Leu Val Asp Ala 35 40 Ser Lys Ala Met Phe Glu Ser Gln Ser Glu Asp Glu Leu Thr Pro Phe 55 Asp Met Ser Ile Gln Cys Ile Gln Ser Val Tyr Ile Ser Lys Ile Ile Ser Ser Asp Arg Asp Leu Leu Ala Val Val Phe Tyr Gly Thr Glu Lys 85 90 Asp Lys Asn Ser Val Asn Phe Lys Asn Ile Tyr Val Leu Gln Glu Leu 100 105 Asp Asn Pro Gly Ala Lys Arg Ile Leu Glu Leu Asp Gln Phe Lys Gly 120 Gln Gln Gly Gln Lys Arg Phe Gln Asp Met Met Gly His Gly Ser Asp 135 Tyr Ser Leu Ser Glu Val Leu Trp Val Cys Ala Asn Leu Phe Ser Asp 145 Val Gln Phe Lys Met Ser His Lys Arg Ile Met Leu Phe Thr Asn Glu 165 170 Asp Asn Pro His Gly Asn Asp Ser Ala Lys Ala Ser Arg Ala Arg Thr 185 Lys Ala Gly Asp Leu Arg Asp Thr Gly Ile Phe Leu Asp Leu Met His 200 Leu Lys Lys Pro Gly Gly Phe Asp Ile Ser Leu Phe Tyr Arg Asp Ile 210 215 Ile Ser Ile Ala Glu Asp Glu Asp Leu Arg Val His Phe Glu Glu Ser 225 235 230 Ser Lys Leu Glu Asp Leu Leu Arg Lys Val Arg Ala Lys Glu Thr Arg 250 Lys Arg Ala Leu Ser Arg Leu Lys Leu Lys Leu Asn Lys Asp Ile Val 260 265 Ile Ser Val Gly Ile Tyr Asn Leu Val Gln Lys Ala Leu Lys Pro Pro 280 275

Pro Ile Lys Leu Tyr Arg Glu Thr Asn Glu Pro Val Lys Thr Lys Thr

	290					295					300				
Arg 305	Thr	Phe	Asn	Thr	Ser 310		Gly	Gly	Leu	Leu 315	Leu	Pro	Ser	Asp	Thr 320
Lys	Arg	Ser	Gln	Ile 325	Tyr	Gly	Ser	Arg	Gln 330		Ile	Leu	Glu	Lys 335	Glu
Glu	Thr	Glu	Glu 340	Leu	Lys	Arg	Phe	Asp 345	Asp	Pro	Gly	Leu	Met 350	Leu	Met
Gly	Phe	Lys 355	Pro	Leu	Val	Leu	Leu 360	Lys	Lys	His	His	Tyr 365	Leu	Arg	Pro
ser	Leu 370	Phe	Val	Туг	Pro	Glu 375	Glu	Ser	Leu	Val	Ile 380	Gly	Ser	Ser	Thr
Leu 385	Phe	Ser	Ala	Leu	Leu 390	Ile	Lys	Cys	Leu	Glu 395	Lys	Glu	Val	Ala	Ala 400
Leu	Cys	Arg	Tyr	Thr 405	Pro	Arg	Arg	Asn	Ile 410	Pro	Pro	Tyr	Phe	Val 415	Ala
Leu	Val	Pro	Gln 420	Glu	Glu	Glu	Leu	Asp 425	Asp	Glņ	Lys	Ile	Gln 430	Val	Thr
Pro	Pro	Gly 435	Phe	Gln	Leu	Val	Phe 440	Leu	Pro	Phe	Ala	Asp 445	Asp	Lys	Arg
Lys	Met 450	Pro	Phe	Thr	Glu	Lys 455	Ile	Met	Ala	Thr	Pro 460	Glu	Gln	Val	Gly
Lys 465	Met	Lys	Ala	Ile	Val 470	Glu	Lys	Leu	Arg	Phe 475	Thr	Tyr	Arg	Ser	Asp 480
Ser	Phe	Glu	Asn	Pro 485	Val	Leu	Gln	Gln	His 490	Phe	Arg	Asn	Leu	Glu 495	Ala
Leu	Ala	Leu	Asp 500	Leu	Met	Glu	Pro	Glu 505	Gln	Ala	Val	Asp	Leu 510	Thr	Leu
Pro	Lys	Val 515	Glu	Ala	Met	Asn	Lys 520	Arg	Leu	Gly	Ser	Leu 525	Val	Asp	Glu
Phe	Lys 530	Glu	Leu	Val	Tyr	Pro 535	Pro	Asp	Tyr	Asn	Pro 540	Glu	Gly	Lys	Val
Thr 545	Lys	Arg	Lys	His	Asp 550	Asn	Glu	Gly	Ser	Gly 555	Ser	Lys	Arg	Pro	Lys 560
Val	Glu	Tyr	Ser	Glu	Glu	Glu	Leu	Lys	Thr	His	Ile	Ser	Lys	Gly	Thr

565 570 575

Leu Gly Lys Phe Thr Val Pro Met Leu Lys Glu Ala Cys Arg Ala Tyr 580 585 590

Gly Leu Lys Ser Gly Leu Lys Lys Gln Glu Leu Leu Glu Ala Leu Thr 595 600 605

Lys His Phe Gln Asp 610

<210> 963

<211> 352

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (281)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 963

Arg Val Glu Glu Asn Ala Arg Leu Lys Lys Lys Glu Gln Leu 1 5 10 15

Gln Glu Ile Glu Asp Trp Ser Lys Leu His Ala Glu Leu Ser Glu 20 25 30

Gln Ile Lys Ser Phe Glu Lys Ser Gln Lys Asp Leu Glu Val Ala Leu $35 \hspace{1cm} 40 \hspace{1cm} 45$

Thr His Lys Asp Asp Asn Ile Asn Ala Leu Thr Asn Cys Ile Thr Gln
50 55 60

Leu Asn Leu Leu Glu Cys Glu Ser Glu Ser Glu Gly Gln Asn Lys Gly 65 70 75 80

Gly Asn Asp Ser Asp Glu Leu Ala Asn Gly Glu Val Gly Gly Asp Arg
85 90 95

Asn Glu Lys Met Lys Asn Gln Ile Lys Gln Met Met Asp Val Ser Arg 100 105 110

Thr Gln Thr Ala Ile Ser Val Val Glu Glu Asp Leu Lys Leu Gln 115 120 125

Leu Lys Leu Arg Ala Ser Val Ser Thr Lys Cys Asn Leu Glu Asp Gln 130 135 140

Val 145	Lys	Lys	Leu	Glu	Asp 150	Asp	Arg	Asn	Ser	Leu 155	Gln	Ala	Ala	Lys	Ala 160
Gly	Leu	Glu	Asp	Glu 165	Cys	Lys	Thr	Leu	Arg 170	Gln	Lys	Val	Glu	Ile 175	Leu
Asn	Glu	Leu	Туг 180	Gln	Gln	Lys	Glu	Met 185	Ala	Leu	Gln	Lys	Lys 190	Leu	Ser
Gln	Glu	Glu 195	Tyr	Glu	Arg	Gln	Glu 200	Arg	Glu	His	Arg	Leu 205	Ser	Ala	Ala
Asp	Glu 210	Lys	Ala	Val	Ser	Ala 215	Ala	Glu	Glu	Val	Lys 220	Thr	Tyr	Lys	Arg
Arg 225	Ile	Glu	Glu	Met	Glu 230	Asp	Glu	Leu	Gln	Lys 235	Thr	Glu	Arg	Ser	Phe 240
Lys	Asn	Gln	Ile	Ala 245	Thr	His	Glu	Lys	Lys 250	Ala	His	Glu	Asn	Trp 255	Leu
Lys	Ala	Arg	Ala 260	Ala	Glu	Arg	Ala	11e 265	Ala	Glu	Glu	Lys	Arg 270	Glu	Ala
Ala	Asn	Leu 275	Arg	His	Lys	Leu	Leu 280	Xaa	Leu	Thr	Gln	Lys 285	Met	Ala	Met
Leu	Gln 290	Glu	Glu	Pro	Val	Ile 295	Val	Lys	Pro	Met	Pro 300	Gly	Lys	Pro	Asn
305					310	-	Gly			315					320
			-	325	-		Arg		330					335	
Ala	Thr	Arg	Glu 340	Thr	Ser	Leu	Cys	Tyr 345	Ser	Gln	Ser	Lys	Arg 350	Tyr	Ala

<210> 964

<211> 553

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (133) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (375) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (438) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (549) <223> Xaa equals any of the naturally occurring L-amino acids <400> 964 Thr Leu Glu Ala Glu Lys Glu Arg Arg Lys Ser Gly Leu Ser Ser Arg 10 Val Gln Phe Arg Asn Gln Gly Ser Glu Pro Lys Tyr Thr Gln Glu Leu 25 Thr Leu Lys Arg Gln Lys Gln Lys Val Cys Met Glu Glu Thr Leu Trp 35 40 Leu Gln Asp Asn Ile Arg Asp Lys Leu Arg Pro Ile Pro Ile Thr Ala 50 Ser Val Glu Ile Gln Glu Pro Ser Ser Arg Arg Arg Val Asn Ser Leu 70 Pro Glu Val Leu Pro Ile Leu Asn Ser Asp Glu Pro Lys Thr Ala His 90 Ile Asp Val His Phe Leu Lys Glu Gly Cys Gly Asp Asp Asn Val Cys 105 110 100 Asn Ser Asn Leu Lys Leu Glu Tyr Lys Phe Cys Thr Arg Glu Gly Asn 115 120 Gln Asp Lys Phe Xaa Tyr Leu Pro Ile Gln Lys Gly Val Pro Glu Leu 135 Val Leu Lys Asp Gln Lys Asp Ile Ala Leu Glu Ile Thr Val Thr Asn 155 150 Ser Pro Ser Asn Pro Arg Asn Pro Thr Lys Asp Gly Asp Asp Ala His

170

175

Glu	Ala	Lys	Leu 180		Ala	Thr	Phe	Pro 185	_	Thr	Leu	Thr	Туг 190		Ala
Tyr	Arg	Glu 195		Arg	Ala	Phe	200		Lys	Gln	Leu	Ser 205	_	Val	Ala
Asn	Gln 210		Gly	Ser	Gln	Ala 215	_	Cys	Glu	Leu	Gly 220		Pro	Phe	Lys
Arg 225		Ser	Asn	Val	Thr 230	Phe	туг	Leu	Val	Leu 235		Thr	Thr	Glu	Val 240
Thr	Phe	Asp	Thr	Pro 245	Asp	Leu	Asp	Ile	250		Lys	Leu	Glu	Thr 255	Thr
Ser	Asn	Gln	Asp 260	Asn	Leu	Ala	Pro	Ile 265		Ala	Lys	Ala	Lys 270	Val	Val
Ile	Glu	Leu 275	Leu	Leu	Ser	Val	Ser 280	Gly	Val	Aļa	Lys	Pro 285	Ser	Gln	Val
Tyr	Phe 290	Gly	Gly	Thr	Val	Val 295	_	Glu	Gln	Ala	Met 300	Lys	Ser	Glu	Asp
Glu 305	Val	Gly	Ser	Leu	11e 310	Glu	Tyr	Glu	Phe	Arg 315	Val	Ile	Asn	Leu	Gly 320
Lys	Pro	Leu	Thr	Asn 325	Leu	Gly	Thr	Ala	Thr 330	Leu	Asn	Ile	Gln	Trp 335	Pro
Lys	Glu	Ile	Ser 340	Asn	Gly	Lys	Trp	Leu 345	Leu	туг	Leu	Val	Lys 350	Val	Glu
Ser	Lys	Gly 355	Leu	Glu	Lys	Val	Thr 360	Cys	Glu	Pro	Gln	Lys 365	Glu	Ile	Asn
Ser	Leu 370	Asn	Leu	Thr	Glu	Xaa 375	His	Asn	Ser	Arg	Lys 380	Lys	Arg	Glu	Ile
Thr 385	Glu	Lys	Gln	Ile	Asp 390	Asp	Asn	Arg	Lys	Phe 395	Ser	Leu	Phe	Ala	Glu 400
Arg	Lys	Туr	Gln	Thr 405	Leu	Asn	Cys	Ser	Val 410	Asn	Val	Asn	Cys	Val 415	Asn
Ile	Arg	Cys	Pro 420	Leu	Arg	Gly	Leu	Asp 425	Ser	Lys	Ala	Ser	Leu 430	Ile	Leu
Arg		Arg 435	Leu	Trp	Xaa	Ser	Thr 440	Phe	Leu	Glu	Glu	Tyr 445	Ser	Lys	Leu

Asn Tyr Leu Asp Ile Leu Met Arg Ala Phe Ile Asp Val Thr Ala Ala 450 455 460

Ala Glu Asn Ile Arg Leu Pro Asn Ala Gly Thr Gln Val Arg Val Thr 465 470 475 480

Val Phe Pro Ser Lys Thr Val Ala Gln Tyr Ser Gly Val Pro Trp Trp 485 490 495

Ile Ile Leu Val Ala Ile Leu Ala Gly Ile Leu Met Leu Ala Leu Leu 500 505 510

Val Phe Ile Leu Trp Lys Cys Gly Phe Phe Lys Arg Asn Lys Lys Asp 515 520 525

His Tyr Asp Ala Thr Tyr His Lys Ala Glu Ile His Ala Gln Pro Ser 530 535 540

Asp Lys Glu Arg Xaa Thr Ser Asp Ala 545 550

<210> 965

<211> 220

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (70)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (217)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 965

Gln Tyr Gly Arg Ile Pro Gly Ser Thr His Ala Ser Ala Glu Pro Leu 1 5 10 15

Glu Asn Pro Phe Lys Lys Met Lys Asn Asn Ile Val Asp Ala Ala Asn 20 25 30

Asn His Ser Ala Pro Glu Val Leu Tyr Gly Ser Leu Leu Asn Gln Glu 35 40 45

Glu Leu Lys Phe Ser Arg Asn Asp Leu Glu Phe Lys Tyr Pro Ala Gly 50 55 60

His Gly Ser Ala Ser Xaa Ser Glu His Arg Ser Trp Ala Arg Glu Ser 65 70 80

Lys Ser Phe Asn Val Leu Lys Gln Leu Leu Leu Ser Glu Asn Cys Val 85 90 95

Arg Asp Leu Ser Pro His Arg Ser Asn Ser Val Ala Asp Ser Lys Lys
100 105 110

Lys Gly His Lys Asn Asn Val Thr Asn Ser Lys Pro Glu Phe Ser Ile 115 120 125

Ser Ser Leu Asn Gly Leu Met Tyr Ser Ser Thr Gln Pro Ser Ser Cys 130 135 140

Met Asp Asn Arg Thr Phe Ser Tyr Pro Gly Val Val Lys Thr Pro Val 145 150 155 160

Ser Pro Thr Phe Pro Glu His Leu Gly Cys Ala Gly Ser Arg Pro Glu 165 170 175

Ser Gly Leu Leu Asn Gly Cys Ser Met Pro Ser Glu Lys Gly Pro Ile 180 185 190

Lys Trp Val Ile Thr Asp Ala Glu Lys Met Ser Met Lys Ser Leu Ser 195 200 205

Arg Leu Thr Lys Pro Pro His Thr Xaa Leu His Ala 210 215 220

<210> 966

<211> 385

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (221)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 966

Trp Ile Pro Arg Ala Ala Gly Phe Gly Thr Arg Pro Leu Pro Gly Ala
1 5 10 15

Ala Gly Gly Ala Ala Gly Cys Thr Gln Arg Arg Ser Arg Glu Leu Ala 20 25 30

Ala Ala Met Ser His Gln Thr Gly Ile Gln Ala Ser Glu Asp Val

Lys Glu Ile Phe Ala Arg Ala Arg Asn Gly Lys Tyr Arg Leu Leu Lys Ile Ser Ile Glu Asn Glu Gln Leu Val Ile Gly Ser Tyr Ser Gln Pro Ser Asp Ser Trp Asp Lys Asp Tyr Asp Ser Phe Val Leu Pro Leu Leu Glu Asp Lys Gln Pro Cys Tyr Ile Leu Phe Arg Leu Asp Ser Gln Asn Ala Gln Gly Tyr Glu Trp Ile Phe Ile Ala Trp Ser Pro Asp His Ser His Val Arg Gln Lys Met Leu Tyr Ala Ala Thr Arg Ala Thr Leu Lys Lys Glu Phe Gly Gly His Ile Lys Asp Glu Val Phe Gly Thr Val Lys Glu Asp Val Ser Leu His Gly Tyr Lys Lys Tyr Leu Leu Ser Gln Ser Ser Pro Ala Pro Leu Thr Ala Ala Glu Glu Glu Leu Arg Gln Ile Lys Ile Asn Glu Val Gln Thr Asp Val Gly Val Asp Thr Lys His Gln Thr Leu Gln Gly Val Ala Phe Pro Ile Ser Arg Glu Xaa Phe Gln Ala Leu Glu Lys Leu Asn Asn Arg Gln Leu Asn Tyr Val Gln Leu Glu Ile Asp Ile Lys Asn Glu Ile Ile Ile Leu Ala Asn Thr Thr Asn Thr Glu Leu Lys Asp Leu Pro Lys Arg Ile Pro Lys Asp Ser Ala Arg Tyr His Phe Phe Leu Tyr Lys His Ser His Glu Gly Asp Tyr Leu Glu Ser Ile Val Phe Ile Tyr Ser Met Pro Gly Tyr Thr Cys Ser Ile Arg Glu Arg Met Leu Tyr Ser Ser Cys Lys Ser Arg Leu Leu Glu Ile Val Glu Arg

310 315 320 305 Gln Leu Gln Met Asp Val Ile Arg Lys Ile Glu Ile Asp Asn Gly Asp 330 325 Glu Leu Thr Ala Asp Phe Leu Tyr Glu Glu Val His Pro Lys Gln His 345 Ala His Lys Gln Ser Phe Ala Lys Pro Lys Gly Pro Ala Gly Lys Arg 360 Gly Ile Arg Arg Leu Ile Arg Gly Pro Ala Glu Thr Glu Ala Thr Thr 375 Asp 385 <210> 967 <211> 221 <212> PRT <213> Homo sapiens <400> 967 Arg Lys Lys Asp Lys Ser Ser Arg Pro Pro Leu Thr Pro Ser Leu Pro 5 10 Leu Ser Leu Pro Pro Gly Glu Glu Ala Arg Gly Gly Cys Ser Ala Val 25 20 Gly Ala Ala Pro Pro Ser Pro Gly Arg Pro Gly Pro Pro Pro His Ala Ala Pro Met His Pro Phe Tyr Thr Arg Ala Ala Thr Met Ile Gly Glu 55 Ile Ala Ala Ala Val Ser Phe Ile Ser Lys Phe Leu Arg Thr Lys Gly 70 65 Leu Thr Ser Glu Arg Gln Leu Gln Thr Phe Ser Gln Ser Leu Gln Glu 85 Leu Leu Ala Glu His Tyr Lys His His Trp Phe Pro Glu Lys Pro Cys 105 Lys Gly Ser Gly Tyr Arg Cys Ile Arg Ile Asn His Lys Met Asp Pro 120

Leu Ile Gly Gln Ala Ala Gln Arg Ile Gly Leu Ser Ser Gln Glu Leu

135

130

Phe Arg Leu Leu Pro Ser Glu Leu Thr Leu Trp Val Asp Pro Tyr Glu 145 150 155 160

Val Ser Tyr Arg Ile Gly Glu Asp Gly Ser Ile Cys Val Leu Tyr Glu . 165 170 175

Ala Ser Pro Ala Gly Gly Ser Thr Gln Asn Ser Thr Asn Val Gln Met 180 185 190

Val Asp Ser Arg Ile Ser Cys Lys Glu Glu Leu Leu Gly Arg Thr 195 200 205

Ser Pro Ser Lys Asn Tyr Asn Met Met Thr Val Ser Gly 210 215 220

<210> 968

<211> 212

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (1)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (15)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 968

Xaa Leu Thr Lys Gly Thr Lys Ala Gly Ser Ser Thr Ala Val Xaa Thr
1 5 10 15

Ala Leu Glu Leu Val Asp Pro Pro Gly Cys Arg Asn Ser Ala Glu Phe 20 25 30

Asp Leu Cys Cys Ser Pro Cys Arg Arg Arg Leu Leu Gly Arg Glu Glu
35 40 45

Ala Gly Glu Glu Pro Thr Ser Pro Val Thr Gln Tyr Leu Gln Pro Arg
50 55 60

Ser Pro Glu Glu Cys Lys Met Phe Ala Cys Ala Lys Leu Ala Cys Thr 65 70 75 80

Pro Ser Leu Ile Arg Ala Gly Ser Arg Val Ala Tyr Arg Pro Ile Ser 85 90 95

Ala Ser Val Leu Ser Arg Pro Glu Ala Ser Arg Thr Gly Glu Gly Ser 100 105 Thr Val Phe Asn Gly Ala Gln Asn Gly Val Ser Gln Leu Ile Gln Arg Glu Phe Gln Thr Ser Ala Ile Ser Arg Asp Ile Asp Thr Ala Ala Lys 135 Phe Ile Gly Ala Gly Ala Ala Thr Val Gly Val Ala Gly Ser Gly Ala 155 150 Gly Ile Gly Thr Val Phe Gly Ser Leu Ile Ile Gly Tyr Ala Arg Asn 165 170 Pro Ser Leu Lys Gln Gln Leu Phe Ser Tyr Ala Ile Leu Gly Phe Ala 180 185 Leu Ser Glu Ala Met Gly Leu Phe Cys Leu Met Val Ala Phe Leu Ile 200 205 195 Leu Phe Ala Met 210 <210> 969 <211> 224 <212> PRT <213> Homo sapiens <220> <221> SITE <222> (140) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (142) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (206) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (224) <223> Xaa equals any of the naturally occurring L-amino acids

<400> 969

Tyr Leu Asp Ala Glu Lys Met Gly Gln Lys Ala Ser Gln Gln Leu Ala 1 5 10 15

Leu Lys Asp Ser Lys Glu Val Pro Val Val Cys Glu Val Val Ser Glu
20 25 30

Ala Ile Val His Ala Ala Gln Lys Leu Lys Glu Tyr Leu Gly Phe Glu
35 40 45

Tyr Pro Pro Ser Lys Leu Cys Pro Ala Ala Asn Thr Leu Asn Glu Ile 50 55 60

Phe Leu Ile His Phe Ile Thr Phe Cys Gln Glu Lys Gly Val Asp Glu 65 70 75 80

Trp Leu Thr Thr Lys Met Thr Lys His Gln Ala Phe Leu Phe Gly
85 90 95

Ala Asp Trp Ile Trp Thr Phe Trp Gly Ser Asp Lys Gln Ile Lys Leu 100 105 110

Gln Leu Ala Val Gln Thr Leu Gln Met Ser Ser Pro Pro Pro Val Glu 115 120 125

Ser Lys Pro Cys Asp Leu Ser Asn Pro Glu Ser Xaa Val Xaa Glu Ser 130 135 140

Ser Trp Lys Lys Ser Arg Phe Asp Lys Leu Glu Glu Phe Cys Asn Leu 145 150 155 160

Ile Gly Glu Asp Cys Leu Gly Leu Phe Ile Ile Phe Gly Met Pro Gly
165 170 175

Lys Pro Lys Asp Ile Arg Gly Val Val Leu Asp Ser Val Lys Ser Gln 180 185 190

Met Val Arg Ser His Leu Pro Gly Gly Lys Ala Val Ala Xaa Phe Val 195 200 205

Leu Glu Thr Glu Asp Cys Val Phe Ile Lys Glu Leu Leu Lys Ile Xaa 210 215 220

PCT/US00/05883 WO 00/55351

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (166)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 970

Leu Gly Leu Ser Arg Val Asp Asp Ala Val Ala Ala Asn Thr Arg Gln 10

Cys Ala Gln Arg Arg Asp Arg Gly Gly Glu Gly Arg Gly Gln Gly

Ile Glu Pro Ser Pro Ala Ser Ala Thr Pro Gly Thr Arg Gly Val Cys

Arg Met Pro Val Thr Arg Leu His Glu Gly Arg Phe His Leu Arg His 50 55 60

Arg His Arg His Gly Leu Trp Leu Ala Asp Val His Ser Glu Glu Val 65 70 75

Ser Ile Pro Phe Ala Val Glu Pro Pro Ser Gly Arg Gly Cys Arg Leu

Cys Gly Gln Leu Arg Gly Asp Glu Ser Gly Val Gly Glu Met Gln Gln 105

Pro Leu Ala Leu Pro Gly Asp Arg Ala Ala Pro Gln Arg Gln Glu His 115 120

Arg Ser Glu Lys Leu Gly Glu Leu Gln Gln Gly His Arg Gly Leu Gly 135 130

Ala Gly Gly Val Trp Asn Thr Ala Phe Met Pro Pro Asp Pro Arg Pro 150 155

Thr Leu Pro Thr Pro Xaa Gly Thr Pro Val Val Ser Ser Val Arg Met 165 170

Cys Gly Gln Ala 180

<210> 971

<211> 130

<212> PRT

<213> Homo sapiens

```
<220>
<221> SITE
<222> (85)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (91)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (103)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (106)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (112)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (116)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (118)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (126)
<223> Xaa equals any of the naturally occurring L-amino acids
Pro Arg Val Arg Pro Arg Val Leu Asp Leu Cys Lys Asn Met Lys
                  5
                                     10
His Leu Trp Phe Phe Leu Leu Val Ala Ala Pro Arg Trp Val Leu
             20
Ser Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser
                             40
```

```
Gln Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser
                          55
Gly Ala Tyr Tyr Trp Ser Trp Ile Arg Gln His Pro Gly Lys Gly Leu
                      70
                                          75
Glu Trp Ile Gly Xaa Ile Tyr Tyr Ser Gly Xaa Thr Tyr Tyr Asn Pro
Ser Leu Lys Ser Leu Val Xaa Ile Ser Xaa Asp Thr Ser Lys Asn Xaa
            100
                                 105
Phe Ser Leu Xaa Leu Xaa Ser Val Thr Ala Ala Asp Thr Xaa Val Tyr
                             120
                                                 125
Tyr Cys
    130
<210> 972
<211> 210
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (14)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (38)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (52)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (67)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (73)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
```

<221> SITE

<222> (110)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 972

Ala Gly Ser Ser Trp Lys Cys Arg Gly Cys Ser Leu Pro Xaa Leu Pro 1 5 10 15

Pro Pro Pro Ala Cys Ala Leu Leu Leu Pro Trp Pro Arg Thr Trp Val 20 25 30

Phe Pro Ser Pro Ala Xaa Gly Trp Arg Trp Leu Thr Arg Ser Arg Tyr 35 40 45

Pro Leu Thr Xaa Ser Arg Thr Ser Thr Arg Ser Ser Met Gly Met Ser 50 55 60

Leu Val Xaa Gly Pro Leu Gln Gly Xaa Leu Pro Cys Arg Arg Asp Pro 65 70 75 80

Arg Val Cys Pro Gly Thr Pro Ser Ser Gln Arg His Leu Pro Val Gly 85 90 95

Glu Val Val Lys Gln Ala Asp Val Val Leu Leu Gly Tyr Xaa Val Pro 100 105 110

Phe Ser Leu Ser Pro Asp Val Arg Arg Lys Asn Leu Glu Ile Tyr Glu 115 120 125

Ala Val Thr Ser Pro Gln Gly Pro Ala Met Thr Trp Ser Met Phe Ala 130 135 140

Val Gly Trp Met Glu Leu Lys Asp Ala Val Arg Ala Arg Gly Leu Leu 145 150 155 160

Asp Arg Ser Phe Ala Asn Met Ala Glu Pro Phe Lys Val Trp Thr Glu 165 170 175

Asn Ala Asp Gly Ser Gly Ala Val Asn Phe Leu Thr Gly Met Gly Gly 180 185 190

Phe Cys Arg Arg Trp Ser Ser Gly Ala Arg Gly Ser Gly Ser Pro Glu 195 200 205

Arg Val

210

<210> 973

<211> 248

<212> PRT <213> Homo sapiens

<400> 973

Ser Arg Val Arg Gly Cys Ser Arg Ser Arg Gln Pro Gln Ala Arg Gly
1 5 10 15

Gly Arg Trp Ala Arg Asp Pro Thr Leu Val Val Met Glu Ala Gly Gly
20 25 30

Phe Leu Asp Ser Leu Ile Tyr Gly Ala Cys Val Val Phe Thr Leu Gly 35 40 45

Met Phe Ser Ala Gly Leu Ser Asp Leu Arg His Met Arg Met Thr Arg 50 55 60

Ser Val Asp Asn Val Gln Phe Leu Pro Phe Leu Thr Thr Glu Val Asn 65 70 75 80

Asn Leu Gly Trp Leu Ser Tyr Gly Ala Leu Lys Gly Asp Gly Ile Leu 85 90 95

Ile Val Val Asn Thr Val Gly Ala Ala Leu Gln Thr Leu Tyr Ile Leu 100 105 110

Ala Tyr Leu His Tyr Cys Pro Arg Lys Arg Val Val Leu Leu Gln Thr 115 120 125

Ala Thr Leu Leu Gly Val Leu Leu Gly Tyr Gly Tyr Phe Trp Leu 130 135 140

Leu Val Pro Asn Pro Glu Ala Arg Leu Gln Gln Leu Gly Leu Phe Cys 145 150 155 160

Ser Val Phe Thr Ile Ser Met Tyr Leu Ser Pro Leu Ala Asp Leu Ala 165 170 175

Lys Val Ile Gln Thr Lys Ser Thr Gln Cys Leu Ser Tyr Pro Leu Thr 180 . 185 . 190

Ile Ala Thr Leu Leu Thr Ser Ala Ser Trp Cys Leu Tyr Gly Phe Arg 195 200 205

Leu Arg Asp Pro Tyr Ile Met Val Ser Asn Phe Pro Gly Ile Val Thr 210 215 220

Ser Phe Ile Arg Phe Trp Leu Phe Trp Lys Tyr Pro Gln Glu Gln Asp 225 230 235 240

Arg Asn Tyr Trp Leu Leu Gln Thr

```
<210> 974
<211> 202
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (2)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (10)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (60)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 974
Ser Xaa Leu Pro Phe Ile Lys Gly Asn Xaa Ser Trp Ser Phe His Arg
Gly Gly Gly Arg Ser Arg Thr Ser Gly Ser Pro Gly Leu Gln Glu Phe
                                 25
Gly Thr Arg Arg Glu Leu Val Ser Arg Arg Ala Gln Arg Thr Ala Thr
                             40
                                                 45
         35
Asp Ser Pro Gly His Pro Pro Thr Ala His Gly Xaa Gln Gln Ser Arg
Lys Ala Arg Pro Gly Gln Arg Lys Pro Ser Arg Ala Gly Trp Arg Leu
Arg Ala Ala Pro Thr Gly Gln Arg Pro Pro His Val Pro Ala Pro
                                     90
                                                         95
                 85
Thr Pro Arg Pro Ser Gly Gln His Glu Ala Pro Gly Gly Arg Ala Ala
                                105
            100
Pro Ala Ala Ala Gly Ala Val His Arg Ala Cys Gly Arg Val Gln Met
        115
                            120
Gln Val Leu Pro Glu Gly Pro Lys Ile Arg Tyr Ser Asp Val Lys Lys
                        135
                                            140
```

Leu Glu Met Lys Pro Lys Tyr Pro His Cys Glu Glu Lys Met Val Ile 145 150 155 160

Ile Thr Thr Lys Ser Val Ser Arg Tyr Arg Gly Gln Glu His Cys Leu 165 170 175

His Pro Lys Leu Gln Ser Thr Lys Arg Phe Ile Lys Trp Tyr Asn Ala 180 185 190

Trp Asn Glu Lys Arg Arg Val Tyr Glu Glu 195 200

<210> 975

<211> 260

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (212)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 975

Leu Cys Leu Pro Phe Pro Thr Gly Glu Thr Pro Ser Leu Gly Phe Thr 1 5 10 15

Val Thr Leu Val Leu Leu Asn Ser Leu Ala Phe Leu Leu Met Ala Val 20 25 30

Ile Tyr Thr Lys Leu Tyr Cys Asn Leu Glu Lys Glu Asp Leu Ser Glu 35 40 45

Asn Ser Gln Ser Ser Met Ile Lys His Val Ala Trp Leu Ile Phe Thr 50 55 60

Asn Cys Ile Phe Phe Cys Pro Val Ala Phe Phe Ser Phe Ala Pro Leu 65 70 75 80

Ile Thr Ala Ile Ser Ile Ser Pro Glu Ile Met Lys Ser Val Thr Leu 85 90 95

Ile Phe Phe Pro Leu Pro Ala Cys Leu Asn Pro Val Leu Tyr Val Phe 100 105 110

Phe Asn Pro Lys Phe Lys Glu Asp Trp Lys Leu Leu Lys Arg Arg Val

Thr Lys Lys Ser Gly Ser Val Ser Val Ser Ile Ser Ser Gln Gly Gly 130 135 140

Cys Leu Glu Gln Asp Phe Tyr Tyr Asp Cys Gly Met Tyr Ser His Leu 145 150 155 160

Gln Gly Asn Leu Thr Val Cys Asp Cys Cys Glu Ser Phe Leu Leu Thr 165 170 175

Lys Pro Val Ser Cys Lys His Leu Ile Lys Ser His Ser Cys Pro Ala 180 185 190

Leu Ala Val Ala Ser Cys Gln Arg Pro Glu Gly Tyr Trp Ser Asp Cys
195 200 205

Gly Thr Gln Xaa Ala His Ser Asp Tyr Ala Asp Glu Glu Asp Ser Phe 210 215 220

Val Ser Asp Ser Ser Asp Gln Val Gln Ala Cys Gly Arg Ala Cys Phe 225 230 235 240

Tyr Gln Ser Arg Gly Phe Pro Leu Val Arg Tyr Ala Tyr Asn Leu Pro 245 250 255

Arg Val Lys Asp 260

<210> 976

<211> 114

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (10)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 976

Arg Ser Arg Lys Gln Glu Ala Ala Cys Xaa Pro Gln Asp Leu Pro Gly
1 5 10 15

Trp Gly Asn Trp Arg Leu Leu Gly Gly Gly Thr Val His Ala Lys Met
20 25 30

Ala Val Ser Thr Glu Glu Leu Glu Ala Thr Val Gln Glu Val Leu Gly
35 40 45

Arg Leu Lys Ser His Gln Phe Phe Gln Ser Thr Trp Asp Thr Val Ala
50 55 60

Phe Ile Val Phe Leu Thr Phe Met Gly Thr Val Leu Leu Leu Leu Leu

65 70 75 80

Leu Val Val Ala His Cys Cys Cys Ser Ser Pro Gly Pro Arg Arg 85 90 95

Glu Ser Pro Arg Lys Glu Arg Pro Lys Gly Val Asp Asn Leu Ala Leu 100 105 110

Glu Pro

<210> 977

<211> 413

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (58)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (75)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (125)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 977

Thr Pro Pro Thr His Gly Pro Thr Ala Asp Gln Pro Met Arg Pro Val 1 5 10 15

Arg Val Pro Glu Arg Gly Pro Val His Arg Gly Ala Ala Gly Ala His 20 25 30

Leu Pro Leu Pro Thr Arg Leu Arg Pro Gln Met Arg Glu Ala His
35 40 45

His Cys Gln Leu Arg Gly Gln Arg Leu Xaa Arg Gly Thr Gly Leu Arg 50 55 60

Gln Gly Pro Thr Pro Gly Gln His Leu Pro Xaa Gly Gly Pro Asp Lys 65 70 75 80

Asp Asn Gly Ile Leu Leu Tyr Lys Gly Asp Asn Asp Pro Leu Ala Leu 85 90 95

Glu	Leu	Tyr	Gln 100	Gly	His	Val	Arg	Leu 105	Val	Tyr	Asp	Ser	Leu 110	Ser	Ser
Pro	Pro	Thr 115	Thr	Val	Tyr	Ser	Val 120	Glu	Thr	Val	Asn	Xaa 125	Gly	Gln	Phe
His	Ser 130	Val	Glu	Leu	Val	Thr 135	Leu	Asn	Gln	Thr	Leu 140	Asn	Leu	Val	Val
Asp 145	Lys	Gly	Thr	Pro	Lys 150	Ser	Leu	Gly	Lys	Leu 155	Gln	Lys	Gln	Pro	Ala 160
Val	Gly	Ile	Asn	Ser 165	Pro	Leu	Tyr	Leu	Gly 170	Gly	Ile	Pro	Thr	Ser 175	Thr
Gly	Leu	Ser	Ala 180	Leu	Arg	Gln	Gly	Thr 185	Asp	Arg	Pro	Leu	Gly 190	Gly	Phe
His	Gly	Cys 195	Ile	His	Glu	Val	Arg 200	Ile	Asn	Asn	Glu	Leu 205	Gln	Asp	Phe
Lys	Ala 210	Leu	Pro	Pro	Gln	Ser 215	Leu	Gly	.Val	Ser	Pro 220	Gly	Cys	Lys	Ser
225			Cys		230					235					240
Val	Val	Cys	Glu	Cys 245	Arg	Pro	Gly	Trp	Thr 250	Gly	Pro	Leu	Cys	Asp 255	Gln
Glu	Ala	Arg	Asp 260	Pro	Cys	Leu	Gly	His 265	Arg	CÀa	His	His	Gly 270	Lys	Cys
Val	Ala	Thr 275	Gly	Thr	Ser	Tyr	Met 280	Cys	Lys	Cys	Ala	Glu 285	Gly	Tyr	Gly
Gly	Asp 290	Leu	Cys	Asp	Asn	Lys 295	Asn	Asp	Ser	Ala	Asn 300	Ala	Cys	Ser	Ala
Phe 305	Lys	Cys	His	His	Gly 310	Gln	Cys	His	Ile	Ser 315	Asp	Gln	Gly	Glu	Pro 320
Tyr	Cys	Leu	Cys	Gln 325	Pro	Gly	Phe	Ser	Gly 330	Glu	His	Cys	Gln	Gln 335	Glu
Asn	Pro	Cys	Leu 340	Gly	Gln	Val	Val	Arg 345	Glu	Val	Ile	Arg	Arg 350	Gln	Lys
Gly	Tyr	Ala 355	Ser	Cys	Ala	Thr	Ala 360	Ser	Lys	Val	Pro	11e 365	Met	Glu	Cys

Arg Gly Gly Cys Gly Pro Gln Cys Cys Gln Pro Thr Arg Ser Lys Arg 370 375 380

Arg Lys Tyr Val Phe Gln Cys Thr Asp Gly Ser Ser Phe Val Glu 385 390 395 400

Val Glu Arg His Leu Glu Cys Gly Cys Leu Ala Cys Ser 405 410

<210> 978

<211> 271

<212> PRT

<213> Homo sapiens

<400> 978

Thr Gln Arg Met Ser Gly Lys His Tyr Lys Gly Pro Glu Val Ser Cys
1 5 10 15

Cys Ile Lys Tyr Phe Ile Phe Gly Phe Asn Val Ile Phe Trp Phe Leu 20 25 30

Gly Ile Thr Phe Leu Gly Ile Gly Leu Trp Ala Trp Asn Glu Lys Gly
35 40 45

Val Leu Ser Asn Ile Ser Ser Ile Thr Asp Leu Gly Gly Phe Asp Pro
50 55 60

Val Trp Leu Phe Leu Val Val Gly Gly Val Met Phe Ile Leu Gly Phe 65 70 75 80

Ala Gly Cys Ile Gly Ala Leu Arg Glu Asn Thr Phe Leu Leu Lys Phe 85 90 95

Phe Ser Val Phe Leu Gly Ile Ile Phe Phe Leu Glu Leu Thr Ala Gly 100 105 . 110

Val Leu Ala Phe Val Phe Lys Asp Trp Ile Lys Asp Gln Leu Tyr Phe 115 120 125

Phe Ile Asn Asn Asn Ile Arg Ala Tyr Arg Asp Asp Ile Asp Leu Gln 130 135 140

Asn Leu Ile Asp Phe Thr Gln Glu Tyr Trp Gln Cys Cys Gly Ala Phe 145 150 155 160

Gly Ala Asp Asp Trp Asn Leu Asn Ile Tyr Phe Asn Cys Thr Asp Ser 165 170 175

WO 00/55351 1080

Asn Ala Ser Arg Glu Arg Cys Gly Val Pro Phe Ser Cys Cys Thr Lys 185 180

Asp Pro Ala Glu Asp Val Ile Asn Thr Gln Cys Gly Tyr Asp Ala Arg 200

Gln Lys Pro Glu Val Asp Gln Gln Ile Val Ile Tyr Thr Lys Gly Cys 215

Val Pro Gln Phe Glu Lys Trp Leu Gln Asp Asn Leu Thr Ile Val Ala 235 230 225

Gly Ile Phe Ile Gly Ile Ala Leu Leu Gln Ile Phe Gly Ile Cys Leu 250

Ala Gln Asn Leu Val Ser Asp Ile Glu Ala Val Arg Ala Ser Trp 265

<210> 979

<211> 674

<212> PRT

<213> Homo sapiens

<400> 979

Pro Gly Arg Thr Gly Ala Ala Gly Pro Ala Gly Pro Ala Gly Pro Arg

Gly Ser Pro Gly Glu Arg Gly Glu Val Gly Pro Ala Gly Pro Asn Gly

Phe Ala Gly Pro Ala Gly Ala Ala Gly Gln Pro Gly Ala Lys Gly Glu 35

Arg Gly Ala Lys Gly Pro Lys Gly Glu Asn Gly Val Val Gly Pro Thr 50 55

Gly Pro Val Gly Ala Ala Gly Pro Ala Gly Pro Asn Gly Pro Pro Gly

Pro Ala Gly Ser Arg Gly Asp Gly Gly Pro Pro Gly Met Thr Gly Phe . 90

Pro Gly Ala Ala Gly Arg Thr Gly Pro Pro Gly Pro Ser Gly Ile Ser 100

Gly Pro Pro Gly Pro Pro Gly Pro Ala Gly Lys Glu Gly Leu Arg Gly 120 115

Pro Arg Gly Asp Gln Gly Pro Val Gly Arg Thr Gly Glu Val Gly Ala

Val Gly Pro Pro Gly Phe Ala Gly Glu Lys Gly Pro Ser Gly Glu Ala Gly Thr Ala Gly Pro Pro Gly Thr Pro Gly Pro Gln Gly Leu Leu Gly Ala Pro Gly Ile Leu Gly Leu Pro Gly Ser Arg Gly Glu Arg Gly Leu Pro Gly Val Ala Gly Ala Val Gly Glu Pro Gly Pro Leu Gly Ile Ala Gly Pro Pro Gly Ala Arg Gly Pro Pro Gly Ala Val Gly Ser Pro Gly Val Asn Gly Ala Pro Gly Glu Ala Gly Arg Asp Gly Asn Pro Gly Asn Asp Gly Pro Pro Gly Arg Asp Gly Gln Pro Gly His Lys Gly Glu Arg Gly Tyr Pro Gly Asn Ile Gly Pro Val Gly Ala Ala Gly Ala Pro Gly Pro His Gly Pro Val Gly Pro Ala Gly Lys His Gly Asn Arg Gly Glu Thr Gly Pro Ser Gly Pro Val Gly Pro Ala Gly Ala Val Gly Pro Arg Gly Pro Ser Gly Pro Gln Gly Ile Arg Gly Asp Lys Gly Glu Pro Gly Glu Lys Gly Pro Arg Gly Leu Pro Gly Leu Lys Gly His Asn Gly Leu Gln Gly Leu Pro Gly Ile Ala Gly His His Gly Asp Gln Gly Ala Pro Gly Ser Val Gly Pro Ala Gly Pro Arg Gly Pro Ala Gly Pro Ser Gly Pro Ala Gly Lys Asp Gly Arg Thr Gly His Pro Gly Thr Val Gly Pro Ala Gly Ile Arg Gly Pro Gln Gly His Gln Gly Pro Ala Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly Val Ser Gly Gly Tyr

Asp Phe Gly Tyr Asp Gly Asp Phe Tyr Arg Ala Asp Gln Pro Arg Ser Ala Pro Ser Leu Arg Pro Lys Asp Tyr Glu Val Asp Ala Thr Leu Lys Ser Leu Asn Asn Gln Ile Glu Thr Leu Leu Thr Pro Glu Gly Ser Arg Lys Asn Pro Ala Arg Thr Cys Arg Asp Leu Arg Leu Ser His Pro Glu Trp Ser Ser Gly Tyr Tyr Trp Ile Asp Pro Asn Gln Gly Cys Thr Met Asp Ala Ile Lys Val Tyr Cys Asp Phe Ser Thr Gly Glu Thr Cys Ile Arg Ala Gln Pro Glu Asn Ile Pro Ala Lys Asn Trp Tyr Arg Ser Ser Lys Asp Lys Lys His Val Trp Leu Gly Glu Thr Ile Asn Ala Gly Ser Gln Phe Glu Tyr Asn Val Glu Gly Val Thr Ser Lys Glu Met Ala Thr Gln Leu Ala Phe Met Arg Leu Leu Ala Asn Tyr Ala Ser Gln Asn Ile Thr Tyr His Cys Lys Asn Ser Ile Ala Tyr Met Asp Glu Glu Thr Gly Asn Leu Lys Lys Ala Val Ile Leu Gln Gly Ser Asn Asp Val Glu Leu Val Ala Glu Gly Asn Ser Arg Phe Thr Tyr Thr Val Leu Val Asp Gly Cys Ser Lys Lys Thr Asn Glu Trp Gly Lys Thr Ile Ile Glu Tyr Lys Thr Asn Lys Pro Ser Arg Leu Pro Phe Leu Asp Ile Ala Pro Leu Asp Ile Gly Gly Ala Asp Gln Glu Phe Phe Val Asp Ile Gly Pro Val Cys

Phe Lys

<210> 980 <211> 120

<212> PRT

<213> Homo sapiens

<400> 980

Cys Pro Leu Cys Ser Ala Ala Gly Ser Arg Arg Thr Ala Gly Arg Met

1 5 10 15

Thr Gln Asn Thr Val Ile Val Asn Gly Val Ala Met Ala Ser Arg Pro 20 25 30

Ser Gln Pro Thr His Val Asn Val His Ile His Gln Glu Ser Ala Leu 35 40 45

Thr Gln Leu Lys Ala Gly Gly Ser Leu Lys Lys Phe Leu Phe His 50 55 60

Pro Gly Asp Thr Val Pro Ser Thr Ala Arg Ile Gly Tyr Glu Gln Leu 65 70 75 80

Ala Leu Gly Val Thr Gln Ile Leu Leu Gly Val Val Ser Cys Val Leu 85 90 95

Gly Val Cys Leu Ser Leu Gly Pro Trp Thr Val Leu Ser Ala Ser Ala 100 105 110

Val Pro Ser Gly Arg Gly Leu Trp 115 120

<210> 981

<211> 76

<212> PRT

<213> Homo sapiens

<400> 981

Phe Met Lys Asn Val Phe Lys Tyr Cys Phe Leu Leu Cys Ser Ala 20 25 30

Leu Ser Leu Val Leu Pro Leu Ser Pro Glu Cys Ser Ile Ile Tyr Arg

```
Leu Tyr Ile Thr Thr Ser Ile Ala Phe Gly Gly Lys Ser Arg Phe Ser
                         55
Cys Asn Phe Pro Ala Val Lys Met Leu Pro Cys Ile
                    70
<210> 982
<211> 208
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (1)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222>(4)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (9)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (180)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (192)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (193)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (194)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (195)
```

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (200)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 982

Xaa Ser Phe Xaa Thr Gln Pro Ser Xaa Ser Thr Thr Thr Ser Pro Leu 1 5 10 15

Trp Ala Asn Thr Val Thr Leu Ala Gly Gly Lys Leu His Ser Lys Gly
20 25 30

Leu Lys Tyr Phe His His Phe Thr Leu Ser Leu Cys Gly Asn Gln Gly 35 40 45

Arg Lys Met Ser Val Cys Thr Asp Asn Val Thr Asp Leu Arg Ile Pro 50 55 60

Glu Gly Glu Ser Gly Phe Ser Lys Ser Ile Thr Ala Tyr Val Cys Gln 65 70 75 80

Ala Val Ile Ile Pro Pro Glu Val Thr Gly Tyr Lys Ala Gly Val Ser 85 90 95

Ser Gln Pro Val Ser Leu Ala Asp Arg Leu Ile Gly Val Thr Thr Asp 100 105 110

Met Thr Leu Asp Gly Ile Thr Ser Pro Ala Glu Leu Phe His Leu Glu 115 120 125

Ser Leu Gly Ile Pro Asp Val Ile Phe Phe Tyr Arg Ser Asn Asp Val 130 135 140

Thr Gln Ser Cys Ser Ser Gly Arg Ser Thr Thr Ile Arg Val Arg Cys 145 150 155 160

Ser Pro Gln Lys Thr Val Pro Gly Ser Leu Leu Pro Gly Thr Cys 165 170 175

Ser Asp Gly Xaa Cys Asp Gly Cys Asn Phe His Phe Leu Trp Glu Xaa 180 185 190

Xaa Xaa Xaa Ala Arg Ser Ala Xaa Trp Leu Thr Thr Met Leu Ser Ser 195 200 205

```
<210> 983
<211> 261
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (91)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (92)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (259)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (260)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 983
Val Thr Gly Glu Leu Phe Glu Asp Ile Val Ala Arg Glu Tyr Tyr
                  5
Ser Glu Ala Asp Ala Ser His Cys Ile Gln Gln Ile Leu Glu Ala Val
             20
Leu His Cys His Gln Met Gly Val Val His Arg Asp Leu Lys Pro Glu
                             40
Asn Leu Leu Leu Ala Ser Lys Ser Lys Gly Ala Ala Val Lys Leu Ala
Asp Phe Gly Leu Ala Ile Glu Val Gln Gly Asp Gln Gln Ala Trp Phe
                                         75
65
                     70
Gly Phe Ala Gly Thr Pro Gly Tyr Leu Ser Xaa Xaa Val Leu Arg Lys
                                     90
                 85
Asp Pro Tyr Gly Lys Pro Val Asp Met Trp Ala Cys Gly Val Ile Leu
Tyr Ile Leu Leu Val Gly Tyr Pro Pro Phe Trp Asp Glu Asp Gln His
                            120
                                                125
```

Arg Leu Tyr Gln Gln Ile Lys Ala Gly Ala Tyr Asp Phe Pro Ser Pro 130 135 140

Glu Trp Asp Thr Val Thr Pro Glu Ala Lys Asp Leu Ile Asn Lys Met 145 150 155 160

Leu Thr Ile Asn Pro Ala Lys Arg Ile Thr Ala Ser Glu Ala Leu Lys 165 170 175

His Pro Trp Ile Cys Gln Arg Ser Thr Val Ala Ser Met His Arg 180 185 190

Gln Glu Thr Val Asp Cys Leu Lys Lys Phe Asn Ala Arg Arg Lys Leu 195 200 205

Lys Gly Ala Ile Leu Thr Thr Met Leu Ala Thr Arg Asn Phe Ser Ala 210 215 220

Ala Lys Ser Leu Leu Lys Lys Pro Asp Gly Val Lys Glu Ser Thr Glu 225 230 235 240

Ser Ser Asn Thr Thr Ile Glu Asp Glu Phe Ser Leu Asp Leu Thr Arg 245 250 255

Leu Thr Xaa Xaa Gly 260

<210> 984

<211> 283

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (103)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (268)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 984

Ser Thr His Ala Ser Gly Arg Met Ala Ala Glu Gly Trp Ile Trp Arg

1 5 10 15

Trp Gly Trp Gly Arg Arg Cys Leu Gly Arg Pro Gly Leu Leu Gly Pro 20 25 30

Gly Pro Gly Pro Thr Thr Pro Leu Phe Leu Leu Leu Leu Gly Ser 35 40 45

Val Thr Ala Asp Ile Thr Asp Gly Asn Ser Glu His Leu Lys Arg Glu
50 55 60

His Ser Leu Ile Lys Pro Tyr Gln Gly Val Gly Ser Ser Ser Met Pro 65 70 75 80

Leu Trp Asp Phe Gln Gly Ser Thr Met Leu Thr Ser Gln Tyr Val Arg 85 90 95

Leu Thr Pro Asp Glu Arg Xaa Lys Glu Gly Ser Ile Trp Asn His Gln
100 105 110

Pro Cys Phe Leu Lys Asp Trp Glu Met His Val His Phe Lys Val His
115 120 125

Gly Thr Gly Lys Lys Asn Leu His Gly Asp Gly Ile Ala Leu Trp Tyr 130 135 140

Thr Arg Asp Arg Leu Val Pro Gly Pro Val Phe Gly Ser Lys Asp Asn 145 150 155 160

Phe His Gly Leu Ala Ile Phe Leu Asp Thr Tyr Pro Asn Asp Glu Thr 165 170 175

Thr Glu Arg Val Phe Pro Tyr Ile Ser Val Met Val Asn Asn Gly Ser 180 185 190

Leu Ser Tyr Asp His Ser Lys Asp Gly Arg Trp Thr Glu Leu Ala Gly
195 200 205

Cys Thr Ala Asp Phe Arg Asn Arg Asp His Asp Thr Phe Leu Ala Val 210 215 220

Arg Tyr Ser Arg Gly Arg Leu Thr Val Met Thr Asp Leu Glu Asp Lys 225 230 235 240

Asn Glu Trp Lys Asn Cys Ile Asp Ile Thr Gly Val Arg Leu Pro Thr 245 250 255

Gly Tyr Tyr Phe Gly Ala Ser Ala Gly Thr Gly Xaa Leu Ser Asp Asn 260 265 270

His Asp Ile Ile Ser Met Lys Ala Val Pro Ser 275 280 <211> 144

<212> PRT

<213> Homo sapiens

<400> 985

Ala Arg Gly Arg Ala Glu Val Leu Gly Arg Ala Val Glu Pro Pro Pro 1 5 10 15

Gly Arg Cys Trp Ser Thr Pro Pro Val Ala Pro Pro Ala Arg Ser Ala 20 25 30

Ser Ala Ala Met Gly Val Gln Val Glu Thr Ile Ser Pro Gly Asp
35 40 45

Gly Arg Thr Phe Pro Lys Arg Gly Gln Thr Cys Val Val His Tyr Thr
50 55 60

Gly Met Leu Glu Asp Gly Lys Lys Phe Asp Ser Ser Arg Asp Arg Asn 65 70 75 80

Lys Pro Phe Lys Phe Met Leu Gly Lys Gln Glu Val Ile Arg Gly Trp 85 90 95

Glu Glu Gly Val Ala Gln Met Ser Val Gly Gln Arg Ala Lys Leu Thr 100 105 110

Ile Ser Pro Asp Tyr Ala Tyr Gly Ala Thr Gly His Pro Gly Ile Ile 115 120 125

Pro Pro His Ala Thr Leu Val Phe Asp Val Glu Leu Leu Lys Leu Glu 130 135 140

<210> 986

<211> 75

<212> PRT

<213> Homo sapiens

<400> 986

Ile Phe Val Cys Leu Cys Val Cys Leu Ser Cys Val Ile Leu Leu Gly
1 5 10 15

Ala Ser Ala Asn Ser Leu Thr Val Val Pro Ser Leu Thr Leu Pro Val
20 25 30

His His Leu Arg Arg Leu Asp Pro Ser Leu Thr Ser Pro Phe Leu Lys 35 40 45 Pro Val Ser Phe Ser Leu Leu Pro Asn Trp Leu Trp Leu Phe Leu Gln 50 55 60

Pro Phe His Ser Arg Ala Ile Phe Ala Lys Glu 65 70 75

<210> 987

<211> 332

<212> PRT

<213> Homo sapiens

<400> 987

Arg Thr Arg Gly Arg Thr Arg Gly Arg Thr Arg Gly Arg Val Ala Trp

1 5 10 15

Trp Leu Arg Leu Ser Val Arg Pro Pro Ala Gly Ala Ile Met Ala Asp
20 25 30

Ala Ala Ser Gln Val Leu Leu Gly Ser Gly Leu Thr Ile Leu Ser Gln 35 40 45

Pro Leu Met Tyr Val Lys Val Leu Ile Gln Val Gly Tyr Glu Pro Leu 50 55 60

Pro Pro Thr Ile Gly Arg Asn Ile Phe Gly Arg Gln Val Cys Gln Leu 65 70 75 80

Pro Gly Leu Phe Ser Tyr Ala Gln His Ile Ala Ser Ile Asp Gly Arg
85 90 95

Arg Gly Leu Phe Thr Gly Leu Thr Pro Arg Leu Cys Ser Gly Val Leu 100 105 110

Gly Thr Val Val His Gly Lys Val Leu Gln His Tyr Gln Glu Ser Asp 115 120 125

Lys Gly Glu Glu Leu Gly Pro Gly Asn Val Gln Lys Glu Val Ser Ser 130 135 140

Ser Phe Asp His Val Ile Lys Glu Thr Thr Arg Glu Met Ile Ala Arg 145 150 155 160

Ser Ala Ala Thr Leu Ile Thr His Pro Phe His Val Ile Thr Leu Arg 165 170 175

Ser Met Val Gln Phe Ile Gly Arg Glu Ser Lys Tyr Cys Gly Leu Cys 180 185 190 Asp Ser Ile Ile Thr Ile Tyr Arg Glu Glu Gly Ile Leu Gly Phe Phe 195 200 205

Ala Gly Leu Val Pro Arg Leu Leu Gly Asp Ile Leu Ser Leu Trp Leu 210 215 220

Cys Asn Ser Leu Ala Tyr Leu Val Asn Thr Tyr Ala Leu Asp Ser Gly 225 230 235 240

Val Ser Thr Met Asn Glu Met Lys Ser Tyr Ser Gln Ala Val Thr Gly
245 250 255

Phe Phe Ala Ser Met Leu Thr Tyr Pro Phe Val Leu Val Ser Asn Leu 260 265 270

Met Ala Val Asn Asn Cys Gly Leu Ala Gly Gly Cys Pro Pro Tyr Ser 275 280 285

Pro Ile Tyr Thr Ser Trp Ile Asp Cys Trp Cys Met Leu Gln Lys Glu 290 295 300

Gly Asn Met Ser Arg Gly Asn Ser Leu Phe Phe Arg Lys Val Pro Phe 305 310 315 320

Gly Lys Thr Tyr Cys Cys Asp Leu Lys Met Leu Ile 325 330

<210> 988

<211> 909

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (32)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (41)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (47)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

```
<222> (48)
 <223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (52)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (58)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (62)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (125)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (632)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (851)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 988
Gly Lys Lys Ala Glu Gly Ala Gln Asn Gln Gly Lys Lys Ala Glu Gly
Ala Gln Asn Gln Gly Lys Lys Ala Glu Gly Ala Gln Asn Gln Gly Xaa
             20
                                 25
                                                      30
Lys Ala Glu Gly Ala Gln Asn Gln Xaa Lys Lys Ala Glu Gly Xaa Xaa
         35
Asn Gln Gly Xaa Lys Ala Glu Gly Ala Xaa Asn Gln Gly Xaa Lys Ala
Glu Gly Ala Gln Asn Gln Gly Lys Lys Ala Glu Gly Ala Gln Asn Gln
65
                     70
                                         75
Gly Lys Lys Ala Glu Gly Ala Gln Asn Gln Gly Lys Lys Ala Glu Gly
                 85
                                     90
```

Ala	Gln	Asn	Gln 100	Gly	Lys	Lys	Ala	Glu 105		Ala	Gln	Asn	Gln 110	Gly	Lys
Lys	Ala	Glu 115	Gly	Ala	Gln	Asn	Gln 120	Gly	Lys	Lys	Val	Xaa 125	Gly	Ala	Gln
Asn	Gln 130	Gly	Lys	Lys	Ala	Glu 135	Gly	Ala	Gln	Asn	Gln 140	Gly	Lys	Lys	Ala
Glu 145	Gly	Ala	Gln	Asn	Gln 150	Gly	Lys	Lys	Ala	Glu 155	Gly	Ala	Gln	Asn	Gln 160
Gly	Gln	Lys	Gly	Glu 165	Gly	Ala	Gln	Asn	Gln 170	Gly	Lys	Lys	Thr	Glu 175	Gly
Ala	Gln	Gly	Lys 180	Lys	Ala	Glu	Arg	Ser 185	Pro	Asn	Gln	Gly	Lys 190	Lys	Gly
Glu	Gly	Ala 195	Pro	Ile	Gln	Gly	Lys 200	Lys	Ala	Asp	Ser	Val 205	Ala	Asn	Gln
Gly	Thr 210	Lys	Val	Glu	Gly	11e 215	Thr	Asn	Gln	Gly	Lys 220	Lys	Ala	Glu	Gly
Ser 225	Pro	Ser	Glu	Gly	Lys 230	Lys	Ala	Glu	Gly	Ser 235	Pro	Asn	Gln	Gly	Lys 240
Lys	Ala	Asp	Ala	Ala 245	Ala	Asn	Gln	Gly	Lys 250	Lys	Thr	Glu	Ser	Ala 255	Ser
Val	Gln	Gly	Arg 260	Asn	Thr	Asp	Val	Ala 265	Gln	Ser	Pro	Glu	Ala 270	Pro	Lys
Gln	Glu	Ala 275	Pro	Ala	Lys	Lys	Lys 280	Ser	Gly	Ser	Lys	Lys 285	Lys	Gly	Glu
Pro	Gly 290	Pro	Pro	Asp	Ala	Asp 295	Gly	Pro	Leu	Tyr	Leu 300	Pro	Tyr	Lys	Thr
Leu 305	Val	Ser	Thr	Val	Gly 310	Ser	Met	Val	Phe	Asn 315	Glu	Gly	Glu	Ala	Gln 320
Arg	Leu	Ile	Glu	Ile 325	Leu	Ser	Glu	Lys	Ala 330	Gly	Ile	Ile	Gln	Asp 335	Thr
Trp	His	Lys	Ala 340	Thr	Gln	Lys	Gly	Asp 345	Pro	Val	Ala	Ile	Leu 350	Lys	Arg
Gln	Leu	Glu 355	Glu	Lys	Glu	Lys	Leu 360	Leu	Ala	Thr	Glu	Gln 365	Glu	Asp	Ala

Ala	Val 370	Ala	Lys	Ser	Lys	Leu 375	_	Glu	Leu	Asn	Lys 380		Met	Ala	Ala
Glu 385	Lys	Ala	Lys	Ala	Ala 390	Ala	Gly	Glu	Ala	Lys 395		Lys	Lys	Gln	Leu 400
Val	Ala	Arg	Glu	Gln 405		Ile	Thr	Ala	Val 410		Ala	Arg	Met	Gln 415	Ala
Ser	Tyr	Arg	Glu 420	His	Val	Lys	Glu	Val 425		Gln	Leu	Gln	Gly 430	Lys	Ile
Arg	Thr	Leu 435	Gln	Glu	Gln	Leu	Glu 440	Asn	Gly	Pro	Asn	Thr 445	Gln	Leu	Ala
Arg	Leu 450	Gln	Gln	Glu	Äsn	Ser 455	Ile	Leu	Arg	Asp	Ala 460	Leu	Asn	Gln	Ala
Thr 465	Ser	Gln	Val	Glu	Ser 470	Lys	Gln	Asn	Ala	Glu 475	Leu	Ala	Lys	Leu	Arg 480
Gln	Glu	Leu	Ser	Lys 485	Val	Ser	Lys	Glu	Leu 490	Val	Glu	Lys	Ser	Glu 495	Ala
Val	Arg	Gln	Asp 500	Glu	Gln	Gln	Arg	Lys 505	Ala	Leu	Glu	Ala	Lys 510	Ala	Ala
Ala	Phe	Glu 515	Lys	Gln	Val	Leu	Gln 520	Leu	Gln	Ala	Ser	His 525	Arg	Glu	Ser
Glu	Glu 530	Ala	Leu	Gln	Lys	Arg 535	Leu	Asp	Glu	Val	Ser 540	Arg	Glu	Leu	Cys
His 545	Thr	Gln	Ser	Ser	His 550	Ala	Ser	Leu	Arg	Ala 555	Asp	Ala	Glu	Lys	Ala 560
Gln	Glu	Gln	Gln	Gln 565	Gln	Met	Ala	Glu	Leu 570	His	Ser	Lys	Leu	Gln 575	Ser
Ser	Glu	Ala	Glu 580	Val	Arg	Ser	Lys	Cys 585	Glu	Glu	Leu	Ser	Gly 590	Leu	His
Gly	Gln	Leu 595	Gln	Glu	Ala	Arg	Ala 600	Glu	Asn	Ser	Gln	Leu 605	Thr	Glu	Arg
	Arg 610	Ser	Ile	Glu	Ala	Leu 615	Leu	Glu	Ala	Gly	Gln 620	Ala	Arg	Asp	Ala
Gln 625	Asp	Val	Gln	Ala	Ser 630	Gln	Xaa	Glu	Ala	Asp 635	Gln	Gln	Gln	Thr	Arg 640

Leu	Lys	Glu	Leu	Glu 645		Gln	Val	Ser	Gly 650		Glu	Lys	Glu	Ala 655	Ile
Glu	Leu	Arg	Glu 660		Val	Glu	Gln	Gln 665	-	Val	Lys	Asn	Asn 670		Leu
Arg	Glu	Lys 675		Trp	Lys	Ala	Met 680		Ala	Leu	Ala	Thr 685		Glu	Gln
Ala	Cys 690	_	Glu	Lys	Leu	His 695		Leu	Thr	Gln	Ala 700	_	Glu	Glu	Ser
Glu 705	-	Gln	Leu	Cys	Leu 710	Ile	Glu	Ala	Gln	Thr 715		Glu	Ala	Leu	Leu 720
Ala	Leu	Leu	Pro	Glu 725	Leu	Ser	Val	Leu	Ala 730	Gln	Gln	Asn	Tyr	Thr 735	Glu
Trp	Leu	Gln	Asp 740	Leu	Lys	Glu	Lys	Gly 745	Pro	Thr	Leu	Leu	Lys 750	His	Pro
Pro	Ala	Pro 755	Ala	Glu	Pro	Ser	Ser 760	Asp	Leu	Ala	Ser	Lys 765	Leu	Arg	Glu
Ala	Glu 770	Glu	Thr	Gln	Ser	Thr 775	Leu	Gln	Ala	Glu	Cys 780	Asp	Gln	Tyr	Arg
Ser 785	Ile	Leu	Ala	Glu	Thr 790	Glu	Gly	Met	Leu	Arg 795	Asp	Leu	Gln	Lys	Ser 800
				805			_		810	_			Ala	815	
			820					825					830		Ile
Val	Glu	Lys 835	Leu	Lys	Gly	Glu	Leu 840	Glu	Ser	Ser	Asp	Gln 845	Val	Arg	Glu
His	Thr 850	Xaa	His	Leu	Glu	Ala 855	Glu	Leu	Glu	Lys	His 860	Met	Ala	Ala	Ala
865					870					875			Leu		880
Leu	Leu	Leu		Ser 885	Gln	Ser	Gln	Leu	Asp 890	Ala	Ala	Lys	Ser	Glu 895	Ala

Arg Asn Arg Ala Met Ser Leu Pro Trp Ser Gly Ser Ser

905

900

PCT/US00/05883

<210> 989

<211> 100

<212> PRT

<213> Homo sapiens

<400> 989

Trp Cys Ser Arg Ala Val Pro Pro Pro Ser Leu Leu Pro Ala Ser Thr 1 5 10 15

Ser Pro Pro Arg Ser Val Pro Pro Pro Ser Phe Ser Leu Ser Leu Lys
20 25 30

Ser Val Ser Phe Gly Ser Pro Arg Ala Ser Leu Pro Arg Pro Ser Trp 35 40 45

Met Arg Pro Pro Ser Pro Lys Pro Ala Cys Phe Ala Val Ser Pro Gly
50 55 60

Ser Trp Lys Leu Ala Gly Ala Arg Gly Trp Arg Gly His Gly Gly Val 65 70 75 80

Gly Glu Gly Ser Leu Pro Phe Leu Val Arg Ser Ile Ile Val Asn Gly
85 90 95

Cys Thr Leu Phe 100

<210> 990

<211> 214

<212> PRT

<213> Homo sapiens

<400> 990

Leu Arg Ile Glu Tyr Ile Asp Asn Gly Cys Val Ile Asn Gly His Leu
1 5 10 15

Asp Phe Pro Ser Thr Thr Pro Leu Ser Gly Met Glu Ser Arg Asn Gly
20 25 30

Gln Cys Leu Thr Gly Thr Asn Gly Ile Ser Ser Gly Leu Ala Pro Gly
35 40 45

Gln Pro Phe Pro Ser Ser Gln Gly Ser Leu Cys Ile Ser Gly Thr Glu
50 55 60

Glu Pro Glu Lys Thr Leu Arg Ala Asn Pro Glu Leu Cys Gly Ser Leu

65 70 75 80

His Leu Asn Gly Ser Pro Ser Ser Cys Ile Ala Ser Arg Pro Ser Trp 85 90 95

Val Glu Asp Ile Gly Asp Asn Leu Tyr Tyr Gly His Tyr His Gly Phe 100 105 110

Gly Asp Thr Ala Glu Ser Met Pro Arg Thr Glu Gln Cys Gly Arg Ala 115 120 125

Phe Gln Val Arg Glu Gly Ala Gly Ala Val Arg Gln Cys Arg Ala Gly 130 135 140

His His Ala Pro Ala Pro Arg Leu Leu Glu Thr Leu Thr Trp Leu Ser 145 150 155 160

Glu Thr Gln Glu Ser Phe Leu Val Ala Ser Ser Glu Tyr Pro Cys Ser 165 170 175

Ser Asn Leu Asn Glu Cys His Asn Leu Tyr Phe Phe Tyr Ile Leu Gln 180 185 190

Leu Ser Glu Lys Val Asn Phe Asp Lys Phe Pro Ala Thr Ala Cys Leu 195 200 205

Cys Met Ser Arg Ala Tyr 210

<210> 991

<211> 263

<212> PRT

<213> Homo sapiens

<400> 991

Gly Pro Val Gly Pro Ala Gly Thr Arg Arg Ser His Ala Leu Gly Pro 1 5 10 15

Arg Pro Gly Ala Arg Ser Ser Phe Arg Leu Arg Cys Glu Leu Arg Arg
20 25 30

Cys Met Cys Gly Asn Asn Met Ser Thr Pro Leu Pro Ala Ile Val Pro
35 40 45

Ala Ala Arg Lys Ala Thr Ala Ala Val Ile Phe Leu His Gly Leu Gly 50 55 60

Asp Thr Gly His Gly Trp Ala Glu Ala Phe Ala Gly Ile Arg Ser Ser 65 70 75 80

His Ile Lys Tyr Ile Cys Pro His Ala Pro Val Arg Pro Val Thr Leu 85 90 95

Asn Met Asn Val Ala Met Pro Ser Trp Phe Asp Ile Ile Gly Leu Ser
100 105 110

Pro Asp Ser Gln Glu Asp Glu Ser Gly Ile Lys Gln Ala Ala Glu Asn 115 120 125

Ile Lys Ala Leu Ile Asp Gln Glu Val Lys Asn Gly Ile Pro Ser Asn 130 135 140

Arg Ile Ile Leu Gly Gly Phe Ser Gln Gly Gly Ala Leu Ser Leu Tyr 145 150 155 160

Thr Ala Leu Thr Thr Gln Gln Lys Leu Ala Gly Val Thr Ala Leu Ser 165 170 175

Cys Trp Leu Pro Leu Arg Ala Ser Phe Pro Gln Gly Pro Ile Gly Gly
180 185 190

Ala Asn Arg Asp Ile Ser Ile Leu Gln Cys His Gly Asp Cys Asp Pro 195 200 205

Leu Val Pro Leu Met Phe Gly Ser Leu Thr Val Glu Lys Leu Lys Thr 210 215 220

Leu Val Asn Pro Ala Asn Val Thr Phe Lys Thr Tyr Glu Gly Met Met 225 230 235 240

His Ser Ser Cys Gln Gln Glu Met Met Asp Val Lys Gln Phe Ile Asp 245 250 255

Lys Leu Leu Pro Pro Ile Asp 260

<210> 992

<211> 256

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (229)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 992

Val Pro Arg Arg Val Leu Glu Pro Leu Leu Gln Arg Ile His Glu Glu

1				5					10					15	
Glu	Ser	Ala	Val 20	Val	Cys	Pro	Val	Ile 25	Asp	Val	Ile	Asp	Trp	Asn	Thr
Phe	Glu	Tyr 35	Leu	Gly	Asn	Ser	Gly 40	Glu	Pro	Gln	Ile	Gly 45	Gly	Phe	Asp
Trp	Arg 50	Leu	Val	Phe	Thr	Trp 55	His	Thr	Val	Pro	Glu 60	Arg	Glu	Arg	Ile
Arg 65	Met	Gln	Ser	Pro	Val 70	Asp	Val	Ile	Arg	Ser 75	Pro	Thr	Met	Ala	Gly 80
Gly	Leu	Phe	Ala	Val 85	Ser	Lys	Lys	Tyr	Phe 90	Glu	Tyr	Leu	Gly	Ser 95	Tyr
Asp	Thr	Gly	Met 100	Glu	Val	Trp	Gly	Gly 105	Glu	Asn	Leu	Glu	Phe 110	Ser	Phe
Arg	Ile	Trp 115	Gln	Cys	Gly	Gly	Val 120	Leu	Glu	Thr	His	Pro 125	Cys	Ser	His
Val	Gly 130	His	Val	Phe	Pro	Lys 135	Gln	Ala	Pro	Tyr	Ser 140	Arg	Asn	Lys	Ala
Leu 145	Ala	Asn	Ser	Val	Arg 150	Ala	Ala	Glu	Val	Trp 155	Met	Asp	Glu	Phe	Lys 160
Glu	Leu	Tyr	Tyr	His 165	Arg	Asn	Pro	Arg	Ala 170	Arg	Leu	Glu	Pro	Phe 175	Gly
Asp	Val	Thr	Glu 180	Arg	Lys	Gln	Leu	Arg 185	Asp	Lys	Leu	Gln	Cys 190	Lys	Asp
Phe	Lys	Trp 195	Phe	Leu	Glu	Thr	Val 200	Tyr	Pro	Glu	Leu	His 205	Val	Pro	Glu
Asp	Arg 210	Pro	Gly	Phe	Phe	Gly 215	Met	Leu	Gln	Asn	Lys 220	Gly	Leu	Thr	Asp
Tyr 225	Cys	Phe	Asp	Xaa	Asn 230	Pro	Pro	Asp	Glu	Asn 235	Gln	Ile	Val	Gly	His 240
Gln	Val	Ile	Leu	Tyr 245	Leu	Cys	His	Gly	Met 250	Gly	Gln	Asn	Asp	Leu 255	Val

PCT/US00/05883

<210> 993

<211> 70

<212> PRT

<213> Homo sapiens

<400> 993

Val Val Trp Ser Arg Val Cys Gly Phe Ser Gly Pro Ile Ile Met Ala 1 5 10 15

Ala Ser Glu Ser Glu Glu Ser His Arg Ala Val Gly Glu Leu Leu 20 25 30

Pro Ser Pro Ser Pro Phe Val Ala Pro Thr Leu Ala Ala Tyr Phe Cys
35 40 45

Ser Ser Ala Gly Glu Ser Val Trp Ala Ser Ser Ser Pro Ser Leu Ser 50 55 60

Pro Cys Tyr Phe Met Gly 65 70

<210> 994

<211> 220

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (4)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 994

Asp Tyr Ala Xaa Thr Pro Gln Gly Leu Cys Tyr Asp Val Ala Cys Thr 1 5 10 15

Arg Lys Leu Gly Pro Leu Glu Gly Ser Ser Arg Ala Ala Ala Ala Ala 20 25 30

Phe Gly Glu Ser Ala Gly Gln Met Ser Asn Glu Arg Gly Phe Glu Asn 35 40 45

Val Glu Leu Gly Val Ile Gly Lys Lys Lys Lys Val Pro Arg Arg Val 50 55 60

Ile His Phe Val Ser Gly Glu Thr Met Glu Glu Tyr Ser Thr Asp Glu 65 70 75 80

Asp Glu Val Asp Gly Leu Glu Lys Lys Asp Val Leu Pro Thr Val Asp

85 90 95

Pro Thr Lys Leu Thr Trp Gly Pro Tyr Leu Trp Phe Tyr Met Leu Arg

Ala Ala Thr Ser Thr Leu Ser Val Cys Asp Phe Leu Gly Glu Lys Ile 115 120 125

Ala Ser Val Leu Gly Ile Ser Thr Pro Lys Tyr Gln Tyr Ala Ile Asp 130 135 140

Glu Tyr Tyr Arg Met Lys Lys Glu Glu Glu Glu Glu Glu Glu Glu Glu Asn 145 150 155 160

Arg Met Ser Glu Glu Ala Glu Lys Gln Tyr Gln Gln Asn Lys Leu Gln 165 170 175

Thr Asp Ser Ile Val Gln Thr Asp Gln Pro Glu Thr Val Ile Ser Ser 180 185 190

Ser Phe Val Asn Val Asn Phe Glu Met Glu Gly Asp Ser Glu Val Ile 195 200 205

Met Glu Ser Lys Gln Asn Pro Val Ser Val Pro Pro 210 215 220

<210> 995

<211> 107

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (23)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 995

Lys Ile Gln Gly Pro Glu Leu Trp Lys Leu Gln Ala Lys Gly Met Gly
1 5 10 15

Leu Gly Leu Ser Cys Val Xaa Ile Leu Ile Arg Lys Gly Tyr Ala His 20 25 30

Thr Leu Ala Cys Ser Asp Ser Lys Thr Glu Gly Phe Thr Arg Pro Thr

Pro Gly Lys Trp Ala Ser Leu Pro Pro Met Leu Ser Phe Asn Leu Cys 50 55 60

Asn Leu Pro Val Ser Ile Gly Gly His Leu Thr Pro Ser Lys Glu Pro 65 70 75 80

Ser Leu Phe Cys Pro Leu Pro Cys Thr Val Phe Leu Cys Ile Ser Pro 85 90 95

Ser Trp Ala Leu Phe Tyr Ser His Leu Gly Leu 100 105

<210> 996

<211> 146

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (13)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (14)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (16)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 996

Thr Ile Gln Pro Arg Arg Ser Pro Ser Thr Arg Phe Xaa Xaa Asn Xaa 1 5 10 15

Ser Leu Val Gln Glu Asn Leu Tyr Phe Gln Arg Cys Leu Asp Trp Asn 20 25 30

Arg Asp Ile Leu Lys Lys Glu Leu Gly Leu Thr Glu Gln Asp Ile Ile 35 40 45

Asp Leu Pro Ala Leu Phe Lys Met Asp Glu Asp His Arg Ala Arg Ala 50 55 60

Phe Phe Pro Asn Met Val Asn Met Ile Val Leu Asp Lys Asp Leu Gly 65 70 75 80

Ile Pro Lys Pro Phe Gly Pro Gln Val Glu Glu Glu Cys Cys Leu Glu 85 90 95

Met His Val Arg Gly Leu Leu Glu Pro Leu Gly Leu Glu Cys Thr Phe

100 105 110

Ile Asp Asp Ile Ser Ala Tyr His Lys Phe Leu Gly Glu Val His Cys 115 120 125

Gly Thr Asn Val Arg Arg Lys Pro Phe Thr Phe Lys Trp Trp His Met 130 135 140

Val Pro 145

<210> 997

<211> 123

<212> PRT

<213> Homo sapiens

<400> 997

Leu Thr Gln Lys Ala Thr Leu Leu Phe Leu Val Lys Met Ala Gly Lys

1 5 10 15

Gln Ala Val Ser Ala Ser Gly Lys Trp Leu Asp Gly Ile Arg Lys Trp
20 25 30

Tyr Tyr Asn Ala Ala Gly Phe Asn Lys Leu Gly Leu Met Arg Asp Asp 35 40 45

Thr Ile Tyr Glu Asp Glu Asp Val Lys Glu Ala Ile Arg Arg Leu Pro 50 55 60

Glu Asn Leu Tyr Asn Asp Arg Met Phe Arg Ile Lys Arg Ala Leu Asp 65 70 75 80

Leu Asn Leu Lys His Gln Ile Leu Pro Lys Glu Gln Trp Thr Lys Tyr
85 90 95

Glu Glu Glu Asn Phe Tyr Leu Glu Pro Tyr Leu Lys Glu Val Ile Arg 100 105 110

Glu Arg Lys Glu Arg Glu Glu Trp Ala Lys Lys 115 120

<210> 998

<211> 762

<212> PRT

<213> Homo sapiens

<400> 998

His Gly Leu Thr Arg Asp Ser Ser Glu Gln Gly Arg Thr Gly Asp Thr Leu Gly Arg Pro Ser Ala Cys Met Asp Ala Leu Lys Pro Pro Cys Leu 25 Trp Arg Asn His Glu Arg Gly Lys Lys Asp Arg Asp Ser Cys Gly Arg 40 Lys Asn Ser Glu Pro Gly Ser Pro His Ser Leu Glu Ala Leu Arg Asp 55 Ala Ala Pro Ser Gln Gly Leu Asn Phe Leu Leu Phe Thr Lys Met 70 75 Leu Phe Ile Phe Asn Phe Leu Phe Ser Pro Leu Pro Thr Pro Ala Leu 90 Ile Cys Ile Leu Thr Phe Gly Ala Ala Ile Phe Leu Trp Leu Ile Thr 100 105 Arg Pro Gln Pro Val Leu Pro Leu Leu Asp Leu Asn Asn Gln Ser Val 115 120 Gly Ile Glu Gly Gly Ala Arg Lys Gly Val Ser Gln Lys Asn Asn Asp 135 140 Leu Thr Ser Cys Cys Phe Ser Asp Ala Lys Thr Met Tyr Glu Val Phe 150 155 Gln Arg Gly Leu Ala Val Ser Asp Asn Gly Pro Cys Leu Gly Tyr Arg 165 170 175 · Lys Pro Asn Gln Pro Tyr Arg Trp Leu Ser Tyr Lys Gln Val Ser Asp 180 185 Arg Ala Glu Tyr Leu Gly Ser Cys Leu Leu His Lys Gly Tyr Lys Ser 200 Ser Pro Asp Gln Phe Val Gly Ile Phe Ala Gln Asn Arg Pro Glu Trp 210 215 Ile Ile Ser Glu Leu Ala Cys Tyr Thr Tyr Ser Met Val Ala Val Pro 225 235 230 Leu Tyr Asp Thr Leu Gly Pro Glu Ala Ile Val His Ile Val Asn Lys 250

Ala Asp Ile Ala Met Val Ile Cys Asp Thr Pro Gln Lys Ala Leu Val

265

Leu	Ile	Gly 275		Val	. Glu	Lys	Gly 280		Thr	Pro	Ser	Leu 285		Val	Ile
Ile	200		. Asp	Pro	Phe	Asp 295	-	Asp	Leu	Lys	Gln 300	-	Gly	Glu	Lys
Ser 305	Gly	Ile	Glu	Ile	Leu 310		Leu	Tyr	Asp	Ala 315		Asn	Leu	Gly	Lys 320
Glu	His	Phe	Arg	Lys 325		Val	Pro	Pro	Ser 330		Glu	Asp	Leu	Ser 335	Val
Ile	Cys	Phe	Thr 340		Gly	Thr	Thr	Gly 345	-	Pro	Lys	Gly	Ala 350	Met	Ile
Thr	His	Gln 355		Ile	Val	Ser	Asn 360		Ala	Ala	Phe	Leu 365	Lys	Cys	Val
Glu	His 370	Ala	Tyr	Glu	Pro	Thr 375	Pro	Asp	Asp	Val	Ala 380	Ile	Ser	Tyr	Leu
Pro 385	Leu	Ala	His	Met	Phe 390	Glu	Arg	Ile	Val	Gln 395	Ala	Val	Val	Tyr	Ser 400
Cys	Gly	Ala	Arg	Val 405	Gly	Phe	Phe	Gln	Gly 410	Asp	Ile	Arg	Leu	Leu 415	Ala
Asp	Asp	Met	Lys 420	Thr	Leu	Lys	Pro	Thr 425	Leu	Phe	Pro	Ala	Val 430	Pro	Arg
Leu	Leu	Asn 435	Arg	Ile	туг	Asp	Lys 440	Val	Gln	Asn	Glu	Ala 445	Lys	Thr	Pro
Leu	Lys 450	Lys	Phe	Leu	Leu	Lys 455	Leu	Ala	Val	Ser	Ser 460	Lys	Phe	Lys	Glu
Leu 465	Gln	Lys	Gly	Ile	Ile 470	Arg	His	Asp	Ser	Phe 475	Trp	Asp	Lys	Leu	Ile 480
Phe	Ala	Lys	Ile	Gln 485	Asp	Ser	Leu	Gly	Gly 490	Arg	Val	Arg	Val	Ile 495	Val
Thr	Gly	Ala	Ala 500	Pro	Met	Ser	Thr	Ser 505	Val	Met	Thr	Phe	Phe 510	Arg	Ala
Ala	Met	Gly 515	Cys	Gln	Val	Tyr	Glu 520	Ala	Tyr	Gly	Gln	Thr 525	Glu	Cys	Thr
Gly	Gly	Cys	Thr	Phe	Thr	Leu	Pro	Gly	Asp	Trp	Thr	Ser	Gly	His	Val

Gly Val Pro Leu Ala Cys Asn Tyr Val Lys Leu Glu Asp Val Ala Asp 550 555 Met Asn Tyr Phe Thr Val Asn Asn Glu Gly Glu Val Cys Ile Lys Gly 565 570 Thr Asn Val Phe Lys Gly Tyr Leu Lys Asp Pro Glu Lys Thr Gln Glu 585 Ala Leu Asp Ser Asp Gly Trp Leu His Thr Gly Asp Ile Gly Arg Trp 600 595 Leu Pro Asn Gly Thr Leu Lys Ile Ile Asp Arg Lys Lys Asn Ile Phe Lys Leu Ala Gin Gly Glu Tyr Ile Ala Pro Glu Lys Ile Glu Asn Ile 630 635 Tyr Asn Arg Ser Gln Pro Val Leu Gln Ile Phe Val His Gly Glu Ser 645 650 Leu Arg Ser Ser Leu Val Gly Val Val Val Pro Asp Thr Asp Val Leu 660 665 Pro Ser Phe Ala Ala Lys Leu Gly Val Lys Gly Ser Phe Glu Glu Leu Cys Gln Asn Gln Val Val Arg Glu Ala Ile Leu Glu Asp Leu Gln Lys 700 695 Ile Gly Lys Glu Ser Gly Leu Lys Thr Phe Glu Gln Val Lys Ala Ile 705 710 715 Phe Leu His Pro Glu Pro Phe Ser Ile Glu Asn Gly Leu Leu Thr Pro 725 730

Thr Leu Lys Ala Lys Arg Gly Glu Leu Ser Lys Tyr Phe Arg Thr Gln 740 745 750

Ile Asp Ser Leu Tyr Glu His Ile Gln Asp 755 760

<210> 999

<211> 130

<212> PRT

<213> Homo sapiens

<400> 999

Thr Asn Val Asp Lys Leu Val Lys Asp Ile Tyr Gly Gly Asp Tyr Glu

WO 00/55351 PCT/US00/05883

1 10 15 Arg Phe Gly Leu Gln Gly Ser Ala Val Ala Ser Ser Phe Gly Asn Met 20 25 Met Ser Lys Glu Lys Arg Asp Ser Ile Ser Lys Glu Asp Leu Ala Arg 40 Ala Thr Leu Val Thr Ile Thr Asn Asn Ile Gly Ser Ile Ala Arg Met 55 Cys Ala Leu Asn Glu Asn Ile Asp Arg Val Val Phe Val Gly Asn Phe 65 70 75 Leu Arg Ile Asn Met Val Ser Met Lys Leu Leu Ala Tyr Ala Met Asp 85 90 Phe Trp Ser Lys Gly Gln Leu Lys Ala Leu Phe Leu Glu His Glu Gly 105 Tyr Phe Gly Ala Val Gly Ala Leu Leu Glu Leu Phe Lys Met Thr Asp 120 Asp Lys 130 <210> 1000 <211> 270 <212> PRT <213> Homo sapiens <220> <221> SITE <222> (61) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (71) <223> Xaa equals any of the naturally occurring L-amino acids <400> 1000 Gln Gln Asn Glu Ala Lys Ile Lys Gly Val Ser Lys Gly Arg Asn Ile Cys Val Val Cys Cys Gln His Lys Met Glu Glu Leu Lys Glu Gly Leu 20 25

Arg Gln Arg Asp Glu Leu Ile Glu Glu Lys Gln Arg Met Gln Gln Lys

PCT/US00/05883 WO 00/55351

35 40 45 Ile Asp Thr Met Thr Lys Glu Val Phe Asp Leu Gln Xaa Thr Leu Leu 55 Trp Lys Asp Lys Lys Ile Xaa Lys His Gly Leu Val Ile Ile Pro Asp Gly Thr Pro Asn Gly Asp Val Ser His Glu Pro Val Ala Gly Ala Ile 85 90 Thr Val Val Ser Gln Glu Ala Ala Gln Val Leu Glu Ser Ala Gly Glu 100 105 110 Gly Pro Leu Asp Val Arg Leu Arg Lys Leu Ala Gly Glu Lys Glu Glu 120 Leu Leu Ser Gln Ile Arg Lys Leu Lys Leu Gln Leu Glu Glu Glu Arg 135 Gln Lys Cys Ser Arg Asn Asp Gly Thr Val Gly Asp Leu Ala Gly Leu 150 155 Gln Asn Gly Ser Asp Leu Gln Phe Ile Glu Met Gln Arg Asp Ala Asn 165 170 175 Arg Gln Ile Ser Glu Tyr Lys Phe Lys Leu Ser Lys Ala Glu Gln Asp 180 185 Ile Thr Thr Leu Glu Gln Ser Ile Ser Arg Leu Glu Gly Gln Val Leu 200 Arg Tyr Lys Thr Ala Ala Glu Asn Ala Glu Lys Val Glu Asp Glu Leu 210 220 215 Lys Ala Glu Lys Arg Lys Leu Gln Arg Glu Leu Arg Thr Ala Leu Asp 225 230 235 Lys Ile Glu Glu Met Glu Met Thr Asn Ser His Leu Ala Lys Arg Leu

250

265

Glu Lys Met Lys Ala Asn Arg Thr Ala Leu Leu Ala Gln Gln

<210> 1001

<211> 124

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (110)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (111)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 1001

Leu His Ser Gln Val Phe Pro Ala Leu Thr Pro Lys Arg Trp Thr Gln
1 5 10 15

Val Arg Arg Gly Thr Ala Thr Val Gly Gly Met Ala Ile Leu Gln Val 20 25 30

Thr Ala Gly His Pro Leu Ala Met Ala Gln Gly Pro Ala Gly His Pro
35 40 45

Pro Thr Met Ala Gln Gly Pro Ala Gly His Pro Pro Thr Met Val Gln 50 55 60

Gly Pro Ala Gly His Pro Leu Ala Met Ala Gln Gly Pro Ala Gly His 65 70 75 80

Pro Pro Thr Met Val Gln Gly Pro Ala Gly Leu Pro Leu Ala Met Ala 85 90 95

Gln Val Thr His Pro Leu Val His Ile Thr Glu Glu Val Xaa Xaa Asn 100 105 110

Arg Thr Gln Asp Gly Lys Pro Glu Arg Asn Cys Pro 115 120

<210> 1002

<211> 647

<212> PRT

<213> Homo sapiens

<400> 1002

Thr Ile Gln Ile Val Asn Met Gly Arg Arg Ser Thr Ser Ser Thr Lys

1 5 10 15

Ser Gly Lys Phe Met Asn Pro Thr Asp Gln Ala Arg Lys Glu Ala Arg 20 25 30

Lys Arg Glu Leu Lys Lys Asn Lys Lys Gln Arg Met Met Val Arg Ala 35 40 45

Ala	Val 50	Leu	Lys	Met	Lys	Asp 55	Pro	Lys	Gln	Ile	Ile 60	Arg	Asp	Met	Glu
Lys 65	Leu	Asp	Glu	Met	Glu 70	Phe	Asn	Pro	Val	Gln 75	Gln	Pro	Gln	Leu	Asn 80
Glu	Lys	Val	Leu	Lys 85	Asp	Lys	Arg	Lys	Lys 90	Leu	Arg	Glu	Thr	Phe 95	Glu
Arg	Ile	Leu	Arg 100	Leu	Tyr	Glu	Lys	Glu 105	Asn	Pro	Asp	Ile	Tyr 110	Lys	Glu
Leu	Arg	Lys 115	Leu	Glu	Val	Glu	Туг 120	Glu	Gln	Lys	Arg	Ala 125	Gln	Leu	Ser
Gln	Tyr 130	Phe	Asp	Ala	Val	Lys 135	Asn	Ala	Gln	His	Val 140	Glu	Val	Glu	Ser
Ile 145	Pro	Leu	Pro	Asp	Met 150	Pro	His	Ala	Pro	Ser 155	Asn	Ile	Leu	Ile	Gln 160
Asp	Ile	Pro	Leu	Pro 165	Gly	Ala	Gln	Pro	Pro 170	Ser	Ile	Leu	Lys	Lys 175	Thr
Ser	Ala	Tyr	Gly 180	Pro	Pro	Thr	Arg	Ala 185	Val	Ser	Ile	Leu	Pro 190	Leu	Leu
Gly	His	Gly 195	Val	Pro	Arg	Leu	Pro 200	Pro	Gly	Arg	Lys	Pro 205	Pro	Gly	Pro
Pro	Pro 210	Gly	Pro	Pro	Pro	Pro 215	Gln	Val	Val	Gln	Met 220	Tyr	Gly	Arg	Lys
Val 225	Gly	Phe	Ala	Leu	Asp 230	Leu	Pro	Pro	Arg	Arg 235	Arg	Asp	Glu	Asp	Met 240
Leu	туг	Ser	Pro	Glu 245	Leu	Ala	Gln	Arg	Gly 250		Asp	Asp	Asp	Val 255	Ser
Ser	Thr	Ser	Glu 260	Asp	Asp	Gly	туr	Pro 265	Glu	Asp	Met	Asp	Gln 270	Asp	Lys
His	Asp	Asp 275	Ser	Thr	Asp	Asp	Ser 280	Asp	Thr	Asp	Lys	ser 285	Asp	Gly	Glu
Ser	Asp 290	Gly	Asp	Glu	Phe	Val 295	His	Arg	Asp	Asn	Gly 300	Glu	Arg	Asp	Asn
Asn 305	Glu-	Glu	Lys	Lys	Ser 310	Gly	Leu	Ser	Val	Arg 315	Phe	Ala	Asp	Met	Pro 320

Gly	Lys	Ser	Arg	Lys 325	-	Lys	Lys	Asn	Met 330	_	Glu	Leu	Thr	Pro 335	Leu
Gln	Ala	Met	Met 340		Arg	Met	Ala	Gly 345	Gln	Glu	Ile	Pro	Glu 350	Glu	Gly
Arg	Glu	Val 355		Glu	Phe	Ser	Glu 360	Asp	Asp	Asp	Glu	Asp 365	Asp	Ser	Asp
Asp	Ser 370		Ala	Glu	Lys	Gln 375		Gln	Lys	Gln	His 380	Lys	Glu	Glu	Ser
His 385	Ser	Asp	Gly	Thr	Ser 390	Thr	Ala	Ser	Ser	Gln 395	Gln	Gln	Ala	Pro	Pro 400
Gln	Ser	Val	Pro	Pro 405	Ser	Gln	Ile	Gln	Ala 410	Pro	Pro	Met	Pro	Gly 415	Pro
Pro	Pro	Leu	Gly 420	Pro	Pro	Pro	Ala	Pro 425	Pro	Leu	Arg	Pro	Pro 430	Gly	Pro
Pro	Thr	Gly 435	Leu	Pro	Pro	Gly	Pro 440	Pro	Pro	Gly	Ala	Pro 445	Pro	Phe	Leu
Arg	Pro 450	Pro	Gly	Met	Pro	Gly 455	Leu	Arg	Gly	Pro	Leu 460	Pro	Arg	Leu	Leu
Pro 465	Pro	Gly	Pro	Pro	Pro 470	Gly	Arg	Pro	Pro	Gly 475	Pro	Pro	Pro	Gly	Pro 480
Pro	Pro	Gly	Leu	Pro 485	Pro	Gly	Pro	Pro	Pro 490	Arg	Gly	Pro	Pro	Pro 495	Arg
Leu	Pro	Pro	Pro 500	Ala	Pro	Pro	Gly	Ile 505	Pro	Pro	Pro	Arg	Pro 510	Gly	Met
Met	Arg	Pro 515	Pro	Leu	Val	Pro	Pro 520	Leu	Gly	Pro	Ala	Pro 525	Pro	Gly	Leu
Phe	Pro 530	Pro	Ala	Pro	Leu	Pro 535	Asn	Pro	Gly	Val	Leu 540	Ser	Ala	Pro	Pro
Asn 545	Leu	Ile	Gln	Arg	Pro 550	Lys	Ala	Asp	Asp	Thr 555	Ser	Ala	Ala	Thr	Ile 560
Glu	Lys	Lys	Ala	Thr 565	Ala.	Thr	Ile	Ser	Ala 570	Lys	Pro	Gln	Ile	Thr 575	Asn
Pro	Lys	Ala	Glu 580	Ile	Thr	Arg	Phe	Val 585	Pro	Thr	Ala	Leu	Arg 590	Val	Arg

Arg Glu Asn Lys Gly Ala Thr Ala Ala Pro Gln Arg Lys Ser Glu Asp 595 600 605

Asp Ser Ala Val Pro Leu Ala Lys Ala Ala Pro Lys Ser Gly Pro Ser 610 620

Val Pro Val Ser Val Gln Thr Lys Asp Asp Val Tyr Glu Ala Phe Met 625 630 635 640

Lys Glu Met Glu Gly Leu Leu 645

<210> 1003

<211> 342

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (109)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (251)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (253)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 1003

Leu Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys
1 5 10 15

Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly 20 25 30

Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro 35 40 45

Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr
50 55 60

Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val 65 70 75 80

Val	Thr	Val	Pro	Ser 85	Ser	Ser	Leu	Gly	Thr 90		Thr	Tyr	Ile	Cys 95	Asn
Val	Asn	His	Lys 100	Pro	Ser	Asn	Thr	Lys 105	Val	Asp	Lys	Xaa	Val 110	Glu	Pro
Lys	Ser	Cys 115	-	Lys	Thr	His	Thr 120	Суз	Pro	Pro	Cys	Pro 125	Ala	Pro	Glu
Leu	Leu 130	Gly	Gly	Pro	Ser	Val 135	Phe	Leu	Phe	Pro	Pro 140	Lys	Pro	Lys	Asp
Thr 145	Leu	Met	Ile	Ser	Arg 150	Thr	Pro	Glu	Val	Thr 155	Cys	Val	Val	Val	Asp 160
Val	Ser	His	Glu	Asp 165	Pro	Glu	Val	Lys	Phe 170	Asn	Trp	Tyr	Val	Asp 175	Gly
Val	Glu	Val	His 180	Asn	Ala	Lys	Thr	Lys 185	Pro	Arg	Glu	Glu	Gln 190	Tyr	Asn
Ser	Thr	Туг 195	Arg	Val	Val	Ser	Val 200	Leu	Thr	Val	Leu	His 205	Gln	Asp	Trp
Leu	Asn 210	Gly	Lys	Glu	Tyr	Lys 215	Суѕ	Lys	Val		Asn 220	Lys	Ala	Leu	Pro
Ala 225	Pro	Ile	Glu	Lys	Thr 230	Ile	Ser	Lys	Ala	Lys 235	Gly	Gln	Pro	Arg	Glu 240
Pro	Gln	Val	Tyr	Thr 245	Leu	Pro	Pro	Ser	Arg 250	Xaa	Glu	Xaa	Thr	Lys 255	Asn
Gln	Val	Ser	Leu 260	Thr	Cys	Leu	Val	Lys 265	Gly	Phe	Tyr	Pro	Ser 270	Asp	Ile
Ala	Val	Glu 275	Trp	Glu	Ser	Asn	Gly 280	Gln	Pro	Glu	Asn	Asn 285	Tyr	Lys	Thr
Thr	Pro 290	Pro	Val	Leu	_	Ser 295	Asp	Gly	Ser	Phe	Phe 300	Leu	Tyr	Ser	Lys
Leu 305	Thr	Val	Asp	Lys	Ser 310	Arg	Trp	Gln	Gln	Gly 315	Asn	Val	Phe	Ser	Cys 320
Ser	Val	Met	His	Glu 325	Ala	Leu	His	Asn	His 330	Tyr	Thr	Gln	Lys	Ser 335	Leu

Ser Leu Ser Pro Gly Lys 340

<210> 1004 <211> 544 <212> PRT <213> Homo sapiens <220> <221> SITE <222> (27) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (531) <223> Xaa equals any of the naturally occurring L-amino acids <400> 1004 Arg Leu Pro Pro Ala Ser Ala Thr Ala Arg Arg Pro Arg Pro Ser Ser 5 10 15 Ala Leu Cys Cys Pro Arg Ser Arg Arg Arg Xaa Gly Gln Arg Pro Gly 20 25 Ala Ala Gln Gly Cys His Pro Arg Arg Phe Pro Lys Lys Ala Ser Arg Thr Ala Arg Ile Ala Ser Asp Glu Glu Ile Gln Gly Thr Lys Asp Ala 55 Val Ile Gln Asp Leu Glu Arg Lys Leu Arg Phe Lys Glu Asp Leu Leu 65 70 Asn Asn Gly Gln Pro Arg Leu Thr Tyr Glu Glu Arg Met Ala Arg Arg Leu Leu Gly Ala Asp Ser Ala Thr Val Phe Asn Ile Gln Glu Pro Glu 105 Glu Glu Thr Ala Asn Gln Glu Tyr Lys Val Ser Ser Cys Glu Gln Arg 115 120 Leu Ile Ser Glu Ile Glu Tyr Arg Leu Glu Arg Ser Pro Val Asp Glu

135

150

Ser Gly Asp Glu Val Gln Tyr Gly Asp Val Pro Val Glu Asn Gly Met

Ala Pro Phe Phe Glu Met Lys Leu Lys His Tyr Lys Ile Phe Glu Gly

155

170

130

Met	Pro	Val	Thr 180	Phe	Thr	Cys	Arg	Val 185		Gly	Asn	Pro	Lys 190	Pro	Lys
Ile	Tyr	Trp 195		Lys	Asp	Gly	Lys 200	Gln	Ile	Ser	Pro	Lys 205	Ser	Asp	His
Tyr	Thr 210	Ile	Gln	Arg	Asp	Leu 215	Asp	Gly	Thr	Cys	Ser 220	Leu	His	Thr	Thr
Ala 225	Ser	Thr	Leu	Asp	Asp 230	Asp	Gly	Asn	Tyr	Thr 235	Ile	Met	Ala	Ala	Asn 240
Pro	Gln	Gly	Arg	Ile 245	Ser	Cys	Thr	Gly	Arg 250	Leu	Met	Val	Gln	Ala 255	Val
Asn	Gln	Arg	Gly 260	Arg	Ser	Pro	Arg	Ser 265	Pro	Ser	Gly	His	Pro 270	His	Val
Arg	Arg	Pro 275	Arg	Ser	Arg	Ser	Arg 280	Asp	Ser	Gly	Asp	Glu 285	Asn	Glu	Pro
Ile	Gln 290	Glu	Arg	Phe	Phe	Arg 295	Pro	His	Phe	Leu	Gln 300	Ala	Pro	Gly	Asp
Leu 305	Thr	Val	Gln	Glu	Gly 310	Lys	Leu	Суѕ	Arg	Met 315	Asp	Cys	Lys	Val	Ser 320
Gly	Leu	Pro	Thr	Pro 325	Asp	Leu	Ser	Trp	Gln 330	Leu	Asp	Gly	Lys	Pro 335	Val
Arg	Pro	Asp	Ser 340	Ala	His	Lys	Met	Leu 345	Val	Arg	Glu	Asn	Gly 350	Val	His
Ser	Leu	11e 355	Ile	Glu	Pro	Val	Thr 360	Ser	Arg	Asp	Ala	Gly 365	Ile	Tyr	Thr
Cys	11e 370	Ala	Thr	Asn	Arg	Ala 375	Gly	Gln	Asn	Ser	Phe 380	Ser	Leu	Glu	Leu
Val 385	Val	Ala	Ala	Lys	Glu 390	Ala	His	Lys	Pro	Pro 395	Val	Phe	Ile	Glu	Lys 400
Leu	Gln	Asn	Thr	Gly 405	Val	Ala	Asp	Gly	Tyr 410	Pro	Val	Arg	Leu	Glu 415	Cys
Arg	Val	Leu	Gly 420	Val	Pro	Pro	Pro	Gln 425	Ile	Phe	Trp	Lys	Lys 430	Glu	Asn
Glu	Ser	Leu 435	Thr	His	Ser	Thr	Asp 440	Arg	Val	Ser	Met	His 445	Gln	Asp	Asn

His Gly Tyr Ile Cys Leu Leu Ile Gln Gly Ala Thr Lys Glu Asp Ala 450 455 460

Gly Trp Tyr Thr Val Ser Ala Lys Asn Glu Ala Gly Ile Val Ser Cys 465 470 475 480

Thr Ala Arg Leu Asp Val Tyr Thr Gln Trp His Gln Gln Ser Gln Ser 485 490 495

Thr Lys Pro Lys Lys Val Arg Pro Ser Ala Ser Arg Tyr Ala Ala Leu 500 505 510

Ser Asp Gln Gly Leu Asp Ile Lys Ala Ala Phe Gln Pro Glu Ala Asn 515 520 525

Pro Ser Xaa Leu Thr Leu Asn Thr Ala Leu Val Glu Ser Glu Asp Leu 530 540

<210> 1005

<211> 194

<212> PRT

<213> Homo sapiens

<400> 1005

Ala Ala Pro Gln Pro Thr Pro Glu Glu Arg Pro Ala Gly Val Arg Arg
1 5 10 15

Ala Gln Glu Leu Gly Met Ser Tyr Lys Pro Ile Ala Pro Ala Pro Ser 20 25 30

Ser Thr Pro Gly Ser Ser Thr Pro Gly Pro Gly Thr Pro Val Pro Thr

Gly Ser Val Pro Ser Pro Ser Gly Ser Val Pro Gly Ala Gly Ala Pro
50 55 60

Phe Arg Pro Leu Phe Asn Asp Phe Gly Pro Pro Ser Met Gly Tyr Val 65 70 75 80

Gln Ala Met Lys Pro Pro Gly Ala Gln Gly Ser Gln Ser Thr Tyr Thr 85 90 95

Asp Leu Leu Ser Val Ile Glu Glu Met Gly Lys Glu Ile Arg Pro Thr 100 105 110

Tyr Ala Gly Ser Lys Ser Ala Met Glu Arg Leu Lys Arg Gly Ser Ala

115 120 125

Ser Ala Ser Ala Ser Gly Pro Ile Arg Pro Leu Gln Ser Thr Arg Phe 130 135 140

Ser Leu Ala Phe Ile Pro Ser Cys Thr Asn His Pro Gly Leu Pro Val 145 150 155 160

Leu Cys Pro Leu Val Gly Pro Leu Gln Glu Pro Arg Ser Gly Pro Pro 165 170 175

Gly Gly Ser Thr Lys Asp Thr Pro Pro Gln Gln Glu Leu Ala Ala Arg 180 185 190

Ser Pro

<210> 1006

<211> 312

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (105)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (220)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (222)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (231)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (244)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (298) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (299) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (309) <223> Xaa equals any of the naturally occurring L-amino acids <400> 1006 Ala Val Arg Leu Pro Ala Ala Tyr Ile Lys Ala Pro Gly His Ala Glu 10 Pro Ser Ser Arg Thr Arg Pro Thr Thr Met Arg Ser Cys Leu Trp Arg 25 Cys Arg His Leu Ser Gln Gly Val Gln Trp Ser Leu Leu Leu Ala Val 40 Leu Val Phe Phe Leu Phe Ala Leu Pro Ser Phe Ile Lys Glu Pro Gln 50 55 Thr Lys Pro Ser Arg His Gln Arg Thr Glu Asn Ile Lys Glu Arg Ser 70 Leu Gln Ser Leu Ala Lys Pro Lys Ser Gln Ala Pro Thr Arg Ala Arg Arg Thr Thr Ile Tyr Ala Glu Pro Xaa Pro Glu Asn Asn Ala Leu Asn 100 105 110 Thr Gln Thr Gln Pro Lys Ala His Thr Thr Gly Asp Arg Gly Lys Glu 115 120 Ala Asn Gln Ala Pro Pro Glu Glu Gln Asp Lys Val Pro His Thr Ala 135 Gln Arg Ala Ala Trp Lys Ser Pro Glu Lys Glu Lys Thr Met Val Asn 150 155 Thr Leu Ser Pro Arg Gly Gln Asp Ala Gly Met Ala Ser Gly Arg Thr 165 Glu Ala Gln Ser Trp Lys Ser Gln Asp Thr Lys Thr Thr Gln Gly Asn

185

Gly Gln Thr Arg Lys Leu Thr Ala Ser Arg Thr Val Ser Glu Lys

195 200 205

His Gln Gly Lys Ala Ala Thr Thr Ala Lys Thr Xaa Ile Xaa Lys Ser 210 215 220

Gln His Arg Met Leu Ala Xaa Thr Gly Ala Val Ser Thr Arg Thr Arg 225 230 235 240

Gln Lys Gly Xaa Thr Thr Ala Val Ile Pro Pro Lys Glu Lys Lys Pro 245 250 255

Gln Ala Thr Pro Pro Pro Ala Pro Phe Gln Ser Pro Thr Thr Gln Arg
260 265 270

Asn Gln Arg Leu Lys Gly Gly Asn Phe Lys Ser Glu Pro Arg Trp Asp 275 280 285

Phe Glu Glu Lys Tyr Lys Leu Arg Asn Xaa Xaa Ala Ser Asp Asp Leu 290 295 300

Ala Leu Thr Leu Xaa Arg Ser Lys 305 310

<210> 1007

<211> 365

<212> PRT

<213> Homo sapiens

<400> 1007

Pro Glu Pro Ala Met Ala Leu Pro His Arg Arg Leu Ser Pro Trp Leu
1 5 10 15

Arg Gln Arg His Gln Gly Pro Gly Gln Val Cys Gly Pro Gln Ala Ala 20 25 30

Glu His Asp Arg Arg Asp Ala Gly Cys Thr Ala Asp Leu Leu Val Gly
35 40 45

Arg Ala Met Thr Phe His Gly His Gly Phe Leu Arg Leu Ala Leu Ser 50 55 60

Asn Val Ala Pro Leu Thr Gly Asn Val Tyr Ser Gly Phe Gly Phe His 65 70 75 80

Ser Ala Gln Asp Ser Ala Leu Leu Tyr Tyr Arg Ala Ser Pro Asp Gly
85 90 95

Leu Cys Gln Val Ser Leu Gln Gln Gly Arg Val Ser Leu Gln Leu Leu 100 105 110

Arg	Thr	Glu 115		Lys	Thr	Gln	Ala 120	_	Phe	Ala	Asp	Gly 125		Pro	His
Туr	Val 130	Ala	Phe	Туг	Ser	Asn 135		Thr	Gly	Val	Trp 140		Tyr	Val	Asp
Asp 145	·Gln	Leu	Gln	Gln	Met 150	Lys	Pro	His	Arg	Gly 155		Pro	Pro	Glu	Leu 160
Gln	Pro	Gln	Pro	Glu 165	Gly	Pro	Pro	Arg	Leu 170	Leu	Leu	Gly	Gly	Leu 175	Pro
Glu	Ser	Gly	Thr 180		Tyr	Asn	Phe	Ser 185	_	Cys	Ile	Ser	Asn 190	Val	Phe
		195			Gly		200					205			
	210				Val	215			-		220				
225					Gly 230					235					240
			_	245	Arg				250					255	
			260		Thr		_	265					270	_	
		275			Glu		280	_				285			
-	290				Met	295					300	į.	_	_	
305					Arg 310					315					320
				325	His				330					335	
			340		Ser			345					350	стА	TNT
AT 9	361	ETO	cys	wrd	Gly	AL Y	ur A	TIIT	GIY	SET	Cys	115			

PCT/US00/05883

<210> 1008 <211> 196 <212> PRT

<213> Homo sapiens

<400> 1008

Ala Thr Pro Pro Pro Pro Glu Gln Ala Met Val Ala Ala Thr Val Ala 1 5 10 15

Ala Ala Trp Leu Leu Leu Trp Ala Ala Ala Cys Ala Gln Gln Gln Gln 20 25 30

Asp Phe Tyr Asp Phe Lys Ala Val Asn Ile Arg Gly Lys Leu Val Ser

Leu Glu Lys Tyr Arg Gly Ser Val Ser Leu Val Val Asn Val Ala Ser 50 55 60

Glu Cys Gly Phe Thr Asp Gln His Tyr Arg Ala Leu Gln Gln Leu Gln 65 70 75 80

Arg Asp Leu Gly Pro His His Phe Asn Val Leu Ala Phe Pro Cys Asn 85 90 95

Gln Phe Gly Gln Gln Glu Pro Asp Ser Asn Lys Glu Ile Glu Ser Phe 100 105 110

Ala Arg Arg Thr Tyr Ser Val Ser Phe Pro Met Phe Ser Lys Ile Ala 115 120 125

Val Thr Gly Thr Gly Ala His Pro Ala Phe Lys Tyr Leu Ala Gln Thr 130 135 140

Ser Gly Lys Glu Pro Thr Trp Asn Phe Trp Lys Tyr Leu Val Ala Pro 145 150 155 160

Asp Gly Lys Val Val Gly Ala Trp Asp Pro Thr Val Ser Val Glu Glu
165 1.70 175

Val Arg Pro Gln Ile Thr Ala Leu Val Arg Lys Leu Ile Leu Leu Lys 180 185 190

Arg Glu Asp Leu 195

<210> 1009

<211> 227

<212> PRT

<213> Homo sapiens

```
<220>
<221> SITE
<222> (156)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (196)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (204)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (210)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (212)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (215)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (220)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (222)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1009
Asp Pro Arg Val Arg Ala Ala Ala Gly Pro Met Ala Asp Thr Gln
                  5
                                     10
Tyr Ile Leu Pro Asn Asp Ile Gly Val Ser Ser Leu Asp Cys Arg Glu
             20
                                 25
Ala Phe Arg Leu Leu Ser Pro Thr Glu Arg Leu Tyr Ala Tyr His Leu
                             40
```

Ser Arg Ala Ala Trp Tyr Gly Gly Leu Ala Val Leu Leu Gln Thr Ser 50 55 60

Pro Glu Ala Pro Tyr Ile Tyr Ala Leu Leu Ser Arg Leu Phe Arg Ala 65 70 75 80

Gln Asp Pro Asp Gln Leu Arg Gln His Ala Leu Ala Glu Gly Leu Thr 85 90 95

Glu Glu Glu Tyr Gln Ala Phe Leu Val Tyr Ala Ala Gly Val Tyr Ser 100 105 110

Asn Met Gly Asn Tyr Lys Ser Phe Gly Asp Thr Lys Phe Val Pro Asn 115 120 125

Leu Pro Lys Glu Lys Leu Glu Arg Val Ile Leu Gly Ser Glu Ala Ala 130 135 140

Gln Gln His Pro Glu Glu Val Arg Gly Leu Trp Xaa Thr Cys Gly Glu 145 150 155 160

Leu Met Phe Ser Leu Glu Pro Arg Leu Arg His Leu Gly Leu Gly Lys 165 170 175

Glu Gly Ile Thr Thr Tyr Phe Ser Gly Asn Cys Thr Met Glu Asp Ala 180 185 190

Lys Leu Ala Xaa Ile Ser Gly Leu Thr Glu Pro Xaa Cys Leu Gln Gln 195 200 205

Pro Xaa Leu Xaa Arg Ser Xaa Trp Glu Lys Gly Xaa Pro Xaa Thr Lys 210 215 220

Val Arg Val 225

<210> 1010

<211> 344

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (31)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 1010

Asp Pro Ala Ser Asn Met Trp Gln Leu Trp Ala Ser Leu Cys Cys Leu 1 5 10 15

Leu	Val	Leu	Ala 20		Ala	Arg	Ser	Arg 25		Ser	Phe	His	Pro 30	Хаа	Ser
Asp	Glu	Leu 35		Asn	Tyr	Val	Asn 40	-	Arg	Asn	Thr	Thr 45	Trp	Gln	Ala
Gly	His 50	Asn	Phe	туг	Asn	Val 55	_	Met	Ser	Tyr	Leu 60	Lys	Arg	Leu	Cys
Gly 65	Thr	Phe	Leu	Gly	Gly 70	Pro	Lys	Pro	Pro	Gln 75	Arg	Val	Met	Phe	Thr 80
Glu	Asp	Leu	Lys	Leu 85	Pro	Ala	Ser	Phe	Asp 90	Ala	Arg	Glu	Gln	Trp 95	Pro
Gln	Cys	Pro	Thr 100	Ile	Lys	Glu	Ile	Arg 105	Asp	Gln	Gly	Ser	Cys 110	Gly	Ser
Cys	Trp	Ala 115	Phe	Gly	Ala	Val	Glu 120	Ala	Ile	Ser	Asp	Arg 125	Ile	Cys	Ile
His	Thr 130	Asn	Ala	His	Val	Ser 135	Val	Glu	Val	Ser	Ala 140	Glu	Asp	Leu	Leu
Thr 145	Cys	Cys	Gly	Ser	Met 150	Cys	Gly	Asp	Gly	Cys 155	Asn	Gly	Gly	Tyr	Pro 160
Ala	Glu	Ala	Trp	Asn 165	Phe	Trp	Thr	Arg	Lys 170	Gly	Leu	Val	Ser	Gly 175	Gly
Leu	Tyr	Glu	Ser 180	His	Val	Gly	Суѕ	Arg 185	Pro	Tyr	Ser	Ile	Pro 190	Pro	Cys
Glu	His	His 195	Val	Asn	Gly	Ser	Arg 200	Pro	Pro	Cys	Thr	Gly 205	Glu	Gly	Asp
Thr	Pro 210	Lys	Cys	Ser	Lys	11e 215	Cys	Glu	Pro	Gly	туг 220	Ser	Pro	Thr	Tyr
Lys 225	Gln	Asp	Lys	His	Tyr 230	Gly	Tyr	Asn	Ser	Туг 235	Ser	Val	Ser	Asn	Ser 240
Glu	Lys	Asp	Ile	Met 245	Ala	Glu	Ile	Tyr	Lys 250	Asn	Gly	Pro	Val	Glu 255	Gly
Ala	Phe	Ser	Val 260	Tyr	Ser	Asp	Phe	Leu 265	Leu	Tyr	Lys	Ser	Gly 270	Val	Tyr

Gln His Val Thr Gly Glu Met Met Gly Gly His Ala Ile Arg Ile Leu

285

280

Gly Trp Gly Val Glu Asn Gly Thr Pro Tyr Trp Leu Val Ala Asn Ser 290 295 300

Trp Asn Thr Asp Trp Gly Asp Asn Gly Phe Phe Lys Ile Leu Arg Gly 305 310 315 320

Gln Asp His Cys Gly Ile Glu Ser Glu Val Val Ala Gly Ile Pro Arg 325 330 335

Thr Asp Gln Tyr Trp Glu Lys Ile 340

<210> 1011

<211> 384

<212> PRT

<213> Homo sapiens

<400> 1011

Ala Gly Thr Arg Gly Pro Gly Ala His Ile Arg Pro Trp His Pro Asp 1 5 10 15

Val Ala Thr Met Leu Asn Ile Leu Ala Leu Val Tyr Arg Asp Gln Asn 20 25 30

Lys Tyr Lys Glu Ala Ala His Leu Leu Asn Asp Ala Leu Ser Ile Arg 35 40 45

Glu Ser Thr Leu Gly Pro Asp His Pro Ala Val Ala Ala Thr Leu Asn 50 55 60

Asn Leu Ala Val Leu Tyr Gly Lys Arg Gly Lys Tyr Lys Glu Ala Glu 65 70 75 80

Pro Leu Cys Gln Arg Ala Leu Glu Ile Arg Glu Lys Val Leu Gly Thr 85 90 95

Asn His Pro Asp Val Ala Lys Gln Leu Asn Asn Leu Ala Leu Leu Cys 100 105 110

Gln Asn Gln Gly Lys Tyr Glu Ala Val Glu Arg Tyr Tyr Gln Arg Ala 115 120 125

Leu Ala Ile Tyr Glu Gly Gln Leu Gly Pro Asp Asn Pro Asn Val Ala 130 135 140

Arg Thr Lys Asn Asn Leu Ala Ser Cys Tyr Leu Lys Gln Gly Lys Tyr 145 150 155 160

Ala	Glu	Ala	Glu	Thr 165	Leu	Tyr	Lys	Glu	Ile 170	Leu	Thr	Arg	Ala	His 175	Val
Gln	Glu	Phe	Gly 180	Ser	Val	Asp	Asp	Asp 185	His	Lys	Pro	Ile	Trp 190	Met	His
Ala	Glu	Glu 195	Arg	Glu	Glu	Met	Ser 200	Lys	Ser	Arg	His	His 205	Glu	Gly	Gly
Thr	Pro 210	Tyr	Ala	Glu	Tyr	Gly 215	Gly	Trp	Tyr	Lys	Ala 220	Cys	Lys	Val	Ser
Ser 225	Pro	Thr	Val	Asn	Thr 230	Thr	Leu	Arg	Asn	Leu 235	Gly	Ala	Leu	Tyr	Arg 240
Arg	Gln	Gly	Lys	Leu 245	Glu	Ala	Ala	Glu	Thr 250	Leu	Glu	Glu	Cys	Ala 255	Leu
Arg	Ser	Arg	Arg 260	Gln	Gly	Thr	Asp	Pro 265	Ile	Ser	Gln	Thr	Lys 270	Val	Ala
Glu	Leu	Leu 275	Gly	Glu	Ser	Asp	Gly 280	Arg	Arg	Thr	Ser	Gln 285	Glu	Gly	Pro
Gly	Asp 290	Ser	Val	Lys	Phe	Glu 295	Gly	Gly	Glu	Asp	Ala 300	Ser	Val	Ala	Val
Glu 305	Trp	Ser	Gly	Asp	Gly 310	Ser	Gly	Thr	Leu	Gln 315	Arg	Ser	Gly	Ser	Leu 320
Gly	Lys	Ile	Arg	Asp 325	Val	Leu	Arg	Arg	Ser 330	Ser	Glu	Leu	Leu	Val 335	Arg
Lys	Leu	Gln	Gly 340	Thr	Glu	Pro	Arg	Pro 345	Ser	Ser	Ser	Asn	Met 350	Lys	Arg
Ala	Ala	Ser 355	Leu	Asn	Tyr	Leu	Asn 360	Gln	Pro	Ser	Ala	Ala 365	Pro	Leu	Gln

Val Ser Arg Gly Leu Ser Ala Ser Thr Met Asp Leu Ser Ser Ser

375

380

<210> 1012

<211> 130

<212> PRT

<213> Homo sapiens

<400> 1012

Ala Asp Ala Trp Ala Trp Ser Gln Tyr Gly Ala Val Leu Gly Ser Tyr 10

Ser Pro Glu Pro Pro Thr Ser Ala Gly Ser Gln Ile Pro Leu Cys Ala 25

Asn Leu Val Pro Val Pro Ile Thr Asn Ala Thr Leu Asp Arg Ile Thr 40

Gly Lys Trp Phe Tyr Ile Ala Ser Ala Phe Arg Asn Glu Glu Tyr Asn 50 55

Lys Ser Val Gln Glu Ile Gln Ala Thr Phe Phe Tyr Phe Thr Pro Asn 70

Lys Thr Glu Asp Thr Ile Phe Leu Arg Glu Tyr Gln Thr Arg Gln Asn 90

Gln Cys Phe Tyr Asn Ser Ser Tyr Leu Asn Val Gln Arg Glu Asn Gly 105 100

Thr Val Ser Arg Tyr Glu Gly Gly Arg Glu Thr Cys Cys Ser Pro Ala 120 125 115

Val Pro 130

<210> 1013

<211> 25

<212> PRT

<213> Homo sapiens

<400> 1013

Lys Ile Leu Trp Pro Gly Val Val Ala His Ala Cys Asn Pro Ser Thr 10 15 5

Leu Gly Gly Arg Gly Gly Arg Ile Ala 20

<210> 1014

<211> 233

<212> PRT

<213> Homo sapiens

<220>

<22 <22		44)	qual	s an	y of	the	nat	ural	ly d	occur	ring	L-a	mino	aci	ds
<22 <22	1> S 2> (3> X	56)	qual	s an	y of	the	nat	ural	ly o	occur	ring	L-a	mino	aci	ds
<22	1> s 2> (71)	qual	s an	y of	the	nat	ural	ly c	occur	ring	L-a	mino	aci	ds
	0> 1												_	_	_
Asn 1	Cys	Asn	Leu	Asn 5	Pro	Ala	Ile	His	Phe 10	e Gly	Phe	Phe	Leu	Ser 15	Asp
Thr	Met	Cys	Gly 20	Lys	Leu	Phe	Cys	Gln 25	Gly	Gly	Ser	Asp	Asn 30	Leu	Pro
Trp	Lys	Gly 35	Arg	Ile	Val	Thr	Phe 40	Leu	Thr	Cys	Xaa	Thr 45	Phe	Asp	Pro
Glu	Asp 50	Thr	Ser	Gln	Glu	Ile 55	Xaa	Met	Val	Ala	Asn 60	Gly	Thr	Lys	Cys
Gly 65	Asp	Asn	Lys	Val	Cys 70	Xaa	Asn	Ala	Glu	Cys 75	Val	Asp	Ile	Glu	Lys 80
Ala	Туг	Lys	Ser	Thr 85	Asn	Суѕ	Ser	Ser	Lys 90	Cys	Lys	Gly	His	Ala 95	Val
Суз	Asp	His	Glu 100	Leu	Gln	Cys	Gln	Cys 105	Glu	Glu	Gly	Trp	Ile 110	Pro	Pro
Asp	Cys	Asp 115	Asp	Ser	Ser	Val	Val 120	Phe	His	Phe	Ser	Ile 125	Val	Val	Gly
Val	Leu 130	Phe	Pro	Met	Ala	Val 135	Ile	Phe	Val	Val	Val 140	Ala	Met	Val	Ile
Arg 145	His	Gln	Ser	Ser	Arg 150	Glu	Lys	Gln	Lys	Lys 155	Asp	Gln	Arg	Pro	Leu 160
Ser	Thr	Thr	Gly	Thr 165	Arg	Pro	His	Lys	Gln 170	Lys	Arg	Lys	Pro	Gln 175	Met
Val	Lys	Ala	Val 180	Gln	Pro	Gln	Glu	Met 185	Ser	Gln	Met	Lys	Pro 190	His	Val

Tyr Asp Leu Pro Val Glu Gly Asn Glu Pro Pro Ala Ser Phe His Lys 195 200 205

Asp Thr Asn Ala Leu Pro Pro Thr Val Phe Lys Asp Asn Pro Met Ser 210 215 220

Thr Pro Lys Asp Ser Asn Pro Lys Ala 225 230

<210> 1015

<211> 573

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (14)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (28)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (179)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 1015

His Glu Tyr Lys Val Ala Ala Leu Gly Leu Ala Thr Gly Xaa Val Leu 1 5 10 15

Val Leu Leu Leu Cys Leu Tyr Arg Val Leu Xaa Pro Arg Asn Tyr
20 25 30

Gly Gln Leu Gly Gly Gly Pro Gly Arg Arg Arg Gly Glu Leu Pro 35 40 45

Cys Asp Asp Tyr Gly Tyr Ala Pro Pro Glu Thr Glu Ile Val Pro Leu 50 55 60

Val Leu Arg Gly His Leu Met Asp Ile Glu Cys Leu Ala Ser Asp Gly 65 70 75 80

Met Leu Leu Val Ser Cys Cys Leu Ala Gly His Ile Cys Val Trp Asp 85 90 95

Ala Gln Thr Gly Asp Cys Leu Thr Arg Ile Pro Arg Pro Gly Arg Gln

			100					105					110		
Arg	Arg	Asp 115		Gly	Val	Gly	Ser 120	_	Leu	Glu	Ala	Gln 125		Ser	Trp
Glu	Arg 130		Ser	Asp	Gly	Gly 135		Ala	Gly	Pro	Glu 140		Pro	Gly	Asp
Ser 145	Pro	Pro	Leu	Arg	His 150	Arg	Pro	Arg	Gly	Pro 155		Pro	Pro	Ser	Leu 160
Phe	Gly	Asp	Gln	Pro 165	_	Leu	Thr	Cys	Leu 170	Ile	Asp	Thr	Asn	Phe 175	Ser
Ala	Gln	Xaa	Arg 180	Ser	Ser	Gln	Pro	Thr 185	Gln	Pro	Glu	Pro	Arg 190	His	Arg
Ala	Val	Cys 195	Gly	Arg	Ser	Arg	Asp 200	Ser	Pro	Gly	Tyr	Asp 205	Phe	Ser	Cys
Leu	Val 210	Gln	Arg	Val	Tyr	Gln 215	Glu	Glu	Gly	Leu	Ala 220	Ala	Val	Cys	Thr
Pro 225	Ala	Leu	Arg	Pro	Pro 230	Ser	Pro	Gly	Pro	Val 235	Leu	Ser	Gln	Ala	Pro 240
Glu	Asp	Glu	Gly	Gly 245	Ser	Pro	Glu	Lys	Gly 250	Ser	Pro	Ser	Leu	Ala 255	Trp
Ala	Pro	Ser	Ala 260	Glu	Gly	Ser	Ile	Trp 265	Ser	Leu	Glu	Leu	Gln 270	Gly	Asn
Leu	Ile	Val 275	Val	Gly	Arg	Ser	Ser 280	Gly	Arg	Leu	Glu	Val 285	Trp	Asp	Ala
Ile	Glu 290	Gly	Val	Leu	-	Cys 295		Ser	Glu	Glu	Val 300	Ser	Ser	Gly	Ile
Thr 305	Ala	Leu	Val	Phe	Leu 310	Asp	Lys	Arg	Ile	Val 315	Ala	Ala	Arg	Leu	Asn 320
Gly	Ser	Leu	Asp	Phe 325	Phe	Ser	Leu	Glu	Thr 330	His	Thr	Ala	Leu	Ser 335	Pro
Leu	Gln	Phe	Arg 340	Gly	Thr	Pro	Gly	Arg 345	Gly	Ser	Ser	Pro	Ala 350	Ser	Pro
Val	Tyr	Ser 355	Ser	Ser	Asp	Thr	Val 360	Ala	Cys	His	Leu	Thr 365	His	Thr	Val
Pro	Cys	Ala	His	Gln	Lys	Pro	Ile	Thr	Ala	Leu	Lys	Ala	Ala	Ala	Gly

WO 00/55351 1131

370 375 380 Arg Leu Val Thr Gly Ser Gln Asp His Thr Leu Arg Val Phe Arg Leu 395 385 390 Glu Asp Ser Cys Cys Leu Phe Thr Leu Gln Gly His Ser Gly Ala Ile 410 405 Thr Thr Val Tyr Ile Asp Gln Thr Met Val Leu Ala Ser Gly Gly Gln 425 Asp Gly Ala Ile Cys Leu Trp Asp Val Leu Thr Gly Ser Arg Val Ser 440 His Val Phe Ala His Arg Gly Asp Val Thr Ser Leu Thr Cys Thr Thr 455 Ser Cys Val Ile Ser Ser Gly Leu Asp Asp Leu Ile Ser Ile Trp Asp 475 470 Arg Ser Thr Gly Ile Lys Phe Tyr Ser Ile Gln Gln Asp Leu Gly Cys 485 490 Gly Ala Ser Leu Gly Val Ile Ser Asp Asn Leu Leu Val Thr Gly Gly 500 505 Gln Gly Cys Val Ser Phe Trp Asp Leu Asn Tyr Gly Asp Leu Leu Gln 520 515 Thr Val Tyr Leu Gly Lys Asn Ser Glu Ala Gln Pro Ala Arg Gln Ile 535 Leu Val Leu Asp Asn Ala Ala Ile Val Cys Asn Phe Gly Ser Glu Leu 560 550 Ser Leu Val Tyr Val Pro Ser Val Leu Glu Lys Leu Asp

<210> 1016

<211> 45

<212> PRT

<213> Homo sapiens

565

<400> 1016

Lys Phe Tyr Ser Tyr Ser Val Tyr Val Ala Gln Pro Gly Leu Glu Pro 5

570

Phe Gly Ser Ser Asp Pro Pro Ala Leu Ala Ser Gln Ser Ala Gly Ile 20 25 30

PCT/US00/05883

1132

Thr Asp Gly Ser His Arg Val Trp Pro Ile Pro Ala Ser 35 40 45

<210> 1017

<211> 105

<212> PRT

<213> Homo sapiens

<400> 1017

Gly Lys Val His Gly Leu Ile Pro Gln Val Lys Asn Val Phe Thr Leu
1 5 10 15

Leu Ile Ala Val Ser Leu Tyr Leu Tyr Ile Arg Tyr Ile Ser Tyr Glu 20 25 30

His Lys Phe Val Val Lys Val Ser Ser Val Trp Ala Met Ala His Thr 35 40 45

Cys Asn Ser Asn Thr Leu Gly Gly Ser Gly Gly Arg Ile Ser Ser Pro 50 55 60

Gln Glu Phe Glu Thr Ser Leu Gly Asn Lys Leu Asp Pro Met Ser Leu 65 70 75 80

Lys Asn Val Lys Asn Ile Lys Arg Leu Ser Gln Glu Asp His Leu Ser 85 90 95

Leu Gly Val Gln Gly Cys Ser Lys Leu 100 105

<210> 1018

<211> 30

<212> PRT

<213> Homo sapiens

<400> 1018

Asn Pro Val Ser Thr Lys Asn Thr Lys Ile Ser Trp Val Trp Trp 1 5 10 15

Ala Pro Val Val Pro Ala Thr Arg Glu Ala Glu Ala Gly Val

<210> 1019

<211> 72

```
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (11)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (22)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (43)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1019
Pro Gly Trp Ser Arg Ser Pro Asp Leu Val Xaa Arg Ala Pro Arg Pro
Pro Lys Val Leu Gly Xaa Thr Gly Val Ser His Arg Ala Arg Pro Asp
                                 25
Ser Leu Lys Ile Glu Glu Val Leu Pro Arg Xaa Ser Asp Leu Thr Gln
         35
                             40
                                                  45
Met His Arg Pro Cys Ser Trp Tyr Leu Phe Ser Leu Cys Trp Gly Ala
                         55
Val Val Pro Ser Phe Leu Gly Gly
 65
                     70
<210> 1020
<211> 57
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (17)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1020
Ser Gln Leu Leu Gly Glu Ala Glu Ala Gly Glu Ser Leu Glu Pro Gly
                                     10
                  5
Xaa Gly Asp Cys Ser Glu Pro Arg Ser His His Cys Thr Pro Val Trp
```

WO 00/55351 PCT/US00/05883

20 25 30

Pro Thr Glu Gln Asp Ser Ile Ser Lys Lys Lys Arg Lys Gly Asp Ser 35 40 45

Asp Leu Val Leu Leu Asn Thr Ser Phe 50 55

<210> 1021

<211> 18

<212> PRT

<213> Homo sapiens

<400> 1021

Val Ala Gly Ala Tyr Asn Pro Ser Tyr Ser Gly Gly Gln Gly Arg Arg
1 5 10 15

Ile Ala

<210> 1022

<211> 91

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (39)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 1022

Ser Gly Asn His Val Gln Asn Pro Ser Ser Gly Thr Ala Cys Cys Leu 1 5 10 15

Gln Pro Leu Ser Pro Gly Leu Arg Val Val Tyr Gly His Thr Trp Arg

Phe Phe Val Val Val Phe Xaa Thr Glu Phe His Ser Cys Cys Pro Gly 35 40 45

Trp Ser Ala Met Ala Pro Ser Arg Leu Thr Ala Thr Ser Trp 50 55 60

Phe Lys Arg Ser Gln Ala Ser Ala Ser Gln Val Val Gly Ile Thr Gly 65 70 75 80

Ala Cys His His Thr Trp Leu Ile Leu Tyr Phe

<210> 1024 <211> 60 <212> PRT <213> Homo sapiens <220> <221> SITE <222> (8) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (10) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (13) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (26) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (38) <223> Xaa equals any of the naturally occurring L-amino acids <400> 1024

Lys Val Asn Ile Gly Glu Gly Xaa Arg Xaa Arg Ser Xaa Val Pro Val

10

15

5

Arg Asn Ser Arg Val Asp Pro Arg Val Xaa Leu Leu Val Gln Ala Gly
20 25 30

Leu Glu Leu Ala Thr Xaa Gly Asp Pro Pro Ala Ser Ala Ser Gln Ser 35 40 45

Gly Gly Ile Thr Gly Val Ser His Arg Ala Gln Pro 50 55 60

<210> 1025

<211> 67

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (17)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (26)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (47)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (65)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 1025

Ala Asn Leu Cys Ile Phe Ser Gly Asn Gly Val Leu Pro Arg Trp Pro 1 5 10 15

Xaa Trp Ser Arg Thr Pro Asp Leu Arg Xaa Ser Thr His Pro Ser Leu 20 25 30

Pro Lys Cys Trp Asp Tyr Arg Arg Glu Pro Leu Ser Pro Ala Xaa Phe 35 40 45

Ser Val Phe Asn Ile Ile Phe Val Leu Ser Thr Thr Phe Gln Val Leu 50 55 60

Xaa Val Gln

PCT/US00/05883

```
<210> 1026
<211> 71
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (3)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1026
Glu Lys Xaa Leu Lys Glu Glu Gly Lys Ala Gly Trp Gly Gly Trp Gly
          5
                                    10
Lys Glu Ala Gly Ser Ala Asp His Ser Pro Ser Met Ser Cys Phe Leu
             20
Lys Met Leu Glu Leu Gly Gln Ala Trp Trp Leu Thr Pro Val Ile Pro
Ala Leu Trp Glu Ala Glu Ala Gly Arg Ser Leu Glu Val Arg Ser Ser
                                             60
Arg Pro Ala Trp Pro Thr Trp
65
                     70
<210> 1027
<211> 72
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (41)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (69)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (72)
```

<223> Xaa equals any of the naturally occurring L-amino acids

```
<400> 1027
Asn Pro Val Ser Thr Lys Asn Thr Lys Ile Ser Arg Ala Trp Trp Gln
                                      10
Ala Pro Val Ile Pro Ala Thr Arg Glu Ala Glu Ala Gly Lys Ser Leu
                                  25
Glu Pro Gly Ser Arg Lys Leu Gln Xaa Ala Lys Val Met Ser Ser Leu
                             40
His Ser Ser Leu Gly Asn Lys Ser Glu Asp Phe Val Ser Lys Lys Lys
     50
                         55
Leu Thr Asp Phe Xaa Phe Leu Xaa
<210> 1028
<211> 27
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (16)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (18)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (23)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1028
Ser Gln Leu Leu Gly Arg Leu Arg Gln Glu Asn Cys Leu Ser Pro Xaa
Gly Xaa Gly Cys Ser Glu Xaa Arg Ser Gly His
            20
```

<210> 1029 <211> 121 <212> PRT

```
<213> Homo sapiens
<220>
<221> SITE
<222> (9)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (108)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1029
Asp Met Asn Ser Leu Met Met Gly Xaa Asp Lys Ile Lys Phe Lys His
                  5
Ile Thr Pro Leu Gln Glu Gln Ser Lys Glu Val Ala Ile Arg Ile Phe
Gln Gly Cys Gln Phe Arg Ser Val Glu Ala Val Gln Glu Ile Thr Glu
                             40
Tyr Ala Lys Ser Ile Pro Gly Phe Val Asn Leu Asp Leu Asn Asp Gln
                        55
                                             60
Val Thr Leu Leu Lys Tyr Gly Val His Glu Ile Ile Tyr Thr Met Leu
 65
                     70
                                         75
Ala Ser Leu Met Asn Lys Asp Gly Val Leu Ile Ser Glu Gly Pro Ser
                 85
Phe Met Thr Arg Glu Phe Leu Lys Ser Leu Arg Xaa Leu Leu Val Thr
                                105
Leu Trp Glu Pro Ser Leu Ser Leu Pro
  115
                           120
<210> 1030
<211> 34
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (34)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1030
```

Ala Glu Glu Thr Pro His Pro Trp Gln Lys Phe Arg Thr Lys Pro Gln

1 5 10 15 Gly Asp Gln Asp Thr Gly Lys Glu Ala Asp Asp Gly Cys Ala Leu Gly 20 Gly Xaa <210> 1031 <211> 117 <212> PRT <213> Homo sapiens <220> <221> SITE <222> (107) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (108) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (117) <223> Xaa equals any of the naturally occurring L-amino acids <400> 1031 Ser Glu Ser Gly Pro Arg Cys Ser Ser Pro Val Asp Thr Glu Cys Ser His Ala Glu Gly Ser Arg Ser Gln Gly Pro Glu Lys Ala Phe Ser Pro 20 25 Ala Ser Pro Cys Ala Trp Asn Val Cys Val Thr Arg Lys Ala Pro Leu Leu Ala Ser Asp Ser Ser Ser Ser Gly Gly Ser His Ser Glu Asp Gly 55 Asp Gln Lys Ala Ala Ser Ala Met Asp Ala Val Ser Arg Gly Pro Gly 75 70 Arg Glu Ala Pro Arg Cys Pro Gln Trp Pro Arg Gln Lys Lys Leu Leu 85 90 Ala Arg Phe Gly Phe Leu Thr Thr Gly Phe Xaa Xaa Leu Pro Cys Pro

105

100

Arg Ala Lys Arg Xaa 115

<210> 1032

<211> 46

<212> PRT

<213> Homo sapiens

<400> 1032

Lys Leu Thr Asp Glu Glu Val Asp Glu Met Ile Arg Glu Ala Asp Ile 1 5 10 15

Asp Gly Asp Gly Gln Val Asn Tyr Glu Glu Phe Val Gln Asn Asp Asp 20 25 30

Cys Lys Met Lys Thr Tyr Phe Gln Leu Leu Phe Pro Pro Ser 35 40 45

<210> 1033

<211> 118

<212> PRT

<213> Homo sapiens

<400> 1033

Thr Val Cys Ile Leu Arg Lys Leu Phe Ser His Asn Met Thr Arg Leu

1 5 10 15

Arg Lys Phe Met Val Tyr Phe Gly Lys Asn Gln Ser Leu Gln Lys Ile 20 25 30

Gln Lys Thr Pro Leu Phe Val Ala Ala Ile Cys Ala His Trp Phe Gln
35 40 45

Tyr Pro Phe Asp Pro Ser Phe Asp Asp Val Ala Val Phe Lys Ser Tyr 50 55 60

Met Glu Arg Leu Ser Leu Arg Asn Lys Ala Thr Leu Lys Ile Leu Lys 65 70 75 80

Ala Thr Val Ser Ser Cys Gly Glu Leu Ala Leu Lys Gly Phe Phe Ser 85 90 95

Cys Cys Phe Glu Phe Asn Gly Trp Met Asp Leu Ala Glu Ala Gly Gly
100 105 110

Gly Trp Lys Met Lys Ile

```
<210> 1034
<211> 70
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (5)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (15)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (16)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (20)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (24)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (25)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (30)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (33)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
```

```
<222> (42)
<223> Kaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (49)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (50)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (56)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (59)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (60)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (62)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (65)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1034
Val Lys Ser Gly Xaa Tyr Val Val Ile Glu Val Lys Val Ala Xaa Xaa
                                                          15
                  5
                                     10
Tyr Gly Ile Xaa Ile Thr Cys Xaa Xaa Tyr Leu Met Thr Xaa Tyr Gln
             20
                                 25
Xaa Ala Pro Pro Ser Pro Gln Tyr Arg Xaa Ile Ile Cys Met Gly Ala
         35
Xaa Xaa Asn Gly Leu Pro Leu Xaa Tyr Gln Xaa Xaa Leu Xaa Ala Leu
                         55
```

```
Xaa Pro Asn Asp Tyr Thr
 65
 <210> 1035
 <211> 163
 <212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (1)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (147)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (155)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (159)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (161)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (162)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1035
Xaa Asp Ala Trp Val Arg Asp Glu Glu Trp Gly Gly His Ser Pro Arg
 1
                  5
                                      10
Ser Pro Arg Gly Trp Asp Gln Glu Pro Ala Arg Glu Gln Ala Gly Gly
             20
Gly Trp Arg Ala Arg Arg Pro Arg Ala Arg Ser Val Asp Ala Leu Asp
         35
                             40
                                                  45
Asp Leu Thr Pro Pro Ser Thr Ala Glu Ser Gly Ser Arg Ser Pro Thr
```

50 55 60

Ser Asn Gly Gly Arg Arg Ser Arg Ala Tyr Met Pro Pro Arg Ser Arg 65 70 75 80

Ser Arg Asp Asp Leu Tyr Asp Gln Asp Asp Ser Arg Asp Phe Pro Arg 85 90 95

Ser Arg Asp Pro His Tyr Asp Asp Phe Arg Ser Arg Glu Arg Pro Pro 100 105 110

Ala Asp Pro Arg Ser His His His Arg Thr Arg Asp Pro Arg Asp Asn 115 120 125

Gly Ser Arg Ser Gly Asp Leu Pro Tyr Asp Gly Arg Leu Leu Glu Glu 130 135 140

Xaa Xaa Glu

<210> 1036

<211> 30

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (7)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (17)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (25)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 1036

Gly Cys Pro Pro Arg Ala Xaa Ser Leu Pro Gly Ser Pro Arg Cys Arg
1 5 10 15

Xaa Arg Cys His Thr Met Ala Phe Xaa Thr Arg Gln Phe Met

20

25

30

```
<210> 1037
<211> 65
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (5)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (26)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (29)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (49)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (55)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (57)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (60)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (65)
<223> Xaa equals any of the naturally occurring L-amino acids
Thr His Phe Phe Xaa Gln His Gln Lys Leu Val Pro Leu Leu Met Ser
 1
                  5
                                     10
```

Ile Met Pro Arg Ile Gln Lys Ala Tyr Xaa Val Phe Xaa Tyr Leu Val 20 25 30

Gln Asp Leu Lys Cys Leu Val Phe Ser Leu Ile Gly Leu His Phe Lys 35 40 45

Xaa Lys Pro Ser Arg Leu Xaa Ile Xaa Val Gly Xaa Gly Gly Trp 50 55 60

Xaa

65

<210> 1038

<211> 90

<212> PRT

<213> Homo sapiens

<400> 1038

Cys Pro Arg Val Arg Pro Arg Val Arg Pro Arg Val Arg Pro Arg Val 1 5 10 15

Arg Thr Pro Ile Pro Val Pro Ala Tyr Phe Arg His Ala Glu Pro Gly 20 25 30

Phe Ser Leu Lys Arg Pro Arg Gly Leu Ser Arg Ser Leu Pro Pro Pro 35 40 45

Pro Pro Ala Lys Gly Ser Ile Pro Ile Ser Arg Leu Phe Pro Pro Arg
50 60

Thr Pro Gly Trp His Gln Leu Gln Pro Arg Gly Cys His Ser Gly Arg
65 70 75 80

Arg Pro Arg Asp Ser Ala Glu Pro Trp Val 85 90

<210> 1039

<211> 104

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (7)

<223> Xaa equals any of the naturally occurring L-amino acids

```
<220>
<221> SITE
<222> (12)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (14)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (31)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (33)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (39)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (51)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (60)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (70)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (78)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (86)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
```

<221> SITE <222> (91) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (94) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (98) <223> Xaa equals any of the naturally occurring L-amino acids <400> 1039 Ala Ala Ala Gly Pro Gly Xaa Cys Trp Ala Phe Xaa Pro Xaa Arg Leu 5 10 His Ala Pro Thr Ala Arg Ser Thr Tyr Ser Phe Gln Ala Arg Xaa Leu 20 25 Xaa Glu Lys Glu Phe Ser Xaa Leu Ile Ser Leu Gly Thr Asp Arg Leu 40 Leu Asp Xaa Asp Met Arg Gln Val Phe Gln Phe Xaa Pro His Pro Gly 55 Gly Arg Cys Ser Gly Xaa Lys Asp Leu Arg Gly Val Thr Xaa Arg Leu 65 70 75

Thr Glu Met Leu Pro Xaa Asn Phe Arg Ser Xaa Ala Ala Xaa Phe Leu

Gly Xaa Ser Gly Ala Pro Phe Ser 100

<210> 1040

<211> 109

<212> PRT

<213> Homo sapiens

<400> 1040

Gly Arg Trp Leu Lys Asp Gln Glu Leu Ser Pro Arg Glu Pro Val Leu 1 5 10

Pro Pro Gln Lys Met Gly Pro Met Glu Lys Phe Trp Asn Lys Phe Leu 20 25 30

Glu Asn Lys Ser Pro Trp Arg Lys Met Val His Gly Val Tyr Lys Lys

35 40 45

Ser Ile Phe Val Phe Thr His Val Leu Val Pro Val Trp Ile Ile His 50 55 60

Tyr Tyr Met Lys Tyr His Val Ser Glu Lys Pro Tyr Gly Ile Val Glu 65 70 75 80

Lys Lys Ser Arg Ile Phe Pro Gly Asp Thr Ile Leu Glu Thr Gly Glu 85 90 95

Val Ile Pro Pro Met Lys Glu Phe Pro Asp Gln His His 100 105

<210> 1041

<211> 197

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (3)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 1041

Ala Ser Xaa His Gln Pro Ser Leu Lys Gly Thr Lys Ala Gly Ala Pro 1 5 10 15

Pro Arg Cys Gly Arg Ser Arg Thr Ser Gly Ser Pro Gly Leu Gln Glu 20 25 30

Phe Gly Thr Arg Ser Val Ser Gly Ala Asp Gly Gly Ser Ala Ala Cys 35 40 45

Ser Trp Lys Phe Arg Leu Gly Cys Leu Leu Gly Ala Met Glu Ser Asp 50 55 60

Phe Tyr Leu Arg Tyr Tyr Val Gly His Lys Gly Lys Phe Gly His Glu 65 70 75 80

Phe Leu Glu Phe Glu Phe Arg Pro Asp Gly Lys Leu Arg Tyr Ala Asn 85 90 95

Asn Ser Asn Tyr Lys Asn Asp Val Met Ile Arg Lys Glu Ala Tyr Val

His Lys Ser Val Met Glu Glu Leu Lys Arg Ile Ile Asp Asp Ser Glu 115 120 125

Ile Thr Lys Glu Asp Asp Ala Leu Trp Pro Pro Pro Asp Arg Val Gly 130 135 140 Arg Gln Glu Leu Glu Ile Val Ile Gly Asp Glu His Ile Ser Phe Thr 155 150 Thr Ser Lys Ile Gly Ser Leu Ile Asp Val Asn Gln Ser Lys Asp Pro 165 170 Glu Gly Leu Arg Val Phe Tyr Tyr Leu Val Gln Asp Leu Lys Cys Leu 180 185 Val Phe Ser Leu Ile 195 <210> 1042 <211> 110 <212> PRT <213> Homo sapiens <220> <221> SITE <222> (7) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (80) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (92) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (99) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (107) <223> Xaa equals any of the naturally occurring L-amino acids <400> 1042 Ala Gly Phe Gly Ser Gln Xaa Leu Phe Val Asp Cys Cys Asp Arg His 10 15

Leu Thr Met Gln Ile Phe Val Lys Thr Leu Thr Gly Lys Thr Ile Thr
20 25 30

Leu Glu Val Glu Pro Ser Asp Thr Ile Glu Asn Val Lys Ala Lys Ile 35 40 45

Gln Asp Lys Glu Gly Ile Pro Pro Asp Gln Gln Arg Leu Ile Phe Ala 50 55 60

Gly Lys Gln Leu Glu Asp Gly Arg Thr Leu Ser Asp Tyr Asn Ile Xaa 65 70 75 80

Lys Glu Ser Thr Leu His Leu Val Leu Arg Leu Xaa Gly Gly Met Gln 85 90 95

Ile Phe Xaa Lys Thr Leu Thr Gly Lys Thr Xaa Thr Leu Glu 100 105 110

<210> 1043

<211> 109

<212> PRT

<213> Homo sapiens

<400> 1043

Leu His Gln Pro Ala Lys Met Ala Met Gln Ala Ala Lys Arg Ala Asn 1 5 10 15

Ile Arg Leu Pro Pro Glu Val Asn Arg Ile Leu Tyr Ile Arg Asn Leu
20 25 30

Pro Tyr Lys Ile Thr Ala Glu Glu Met Tyr Asp Ile Phe Gly Lys Tyr 35 40 45

Gly Pro Ile Arg Gln Ile Arg Val Gly Asn Thr Pro Glu Thr Arg Gly 50 55 60

Thr Ala Tyr Val Val Tyr Glu Asp Ile Phe Asp Ala Lys Asn Ala Cys 65 70 75 80

Asp His Leu Ser Gly Phe Asn Val Cys Asn Arg Tyr Leu Val Val Leu 85 90 95

Tyr Tyr Asn Ala Asn Arg Ala Phe Gln Lys Met Asp Thr 100 105

<210> 1044

<211> 16

```
<212> PRT
<213> Homo sapiens

<400> 1044
Lys Leu Ile Gln Val Gly Lys Leu Asp Arg Thr Phe His Leu Ser Tyr
1 5 10 15
```

```
<210> 1045
<211> 100
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (3)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (12)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (16)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (19)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (23)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (38)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (43)
<223> Xaa equals any of the naturally occurring L-amino acids
```

```
<220>
<221> SITE
<222> (48)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (49)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (53)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (75)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (78)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (89)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (91)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (99)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1045
Ser Ser Xaa Pro Thr Pro Pro Ser Ser Cys Leu Xaa Pro Pro Gly Xaa
                  5
                                     10
Arg Pro Xaa Asp Ser Thr Xaa Val Pro Ala Asn Ser Met Arg Leu Lys
                                 25
Tyr Gln His Thr Gly Xaa Val Leu Asp Cys Xaa Phe Tyr Gly Pro Xaa
                             40
```

Xaa Ala Trp Ser Xaa Gly Leu Asp His Gln Leu Lys Met His Asp Leu 50 55 60

Thr Leu Ile Lys Lys Ile Ser Trp Thr His Xaa Ala Leu Xaa Asp Val 65 70 75 80

Leu Asn Thr Val Arg Ser Glu Leu Xaa Trp Xaa Trp Lys Leu Gly Leu 85 90 95

Ala Ser Xaa Pro 100

<210> 1046

<211> 114

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (62)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (63)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (110)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 1046

Phe Ile Ser Val Ser Glu Lys Ser Lys Asp Arg Gly Ser Asn Thr Ile
1 5 10 15

Gly Ala Arg Leu Asn Arg Val Glu Asp Lys Val Thr Gln Leu Asp Gln
20 25 30

Arg Leu Ala Leu Ile Thr Asp Met Leu His Gln Leu Leu Ser Leu His
35 40 45

Gly Gly Ser Thr Pro Glu Pro Thr Val Arg Gly Ala Pro Xaa Xaa Asn 50 55 60

Pro Ser Pro Ser Pro Ser Ser Gln Pro Asn Thr Gln Lys Gly Thr Ala
65 70 75 80

Thr Phe Pro Cys Gln Leu Leu Ser Arg Arg Glu Val Thr Val Pro Thr

85 90 95

Gln Asp Arg Gly Ser Phe Trp Ala Leu His Arg Ile Glu Xaa Asn Asn
100 105 110

Leu Trp

<210> 1047 <211> 92

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (32)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (85)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (88)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (89)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (90)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 1047

Asp Arg Phe Ser Gly Ser Lys Ser Ala Ser Thr Ala Ser Leu Thr Ile
1 5 10 15

Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Xaa 20 25 30

Thr Ser Ser Ile Ser Tyr Val Phe Gly Thr Gly Thr Lys Val Thr Val
35 40 45

Leu Val Gln Pro Lys Ala Asn Pro Thr Val His Ser Cys Phe Pro Pro

50 55 60

Ser Ser Leu Arg Thr Ser Lys Pro Asn Lys Gly Asn Tyr Val Phe Trp 65 70 75 80

Asn His Tyr Phe Xaa Pro Gly Xaa Xaa Xaa Lys Cys 85 90

<210> 1048 <211> 91 <212> PRT <213> Homo sapiens <220> <221> SITE <222> (7) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (10) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (20) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (31) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (32) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (39) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (40) <223> Xaa equals any of the naturally occurring L-amino acids

<220>

WO 00/55351 PCT/US00/05883

```
<221> SITE
<222> (50)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (54)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (61)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (64)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (77)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (82)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (91)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1048
Arg Gly Arg Gly Lys Arg Xaa Pro Asp Xaa Lys Pro Pro Ala Leu Pro
                  5
                                     10
Arg Pro Ile Xaa Asn Leu Glu Val Glu Phe Thr Lys Ile Phe Xaa Xaa
             20
                                 25
Asn Gly Met Gly Arg Ile Xaa Xaa Trp Glu Lys Val Cys Tyr Met Leu
                             40
Pro Xaa Asn Ser Gly Xaa Lys Tyr Val Lys Trp Lys Xaa Glu Ile Xaa
     50
                     55
Pro Thr Trp Asp Glu Gly Cys Gly Ser Cys Thr Gly Xaa Leu Pro Lys
65
                     70
                                         75
                                                              80
```

Arg Xaa Pro Pro Trp Ala Pro Gly Gly Met Xaa

<210> 1049

<211> 149

<212> PRT

<213> Homo sapiens

<400> 1049

Pro Gly Gln Ser Pro Glu Leu Gln Thr Met Ser Val Ser Phe Leu Ile
1 5 10 15

Phe Leu Pro Val Leu Gly Leu Pro Trp Gly Val Leu Ser Gln Val Gln
20 25 30

Leu Gln Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Gln Thr Leu Ser
35 40 45

Leu Thr Cys Ala Ile Ser Gly Asp Thr Val Ser Arg Asn Ser Ala Gly 50 55 60

Trp Asn Trp Ile Arg Gln Ser Pro Ser Arg Gly Leu Glu Trp Leu Gly 65 70 75 80

Arg Thr Tyr Tyr Arg Ser Lys Trp Tyr Asn Asp Tyr Ala Val Ser Val 85 90 95

Lys Ser Arg Ile Thr Ile Asn Ala Asp Ser Thr Lys Asn Gln Phe Ser 100 105 110

Leu Gln Leu Asn Ser Val Thr Pro Glu Asp Thr Ala Leu Tyr Tyr Cys 115 120 125

Ala Arg Asp Arg Gly Ser Trp Ser Asp Glu Ala Glu Gly Leu Pro Pro 130 135 140

Arg Tyr Phe Tyr Tyr 145

<210> 1050

<211> 146

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (123)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 1050

Ala Gln Leu Leu Thr Met Asp Trp Thr Trp Arg Ile Leu Phe Leu Val 1 5 10 15

Ala Ala Ala Thr Ser Ala His Ser Gln Val Gln Leu Val Gln Ser Gly
20 25 30

Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala 35 40 45

Ser Gly Tyr Thr Phe Thr Ser Tyr Asp Ile Asn Trp Val Arg Gln Ala 50 55 60

Thr Gly Gln Gly Leu Glu Trp Val Gly Trp Met Asn Pro Asn Ser Ala 65 70 75 80

Asn Thr Gly Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg 85 90 95

Asn Thr Ser Ile Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser 100 105 110

Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Xaa Arg Arg Trp Glu Leu 115 120 125

Leu Gly Met Met Trp Asp Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val 130 135 140

Thr Val

<210> 1051

<211> 55

<212> PRT

<213> Homo sapiens

<400> 1051

Gly Arg Gly Ile Ser Gly Leu Leu Phe Leu Ser Ser Thr Ile Met Gly
1 5 10 15

Ser Thr Ala Ile Leu Ala Leu Leu Leu Ala Val Leu Gln Gly Val Cys
20 25 30

Gly Glu Val Gln Leu Val His Ala Gly Gly Glu Met Arg Lys Ala Arg
35 40 45

Gly Val Ser Glu Asp Leu Leu 50 55

```
<210> 1052
<211> 144
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (40)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (50)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (70)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (108)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (120)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (124)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (128)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (134)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1052
Thr Met Ala Trp Thr Pro Leu Leu Phe Leu Thr Leu Leu Leu His Cys
 1
                  5
                                     10
```

Thr Gly Ser Leu Ser Gln Leu Val Leu Thr Gln Ser Pro Ser Ala Ser 20 25 30

Ala Ser Leu Gly Ala Ser Val Xaa Leu Thr Cys Thr Leu Ser Ser Gly 35 40 45

His Xaa Asp Tyr Ala Ile Ala Trp His Gln Gln Pro Glu Lys Gly
50 55 60

Pro Arg Tyr Leu Leu Xaa Leu Asn Thr Asp Gly Ser His Arg Lys Gly 65 70 75 80

Asp Gly Ile Pro Asp Arg Phe Ser Gly Ser Ser Ser Gly Ala Glu Arg 85 90 95

Tyr Leu Thr Ile Ser Ser Leu Gln Ser Glu Asp Xaa Ala Asp Tyr Tyr 100 105 110

Cys Gln Asn Trp Gly Phe Gly Xaa Val Phe Gly Xaa Arg Asp Gln Xaa 115 120 125

Glu Arg Pro Lys Ser Xaa Gln Gly Cys Pro Leu Gly Gln Ser Val Pro 130 135 140

<210> 1053

<211> 52

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (26)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 1053

Gly Thr Ser Ser Pro Ser Leu Ala Glu Asp Pro Phe Gln Gly Gln
1 5 10 15

Val Cys Ala Pro Ser Arg Ala Ile Gln Xaa Ile Cys Leu Pro Ser Met
20 25 30

Tyr Asn Asp Pro Gln Phe Gly Thr Ser Cys Glu Ile Thr Gly Leu Trp
35 40 45

Lys Lys Glu Phe

<210> 1054

<211> 67

<212> PRT

<213> Homo sapiens

<400> 1054

Gln Val Gly Ala Ala Ala Val Ala Met Thr Arg Gly Asn Gln Arg Glu
1 5 10 15

Leu Ala Arg Gln Lys Asn Met Lys Lys Gln Ser Asp Ser Val Lys Gly
20 25 30

Lys Arg Arg Asp Asp Gly Leu Ser Ala Ala Ala Arg Lys Gln Arg Asp
35 40 45

Ser Glu Ile Met Gln Gln Lys Gln Lys Lys Ala Asn Glu Lys Lys Glu 50 60

Glu Pro Lys 65

<210> 1055

<211> 121

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (4)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 1055

Glu Ala Glu Xaa Lys Met Ser Ser Tyr Ala Phe Phe Val Gln Thr Cys
1 5 10 15

Arg Glu Glu His Lys Lys Lys His Pro Asp Ala Ser Val Asn Phe Ser 20 25 30

Glu Phe Ser Lys Lys Cys Ser Glu Arg Trp Lys Thr Met Ser Ala Lys
35 40 45

Glu Lys Gly Lys Phe Glu Asp Met Ala Lys Ala Asp Lys Ala Arg Tyr 50 55 60

Glu Arg Glu Met Lys Thr Tyr Ile Pro Pro Lys Gly Glu Thr Lys Lys

65 70 75 80

Lys Phe Lys Asp Pro Asn Ala Pro Lys Arg Pro Pro Ser Ala Phe Phe 85 90 95

Leu Phe Cys Ser Glu Tyr Arg Pro Lys Ile Lys Gly Glu His Pro Gly
100 105 110

Leu Ser Ile Gly Asp Val Ala Lys Lys 115 120

<210> 1056

<211> 57

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (1)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (3)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (13)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 1056

Xaa Cys Xaa Ile Lys Thr Asn Lys Asn Val Lys Arg Xaa Lys Ser Gln
1 5 10 15

Arg Ala Thr Lys Arg Ile Ser His Met Pro Ser Arg Pro Glu Leu Ser 20 25 30

Ala Val Ala Thr Arg Glu Glu Arg Thr Met Trp Ile Pro Cys Gly Tyr $35 \hspace{1cm} 40 \hspace{1cm} 45$

Ala Asp Thr Tyr Leu Thr Glu Leu Leu 50 55

<210> 1057

<211> 118

<212> PRT

<213> Homo sapiens

<400> 1057

Lys Leu Arg Gln Ala Phe Gln Gly Asp Ser Ile Pro Val Phe Asp Leu
1 5 10 15

Leu Ile Leu Gly Val Gly Pro Asp Gly His Thr Cys Ser Leu Phe Pro 20 25 30

Asp His Pro Leu Leu Gln Glu Arg Glu Lys Ile Val Ala Pro Ile Ser 35 40 45

Asp Ser Pro Lys Pro Pro Pro Gln Arg Val Thr Leu Thr Leu Pro Val 50 55 60

Leu Asn Ala Ala Arg Thr Val Ile Phe Val Ala Thr Gly Glu Gly Lys
65 70 75 80

Ala Ala Val Leu Lys Arg Ile Leu Glu Asp Gln Glu Glu Asn Pro Leu 85 90 95

Pro Ala Ala Trp Ser Ser Pro Thr Pro Gly Asn Cys Ala Gly Leu Gly
100 105 110

Arg Gly Gly Arg Arg Phe 115

<210> 1058

<211> 104

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (2)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (3)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (8)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

```
<222> (22)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (62)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (78)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (91)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (99)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (100)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1058
Val Xaa Xaa Glu Pro His Gly Xaa Thr Leu Val Phe Ala Arg His Gly
Arg Glu Arg Leu Gly Xaa Gly Asp Gly Ala Ala Gln Glu Gly Pro Tyr
             20
                                 25
                                                      30
Gly Arg Pro Ala Thr Ser Lys Gln Ala Ile Leu Ala Ala Gln Arg Leu
         35
                             40
Gly Glu Asp Val Glu Thr Ser Asn Lys Trp Ala Ala Gly Xaa Asn Lys
Gln His Ser Ile Thr Lys Asn Thr Ala Lys Leu Asp Arg Xaa Thr Glu
                    70
                                         75
Cys Cys Thr Met Thr Gly Asp Pro Glu Val Xaa Gln Val Ile Gln Gln
                 85
                                                         95
                                     90
Val Gly Xaa Xaa Arg Ala Tyr Thr
```

PCT/US00/05883

<210> 1060 <211> 100 <212> PRT <213> Homo sapiens <220> <221> SITE <222> (74) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (75) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (79) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (99) <223> Xaa equals any of the naturally occurring L-amino acids Arg Asn Val Thr His Ile Asp Gln Ala Leu Gln Glu Ala His Arg Val 1 10 5 15

Leu Lys Pro Gly Gly Arg Phe Leu Cys Leu Glu Phe Ser Gln Val Asn

30 20 25 Asn Pro Leu Ile Ser Arg Leu Tyr Asp Leu Tyr Ser Phe Gln Val Ile 40 35 Pro Val Leu Gly Glu Val Ile Ala Gly Asp Trp Lys Ser Tyr Gln Tyr 55 Leu Val Glu Ser Ile Arg Arg Phe Pro Xaa Xaa Glu Glu Phe Xaa Asp Met Ile Glu Asp Ala Gly Phe His Lys Val Thr Tyr Glu Ser Leu Thr 90 Ser Gly Xaa Val 100 <210> 1061 <211> 137 <212> PRT <213> Homo sapiens <220> <221> SITE <222> (19) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (21) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (30) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (32) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (33) <223> Xaa equals any of the naturally occurring L-amino acids

<220> <221> SITE

```
<222> (35)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (49)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (51)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (52)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (56)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (67)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (68)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (69)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (70)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (72)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (84)
```

```
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (97)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (99)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (105)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (106)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (110)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE -
<222> (116)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (118)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (121)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (124)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (126)
<223> Xaa equals any of the naturally occurring L-amino acids
```

<220> <221> SITE <222> (128) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (130) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (134) <223> Xaa equals any of the naturally occurring L-amino acids <400> 1061 Phe Gly Thr Arg Glu Arg Glu Arg Glu Arg Glu Arg Glu Arg Val Ala Xaa Val Xaa Val Ser Ser Val Ser Arg Leu Leu Xaa Arg Xaa 25 Xaa Pro Xaa Leu Gly Arg Ser Met Ser Ser Gly Ala His Gly Glu Glu 35 40 Xaa Ser Xaa Xaa Met Trp Lys Xaa Leu Thr Phe Phe Val Ala Leu Pro 55 Gly Val Xaa Xaa Xaa Leu Xaa Val Tyr Leu Lys Ser His His Gly 70 Glu His Glu Xaa Pro Glu Phe Ile Val Tyr Pro Tyr Leu Arg Ile Arg 85 90 Xaa Lys Xaa Phe Pro Trp Gly Asp Xaa Xaa His Thr Phe Xaa His Asn 100 105 Pro Tyr Val Xaa Pro Xaa Pro Leu Xaa Thr Glu Xaa Tyr Xaa Glu Xaa 120 125 115

<210> 1062 <211> 61 <212> PRT

130

<213> Homo sapiens

Leu Xaa Ile Thr Gly Xaa Thr Gly Pro

WO 00/55351 PCT/US00/05883

```
<220>
<221> SITE
<222> (3)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (5)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (9)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (12)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (34)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (48)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (53)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (59)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1062
Gly Leu Xaa Phe Xaa Gly Met His Xaa Met Ala Xaa Thr His Trp Pro
                                     10
Cys Pro Trp Pro Ala Leu Met Thr Arg Trp Thr Val Ser Leu Arg Ala
             20
                                                      30
Pro Xaa Leu Ala Gln Leu Ser Asp Val Ala Met His Ser Leu Gly Xaa
         35
                             40
                                                  45
```

Ala Phe Ile Tyr Xaa Gln Thr Asp Asp Ile Xaa Asp Val

```
<210> 1063
<211> 68
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (3)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (5)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (7)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (15)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (21)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (35)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (44)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (49)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
```

<222> (53) <223> Xaa equals any of the naturally occurring L-amino acids <400> 1063 Thr Tyr Xaa Pro Xaa Ser Xaa Gly Ile Cys Arg Val Ser Leu Xaa Leu 5 10 Pro Gln Gln Trp Xaa Thr Phe Ala Lys Ile Trp Tyr Ile Leu Asp Gly 20 25 Lys Met Xaa Pro Pro Gly Lys Leu Ala Ala Met Xaa Ser Ile Arg Leu 40 Xaa Gly Leu His Xaa Pro Ala Tyr His Ala Leu Thr Asp Cys Gly Asp His Val Cys Tyr 65 <210> 1064 <211> 139 <212> PRT <213> Homo sapiens <220> <221> SITE <222> (11) <223> Xaa equals any of the naturally occurring L-amino acids <400> 1064 Arg Asp Ile Glu Pro Gly Glu Glu Ile Ser Xaa Tyr Tyr Gly Asp Gly 5 15 Phe Phe Gly Glu Asn Asn Glu Phe Cys Glu Cys Tyr Thr Cys Glu Arg 20 25 Arg Gly Thr Gly Ala Phe Lys Ser Arg Val Gly Leu Pro Ala Pro Ala Pro Val Ile Asn Ser Lys Tyr Gly Leu Arg Glu Thr Asp Lys Arg Leu Asn Arg Leu Lys Lys Leu Gly Asp Ser Ser Lys Asn Ser Asp Ser Gln

Ala Thr Ser Asn Arg Lys Ser Ser Val Gly Val Lys Lys Asn Ser Lys

Ser Val Ser Ser Asn Thr Asp Ala Asp Thr Thr Gln Glu Lys Asn Asn

70

85

```
100
                               105
                                                    110
Ser Arg Thr Leu Thr Arg Gln Ser Met Ser Arg Ile Pro Ala Ser Ser
        115
                             120
                                                 125
Asn Ser Thr Ser Ser Lys Leu Asn Ser Tyr Lys
     130
                        135
<210> 1065
<211> 78
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (5)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (6)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (14)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (26)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (37)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (41)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (43)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
```

```
<221> SITE
<222> (55)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (62)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (64)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (70)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (75)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1065
Gly Thr Cys His Xaa Xaa Pro Trp Gly Pro Met Glu Pro Xaa Lys Arg
                  5
                                     10
Pro Trp Arg Leu Leu Met Asp Thr Phe Xaa Cys Lys Leu Leu Pro Trp
             20
                                 25
Gly Val Lys Val Xaa His His Pro Xaa Trp Xaa Leu Gln Asp Arg Val
                             40
Ser Glu Glu Thr Trp Val Xaa Trp Glu Lys Arg Gln Gln Xaa Ala Xaa
                         55
Gly Pro Thr Leu Ser Xaa Glu Leu Leu Gln Xaa Leu Arg Glu
 65
                    70
<210> 1066
<211> 67
<212> PRT
<213> Homo sapiens
<400> 1066
Leu Glu Arg His His Leu Glu Phe Gly Lys Thr Leu Leu Arg Asp Glu
                                     10
```

```
Ser Leu Asn Ile Phe Gln Asn Leu Asn Arg Arg Gln His Glu His Ala
                                  25
Ile His Met Met Asp Ile Ala Ile Ile Ala Thr Asp Leu Ala Leu Tyr
                              40
Phe Lys Lys Arg Thr Met Phe Gln Lys Ile Val Asp Gln Ser Lys Thr
                          55
Tyr Glu Ser
 65
<210> 1067
<211> 98
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (4)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (8)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (27)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (37)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (68)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (69)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
```

<222> (73) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (83) <223> Xaa equals any of the naturally occurring L-amino acids <400> 1067 Ser Ala Arg Xaa Trp Asn Thr Xaa Trp Asn Pro Lys Asn Ser Asp Ser 10 15 5 Gly Lys Tyr Trp Gly Lys Ser Trp Leu Pro Xaa Asn Tyr Thr Leu Val 25 Asp Met Lys Ile Xaa Phe Gly Val Asp Ile Thr Thr Lys Glu Met Val 40 Leu Ala Asp Asp Ser Trp Arg Leu Ala Ile Thr Ser Ile Glu Ala Asn 60 50 55 Ser Lys Asp Xaa Xaa Ser Tyr Trp Xaa Leu Lys Glu Val Thr Pro Glu 70 75 65 Gly Leu Xaa Met Val Lys Lys Ser Phe Glu Ala Gly His Gly Asp Ser 85 90 Cys Leu <210> 1068 <211> 167 <212> PRT <213> Homo sapiens <220> <221> SITE <222> (68) <223> Xaa equals any of the naturally occurring L-amino acids

<221> SITE <222> (69)

<223> Xaa equals any of the naturally occurring L-amino acids

· <220>

<220>

<221> SITE

<222> (92)

<223> Xaa equals any of the naturally occurring L-amino acids

```
<220>
<221> SITE
<222> (95)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (103)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (106)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (115)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (121)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (127)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (140)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (141)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (142)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (143)
<223> Xaa equals any of the naturally occurring L-amino acids
```

```
<220>
<221> SITE
<222> (144)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (146)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (147)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (148)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (149)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (154)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (157)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (165)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1068
Ser Val Ser Leu Met Ser Asp Leu Glu Gly Asn Thr Lys Ser Arg Val
                  5
                                     10
Arg Leu Leu Val Leu Val Pro Pro Ser Lys Pro Glu Cys Gly Ile Glu
             20
                                 25
                                                      30
Gly Glu Thr Ile Ile Gly Asn Asn Ile Gln Leu Thr Cys Gln Ser Lys
         35
                             40
                                                  45
Glu Gly Ser Pro Thr Pro Pro Val Gln Leu Glu Arg Ser Tyr Asn Ile
```

50 55 60

Leu Asn Gln Xaa Xaa Pro Leu Ala Pro Pro Thr Ser Gly Ser Thr Cys
65 70 75 80

Ser Pro Leu Lys Asn Ile Ser His Arg Thr His Xaa Val Tyr Xaa Leu 85 90 95

Val Pro Pro Ser Asn Lys Xaa Gly Asn Xaa Phe Leu Gln Leu His Gly
100 105 110

Gly Leu Xaa Asn Leu Pro Pro Ile Xaa Phe Gly Pro Phe Phe Xaa Leu 115 120 125

Pro Gly Gly Val Phe Phe Phe Thr Pro Leu Ile Xaa Xaa Xaa Xaa Xaa Xaa 130 135 140

Leu Xaa Xaa Xaa Xaa Pro Gly Glu Arg Xaa Asn Pro Xaa Lys Lys Gly 145 150 155 160

Lys Pro Gly Thr Xaa Thr Leu 165

<210> 1069

<211> 142

<212> PRT

<213> Homo sapiens

<400> 1069

Val Leu Pro Pro Leu Leu Ile Met Leu Val Ile Tyr Ile Lys Ile Phe 1 5 10 15

Leu Val Ala Cys Arg Gln Leu Gln Arg Thr Glu Leu Met Asp His Ser 20 25 30

Arg Thr Thr Leu Gln Arg Glu Ile His Ala Ala Lys Ser Leu Ala Met 35 40 45

Ile Val Gly Ile Phe Ala Leu Cys Trp Leu Pro Val His Ala Val Asn
50 60

Cys Val Thr Leu Phe Gln Pro Ala Gln Gly Lys Asn Lys Pro Lys Trp
65 70 75 80

Ala Met Asn Met Ala Ile Leu Leu Ser His Ala Asn Ser Val Val Asn 85 90 95

Pro Ile Val Tyr Ala Tyr Arg Asn Arg Asp Phe Arg Tyr Thr Phe His 100 105 110

```
Lys Ile Ile Ser Arg Tyr Leu Leu Cys Gln Ala Asp Val Lys Ser Gly
        115
                             120
Asn Gly Gln Ala Gly Val Gln Pro Ala Leu Gly Val Gly Leu
    130
                                             140
                        135
<210> 1070
<211> 44
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (15)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (22)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (25)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (28)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (30)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (35)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (36)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
```

```
<222> (39)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (44)
<223> Xaa equals any of the naturally occurring L-amino acids
Ala Glu Arg Lys Ala Leu Leu Gln Gly Ser Asn Glu Ile Xaa Ile
                                      10
Arg Ala Arg Gly Gln Xaa Pro Leu Xaa Leu Gln Xaa His Xaa Arg Trp
                                  25
Leu His Xaa Xaa His Arg Xaa Pro Gly Ala Arg Xaa
                             40
<210> 1071
<211> 97
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (8)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (55)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (67)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (79)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1071
Met Glu Ala Ala Asp Tyr Arg Xaa Ala Ser Ser Gln Gln Gly Leu Ala
                                     10
                  5
Tyr Ala Thr Glu Ala Val Tyr Glu Ser Ala Glu Ala Pro Gly His Tyr
             20
                                 25
```

```
Pro Ala Glu Asp Ser Thr Tyr Asp Glu Tyr Glu Asn Asp Leu Gly Ile
35 40 45
```

Thr Ala Val Ala Leu Tyr Xaa Tyr Gln Ala Ala Gly Asp Asp Glu Ile 50 55 60

Ser Phe Xaa Pro Asp Asp Ile Ile Thr Asn Ile Glu Met Ile Xaa Asp 65 70 75 80

Gly Trp Trp Arg Gly Val Cys Lys Gly Arg Phe Arg Glu Leu Ala Phe 85 90 95

Ser

<221> SITE <222> (42)

```
<210> 1072
<211> 76
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (9)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (18)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (24)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (35)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (36)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
```

```
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (48)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (49)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (53)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (55)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (56)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (57)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (62)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (63)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (64)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (68)
<223> Xaa equals any of the naturally occurring L-amino acids
```

```
<220>
<221> SITE
<222> (69)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (74)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1072
Pro Cys Lys Asp Ile Asn Thr Phe Xaa His Gly Asn Lys Arg Arg Phe
Lys Xaa Ile Cys Glu Asn Lys Xaa Trp Lys Pro Leu Gln Gly Asn Leu
                                 25
Arg Phe Xaa Xaa Val Phe Phe Gln Xaa Thr Ile Trp Lys Val Xaa
         35
                             40
                                                  45
Xaa Gly Val Ser Xaa Gly Xaa Xaa Xaa Thr Phe Pro Gly Xaa Xaa Xaa
                         55
Gly Leu Lys Xaa Xaa Phe Phe Phe Yaa Lys Arg
                     70
<210> 1073
<211> 115
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (14)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (32)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (36)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
```

```
<222> (92)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (99)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (106)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (107)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (110)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1073
His Lys Gln Phe Ala Ser Leu Glu His Gly Ile Val Pro Xaa Thr Ser
Asp Cys Gln Tyr Leu Phe Pro Ala Lys Val Val Ser Arg Leu Val Xaa
                                 25
Trp Val Thr Xaa Ala His Glu Asp Tyr Met Glu Leu His Phe Thr Lys
         35
                             40
Asp Ile Val Asp Ala Gly Leu Ala Gly Asp Thr Asn Leu Tyr Tyr Met
     50
                         55
Ala Leu Ile Glu Arg Gly Thr Ala Lys Leu Gln Ala Ala Val Val Leu
                                         75
Asn Pro Gly Tyr Ser Ser Ile Pro Pro Val Phe Xaa Leu Cys Leu Asn
Trp Lys Xaa Glu Lys Thr Asn Ser Asn Xaa Xaa Asn Ile Xaa Gly His
            100
                                105
                                                     110
Gly Gly Arg
        115
```

```
<211> 56
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (4)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (13)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (19)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (24)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (37)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (41)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (54)
<223> Xaa equals any of the naturally occurring L-amino acids
Ser Ala His Xaa Cys Leu Ile Asn Ala Thr Ser Thr Xaa Thr Glu Phe
                  5
                                     10
Leu Lys Xaa Leu Val Leu Pro Xaa Ile Gly Ser Phe Thr Ile Ile Asp
Gly Asn Gln Val Xaa Gly Gln Asn Xaa Gly Asn Asn Phe Phe Leu Gln
Lys Ile Leu Ser Ala Xaa Thr Asp
     50
                         55
```

```
<210> 1075
<211> 146
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (41)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (108)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (114)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (121)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (128)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1075
Gly Thr Ser Glu Thr Pro Ala Gly Thr Ile Leu Tyr His Ala His Leu
Asp Ile Glu Ala Phe Thr Met Asp Arg Glu Val Arg Lys Ile Lys Gln
             20
Gly Leu Gly Leu Lys Phe Ala Glu Xaa Val Tyr Thr Gly Phe Trp His
         35
                             40
Ser Pro Glu Cys Glu Phe Val Arg His Cys Ile Ala Lys Ser Gln Glu
                         55
Arg Val Glu Gly Lys Val Gln Val Ser Val Leu Lys Gly Gln Val Tyr
65
                     70
Ile Leu Gly Arg Glu Ser Pro Leu Ser Leu Tyr Asn Glu Glu Leu Val
                 85
                                     90
```

PCT/US00/05883

Ser Met Asp Glu Asn Leu Met His Ile Ser Tyr Xaa Ala Gly Ile Leu 100 105 110

Glu Xaa Pro Lys Asn Gln Ala Leu Xaa Val Leu Asn Glu Asp Pro Xaa . 115 120 125

Pro Ser Gln Ser Pro Asn Asn Pro Asp Ile Ser Glu Ile Glu Phe Lys 130 135 140

Lys Gly

<210> 1076

<211> 130

<212> PRT

<213> Homo sapiens

<400> 1076

Trp Ile Pro Arg Ala Ala Gly Arg His Val Gly Val Cys Gly Ser Gly
1 5 10 15

Gly Arg Cys Ser Gly Leu Arg Gly Leu Ala Glu Thr His Pro Phe Ser 20 25 30

Val Ala Ala Pro Ser Ser Ala Leu Thr Ala Gly Arg Pro Thr Ala Val 35 40 45

His Pro Gly Glu Ser Thr Val Arg Thr Ile Ala Met Asp Gly Thr Glu
50 55 60

Gly Leu Val Arg Gly Gln Lys Val Leu Asp Ser Gly Ala Pro Ile Lys
65 70 75 80

Ile Pro Val Gly Pro Glu Thr Leu Gly Arg Ile Met Asn Val Ile Gly
85 90 95

Glu Pro Ile Asp Glu Arg Gly Pro Ile Lys Thr Lys Gln Phe Ala Pro
100 105 110

Ile His Ala Glu Ala Pro Glu Phe Met Glu Met Ser Val Glu Gln Glu
115 120 125

Ile Leu 130 <211> 55

<212> PRT

<213> Homo sapiens

<400> 1077

Gly Gln Gly Gln Asp Gly Ala Thr Gly Ala Gly Leu Ser Ala His Gln

Asp Tyr Leu Lys Pro Arg Ala Glu Glu Glu Arg Arg Ile Ala Ala Glu 25

Glu Lys Lys Cln Asp Glu Leu Lys Arg Ile Ala Arg Glu Leu Ala 35 40 45

Glu Asp Asp Ser Ile Leu Lys

<210> 1078

<211> 71

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (45)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (48)

<223> Xaa equals any of the naturally occurring L-amino acids

Glu Arg Gln Arg Arg Gly Leu His Val Gln Arg Leu Ser Gly His Leu 5 10

Arg Val Gln Asp Tyr Asn Ser Arg Gln Gly Ala Gln Asn Asp Arg Pro

Arg Gln Arg Arg Leu Thr Arg Ile Ser Met Ile Leu Xaa Arg Leu Xaa 40

Arg Phe Ser Ser Val Ile Arg Ser Ala Val Ser Val His Leu Arg Arg 50 55 60

Asn Ile Gly Val Thr Ala Val 70

```
<210> 1079
<211> 74
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (1)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (7)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (14)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (23)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (36)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (38)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (42)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (43)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (57)
<223> Xaa equals any of the naturally occurring L-amino acids
```

```
<220>
<221> SITE
<222> (60)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (67)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1079
Xaa Gly Ala Val Ile Ile Xaa Phe Arg Ser Lys Ile Lys Xaa Ala Leu
                  5
Ala His Phe Leu Ser Lys Xaa Thr Pro Thr Pro Leu Ile Pro Ile Leu
             20
                                 25
Val Ile Met Xaa Asn Xaa Ile Leu Leu Xaa Xaa Pro Ile Ala Leu Gly
                             40
Val Ser Leu Ile Ala Tyr Ile Thr Xaa Gly His Xaa Leu Met His Leu
                        55
Ile Gly Xaa Val Pro Tyr Asn Ile Asn His
 65
                    70
<210> 1080
<211> 39
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (5)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (11)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (13)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (25)
```

```
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (38)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1080
Thr Asp Tyr Gly Xaa Thr Ala Thr Lys Gln Xaa Val Xaa Ala Gly Thr
Phe Phe Trp Ser Val Val Ile Pro Xaa Leu Arg Arg Ile Leu Thr Ile
             20
                                  25
Leu Gln Trp Leu Thr Xaa Pro
         35
<210> 1081
<211> 76
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (3)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (4)
<223> Xaa equals any of the naturally occurring L-amino acids
Gly Arg Xaa Xaa Lys Val Leu Lys Arg Leu Arg Leu Gln Lys Arg Gly
                  5
                                     10
Thr Gly Gly Val Asp Thr Ala Ala Val Gly Gly Val Phe Asp Val Ser
Asn Ala Asp Arg Leu Gly Phe Ser Glu Val Glu Leu Val Gln Met Val
                             40
Val Asp Gly Val Lys Leu Leu Ile Glu Met Glu Gln Arg Leu Glu Gln
    50
                         55
Gly Gln Ala Ile Asp Asp Leu Met Pro Ala Gln Lys
```

65

```
<210> 1082
```

<211> 144

<212> PRT

<213> Homo sapiens

<400> 1082

Pro Val Thr Asn Glu Gly Ser Arg Asp Trp Thr Asp Ala Ala Met Pro

1 5 10 15

Leu Arg Leu Asp Ile Lys Arg Lys Leu Thr Ala Arg Ser Asp Arg Val
20 25 30

Lys Ser Val Asp Leu His Pro Thr Glu Pro Trp Met Leu Ala Ser Leu 35 40 45

Tyr Asn Gly Ser Val Cys Val Trp Asn His Glu Thr Gln Thr Leu Val
50 60

Lys Thr Phe Glu Val Cys Asp Leu Pro Val Arg Ala Ala Lys Phe Val 65 70 75 80

Ala Arg Lys Asn Trp Val Val Thr Gly Ala Asp Asp Met Gln Ile Arg 85 90 95

Val Phe Asn Tyr Asn Thr Leu Glu Arg Val His Met Phe Glu Ala His 100 105 110

Ser Asp Tyr Ile Arg Cys Ile Ala Val His Pro Thr Gln Pro Phe Ile 115 120 125

Leu Thr Ser Ser Asp Asp Met Leu Ile Lys Leu Trp Asp Trp Asp Lys 130 135 140

<210> 1083

<211> 120

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (3)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (76) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (82) <223> Xaa equals any of the naturally occurring L-amino acids Glu Met Xaa Arg Ser Val Ala Leu Ala Val Leu Ala Leu Leu Ser Leu 10 Ser Gly Leu Glu Ala Ile Gln Arg Thr Pro Lys Ile Gln Val Tyr Ser Arg His Pro Ala Glu Asn Gly Lys Ser Asn Phe Leu Asn Cys Tyr Val 40 Ser Gly Phe His Pro Ser Asp Ile Glu Val Asp Leu Leu Lys Asn Gly 50 55 Glu Arg Ile Glu Lys Val Glu His Ser Asp Leu Xaa Phe Ser Lys Asp 70 Trp Xaa Phe Tyr Leu Leu Tyr Tyr Thr Glu Phe Thr Pro Thr Glu Lys 90 Asp Glu Tyr Ala Cys Arg Val Asn His Val Thr Leu Ser Gln Pro Lys 105 Ile Val Lys Trp Asp Arg Asp Met 115 120 <210> 1084 <211> 149 <212> PRT <213> Homo sapiens <220> <221> SITE <222> (17) <223> Xaa equals any of the naturally occurring L-amino acids

Xaa Gln Lys Gly Ile Pro Glu Ala Asp Ser Ile Arg Ala Glu Met Ser 20 25 30

Pro Pro Ala Gly Thr Gly Pro Glu Phe Pro Gly Thr Ala Ala Arg Arg

10

15

5

<400> 1084

Arg Ser Val Ala Leu Ala Val Leu Ala Leu Leu Ser Leu Ser Gly Leu 35 40 45

Glu Ala Ile Gln Arg Thr Pro Lys Ile Gln Val Tyr Ser Arg His Pro 50 55 60

Ala Glu Ser Gly Lys Ser Asn Phe Leu Asn Cys Tyr Val Ser Gly Phe 65 70 75 80

His Pro Ser Asp Ile Glu Val Asp Leu Leu Lys Asn Gly Glu Arg Ile 85 90 95

Glu Lys Val Glu His Ser Asp Leu Ser Phe Ser Lys Asp Trp Ser Phe
100 105 110

Tyr Leu Leu Tyr Tyr Thr Glu Phe Thr Pro Thr Glu Lys Asp Glu Tyr
115 120 125

Ala Cys Arg Val Asn His Val Thr Leu Ser Gln Pro Lys Ile Val Lys 130 135 140

Trp Asp Arg Asp Met 145

<210> 1085

<211> 176

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (2)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (5)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (7)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (11)

<223> Xaa equals any of the naturally occurring L-amino acids

```
<220>
 <221> SITE
 <222> (12)
 <223> Xaa equals any of the naturally occurring L-amino acids
 <220>
 <221> SITE
 <222> (40)
 <223> Xaa equals any of the naturally occurring L-amino acids
 <220>
 <221> SITE
 <222> (87)
 <223> Xaa equals any of the naturally occurring L-amino acids
 <220>
 <221> SITE
 <222> (88)
 <223> Xaa equals any of the naturally occurring L-amino acids
 <220>
 <221> SITE
 <222> (100)
 <223> Xaa equals any of the naturally occurring L-amino acids
 <220>
 <221> SITE
 <222> (104)
 <223> Xaa equals any of the naturally occurring L-amino acids
 <220>
 <221> SITE
 <222> (109)
 <223> Xaa equals any of the naturally occurring L-amino acids
 <220>
 <221> SITE
 <222> (110)
 <223> Xaa equals any of the naturally occurring L-amino acids
<220>
 <221> SITE
 <222> (117)
 <223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (122)
<223> Xaa equals any of the naturally occurring L-amino acids
```

```
<220>
<221> SITE
<222> (134)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (142)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (146)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (170)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (176)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1085
Glu Xaa Pro Gly Xaa Asp Xaa Thr Arg Pro Xaa Xaa Lys Phe Leu Lys
Lys Lys Lys Lys Lys Lys Lys Gly Gly Arg Ser Arg Gly Ser
                                 25
Lys Leu Thr Tyr Ala Cys Met Xaa Arg His Ser Ser Ser Ile Val Ser
         35
                             40
                                                 45
Pro Lys Phe Asn Ser Leu Ala Val Val Leu Gln Arg Arg Asp Trp Glu
     50
                         55
Asn Pro Gly Val Thr Gln Leu Asn Arg Leu Ala Ala His Pro Pro Phe
Ala Ser Trp Arg Asn Ser Xaa Xaa Ala Arg Thr Asp Arg Pro Ser Gln
                                     90
Gln Leu Arg Xaa Leu Asn Gly Xaa Trp Asp Ala Pro Xaa Xaa Gly Ala
           100
                                105
                                                    110
Leu Ser Ala Ala Xaa Glu Val Val Thr Xaa Ser Val Thr Ala Thr Leu
       115
                            120
```

Ala Ser Ala Leu Ala Xaa Ala Pro Phe Ala Phe Phe Pro Xaa Phe Leu

130 135 140

Ala Xaa Phe Ala Gly Phe Pro Arg Gln Ala Leu Asn Arg Gly Leu Pro 145 150 155 160

Leu Gly Phe Arg Phe Ser Ala Leu Arg Xaa Leu Arg Pro Gln Lys Xaa 165 170 175

<210> 1086 <211> 166 ' <212> PRT <213> Homo sapiens <220> <221> SITE <222> (4) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (18) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (88) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (99) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (124) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (144) <223> Xaa equals any of the naturally occurring L-amino acids <400> 1086 10

Arg Xaa Arg Gly Ser Lys Leu Thr Tyr Ala Cys Met Arg Arg His Ser 20 25 30

Ser Ser Ile Val Ser Pro Lys Phe Asn Ser Leu Ala Val Val Leu Gln 35 40 45

Arg Arg Asp Trp Glu Asn Pro Gly Val Thr Gln Leu Asn Arg Leu Ala 50 55 60

Ala His Pro Pro Phe Ala Ser Trp Arg Asn Ser Glu Glu Ala Arg Thr 65 70 75 80

Asp Arg Pro Ser Gln Gln Leu Xaa Ser Leu Asn Gly Glu Trp Asp Ala 85 90 95

Pro Cys Xaa Gly Ala Leu Ser Ala Ala Gly Val Val Val Thr Arg Ser

Val Thr Val Thr Leu Ala Ser Ala Leu Ala Pro Xaa Pro Phe Ala Phe 115 120 125

Phe Pro Ser Phe Leu Ala Thr Phe Ala Gly Phe Pro Arg Gln Ala Xaa 130 135 140

Asn Arg Gly Leu Pro Leu Gly Phe Arg Phe Ser Ala Leu Arg His Leu 145 150 155 160

Asp Pro Lys Lys Leu Asp 165

<210> 1087

<211> 154

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (40)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (42)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (52)

```
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (75)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (83)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (84)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (85)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (86)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (99)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (113)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (115)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (122)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (124)
<223> Xaa equals any of the naturally occurring L-amino acids
```

PCT/US00/05883

```
<220>
<221> SITE
<222> (129)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (132)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (146)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (147)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (149)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (153)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1087
Pro Thr Arg Pro Pro Thr Arg Pro Lys Lys Lys Lys Lys Lys Lys
                  5
                                     10
                                                         15
Lys Lys Lys Lys Lys Lys Lys Gly Gly Arg Ser Lys Gly Ser Lys
             20
                                 25
Leu Thr Tyr Ala Cys Met Gln Xaa His Xaa Ser Pro Ile Val Ser Pro
Lys Phe Asn Xaa Leu Ala Val Val Leu Gln Arg Arg Asp Trp Glu Asn
                         55
                                             60
Pro Gly Val Thr Gln Leu Asn Arg Leu Ala Xaa His Pro Pro Phe Ala
65
                    70
                                         75
Ser Trp Xaa Xaa Xaa Lys Ala Arg Thr Asp Arg Pro Ser Gln Gln
```

Leu Arg Xaa Leu Asn Gly Lys Trp Asp Ala Pro Cys Tyr Gly Ala Leu

100 105 110 Xaa Pro Xaa Gly Val Val Thr Pro Xaa Val Xaa Arg Tyr Thr Cys 115 120 Xaa Arg Pro Xaa Ala Arg Ser Phe Arg Phe Leu Pro Phe Leu Ser Arg 135 Gln Xaa Xaa Pro Xaa Phe Pro Val Xaa Leu 150 <210> 1088 <211> 166 <212> PRT <213> Homo sapiens <220> <221> SITE <222> (13) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (15) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (36) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (84) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (122) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (125) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE

<222> (131)

<223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (144) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (159) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (161) <223> Xaa equals any of the naturally occurring L-amino acids <400> 1088 Phe Phe Ile Asn His Gly Cys Ser Gln Lys Lys Lys Xaa Lys Xaa Lys 5 Lys Lys Lys Lys Gly Gly Arg Ser Arg Gly Ser Lys Leu Thr Tyr Ala Cys Met Xaa Arg His Ser Ser Ser Ile Val Ser Pro Lys Phe Asn 40 Ser Leu Ala Val Val Leu Gln Arg Arg Asp Trp Glu Asn Pro Gly Val 55 Thr Gln Leu Asn Arg Leu Ala Ala His Pro Pro Phe Ala Ser Trp Arg 65 70 Asn Ser Glu Xaa Ala Arg Thr Asp Arg Pro Ser Gln Gln Leu Arg Ser 90 Leu Asn Gly Glu Trp Asp Ala Pro Cys Ser Gly Ala Leu Ser Ala Ala 105 Gly Val Val Thr Arg Ser Val Thr Xaa Thr Leu Xaa Ser Ala Leu 115 120 125 Thr Pro Xaa Pro Phe Ala Phe Phe Pro Ser Phe Leu Pro Arg Ser Xaa 130 135 Gly Phe Pro Ser Ser Ser Lys Ser Gly Ala Pro Leu Arg Val Xaa Ile 155

Xaa Gly Phe Thr Gly Pro

```
<210> 1089
<211> 104
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (22)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (74)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (90)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (93)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (95)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (99)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1089
Asn Lys Lys Lys Lys Arg Ala Ala Ala Leu Glu Asp Pro Lys Leu
Thr Tyr Ala Cys Met Xaa Arg His Ser Ser Ser Ile Val Ser Pro Lys
                                 25
Phe Asn Ser Leu Gly Arg Arg Phe Thr Thr Ser Val Thr Gly Lys Thr
         35
                             40
Leu Ala Leu Pro Asn Leu Ile Arg Leu Ala Ala His Pro Pro Phe Ala
     50
                                             60
                         55
Ser Trp Arg Asn Ser Glu Glu Ala Arg Xaa Asp Arg Pro Ser Gln Gln
```

80 65 70 75 Leu Arg Met Leu Asn Gly Glu Trp Asp Xaa Pro Cys Xaa Gly Xaa Ile 85 90 Lys Ala Xaa Arg Val Trp Trp Leu 100 <210> 1090 <211> 129 <212> PRT <213> Homo sapiens <220> <221> SITE <222> (3) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (10) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (20) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (24) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (25) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (35) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (37)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE <222> (42) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (83) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (94) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (99) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (114) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (117) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (119) <223> Xaa equals any of the naturally occurring L-amino acids <400> 1090 Pro Thr Xaa Pro Lys Lys Lys Lys Xaa Lys Lys Lys Lys Lys Lys 5 10 Lys Lys Lys Xaa Gly Gly Arg Xaa Xaa Gly Ser Lys Leu Thr Tyr Ala 20 25 Cys Met Xaa Arg Xaa Ser Ser Ser Ile Xaa Ser Pro Lys Phe Asn Ser 40 45 Leu Ala Val Val Leu Gln Arg Arg Asp Trp Glu Asn Pro Gly Val Thr 50 55 Gln Leu Asn Arg Leu Ala Ala His Pro Pro Phe Ala Ser Trp Arg Asn 65 70 75

Ser Glu Xaa Ala Arg Thr Asp Arg Pro Ser Gln Gln Leu Xaa Ser Leu

85 90 95

Asn Gly Xaa Trp Asp Ala Pro Cys Ser Gly Ala Leu Ser Ala Ala Gly
100 105 110

Val Xaa Val Thr Xaa Ser Xaa Thr Val Thr Leu Ala Ser Ala Leu Ala 115 120 125

Pro

<210> 1091 <211> 78

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (38)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (39)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (40)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (41)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (43)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (44)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (46)

```
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (47)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (48)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (56)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (64)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (66)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (68)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (70)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (71)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (75)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1091
Glu Thr Ala Met Thr Met Ile Thr Pro Ser Ser Asn Thr Thr His Tyr
                                                          15
                                     10
```

```
Arg Glu Ser Trp Tyr Ala Cys Arg Tyr Arg Ser Gly Ile Pro Gly Ser
                                  25
Thr His Ala Ser Gly Xaa Xaa Xaa Xaa Gly Xaa Xaa Ser Xaa Xaa Xaa
                              40
Arg Lys Ile Val Gln Arg Gly Xaa Asn Glu Cys Gly Ser Arg Gly Xaa
                          55
                                              60
Pro Xaa Ser Xaa Gly Xaa Xaa Ser Phe Gly Xaa Lys Lys Cys
                      70
<210> 1092
<211> 77
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (18)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (33)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (65)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (68)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (69)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (70)
<223> Xaa equals any of the naturally occurring L-amino acids
```

<220> <221> SITE

```
<222> (72)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1092
5
                                   10
                                                      15
Ser Xaa Gly Ser Lys Leu Thr Tyr Ala Cys Met Arg Arg His Ser Ser
            20
                               25
Xaa Ile Val Ser Pro Lys Phe Asn Ser Leu Ala Val Val Leu Gln Arg
                           40
Arg Asp Trp Glu Asn Pro Gly Val Thr Gln Leu Asn Arg Leu Ala Ala
                       55
Xaa Pro Pro Xaa Xaa Xaa Trp Xaa Ile Pro Lys Gly Pro
                    70
<210> 1093
<211> 93
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (63)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (71)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (75)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1093
Thr Phe Gln Asn Leu Lys Lys Lys Lys Gly Gly Arg Ser Arg Gly
                5
                                  10
Ser Lys Leu Thr Tyr Ala Cys Met Arg Arg His Ser Ser Ser Ile Val
                               25
```

Ser Pro Lys Phe Asn Ser Leu Ala Val Val Leu Gln Arg Arg Asp Trp 35 40 45

Glu Asn Pro Gly Val Thr Gln Leu Asn Arg Leu Ala Ala His Xaa Pro $50 \hspace{1cm} 55 \hspace{1cm} 60$

Phe Ala Ala Gly Val Ile Xaa Lys Arg Pro Xaa Arg Ser Pro Phe Pro 65 70 75 80

Thr Val Ala Gin Pro Glu Trp Arg Met Gly Arg Ala Leu 85 90

<210> 1094

<211> 44

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (1)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (4)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (36)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 1094

Xaa Arg Pro Xaa Leu Glu Thr Pro Asp Tyr Arg Glu Ser Trp Tyr Ala 1 5 10 15

Cys Arg Tyr Arg Ser Gly Ile Pro Gly Ser Thr His Ala Ser Ala Arg
20 25 30

Leu Glu Ala Xaa Arg Arg Met Leu Gly Ile Ser Pro 35 40

<210> 1095

<211> 69

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (15)

```
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (22)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (65)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (66)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (67)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (69)
<223> Xaa equals any of the naturally occurring L-amino acids
Asn Val Pro Cys Lys Tyr Lys His Ile Leu Ser Glu Lys Lys Xaa Lys
Lys Gly Gly Arg Ser Xaa Gly Ser Lys Leu Thr Tyr Ala Cys Met Arg
                                 25
Arg His Ser Ser Ser Ile Val Ser Pro Lys Phe Asn Ser Leu Ala Val
         35
                             40
Val Leu Gln Arg Arg Asp Trp Glu Lys Pro Trp Ala Leu Pro Asn Leu
     50
                         55
Xaa Xaa Xaa Cys Xaa
 65
<210> 1096
<211> 48
<212> PRT
<213> Homo sapiens
```

<220>

```
<221> SITE
 <222> (2)
 <223> Xaa equals any of the naturally occurring L-amino acids
 <220>
 <221> SITE
 <222> (3)
 <223> Xaa equals any of the naturally occurring L-amino acids
 <220>
 <221> SITE
 <222> (7)
 <223> Xaa equals any of the naturally occurring L-amino acids
 <220>
 <221> SITE
 <222> (19)
 <223> Xaa equals any of the naturally occurring L-amino acids
. <220>
 <221> SITE
 <222> (47)
 <223> Xaa equals any of the naturally occurring L-amino acids
 <220>
 <221> SITE
 <222> (48)
 <223> Xaa equals any of the naturally occurring L-amino acids
 <400> 1096
 Gly Xaa Xaa Ser Thr Val Xaa Ile Pro Gly Ser Arg Asp Pro Ser Leu
                  5
                                      10
 Arg Thr Xaa His Ala Arg His Ser Ser Ser Ile Val Ser Pro Lys Phe
              20
                                  25
 Asn Ser Leu Ala Val Val Leu Gln Arg Arg Asp Trp Glu Asn Xaa Xaa
                              40
```

<210> 1097 <211> 47 <212> PRT <213> Homo sapiens <220> <221> SITE

```
<222> (2)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (3)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (5)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (18)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (41)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1097
Lys Xaa Xaa Lys Xaa Gly Gly Arg Ser Arg Gly Ser Lys Leu Thr Tyr
Ala Xaa Met Arg Arg His Ser Ser Ser Ile Gly Ser Pro Lys Phe Asn
                                 25
             20
Ser Leu Ala Val Val Leu Gln Arg Xaa Asp Trp Glu Asn Pro Gly
         35
                             40
                                                  45
<210> 1098
<211> 48
<212> PRT
<213> Homo sapiens
<400> 1098
```

Val Val Leu Gln Arg Arg Asp Trp Glu Asn Pro Gly Arg Tyr Pro Thr

Ser Glu Thr Pro Ser Gln Lys Lys Lys Lys Thr Arg Gly Gly Ala

Arg Tyr Pro Ile Arg Pro Ile Val Ser Arg Ile Thr Ile Pro Leu Ala

20

10

```
<210> 1099
<211> 66
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (2)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (3)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (12)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (55)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (58)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (62)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (65)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (66)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1099
Thr Xaa Xaa Lys Lys Lys Arg Ala Ala Ala Leu Xaa Asp Pro Ser Leu
```

```
1
                                      10
                   5
                                                          15
Arg Thr Pro Cys Met Arg Arg His Asn Ser Ser Ile Gly Ala Pro Lys
             20
Phe Asn Ser Leu Ala Arg Arg Leu Gln Arg Leu Thr Gly Lys Thr Leu
Ala Leu Pro Asn Leu Ile Xaa Leu Gln Xaa Ile Pro Phe Xaa Gln Leu
                         55
Xaa Xaa
 65
<210> 1100
<211> 71
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (19)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (21)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (28)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (32)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (33)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (34)
<223> Xaa equals any of the naturally occurring L-amino acids
```

```
<220>
<221> SITE
<222> (44)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (49)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (71)
<223> Xaa equals any of the naturally occurring L-amino acids
Gly Gly Xaa Ser Xaa Gly Ser Lys Leu Thr Tyr Xaa Cys Met Gln Xaa
Xaa Xaa Ser Ser Ile Val Ser Pro Lys Phe Asn Xaa Leu Ala Val Asp
                           40
Xaa Gln Arg Arg Asp Trp Glu Asn Pro Gly Val Thr Gln Leu Asn Arg
    50
                       55
Leu Ala Ala His Pro Pro Xaa
<210> 1101
<211> 114
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (7)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (8)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (9)
```

```
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (12)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (13)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (22)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (26)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (32)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (63)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (88)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (93)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (102)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (113)
<223> Xaa equals any of the naturally occurring L-amino acids
```

<400> 1101

Pro Val Ser Arg Arg Ser Xaa Xaa Xaa Lys Lys Xaa Xaa Lys Lys Asn 1 5 10 15

Ser Lys Ser Phe Ser Xaa Val Leu Leu Xaa Arg Pro Arg Ala His Xaa 20 25 30

Phe Ser Thr Arg Val Gly Tyr Gln Val Ser Val Pro Asn Ser Pro Tyr 35 40 45

Ser Glu Ser Tyr Tyr Asn Ser Leu Ala Val Val Leu Gln Arg Xaa Asp 50 55 60

Trp Glu Asn Pro Gly Val Thr Gln Leu Asn Arg Leu Ala Ala His Pro 65 70 75 80

Pro Phe Ala Ser Trp Arg Asn Xaa Glu Lys Gly Arg Xaa Asp Arg Pro 85 90 95

Ser Gln Gln Phe Ala Xaa Pro Glu Met Ala Asn Gly Asn Gln Phe Leu 100 105 110

Xaa Val

<210> 1102

<211> 152

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (2)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (7)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (11)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (29)

```
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (32)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (65)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (76)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (80)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (88)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (89)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (93)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (94)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (95)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (99)
<223> Xaa equals any of the naturally occurring L-amino acids
```

PCT/US00/05883 WO 00/55351

```
<220>
<221> SITE
<222> (111)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (116)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (118)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (119)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (127)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (151)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1102
Asn Xaa Lys Lys Lys Xaa Lys Lys Xaa Lys Lys Lys Gly Gly
                  5
                                     10
                                                         15
Arg Ser Lys Gly Ser Lys Leu Thr Tyr Ala Cys Met Xaa Arg His Xaa
             20
                                 25
Ser Ala Ile Val Ser Pro Lys Phe Asn Ser Leu Ala Val Val Leu Gln
                             40
         35
Arg Arg Asp Trp Glu Asn Pro Gly Val Thr Gln Leu Asn Arg Leu Ala
                        55
Xaa His Pro Pro Phe Ala Arg Trp Arg Asn Ser Xaa Lys Ala Arg Xaa
 65
                     70
Asp Arg Pro Ser Gln Gln Leu Xaa Xaa Leu Asn Gly Xaa Xaa Xaa Ala
                                     90
                 85
Pro Cys Xaa Gly Ala Leu Ser Ala Ala Gly Val Val Thr Xaa Arg
```

```
100
                                105
                                                    110
Val Thr Ala Xaa Leu Xaa Xaa Ala Leu Ala Pro Gly Pro Phe Xaa Phe
        115
                             120
                                                 125
Phe Pro Ser Phe Leu Ala Thr Phe Ala Gly Phe Pro Arg Gln Ala Leu
                         135
                                             140
Asn Arg Gly Val Pro Phe Xaa Val
                     150
<210> 1103
<211> 143
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (20)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (30)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (37)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (100)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (123)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (132)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (135)
```

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (143)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 1103

Gly Arg Ser Xaa Gly Ser Lys Leu Thr Tyr Ala Cys Met Xaa Arg His 20 25 30

Ser Ser Ser Ile Xaa Ser Pro Lys Phe Asn Ser Leu Ala Val Leu 35 40 45

Gln Arg Arg Asp Trp Glu Asn Pro Gly Val Thr Gln Leu Asn Arg Leu
50 60

Ala Ala His Pro Pro Phe Ala Ser Trp Arg Asn Ser Glu Lys Ala Arg
65 70 75 80

Thr Asp Arg Pro Ser Gln Gln Leu Arg Ser Leu Asn Gly Glu Trp Asp
85 90 95

Ala Pro Cys Xaa Gly Ala Leu Ser Ala Ala Gly Val Val Thr Arg
100 105 110

Ser Val Thr Val Thr Leu Ala Ser Ala Leu Xaa Pro Ala Pro Phe Val 115 120 125

Ser Ser Leu Xaa Phe Ser Xaa Arg Ser Pro Val Ser Pro Leu Xaa 130 135 140

<210> 1104

<211> 93

<212> PRT

<213> Homo sapiens

<400> 1104

Arg Lys Lys Lys Lys Gly Gly Arg Ser Arg Gly Ser Lys Leu Thr
1 5 10 15

Tyr Ala Cys Met Arg Arg His Ser Ser Ser Ile Val Ser Pro Lys Phe 20 25 30

Asn Ser Leu Ala Val Val Leu Gln Arg Arg Asp Trp Glu Asn Pro Gly
35 40 45

Val Thr Gln Leu Asn Arg Leu Ala Ala His Pro Pro Phe Ala Ser Trp
50 55 60

Arg Asn Ser Glu Glu Ala Arg Thr Asp Arg Pro Ser Gln Gln Leu Arg 65 70 75 80

Ser Leu Asn Gly Glu Trp Asp Ala Pro Cys Thr Ala His
85 90

<210> 1105

<211> 55

<212> PRT

<213> Homo sapiens

<400> 1105

Ile Arg Gln Arg Tyr Ser Trp Leu Ile Asn Gly Thr Phe Gln Gln Ser
1 5 10 15

Thr Gln Glu Leu Phe Ile Pro Asn Ile Thr Val Asn Asn Ser Gly Ser
20 25 30

Tyr Thr Cys His Ala Asn Asn Ser Val Thr Gly Cys Asn Arg Ala Thr 35 40 45

Val Lys Thr Met His Ser His 50 55

<210> 1106

<211> 73

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (30)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (36)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (37)

<223> Xaa equals any of the naturally occurring L-amino acids

```
<220>
<221> SITE
<222> (54)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (62)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (70)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1106
Pro Trp His Val Phe Cys Ile Ser Gly Arg Pro Ala Ala Gln Asp His
Ser Asn Asp Pro Pro Asn Lys Met Asn Glu Val Thr Tyr Xaa Thr Leu
             20
                                 25
Asn Phe Glu Xaa Xaa Gln Pro Thr Gln Pro Thr Ser Ala Ser Pro Ser
         35
                             40
Leu Thr Ala Thr Glu Xaa Ile Tyr Ser Arg Ser Lys Lys Xaa Val Met
Lys Pro Gly Pro Ala Xaa Cys Ser Ala
 65
                     70
<210> 1107
<211> 137
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (121)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1107
Ser Ser His Asn Arg Val Asn Ala Arg Leu Ala Gly Ala Pro Ser Glu
Asp Pro Gln Phe Pro Lys Val Gln Trp Pro Pro Arg Glu Leu Cys Ser
```

25

Ala Cys His Asn Glu Arg Leu Asp Val Pro Val Trp Asp Val Glu Ala 40

Thr Leu Asn Phe Leu Lys Ala His Phe Ser Pro Ser Asn Ile Ile Leu 55

Asp Phe Pro Ala Ala Gly Ser Thr Cys Pro Arg Asp Val Gln Asn Val 75

Ala Ser Arg Pro Lys Leu Ala Met Gly Ala Leu Glu Leu Glu Ser Arg

Asn Ser Thr Leu Asp Pro Gly Lys Pro Glu Met Met Lys Ser Pro Thr 100 105

Asn Thr Thr Pro His Val Pro Ala Xaa Gly Pro Glu Ala Ser Arg Pro 120

Pro Lys Leu Ala Pro Trp Pro Lys Thr 130

<210> 1108

<211> 39

<212> PRT

<213> Homo sapiens

<400> 1108

Gln Tyr Lys Gly Ser Trp Pro Ala Leu Gln Leu Gln His Leu Pro His

Pro Glu Trp Glu Ser Gly Gly Ala Thr Cys Trp Ala Pro Pro Glu Leu 25 30

Cys Thr His Leu Ala Met Tyr 35

<210> 1109

<211> 31

<212> PRT

<213> Homo sapiens

<400> 1109

Ala Asp Phe Asp Arg Phe Lys Val Met Lys Ala Lys Lys Met Arg Asn 5

Arg Ile Ile Lys Asn Glu Leu Arg Ser Phe Lys Arg Gln Leu Ser 20

```
<210> 1110
<211> 71
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (14)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (30)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (37)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (38)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (48)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (57)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (59)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (63)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1110
Lys Ile Met Ala Ser Pro Asp Trp Gly Tyr Asp Asp Lys Xaa Gly Pro
 1
                                     10
                                                          15
                  5
```

Glu Gln Trp Ser Lys Leu Tyr Pro Ile Ala Asn Gly Asn Xaa Gln Ser 20 25 30

Pro Val Asp Ile Xaa Xaa Ser Glu Thr Lys His Asp Thr Ser Leu Xaa 35 40 45

Pro Ile Ser Val Ser Tyr Asn Pro Xaa Thr Xaa Lys Glu Ile Xaa Gln 50 55 60

Cys Gly Gly Ile Pro Ser Met 65 70

<210> 1111

<211> 88

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (78)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 1111

Lys Ile Met Ala Ser Pro Asp Trp Gly Tyr Asp Asp Lys Asn Gly Pro

1 10 15

Glu Gln Trp Ser Lys Leu Tyr Pro Ile Ala Asn Gly Asn Asn Gln Ser

Pro Val Asp Ile Lys Thr Ser Glu Thr Lys His Asp Thr Ser Leu Lys 35 40 45

Pro Ile Ser Val Ser Tyr Asn Pro Ala Thr Ala Lys Glu Ile Ile Asn 50 55 60

Val Gly His Ser Phe His Val Asn Phe Glu Asp Asn Asp Xaa Arg Ser 65 70 75 80

Ser Ala Glu Arg Trp Ser Phe Leu 85

<210> 1112

<211> 120

<212> PRT

<213> Homo sapiens

```
<220>
<221> SITE
<222> (11)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (14)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (17)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (46)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (54)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (58)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (86)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (90)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1112
Gly Ala Asp Ser Cys Pro Ala Pro Thr Ala Xaa Arg Thr Xaa Ser His
                                     10
Xaa Trp Gly Tyr Gly Lys His Asn Gly Pro Lys His Trp His Lys Asp
             20
Phe Pro Ile Ala Lys Gly Arg Ala Pro Val Pro Leu Leu Xaa Ser Thr
                             40
         35
```

Leu His Thr Ala Lys Xaa Glu Pro Phe Xaa Glu Ser Pro Cys Leu Phe

50 55 60

Pro Met Asn Gln Ala Thr Ser Leu Arg Ile Leu Asn Asn Gly His Ala 65 70 75 80

Phe Asn Val Gly Val Xaa Met Thr Leu Xaa Asp Lys Ala Val Leu Gln 85 90 95

Gly Lys Asp Pro Trp Val Gly His Phe Thr Asp Trp Phe Ser Phe Phe 100 105 110

Gln Phe Ser Met Gly Val Ser Ile 115 120

<210> 1113

<211> 50

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (22)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (36)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 1113

Met Leu Leu Glu Asn Lys Ala Ser Ile Phe Gly Gly Gly Leu Pro Ala 1 5 10 15

Pro Tyr Gln Val Lys Xaa Leu His Leu His Trp Ser Asp Leu Pro Tyr 20 25 30

Lys Gly Ser Xaa His Ser Leu Glu Trp Gly Ala Leu Cys His Gly Arg 35 40 45

Cys Thr 50

<210> 1114

<211> 84

<212> PRT

<213> Homo sapiens

```
<220>
<221> SITE
<222> (21)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (33)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (51)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (57)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (62)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (65)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1114
Lys Pro Phe Lys Met Ile Pro Gly Val Val Asp Gly Val Phe Leu Pro
Arg His Pro Gln Xaa Leu Leu Ala Ser Ala Asp Phe Gln Pro Val Pro
                                 25
Xaa Ile Val Gly Val Asn Asn Glu Phe Gly Trp Leu Ile Pro Lys
                             40
                                                 45
         35
Val Met Xaa Ile Tyr Asp Thr Gln Xaa Glu Met Asp Arg Xaa Ala Ser
     50
                         55
Xaa Ala Ala Leu Gln Lys Met Leu Thr Leu Leu Ile Cys Leu Leu His
                     70
Leu Val Thr Cys
```

```
<210> 1115
<211> 40
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (18)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (19)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (38)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1115
Cys Thr Gln Glu Leu Phe Ile Pro Asn Ile Thr Val Asn Asn Arg Gly
                                     10
Ser Xaa Xaa Cys Gln Ala His Asn Ser Thr Leu Ala Leu Ile Gly Ala
                                 25
             20
Gln Ser Arq Ile Ser Xaa Ser Met
         35
<210> 1116
<211> 151
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (132)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (141)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1116
Gly Thr Ala Glu Leu Thr Val Thr Ala Ala Leu Thr Arg Glu Phe Leu
                                     10
```

Glu Pro Lys Leu Phe Ser Thr Glu Asp Lys Gln Ala Ala Glu Thr Met
20 25 30

Gly Ser Pro Ser Ala Cys Pro Tyr Arg Val Cys Ile Pro Trp Gln Gly
35 40 45

Leu Leu Leu Thr Ala Ser Leu Leu Thr Phe Trp Asn Leu Pro Asn Ser 50 55 60

Ala Gln Thr Asn Ile Asp Val Val Pro Phe Asn Val Ala Glu Gly Lys 65 70 75 80

Glu Val Leu Leu Val Val His Asn Glu Ser Gln Asn Leu Tyr Gly Tyr 85 90 95

Asn Trp Tyr Lys Gly Glu Arg Val His Ala Asn Tyr Arg Ile Ile Gly 100 105 110

Tyr Cys Lys Lys Tyr Lys Ser Arg Lys Cys Pro Arg Pro Asp Thr Thr 115 120 125

Ser Arg Asp Xaa Tyr Pro Met Glu Pro Cys Val Pro Xaa Val Pro His 130 135 140

Ala Gln Asp Phe Ser Ser Leu 145 150

<210> 1117

<211> 115

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (35)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (113)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 1117

Arg Glu Gln Lys Leu Glu Leu His Arg Gly Ala Thr Ala Leu Glu Leu 1 5 10 15

Val Asp Pro Pro Gly Cys Arg Asn Ser Ala Arg Gly Arg Pro Gly Leu 20 25 30

```
Ala Arg Xaa Pro Arg Arg Gly Leu Glu Ala Arg Pro Gly Ala Pro Glu
                              40
Arg Glu Ser Glu Arg Arg Gly Asp Gln Ile Asn Ala Ser Lys Asn
Glu Glu Asp Ala Gly Lys Met Phe Val Gly Gly Leu Ser Trp Asp Thr
                     70
                                          75
Ser Lys Lys Asp Leu Lys Asp Tyr Phe Thr Lys Phe Gly Glu Val Val
                                      90
                 85
Asp Cys Thr Ile Lys Met Asp Pro Asn Thr Gly Arg Ser Arg Gly Phe
                                105
Xaa Phe Ile
        115
<210> 1118
<211> 50
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (4)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (14)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (16)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (20)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (28)
<223> Xaa equals any of the naturally occurring L-amino acids
```

<220>

<221> SITE <222> (29) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (41) <223> Xaa equals any of the naturally occurring L-amino acids <400> 1118 Arg Pro Thr Xaa Pro Gly Arg Thr Met Ala Arg Gly Ala Xaa Leu Xaa Leu Leu Leu Xaa Gly Leu Leu Gly Val Leu Val Xaa Xaa Pro Asp Gly 25 Gly Phe Asp Leu Ser Asp Ala Leu Xaa Asp Asn Glu Asn Lys Lys Pro 35 45 40 Thr Ala 50 <210> 1119 <211> 147 <212> PRT <213> Homo sapiens <220> <221> SITE <222> (1) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (11) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (13) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (95) <223> Xaa equals any of the naturally occurring L-amino acids <400> 1119 Xaa Ser Glu Cys Lys Ser Pro Ser Glu Pro Xaa Ile Xaa Lys Arg Val

WO 00/55351 PCT/US00/05883

1 5 10 15

Gly Leu Ile His Ile Ser Gln Val Ile Ser Glu Ile Asp Gly Asn Arg
20 25 30

Met Thr Leu Ser Gln Glu Gly Ala Gln Asp Ser Phe Pro Leu Gln Gln 35 40 45

Lys Ile Leu Val Cys Ser Leu Met Leu Leu Ile Arg Gln Leu Lys Ile 50 55 60

Lys Glu Val Thr Leu Gly Lys Leu Tyr Glu Ala Tyr Ser Lys Val Cys 65 70 75 80

Arg Lys Gln Gln Val Ala Ala Val Asp Gln Ser Glu Cys Leu Xaa Leu 85 90 95

Ser Gly Leu Leu Glu Ala Arg Gly Ile Leu Gly Leu Lys Arg Asn Lys 100 105 110

Glu Thr Arg Leu Thr Lys Val Phe Phe Lys Ile Glu Glu Lys Glu Ile 115 120 125

Glu His Ala Leu Lys Asp Lys Ala Leu Ile Gly Asn Ile Leu Ala Thr 130 135 140

Gly Leu Pro 145

<210> 1120

<211> 45

<212> PRT

<213> Homo sapiens

<400> 1120

His Glu Arg Asn Met Glu Arg Leu Thr Leu Ala Cys Gly Gly Val Ala 1 5 10 15

Leu Asn Ser Phe Glu Asp Leu Ser Pro Asp Cys Leu Gly His Ala Gly
20 25 30

Leu Val Tyr Glu Tyr Thr Leu Gly Glu Val His Leu Tyr
35 40 45

<210> 1121

<211> 67

<212> PRT

1239

```
<213> Homo sapiens
<220>
<221> SITE
<222> (7)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (52)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (53)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (60)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (66)
<223> Xaa equals any of the naturally occurring L-amino acids
Asn Trp Arg Met Arg Met Xaa His Val Met Leu Pro Lys Asp Ile Ala
                  5
                                     10
Lys Leu Val Pro Lys Thr His Leu Met Ser Glu Ser Glu Trp Arg Asn
Leu Gly Val Gln Gln Ser Gln Gly Trp Val His Tyr Met Ile His Glu
                             40
Pro Glu Pro Xaa Xaa Leu Leu Phe Arg Gly His Xaa Gln Glu Pro Arg
     50
                         55
                                             60
Asn Xaa Val
 65
<210> 1122
<211> 64
<212> PRT
<213> Homo sapiens
```

<220>

```
<221> SITE
<222> (13)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (17)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (19)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (20)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (22)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (23)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (25)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (28)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (41)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (42)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
```

<222> (47) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (60) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (64) <223> Xaa equals any of the naturally occurring L-amino acids Ser Cys Cys Leu Gly Trp Thr Trp Phe Cys Leu Leu Xaa Pro Leu Leu 5 10 Xaa Leu Xaa Xaa Asn Xaa Xaa Gln Xaa Ala Ser Xaa Met Val His Lys 25 Gln Ile Tyr Tyr Ser Asp Lys Tyr Xaa Xaa Glu His Tyr Glu Xaa Arg

Asp Gly Met Leu Pro Arg Glu Leu Asp Lys Gln Xaa Pro Lys Thr Xaa 50 55 60

40

<210> 1123 <211> 155 <212> PRT <213> Homo sapiens <220> <221> SITE <222> (10) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (14) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (15) <223> Xaa equals any of the naturally occurring L-amino acids

<220> <221> SITE <222> (31) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (143) <223> Xaa equals any of the naturally occurring L-amino acids <400> 1123 Gln Leu Val Gly Pro Pro Gly Leu Gln Xaa Phe Gly Ser Xaa Xaa Lys 5 Pro Tyr Gly Val Thr Ala Met Cys Trp Asn Trp Glu Gln Val Xaa Ala 25 20 Ala Gly Arg His Pro Glu Ser Arg Pro Phe Arg Phe Thr Gly Ala Ala Thr Ser Pro Arg Ser Ser Cys Ser Arg Ala Cys Ile Val Lys Val Val 55 Arg Arg Leu Ala Glu Lys Arg Ile Gly Val Arg Asp Val Arg Leu 70 65 Asn Gly Ser Ala Ala Ser His Val Leu His Gln Asp Ser Gly Leu Gly Tyr Lys Asp Leu Asp Leu Ile Phe Cys Ala Asp Leu Arg Gly Glu Gly Glu Phe Gln Thr Val Lys Asp Val Val Leu Asp Cys Leu Leu Asp Phe 125 115 120 Leu Pro Glu Gly Val Asn Lys Glu Lys Ile Thr Pro Leu Thr Xaa Lys 140 130 135

<210> 1124 <211> 117 <212> PRT <213> Homo sapiens <220>

Glu Ala Tyr Val Gln Lys Met Val Lys Val Cys 150

<221> SITE <222> (7)

145

```
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (87)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (97)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (99)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (110)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1124
Ala Lys Ser Phe Glu Tyr Xaa Ala Arg Ile Phe Lys Gln His Phe Met
                  5
                                     10
Asp Ser Arg Ile Pro Cys Leu Ile Val Ala Ala Lys Ser Asp Leu His
                                 25
Glu Val Lys Gln Glu Tyr Ser Ile Ser Pro Thr Asp Phe Cys Arg Lys
                             40
His Lys Met Pro Pro Pro Gln Ala Phe Thr Cys Asn Thr Ala Asp Ala
     50
                         55
Pro Ser Lys Asp Ile Phe Gly Lys Leu Thr Thr Met Ala Met Tyr Pro
                                         75
65
                     70
His Ala Arg Leu Arg Cys Xaa Cys Thr Cys Asn Arg Cys Thr Phe Cys
                                     90
Xaa Cys Xaa Asn Phe Leu Asn Leu Tyr Phe Ala Ala Asn Xaa Val Lys
                                105
```

<210> 1125 <211> 169

Glu Gln Lys Ser Phe 115 <212> PRT <213> Homo sapiens

<400> 1125

Ile Met Lys Leu Leu Thr Arg Ala Gly Ser Phe Ser Arg Phe Tyr Ser 1 5 10 15

Leu Lys Val Ala Pro Lys Val Lys Ala Thr Ala Ala Pro Ala Gly Ala 20 25 30

Pro Pro Gln Pro Gln Asp Leu Glu Phe Thr Lys Leu Pro Asn Gly Leu
35 40 45

Val Ile Ala Ser Leu Glu Asn Tyr Ser Pro Val Ser Arg Ile Gly Leu 50 55. 60

Phe Ile Lys Ala Gly Ser Arg Tyr Glu Asp Phe Ser Asn Leu Gly Thr 65 70 75 80

Thr His Leu Leu Arg Leu Thr Ser Ser Leu Thr Thr Lys Gly Ala Ser 85 90 95

Ser Phe Lys Ile Thr Arg Gly Ile Glu Ala Val Gly Gly Lys Leu Ser 100 105 110

Val Thr Ala Thr Arg Glu Asn Met Ala Tyr Thr Val Glu Cys Leu Arg 115 120 125

Gly Asp Val Asp Ile Leu Met Glu Phe Leu Leu Asn Val Thr Thr Ala 130 135 140

Pro Glu Phe Arg Arg Trp Glu Val Ala Asp Leu Gln Pro Gln Leu Lys 145 150 155 160

Ile Asp Lys Ala Val Ala Phe Gln Asn 165

<210> 1126

<211> 56

<212> PRT

<213> Homo sapiens

<400> 1126

Pro Pro Val Val His Lys Asn Pro Ile His Ile Lys Thr Pro Ser Pro 1 5 10 15

Cys Leu Gln Ala Ser Thr Ala Ile Asn Pro Gln Leu Ser His Ile Asn 20 25 30 Cys Asn Ser Lys Ala Thr Pro His Pro Leu Gly Tyr Gln Gln Thr Tyr
35 40 45

Pro Pro Leu Thr Val His Ser Thr 50 55

<210> 1127

<211> 195

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (39)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 1127

Arg Glu Gln Lys Leu Glu Leu His Arg Gly Ala Ala Ala Leu Glu Leu 1 5 10 15

Val Asp Pro Pro Gly Cys Arg Asn Ser Ala Arg Ala Gly Gly Cys Val 20 25 30

Leu Gly Lys Ala Gly Gly Xaa Gly Gly Arg Leu Phe Tyr Gly Ser Arg 35 40 45

Asp Arg Pro Val Leu Leu Pro Phe Pro Pro Ser Leu Pro Pro Leu Ser 50 55 60

Arg Arg Gly Ala Ala Ala Leu Asp Phe Ala Val Phe Pro Arg Gly 65 70 75 80

Asp Arg Phe Gln His Tyr Thr Cys Thr Met Ser Leu Lys Pro Arg Val 85 90 95

Val Asp Phe Asp Glu Thr Trp Asn Lys Leu Leu Thr Thr Ile Lys Ala 100 105 110

Val Val Met Leu Glu Tyr Val Glu Arg Ala Thr Trp Asn Asp Arg Phe 115 120 125

Ser Asp Ile Tyr Ala Leu Cys Val Ala Tyr Pro Glu Pro Leu Gly Glu 130 135 140

Arg Leu Tyr Thr Glu Thr Lys Ile Phe Leu Glu Asn His Val Arg His 145 150 155 160

Leu His Lys Arg Val Leu Glu Ser Glu Glu Gln Val Leu Val Met Tyr 165 170 175 His Arg Tyr Trp Glu Glu Tyr Ser Lys Gly Ala Asp Tyr Met Asp Cys 180 185 190

Leu Tyr Arg 195

<210> 1128

<211> 130

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (116)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (122)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 1128

Ser Ile Ile Asp Arg Phe Met Gln Asn Asn Cys Val Pro Lys Lys Met
1 5 10 15

Leu Gln Leu Val Gly Val Thr Ala Met Phe Ile Ala Ser Lys Tyr Glu 20 25 30

Glu Met Tyr Pro Pro Glu Ile Gly Asp Phe Ala Phe Val Thr Asp Asn 35 40 45

Thr Tyr Thr Lys His Gln Ile Arg Gln Met Glu Met Lys Ile Leu Arg
50 55 60

Ala Leu Asn Phe Gly Leu Gly Arg Pro Leu Pro Leu His Phe Leu Arg 65 70 75 80

Arg Ala Ser Lys Ile Gly Glu Val Asp Val Glu Gln His Thr Leu Ala 85 90 95

Lys Tyr Leu Met Glu Leu Thr Met Leu Asp Tyr Asp Met Val His Phe 100 105 110

Pro Pro Ser Xaa Ile Ala Ala Gly Ala Xaa Cys Leu Ala Leu Lys Ile 115 120 125

Leu Gly

```
<210> 1129
<211> 125
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (90)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1129
Gly Asp Glu Glu Ala Cys Pro Glu Asp Lys Gly Pro Gln Asp Pro Gln
Ala Leu Ala Leu Asp Thr Gln Ile Pro Ala Thr Pro Gly Pro Lys Pro
                                 25
Leu Val Arg Thr Ser Arg Glu Pro Gly Lys Asp Val Thr Thr Ser Gly
                             40
Tyr Ser Ser Val Ser Thr Ala Ser Pro Thr Ser Ser Val Asp Gly Gly
                         55
                                             60
Leu Gly Ala Leu Pro Gln Pro Thr Ser Val Leu Ser Leu Asp Ser Asp
                     70
                                         75
Ser His Thr Gln Pro Cys His His Gln Xaa Arg Lys Ser Cys Leu Gln
                                     90
Cys Arg Pro Pro Ser Pro Pro Glu Ser Ser Val Pro Gln Gln Val
            100
                                105
Lys Arg Ile Asn Tyr Ala Tyr Thr Val Lys Arg Arg Thr
                                                125
        115
                            120
<210> 1130
<211> 118
```

<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (1)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 1130

Val Ala Ala Lys Met Met Cys Gly Ala Pro Ser Ala Thr Gln Pro Ala 20 25 30

Thr Ala Glu Thr Gln His Ile Ala Asp Gln Val Arg Ser Gln Leu Glu 35 40 45

Glu Lys Glu Asn Lys Lys Phe Pro Val Phe Lys Ala Val Ser Phe Lys
50 55 60

Ser Gln Val Val Ala Gly Thr Asn Tyr Phe Ile Lys Val His Val Gly
65 70 75 80

Asp Glu Asp Phe Val His Leu Arg Val Phe Gln Ser Leu Pro His Glu 85 . 90 95

Asn Lys Pro Leu Thr Leu Ser Asn Tyr Gln Thr Asn Lys Ala Lys His 100 105 110

Asp Glu Leu Thr Tyr Phe 115

<210> 1131

<211> 64

<212> PRT

<213> Homo sapiens

<400> 1131

Ala Val Pro Thr Leu Gly Leu Lys Thr Asp Ala Ile Pro Gly Arg Leu 1 5 10 15

Asn Gln Thr Thr Phe Thr Ala Thr Arg Pro Gly Val Tyr Tyr Gly Gln 20 25 30

Cys Ser Glu Ile Cys Gly Ala Asn His Ser Phe Met Pro Ile Val Leu 35 40 45

Glu Leu Ile Pro Leu Lys Ile Phe Glu Ile Gly Pro Val Phe Thr Leu
50 55 60

<210> 1132

<211> 35

```
<212> PRT
<213> Homo sapiens
<400> 1132
Ala Arg Ala His Lys Glu Ile Tyr Pro Tyr Val Ile Gln Glu Leu Arg
                   5
Pro Thr Leu Asn Glu Leu Gly Ile Ser Thr Pro Glu Glu Leu Gly Leu
                                  25
Asp Lys Val
         35
<210> 1133
<211> 69
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (9)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (26)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (61)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (66)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1133
Pro Tyr Thr Asn Asp Gly Ala Met Xaa His Glu Glu Ser Thr Tyr Gln
                  5
                                     10
Gly His His Thr Pro Pro Val Gln Lys Xaa Leu Arg Tyr Gly Ile Ile
             20
Leu Phe Ile Thr Ser Glu Val Phe Phe Phe Ala Gly Phe Ser Glu Leu
         35
                             40
```

Leu His Ser Ser Leu Ala Leu Pro Pro Thr Lys Lys Xaa Leu Ala Pro

50

55

60

Thr Xaa Ile Thr Arg 65

<210> 1134

<211> 64

<212> PRT

<213> Homo sapiens

<400> 1134

Ala Val Pro Thr Leu Gly Leu Lys Thr Asp Ala Ile Pro Gly Arg Leu 1 5 10 15

Asn Gln Thr Thr Phe Thr Ala Thr Arg Pro Gly Val Tyr Tyr Gly Gln 20 25 30

Cys Ser Glu Ile Cys Gly Ala Asn His Ser Phe Met Pro Ile Val Leu 35 40 45

Glu Leu Ile Pro Leu Lys Ile Phe Glu Ile Gly Pro Val Phe Thr Leu
50 55 60

<210> 1135

<211> 56

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (3)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 1135

Thr Tyr Xaa Val His Arg Leu Arg Arg Thr Asn Leu Gln Leu Leu His
1 5 10 15

Thr Ser Pro Leu Phe Leu Glu Pro Gly Asp Leu Arg Leu Leu Asp Val 20 25 30

Asp Asn Arg Val Val Leu Pro Ile Glu Ala Pro Ile Arg Ile Ile Ile 35 40 45

Thr Ser Gln Asp Val Leu His Ser

50 55

<210> 1136

<211> 60

<212> PRT

<213> Homo sapiens

<400> 1136

Ala Gln Val Gly Leu Gln Asp Ala Thr Ser Pro Ile Ile Glu Glu Leu

Ile Thr Phe His Asp His Ala Leu Ile Ile Ile Phe Leu Ile Cys Phe 25 30

Leu Val Leu Tyr Ala Leu Phe Leu Thr Leu Thr Thr Lys Leu Thr Asn 40

Thr Asn Ile Ser Asp Ala Gln Glu Ile Glu Thr Val 50 55

<210> 1137

<211> 49

<212> PRT

<213> Homo sapiens

<400> 1137

Thr Tyr Glu Tyr Thr Asp Tyr Gly Gly Leu Ile Phe Asn Ser Tyr Ile 10

Leu Pro Pro Leu Phe Leu Glu Pro Gly Asp Leu Arg Leu Leu Asp Val 20 25

Asp Asn Arg Val Val Leu Pro Ile Glu Ala Pro Ile Arg Ile Ile Ile 40

Asn

<210> 1138

<211> 80

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

```
<222> (74)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (79)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (80)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1138
Ala Val Pro Thr Leu Gly Leu Lys Thr Asp Ala Ile Pro Gly Arg Leu
                                     10
Asn Gln Thr Thr Phe Thr Ala Thr Arg Pro Gly Val Tyr Tyr Gly Gln
                                 25
Cys Ser Glu Ile Cys Gly Ala Asn His Ser Phe Met Pro Ile Val Leu
Glu Leu Ile Pro Leu Lys Ile Phe Gly Asn Arg Ala Arg Ile Tyr Pro
     50
Ile Ala Pro Pro Leu Pro Pro Leu Glu Xaa Lys Lys Lys Xaa Xaa
65
                     70
                                         75
```

```
<210> 1139
<211> 75
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (17)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (51)
<223> Xaa equals any of the naturally occurring L-amino acids
```

<222> (70)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 1139

Phe Glu Ala Asn Asp Pro Ser Leu Thr Ile Lys Ser Ile Gly His Gln 1 5 10 15

Xaa Tyr Arg Thr Tyr Glu Tyr Thr Asp Tyr Gly Gly Leu Ile Phe Asn
20 25 30

Ser Tyr Ile Leu Pro Pro Leu Phe Leu Glu Pro Gly Asp Leu Arg Leu
35 40 45

Leu Asp Xaa Asp Asn Arg Val Val Leu Pro Ile Glu Thr Pro Ile Arg 50 55 60

Ile Ile Ile Thr Tyr Xaa Asp Val Leu His Ser 65 70 75

<210> 1140

<211> 200

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (2)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 1140

His Xaa Pro Ser Leu Lys Gly Thr Lys Ala Gly Ala Pro Pro Arg Cys
1 5 10 15

Gly Arg Ser Arg Thr Ser Gly Ser Pro Gly Leu Gln Glu Phe Gly Thr
20 25 30

Arg Glu Trp Arg Leu Pro Ser Leu Arg Arg Ala Thr Leu Trp Ile Pro
35 40 45

Gln Trp Phe Ala Lys Lys Ala Ile Phe Asn Ser Pro Leu Glu Ala Ala 50 55 60

Met Ala Phe Pro His Leu Gln Gln Pro Ser Phe Leu Leu Ala Ser Leu 65 70 75 80

Lys Ala Asp Ser Ile Asn Lys Pro Phe Ala Gln Gln Cys Gln Asp Leu 85 90 95

Val Lys Val Ile Glu Asp Phe Pro Ala Lys Ser Glu Pro Ile Arg Val

100 105 110 Leu Val Thr Gly Ala Ala Gly Gln Ile Ala Tyr Ser Leu Leu Tyr Ser 120 Ile Gly Asn Gly Ser Val Phe Gly Lys Asp Gln Met Ser Ser Gln Gln 135 Ile Lys Lys Thr Leu Pro Ser Lys Thr Trp Asp Val Ala Ile Leu Val 145 150 155 Gly Ser Met Pro Arg Arg Glu Gly Met Glu Arg Lys Asp Leu Leu Lys 170 Ala Asn Val Lys Ile Phe Lys Ser Gln Gly Ala Ala Leu Asp Lys Tyr 180 185 Gly Lys Lys Ser Val Lys Gly Tyr 195 200 <210> 1141 <211> 182 <212> PRT <213> Homo sapiens <220> <221> SITE <222> (123) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (126) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (128) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (137) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (143) <223> Xaa equals any of the naturally occurring L-amino acids

```
<220>
<221> SITE
<222> (157)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (163)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (165)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (176)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1141
His Glu Glu His Ser Ile Tyr Cys Thr Val Asn Asn Asp Glu Gly Glu
                  5
Trp Ser Gly Pro Pro Pro Glu Cys Arg Gly Lys Ser Leu Thr Ser Lys
             20
Val Pro Pro Thr Val Gln Lys Pro Thr Thr Val Asn Val Pro Thr Thr
         35
                             40
Glu Val Ser Pro Thr Ser Gln Lys Thr Thr Thr Lys Thr Thr Pro
                         55
Asn Ala Gln Gly Thr Glu Thr Pro Ser Val Leu Gln Lys His Thr Thr
 65
                     70
                                         75
Glu Asn Val Ser Ala Thr Arg Thr Pro Pro Thr Pro Gln Lys Pro Thr
                 85
Thr Val Asn Val Pro Ala Thr Ile Val Thr Pro Thr Pro Gln Lys Pro
                                105
Thr Thr Leu Met Phe Gln Leu Gln Glu Ser Xaa Gln His Xaa Lys Xaa
                            120
His Leu Val Met Phe Gln Leu Gln Xaa Leu Pro Leu Phe Gly Xaa His
   130
                        135
Arg Gly Asn Val Arg His His Ser Arg Ala Phe Gly Xaa Ser Phe Lys
145
                    150
                                        155
                                                             160
```

Thr Phe Xaa Lys Xaa Phe Cys Val Arg Ser Cys Gly Met Phe Cys Xaa 165 170 175

Arg Pro Leu Arg Pro Gly 180

<210> 1142

<211> 143

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (4)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (141)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 1142

Asp Gly Ala Xaa Pro Gly Arg Ala Tyr Ala Leu Leu Leu Leu Leu Ile 1 5 10 15

Cys Phe Asn Val Gly Ser Gly Leu His Leu Gln Val Leu Ser Thr Arg
20 25 30

Asn Glu Asn Lys Leu Leu Pro Lys His Pro His Leu Val Arg Gln Lys 35 40 45

Arg Ala Trp Ile Thr Ala Pro Val Ala Leu Arg Glu Gly Glu Asp Leu 50 55 60

Ser Lys Lys Asn Pro Ile Ala Lys Ile His Ser Asp Leu Ala Glu Glu 65 70 75 80

Arg Gly Leu Lys Ile Thr Tyr Lys Tyr Thr Gly Lys Gly Ile Thr Glu 85 · 90 95

Pro Pro Phe Gly Ile Phe Val Phe Asn Lys Asp Thr Gly Glu Leu Asn 100 105 110

Val Thr Ser Ile Leu Asp Arg Glu Glu Thr Pro Phe Phe Leu Leu Thr 115 120 125

Gly Leu Arg Phe Gly Cys Lys Arg Glu Gln Cys Arg Xaa Thr Leu
130 135 140

```
<210> 1143
<211> 111
<212> PRT
<213> Homo sapiens
<400> 1143
Ala Gln Ser Pro Ser Arg Ser Thr Gly Gln Asp Val Ala Ala Glu Trp
Gly Ser Glu Glu Ser Val Ala Gly Ser Leu Glu Ala Glu Phe Glu Lys
                                 25
Ala Ala Glu Glu Val Arg His Leu Lys Thr Lys Pro Ser Asp Glu Glu
         35
                             40
```

Met Leu Phe Ile Tyr Gly His Tyr Lys Gln Ala Thr Val Gly Asp Ile

45

55

Asn Thr Glu Arg Pro Gly Met Leu Asp Phe Thr Gly Lys Ala Lys Trp 70

Asp Ala Trp Asn Glu Leu Lys Gly Thr Ser Lys Glu Asp Ala Met Lys

Ala Tyr Ile Asn Lys Val Glu Glu Leu Lys Lys Lys Tyr Gly Ile 105 100 110

```
<210> 1144
<211> 74
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (9)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (20)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (23)
```

<223> Xaa equals any of the naturally occurring L-amino acids

```
<220>
<221> SITE
<222> (30)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (36)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (38)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (57)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (64)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (68)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (72)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1144
Ala Cys Ala Tyr Thr Pro Pro Ser Kaa Lys Ala Val Gln Arg Ile Ala
                                     10
Glu Ser His Xaa Gln Ser Xaa Ser Asn Leu Asn Glu Asn Xaa Ala Ser
            20
                                 25
Glu Glu Kaa Glu Kaa Gly Glu Leu Arg Glu Leu Gly Tyr Pro Arg
                             40
Glu Glu Asp Glu Glu Glu Glu Kaa Asp Glu Glu Glu Asp Xaa
     50
                                             60
Glu Asp Ser Xaa Ala Glu Asp Xaa Ser Gly
                    70
65
```

```
<210> 1145
<211> 153
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (2)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (18)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (30)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (35)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222>(47)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (59)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (70)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (110)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (132)
```

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (143)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 1145

Asn Xaa Pro Asn Ala Glu Leu Gly Gly Pro Phe Asn Gln Met Asn Gly
1 5 10 15

Val Xaa Gly Asn Gly Met Asn Asn Ile Asp Met Thr Gly Xaa Lys Lys
20 25 30

Ser Leu Xaa Leu Pro Tyr Pro Ser Ser Phe Ala Pro Val Ser Xaa Pro 35 40 45

Arg Asn Gln Thr Phe Thr Tyr Met Gly Lys Xaa Ser Ile Asp Pro Gln 50 55 60

Tyr Pro Gly Ala Ser Xaa Tyr Pro Glu Gly Ile Ile Asn Ile Val Ser
65 70 75 80

Ala Gly Ile Leu Gln Gly Val Thr Ser Pro Ala Ser Thr Thr Ala Ser

85
90
95

Ser Ser Val Thr Ser Ala Ser Pro Asn Pro Leu Ala Thr Xaa Pro Leu 100 105 110

Gly Val Cys Thr Met Ser Gln Thr Gln Pro Asp Leu Asp His Leu Tyr 115 120 125

Ser Pro Pro Xaa Pro Pro Pro Pro Tyr Ser Gly Cys Ala Gly Xaa Leu 130 135 140

Tyr Gln Asp Pro Ser Ala Phe Leu Leu 145 150

<210> 1146

<211> 32

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (1)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

```
<221> SITE
<222> (7)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1146
Xaa Phe Gln Ile Asp Pro Xaa Leu Gly Thr Val Gly Phe Gly Ser Gly
1 5 10 15
Leu His Gly Trp Ala Phe Thr Leu Lys Ala Val Cys Arg Glu Cys Met
20 25 30
```

```
<210> 1147
<211> 62
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (2)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (6)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (7)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (8)
<223> Xaa equals any of the naturally occurring L-amino acids
Ala Xaa His Gln Arg Xaa Xaa Ile Lys Arg Leu Ser Thr Glu His
Ser Ser Val Ser Glu Tyr His Pro Ala Asp Gly Tyr Ala Phe Ser Ser
                                 25
```

Asn Ile Tyr Thr Arg Gly Ser His Leu Asp Gln Gly Glu Ala Ala Val

45

40

```
Ala Phe Lys Pro Thr Ser Asn Arg His Ile Arg Leu Lys Leu
     50
                         55
<210> 1148
<211> 60
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (7)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (54)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1148
Gly Arg Ala Leu Arg Ala Xaa Arg Leu Thr Gln Leu Thr Glu Ile Leu
                                     10
Ser Gly Gly Val Tyr Ile Glu Lys Asn Asp Lys Leu Cys His Met Asp
                                 25
Thr Ile Asp Trp Arg Asp Ile Val Arg Asp Arg Asp Ala Glu Ile Val
         35
                             40
                                                  45
Val Lys Asp Asn Gly Xaa Lys Leu Ser Pro Leu Ser
                         55
<210> 1149
<211> 49
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (23)
<223> Xaa equals any of the naturally occurring L-amino acids
```

Leu Ser Thr Ser Asp Arg Xaa Gly Pro Ile Phe Lys Ser Pro Gln Thr
20 25 30

Phe Gln Thr Arg Asn Leu Gln Val Thr Leu Glu Asp Gly Tyr Ile Glu

```
Tyr Met Asp Gly Leu Leu His Tyr Val Ser Val Ile Ser Asp Asn Ser 35 40 45
```

Gly

```
<210> 1150
<211> 55
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (5)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (6)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (21)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (37)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1150
Pro Ala Ala Arg Xaa Xaa Val Pro Arg Ala Met Glu Arg Ala Ser Leu
Ile Gln Lys Ala Xaa Leu Ala Glu Gln Ala Glu Arg Tyr Glu Asp Met
```

Ala Ala Phe Met Xaa Gly Ala Val Glu Lys Gly Glu Glu Ser Pro Ala

40

45

Lys Ser Glu Thr Cys Ser Gln 50 55

35

<210> 1151 <211> 162

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (3)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (14)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 1151

Val Ser Xaa Gly Thr Gly Asn Ser Arg Val Arg Thr His Xaa Val Pro 1 5 10 15

Pro Arg Pro Leu Pro Cys Ser Glu Gly Gly Glu Arg Leu Leu Pro Thr 20 25 30

Gln Lys Gln Pro Gly Gly Gln Val Asn Ser Ser Arg Tyr Lys Thr
35 40 45

Glu Leu Cys Arg Pro Phe Glu Glu Asn Gly Ala Cys Lys Tyr Gly Asp 50 55 60

Lys Cys Gln Phe Ala His Gly Ile His Glu Leu Arg Ser Leu Thr Arg 65 70 75 80

His Pro Lys Tyr Lys Thr Glu Leu Cys Arg Thr Phe His Thr Ile Gly 85 90 95

Phe Cys Pro Tyr Gly Pro Arg Cys His Phe Ile His Asn Ala Glu Glu 100 105 110

Arg Arg Ala Leu Ala Gly Ala Arg Asp Leu Ser Ala Asp Arg Pro Arg 115 120 125

Leu Gln His Ser Phe Ser Leu Leu Gly Phe Pro Val Pro Leu Pro Pro 130 135 140

Pro Leu Pro Pro Gly Cys Trp Thr Ala His Val His Gln Pro Asn Pro 145 150 155 160

Tyr Phe

<210> 1152

<211> 124

```
<212> PRT
 <213> Homo sapiens
 <220>
 <221> SITE
 <222> (15)
 <223> Xaa equals any of the naturally occurring L-amino acids
 <220>
 <221> SITE
 <222> (41)
 <223> Xaa equals any of the naturally occurring L-amino acids
 <220>
 <221> SITE
 <222> (114)
 <223> Xaa equals any of the naturally occurring L-amino acids
- <400> 1152
 His Glu Gly Ala Ser Arg Cys Gly His Leu Cys Arg Gly Arg Xaa Ala
 Ala Ser Tyr Pro Ala Leu Arg Ala Ser Leu Leu Pro Gln Ser Leu Ala
              20
                                 25
 Ala Ala Ala Ala Phe Pro Thr Arg Xaa Asn Ser Gln Glu Ser Lys Thr
          35
                              40
 Thr Tyr Leu Glu Asp Leu Pro Pro Pro Pro Glu Tyr Glu Leu Ala Pro
 Ser Lys Leu Glu Glu Val Asp Asp Val Phe Leu Ile Arg Ala Gln
                      70
                                          75
 Gly Leu Pro Trp Val Met Ala Leu Trp Glu Asp Val Ala Leu Thr Phe
                  85
                                      90
 Phe Phe Gln Thr Cys Arg Ile Arg Gln Arg Leu Ser Asn Gly Asn Tyr
             100
                                 105
 Ile Xaa Leu Pro Lys Asn Lys Arg Trp Gly Lys Thr
         115
                             120
```

<210> 1153 <211> 151 <212> PRT <213> Homo sapiens

<220>

```
<221> SITE
<222> (105)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (140)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (147)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (149)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1153
Ala Met Val Arg Leu Val Lys Cys Asp Val Tyr Pro Cys Pro Asn Thr
                  5
Val Asp Cys Phe Val Ser Arg Pro Thr Glu Lys Thr Val Phe Thr Val
                                 25
Phe Met Leu Ala Ala Ser Gly Ile Cys Ile Ile Leu Asn Val Ala Glu
                             40
Val Val Tyr Leu Ile Ile Arg Ala Cys Ala Arg Arg Ala Gln Arg Arg
     50
                         55
Ser Asn Pro Pro Ser Arg Lys Gly Ser Gly Phe Gly His Arg Leu Ser
65
                     70
Pro Glu Tyr Lys Gln Asn Glu Ile Asn Lys Leu Leu Ser Glu Gln Asp
                 85
                                     90
Gly Ser Leu Lys Asp Ile Leu Arg Xaa Thr Leu Ala Arg Gly Leu Gly
                                105
Trp Leu Lys Lys Thr Thr Val Leu Gly Cys Asp Ala Thr Tyr Gln Ala
        115
                            120
Thr Ser His Pro Thr Pro Thr Leu Pro Gly Arg Xaa Pro Pro Ser Pro
                      135
Cys Arg Xaa Pro Xaa Ala His
145
                   150
```

```
<210> 1154
<211> 113
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (26)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (37)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (103)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (111)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1154
Gly Ser Pro Trp Pro Asn Ser Cys Arg Pro Glu Ala Arg Arg Asp Arg
                  5 .
                                      10
                                                          15
Leu Gln Pro Leu Gly Gly Val Cys Glu Xaa Ala Ser Glu His Asp Val
             20
                                 25
Val Asn Leu Gly Xaa Gly Phe Pro Asp Phe Pro Pro Pro Asp Phe Ala
Val Glu Ala Phe Gln His Ala Val Ser Gly Asp Phe Met Leu Asn Gln
                         55
Tyr Thr Lys Thr Phe Gly Tyr Pro Pro Leu Asp Glu Asp Pro Gly Asn
65
                     70
Phe Phe Gly Gly Ala Ala Gly Ser Arg Ile Arg Pro Val Gln Gly Cys
Ala Gly Asp Cys Trp Trp Xaa Trp Gly Pro Val Ser Lys Ala Xaa Pro
            100
                                105
```

Gly

<210> 1155 <211> 104 <212> PRT <213> Homo sapiens <220> <221> SITE <222> (78) <223> Xaa equals any of the naturally occurring L-amino acids · <220> <221> SITE <222> (91) <223> Xaa equals any of the naturally occurring L-amino acids <400> 1155 Gly Thr Thr Val Arg Asp Tyr Thr Gln Met Asn Glu Leu Gln Arg Arg Leu Gly Pro Arg Gly Leu Val Val Leu Gly Phe Pro Cys Asn Gln Phe 25 Gly His Gln Glu Asn Ala Lys Asn Glu Glu Ile Leu Asn Ser Leu Lys Tyr Val Arg Pro Gly Gly Gly Phe Glu Pro Asn Phe Met Leu Phe Glu 60 50 55 Lys Cys Glu Val Asn Gly Ala Gly Ala His Pro Leu Phe Xaa Phe Leu 70 75 65 Arg Glu Ala Leu Pro Ala Pro Ser Asp Asp Xaa Thr Ala Leu Met Thr 85 90 Asp Pro Lys Leu Ile Thr Trp Ser

100

<210> 1156

<211> 38

<212> PRT

<213> Homo sapiens

<400> 1156

Ala Phe Ile Ala Lys Ser Phe Tyr Asp Leu Ser Ala Ile Ser Leu Asp 1 5 10 15

Gly Glu Lys Val Asp Phe Asn Thr Ser Arg Gly Arg Ala Val Leu Ile

20 25 30

Glu Asn Val Ala Ser Leu 35

<210> 1157

<211> 63

<212> PRT

<213> Homo sapiens

<400> 1157

Asp Thr Thr Arg Asp Phe Thr Gln Leu Asn Glu Leu Gln Cys Arg

1 5 10 15

Phe Pro Arg Arg Leu Val Val Leu Gly Phe Pro Cys Asn Gln Phe Gly 20 25 30

His Gln Ser Arg Arg Asp Arg Ser Ser Lys Pro Ser Phe Glu Met Ser 35 40 45

Leu Gln Pro Gln Lys Tyr Leu Gln Pro His Thr Ile Ser Ser Ala
50 55 60

<210> 1158

<211> 67

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (50)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 1158

Thr Leu Lys Phe Phe Pro Ala Ser Ala Asp Arg Thr Val Ile Asp Tyr 1 5 10 15

Asn Gly Glu Arg Thr Leu Asp Gly Phe Lys Lys Phe Leu Glu Ser Gly 20 25 30

Gly Gln Asp Gly Ala Gly Asp Asp Asp Leu Glu Asp Leu Glu Glu 35 40 45

Ala Xaa Glu Pro Asp Met Glu Glu Asp Asp Asp Gln Lys Ala Val Lys
50 55 60

Asp Glu Leu

```
<210> 1159
<211> 214
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (202)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (207)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1159
Ala Val Ile Met Gly Ala Pro Gly Ser Gly Lys Gly Thr Val Ser Ser
                  5
                                     10
                                                          15
Arg Ile Thr Thr His Phe Glu Leu Lys His Leu Ser Ser Gly Asp Leu
                                 25
Leu Arg Asp Asn Met Leu Arg Gly Thr Glu Ile Gly Val Leu Ala Lys
Ala Phe Ile Asp Gln Gly Lys Leu Ile Pro Asp Asp Val Met Thr Arg
                        55
                                           60
Leu Ala Leu His Glu Leu Lys Asn Leu Thr Gln Tyr Ser Trp Leu Leu
 65
                                         75
                     70
Asp Gly Phe Pro Arg Thr Leu Pro Gln Ala Glu Ala Leu Asp Arg Ala
               85
                                     90
Tyr Gln Ile Asp Thr Val Ile Asn Leu Asn Val Pro Phe Glu Val Ile
                                105
Lys Gln Arg Leu Thr Ala Arg Trp Ile His Pro Ala Ser Gly Arg Val
       115
                            120
                                                125
Tyr Asn Ile Glu Phe Asn Pro Pro Lys Thr Val Gly Ile Asp Asp Leu
    130
                                            140
                       135
Thr Gly Glu Pro Leu Ile Gln Arg Glu Asp Asp Lys Pro Glu Thr Val
                                        155
145
                   150
Ile Lys Arg Leu Lys Ala Tyr Glu Asp Gln Thr Lys Pro Val Leu Glu
```

165 170 175

Tyr Tyr Gln Lys Lys Gly Val Leu Glu Thr Phe Ser Gly Thr Glu Thr 180 . 185 . 190

Asn Lys Ile Trp Pro Tyr Val Tyr Ala Xaa Leu Gln Leu Lys Xaa His 195 200 205

Lys Glu Ala Arg Lys Leu 210

<210> 1160

<211> 33

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (2)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (4)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 1160

Leu Xaa Ser Xaa Lys Trp Ile Tyr Asn Gly Phe Ser Ser Val Leu Gln
1 5 10 15

Phe Leu Gly Leu Tyr Lys Lys Ser Gly Lys Leu Val Phe Phe Arg Leu 20 25 30

Gly

<210> 1161

<211> 123

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (17)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

```
<221> SITE
<222> (28)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (30)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (66)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (88)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (96)
<223> Xaa equals any of the naturally occurring L-amino acids
Gly Asn Ser Lys Thr Glu Asp Gln Arg Asn Glu Glu Lys Ala His Val
Xaa Ala Asn Lys Lys Ile Glu Lys Gln Leu Gln Xaa Asp Xaa Gln Val
                                 25
             20
Tyr Arg Ala Thr His Arg Leu Leu Leu Gly Ala Gly Glu Ser Gly
                             40
Lys Ser Thr Ile Val Lys Gln Met Arg Ile Leu His Val Asn Gly Phe
     50
                         55
Asn Xaa Asp Ser Glu Lys Ala Thr Lys Val Gln Asp Ile Lys Asn Asn
                                         75
                     70
Leu Lys Glu Ala Ile Glu Thr Xaa Val Ala Ala Met Ser Asn Leu Xaa
                                     90
Ala Pro Arg Gly Ala Gly Gln Pro Arg Glu Thr Ser Ser Glu Trp Thr
                                105
            100
Thr Ser Trp Ser Val Met Asn Val Pro Gly Phe
```

120

```
<210> 1162
<211> 87
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (60)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (61)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (70)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (80)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1162
Pro Thr Arg Pro Pro Thr Arg Pro Glu Leu Lys Asp Leu Gln Glu Pro
Gln Glu Pro Arg Val Gly Lys Leu Arg Asn Phe Ala Pro Ile Pro Gly
                                 25
Glu Pro Val Val Pro Ile Leu Cys Ser Asn Pro Asn Phe Pro Glu Glu
         35
                             40
Leu Lys Pro Leu Cys Lys Ser Pro Met Pro Arg Xaa Xaa Phe Arg Gly
                         55
Trp Arg Lys Ser Leu Xaa Asp Pro Gly His Met Trp Lys Ser Val Xaa
                                         75
Thr Leu Ala Cys Thr Gly Cys
                 85
```

<210> 1163 <211> 100 <212> PRT <213> Homo sapiens

```
<220>
<221> SITE
<222> (67)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (68)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1163
Val Gln Gly Pro Tyr Val Leu Gly Thr Gly Leu Ile Leu Tyr Ala Leu
                  5
                                      10
Ser Lys Glu Ile Tyr Val Ile Ser Ala Glu Thr Phe Thr Ala Leu Ser
             20
                                  25
Val Leu Gly Val Met Val Tyr Gly Ile Lys Lys Tyr Gly Pro Phe Val
Ala Asp Phe Ala Asp Lys Leu Asn Glu Gln Lys Leu Ala Gln Leu Glu
     50
                         55
                                              60
Glu Ala Xaa Xaa Ala Ser Ile Gln His Ile Gln Asn Ala Ile Asp Thr
 65
                     70
                                          75
Glu Lys Ser Gln Gln Ala Leu Val Gln Lys Arg His Tyr Leu Phe Gly
                                     90
                 85
Cys Ala Lys Glu
            100
<210> 1164
<211> 186
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (171)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (180)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1164
Trp Ile Pro Arg Ala Ala Gly Ile Arg His Glu Val Leu Cys Gly His
```

15 . 1 5 . 10 Leu Ala Lys Met Pro Glu Glu Thr Gln Thr Gln Asp Gln Pro Met Glu 20 Glu Glu Val Glu Thr Phe Ala Phe Gln Ala Glu Ile Ala Gln Leu Met Ser Leu Ile Ile Asn Thr Phe Tyr Ser Asn Lys Glu Ile Phe Leu 55 Arg Glu Leu Ile Ser Asn Ser Ser Asp Ala Leu Asp Lys Ile Arg Tyr 65 70 75 Glu Ser Leu Thr Asp Pro Ser Lys Leu Asp Ser Gly Lys Glu Leu His 85 Ile Asn Leu Ile Pro Asn Lys Gln Asp Arg Thr Leu Thr Ile Val Asp 105 Thr Gly Ile Gly Met Thr Lys Ala Asp Leu Ile Asn Asn Leu Gly Thr 120 Ile Ala Lys Ser Gly Thr Lys Ala Phe Met Glu Ala Leu Gln Ala Gly 130 135 Ala Asp Ile Ser Met Ile Gly Gln Phe Gly Val Gly Phe Tyr Ser Ala 150 Tyr Leu Val Ala Glu Lys Val Thr Val Ile Xaa Lys His Asn Asp Asp 170 Glu Gln Tyr Xaa Trp Glu Ser Ser Ala Gly 180 185 <210> 1165 <211> 199 <212> PRT <213> Homo sapiens <220> <221> SITE

<220>

<221> SITE

<222> (2)

<222> (54)

<223> Xaa equals any of the naturally occurring L-amino acids

<223> Xaa equals any of the naturally occurring L-amino acids

<220> <221> SITE <222> (173) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (191) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (196) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (197) <223> Xaa equals any of the naturally occurring L-amino acids <400> 1165 Ala Xaa Ile Cys Leu Leu Glu Thr Ala Pro Ser Ser Arg Glu Ser Gln Lys Glu Asp Met Ala Ala Gly Gln Arg Glu Ala Arg Pro Gln Val Ser 20 25 30 Leu Thr Phe Glu Asp Val Ala Val Leu Phe Thr Trp Asp Glu Trp Arg 45 35 40 Lys Leu Ala Pro Ser Xaa Arg Asn Leu Tyr Arg Asp Val Met Leu Glu 55 Asn Tyr Arg Asn Leu Val Ser Leu Gly Leu Ser Phe Thr Lys Pro Lys 70 Val Ile Ser Leu Leu Gln Gln Gly Glu Asp Pro Trp Glu Val Glu Lys 90 95 85 Asp Ser Ser Gly Val Ser Ser Leu Gly Cys Lys Ser Thr Pro Lys Met 100 105 Thr Lys Ser Thr Gln Thr Gln Asp Ser Phe Gln Glu Gln Ile Arg Lys 115 120 Arg Leu Lys Arg Asp Glu Pro Trp Asn Phe Ile Ser Glu Arg Ser Cys 135

Ile Tyr Glu Glu Lys Leu Lys Lys Gln Gln Asp Lys Asn Glu Asn Leu

155

150

145

Gln Ile Ile Ser Val Ala His Thr Lys Ile Leu Thr Xaa Asp Arg Ser 165 170 175

His Lys Asn Val Glu Phe Ala Gln Asn Phe Tyr Leu Lys Ser Xaa Phe 180 185 190

Ile Lys His Xaa Xaa Ile Ala 195

<210> 1166

<211> 91

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (86)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 1166

Trp Cys Cys Ser His Leu Trp Phe Gln Gly Arg Ala Thr Pro Glu Asn 1 5 10 15

Tyr Leu Phe Gln Gly Arg Gln Glu Cys Tyr Ala Phe Asn Gly Asn Ser 20 25 30

Gln Lys Asp Ile Leu Glu Glu Lys Ala Gly Ser Ala Gly Thr Gly Cys

Ala Asp Thr Thr Tyr Gly Ala Gly Arg Ala His Gly Pro Cys Ser Ala
50 55 60

Glu Phe Gln Pro Arg Val Glu Cys Phe Pro Pro Pro Ser Arg Gly Pro 65 70 75 80

Leu Ala Ala Thr Gln Xaa Ala Cys Leu Ala Lys 85 90

<210> 1167

<211> 118

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (82)

```
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (94)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (111)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (113)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (114)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (117)
<223> Xaa equals any of the naturally occurring L-amino acids
Asn Val Pro Ala Tyr Lys Ser Ser Gly Gln Ile Met Ser Ser Leu Tyr
                  5
Tyr Ala Asn Ala Leu Phe Ser Lys Tyr Pro Ala Ser Ser Ser Val Phe
                                 25
             20
Ala Thr Gly Ala Phe Pro Glu Gln Thr Ser Cys Ala Phe Ala Ser Asn
                             40
Pro Gln Arg Pro Gly Tyr Gly Ala Gly Ser Gly Ala Ser Phe Ala Ala
     50
                         55
Ser Met Gln Gly Leu Tyr Pro Gly Gly Gly Met Ala Gly Gln Ser
                                         75
65
                     70
Ala Xaa Gly Val Tyr Ala Ala Gly Tyr Gly Leu Glu Pro Xaa Ser Phe
                                     90
Asn Met His Cys Ala Pro Phe Glu Gln Lys Pro Leu Arg Gly Xaa Pro
                                105
                                                     110
            100
```

Xaa Xaa Ile Pro Xaa Arg 115

```
<210> 1168
<211> 77
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (18)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (22)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (23)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (48)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1168
Ser Arg Ser Trp Gly Phe Gly Cys Ser Met Leu Ala Leu Glu Thr Arg
Ala Xaa Pro Gly His Xaa Xaa Gly Cys Val Thr Phe Val Leu Asn Asp
                                                     30
             20
                                 25
His Ser Met Ala Phe Thr Gly Asp Ala Leu Leu Ile Arg Gly Cys Xaa
                             40
         35
Arg Thr Asp Phe Gln Gln Gly Cys Cys Gln Asp Leu Val Thr Ile Arg
Ser Met Lys Arg Ser Phe Lys Ile Ser Arg Arg Leu Ser
                     70
<210> 1169
```

<211> 115 <212> PRT

<400> 1169

Gly Pro Arg His Ala Asp Phe Pro Cys Ser Ala Val Val Arg Lys Cys
1 5 10 15

Leu Ala Ala Pro Gly Arg Arg Gly Arg Gln Thr Tyr Ser Arg Phe
20 25 30

Gln Thr Leu Glu Leu Glu Lys Glu Phe Leu Phe Asn Pro Tyr Leu Thr
35 40 45

Arg Lys Arg Arg Ile Glu Val Ser His Ala Leu Ala Leu Thr Glu Arg 50 55 60

Gln Val Lys Ile Trp Phe Gln Asn Arg Arg Met Lys Trp Lys Lys Glu 65 70 75 80

Asn Asn Lys Asp Lys Phe Pro Val Ser Arg Gln Glu Val Lys Asp Gly 85 90 95

Glu Thr Lys Lys Glu Ala Gln Glu Leu Glu Glu Asp Arg Ala Glu Gly
100 105 110

Leu Thr Asn 115

<210> 1170

<211> 55

<212> PRT

<213> Homo sapiens

<400> 1170

Tyr Leu Lys Arg Leu Ala Thr Met Ser Lys Pro Glu Leu Lys Glu Asp 1 5 10 15

Lys Met Leu Glu Val His Phe Val Gly Asp Asp Asp Val Leu Asn His 20 25 30

Ile Leu Asp Arg Glu Gly Gly Ala Lys Leu Lys Lys Glu Arg Ala His
35 40 45

Phe Trp Ser Thr Pro Lys Lys 50 55

<210> 1171

<211> 130

<212> PRT

```
<220>
<221> SITE
<222> (5)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (7)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (23)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (26)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (34)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (37)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (39)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (45)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (87)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (108)
<223> Xaa equals any of the naturally occurring L-amino acids
```

<220> <221> SITE <222> (128) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (129) <223> Xaa equals any of the naturally occurring L-amino acids <400> 1171 Pro Thr Arg Pro Xaa Thr Xaa Pro Phe Gly Pro Arg Trp His Gly Met 5 Arg Lys Ala Leu Pro Trp Xaa Leu Val Xaa Leu Ala Ser Leu Arg Ala 25 Val Xaa Thr Ser Xaa Met Xaa Thr Leu Pro Lys Arg Xaa Lys Ile Val 40 . Glu Val Gly Pro Arg Asp Gly Leu Gln Asn Glu Lys Asn Ile Val Ser 55 Thr Pro Val Lys Ile Lys Leu Ile Asp Met Leu Ser Glu Ala Gly Leu 65 70 Ser Val Ile Glu Thr Thr Xaa Phe Glu Ser Pro Lys Trp Val Pro Gln 90 Met Gly Asp His Thr Glu Val Leu Lys Gly Ile Xaa Lys Phe Pro Gly 105 Ile Asn Tyr Pro Val Leu Thr Pro Asn Leu Lys Gly Phe Glu Ala Xaa 115 120 Xaa Pro 130 <210> 1172 <211> 106 <212> PRT <213> Homo sapiens <220>

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE <222> (13)

```
<221> SITE
<222> (28)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (46)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (51)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (101)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (103)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1172
Ala Arg Glu Asp Leu Asp Lys Ala Leu Leu Lys Ala Xaa Gln Asp Met
                  5
Phe Asp Lys Lys Thr Lys Ala Ser Leu Tyr Leu Xaa Thr His Asn Gly
             20
                                 25
Asn Met Tyr Thr Ser Ser Leu Tyr Gly Cys Leu Ala Ser Xaa Leu Ser
His His Xaa Ala Gln Glu Leu Ala Gly Ser Arg Ile Gly Ala Phe Ser
                         55
Tyr Gly Ser Gly Leu Ala Ala Ser Phe Phe Ser Phe Arg Val Ser Arg
65
                     70
Leu Lys Val Phe Cys Arg Ser Met Glu Ser Phe Trp Glu Thr Tyr Ala
                 85
                                                         95
Ser Arg Ala Ser Xaa Arg Xaa Ser Tyr Phe
                                105
            100
```

<210> 1173 <211> 28 <212> PRT <213> Homo sapiens

<400> 1173

Pro Cys Lys Gly Ser Ile Ile Thr Cys Ser Leu Asn Arg Asp Leu Tyr 1 5 10 15

Glu Trp Leu His Glu Gly Ser Ala Val Ser Tyr Phe
20 25

<210> 1174

<211> 23

<212> PRT

<213> Homo sapiens

<400> 1174

Ile Ile Thr Cys Ser Leu Ile Arg Asp Leu Tyr Glu Trp Leu His Glu
1 5 10 15

Gly Ser Ala Val Ser Tyr Phe 20

<210> 1175

<211> 45

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (8)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 1175

Ala Ala Ser Ser Ile Cys Leu Xaa Gln Arg Leu Ser His Ala Cys Leu 1 5 10 15

Ser Thr His Gly Arg Tyr Ser Glu Thr Ala Asn Gly Ser Leu Asn Gln 20 25 30

Leu Trp Phe Leu Trp Ser Leu Ala Pro Leu Leu Gly 35 40 45

<210> 1176

<211> 86

<212> PRT

```
<220>
<221> SITE
<222> (24)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (35)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (36)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (45)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (66)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1176
Arg Pro Glu Asp Ser Leu Phe Cys Pro Lys Met Glu Asn Ser Thr Thr
                  5
                                     10
                                                          15
Thr Ile Ser Arg Glu Glu Leu Xaa Glu Leu Gln Glu Ala Phe Asn Lys
             20
                                 25
Ile Asp Xaa Xaa Asn Ser Gly Tyr Val Ser Asp Tyr Xaa Leu Gln Asp
                             40
Leu Phe Lys Glu Ala Ser Leu Pro Leu Pro Gly Tyr Lys Val Arg Glu
                         55
Ile Xaa Glu Lys Ile Leu Ser Val Ala Asp Ser Asn Lys Asp Gly Lys
                                         75
65
                     70
Ile Asn Phe Glu Glu Phe
                 85
```

<210> 1177 <211> 166

<212> PRT

```
<220>
<221> SITE
<222> (157)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (158)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (163)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1177
Ile Thr Ile Ser Phe Phe Leu Cys Leu Arg Pro Pro Thr Phe Phe Ser
Phe Pro Phe Ser Leu Trp Gly Pro Ser Pro Met Leu Pro Cys Pro Ile
                                 25
                                                      30
             20
Pro Phe Ser Pro Ser Arg Leu Leu Ile Pro Pro Phe Pro Ser Phe Pro
         35
                             40
                                                  45
Ser Asn Tyr Gln Leu Trp Leu Gly Arg His Asn Leu Phe Asp Asp Glu
                         55
Asn Thr Ala Gln Phe Val His Val Ser Glu Ser Phe Pro His Pro Gly
                    70
                                         75
Phe Asn Met Ser Leu Leu Glu Asn His Thr Arg Gln Ala Asp Glu Asp
                 85
                                     90
Tyr Ser His Asp Leu Met Leu Leu Arg Leu Thr Glu Pro Ala Asp Thr
                                105
            100
Ile Thr Asp Ala Val Lys Val Gly Lys Leu Pro Thr Gln Glu Pro Glu
                            120
Val Gly Glu His Leu Val Gly Phe Arg Leu Gly Gln Ala Leu Asn Gln
    130
                        135
                                            140
Lys Asn Phe Leu Ile Ser Glu Asp Leu Gln Met Val Xaa Xaa Leu Gln
                                                             160
145
                                        155
                    150
```

Lys Ser Xaa Leu Lys Glu

165

```
<210> 1178
<211> 79
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (2)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1178
Cys Xaa Ala Ala Gly Pro Ser Cys Ala Leu Lys Ala Gly Lys Thr Ala
Ser Gly Ala Gly Glu Val Val Arg Cys Leu Ser Glu Gln Ser Val Gly
                                 25
His Leu Ala Leu Arg Arg Gly Pro Gly Ala Arg Leu Pro Ala Leu Leu
         35
                             40
                                                 45
Asp Glu Gln Gln Val Asn Val Leu Leu Tyr Asp Met Asn Gly Cys Tyr
                         55
Ser Arg Leu Lys Glu Leu Val Pro Thr Leu Pro Gln Asn Arg Lys
                     70
                                         75
<210> 1179
<211> 51
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (2)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (8)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (9)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
```

```
<222> (14)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (19)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (29)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (41)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (47)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (50)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1179
Ala Xaa Val Gln Leu Thr Leu Xaa Xaa Thr Gln Cys Pro Xaa Gly Lys
Ser Val Xaa Cys His Val Lys Ala Leu His Asp Ser Xaa Pro Gly Cys
                                                      30
             20
                                  25
Asn Cys Ala Pro Ala Gln Phe Pro Xaa Leu Pro His Ala Ala Xaa Pro
                              40
                                                  45
         35
Asp Xaa Gly
     50
<210> 1180
<211> 96
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (42)
```

```
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (50)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (75)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (81)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (89)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (95)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1180
Ile Ser Arg Thr Pro Glu Gly His Val Arg Gly Gly Arg Glu Ala
                                     10
Arg Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu
                                 25
Val His Asn Ala Lys Thr Lys Pro Arg Xaa Glu Gln Phe Asn Ser Thr
         35
                             40
Tyr Xaa Trp Phe Ser Val Leu His Arg Pro Ala Pro Gly Trp Leu Glu
     50
                         55
Arg Gln Gly Ser Tyr Lys Trp Gln Gly Phe Xaa Thr Lys Gly Phe Pro
65
                     70
Xaa Phe Leu Gly Glu Asn Leu Phe Xaa Lys Ala Lys Gly Gln Xaa Arg
                 85
                                     90
```

```
<210> 1181
<211> 76
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (34)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (46)
<223> Xaa equals any of the naturally occurring L-amino acids
Gly Gly Tyr Cys Ser Gly Gly Ser Cys Ser Asn Phe Tyr Phe Tyr His
Met Asp Val Trp Gly Glu Arg Thr Thr Val Thr Val Ser Ser Ala Ser
                                 25
Thr Xaa Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Xaa Asn Thr
                     40
Ser Glu Asn Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro
     50
                         55
Glu Thr Gly Asp Gly Val Leu Glu Leu Arg Gly Leu
                     70
<210> 1182
<211> 137
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (14)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (22)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (79)
```

```
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (90)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (112)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (125)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (132)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (136)
<223> Xaa equals any of the naturally occurring L-amino acids
Asp Pro Tyr Gly Thr Met Glu Ala Pro Ala Gln Leu Leu Xaa Leu Leu
                                     10
Leu Leu Trp Leu Pro Xaa Thr Thr Gly Glu Ile Leu Met Thr Gln Ser
             20
                                 25
Pro Ala Thr Leu Ser Val Ser Pro Gly Glu Arg Val Thr Leu Ser Cys
                             40
         35
Arg Ala Gly Gln Ser Val Tyr Ser Asn Leu Ala Trp Tyr Gln Gln Lys
     50
                         55
Pro Gly Gln Ala Pro Arg Leu Leu Met Tyr Gly Ser Ser Thr Xaa Ala
                     70
                                          75
Thr Asp Val Pro Val Arg Phe Ser Gly Xaa Gly Ser Gly Thr Glu Phe
                                     90
Thr Leu Thr Ile Ser Ser Leu Gln Ser Asp Asp Ser Ala Val Tyr Xaa
           100
                                105
Cys Gln Gln Tyr Ile Met Trp Pro Gly Thr Phe Gly Xaa Gly Thr Lys
        115
                            120
```

Gly Glu Ile Xaa Arg Thr Gly Xaa Ala 130 135

<210> 1183

<211> 93

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (3)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (4)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (5)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 1183

Val Arg Xaa Xaa Xaa Phe Gly Ser Thr Ala Pro Ser Ala Asp Ala Trp

1 5 10 15

Val Arg Thr Arg Gly Arg Thr Arg Gly Ala Glu Ala Ala Lys Met Leu 20 25 30

Gly Glu Ala Leu Ser Lys Asn Pro Gly Tyr Ile Lys Leu Arg Lys Ile 35 40 45

Arg Ala Ala Gln Asn Ile Ser Lys Thr Ile Ala Thr Ser Gln Asn Arg
50 55 60

Ile Tyr Leu Thr Ala Asp Asn Leu Val Leu Asn Leu Gln Asp Glu Ser 65 70 75 80

Phe Thr Arg Gly Ser Asp Ser Leu Ile Lys Gly Lys Lys 85 90

<210> 1184

<211> 46

<212> PRT

```
<220>
<221> SITE
<222> (22)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (32)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (34)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (40)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (46)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1184
Ile Asp Leu Met Cys Lys Lys Met Lys His Leu Trp Phe Phe Leu Leu
                  5
Leu Val Ala Val Ser Xaa Met Arg Pro Val Pro Gly Ala Ala Xaa
             20
Val Xaa Ala Arg Thr Gly Glu Xaa Phe Gly Asp Pro Val Xaa
         35
                             40
<210> 1185
<211> 142
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (69)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (119)
```

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (138)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (141)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (142)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 1185

Ser Ala Leu Asn Thr Glu Leu Thr Met Glu Phe Gly Leu Ser Trp Val 1 5 10 15

Phe Leu Val Val Ile Leu Lys Gly Val Gln Cys Glu Val Gln Leu Val
20 25 30

Glu Ser Gly Gly Ala Val Val Gln Pro Gly Gly Ser Leu Arg Leu Ser 35 40 45

Cys Glu Ala Ser Gly Phe Thr Phe Asp Asn Tyr Ala Met His Trp Val 50 55 60

Arg Gln Ala Pro Xaa Lys Gly Leu Glu Trp Val Cys Leu Ile Ser Arg 65 70 75 80

Asp Gly Arg Lys Thr Tyr Phe Ala Asp Ser Met Lys Gly Arg Phe Thr 85 90 95

Ile Ser Arg Asp Asn Ser Lys Asn Cys Leu Tyr Leu Gln Val Asn Ser 100 105 110

Leu Arg Val Glu Asp Thr Xaa Leu Tyr Tyr Cys Ala Lys Asp Ile Pro 115 120 125

Gly Ser Ser Val Trp Thr Ser Gly Val Xaa Gly His Xaa Xaa 130 135 140

<210> 1186

<211> 68

<212> PRT

```
<220>
<221> SITE
<222> (61)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (62)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1186
Ser Trp Thr Pro Arg Pro Phe His Leu Val Ile Ser Thr Glu His Arg
                                      10
Gly Leu Thr Met Glu Leu Gly Leu Ser Trp Val Phe Leu Val Ala Ile
                                 25
Leu Glu Gly Val Gln Cys Glu Val Gln Leu Val Glu Ser Gly Gly Gly
         35
                              40
Leu Val Gln Ala Gly Gly Val Pro Glu Thr Leu Leu Xaa Xaa Leu Trp
     50
                         55
                                              60
Leu Pro Pro Leu
 65
<210> 1187
<211> 191
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (5)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (121)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (157)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
```

```
<222> (171)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (176)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (180)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (182)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (191)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1187
Gly Arg Glu Ile Xaa Arg Ser Phe His Leu Val Ile Ser Thr Glu His
                                     10
Arg Pro Pro Thr Met Glu Phe Gly Pro Ser Trp Val Phe Leu Val Ala
                                 25
                                                      30
Ile Leu Lys Gly Val His Cys Glu Val Gln Leu Val Glu Ser Gly Gly
                                                  45
         35
                             40
Gly Leu Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Thr Thr Ser
                         55
Gly Phe Thr Phe Gly Asp Tyr Ser Met Ser Trp Val Arg Gln Ala Pro
                     70
Gly Lys Gly Leu Glu Trp Val Gly Phe Ile Arg Ser Lys Ala His Gly
                 85
                                     90
Gly Thr Thr Glu Tyr Ala Ala Ser Val Lys Arg Gln Ile His His Leu
                                105
            100
Lys Glu Met Ile Pro Gln Ala Ser Xaa Ile Trp Gln Met Asn Ser Leu
                            120
Lys Pro Arg Thr Gln Thr Leu Leu Leu Ser Arg His Asp Tyr Arg His
                        135
                                            140
```

Thr Pro Gly Tyr Trp Gly Gln Gly Thr Leu Val Thr Xaa Phe Ser Gly 145 155 150 Phe His Gln Gly Pro Ser Ser Pro Trp Xaa Pro Cys Ser Arg Xaa 165 170 Thr Ser Glu Xaa Gln Xaa Pro Gly Leu Ala Gly Gln Gly Leu Xaa 190 180 185 <210> 1188 <211> 121 <212> PRT <213> Homo sapiens <220> <221> SITE <222> (13) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (22) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (35) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (47) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (53) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (64) <223> Xaa equals any of the naturally occurring L-amino acids <220>

<223> Xaa equals any of the naturally occurring L-amino acids

<221> SITE <222> (67)

```
<220>
<221> SITE
<222> (90)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (94)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (99)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (101)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (104).
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (108)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (110)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (111)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (117)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (119)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1188
```

Val Gln Cys Glu Val Gln Leu Val Glu Ser Gly Gly Xaa Leu Val Gln 1 5 10 15

Pro Gly Gly Ser Leu Xaa Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe 20 25 30

Ser Ser Xaa Asp Met His Trp Val Arg Gln Val Ala Gly Lys Xaa Leu 35 40 45

Glu Trp Val Ser Xaa Ile Asp Pro Ala Gly Asn Thr Asn Tyr Pro Xaa
50 55 60

Ser Val Xaa Gly Arg Phe Ile Ile Ser Arg Glu Asn Asp Lys Ser Ser 65 70 75 80

Ser Tyr Leu Gln Asn Glu Trp Ala Asp Xaa Arg Gly Lys Xaa Cys Val 85 90 95

Ile Leu Xaa Lys Xaa Lys Leu Xaa Phe Leu Val Xaa Gly Xaa Xaa Arg
100 105 110

Ser Leu Gly Ala Xaa Gly Xaa Leu Gly 115 120

<210> 1189

<211> 125

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (8)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (16)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (49)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (104)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (123)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 1189

Gly Thr Ser Asn Ala Gly Asn Xaa Asn Thr Lys Tyr Ser Gln Lys Xaa 1 5 10 15

Gln Asp Arg Val Thr Ile Thr Arg Asp Thr Ser Thr Asn Thr Ala Tyr 20 25 30

Met Asp Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
35 40 45

Xaa Arg Gly Phe Phe Gly Asp Arg Asp Tyr Tyr Tyr Tyr Tyr Tyr Met 50 55 60

Asp Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser Ala Ser Pro 65 70 75 80

Thr Ser Pro Lys Val Phe Pro Leu Ser Leu Cys Ser Thr Gln Pro Asp 85 90 95

Gly Asn Val Val Ile Ala Cys Xaa Val Gln Gly Phe Phe Pro Gln Glu 100 105 110

Pro Leu Gln Cys Gly Pro Gly Ala Lys Gly Xaa Arg Ala 115 120 125

<210> 1190

<211> 31

<212> PRT

<213> Homo sapiens

<400> 1190

Asn Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp 1 5 10 15

Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Leu Pro Ala Glu 20 25 30

<210> 1191

<211> 102

<212> PRT

```
<220>
<221> SITE
<222> (42)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (44)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (60)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (87)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (90)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (94)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (99)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1191
Ser Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Ala
Met Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Ser Ser Ala Val
             20
                                 25
                                                      30
Val Phe Gly Gly Thr Arg Leu Thr Xaa Leu Xaa Gln Pro Lys Ala
         35
                             40
Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Xaa Glu Leu Gln Ala
                         55
Asn Lys Ala Thr Leu Val Cys Leu Ile Asn Asp Phe Tyr Pro Gly Ser
65
                     70
                                         75
```

```
Arg Asp Ser Gly Leu Glu Xaa Gln Ile Xaa Thr Pro Phe Xaa Ala Glu
                 85
                                      90
Leu Gly Xaa Thr Thr Thr
            100
<210> 1192
<211> 160
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (123)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (147)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (150)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (154)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1192
Arg Pro Thr Arg Pro Gln Leu Trp Ala Gln Glu Ala Ala Leu Arg Thr
                  5
Ile Ser Ser Met Ala Trp Ser Pro Leu Leu Leu Thr Leu Leu Ala His
             20
                                 25
Cys Thr Gly Ser Trp Ala Gln Ser Val Leu Thr Gln Pro Pro Ser Val
                             40
                                                  45
Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser
                         55
Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro
65
                     70
Gly Thr Ala Pro Lys Val Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser
```

90

85

```
<210> 1193
<211> 153
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (7)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (24)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (28)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (29)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (33)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (37)
```

```
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (146)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (149)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (151)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (152)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (153)
<223> Xaa equals any of the naturally occurring L-amino acids
Thr Gly Phe Arg Thr Ile Xaa Thr Met Ala Gly Phe Pro Leu Leu
                                     10
Thr Leu Leu Thr His Cys Ala Xaa Ser Trp Ala Xaa Xaa Val Leu Thr
                                 25
Xaa Pro Pro Ser Xaa Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser
                                                  45
                             40
Cys Ser Gly Ser Ser Ser Asn Ile Gly Thr Asn Tyr Val Tyr Trp Tyr
     50
                         55
                                             60
Gln Gln Leu Pro Gly Thr Ala Pro Glu Val Leu Ile Tyr Lys Asn Asp
65
                     70
Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly
                                     90
Thr Ser Ala Ser Leu Ala Ile Gly Gly Leu Arg Ser Glu Asp Glu Ala
            100
                                105
                                                     110
Asp Tyr Tyr Cys Ala Ser Trp Asp Asp Ser Leu Ser Gly Pro Val Phe
        115
                            120
                                                 125
```

Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln Pro Lys Ala Ala Pro 130 135 140

<210> 1194

<211> 114

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (108)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 1194

Gly Gly Arg Ala Leu Gly Ile Ser Pro Trp Pro Gly Pro Leu Ser Cys
1 5 10 15

Ser Pro Ser Ser Leu Ser Ala Gln Arg Lys Arg Gly Gln Ala Pro Val 20 25 30

Val Val Ile Tyr Glu Asp Asn Lys Arg Pro Ser Gly Ile Pro Glu Arg
35 40 45

Phe Ser Gly Ser Thr Ser Gly Thr Leu Ala Thr Val Ile Ile Ser Gly 50 55 60

Ala Gln Val Asp Asp Asp Thr Asp Phe Tyr Cys Gln Ser Thr His Ser 65 70 75 80

Ser Asn Asn Gly Arg Ser Val Cys Leu Arg Asn Trp Asp Gln Gly His

Arg Pro Trp Ser Ala Gln Gly Gln Pro Gln Cys Xaa Ser Val Pro Gly 100 105 110

Leu Leu

<210> 1195

<211> 97

<212> PRT

```
<220>
<221> SITE
<222> (4)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (34)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (41)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (45)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (48)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1195
Gln Asn Ser Xaa Cys Leu Thr Met Ala Trp Ile Pro Leu Leu Pro
                                     10
Leu Leu Thr Leu Cys Thr Asp Ser Glu Ala Ser His Glu Leu Arg Gln
                                 25
Pro Xaa Ser Val Ser Val Ser Pro Xaa Gln Thr Ala Xaa Ile Thr Xaa
         35
                             40
                                                 45
Ser Gly Asp Ala Leu Pro Glu Gln Ser Ile Phe Trp Tyr Gln Gln Lys
                         55
Pro Gly Gln Ala Pro Val Leu Val Ile Tyr Lys Val His Glu Arg Pro
                     70
Ser Asp Ala Leu Asn Asp Ser Leu Ala Pro Gly His Arg Gln Gln Ser
                85
```

Arg

<210> 1196 <211> 192

```
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (2)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (14)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (21)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (32)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (33)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (36)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (38)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (50)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (52)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (57)
```

```
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (60)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (61)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (62)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (63)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (66)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (70)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (79)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (80)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (84)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (86)
<223> Xaa equals any of the naturally occurring L-amino acids
```

```
<220>
<221> SITE
<222> (92)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (105)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (108)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (125)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (131)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (132)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (136)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (146)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (158)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (164)
<223> Xaa equals any of the naturally occurring L-amino acids
```

```
<220>
<221> SITE
<222> (165)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (177)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (178)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (187)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1196
Ile Xaa Leu Thr Lys Gly Asn Lys Arg Trp Ser Ser Thr Xaa Val Ala
                                     10
Ala Ala Leu Glu Xaa Leu Asp Pro Pro Gly Cys Pro Gly Ser Ala Xaa
                                 25
Xaa Asp Asn Xaa Gly Xaa Val Gly Ser Gly Pro Pro Asn Pro Asp Leu
                             40
Ser Xaa Thr Xaa Leu Asp Gln Tyr Xaa Ala Met Xaa Xaa Xaa His
     50
Gly Xaa Asn Met Glu Xaa Ala Leu Gly Met Leu Phe Trp His Xaa Xaa
                                         75
65
                     70
Asn Ile Gln Xaa Ser Xaa Ala Asp Leu Pro Asn Xaa Thr Pro Phe Pro
                                     90
Asp Lys Trp Thr Val Glu Asp Lys Xaa Leu Phe Xaa Gln Ala Phe Thr
       100
Phe His Gly Lys Thr Phe His Thr Ile Gln Pro Met Xaa Pro His Lys
        115
                           120
Ser Ile Xaa Xaa Leu Val Lys Xaa Tyr Tyr Ser Trp Lys Lys Asp Glu
                       135
Asp Xaa Asn Tyr Cys Asp Gly Ser Pro Cys Pro Gly Asn Xaa Thr Gly
                   150
                                        155
```

Arg Glu Glu Xaa Xaa Asp Glu Leu Glu Gln Ala Asn Gly Thr Ile Pro 165 170 175

Xaa Xaa Leu Lys Leu Asp Pro Asn Gln Glu Xaa Gln Arg Glu Val Pro 180 185 190

```
<210> 1197
<211> 43
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (10)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (27)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (28)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (29)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (40)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (42)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1197
Glu Gln Asn Leu Asp Arg Gln Val Leu Xaa Thr Gln Cys Ile Arg Leu
```

Glu Ala Arg Tyr Tyr Ser Leu Ser Leu Thr Xaa Xaa Xaa Leu Ser His

20 25 30

Ile Val Ala Glu Leu Arg Asn Xaa Lys Xaa Lys 35 40

<210> 1198

<211> 98

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (88)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 1198

Val Ser Pro Ala Ser Thr Asn Cys Gln Ser Gln Glu Asn Phe Glu Ala 1 5 10 15

Phe Met Lys Ala Ile Gly Leu Pro Glu Glu Leu Ile Gln Lys Gly Lys
20 25 30

Asp Ile Lys Gly Val Ser Glu Ile Val Gln Asn Gly Lys His Phe Lys
35 40 45

Phe Thr Ile Thr Ala Gly Ser Lys Val Ile Gln Asn Glu Phe Thr Val 50 55 60

Gly Glu Glu Cys Glu Leu Glu Thr Met Thr Gly Glu Lys Val Lys Thr 65 70 75 80

Val Val Gln Leu Glu Gly Asp Xaa Lys Leu Val Thr Thr Phe Lys Asn 85 90 95

Ile Lys

<210> 1199

<211> 184

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (26)

<223> Xaa equals any of the naturally occurring L-amino acids

```
<220>
<221> SITE
<222> (31)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (35)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (37)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (38)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (40)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (41)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (43)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (44)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (45)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (46)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
```

```
<221> SITE
<222> (52)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (54)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (65)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (77)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (78)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (80)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (83)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (87)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (88)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (95)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
```

```
<222> (97)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (100)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (108)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (116)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (123)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (129)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (131)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (133)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (136)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (139)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (162)
```

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (178)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 1199

Lys Lys Lys Lys Lys Lys Lys Lys Xaa Gly Gly Arg Phe Xaa Gly
20 25 30

Ser Lys Xaa Thr Xaa Xaa Cys Xaa Xaa Arg Xaa Xaa Xaa Xaa Ile Gly
35 40 45

Ser Pro Lys Xaa Asn Xaa Leu Ala Val Val Leu Gln Arg Arg Asp Trp 50 55 60

Xaa Asn Pro Gly Val Thr Gln Leu Asn Arg Leu Ala Xaa Xaa Pro Xaa 65 70 75 80

Phe Ala Xaa Trp Arg Asn Xaa Xaa Lys Ala Arg Thr Asp Arg Xaa Ser 85 90 95

Xaa Gln Leu Xaa Ser Leu Asn Gly Lys Trp Asp Xaa Pro Cys Ser Gly
100 105 110

Ala Leu Ser Xaa Ala Gly Val Gly Val Thr Xaa Ser Val Thr Val Thr
115 120 125

Xaa Ala Xaa Ala Xaa Ala Pro Xaa Pro Phe Xaa Phe Phe Pro Ser Phe 130 135 140

Phe Ala Thr Phe Ala Gly Phe Pro Arg Lys Ala Leu Asn Gly Gly Leu 145 150 155 160

Pro Xaa Gly Phe Arg Phe Arg Ala Leu Arg Asp Leu Asp Pro Lys Lys 165 170 175

Leu Xaa Leu Gly Gly Trp Phe Thr 180

<210> 1200

<211> 83

<212> PRT

<213> Homo sapiens

<400> 1200

Gly Pro Glu Met Gln Val Lys Leu Leu Gln Ser Leu Gly Leu Lys Ser 1 5 10 15

Thr Leu Ile Thr Asp Gly Ser Thr Pro Ile Asn Leu Phe Asn Thr Ala 20 25 30

Phe Gly Leu Leu Gly Met Gly Pro Glu Gly Pro Ala Pro Gly Gln Lys
35 40 45

Gly Trp His Trp Ala Gln Pro Trp Lys Gly Asp Ile Pro Pro Val Leu 50 55 60

Leu Lys Pro Leu Lys Leu Leu Glu Asn Thr Thr Leu Cys Leu Phe Cys 65 70 75 80

Ala Tyr Ser

<210> 1201

<211> 75

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (74)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 1201

Leu Leu Phe Leu Gly Pro Val Gly Leu Ile Met Tyr Leu Gly Gly Val
1 5 10 15

Phe Phe Ile Asn Arg Gln Arg Ser Ser Thr Ala Met Thr Val Met Ala 20 25 30

Asp Leu Gly Glu Arg Met Val Arg Glu Asn Leu Lys Val Trp Ile Tyr 35 40 45

Pro Glu Gly Thr Arg Asn Asp Asn Gly Asp Leu Leu Pro Phe Lys Lys 50 55 60

Gly Ala Phe Tyr Leu Ala Val Gln Ala Xaa Val 65 70 75

<210> 1202

<211> 179

```
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (44)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (108)
<223> Xaa equals any of the naturally occurring L-amino acids .
<220>
<221> SITE
<222> (125)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (131)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (132)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (138)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (144)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (145)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (147)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (153)
```

<223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (157) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (158) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (161) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (166) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (176) <223> Xaa equals any of the naturally occurring L-amino acids <400> 1202 Lys Gln Arg Ser Glu Asp Ser Met Tyr Thr Ala Ile Pro Gln Ser Gly 10 Ser Pro Phe Pro Gly Ser Val Gln Asp Pro Gly Leu His Val Trp Arg Val Glu Lys Leu Lys Pro Val Pro Val Ala Gln Xaa Asn Gln Gly Ile 35 40 Phe Phe Ser Gly Asp Ser Tyr Leu Val Leu His Asn Gly Pro Glu Glu 50 55 Val Ser His Leu His Leu Asn Thr Leu Leu Gly Glu Arg Pro Val Gln 70 75 His Arg Glu Val Arg Gly Asn Glu Ser Asp Leu Phe Met Ser Tyr Phe 90 Pro Arg Gly Phe Lys Tyr Gln Glu Gly Gly Leu Xaa Ser Ala Phe His 100 105 Lys Thr Ser Thr Gly Ala Pro Val Ala Ile Lys Lys Xaa Tyr Gln Val

120

115

Lys Gly Xaa Xaa Lys Ser Val Gln Arg Xaa Gly Met Asn Trp Glu Xaa 130 135 140

Xaa Asn Gln Ile Trp Xaa Lys Arg Gly Asp Cys Leu Asp Arg Asp Xaa 165 170 175

Gln Gly Ser

<210> 1203

<211> 145

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (135)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (140)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 1203

Leu Phe Leu Asp Ser Val Gly Gly Gly Ala Trp Pro Phe Leu Val Gly
1 5 10 15

Gly Ala Ile Cys Leu Val Asn Ser Asp Asn Glu Arg Asp Ser Gly Met 20 25 30

Leu Thr Ser Tyr Ala Thr Pro Glu Arg Ser Ala Ser Pro Asn Phe Leu 35 40 45

Glu Gly Gln Val Ala Phe Ser His Pro Arg Leu Ser Asn Asn Arg Ser 50 55 60

Val Met Pro Leu Asp Val Arg Gly Cys Thr Arg Ala Thr Leu Thr Gly 65 70 75 80

Ser Ala Cys Ala Tyr Pro Thr Pro Ala Gly Ala Gly Asn Pro Leu Asn 85 90 95

Pro Ile Arg Asp Gly Asp Arg Gly Leu Gln Leu Phe Pro Met Asn Glu 100 105 110

```
Glu Phe Pro Val Ser Ala Gly His Lys Leu Ala Leu Ile Lys Ser Leu
        115
                             120
                                                 125
Pro Leu Gln Pro Phe Trp Xaa Phe Gly Pro Leu Xaa Leu Phe His Leu
    130
                        135
Ser
145
<210> 1204
<211> 72
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (12)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (19)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (20)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (28)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (35)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (36)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (48)
<223> Xaa equals any of the naturally occurring L-amino acids
```

```
<220>
<221> SITE
<222> (53)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (56)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (57)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (60)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1204
Pro Arg Pro Ala Gly Asn Ser Ser Arg Val His Xaa Glu Gly Thr Thr
                                    10
                  5
Val Leu Xaa Xaa Gln Phe Gly Leu Asn Ala Ser Xaa Ser Arg Phe Phe
                                 25
                                                     30
             20
Leu Gln Xaa Xaa Gln Leu Ile Thr Ile Leu Pro Val Arg Gln Arg Xaa
         35
                             40
Leu Pro Leu Lys Xaa Ala Asn Xaa Xaa Leu Thr Xaa Pro Ala Ala Thr
Val Arg Gln Phe Leu Gln Val Pro
                     70
<210> 1205
<211> 159
<212> PRT
<213> Homo sapiens
<400> 1205
Thr Pro Leu Gly Val Pro Val Ile Gln Pro Tyr Arg Leu Asp Ser Lys
Val Lys Gln Ile Gly Gly Gly Ile Gln Ser Ile Thr Tyr Thr His Asn
                                25
```

Gly Asp Ile Ser Arg Lys Pro Asn Thr Arg Lys Gln Lys Asn Gly Phe 35 40 45

Pro Pro Asn Phe Ile His Ser Leu Asp Ser Ser His Met Met Leu Thr 50 55 60

Ala Leu His Cys Tyr Arg Lys Gly Leu Thr Phe Val Ser Val His Asp
65 70 75 80

Cys Tyr Trp Thr His Ala Ala Asp Val Ser Val Met Asn Gln Val Cys
85 90 95

Arg Glu Gln Phe Val Arg Leu His Ser Glu Pro Ile Leu Gln Asp Leu 100 105 110

Ser Arg Phe Leu Val Lys Arg Phe Cys Ser Glu Pro Gln Lys Ile Leu 115 120 125

Glu Ala Ser Gln Leu Lys Glu Thr Leu Gln Ala Val Pro Lys Pro Gly
130 135 140

Ala Phe Asp Leu Glu Gln Val Lys Arg Ser Thr Tyr Phe Phe Ser 145 150 155

<210> 1206

<211> 109

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (9)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (41)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (44)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (47)

<223> Xaa equals any of the naturally occurring L-amino acids

```
<220>
<221> SITE
<222> (75)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (82)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (89)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (97)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (105)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1206
Gln Met Tyr Gly Thr Asn Lys Met Xaa Pro Tyr Arg Asp Ser Lys Leu
Thr His Leu Phe Lys Asn Tyr Phe Asp Gly Glu Gly Lys Val Arg Met
Ile Val Tyr Val Asn Pro Lys Ala Xaa Asp Tyr Xaa Glu Asn Xaa Gln
                                                  45
         35
                             40
Val Met Arg Phe Ala Glu Val Thr Gln Glu Val Glu Val Ala Arg Pro
                                             60
     50
                         55
Val Asp Lys Val Ile Cys Gly Leu Thr Pro Xaa Arg Arg Tyr Arg Asn
65
                     70
Gln Xaa Arg Gly Pro Val Gly Asn Xaa Pro Leu Gly Thr Asp Val Val
Xaa Gln Ser Phe Pro Pro Leu Pro Xaa Met Arg Asn Phe
```

105

<210> 1207 <211> 84

100

```
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (2)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (68)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1207
Asn Xaa Lys Leu Ser Glu Gln Glu Leu Gln Phe Arg Arg Leu Ser Gln
                                      10
Glu Gln Val Asp Asn Phe Thr Leu Asp Ile Asn Thr Ala Tyr Ala Arg
             20
Leu Arg Gly Ile Glu Gln Ala Val Gln Ser His Ala Val Ala Glu Glu
                             40
Glu Ala Arg Lys Ala His Gln Leu Trp Leu Ser Val Glu Ala Leu Lys
     50
                          55
Tyr Ser Met Xaa Asp Leu His Leu Ala Glu Thr Pro Thr Ile Pro Leu
                     70
                                          75
 65
Gly Ser Gly Ser
<210> 1208
<211> 57
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (37)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (46)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
```

<221> SITE

```
<222> (52)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (53)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1208
Pro Cys Ser Thr Val Pro Val Thr Thr Glu Val Ser Tyr Ala Gly Cys
                  5
                                      10
Thr Lys Thr Val Leu Met Asn His Cys Ser Gly Ser Cys Gly Thr Phe
             20
                                 25
Val Met Tyr Ser Xaa Gln Ala Gln Ala Leu Asp His Ser Xaa Leu Leu
Leu Gln Arg Xaa Xaa Asn Gln Pro Ala
     50
<210> 1209
<211> 84
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (2)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (26)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (59)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (64)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (72)
```

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 1209

Ala Xaa Asp Gln Ala Gly Glu Val Asp His Thr Leu Leu Gly Gln Cys
1 5 10 15

Thr Gly Gly Gly Tyr Phe Met Gln Phe Xaa Thr Ser Ser Gly Ser Ala 20 25 30

Glu Glu Ala Ala Leu Leu Glu Ser Arg Ile Leu Tyr Pro Lys Arg Lys
35 40 45

Gln Gln Cys Leu Gln Phe Phe Tyr Lys Met Xaa Gly Glu Val Leu Xaa 50 55 60

Asp Arg Leu Arg Cys Leu Gly Xaa Gly Gly Asp Asp Ser Thr Gly Asn 65 70 75 80

Val Arg Asn Trp

<210> 1210

<211> 129

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (106)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (124)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (128)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (129)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 1210

Leu Leu Asn Asp Ala Val Thr Val Val Leu Tyr His Leu Phe Glu Glu
1 5 10 15

Phe Ala Asn Tyr Glu His Val Gly Ile Val Asp Ile Phe Leu Gly Phe 20 25 30

Leu Ser Phe Phe Val Val Ala Leu Gly Gly Val Leu Val Gly Val Val 35 40 45

Tyr Gly Val Ile Ala Ala Phe Thr Ser Arg Phe Thr Ser His Ile Arg

Val Ile Glu Pro Leu Phe Val Phe Leu Tyr Ser Tyr Met Ala Tyr Leu 65 70 75 80

Ser Ala Glu Leu Phe His Leu Ser Gly Ile Met Ala Leu Ile Ala Ser 85 90 95

Gly Val Val Met Arg Pro Tyr Val Gly Xaa Gln His Phe His Lys Phe 100 105 110

Pro Gln Gln His Gln Ile Ile Ser Trp Lys Met Xaa Glu Gln Arg Xaa 115 120 125

Xaa

<210> 1211

<211> 43

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (6)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (17)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 1211

Leu His Ala Phe Cys Xaa Ile Asn Asn Ile Lys Pro Ser Trp Thr Arg

1 10 15

Xaa Asn Thr Leu Met Phe Ile His Leu Ser Pro Ile Leu Leu Leu Ser 20 25 30

Leu Asn Pro Asp Ile Ile Thr Gly Phe Ser Ser 35 40

```
<210> 1212
<211> 29
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (17)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (20)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (27)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1212
Gln Gly Phe Lys Val Glu Arg Met His Ile Thr Asp Met Lys Leu Ala
Xaa Leu Pro Xaa Leu Glu Ala Leu Gly Val Xaa Val Asn
             20
                                  25
<210> 1213
<211> 137
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (29)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (70)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (77)
<223> Xaa equals any of the naturally occurring L-amino acids
```

```
<220>
<221> SITE
<222> (82)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (92)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (114)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (116)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (135)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (137)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1213
Ala Lys Val His Pro Asn Ser Val His Ile Cys Ala Val Val Glu
                  5
                                      10
                                                          15
Tyr Glu Thr Lys Ala Gly Arg Ile Asn Lys Gly Val Xaa Thr Asn Trp
             20
Leu Arg Ala Lys Glu Pro Ala Gly Glu Asn Gly Gly Arg Ala Leu Val
                             40
Pro Met Phe Val Arg Lys Ser Gln Phe Arg Leu Pro Phe Lys Ala Thr
                         55
Thr Pro Val Ile Met Xaa Gly Pro Gly Thr Gly Val Xaa Pro Phe Ile
65
                     70
Gly Xaa Ile Gln Glu Arg Ala Trp Leu Arg Gln Xaa Gly Lys Glu Val
                 85
                                     90
Gly Glu Thr Leu Leu Asn Tyr Gly Cys Arg Arg Ser Asp Glu Asp Tyr
```

```
100
                                 105
                                                     110
Leu Xaa Arg Xaa Glu Leu Ala Gln Phe His Arg Asp Gly Ala Leu Thr
                                                 125
        115
                            120
Gln Leu Asn Val Ala Phe Xaa Arg Xaa
    130
                         135
<210> 1214
<211> 207
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (3)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (25)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (54)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (78)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (84)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (97)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (122)
<223> Xaa equals any of the naturally occurring L-amino acids
```

<220>

```
<221> SITE
<222> (136)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (145)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (150)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (158)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (165)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (168)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (170)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (180)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (187)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (196)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
```

<222> (207)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 1214

Ala Ser Xaa His His Ser Ala Cys Phe Leu Gly Pro Glu Ile Met Pro 1 5 10 15

Leu Gly Leu Leu Trp Leu Gly Leu Xaa Leu Leu Gly Ala Leu His Ala 20 25 30

Gln Ala Gln Asp Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro Leu Ser 35 40 45

Lys Val Pro Leu Gln Xaa Asn Phe His Asp Asn Gln Phe His Gly Lys
50 55 60

Trp Tyr Val Val Arg Leu Ala Arg Asn Ala Ile Leu Arg Xaa His Lys
65 70 75 80

Asp Pro Gln Xaa Met Tyr Ala Thr Ile Tyr Glu Leu Lys Glu Thr Arg
85 90 95

Xaa Thr Met Ser Leu Arg Leu Phe Lys Lys Lys Cys Asp Tyr Leu 100 105 110

Asp Gln Glu Phe Trp Ser Lys Val Ala Xaa Arg Arg Ile Pro Pro Trp 115 120 125

Gly Pro Leu Lys Leu Pro Trp Xaa Asn Gln Phe Pro Pro Ser Asn Cys 130 135 140

Xaa His Gln Leu Gln Xaa Pro Ser Phe Gly Phe Leu Pro Xaa Asn Phe 145 150 155 160

Ser Lys Gln Gly Xaa Leu Pro Xaa Pro Xaa Phe Arg Lys Asn Lys Glu 165 170 175

Leu Ile Pro Xaa Leu Lys Glu Lys Phe Ser Xaa Leu Pro Phe Leu Gly 180 185 190

Pro Pro Lys Xaa Lys Phe Val Phe Pro Phe Pro Thr Asn Ile Xaa 195 200 205

<210> 1215

<211> 69

<212> PRT

<213> Homo sapiens

<220>

```
<221> SITE
<222> (15)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (19)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (25)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (31)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (40)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (43)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (59)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (65)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (69)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1215
Gly Ser His Thr Ala Arg Arg Leu Gly Arg Leu Arg Gly Ser Xaa Ala
                                     10
Arg Leu Xaa Gly Pro Arg Arg Ala Xaa Gly Gly Lys Met Ala Xaa Gly
             20
                                 25
```

<210> 1216 <211> 58 <212> PRT <213> Homo sapiens <220> <221> SITE <222> (42) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (53) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (56) <223> Xaa equals any of the naturally occurring L-amino acids <400> 1216 Leu Asn Pro Leu Gly Ile Lys Tyr Ile Val Ala Arg Pro Val Tyr Ser 5 10

Thr Asn Ala Phe Glu Glu Asn His Lys Lys Thr Gly Arg His His Lys 20 25 30

Thr Phe Leu Asp His Leu Lys Val Cys Xaa Asn Cys Ser Pro Gln Lys 35 40 45

Ala Arg Glu Leu Xaa Ser Leu Xaa Phe Pro 50 55

<210> 1217 <211> 144 <212> PRT <213> Homo sapiens <220>

<221> SITE

<222> (126)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 1217

Ala Gly Leu Gln Met Gly Arg Ser Arg Ser Arg Ser Pro Arg Arg Glu
1 5 10 15

Arg Arg Arg Ser Arg Ser Thr Ser Arg Glu Arg Glu Arg Arg Arg Arg 20 25 30

Glu Arg Ser Arg Ser Arg Glu Arg Asp Arg Arg Ser Arg Ser Arg
35 40 45

Ser Pro His Arg Arg Arg Ser Arg Ser Pro Arg Arg His Arg Ser Thr 50 55 60

Ser Pro Ser Pro Ser Arg Leu Lys Glu Arg Arg Asp Glu Glu Lys Lys 65 70 75 80

Glu Thr Lys Glu Thr Lys Ser Lys Glu Arg Gln Ile Thr Glu Glu Asp 85 90 95

Leu Glu Gly Lys Thr Glu Glu Glu Ile Glu Met Met Lys Leu Met Gly
100 105 110

Phe Ala Ser Phe Asp Ser Thr Lys Gly Lys Lys Val Asp Xaa Ser Val 115 120 125

Asn Ala Tyr Ala Ile Asn Val Ser Gln Lys Arg Lys Tyr Arg Tyr Ala 130 135 140

<210> 1218

<211> 70

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (2)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 1218

Gln Xaa Leu Cys Gln Ala Gly Asp Asp Ser Asn Ser Asn Lys Lys Asn
1 5 10 15

Ala Asp Leu Gln Val Leu Lys Pro Glu Pro Glu Leu Val Tyr Glu Asp 20 25 30

Leu Arg Gly Ser Val Thr Phe His Cys Ala Leu Gly Pro Glu Val Ala 35 40 45

Asn Val Ala Lys Ile Leu Ser Gly Arg Glu Trp Gly Lys Asp Ala Val 50 55 60

Ser Ser Leu Gln Ile Cys 65 70

<210> 1219

<211> 104

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (7)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (8)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (102)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 1219

Ser Thr His Ala Ser Ala Xaa Xaa Ser Leu Val Leu Arg Ile Ala Thr 1 5 10 15

Asp Asp Ser Lys Ala Val Cys Arg Leu Ser Val Lys Phe Gly Ala Thr 20 25 30

Leu Lys Ile Ser Arg Leu Leu Glu Arg Ala Arg Glu Leu Asn Ile 35 40 45

Asp Ile Ile Gly Val Ser Phe His Val Gly Ser Gly Cys Thr Asp Pro

Gly Asp Leu Arg Ala Ser His Leu Arg Cys Pro Leu Cys Leu Arg His
65 70 75 80

```
Gly Glu Leu Arg Leu Val Ser Thr Cys Ile Cys Leu Ile Ser Val Val
                                      90
Gly Phe Pro Gly Ile Xaa Arg Met
            100
<210> 1220
<211> 89
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (4)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (7)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (15)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (20)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (45)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (47)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (53)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (69)
```

<223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (87) · <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (88) <223> Xaa equals any of the naturally occurring L-amino acids <400> 1220 Gly Thr Arg Xaa Cys Pro Xaa Arg Val Arg Val Ala Met Gly Xaa Ile Glu Trp Ala Xaa Trp Ala Asn Glu Gln Ala Leu Ala Ser Gly Leu Ile 25 Leu Ile Thr Gly Gly Ile Val Ala Thr Ala Gly Arg Xaa Thr Xaa Trp Tyr Phe Gly Ala Xaa Ser Ile Val Ala Gly Val Phe Val Cys Leu Leu 55 Glu Tyr Pro Arg Xaa Lys Arg Lys Lys Gly Ser Thr Met Val Arg Trp 75 Gly Gln Lys Tyr Met Thr Xaa Xaa Val 85 <210> 1221 <211> 141 <212> PRT <213> Homo sapiens

<400> 1221

Asp Thr Phe Ile Arg His Ile Ala Leu Leu Gly Phe Glu Lys Arg Phe 1 5 10 15

Val Pro Ser Gln His Tyr Val His Val Pro Gly Glu Met Ala Gly Pro 20 25 30

Val Gly Glu Gly Leu Pro Ala Leu His Arg Asp Leu Arg Val Pro
35 40 45

Ser Pro Lys Trp Phe Asp Gly Gln Arg Ala Ala Glu Asn His Gln Gly 50 55 60

Thr Leu Thr Glu Tyr Cys Gly Thr Leu Met Ser Leu Pro Thr Lys Ile
65 70 75 80

Ser Arg Cys Pro His Leu Leu Asp Phe Phe Lys Val Arg Pro Asp Asp 85 90 95

Leu Lys Leu Pro Thr Asp Asn Gln Thr Lys Lys Pro Glu Thr Tyr Leu 100 105 110

Met Pro Lys Asp Gly Lys Ser Thr Ala Thr Asp Ile Thr Gly Pro Ile 115 120 125

Ile Leu Gln Thr Tyr Arg Ala Ile Ala Asn Tyr Glu Lys 130 135 140

<210> 1222

<211> 29

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (9)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (24)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 1222

Arg Cys Pro Val Thr Val Cys Gly Xaa Val His Gly Gln Phe His Asp 1 5 10 15

Leu Met Glu Leu Phe Arg Ile Xaa Gly Lys Ser Pro Asp 20 25

<210> 1223

<211> 43

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (2)

<223> Xaa equals any of the naturally occurring L-amino acids

```
<220>
<221> SITE
<222> (3)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (6)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (8)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (10)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (19)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (24)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (37)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (40)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (41)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1223
Leu Xaa Kaa Gln Ile Xaa Tyr Xaa Thr Xaa Pro Thr Ser Leu Pro Arg
                  5
                                     10
Thr Ser Xaa Cys Leu His Ala Xaa Thr Ser Trp Lys Gln Ser Leu Leu
                                                      30
            20
                                 25
```

Gly Cys Leu Asn Xaa Lys Leu Xaa Xaa Ala Thr 35 40

<210> 1224

<211> 94

<212> PRT

<213> Homo sapiens

<400> 1224

Ala Asp Ala Trp Gly Lys Thr Phe Ala Arg Tyr Leu Ser Phe Arg Arg
1 5 10 15

Asp Asn Asn Glu Leu Leu Leu Phe Ile Leu Lys Gln Leu Val Ala Glu 20 25 30

Gln Val Thr Tyr Gln Arg Asn Arg Phe Gly Ala Gln Gln Asp Thr Ile 35 40 45

Glu Val Pro Glu Lys Asp Leu Val Asp Lys Ala Arg Gln Ile Asn Ile
50 55 60

His Asn Leu Ser Ala Phe Tyr Asp Ser Glu Leu Phe Arg Met Asn Lys
65 70 75 80

Phe Ser His Asp Leu Lys Arg Lys Met Ile Leu Gln Gln Phe 85 90

<210> 1225

<211> 71

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (10)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 1225

Gly Arg Pro Thr Arg Pro Pro Thr Leu Xaa Leu Ala Trp Thr Ser Gly
1 5 10 15

Thr Asn Cys Thr Arg Phe Gly Ile Ala Ala Lys Tyr Gln Leu Asp Pro 20 25 30

Thr Ala Ser Ile Ser Ala Lys Val Asn Asn Ser Ser Leu Ile Gly Val
35 40 45

```
Gly Tyr Thr Gln Thr Leu Arg Pro Gly Val Lys Leu Thr Leu Ser Gly
     50
Ser Gly Arg Trp Glu Glu His
                     70
<210> 1226
<211> 154
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (105)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (131)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (135)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (142)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (145)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (151)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1226
Gly Lys Met Val Leu Gln Thr Gln Val Phe Ile Ser Leu Leu Trp
Ile Ser Gly Ala Tyr Gly Asp Ile Val Met Thr Gln Ser Pro Asp Ser
             20
                                 25
```

Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser 35 40 45

Gln Ser Val Leu Tyr Ser Ser Asn Asn Lys Asn Tyr Leu Thr Trp Tyr 50 55 60

Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Leu Tyr Trp Ala Ser 65 70 75 80

Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly 85 90 95

Thr Asp Phe Thr Leu Thr Ile Ser Xaa Leu Gln Ala Glu Asp Val Ala 100 105 110

Asp Tyr Tyr Cys Gln Gln Tyr Tyr Thr Thr Pro Trp Thr Phe Gly His 115 120 125

Trp Thr Xaa Val Glu Ile Xaa Arg Asn Cys Gly Cys Thr Xaa Cys Leu 130 135 140

Xaa Phe Pro Pro Ser Gly Xaa Gln Leu Lys 145 150

<210> 1227

<211> 101

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (32)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 1227

Trp Leu Ile Leu Ala Val Ile Ser Val Tyr Asp Leu Val Ala Val Leu 1 5 10 15

Cys Pro Lys Gly Pro Leu Arg Met Leu Val Glu Thr Ala Gln Glu Xaa 20 25 30

Asn Glu Thr Leu Phe Pro Ala Leu Ile Tyr Ser Ser Thr Met Val Trp 35 40 45

Leu Val Asn Met Ala Glu Gly Asp Pro Glu Ala Gln Arg Arg Val Ser 50 55 60

Lys Asn Ser Lys Tyr Asn Ala Glu Ser Thr Glu Arg Ser His Lys Thr 65 70 75 80

Leu Leu Gln Arg Met Met Met Ala Gly Ser Val Arg Asn Gly Lys Pro

```
90
Arg Arg Thr Val Ile
             100
<210> 1228
<211> 75
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (22)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (32)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (33)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (39)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (46)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (57)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (69)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
```

```
<222> (72)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1228
Leu Ile Ser Gly Lys Asp Cys Ala Val Ile Val Thr Gln Lys Lys Val
Pro Asp Lys Leu Leu Xaa Ser Ser Thr Val Thr His Leu Phe Lys Xaa
                                 25
Xaa Gly Asn Ile Gly Cys Xaa Lys Thr Gly Met Ser Ala Xaa Ser Arg
         35
                             40
Ser Gln Val Gln Arg Ala Arg Tyr Xaa Ala Ala Asn Leu Glu Tyr Lys
Tyr Gly Tyr Glu Xaa Pro Val Xaa Met Pro Val
                     70
<210> 1229
<211> 46
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (6)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1229
Asn Thr Leu Ile Leu Xaa Pro Ser Lys Asn His Leu Lys Ala Ala Gly
                                     10
His Leu Tyr Ile Val Met Glu Tyr Cys Asp Gly Arg Asp Leu Met Gln
                                25
Lys Ile Lys Gln Gln Lys Arg Lys Ser Tyr Phe Leu Lys Thr
         35
                             40
<210> 1230
<211> 136
<212> PRT
<213> Homo sapiens
```

<220> <221> SITE <222> (51)

```
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (64)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (73)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (120)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (123)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (129)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (134)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1230
Lys Thr Ile Arg Cys Val Cys Thr Trp Arg Leu His Leu Leu Ala Ser
                  5
Thr Tyr Ala Cys Ser Gln Asn Thr Asn Lys Thr Cys Glu Glu Cys Leu
                                 25
                                                      30
             20
Lys Asn Val Ser Cys Leu Trp Cys Asn Thr Asn Lys Leu Val Leu Asp
         35
                             40
Tyr Gln Xaa Gln Ser Leu Ala Thr Gly Phe Pro Leu Leu Ile Asn Xaa
Leu His Leu Gly Asn Phe Val Gly Xaa Asn Leu Glu Ala Leu Asn His
65
                     70
                                          75
His Met Phe Gly Ser Pro Gly Asn Pro Pro Pro Gly Ala Leu Ala Ser
                                                          95
                 85
                                      90
```

Ala Ala Cys Leu Leu Ala Ala Arg Arg Lys Lys Glu Pro Glu Thr Arg

105

100

```
Thr Gly Ile Lys Glu Lys Arg Xaa Cys Val Xaa Pro Glu Arg Lys Ser
                             120
Xaa Ile Pro Ala Gly Xaa Thr Glu
    130
                        135
<210> 1231
<211> 105
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (3)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (84)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (93)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (102)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1231
Leu Pro Xaa Gly Ala Gly Gly Met Ser Lys Gly Leu Pro Ala Arg Gln
Asp Met Glu Lys Glu Arg Glu Thr Leu Gln Ala Trp Lys Glu Arg Val
                                 25
Gly Gln Glu Leu Asp Arg Val Val Ala Phe Trp Met Glu His Ser His
         35
                             40
Asp Gln Glu His Gly Gly Phe Phe Thr Cys Leu Gly Arg Glu Gly Arg
     50
                         55
Val Tyr Asp Asp Leu Lys Tyr Val Trp Leu Gln Gly Arg Gln Val Trp
65
                     70
                                         75
```

WO 00/55351 1349 PCT/US00/05883

Met Tyr Cys Xaa Pro Val Pro His Phe Arg Ala Leu Xaa Pro Cys Ser 85 90 95

Ala Ser Gly Arg Ser Xaa Ser Arg Trp
100 105

<210> 1232

<211> 99

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (14)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (95)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 1232

Asn Ser Ala Arg Ala Glu Val Thr Asp Glu Tyr Lys Asn Xaa Val Lys 1 5 10 15

Asn Arg Ser Val Tyr Ile Lys Gly Phe Pro Thr Asp Ala Thr Leu Asp 20 25 30

Asp Ile Lys Glu Trp Leu Glu Asp Lys Gly Gln Val Leu Asn Ile Gln 35 40 45

Met Arg Arg Thr Leu His Lys Ala Phe Lys Gly Ser Ile Phe Val Val 50 55 60

Phe Asp Ser Ile Glu Ser Ala Lys Lys Phe Val Glu Ala Pro Gly Gln 65 70 75 80

Lys Tyr Lys Glu Pro Asp Leu Leu Ile Leu Phe Lys Ala Gly Xaa Phe 85 90 95

Ala Lys Lys ·

<210> 1233

<211> 80

<212> PRT

WO 00/55351 1350 PCT/US00/05883

<213> Homo sapiens

<400> 1233

Pro Phe Gly Thr Gly Pro Glu Phe Pro Gly Leu Pro Ser Ser Phe
1 5 10 15

Leu Arg His Arg Gly Val Phe Leu Thr Pro Leu Leu Ala Met Ser Ser 20 25 30

His Lys Thr Phe Arg Ile Lys Arg Phe Leu Ala Lys Lys Gln Lys Gln 35 40 45

Asn Arg Pro Ile Pro Gln Trp Ile Arg Met Lys Thr Gly Asn Lys Ile
50 55 60

Arg Tyr Asn Ser Lys Arg Arg His Trp Arg Arg Thr Lys Leu Gly Leu 65 70 75 80

<210> 1234

<211> 83

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (4)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 1234

Val Thr Leu Xaa Lys Val Arg Leu Gln Val Pro Val Arg Asn Ser Arg

1 5 10 15

Val Asp Pro Arg Val Arg Arg Pro Thr Arg Pro Pro Thr Arg Pro Pro 20 25 30

Thr Arg Pro Pro Thr Arg Pro Leu Cys Arg Lys Met Gly Val Pro Tyr 35 40 45

Cys Ile Ile Lys Gly Lys Ala Arg Leu Gly Arg Leu Val His Arg Lys 50 55 60

Thr Cys Thr Thr Val Ala Phe Thr Gln Val Asn Ser Glu Arg Gln Arg 65 70 75 80

Arg Phe Gly

<210> 1235 <211> 161 <212> PRT <213> Homo sapiens <400> 1235 Arg Glu Gln Lys Lee

Arg Glu Gln Lys Leu Glu Leu His Arg Gly Ala Ala Ala Leu Glu Leu 1 5 10 15

Val Asp Pro Pro Gly Cys Arg Asn Ser Ala Arg Gly Ala Ala Thr Met 20 25 30

Val Arg Met Asn Val Leu Ala Asp Ala Leu Lys Ser Ile Asn Asn Ala 35 40 45

Glu Lys Arg Gly Lys Arg Gln Val Leu Ile Arg Pro Cys Ser Lys Val
50 55 60

Ile Val Arg Phe Leu Thr Val Met Met Lys His Gly Tyr Ile Gly Glu 65 70 75 80

Phe Glu Ile Ile Asp Asp His Arg Ala Gly Lys Ile Val Val Asn Leu $85 \hspace{1cm} 90 \hspace{1cm} 95$

Thr Gly Arg Leu Asn Lys Cys Gly Val Ile Ser Pro Arg Phe Asp Val

Gln Leu Lys Asp Leu Glu Lys Trp Gln Asn Asn Leu Leu Pro Ser Arg 115 120 125

Gln Phe Gly Phe Ile Val Leu Thr Thr Ser Ala Gly Ile Met Asp His 130 135 140

Glu Glu Ala Arg Arg Lys His Thr Gly Gly Lys Ile Leu Gly Phe Phe 145 150 155 160

Phe

<210> 1236

<211> 152

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

```
<222> (2)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (43)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (106)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (138)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (150)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (151)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (152)
<223> Xaa equals any of the naturally occurring L-amino acids
Leu Xaa Arg Ala Leu Phe Lys Arg Asn Pro Ala Asn Arg Leu Gly Ser
                  5
                                     10
Gly Pro Asp Gly Ala Glu Glu Ile Lys Arg His Val Phe Tyr Ser Thr
                                 25
             20
Ile Asp Trp Asn Lys Leu Tyr Arg Arg Glu Xaa Thr Pro Pro Phe Lys
                              40
Pro Ala Val Ala Gln Pro Asp Asp Thr Phe Tyr Phe Asp Thr Glu Phe
     50
                         55
Thr Ser Arg Thr Pro Lys Asp Ser Pro Gly Ile Pro Pro Ser Ala Gly
                                         75
                     70
Ala His Gln Leu Phe Arg Gly Phe Ser Phe Val Ala Thr Gly Leu Met
                                     90
                 85
```

```
Glu Asp Asp Gly Lys Pro Arg Ala Pro Xaa Ala Pro Leu His Ser Val
                                105
            100
Val Gln Gln Leu His Gly Lys Asn Leu Val Phe Ser Asp Gly Tyr Val
                            120
Val Lys Glu Thr Ile Gly Val Gly Ser Xaa Ser Glu Cys Lys Arg Cys
                                            140
Val His Lys Gly Pro Xaa Xaa Xaa
145
                    150
<210> 1237
<211> 73
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (6)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (14)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (20)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (23)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (24)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (43)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
```

WO 00/55351 1354 PCT/US00/05883

```
<221> SITE
<222> (53)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (57)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (71)
<223> Xaa equals any of the naturally occurring L-amino acids
Arg Asp Thr Ser His Xaa Val Ala Gly Ala Leu Arg Pro Xaa Val Gln
Ala Thr Val Xaa Ala Thr Xaa Xaa Gln Pro Val Leu Asp Leu Lys Arg
                                 25
Pro Phe Leu Ser Arg Glu Ser Leu Ser Gly Xaa Ala Cys Asp Arg Leu
                             40
Val Val Asp Ser Xaa Gly Ala Gln Xaa Pro Cys Phe Phe Leu Leu Ile
                         55
     50
Pro Thr Gln Thr Ser Arg Xaa Leu Ile
                     70
65
<210> 1238
<211> 41
<212> PRT
<213> Homo sapiens
<400> 1238
Met Gly Phe Ser Leu Ile Pro Ser Ser Phe Ser His Leu Ala Asp Asn
                                     10
                  5
Thr Thr Ser Leu Thr Asp Lys His Leu Asp Pro Ile Arg Glu Asn Leu
             20
                                 25
```

<210> 1239 <211> 42

35

Gly Lys His Trp Glu Lys Leu Cys Pro

```
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (7)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (18)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (29)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (39)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (41)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1239
His Asp Ser Cys Lys Lys Xaa Thr Lys His Tyr Glu Met Leu Ala Asn
                  5
Arg Xaa Ala Ala Asn Gly His Cys Ile Asp Ile Tyr Xaa Cys Ala Pro
Asp Gln Thr Gly Leu Leu Xaa Leu Xaa Cys
         35
<210> 1240
<211> 106
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (13)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
```

WO 00/55351

1356

<221> SITE <222> (65)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (98)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 1240

Leu Glu Ser Leu Gln Glu Asn His Phe Gln Glu Asp Xaa Gln Phe Leu
1 5 10 15

Gly Ala Val Met Pro Arg Leu Gly Ile Gly Met Asp Thr Cys Val Ile
20 25 30

Pro Leu Lys His Gly Gly Leu Ser Leu Val Gln Thr Thr Asp Tyr Ile 35 40 45

Tyr Pro Ile Val Asp Asp Pro Tyr Met Met Thr Pro Ala Val Ala Glu
50 55 60

Xaa Arg Pro Val Pro Cys Pro His Leu Ala Leu Gly Ile Lys Gln Leu 65 70 75 80

Gly Arg Lys Gln Glu Ser Pro Leu Leu Leu Leu Gln Leu Asn Thr Cys 85 90 95

Trp Xaa Asp Asn Met Cys Gln Cys Pro Gln 100 105

<210> 1241

<211> 77

<212> PRT

<213> Homo sapiens

<400> 1241

Ser Arg Pro Val Gly Ser Gly Cys Asp Asn Pro Ser Asn Val Glu Lys
1 5 10 15

Pro Gly Ala Cys Leu Ala Leu Cys Leu Leu Pro Ser Gly Gly Thr Glu 20 25 30

Ser Gln Asp Gln Ser Ser Leu Cys Lys Gln Pro Pro Ala Gly His Lys
35 40 45

Arg Ser Arg Ser Met Leu Asn Ser Asn Gly Ser Val Thr Val Val Val 50 55 60

Phe Phe Lys Pro Ala Asp Thr Cys His Thr Ala Gly Ile 65 70 75

<210> 1242

<211> 110

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (103)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 1242

Arg Leu Ala Ile Thr Gly Leu Thr Met Glu Arg Lys Val Leu Ala Leu 1 5 10 15

Gln Ala Arg Lys Lys Arg Thr Lys Ala Lys Lys Asp Lys Ala Gln Arg
20 25 30

Lys Ser Glu Thr Gln His Arg Gly Ser Ala Pro His Ser Glu Ser Asp 35 40 45

Leu Pro Glu Glu Glu Glu Ile Leu Gly Ser Asp Asp Glu Gln 50 55 60

Glu Asp Pro Asn Asp Tyr Cys Lys Gly Gly Tyr His Leu Val Lys Ile
65 70 75 80

Gly Asp Leu Phe Asn Gly Arg Tyr His Val Ile Arg Lys Leu Gly Trp
85 90 95

Gly His Phe Ser Thr Val Xaa Val Ile Met Gly Tyr Ser Ser 100 105 110

<210> 1243

<211> 101

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (1)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

```
<222> (4)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (7)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (11)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (34)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (38)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (50)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (63)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (74)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (86)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (88)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (93)
```

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (94)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 1243

Xaa Thr Ile Xaa Glu Glu Xaa Val Pro Leu Xaa Val Pro Val Arg Asn 1 5 10 15

Ser Arg Val Asp Pro Arg Val Arg Tyr Asp Asn Leu Ile Thr Pro Ala 20 25 30

Met Xaa Gly Ala Gly Xaa Leu Gln Gly Asn Val Asp Ser Cys Gln Gly 35 40 45

Asp Xaa Gly Gly Pro Leu Val Thr Ser Lys Asn Asn Ile Trp Xaa Leu 50 55 60

Ile Gly Asp Thr Ser Trp Gly Ser Gly Xaa Ala Lys Ala Tyr Arg Pro 65 70 75 80

Gly Val Tyr Gly Asn Xaa Met Xaa Phe Thr Asp Trp Xaa Xaa Arg Gln 85 90 95

Met Arg Ala Asp Gly 100

<210> 1244

<211> 80

<212> PRT

<213> Homo sapiens

<400> 1244

Gly Val Tyr Thr Met Ser Lys Ala His Pro Pro Glu Leu Lys Lys Phe 1 5 10 15

Met Asp Lys Leu Ser Leu Lys Leu Asn Gly Gly Arg His Val Gln
20 25 30

Gly Ile Leu Arg Gly Phe Asp Pro Phe Met Asn Leu Val Ile Asp Glu 35 40 45

Cys Val Glu Met Ala Thr Ser Gly Gln Gln Asn Asn Ile Gly Met Val 50 55 60

Val Ile Arg Gly Asn Ser Ile Ile Met Leu Glu Ala Leu Glu Arg Val 65 70 75 80

PCT/US00/05883

<210> 1245 <211> 129 <212> PRT <213> Homo sapiens <220> <221> SITE <222> (128) <223> Xaa equals any of the naturally occurring L-amino acids <400> 1245 Phe Ile Met Asp Asn Leu Ser Ser Glu Glu Ile Gln Gln Arg Ala His Gln Ile Thr Asp Glu Ser Leu Glu Ser Thr Arg Arg Ile Leu Gly Leu 20 Ala Ile Glu Ser Gln Asp Ala Gly Ile Lys Thr Ile Thr Met Leu Asp 40 35 Glu Gln Lys Glu Gln Leu Asn Arg Ile Glu Glu Gly Leu Asp Gln Ile Asn Lys Asp Met Arg Glu Thr Glu Lys Thr Leu Thr Glu Leu Asn Lys 70 75 Cys Cys Gly Leu Cys Val Cys Pro Cys Asn Arg Thr Lys Asn Phe Glu 85 Ser Gly Lys Ala Tyr Lys Thr Thr Trp Gly Asp Gly Glu Asn Ser 100 105 Pro Cys Asn Val Val Ser Lys Gln Pro Gly Pro Val Thr Asn Gly Xaa 125 120

Leu

<210> 1246 <211> 136 <212> PRT

<213> Homo sapiens

<220> <221> SITE <222> (134) <223> Xaa equals any of the naturally occurring L-amino acids <400> 1246 Ser Thr Glu Gly Tyr Gly Cys Glu Lys Thr Thr Glu Gly Tyr Gly Cys 5 Glu Lys Thr Thr Glu Gly Gly Ser Met Ala Tyr Pro Gly His Pro Gly 20 Ala Gly Gly Gly Tyr Tyr Pro Gly Gly Tyr Gly Gly Ala Pro Gly Gly 40 Pro Ala Phe Pro Gly Gln Thr Gln Asp Pro Leu Tyr Gly Tyr Phe Ala 55 Ala Val Ala Gly Gln Asp Gly Gln Ile Asp Ala Asp Glu Leu Gln Arg 65 70 Cys Leu Thr Gln Ser Gly Ile Ala Gly Gly Tyr Lys Pro Phe Asn Leu Glu Thr Cys Arg Leu Met Val Ser Met Leu Asp Arg Asp Met Ser Gly 105 Thr Met Gly Phe Asn Glu Phe Lys Glu Leu Trp Ala Val Leu Asn Gly 120 Trp Arg Gln His Phe Xaa Asn Phe 130 135 <210> 1247 <211> 87 <212> PRT <213> Homo sapiens <220> <221> SITE <222> (6) <223> Xaa equals any of the naturally occurring L-amino acids <220>

<223> Xaa equals any of the naturally occurring L-amino acids

<221> SITE <222> (23)

<220>

```
<221> SITE
<222> (34)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (43)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (50)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (61)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (62)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (78)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (83)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1247
His Ser Gly Gly Pro Xaa Arg Pro Ala Val Ala Asp Val Gly Leu Gly
                  5
                                     10
Gly Arg Ala Arg Arg Xaa Pro Thr Gly Ala Ser Thr Trp Gly Thr
                                 25
Ser Xaa Arg Arg Ala Arg Glu Gly Thr Trp Xaa Asp Leu Phe Tyr Lys
                             40
Tyr Xaa Arg Ile Arg Glu Ile Glu Leu Lys Asn Arg Xaa Xaa Ser Ser
     50
                                             60
                         55
Cys Arg Pro Ser Cys Ala Ser Arg Asn Pro Arg Asp Ala Xaa Asp Ala
                                         75
65
                     70
```

Ile Tyr Xaa Lys Lys Trp Leu

```
<210> 1248
<211> 112
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (1)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (3)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (6)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (40)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (43)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (57)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (58)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (68)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
```

```
<222> (84)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (95)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (100)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (103)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (106)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1248
Xaa Ser Xaa Phe Gly Xaa Pro Ala Arg Arg Ser Gly Pro Glu Leu Pro
Gly Arg Pro Thr Arg Pro Ala Thr Ile Leu Lys Gln Met Gln Val Leu
His Pro Ala Ala Arg Met Leu Xaa Glu Leu Xaa Lys Ala Gln Asp Ile
         35
Glu Ala Gly Asp Gly Thr Thr Ser Xaa Xaa Ile Ile Ala Gly Ser Leu
                         55
Leu Asp Ser Xaa Thr Lys Leu Leu Gln Lys Gly Ile His Pro Thr Ile
                     70
                                         75
Ile Ser Glu Xaa Phe Gln Lys Ala Leu Glu Lys Gly Ile Glu Xaa Leu
                                     90
Thr Asp Met Xaa Arg Pro Xaa Glu Leu Xaa Asp Arg Glu Thr Leu Val
            100
                                105
                                                    110
```

<211> 113 <212> PRT <213> Homo sapiens <220> <221> SITE <222> (110) <223> Xaa equals any of the naturally occurring L-amino acids <400> 1249 Lys Phe Met Asn Ser Arg Val Phe Lys Lys Ile Gln Ala Leu Lys Ala Ser Pro Ser Lys Lys Arg Cys Asn Ser Ile Ala Ala Leu Lys Ala Thr 25 Ser Gln Glu Ile Val Ser Ser Ile Ser Gln Glu Trp Lys Asp Glu Lys 35 40 Arg Asp Leu Leu Thr Glu Gly Gln Ser Phe Ser Ser Leu Asp Glu Glu 55 Ala Leu Gly Ser Arg His Arg Pro Asp Leu Val Pro Ser Thr Pro Ser 75 Leu Phe Glu Ala Ala Ser Leu Ala Thr Thr Ile Ser Leu Leu Pro Ile 85 90 95 Arg Gln Trp Ala Leu Ser Thr Arg Gln Gly Leu Gln Phe Xaa Gln Thr 105 100 Arg <210> 1250 <211> 76 <212> PRT <213> Homo sapiens <220> <221> SITE

<223> Xaa equals any of the naturally occurring L-amino acids

<223> Xaa equals any of the naturally occurring L-amino acids

<222> (2)

<220> <221> SITE <222> (24)

```
<220>
<221> SITE
<222> (37)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (53)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (75)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1250
Gly Xaa His Val Phe Arg Asn Ile His Lys Thr Asn Leu Cys Asp Leu
  1
                                     10
Ile Thr Ser Leu Leu Cys Leu Xaa Val Leu Leu Pro Thr Lys Glu Leu
                                 25
Asn Glu His Phe Xaa Ser Lys Leu Lys Ala Pro Ile Pro Ile Glu Leu
                             40
Val Val Val Xaa Ala Thr Leu Thr Ser His Phe Gly Lys Leu His
     50
Glu Asn Tyr Asn Ser Ser Ile Ala Gly His Xaa Pro
 65
                     70
<210> 1251
<211> 151
<212> PRT
<213> Homo sapiens
<400> 1251
Leu Val Ser Asn Gly Pro Ala Asp Thr Leu Asp Leu Thr Tyr Trp Ile
                  5
Asp Gly Thr Arg His Val Val Ser Leu Glu Asp Val Gly Leu Ala Asp
             20
                                 25
Ser Gln Trp Lys Asn Val Thr Val Gln Val Ala Gly Glu Thr Tyr Ser
                             40
```

Leu His Val Gly Cys Asp Leu Ile Asp Ser Phe Ala Leu Asp Glu Pro

Phe Tyr Glu His Leu Gln Ala Glu Lys Ser Arg Met Tyr Val Ala Lys 65 70 75 80

Gly Ser Ala Arg Glu Ser His Phe Arg Gly Leu Leu Gln Asn Val His
85 90 95

Leu Val Phe Glu Asn Ser Val Glu Asp Ile Leu Ser Lys Lys Gly Cys
100 105 110

Gln Gln Gly Gln Gly Gly Arg Cys Val Val Lys Asn Ala Phe Tyr Ile 115 120 125

Leu Ala Trp Met Asp Phe Tyr Cys Asp Met Val Tyr Val Cys Val Cys 130 135 140

Met Cys Val His Ser Cys Leu 145 150

<210> 1252

<211> 56

<212> PRT

<213> Homo sapiens

<400> 1252

Lys Asn Gly Thr Ser Leu Cys Phe Ser Ser Ala Thr Met Ser Asp Lys
1 5 10 15

Pro Asp Met Ala Glu Ile Glu Lys Phe Asp Lys Ser Lys Leu Lys Lys
20 25 30

Thr Glu Thr Glu Lys Asn Pro Leu Pro Ser Lys Glu Thr Ile Glu
35 40 45

Gln Glu Lys Gln Ala Gly Glu Ser 50 55

<210> 1253

<211> 74

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (5)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

```
<221> SITE
<222> (22)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (32)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (42)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (43)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (44)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (45)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (49)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (54)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (60)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (62)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
```

```
<222> (65)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (67)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1253
Ala Glu Gly Pro Xaa Ala Ala Leu Leu Leu Ser Leu Leu Leu Phe
                                     10
                  5
Gly Phe Thr Leu Val Xaa Gly Thr Gly Ala Glu Lys Thr Gly Val Xaa
Pro Glu Leu Gln Ala Ala Pro Ala Thr Xaa Xaa Xaa Cys Val Leu
                             40
Xaa Asn Ser Glu Met Xaa Arg Thr Thr Ser Lys Xaa Leu Xaa Gly Gly
     50
                         55
                                              60
Xaa Val Xaa Pro Ser Ala Ser Leu Pro Gln
 65
                     70
<210> 1254
<211> 129
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (94)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (109)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (112)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (116)
<223> Xaa equals any of the naturally occurring L-amino acids
```

<220> <221> SITE <222> (121) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (125) <223> Xaa equals any of the naturally occurring L-amino acids <400> 1254 Ser Pro Ala Arg Pro Leu Ile Arg Ser Asp Lys Met Lys Glu Thr Ile 5 10 Met Asn Gln Glu Lys Leu Ala Lys Leu Gln Ala Gln Val Arg Ile Gly 20 Gly Lys Gly Thr Ala Arg Arg Lys Lys Lys Val Val His Arg Thr Ala Thr Ala Asp Asp Lys Lys Leu Gln Phe Ser Leu Lys Lys Leu Gly Val 55 Asn Asn Ile Ser Gly Ile Glu Glu Val Asn Met Phe Thr Asn Gln Gly 70 65 Thr Val Ile His Phe Asn Asn Pro Lys Val Gln Ala Ser Xaa Ala Ala Asn Thr Phe Thr Ile Thr Gly His Ala Glu Thr Lys Xaa Leu Thr Xaa 105

Phe

115

<210> 1255
<211> 188
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (1)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>

Met Leu Pro Xaa Ile Leu Asn Gln Xaa Gly Ala Asp Xaa Leu Thr Lys

120

```
<221> SITE
<222> (31)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (99)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (102)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (165)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (183)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (188)
<223> Xaa equals any of the naturally occurring L-amino acids
Xaa Thr Ser Leu Glu Thr Pro Val Pro Val Leu Asn Ser Arg Leu Asp
                                      10
                  5
Pro Arg Val Arg Met Thr Val Pro Gly Ala Ser Pro Glu Asp Xaa Trp
                                 25
             20
Val Lys Val Glu Tyr Ala Tyr Ser Asp Asn Ser Leu Asp Pro Gly Leu
                             40
Phe Val Glu Ser Thr Arg Lys Gly Ser Val Val Ser Arg Ala Asn Ser
     50
                         55
Ile Gly Ser Thr Ser Ala Ser Ser Val Pro Asn Thr Asp Asp Glu Asp
 65
                     70
Ser Asp Tyr His Gln Glu Ala Tyr Lys Glu Ser Tyr Lys Asp Arg Arg
                                     90
Arg Arg Xaa Thr His Xaa Arg Leu Glu Gln Lys Arg Arg Asp Ala Ile
            100
                                105
```

Lys Arg Gly Tyr Asp Asp Leu Gln Thr Ile Val Pro Thr Cys Gln Gln 115 120 125

Gln Asp Phe Ser Ile Gly Ser Gln Lys Leu Ser Lys Ala Ile Val Tyr 130 135 140

Lys Arg Pro Leu Thr Thr Phe Ser Phe Cys Thr Arg Arg Arg Lys Ser 145 150 155 160

Arg Arg Arg Arg Xaa His Val Thr Gln Gly Cys Thr Gly Leu Lys Ile 165 170 175

Met Lys Val Asn Tyr Glu Xaa Ile Val Lys Ala Xaa 180 185

<210> 1256

<211> 66

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (17)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (27)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (39)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (55)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (65)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 1256

Leu Pro Cys Val Lys Val Pro Val Arg Asn Ser Arg Val Asp Pro Arg

1 5 10 15

```
Xaa Arg Ala Arg Met Leu Asn Leu Leu Leu Xaa Ala Leu Ala Val Leu
                                  25
Ala Ser Arg Ala Tyr Ala Xaa Pro Ala Pro Gly Gln Ala Leu Gln Arg
Val Gly Ile Val Gly Gly Xaa Glu Ala Pro Arg Ser Lys Trp Pro Trp
     50
Xaa Val
 65
<210> 1257
<211> 146
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (2)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (6)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (12)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (131)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (135)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (138)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
```

<222> (145) <223> Xaa equals any of the naturally occurring L-amino acids <400> 1257 Gly Xaa Glu Gly Lys Xaa Phe Ser Val Ser Gly Xaa Trp Ser Ser Thr 5 Ala Val Ala Ala Ala Leu Glu Leu Val Asp Pro Pro Gly Cys Arg Asn 20 25 Ser Ala Arg Ala Ala Gln Gln Arg Leu Thr Leu Cys Leu Arg Gly Arg Glu Ser Pro Gly Gly Arg His Gly Gly Val Gly Glu Pro Ala Gln Glu 60 Asn Gly Val Gln Val Phe Asn Asp Gly Ser Ser Arg Glu Leu Met Asn 75 65 70 Leu Thr Gly Thr Ile Pro Val Pro Tyr Arg Gly Asn Thr Tyr Asn Ile 90 Pro Ile Cys Leu Trp Leu Leu Asp Thr Tyr Pro Tyr Asn Pro Pro Ile 105 Cys Phe Val Lys Pro Thr Ser Ser Met Thr Ile Lys Thr Gly Lys His 115 Val Asp Xaa Pro Lys Lys Xaa Gly Gly Xaa Lys Lys Gly Lys Ile Leu 130 135 Xaa Phe 145 <210> 1258

<211> 35
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (1)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (20)
<221> SITE

```
<220>
<221> SITE
<222> (21)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (26)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (27)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (32)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1258
Xaa Ile Pro Pro Asp His Gln Thr Leu Ile Phe Ala Gly Lys His Leu
                                      10
  1
Glu Asn Gly Xaa Xaa Leu Ser Asp Tyr Xaa Xaa His Lys Glu Ser Xaa
                                  25
Leu His Leu
         35
<210> 1259
<211> 73
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (8)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (11)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (43)
<223> Xaa equals any of the naturally occurring L-amino acids
```

```
<220>
<221> SITE
<222> (48)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1259
Val Lys Val Cys Met Met Met Xaa Leu Leu Xaa His Arg Leu Leu Lys
                                     10
Trp Ser Trp Ile Val Arg Ser Lys Leu Leu Gln Asp Pro Pro Val
                                 25
Thr Tyr Ile Gln Gln Phe Ala Asp Ala Ala Xaa Asn Leu Thr Ser Xaa
                             40
                                                 45
Asp Ser Glu Lys Trp Asn Ser Val Phe Pro Lys Pro Gly Thr Leu Val
                                             60
                         55
Gln Val Leu Glu Ala Ala Lys Phe Ala
                     70
 65
<210> 1260
<211> 95
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (5)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (6)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (7)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (38)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
```

```
<222> (40)
  <223> Xaa equals any of the naturally occurring L-amino acids
  <220>
  <221> SITE
  <222> (42)
  <223> Xaa equals any of the naturally occurring L-amino acids
  <220>
  <221> SITE
  <222> (52)
  <223> Xaa equals any of the naturally occurring L-amino acids
  <220>
  <221> SITE
  <222> (65)
  <223> Xaa equals any of the naturally occurring L-amino acids
  <220>
  <221> SITE
  <222> (68)
  <223> Xaa equals any of the naturally occurring L-amino acids
  <220>
  <221> SITE
  <222> (76)
 <223> Xaa equals any of the naturally occurring L-amino acids
. <220>
 <221> SITE
 <222> (80)
 <223> Xaa equals any of the naturally occurring L-amino acids
 <400> 1260
 Leu Cys Ser Thr Xaa Xaa Xaa Arg His Asn Ile Gln Lys Glu Leu Cys
                    5
                                       10
                                                            15
 Leu His Ala Ala Gln Gly Leu Ala Gln Leu Lys Ala Cys Thr Tyr Lys
                                   25
               20
 Gly His Lys Thr Gly Xaa Thr Xaa Glu Xaa Ile Trp Glu Ile Gln Lys
                               40
 Asp Gln Leu Xaa Tyr Tyr Pro Phe Leu Lys Met Cys Leu Ser Ala Asn
                           55
 Xaa Glu His Xaa Ser Leu Val Asp Ala Thr His Xaa Asn His Ser Xaa
  65
                       70
                                           75
 Asn Gly Tyr Leu Ala Lys Met Ile Lys Arg Ser Leu Lys Leu Thr
```

90

85

```
<210> 1261
<211> 94
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (44)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (86)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (91)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1261
Phe Gly Thr Arg Lys Arg Met Glu Thr Lys Gly Ala Gly Val Thr Leu
Asn Val Leu Glu Met Thr Ser Glu Asp Leu Glu Asn Ala Leu Lys Ala
             20
                                 25
Val Ile Asn Asp Lys Ser Tyr Lys Glu Asn Ile Xaa Arg Leu Ser Ser
         35
Leu His Lys Asp Arg Pro Val Glu Pro Leu Asp Leu Ala Val Phe Trp
                         55
Val Glu Phe Val Met Arg His Lys Gly Ala Pro His Leu Arg Pro Ala
                     70
                                         75
Pro His Gly Pro His Xaa Val Pro Val Pro Xaa Pro Trp Pro
                 85
<210> 1262
<211> 66
```

<213> Homo sapiens
<400> 1262
Gly Thr Gly Gln His Trp His Ser Gln Ala Val Gly Lys Gly Arg Asp

<212> PRT

15 1 5 10 Ala Glu Val Val Ser Ile Leu Thr Phe Arg Gly Leu Phe Leu Phe Val 20 25 Leu Ile Phe Ala Arg Leu Ile Leu Lys Thr His Val Glu Glu Leu Lys 40 Glu Cys Leu Glu Asp Gln Lys Ser Pro Met Thr Gly Thr Lys Ala Thr Asn Phe 65 <210> 1263 <211> 121 <212> PRT <213> Homo sapiens <220> <221> SITE <222> (80) <223> Xaa equals any of the naturally occurring L-amino acids <400> 1263 Asn Thr Met Ala Val Ala Ala Val Lys Trp Val Met Ser Lys Arg Thr 5 10 Ile Leu Lys His Leu Phe Pro Val Gln Asn Gly Ala Leu Tyr Cys Val . 30 20 Cys His Lys Ser Thr Tyr Ser Pro Leu Pro Asp Asp Tyr Asn Cys Asn 40 Val Glu Leu Ala Leu Thr Ser Asp Gly Arg Thr Ile Val Cys Tyr His 55 Pro Ser Val Asp Ile Pro Tyr Glu His Thr Lys Pro Ile Pro Arg Xaa 65 70 Asp Pro Val His Asn Asn Glu Glu Thr His Asp Gln Val Leu Lys Thr 90 85 Arg Leu Glu Glu Lys Val Glu His Leu Glu Glu Gly Pro Met Ile Glu 105 Gln Leu Ser Lys Met Phe Leu Tyr Tyr

```
<210> 1264
<211> 101
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (67)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (96)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (100)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (101)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1264
Val Ala Ser Gly Val Gly Arg Val Thr Val Asn Ala Tyr Val Ser Leu
Phe Tyr Thr Ile Lys Arg Ala Gln Val Val Ser Pro Glu Arg Val Gly
                                 25
Ser Trp His Ile Gly Arg Pro Ser Asp Pro Val Gln Cys Leu Leu Ala
         35
                             40
                                                 45
Ile Leu Pro Glu Gln Ala Leu Lys Pro Lys Ser His Pro Arg Pro Val.
     50
                         55
Ser Ala Xaa Ala Lys Ala Ser Leu Ser Ser Gly Arg Arg Gly Lys Gly
                     70
65
Ala Gly Asp Gln Ala Leu Ala Leu Gly Pro Ser Phe Ser Pro His Xaa
                                     90
Gly Asn Lys Xaa Xaa
```

```
<210> 1265
<211> 43
<212> PRT
<213> Homo sapiens
<400> 1265
Asp Leu Leu Met Lys Met Thr Ile Ser Cys Cys Phe Tyr Pro Thr Ser
                                      10
                   5
Ala Phe Ser Pro Phe Lys Ala Ala Val Ser Cys Leu Ile Lys Glu Tyr
                                  25
              20
Trp Pro Val Leu Gln Ile Leu Thr Gly Phe Gly
         35
                             40
<210> 1266
<211> 29
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (7)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (9)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (16)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (19)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1266
Gly Ser Trp Pro Gly Ala Xaa Gly Xaa Arg Asp Gly Ser His Gly Xaa
Arg Leu Xaa Ala His Gly Pro Ile Asn Leu Glu Arg Ile
             20
                                 25
```

```
<210> 1267
<211> 59
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (1)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (3)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (5)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (16)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (19)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (42)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (43)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (51)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (59)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1267
```

Xaa Pro Xaa Phe Xaa Gln Glu Leu Ile Gln Asn Phe Pro Asp Lys Xaa Asn Leu Xaa Leu Val Phe Leu Leu Phe Phe Val Leu Val Asn Leu Gly 25 Ser Asn Val Ile Arg Asn Ser Leu Trp Xaa Xaa Ala Thr Asp Ala Gln 40 35 Pro Val Xaa Val Asp Tyr Ser Ser Ser Asn Xaa 55 50 <210> 1268 <211> 49 <212> PRT <213> Homo sapiens <220> <221> SITE <222> (9) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (28) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (37) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (39) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (41) <223> Xaa equals any of the naturally occurring L-amino acids <400> 1268 Val Phe Lys Lys Asn Met Ser Cys Xaa Leu Ser Lys Asn Lys Met His 10

Leu Asn Ser Lys Lys Lys Lys Lys Lys Lys Lys Xaa Gly Gly Arg

```
Gly Lys Lys Lys Xaa Glu Xaa Glu Xaa Leu Lys Lys Gly Arg Gly Ala
                             40
         35
Pro
<210> 1269
<211> 61
<212> PRT
<213> Homo sapiens
<400> 1269
Pro Thr Leu Pro Glu Glu Asn Ser Val Phe Phe Thr Phe His Thr Val
                                     10
Phe Pro Met Arg Glu Gly Ala Gln Pro Glu Ser Thr Thr Ile Met Val
                                 25
Lys Phe Pro Thr Glu Ser Ser Cys Glu Trp Ile Ile Arg Lys Asn Glu
                             40
         35
Glu Ser Lys Arg Gln Lys Ser Lys Asn Arg Trp Gly Leu
                                             60
                         55
<210> 1270
<211> 29
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (27)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (28)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (29)
<223> Xaa equals any of the naturally occurring L-amino acids
Asn Ile Asn Lys Asp His Leu Met His Ala Phe Lys Lys Lys Lys
                                     10
                  5
                                                         15
```

```
Lys Lys Lys Lys Lys Lys Lys Lys Xaa Xaa Xaa 20 25
```

```
<210> 1271
<211> 113
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (35)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (37)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (53)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (60)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (81)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (82)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (111)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1271
Gly Pro Lys Glu Glu Leu Arg Gly Gly Gly Gly Asp Met Ala Asp Leu
```

Pro Arg Arg Val Thr Arg Pro Leu Met Met Gly Leu Gln Gly Ser Ser

20 25 30

Gly Leu Xaa Ala Xaa Thr Val Gln Arg Lys Arg Ala Gly Ile Val Thr 35 40 45

Gly Ser Asp Gly Xaa His Arg Ser Glu Arg Glu Xaa Ala Gly Thr Gly 50 55 60

Ile Val Thr Val Thr Val Thr Ala Ser Thr Asn Gly Gly Ser Gly Ala 65 70 75 80

Xaa Xaa Arg Gly Arg Asp Glu Ala Arg Ser Trp Gly Arg Trp Pro Gly 85 90 95

Gln Arg Val Gly Arg Phe Gly Gln Arg Gln Pro Arg Ile Leu Xaa Glu 100 105 110

Phe

<210> 1272

<211> 87

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (8)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (14)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (20)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (26)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (35)

<223> Xaa equals any of the naturally occurring L-amino acids

```
<220>
<221> SITE
<222> (54)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (70)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (71)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (73)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (76)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1272
Gly Lys Ser Asn Val Leu Trp Xaa Gln Arg Arg Gly Arg Xaa Gln His
                                      10
                                                          15
  1
                  5
Leu Ala Trp Xaa Ser Gln Gly Thr Gln Xaa Arg Ser Pro Pro Gly His
             20
                                 25
Asn Thr Xaa Lys Ala Ser Tyr Ser Gly Val Glu Ser Phe Gln Gln Pro
Gly Pro Val Leu Gly Xaa Tyr Ser His Pro Pro Tyr Arg Cys Val Tyr
                        55
Val Thr Leu Cys His Xaa Xaa Ser Xaa Thr Ile Xaa Asn Ser Gln Glu
                                        75
                                                              80
65
                     70
Ser Pro His Phe Tyr Asn Leu
                 85
```

<210> 1273 <211> 115 <212> PRT

<213> Homo sapiens

<220> <221> SITE <222> (103) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (105) <223> Xaa equals any of the naturally occurring L-amino acids <400> 1273 His Lys Ala Pro Leu Glu His Leu Pro Gly Trp Gln Asp His Ala Ile Ser Val Glu Lys Val Leu Gly Arg Glu Val Leu Pro Val Pro His Gly 25 Val Arg Pro Cys Pro Cys Trp Gly Leu Trp Gly Gly Ile Trp Tyr Ser 35 40 Gly Gly Leu Ala Gln Leu Ser Leu Arg Ser Phe Pro Ile Arg Met Leu 55 Val Asn Ile Leu Arg Ser Ser Leu Phe Ser Asn Lys Glu Tyr Ser Phe Asn Ser Cys Ser Ser Ser Gln Phe Thr Thr Pro Ile Cys Leu Ser Lys 90 Ile His Pro Asn Gly Ile Xaa Gly Xaa Gly Pro Pro Trp Ile Gln Ser 105 100 Val Ser Trp 115 <210> 1274 <211> 37 <212> PRT

<213> Homo sapiens <400> 1274 Glu Leu Val Ser Ser Phe Phe Phe Phe Phe Leu Phe Phe Gly Ser 5 Phe Lys Gly Asn Gly Pro Ser Met Ser Ile Phe Asn Ile Leu His Ser 25

Leu Phe Leu Trp Cys

```
<210> 1275
<211> 107
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (25)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (50)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (57)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (58)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (66)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (67)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (68)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (79)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
```

```
<222> (84)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (87)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (91)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (101)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (102)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (104)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (106)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1275
Asp Cys Gly Thr Leu Ile Ile Tyr His Ala Gly Ser Pro Gln Lys Pro
                                                          15
 1
                  5
                                      10
Cys Ala His Glu Pro Leu Trp Ala Xaa Gly Glu Lys Arg Gly Leu Arg
             20
                                 25
Glu Leu Pro Glu Arg Ala Val Ser Trp Glu Gln Gly Asp Ile Ser Ser
                             40
Pro Xaa Thr Arg Asn Met Thr Gln Xaa Xaa Gly Asn Lys Lys Pro Ser
                         55
Pro Xaa Xaa Xaa Gly Gly Ala Arg Pro Leu Lys Ser Thr Met Xaa Ala
65
                     70
                                         75
Gly Gly Ile Xaa Val Lys Xaa Ser Gly Phe Xaa Lys Asp His Ile Phe
                                                          95
                 85
                                     90
```

Phe Ser Gln Phe Xaa Xaa Pro Xaa Phe Xaa Cys
100 105

```
<210> 1276
<211> 85
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (6)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (16)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (17)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (20)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (25)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (26)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (28)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (32)
<223> Xaa equals any of the naturally occurring L-amino acids
```

```
<220>
<221> SITE
<222> (63)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (71)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (72)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (81)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1276
Ile Asn Lys Ile Cys Xaa Asn Leu Tyr Pro Leu Leu Trp His Phe Xaa
Xaa Ile Ile Xaa Ala Arg Lys Met Xaa Xaa Asn Xaa Gly Pro Gly Xaa
                                 25
Glu Gly Lys Glu Pro Phe Leu Val Ala Gly Asn Cys Val Gly Lys Glu
                                                  45
                             40
         35
Val Gln Ile Cys Ala Tyr Glu Ile Ser Arg Asn Arg Trp Asn Xaa Thr
                         55
     50
Pro Met Gln Leu Leu Xaa Xaa Lys Gln Gly Ala Trp Ser Asn Gly
                                         75
Xaa Thr Leu Cys Leu
<210> 1277
<211> 40
<212> PRT
<213> Homo sapiens
```

<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (33)

```
<400> 1277
Trp Val Tyr Thr Val Val Arg Gln Val Ser Phe Thr Leu Leu Met Met
Cys Cys Cys His Gly Asn Pro Ala Gln Tyr Glu Arg Asn Arg Arg Phe
             20
                                  25
Xaa His Leu Val Tyr Val Leu Gly
         35
<210> 1278
<211> 65
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (8)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (18)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (30)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (37)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (47)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (56)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (64)
<223> Xaa equals any of the naturally occurring L-amino acids
```

```
<220>
<221> SITE
<222> (65)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1278
Asn Tyr His Ser Gly Gly Pro Xaa Lys Thr Pro Ala Gly Asp His Leu
Ala Xaa Trp Leu Lys Pro Pro Val Ser Ile Ser Lys Phe Xaa Pro Lys
                                 25
Glu Gly Val Gly Xaa Lys Ile Trp Gly Asn Leu Ser Pro Phe Xaa Phe
         35
                              40
                                                  45
Phe Pro Gly Thr Pro Pro Leu Xaa Gly Glu Thr Leu Ala Arg Gly Xaa
                         55
Xaa
 65
<210> 1279
<211> 28
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (11)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (24)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1279
Val Ile Ala Asp Cys Ile Ala Leu Phe Leu Xaa Arg Leu Ser Ile Leu
Ile Gln Lys Val Ser Ile Phe Xaa Asn His Glu Ile
            20
                                 25
```

<210> 1280 <211> 22

<212> PRT

```
<213> Homo sapiens
<220>
<221> SITE
<222> (18)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (22)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1280
10
                                                      15
                 5
Phe Xaa Pro Pro Pro Xaa
            20
<210> 1281
<211> 49
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (1)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (2)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (15)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (17)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (23)
<223> Xaa equals any of the naturally occurring L-amino acids
```

```
<220>
<221> SITE
<222> (32)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1281
Xaa Xaa Leu Lys Asp Thr Cys Leu Lys Ala Glu Met Glu Ala Xaa Cys
                   5
Xaa Arg Arg Ile Leu Cys Xaa Asn Leu Ala Met Cys Phe Pro Cys Xaa
              20
                                  25
Trp Ala Asp Glu Cys Leu Leu Asn Asp Glu Ile Leu Thr Ser Lys Gly
                              40
Gly
<210> 1282
<211> 86
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (25)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (33)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (37)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (49)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (67)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
```

<221> SITE <222> (80) <223> Xaa equals any of the naturally occurring L-amino acids <400> 1282 His Glu Pro Ala Ser Leu Ser Pro Ala Ala Trp Ala Arg Lys Val Cys 10 Gly Ser Phe Ser Gly Ser Asp Phe Xaa Thr Glu Leu His Arg Pro Thr 25 Xaa Leu Ser Pro Xaa Gly Leu Gln Gly Pro Gly Ser Arg Pro Lys Pro Xaa Lys Ser Lys Thr Ser Leu Glu Lys Phe Arg Asp Arg Pro Gly Glu 55 Met Gly Xaa Arg Tyr Gly Val Ser His Leu Thr Pro Glu Asp Ala Xaa 75 Phe Ser Leu Gln Gly Ala 85 <210> 1283 <211> 91 <212> PRT <213> Homo sapiens <220> <221> SITE <222> (88) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (91) <223> Xaa equals any of the naturally occurring L-amino acids <400> 1283 Thr Pro Leu Ser Gln Asn Pro Ala Gln Ala Glu Arg Tyr Gly Ser Ala 5 Ala Glu Pro Arg Leu Ala Ser Asp Ser Arg Ser Pro Ala Cys Pro Arg 20

Arg Arg Ala Ala Pro Pro Ser Thr Arg Pro Ala Arg Ala Gly Gly Arg

Val Pro Arg Arg Ala Pro Gly Pro Gly Ser Gly Ala Glu Cys Pro Ser

40

PCT/US00/05883

50 55 60

Ser Trp Glu Thr Gly Pro Gly Trp Lys Gly Gly Arg Leu Glu Asp Pro 65 70 75 80

Ser Leu Arg Thr Arg Ala Cys Xaa Ala Ile Xaa 85 90

<210> 1284

<211> 61

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (1)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (3)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (30)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 1284

Xaa Glu Xaa Ala Gly Lys Ala Ser Thr Pro Ala Gly Thr Gly Pro Glu
1 5 10 15

Phe Pro Gly Leu Pro Thr Phe Pro His Arg Cys Ser Tyr Xaa Tyr Met 20 25 30

Gln Asn Ile Cys Gln Ala Leu Cys Gln Leu Ser Cys Thr Tyr Gly Ile 35 40 45

Glu Thr Met Glu Leu Gly Thr Ser Trp Ile Phe Phe Leu 50 55 60

<210> 1285

<211> 63

<212> PRT

<213> Homo sapiens

<400> 1285

```
Leu Thr Lys Ser Phe Lys Ile Phe Cys Asp Asn Val Leu Ile Glu Ala
                                      10
Tyr Ile Ile Leu Gln Phe Leu Glu Ser Lys Met Met Tyr Pro Leu Arg
                                 25
Ile Tyr Thr Ser Cys Phe Ile Gly Leu Arg Gly Leu Ile Phe Ile Arg
         35
                              40
                                                  45
Arg Asp Leu Leu Val Phe Thr Ile Cys Pro Leu Ser Trp His Val
     50
                          55
<210> 1286
<211> 35
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (12)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (28)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1286
Ser Leu Tyr Pro Ile His Met Leu Phe Lys Asn Xaa Ala Ile Thr Lys
                                     10
                  5
Lys Gln Ile Met Val Phe Phe Arg Asn Leu Ile Xaa Val Tyr Ser Thr
             20
                                 25
Lys Tyr Phe
        35
<210> 1287
<211> 73
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (1)
```

<223> Xaa equals any of the naturally occurring L-amino acids

```
<220>
<221> SITE
<222> (7)
<223> Xaa equals any of the naturally occurring L-amino acids
<22Ò>
<221> SITE
<222> (8)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (21)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (30)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (42)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (47)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (48)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (49)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (52)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (54)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
```

```
<221> SITE
<222> (56)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (63)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (70)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1287
Xaa Glu Gly Val Gly Phe Xaa Xaa Val Asp Gly Gly Glu Gly Arg
                  5
Pro Pro Glu Leu Xaa Leu Met Gln Ser Phe Leu Ala Met Xaa Asn Leu
             20
                                  25
Ser Val Ile Val Leu Ile Ile Lys Phe Xaa Val Phe Lys Lys Xaa Xaa
                              40
         35
Xaa Leu Ser Xaa Leu Xaa Phe Xaa Thr Pro Trp Lys Val Pro Xaa Gly
Gly Gly Ala Gln Ser Xaa Trp Phe Ser
                     70
<210> 1288 -
<211> 77
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (29)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (38)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (41)
<223> Xaa equals any of the naturally occurring L-amino acids
```

```
<220>
<221> SITE
<222> (67)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (69)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (70)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (75)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (77)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1288
Gly Gln Met Leu Ile Phe Cys Leu Gln Lys Lys Leu Gly Phe Pro Lys
                 5
                                   10
                                                      15
  1
Gln Phe Tyr Tyr Pro Val His Asn Ser Phe Thr Gln Xaa Ser Ser His
            20
                               25
Gly Ile His Gly Ser Kaa Ser Phe Kaa Leu Pro Asp Gly Arg Asn Lys
55
Lys Arg Xaa Ala Xaa Xaa Glu Asp Pro Ser Xaa Arg Xaa
65
                   70
<210> 1289
```

<210> 1289 <211> 27 <212> PRT <213> Homo sapiens <220> <221> SITE

```
<222> (5)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (7)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (12)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1289
Ala Arg Thr Ala Xaa Ala Xaa Glu Gly Val Arg Xaa Trp Asp Leu Thr
Val Gly Pro Ile Ser Leu Phe Ser Ala Leu Leu
            20
<210> 1290
<211> 41
<212> PRT
<213> Homo sapiens
<400> 1290
Asn Ser Ala Arg Ala His Leu His Leu Pro His Ser Pro Pro Leu Leu
                  5
                                     10
Val Pro Asp Thr Ser Thr Pro Thr Trp Ser Ser Pro Ile Ala His Lys
                                25
            20
Arg Gly Gly Thr Arg Asp Glu Leu Ser
<210> 1291
<211> 93
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (11)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
```

```
<222> (38)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (81)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (86)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (88)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1291
Ser Arg Arg Pro Gly Pro Arg Gly Leu Val Xaa Ala Ser Gly Arg Gly
Pro Gly Ser Ser Gln Ser Phe Pro Ser Pro Asn Asp Val Ala Phe Phe
                                 25
             20
Val Val Cys Phe Arg Xaa Leu Lys Gln Pro Arg Arg Leu Tyr Trp
         35
Leu Ser Ala Leu Ala Thr Ala Val Val Met Val Thr Gly Pro Asn Ser
Arg Trp Pro Lys Pro Thr Cys His Arg Ala Gly Ser Leu Val Gly Arg
                     70
Xaa Gln Ala Arg Gly Xaa Ala Xaa Ala Glu His Ser Phe
                 85
```

```
<210> 1292
<211> 130
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (112)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
```

<222> (119) <223> Xaa equals any of the naturally occurring L-amino acids <400> 1292 Gln Ala Ala Glu Pro Lys Glu Phe Ala Pro Arg Cys Gly Pro Thr Trp Leu Gly Pro Cys Pro Gly Arg Val Ile Leu Cys Ser Glu Ala Ile Ser Gly Thr Gly Pro Pro Arg Pro Thr Pro Pro Glu His Gly Ser Arg Leu 40 Pro Gln Pro Ser Trp Leu Arg Arg Leu Ser Glu Pro Arg Gly Gly Leu 55 50 Glu Gly Arg Phe Val Cys Arg Asp Gly Ala Arg Ala Gln Val Leu Asp 70 Val Val Cys Ile Glu Arg Pro Lys Ala Gly Gly Lys Cys Thr Gly His 90 Lys Arg Ser Leu Ser Cys Asp Ala Gln Val Leu Arg Ser Gly Arg Xaa 105 100 Pro Ala Gly Ser Gly His Xaa Trp Val His Arg Gly Ala Phe Gln Thr 115 120 Asn Met 130 <210> 1293 <211> 31 <212> PRT <213> Homo sapiens <220> <221> SITE <222> (9) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (19) <223> Xaa equals any of the naturally occurring L-amino acids

<220> <221> SITE <222> (23)

```
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (30)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1293
Trp Phe Pro His Ser Arg Cys Phe Xaa Ile Arg Ile Arg Val Leu Leu
Glu Arg Xaa Ser Cys Ser Xaa Tyr Arg Ile Val Val Xaa Phe
                                  25
             20
<210> 1294
<211> 35
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (3)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (19)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (21)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (23)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (30)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1294
Gly Gly Xaa Val Pro Asn Cys Pro Tyr Ser Glu Cys Val Leu Gln Leu
                                     10
Thr Gly Xaa Trp Xaa Tyr Xaa Val Val Asp Trp Glu Lys Xaa Trp Gly
```

20 25 30 Tyr Pro Thr 35 <210> 1295 <211> 84 <212> PRT <213> Homo sapiens <220> <221> SITE <222> (39) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (44) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (46) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (76) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (79) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (83) <223> Xaa equals any of the naturally occurring L-amino acids <400> 1295 Phe Gln Phe Ala Asn Arg Thr Asn Thr Gly Glu Asn Leu Pro Lys Thr 1 5 10 Leu Val Ile Lys Tyr Ile Ser Ser Thr Phe Arg Ser Phe Phe Trp 20 30 25

Asp Ser Val Ser Asn Lys Xaa Ile Lys Ile Lys Xaa Gly Xaa His Phe

45

40

```
Ala Val Ala Ala Val Gln Arg Thr Leu Leu Asn Leu Tyr Val Arg His
50 55 60
```

Ser Met Leu Tyr Trp Gly Asn Leu Gly Arg Ser Xaa Val Phe Xaa Ile 65 70 75 80

His Ile Xaa Ile

```
<210> 1296
<211> 35
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (2)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (6)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (15)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (25)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (34)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1296
Ser Xaa Asn Val Val Xaa Leu Pro Phe Val Lys Ala Pro Lys Xaa Arg
                                    10
Asn Pro Asn Leu Thr Cys Asn Thr Xaa Leu Thr Gln Asn Gly Ser Tyr
                                25
```

Ile Xaa Leu

```
<210> 1297
<211> 102
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (7)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (8)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (9)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (27)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (28)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (80)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (94)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (97)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (102)
```

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 1297

Gly Val Leu Ala Arg Ala Xaa Xaa Xaa Pro Gly Ala Ala Asp Gly Arg
1 5 10 15

Ala Arg Leu Cys Gly Pro Glu Val Gly Ala Xaa Xaa Ala Lys Val Ala 20 25 30

Gly Ala Ala Glu Pro Asp Glu Asp Gly Gly Arg Ser Gly Phe Gly Thr 35 40 45

Ala Glu Thr Thr His Arg Ala Ser Ala Trp Ala Arg Arg Ser Asp Ala 50 55 60

Val Val Pro Gly Arg His Ser Gly Arg His Arg Asp Gly Gln Lys Xaa 65 70 75 80

Arg Arg Val Phe Val Val Phe Val Ala Val Met Met Asn Xaa Leu His
85 90 95

Xaa Trp Leu Gln Val Xaa 100

<210> 1298

<211> 51

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (33)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (34)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (37)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 1298

Cys Lys Gln Tyr Leu Thr Asn Pro Gln Val Leu Asn Tyr Gln Thr Cys

1 5 10 15

Ile Lys Asn Phe Gly Trp Gly Asp Leu Gly Ala Glu Pro Ser Leu Arg

```
20
                                  25
                                                       30
Xaa Xaa His Ala Xaa Thr Ser Pro Val Lys Ala Asn Tyr Tyr Thr Arg
                              40
                                                   45
Leu Ile Gln
     50
<210> 1299
<211> 64
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (3)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (16)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (22)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (23)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (24)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (26)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (42)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
```

<210> 1300 <211> 58 <212> PRT <213> Homo sapiens <220> <221> SITE <222> (14) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (48) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (49) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (58) <223> Xaa equals any of the naturally occurring L-amino acids <400> 1300 -Lys Met Lys Leu Cys Arg Lys Cys Ser Pro Gln His Asp Xaa Glu Arg 5 10

```
Asn Ser Gly Thr Arg Phe Phe Pro Val Pro Leu Phe Ser Gln Gly Ser
              20
                                  25
Ala Gly Ile Gln Gly Gln Arg Ile Ser Leu Pro Glu Cys Ala Lys Xaa
                             40
Xaa Glu Lys Gly Asn Cys Leu Ser Leu Xaa
     50
<210> 1301
<211> 37
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (5)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (13)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (20)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (32)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (36)
<223> Xaa equals any of the naturally occurring L-amino acids
Thr Leu Val Gln Xaa Val Val Ser Gly Ala Ser Val Xaa Gly Lys Ser
                5
Pro Pro Tyr Xaa Lys Trp Asn Ser Pro Glu Pro Val Cys Glu Arg Xaa
                                 25
```

Thr Gly Val Xaa Ser

```
<210> 1302
<211> 75
<212> PRT
<213> Homo sapiens
<400> 1302
Gln Glu Glu Ala Leu His Ile Leu Gly Phe Gln Pro Pro Phe Glu Asp
Ile Arg Phe Gly Pro Phe Thr Gly Asn Thr Thr Leu Met Arg Trp Phe
                                  25
             20
Arg Gln Ile Asn Asp His Phe His Val Lys Gly Cys Ser Tyr Val Leu
                              40
Tyr Lys Pro His Gly Lys Asn Lys Thr Ala Gly Glu Thr Ala Ser Gly
Ala Leu Ser Lys Leu Thr Arg Gly Ile Glu Arg
 65
                     70
<210> 1303
<211> 26
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (2)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (3)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (8)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (9)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
```

```
<221> SITE
<222> (11)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1303
Ala Xaa Xaa His His Pro Trp Xaa Xaa Leu Xaa Trp Glu Arg Phe Arg
                                      10
Cys Asn Ile Asn Cys Asp Glu Asp Pro Lys
<210> 1304
<211> 46
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (5)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (7)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (13)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (16)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (17)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (18)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (31)
```

```
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (42)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (45)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1304
Gly Arg Val Lys Xaa Phe Xaa Gly Ala Pro Gly Asn Xaa Ala Asp Xaa
                · 5
                                                         15
Xaa Xaa Phe Arg Thr Gln Met Met Asp Leu Glu Leu Ala Met Xaa Arg
                                  25
             20
Gln Asn His Gly Leu Ser Ser Tyr Asp Xaa Gly Gly Xaa Val
         35
                              40
<210> 1305
<211> 70
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (5)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (18)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (31)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (32)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
```

```
<222> (34)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (37)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (38)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (42)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (50)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (52)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (53)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (55)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (64)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (68)
<223> Xaa equals any of the naturally occurring L-amino acids
Lys Ser Glu Gly Xaa Met Phe Cys Glu Thr Phe Ile Phe Leu Lys Glu
                                                          15
                  5
                                     10
```

```
Lys Xaa Lys Gly Arg Pro Ile Ser Ser Gln Asp His Thr His Xaa Xaa
              20
                                 25
Gly Xaa Gly His Xaa Xaa Ser Met Ala Xaa Phe Val Lys Phe Gly Cys
         35
                             40
                                                  45
Phe Xaa Asn Xaa Xaa Leu Xaa Lys Trp Met Trp Pro Lys Thr Phe Xaa
                          55
Leu Gly Trp Xaa Gly Lys
<210> 1306
<211> 45
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (1)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (11)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (18)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (30)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (31)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (34)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
```

```
<221> SITE
<222> (40)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (41)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1306
Xaa Leu Thr Val Lys Asp Ala Gly Gly Gln Xaa Ile Pro Gly Val Pro
Glu Xaa Ser Cys His Val Gly Val Lys Ala Glu Gly Ala Xaa Xaa Thr
                                 25
Gln Xaa Asp Arg Gly Ala Arg Xaa Xaa Ser Gln Ala Phe
                             40
<210> 1307
<211> 38
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (16)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1307
Gln Ser Thr Arg Ala Glu Tyr Glu Ser Lys Ala Glu Gly Val Met Xaa
                  5
Gly Gln Ala Phe Arg Lys Phe Gln Gln Gly Ala Ala Gly Asn Met Lys
             20
                                 25
Gly Met Met Gly Ile Gln
         35
<210> 1308
<211> 59
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (1)
```

```
<223> Xaa equals any of the naturally occurring L-amino acids
 <220>
 <221> SITE
 <222> (4)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (10)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (18)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (33)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (35)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (36)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (37)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (41)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (42)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (43)
<223> Xaa equals any of the naturally occurring L-amino acids
```

```
<220>
<221> SITE
<222> (44)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (47)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (48)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (49)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (59)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1308
Xaa Val Ser Xaa Phe Arg Lys Pro Leu Xaa Cys Ala Asn His Ser Arg
  1
                  5
                                     10
                                                          15
Lys Xaa Asn Leu Tyr Leu Gly Tyr Asn Thr Thr Val Ser Tyr Val Thr
             20
                                 25
                                                     30
Xaa Ala Xaa Xaa Pro Leu Cys Xaa Xaa Xaa Ala Lys Xaa Xaa
                             40
Xaa Arg Lys Lys Gly Lys Arg Lys Thr Asn Xaa
     50
                         55
<210> 1309
<211> 30
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (12)
<223> Xaa equals any of the naturally occurring L-amino acids
```

```
<220>
 <221> SITE
 <222> (19)
 <223> Xaa equals any of the naturally occurring L-amino acids
 <220>
 <221> SITE
 <222> (23)
<223> Xaa equals any of the naturally occurring L-amino acids
 <400> 1309
Gly Thr Arg Ser Leu Glu His Ala Ala Gly Leu Xaa Gly Leu Ser Gln
                                      10
                   5
Val Cys Xaa Pro Arg Arg Xaa Ser Ala Arg Pro Val Gln Pro
                                  25
              20
<210> 1310
<211> 67
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (46)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1310
Ser Tyr Asn His Gly Thr Lys Asn Phe Ile Glu Ile Phe Lys His Leu
                  5
                                      10
Ile Lys Leu Lys Leu Phe Gln Met Phe Lys Phe Tyr His Pro Phe
                                 25
Phe Ser His Glu Phe Leu Lys Asp Tyr Ala Leu Met Leu Xaa Ser Ile
                            40
Leu Leu Phe Leu Lys Ile Pro Gly Ile Phe Trp Tyr His Val Gln Pro
     50
                                             60
                         55
Thr Ser Leu
 65
<210> 1311
```

<211> 99 <212> PRT

<213> Homo sapiens

```
<220>
<221> SITE
<222> (70)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (81)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (91)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (97)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1311
Ser Pro Ser Leu Trp Val Val Pro Trp Arg Gly Trp Ser Ser Ser Ser
                 5
                                    10
Ser Ser Pro Thr Ser Ser Ala Gly Arg Gly Val Thr Gln Ala Thr Arg
             20
                                 25
Leu Ser Ser Leu Val His Ala Gly Thr Ala Ala Ala Gly Ala Ser Val
                             40
Pro Phe Ser Gly Leu Arg Val Leu Ser Lys Gly Gly His Thr Phe Trp
                         55
Gln Thr Phe Leu Lys Xaa Gly Ser Ser Asn Val Lys Phe His Leu Gly
                                         75
                     70
Xaa His Leu Thr Met His Asn Arg Leu Ile Xaa Glu Met Asp Gly Val
                 85
                                    90
                                                         95
```

Xaa Phe Gly

<210> 1312 <211> 34 <212> PRT <213> Homo sapiens

```
<221> SITE
<222> (3)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (15)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (27)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1312
Gly Ile Xaa Val Gln Glu Gly Arg Gly Leu Ala Val Ala Glu Xaa His
                5
                                      10
Lys Lys Val Thr Arg Pro Gly Ala Ala Asp Xaa Ala Arg Arg Pro His
             20
                                 25
Leu Tyr
<210> 1313
<211> 50
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (26)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (50)
<223> Xaa equals any of the naturally occurring L-amino acids
Thr Val Val Arg Gln Val Ser Phe Thr Leu Leu Met Met Cys Cys Cys
                                     10
His Gly Asn Pro Ala Gln Tyr Glu Arg Xaa Arg Ser Ser Asp Ile Gly
Val Cys Ala Gly Leu Arg Ser Gln Trp Gly Glu Thr Thr His Leu Trp
        35
                             40
```

```
Gly Xaa
      50
 <210> 1314
 <211> 54
 <212> PRT
 <213> Homo sapiens
 <400> 1314
Thr Val Val Arg Gln Val Ser Phe Thr Leu Leu Met Met Cys Cys
                   5
                                      10
His Gly Asn Pro Ala Gln Tyr Glu Arg Asn Arg Ser Ser Asp Ile Trp
              20
                                  25
Cys Met Cys Leu Ala Glu Glu Pro Met Gly Arg Thr Thr Ile Cys Gly
Ile Met Thr Glu Arg Leu
     50
<210> 1315
<211> 84
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (63)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (75)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (79)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (82)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
```

```
<221> SITE
 <222> (83)
 <223> Xaa equals any of the naturally occurring L-amino acids
 <400> 1315
 Thr Ala Gly Arg Trp Pro Trp Lys Ser Glu Ser Ala Lys Glu Cys Val
                                       10
 Thr Thr His Leu Pro Asn Gln Leu Ala Leu Lys Met Asp Gly Ala Gly
                                  25
 Ala Ser Gly Pro Tyr Pro Ala Val Ala Gly Ser Arg Glu Trp Thr Gly
          35
                              40
Ala Ala Gly Ala Ala Arg Ala Arg Ala Val Leu Val Phe Ala Xaa Phe
                          55
 Pro Val Gly Lys Arg Pro Asn Pro Leu Pro Xaa Trp Phe Leu Xaa Pro
                      70
                                          75
Gln Xaa Xaa Thr
<210> 1316
<211> 68
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (13)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (20)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (62)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (66)
<223> Xaa equals any of the naturally occurring L-amino acids
```

```
<221> SITE
 <222> (68)
 <223> Xaa equals any of the naturally occurring L-amino acids
 <400> 1316
 Lys Ser Thr Ser Thr Gln Gly Trp Ser Ala Gln Trp Xaa Thr Glu His
 Gly Leu Leu Xaa Ser Leu Gln Tyr Phe Glu Phe Ile Phe Leu Pro Ile
                                 25
 Tyr Val Leu Tyr Ala Ala Gly Ala Pro Leu Lys Phe Tyr Ser Val Leu
          35
                              40
Gln Lys Lys Lys Lys Lys Lys Lys Arg Gly Ala Pro Xaa Lys Gly
                          55
 Pro Xaa Phe Xaa
  65
 <210> 1317
 <211> 51
 <212> PRT
 <213> Homo sapiens
 <220>
 <221> SITE
 <222> (2)
 <223> Xaa equals any of the naturally occurring L-amino acids
 <220>
 <221> SITE
 <222> (3)
 <223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (5)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (14)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (16)
<223> Xaa equals any of the naturally occurring L-amino acids
```

```
<221> SITE
<222> (28)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (35)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (38)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (40)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1317
Ile Xaa Kaa Pro Xaa Gly Gly Pro Lys Pro Pro Pro Phe Xaa Lys Xaa
Phe Ser Pro Pro Pro Pro Pro Arg Asn Pro Pro Xaa Phe Phe Ser Pro
             20
                                 25
                                                      30
Pro Pro Xaa Asp Pro Xaa Pro Xaa Lys Lys Phe Phe Phe Leu Lys
         35
                              40
Thr Pro Pro
     50
<210> 1318
<211> 78
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (17)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (43)
<223> Xaa equals any of the naturally occurring L-amino acids
```

```
<220>
<221> SITE
<222> (54)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (60)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (73)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1318
Asp Phe Asn Leu His Gln Pro Leu Lys Cys Arg Pro Leu Cys Asp Trp
                                      10
Xaa Tyr Ala Leu Leu Lys Cys His Lys Ala Ala Ser His Leu Trp Gly
              20
                                  25
Tyr Cys Tyr Lys Phe Phe Leu Ser Leu Lys Xaa Pro Phe Leu Leu Ser
                             40
Ser Val Gly Lys Phe Xaa Gln Ile Ser Ser Ser Xaa Pro Gly Arg Asn
     50
                         55
                                              60
His Ser Pro Gln Gly Asn Leu Pro Xaa Leu Phe Leu Gly Cys
 65
                      70
                                          75
<210> 1319
<211> 28
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (17)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (23)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (28)
```

```
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1319
His Leu Asp Val Pro Ser Cys Leu Leu Lys Lys Lys Lys Thr Arg
Xaa Gly Ala Arg Tyr Pro Xaa Pro Pro Asn Ser Xaa
             20
                                  25
<210> 1320
<211> 27
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (13)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (14)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (18)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (19)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (21)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1320
Gly Lys His Gly Lys Gly Ser Gly Lys Trp Ala Cys Xaa Xaa Leu Gly
Arg Xaa Xaa Leu Xaa Pro Ala Leu Met Val Thr
             20
                                 25
```

```
<211> 71
<212> PRT
<213> Homo sapiens
<400> 1321
Gln Ser Pro Ile His Phe Ser Cys Thr Arg Met Leu Trp Lys Ser Leu
                  5
                                      10
Met Thr Arg Thr Val Phe Ser Leu His Cys Leu Ala Leu Gly Phe Glu
                         25
Lys Lys Ile Arg Glu Gly Arg Ser Gly Ile Ser Trp Pro Lys Phe Pro
         35
                              40
Leu Gly Arg Thr Gly Arg Cys Cys Ser Ser Lys Arg Glu Gly Phe Phe
                          55
                                              60
Gln Ser His Leu Pro Glu Ser
                     70
<210> 1322
<211> 80
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (32)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (59)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (63)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (66)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (73)
<223> Xaa equals any of the naturally occurring L-amino acids
```

```
<220>
<221> SITE
<222> (74)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (79)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (80)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1322
Gly Gly Ser Thr Ser Ser Leu Lys Ile Leu Glu Gly Met Glu Glu Ser
Gln His Val Phe Leu Thr Gln Asp Pro Trp Phe Val Leu Lys Ala Xaa
             20
                                 25
Asn Pro Gln Val Pro Ala Phe Asp Asp Val Tyr Arg Lys Cys Trp Leu
         35
                             40
Thr Glu His Ile Cys Pro Ile Pro Gly Val Xaa Arg Lys Pro Xaa Ile
                         55
Phe Xaa Ile Pro Asn Phe Phe Leu Xaa Xaa Lys Lys Lys Met Xaa Xaa
                     70
                                         75
```

```
<210> 1323
<211> 57
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (12)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (14)
<223> Xaa equals any of the naturally occurring L-amino acids
```

```
<220>
<221> SITE
<222> (30)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1323
Gln Gly Leu Asn Pro Tyr Thr Phe Trp His Asn Xaa Ile Xaa Leu Gly
Asn Glu Leu Cys Lys Gly Glu Pro Lys Leu Lys Thr Pro Xaa Asn Gln
                                 25
Thr Glu Leu Thr Leu Arg Asn Ser Leu Lys Glu Ala His Pro Ser Tyr
                             40
Val Gly Lys Ile Val Gly Lys Val Phe
<210> 1324
<211> 31
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (12)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (19)
<223> Xaa equals any of the naturally occurring L-amino acids
Lys Arg Lys Leu Arg Glu Gly Arg Asn Leu Asn Xaa Leu Met Lys Ile
                  5
Met Leu Xaa Ile Ile Lys Thr Gly Tyr Glu Tyr Ser Asn Pro Phe
             20
                                 25
                                                      30
```

<210> 1325 <211> 40 <212> PRT <213> Homo sapiens

```
<221> SITE
<222> (32)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1325
Leu Glu Ile Thr Leu Gln Gly Glu Pro Lys Leu Arg Pro Pro Lys Pro
Asp Glu Leu Pro Lys Lys Gln Leu Lys Glu His Thr Arg Leu Cys Xaa
                                25
Lys Ile Val Gly Arg Phe Ile Gly
         35
<210> 1326
<211> 65
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (14)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (15)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (54)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (55)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1326
Ala Tyr Lys Lys Glu Lys Glu Gln Ser Gln Glu Arg Thr Xaa Xaa Lys
                                     10
Cys Phe Gly Thr Ser Leu Phe Leu Asp Phe Glu Leu Ser Asn Trp Phe
```

```
20
                                  25
                                                       30
Ser Gln Val Lys Leu Lys Asn Ser Glu Thr Trp Phe Tyr Glu Ser Cys
          35
                              40
                                                   45
Ser Tyr Thr Phe Leu Xaa Xaa Gly Pro Xaa Leu Leu Pro Arg Leu Leu
                          55
Thr
 65
<210> 1327
<211> 48
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (7)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> '(23)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (33)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (37)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (38)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (44)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (48)
```

```
<210> 1328
<211> 72
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (7)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (12)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (14)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (18)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (30)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (34)
<223> Xaa equals any of the naturally occurring L-amino acids
```

```
<220>
<221> SITE
<222> (44)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (60)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (63)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (68)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (69)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1328
Leu Asp Gln Lys Lys Ser Xaa Leu Phe Asp Leu Xaa Arg Xaa Asn Leu
                  5
                                     10
Pro Xaa Leu Tyr Thr His Val Cys Val Ser Leu Lys Arg Xaa Val Arg
             20
Leu Xaa Lys Ile Leu Ile Val Ile Asn His Val Xaa Thr Ser Cys Asn
         35
                             40
Glu Leu His Asp Leu Ile Leu Ser Leu Leu Ala Xaa Thr Thr Xaa Tyr
                         55
Phe Ser Asn Xaa Xaa Ile Ser Pro
 65
                    70
<210> 1329
<211> 19
<212> PRT
<213> Homo sapiens
```

<220> <221> SITE

```
<222> (3)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (16)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (19)
<223> Xaa equals any of the naturally occurring L-amino acids
Thr Ile Xaa Cys Glu Leu Leu Lys Trp Ile Ile Gly His Gly Leu Xaa
                  5
                                      10
Ala Ala Xaa
<210> 1330
<211> 80
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (25)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (27)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (41)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (46)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (49)
<223> Xaa equals any of the naturally occurring L-amino acids
```

```
<220>
<221> SITE
<222> (62)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (64)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (65)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (68)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (74)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1330
Pro Leu Tyr Leu Leu His Asn Glu Leu Thr Arg Asn Asn Phe Ala Arg
 1
                  5
                                     10
Arg Ala Lys Ala Lys Thr Pro Glu Xaa Arg Xaa Ala Thr Leu Glu Gln
                                 25
             20
Leu Lys Glu His Thr Arg Leu Cys Xaa Lys Ile Val Gly Xaa Ile Tyr
         35
                             40
Xaa Leu Lys Arg Gln Thr Tyr Arg Pro Gly Asp Thr Gly Xaa Pro Xaa
Xaa Ile Leu Xaa His Phe Asn Leu Pro Xaa Asn Leu Leu Ile Pro Cys
                                        75
65
                     70
                                                              80
```

<210> 1331

<211> 61

<212> PRT

```
<220>
<221> SITE
<222> (21)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (50)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (55)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1331
Ile Ile Asn Asn Asn Lys Asn Lys Ala Asn Thr Leu Asp Ile Thr Leu
                                      10
Pro Ser Gly Ala Xaa Lys Lys Val Lys Ala Gly Ile Ser Phe Ser Tyr
Leu Asn Leu Ser Val Leu Ser Gln Gly Ile Phe Ser Glu Asn Arg Trp
         35
                              40
Asn Xaa Val Arg Leu Trp Xaa Met Leu Ser Ile Ile Gly
     50
                         55
<210> 1332
<211> 97
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (3)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (6)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (17)
<223> Xaa equals any of the naturally occurring L-amino acids
```

```
<220>
<221> SITE
<222> (25)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (36)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (42)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (59)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (61)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (62)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (67)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (78)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (92)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (95)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
```

```
<221> SITE
<222> (96)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1332
Lys Val Xaa Gly Leu Xaa Ser Pro Gly Pro Glu Ile Pro Gly Ser Thr
Xaa Thr Val Arg Ile Asn Thr Val Xaa Pro Leu Ile Tyr Leu Leu Leu
                                25
Ser Pro Ile Xaa Asn Thr His Ala Ala Xaa Leu Ser Val Asp Gly Gly
         35
                             40
Tyr His Leu Asp Pro Leu Leu Leu Glu Xaa Pro Xaa Xaa Leu Trp
Ala Leu Xaa Arg Lys Ser Arg Ile Ile Trp Lys Thr Leu Xaa Phe Ser
                     70
                                         75
Ser Arg Leu Tyr Gln Lys Ile Pro Lys Thr Asp Xaa Ala Val Xaa Xaa
                                      90
                 85
Gln
<210> 1333
<211> 94
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (1)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (15)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (38)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (42)
```

```
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (53)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (88)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1333
Xaa Phe Leu Pro Pro Ser Ala Arg Pro Arg Ala Gly Arg Arg Xaa Pro
                                      10
                                                          15
                  5
Leu Arg Gly Gln Cys Gln Val Gly Ser Leu Thr Gly Ala Val His Leu
                                  25
             20
Ser Asn Gly Asn Ala Xaa Val Leu Arg Xaa Ala Gln Gly Gln Lys
                              40
Pro Pro Val Glu Xaa Lys Gly Lys Ser Ser Leu Asp Leu Asp Phe Gln
                         55
                                              60
Tyr Glu Tyr Lys Thr Val Lys Ala Gly Pro His Asp Pro Ser Asp Leu
                                          75
                                                              80
                     70
 65
Leu Gly Phe Lys Gln Glu Val Xaa Glu Lys Leu Pro Gln Gly
                 85
                                     90
<210> 1334
<211> 55
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (10)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (49)
<223> Xaa equals any of the naturally occurring L-amino acids
```

<220> <221> SITE <222> (52)

```
<223> Xaa equals any of the naturally occurring L-amino acids
 <220>
 <221> SITE
 <222> (54)
  <223> Xaa equals any of the naturally occurring L-amino acids
 <220>
<221> SITE
 <222> (55)
 <223> Xaa equals any of the naturally occurring L-amino acids
 <400> 1334
 Thr Cys Gly Pro Pro Val Lys Tyr His Xaa Ser Asp Arg Phe Phe Thr
                   5
                                       10
 Asp Pro Val Arg Arg Gly Glu Pro Arg Gly Ala Leu Ala Ser Gly
                                   25
              20
 Ala Lys Arg Pro Ala Ala Arg Arg Pro Gly Ala Thr Arg Ser Gly Asp
 Xaa Ala Arg Xaa Gly Xaa Xaa
 <210> 1335
 <211> 143
 <212> PRT
 <213> Homo sapiens
 <220>
 <221> SITE
 <222> (1)
 <223> Xaa equals any of the naturally occurring L-amino acids
 <220>
 <221> SITE
 <222> (6)
 <223> Xaa equals any of the naturally occurring L-amino acids
 <220>
 <221> SITE
 <222> (7)
 <223> Xaa equals any of the naturally occurring L-amino acids
 <220>
 <221> SITE
 <222> (36)
 <223> Xaa equals any of the naturally occurring L-amino acids
```

<220> <221> SITE <222> (38) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (127) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (128) <223> Xaa equals any of the naturally occurring L-amino acids <400> 1335 Xaa Thr Ile Val Leu Xaa Xaa Thr Pro Ala Gly Thr Gly Pro Glu Phe Pro Gly Arg Pro Thr Arg Pro Pro Ile Phe Pro Val Asp Asn Ala Ile 20 25 Asp Asn Gly Xaa Glu Xaa Gln Val Ala Leu Pro Ile Leu Met Ala Ala 35 40 Tyr Ala Met Ala Glu Ala Phe Met Ser Thr Gly Val Gly Ala Ser Leu 55 Ile Leu Ile Ala Leu Lys Val Gly Ile Thr Ala Lys Thr Val Ala Val 65 70 75 Ile Gly Ala Ile Val Thr Ser Ile Leu Ser Ile Ala Thr Gly Thr Ser 85 90 Trp Gly Thr Phe Ala Ala Cys Ala Pro Ile Phe Leu Trp Leu Asn His 100 105 Ile Val Gly Gly Asn Ile Leu Phe Asp Asn Lys Gln Leu Leu Xaa Xaa 120

Glu His Val Leu Glu Asp Asn Ile Gly Leu Phe Gln Ile Leu Gln

140

135

<210> 1336

130

<211> 65

<212> PRT

```
<220>
<221> SITE
<222> (1)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (13)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (26)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (44)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (55)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (58)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1336
Xaa Ala Leu Gly Leu Ala Leu Pro Gly Arg Leu Leu Xaa Ser His Ser
                  5
Arg Arg Thr Pro Ser Arg Glu Ser Arg Xaa Pro Pro Ala Pro Leu Tyr
                                                      30
             20
                                 25
Ser Ala Arg Ala Gln His Gly Ala Pro Ala Gly Xaa His Val Arg Ala
         35
                             40
Ser Asp Cys Arg Gly Asp Xaa Asp Phe Xaa Arg Ser Ser Gly Arg Met
                         55
Glu
65
<210> 1337
<211> 42
<212> PRT
```

```
<213> Homo sapiens
<220>
<221> SITE
<222> (2)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (7)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (8)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (12)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (23)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (34)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (40)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1337
Thr Xaa Ala His Ser Val Xaa Xaa Pro His Ser Xaa Gly His Cys Gly
                                     10
Gln Arg Val Leu Ala Cys Xaa Leu Leu Ser Ile Leu Lys Ala Met Asp
                                 25
                                                     30
             20
Phe Xaa Gly Pro Phe Ser Ser Xaa Leu Pro
                             40
         35
```

<210> 1338 <211> 35

```
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (25)
<223> Xaa equals any of the naturally occurring L-amino acids
Phe Asn Lys Leu Ser Ser Ala Leu Ser Glu Phe Ser Gly Pro Asn Ile
                  5
Tyr Val Glu Lys Asp Gly Gly Val Xaa His Leu Cys Thr Asp His Leu
                                  25
Tyr Val Arg
         35
<210> 1339
<211> 79
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (32)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (33)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (47)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (59)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (68)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1339
```

Asp Ile Glu Ala Lys Pro Ser His Tyr Gln Leu Val Ser Gly Ser Ser 1 5 10 15

Thr Glu Asp Ser Leu His Val His Ala Gln Met Ala Glu Asn Glu Xaa 20 25 30

Xaa Gly Ser Gly Gly Gly Ser Glu Glu Asp Pro Pro Cys Xaa His
35 40 45

Gln Ser Cys Glu Gln Lys Asp Cys Leu Ala Xaa Lys Pro Trp Asp Ile 50 55 60

Ser Leu Ala Xaa Pro Glu Ser Ile Arg Ser Asp Leu Glu Ser Ser 65 70 75

<210> 1340

<211> 69

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (9)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (60)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (65)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (67)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (69)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 1340

Gly Lys Gly Thr Phe Pro Lys Asn Xaa Phe Trp Gly Asn Lys Asn Val 1 5 10 15

```
25
          20
40
       35
55
    50
Xaa Lys Xaa Lys Xaa
<210> 1341
<211> 70
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (1)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (4)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (64)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (68)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1341
Xaa Trp Ser Xaa Leu Ala Ala Gln Lys Glu Gln Ser Gly Leu Glu Gly
Ser Ile Lys Phe Tyr Thr His Lys Leu Gln Leu Glu Val Ser Phe Leu
                          25
                                          30
Lys Cys Pro Ala Phe Ala Gln Leu Phe Gln Ile Ile Ser Phe Leu Arg
       35
                       40
Leu Trp Gln Val Ser Cys Pro Pro Ser Tyr Ser Ser Val Phe Thr Xaa
```

55

60

50

Ser Arg Gln Xaa Ser Gly 65 70

<210> 1342

<211> 121

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (95)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 1342

Glu Pro Asp Pro Asn Ser Glu Asn Ile Ala Ala Ile Ser Gln Ser Ser 1 5 10 15

Val Gly Ser Asp Leu Phe Val Phe Lys Pro Ser Glu Pro Arg Pro Leu 20 25 30

Tyr Ile Gln Lys Gly Ile Ser Arg Glu Lys Val Gln Trp Gly Val Phe
35 40 45

Val Pro Arg Asp Val Pro Glu Ser Phe Thr Ser Glu Ala Tyr Gln Trp 50 55 60

Leu Asn Arg Ser Gln Phe Tyr Phe Leu Thr Lys Ser Gln Ser Leu Leu 65 70 75 80

Thr Phe Ser Thr Lys Ser Pro Glu Glu Lys Leu Thr Pro Thr Xaa Gln 85 90 95

Thr Ala Ala Ser Arg Arg Lys Ser Ser His Asn Pro Ile Leu Phe His 100 105 110

Ile Gly Lys Thr Gln Ala Thr Ala Gly
115 120

<210> 1343

<211> 36

<212> PRT

<213> Homo sapiens

<400> 1343

Asn Thr Lys Gly Asp Arg Glu Glu Leu Lys Asp Leu Gln Tyr Cys Thr
1 5 10 15

```
Gln Lys Leu Ile Ile Leu Cys Thr Phe Tyr Leu Phe Trp Arg Phe Tyr
             20
                                  25
                                                   ' 30
Met Ile Phe Asn
         35
<210> 1344
<211> 32
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (15)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (21)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (31)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (32)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1344
Ala Val Ala Val Ser Gly Pro Gly Pro Val Gly Val Leu Leu Xaa Leu
Trp Leu Thr Pro Xaa Pro Gly Thr Leu Asn Asp Arg Ser Arg Xaa Xaa
                                 25
<210> 1345
<211> 63
```

<212> PRT

```
<220>
<221> SITE
<222> (19)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (28)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (46)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (52)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (54)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (61)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1345
His Leu Val Lys Ala Gly Arg Lys Ile Asn Asn Thr Lys Leu Cys Tyr
Leu Ile Xaa Leu Leu Glu Arg Val Arg Phe Thr Xaa Tyr Ile Phe Lys
             20
                                 25
                                                      30
Leu Ile His Val Lys Asn Asp Ser Asp Phe Asp Val Ile Xaa Leu Leu
                             40
         35
Ile Glu Ser Xaa Ile Xaa Lys Ala Asn Asn Leu Lys Xaa Ala Ile
     50
                         55
<210> 1346
<211> 64
<212> PRT
```

<220>

```
<221> SITE
 <222> (11)
 <223> Xaa equals any of the naturally occurring L-amino acids
<220>
 <221> SITE
<222> (15)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (50)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (52)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (57)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (63)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (64)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1346
Ala Gly Ala Asp Arg Gly Gly Gly Trp Xaa Arg Leu Gly Xaa Ile
Asn Leu Leu Ile Asp Cys Asp Ser Lys Lys Lys Lys Lys Lys Lys
                              25
35
                           40
                                             45
Lys Xaa Lys Xaa Lys Lys Lys Lys Lys Lys Lys Lys Lys Xaa Xaa
    50
                      55
```

```
<210> 1347
 <211> 45
 <212> PRT
 <213> Homo sapiens
 <220>
 <221> SITE
<222> (33)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (42)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1347
Phe Leu Ile Met Ser Asn Asp Cys Lys Ser Ala Trp Ile Phe Thr Cys
Lys Gly Tyr Ser Cys Ile Val Arg Ser Pro Ser Pro Ala Glu Ser Ser
             20
                                  25
Xaa His Trp Leu Ala Val Cys Cys Val Xaa His Ser Phe
         35
                              40
                                                  45
<210> 1348
<211> 59
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (53)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1348
Gly Phe Leu Val Leu Met Leu Val Lys Val Cys Ala Gly Ile Ser Lys
                  5
Ser Leu Lys Lys Val Phe Thr Gly His Trp Ala Val Val Arg Glu Gly
             20
                                 25
Leu Thr Asn Pro Trp Ile Pro Asp Asn Trp Ser Trp Gly Gly Val Ala
Ser Glu His Cys Xaa Cys Tyr Arg Val Leu His
     50
                         55
```

```
<210> 1349
```

<211> 63

<212> PRT

<213> Homo sapiens

<400> 1349

Phe Cys Pro Cys Val Arg Gln Ser Glu Gln Arg Val Ile Gln Ser Ala 1 5 10 15

Ala Asn Lys Ala Ala Asp Ser Ser Val Gln Lys Ala Lys Lys Glu Leu 20 25 30

Tyr Val Arg His Leu Phe Leu Leu Ile Ser Ile Phe Leu Leu Thr His 35 40 45

Thr Leu Ser His Val Lys Arg Lys Ile Asn Lys Trp Ser Glu Leu 50 55 60

<210> 1350

<211> 38

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (30)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 1350

Tyr Ile Tyr Tyr Arg Pro Asn Glu Leu Asn Ile Ala Leu Leu Tyr Ser

1 5 10 15

Pro Lys Gly Leu Asn Ser Cys Phe Phe Pro Ser Phe Ile Xaa Arg Lys
20 25 30

His Tyr Asp Arg Ile Ser 35

<210> 1351

<211> 77

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

```
<222> (12)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (66)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1351
Leu Leu Pro Glu Asp Gln Val Gln Leu Gln Pro Xaa Gly Arg Trp Leu
  1
                  5
                                     10
Pro Thr Ser Ser Pro Gly Leu Ser Ser Pro Ser Ser Pro Val Ile
                                 25
Leu Cys Cys Leu Asp Ser Thr Ile Pro Ser Leu Phe Leu Leu His Leu
                            40
Leu Pro Leu Glu Pro Pro Leu Pro Ser Trp Asp Phe Trp Glu Val Pro
     50
                         55
Ala Xaa Gln Pro Arg His Lys Thr Ile Met Val Thr Trp
                     70
                                         75
<210> 1352
<211> 28
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (1)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (6)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (21)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (26)
<223> Xaa equals any of the naturally occurring L-amino acids
```

```
<400> 1352
Xaa Leu Leu Arg Asp Xaa Met Gly His Tyr Val Trp Leu Phe Tyr Ile
   1
                   5
                                      10
Lys Pro Thr Thr Xaa Phe Arg Val Gly Xaa Met Asn
                                  25
              20
<210> 1353
<211> 79
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (11)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (17)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (18)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (30)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (36)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (62)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (70)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
```

```
<222> (74)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (76)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (78)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1353
Pro Arg Leu Gln Thr Leu Asn Leu Val Leu Xaa Ser Ala Asp Asn Gly
Xaa Xaa Pro Arg Leu Tyr Asn Arg Arg Ser Ala Lys Asp Xaa Gly Val
                                  25
Leu Gly Gly Xaa Leu Val Phe Pro Lys Val Phe Gln Ile Lys Val Val
                                                  45
         35
                              40
Phe Val Leu Lys Lys Lys Lys Lys Lys Leu Gly Gly Xaa Phe Leu
                         55
Gly Gly Ala Arg Gly Xaa His Gly Phe Xaa Gln Xaa Gly Xaa Gly
                     70
<210> 1354
<211> 40
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (21)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (22)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (24)
<223> Xaa equals any of the naturally occurring L-amino acids
```

```
<220>
 <221> SITE
<222> (33)
 <223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (35)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1354
Gly Asp Pro Ala Gln Phe Pro Gly Arg Pro Arg Val Arg Thr Ile Gly
                                      10
Arg Arg Ser Phe Xaa Xaa Trp Xaa Asn Ser His Phe Pro His Glu Glu
             20
                                  25
Xaa Lys Xaa Gly Gln Lys Pro Asn
<210> 1355
<211> 40
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (25)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (34)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (36)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1355
Asp Ile Asn Gly Asp Phe Lys Val Glu Ile Asn Met Tyr Ser Met Phe
Leu Lys Lys Lys Lys Lys Lys Xaa Pro Gly Gly Ala Pro Val Pro
             20
                                 25
                                                     30
Ile Xaa Pro Xaa Gly Gly Pro Phe
         35
                             40
```

```
<210> 1356
<211> 81
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (18)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1356
Pro Gly Glu Ala Gly Gly Arg Ala Pro Arg Gly Ser Arg Phe Trp Arg
Gln Xaa Pro Gly Arg Ala Pro Ala Gly Arg Asp Pro Leu Arg Gly Gln
                                  25
Cys Gln Val Gly Ser Leu Thr Gly Ala Val His Leu Ser Asn Gly Asn
         35
                              40
Ala Gly Val Leu Arg Arg Ala Gln Gly Gly Gln Lys Pro Pro Val Glu
     50
                          55
Gln Lys Gly Lys Ser Ser Leu Asp Leu Asp Phe Gln Tyr Glu Tyr Arg
                     70
                                          75
Pro
<210> 1357
<211> 73
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (38)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (42)
<223> Xaa equals any of the naturally occurring L-amino acids
```

Thr Pro Leu Ser Gln Asn Pro Ala Gln Ala Glu Arg Tyr Gly Ser Ala

<400> 1357

```
1
                                      10
                                                           15
Ala Glu Pro Arg Leu Ala Ser Asp Ser Arg Ser Pro Ala Cys Pro Arg
              20
                                  25
Arg Arg Ala Ala Pro Xaa Ser Thr Arg Xaa Ala Arg Ala Gly Gly Arg
                              40
Val Pro Arg Arg Ala Pro Gly Pro Gly Ser Gly Ala Glu Cys Pro Ser
     50
                          55
Ser Trp Glu Thr Gly Arg Gly Arg Lys
                     70
 65
<210> 1358
<211> 66
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (2)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (6)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (19)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (34)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (51)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (54)
<223> Xaa equals any of the naturally occurring L-amino acids
```

```
<220>
<221> SITE
<222> (62)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1358
Gly Xaa Arg Pro Arg Xaa Trp Ile Arg Thr Ser Arg Trp Cys. Ser Arg
                  5
Tyr Lys Xaa Phe Val Cys Ser Thr Ile Lys Val Leu Arg Asp Leu Asn
                                  25
Ser Xaa Arg Ser Asn Pro Gly Arg Phe Leu Ser Thr Ser Asn Ser Ser
                             40
Leu Tyr Xaa Arg Thr Xaa Arg Tyr Lys Ala Tyr Phe Ser Xaa Arg Leu
                         55
Pro Pro
 65
<210> 1359
<211> 73
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (62)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (64)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (73)
<223> Xaa equals any of the naturally occurring L-amino acids
Arg Pro Lys Trp Arg Arg Val Pro Cys Glu Gln Gln Leu Asn Met Gly
                  5
Gln Ser Val Leu Arg Asp Gly Arg Ala Pro Phe Arg Arg Asp Gly Arg
                                 25
```

Trp Pro Pro Leu Pro Ser Ala Asp Arg Lys Gly Val Gly Phe Arg Ser

35 40 45

Pro Asn Pro Glu Trp Arg Arg Trp Arg Arg Glu Ala Ser Xaa Arg Xaa 50 55 60

Arg Asp Arg Ser Arg Arg Ser Pro Xaa 65 70

<210> 1360

<211> 38

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (21)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 1360

Thr Arg Pro Val Asn Asn Lys Lys Gly Val Ile Arg Ile Gly Met Trp

1 10 15

Ile Phe Thr Val Xaa Thr Thr His Leu Gln Phe Cys Asn Ala Arg Met 20 25 30

Gln Phe Lys Asn Val Lys 35

<210> 1361

<211> 54

<212> PRT

<213> Homo sapiens

<400> 1361

Arg Tyr Ala Cys Arg Tyr Arg Ser Gly Ile Pro Gly Ser Thr His Ala 1 5 10 15

Ser Ala Asp Ala Trp Gly Leu Leu Arg Asn Ile Ala Glu Val Ile Thr 20 25 30

Thr Ala Ile Lys Leu Phe Lys Lys Asp Leu Tyr Asn Val Tyr Lys Ser 35 40 45

Gly Ile Lys Asp Phe Ser

```
<210> 1362
 <211> 139
 <212> PRT
 <213> Homo sapiens
 <220>
<221> SITE
<222> (58)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (62)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (69)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (70)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (111)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (112)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (124)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (138)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1362
Ser Phe Asp Val Gly Ser Ser Tyr His Cys Glu Ala Glu Phe Thr Lys
```

Arg Trp Ile Val His Pro His Glu Pro Cys Ala Phe Gly Val Asn Asn

20 25 30

Val Gln Phe Val Asp Val Ile Glu Ser Arg Gly Leu Ser Pro Phe Tyr 35 40 45

Ile Cys Ile Asn Phe Asn Leu Leu Lys Xaa Lys Lys Glu Xaa Glu Lys 50 55 60

Gln Phe Ile Lys Xaa Xaa Lys Ser Asn Gln Pro Gln Gln Gln Lys Arg
65 70 75 80

Met Val Trp Tyr Trp Arg Arg Asp Gly Gln Leu Ser Leu Leu Ala His
85 90 95

Asp Gly Met Asp Leu Gly Pro Gly Thr Thr Phe Ile Leu Arg Xaa Xaa 100 105 110

Leu Trp Ile Pro Arg Glu Gly Gln Pro Phe Arg Xaa Gly Leu Tyr Pro 115 120 125

Glu Gly Gly Thr Glu Phe Gly Gln Thr Xaa His 130 135

<210> 1363

<211> 58

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (11)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (56)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 1363

Ala Phe Arg Lys Tyr Tyr Val Lys Asn Leu Xaa Ser Leu His Ala Arg 1 5 10 15

His Ser Phe Asn His Phe Ser Asp His Phe Ser Lys Ile Leu Lys His 20 25 30

Pro His Leu Gly Phe Ser Leu Asn Leu Gly Val Pro Ser Pro His Pro 35 40 45

Ala Ala Phe Cys Val Arg Gly Xaa Arg Ser

```
<210> 1364
<211> 21
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (16)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (18)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (19)
<223> Xaa equals any of the naturally occurring L-amino acids
Pro Tyr Ser Glu Ser Tyr Tyr Asn Ser Leu Ala Val Val Leu Gln Xaa
                                      10
Arg Xaa Xaa Glu Asn
             20
<210> 1365
<211> 69
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (12)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (21)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (22)
```

```
<223> Xaa equals any of the naturally occurring L-amino acids
 <220>
 <221> SITE
 <222> (23)
 <223> Xaa equals any of the naturally occurring L-amino acids
<220>
 <221> SITE
 <222> (24)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (25)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (26)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (31)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (34)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (46)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (51)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (54)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (58)
<223> Xaa equals any of the naturally occurring L-amino acids
```

```
<220>
<221> SITE
<222> (64)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (65)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (69)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1365
Tyr Thr Ala Ile Met Ser Ile Met Ser Tyr Asn Xaa Gly Ala Val Met
                                      10
Ala Met Lys Gly Xaa Xaa Xaa Xaa Xaa His Arg Cys Arg Xaa Ala
             20
                                  25
                                                      30
Leu Xaa Glu Ser Arg Pro Arg Met Val Asn His Gly Thr Xaa Arg Lys
         35
                              40
Ile Phe Xaa His Gly Xaa Asn Arg Leu Xaa Met Gly Leu Gly Arg Xaa
Xaa Gln Leu Arg Xaa
 65
<210> 1366
<211> 42
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (29)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (33)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
```

```
<222> (34)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (41)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1366
Leu Ala Ile Leu Arg Leu Phe Lys Val Phe Ser Asn Ile Lys Lys Tyr
                                      10
His Gln Arg Ser Pro Ala Met Leu Lys Thr Asn Asn Xaa Lys Gln Thr
                                 25
Xaa Xaa Lys Asn Leu Lys Lys Lys Xaa Gly
         35
                             40
<210> 1367
<211> 24
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (16)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (24)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1367
Ser Thr Leu Ser Asn Arg Leu Val Trp Val His Trp His Ser Leu Xaa
                 5
                                 10
Tyr Cys Leu Ile Ala Asp Thr Xaa
            20
```

<210> 1368 <211> 79 <212> PRT <213> Homo sapiens <220> <221> SITE

```
<222> (1)
 <223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (3)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (9)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (11)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (16)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (23)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (65)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (68)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (78)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1368
Xaa His Xaa Trp Lys Leu Ile Leu Xaa Leu Xaa Leu Gly Tyr Phe Xaa
                  5
Phe Gly Gly Glu Ser Ala Xaa Phe Phe Arg Arg Gly Pro Gly Phe Phe
             20
                                 25
```

Lys Gly Lys Lys His Ser Tyr Ser Lys Leu Gln Asn Asn Gly Val Asn

35 40 45

Met Leu Asn Arg Ser Ile Arg Lys Pro Asn Thr Gly Leu Ser Arg Arg 50 55 60

Xaa Leu Val Xaa Arg Ala Leu Gly Lys Asn Lys Gly Lys Xaa Lys 65 70 75

<210> 1369

<211> 76

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (76)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 1369

Asn Gln Arg Gln Leu Ser Cys Cys Val Ser Ser Cys Trp Ile Leu Ser 1 5 10 15

Leu Gly Pro Thr Val Cys Gln Tyr Ser Cys Glu Leu Tyr Val Pro Pro
20 25 30

Val Leu His Thr Gln Val Cys Val Ser Val Tyr Ala Cys Phe Lys Gln 35 40 45

Thr Leu Asn Val His Met Tyr Ile Ile Tyr Thr Tyr Leu Tyr His Ile 50 55 60

Ser Ser Phe Ile Thr Ile Asp Tyr Thr Asn Trp Xaa 65 70 75

<210> 1370

<211> 50

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (33)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (35)

```
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (44)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (49)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1370
Ala Arg Ala Tyr Leu Leu Val Ala Ser Asn Leu Thr Pro Ser Leu Ser
                   5
                                      10
Glu Tyr Val Gln Pro Lys Arg Thr Asn Trp Leu Leu Cys Thr Ser Leu
                                  25
Xaa Ile Xaa Leu Leu Ser Met Val Leu Arg Ser Xaa Thr Val Tyr Leu
                              40
Xaa Leu
     50
<210> 1371
<211> 76
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (20)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (46)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (53)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (64)
<223> Xaa equals any of the naturally occurring L-amino acids
```

<220> <221> SITE <222> (65) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (68) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (76) <223> Xaa equals any of the naturally occurring L-amino acids <400> 1371 Glu Lys Thr Phe Val Glu Arg Val Lys Asn Leu Thr Pro His Ser Arg 10 Pro Lys Ser Xaa His Gln Leu Lys Lys Ala Phe Lys Leu Gln His Pro 20 25 Leu Pro Lys Lys Phe Gln Thr Tyr Asn Trp Asn Phe Leu Xaa Pro Asn 40 Trp Asp Gln Phe Xaa Thr Pro Ile Arg Lys Leu Met Val Ser Xaa 55 Xaa Val Thr Xaa Glu Lys His Phe Ser Phe Arg Xaa 70 <210> 1372 <211> 58 <212> PRT <213> Homo sapiens <400> 1372 Ile Cys Pro Gln Asn Pro Leu Asn Pro Leu Val Asn Leu Thr Val Ser 10

Pro Lys Arg Asn Ser Ser Leu Asp Thr Arg Lys Lys Pro Cys Arg Glu 20 25 30

Ser Lys Lys Phe Asn Thr His Ser Arg Pro Lys Ser Ser His Gln Leu 35 40 45

Arg Lys Arg Ser Ser Ser Thr Pro Thr Thr
50 55

```
<210> 1373
<211> 52
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (17)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (20)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1373
Ser Leu Asp Leu Ile Cys Pro Tyr Glu Arg Pro Gly Lys Asn Arg Leu
Xaa Ala Pro Xaa Leu Val Glu Leu Cys Pro Ser Ser Asp Ala Cys Gln
                                  25
                                                      30
             20
Glu Arg Val Glu Pro Arg Thr Leu Thr Lys Gly Gly Pro Gly Tyr Pro
                                                  45
         35
                              40
Ile Ala Ala Leu
     50
<210> 1374
<211> 114
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (14)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (93)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (108)
```

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (113)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 1374

Ala Arg Ala Glu Asp Pro His Ile Asp Glu Ser Lys Ala Xaa His Gln
1 5 10 15

Ala Ile Ile Met Ser Thr Ser Leu Arg Val Ser Pro Ser Ile His Gly
20 25 30

Tyr His Phe Asp Thr Ala Ser Arg Lys Lys Ala Val Gly Asn Ile Phe 35 40 45

Glu Asn Thr Asp Gln Glu Ser Leu Glu Arg Leu Phe Arg Asn Ser Gly
50 55 60

Asp Lys Lys Ala Glu Glu Arg Ala Lys Ile Ile Phe Ala Ile Asp Gln 65 70 75 80

Asp Val Glu Glu Lys Thr Arg Ala Leu Met Ala Leu Xaa Glu Glu Asp 85 90 95

Lys Arg Gln Ala Phe Pro Phe Leu Lys Leu Arg Xaa Phe Ser Phe Lys
100 105 110

Xaa His

<210> 1375

<211> 105

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (76)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (87)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

```
<222> (94)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (102)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1375
Ala Arg Gln Asp Thr Gln Glu Glu Arg Ala Ala Pro Gly Ser Arg Pro
                                      10
Gly Leu His Ala Glu Ala Gly Gly Arg Arg Cys Pro Ala Glu Ser Pro
                                  25
Glu Leu Arg Arg Pro Ala Leu Val Pro Ala Pro Ser Gly Arg Arg Phe
         35
                              40
Glu Ser Asp Trp Cys Leu Ala Ala Ser Ser Ser Val Arg Asp His Glu
     50
                         55
Val Leu Pro Ser Val Val Leu Lys Leu Phe Leu Xaa Ser Phe Ser Ser
                     70
                                          75
Ala Leu Val Thr Gly Glu Xaa Pro Gly Asn Gly Phe Arg Xaa Arg Leu
                 85
Thr Ala Gly Asn Lys Xaa Thr Gly Thr
            100
<210> 1376
<211> 25
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (11)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
```

<220>
<221> SITE

<222> (20)

<221> SITE <222> (15)

<223> Xaa equals any of the naturally occurring L-amino acids

<223> Xaa equals any of the naturally occurring L-amino acids

```
<400> 1376
 Arg Pro Thr Arg Pro Pro Thr Arg Pro Val Xaa Ser Ile Pro Xaa Leu
                                      10
 Trp Ala Ala Xaa Val Ser Pro Pro Lys
              20
<210> 1377
<211> 38
 <212> PRT
 <213> Homo sapiens
<220>
<221> SITE
<222> (3)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (22)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1377
Phe Thr Xaa Asn Ser Leu Tyr Phe Ser Cys Ile Lys Thr Leu Cys Cys
Ser His Ser Trp Ser Xaa Ser Pro Leu His Gly Asp Cys Gly Val Gly
             20
                                  25
Leu Asp Glu Val Gly Gln
         35
<210> 1378
<211> 46
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (2)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (12)
<223> Xaa equals any of the naturally occurring L-amino acids
```

```
<220>
<221> SITE
<222> (23)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (30)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (40)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (45)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (46)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1378
Phe Xaa Lys Arg Gly Pro Ser Ser Pro Val Ala Xaa Val Leu Glu Leu
                  5
                                     10
                                                          15
Leu Asp Pro Pro Gly Cys Xaa Asn Ser Ala Arg Glu Gly Xaa Val Gly
             20
                                 25
Arg Ala Arg Arg Phe Pro Ala Xaa Val Ser Ala Arg Xaa Xaa
         35
                             40
```

```
<210> 1379
<211> 34
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (4)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (6)
```

```
<223> Xaa equals any of the naturally occurring L-amino acids
 <220>
 <221> SITE
 <222> (14)
 <223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (29)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1379
Leu Leu Lys Xaa Thr Xaa Ser Cys Ser Tyr Pro Pro Leu Xaa Ala Glu
                   5
Pro Cys Leu Ile Gln Gln Pro Gly Gly Thr Thr Arg Xaa Pro Ser Leu
             20
                                  25
Thr Leu
<210> 1380
<211> 26
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (15)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (19)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (21)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (24)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1380
His Arg His Ala His Lys Glu Arg Leu Lys Lys Lys Lys Xaa Ser
```

1 5 10 15 Arg Gly Xaa Pro Xaa Thr Lys Xaa Ala Pro 20 <210> 1381 <211> 120 <212> PRT <213> Homo sapiens <220> <221> SITE <222> (44) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (46) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (120) <223> Xaa equals any of the naturally occurring L-amino acids <400> 1381 Asp Ala Glu Gly Arg Pro Glu Gly Arg Leu Phe Gly Met Thr Gly Ala Gly Leu Gly Arg Asp Ser Gly Arg Trp Arg Glu Val Ser Phe Phe Gly 25 Glu Thr Glu Arg Ala Arg Gly Gly Thr Val Gly Xaa Arg Xaa His Ser 35 40 Val Ala Ala Ala Gly Val Arg Asp Ser Pro Pro Ile Ser Cys Ser Leu Gly Pro Trp Gly Arg Ser Gly His Arg Ser Asp Cys His Ala Asp Gly 75 Asp His Arg Arg Glu Leu Gly Gly Arg Lys Ala Pro Pro Pro Ala Gly 85 90 95 Arg Gly Pro Leu Thr Thr Ser Arg Leu Pro Val Pro Leu Leu Lys Ser 100 105 110

Asn Cys Cys Pro Phe Glu Ala Xaa

```
<210> 1382
<211> 50
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (9)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1382
Phe Lys Cys Ser Ile Leu Met Pro Xaa Asn Lys Ser Phe Gly Asn Thr
Asn Trp Ser Ile Ile Gly Asn Ala Gly Met Phe Arg Leu Ser Gln Gln
                                25
Cys Phe Ala Phe Leu Cys Leu Phe Ser Val Asn Thr Asn Glu Val Asn
         35
                             40
Ile Ala
     50
<210> 1383
<211> 92
<212> PRT
<213> Homo sapiens
<400> 1383
Gln Ser Ala Ala Leu Pro Pro Val Thr Leu Ala Leu Leu Cys Leu Asp
                  5
Gly Val Phe Leu Ser Ser Ala Glu Asn Asp Phe Val His Arg Ile Gln
                                 25
Glu Val Glu Glu Asp Gly Pro Ser Ser Cys Ser Glu Asp Asp Tyr Ser
                             40
Glu Leu Leu Gln Glu Ile Thr Asp Asn Leu Thr Arg Lys Glu Ile Gln
     50
                                             60
```

Ile Glu Lys Ile His Leu Asp Thr Ser Ser Phe Met Glu Glu Leu Pro

90

70

85

Gly Glu Lys Asp Leu Ala His Val Val Glu Ile Leu

```
<210> 1384
<211> 106
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (56)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (78)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (96)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (103)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (105)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1384
Asn Pro Ser Ala His Pro Ser Ile His Pro Ser Val Arg Pro Ser Met
  1
                  5
                                     10
Ser Pro Val Asp Arg Pro Ala Pro Leu Ala Gly Trp Val His Pro Pro
             20
                                 25
Ser Thr Trp Leu Thr Cys His Gly Arg Leu Cys Pro Ala Ser Asn Pro
                             40
Ile Leu Asn Ser Pro Lys Ala Xaa Gly Ala Val Gln Thr Gly Val Pro
                         55
Ser Ile Phe Ser Pro Thr Gly Val Phe Pro His Ala Val Xaa Tyr Asn
65
                     70
Pro His Ser Phe Leu Gly Pro Met Asn Phe Arg Ala Val Pro Phe Xaa
                 85
                                     90
```

```
Pro Gly His Leu Leu Cys Xaa Leu Xaa Lys
100 105
```

```
<210> 1385
 <211> 66
 <212> PRT
 <213> Homo sapiens
<220>
<221> SITE
<222> (5)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (6)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (7)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (18)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (22)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (26)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (28)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (35)
<223> Xaa equals any of the naturally occurring L-amino acids
```

```
<220>
<221> SITE
<222> (43)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (46)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (51)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (57)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (59)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (60)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (64)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1385
Ile Gln Gly Leu Xaa Xaa Xaa Gly Ser Ser Leu Pro Ser Pro Ser Thr
                  5
                                      10
                                                          15
Arg Xaa Ser Leu Thr Xaa Ala Thr Gly Xaa Leu Xaa Arg Gly Phe Arg
             20
Ser Leu Xaa Gly Trp Val Pro Gly Asn Gly Xaa Arg Ser Xaa Leu Gly
         35
Ala Pro Xaa Gly Cys Pro Met Gly Xaa Leu Xaa Xaa Phe Arg Gly Xaa
                         55
Trp Gly
65
```

```
<210> 1386
<211> 48
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (5)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (13)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (15)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (40)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1386
Lys Ile Ser Ser Xaa Trp Ala Glu Lys Leu Thr Gly Xaa Tyr Xaa Val
                                     10
Thr Asn Arg Ile Gln Val Gly Trp Pro Leu Cys Thr Glu Leu Gln Val
                                25
Thr Ser Gly Glu Thr Trp Ala Xaa Thr Trp Lys Ala Lys Thr Glu Ala
         35
                             40
```

```
<210> 1387
<211> 37
<212> PRT
<213> Homo sapiens

<220>
<221> SITE

<222> (23)

<223> Xaa equals any of the naturally occurring L-amino acids
```

```
<220>
<221> SITE
<222> (24)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (25)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (27)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (35)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1387
Ala Ile Tyr Arg Ile Val Trp Ala Phe Ser Cys Lys Trp Ser Glu Gly
                  5
                                     10
Val Thr Phe Ser Pro Leu Xaa Xaa Val Xaa Pro Ile Leu Asn Lys
             20
Gly Arg Xaa Glu Thr
         35
<210> 1388
<211> 41
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (2)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (11)
```

```
<223> Xaa equals any of the naturally occurring L-amino acids
 <400> 1388
 Gly Xaa Ala Arg Lys Xaa Asp Ala Arg Ile Xaa Lys Ala Trp Val Arg
                  5
                                       10
Arg Ala Gly Thr Gly Ser Gly Asn Ser Arg Gly Arg Pro Thr Arg Ser
              20
                                  25
Gly Ile Met Glu Tyr Asn Met Ser Ser
          35
<210> 1389
<211> 41
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (1)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (4)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (6)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (13)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (16)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (25)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
```

```
<222> (33)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (38)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1389
Xaa Cys Leu Xaa Phe Xaa Cys Arg Ser Leu Leu Val Xaa Ser Gly Xaa
                                      10
Thr Arg Arg His Val Ser Pro Pro Xaa Ser Ser Pro Ile Phe Arg Val
                                  25
Xaa Pro Leu Leu Asn Xaa Gln Arg Pro
         35
                              40
<210> 1390
<211> 39
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (10)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1390
Gly Leu Cys Thr Phe Gly Ser Phe Tyr Xaa Lys Leu Lys Cys Tyr Tyr
                                    10
Leu Gly Leu Tyr Leu Ala Ser Ala Phe Ser Phe Asn Cys Lys Val Glu
             20
Ala Ile Lys Gln Tyr Phe Ser
         35
<210> 1391
<211> 71
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (9)
```

<223> Xaa equals any of the naturally occurring L-amino acids

```
<220>
 <221> SITE
 <222> (50)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (70)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1391
Lys Ala Arg Val Tyr Pro Met Lys Xaa Ala Gly Ser Gln Leu Pro Pro
Gln Pro Phe Lys Arg Lys His Leu Leu His Arg Ala Val Leu Gly Val
              20
Lys Arg Leu Leu Thr Tyr Asp Arg Val Arg Lys Ser His Ile Leu Val
         35
                             40
Asn Xaa Pro Phe Gly Leu Lys Lys Lys Lys Asn Ser Arg Gly Gly
Pro Gly Tyr Pro Ile Xaa Pro
<210> 1392
<211> 58
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (26)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (46)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1392
Arg Arg Ile Thr Phe Trp Gly Ser His Ala Glu Gly Gly Ser Val Thr
Leu Pro Glu Lys Arg Val Ser Tyr Pro Xaa Ser Pro Gly Ser Thr Leu
             20
```

PCT/US00/05883

```
Lys Lys Asp Leu Ala Thr Glu Gly Ala Leu Gly Leu Pro Xaa Ser Leu
                              40
Asp Ser Ser Tyr Lys Cys Pro Cys Ser Gln
                          55
<210> 1393
<211> 42
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (4)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (9)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (32)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (42)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1393
Gly Arg Ala Xaa Ala Ala Gly Pro Xaa Pro Ala Ala Gly Ala Val Ala
                                                          15
 1
                  5
                                     10
Ser Tyr Asp Tyr Leu Val Ile Gly Gly Gly Ser Gly Gly Leu Ala Xaa
             20
                                 25
Val Val Glu Ser His Lys Leu Gly Gly Xaa
         35
                             40
<210> 1394
<211> 38
<212> PRT
<213> Homo sapiens
<220>
```

```
<221> SITE
```

<222> (29)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (38)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 1394

Gly Thr Arg Leu Ser Thr Ala Gln Leu Ser Pro Ala Gln Ser Asn Pro 1 5 10 15

Ala Gln Pro Ser Pro Thr Gln Pro Ser Ser Ala Gln Xaa Ser Pro Ala
20 25 30

Gln Leu Ser Ser Ala Xaa 35

<210> 1395

<211> 66

<212> PRT

<213> Homo sapiens

<400> 1395

Lys Leu Lys Lys His Phe Leu Lys Gly Ala Leu Ile Lys Ser Glu Val 1 5 10 15

Phe Trp Leu Ser Phe Phe Ser Val Tyr Ile Phe Phe Leu Ser Leu Trp 20 25 30

His Arg Val Asp Leu Lys Tyr Ser Ser Ser Ile Leu His Ser Ser Pro 35 40 45

Ser Ile Gly Ser Ser Ser Phe Asn Glu Phe Gln Leu Tyr Leu Thr Ser 50 55 60

Ala Ser

65

<210> 1396

<211> 46

<212> PRT

<213> Homo sapiens

<400> 1396

Leu Leu Lys Arg Phe Pro Phe Leu Phe Lys Leu Leu Met Asp Gln

1 5 10 15 Arg Thr Ile Val Tyr Phe Phe Ser Leu Val Leu Asp Ile Asn Asp Asn 20 25 Leu Val Gly Asn Phe Phe Ser Lys Glu Asn Ile Phe Met Asn 40 <210> 1397 <211> 45 <212> PRT <213> Homo sapiens <220> <221> SITE <222> (39) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (40) <223> Xaa equals any of the naturally occurring L-amino acids <400> 1397 Met Glu Phe Arg Leu Leu Thr Phe Asn Val Ile Ile Asn Ile Val Gly Phe Lys Cys Thr Val Leu Leu Phe Val Ser Tyr Leu Cys Gln Leu Phe 25 Phe Asn Val Phe Cys Ser Xaa Xaa Phe Leu Phe Phe Pro 35 40 <210> 1398 <211> 63 <212> PRT <213> Homo sapiens <220> <221> SITE <222> (5) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE

<223> Xaa equals any of the naturally occurring L-amino acids

<222> (26)

```
<220>
 <221> SITE
 <222> (40)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (45)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (49)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (54)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (57)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (58)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (62)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1398
Asn Phe Tyr Ser Xaa Lys Asn Leu Gly Phe Pro Leu Asn Ile Pro Pro
                  5
                                     10
Phe Phe Pro Ser Phe Pro Gln Ile Pro Xaa Phe Tyr Phe Phe Gly Glu
             20
                                 25
Ile Arg Phe Ala Pro Phe Phe Xaa Pro Thr Leu Leu Xaa Glu Met Pro
                             40
Xaa Pro Trp Asn Glu Xaa Lys Gly Xaa Xaa Leu Arg Leu Xaa Gly
     50
                        55
                                             60
```

```
<210> 1399
 <211> 45
 <212> PRT
 <213> Homo sapiens
<220>
<221> SITE
<222> (3)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (8)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (13)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (35)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (44)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (45)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1399
Ile Leu Xaa His Phe Lys Phe Xaa His Arg Thr Ser Xaa Ser Leu Val
                                    10
Asn Leu Met Leu Ser Lys Lys Glu Gln Leu Leu Gly Pro Lys Lys
            20
                                 25
Leu Val Xaa Lys Leu Lys Phe Thr Pro Cys Ser Xaa Xaa
        35
                       40
```

<210> 1400

<211> 69

<212> PRT

<213> Homo sapiens

```
<220>
 <221> SITE
 <222> (33)
 <223> Xaa equals any of the naturally occurring L-amino acids
 <220>
 <221> SITE
 <222> (35)
 <223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (49)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (50)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (60)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1400
Asp Phe Ala Lys Ser Tyr Leu Arg Asn Thr Ile Glu Gly Thr Pro Ala
  1
                  5
Gly Thr Gly Pro Glu Phe Pro Gly Arg Pro Thr Arg Pro Val Leu Gly
             20
                                  25
Xaa Thr Xaa Gln Thr Gln Asp Arg Val Asp Ser Ala Cys Asp Gly Val
Xaa Xaa Leu Leu Ala Pro Leu His Gln Cys Leu Xaa His Ile Tyr Ile
                         55
Trp Cys Ala Gln Glu
 65
<210> 1401
<211> 29
<212> PRT
<213> Homo sapiens
<220>
```

<221> SITE

```
<222> (10)
 <223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (19)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (23)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (24)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1401
Arg Leu Lys Asn Ala Arg Gly Tyr Trp Xaa Ile Ser Ser Tyr Glu Glu
Arg Ser Xaa Ser Met Lys Xaa Xaa Gly Arg Lys Met Ser
                                  25
<210> 1402
<211> 74
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (4)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (37)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (47)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (49)
<223> Xaa equals any of the naturally occurring L-amino acids
```

```
<220>
 <221> SITE
 <222> (51)
 <223> Xaa equals any of the naturally occurring L-amino acids
 <400> 1402
 Ser Cys Ser Xaa Arg His Glu Pro Gln Val Gln Thr Phe Gly Val Cys
                                       10
 Ala Trp Leu Arg Ser Gln Trp Gly Glu Ala Thr Ile Cys Gly Ile Met
                                  25
 Thr Glu Arg Leu Xaa Val Arg Ile Pro Pro Arg Arg Asn Asp Xaa Ala
          35
                              40
Xaa Pro Xaa Ile Leu Gly Trp Pro Leu Ile Ser Gly Pro Pro Pro Val
                          55
                                              60
Pro Ala Gly Gly Ala Gly Pro Gly Ser Arg
                      70
<210> 1403
<211> 64
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (19)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (34)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (44)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (52)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
```

```
<210> 1404
<211> 42
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (2)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (6)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (16)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (17)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (18)
<223> Xaa equals any of the naturally occurring L-amino acids
```

```
<220>
<221> SITE
<222> (22)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (27)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (34)
<223> Xaa equals any of the naturally occurring L-amino acids
Gly Xaa Asn Thr His Xaa Lys Ser Pro His Leu Thr Ile Pro Pro Xaa
                                     10
Xaa Xaa Lys Asn Ala Xaa Ile Arg Met Thr Xaa Val Phe Leu Leu Ser
Lys Xaa Asp Pro Ser Cys Ala Pro Leu Ala
         35
                             40
<210> 1405
<211> 84
<212> PRT
<213> Homo sapiens
<400> 1405
Lys Leu Leu Gln Gly Leu Ala Thr Cys Arg Gln Glu Glu Ala Glu
Leu Asp Ile Arg Pro Gln Gly Cys His Leu Ser Cys Arg Ala Trp Pro
                                 25
Cys Gly Gln Gly Ala Val Leu Cys Leu Val Gly Pro Gln Pro Leu Arg
```

40

55

70

Ala Glu Met Leu Ser Val Pro Gln Gly Lys Gly Arg Val Phe Trp Lys

Ala Leu Pro Trp Thr Phe Val Leu Gly Leu Arg Gly Pro Thr Leu Pro

75

His Thr Cys Pro

<210> 1406 <211> 60 <212> PRT <213> Homo sapiens

<400> 1406

Leu Leu Gly Asp Lys Lys Ala Trp Glu Gly Pro Val Pro Lys Pro Ser
1 5 10 15

Leu Pro Gly Asp Trp Ala Val Ile Pro Leu Pro Gly Leu Leu Pro
20 25 30

Trp Pro Pro Arg Gly Ala Asp Thr Leu Ala Pro Gly Ala Gly Glu Asn 35 40 45

Pro Pro Gly Gly Arg Arg Lys Ala Arg Ala Gly Asp
50 55 60

<210> 1407 <211> 97 <212> PRT <213> Homo sapiens

<400> 1407

Gln Asn Pro Leu Ser Ser Pro Phe Gly Pro Gly Leu Arg Gly Pro Gly
1 5 10 15

Gly Ala Gly Glu Leu Ser Gly Ala Thr Thr Pro Cys Pro Gln Trp
20 25 30

Thr Asn His Ser Ser Ser Gln Gly Trp Ala Leu Glu Val Pro Gly Arg
35 40 45

Arg Val Pro Leu Pro Ser Ala Ile His Val Arg Ser Leu Val Gly Gly 50 55 60

Pro Gln Ser His Ser Gly Lys Gly Ser Arg Val Gln Pro Ser Ser Cys 65 70 75 80

Ser Phe Pro Ser Leu Ile Ser Ile Asn Leu Ser Thr Pro Leu Leu Trp 85 90 95

Gly

```
<210> 1408
 <211> 36
 <212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (4)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (6)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (8)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (12)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (13)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (36)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1408
Asn Pro Gly Xaa Pro Xaa Val Xaa Phe Pro Pro Xaa Xaa Lys Glu Thr
25
            20
                                                  30
Asn Lys Glu Xaa
        35
<210> 1409
<211> 70
<212> PRT
<213> Homo sapiens
```

```
<220>
 <221> SITE
 <222> (37)
 <223> Xaa equals any of the naturally occurring L-amino acids
 <220>
 <221> SITE
 <222> (44)
 <223> Xaa equals any of the naturally occurring L-amino acids
 <220>
 <221> SITE
 <222> (46)
 <223> Xaa equals any of the naturally occurring L-amino acids
 <220>
 <221> SITE
 <222> (67)
 <223> Xaa equals any of the naturally occurring L-amino acids
 <400> 1409
Cys Gln Glu Cys Arg Leu Val Tyr Val Pro Gly Gly Gly Thr Gln Arg
                   5
Gly Ala Pro Gly Phe Pro Cys Pro Pro Ala Ala Leu Pro Leu Phe Pro
             20
                                  25
Phe Phe Pro Asp Xaa Arg Pro Glu Pro Val Pro Xaa Leu Xaa Ile Asn
                              40
Leu Cys Glu Ile Lys Lys Lys Lys Lys Lys Asn Ser Gly Gly Pro
                         55
Val Pro Xaa Trp Ala Leu
 65
<210> 1410
<211> 149
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (20)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
```

```
<222> (22)
 <223> Xaa equals any of the naturally occurring L-amino acids
 <220>
 <221> SITE
 <222> (24)
 <223> Xaa equals any of the naturally occurring L-amino acids
 <220>
 <221> SITE
 <222> (40)
 <223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (45)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (47)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (53)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (74)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (85)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (100)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (122)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (123)
```

<223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (124) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (130) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (138) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (143) <223> Xaa equals any of the naturally occurring L-amino acids Gly Arg Ala Pro Glu Glu Gln Asp Ala Leu Tyr Leu Gln Arg Arg Glu 5 10 Ala Ala Ser Xaa Pro Xaa Leu Xaa Leu Pro Glu Ser Arg Lys Asp Pro 25 Pro Trp Asp Ser Ser Val Cys Xaa Lys Asp Ala Pro Xaa Leu Xaa Pro 35 40 Gly Phe Pro Ser Xaa Arg His Arg Thr Gln Phe Ser Arg Pro Gly Gly 50 55 Arg Ala Pro Ile Thr Pro Gln Ala Lys Xaa Lys Pro Pro Cys Pro Gly 70 Pro Lys Pro Leu Xaa Pro Pro Phe Pro Trp Phe Pro Arg Glu Pro Val

Ser Pro Arg Gly Gln Leu Val Pro Asn Xaa Xaa Xaa Arg Leu Gly Phe 115 120 125

Thr Thr Leu Xaa Arg Ala Leu Thr Pro Met Ala Ser Phe Leu Trp Phe

105

90

110

Pro Xaa Lys Lys Asn Phe Gly Phe Ile Xaa Lys Lys Lys Arg Xaa Gly
130 135 140

Gly Gly Gly Pro Gly

```
<210> 1411
<211> 65
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (2)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (6)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (10)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (19)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (27)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (37)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (48)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (50)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
```

<222> (55) <223> Xaa equals any of the naturally occurring L-amino acids <400> 1411 Pro Xaa Leu Gly Ile Xaa Asn Leu Leu Xaa Ser Ser His Cys Pro Lys 5 Pro Ser Xaa Cys Leu Leu Asp Ala Tyr Ser Xaa Cys Gly Tyr Gly Gly 25 Ser Leu Ser Pro Xaa Ser Asp Met Ser Ser Leu Leu Gly Val Asn Xaa 40 Ser Xaa Glu Asp Thr Phe Xaa Asn Lys Leu Phe Pro Gln Leu Ile Ser Val 65 <210> 1412 <211> 116 <212> PRT <213> Homo sapiens <220> <221> SITE <222> (78) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (79) <223> Xaa equals any of the naturally occurring L-amino acids <400> 1412 Glu Phe Gln Ser Met Gly Ser Arg Leu Ser Gln Pro Phe Glu Ser Tyr 15 5 Ile Thr Ala Pro Pro Gly Thr Ala Ala Pro Ala Lys Pro Ala Pro 20 25 Pro Ala Thr Pro Gly Ala Pro Thr Ser Pro Ala Glu His Arg Leu Leu 40 Lys Thr Cys Trp Ser Cys Arg Val Leu Ser Gly Leu Gly Leu Met Gly 50

Ala Gly Gly Tyr Val Tyr Trp Val Ala Arg Lys Pro Met Xaa Xaa Gly

70

65

```
Tyr Pro Pro Ser Pro Trp Thr Ile Thr Gln Met Val Ile Gly Leu Ser
                 85
                                      90
Glu Asn Gln Gly Ile Ala Thr Trp Gly Ile Val Val Met Ala Asp Pro
                                105
Lys Gly Lys Ala
        115
<210> 1413
<211> 52
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (17)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (41)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (46)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1413
Asn Leu Ser Ser Thr Leu Asn Leu Pro Gln Asn Pro Leu Asn Pro Leu
Xaa Asn Leu Thr Val Val Gln Arg Gly Thr Ala Leu Trp Thr Leu Gly
```

25

Lys Asn Leu Val Glu Arg Gly Lys Xaa Tyr Thr His Ser Xaa Pro Lys

Ser Ser Thr Asn 50

35

20

<210> 1414 <211> 52 <212> PRT

<213> Homo sapiens

```
<220>
<221> SITE
<222> (49)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1414
Pro Thr Glu Gln Val Thr Leu Gly Ile Thr Ala Gln Ser Tyr Ser Arg
Val His Ile Asn Asn Arg Val Tyr Asp Leu Asp Val Gly Ser Gly His
              20
                                  25
Pro Asp Gly Ala Ala Ala Ile Lys Gly Ser Phe Gly Gln Arg Leu Lys
         35
                              40
Xaa Tyr Val Ile
     50
<210> 1415
<211> 55
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (5)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (27)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (28)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (29)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (41)
<223> Xaa equals any of the naturally occurring L-amino acids
```

<220>

<221> SITE

<222> (45)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 1415

Ser Lys Ser Ala Xaa Phe Gln Arg Leu Trp Tyr Gly Leu Ser Ala Ala 1 5 10 15

Ser Asn Lys Met Lys Ser Gln Asn Arg Ala Xaa Xaa Xaa Lys Ser Ile 20 25 30

Phe Ser Ala Val Leu Asp Cys Thr Xaa Ala Leu Pro Xaa Ile Asp Thr 35 40 45

Gln Thr Pro Leu Gln Thr Gln
50 55

<210> 1416

<211> 65

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (34)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 1416

Ile Cys Pro Gln Asn Pro Leu Asn Pro Leu Val Asn Leu Thr Val Ser 1 5 10 15

Pro Lys Arg Asn Ser Ser Leu Asp Thr Arg Lys Lys Pro Cys Arg Glu 20 25 30

Ser Xaa Lys Phe Asn Thr His Ser Arg Pro Lys Ser Ser His Gln Leu $35 \hspace{1.5cm} 40 \hspace{1.5cm} 45$

Arg Lys Arg Gln Ala Gln His Pro Leu Pro Lys Lys Ser Gln Thr Tyr 50 55 60

Asn

65

<210> 1417

<211> 22

<212> PRT

<213> Homo sapiens

```
<220>
<221> SITE
<222> (4)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (14)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (20)
<223> Xaa equals any of the naturally occurring L-amino acids
Asp Thr Ser Xaa Gly Thr Gly Pro Met Glu Met Tyr Arg Xaa Phe Pro
                  5
Ile Leu Val Xaa Ser Leu
             20
<210> 1418
<211> 54
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (19)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (27)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (31)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (43)
<223> Xaa equals any of the naturally occurring L-amino acids
```

```
<220>
<221> SITE
<222> (45)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (52)
<223> Xaa equals any of the naturally occurring L-amino acids
Gly Ile Arg Ile Phe Cys Lys Trp Arg His Ile Gln Lys Lys Ser Leu
Asn Gly Xaa Ile Gly Met Glu Trp Gly Lys Xaa Phe Trp Lys Xaa Ile
Pro Ile Leu Pro Gly Arg Leu Phe Glu Val Xaa Ile Xaa Val Pro Asn
                            40
Lys Val Asn Xaa Phe Leu
     50
<210> 1419
<211> 39
<212> PRT
<213> Homo sapiens
<400> 1419
Gln Leu Leu Ser Val Arg Leu His Phe Ala Pro Tyr Asn Tyr Cys
                                     10
Phe Gln Ile Ser Thr Cys Met Cys Leu Ser Leu Lys Ala Leu Val Lys
             20
Ser His Ile Leu Tyr Ser Ala
         35
<210> 1420
<211> 45
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (5)
```

<223> Xaa equals any of the naturally occurring L-amino acids

```
<220>
 <221> SITE
 <222> (37)
 <223> Xaa equals any of the naturally occurring L-amino acids
 <220>
 <221> SITE
 <222> (38)
 <223> Xaa equals any of the naturally occurring L-amino acids
 <220>
 <221> SITE
 <222> (39)
<223> Xaa equals any of the naturally occurring L-amino acids
 <220>
<221> SITE
<222> (44)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1420
Gly Gly Gly Ala Xaa Pro Glu Gly Leu Ser Leu Leu Ala Pro Ser Ala
                                                           15
                                      10
  1
                   5
Arg Ser Arg Ala Gly Arg Ala Leu Pro Ala Pro Gly Thr Val Pro Gly
              20
                                  25
Gly Glu Tyr Asp Xaa Xaa Xaa Thr Pro Val Lys Xaa Glu
         35
                              40
<210> 1421
<211> 136
<212> PRT
<213> Homo sapiens
<400> 1421
Ala Ala Ala Ala Gly Asp Pro Gly Ala Met Gly Arg Ala Arg Asp
                   5
Ala Ile Leu Asp Ala Leu Glu Asn Leu Thr Ala Glu Glu Leu Lys Lys
              20
                                  25
Phe Lys Leu Lys Leu Ser Val Pro Leu Arg Glu Gly Tyr Gly Arg
                              40
```

Ile Pro Arg Gly Ala Leu Leu Ser Met Asp Ala Leu Asp Leu Thr Asp

55

50

Lys Leu Val Ser Phe Tyr Leu Glu Thr Tyr Gly Ala Glu Leu Thr Ala 65 70 75 80

Asn Val Leu Arg Asp Met Gly Leu Gln Glu Met Ala Gly Gln Leu Gln 85 90 95

Ala Ala Thr His Gln Gly Ser Gly Ala Ala Pro Leu Gly Ser Arg Pro 100 105 110

Leu Leu Ser Arg Gln Pro Ser Gln Ala Cys Thr Leu Ile Asp Gln His 115 120 125

Arg Ala Ser Leu Ser Arg Arg Ser 130 135

<210> 1422

<211> 115

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (96)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (111)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 1422

Gly Met Thr Pro Phe Cys Gly Leu Lys Cys Asp Ala Leu Gln Lys His 1 5 10 15

His Ser Asp Gly Gln Leu Asp Ser Gly Val Leu Arg Leu Cys Pro Leu 20 25 30

Pro Thr Ala Ser Leu Pro His Pro Ser Leu Gln Ser His Phe Ser Asp 35 40 45

Arg Ala Ile Pro Lys Asn Thr Glu Gly Leu Glu Cys Trp Leu Ala Thr
50 55 60

Leu Cys Leu Ser Gly Leu Pro Lys Ala Trp Lys Lys Glu Gly Pro Asp
65 70 75 80

Cys Gln Gly Asn Leu Leu Ile Gly Leu Arg Arg His Trp Ser Leu Xaa 85 90 95

```
Cys Gly Ala Pro Gln Ser Cys Arg Ser Asn Ala Leu Leu Ala Xaa Leu
                                105
Ala Trp Leu
       115
<210> 1423
<211> 52
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (9)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (43)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (49)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1423
Arg Ala His Pro Ser Ile Phe Ala Xaa Ile Val Gly Lys Ile Tyr Arg
                                                          15
 1
                  5
                                     10
Phe Glu Gly Glu Gln Thr Tyr Arg Ala Trp Leu Ile Ser Leu Phe Val
             20
                                  25
Pro Arg Leu Glu Ser Leu Phe Pro Thr Phe Xaa Phe Leu Pro His Gln
         35
                             40
Xaa Pro Ser Phe
    50
<210> 1424
<211> 53
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (38)
```

```
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (52)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1424
Leu Cys Lys Gly Glu Pro Lys Leu Arg Pro Pro Lys Pro Asp Glu Leu
                   5
                                      10
Pro Lys Lys Gln Leu Lys Glu His Thr Arg Leu Cys Ser Lys Ile Val
              20
                                  25
Gly Arg Phe Ile Gly Xaa Gly Asp Lys Pro Thr Glu Pro Gly Asp Ser
                              40
Trp Phe Pro Xaa Glu
     50
<210> 1425
<211> 23
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (7)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (8)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (11)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (14)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1425
Leu Phe Phe Leu Asn Xaa Xaa Leu His Xaa Phe Ser Xaa Phe Gln
                  5
                                     10
                                                          15
```

```
Asp Gly Arg Cys Tyr Gly Phe
             20
<210> 1426
<211> 75
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (7)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (12)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (19)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (21)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (22)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (25)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (29)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (32)
<223> Xaa equals any of the naturally occurring L-amino acids
```

<220>

```
<221> SITE
<222> (35)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (36)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (37)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (43)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (44)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (47)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (48)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (52)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (56)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (63)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
```

```
<222> (70)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (72)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (75)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1426
Lys Gly Leu Glu Lys Gln Xaa Arg Leu Lys Ala Xaa Ser Ser Lys Pro
Asn Gln Xaa Ser Xaa Xaa Gly Gln Xaa Val Ala Leu Xaa Val Pro Xaa
                                  25
Gln Lys Xaa Xaa Xaa Trp Glu Lys Gly Glu Xaa Xaa Gly Asn Xaa Xaa
         35
                             40
                                                  45
Leu Lys Leu Xaa Leu Leu Gly Xaa Ile Pro Pro Trp Lys Leu Xaa Ser
                         55
                                              60
Phe Leu Gly Lys Arg Xaa Lys Xaa Gln Pro Xaa
 65
                    70
<210> 1427
<211> 174
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (59)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (89)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (119)
<223> Xaa equals any of the naturally occurring L-amino acids
```

```
<220>
<221> SITE
<222> (127)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (149)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (162)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (172)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1427
Pro Pro Cys Cys Cys Pro Thr Thr Pro Thr Cys Ser Arg Cys Gly Arg
                                     10
Cys Arg Gly Gly Trp Ala Ala Gln Leu Thr Gly Arg Arg His Ser Pro
                                 25
Arg His Ala Gly Ser Pro Arg Pro Ala Arg Trp Pro Cys Lys Thr Ala
         35
                             40
Ser Gly Pro Ser Pro Ser Cys His Ala Ala Xaa Gly Asp Met Gly Arg
                         55
Val Ala Leu Lys Ser Arg Gly Ala Val Gly Thr Asp Cys Gly Gln Glu
Ala Trp Lys Val Trp Cys Gly Cys Xaa Cys Glu Ser Glu Cys Glu Cys
                 85
Ala Gly Arg Pro Gln Gly Gln Glu Ala Ala Pro Arg Leu Lys Ala
            100
                                105
Met Ala Ala Met Asp Leu Xaa Gln Gly Pro Arg Leu His Gly Xaa Arg
        115
                            120
Thr Trp Asn His Asp Ser Gly His Trp Ile Trp Gly Gln Gly His Val
                        135
Asp Lys Thr Phe Xaa Thr Val Phe Phe Thr Lys Ala Glu Glu Pro Arg
                                     155
145
                    150
                                                            160
```

Met Xaa Pro His Ala Pro Pro Asn Asn Cys Pro Xaa Leu Arg 165 170

<210> 1428

<211> 64

<212> PRT

<213> Homo sapiens

<400> 1428

Ser Ile Gly Ser Gly Thr Ser Cys Arg Thr Gln Leu Lys Thr His Val 1 5 10 15

Phe Phe His Arg Ile Met Cys Gln Phe Phe Val Ala Met Ile Phe Leu 20 25 30

Leu Glu Ser Gln Lys Cys Phe Val Pro Glu His Leu Gln Thr Ala Leu 35 40 45

Arg Lys Asn Ser Gln Asn His Pro Leu Phe Pro Phe Leu Tyr Tyr Leu 50 55 60

<210> 1429

<211> 120

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (2)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (41)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (45)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (112)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (118)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 1429

Asp Xaa Gly Phe Arg Met Ala Ala Pro Val Arg Ile Thr Val Leu Cys
1 5 10 15

Ser Lys Glu Asn Asp Ser Thr Cys Ser Phe Ser Leu Val Glu Val Thr 20 25 30

Leu Val Ser Cys Trp Gly Gly Gly Xaa His Phe Phe Xaa Val Ser Val
35 40 45

Glu Ser Lys Met Asn Asn Lys Ala Gly Ser Phe Phe Trp Asn Leu Arg 50 55 60

Gln Phe Ser Thr Leu Val Ser Thr Ser Arg Thr Met Arg Leu Cys Cys
65 70 75 80

Leu Gly Leu Cys Lys Pro Lys Ile Val Pro Phe Lys Leu Glu His Phe
85 90 95

Glu Ile Thr Phe Ile Thr Glu Cys Asn Gln Arg Met Ile Ile Glu Xaa 100 105 110

Ala Leu Ala Gly Cys Xaa His Phe 115 120

<210> 1430

<211> 54

<212> PRT

<213> Homo sapiens

<400> 1430

Thr Cys Val Thr Lys Lys Lys Met Asn Val Leu Lys Arg Val Leu Gly
1 5 10 15

Gly Trp Phe Asn Lys Glu Thr Lys Met Leu Trp Cys Leu Asp Leu Trp
20 25 30

Leu Leu Lys Met Ser Ser Gln Val Lys Ser Leu Val Cys Leu His Leu 35 40 45

Ile His Phe Cys Thr Asn

```
<210> 1431
<211> 132
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (5)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (6)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (120)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (126)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (128)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (131)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (132)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1431
Thr Val Thr Val Xaa Xaa Ser Arg Val Arg Pro Ser Ala Ser Gly Arg
 1
                  5
                                      10
                                                          15
Val Phe Met Trp Thr Val Ser Gly Thr Pro Cys Arg Glu Phe Trp Ser
             20
                                 25
Arg Phe Arg Lys Glu Lys Glu Pro Val Val Val Glu Thr Val Glu Glu
```

35 40 45

Lys Lys Glu Pro Ile Leu Val Cys Pro Pro Leu Arg Ser Arg Ala Tyr 50 55 60

Thr Pro Pro Glu Asp Leu Gln Ser Arg Leu Glu Ser Tyr Val Lys Glu
65 70 75 80

Val Phe Gly Ser Ser Leu Pro Ser Asn Trp Gln Asp Ile Ser Leu Glu 85 90 95

Asp Ser Arg Leu Lys Phe Asn Leu Leu Ala His Leu Ala Asp Asp Leu 100 105 110

Gly His Val Val Pro Lys Leu Xaa Thr Pro Pro Asp Val Xaa Gly Xaa 115 120 125

Arg Cys Xaa Xaa 130

<210> 1432

<211> 30

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (8)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (10)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (11)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (22)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 1432

Ser Gly Thr Val Lys Arg His Xaa Arg Xaa Xaa Ile Ser Gly Arg Pro 1 5 10 15

```
Pro Ala Pro Pro Arg Xaa Pro Arg Glu Gly Pro Gly Ala Gly
20 25 30
```

```
<210> 1433
<211> 43
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (37)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (38)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (39)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (41)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1433
Thr Pro Leu Ser Gln Asn Pro Ala Gln Ala Glu Arg Tyr Gly Ser Ala
Ala Glu Pro Arg Leu Ala Ser Asp Ser Arg Ser Pro Arg Cys Pro Arg
             20
                                 25
                                                     30
Arg Arg Ala Ala Xaa Xaa Xaa Arg Xaa Pro Pro
```

<210> 1434
<211> 47
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (31)
<223> Xaa equals any of the naturally occurring L-amino acids

40

```
<220>
<221> SITE
<222> (40)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (43)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1434
Leu Asn Ala Ser Lys Ser Glu Ser Arg Pro Gly Gly Thr Ile Arg Gln
Arg Arg Gly Ala Ser Asp Gly Ser Asp Ser Arg Ser Pro Ala Xaa Pro
             20
                                  25
Arg Arg Arg Ala Ala Pro Pro Xaa Arg Ala Xaa Arg Ala Arg Glu
         35
                              40
<210> 1435
<211> 51
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (17)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (23)
<223> Xaa equals any of the naturally occurring L-amino acids
Cys Leu Ser Phe Leu Tyr Tyr His Arg Tyr Phe Pro His Ser Leu Ala
                  5
                                     10
Xaa Ala Cys Arg Met Leu Xaa Lys Ser Leu Ile Asn His Trp Ala Lys
Tyr Thr Glu Gly Glu Ala Ser Ser Ile Phe Lys Leu Val Ser Lys Phe
                             40
Phe Ile Ala
```

```
<210> 1436
<211> 96
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (53)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (73)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (80)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (83)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (89)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (90).
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1436
Glu Gln Leu Lys Glu His Thr Arg Leu Cys Ser Lys Ile Val Gly Arg
                                      10
                                                          15
Phe Ile Gly Arg Gly Asp Lys Pro Thr Glu Pro Gly Asp Ser Trp Val
             20
                                                      30
Val Gln Asp Arg Ile Leu Ser Ser Thr Leu Asn Leu Pro Gln Asn Pro
         35
                             40
Leu Asn Pro Leu Xaa Asn Leu Thr Gly Ser Pro Lys Arg Asn Ser Ser
                         55
```

Leu Asp Thr Arg Lys Lys Pro Cys Xaa Glu Ser Lys Lys Ile Asn Xaa

65 70 75 80

His Ser Xaa Pro Lys Ser Ser Thr Xaa Xaa Lys Ala Val Lys Leu Thr 85 90 95

<210> 1437

<211> 58

<212> PRT

<213> Homo sapiens

<400> 1437

Ile Cys Pro Gln Asn Pro Leu Asn Pro Leu Val Asn Leu Thr Val Ser 1 5 10 15

Pro Lys Arg Asn Ser Ser Leu Asp Thr Arg Lys Lys Pro Cys Arg Glu 20 25 30

Ser Lys Lys Phe Asn Thr His Ser Arg Pro Lys Ser Ser His Gln Leu 35 40 45

Arg Lys Arg Ser Ser Ser Thr Pro Thr Thr 50 55

<210> 1438

<211> 121

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (108)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 1438

Asp Gly Gly Ser Ser Val Gln Ser Glu Ala Glu Ala Ser Val Asp Pro 1 5 10 15

Ser Leu Ser Trp Gly Gln Arg Lys Lys Leu Tyr Tyr Asp Thr Asp Tyr 20 25 30

Gly Ser Lys Ser Arg Gly Arg Gln Ser Gln Gln Glu Ala Glu Glu Glu 35 40 45

Glu Arg Glu Glu Glu Glu Ala Gln Ile Ile Gln Arg Arg Leu Ala

50 55 60

Gln Ala Leu Gln Glu Asp Asp Phe Gly Val Ala Trp Val Glu Ala Phe
65 70 75 80

Ala Lys Pro Val Pro Gln Val Asp Glu Ala Glu Thr Arg Val Val Lys
85 90 95

Asp Leu Ala Lys Gly Ser Val Glu Arg Lys Thr Xaa Lys Cys Cys Lys
100 105 110

Arg Asn His Gln Asn Ser Trp Ser Leu 115 120

<210> 1439

<211> 78

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (71)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (72)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 1439

Leu Leu Asn Ile Leu Glu Phe Phe Tyr Ser Trp Tyr Leu Lys Lys 1 5 10 15

Lys Lys Arg Ala Ala Ala Leu Glu Asp Pro Ser Arg Gly Pro Ser Phe 20 25 30

Thr Arg Ala Cys Asp Val His Ser Ser Leu Pro Ile Val Ser Arg Ile
35 40 45

Ile Lys Leu Gly Thr Gly Arg Ala Val Tyr Asn Val Arg Gly Leu Gly 50 55 60

Arg Ser Ala Ser Leu Gly Xaa Xaa Val Glu Gly Thr Leu Leu 65 70 75

<210> 1440

<211> 121

```
<212> PRT
 <213> Homo sapiens
 <220>
 <221> SITE
 <222> (24)
 <223> Xaa equals any of the naturally occurring L-amino acids
 <220>
<221> SITE
 <222> (26)
 <223> Xaa equals any of the naturally occurring L-amino acids
 <220>
 <221> SITE
 <222> (87)
 <223> Xaa equals any of the naturally occurring L-amino acids
 <220>
 <221> SITE
 <222> (101)
 <223> Xaa equals any of the naturally occurring L-amino acids
 <220>
 <221> SITE
 <222> (105)
 <223> Xaa equals any of the naturally occurring L-amino acids
 <400> 1440
 Leu Cys Ala Phe Ser Ala Pro Phe Ser Gly Cys Pro Thr Leu Pro Leu
  1
                   5
                                      10
                                                          15
His Ala Ala Trp Ala Ala Arg Xaa Arg Xaa Pro Thr Gly Ser Lys Cys
              20
                                  25
Ala Phe Leu Arg Ala Leu Pro Glu Ser Ser Thr Ala His Pro Val Ala
Pro Cys Leu Ala Trp Pro Gly Leu Pro Gly Pro Ser Leu Pro Met Leu
                                              60
                          55
Leu His Val Leu Ile Phe Leu Phe Gly Pro Leu Pro Pro Leu Ala
                                          75
 65
                     70
Val Leu Pro Leu Gly Leu Xaa Pro Ser Cys Leu Asn Leu Gly Lys Val
                 85
Leu Ser Leu Trp Xaa Ser Ser Ser Xaa Pro Arg Val Leu Glu Pro Gly
```

Leu Phe Pro Thr Gly Pro Thr Leu Thr

```
<210> 1441
<211> 121
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (2)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (57)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (79)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (81)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (109)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (110)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (117)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (119)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
```

<222> (120)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 1441

Gln Xaa Ile Ser Ala Pro Trp Gly Leu Glu Gln Asn Trp Gln Arg Gly
1 5 10 15

Lys Arg Ser Leu Arg Ala Ser Val Thr Gln Asp Leu Pro Pro Ala Cys 20 25 30

Pro Ser Pro Ala Arg Leu Leu Glu Asn Gly His Cys Ala Gln Pro Gly 35 40 45

Pro Trp Ala Ala Gln Ala Gly Val Xaa His Gly Pro Gly Pro Pro Ser 50 55 60

Leu Pro Leu Leu Arg Pro Pro Ala Phe Arg Gln Ala Lys Ala Xaa Phe 65 70 75 80

Xaa Pro Thr Arg Pro Pro Gln Gly Ala Ser Gly Ala Gln Val Gly Pro 85 90 95

Ser Phe Asn Leu Pro Val Val Val Gly Ala Leu Xaa Xaa Pro Gln
100 105 110

Arg Ser His Phe Xaa Gly Xaa Xaa Trp 115 120

<210> 1442

<211> 37

<212> PRT

<213> Homo sapiens

<400> 1442

Glu Gln Leu Lys Glu His Thr Arg Leu Cys Ser Lys Ile Val Gly Arg
1 5 10 15

Phe Ile Gly Arg Gly Asp Lys Pro Thr Glu Pro Gly Asp Ser Trp Leu 20 25 30

Ser Lys Ile Glu Ser

35

<210> 1443

<211> 61

<212> PRT

<213> Homo sapiens

```
<220>
 <221> SITE
 <222> (4)
 <223> Xaa equals any of the naturally occurring L-amino acids
 <220>
 <221> SITE
 <222> (13)
 <223> Xaa equals any of the naturally occurring L-amino acids
 <220>
 <221> SITE
 <222> (26)
 <223> Xaa equals any of the naturally occurring L-amino acids
 <220>
 <221> SITE
 <222> (33)
 <223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (34)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (47)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (49)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (50)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (52)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (53)
<223> Xaa equals any of the naturally occurring L-amino acids
```

Xaa Xaa Ile His Ile Leu Pro Pro Gly Lys His Glu Lys Leu Xaa Pro
35 40 45

Xaa Xaa Ile Xaa Xaa Gly Leu Thr Pro Ile Pro Ser Ala 50 55 60

<210> 1444

<211> 35

<212> PRT

<213> Homo sapiens

<400> 1444

Asn Ala Tyr Val Asn Phe Phe Leu Phe Leu Ser Ile His Pro Asn Lys

1 5 10 15

Lys Ile Thr Gly Lys Pro Met Phe Leu Arg Cys His Tyr Ser Lys Gln
20 25 30

Asn Lys Arg

<210> 1445

<211> 79

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (21)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (25)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (38)

<223> Xaa equals any of the naturally occurring L-amino acids

```
<220>
<221> SITE
<222> (56)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (57)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (70)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (71)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (76)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (79)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1445
Gly Arg Gly Ser Ser Gly Leu Met Leu Gly Cys Arg Ser Ala Pro Val
                  5
                                     10
Ala Thr Pro Pro Xaa Gln Pro Gly Xaa Leu Gly Ala Arg Leu Gly Val
             20
Leu Thr Gly Val Gly Xaa Thr Pro Asn Ser Lys Ser Leu Arg Lys Arg
                             40
Glu Val Glu Gly Glu Ala Ser Xaa Xaa Ile Lys Ala Pro Ile Arg Ser
     50
Lys Lys Lys Lys Xaa Xaa Gly Gly Pro Xaa Pro Asn Xaa
65
                    70
                                         75
```

<210> 1446 <211> 104 <212> PRT

<213> Homo sapiens

<400> 1446

Phe Ala Cys Ser Arg Arg Gly Val Ala Leu Ile Ser Ala Met Ser Ser 1 5 10 15

Gln Lys Gly Asn Val Ala Arg Ser Arg Pro Gln Lys His Gln Asn Thr 20 25 30

Phe Ser Phe Lys Asn Asp Lys Phe Asp Lys Ser Val Gln Thr Lys Lys 35 40 45

Ile Asn Ala Lys Leu His Asp Gly Val Cys Gln Arg Cys Lys Glu Val
50 55 60

Leu Glu Trp Arg Val Lys Tyr Ser Lys Tyr Lys Pro Leu Ser Lys Pro 65 70 75 80

Lys Lys Cys Val Lys Cys Leu Gln Lys Thr Val Lys Asp Ser Tyr His 85 90 95

Val Met Cys Arg Pro Cys Ala Leu 100

<210> 1447

<211> 34

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (4)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (6)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (31)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 1447

Tyr Pro Arg Xaa Leu Xaa Cys His Arg Val Ala Gln Ala Cys Pro Ala 1 5 10 15

```
Thr Pro Arg Ile Thr Leu Trp Pro Ser Ala Ser Gly Met Ser Xaa Arg 20 25 30
```

Trp Ser

```
<210> 1448
 <211> 80
 <212> PRT
 <213> Homo sapiens
<220>
<221> SITE
<222> (2)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (3)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (6)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (9)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (15)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (16)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (22)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (26)
```

```
<223> Xaa equals any of the naturally occurring L-amino acids
 <220>
 <221> SITE
 <222> (39)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (59)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (64)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (65)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (68)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (78)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1448
His Xaa Xaa Asn Pro Xaa Ser Asn Xaa Lys Tyr His Arg His Xaa Xaa
His Lys Glu Tyr Lys Xaa His His Pro Xaa Ala Trp Glu Asn Val Val
                                 25
Glu Asn Leu His Leu Tyr Xaa Ile Leu Lys Met Lys Leu Gly Val Val
         35
                             40
                                                  45
Val His Thr Cys Gly Pro Ser Leu Leu Gly Xaa Leu Gln Pro Gly Xaa
     50
                         55
Xaa Ala Pro Xaa Gln Gly Leu Val Ala Ala Met Ser Ser Xaa Leu Ala
                     70
                                         75
```

```
<210> 1449
 <211> 110
 <212> PRT
 <213> Homo sapiens
<220>
<221> SITE
<222> (34)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (102)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (108)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1449
Gly Thr Val Tyr Leu Glu Leu Arg Gly Phe Pro Arg Thr Met Gly Met
                                      10
Ala Lys Asn Lys Leu Val Lys Ser Asp Pro Gly Thr Gln Gln Leu Ile
                                  25
Leu Xaa Phe Phe Leu Ser Leu Ser Arg Val Phe Phe Pro Pro Trp Ala
         35
                             40
Gly Met His Thr Ala Ala Ala Leu Val Ser Gly Gln Ala Asp Gly Leu
     50
Gly Ala Ser Pro Arg Gly Val Ala Gly Ala Glu Asp Pro Pro Arg Arg
 65
                     70
Thr Pro Ala Ser Ser Ala Gly Gln Arg Gln Ala Gly Arg Ala Phe Arg
                                     90
Gly Ala Arg Ala Phe Xaa Gln Ala Cys Ser Pro Xaa Cys Ser
           100
                                105
                                                    110
```

<210> 1450 <211> 111 <212> PRT <213> Homo sapiens

```
<220>
 <221> SITE
 <222> (1)
 <223> Xaa equals any of the naturally occurring L-amino acids
 <220>
 <221> SITE
 <222> (13)
 <223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (14)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (33)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (66)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (96)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (97)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1450
Xaa Ser Ala Glu His Phe His Arg Leu Pro Arg Arg Xaa Xaa Gln Leu
                5
                            . 10
Arg Asp Val His His Gly Trp Ala Pro Arg Gly Glu Arg Arg Pro Thr
             20
                                 25
                                                     30
Xaa Ala Val Pro Val Arg Glu Arg Glu Gly Phe Arg Gly Val Arg Arg
         35
                             40
Arg Thr Leu Gly Pro Pro Ala Ala Val Tyr Arg Ala Ser His Leu Leu
Ser Xaa Phe Pro Leu Ser Arg Ser Lys Asn Thr Lys Leu Gly Thr Pro
65
                    70
                                         75
```

```
Ser Ala Pro Pro Pro Arg Leu Pro Gly Pro Ile His Asn Phe Asn Xaa
85 90 95
```

Xaa Pro Gly Ser Pro Ser Phe Arg Gly Gly Leu Gly Arg Gly Cys
100 105 110

```
<210> 1451
<211> 40
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (1)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (13)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (32)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (34)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (35)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (38)
<223> Xaa equals any of the naturally occurring L-amino acids
Xaa Lys Leu Trp Ser Phe Cys Leu Val Ala Leu Lys Xaa Phe Cys Ala
                  5
```

Ile Met Gln Gln Tyr Gly Gly Lys Ile Leu Trp Lys Asn Gly Asp Xaa

Leu Xaa Xaa Pro Gln Xaa Ile Lys

```
<210> 1452
<211> 40
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (17)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (19)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (21)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (34)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (36)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1452
Thr Ser Ser Gly Thr Arg Asp Leu Pro Leu Gly Trp Pro Ala Arg Arg
                                     10
Xaa Arg Xaa Gly Xaa Pro Gly Ser Thr His Ala Ser Ala Ile Leu Leu
                                 25
```

<210> 1453 <211> 67 <212> PRT <213> Homo sapiens

Glu Xaa Ile Xaa Leu Ser Pro Pro

<220>

```
<221> SITE
<222> (1)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (43)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (45)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (59)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (67)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1453
Xaa Ser Ala Thr Gln Glu Val Arg Ile Leu Leu Ala Ser Ala Gly Cys
Cys Phe Phe Ser Gly Ser Gly Thr Gly Arg Gly Pro Val Val Tyr Leu
                                 25
Thr Gln Met Gly Asp Glu Lys Val Leu Leu Xaa Lys Xaa Lys Thr Leu
         35
                             40
                                                  45
Asp Gly Asn Ser Ser Gly Lys Arg Asn Glu Xaa Arg Asn Lys Arg Arg
     50
                         55
Lys Gln Xaa
65
<210> 1454
<211> 44
<212> PRT
<213> Homo sapiens
<400> 1454
Asn Ser Glu His Ser Thr His Val Trp His Phe Lys Val Lys Thr Ser
 1
                 5
                                                          15
                                     10
```

```
Val Thr Ser Arg Thr Lys Glu Ile Val Ser Tyr Thr Phe Ile Phe Met 20 25 30
```

Asn Ser Phe Ile Phe Leu Phe Asn Asp Ser Leu Phe 35

```
<210> 1455
<211> 39
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (18)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (.19)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (20)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (21)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (34)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1455
Thr Ser Thr Ser Trp Cys Val Ser Leu Thr Gly Val Glu Asp Gln Thr
                                     10
Gly Xaa Xaa Xaa Cys Ser Glu Arg Val Arg Ser Tyr Trp Ile Ile
```

25

30

Ile Xaa Leu Asn Pro Lys Gln

20

```
<210> 1456
 <211> 149
 <212> PRT
 <213> Homo sapiens
 <220>
 <221> SITE
 <222> (54)
 <223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (81)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (104)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (112)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (113)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (121)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (122)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (125)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (126)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
```

```
<221> SITE
<222> (137)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (148)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1456
Ser Pro Pro Pro Gly Leu Ala Leu Pro Gly Gly Tyr Asp Trp Ser
His Trp Ser Arg Arg Ile Pro Ala Ser Ser Val Ala Ala Ser Thr Ser
             20
Leu Ser Arg Pro Arg Pro Ala Pro Arg Arg Leu Leu Trp Val Arg Pro
Pro Arg Gly Ala Ala Xaa Ser Gln Ala Ala Gly Gln Ala Arg Leu Lys
Ser Leu Gln Trp Leu Thr Asn Leu Ser Leu Ser Val Leu Thr Trp Pro
                                         75
 65
                     70
Xaa Ile Asp Tyr Gly Arg Leu Gly Val Asn Ser Ile Pro Thr Ile Lys
                 85
Val Ile Ser Gln Ser Pro Leu Xaa Gln Ala Thr Val Met Ser Ser Xaa
            100
                                105
Xaa Phe Gly Gly Ile Ala His Thr Xaa Xaa Thr Glu Xaa Xaa Arg Asn
                          120
Asp Thr Asn Met Ser Gln Ser Phe Xaa Gly Asn Leu Asp Pro Trp Asn
                                            140
   130
                        135
Val Phe Ser Xaa Trp
145
```

<210> 1457 <211> 140 <212> PRT <213> Homo sapiens <220> <221> SITE <222> (117)

<223> Xaa equals any of the naturally occurring L-amino acids

<220> <221> SITE <222> (124) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (135) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (138) <223> Xaa equals any of the naturally occurring L-amino acids <400> 1457 Glu Ala Ala Ala Leu Gly Leu Ser Gln Pro Ser Gly Cys Trp Cys Cys His Pro Pro Ala Leu Ser Leu Trp His Phe Pro Pro Leu Arg Pro Trp 20 Arg Ala Leu Pro Val Gly Leu Ala Ala Pro Gln Asn Leu Gly Pro Ser 40 Ser Ser Ile Gly Phe Ser Pro Gly Phe His Leu Leu Pro Arg Ala Gln Pro Leu Thr Cys Phe Ile Gly His Ser Gly Cys Ser Leu Thr Gln Trp 70 75 Leu Val Gly Arg Gly Val Thr Glu Gly Ser Gln Gly Pro Val Gly Val Pro Gly Gln Lys Asn Trp Leu Gln Leu Pro Val Trp Ser Arg Val Phe 100 105 Arg Val Asn Val Xaa Asn Phe Lys Gly His Ser Xaa Asn Gln Leu Gly 120

Val Lys Ser Leu Arg Met Xaa Asn Leu Xaa Gly Arg

135

<210> 1458 <211> 41 <212> PRT <213> Homo sapiens

```
<220>
 <221> SITE
 <222> (8)
 <223> Xaa equals any of the naturally occurring L-amino acids
 <220>
 <221> SITE
 <222> (11)
 <223> Xaa equals any of the naturally occurring L-amino acids
 <220>
 <221> SITE
 <222> (12)
 <223> Xaa equals any of the naturally occurring L-amino acids
 <220>
 <221> SITE
<222> (35)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1458
Pro Pro Arg Cys Ser Arg Ser Xaa Thr Ser Xaa Xaa Pro Gly Cys Arg
                                      10
Asn Ser Ala Arg Ala Cys Lys Thr Ala Gly Cys Thr Ala Ser Ser Lys
Pro Arg Xaa Ser Glu Gln Ile Leu Arg
         35
                              40
<210> 1459
<211> 56
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (29)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (41)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1459
Arg Val Phe Phe Phe Phe Phe Phe Leu Asp Gly Ile Phe Asn Leu
 1
```

Phe Ile Met Phe Val Ser Tyr Arg His Leu Cys Phe Xaa Gln Gln Phe 20 25 30

Ile Ile Val Thr Ser His Thr Ser Xaa Ile Thr Thr Glu Arg Thr Leu $35 \hspace{1cm} 40 \hspace{1cm} 45$

Lys Tyr Lys Glu Arg Leu Gln Lys 50 55

<210> 1460

<211> 56

<212> PRT

<213> Homo sapiens

<400> 1460

Pro Gln Asn Pro Leu Asn Pro Leu Val Asn Leu Thr Val Ser Pro Lys
1 5 10 15

Arg Asn Ser Ser Leu Asp Thr Arg Lys Lys Pro Cys Arg Glu Ser Lys
20 25 30

Lys Phe Asn Thr His Ser Arg Pro Lys Ser Ser His Gln Leu Arg Lys
35 40 45

Arg Ser Ser Ser Thr Pro Thr Thr 50 55

<210> 1461

<211> 124

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (9)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (47)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (50)

<223> Xaa equals any of the naturally occurring L-amino acids

```
<220>
 <221> SITE
 <222> (51)
 <223> Xaa equals any of the naturally occurring L-amino acids
 <220>
 <221> SITE
 <222> (52)
 <223> Xaa equals any of the naturally occurring L-amino acids
 <220>
 <221> SITE
 <222> (53)
 <223> Xaa equals any of the naturally occurring L-amino acids
 <220>
 <221> SITE
 <222> (54)
 <223> Xaa equals any of the naturally occurring L-amino acids
<220>
 <221> SITE
<222> (55)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (56)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (57)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (59)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (60)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (65)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
```

```
<221> SITE
 <222> (69)
 <223> Xaa equals any of the naturally occurring L-amino acids
 <220>
 <221> SITE
 <222> (75)
 <223> Xaa equals any of the naturally occurring L-amino acids
 <220>
 <221> SITE
 <222> (82)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (88)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (98)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (103)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (104)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (106)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (113)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (121)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
```

<222> (123)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1461

Gly Phe Arg Glu Asn Lys Leu Lys Xaa Ile Lys Phe Val Lys Ser Asn 1 5 10 15

Tyr Ile Tyr Ile Lys Lys Pro Ile Cys Ile Arg Gln Lys Leu Phe Leu 20 25 30

Phe Ile Ser Val Arg Tyr Pro Leu Asn Lys Tyr Phe Ser Gly Xaa Lys 35 40 45

Lys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asn Xaa Xaa Lys Gly Gly Arg
50 55 60

Xaa Lys Gly Ser Xaa Leu Thr Phe Ala Cys Xaa Gln Arg His Thr Ser 65 70 75 80

Pro Xaa Leu Ser Pro Asn Phe Xaa Pro Leu Ala Val Phe Leu Gln Pro 85 90 95

Ser Xaa Leu Gly Lys Ser Xaa Xaa Val Xaa Gln Leu Lys Pro Pro Cys 100 105 110

Xaa Tyr Ile Pro Phe Ser Pro Ala Xaa Arg Xaa Phe 115 120

<210> 1462

<211> 51

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (51)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 1462

His Glu Ala Ala Pro Glu Phe Gly Arg Lys Ile Glu Ala Glu Asp Val 1 5 10 15

Glu Gly Ser Cys Gly Gly Gly Ser Asp Ala Ser Gly Thr Lys Leu Arg
20 25 30

Asn Ser Leu Thr Asp Pro Val Pro Arg Glu Arg Gly Ser Pro Gln Ala 35 40 45

Leu Leu Xaa

```
<210> 1463
  <211> 80
 <212> PRT
 <213> Homo sapiens
 <220>
 <221> SITE
 <222> (2)
 <223> Xaa equals any of the naturally occurring L-amino acids
 <220>
 <221> SITE
 <222> (11)
 <223> Xaa equals any of the naturally occurring L-amino acids
 <220>
 <221> SITE
 <222> (14)
 <223> Xaa equals any of the naturally occurring L-amino acids
 <220>
 <221> SITE
 <222> (35)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (46)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (61)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (74)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1463
His Xaa Phe Ala Thr Val Met Asp Val Tyr Xaa Asn Pro Xaa Arg Val
Cys Leu Pro Ala Leu His Pro Lys Ala His Leu Leu Pro Pro Leu His
                                 25
```

Leu Arg Xaa Lys Thr Leu Gln Thr Ala Asp Thr Arg Lys Xaa Asn Ser 35 40 40 45

Gln Leu Cys Leu Met Leu Leu Val Ser Ser Thr Ser Xaa Gln Asn Arg 50 55 60

Tyr His Ala Glu Phe Arg Gly Pro Cys Xaa Ser Lys Ser Leu Leu Phe

70

65

<210> 1464 <211> 81 <212> PRT <213> Homo sapiens <220> <221> SITE <222> (11) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (23) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (24) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (40) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (41) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (48) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE

```
<222> (53)
 <223> Xaa equals any of the naturally occurring L-amino acids
 <220>
 <221> SITE
 <222> (57)
 <223> Xaa equals any of the naturally occurring L-amino acids
 <220>
 <221> SITE
 <222> (59)
 <223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (60)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (61)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (65)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (73)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (74)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (75)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (80)
<223> Xaa equals any of the naturally occurring L-amino acids
Val Phe Leu Cys Leu Cys Ala Ser Ala Met Xaa Lys Asn Thr Arg Gln
 1
                  5
                                    10
                                                          15
```

Thr Thr Met Arg Ile Asn Xaa Xaa Asp Ala Leu Cys Thr Pro His Ser 20 25 30

His Glu Pro Lys Lys Ile Phe Xaa Xaa Phe Leu Met Lys Glu Lys Xaa 35 40 45

Cys Pro Leu Trp Xaa Leu Pro Pro Xaa Phe Xaa Xaa Xaa Ile Leu Phe 50 55 60

Xaa Leu Pro Pro Pro Lys Asn Pro Xaa Xaa Xaa Cys Phe Leu Ala Xaa 65 70 75 80

Pro

```
<210> 1465
```

<211> 34

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (13)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (25)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (33)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (34)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 1465

Ile Gln Leu Gly Glu Pro Ala Gly Leu Val Arg Gln Xaa Leu Gly Leu 1 5 10 15

Cys Gln Gln Glu Val Lys Arg Xaa Thr Leu Pro Pro Ser Pro Pro 20 25 30

Xaa Xaa

```
<210> 1466
<211> 151
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (5)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (7)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (14)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (15)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (21)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (41)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (46)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (56)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
```

```
<222> (58)
 <223> Xaa equals any of the naturally occurring L-amino acids
 <220>
 <221> SITE
 <222> (62)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (64)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (82)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (85)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (92)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (94)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (97)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (101)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (105)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (106)
```

```
<223> Xaa equals any of the naturally occurring L-amino acids
 <220>
 <221> SITE
 <222> (112)
 <223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (113)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (118)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (127)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (130)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (135)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (142)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1466
Thr Val Leu Pro Xaa Met Xaa Ser Pro Met Gly His Pro Xaa Xaa Phe
Pro Lys Pro Pro Xaa Lys His Thr Trp Ser Gln Ser Leu Leu Pro Pro
             20
                                 25
Ala Leu Pro Leu Asn Trp Lys Gln Xaa Cys Ala Arg Trp Xaa Gly Leu
         35
                             40
                                                 45
Pro Gly Arg Gln Pro Leu Pro Xaa Ser Xaa Ala Lys Pro Xaa Ala Xaa
     50
                         55
                                             60
Glu Arg Leu Leu Arg Cys Pro Cys Pro Gly Leu Leu Thr Leu Ala
```

65 70 75 80 Thr Xaa Thr Tyr Xaa Ala Leu Gly Leu Gln Pro Xaa Pro Xaa Leu His 85 90 Xaa Cys Trp Pro Xaa Arg Leu Leu Xaa Xaa Ser Ile Asp Leu Val Xaa 105 Xaa Lys Ser His Trp Xaa Ser Trp His Trp Arg Val Leu Val Xaa Gly 120 Leu Xaa Ser Glu Ala Cys Xaa Arg Val Ser Leu Asn Ser Xaa Met His 130 135 Ala Leu Gly Leu Ser Cys Ser 145 150 <210> 1467 <211> 34 <212> PRT <213> Homo sapiens <220> <221> SITE <222> (4) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (18) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (26) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (31) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (33) <223> Xaa equals any of the naturally occurring L-amino acids <400> 1467

Gly Asn Leu Xaa Gly Gly Cys Gln Asn Leu Asn Lys Lys Met Ala Pro

```
1
                   5
                                      10
                                                          15
 Thr Xaa His Ser Gln Thr Pro Leu Trp Xaa Leu Ala Leu Lys Xaa Lys
              20
                                  25
 Xaa Arg
<210> 1468
<211> 40
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (21)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (22)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (39)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1468
His Val Leu Met Leu Ala Ala Asp Leu Asn Thr Leu Lys Val Leu Cys
                                    10
Arg Lys Lys Xaa Xaa Arg Ala Ala Leu Glu Asp Pro Ser Leu
                                                     30
             20
                                 25
Arg Thr Arg Ala Cys Asp Xaa Ile
         35
                             40
<210> 1469
<211> 30
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (14)
<223> Xaa equals any of the naturally occurring L-amino acids
```

```
<220>
<221> SITE
<222> (17)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (23)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1469
Ala Leu Cys Phe Lys Arg Leu Thr Gly Asn Tyr Ile Trp Xaa Thr Phe
Xaa Ala Leu Thr Leu Lys Xaa Leu Lys Ile Gln Val Asp Lys
                              25
                                                      30
<210> 1470
<211> 87
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (14)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (70)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (75)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (79)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (84)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1470
```

Thr Ser Pro Ser Arg Lys Cys Glu Glu Pro Gln Ala His Xaa Cys Ser 1 5 10 15

Ser Ala Pro Ser Leu Thr Phe Ser Pro Gly Gln Val Cys Ile Cys Ser 20 25 30

Leu His Trp His Phe Tyr Phe Gln Pro Leu Gly Ser Cys Phe Cys Leu
35 40 45

Leu Leu Arg Asn Leu Ser Pro Trp Gly Ser Phe Thr Thr Pro Ser Asn 50 55 60

Pro Asn Phe Xaa Arg Glu Phe 85

<210> 1471

<211> 65

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (47)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 1471

Gly Ala Glu Asp Gly Gly Cys Ser Ile Cys Val Val Leu Leu Ser Thr
1 5 10 15

Leu Leu Cys Leu Ala Pro Asp Ser Ala Leu Cys Ser Leu Ala Gln Gln 20 25 30

Leu Cys Leu His Ile Ile Phe Met Val Leu Leu Cys Asn Ser Xaa Leu 35 40 45

Arg Trp Val Ala Thr Val Gln Ile Phe Ile Thr Leu Phe Arg Leu Ser 50 55 60

Glu

65

<210> 1472

<211> 68

<212> PRT

```
<213> Homo sapiens
 <400> 1472
 Thr Pro Ile Asn Leu Thr Thr Ser Cys Ser Ala Tyr Ile Pro Pro Ser
                   5
                                     10
 Ser Ala Asn Pro Asp Glu Gly Tyr Lys Val Ser Ala Ser Thr His Val
             20
                                  25
 Lys Thr Leu Gly Gln Gly Val Ala His Glu Val Ala Arg Asn Gly Leu
                              40
 His Phe Leu Pro Gln Lys Thr Thr Ile Ala Leu Met Lys Leu Lys Gly
                         55
                                              60
 Arg Arg Trp Ile
 65
<210> 1473
<211> 132
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (1)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (7)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (10)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (17)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (19)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
```

```
<221> SITE
 <222> (30)
 <223> Xaa equals any of the naturally occurring L-amino acids
 <220>
 <221> SITE
 <222> (38)
 <223> Xaa equals any of the naturally occurring L-amino acids
 <220>
 <221> SITE
 <222> (40)
 <223> Xaa equals any of the naturally occurring L-amino acids
 <220>
 <221> SITE
 <222> (46)
 <223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (47)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (51)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (52)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (55)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (57)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (63)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
```

```
<222> (64)
  <223> Xaa equals any of the naturally occurring L-amino acids
  <220>
  <221> SITE
  <222> (68)
  <223> Xaa equals any of the naturally occurring L-amino acids
  <220>
  <221> SITE
  <222> (70)
  <223> Xaa equals any of the naturally occurring L-amino acids
  <220>
  <221> SITE
  <222> (85)
  <223> Xaa equals any of the naturally occurring L-amino acids
  <220>
  <221> SITE
  <222> (89)
  <223> Xaa equals any of the naturally occurring L-amino acids
 <220>
 <221> SITE
 <222> (92)
 <223> Xaa equals any of the naturally occurring L-amino acids
 <220>
 <221> SITE
 <222> (104)
 <223> Xaa equals any of the naturally occurring L-amino acids
 <220>
 <221> SITE
 <222> (107)
 <223> Xaa equals any of the naturally occurring L-amino acids
 <220>
 <221> SITE
 <222> (117)
 <223> Xaa equals any of the naturally occurring L-amino acids
 <400> 1473
Xaa Gly Gly Gly Glu Xaa Phe Phe Xaa Pro Pro Ser Arg Gly Gly
                   5
 Xaa Leu Xaa Phe Gly Val Asn Lys Pro Leu Pro Pro Gly Xaa Pro Arg
              20
                                  25
 Gly Ser Pro Gly Lys Xaa Phe Xaa Pro Gly Gly Phe Arg Xaa Xaa Leu
```

35 40 . 45

Ile Ala Xaa Xaa Pro Gly Xaa Phe Xaa Pro Lys Lys Asn Lys Xaa Xaa 50 55 60

Phe Pro Phe Xaa Pro Xaa Leu Thr Trp Ala Ala Phe Ala Gln Lys Gly 65 70 75 80

Phe Gly Gly Xaa Lys Gly Gln Xaa Pro Leu Xaa Leu Glu Thr Gly
85 90 95

Glu Lys Leu Gln Leu Trp His Xaa Ala Leu Xaa Val Val Pro Thr Cys 100 105 110

Lys Arg Gly Gln Xaa Gly Gly Asn Leu Asn Leu Pro Ser Lys Lys Lys 115 120 125

Leu Ala Lys Tyr 130

<210> 1474

<211> 32

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (25)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (30)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (31)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 1474

Ile Ile Met Ala Lys Lys Ser Ser Leu Arg Asn Lys Val Pro Phe Ser 1 5 10 15

Glu Lys Lys Lys Lys Lys Lys Lys Xaa Gly Gly Pro Phe Xaa Xaa Thr 20 25 30

```
<210> 1475
 <211> 51
 <212> PRT
 <213> Homo sapiens
<400> 1475
Tyr Val Ala Leu Leu Asn Ile Thr Leu Arg Thr Arg Arg Leu Glu Thr
                                      10
Thr Asn Pro Asn Tyr Val Ile Gly Lys Cys Arg Ile Lys Arg Pro Met
                                 25
Tyr Ile Ser Thr Asp His Trp Ala Ile Met Leu Leu Arg Leu Tyr
                             40
Ala Val Leu
     50
<210> 1476
<211> 70
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (18)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (50)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (54)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1476
Thr Phe Leu Ser Gly Gly Glu Val Val Asn Gly Gly Cys Ala Cys
Val Xaa Ala Arg Val Ile Trp Glu Phe Ser Val Pro Ser Val Gln Phe
```

Cys Tyr Glu Pro Lys Thr Ala Leu Lys Asn Asn Leu Cys Phe Lys Lys

35 40 45

Val Xaa Val Leu Tyr Xaa Leu Leu Glu Ile Phe Val Ala Ile Phe 50 55 60

Thr Trp Lys Asn Thr Gly 65 70

<210> 1477
<211> 90
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (53)

<220>

<221> SITE

<222> (76)

<223> Xaa equals any of the naturally occurring L-amino acids

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (87)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 1477

His Arg Thr Pro Val Pro Ala Arg Gly Gly Ala Arg Ala Leu Pro Arg
1 5 10 15

Ala Arg Gly Ala Trp Arg Gly Gly Arg Pro Ala Gly Gly Asp Arg Arg 20 25 30

Gly Thr Gly Tyr Pro Arg Pro Thr Glu Ala Pro Arg Arg Cys Arg Ile
35 40 45

Val Pro Pro Gly Xaa Asp Ser Asp Leu Glu Ala Phe Ser His Asn Pro 50 55 60

Thr Asp Gly Ser Phe Ala Pro Leu Ala Pro Gln Xaa Ser Thr Tyr Thr 65 70 75 80

Lys Cys Leu Asn Leu Arg Xaa Leu Ser Tyr

85

```
<210> 1478
<211> 70
<212> PRT
<213> Homo sapiens
<400> 1478
Ile Pro Asn Ile Leu Phe Asn Met Ile Lys Leu Ile Leu Asn Glu Ile
                   5
Leu Cys Cys Ser Leu Val Asn Leu Ser Phe Val Ile Leu Leu Val Cys
             20
                                  25
Leu Ser Cys Glu Gly Leu Gln Ser Asp Met Pro Ile Phe His Ser Gln
                              40
Ser Asn Tyr Lys Arg Ile Val Thr Ile Thr Gln Leu Cys Gln Glu Ile
     50
Phe Phe Asn Ser Leu Arg
                      70
<210> 1479
<211> 59
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (10)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (15)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (21)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (27)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (32)
```

```
<223> Xaa equals any of the naturally occurring L-amino acids
 <220>
 <221> SITE
 <222> (44)
 <223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (52)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1479
Pro Val Pro Pro Ser Ser Ala Arg Xaa Gly Gly Gly Xaa Arg
                  5
Arg Gly Arg Gly Xaa Val Pro Pro Ala Gly Xaa Ala Pro Gly Ala Xaa
              20
                                  25
Val Pro Ala Ala Pro Arg Leu Gly Arg Arg Leu Xaa Ala Asp Leu Glu
                             40
Leu Val Arg Xaa Arg Gly Ile Arg Leu Phe Asn
<210> 1480
<211> 99
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (21)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (35)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (38)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (54)
<223> Xaa equals any of the naturally occurring L-amino acids
```

```
<220>
<221> SITE
<222> (57)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (76)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (79)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (84)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (86)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (91)
<223> Xaa equals any of the naturally occurring L-amino acids
Leu His Pro Arg Pro Gly Leu Asp Val Met Gly Cys Gly Pro Leu Pro
Ala Glu Pro Ile Xaa Arg Gln Val Arg Ala Ala Leu Gln Thr Phe Ala
             20
                                  25
His Leu Xaa Ala Ser Xaa Pro Lys Val Pro Gly Gln Pro Glu Ala Pro
Arg Pro Gln Pro Arg Xaa Pro Gln Xaa Phe Glu Ser Gly Ala His Ser
     50
                         55
                                              60
Arg Ser Pro Leu Ala Leu Pro Thr Pro Ala Arg Xaa Gly Gly Xaa Ser
65
                     70
                                          75
Cys Pro Arg Xaa Arg Xaa Ala Pro Glu Asn Xaa Thr Pro Pro Leu Arg
                 85
                                     90
```

Arg Thr Asn

```
<210> 1481
<211> 41
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (7)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (14)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1481
Ser Pro Ser Leu Ile Arg Xaa Pro Ile Gly Lys Ala Glu Xaa Ala Cys
                   5
                                      10
                                                           15
Arg Tyr Arg Val Arg Glu Phe Pro Gly Arg Pro Thr Arg Pro Ile Thr
             20
Ser Cys Arg Pro Pro Asn Ile Asn Leu
<210> 1482
<211> 99
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (3)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (20)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (25)
<223> Xaa equals any of the naturally occurring L-amino acids
```

<220> <221> SITE

<222> (27)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (95)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 1482

Pro Arg Xaa Arg Glu Ile Pro Gly Gly Arg Thr His Ala Phe Arg Glu
1 5 10 15

Lys Ala Cys Xaa Lys Gln Gly Glu Xaa Arg Xaa Glu Lys Gly Gly Leu 20 25 30

Val Ile Ser Lys Ser Leu Glu Arg Trp Glu Trp Thr Lys Lys Met Gly
35 40 45

Thr Pro Pro Leu Phe Gln Ala Trp Glu Gly Val Leu Asn Gly Arg Asp
50 55 60

Phe Leu Phe Pro Ala Thr Lys Arg Leu Phe Thr Thr Tyr Pro Val Lys 65 70 75 80

Ser Lys Phe Ile Phe Gln Glu Phe Asn Met Tyr Phe Ser Trp Xaa Tyr 85 90 95

Leu Cys Gln

<210> 1483

<211> 49

<212> PRT

<213> Homo sapiens

<400> 1483

Cys Asn Ser Val Ser Phe Arg Phe Leu Ser Cys Phe Cys Lys Leu Trp

1 5 10 15

Glu Arg Leu Thr Met Gln Met Cys Gln Arg His Thr Val Gly Cys Asn 20 25 30

Ile Asn Asn Phe Lys Cys Lys Phe Leu Trp Ile Asn Tyr Phe Tyr Ile 35 40 45

Leu

```
<211> 51
<212> PRT
<213> Homo sapiens
<400> 1484
Cys Lys Gln Tyr Leu Thr Asn Pro Gln Val Leu Asn Tyr Gln Thr Cys
                   5
                                      10
Ile Lys Asn Phe Gly Trp Gly Asp Leu Gly Ala Glu Pro Asn Leu Arg
                                  25
Ala Val His Ala Lys Thr Ser Pro Val Lys Ala Asn Tyr Tyr Thr Gln
Leu Ile Gln
     50
<210> 1485
<211> 22
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (7)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (12)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (13)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (14)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (22)
```

<210> 1484

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 1485

Leu Ser Leu Leu His Glu Xaa Pro His Val Gly Xaa Xaa Xaa Phe Asp 1 5 10 15

Ile Leu Val Pro Arg Xaa 20

<210> 1486

<211> 126

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (112)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 1486

Glu Gln Thr Cys Phe Leu Asn Leu Val Ile Phe Val Lys Asn Cys Leu
1 5 10 15

Asp Ser Phe Ser His Gln Arg Glu Ser Thr Ser Ser Glu Ser Ala Ser 20 25 30

Ala Pro Cys Ser Leu Leu Leu Arg Gly Arg Val Thr Ser His Trp Gln 35 40 45

Ala Ser Gly Ile Val Cys Glu Ala Leu Gln Arg Ala Ala Pro Gly Ser 50 55 60

Cys Leu Tyr Lys Asn Ile Leu Leu Pro Ala Ala Leu Ser Leu Ala Leu 65 70 75 80

His Phe Gly His Asp Ile Arg Cys Val Phe Ile Gln Leu Val Val Lys

Met Leu Leu Asn Gly Ser Ala Tyr Leu Cys Leu His Gly Leu Xaa 100 105 110

Glu Val Gly Phe His Gly His Ser Val Ser Thr Asp Leu Glu 115 120 125

<210> 1487

<211> 51

<212> PRT

```
<213> Homo sapiens
<220>
<221> SITE
<222> (14)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (30)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (32)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (37)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (41)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (48)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1487
Val Glu Ala Thr Asn Leu Pro Glu Pro Gly Asp Ser Trp Xaa Val Gln
Asp Lys Asn Leu Ser Ser Thr Phe Lys Phe Trp Pro Thr Xaa Pro Xaa
             20
                                 25
Lys Phe Pro Trp Xaa Ile Asn Arg Xaa Val Gln Glu Gly Pro Gly Xaa
         35
                             40
                                                  45
Gly Thr Pro
     50
<210> 1488
<211> 37
<212> PRT
<213> Homo sapiens
```

```
<400> 1488
Glu Gln Leu Lys Glu His Thr Arg Leu Cys Ser Lys Ile Val Gly Arg
                                      10
Phe Ile Gly Arg Gly Asp Lys Pro Thr Glu Pro Gly Asp Ser Trp Leu
                                  25
Ser Lys Ile Glu Ser
          35
<210> 1489
<211> 26
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (5)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (13)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (25)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (26)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1489
Gly Gly Met Arg Xaa Ser His Leu Gln Leu Leu Ser Xaa Glu Arg Thr
                  5
                                     10
                                                          15
Leu Gly Thr Glu Lys Asn Arg Gly Xaa Xaa
             20
<210> 1490
<211> 39
<212> PRT
<213> Homo sapiens
```

<220>
<221> SITE
<222> (5)

```
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (8)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (12)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (28)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (35)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (37)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1490
Ser Phe Leu Ile Xaa Ser Phe Xaa Ile Lys Arg Xaa Arg Asn Leu Met
Thr Gly Arg His Ser Phe Lys Thr Tyr Ser Gln Xaa Pro Ile Thr Ala
             20
                                 25
Gln Asn Xaa Ile Xaa Cys Leu
<210> 1491
<211> 55
<212> PRT
<213> Homo sapiens
<400> 1491
Thr Leu Ala Tyr Phe Val Ile Asp Tyr Lys Gln Ile Glu Glu Ile Thr
                                     10
  1
                  5
```

Ile Ser His Phe Cys Ile Phe Ser Lys Ile Ile Leu Leu Gln Ser Ser 20 25 30

Ile Tyr Cys Val Pro Leu Ile Phe Tyr Cys Glu Ser Lys Glu Phe His
35 40 45

Gln Asn Ile Leu Asn Tyr Glu 50 55

<210> 1492

<2.11> 37

<212> PRT

<213> Homo sapiens

<400> 1492

Glu Gln Leu Lys Glu His Thr Arg Leu Cys Ser Lys Ile Val Gly Arg
1 5 10 15

Phe Ile Gly Arg Gly Asp Lys Pro Thr Glu Pro Gly Asp Ser Trp Leu 20 25 30

Ser Lys Ile Glu Ser 35

<210> 1493

<211> 58

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (4)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 1493

Ile Cys Pro Xaa Asn Pro Leu Asn Pro Leu Val Asn Leu Thr Val Ser
1 5 10 15

Pro Lys Arg Asn Ser Ser Leu Asp Thr Arg Lys Lys Pro Cys Arg Glu 20 25 30

Ser Lys Lys Phe Asn Thr His Ser Arg Pro Lys Ser Ser His Gln Leu 35 40 45

Arg Lys Arg Ser Ser Ser Thr Pro Thr Thr 50 55

```
<210> 1494
<211> 95
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (91)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (93)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (94)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (95)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1494
Glu Ser Trp Leu Cys Ser Gly Gly Gly Met Gln Gly His Leu Leu Lys
                  5
                                                          15
Glu Gly His Gly Gln Asn Asn Ile Glu Phe Pro Ala Pro Leu Gly Ser
             20
                                 25
Asp Leu Leu Asp Thr Glu Pro Pro Phe Lys Met Gly Gln Gly Lys Gly
                              40
Gly Ser Val Gln Ser Pro Asp Leu Glu Leu Pro Glu Ala Ile Ala Ala
                         55
Leu Phe Thr Ser Lys Gly Pro Val Leu Arg Leu Phe Val Leu Ile Tyr
 65
                     70
Phe Lys Leu Gly Lys Ala Gly Gly Arg Val Xaa Pro Xaa Xaa Xaa
                 85
                                     90
```

<210> 1495 <211> 67

```
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (16)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (18)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (21)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (22)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (46)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (55)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (59)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (61)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (67)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1495
Leu Ala Pro Gln Ala Gly Val Pro Pro His Ser Ala Pro Arg Pro Xaa
                                     10
                                                          15
 1
                  5
```

```
Ser Xaa Leu Ser Xaa Xaa Pro Gly Pro Ala Pro Val Pro Pro Arg Pro
              20
                                  25
                                                       30
 Arg Ser Ala Gly Pro Pro Trp Ser Ala Gly Leu Asp Arg Xaa Gly Gly
                              40
                                                   45
Ala Trp Leu Leu Val Ala Xaa Arg Ala Leu Xaa Gln Xaa Leu Ser Ser
                          55
                                               60
Asp Leu Xaa
 65
<210> 1496
<211> 76
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (13)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (14)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (16)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (22)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (24)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (31)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
```

```
<221> SITE
<222> (37)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (41)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (51)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (67)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1496
Glu Asn Pro Ser Lys Val Asn Ser Pro Ala Leu Gly Xaa Xaa Ser Xaa
                  5
                                      10
Ala Ser Trp Arg Leu Xaa Val Xaa Leu Ile Ser Gly Asn Pro Xaa Gln
             20
                                  25
Ile Cys Ser Tyr Xaa Ser Arg Arg Xaa Ile Gly Ser Val Tyr Cys Asp
                             40
Gly Asn Xaa Asn Val Thr Val Lys Arg Phe Ala Phe Cys Gly Leu Gly
     50
Arg Ala Xaa Asn Phe Leu Leu Arg Leu Ser Leu His
 65
                    70
                                         75
<210> 1497
<211> 103
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (50)
<223> Xaa equals any of the naturally occurring L-amino acids
```

<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (57)

```
<220>
 <221> SITE
 <222> (68)
 <223> Xaa equals any of the naturally occurring L-amino acids
 <220>
 <221> SITE
 <222> (72)
 <223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (80)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (83)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (99)
<223> Xaa equals any of the naturally occurring L-amino acids
Leu Pro Arg Cys Ala Pro Gly Ser Gln Ala Pro Pro Glu Gly Pro Trp
                                     10
                                                          15
Pro Arg Arg Ile Arg Arg Val Arg Pro Gly Pro Arg Val Arg Gln Pro
                                 25
Arg Arg Pro Ser Ala Ser Leu Arg Pro Ser Arg Ala Arg Pro Gly Arg
                             40
Ser Xaa Phe Pro Arg Pro Pro Pro Xaa Arg Leu Pro Ala Ala Ser Arg
     50
                         55
                                             60
Val Gly Ala Xaa Arg Gly Leu Xaa Pro Leu Lys Phe Glu Ser Xaa
 65
                     70
                                         75
Asn Gln Xaa Val Arg Asn Pro Glu Ile Pro Asp Pro Leu Arg Lys Met
                                     90
                                                         95
Phe Ser Xaa Glu Gly Glu Arg
```

100

```
<211> 32
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (3)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (16)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (30)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1498
Gly Arg Xaa Gly Gly Arg Ala Gly Gly His Glu Ala Arg Ala Ala Xaa
                  5
Ala Gly Gly Val Gly Arg Arg Ala Arg Gly Gly Gly Arg Xaa Gly Met
             20
                                 25
```

```
<210> 1499
<211> 69
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (15)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>.
<221> SITE
<222> (30)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (46)
<223> Xaa equals any of the naturally occurring L-amino acids
```

```
<220>
<221> SITE
<222> (60)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (62)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (68)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1499
Val Ser His Leu Leu Ala Gly Phe Cys Val Trp Val Val Leu Xaa Trp
Val Gly Gly Ser Val Pro Asn Leu Gly Pro Ala Glu Gln Xaa Gln Asn
             20
                                 25
His Tyr Leu Pro Ser Cys Leu Ala Val Arg Arg Glu Trp Xaa Ala Asp
         35
                             40
                                                  45
Cys Lys Gly Leu Gly Ala Val Phe His Asn Leu Xaa Leu Xaa Gln Val
     50
                         55
                                             60
Gln Gly Leu Xaa Leu
 65
<210> 1500
<211> 109
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (89)
<223> Xaa equals any of the naturally occurring L-amino acids
Asn His Glu Arg Asn Lys Lys Glu Thr Lys Gln Lys Arg Asn Glu Lys
Asp Ile Met Met Ser Ser Lys Pro Thr Ser His Ala Glu Val Asn Glu
```

Thr Ile Pro Asn Pro Tyr Pro Pro Ser Ser Phe Met Ala Pro Gly Phe

25

35 40 45 Gln Gln Pro Leu Gly Ser Ile Asn Leu Glu Asn Gln Ala Gln Gly Ala 55 Gln Arg Ala Gln Pro Tyr Gly Ile Thr Ser Pro Gly Ile Phe Ala Ser 70 75 Ser Gln Pro Gly Gln Gly Asn Ile Xaa Met Ile Asn Pro Ser Val Gly Thr Ala Val Met Asn Phe Lys Arg Lys Lys Gln Arg His 100 105 <210> 1501 <211> 71 <212> PRT <213> Homo sapiens <220> <221> SITE <222> (11) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (12) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (29) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (56) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (60) <223> Xaa equals any of the naturally occurring L-amino acids <400> 1501

Asn His Phe Ser Ile His Leu Pro Ile Leu Asn Leu Xaa Asn Lys Val

Val Asp Glu Gly Gly Tyr Trp Gly Trp Leu Xaa Xaa Lys Ile Met Glu

```
20
                                   25
                                                       30
 Ile Tyr Cys Lys Val Leu Cys Pro Leu Lys Glu Val Leu Lys Arg Val
                               40
 Arg Met Asp Leu Lys Lys Asn Xaa Asn Leu Glu Xaa Phe Lys Met Val
                          55
Phe Val Gly Arg Phe Leu Leu
 65
                      70
<210> 1502
<211> 52
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (13)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (18)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (19)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (29)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (34)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (40)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (50)
```

```
<223> Xaa equals any of the naturally occurring L-amino acids
 <400> 1502
Val Pro Leu Gln Val Pro Val Arg Asn Ser Arg Val Xaa Pro Arg Val
Arg Xaa Xaa Ser Asn Val Cys Gln Asn Ser Gln Phe Xaa Ala Ser Lys
             20
                               25
Ser Xaa Tyr Ile Glu Ser Ala Xaa Phe Leu Phe Phe Leu Phe Phe
                           40
                                              45
Phe Xaa Phe Phe
     50
<210> 1503
<211> 34
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (6)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (14)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (30)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (33)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1503
Leu Asp Ile Lys Gln Xaa Thr Met His Gln Glu Tyr Lys Xaa Gly Lys
                                 10
20
                             25
```

Xaa Lys

```
<210> 1504
  <211> 36
  <212> PRT
  <213> Homo sapiens
  <220>
  <221> SITE
  <222> (1)
  <223> Xaa equals any of the naturally occurring L-amino acids
  <220>
  <221> SITE
  <222> (9)
  <223> Xaa equals any of the naturally occurring L-amino acids
  <220>
  <221> SITE
  <222> (12)
  <223> Xaa equals any of the naturally occurring L-amino acids
 <220>
  <221> SITE
  <222> (21)
 <223> Xaa equals any of the naturally occurring L-amino acids
 <220>
 <221> SITE
 <222> (28)
 <223> Xaa equals any of the naturally occurring L-amino acids
 <400> 1504
 Xaa Leu Glu Pro Gln Pro Gly Pro Xaa Arg Pro Xaa Arg Pro Pro Ser
                                       10
                   5
. Arg Arg Ser Trp Xaa Gln Gly Lys Pro Thr Gly Xaa Glu Arg Glu Ala
              20
 Ala Ala Arg Ser
          35
 <210> 1505
 <211> 55
 <212> PRT
 <213> Homo sapiens
 <220>
```

```
<221> SITE
<222> (3)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (41)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (50)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1505
Ala Val Xaa Phe Asn Phe Leu Ser Ala Ala Ser Cys Val His Phe Leu
          5
Leu Lys Val Ile Gly Phe Cys Leu Ser Ser Lys His Lys Asn Leu Lys
             20
                                 25
Gly Val Leu Gln Ile Phe Cys Ala Xaa Arg Trp Leu Phe Pro Ser Gly
                             40
                                                 45
Ser Xaa Phe Leu Asn Asn Asn
    50
<210> 1506
<211> 58
<212> PRT
<213> Homo sapiens
<400> 1506
Ile Cys Ile Val Pro Pro Pro Val Ser Leu Ile Arg Met Thr Cys Ala
                 5
Ile Phe Gln Arg Thr Cys Arg Gln Ala Gly Ile Leu Asp Tyr Phe Ser
```

Tyr Ser Glu Thr Trp Pro Val Trp Glu Cys Gly Ile Gln Arg Trp Ser

40

His Arg Cys Pro Tyr Cys Lys Trp Gln Phe 50 55

<210> 1507 <211> 49

35

```
<212> PRT
 <213> Homo sapiens
 <220>
 <221> SITE
 <222> (3)
 <223> Xaa equals any of the naturally occurring L-amino acids
 <220>
 <221> SITE
 <222> (5)
 <223> Xaa equals any of the naturally occurring L-amino acids
 <220>
 <221> SITE
<222> (9)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (21)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (31)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (43)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1507
Leu Thr Xaa Ile Xaa Tyr Tyr Arg Xaa Ser Trp Tyr Ala Cys Arg Tyr
  1
                  5
                                     10
                                                          15
Arg Ser Gly Ile Xaa Gly Ser Thr His Ala Ser Ala Asp Ala Xaa Val
             20
                                 25
Gly Gly Gln Gly Lys Val Tyr Ser Lys Ser Xaa Lys Pro Cys Gln Leu
                             40
Lys
```

<210> 1508 <211> 120 <212> PRT

```
<213> Homo sapiens
 <220>
 <221> SITE
 <222> (58)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (103)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (105)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (109)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (111)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (115)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1508
Val Pro Leu Pro Pro Ser Leu Arg Ser Pro Gly Ser His Arg Arg His
His Ala Ser Gly Lys Pro Gln Arg Gly Leu Pro Ala Ser Gln Pro Pro
                                 25
Arg Arg Ala Leu Cys Pro Pro Ala Arg Ala Pro Thr Ala Leu Gly Ser
         35
Arg Pro Ser Pro Arg Pro Phe Gly Pro Xaa Gly Ala His Gly Ser Asp
                         55
Gly Asp His Gly Arg Arg Gly Ser Arg Gly Leu Gly Cys Gly Thr Arg
                     70
His Gly Gln Arg Pro Asp Arg Ser Leu Gln Arg Gly Glu Leu Gly Ala
                 85
                                     90
```

```
Leu Pro Ala Cys Cys Pro Xaa Gly Xaa His Pro Arg Xaa Pro Xaa Ala
             100
                                 105
                                                      110
Pro Ala Xaa Gly Ala Leu Arg Leu
        115
<210> 1509
<211> 100
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (13)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (15)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (17)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (18)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (22)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (29)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (37)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
```

<222> (50)

```
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (51)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (54)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (55)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (57)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (63)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (77)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (79)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (89)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (99)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1509
Val Ser Ile Val Ala Ala Gln Met Phe Leu Phe Phe Xaa Val Xaa Leu
                  5
```

```
Xaa Xaa Ile Ser Pro Xaa His Leu Thr Ser Leu Trp Xaa Ile Met Val
20 25 30
```

Ser Glu Leu Ile Xaa Thr Phe Thr Gln Leu Glu Glu Asn Leu Lys Asp 35 40 45

Glu Xaa Xaa Ser Leu Xaa Xaa Thr Xaa Lys Val Asn Arg Ile Xaa Val 50 55 60

Ser Val Pro Asp Ala Asn Gly Pro Ser Val Gly Glu Xaa Pro Xaa Ser 65 70 75 80

Glu Leu Ile Leu Tyr Leu Ser Ala Xaa Lys Phe Leu Asp Thr Ala Ala 85 90 95

Phe Phe Xaa Thr

```
<210> 1510
<211> 48
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (11)
<223> Xaa equals any of the naturally occurring L-amino acids
```

<221> SITE <222> (24) <223> Xaa equals any of the naturally occurring L-amino acids

<220>

<220>

<221> SITE

<222> (32)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (34)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (42)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

40

<210> 1511 <211> 33 <212> PRT <213> Homo sapiens <220> <221> SITE <222> (3) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (15) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (33) <223> Xaa equals any of the naturally occurring L-amino acids <400> 1511 Val Arg Xaa Ser Phe Leu Cys Thr Val Phe Leu Arg Arg Met Xaa Leu Asp Ser Cys Leu Leu Ser Cys Ser Pro Ser Leu Ile Met Glu Leu Ser

25

Xaa

```
<210> 1512
 <211> 61
 <212> PRT
 <213> Homo sapiens
<400> 1512
Lys Leu Val Pro Leu Gln Val Pro Val Arg Asn Ser Arg Ala Lys Tyr
                   5
                                      10
Glu Asn Lys Ser Phe Glu Lys Asn Thr Val Cys Lys Ile Cys Ser Phe
                                  25
Val Glu Val Met Val Leu Cys Phe Tyr Lys Ile Val Pro Thr Pro Phe
                              40
Phe Tyr Phe Arg Tyr Phe Ile Ser Thr Ile Ser Ile Asn
     50
                          55
<210> 1513
<211> 61
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (3)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (8)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (26)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (36)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (41)
<223> Xaa equals any of the naturally occurring L-amino acids
```

<220>

<221> SITE <222> (46) <223> Xaa equals any of the naturally occurring L-amino acids <220> <221> SITE <222> (57) <223> Xaa equals any of the naturally occurring L-amino acids <400> 1513 Ile Pro Xaa Ser Ser Leu Gly Xaa Tyr Pro Cys Arg Tyr Arg Ser Gly 10 Ile Pro Gly Ser Thr His Ala Ser Val Xaa Leu Arg Cys Gly Ala Pro 20 25 Thr Ala Asp Xaa Ala Ala Gly Pro Xaa Arg Ser Ala Ala Xaa Arg Ser 40 Gln Glu Ala Gly Thr Ser Trp Lys Xaa Arg Pro Ala Arg 55 <210> 1514 <211> 45 <212> PRT <213> Homo sapiens

<220>

<221> SITE

<222> (3)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 1514

Pro Arg Xaa Arg Ala Arg Ala Glu Asp Gly Ile Gly Leu Asp Leu

Pro Leu Tyr Pro Ala His Pro Gln Asp Phe His Glu Val Glu Asp Leu 25

Ile Lys Thr Ala Ile Gly Asn Thr Leu Val Gln Asp Ile 35

<210> 1515

<211> 39

<212> PRT

<213> Homo sapiens

```
<220>
<221> SITE
<222> (31)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (33)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (35)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (39)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1515
Ala Ser Ser Arg Ser Arg Ala Ala Leu Phe Phe Phe Phe Phe
                                     10
Phe Phe Phe Phe Ser Phe Ile Leu Leu Phe Ile Phe Pro Xaa Tyr
                                25
Xaa Asn Xaa Gln Gln Leu Xaa
         35
<210> 1516
<211> 66
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (3)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (9)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (12)
<223> Xaa equals any of the naturally occurring L-amino acids
```

<220>

```
<221> SITE
 <222> (28)
 <223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (33)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (47)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (52)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1516
Thr Leu Xaa Gly Leu Pro His Gln Xaa Gln His Xaa Asp Arg Pro Gln
                   5
Ser Cys Thr Phe Ala Pro Lys Leu Leu Phe Thr Xaa Pro Phe Asn Leu
             20
                                  25
                                                      30
Xaa Ala Ala Thr Thr Ser Gln Gly Arg His Arg Glu Gly Glu Xaa Arg
Lys Lys Ser Xaa Ser Leu Leu Ser Ser Lys Thr Thr Thr Asn Tyr Thr
                         55
Gly Phe
 65
<210> 1517
<211> 75
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (7)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
```

```
<222> (73)
 <223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (74)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (75)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1517
Arg Thr Arg His Glu Lys Xaa Gly Asp Lys Ser Arg Ile Asn Thr Gly
Cys Ser Gln Phe Cys Leu Leu Lys Lys Lys Lys Lys Lys Lys Lys Lys
                            25
35
                          40
50
                      55
Lys Lys Lys Gly Gly Pro Val Xaa Xaa Xaa
 65
                  70
<210> 1518
<211> 84
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (16)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (19)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (21)
<223> Xaa equals any of the naturally occurring L-amino acids
```

<400> 1518

Ser Trp Tyr Ala Cys Arg Tyr Arg Ser Gly Ile Pro Gly Ser Thr Xaa 1 5 10 15

Ala Ser Xaa Lys Xaa Lys Gly Leu Gln Lys His Ser Phe Leu Cys Cys
20 25 30

Ser Leu Leu Gly Phe Met Gln Arg Gln Phe Cys Val Asn Val Gln Leu
35 40 45

Thr Leu Ile Trp Lys Tyr Glu Asn Gln Ser Ile Leu Val Ile Lys Asn 50 55 60

Phe Phe Thr Ile Val Ile Ile Leu Met Phe Ile Leu Cys Lys Ile Thr 65 70 75 80

His Leu Ile Lys

<210> 1519

<211> 52

<212> PRT

<213> Homo sapiens

<400> 1519

Phe Gln Leu Ser Pro Gly Thr Pro Lys Pro Leu Pro Leu Gly Leu Pro 1 5 10 15

Ser Gln Pro Val Pro Arg Thr Ser Ser Ser Pro Phe Gln Ile Ile Lys
20 25 30

Ser Met Asp Arg Ala Val Ser Glu Val Leu Thr Gln Gly Lys Lys Lys 35 40 45

Lys Lys Lys 50

<210> 1520

<211> 45

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (32)

<223> Xaa equals any of the naturally occurring L-amino acids

```
<220>
 <221> SITE
 <222> (39)
 <223> Xaa equals any of the naturally occurring L-amino acids
 <220>
 <221> SITE
 <222> (41)
 <223> Xaa equals any of the naturally occurring L-amino acids
 <220>
 <221> SITE
 <222> (44)
 <223> Xaa equals any of the naturally occurring L-amino acids
 <220>
 <221> SITE
 <222> (45)
 <223> Xaa equals any of the naturally occurring L-amino acids
 <400> 1520
 Ile Asn Ile Cys Ser Phe Gln Lys Lys Lys Lys Lys Lys Lys Lys
                                   10
20
                               25
Gly Gly Arg Phe Lys Gly Xaa Lys Xaa Thr Tyr Xaa Xaa
         35
                           40
<210> 1521
<211> 71
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (1)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (11)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (19)
<223> Xaa equals any of the naturally occurring L-amino acids
```

```
<220>
 <221> SITE
 <222> (24)
 <223> Xaa equals any of the naturally occurring L-amino acids
 <220>
 <221> SITE
 <222> (26)
 <223> Xaa equals any of the naturally occurring L-amino acids
 <220>
 <221> SITE
 <222> (34)
 <223> Xaa equals any of the naturally occurring L-amino acids
 <220>
 <221> SITE
 <222> (35)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (37)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (42)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (46)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (53)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (70)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1521
Xaa Thr His Leu Arg Ser Asp Trp Thr Arg Xaa Ile Ile Leu Arg Ile
                                     10
                                                          15
```

Ala Asn Xaa Ser Leu Gly Leu Xaa Leu Xaa Val Asp Phe Ser Met Leu

20 25 30

Arg Xaa Xaa Pro Xaa Arg Leu Glu Leu Xaa Leu Asp Asp Xaa Glu Glu 35 40 45

Phe Glu Asn Ile Xaa Lys Asp Leu Glu Thr Arg Lys Lys Gln Lys Glu 50 55 60

Asp Val Glu Val Val Xaa Gly 65 70

<210> 1522

<211> 41

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (34)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (38)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 1522

Ser Glu Lys Val Lys Thr Ala Phe Thr Lys Pro Gly Arg Trp Gly Leu
1 5 10 15

Cys Glu Pro Leu Cys Thr Gly Ser Leu Arg Asp Ser Ala Trp Cys Ser 20 25 30

Arg Xaa Ile Leu Ala Xaa Val Gly Glu 35 40

<210> 1523

<211> 58

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (52)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

```
<221> SITE
<222> (55)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (58)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1523
Gly His Ala Leu Leu His Leu Lys Asn Lys Leu Cys Ser Asn Cys His
20
40
Lys Lys Lys Xaa Gly Gly Xaa Phe Lys Xaa
    50
                     55
<210> 1524
<211> 24
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (14)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (15)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (23)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1524
Pro Val Leu Thr His Gly Met Pro Pro Ala Ile Arg Pro Xaa Xaa Ser
                              10
```

Ser Trp Ser Ser Ser Thr Xaa Thr 20

```
. <210> 1525
  <211> 35
  <212> PRT
  <213> Homo sapiens
  <220>
  <221> SITE
  <222> (29)
  <223> Xaa equals any of the naturally occurring L-amino acids
  <400> 1525
  Ser Lys Ser Arg Glu Leu Pro Leu Leu Leu Val Thr Cys Pro Leu Leu
                   5
                                       10
  Ser Ser Phe Cys Ser Gly Lys Pro Trp Asp Ser Ala Xaa Thr Tyr His
                                  25
  Cys Arg Cys
          35
 <210> 1526
 <211> 33
  <212> PRT
 <213> Homo sapiens
 <400> 1526
 Ser Leu Ala Lys His Leu Asn His Leu Ser Ile Leu Ser Trp Phe Ile
 Ile Ile Lys Ala Gln Asn Asn Leu Leu Glu Asn Met Cys Phe Tyr
                                 25
              20
 Lys
 <210> 1527
 <211> 85
 <212> PRT
 <213> Homo sapiens
 <220>
 <221> SITE
 <222> (1)
 <223> Xaa equals any of the naturally occurring L-amino acids
```

```
<220>
 <221> SITE
 <222> (3)
 <223> Xaa equals any of the naturally occurring L-amino acids
 <220>
 <221> SITE
 <222> (9)
 <223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (28)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (29)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (31)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (32)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (34)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (36)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (38)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (39)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
```

```
<221> SITE
<222> (42)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (43)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (47)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (52)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (53)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (55)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (60)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (66)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (70)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (71)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
```

<222> (83)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 1527

Xaa Gly Xaa Gly Glu Thr Gln Gly Xaa Ala Met Gly Cys Met Val Ala 1 5 10 15

Ser Gly Leu Leu Thr Gly Leu Ala Glu Val Leu Xaa Xaa Leu Xaa Xaa 20 25 30

Thr Xaa Gln Xaa Gly Xaa Xaa Gln Tyr Xaa Xaa Phe Arg Val Xaa Leu 35 40 45

Glu Ser Met Xaa Xaa Leu Xaa Asp Leu Glu Ala Xaa Trp Ala Pro Ser 50 55 60

Pro Xaa Leu Glu Ala Xaa Xaa Leu Leu Ala Ala Val Cys His His Pro 65 70 75 80

Ala Leu Xaa Leu Arg

85

<210> 1528

<211> 58

<212> PRT

<213> Homo sapiens

<400> 1528

Ile Cys Pro Gln Asn Pro Leu Asn Pro Leu Val Asn Leu Thr Val Ser
1 5 10 15

Pro Lys Arg Asn Ser Ser Leu Asp Thr Arg Lys Lys Pro Cys Arg Glu 20 25 30

Ser Lys Lys Phe Asn Thr His Ser Arg Pro Lys Ser Ser His Gln Leu 35 40 45

Arg Lys Arg Ser Ser Ser Thr Pro Thr Thr 50 55

<210> 1529

<211> 90

<212> PRT

<213> Homo sapiens

<400> 1529

Cys Phe Ser Leu Cys Met Gly Gly Thr Ser Ala Val Ser Glu Ser Thr

1 5 10 15

Thr Ile Ser Ser Gly Ala Gly Pro Ser Ala Arg Pro Gln Lys Asn Arg
20 25 30

Arg Pro Gln Glu Ser Cys Arg Thr Gly Gly Leu Phe Leu Leu Ser Arg
35 40 45

Glu Ala Gln Gly Met Leu Trp Arg Asp Phe Thr Cys His His Phe Gln 50 55 60

Val Asn Arg Thr Arg Ala Leu Met Val Phe Lys Pro Cys Trp Lys Lys 65 70 75 80

Val Pro Met Val Ser Leu Val Leu Pro Val 85 90

<210> 1530

<211> 62

<212> PRT

<213> Homo sapiens

<400> 1530

Ala Asn Leu Gln Pro Lys Asn Leu Phe Lys Arg His Leu Trp Ser Cys
1 5 10 15

Asp Glu Thr Ser Ser Lys Thr His Ser Lys Thr Pro Leu Pro Pro Val 20 25 30

Gly His Gln Ser Ala Thr Lys His Glu Gln Ile Leu Leu Leu Ile Gly
35 40 45

Phe Pro Cys Asp Leu Val Pro Glu Val Phe Gly Ser Val Gln 50 55 60

<210> 1531

<211> 31

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (8)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

```
<222> (19)
 <223> Xaa equals any of the naturally occurring L-amino acids
 <220>
 <221> SITE
 <222> (27)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (28)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (30)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1531
Cys Asn Ile Ile Glu Met Lys Xaa Ser Leu Val Gly Thr Asp Ser Leu
Phe Ile Xaa Leu Gln Ser Leu Arg Ile His Xaa Xaa Lys Xaa His
             20
                                  25
<210> 1532
<211> 26
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (15)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (16)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (17)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (19)
<223> Xaa equals any of the naturally occurring L-amino acids
```

<400> 1532

```
Ala Val Ser Ala Val Gln Tyr Ser Thr Asp Arg Trp Thr Gln Xaa Xaa
Xaa His Xaa Gly Asn Arg His Leu Ser Ser
              20
<210> 1533
<211> 55
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (2)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (10)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (11)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (14)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (21)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (22)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (24)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
```

```
<221> SITE
 <222> (34)
 <223> Xaa equals any of the naturally occurring L-amino acids
 <220>
 <221> SITE
 <222> (41)
 <223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (47)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (55)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1533
His Xaa Ser Val Gln Leu Arg Thr Val Xaa Xaa Pro Ala Xaa Val Asn
                  5
Glu Pro Val Pro Xaa Xaa Ser Xaa Ser Lys Pro Pro Met Ser Ile Ser
             20
                                 25
Phe Xaa Ala His Leu Asn Thr Cys Xaa Tyr Ile Leu Tyr Ser Xaa Gln
                             40
Asn Asn Leu Tyr Leu Ile Xaa
    50
<210> 1534
<211> 48
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (8)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (10)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
```

```
<222> (19)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (30)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (31)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (32)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (41)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1534
Gly Thr Leu Val Leu Asn Gln Xaa Ser Xaa Ser Leu Phe Met Tyr Cys
Phe Thr Xaa Phe Tyr Ser Tyr Val Lys Phe Trp Ile Asn Xaa Xaa Xaa
                                 25
Cys Asn Tyr Lys Leu Arg Pro Val Xaa Leu Phe Leu Lys Ala Pro Tyr
         35
                             40
                                                 45
```

```
<210> 1535
<211> 53
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (7)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (8)
```

```
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (26)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (27)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (41)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (44)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (47)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1535
Met Gly Pro Leu Ser Ala Xaa Xaa Cys Arg Leu His Val Pro Trp Lys
                                     10
Glu Val Leu Leu Thr Ala Leu Leu Val Xaa Xaa Trp Asn Pro Pro Thr
                                 25
Thr Ala Lys Leu Thr Ile Glu Ser Xaa Pro Phe Xaa Val Ala Xaa Gly
                             40
         35
Lys Glu Val Leu Leu
     50
<210> 1536
<211> 70
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (1)
<223> Xaa equals any of the naturally occurring L-amino acids
```

<220> <221> SITE

<222> (17)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 1536

Xaa Ile Ile Asn Thr Leu Leu Ala Leu Leu Ile Ile Ile Thr Phe 1 5 10 15

Xaa Leu Pro Gln Leu Asn Gly Tyr Ile Glu Lys Ser Thr Pro Tyr Glu 20 25 30

Cys Gly Phe Asp Pro Ile Ser Pro Ala Arg Val Pro Phe Ser Ile Lys 35 40 45

Phe Phe Leu Val Ala Ile Thr Phe Leu Leu Phe Asp Leu Glu Ile Ala 50 55 60

Leu Leu Pro Leu Pro 65 70

<210> 1537

<211> 53

<212> PRT

<213> Homo sapiens

<400> 1537

Leu Pro Gln Leu Asn Gly Tyr Ile Glu Lys Ser Thr Pro Tyr Glu Cys
1 5 10 15

Gly Phe Asp Pro Ile Ser Pro Ala Arg Val Pro Phe Ser Ile Lys Phe 20 25 30

Phe Leu Val Ala Ile Thr Phe Leu Leu Phe Asp Leu Glu Ile Ala Leu 35 40 45

Leu Leu Pro Leu Pro 50

<210> 1538

<211> 53

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

```
<222> (15)
 <223> Xaa equals any of the naturally occurring L-amino acids
 <220>
 <221> SITE
 <222> (36)
 <223> Xaa equals any of the naturally occurring L-amino acids
 Leu Pro Gln Leu Asn Gly Tyr Ile Lys Lys Ser Thr Pro Tyr Xaa Cys
                                    10
Gly Phe Asp Pro Ile Ser Pro Ala Arg Val Pro Phe Ser Ile Lys Phe
                                 25
Phe Leu Val Xaa Ile Thr Phe Leu Leu Phe Asp Leu Lys Ile Ala Leu
                                 . 45
               40
Leu Leu Pro Leu Pro
     50
<210> 1539
<211> 53
<212> PRT
<213> Homo sapiens
<400> 1539
Leu Pro Gln Leu Asn Gly Tyr Ile Glu Lys Ser Thr Pro Tyr Glu Cys
                                   10
Gly Phe Asp Pro Ile Ser Pro Ala Arg Val Pro Phe Ser Ile Lys Phe
             20
                                25
Phe Leu Val Ala Ile Thr Phe Leu Leu Phe Asp Leu Glu Ile Ala Leu
         35
                           40
Leu Leu Pro Leu Pro
     50
<210> 1540
<211> 57
<212> PRT
<213> Homo sapiens
<400> 1540
Val Cys Phe Lys Gly Leu Tyr Leu Thr Asn Gly Phe Pro Leu Thr Glu
```

10

Leu Val Phe Ile Ser Asp Leu Thr Pro Leu Leu Asn Gly Ser Ser Gln
20 25 30

Asp Arg Met Phe Val Thr Thr Val Leu Glu Ile Glu Gln Leu Leu Ala
35 40 45

Arg Val Gly Val Leu Lys Asp Ser Ile 50 55

<210> 1541

<211> 137

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (87)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 1541

Trp Ile Pro Arg Ala Ala Gly Ile Arg His Glu Gly Ser Ser Asp Trp

1 5 10 15

Ser Tyr Gly Leu Glu Lys Gly Ser Leu Gly Met Pro Ser Glu Val Gly
20 25 30

Asp Arg Ala Gly Ala Gln Ala Pro Val Arg Asn Gly Arg Tyr Leu Ala 35 40 45

Ser Cys Gly Ile Leu Met Ser Arg Thr Leu Pro Leu His Thr Ser Ile 50 55 60

Leu Pro Lys Glu Ile Cys Ala Arg Thr Phe Phe Lys Ile Thr Ala Pro 65 70 75 80

Leu Ile Asn Lys Arg Lys Xaa Tyr Ser Glu Arg Arg Ile Leu Gly Tyr 85 90 95

Ser Met Gln Glu Met Tyr Asp Val Val Ser Gly Val Glu Asp Tyr Lys
100 105 110

His Phe Val Pro Trp Cys Lys Lys Ser Asp Val Ile Ser Lys Arg Ser 115 120 125

Gly Tyr Cys Lys Thr Arg Leu Glu Ile 130 135

```
<210> 1542
 <211> 122
 <212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (46)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (75)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (81)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (82)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (87)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (92)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (110)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (111)
<223> Xaa equals any of the naturally occurring L-amino acids
<220>
<221> SITE
<222> (118)
<223> Xaa equals any of the naturally occurring L-amino acids
```

<220>
<221> SITE
<222> (121)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 1542

Ala Arg Glu Arg Leu Gly Met Asp Ala Leu Val Ala Glu Glu Glu Ala 1 5 10 15

Glu Ala Lys Gly Asn Glu Val Arg Pro Ser Gly Arg Val Phe Leu Ser 20 25 30

Ser Ala Ala Leu Arg Leu Thr Cys Thr Phe Ser Ser Gly Xaa Gly Pro 35 40 45

Ser Cys Gln Pro Phe Gln Asn Ile Phe Pro Trp Ile Leu Arg Tyr Leu
50 60

Thr Phe Gln Asp Ser Arg Val Leu Ile Ile Xaa Leu Gly Asn Phe Trp
65 70 75 80

Xaa Xaa Trp Thr Gln Ser Xaa Phe Leu Lys Phe Xaa Pro Gln Gly Leu 85 90 95

Pro Ala Leu Gly Gly Ser Lys Val Phe Pro Lys Gly Pro Xaa Xaa Pro 100 105 110

Ala Pro Phe Phe Lys Xaa Arg Ile Xaa Ser 115 120

<210> 1543

<211> 57

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (48)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (55)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (57)

<223> Xaa equals any of the naturally occurring L-amino acids

Lys Cys Val Glu Lys Pro Gly Asn Arg Leu Asp Ser Arg Thr Glu Asn 20 25 30

Cys Leu Ser Ser Cys Val Asp Arg Phe Ile Asp Thr Thr Leu Ala Xaa 35 40 45

Thr Gln Ser Val Cys Pro Xaa Leu Xaa 50 55

<210> 1544

<211> 63

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (5)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (22)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 1544

Gly Gly Ile Ala Xaa Ala Gly Ser Gly His Met Asn Tyr Ile Gln Val 1 5 10 15

Thr Pro Gln Glu Lys Xaa Ala Ile Glu Arg Leu Lys Ala Leu Gly Phe 20 25 30

Pro Glu Gly Leu Val Ile Gln Ala Tyr Phe Ala Cys Glu Lys Asn Glu
35 40 45

Asn Leu Ala Ala Asn Phe Leu Leu Gln Gln Asn Phe Asp Glu Asp 50 55 60

<210> 1545

<211> 124

<212> PRT

<213> Homo sapiens

<220> <221> SITE <222> (99) <223> Xaa equals any of the naturally occurring L-amino acids <400> 1545 Glu Gly Leu Thr Pro Gln Glu Ile Cys Asp Lys Tyr His Ile Ile Gln 5 10 Ser Leu Gly Leu Cys Cys Cys Thr Ile Leu Ile Cys Pro Thr Gln Ile 25 Glu Gly Val Pro Leu Ala Glu Gly Leu Thr Pro Gln Glu Ile Cys Asp Lys Tyr His Ile Ile His Ala Asp Ile Tyr Arg Trp Phe Asn Ile Ser 55 60 Phe Asp Ile Phe Gly Arg Thr Thr Pro Gln Gln Thr Lys Ile Thr 65 70 75 Gln Asp Ile Phe Gln Gln Leu Leu Lys Arg Ser Phe Val Leu Gln Asp Thr Val Xaa Gln Leu Arg Cys Glu His Cys Ala Arg Phe Leu Ala Asp 105 Arg Phe Arg Gly Arg Arg Val Ser Leu Leu Trp Leu 115 120 <210> 1546 <211> 184 <212> PRT <213> Homo sapiens <220> <221> SITE <222> (1) <223> Xaa equals any of the naturally occurring L-amino acids <220>

<223> Xaa equals any of the naturally occurring L-amino acids

<221> SITE <222> (167)

Lys His Asp Ala Asp Ser Phe Tyr Gln Phe Ser Cys Asn Ile Cys Gly 20 25 30

Lys Lys Phe Glu Lys Lys Asp Ser Val Val Ala His Lys Ala Lys Ser 35 40 45

His Pro Glu Val Leu Ile Ala Glu Ala Leu Ala Ala Asn Ala Gly Ala 50 55 60

Leu Ile Thr Ser Thr Asp Ile Leu Gly Thr Asn Pro Glu Ser Leu Thr 65 70 75 80

Gln Pro Ser Asp Gly Gln Gly Leu Pro Leu Pro Glu Pro Leu Gly
85 90 95

Asn Ser Thr Ser Gly Glu Cys Leu Leu Leu Glu Ala Glu Gly Met Ser 100 105 110

Lys Ser Tyr Cys Ser Gly Thr Glu Arg Val Ser Leu Met Ala Asp Gly 115 120 125

Lys Ile Phe Val Gly Ser Gly Ser Ser Gly Gly Thr Glu Gly Leu Val 130 135 140

Met Asn Ser Asp Ile Leu Gly Ala Thr Thr Glu Val Leu Ile Glu Asp 145 150 155 160

Ser Asp Ser Ala Gly Pro Xaa Trp Thr Gly Arg Leu Gly Ala Trp Asp 165 170 175

Ser Ser Asp Phe Val Phe Lys Ser 180

<210> 1547

<211> 733

<212> DNA

<213> Homo sapiens

<400> 1547

gggatccgga gcccaaatct tctgacaaaa ctcacacatg cccaccgtgc ccagcacctg 60 aattcgaggg tgcaccgtca gtcttcctct tcccccaaa acccaaggac accctcatga 120 tctcccggac tcctgaggtc acatgcgtgg tggtggacgt aagccacgaa gaccctgagg 180 tcaagttcaa ctggtacgtg gacggcgtgg aggtgcataa tgccaagaca aagccgcggg 240 aggagcagta caacagcacg taccgtgtgg tcagcgtcct caccgtcctg caccaggact 300 ggctgaatgg caaggagtac aagtgcaagg tctccaacaa agccctccca acccccatcg 360 agaaaaccat ctccaaagcc aaagggcagc cccgagaacc acaggtgtac accctgccc 420 catcccggga tgagctgacc aagaaccagg tcagcctgac ctgcctggtc aaaggcttct 480 atccaagcga catcgccgtg gagtggaga gcaatgggca gccggagaac aactacaaga 540

```
ccacgcetee egtgetggae teegaegget cettetteet etacageaag eteacegtgg 600
acaagagcag gtggcagcag gggaacgtct tctcatgctc cgtgatgcat gaggctctgc 660
acaaccacta cacgcagaag agcctctccc tgtctccggg taaatgagtg cgacggccgc 720
                                                                   733
gactctagag gat
<210> 1548
<211> 5
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (3)
<223> Xaa equals any of the naturally occurring L-amino acids
<400> 1548
Trp Ser Xaa Trp Ser
  1
<210> 1549
<211> 86
<212> DNA
<213> Homo sapiens
<400> 1549
gcgcctcgag atttccccga aatctagatt tccccgaaat gatttccccg aaatgatttc 60
cccgaaatat ctgccatctc aattag
<210> 1550
<211> 27
<212> DNA
<213> Homo sapiens
<400> 1550
                                                                   27
gcggcaagct ttttgcaaag cctaggc
<210> 1551
<211> 271
<212> DNA
<213> Homo sapiens
<400> 1551
ctcgagattt ccccgaaatc tagatttccc cgaaatgatt tccccgaaat gatttccccg 60
aaatatetge cateteaatt agteageaae catagteeeg cecetaaete egeceateee 120
geocetaact eegeceagtt eegeceatte teegeceeat ggetgactaa tttttttat 180
```

		ag gccgaggcc			c cagaagtag	t gaggaggett	240
	ccccyyay	gc ctaggcttt	c ycaaaaayc				273
	<210> 15	52					
	<211> 32						
	<212> DN2						
	<213> Hor	no sapiens					
	<400> 155	52					
	gcgctcga	gg gatgacagc	g atagaaccc	gg gg			32
	<210> 155	33					
	<211> 31						
	<212> DNA						
	<213> Hon	no sapiens					
	<400> 155	i3					
	gcgaagctt	c gcgactccc	c ggatccgcct	: с			31
	<210> 155	4					
	<211> 12						
	<212> DNA						
	<213> Hom	o sapiens					
	<400> 155	4					
4	ggggacttt	c cc					12
	<210> 155	5					
•	<211> 73						
	<212> DNA						
•	<213> Hom	o sapiens					
•	<400> 155	5	,				
ç	gcggcctcg	a ggggactttc	ccggggactt	tccggggact	ttccgggact	ttccatcctg	60
(catctcaa	t tag					73
				`			
<	<210> 155	6					
<	<211> 256					•	
	212> DNA						
<	213> Home	o sapiens					
<	400> 1550	5					
C	tcgagggg	a ctttcccggg	gactttccgg	ggactttccg	ggactttcca	tctgccatct	60
		a gcaaccatag			_	_	
		c catteteege					
9	geegeete	g gcctctgagc	tattccagaa	gtagtgagga	ggcttttttg	gaggcctagg	240

WO 00/55351

1629

PCT/US00/05883

cttttgcaaa aagctt

256

International application No.

PCT/US00/05883

IPC(6) : C12P 21/04; C12N 15/00; C07H 21/02 US CL : 435/70.1, 320.1; 536/23.1					
According to International Patent Classification (IPC) or to both	national classification and IPC				
B. FIELDS SEARCHED					
Minimum documentation searched (classification system follows U.S.: 435/70.1, 320.1; 536/23.1	ed by classification symbols)				
Documentation searched other than minimum documentation to	the extent that such documents are includ	led in the fields searched			
Electronic data base consulted during the international search (na Please See Continuation Sheet	ame of data base and, where practicable,	search terms used)			
C. DOCUMENTS CONSIDERED TO BE RELEVANT					
Category * Citation of document, with indication, where	appropriate, of the relevant passages	Relevant to claim No.			
X SCANLAN et al. Characterization of Human Colo	SCANLAN et al. Characterization of Human Colon Cancer Antigens Recognized by				
Autologous Antibodies, Int. J. Cancer, 1998, Vol.	76, pages 652-658.	***************************************			
		5-10, 14-15			
TANAKA et al. A Novel Variant of Human Grb7 Carcinoma, J. Clin. Invest., August 1998, Vol. 10	Is Associated with Invasive Esophageal	1-4, 11-12, 16			
Y	, 110. 4, pages 621-627.	5-10, 14-15			
X KISHI et al. Molecular Cloning of Human GRB-7 2 in Primary Gastric Cancer, Biochemical and Biog	Co-amplified with CAB1 and c-ERBB-	1-4, 11-12, 16			
Y 1997, Vol. 232, pages 5-9.	physical research communications,	5-10, 14-15			
JIANG et al. Subtraction hybridization identifies a associated gene, mda-7, modulated during human r	novel melanoma differentiation melanoma differentiation, growth and	1-4, 11-12, 16			
Y progression, Oncogenes, 1995, Vol. 11, pages 247	7-2486.	5-10, 14-15			
MUELLER et al. Polymerase Chain Reaction Selection CD40-Activated Germinal Center Dendritic Cells,	cts a Novel Disintegrin Proteinase from	1-4, 11-12, 16			
Y No. 5, pages 655-663.		5-10, 14-15			
Further documents are listed in the continuation of Box C.					
Special categories of cited documents:	See patent family annex.				
"A" document defining the general state of the art which is not considered to be of particular relevance	date and not in conflict with the applic	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention			
E" earlier application or patent published on or after the international filing date	considered novel or cannot be consider	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination			
'L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the considered to involve an inventive ste				
O" document referring to an oral disclosure, use, exhibition or other means	being obvious to a person skilled in th	e ari			
P" document published prior to the international filing date but later than the priority date claimed	"&" document member of the same patent family				
Date of the actual completion of the international search	Date of mailing of the international search report 1 3 1UN 2000				
8 May 2000 (18.05.2000) Vame and mailing address of the ISA/US	Authorized officer \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \				
Commussioner of Patents and Trademarks Box PCT	Young J. Kim Derry J. Dey for				
Washington, D.C. 20231 Facsimile No. (703)305-3230	Telephone No. (703) 308-0196	$\bigcup U^{-1}$			
orm PCT/ISA/210 (second sheet) (July 1998)					

International application No.

PCT/US00/05883

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Delegges to alake N.
zategury	FOJO et al. Donor Splice Site Mutation in the Apolipoprotein (Apo) C-II Gene (APO C-IIhamburg) of a Patient with APO C-II Deficiency, The Journal of Clinical Investigations, November 1988, Vol. 82,	Relevant to claim No.
	pages 1489-1494.	5-10, 14-15
	JACKSON et al. Isolation of cDNA and Genomic Clones for Apolipoprotein C-II, Methods in Enzymology, 1986, Vol. 128, pages 788-800.	1-4, 11-12, 16
		5-10, 14-15
	HILLIER et al. Generation and Analysis of 280,000 Human Expressed Sequence Tags, Genome Research, 1996, Vol. 6, No. 9, pages 807-828.	1-4, 11-12, 16
		5-10, 14-15
-	WATSON et al. The Science Used in the Recombinant DNA Industry. In: Recombinant DNA, W.H. Freeman and Company, 1983, pages 231-241.	7-10, 14-15
}		
İ		

Intern. nal application No.

PCT/US00/05883

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)						
This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:						
1. [Claim Nos.: because they relate to subject matter not required to be searched by this Authority, namely:					
2.	Claim Nos.: because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:					
3. <u></u>	Claim Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 4(a).					
Вох П	Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)					
This Int	ernational Searching Authority found multiple inventions in this international application, as follows: See Continuation Sheet					
1.	As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:					
4. Remark	No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: 1-12,14,15,16,21 The additional search fees were accompanied by the applicant's protest. No protest accompanied the payment of additional search fees.					

International application No.

PCT/US00/05883

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. In order for all inventions to be examined, the appropriate additional examination fees must be paid.

Group I, claim(s) 1-12, 14, 15, 16, and 21, drawn to cDNA, polypeptides, genes, a method of using the cDNA to make host cells comprising the cDNA, and a method of making the polypeptide.

Group II, claim(s) 13, drawn to an antibody specific for the polypeptides of Group I.

Group III, claim(s) 17, drawn to a therapeutic method of using the cDNA or the polypeptide of Group I.

Group IV, claim(s) 18 and 19, drawn to a diagnostic method of using the cDNA or polypeptide of Group I.

Group V, claim(s) 20, drawn to a method of using the polypeptide of Group I to isolate a binding partner.

Group VI, claim(s) 22, drawn to a method of using the cDNA of Group I to identify the activity of the polypeptide encoded by the cDNA.

Group VII, claim(s) 23, drawn to the binding partner made by the method of Group V.

The inventions listed as Groups I-VII do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: PCT Rule 13.1 and Annex B do not provide for unity of invention between two or more different products or methods of use that share a special technical feature.

In addition, each Group detailed above reads on distinct Groups drawn to multiple SEQ ID Numbers. The sequences are distinct because they are unrelated sequences, and a further lack of unity is applied to each Group. The lack of unity is partially waived and the Applicants must further elect 10 SEQ ID Numbers for examination in the cleated Group detailed above.

Continuation of B. FIELDS SEARCHED Item 3: SEQUENCE DATABASES (US PATENT, INTERFERENCE, COMMERCIAL)

STN COMMERCIAL DATABASE (Biosis, Medline, Embase, Embal, SciSearch, BiotechDS, CaPlus) Search Terms: Recombinant, Host, Cell, Vector, peptide, protein, cDNA

Form PCT/ISA/210 (extra sheet) (July 1998)